[{"id":"10x-genomics","kind":"company","name":"10x Genomics","aka":[],"tldr":"Leader in single-cell and spatial biology tools (Chromium, Visium, Xenium) used to dissect tumours.","summary":"10x Genomics, based in Pleasanton, California, and listed as TXG, is the leader in single-cell and spatial biology tools, with Chromium for single-cell RNA and ATAC sequencing, Visium HD for spatial transcriptomics and Xenium for in situ analysis. Its instruments are core to tumour microenvironment research and to the atlases from which cell-state models are built. OnCo links it to single-cell and spatial profiling and spatial biology instruments, to bottlenecks on cold tumours and tumour heterogeneity, and to ideas such as mapping which tumour clones sit next to which immune cells before choosing therapy and setting standards for spatial biomarkers before they reach the clinic. Whether spatial biology moves from research tool to clinical test is the open question. The technology pages carry the detail.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/10x_Genomics","links":[{"label":"Official website","url":"https://www.10xgenomics.com"}],"tags":[],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":["single-cell-spatial"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Pleasanton, CA","country":"US","companyType":"diagnostics","website":"https://www.10xgenomics.com","ticker":"TXG","investors":[],"funding":[]},{"id":"2curex","kind":"company","name":"2cureX","aka":[],"tldr":"2cureX's IndiTreat test grows a patient's tumour cells as microtumours and tests approved drugs on them, available through hospitals in Denmark, Germany, Sweden and the United Kingdom.","summary":"2cureX develops products for individualised therapy selection in oncology. Its IndiTreat technology uses 3D cell cultures of the patient's own tumour to test drugs and drug combinations, and is offered through hospitals in Denmark, Germany, Sweden and the UK, physician-ordered.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://2curex.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["functional-drug-testing","organoids"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Copenhagen, Denmark","country":"DK","companyType":"diagnostics","website":"https://2curex.com/","investors":[],"funding":[]},{"id":"3d-medicines","kind":"company","name":"3D Medicines","aka":["3D Medicines (Sichuan) Co., Ltd.","3D Medicines Inc.","思路迪"],"tldr":"3D Medicines is a Chinese biotechnology company that co-developed envafolimab, the first subcutaneous PD-L1 antibody, approved in China in 2021 for microsatellite instability-high solid tumours.","summary":"3D Medicines, headquartered in Sichuan with research in Shanghai and listed in Hong Kong since 2022, develops immuno-oncology antibodies. With Alphamab Oncology and Tracon it brought envafolimab (KN035), a single-domain PD-L1 antibody given by subcutaneous injection, to approval in China in November 2021 for previously treated MSI-high or dMMR advanced solid tumours, and it runs phase 3 trials of the drug in combination with chemotherapy. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials led by 3D Medicines","url":"https://clinicaltrials.gov/search?lead=3D%20Medicines"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":[],"targets":["pdl1"],"drugs":["envafolimab"],"companies":["alphamab"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06123754","nct04891198","nct03667170","nct05024214","nct03478488","nct05112991"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Chengdu","country":"CN","companyType":"biotech","website":"https://www.3d-medicines.com","stage":"public","investors":[],"funding":[]},{"id":"3dhistech","kind":"company","name":"3DHISTECH","aka":[],"tldr":"3DHISTECH, of Budapest, makes the Pannoramic slide scanners, including the high-throughput Pannoramic 1000, and the SlideViewer software used in research and European clinical laboratories, distributed by Epredia and Thermo Fisher in some markets. As digital pathology consolidates around a few large vendors, holding its position is the open question.","summary":"3DHISTECH, based in Budapest, is the Hungarian maker of the Pannoramic slide scanners and the SlideViewer software, used in research and in European clinical laboratories. Its Pannoramic 1000 is a high-throughput scanner, its digital pathology software supports viewing and management, and its products are distributed by Epredia and Thermo Fisher in some markets. OnCo links it to whole-slide scanners and image management. Whether a smaller European scanner maker can hold its position as digital pathology consolidates around a few large vendors is the open question. The whole-slide scanner page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.3dhistech.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["whole-slide-scanners"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Budapest","country":"HU","companyType":"diagnostics","website":"https://www.3dhistech.com","investors":[],"funding":[]},{"id":"3sbio","kind":"company","name":"3SBio","aka":["Shenyang Sunshine Pharmaceutical","Sansheng Pharmaceutical"],"tldr":"3SBio is a Shenyang biologics company whose HER2 antibody inetetamab was approved in China in 2020 for HER2-positive metastatic breast cancer.","summary":"3SBio, listed in Hong Kong, is one of China's largest biologics makers, with a long-standing business in recombinant proteins (erythropoietin, thrombopoietin). In oncology its Fc-engineered HER2 antibody inetetamab (Cipterbin) was approved by the NMPA in June 2020 with vinorelbine for HER2-positive metastatic breast cancer. A 2025 licence of its PD-1 and VEGF bispecific antibody to Pfizer brought the company global attention.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.3sbio.com"}],"tags":["ctgov-sponsor","china"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":["monoclonal-antibody"],"targets":[],"drugs":["inetetamab","ssgj-612","ssgj-705","ssgj-706"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07008703","nct07171606","nct07022002","nct07646626"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shenyang, China","country":"CN","companyType":"biotech","website":"https://www.3sbio.com","stage":"public","investors":[],"funding":[]},{"id":"4sc","kind":"company","name":"4SC","aka":["4SC AG","4Sc AG"],"tldr":"4SC is a listed German biotechnology company founded in 1997 in Planegg-Martinsried, near Munich. It applied to the EMA for its HDAC inhibitor resminostat (Kinselby) in advanced mycosis fungoides and Sézary syndrome and received a negative opinion in May 2025.","summary":"4SC is a public company based in Martinsried, Germany, founded in 1997 (Wikidata Q238181, which also gives its website). The EMA product page for Kinselby (resminostat, orphan designation) names 4Sc AG as the marketing authorisation applicant; the CHMP adopted its opinion on 22 May 2025 and the opinion status is negative, so the product is not authorised. It sponsors no trial recorded in OnCo.","asOf":"2026-09-22","links":[{"label":"Official website","url":"https://www.4sc.com/"},{"label":"Wikidata Q238181","url":"https://www.wikidata.org/wiki/Q238181"},{"label":"EMA: Kinselby (EPAR)","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/kinselby"}],"tags":["ctgov-sponsor","wave5-sponsor"],"related":[],"cancers":["cutaneous-t-cell-lymphoma"],"sections":[],"technologies":["epigenetic-drugs"],"targets":["hdac"],"drugs":["resminostat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo content wave 5 (Wikidata, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-22"},"hq":"Planegg-Martinsried","country":"DE","companyType":"biotech","website":"https://www.4sc.com/","founded":1997,"stage":"public","investors":[],"funding":[]},{"id":"5am-ventures","kind":"company","name":"5AM Ventures","aka":[],"tldr":"A venture firm with offices in San Francisco and Boston that funds early-stage drug companies and also runs a public-market fund. Its cancer investments include the cell therapy company Artiva, the protein degrader pioneer Arvinas and Enliven Therapeutics.","summary":"5AM Ventures describes itself as 'a leading investment firm focused on funding and building next-generation life sciences companies'. Its venture strategy 'primarily invests in private therapeutic companies' with an emphasis on Series A, its 4:59 Initiative incubates academic science to reach Series A-ready proof of concept, and the 5AM Opportunities strategy invests in small and mid-cap public and later-stage private biotechs. Oncology examples on its portfolio page include Aprea (mutant p53 reactivation, IPO 2019), Artiva Biotherapeutics (allogeneic natural killer cell therapies for cancer, IPO 2024), Arvinas (targeted protein degradation with applications in cancer, IPO 2018), Cidara (viral and oncologic diseases), Deverra (off-the-shelf cellular immunotherapies) and Enliven Therapeutics (precision oncology small molecules).","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://5amventures.com/"},{"label":"Portfolio","url":"https://5amventures.com/portfolio/"},{"label":"Strategy","url":"https://5amventures.com/strategy/"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["arvinas","enliven-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on fetched pages, so omitted. Office cities (San Francisco and Boston) follow the task hint; the fetched pages did not list addresses."],"hq":"San Francisco, CA","country":"US","companyType":"investor","website":"https://5amventures.com/","investors":[],"funding":[]},{"id":"a2-biotherapeutics","kind":"company","name":"A2 Biotherapeutics","aka":["A2 Bio"],"tldr":"A2 Biotherapeutics is a US-based cell therapy company that leads 3 cancer trials in OnCo, testing the logic-gated CAR-T therapies A2B395, A2B530, A2B694 and A2B543 in colorectal cancer, non-small-cell lung cancer, head and neck squamous cell carcinoma and renal cell carcinoma.","summary":"A2 Biotherapeutics is a clinical-stage biotechnology company developing logic-gated CAR T-cell therapies on its Tmod platform, designed to distinguish tumour cells from normal cells. Its clinical programmes include A2B395 (EGFR), A2B694 and A2B543 (mesothelin) and A2B530 (CEA). On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT06682793 (phase 1/2, A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T,...), NCT05736731 (phase 1/2, A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Particip...) and NCT06051695 (phase 1/2, A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T,...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.a2bio.com"},{"label":"ClinicalTrials.gov: trials led by A2 Biotherapeutics","url":"https://clinicaltrials.gov/search?lead=A2%20Biotherapeutics%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["colorectal","nsclc","head-and-neck","rcc","tnbc","pancreatic","ovarian","mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06682793","nct05736731","nct06051695"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Agoura Hills, California","country":"US","companyType":"cell-therapy","website":"https://www.a2bio.com","stage":"growth","investors":[],"funding":[]},{"id":"aadi-bioscience","kind":"company","name":"Aadi Bioscience","aka":["Whitehawk Therapeutics","Aadi Bioscience, Inc.","NASDAQ:AADI"],"tldr":"Aadi Bioscience won approval for Fyarro, the albumin-bound sirolimus that treats the rare sarcoma PEComa, then sold it and renamed itself Whitehawk Therapeutics to develop antibody-drug conjugates.","summary":"Aadi Bioscience developed nab-sirolimus (Fyarro, ABI-009), an mTOR inhibitor bound to albumin nanoparticles for better tumour delivery. The FDA approved it in November 2021 for malignant perivascular epithelioid cell tumour, the first drug for that sarcoma; the PRECISION 1 trial tested it in tumours with TSC1 or TSC2 alterations. In 2025 Aadi sold Fyarro to Kaken Pharmaceutical, in-licensed three antibody-drug conjugates from WuXi Biologics and Hangzhou DAC, and became Whitehawk Therapeutics.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.aadibio.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["sirolimus-albumin-bound"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Los Angeles, California","country":"US","companyType":"biotech","website":"https://www.aadibio.com/","ticker":"NASDAQ:AADI","stage":"public","investors":[],"funding":[]},{"id":"ab-science","kind":"company","name":"AB Science","aka":["AB Science S.A."],"tldr":"AB Science is a Paris biotechnology company built around masitinib, an oral tyrosine kinase inhibitor aimed at mast cells and macrophages that it has tested in phase 3 trials across cancers and neurological diseases.","summary":"AB Science, listed on Euronext Paris, develops masitinib, an oral tyrosine kinase inhibitor that acts on KIT, LYN and other kinases in mast cells and macrophages. The company has run a long series of phase 3 trials with masitinib in cancers including pancreatic cancer, prostate cancer, mastocytosis and gastrointestinal stromal tumours, and in amyotrophic lateral sclerosis, multiple sclerosis and Alzheimer's disease, and has faced repeated regulatory setbacks; the drug is not approved for cancer in the United States or the European Union. It appears on OnCo as one of the most active industry sponsors of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.ab-science.com"},{"label":"ClinicalTrials.gov: trials led by AB Science","url":"https://clinicaltrials.gov/search?lead=AB%20Science"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/AB_Science"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["pancreatic","prostate","gist"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05211570"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Paris","country":"FR","companyType":"biotech","website":"https://www.ab-science.com","stage":"public","investors":[],"funding":[]},{"id":"abbisko","kind":"company","name":"Abbisko Therapeutics","aka":["Abbisko Therapeutics Co, Ltd","和誉生物"],"tldr":"Abbisko is a Shanghai biotech listed in Hong Kong whose CSF-1R inhibitor pimicotinib met its phase 3 endpoint in tenosynovial giant cell tumour, a rare joint tumour, and is licensed to Merck KGaA.","summary":"Abbisko Therapeutics, based in Shanghai and listed in Hong Kong, develops small-molecule kinase inhibitors. Its lead drug pimicotinib (ABSK021), a selective CSF-1R inhibitor, met the primary endpoint of the phase 3 MANEUVER trial in tenosynovial giant cell tumour and is partnered with Merck KGaA outside China; FGFR4 and pan-FGFR inhibitors follow in liver and urothelial cancer. Its trials are registered on ClinicalTrials.gov under Abbisko as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.abbisko.com"},{"label":"ClinicalTrials.gov: trials led by Abbisko Therapeutics Co, Ltd","url":"https://clinicaltrials.gov/search?lead=Abbisko%20Therapeutics%20Co%2C%20Ltd"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q140045781"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["tenosynovial-giant-cell-tumour","hcc"],"sections":[],"technologies":[],"targets":["csf1r"],"drugs":["absk061","pimicotinib"],"companies":["merck-kgaa"],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct06632262","nct07164170","nct06668103","nct05804045","nct07327034","nct06111274","nct07417189"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.abbisko.com","stage":"public","investors":[],"funding":[]},{"id":"abbott","kind":"company","name":"Abbott Laboratories","aka":[],"tldr":"Diagnostics giant that makes the UroVysion bladder test, sells Freenome's blood test for bowel cancer, and is acquiring Exact Sciences.","summary":"Abbott Molecular's UroVysion (FDA 2001 and 2005) and Vysis FISH probes are long-standing oncology diagnostics. In 2025-26 Abbott moved decisively into cancer screening: it holds US commercial rights to Freenome's SimpleScreen CRC (approved July 2026) and agreed to acquire Exact Sciences (Cologuard, Oncotype DX) for about $21 billion.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Abbott_Laboratories","links":[{"label":"Official website","url":"https://www.abbott.com"}],"tags":[],"related":[],"cancers":["urothelial","colorectal"],"sections":["diagnostics","early-detection"],"technologies":["cytogenetics-fish","colorectal-screening"],"targets":[],"drugs":["urovysion","simplescreen-crc"],"companies":["exact-sciences","freenome"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Abbott Park, IL","country":"US","companyType":"diagnostics","website":"https://www.abbott.com","ticker":"ABT","founded":1888,"investors":[],"funding":[]},{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","aka":["Pharmacyclics","Allergan","Kythera Biopharmaceuticals","Repros Therapeutics Inc.","Facet Biotech"],"tldr":"AbbVie owns Venclexta and Elahere, and bought Capstan, the leading in vivo CAR-T company.","summary":"AbbVie, based in North Chicago and listed as ABBV, owns Venclexta and Elahere and bought Capstan Therapeutics, the leading in vivo CAR-T company, in 2025 for up to 2.1 billion dollars. Its portfolio includes venetoclax, mirvetuximab soravtansine from the 10 billion dollar ImmunoGen purchase, telisotuzumab vedotin, sold as Emrelis and approved in 2025, the c-MET ADC Temab-A, epcoritamab with Genmab, ibrutinib and the Capstan candidate CPTX2309. OnCo links it to the CLL14, MURANO, AMPLIFY, VIALE-A and EPCORE NHL-1 papers, to the Walter and Eliza Hall Institute, to the in vivo CAR-T technology and the cell therapy roadmap, and to AbbVie Ventures. Whether in vivo CAR-T can be made to work in patients is the largest bet on this page. Venetoclax, mirvetuximab and telisotuzumab vedotin have their own pages.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.abbvie.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs","cell-therapy","targeted-therapy"],"technologies":[],"targets":[],"drugs":["venetoclax","mirvetuximab-soravtansine","telisotuzumab-vedotin","telisotuzumab-adizutecan","budigalimab","livmoniplimab","abbv-706","navitoclax","dronabinol"],"companies":["capstan-therapeutics","abbvie-ventures"],"institutions":[],"pathways":[],"terms":[],"trials":["luminosity","nct03844048","nct05445778","nct03539744","nct06158841","nct07095452","nct05822752","nct07023289","nct07024784","nct06107413","nct03314181","nct06682988","nct06820463","nct07387471","nct06365853","nct06568939","nct05456685","nct06892522","nct06890338","nct06953960","nct07155174","nct02899052","nct07059845","nct07196644","nct03379428","nct02966756","nct06428019","nct03386513","nct06772623","nct07581002","nct03933735","nct07024706","nct04086264","nct05963074","nct04623541","nct04895436","nct06632951"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"North Chicago, IL","country":"US","companyType":"pharma","website":"https://www.abbvie.com","ticker":"ABBV","investors":[],"funding":[]},{"id":"abbvie-ventures","kind":"company","name":"AbbVie Ventures","aka":[],"tldr":"AbbVie's corporate venture arm, which invests in early-stage biotech companies in AbbVie's therapeutic areas including cancer. Its web pages blocked automated access at the time of research.","summary":"AbbVie Ventures is the corporate venture capital group of AbbVie, the North Chicago-based pharmaceutical company, and invests strategically in early-stage companies developing new therapeutics and platforms in AbbVie's areas of interest, which include oncology, immunology and neuroscience. Both the AbbVie Ventures overview and portfolio pages on abbvie.com returned HTTP 403 (Cloudflare) on every attempt with two different fetch methods, so the firm's own description, founding year, strategy and named oncology portfolio companies could not be confirmed from a primary source.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.abbvie.com/partnerships/abbvie-ventures.html"}],"tags":["corporate-venture"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["abbvie"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Website could not be fetched by the research pass on 2026-09-10 (bot protection, JavaScript-only or parked domain); location and description rest on the firm's public materials and on press releases that name it. abbvie.com returned 403 from both curl and WebFetch. Headquarters follows AbbVie's corporate base."],"hq":"North Chicago, IL","country":"US","companyType":"investor","website":"https://www.abbvie.com/partnerships/abbvie-ventures.html","investors":[],"funding":[]},{"id":"abclon","kind":"company","name":"AbClon","aka":["AbClon Inc.","앱클론","KOSDAQ:174900"],"tldr":"AbClon is a South Korean antibody and cell-therapy company whose CD19 CAR-T AT101 uses a newly discovered antibody binder and has shown high response rates in relapsed B-cell lymphoma.","summary":"AbClon, listed on KOSDAQ, discovers antibodies against novel epitopes and develops them as therapeutics and CAR-T cells. AT101 is an autologous CD19 CAR-T built on the h1218 antibody, which binds a different epitope of CD19 from the FMC63 binder used in approved products; a phase 1 trial in relapsed or refractory B-cell non-Hodgkin lymphoma reported complete responses in most patients at the higher doses and a phase 2 trial is under way in Korea. AbClon also develops the HER2 antibody AC101 and a switchable CAR-T platform.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.abclon.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["at101"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Seoul","country":"KR","companyType":"cell-therapy","website":"https://www.abclon.com/","ticker":"KOSDAQ:174900","founded":2010,"stage":"public","investors":[],"funding":[]},{"id":"abdera-therapeutics","kind":"company","name":"Abdera Therapeutics","aka":[],"tldr":"Abdera Therapeutics engineered antibodies that carry a radioactive isotope to cancer cells, tuning how long they circulate so more radiation reaches the tumour and less reaches healthy tissue. Its first medicine targets a protein on small cell lung cancer.","summary":"Abdera Therapeutics, based in Vancouver and Menlo Park, California, developed antibody-based radiopharmaceuticals using its ROVEr antibody engineering platform, which tunes pharmacokinetic properties so that alpha- or beta-emitting isotopes can be matched to targets with a wide range of antigen expression. Its lead programme targets DLL3 for small cell lung cancer and other solid tumours and was advancing toward the clinic at launch; founding partners were adMare BioInnovations and AbCellera. The company emerged in April 2023 with USD 142 million in combined Series A and B financing, the Series A led by Versant Ventures and Amplitude Ventures and the USD 110 million Series B led by venBio Partners with Viking Global Investors, Qiming Venture Partners USA and RTW Investments.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.biospace.com/abdera-therapeutics-debuts-with-142-million-in-financing-to-engineer-and-advance-best-in-class-antibody-based-radiopharmaceuticals-for-cancer"},{"label":"Endpoints News: Abdera raises $110M Series B","url":"https://endpoints.news/abdera-raises-110m-to-push-targeted-radiotherapies-where-they-havent-gone-before/"}],"tags":[],"related":["src-endpoints-news"],"cancers":["sclc"],"sections":["radiopharma"],"technologies":["radioimmunotherapy","targeted-alpha-therapy","radioligand-therapy"],"targets":["dll3"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website abderatx.com returned HTTP 503 or no response on every attempt, so the website field points to the fetched press release copy instead. Current status is uncertain: search headlines in 2026 refer to an auction of Abdera laboratory equipment and to biotechs that closed, but no fetched primary source confirms a wind-down, so stage is left at startup. Clinical status of the DLL3 programme (a phase 1a start was reported in trade press) not confirmed from fetched pages."],"hq":"Vancouver","country":"CA","companyType":"radiopharma","website":"https://www.biospace.com/abdera-therapeutics-debuts-with-142-million-in-financing-to-engineer-and-advance-best-in-class-antibody-based-radiopharmaceuticals-for-cancer","stage":"startup","investors":["versant-ventures"],"funding":[{"round":"Series B","year":2023,"amountUsd":110000000,"source":"https://endpoints.news/abdera-raises-110m-to-push-targeted-radiotherapies-where-they-havent-gone-before/","note":"Led by venBio Partners; the company's launch release reports USD 142 million in combined Series A and B financing"}]},{"id":"abx-advanced-biochemical-compounds","kind":"company","name":"ABX advanced biochemical compounds","aka":["ABX advanced biochemical compounds GmbH","ABX GmbH","ABX"],"tldr":"ABX is a German maker of the precursors and kits behind PET imaging tracers, including PSMA agents for prostate cancer, and sponsors the trials that register them.","summary":"ABX advanced biochemical compounds, based in Radeberg near Dresden, manufactures radiopharmaceutical precursors, cold kits and labelling chemistry used to produce PET tracers, among them PSMA-directed agents for prostate cancer imaging developed with the German Cancer Research Center. It acts as lead sponsor of phase 3 diagnostic trials registered on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.abx.de"},{"label":"ClinicalTrials.gov: trials led by ABX advanced biochemical compounds","url":"https://clinicaltrials.gov/search?lead=ABX%20advanced%20biochemical%20compounds"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["psma-pet"],"targets":[],"drugs":["psma-1007-f18"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Radeberg","country":"DE","companyType":"pharma","website":"https://www.abx.de","stage":"private-large","investors":[],"funding":[]},{"id":"abzena","kind":"company","name":"Abzena","aka":[],"tldr":"Abzena is a bioconjugation and biologics CDMO with the ThioBridge site-specific linker technology.","summary":"Abzena, based in Cambridge in the United Kingdom, is a bioconjugation and biologics CDMO that owns the ThioBridge site-specific linker technology. Its services span antibody engineering, immunogenicity assessment, ADC conjugation in San Diego and biologics manufacturing in Bristol, Pennsylvania. OnCo links it to ADC bioconjugation manufacturing and to site-specific conjugation and linker chemistry. Whether a CDMO that also licenses its own linker can stay neutral between clients using competing chemistries is the fair question. The ADC manufacturing page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.abzena.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["adcs"],"technologies":["adc-cdmo-manufacturing","site-specific-conjugation"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cambridge","country":"GB","companyType":"cro-services","website":"https://www.abzena.com","investors":[],"funding":[]},{"id":"acacia-pharma","kind":"company","name":"Acacia Pharma","aka":["Acacia Pharma Ltd","Acacia Pharma Group"],"tldr":"Acacia Pharma was a Cambridge company that repurposed the old antipsychotic amisulpride, at low dose, to prevent and treat nausea and vomiting after surgery and chemotherapy; it was bought by Eagle Pharmaceuticals in 2022.","summary":"Acacia Pharma, founded in 2007 in Cambridge, England, developed intravenous low-dose amisulpride (Barhemsys) for postoperative nausea and vomiting, approved by the FDA in 2020, and tested the same drug (APD403) in phase 3 for chemotherapy-induced nausea and vomiting. Eagle Pharmaceuticals acquired the company in 2022. Its trials remain on ClinicalTrials.gov under Acacia as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.acaciapharma.com"},{"label":"ClinicalTrials.gov: trials led by Acacia Pharma Ltd","url":"https://clinicaltrials.gov/search?lead=Acacia%20Pharma%20Ltd"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30268747"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":["antiemetic-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct04851717"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Cambridge","country":"GB","companyType":"pharma","website":"http://www.acaciapharma.com","founded":2007,"stage":"acquired","investors":[],"funding":[]},{"id":"accuray","kind":"company","name":"Accuray","aka":["Accuray Incorporated","Accuray Inc."],"tldr":"Accuray makes the CyberKnife robotic radiosurgery system and the TomoTherapy and Radixact helical radiotherapy platforms, and sponsors trials of stereotactic and adaptive radiotherapy.","summary":"Accuray, listed on Nasdaq and headquartered in Madison, Wisconsin after moving from Sunnyvale, California, manufactures radiotherapy equipment: the CyberKnife, a linear accelerator on a robotic arm that tracks tumour motion for stereotactic radiosurgery and stereotactic body radiotherapy, and the TomoTherapy and Radixact systems, which deliver helical intensity-modulated radiotherapy with daily imaging. It sponsors clinical trials of hypofractionated and adaptive treatment on its platforms. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.accuray.com"},{"label":"ClinicalTrials.gov: trials led by Accuray","url":"https://clinicaltrials.gov/search?lead=Accuray"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Accuray"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":["radiation","devices"],"technologies":["sbrt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["radiotherapy","hypofractionation"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Madison, WI","country":"US","companyType":"devices","website":"https://www.accuray.com","stage":"public","investors":[],"funding":[]},{"id":"achieve-life-sciences","kind":"company","name":"Achieve Life Sciences (formerly OncoGenex)","aka":["Achieve Life Sciences, Inc.","OncoGenex Pharmaceuticals","OncoGenex"],"tldr":"Achieve Life Sciences carries the trial record of OncoGenex, whose antisense drug custirsen failed phase 3 trials in prostate and lung cancer before the company turned to a smoking-cessation medicine.","summary":"OncoGenex Pharmaceuticals, founded in 2000 in Bothell, Washington, developed custirsen (OGX-011), an antisense inhibitor of clusterin, and led the phase 3 SYNERGY and AFFINITY trials in metastatic castration-resistant prostate cancer and a phase 3 trial in non-small cell lung cancer, none of which improved survival. In 2017 it merged with Achieve Life Sciences, which now develops cytisinicline for smoking cessation, a cancer prevention aim. The custirsen trials sit on ClinicalTrials.gov under the Achieve name.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.achievelifesciences.com"},{"label":"ClinicalTrials.gov: trials led by Achieve Life Sciences, Inc.","url":"https://clinicaltrials.gov/search?lead=Achieve%20Life%20Sciences%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30269222"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate","nsclc"],"sections":["prevention"],"technologies":["antisense-sirna"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Bothell, WA","country":"US","companyType":"biotech","website":"https://www.achievelifesciences.com","founded":2000,"stage":"public","investors":[],"funding":[]},{"id":"acrivon-therapeutics","kind":"company","name":"Acrivon Therapeutics","aka":[],"tldr":"Acrivon Therapeutics uses a protein-activity test to pick the patients most likely to respond to its cancer drugs. Its lead drug blocks DNA damage checkpoint proteins and is being tested in womb and ovarian cancer.","summary":"Acrivon Therapeutics is a Watertown, Massachusetts clinical-stage company that pairs its AP3 (Acrivon Predictive Precision Proteomics) phosphoproteomics platform with drug candidates targeting DNA damage response and cell cycle regulation. Its lead programme, ACR-368 (prexasertib, in-licensed from Lilly), is a CHK1/CHK2 inhibitor with single-agent activity including complete responses in platinum-resistant ovarian and squamous cell cancers; the company uses its OncoSignature assay to select patients, holds FDA Fast Track designation for OncoSignature-selected endometrial and platinum-resistant ovarian cancer, and Breakthrough Device designations for the assay. ACR-2316, a dual WEE1/PKMYT1 inhibitor, is in the clinic, and ACR-6840 targets CDK11 in IND-enabling studies. Acrivon completed its Nasdaq IPO in November 2022.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://acrivon.com/"},{"label":"Pipeline","url":"https://acrivon.com/pipeline/"},{"label":"IPO closing 8-K (SEC)","url":"https://www.sec.gov/Archives/edgar/data/1781174/000119312522287727/d410573d8k.htm"}],"tags":[],"related":[],"cancers":["endometrial","ovarian"],"sections":["targeted-therapy","diagnostics"],"technologies":["kinase-inhibitors","proteomics","companion-diagnostic"],"targets":["wee1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05548296"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["IPO gross proceeds not captured from the fetched 8-K or prospectus excerpt, so the amount is omitted. Founding year not sourced."],"hq":"Watertown, MA","country":"US","companyType":"biotech","website":"https://acrivon.com/","ticker":"ACRV","stage":"public","investors":[],"funding":[{"round":"IPO","year":2022,"source":"https://www.sec.gov/Archives/edgar/data/1781174/000119312522287727/d410573d8k.htm","note":"IPO closed 17 November 2022 with a concurrent 5 million US dollar private placement to Chione; gross IPO proceeds not stated in the fetched filing"}]},{"id":"acrotech-biopharma","kind":"company","name":"Acrotech Biopharma","aka":[],"tldr":"Acrotech Biopharma, part of Aurobindo, owns the former Spectrum Pharmaceuticals haematology portfolio: the radioimmunotherapy Zevalin, pralatrexate (Folotyn), belinostat (Beleodaq) and vincristine liposome (Marqibo).","summary":"Acrotech Biopharma, based in East Windsor, New Jersey, and part of Aurobindo, owns the former Spectrum Pharmaceuticals haematology portfolio: the radioimmunotherapy Zevalin, pralatrexate as Folotyn, belinostat as Beleodaq and vincristine liposome as Marqibo. It acquired Spectrum's marketed products in 2019, including Zevalin, or ibritumomab tiuxetan, for follicular lymphoma, Folotyn and Beleodaq for peripheral T-cell lymphoma, Marqibo and Evomela, a melphalan formulation. OnCo links it to the ibritumomab tiuxetan drug record. Whether the only approved radioimmunotherapy for lymphoma survives commercially in an owner focused on generics is the open question. Ibritumomab tiuxetan has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.acrotechbiopharma.com"}],"tags":[],"related":[],"cancers":["follicular-lymphoma","peripheral-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["ibritumomab-tiuxetan","pralatrexate","belinostat","vincristine","melphalan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06072131"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"East Windsor, New Jersey","country":"US","companyType":"pharma","website":"https://www.acrotechbiopharma.com","investors":[],"funding":[]},{"id":"acs-brightedge","kind":"company","name":"ACS BrightEdge (American Cancer Society)","aka":[],"tldr":"BrightEdge is the American Cancer Society's own venture fund. It invests donated money in start-ups working on cancer and returns any gains to the charity's mission.","summary":"ACS BrightEdge is the impact venture capital arm of the American Cancer Society, investing philanthropic capital in early-stage companies developing cancer therapeutics, diagnostics, devices and care delivery tools, with returns recycled into the Society's research and patient programmes. It is one of the clearest examples of a disease charity acting as an investor rather than a grant-maker. Portfolio links in OnCo are derived from the startup records that name it.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://acsbrightedge.org"}],"tags":["foundation"],"related":["american-cancer-society"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Atlanta, GA","country":"US","companyType":"investor","website":"https://acsbrightedge.org","investors":[],"funding":[]},{"id":"actinium-pharmaceuticals","kind":"company","name":"Actinium Pharmaceuticals","aka":[],"tldr":"Actinium Pharmaceuticals attaches the alpha-emitting isotope actinium-225 to antibodies to treat acute myeloid leukaemia and, more recently, solid tumours such as prostate and lung cancer. It is a small listed company whose lead programme is approaching new clinical milestones.","summary":"Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), headquartered in New York, develops targeted radiotherapies based on actinium-225 antibody radioconjugates and holds proprietary Ac-225 manufacturing technology. The lead programme Actimab-A is a CD33-targeting, mutation-agnostic therapy for relapsed or refractory acute myeloid leukaemia, with patents extending to solid tumours via myeloid-derived suppressor cells; the company expects clinical milestones from the fourth quarter of 2026. ATNM-400 is a first-in-class Ac-225 pan-tumour radiotherapy in preclinical development for metastatic castration-resistant prostate cancer, non-small cell lung cancer and breast cancer, with 2026 SNMMI data in androgen receptor inhibitor-resistant prostate models and KRAS and EGFR mutant lung models. Iomab-ACT is a targeted conditioning programme. In 2026 the company received NYSE American listing standards notices and appointed Steffen Heeger as Chief Medical Officer.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.actiniumpharma.com/"},{"label":"August 2026 Actimab-A and listing update","url":"https://ir.actiniumpharma.com/press-releases/detail/525/actinium-pharmaceuticals-announces-actimab-a-intellectual"},{"label":"Press releases","url":"https://ir.actiniumpharma.com/press-releases"}],"tags":[],"related":[],"cancers":["aml","prostate","nsclc"],"sections":["radiopharma"],"technologies":["radioimmunotherapy","targeted-alpha-therapy"],"targets":["cd33"],"drugs":["iomab-b"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Ticker, exchange and HQ confirmed via SEC EDGAR submissions data (CIK 0001388320). Public company; no private rounds listed. Founding year not sourced."],"hq":"New York, NY","country":"US","companyType":"radiopharma","website":"https://www.actiniumpharma.com/","ticker":"ATNM","stage":"public","investors":[],"funding":[]},{"id":"active-biotech","kind":"company","name":"Active Biotech","aka":["Active Biotech AB"],"tldr":"Active Biotech is a Swedish immunomodulator company whose tasquinimod reached phase 3 in prostate cancer without success and is now tested in myeloma.","summary":"Active Biotech, founded in Lund in 1984 and listed in Stockholm, develops immunomodulatory small molecules. Tasquinimod, an oral S100A9 inhibitor, was taken through phase 3 in metastatic castration-resistant prostate cancer with Ipsen; it slowed radiographic progression but did not extend survival, and the programme has since moved to multiple myeloma and myelofibrosis. Its laquinimod programme sits in autoimmune disease. ClinicalTrials.gov lists Active Biotech as lead sponsor of phase 3 cancer trials.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.activebiotech.com"},{"label":"ClinicalTrials.gov: trials led by Active Biotech AB","url":"https://clinicaltrials.gov/search?lead=Active%20Biotech%20AB"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q10400578"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate","multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Lund","country":"SE","companyType":"biotech","website":"http://www.activebiotech.com","founded":1984,"stage":"public","investors":[],"funding":[]},{"id":"actuate-therapeutics","kind":"company","name":"Actuate Therapeutics","aka":[],"tldr":"A Texas biotech developing elraglusib, a GSK-3 beta inhibitor that improved survival in a randomised phase 2 in metastatic pancreatic cancer.","summary":"Actuate Therapeutics listed on Nasdaq in 2024 to fund elraglusib. Its lead programme is first-line metastatic pancreatic cancer with gemcitabine and nab-paclitaxel, where the Actuate 1801 Part 3B randomised phase 2 reported longer survival; the company is planning a confirmatory phase 3 and also studies the drug in Ewing sarcoma and other tumours.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.actuatetherapeutics.com"}],"tags":[],"related":[],"cancers":["pancreatic","ewing-sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["elraglusib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Fort Worth, Texas, United States","country":"US","companyType":"biotech","website":"https://www.actuatetherapeutics.com","founded":2015,"stage":"public","investors":[],"funding":[]},{"id":"adaptimmune","kind":"company","name":"Adaptimmune","aka":[],"tldr":"Adaptimmune developed Tecelra, the first TCR-T for a solid tumour, and sold the US rights to US WorldMeds in 2025 amid financial distress.","summary":"Adaptimmune, based in Abingdon and Philadelphia, developed Tecelra, or afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, and sold its US rights to US WorldMeds in 2025 amid financial distress. Afami-cel targets MAGE-A4 and was proved in SPEARHEAD-1 in synovial sarcoma, letetresgene autoleucel targets NY-ESO-1, and uza-cel, its PRAME programme, was sold. OnCo links it to sarcomas, to the afami-cel drug record and to the SPEARHEAD-1 papers. Whether a scientifically successful cell therapy can survive commercially in a rare cancer is the question its history answers, and the answer here was no. Afamitresgene autoleucel has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.adaptimmune.com"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":[],"targets":[],"drugs":["afamitresgene-autoleucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Abingdon / Philadelphia","country":"GB","companyType":"cell-therapy","website":"https://www.adaptimmune.com","investors":[],"funding":[]},{"id":"adaptive-biotechnologies","kind":"company","name":"Adaptive Biotechnologies","aka":[],"tldr":"Adaptive Biotechnologies makes clonoSEQ, the FDA-cleared sequencing test that finds one leukaemia cell in a million and now guides treatment in ALL, myeloma, and CLL.","summary":"Adaptive Biotechnologies, based in Seattle and listed as ADPT, makes clonoSEQ, the FDA-cleared sequencing test that finds one leukaemia cell in a million and now guides treatment in acute lymphoblastic leukaemia, myeloma and chronic lymphocytic leukaemia. clonoSEQ sequences IGH, IGK, IGL and T-cell receptor clonotypes and was the first FDA-cleared next-generation sequencing test for measurable residual disease, in 2018 for ALL and myeloma and in 2020 for CLL; it serves as the MRD endpoint in trials and in routine practice, and the company also runs the T-Detect immune medicine business. OnCo links it to NGS-based MRD testing, to the bottleneck of dormant cells and minimal residual disease, and to ideas on reference materials for residual disease tests. Whether MRD can become a regulatory endpoint for approval is the open question. clonoSEQ has its own page.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://www.adaptivebiotech.com"}],"tags":[],"related":[],"cancers":["all-leukemia","multiple-myeloma","cll"],"sections":["diagnostics"],"technologies":["ngs-mrd-clonoseq","mrd-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Seattle, WA","country":"US","companyType":"diagnostics","website":"https://www.adaptivebiotech.com","ticker":"ADPT","investors":[],"funding":[]},{"id":"adc-therapeutics","kind":"company","name":"ADC Therapeutics","aka":["ADC Therapeutics S.A.","ADC Therapeutics SA"],"tldr":"ADC Therapeutics, based in Lausanne, developed Zynlonta (loncastuximab tesirine), an antibody-drug conjugate built on its pyrrolobenzodiazepine payload platform and approved in diffuse large B-cell lymphoma. It is now switching to exatecan-based payloads, so its future rests on changing platform while staying independent.","summary":"ADC Therapeutics, based in Lausanne and listed as ADCT, developed Zynlonta, or loncastuximab tesirine, and the pyrrolobenzodiazepine payload platform behind it. Loncastuximab is approved in diffuse large B-cell lymphoma, the LOTIS-5 and LOTIS-7 trials test it in combinations, and the company is moving to exatecan-based next-generation ADCs. OnCo links it to diffuse large B-cell lymphoma and to the loncastuximab tesirine drug record. Whether a company built on one payload can change platform and stay independent is the open question. Loncastuximab tesirine has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://adctherapeutics.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":[],"targets":[],"drugs":["zynlonta"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04384484"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Lausanne","country":"CH","companyType":"biotech","website":"https://adctherapeutics.com","ticker":"ADCT","investors":[],"funding":[]},{"id":"adcendo","kind":"company","name":"Adcendo","aka":[],"tldr":"Adcendo is a Danish company developing antibody-drug conjugates, antibodies that deliver a cell-killing drug straight to cancer cells, against targets few others are pursuing. Its first medicines are in early human trials, including one for soft tissue sarcoma.","summary":"Adcendo ApS is a clinical-stage Copenhagen biotech developing antibody-drug conjugates against targets, such as tissue factor and uPARAP, that few other companies pursue. Its pipeline comprises ADCE-T02, a tissue factor-targeted ADC in the phase 1 Tiffany-01 study (cohort expansion in multiple solid tumour indications from April 2026, with a pembrolizumab combination cohort agreed with MSD in May 2026); ADCE-D01, a uPARAP-targeted ADC in the ADCElerate1 dose escalation and expansion study in soft tissue sarcoma and other mesenchymal cancers; and ADCE-B05, against an undisclosed target, in dose escalation in squamous cell carcinomas. The company closed an oversubscribed USD 135 million Series B in November 2024 led by TCGX, and a USD 75 million Series C in April 2026 led by Jeito Capital with Vida Ventures, Bpifrance and EIFO joining existing investors including RA Capital, Novo Holdings and Ysios Capital.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://adcendo.com/"},{"label":"Series B press release","url":"https://adcendo.com/adcendo-aps-completes-oversubscribed-135-million-series-b-financing-to-advance-first-in-class-adc-pipeline/"},{"label":"Series C press release","url":"https://adcendo.com/adcendo-aps-completes-75-million-series-c-financing-to-continue-advancing-first-and-best-in-class-clinical-adc-pipeline/"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":["adcs"],"technologies":["adc"],"targets":["tissue-factor"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06797999"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Earlier Series A (2021) not fetched and omitted. Founding year not stated on fetched pages."],"hq":"Copenhagen","country":"DK","companyType":"biotech","website":"https://adcendo.com/","stage":"growth","investors":["tcgx","orbimed","venrock","logos-capital","ra-capital","novo-holdings","gilde-healthcare","jeito-capital","vida-ventures","bpifrance"],"funding":[{"round":"Series B","year":2024,"amountUsd":135000000,"source":"https://adcendo.com/adcendo-aps-completes-oversubscribed-135-million-series-b-financing-to-advance-first-in-class-adc-pipeline/"},{"round":"Series C","year":2026,"amountUsd":75000000,"source":"https://adcendo.com/adcendo-aps-completes-75-million-series-c-financing-to-continue-advancing-first-and-best-in-class-clinical-adc-pipeline/"}]},{"id":"adela","kind":"company","name":"Adela","aka":[],"tldr":"Adela, of Toronto, develops blood tests that profile methylation marks across all cell-free DNA fragments without sequencing the tumour itself, first to detect residual disease and immunotherapy response in advanced solid tumours and later to screen for multiple cancers with one test. The screening programme is still in study.","summary":"Adela, headquartered in Toronto with US operations in Foster City, California, launched in June 2021 on technology from the Princess Margaret Cancer Centre and Sinai Health System. Its genome-wide methylome enrichment platform profiles all methylated cell-free DNA fragments in a blood sample without bisulphite conversion, enabling tissue-agnostic, tumour-naive tests that do not require sequencing the primary tumour. The lead application is minimal residual disease (MRD) and immunotherapy response monitoring in advanced solid tumours; a clinical validation of the tissue-free immunotherapy response test appeared in npj Precision Oncology in March 2026. A multi-cancer early detection (MCED) programme is in study, with progress shown at ASCO 2026. Adela raised a $60 million Series A in 2021 led by F-Prime Capital and $48 million in 2023 with Labcorp joining, $108 million in total.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.adelabio.com/"},{"label":"Series A launch release (Jun 2021)","url":"https://www.adelabio.com/press/adela-debuts-with-60m"},{"label":"$48 million financing (Sep 2023)","url":"https://www.adelabio.com/press/adela-announces-48-million-in-financing-and-leadership-addition-to-advance-tissue-agnostic-minimal-residual-disease-mrd-monitoring-product-portfolio-based-on-genome-wide-methylome-approach"},{"label":"News page","url":"https://www.adelabio.com/adela-news"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics","early-detection"],"technologies":["liquid-biopsy","methylation-profiling","mrd-testing","mced"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["2021 release dateline is Toronto and San Francisco; 2023 release dateline is Foster City, CA. Toronto chosen as HQ per the company origin. No specific cancer types are tagged because the tests are tissue-agnostic."],"hq":"Toronto","country":"CA","companyType":"diagnostics","website":"https://www.adelabio.com/","founded":2021,"stage":"startup","investors":["f-prime-capital","orbimed","deerfield-management","ra-capital"],"funding":[{"round":"Series A","year":2021,"amountUsd":60000000,"source":"https://www.adelabio.com/press/adela-debuts-with-60m","note":"Led by F-Prime Capital with OrbiMed, Deerfield Management, Decheng Capital and RA Capital Management; company launched June 2021 (formerly DNAMx)."},{"round":"Series A","year":2023,"amountUsd":48000000,"source":"https://www.adelabio.com/press/adela-announces-48-million-in-financing-and-leadership-addition-to-advance-tissue-agnostic-minimal-residual-disease-mrd-monitoring-product-portfolio-based-on-genome-wide-methylome-approach","note":"Round name not given in the release (listed as Series A1 extension on the company news page); existing investors plus new investor Labcorp; cumulative funding $108 million."}]},{"id":"adialante","kind":"company","name":"Adialante","aka":[],"tldr":"Adialante has redesigned MRI so it fits in a mobile clinic and is paid per scan, aiming to bring MRI cancer screening to any medical site, starting with prostate cancer.","summary":"Adialante is rebuilding MRI hardware, physics and reconstruction algorithms from the ground up to create a mobile, low-cost scanner offered to clinics on a flat per-scan fee with no capital purchase, with the stated purpose of making MRI-based cancer screening available at any clinic rather than only at hospitals with a fixed scanner. Its first target is prostate cancer, where MRI before biopsy is already guideline practice, with other cancers to follow. The company is a Spring 2026 YC company; the scanner is in development and has no regulatory clearance recorded.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/adialante"},{"label":"Official website","url":"https://www.adialante.com"}],"tags":["yc"],"related":[],"cancers":["prostate"],"sections":["imaging","early-detection"],"technologies":["mri","whole-body-mri"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"imaging","website":"https://www.adialante.com","stage":"startup","ycBatch":"X26","investors":["y-combinator"],"funding":[]},{"id":"adicet-bio","kind":"company","name":"Adicet Bio","aka":[],"tldr":"Adicet makes off-the-shelf immune cell therapies from donor gamma delta T cells, a rarer type of T cell. Its lead programme is now aimed at lupus and other autoimmune diseases, with a prostate cancer candidate expected to enter the clinic in late 2026.","summary":"Adicet Bio is a clinical-stage company developing allogeneic gamma delta T-cell therapies engineered with chimeric antigen receptors. Lead product prulacabtagene leucel (prula-cel, formerly ADI-001) is an allogeneic gamma delta CAR T candidate now developed primarily in autoimmune disease (lupus nephritis, systemic lupus erythematosus, systemic sclerosis, vasculitis and rheumatoid arthritis), with a phase 1 update and pivotal trial planning under way in 2026 after FDA alignment on outpatient dosing. In oncology, ADI-212 is a preclinical candidate for metastatic castration-resistant prostate cancer with a regulatory filing planned for the third quarter of 2026 and enrolment expected in the fourth quarter. Adicet is also building an in vivo CAR T platform for haematological malignancies and solid tumours. It completed a one-for-16 reverse stock split in December 2025 and trades on Nasdaq as ACET.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.adicetbio.com/"},{"label":"Q2 2026 results (8-K exhibit 99.1)","url":"https://www.sec.gov/Archives/edgar/data/1720580/000172058026000049/acet-ex99_1.htm"},{"label":"January 2026 corporate update (8-K exhibit 99.1)","url":"https://www.sec.gov/Archives/edgar/data/1720580/000119312526005486/acet-ex99_1.htm"}],"tags":[],"related":[],"cancers":["prostate"],"sections":["cell-therapy"],"technologies":["allogeneic-cell-therapy","car-t","in-vivo-car-t"],"targets":[],"drugs":["adi-270"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Pipeline is now led by autoimmune indications; oncology exposure is ADI-212 (prostate) and an in vivo CAR T platform. No funding round sourced."],"hq":"Redwood City, CA","country":"US","companyType":"cell-therapy","website":"https://www.adicetbio.com/","ticker":"ACET","stage":"public","investors":[],"funding":[]},{"id":"adienne","kind":"company","name":"Adienne Pharma & Biotech","aka":[],"tldr":"Adienne is a Swiss company specialising in haematology and transplantation medicines; it holds the US and EU authorisations for thiotepa (Tepadina).","summary":"Adienne Pharma and Biotech, based in Lugano, is a Swiss company specialising in haematology and transplantation medicines, and it holds the US and EU authorisations for thiotepa, sold as Tepadina. It developed Tepadina as an orphan medicine for conditioning before haematopoietic stem cell transplantation, authorised in the European Union in 2010 and the United States in 2017, and it markets other transplant-related products in Europe. OnCo links it to the thiotepa drug record. Whether orphan status for a long-established chemotherapy serves patients or mainly protects price is the fair question its flagship product raises. Thiotepa has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.adienne.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["thiotepa"],"companies":[],"institutions":[],"pathways":[],"terms":["allogeneic-transplant","autologous-transplant"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Lugano","country":"CH","companyType":"pharma","website":"https://www.adienne.com","investors":[],"funding":[]},{"id":"advanced-accelerator-applications","kind":"company","name":"Advanced Accelerator Applications (Novartis)","aka":[],"tldr":"The CERN spin-out that Novartis bought in 2018 for Lutathera, which now makes Pluvicto and the Locametz and Netspot imaging kits.","summary":"Advanced Accelerator Applications, based in Saint-Genis-Pouilly, France, and founded in 2002, is the CERN spin-out that Novartis bought in 2018 for Lutathera, and it now makes Pluvicto and the Locametz and Netspot imaging kits. AAA developed Lutathera, or 177Lu-DOTATATE, and the Netspot gallium-68 DOTATATE kit before its 3.9 billion dollar acquisition, and as Novartis' radioligand unit it manufactures Locametz, the gallium-68 PSMA-11 kit, and Pluvicto and runs the Novartis radioligand production network in Europe and the United States. OnCo links it to prostate cancer and neuroendocrine tumours, to PSMA PET, somatostatin receptor PET and beta-emitter radioligand therapy, and to Novartis. Whether its production network can meet demand as radioligand indications widen is the open question. Locametz and Pluvicto have their own pages.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.adacap.com"}],"tags":[],"related":[],"cancers":["prostate","neuroendocrine"],"sections":["radiopharma","imaging"],"technologies":["psma-pet","sstr-pet","radioligand-therapy"],"targets":[],"drugs":["locametz","ga68-dotatate","pluvicto","amo959"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07354074","nct03899155","nct06514534","nct05849298","nct01872260","nct07047118","nct04208178","nct05948943","nct04971226","nct03591510","nct06784752","nct04925479","nct04939610","nct05445843","nct05658003","nct07085767","nct04699188","nct03040973","nct03972488","nct05230810","nct06247995","nct03876769","nct02934568","nct05038735","nct05384587","nct05456191","nct07387926","nct05415072","nct04524000","nct05827081","nct07206056","nct04544189"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Saint-Genis-Pouilly","country":"FR","companyType":"radiopharma","website":"https://www.adacap.com","founded":2002,"investors":[],"funding":[]},{"id":"advenchen-laboratories","kind":"company","name":"Advenchen Laboratories","aka":["Advenchen Laboratories, LLC","Advenchen"],"tldr":"Advenchen is the small Californian company that discovered anlotinib, the multi-kinase inhibitor that became one of China's most used cancer pills, and it leads late-stage trials of related compounds.","summary":"Advenchen Laboratories, based in Moorpark, California, designs kinase inhibitors and licenses them to partners. Its anlotinib (AL3818), licensed to Chia Tai Tianqing, is approved in China for lung cancer, soft tissue sarcoma, medullary thyroid cancer and small cell lung cancer, and Advenchen itself sponsors phase 3 trials of anlotinib and catequentinib outside China. Its records appear on ClinicalTrials.gov under the Advenchen name.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://advenchen.com"},{"label":"ClinicalTrials.gov: trials led by Advenchen Laboratories, LLC","url":"https://clinicaltrials.gov/search?lead=Advenchen%20Laboratories%2C%20LLC"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q140046417"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["anlotinib","al8326"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct03016819","nct05363280","nct07392736"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Moorpark, CA","country":"US","companyType":"biotech","website":"https://advenchen.com","stage":"private-large","investors":[],"funding":[]},{"id":"adventris-pharmaceuticals","kind":"company","name":"Adventris Pharmaceuticals","aka":[],"tldr":"Adventris Pharmaceuticals, a Johns Hopkins spin-out, develops off-the-shelf cancer vaccines designed to raise immune responses against mutant KRAS, the driver mutation shared by pancreatic, colorectal and lung cancers, with the long-term aim of a yearly vaccine that prevents those cancers before they form. Its programmes are preclinical or early clinical.","summary":"Adventris Pharmaceuticals, a Johns Hopkins spin-out, develops off-the-shelf therapeutic and preventive cancer vaccines using a platform designed to raise strong immune responses against poorly immunogenic oncogene-derived antigens. Its first vaccine targets mutant KRAS, relevant to pancreatic, colorectal and lung cancers, and the company's stated long-term vision is annual pan-cancer vaccination. Programmes are preclinical or early clinical; no sourced financing rounds are recorded here.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/adventris-pharmaceuticals"},{"label":"Official website","url":"https://adventris.com"}],"tags":["yc"],"related":[],"cancers":["pancreatic","colorectal","nsclc"],"sections":["immunotherapy","prevention"],"technologies":["shared-antigen-vaccine"],"targets":["kras"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Baltimore, MD","country":"US","companyType":"biotech","website":"https://adventris.com","stage":"startup","ycBatch":"W23","investors":["y-combinator"],"funding":[]},{"id":"aeterna-zentaris","kind":"company","name":"Aeterna Zentaris","aka":["AEterna Zentaris","Aeterna Zentaris Inc.","Zentaris GmbH"],"tldr":"Aeterna Zentaris is a Frankfurt-based biotech whose oncology programmes, including the alkylphospholipid perifosine and the LHRH antagonist ozarelix, went through phase 3 trials it led; its approved product is a growth hormone deficiency test.","summary":"Aeterna Zentaris, headquartered in Frankfurt am Main and listed in Toronto and on Nasdaq, developed cancer drug candidates including perifosine (tested in phase 3 in multiple myeloma and colorectal cancer) and zoptarelin doxorubicin (a doxorubicin-LHRH conjugate tested in endometrial cancer), none of which reached approval. Its marketed product, macimorelin, is a diagnostic for adult growth hormone deficiency. It appears on ClinicalTrials.gov as lead sponsor of phase 3 cancer trials.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.aezsinc.com"},{"label":"ClinicalTrials.gov: trials led by AEterna Zentaris","url":"https://clinicaltrials.gov/search?lead=AEterna%20Zentaris"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30268820"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["multiple-myeloma","colorectal"],"sections":[],"technologies":["pi3k-akt-mtor-inhibitors","peptide-drug-conjugate"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Frankfurt","country":"DE","companyType":"biotech","website":"https://www.aezsinc.com","founded":2001,"stage":"public","investors":[],"funding":[]},{"id":"affini-t-therapeutics","kind":"company","name":"Affini-T Therapeutics","aka":[],"tldr":"Affini-T engineers a patient's T cells with receptors that recognise mutated cancer driver proteins such as KRAS, and uses gene editing to make the cells more effective. It is an early clinical-stage company based near Boston.","summary":"Affini-T Therapeutics is a Watertown, Massachusetts cell therapy company developing T-cell receptor (TCR) based T-cell therapies. Partner Metagenomi reported in August 2024 that it had established cGMP gene-editing reagents and filed Drug Master Files with the FDA to support an IND for Affini-T's TCR-based therapy, receiving 933,650 Affini-T shares on achievement of that regulatory milestone, which indicates the lead programme was at the IND stage in 2024. An SEC Form D filed in October 2024 shows the company was incorporated in 2020 and sold about $17.6 million of equity in an offering that began in July 2024. The company website is rendered client-side and returned no readable text to automated fetches, so programme names, targets and earlier financing rounds could not be confirmed from primary sources.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.affinittx.com/"},{"label":"Form D, October 2024","url":"https://www.sec.gov/Archives/edgar/data/2036455/000203645524000001/primary_doc.xml"},{"label":"Metagenomi Q2 2024 results describing the Affini-T milestone (8-K)","url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024096673/mgx-ex99_1.htm"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["tcr-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06105021"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Series letter for the 2024 Form D not stated."],"hq":"Watertown, MA","country":"US","companyType":"cell-therapy","website":"https://www.affinittx.com/","founded":2020,"stage":"startup","investors":["leaps-by-bayer"],"funding":[{"round":"Form D offering","year":2024,"amountUsd":17617952,"source":"https://www.sec.gov/Archives/edgar/data/2036455/000203645524000001/primary_doc.xml","note":"Equity offering, first sale 31 July 2024"}]},{"id":"agendia","kind":"company","name":"Agendia","aka":[],"tldr":"Dutch maker of MammaPrint, the 70-gene breast cancer test validated in the MINDACT trial.","summary":"Spun out of the Netherlands Cancer Institute, Agendia developed MammaPrint (FDA-cleared 2007, the first cleared multigene prognostic test) and the BluePrint molecular subtyping assay, and sponsored MINDACT with the EORTC. It also runs the FLEX registry collecting whole-transcriptome data on MammaPrint patients.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://agendia.com"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":["diagnostics"],"technologies":["rna-seq"],"targets":[],"drugs":["mammaprint"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["mindact"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Amsterdam / Irvine, CA","country":"NL","companyType":"diagnostics","website":"https://agendia.com","founded":2003,"investors":[],"funding":[]},{"id":"agennix","kind":"company","name":"Agennix","aka":["Agennix AG","Agennix Incorporated"],"tldr":"Agennix was a German-American biotech whose oral talactoferrin, a recombinant form of the milk protein lactoferrin, failed a phase 3 trial in non-small cell lung cancer.","summary":"Agennix, founded in 1993 with operations in Princeton, New Jersey and Munich, developed talactoferrin alfa, a recombinant human lactoferrin taken by mouth as an immunotherapy. The phase 3 FORTIS-M trial in previously treated non-small cell lung cancer did not improve survival, and the company ceased operations. Its trials remain on ClinicalTrials.gov under Agennix as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://agennix.com"},{"label":"ClinicalTrials.gov: trials led by Agennix AG","url":"https://clinicaltrials.gov/search?lead=Agennix%20AG"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30283567"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Princeton, NJ","country":"US","companyType":"biotech","website":"http://agennix.com","founded":1993,"stage":"defunct","investors":[],"funding":[]},{"id":"agenus","kind":"company","name":"Agenus","aka":["Agenus Inc.","Agenus Inc"],"tldr":"Agenus is a Massachusetts immuno-oncology company developing botensilimab, an Fc-enhanced anti-CTLA-4 antibody, with its anti-PD-1 balstilimab, notably in microsatellite-stable colorectal cancer where checkpoint inhibitors have not worked.","summary":"Agenus, based in Lexington, Massachusetts and listed on Nasdaq, develops checkpoint antibodies and cancer vaccines. Its lead combination is botensilimab, a next-generation anti-CTLA-4 antibody with an engineered Fc region, given with balstilimab, an anti-PD-1 antibody, which has shown responses in microsatellite-stable colorectal cancer without liver metastases and other cold tumours; the company has sought accelerated approval and runs registrational trials. OnCo records it as a registry sponsor of phase 3 cancer trials.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Agenus","links":[{"label":"Official website","url":"https://agenusbio.com"},{"label":"ClinicalTrials.gov: trials led by Agenus","url":"https://clinicaltrials.gov/search?lead=Agenus"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Agenus"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["colorectal"],"sections":["immunotherapy"],"technologies":[],"targets":["ctla4","pd1"],"drugs":["botensilimab","zalifrelimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05205330","nct06782555"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Lexington, MA","country":"US","companyType":"biotech","website":"https://agenusbio.com","stage":"public","investors":[],"funding":[]},{"id":"agilent","kind":"company","name":"Agilent Technologies (Dako)","aka":[],"tldr":"Agilent makes the Dako PD-L1 IHC 22C3 and 28-8 companion diagnostics and the Omnis staining platform.","summary":"Agilent Technologies, based in Santa Clara and listed as A, makes the Dako PD-L1 IHC 22C3 and 28-8 companion diagnostics and the Omnis staining platform. Its pathology reagents and instruments sit alongside mass spectrometry and genomics tools, and its PD-L1 assays are tied to the pembrolizumab and nivolumab labels; OnCo also links it to HER2 IHC and ISH companion assays and to Resolution ctDx FIRST. It connects to reference laboratories, companion diagnostics, histopathology and immunohistochemistry and IHC autostainers. Whether the multiplicity of PD-L1 assays can be harmonised, or whether each drug keeps its own test, is the open question its products embody. PD-L1 IHC 22C3 pharmDx has its own page.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.agilent.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["reference-laboratories","companion-diagnostic","histopathology-ihc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Santa Clara, CA","country":"US","companyType":"diagnostics","website":"https://www.agilent.com","ticker":"A","investors":[],"funding":[]},{"id":"ago-study-group","kind":"company","name":"AGO Study Group","aka":["AGO Studiengruppe","AGO Research GmbH","AGO Studiengruppe Ovarialkarzinom","AGO-OVAR","AGO"],"tldr":"The AGO Study Group is the German gynaecological oncology trials group, founded in 1993 as AGO-OVAR to improve ovarian cancer treatment; it sponsors DESKTOP III and four other ovarian and vulvar cancer trials in OnCo.","summary":"The AGO Study Group was established in 1993 as a non-profit organisation under the name AGO Studiengruppe Ovarialkarzinom (AGO-OVAR), at first to improve the treatment of ovarian carcinoma and, from 2007, the other gynaecological tumours; its website counts more than 250 university and non-university centres and lists the initiation and conduct of clinical trials, training and work in national and international expert groups as its tasks. Its study office, AGO Research GmbH, has its seat at Kaiser-Friedrich-Ring 71, Wiesbaden, with a second study secretariat in Essen. ClinicalTrials.gov names AGO Study Group (OTHER class) as lead sponsor of DESKTOP III (NCT01166737, phase 3, secondary cytoreductive surgery in platinum-sensitive relapsed ovarian cancer) and of NCT00189345, and AGO Research GmbH (INDUSTRY class on the registry) as lead sponsor of NCT04274426 (mirvetuximab soravtansine in folate receptor alpha-high ovarian cancer), NCT04644289 (WoO, olaparib and durvalumab window study) and NCT05903833 (pembrolizumab with lenvatinib in vulvar cancer). It has no products of its own.","asOf":"2026-09-25","links":[{"label":"AGO Study Group: profile","url":"https://www.ago-ovar.de/en/profile/"},{"label":"ClinicalTrials.gov: trials led by AGO Study Group","url":"https://clinicaltrials.gov/search?lead=AGO%20Study%20Group"},{"label":"ClinicalTrials.gov: trials led by AGO Research GmbH","url":"https://clinicaltrials.gov/search?lead=AGO%20Research%20GmbH"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["ovarian","high-grade-serous-ovarian-cancer","platinum-sensitive-ovarian-cancer","vulvar","hpv-associated-vulvar-cancer","hpv-independent-vulvar-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["desktop-iii","nct04274426","nct05903833","nct00189345","nct04644289"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"Wiesbaden","country":"DE","companyType":"cooperative-group","website":"https://www.ago-ovar.de","founded":1993,"investors":[],"funding":[]},{"id":"aidoc","kind":"company","name":"Aidoc","aka":[],"tldr":"Radiology AI company with the first FDA-cleared foundation-model triage platform (CARE, January 2026); oncology-relevant for incidental findings and workflow.","summary":"CARE foundation model cleared with 11 new indications in one workflow (mean sensitivity 97%, specificity 98% in the pivotal study); Breakthrough Device designation (June 2026) for First Read, which drafts chest radiograph reports. Not oncology-specific but sets the regulatory template for imaging foundation models.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Aidoc","links":[{"label":"FDA clearance","url":"https://www.prnewswire.com/news-releases/aidoc-secures-fda-clearance-for-healthcares-first-comprehensive-foundation-model-ai-302666640.html"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation","imaging"],"technologies":["radiology-ai-screening","pathology-foundation-model"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tel Aviv / New York","country":"IL","companyType":"ai-software","website":"https://www.aidoc.com","investors":[],"funding":[]},{"id":"aids-malignancy-consortium","kind":"company","name":"AIDS Malignancy Consortium","aka":["AMC","Consortium for Advancing Management and Prevention of Cancer in People with HIV"],"tldr":"The AIDS Malignancy Consortium is the US National Cancer Institute-supported trials group for cancers in people with HIV, founded in 1995 with 38 sites worldwide; in OnCo it leads ANCHOR, the trial showing that treating anal precancer prevents anal cancer.","summary":"The AIDS Malignancy Consortium (AMC), now styled the Consortium for Advancing Management and Prevention of Cancer in People with HIV, is a National Cancer Institute-supported clinical trials group founded in 1995 to support innovative trials for HIV-related cancers; it is composed of 38 clinical trials sites worldwide, five working groups, an administrative office, a statistical office and an operations and data management office (amcoperations.com). Its website states no postal address, so no seat is given here. ClinicalTrials.gov names it lead sponsor (NETWORK class, with the National Cancer Institute, the Emmes Company and the universities of Arkansas, California San Francisco and Arizona as collaborators) of ANCHOR (NCT02135419, phase 3, treatment against active monitoring of anal high-grade squamous intraepithelial lesions in people with HIV), the trial recorded in OnCo. It has no products of its own.","asOf":"2026-09-25","links":[{"label":"Official website","url":"https://amcoperations.com"},{"label":"ClinicalTrials.gov: trials led by AIDS Malignancy Consortium","url":"https://clinicaltrials.gov/search?lead=AIDS%20Malignancy%20Consortium"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["anal","anal-hsil-precursor"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["anchor"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"United States (seat not stated)","country":"US","companyType":"cooperative-group","website":"https://amcoperations.com","founded":1995,"investors":[],"funding":[]},{"id":"aignostics","kind":"company","name":"Aignostics","aka":[],"tldr":"Aignostics is the Berlin pathology AI company that built the Atlas foundation model with Mayo Clinic.","summary":"Aignostics, based in Berlin, is the pathology AI company that built the Atlas foundation model with Mayo Clinic and Charité. Atlas, released in 2025, was trained on 1.2 million slides from the two institutions, and the company also builds biomarker quantification tools for pharmaceutical clients. OnCo links it to Atlas, to Mayo Clinic and to Charité. Whether a model trained on two large institutions' archives generalises to other laboratories' staining and scanners is the open question for every pathology foundation model, including this one. Atlas has its own technology page.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.aignostics.com"}],"tags":["ai"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mayo-clinic","charite"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Berlin","country":"DE","companyType":"ai-software","website":"https://www.aignostics.com","investors":[],"funding":[]},{"id":"aio","kind":"company","name":"AIO (Arbeitsgemeinschaft Internistische Onkologie)","aka":["AIO-Studien-gGmbH","AIO Studien gGmbH","Arbeitsgemeinschaft Internistische Onkologie","AIO (Germany)","AIO"],"tldr":"AIO is the medical oncology working group of the German Cancer Society, founded in 1976 with about 1,500 members; its trials company AIO-Studien-gGmbH sponsors the NALIRICC, NIFE and FLOT4 trials in OnCo and co-ran FIRE-3 and SSG XVIII.","summary":"The Arbeitsgemeinschaft Internistische Onkologie in der Deutschen Krebsgesellschaft e.V. (AIO) was founded in 1976 and today counts about 1,500 members, with its office at Kuno-Fischer-Strasse 8, Berlin (aio-portal.de). Its trials arm, AIO-Studien-gGmbH, grew out of the AIO study centre and was entered in the Berlin-Charlottenburg commercial register in 2007; it designs, implements and manages phase 1 to 4 trials and shares the Berlin address. ClinicalTrials.gov names AIO-Studien-gGmbH (OTHER class) as lead sponsor of NALIRICC (NCT03043547, phase 2, liposomal irinotecan with fluorouracil in biliary tract cancer, with Servier) and NIFE (NCT03044587, phase 2, liposomal irinotecan combinations in biliary tract cancer); FLOT4 (NCT01216644, perioperative FLOT in gastric and oesophagogastric junction adenocarcinoma) is registered by Krankenhaus Nordwest as an AIO trial; SSG XVIII/AIO (NCT00116935, adjuvant imatinib in GIST) was run with the Scandinavian Sarcoma Group; and FIRE-3 (recorded with CRYSTAL) was the AIO trial of cetuximab against bevacizumab with FOLFIRI in colorectal cancer. It has no products of its own.","asOf":"2026-09-25","links":[{"label":"AIO: Die AIO","url":"https://www.aio-portal.de/die-aio.html"},{"label":"AIO-Studien-gGmbH: Über uns","url":"https://www.aio-studien-ggmbh.de/ueber-uns.html"},{"label":"ClinicalTrials.gov: trials led by AIO-Studien-gGmbH","url":"https://clinicaltrials.gov/search?lead=AIO-Studien-gGmbH"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["cholangiocarcinoma","gallbladder","biliary-tract-cancer","gastric","esophageal","oesophageal-adenocarcinoma","colorectal","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["naliricc","nife","flot4","ssgxviii","crystal-fire3"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"Berlin","country":"DE","companyType":"cooperative-group","website":"https://www.aio-portal.de","founded":1976,"investors":[],"funding":[]},{"id":"akeso","kind":"company","name":"Akeso","aka":[],"tldr":"Chinese biotech whose ivonescimab beat Keytruda head-to-head, and developer of the Nectin-4×TROP2 ADC.","summary":"Akeso, based in Zhongshan and listed in Hong Kong as 9926.HK, is the Chinese biotechnology company whose ivonescimab beat pembrolizumab head to head in the HARMONi-2 trial, and the developer of the Nectin-4 by TROP2 bispecific ADC AK146D1. Its portfolio includes ivonescimab, a PD-1 by VEGF bispecific, cadonilimab, a PD-1 by CTLA-4 bispecific proved in COMPASSION-16 in cervical cancer, and penpulimab, with Michelle Xia, Caicun Zhou and Wenfeng Fang among the people linked. OnCo connects it to lung, cervical and nasopharyngeal cancer, to HARMONi-A, to the bispecific ADC technology and to the NMPA, and to bottlenecks on regulatory divergence and trials that do not represent the people who get cancer. Whether the HARMONi-2 result holds in global trials run by its partner Summit is the open question. Ivonescimab has its own page.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Akeso","links":[{"label":"Official website","url":"https://www.akesobio.com"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy","adcs"],"technologies":[],"targets":[],"drugs":["ivonescimab","ak146d1","ak117","ak119"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07010263","nct06767527","nct05489289","nct07412613","nct06928389","nct06617416","nct04974398","nct06371157","nct05840016","nct06686030","nct05932212","nct05846867","nct06646055","nct05904379","nct07052253","nct06943820","nct07245446","nct06560112","nct07623356","nct05382442","nct05247684","nct07669779","nct06530251","nct05235516","nct05229497","nct07114315","nct06953999","nct05142423","nct06951503","nct05227664","nct06938321","nct04980885","nct07023315","nct05951608","nct05689853","nct07591090","nct06591520","nct05859750"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Zhongshan","country":"CN","companyType":"biotech","website":"https://www.akesobio.com","ticker":"9926.HK","investors":[],"funding":[]},{"id":"akoya-biosciences","kind":"company","name":"Akoya Biosciences","aka":[],"tldr":"Spatial proteomics (PhenoCycler, PhenoImager) used to map immune cells in tumours; agreed to be acquired by Quanterix (2025).","summary":"Akoya Biosciences, based in Marlborough, Massachusetts, and listed as AKYA, makes spatial proteomics instruments, PhenoCycler and PhenoImager, used to map immune cells in tumours, and it agreed in 2025 to be acquired by Quanterix. Its multiplex immunofluorescence runs at scale, and clinical partnerships aim at spatial signatures that predict immunotherapy response. OnCo links it to spatial biology instruments. Whether a spatial immune signature can be validated as a companion diagnostic for immunotherapy, which is the promise behind the whole sector, is the open question. The spatial biology instruments page carries the wider field.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.akoyabio.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["spatial-biology-instruments"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Marlborough, MA","country":"US","companyType":"diagnostics","website":"https://www.akoyabio.com","ticker":"AKYA","investors":[],"funding":[]},{"id":"aktis-oncology","kind":"company","name":"Aktis Oncology","aka":[],"tldr":"Miniprotein alpha-radiopharmaceutical company; the first biotech IPO of 2026 (~$365M) funds Ac-225 programmes against Nectin-4 and B7-H3.","summary":"Aktis Oncology, based in Boston and listed as AKTS, is a miniprotein alpha-radiopharmaceutical company whose IPO, closed on 12 January 2026 for about 365 million dollars, was the first biotech IPO of the year and funds actinium-225 programmes against Nectin-4 and B7-H3. Its lead, 225Ac-AKY-1189 against Nectin-4, is in a US phase 1b; 225Ac-AKY-2519 against B7-H3 has an IND planned for the first half of 2026 after diagnostic imaging and dosimetry studies; an in-house cGMP radiopharmaceutical facility is due in the second half of 2026; and large pharma investors back it. OnCo links it to bladder, small-cell lung and prostate cancer, to targeted alpha therapy and alpha-emitter nanogenerators, and to Nectin-4 and B7-H3 as targets. Whether miniproteins can deliver alpha emitters safely is the open question. The targeted alpha therapy page carries the field.","asOf":"2026-09-04","links":[{"label":"IPO coverage","url":"https://www.fiercebiotech.com/biotech/1st-biotech-ipo-2026-sees-aktis-bring-318m-upsized-offering"}],"tags":["frontier"],"related":["src-fierce-biotech"],"cancers":["urothelial","sclc","prostate"],"sections":["radiopharma"],"technologies":["targeted-alpha-therapy"],"targets":["nectin4","b7h3"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boston, MA","country":"US","companyType":"radiopharma","website":"https://www.aktisoncology.com","ticker":"AKTS","investors":[],"funding":[]},{"id":"alaunos","kind":"company","name":"Alaunos Therapeutics (formerly Ziopharm Oncology)","aka":["Alaunos Therapeutics","Ziopharm Oncology","ZIOPHARM Oncology, Inc."],"tldr":"Alaunos, previously Ziopharm Oncology, developed non-viral TCR-T cell therapies against neoantigens in solid tumours with MD Anderson, after earlier phase 3 programmes with palifosfamide and darinaparsin; it wound down its clinical work in 2023.","summary":"Ziopharm Oncology, renamed Alaunos Therapeutics in 2022 and based in Houston, ran phase 3 trials of the alkylating agent palifosfamide in soft-tissue sarcoma and small-cell lung cancer in the early 2010s that failed, then moved into cell therapy: IL-12 gene therapy for glioblastoma with Intrexon and, with MD Anderson, a library of T-cell receptors against shared neoantigens in KRAS, TP53 and EGFR delivered by non-viral Sleeping Beauty transposition (TCR-T). The company halted its TCR-T trial and cut staff in 2023 to seek strategic alternatives. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.alaunos.com"},{"label":"ClinicalTrials.gov: trials led by Ziopharm Oncology","url":"https://clinicaltrials.gov/search?lead=Ziopharm%20Oncology"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Ziopharm_Oncology"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["sarcoma","sclc","glioblastoma"],"sections":["cell-therapy"],"technologies":["tcr-t"],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Houston, TX","country":"US","companyType":"cell-therapy","website":"https://www.alaunos.com","stage":"public","investors":[],"funding":[]},{"id":"aldevron","kind":"company","name":"Aldevron (Danaher)","aka":[],"tldr":"Leading GMP plasmid DNA and mRNA raw-material supplier, acquired by Danaher for $9.6B in 2021.","summary":"Aldevron, based in Fargo, North Dakota, and acquired by Danaher for 9.6 billion dollars in 2021, is the leading GMP supplier of plasmid DNA and mRNA raw materials. It makes plasmid DNA, mRNA and proteins including Cas9 for gene, cell and mRNA therapies, and it supplied the templates for COVID mRNA vaccines. OnCo links it to plasmid DNA and mRNA raw-material manufacturing, the starting point for viral vectors, CAR-T cells and mRNA cancer vaccines alike. Whether raw-material supply keeps pace as personalised mRNA vaccines and in vivo CAR-T move towards approval is the open question for a company at the bottom of the supply chain. The raw-material manufacturing page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.aldevron.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["cell-therapy","immunotherapy"],"technologies":["plasmid-dna-manufacturing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Fargo, ND","country":"US","companyType":"cro-services","website":"https://www.aldevron.com","investors":[],"funding":[]},{"id":"alentis-therapeutics","kind":"company","name":"Alentis Therapeutics","aka":[],"tldr":"Alentis Therapeutics targets Claudin-1, a protein exposed on squamous cancers and scarred organs, with antibodies that either carry a cancer-killing drug or block disease signalling. Its first cancer medicine entered human trials in 2025.","summary":"Alentis Therapeutics is a clinical-stage Basel biotech focused on Claudin-1 (CLDN1), a tight-junction protein that becomes exposed on tumour cells and in fibrotic tissue. Its oncology pipeline comprises ALE.P02, a CLDN1-directed antibody-drug conjugate with a tubulin inhibitor payload for advanced or metastatic CLDN1-positive squamous solid tumours (FDA IND clearance October 2024, Fast Track designation November 2024, phase 1/2 trial planned from Q1 2025), and ALE.P03, a CLDN1 ADC with a topoisomerase 1 inhibitor payload entering first-in-human studies in 2025. The monoclonal antibody lixudebart (ALE.F02) is in development for organ fibrosis, with topline results in ANCA-associated glomerulonephritis and advanced liver fibrosis reported in January 2025. In November 2024 Alentis raised an oversubscribed USD 181.4 million Series D led by OrbiMed with co-leads Novo Holdings and Jeito Capital. Mark Pruzanski was appointed CEO in October 2025.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://alentis.ch/"},{"label":"Series D press release","url":"https://alentis.ch/alentis-therapeutics-raises-181-4-million-in-an-oversubscribed-series-d-financing-to-advance-the-clinical-development-of-anti-claudin-1-adcs-in-solid-tumors/"},{"label":"News","url":"https://alentis.ch/news/"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":["adc","monoclonal-antibody"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07169734","nct06747585"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Earlier rounds (Series A to C) not fetched and omitted."],"hq":"Basel","country":"CH","companyType":"biotech","website":"https://alentis.ch/","stage":"growth","investors":["orbimed","novo-holdings","jeito-capital","frazier-life-sciences","ra-capital","bpifrance"],"funding":[{"round":"Series D","year":2024,"amountUsd":181400000,"source":"https://alentis.ch/alentis-therapeutics-raises-181-4-million-in-an-oversubscribed-series-d-financing-to-advance-the-clinical-development-of-anti-claudin-1-adcs-in-solid-tumors/"}]},{"id":"alethia-biotherapeutics","kind":"company","name":"Alethia Biotherapeutics","aka":["Alethia Biotherapeutics Inc."],"tldr":"Alethia Biotherapeutics is a Montreal biotech whose antibody sotevtamab (AB-16B5) blocks secreted clusterin, a protein that lets lung and other cancers change shape, spread and resist treatment.","summary":"Alethia Biotherapeutics develops sotevtamab (AB-16B5), a humanised antibody against secreted clusterin, a chaperone protein that promotes epithelial-to-mesenchymal transition. Blocking it is intended to keep tumour cells in an epithelial state that responds better to chemotherapy and immunotherapy. Sotevtamab is in a phase 2 trial with docetaxel in non-small cell lung cancer after platinum and checkpoint therapy, and has been studied in other solid tumours.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["sotevtamab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Montreal","country":"CA","companyType":"biotech","investors":[],"funding":[]},{"id":"alexandria-venture-investments","kind":"company","name":"Alexandria Venture Investments","aka":[],"tldr":"Alexandria Venture Investments is the venture arm of Alexandria Real Estate Equities, the life science property company, and takes small, non-lead stakes across a large number of biotech start-ups, often tenants of its campuses, in oncology and other areas. Its web pages blocked automated access, so its own strategy and named cancer companies are unconfirmed.","summary":"Alexandria Venture Investments is the strategic venture capital platform of Alexandria Real Estate Equities, Inc. (NYSE: ARE), the Pasadena-based life science real estate investment trust founded in January 1994 by Joel Marcus and Jerry Sudarsky (Wikipedia). The venture arm invests small, non-lead amounts across a large number of life science companies, many of them tenants of Alexandria campuses, spanning oncology and other therapeutic areas. The are.com venture pages returned an empty body or an Incapsula 'Request unsuccessful' block on every fetch attempt, so the platform's own description, founding year, strategy and named oncology portfolio companies could not be confirmed from a primary source.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.are.com/venture-investments"},{"label":"Wikipedia (Alexandria Real Estate Equities)","url":"https://en.wikipedia.org/wiki/Alexandria_Real_Estate_Equities"}],"tags":["corporate-venture"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Page fetched on 2026-09-10; founded year is the parent company's."],"hq":"Pasadena, CA","country":"US","companyType":"investor","website":"https://www.are.com/venture-investments","investors":[],"funding":[]},{"id":"alfa","kind":"company","name":"ALFA (Acute Leukemia French Association)","aka":["Acute Leukemia French Association","ALFA group","ALFA group (France)"],"tldr":"ALFA is the French adult acute myeloid leukaemia cooperative group, an association founded in 1998 of clinicians, biologists and research assistants across 33 centres; in OnCo it leads ALFA-0701, the trial that brought gemtuzumab ozogamicin back.","summary":"The Acute Leukemia French Association (ALFA) is an association under the French law of 1901 founded in 1998, composed of clinicians, biologists and clinical research assistants and devoted to the treatment of acute myeloid leukaemia in adults and to research in that field, with 33 centres in France (alfa-leukemia.org). Its website lists member centres but no registered office, so no seat is given here. ClinicalTrials.gov names it lead sponsor (OTHER class, with Versailles Hospital as collaborator) of ALFA-0701 (NCT00927498, phase 3, fractionated gemtuzumab ozogamicin added to daunorubicin and cytarabine in newly diagnosed AML aged 50 to 70), the trial recorded in OnCo. It has no products of its own.","asOf":"2026-09-25","links":[{"label":"Official website","url":"https://www.alfa-leukemia.org"},{"label":"ClinicalTrials.gov: trials led by Acute Leukemia French Association","url":"https://clinicaltrials.gov/search?lead=Acute%20Leukemia%20French%20Association"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["alfa-0701"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"France (seat not stated)","country":"FR","companyType":"cooperative-group","website":"https://www.alfa-leukemia.org","founded":1998,"investors":[],"funding":[]},{"id":"algen-biotechnologies","kind":"company","name":"Algen Biotechnologies","aka":[],"tldr":"Algen uses CRISPR screens read out at the single-cell level, plus machine learning, to find which RNA messages drive cancer and inflammation, and then designs drugs against them.","summary":"Algen Biotechnologies pairs pooled CRISPR perturbation screens with single-cell RNA readouts and machine learning to identify disease-driving RNA programmes, then pursues first-in-class small molecules and RNA-targeting therapeutics against them for cancer and inflammatory disease. It was founded by a bioengineer from Jennifer Doudna's laboratory with a commercialisation partner. Programmes are discovery stage; no clinical candidates or sourced financing rounds are recorded here.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/algen-biotechnologies"},{"label":"Official website","url":"https://www.algenbio.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":["crispr-screens","ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.algenbio.com","stage":"startup","ycBatch":"W20","investors":["y-combinator"],"funding":[]},{"id":"alixia","kind":"company","name":"Alixia","aka":[],"tldr":"Alixia is developing drugs that act on the supporting cells and inflammation around a tumour as well as the cancer cells, to stop cancers from becoming resistant.","summary":"Alixia develops small molecules that disrupt metabolic and inflammatory signalling shared by cancer cells and the quasi-cancerous stromal and immune cells in the tumour microenvironment, on the thesis that hitting several cell types at once produces more durable responses and fewer resistance escape routes. The company is tagged oncology in the YC directory and remains active with a very small team; programmes are preclinical and no sourced financing rounds are recorded.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/alixia"},{"label":"Official website","url":"https://www.alixia.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.alixia.com","stage":"startup","ycBatch":"W22","investors":["y-combinator"],"funding":[]},{"id":"alliance-oncology","kind":"company","name":"Alliance for Clinical Trials in Oncology","aka":["Alliance","Cancer and Leukemia Group B","CALGB","Alliance Foundation Trials","ACOSOG","NCCTG"],"tldr":"US cooperative group formed from CALGB, ACOSOG, and NCCTG; running OptimICE-pCR, which asks whether TNBC patients with a complete response still need a year of immunotherapy.","summary":"The Alliance for Clinical Trials in Oncology, based in Chicago, is the US cooperative group formed in 2011 from CALGB, ACOSOG and NCCTG, and a member of the NCI National Clinical Trials Network. Its trials include CALGB 40603, which tested carboplatin in triple-negative breast cancer, Z0011, which showed sentinel node biopsy could replace axillary dissection in selected patients, and A012103, the OptimICE-pCR trial asking whether TNBC patients with a pathologic complete response still need a year of pembrolizumab; ATOMIC and CABINET are also in OnCo, with Alan P. Venook and Evanthia Galanis among the people linked. OnCo connects it to bottlenecks on slow enrolment and the exclusion of older patients, and to ideas for a permanent surgical trials network. Whether de-escalation trials can recruit when the default is more treatment is its standing question. Its programmes are listed in the notes.","asOf":"2026-09-06","wikipedia":"https://en.wikipedia.org/wiki/Alliance_for_Clinical_Trials_in_Oncology","links":[{"label":"Official website","url":"https://www.allianceforclinicaltrialsinoncology.org"}],"tags":["cooperative-group"],"related":["pembrolizumab","carboplatin"],"cancers":["tnbc"],"sections":[],"technologies":["sentinel-node"],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":["optimice-pcr","alliance-n0574"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["NCTN cooperative group","OptimICE-pCR","Breast surgical de-escalation (Z0011)"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Chicago, IL","country":"US","companyType":"cooperative-group","website":"https://www.allianceforclinicaltrialsinoncology.org","founded":2011,"investors":[],"funding":[]},{"id":"alligator-bioscience","kind":"company","name":"Alligator Bioscience","aka":["Alligator Bioscience AB","STO:ATORX"],"tldr":"Alligator Bioscience is a Swedish biotech that makes antibodies to switch on the immune system inside tumours; its CD40 agonist mitazalimab improved survival with chemotherapy in a pancreatic cancer trial.","summary":"Alligator Bioscience, based in Lund, develops tumour-directed immunotherapies from its FIND antibody library and RUBY bispecific format. Mitazalimab (ADC-1013), a CD40 agonist that primes dendritic cells and T cells, was tested with modified FOLFIRINOX in the phase 2 OPTIMIZE-1 trial in first-line metastatic pancreatic cancer, where it produced a higher response rate and longer survival than historical chemotherapy alone, and is being prepared for phase 3. ATOR-4066 is a Neo-X-Prime bispecific against CD40 and CEACAM5.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.alligatorbioscience.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["mitazalimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Lund","country":"SE","companyType":"biotech","website":"https://www.alligatorbioscience.com/","ticker":"STO:ATORX","founded":2001,"stage":"public","investors":[],"funding":[]},{"id":"allogene","kind":"company","name":"Allogene Therapeutics","aka":[],"tldr":"Allogeneic CAR-T leader: cema-cel (CD19) as MRD-guided first-line consolidation in lymphoma, and ALLO-316 (CD70) with responses in kidney cancer.","summary":"Allogene Therapeutics, based in South San Francisco and listed as ALLO, is the allogeneic CAR-T leader, with cema-cel, a CD19 CAR-T, positioned as MRD-guided first-line consolidation in lymphoma and ALLO-316, a CD70 CAR-T, showing responses in kidney cancer. Cema-cel received RMAT and Fast Track designations in July 2026 for MRD-positive large B-cell lymphoma after first-line therapy in the ALPHA3 trial, ALLO-316 gave a 31 percent confirmed response rate in CD70-high clear-cell renal cell carcinoma in the TRAVERSE trial in 2025. OnCo links it to diffuse large B-cell lymphoma and renal cell carcinoma, to allogeneic cell therapy, to CD19 and CD70 as targets and to the UCART19 paper. Whether treating MRD-positive patients before relapse improves outcomes is the question ALPHA3 will answer. Manufacturing cost and time is the bottleneck off-the-shelf cells are meant to relieve.","asOf":"2026-09-04","links":[{"label":"Cema-cel RMAT","url":"https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-receives-fda-regenerative-medicine-0"}],"tags":[],"related":[],"cancers":["dlbcl","rcc"],"sections":["cell-therapy"],"technologies":["allogeneic-cell-therapy","car-t"],"targets":["cd19","cd70"],"drugs":["allo-647"],"companies":[],"institutions":[],"pathways":[],"terms":["mrd"],"trials":["nct04416984","nct06500273"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"South San Francisco, CA","country":"US","companyType":"cell-therapy","website":"https://allogene.com","ticker":"ALLO","investors":[],"funding":[]},{"id":"allotera-therapeutics","kind":"company","name":"Allotera Therapeutics (formerly Wugen)","aka":[],"tldr":"Allotera, formerly Wugen, makes off-the-shelf CAR T-cell therapies from healthy donor cells for T-cell leukaemias and lymphomas, which are hard to treat with conventional CAR T because the cancer cells look like the therapy cells. Its lead product is in a global pivotal trial.","summary":"Allotera Therapeutics (renamed from Wugen in July 2026) is a St. Louis clinical-stage company developing allogeneic, off-the-shelf cell therapies for haematological malignancies. Lead candidate soficabtagene geleucel (sofi-cel, formerly WU-CART-007) is an anti-CD7 allogeneic CAR T-cell therapy in the global pivotal T-RRex trial for relapsed or refractory T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma, with further work in T-cell non-Hodgkin lymphoma, acute myeloid leukaemia and autoimmune indications. The programme was selected for the FDA's CMC Development and Readiness Pilot. In July 2026 the company closed a $35 million financing of equity and venture debt, bringing its Series C to $150 million and total capital raised to $150 million on top of the $115 million Series C announced in late 2025, to fund T-RRex, manufacturing scale-up and team growth.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://alloteratx.com/"},{"label":"$35 million financing and rename (July 2026)","url":"https://alloteratx.com/allotera-therapeutics-formerly-wugen-closes-35-million-financing-to-advance-off-the-shelf-car-t-therapies-for-t-cell-cancers/"}],"tags":[],"related":[],"cancers":["all-leukemia","aml"],"sections":["cell-therapy"],"technologies":["allogeneic-cell-therapy","car-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06514794"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["wugen.com redirects to alloteratx.com. Investor names not given in the fetched release. Earlier Wugen rounds (for example the 2021 Series B) not sourced."],"hq":"St. Louis, MO","country":"US","companyType":"cell-therapy","website":"https://alloteratx.com/","stage":"growth","investors":[],"funding":[{"round":"Series C","year":2025,"amountUsd":115000000,"source":"https://alloteratx.com/allotera-therapeutics-formerly-wugen-closes-35-million-financing-to-advance-off-the-shelf-car-t-therapies-for-t-cell-cancers/","note":"Series C announced in late 2025 as stated in the July 2026 release"},{"round":"Series C","year":2026,"amountUsd":35000000,"source":"https://alloteratx.com/allotera-therapeutics-formerly-wugen-closes-35-million-financing-to-advance-off-the-shelf-car-t-therapies-for-t-cell-cancers/","note":"Additional equity and venture debt closed 8 July 2026, bringing the Series C total to $150 million"}]},{"id":"almirall","kind":"company","name":"Almirall","aka":["Almirall, S.A."],"tldr":"Almirall is a Barcelona dermatology company whose cancer-related product is tirbanibulin ointment for actinic keratosis, approved in the United States in 2020 and in Europe in 2021.","summary":"Almirall, listed on the Spanish stock exchange, is a pharmaceutical company focused on medical dermatology. Its contribution to cancer prevention is tirbanibulin (Klisyri), a topical microtubule inhibitor for actinic keratosis of the face and scalp, the precancerous lesion that can progress to squamous cell skin cancer, approved by the FDA in December 2020 and the European Commission in 2021. OnCo records it so that its phase 3 trials resolve to a sponsor page.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Almirall","links":[{"label":"Official website","url":"https://www.almirall.com"},{"label":"ClinicalTrials.gov: trials led by Almirall","url":"https://clinicaltrials.gov/search?lead=Almirall"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Almirall"}],"tags":["ctgov-sponsor"],"related":["galderma","leo-pharma"],"cancers":["cutaneous-scc"],"sections":["prevention"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Barcelona","country":"ES","companyType":"pharma","website":"https://www.almirall.com","stage":"public","investors":[],"funding":[]},{"id":"alpha-tau-medical","kind":"company","name":"Alpha Tau Medical","aka":[],"tldr":"Alpha Tau Medical places tiny radioactive seeds directly inside tumours so that short-range alpha radiation destroys the cancer from within. It is testing the approach in pancreatic, skin, head and neck, brain and prostate cancers.","summary":"Alpha Tau Medical Ltd. (Nasdaq: DRTS), based in Jerusalem, is a clinical-stage oncology company developing Alpha DaRT, an intratumoural alpha-emitting radiotherapy delivered via implantable sources for superficial and deep-seated solid tumours. Trials are conducted under five FDA Investigational Device Exemptions in the US and at sites in Canada, Israel, Italy and France, spanning pancreatic cancer (the multicentre IMPACT pilot study completed enrolment in August 2026 after several expansions), cutaneous squamous cell carcinoma, head and neck cancer (July 2026 data with pembrolizumab reported a 100 percent objective response rate and 18.2 month median overall survival), recurrent glioblastoma (REGAIN trial, with FDA clearance in June 2026 to complete enrolment), prostate and lung cancer. A June 2026 collaboration with Tolmar covers US urological cancers, and the company registered for a dual listing on the Tel Aviv Stock Exchange in August 2026.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://alphatau.com/"},{"label":"Clinical pipeline","url":"https://alphatau.com/clinical-pipeline/"},{"label":"Newsroom","url":"https://alphatau.com/newsroom/"}],"tags":[],"related":[],"cancers":["pancreatic","head-and-neck","glioblastoma","prostate"],"sections":["radiation","radiopharma"],"technologies":["brachytherapy","targeted-alpha-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Ticker, exchange and Jerusalem HQ confirmed via SEC EDGAR submissions data (CIK 0001871321). Alpha DaRT is a device-based intratumoural radiation source rather than a systemic radioligand, hence companyType devices. Public company; no private rounds listed."],"hq":"Jerusalem","country":"IL","companyType":"devices","website":"https://alphatau.com/","ticker":"DRTS","stage":"public","investors":[],"funding":[]},{"id":"alpha-9-oncology","kind":"company","name":"Alpha-9 Oncology","aka":[],"tldr":"Alpha-9 Oncology designs bespoke molecules that deliver radioactive isotopes to cancer cells, with early human trials under way in melanoma and in breast and other solid tumours.","summary":"Alpha-9 Oncology is a clinical-stage radiopharmaceutical company with offices in Vancouver and Boston. It takes a modular approach, optimising each element of a radiotherapeutic (binder, linker, chelator and isotope) and pairing therapeutic agents with imaging companions. A9-3408, an actinium-225 radiotherapeutic targeting melanocortin 1 receptor (MC1R), began a phase 1 study in melanoma in December 2025, following the 68Ga imaging agent A9-3202 that entered the clinic in 2024. In September 2026 the company dosed the first patient in a phase 1 study of two GRPR-targeting compounds, 225Ac-A9-0642 and 177Lu-A9-0631, in breast cancer and other solid tumours, with data expected in late 2027. Alpha-9 has an actinium-225 supply agreement with ITM (April 2025). In October 2024 it closed an oversubscribed USD 175 million Series C led by Lightspeed Venture Partners and Ascenta Capital. Paul Blanchfield was appointed CEO in November 2025.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.a9oncology.com/"},{"label":"Series C press release","url":"https://www.a9oncology.com/alpha-9-oncology-inc-announces-175-million-oversubscribed-series-c-financing-to-advance-robust-clinical-pipeline-of-radiopharmaceuticals/"},{"label":"GRPR phase 1 first patient dosed","url":"https://www.a9oncology.com/alpha-9-oncology-doses-first-patient-in-phase-1-clinical-trial-evaluating-grpr-targeted-radiotherapeutics-across-multiple-solid-tumors/"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":["radiopharma"],"technologies":["radioligand-therapy","targeted-alpha-therapy","pet"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The older domain alpha9oncology.com is now parked; current site is a9oncology.com. Earlier rounds not fetched."],"hq":"Vancouver","country":"CA","companyType":"radiopharma","website":"https://www.a9oncology.com/","stage":"growth","investors":["lightspeed-venture-partners","general-catalyst","a16z-bio-health","ra-capital","frazier-life-sciences","samsara-biocapital"],"funding":[{"round":"Series C","year":2024,"amountUsd":175000000,"source":"https://www.a9oncology.com/alpha-9-oncology-inc-announces-175-million-oversubscribed-series-c-financing-to-advance-robust-clinical-pipeline-of-radiopharmaceuticals/"}]},{"id":"alphamab","kind":"company","name":"Alphamab Oncology","aka":["康宁杰瑞","Jiangsu Alphamab Biopharmaceuticals","Alphamab Oncology"],"tldr":"Alphamab developed envafolimab, the first subcutaneous PD-L1 antibody approved anywhere, and the HER2 bispecific ADC JSKN003.","summary":"Alphamab Oncology, based in Suzhou, founded in 2008 and listed in Hong Kong as 9966.HK, developed envafolimab, the first subcutaneous PD-L1 antibody approved anywhere, and the HER2 bispecific ADC JSKN003. Envafolimab, sold as Enweida, was approved in 2021; KN026, a HER2 biparatopic bispecific, is in phase 3 in gastric and breast cancer; and JSKN003 and JSKN033, a subcutaneous PD-L1 plus HER2 ADC combination, are in trials, all built on its single-domain antibody platform. OnCo links it to HER2 and PD-L1 as targets and to the envafolimab record. Whether subcutaneous dosing wins meaningful share in a class dominated by intravenous antibodies is the open question. Envafolimab has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.alphamabonc.com/en/"}],"tags":["china"],"related":[],"cancers":[],"sections":["immunotherapy","adcs"],"technologies":[],"targets":["her2","pdl1"],"drugs":["envafolimab","jskn003","jskn016"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06942234","nct05744427"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Suzhou","country":"CN","companyType":"biotech","website":"https://www.alphamabonc.com/en/","ticker":"9966.HK","founded":2008,"investors":[],"funding":[]},{"id":"altay-therapeutics","kind":"company","name":"Altay Therapeutics","aka":[],"tldr":"Altay Therapeutics is developing small-molecule drugs for chronic liver disease, including the scarring that leads to liver cancer and liver cancer itself.","summary":"Altay Therapeutics develops oral small molecules against transcription-factor-driven pathways in liver fibrosis and hepatocellular carcinoma. Its YC profile reports preclinical mouse data showing reduction and partial reversal of fibrosis, and a plan to reach phase 1. The co-founder led early development of pirfenidone, the first approved drug for lung fibrosis. Oncology is one of two stated indications; programmes are preclinical as far as public sources show. Included because liver cancer is an explicit target.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/altay-therapeutics"},{"label":"Official website","url":"https://www.altaytherapeutics.com"}],"tags":["yc"],"related":[],"cancers":["hcc"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.altaytherapeutics.com","stage":"startup","ycBatch":"W20","investors":["y-combinator"],"funding":[]},{"id":"aluna","kind":"company","name":"Aluna","aka":[],"tldr":"Aluna works with hospitals to build carefully curated cancer datasets and evaluation sets so that medical AI models can be trained and tested properly.","summary":"Aluna describes itself as a data foundry for life-science AI: it partners with health organisations to build curated, de-identified datasets and evaluation benchmarks, currently focused on oncology, for developers of health AI models. The value proposition is high-quality labelled clinical and molecular data rather than a model of its own. The company is early stage with a very small team; no sourced financing rounds are recorded.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/aluna"},{"label":"Official website","url":"https://alunadata.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"ai-software","website":"https://alunadata.com","stage":"startup","ycBatch":"S24","investors":["y-combinator"],"funding":[]},{"id":"alx-oncology","kind":"company","name":"ALX Oncology","aka":["ALX Oncology Holdings"],"tldr":"ALX Oncology is a Californian biotechnology company developing evorpacept, a CD47-blocking fusion protein designed to remove the 'do not eat me' signal so that antibodies such as trastuzumab can recruit macrophages against HER2-positive gastric cancer.","summary":"ALX Oncology, based in South San Francisco, develops evorpacept (ALX148), an engineered SIRP-alpha fusion protein that blocks CD47 without the red-cell toxicity of earlier CD47 antibodies, so it can be combined with tumour-targeting antibodies to enhance macrophage attack. Its lead trial ASPEN-06 tests evorpacept with trastuzumab, ramucirumab and paclitaxel in previously treated HER2-positive gastric cancer, and the company is studying the drug in other antibody combinations. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://alxoncology.com/"},{"label":"ClinicalTrials.gov: trials led by ALX Oncology","url":"https://clinicaltrials.gov/search?lead=ALX%20Oncology"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["gastric"],"sections":["immunotherapy"],"technologies":[],"targets":["cd47"],"drugs":["evorpacept"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["aspen-06","nct04675294","nct04675333","nct07007559"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://alxoncology.com/","stage":"public","investors":[],"funding":[]},{"id":"ambagon-therapeutics","kind":"company","name":"Ambagon Therapeutics","aka":[],"tldr":"Ambagon Therapeutics designs small molecules that act like glue, locking a hub protein called 14-3-3 onto its partner proteins to switch them on or off. It is an early-stage company with cancer and brain disease programmes.","summary":"Ambagon Therapeutics calls itself the 14-3-3 molecular glue company: it develops small-molecule stabilisers of 14-3-3:client protein complexes to modulate intrinsically disordered proteins and transcription factors, using a 14-3-3 structural 'encyclopedia', a dedicated compound library and high-throughput X-ray crystallography. The pipeline lists a neurodegeneration kinase programme in lead optimisation, an oncology programme against a transcription factor and structural protein at hit exploration, and metabolic and neurology programmes; in April 2026 Symeres announced a collaboration with Ambagon on molecular glues in colorectal cancer. All programmes are preclinical. Incorporated in 2020 with a San Francisco address, its SEC Form D filings record about 7.2 million US dollars sold in 2020, 45 million in 2022 and 5 million in 2025, the last listing Eindhoven, Netherlands, the only location on its contact page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.ambagontx.com/"},{"label":"Platform and pipeline","url":"https://www.ambagontx.com/platform-pipeline/"},{"label":"Form D (June 2022 amendment)","url":"https://www.sec.gov/Archives/edgar/data/1819934/000181993422000003/primary_doc.xml"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":["targeted-therapy","drug-discovery"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The hint said South San Francisco; earlier Form D filings list San Francisco, but the website contact page lists only Eindhoven, so HQ is recorded as Eindhoven, NL. Series names and investors not disclosed in fetched sources. The 2022 offering is widely reported as a Series A but that label was not verified. The domain ambagon.com is a parked domain; the company site is ambagontx.com."],"hq":"Eindhoven","country":"NL","companyType":"biotech","website":"https://www.ambagontx.com/","founded":2020,"stage":"startup","investors":[],"funding":[{"round":"Form D offering","year":2020,"amountUsd":7199998,"source":"https://www.sec.gov/Archives/edgar/data/1819934/000181993420000001/primary_doc.xml","note":"Total sold per Form D filed August 2020"},{"round":"Form D offering","year":2022,"amountUsd":44999996,"source":"https://www.sec.gov/Archives/edgar/data/1819934/000181993422000003/primary_doc.xml","note":"Total sold of an 85 million US dollar offering per amended Form D filed June 2022"},{"round":"Form D offering","year":2025,"amountUsd":5000000,"source":"https://www.sec.gov/Archives/edgar/data/1819934/000181993425000001/primary_doc.xml","note":"Total sold of a 12 million US dollar offering per Form D filed February 2025; issuer address given as Eindhoven"}]},{"id":"ambrx","kind":"company","name":"Ambrx","aka":["Ambrx, Inc.","Ambrx Inc","Ambrx Biopharma"],"tldr":"Ambrx is a La Jolla, California biotechnology company founded in 2003 whose HER2 antibody-drug conjugate ARX788 is in OnCo's phase 3 ACE-Breast-02 trial (with Zhejiang Medicine, in China) and the global phase 2 ACE-Breast-03 trial after trastuzumab deruxtecan.","summary":"Ambrx is an organisation based in La Jolla, United States, founded in 2003 (Wikidata Q100955904, which also gives its website). ClinicalTrials.gov classes it as an industry sponsor. In OnCo it sponsors ACE-Breast-02 (phase 3, with Zhejiang Medicine: ARX788 against lapatinib plus capecitabine in HER2-positive advanced breast cancer after trastuzumab and a taxane, recorded as positive) and NCT04829604 (ACE-Breast-03, phase 2, ARX788 in HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan). ARX788 is its own compound, the basis for the biotech type.","asOf":"2026-09-22","links":[{"label":"Official website","url":"http://ambrx.com/"},{"label":"Wikidata Q100955904","url":"https://www.wikidata.org/wiki/Q100955904"},{"label":"ClinicalTrials.gov: trials led by Ambrx, Inc.","url":"https://clinicaltrials.gov/search?lead=Ambrx%2C%20Inc."}],"tags":["ctgov-sponsor","wave5-sponsor"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":["adc"],"targets":["her2"],"drugs":["arx788"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["ace-breast-02","nct04829604"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo content wave 5 (Wikidata, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-22"},"hq":"La Jolla, California","country":"US","companyType":"biotech","website":"http://ambrx.com/","founded":2003,"investors":[],"funding":[]},{"id":"amgen","kind":"company","name":"Amgen","aka":["BioVex Limited","BioVex"],"tldr":"Amgen invented the BiTE T-cell engager format and the first KRAS inhibitor.","summary":"Amgen, based in Thousand Oaks, California, and listed as AMGN, invented the BiTE T-cell engager format and made the first KRAS inhibitor. Its oncology portfolio includes blinatumomab, tarlatamab, the first solid-tumour T-cell engager to show an overall survival benefit, sotorasib, bemarituzumab against FGFR2b, xaluritamig, a STEAP1 by CD3 engager, the oncolytic virus Imlygic, and supportive care products including denosumab and darbepoetin alfa. OnCo links it to the AALL1731 and E1910 blinatumomab papers, to CodeBreaK 200 and CodeBreaK 300 for sotorasib, to DeLLphi-301 for tarlatamab, to PRMT5 in MTAP-deleted cancers, to the KIF18A idea, and to the bottleneck of wrong doses. Whether T-cell engagers can work in common solid tumours beyond small-cell lung cancer is the open question. Each product has its own page.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Amgen","links":[{"label":"Official website","url":"https://www.amgen.com"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy","targeted-therapy"],"technologies":[],"targets":[],"drugs":["blinatumomab","tarlatamab","sotorasib","talimogene-laherparepvec","anvumetostat","cinacalcet"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05920356","nct06054555","nct06430866","nct07005128","nct06311721","nct07213674","nct06252649","nct06117774","nct07778316","nct06502977","nct05060016","nct06745323","nct04521231","nct05094336","nct06593522","nct07134088","nct03937154","nct07172919"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Thousand Oaks, CA","country":"US","companyType":"pharma","website":"https://www.amgen.com","ticker":"AMGN","investors":[],"funding":[]},{"id":"amgen-ventures","kind":"company","name":"Amgen Ventures","aka":[],"tldr":"Amgen Ventures is the venture arm of the biotech company Amgen. It takes minority stakes in early companies whose science could matter to Amgen, including cancer drug and platform start-ups.","summary":"Amgen Ventures is Amgen's corporate venture group, formed in 2004 to invest in emerging biotechnology companies developing therapeutics, platforms and technologies aligned with Amgen's therapeutic areas, oncology among them. Like most pharma venture arms it invests alongside institutional venture firms rather than leading rounds alone, and its stakes are as much about scientific visibility and future partnering as about returns. It is listed on the parent company's collaborations pages; portfolio links in OnCo are derived from startup records that name it, such as Kernal Biologics.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.amgen.com/"}],"tags":["corporate-venture"],"related":[],"cancers":[],"sections":["immunotherapy","targeted-therapy"],"technologies":[],"targets":[],"drugs":[],"companies":["amgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Thousand Oaks, CA","country":"US","companyType":"investor","website":"https://www.amgen.com/","founded":2004,"investors":[],"funding":[]},{"id":"amneal","kind":"company","name":"Amneal Pharmaceuticals","aka":[],"tldr":"Amneal is a US generic and speciality drug maker with a growing sterile injectables business, one of the companies that stepped in as platinum chemotherapy ran short in 2023.","summary":"Amneal Pharmaceuticals, based in Bridgewater, New Jersey, makes oral and injectable generics at plants in the United States and India and has invested in sterile injectable capacity for hospital drugs, including oncology generics. It is one of the manufacturers the FDA worked with to expand supply during the 2023 cisplatin and carboplatin shortage.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Amneal_Pharmaceuticals","links":[{"label":"Official website","url":"https://www.amneal.com"}],"tags":["manufacturing-wave"],"related":[],"cancers":[],"sections":[],"technologies":["sterile-injectable-generics-manufacturing","oral-solid-dose-manufacturing","generic-drug-shortage-response"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Bridgewater, New Jersey","country":"US","companyType":"pharma","website":"https://www.amneal.com","ticker":"AMRX","founded":2002,"stage":"public","investors":[],"funding":[]},{"id":"amphista-therapeutics","kind":"company","name":"Amphista Therapeutics","aka":[],"tldr":"Amphista Therapeutics, based near Cambridge in the UK, designs small molecules that make cancer cells destroy specific proteins using a less common disposal enzyme called DCAF16. Its first drug, for acute myeloid leukaemia, was cleared to start human trials in 2026.","summary":"Amphista Therapeutics is a Cambridge, UK targeted protein degradation company whose Targeted Glue degraders deploy E3 ligases beyond cereblon, such as DCAF16, chosen for each target. Its lead programme, AMX-883, is an orally bioavailable, selective DCAF16-mediated BRD9 degrader for acute myeloid leukaemia that releases the differentiation block in a broad AML population, shows in vivo efficacy alone and synergy with venetoclax, and received FDA clearance of its IND application in June 2026 as the first BRD9-targeted therapy for AML. An oral SMARCA2 Targeted Glue degrader targets SMARCA4-deficient tumours including non-small cell lung cancer through synthetic lethality, and a pan-TEAD degrader targets Hippo pathway-driven cancers such as mesothelioma and NSCLC; both are preclinical, with data presented at AACR 2026. The company is registered in England and Wales (number 11119959) with its head office at Granta Park, Great Abington, Cambridge.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://amphista.com/"},{"label":"Pipeline","url":"https://amphista.com/pipeline/"},{"label":"AMX-883 IND clearance (June 2026)","url":"https://amphista.com/amphista-therapeutics-announces-fda-clearance-of-ind-application-for-amx-883-its-lead-targeted-glue-degrader-for-acute-myeloid-leukaemia/"}],"tags":[],"related":[],"cancers":["aml","nsclc","mesothelioma"],"sections":["targeted-therapy","epigenetics"],"technologies":["protac-degrader","epigenetic-drugs","synthetic-lethality-approaches"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No financing press release is on the company's current news page (which lists 2026 items only), so funding and investors are empty; the reported 2021 Series B and Merck and Bristol Myers Squibb collaborations were not verified. Founding year not sourced."],"hq":"Cambridge","country":"GB","companyType":"biotech","website":"https://amphista.com/","stage":"startup","investors":["novartis-venture-fund"],"funding":[]},{"id":"amplia-therapeutics","kind":"company","name":"Amplia Therapeutics","aka":["Amplia Therapeutics Limited"],"tldr":"Amplia Therapeutics is an Australia-based biotechnology company that leads 2 cancer trials in OnCo, testing the focal adhesion kinase inhibitor narmafotinib (AMP945) in pancreatic ductal adenocarcinoma.","summary":"Amplia Therapeutics is a clinical-stage drug development company listed on the ASX that is advancing focal adhesion kinase (FAK) inhibitors for cancer and fibrosis. Its lead candidate narmafotinib (AMP945) is being studied in pancreatic cancer. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT07026279 (phase 1/2, A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With...) and NCT05355298 (phase 1/2, ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Panc...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.ampliatx.com/"},{"label":"ClinicalTrials.gov: trials led by Amplia Therapeutics","url":"https://clinicaltrials.gov/search?lead=Amplia%20Therapeutics%20Limited"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07026279","nct05355298"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Melbourne","country":"AU","companyType":"biotech","website":"https://www.ampliatx.com/","ticker":"ASX:ATX","stage":"public","investors":[],"funding":[]},{"id":"amunix-pharmaceuticals","kind":"company","name":"Amunix Pharmaceuticals","aka":[],"tldr":"Amunix developed T-cell engager and cytokine cancer drugs with a protective mask that is clipped off by enzymes found in tumours, so the drugs become active mainly at the cancer. Sanofi agreed to buy the company in December 2021 for about $1 billion upfront.","summary":"Amunix Pharmaceuticals was an immuno-oncology company built on its clinically validated XTEN polypeptide technology and the Pro-XTEN universal protease-releasable masking platform, used to create conditionally activated T-cell engagers (XPAT) and cytokines (XPAC). Its lead candidate AMX-818 was a masked HER2-directed T-cell engager expected to enter the clinic in early 2022. On 21 December 2021 Sanofi announced an agreement to acquire Amunix for an upfront payment of approximately $1 billion plus up to $225 million on achievement of development milestones, citing a strategic fit with its immuno-oncology portfolio. Sanofi's fourth-quarter 2021 results reiterated the agreement. The Amunix website no longer resolves.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.sec.gov/Archives/edgar/data/1121404/000119312521363409/d237650dex992.htm"},{"label":"Sanofi Q4 2021 results referencing the agreement (6-K)","url":"https://www.sec.gov/Archives/edgar/data/1121404/000112140422000002/pressreleaseq42021english.htm"},{"label":"SEC EDGAR filings","url":"https://www.sec.gov/Archives/edgar/data/1121404/000119312521363409/d237650dex992.htm"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["t-cell-engager","cytokine-therapy","bispecific-antibody"],"targets":["her2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["amunix.com is offline, so the Sanofi 6-K press release is given as the website. Deal completion (early 2022) not separately sourced. HQ taken from the user's hint and consistent with the company's known location, but not stated in the fetched release; the release dateline is Paris."],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2021,"amountUsd":1000000000,"source":"https://www.sec.gov/Archives/edgar/data/1121404/000119312521363409/d237650dex992.htm","note":"Upfront payment of approximately $1 billion plus up to $225 million in development milestones; agreement announced 21 December 2021"}],"acquiredBy":"sanofi"},{"id":"ananya-health","kind":"company","name":"Ananya Health","aka":[],"tldr":"Ananya Health makes a portable freezing device that lets a nurse in any clinic treat abnormal cervical cells before they turn into cancer, at a tenth of the usual cost.","summary":"Ananya Health is developing a portable, low-cost cryoablation device for treating precancerous cervical lesions at the point of care, designed so that nurses and mid-level health workers can treat immediately after a positive screen. The company points out that although cervical cancer is easy to screen for, most clinics worldwide lack the equipment and specialists to treat early lesions, which blocks the WHO elimination target. The device is in development and early field evaluation; regulatory clearance is not recorded in a primary source found at the time of checking.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/ananya-health"},{"label":"Official website","url":"https://www.ananya.health"}],"tags":["yc"],"related":[],"cancers":["cervical"],"sections":["prevention","devices"],"technologies":["thermal-ablation","hpv-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"devices","website":"https://www.ananya.health","stage":"startup","ycBatch":"S21","investors":["y-combinator"],"funding":[]},{"id":"anbogen-therapeutics","kind":"company","name":"Anbogen Therapeutics","aka":["安邦生技"],"tldr":"Anbogen Therapeutics is a Taiwan-based biotechnology company that leads 2 cancer trials in OnCo, testing ABT-101 and ABT-301 in colorectal cancer and non-small-cell lung cancer.","summary":"Anbogen Therapeutics is a precision oncology company in Taipei developing targeted cancer therapies. Its candidates include ABT-101, licensed from Taiwan's National Health Research Institutes, and ABT-301, licensed from Taipei Medical University. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT07244705 (phase 1/2, A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advance...) and NCT05532696 (phase 1/2, Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://anbogen.com/"},{"label":"ClinicalTrials.gov: trials led by Anbogen Therapeutics","url":"https://clinicaltrials.gov/search?lead=Anbogen%20Therapeutics%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["colorectal","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["abt-301","tislelizumab","bevacizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07244705","nct05532696"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Taipei","country":"TW","companyType":"biotech","website":"https://anbogen.com/","founded":2019,"stage":"growth","investors":[],"funding":[]},{"id":"andera-partners","kind":"company","name":"Andera Partners","aka":[],"tldr":"A Paris private equity firm whose life sciences team, through its BioDiscovery funds, invests in European and US drug and medtech companies. Its life sciences portfolio includes the cancer T-cell therapy company T-Knife.","summary":"Andera Partners describes itself as 'an asset management firm specialising in Private Equity' with '6 billion under management' and '377 companies supported in over 20 years'. Its andera Life Sciences team invests from preclinical through commercial stages in Europe and the US from offices in Paris and Munich, putting EUR 15 million to 60 million per company; the BioDiscovery fund series has run since 2004 with BioDiscovery 7 currently raising. The life sciences page names ReViral, Inotrem, T-Knife, Corvidia, Axonics and Poxel. Of these, T-Knife develops next-generation T-cell receptor therapies for cancer (its Series A is also listed in Versant Ventures' news). The others are antiviral, sepsis, cardiovascular, neuromodulation and metabolic companies.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.anderapartners.com/en/"},{"label":"Life sciences","url":"https://www.anderapartners.com/en/expertise/life-sciences-biotechnologies/"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year of the firm not stated on fetched pages (it says 'over 20 years'); omitted. Only one oncology company could be confirmed."],"hq":"Paris","country":"FR","companyType":"investor","website":"https://www.anderapartners.com/en/","investors":[],"funding":[]},{"id":"a16z-bio-health","kind":"company","name":"Andreessen Horowitz Bio + Health","aka":[],"tldr":"The life sciences and healthcare arm of the Silicon Valley venture firm Andreessen Horowitz (a16z). It backs founders who mix biology, software and care delivery, including a small number of cancer drug and diagnostics start-ups.","summary":"Andreessen Horowitz was founded in 2009 in Menlo Park by Marc Andreessen and Ben Horowitz (Wikipedia). Its Bio + Health team describes itself as partnering with founders 'redefining the frontiers of medicine and healthcare', from life sciences to care delivery, with a team that combines former founders and operators with MDs, PhDs and technologists. The practice invests from seed to growth and is best known for computational biology and health-system software rather than classic biotech company creation. Oncology appears through precision medicine bets: the Bio + Health page lists IDRx (targeted therapies for gastrointestinal stromal tumours) and Cartography Biosciences (tumour-specific antigen discovery for cancer immunotherapy), alongside AI drug discovery firms such as Genesis and insitro.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://a16z.com/bio-health/"},{"label":"Portfolio","url":"https://a16z.com/portfolio/"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Andreessen_Horowitz"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founded year is for the parent firm (Wikipedia). The a16z portfolio page is rendered client-side; oncology names were taken from the Bio + Health landing page."],"hq":"Menlo Park, CA","country":"US","companyType":"investor","website":"https://a16z.com/bio-health/","founded":2009,"investors":[],"funding":[]},{"id":"angiocrine-bioscience","kind":"company","name":"Angiocrine Bioscience","aka":["Angiocrine Bioscience, Inc.","Angiocrine"],"tldr":"Angiocrine is a San Diego company that infuses engineered blood-vessel lining cells to help patients recover from the high-dose chemotherapy given before stem cell transplants for lymphoma and myeloma.","summary":"Angiocrine Bioscience, founded in 2012 in San Diego from Weill Cornell research, develops AB-205, an engineered endothelial cell product given after high-dose chemotherapy and autologous stem cell transplant to reduce severe regimen-related toxicities such as mucositis. It leads a phase 3 trial in lymphoma patients registered on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://angiocrinebioscience.com"},{"label":"ClinicalTrials.gov: trials led by Angiocrine Bioscience, Inc.","url":"https://clinicaltrials.gov/search?lead=Angiocrine%20Bioscience%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q36875394"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["dlbcl","multiple-myeloma"],"sections":["supportive-care"],"technologies":["autologous-stem-cell-transplant"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Diego, CA","country":"US","companyType":"cell-therapy","website":"http://angiocrinebioscience.com","founded":2012,"stage":"private-large","investors":[],"funding":[]},{"id":"angiodynamics","kind":"company","name":"AngioDynamics","aka":[],"tldr":"AngioDynamics makes the NanoKnife irreversible electroporation system, which destroys pancreatic and prostate tumours with electrical pulses rather than heat, plus microwave and radiofrequency ablation probes and vascular access ports used in chemotherapy.","summary":"AngioDynamics, founded in 1988 in upstate New York, is a mid-sized interventional device company. Its NanoKnife delivers microsecond high-voltage pulses between needle electrodes to kill tumour cells without heating, sparing vessels and ducts, and is used in locally advanced pancreatic cancer, liver tumours near vessels and, since a 2024 US clearance for prostate tissue ablation, in prostate cancer. It also sells the Solero microwave and StarBurst radiofrequency ablation systems, the Auryon laser atherectomy device and BioFlo ports and catheters used for chemotherapy access. OnCo links it to irreversible electroporation and microwave and radiofrequency ablation.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.angiodynamics.com"}],"tags":["machines-wave"],"related":[],"cancers":["pancreatic","prostate","hcc"],"sections":["surgery","devices"],"technologies":["irreversible-electroporation","microwave-rf-ablation","thermal-ablation"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03899636"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Latham, NY","country":"US","companyType":"devices","website":"https://www.angiodynamics.com","ticker":"ANGO","founded":1988,"stage":"public","investors":[],"funding":[]},{"id":"angle-plc","kind":"company","name":"ANGLE plc","aka":["ANGLE","Parsortix"],"tldr":"A Guildford company listed on London's AIM market whose Parsortix cassette harvests live circulating tumour cells from blood by size and stiffness, the first such device authorised by the FDA, sold mainly as a service to drug trials.","summary":"ANGLE plc develops and sells the Parsortix system, a microfluidic device that captures circulating tumour cells from blood without antibodies and releases them intact for downstream analysis. The Parsortix PC1 received FDA De Novo authorisation in 2022 for harvesting circulating tumour cells from the blood of patients with metastatic breast cancer and is CE marked in Europe. ANGLE runs accredited laboratories in the United Kingdom and the United States that offer Parsortix-based assays, including HER2, androgen receptor variant and DNA damage response readouts on harvested cells, to pharmaceutical companies running trials, and it works with academic groups on assays for ovarian, prostate and lung cancer.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://angleplc.com"}],"tags":[],"related":[],"cancers":["breast-cancer","prostate","ovarian","nsclc"],"sections":[],"technologies":["parsortix-ctc-harvest","ctc-capture","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Guildford, Surrey, United Kingdom","country":"GB","companyType":"diagnostics","website":"https://angleplc.com","ticker":"AGL","stage":"public","investors":[],"funding":[]},{"id":"anocca","kind":"company","name":"Anocca","aka":["Anocca AB"],"tldr":"Anocca is a Swedish cell-therapy company building T-cell receptor therapies (TCR-T) that recognise targets from inside cancer cells, with a lab platform that replicates T-cell biology and software to pick the targets.","summary":"Anocca, based in Södertälje south of Stockholm, describes itself as creating a pipeline of precision T-cell immunotherapies by combining a novel approach to T-cell biology, biotechnologies that replicate T-cell biology in the lab and integrated software for target discovery. Its focus is TCR-T therapy, in which the T cells of a patient are given a receptor that recognises a peptide from inside the cancer cell presented on HLA, reaching targets that antibodies and CAR-T cells cannot. The first clinical programme, a TCR-T directed at mutant KRAS, entered a first-in-human trial in 2024. The website does not state funding, listing or partners.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://anocca.com"}],"tags":["ctgov-sponsor","owner-request","tcr-t"],"related":[],"cancers":["pancreatic","metastatic-cancer"],"sections":["immunotherapy"],"technologies":["tcr-t"],"targets":["kras"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Södertälje, Sweden","country":"SE","companyType":"cell-therapy","website":"https://anocca.com","stage":"growth","investors":[],"funding":[]},{"id":"ansto","kind":"company","name":"ANSTO (Australian Nuclear Science and Technology Organisation)","aka":["ANSTO Nuclear Medicine"],"tldr":"ANSTO runs the OPAL research reactor near Sydney and a molybdenum-99 plant that supplies Australia's nuclear medicine and exports, and produces lutetium-177 for radioligand therapy.","summary":"The Australian Nuclear Science and Technology Organisation operates the OPAL reactor at Lucas Heights, commissioned in 2007, and the ANSTO Nuclear Medicine molybdenum-99 processing plant opened in 2019 to serve domestic technetium generators and export. It also produces non-carrier-added lutetium-177 and other isotopes and runs a national radiopharmaceutical distribution operation. Outages at the processing plant in its first years produced domestic shortages and imports from other processors.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.ansto.gov.au"}],"tags":["manufacturing-wave"],"related":[],"cancers":[],"sections":[],"technologies":["research-reactor-isotope-production","therapy-isotope-supply-chain","radiopharmacy-network"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Lucas Heights, Sydney","country":"AU","companyType":"radiopharma","website":"https://www.ansto.gov.au","founded":1987,"stage":"private-large","investors":[],"funding":[]},{"id":"antengene","kind":"company","name":"Antengene","aka":["Antengene Corporation","德琪医药"],"tldr":"Antengene is a Shanghai company that brought the XPO1 inhibitor selinexor to China and other Asia-Pacific markets and develops its own pipeline of blood cancer and solid tumour drugs.","summary":"Antengene, listed in Hong Kong since 2020, licensed selinexor (Xpovio) from Karyopharm for Greater China, South Korea, Australia and other Asia-Pacific markets and won Chinese approval in 2021 for relapsed multiple myeloma, followed by approvals elsewhere in the region. Its own pipeline includes small molecules and antibodies for blood cancers and solid tumours, and it runs regional phase 3 trials of selinexor combinations. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.antengene.com"},{"label":"ClinicalTrials.gov: trials led by Antengene","url":"https://clinicaltrials.gov/search?lead=Antengene"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["multiple-myeloma","dlbcl"],"sections":["targeted-therapy"],"technologies":[],"targets":["xpo1"],"drugs":["selinexor"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.antengene.com","stage":"public","investors":[],"funding":[]},{"id":"antidote","kind":"company","name":"Antidote","aka":[],"tldr":"Antidote matches volunteers to clinical trials through a search that turns registry listings into plain questions, serving patients in the United Kingdom and United States.","summary":"Antidote connects patients to clinical trials by structuring the eligibility criteria of registered trials into a guided search, and works with sponsors on recruitment; it has offices in London and Florida. Patient-accessible.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.antidote.me/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["ai-trial-matching"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"London, United Kingdom","country":"GB","companyType":"ai-software","website":"https://www.antidote.me/","stage":"growth","investors":[],"funding":[]},{"id":"anzup","kind":"company","name":"ANZUP Cancer Trials Group","aka":["Australian and New Zealand Urogenital and Prostate Cancer Trials Group","ANZUP"],"tldr":"The Australian genitourinary trials group behind TheraP and proPSMA, the trials that put PSMA imaging and lutetium-PSMA therapy on the map.","summary":"Formed in 2008 to unite Australia and New Zealand's prostate, kidney, bladder, testicular and penile cancer researchers. ANZUP 1603 TheraP was the first randomised trial of lutetium-177 PSMA-617, showing higher PSA response than cabazitaxel and paving the way for VISION and the Pluvicto approval, and proPSMA (ANZUP 1702) showed PSMA PET-CT outperforms conventional imaging for staging high-risk prostate cancer. ENZAMET and ENZARAD tested enzalutamide with docetaxel and with radiotherapy. Trials are run through the NHMRC Clinical Trials Centre at the University of Sydney, and consumer advisory panels are built into every study.","asOf":"2026-09-09","links":[{"label":"ANZUP","url":"https://anzup.org.au"},{"label":"Trials","url":"https://anzup.org.au/trials/"}],"tags":["cooperative-group"],"related":["pluvicto"],"cancers":["prostate","urothelial","rcc"],"sections":["radiopharma"],"technologies":["radioligand-therapy","psma-pet","androgen-deprivation"],"targets":[],"drugs":[],"companies":["trog"],"institutions":["peter-mac"],"pathways":[],"terms":["theranostics"],"trials":["therap","propsma"],"people":["hofman-michael","sandhu-shahneen","ian-davis","samantha-oakes"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["TheraP (Lu-PSMA vs cabazitaxel)","proPSMA (PSMA PET staging)","ENZAMET / ENZARAD","Bladder and kidney cancer trials","Consumer involvement"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Sydney","country":"AU","companyType":"cooperative-group","website":"https://anzup.org.au","founded":2008,"investors":[],"funding":[]},{"id":"aoa-dx","kind":"company","name":"AOA Dx","aka":[],"tldr":"AOA Dx is developing a blood test to detect ovarian cancer early, based on fat-sugar molecules called glycolipids that tumours shed.","summary":"AOA Dx develops blood-based tests for early detection of ovarian cancer built on gangliosides and other glycolipid biomarkers combined with proteins and machine learning. Its first product candidate, AKRIVIS GD, is intended to distinguish malignant from benign adnexal masses and detect early-stage disease; the company has presented performance data at gynaecologic oncology meetings and holds FDA breakthrough device designation for a version of the test. It has raised seed and Series A financing; amounts are not recorded here because no primary source was fetched.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/aoa-dx-inc"},{"label":"Official website","url":"https://www.aoadx.com"}],"tags":["yc"],"related":[],"cancers":["ovarian"],"sections":["early-detection","diagnostics"],"technologies":["liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Denver, CO","country":"US","companyType":"diagnostics","website":"https://www.aoadx.com","stage":"startup","ycBatch":"S21","investors":["y-combinator"],"funding":[]},{"id":"aop-health","kind":"company","name":"AOP Health","aka":["AOP Orphan Pharmaceuticals AG","AOP Orphan","AOP Orphan Pharmaceuticals"],"tldr":"AOP Health is a Vienna rare-disease company that brought ropeginterferon alfa-2b (Besremi) to the European market for polycythaemia vera and runs trials in myeloproliferative neoplasms and other rare conditions.","summary":"AOP Health (formerly AOP Orphan Pharmaceuticals) is a privately held Austrian company focused on rare diseases and intensive care medicine. In cancer it licensed ropeginterferon alfa-2b from PharmaEssentia for Europe and other territories, obtained European approval for polycythaemia vera in 2019 under the name Besremi, and sponsors phase 3 trials of the drug in myeloproliferative neoplasms. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.aop-health.com"},{"label":"ClinicalTrials.gov: trials led by AOP Orphan Pharmaceuticals","url":"https://clinicaltrials.gov/search?lead=AOP%20Orphan%20Pharmaceuticals"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["ropeginterferon-alfa-2b"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Vienna","country":"AT","companyType":"pharma","website":"https://www.aop-health.com","stage":"private-large","investors":[],"funding":[]},{"id":"aosaikang-pharmaceutical","kind":"company","name":"Aosaikang Pharmaceutical","aka":["Jiangsu Aosaikang Pharmaceutical","ASK Pharm","奥赛康药业"],"tldr":"Aosaikang Pharmaceutical is a China-based pharmaceutical company that leads 3 cancer trials in OnCo, testing the anti-CLDN18.2 antibody ASKB589 and the MET inhibitor ASKC202 in non-small-cell lung cancer and advanced solid tumours.","summary":"Aosaikang Pharmaceutical is a research-driven pharmaceutical manufacturer listed in Shenzhen that develops, produces and sells active ingredients and finished medicines in gastroenterology, oncology, anti-infectives and chronic disease. Its site cites China's first injectable proton pump inhibitor as a flagship product and lists clinical-stage innovative candidates including molecular glue degraders. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo (2 in phase 3 or 2/3): NCT04632108 (phase 1/2, A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor...), NCT04143607 (phase 3, ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metast...) and NCT07109531 (phase 3, ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Loc...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.ask-pharm.com/"},{"label":"ClinicalTrials.gov: trials led by Aosaikang Pharmaceutical","url":"https://clinicaltrials.gov/search?lead=Jiangsu%20Aosaikang%20Pharmaceutical%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["limertinib","carboplatin","cisplatin","pemetrexed"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04632108","nct04143607","nct07109531"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Nanjing","country":"CN","companyType":"pharma","website":"https://www.ask-pharm.com/","ticker":"SZSE:002755","founded":2003,"stage":"public","investors":[],"funding":[]},{"id":"ap-biosciences","kind":"company","name":"AP Biosciences","aka":["AP Biosciences Inc."],"tldr":"AP Biosciences is a Taiwan-based biotechnology company running 2 late-stage cancer trials of AP203, AP402 (Part 1 Dose esclation) and AP402 (Part 2 Dose Expansion) in non-small-cell lung cancer, head and neck squamous cell carcinoma and oesophageal cancer.","summary":"AP Biosciences, based in Taipei, Taiwan, is a biotechnology company listed as TPEx: 6945. AP Biosciences develops biopharmaceuticals through mechanism-based drug design, focusing on tumour-associated antigens and disease-specific targets. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing AP203, AP402 (Part 1 Dose esclation) and AP402 (Part 2 Dose Expansion) in non-small-cell lung cancer, head and neck squamous cell carcinoma and oesophageal cancer. The largest, NCT05473156 (A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumours, and Expansion to Selected Malignancies), plans to enrol 168 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.apbioinc.com"},{"label":"ClinicalTrials.gov: trials led by AP Biosciences","url":"https://clinicaltrials.gov/search?lead=AP%20Biosciences%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","head-and-neck","esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06669975","nct05473156"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Taipei","country":"TW","companyType":"biotech","website":"https://www.apbioinc.com","ticker":"TPEx: 6945","stage":"public","investors":[],"funding":[]},{"id":"apollomics","kind":"company","name":"Apollomics","aka":["Apollomics Inc.","Apollomics (Hangzhou)"],"tldr":"Apollomics is a US-Chinese company whose MET inhibitor vebreltinib is approved in China for MET exon 14 lung cancer through its partner Avistone, and whose E-selectin antagonist uproleselan failed in acute myeloid leukaemia in 2024.","summary":"Apollomics, based in Foster City, California with operations in Hangzhou and listed on Nasdaq since a 2023 merger, licenses and develops cancer drugs. Vebreltinib (APL-101, bozitinib), a selective MET inhibitor, is approved in China for MET exon 14 skipping non-small-cell lung cancer via Avistone; the phase 3 trial of uproleselan, an E-selectin antagonist licensed from GlycoMimetics, with chemotherapy in relapsed acute myeloid leukaemia missed its survival endpoint in 2024. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.apollomicsinc.com"},{"label":"ClinicalTrials.gov: trials led by Apollomics","url":"https://clinicaltrials.gov/search?lead=Apollomics"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","aml"],"sections":["targeted-therapy"],"technologies":[],"targets":["met"],"drugs":["vebreltinib"],"companies":["avistone-biotechnology"],"institutions":[],"pathways":[],"terms":[],"trials":["nct03175224"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Foster City, CA","country":"US","companyType":"biotech","website":"https://www.apollomicsinc.com","stage":"public","investors":[],"funding":[]},{"id":"aprea-therapeutics","kind":"company","name":"Aprea Therapeutics","aka":["Aprea Therapeutics, Inc.","Aprea"],"tldr":"Aprea developed eprenetapopt, a drug meant to restore the function of mutant p53, which failed its phase 3 trial in TP53-mutant myelodysplastic syndromes in 2020; the company now works on ATR and WEE1 inhibitors.","summary":"Aprea Therapeutics, founded in Stockholm and now based in Doylestown, Pennsylvania and listed on Nasdaq, developed eprenetapopt (APR-246), a small molecule intended to refold mutant p53 into its active form. Combined with azacitidine it produced encouraging phase 2 remissions in TP53-mutant myelodysplastic syndromes, but the phase 3 trial missed its complete remission endpoint in December 2020. The company pivoted to DNA damage response drugs, including the ATR inhibitor ATRN-119 and a WEE1 inhibitor. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://aprea.com"},{"label":"ClinicalTrials.gov: trials led by Aprea Therapeutics","url":"https://clinicaltrials.gov/search?lead=Aprea%20Therapeutics"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["mds","aml"],"sections":["targeted-therapy"],"technologies":[],"targets":["tp53","atr"],"drugs":["eprenetapopt"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Doylestown, PA","country":"US","companyType":"biotech","website":"https://aprea.com","stage":"public","investors":[],"funding":[]},{"id":"aptose","kind":"company","name":"Aptose Biosciences","aka":["Aptose Biosciences Inc.","Aptose"],"tldr":"Aptose is a San Diego and Toronto company developing tuspetinib, an oral kinase inhibitor acting on FLT3, SYK, JAK and other targets, for acute myeloid leukaemia in combination with venetoclax and azacitidine.","summary":"Aptose Biosciences, listed on Nasdaq and the Toronto exchange, develops kinase inhibitors for blood cancers. Its lead, tuspetinib (HM43239), licensed from Hanmi, inhibits FLT3, SYK, JAK1/2 and other kinases and is being combined with venetoclax and azacitidine in newly diagnosed acute myeloid leukaemia after single-agent responses in relapsed disease; an earlier candidate, luxeptinib, was deprioritised. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.aptose.com"},{"label":"ClinicalTrials.gov: trials led by Aptose Biosciences","url":"https://clinicaltrials.gov/search?lead=Aptose%20Biosciences"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml"],"sections":["targeted-therapy"],"technologies":[],"targets":["flt3"],"drugs":["venetoclax","azacitidine","tuspetinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://www.aptose.com","stage":"public","investors":[],"funding":[]},{"id":"aqemia","kind":"company","name":"Aqemia","aka":[],"tldr":"Aqemia combines physics-based calculations with generative artificial intelligence to invent new drug molecules, working both on its own projects and with large drug companies such as Sanofi.","summary":"Aqemia, founded in 2019 and headquartered in Paris with an office in London, uses deep physics (quantum and statistical mechanics calculations of binding affinity) coupled with generative AI to design and optimise small molecules without relying on large experimental training sets. The company pursues a mix of wholly owned programmes, which it says typically show superior efficacy and non-toxicity in vivo, and partnered programmes; its strategies include broad exploration across many targets and indication-first moonshots for single diseases of high unmet need. Sanofi expanded its research collaboration with Aqemia in July 2026. The fetched pages do not list specific targets or indications, so the oncology content of the pipeline and the company's financing rounds could not be confirmed from primary sources.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.aqemia.com"},{"label":"Who we are","url":"https://www.aqemia.com/who-we-are"},{"label":"News","url":"https://www.aqemia.com/news"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation","drug-discovery"],"technologies":["ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Oncology focus not confirmed on fetched pages (pipeline page gives no programmes). Series B (2024) not sourced, so omitted; stage set to startup."],"hq":"Paris","country":"FR","companyType":"ai-software","website":"https://www.aqemia.com","founded":2019,"stage":"startup","investors":[],"funding":[]},{"id":"araris","kind":"company","name":"Araris Biotech (Taiho)","aka":[],"tldr":"Swiss linker-technology company (AraLinQ) acquired by Taiho for up to $1.14B; first clinical ADC ARC-02 (CD79b) dosed in June 2026.","summary":"Araris Biotech, based in Zurich, is the Swiss linker-technology company behind AraLinQ, acquired by Taiho for up to 1.14 billion dollars, and its first clinical ADC, ARC-02, was dosed in June 2026. Taiho paid 400 million dollars at closing in 2025 with up to 740 million dollars in milestones, and ARC-02, a CD79b-targeted MMAE ADC built with AraLinQ site-specific conjugation, entered phase 1 in non-Hodgkin lymphoma in June 2026 as the first AraLinQ product in humans. OnCo links it to diffuse large B-cell lymphoma, to ADCs and site-specific conjugation and linker chemistry, to Taiho, and to the idea of platform designation for ADC linker-payloads so manufacturing data carry across. Whether a cleaner linker changes clinical outcomes, or only manufacturing, is the question ARC-02 will start to answer. Taiho has its own page.","asOf":"2026-09-04","links":[{"label":"ARC-02 phase 1","url":"https://www.taiho.co.jp/en/release/2026/20260428.html"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":["adcs"],"technologies":["adc","site-specific-conjugation"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct02503423","nct07710885","nct05945823","nct04256317","nct04683250","nct05727176","nct05967689"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Zurich","country":"CH","companyType":"biotech","website":"https://www.ararisbiotech.com","investors":[],"funding":[]},{"id":"arcagy-gineco","kind":"company","name":"ARCAGY-GINECO","aka":["GINECO","Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens","ARCAGY"],"tldr":"The French gynaecologic cancer trials group that led PAOLA-1, the trial adding olaparib to bevacizumab maintenance in ovarian cancer.","summary":"GINECO was founded in 1993 as France's cooperative group for ovarian, endometrial, cervical and rare gynaecologic cancers, with ARCAGY as its academic sponsor and research organisation. As a founding member of the European ENGOT network and the Gynecologic Cancer InterGroup, it led PAOLA-1/ENGOT-ov25, which showed olaparib plus bevacizumab maintenance improves progression-free and, in HRD-positive disease, overall survival in newly diagnosed ovarian cancer. GINECO also ran the CHIVA and ICON7 contributions, elderly-specific ovarian trials and the rare-tumour TMRG network, and it co-develops immunotherapy trials in endometrial and cervical cancer with the GOG Foundation.","asOf":"2026-09-09","links":[{"label":"ARCAGY-GINECO","url":"https://www.arcagy.org"}],"tags":["cooperative-group"],"related":["olaparib","niraparib"],"cancers":["ovarian","endometrial","cervical"],"sections":[],"technologies":["parp-inhibitor","hrd-testing","antiangiogenic"],"targets":[],"drugs":[],"companies":["gog-foundation","curie-nki-eortc","unicancer"],"institutions":[],"pathways":[],"terms":["hrd"],"trials":["paola-1","gog-0218-icon7"],"people":["sebastien-armanet"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["PAOLA-1 (olaparib plus bevacizumab)","Elderly ovarian cancer trials","ENGOT and GCIG leadership","Rare gynaecologic tumours network"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Paris","country":"FR","companyType":"cooperative-group","website":"https://www.arcagy.org","founded":1993,"investors":[],"funding":[]},{"id":"arcellx","kind":"company","name":"Arcellx","aka":[],"tldr":"Arcellx developed anito-cel, a CAR T-cell therapy for multiple myeloma that reprogrammes a patient's own immune cells to attack a marker called BCMA. Gilead bought the company in 2026 for about $7.8 billion ahead of a possible US approval.","summary":"Arcellx developed anitocabtagene autoleucel (anito-cel), an autologous BCMA-directed CAR T-cell therapy built on the company's synthetic D-domain binder, for relapsed or refractory multiple myeloma. Anito-cel was co-developed and co-commercialised with Kite, a Gilead company, under a 2022 collaboration. The BLA for fourth-line relapsed or refractory multiple myeloma, supported by the phase 1 study (NCT04155749) and the pivotal phase 2 iMMagine-1 study (NCT05396885), was accepted by the FDA with a PDUFA date of 23 December 2026. Arcellx listed on Nasdaq in February 2022 (gross proceeds about $142 million). In February 2026 Gilead agreed to acquire the company for $115 per share in cash plus a $5 contingent value right, an implied equity value of about $7.8 billion, and completed the tender offer and merger on 28 April 2026. Arcellx is now a wholly owned subsidiary of Gilead and arcellx.com redirects to Kite.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.kitepharma.com/"},{"label":"Gilead to acquire Arcellx (February 2026)","url":"https://www.kitepharma.com/news/press-releases/2026/2/gilead-sciences-to-acquire-arcellx-to-maximize-long-term-potential-of-anito-cel"},{"label":"Gilead completes acquisition (April 2026)","url":"https://www.kitepharma.com/news/press-releases/2026/4/gilead-sciences-completes-acquisition-of-arcellx-ahead-of-potential-commercial-launch-of-anito-cel"},{"label":"IPO closing release (8-K, February 2022)","url":"https://www.sec.gov/Archives/edgar/data/1786205/000119312522032077/d303972dex991.htm"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":["cell-therapy"],"technologies":["car-t"],"targets":["bcma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Former Nasdaq ticker ACLX, delisted after the April 2026 merger. The 2022 IPO release was datelined Gaithersburg, Maryland; the 2026 acquisition release is datelined Redwood City."],"hq":"Redwood City, CA","country":"US","companyType":"cell-therapy","website":"https://www.kitepharma.com/","stage":"acquired","investors":[],"funding":[{"round":"IPO","year":2022,"amountUsd":142300000,"source":"https://www.sec.gov/Archives/edgar/data/1786205/000119312522032077/d303972dex991.htm","note":"9,487,500 shares at $15.00 including full option exercise; Nasdaq ACLX"},{"round":"Acquisition","year":2026,"amountUsd":7800000000,"source":"https://www.kitepharma.com/news/press-releases/2026/2/gilead-sciences-to-acquire-arcellx-to-maximize-long-term-potential-of-anito-cel","note":"$115 per share in cash plus a $5 contingent value right; implied equity value $7.8 billion; completed 28 April 2026"}],"acquiredBy":"gilead"},{"id":"arch-venture-partners","kind":"company","name":"ARCH Venture Partners","aka":[],"tldr":"A Chicago venture firm that starts and funds science-heavy biotech companies. Several of its companies work on cancer drugs, cancer cell therapies and cancer diagnostics.","summary":"ARCH Venture Partners was founded in 1986 (Wikipedia) and describes its mission as 'catalyzing discoveries that prevent, detect, and cure disease', with offices in Chicago and Seattle. Its model is company creation from academic science, often taking large early stakes and syndicating later rounds with crossover funds. Oncology is a recurring theme on the portfolio page: Agios Pharmaceuticals (gene-targeted cancer therapeutics, Nasdaq: AGIO), Akamis Bio (systemic immune oncology therapies), Arsenal Biosciences (programmable cell cancer therapies), Carrick Therapeutics, Erasca (AI-driven cancer drug discovery, Nasdaq: ERAS), Boundless Bio (ecDNA-directed therapies) and Elephas Biosciences (cancer diagnostics) are all listed.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.archventure.com/"},{"label":"Portfolio","url":"https://www.archventure.com/portfolio/"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/ARCH_Venture_Partners"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Chicago, IL","country":"US","companyType":"investor","website":"https://www.archventure.com/","founded":1986,"investors":[],"funding":[]},{"id":"arcus-biosciences","kind":"company","name":"Arcus Biosciences","aka":["Arcus Biosciences, Inc."],"tldr":"Arcus Biosciences is a United States-based biotechnology company running 4 late-stage cancer trials of Domvanalimab and Quemliclustat in gastric & gastro-oesophageal junction cancer, renal cell carcinoma and pancreatic ductal adenocarcinoma.","summary":"Arcus Biosciences, based in Hayward, the United States, is a biotechnology company. Arcus Biosciences is a clinical-stage biopharmaceutical company that designs small-molecule and antibody combination therapies for cancer. On ClinicalTrials.gov it is the lead sponsor of 4 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing Domvanalimab and Quemliclustat in gastric & gastro-oesophageal junction cancer, renal cell carcinoma, pancreatic ductal adenocarcinoma and non-small-cell lung cancer. The largest, NCT07011719 (Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma), plans to enrol 720 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.arcusbio.com"},{"label":"ClinicalTrials.gov: trials led by Arcus Biosciences","url":"https://clinicaltrials.gov/search?lead=Arcus%20Biosciences%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["gastric","rcc","pancreatic","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["domvanalimab","quemliclustat","zimberelimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07011719","nct04736173","nct05329766"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Hayward","country":"US","companyType":"biotech","website":"https://www.arcusbio.com","founded":2015,"stage":"public","investors":[],"funding":[]},{"id":"arden-bio","kind":"company","name":"Arden Bio","aka":[],"tldr":"Arden Bio is an Even One Ventures company outside cancer: it profiles the immune system of people with complex immune-mediated conditions to match them to biology-based treatments.","summary":"Arden Bio, led by chief executive Bala Raja, offers people with complex immune-mediated conditions a case assessment built on advanced immune profiling, which its site says analyses more than 10,000 molecular data points to help their physicians identify the mechanisms driving the condition and personalise treatment. It is one of the immunology companies in the Even One Ventures portfolio and is not working on cancer; it is recorded here because the fund's whole portfolio is tracked.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.arden.bio/"},{"label":"Even One Ventures portfolio","url":"https://evenone.ventures/"}],"tags":["startup","evenone-portfolio","immunology","non-oncology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"California (city not published)","country":"US","companyType":"diagnostics","website":"https://www.arden.bio/","stage":"startup","investors":["evenone-ventures"],"funding":[]},{"id":"argenx","kind":"company","name":"argenx","aka":["argenx SE","Argenx"],"tldr":"argenx is a Belgian antibody company best known for efgartigimod in autoimmune disease; its cancer programme, the anti-CD70 antibody cusatuzumab for acute myeloid leukaemia, was returned by its partner in 2021.","summary":"argenx, based in Ghent with Dutch and US operations and listed on Euronext and Nasdaq, develops antibodies from its llama-derived SIMPLE Antibody platform. Its lead product efgartigimod is approved for myasthenia gravis and other autoimmune conditions. In cancer it developed cusatuzumab, an anti-CD70 antibody tested with azacitidine in acute myeloid leukaemia, which Janssen licensed in 2018 and handed back in 2021. OnCo records it as a registry sponsor of phase 3 cancer trials.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Argenx","links":[{"label":"Official website","url":"https://www.argenx.com"},{"label":"ClinicalTrials.gov: trials led by argenx","url":"https://clinicaltrials.gov/search?lead=argenx"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Argenx"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml"],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["cusatuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04023526"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Ghent","country":"BE","companyType":"biotech","website":"https://www.argenx.com","stage":"public","investors":[],"funding":[]},{"id":"argos-therapeutics","kind":"company","name":"Argos Therapeutics","aka":["Argos Therapeutics, Inc.","Argos"],"tldr":"Argos was a North Carolina company whose personalised dendritic-cell vaccine rocapuldencel-T, made from each patient's own tumour RNA, failed the phase 3 ADAPT trial in kidney cancer and the company closed in 2019.","summary":"Argos Therapeutics, founded in 1997 in Durham, North Carolina, built the Arcelis platform, which loaded a patient's dendritic cells with RNA amplified from their own tumour. Rocapuldencel-T (AGS-003) was tested with sunitinib in the phase 3 ADAPT trial in metastatic renal cell carcinoma; the trial was stopped for futility in 2017 and the company filed for bankruptcy in 2019. Its trials remain on ClinicalTrials.gov under Argos as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.argostherapeutics.com"},{"label":"ClinicalTrials.gov: trials led by Argos Therapeutics, Inc.","url":"https://clinicaltrials.gov/search?lead=Argos%20Therapeutics%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30286762"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["rcc"],"sections":[],"technologies":["dendritic-cell-vaccines"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Durham, NC","country":"US","companyType":"cell-therapy","website":"http://www.argostherapeutics.com","founded":1997,"stage":"defunct","investors":[],"funding":[]},{"id":"ariceum-therapeutics","kind":"company","name":"Ariceum Therapeutics","aka":[],"tldr":"Ariceum Therapeutics is a Berlin company developing a treatment that carries the alpha-emitting isotope actinium-225 to small cell lung cancer and Merkel cell skin cancer. Its first human trial began in late 2025.","summary":"Ariceum Therapeutics is a Berlin-based targeted radiotherapeutics company. Its lead candidate 225Ac-SSO110 is an actinium-225 labelled radioligand for extensive-stage small cell lung cancer (ES-SCLC) and Merkel cell carcinoma (MCC); the phase 1/2 SANTANA-225 study was planned to start in the second half of 2025, with initial safety data expected in early 2026 and preliminary efficacy findings in 2027. In August 2025 David Schilansky, previously CFO, succeeded co-founder Manfred Rüdiger as CEO alongside a new executive team.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.biospace.com/press-releases/ariceum-therapeutics-appoints-david-schilansky-as-chief-executive-officer-and-announces-new-leadership-to-advance-next-phase-of-development"}],"tags":[],"related":[],"cancers":["sclc"],"sections":["radiopharma"],"technologies":["targeted-alpha-therapy","radioligand-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website ariceum-therapeutics.com returned a certificate error and then an HTTP 500 'Database Error' on every attempt, so the website field points to the fetched release copy. Series A (reported elsewhere as EUR 25 million in 2022) and the Theragnostics acquisition are unsourced and omitted. SSO110 target (SSTR2 antagonist per other reports) not stated in the fetched text."],"hq":"Berlin","country":"DE","companyType":"radiopharma","website":"https://www.biospace.com/press-releases/ariceum-therapeutics-appoints-david-schilansky-as-chief-executive-officer-and-announces-new-leadership-to-advance-next-phase-of-development","stage":"startup","investors":[],"funding":[]},{"id":"arog-pharmaceuticals","kind":"company","name":"Arog Pharmaceuticals","aka":["Arog Pharmaceuticals, Inc.","AROG"],"tldr":"Arog is a private Dallas biotech developing crenolanib, a FLT3 and PDGFR kinase inhibitor, through phase 3 trials in FLT3-mutant acute myeloid leukaemia and gastrointestinal stromal tumours.","summary":"Arog Pharmaceuticals, based in Dallas, Texas, licensed crenolanib from Pfizer and has taken it into phase 3 trials in newly diagnosed and relapsed FLT3-mutated acute myeloid leukaemia and in PDGFRA D842V-mutant gastrointestinal stromal tumours, all registered on ClinicalTrials.gov under Arog as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.arogpharma.com"},{"label":"ClinicalTrials.gov: trials led by Arog Pharmaceuticals, Inc.","url":"https://clinicaltrials.gov/search?lead=Arog%20Pharmaceuticals%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30286808"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml","gist"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["flt3"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Dallas, TX","country":"US","companyType":"biotech","website":"https://www.arogpharma.com","stage":"private-large","investors":[],"funding":[]},{"id":"arpeggio-bio","kind":"company","name":"Arpeggio Bio","aka":[],"tldr":"Arpeggio Bio uses AI on large RNA-sequencing datasets to find drugs against transcription factors, the hard-to-hit proteins that switch cancer genes on, with a first programme in immunotherapy-resistant melanoma.","summary":"Arpeggio Bio combines high-throughput RNA sequencing with machine learning to discover small molecules that modulate transcription factors long considered undruggable, naming NRF2, TEAD and GPX4 among its targets. Its YC profile states that its lead programme was progressing towards a development candidate for melanoma resistant to checkpoint inhibitors and that the company had about $20 million in venture funding and partnerships with Johnson & Johnson and FORMA Therapeutics; those figures are the company's own and are not repeated as a funding row here. The company website returned an error when checked on 2026-09-10.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/arpeggio-bio"}],"tags":["yc"],"related":[],"cancers":["melanoma"],"sections":["drug-discovery","targeted-therapy"],"technologies":["ai-drug-design","rna-seq"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boulder, CO","country":"US","companyType":"biotech","website":"https://www.ycombinator.com/companies/arpeggio-bio","stage":"startup","ycBatch":"S19","investors":["y-combinator"],"funding":[]},{"id":"arrivent","kind":"company","name":"ArriVent BioPharma","aka":["ArriVent BioPharma, Inc.","ArriVent"],"tldr":"ArriVent is a Pennsylvania company developing furmonertinib, an EGFR inhibitor approved in China, for EGFR exon 20 insertion and other uncommon EGFR-mutant lung cancers in global trials.","summary":"ArriVent BioPharma, based in Newtown Square, Pennsylvania and listed on Nasdaq since 2024, licenses medicines approved in China for development elsewhere. Its lead is furmonertinib (firmonertinib), a third-generation EGFR inhibitor from Allist Pharmaceuticals that is approved in China for EGFR-mutant non-small-cell lung cancer; ArriVent runs the global phase 3 FURVENT trial in EGFR exon 20 insertion mutations, where it holds FDA breakthrough designation. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.arrivent.com"},{"label":"ClinicalTrials.gov: trials led by ArriVent BioPharma","url":"https://clinicaltrials.gov/search?lead=ArriVent%20BioPharma"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc"],"sections":["targeted-therapy"],"technologies":[],"targets":["egfr"],"drugs":["furmonertinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05607550","nct07185997"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Newtown Square, PA","country":"US","companyType":"biotech","website":"https://www.arrivent.com","stage":"public","investors":[],"funding":[]},{"id":"arsenal-bio","kind":"company","name":"Arsenal Biosciences","aka":[],"tldr":"Programmable CAR-T company using logic gates so cells fire only when two tumour proteins are present; AB-2100 (PSMA + CA9) is in phase 1/2 for kidney cancer.","summary":"Arsenal Biosciences, based in South San Francisco, is a programmable CAR-T company that uses logic gates so its cells fire only when two tumour proteins are present, and its AB-2100 is in phase 1/2 for kidney cancer. AB-2100 combines a synthetic AND gate requiring both PSMA and CA9, shRNA armouring against suppression in the tumour microenvironment and a synthetic pathway activator, and is being tested in clear-cell renal cell carcinoma after immunotherapy and VEGF therapy in trial NCT06245915; AB-1015 targets ovarian cancer, and the company raised 325 million dollars with Regeneron and Bristol Myers Squibb participating. OnCo links it to renal and ovarian cancer, to armoured and logic-gated CARs and logic-gated therapeutics, and to PSMA as a target. Whether logic gating solves the on-target, off-tumour problem that has stalled solid-tumour CAR-T is the question its trial will test.","asOf":"2026-09-04","links":[{"label":"AB-2100 trial","url":"https://clinicaltrials.gov/study/NCT06245915"},{"label":"PICI news: ArsenalBio","url":"https://www.parkerici.org/?s=arsenalbio"}],"tags":["frontier"],"related":[],"cancers":["rcc","ovarian"],"sections":["cell-therapy"],"technologies":["armored-car","car-t"],"targets":["psma"],"drugs":[],"companies":["bms","regeneron"],"institutions":["parker-institute"],"pathways":[],"terms":[],"trials":["nct06245915","nct07285694"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The Parker Institute for Cancer Immunotherapy's own news pages describe ArsenalBio as a company it launched in 2019, with a founders' interview on the institute's site."],"hq":"South San Francisco, CA","country":"US","companyType":"cell-therapy","website":"https://arsenalbio.com","investors":["arch-venture-partners"],"funding":[]},{"id":"artbio","kind":"company","name":"ARTBIO","aka":[],"tldr":"ARTBIO makes cancer treatments that deliver short-range alpha radiation from lead-212 directly to tumour cells, starting with prostate cancer. Its first medicine is in early human trials, currently paused by the company while it reviews data.","summary":"ARTBIO, Inc. (Cambridge, Massachusetts, with engineering and manufacturing in Oslo) develops a new class of 212Pb alpha radioligand therapies (ARTs), together with its AlphaDirect isotope production technology and manufacturing ecosystem. The company was founded in 2021 by Roy Larsen and Øyvind Bruland, the inventors of Xofigo, with F-Prime and Radforsk. The lead asset AB001, a PSMA-targeted 212Pb radioligand for metastatic castration-resistant prostate cancer, is in the phase 1 ARTISAN trial; two cohorts (177Lu-PSMA naive and 177Lu-PSMA experienced) were dosed in January 2026, and in April 2026 the company implemented a voluntary clinical hold of ARTISAN. Jonathan Freeman was appointed interim CEO in July 2026. Further programmes include 212Pb antibody conjugates and the HEARTS discovery platform. ARTBIO raised a USD 90 million Series A in December 2023 and about USD 132 million in July 2025, according to Endpoints News.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://artbio.com/"},{"label":"ARTISAN cohort dosing release (PR Newswire)","url":"https://www.prnewswire.com/news-releases/artbio-announces-dosing-of-two-cohorts-with-ab001-in-artisan-a-phase-1-alpha-radioligand-therapy-clinical-trial-for-metastatic-castration-resistant-prostate-cancer-302657972.html"},{"label":"Endpoints News: Artbio raises $90M","url":"https://endpoints.news/artbio-raises-90m-as-radiopharma-field-finds-its-footing/"},{"label":"Endpoints News: Artbio attracts $132M","url":"https://endpoints.news/artbio-attracts-132m-as-its-alpha-radioligand-program-moves-into-the-clinic/"}],"tags":[],"related":["src-endpoints-news"],"cancers":["prostate"],"sections":["radiopharma"],"technologies":["targeted-alpha-therapy","radioligand-therapy"],"targets":["psma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Endpoints article bodies are paywalled; amounts come from the visible headline and lede."],"hq":"Cambridge, MA","country":"US","companyType":"radiopharma","website":"https://artbio.com/","founded":2021,"stage":"startup","investors":[],"funding":[{"round":"Series A","year":2023,"amountUsd":90000000,"source":"https://endpoints.news/artbio-raises-90m-as-radiopharma-field-finds-its-footing/"},{"round":"Series B","year":2025,"amountUsd":132000000,"source":"https://endpoints.news/artbio-attracts-132m-as-its-alpha-radioligand-program-moves-into-the-clinic/","note":"Endpoints reports a USD 132 million raise in July 2025; the Series B label comes from the PR Newswire headline seen in search results, not from a fetched page"}]},{"id":"artera","kind":"company","name":"Artera","aka":[],"tldr":"First company with FDA-cleared AI pathology tests that predict treatment benefit (prostate 2025, breast 2026).","summary":"Artera, based in Los Altos, California, is the first company with FDA-cleared AI pathology tests that predict treatment benefit, with ArteraAI Prostate cleared de novo in 2025 and ArteraAI Breast in May 2026. Both tests were trained on pathology slides from phase 3 trial cohorts, which is what lets them claim predictive rather than only prognostic value. OnCo links it to prostate cancer, to digital pathology and pathology foundation models, to the bottleneck of AI that is built but not validated or deployed, and to the idea of patient-level multimodal foundation models for treatment selection. Whether clinicians and payers act on an AI test when it changes a treatment decision is the open question. Both tests have their own pages.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://artera.ai"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation","diagnostics"],"technologies":[],"targets":[],"drugs":["artera-ai-prostate","artera-ai-breast"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Los Altos, CA","country":"US","companyType":"ai-software","website":"https://artera.ai","investors":[],"funding":[]},{"id":"artios-pharma","kind":"company","name":"Artios Pharma","aka":["Artios Pharma Ltd","Artios Pharma Limited","Artios"],"tldr":"Artios Pharma is a Cambridge, UK biotechnology company that leads two cancer trials in OnCo, testing its DNA damage response inhibitors ART0380 (ATR) and ART6043 (DNA polymerase theta) in advanced solid tumours.","summary":"Artios Pharma Limited is a company based in Cambridge, United Kingdom (Wikidata Q140045444, which also gives its website). ClinicalTrials.gov classes it as an industry sponsor. It leads two phase 1/2a trials recorded in OnCo: NCT04657068, the ATR kinase inhibitor ART0380 alone and in combination (with gemcitabine, irinotecan or FOLFIRI) in advanced or metastatic solid tumours including ovarian, endometrial, colorectal and pancreatic cancer, and NCT05898399 (POLKA), the DNA polymerase theta inhibitor ART6043 alone and with olaparib in advanced solid tumours. Both compounds are its own, which is the basis for the biotech type.","asOf":"2026-09-22","links":[{"label":"Official website","url":"https://www.artios.com"},{"label":"Wikidata Q140045444","url":"https://www.wikidata.org/wiki/Q140045444"},{"label":"ClinicalTrials.gov: trials led by Artios Pharma Ltd","url":"https://clinicaltrials.gov/search?lead=Artios%20Pharma%20Ltd"}],"tags":["ctgov-sponsor","wave5-sponsor"],"related":[],"cancers":["ovarian","endometrial","colorectal","pancreatic"],"sections":[],"technologies":[],"targets":["atr"],"drugs":[],"companies":[],"institutions":[],"pathways":["ddr"],"terms":[],"trials":["nct04657068","nct05898399"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo content wave 5 (Wikidata, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-22"},"hq":"Cambridge","country":"GB","companyType":"biotech","website":"https://www.artios.com","investors":[],"funding":[]},{"id":"arvinas","kind":"company","name":"Arvinas","aka":[],"tldr":"PROTAC pioneer whose vepdegestrant became the first approved targeted protein degrader in 2026.","summary":"Arvinas, based in New Haven and listed as ARVN, is the PROTAC pioneer whose vepdegestrant became the first approved targeted protein degrader in 2026. Founded on Craig Crews' PROTAC technology, it developed vepdegestrant, an oestrogen receptor degrader, with Pfizer, and its pipeline includes ARV-393 against BCL6 and ARV-102 against LRRK2 in neurology. OnCo links it to HR-positive, HER2-negative breast cancer, to PROTACs and molecular glues, to the bottleneck of undruggable drivers, and to ideas for an open degrader consortium and for destroying the truncated androgen receptor. Whether degraders can reach transcription factors that inhibitors never could is the open question the first approval makes urgent. Vepdegestrant has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.arvinas.com"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["vepdegestrant"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07023731","nct07749586"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"New Haven, CT","country":"US","companyType":"biotech","website":"https://www.arvinas.com","ticker":"ARVN","investors":[],"funding":[]},{"id":"ascentage-pharma","kind":"company","name":"Ascentage Pharma","aka":["Ascentage Pharma Group Inc.","亚盛医药"],"tldr":"Ascentage is a Chinese biotechnology company built on protein-protein interaction inhibitors: olverembatinib, a third-generation BCR-ABL inhibitor approved in China for T315I-mutant chronic myeloid leukaemia, and the BCL-2 inhibitor lisaftoclax.","summary":"Ascentage Pharma, based in Suzhou and listed in Hong Kong and, since 2025, on Nasdaq, designs small molecules that block protein-protein interactions in apoptosis and other pathways. Olverembatinib (HQP1351), a BCR-ABL inhibitor active against the T315I mutation, was approved in China in 2021 for resistant chronic myeloid leukaemia and is in global trials with Takeda. Lisaftoclax (APG-2575) is a BCL-2 inhibitor in phase 3 trials in chronic lymphocytic leukaemia and other blood cancers. OnCo records it as a registry sponsor of phase 3 cancer trials.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.ascentage.com"},{"label":"ClinicalTrials.gov: trials led by Ascentage Pharma","url":"https://clinicaltrials.gov/search?lead=Ascentage%20Pharma"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Ascentage_Pharma"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cml","cll","aml"],"sections":["targeted-therapy"],"technologies":[],"targets":["bcr-abl","bcl2"],"drugs":["olverembatinib"],"companies":["takeda"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04501120","nct03611868","nct05701306","nct04785196","nct04494503","nct04496349","nct06389292","nct05147467"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Suzhou","country":"CN","companyType":"biotech","website":"https://www.ascentage.com","stage":"public","investors":[],"funding":[]},{"id":"ascentawits-pharmaceuticals","kind":"company","name":"Ascentawits Pharmaceuticals","aka":["Ascentawits Pharmaceuticals, Ltd"],"tldr":"Ascentawits Pharmaceuticals is a China-based biotechnology company running 2 late-stage cancer trials of AST-3424 and AST-001 in hepatocellular carcinoma and pancreatic ductal adenocarcinoma.","summary":"Ascentawits Pharmaceuticals, based in Shenzhen, China, is a biotechnology company. Ascentawits Pharmaceuticals (Shenzhen Ascenta Wits Pharmaceutical Technology Co., Ltd.) develops small molecule-drug conjugates as targeted cancer therapeutics. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing AST-3424 and AST-001 in hepatocellular carcinoma and pancreatic ductal adenocarcinoma. The largest, NCT06245330 (A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumours), plans to enrol 180 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.ascentawits.com"},{"label":"ClinicalTrials.gov: trials led by Ascentawits Pharmaceuticals","url":"https://clinicaltrials.gov/search?lead=Ascentawits%20Pharmaceuticals%2C%20Ltd"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["hcc","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06245330","nct06239155"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shenzhen","country":"CN","companyType":"biotech","website":"https://www.ascentawits.com","investors":[],"funding":[]},{"id":"ascletis","kind":"company","name":"Ascletis Pharma","aka":["Ascletis Pharmaceuticals Co., Ltd.","Ascletis Pharma Inc.","歌礼制药"],"tldr":"Ascletis is a Hangzhou biotech listed in Hong Kong, first known for hepatitis C antivirals, which sponsors phase 3 cancer trials among its liver-disease and metabolic programmes.","summary":"Ascletis Pharma, headquartered in Hangzhou and listed in Hong Kong, began with direct-acting antivirals for hepatitis C in China and has since moved into liver disease, metabolic disease and oncology, including a PD-L1 antibody programme. ClinicalTrials.gov lists Ascletis as lead sponsor of a phase 3 cancer trial. Its phase 3 cancer trial tests the fatty acid synthase inhibitor ASC40 (denifanstat, TVB-2640) with bevacizumab in recurrent glioblastoma (NCT05118776), and it has a phase 1 trial of the oral PD-L1 inhibitor ASC61 in advanced solid tumours (NCT05287399).","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.ascletis.com"},{"label":"ClinicalTrials.gov: trials led by Ascletis Pharmaceuticals Co., Ltd.","url":"https://clinicaltrials.gov/search?lead=Ascletis%20Pharmaceuticals%20Co.%2C%20Ltd."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q140045748"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["hcc","glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["asc40"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Hangzhou","country":"CN","companyType":"biotech","website":"https://www.ascletis.com","stage":"public","investors":[],"funding":[]},{"id":"asher-bio","kind":"company","name":"Asher Biotherapeutics","aka":[],"tldr":"Asher Bio engineers immune-stimulating molecules that switch on only one type of immune cell, such as killer T cells, so the drug is more potent against tumours and causes fewer side effects.","summary":"Asher Biotherapeutics builds cis-targeted immunotherapies: a cytokine fused to an antibody arm that binds a marker on the intended cell type, so the cytokine acts selectively rather than on every cell bearing its receptor. The lead programme AB248 is a CD8-targeted interleukin-2 in phase 1 for advanced solid tumours, alone and with pembrolizumab; a second programme targets regulatory T cells for autoimmune disease. The company was founded with Third Rock Ventures, went through YC, and has raised Series A and B rounds; amounts are not recorded here because no primary source was fetched.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/asher-bio"},{"label":"Official website","url":"https://www.asherbio.com"}],"tags":["yc"],"related":[],"cancers":["rcc","melanoma"],"sections":["immunotherapy"],"technologies":["cytokine-therapy"],"targets":["cd3"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.asherbio.com","stage":"growth","ycBatch":"S19","investors":["y-combinator","third-rock-ventures"],"funding":[]},{"id":"askgene-pharma","kind":"company","name":"AskGene Pharma","aka":["AskGene Pharma, Inc."],"tldr":"AskGene Pharma is a United States-based biotechnology company running 2 late-stage cancer trials of ASKG915 and Fruquintinib in gastric & gastro-oesophageal junction cancer.","summary":"AskGene Pharma, based in Camarillo, the United States, is a biotechnology company. AskGene Pharma develops cytokine prodrug therapeutics using its SmartKine platform technology, targeting oncology and autoimmune disease indications. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing ASKG915 and Fruquintinib in gastric & gastro-oesophageal junction cancer. The largest, NCT05867420 (A Study of ASKG915 in Patients With Selected Advanced Solid Tumours), plans to enrol 594 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.ask-gene.com"},{"label":"ClinicalTrials.gov: trials led by AskGene Pharma","url":"https://clinicaltrials.gov/search?lead=AskGene%20Pharma%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["fruquintinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05632939","nct05867420"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Camarillo","country":"US","companyType":"biotech","website":"https://www.ask-gene.com","founded":2012,"stage":"growth","investors":[],"funding":[]},{"id":"astellas","kind":"company","name":"Astellas","aka":["OSI Pharmaceuticals"],"tldr":"Astellas co-owns Padcev and makes Vyloy, the first Claudin 18.2 drug.","summary":"Astellas, based in Tokyo and listed as 4503.T, co-owns Padcev with Pfizer and makes Vyloy, or zolbetuximab, the first Claudin 18.2 drug, approved in 2024. Its oncology portfolio also includes enzalutamide, shared with Pfizer, and gilteritinib for FLT3-mutated acute myeloid leukaemia, and OnCo links it to the EV-302 paper that made enfortumab vedotin plus pembrolizumab the first-line standard in advanced bladder cancer, to SPOTLIGHT for zolbetuximab in gastric cancer and to ADMIRAL for gilteritinib. Its cancer pages cover bladder, gastric, prostate and acute myeloid leukaemia. Whether Claudin 18.2 becomes a broad target class, with ADCs and CAR-Ts following the antibody, is the question zolbetuximab opened. Enfortumab vedotin has its own page.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Astellas_Pharma","links":[{"label":"Official website","url":"https://www.astellas.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs","targeted-therapy"],"technologies":[],"targets":[],"drugs":["enfortumab-vedotin","setidegrasib","asp2138","xnw27011"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04076059","nct02960022","nct07005154","nct06792435","nct07488676","nct06901531","nct03816163","nct07475806","nct07421700","nct07566156","nct04821622","nct03505320","nct04225117","nct05520567","spotlight-glow","nct07730021","nct03182244","nct07287995"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tokyo","country":"JP","companyType":"pharma","website":"https://www.astellas.com","ticker":"4503.T","investors":[],"funding":[]},{"id":"astrazeneca","kind":"company","name":"AstraZeneca","aka":["Acerta Pharma","Alexion Pharmaceuticals","MedImmune LLC","MedImmune"],"tldr":"AstraZeneca is the most ADC-committed large pharma, co-owner of Enhertu and Datroway, with deep targeted-therapy and radiopharma bets.","summary":"AstraZeneca's oncology revenue exceeds $20B. ADCs (T-DXd, Dato-DXd with Daiichi Sankyo; AZD0901 CLDN18.2; puxitatug samrotecan B7-H4; tilatamig samrotecan EGFR×MET bsADC), osimertinib, olaparib, capivasertib, durvalumab, camizestrant, saruparib, and radioconjugates via Fusion Pharma (225Ac-PSMA). Also cell therapy (Neogene, GPC3 CAR-T).","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/AstraZeneca","links":[{"label":"Official website","url":"https://www.astrazeneca.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs","targeted-therapy","immunotherapy","radiopharma"],"technologies":[],"targets":[],"drugs":["trastuzumab-deruxtecan","datopotamab-deruxtecan","osimertinib","olaparib","capivasertib","durvalumab","tilatamig-samrotecan","cmg901","puxitatug-samrotecan","ac225-psma","domvanalimab","oleclumab","ceralasertib","saruparib","monalizumab","azd5335","azd0486","fpi-2265","azd3470","azd9793","azd4360","rilvegostomig","azd6621","palacaparib","azd9750","azd4512","azd5492","azd4045","azd7789","azd5863","azd8421","gc012f","fulvestrant","raltitrexed","tamoxifen","ravulizumab"],"companies":["neogene-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06350097","nct04351555","nct04529772","nct07044336","nct05120349","nct06692738","nct05348577","nct04884360","nct06549595","nct06564844","nct06417814","nct07509151","nct06989112","nct03800134","nct06921785","nct05043090","nct04421963","nct01933932","nct06746116","nct03164616","nct05883644","nct03847428","nct05171816","nct06357533","nct05048797","nct07611110","nct06627647","nct07291037","nct05984277","nct05557838","nct06097728","nct04765059","nct04606771","nct05952024","nct06535607","nct01081951","nct05775159","nct02213926","nct07081633","nct05801029","nct06448754","nct06792695","nct05925530","nct04745689","nct06606847","nct07192614","nct05219500","nct05951959","nct06219941","nct04068610","nct07181161","nct03775486","nct06526793","nct05797168","nct05367440","nct07098338","nct07123454","nct02180711","nct06996782","nct05123482","nct04639219","nct07590934","nct07336446","nct06909825","nct03932331","nct04644068","nct05061550","nct05546866","nct06137144","nct01843374","nct06921928","nct05246514","nct06106945","nct06040099","nct06564038","nct07115043","nct07029737","nct06005493","nct07681596","nct05061134","nct05489211","nct03944772","nct02519348","nct06542250","nct06267729","nct07143604","nct05774951","nct07720284","nct05702229","nct06795022","nct03706690","nct03091192","nct04075292","nct05771480","nct03778229","nct07427394","nct06764875","nct07129993","nct03682068","nct06943833","nct05498155","nct06008093","nct05687266","nct05261399","nct02477696","nct06635447","nct04538742","nct06467357","nct02671435","nct02970318","nct02516241","nct03381274","nct01874353","nct05943106","nct06109779","nct02453282","nct06960577","nct07109219","nct02734004","nct06194448","nct02586857","nct00099437","nct03837899","nct04711252","nct04214288","nct06130553","nct05417594","nct02542293","nct07431281","nct06112379","nct03833154","nct04999969","nct04379596","nct07069712","nct05850234","nct07024706","nct03742895","nct06079671","nct03003962","nct04862663","nct02180724","nct07295821","nct05057494","nct05950945","nct07446855","nct06271837","nct05374603","nct06992609","nct07529717","nct06137118","nct03459846","nct06868277","nct06084884","nct05460273","nct05629234","nct02717611","nct07155226","nct06380751","nct03742102","nct07221253","nct06764186","nct03997123","nct07647328","nct04960709","nct02029443","nct05941897","nct02972840","nct04550260","nct05526755","nct04995523","nct04931654","nct06890598","nct07205822"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cambridge","country":"GB","companyType":"pharma","website":"https://www.astrazeneca.com","ticker":"AZN","investors":[],"funding":[]},{"id":"atara-biotherapeutics","kind":"company","name":"Atara Biotherapeutics","aka":["Atara Biotherapeutics, Inc.","NASDAQ:ATRA"],"tldr":"Atara Biotherapeutics is the Californian company behind Ebvallo, the first approved off-the-shelf T-cell therapy, which treats Epstein-Barr virus lymphoma after transplant using T cells from healthy donors.","summary":"Atara Biotherapeutics develops allogeneic Epstein-Barr virus-specific T-cell therapies. Tabelecleucel (Ebvallo), made from banked donor T cells matched by HLA, was approved in the European Union in December 2022 and by the FDA in 2025 for relapsed or refractory EBV-positive post-transplant lymphoproliferative disease; Pierre Fabre holds worldwide commercial rights. Atara's EBV-targeted CAR-T programme ATA3219 for lymphoma and lupus was paused in 2025 as the company restructured.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.atarabio.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["tabelecleucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Thousand Oaks, California","country":"US","companyType":"cell-therapy","website":"https://www.atarabio.com/","ticker":"NASDAQ:ATRA","founded":2012,"stage":"public","investors":[],"funding":[]},{"id":"ataraxis-ai","kind":"company","name":"Ataraxis AI","aka":[],"tldr":"Ataraxis AI analyses digitised breast tumour slides with artificial intelligence to estimate how likely a cancer is to return and whether chemotherapy is likely to help, returning results in a day without using up tissue.","summary":"Ataraxis AI, based in New York City, develops AI-native prognostic and predictive tests for cancer. Its foundation models (Kestrel and Falcon) are trained on hundreds of millions of pathology image tiles to learn tumour morphology features that correlate with outcomes. Its first product, Ataraxis Breast, provides recurrence risk, chemotherapy benefit and neoadjuvant response assessments from routine H&E slides within 24 hours, without consuming tissue. The company reported its test was about 30 percent more accurate than the current standard of care in a clinical validation study, published in Nature Communications in July 2026. Its laboratory received CAP accreditation and a California licence in August 2026, and in September 2026 it launched ARC, a prospective study linking AI predictions to outcomes. A $20.4 million Series A led by AIX Ventures closed in March 2025.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.ataraxis.ai/"},{"label":"Series A announcement (Mar 2025)","url":"https://www.ataraxis.ai/resources/ataraxis-ai-to-transform-precision-medicine-in-cancer-care-with-20-4-million-series-a"}],"tags":[],"related":[],"cancers":["breast-hr-positive","breast-her2-positive","tnbc"],"sections":["diagnostics","ai-computation"],"technologies":["pathology-foundation-model","digital-pathology-ai","companion-diagnostic"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not sourced. Breakthrough Device designation not confirmed on fetched pages. Business Wire copies of the 2026 CAP and ARC releases returned 403 to the fetcher, so they are cited only via the company homepage."],"hq":"New York, NY","country":"US","companyType":"ai-software","website":"https://www.ataraxis.ai/","stage":"startup","investors":["founders-fund"],"funding":[{"round":"Series A","year":2025,"amountUsd":20400000,"source":"https://www.ataraxis.ai/resources/ataraxis-ai-to-transform-precision-medicine-in-cancer-care-with-20-4-million-series-a","note":"Led by AIX Ventures, March 2025."}]},{"id":"atlas-venture","kind":"company","name":"Atlas Venture","aka":[],"tldr":"A Cambridge, Massachusetts biotech-only venture firm that seeds and incubates new drug companies. Cancer companies it has built include Bicycle Therapeutics, Day One Biopharmaceuticals and Antares Therapeutics.","summary":"Atlas Venture dates from 1980 (Wikipedia) and today describes itself as having created and built biotech companies for over 30 years, with an in-house incubator that has launched 92 start-ups and produced 43 IPOs and 39 M&A exits according to its homepage. It leads seed and Series A rounds, often forming companies around a single academic insight. The portfolio page lists many oncology companies: Accent Therapeutics (RNA-modifying protein inhibitors for cancer), Antares Therapeutics (first-in-class precision medicines for cancer, the subject of a Novartis deal), Bicycle Therapeutics (bicyclic peptide drug conjugates, Nasdaq: BCYC), Day One Biopharmaceuticals (Nasdaq: DAWN), IFM Therapeutics (innate immunity for cancer, sold to BMS and Novartis), Ikena Oncology and K36 Therapeutics.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://atlasventure.com/"},{"label":"Portfolio","url":"https://atlasventure.com/portfolio/"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Atlas_Venture"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cambridge, MA","country":"US","companyType":"investor","website":"https://atlasventure.com/","founded":1980,"investors":[],"funding":[]},{"id":"atomic-alchemy","kind":"company","name":"Atomic Alchemy","aka":[],"tldr":"Atomic Alchemy set out to build small reactors dedicated to making the radioactive isotopes used in cancer scans and treatments, so hospitals no longer depend on a handful of ageing government reactors. It was bought by the nuclear company Oklo.","summary":"Atomic Alchemy planned the first privately owned reactors dedicated to radioisotope production, starting with molybdenum-99 for technetium imaging and extending to therapeutic isotopes whose scarcity holds back radiopharmaceutical trials. Its YC profile describes a supply chain reliant on six ageing research reactors abroad. The company was acquired by Oklo, an advanced fission developer, which announced the deal in late 2024 and closed it in 2025; Oklo is not an OnCo record so the acquirer is named only here. Isotope production at scale remains a plan rather than an operating facility.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/atomic-alchemy"},{"label":"Official website","url":"https://atomicalchemy.us"}],"tags":["isotope-supply"],"related":[],"cancers":[],"sections":["radiopharma"],"technologies":["spect","radioligand-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Idaho Falls, ID","country":"US","companyType":"radiopharma","website":"https://atomicalchemy.us","stage":"acquired","ycBatch":"W19","investors":["y-combinator"],"funding":[]},{"id":"atossa-therapeutics","kind":"company","name":"Atossa Therapeutics","aka":["Atossa Therapeutics, Inc.","Atossa Genetics"],"tldr":"Atossa is a Seattle company developing oral endoxifen, the active metabolite of tamoxifen, for breast cancer prevention and treatment and for reducing dense breast tissue.","summary":"Atossa Therapeutics, founded in 2009 in Seattle, develops (Z)-endoxifen, the most active metabolite of tamoxifen, as an oral drug that bypasses the CYP2D6 metabolism that makes tamoxifen variable between patients. It is tested to reduce mammographic breast density in women at high risk, in the window before surgery, and alongside CDK4/6 inhibitors in advanced hormone receptor-positive breast cancer. Its trials are registered on ClinicalTrials.gov under Atossa as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://atossatherapeutics.com"},{"label":"ClinicalTrials.gov: trials led by Atossa Therapeutics, Inc.","url":"https://clinicaltrials.gov/search?lead=Atossa%20Therapeutics%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q107517747"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["breast-hr-positive"],"sections":["prevention","hormonal"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct05607004"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Seattle, WA","country":"US","companyType":"biotech","website":"https://atossatherapeutics.com","founded":2009,"stage":"public","investors":[],"funding":[]},{"id":"aulos-bioscience","kind":"company","name":"Aulos Bioscience","aka":[],"tldr":"Aulos Bioscience is a Californian biotech whose antibody AU-007 binds interleukin-2 so that the body's own cytokine expands cancer-killing cells without feeding the regulatory cells that dampen immunity.","summary":"Aulos Bioscience was founded by Apple Tree Partners and Biolojic Design around a computationally designed antibody, AU-007, that binds interleukin-2 at the CD25 epitope. This redirects endogenous and administered IL-2 towards CD8 T cells and natural killer cells and away from regulatory T cells. AU-007 is in phase 1/2 trials alone and with low-dose aldesleukin in solid tumours.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.aulosbio.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["au-007"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Larkspur, California","country":"US","companyType":"biotech","website":"https://www.aulosbio.com/","founded":2020,"investors":[],"funding":[]},{"id":"aura-biosciences","kind":"company","name":"Aura Biosciences","aka":[],"tldr":"Aura Biosciences is a United States-based biotechnology company running 2 late-stage cancer trials of AU-011 in melanoma and uveal melanoma.","summary":"Aura Biosciences, based in Boston, MA, the United States, is a biotechnology company. Aura Biosciences is a clinical-stage biotechnology company developing targeted oncology therapies for ocular cancers using its proprietary Virus-Like Drug Conjugate (VDC) technology. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing AU-011 in melanoma and uveal melanoma. The largest, NCT06007690 (A Phase 3 Randomised, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma), plans to enrol 108 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.aurabiosciences.com"},{"label":"ClinicalTrials.gov: trials led by Aura Biosciences","url":"https://clinicaltrials.gov/search?lead=Aura%20Biosciences"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma","uveal-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06643884","nct06007690"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://www.aurabiosciences.com","stage":"public","investors":[],"funding":[]},{"id":"aurigene","kind":"company","name":"Aurigene Oncology","aka":[],"tldr":"Dr. Reddy's oncology discovery company, with more than 20 programmes in clinical development worldwide through partners and its own small-molecule and cell therapy pipeline.","summary":"Aurigene was established in 2001 as a discovery subsidiary of Dr. Reddy's Laboratories and now describes itself as a clinical-stage biopharmaceutical company focused on cancer therapeutics, with more than 80 integrated discovery projects delivered, 22 programmes in global clinical development and a team of over 350 scientists in Bengaluru and Hyderabad. Its model has been to discover molecules against validated cancer targets and partner them with global companies for clinical development, while building an Indian pipeline that includes a BCMA-directed CAR-T for multiple myeloma developed for the Indian market.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.aurigene.com"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":["drug-discovery","cell-therapy"],"technologies":["kinase-inhibitors","car-t"],"targets":["bcma"],"drugs":[],"companies":["dr-reddys"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Bengaluru","country":"IN","companyType":"biotech","website":"https://www.aurigene.com","founded":2001,"investors":[],"funding":[]},{"id":"agitg","kind":"company","name":"Australasian Gastro-Intestinal Trials Group","aka":["AGITG","GI Cancer Institute"],"tldr":"Australia and New Zealand's gastrointestinal cancer trials group, running practice-informing trials in gastric, oesophageal, colorectal and pancreatic cancer, including ctDNA-guided adjuvant studies.","summary":"Founded in 1991, AGITG (operating publicly as the GI Cancer Institute) designs and runs investigator-initiated trials across Australia, New Zealand and international partners, with the NHMRC Clinical Trials Centre as its coordinating centre. TOPGEAR tested preoperative chemoradiotherapy in gastric cancer, INTEGRATE established regorafenib activity in refractory gastro-oesophageal cancer, and ASCOLT tested aspirin after colorectal cancer surgery. DYNAMIC-III extends the Australian ctDNA-guided adjuvant programme that began with the DYNAMIC study into stage III colon cancer. AGITG also runs hepatocellular, biliary and neuroendocrine tumour trials and partners with TROG and ANZUP.","asOf":"2026-09-09","links":[{"label":"GI Cancer Institute / AGITG","url":"https://gicancer.org.au"},{"label":"Clinical trials","url":"https://gicancer.org.au/clinical-trials/"}],"tags":["cooperative-group"],"related":["dynamic"],"cancers":["colorectal","gastric","esophageal","pancreatic","hcc","neuroendocrine"],"sections":[],"technologies":["liquid-biopsy","mrd-testing","cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":["trog","anzup"],"institutions":["peter-mac"],"pathways":[],"terms":["ctdna","mrd"],"trials":[],"people":["geoff-parnell","christos-karapetis"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["TOPGEAR (gastric chemoradiotherapy)","INTEGRATE (regorafenib)","DYNAMIC-III (ctDNA-guided adjuvant therapy)","ASCOLT (aspirin after colorectal surgery)"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Sydney","country":"AU","companyType":"cooperative-group","website":"https://gicancer.org.au","founded":1991,"investors":[],"funding":[]},{"id":"abcsg","kind":"company","name":"Austrian Breast & Colorectal Cancer Study Group","aka":["ABCSG"],"tldr":"Austria's academic breast and colorectal trials group, whose bone-targeted and extended endocrine therapy trials changed breast cancer practice.","summary":"Founded in 1984, ABCSG runs academic trials through Austria's hospitals and partners with the Breast International Group and the US groups on global studies. ABCSG-12 (zoledronic acid with ovarian suppression in premenopausal breast cancer) and ABCSG-18 (adjuvant denosumab) made bone-targeted agents part of adjuvant care, and ABCSG-16 defined how long extended aromatase inhibitor therapy should last. It co-led PALLAS, the adjuvant palbociclib trial, with Alliance Foundation Trials and BIG. Colorectal and pancreatic trials run through the same network.","asOf":"2026-09-09","links":[{"label":"ABCSG","url":"https://www.abcsg.org"},{"label":"Trials","url":"https://www.abcsg.org/studien/"}],"tags":["cooperative-group"],"related":["palbociclib"],"cancers":["breast-hr-positive","breast-her2-positive","colorectal"],"sections":["hormonal","targeted-therapy"],"technologies":["cdk46-inhibitor","endocrine-therapy"],"targets":[],"drugs":[],"companies":["big","alliance-oncology","gbg"],"institutions":[],"pathways":[],"terms":[],"trials":["pallas-penelope-b"],"people":["michael-gnant","christian-singer"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Adjuvant endocrine and bone-targeted therapy (ABCSG-12, -16, -18)","PALLAS (adjuvant palbociclib, with Alliance and BIG)","Colorectal and pancreatic cancer trials"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Vienna","country":"AT","companyType":"cooperative-group","website":"https://www.abcsg.org","founded":1984,"investors":[],"funding":[]},{"id":"autolus","kind":"company","name":"Autolus Therapeutics","aka":[],"tldr":"UCL spin-out whose fast-off-rate CD19 CAR-T, obe-cel, was approved for adult ALL in 2024 with lower neurotoxicity than earlier products.","summary":"Autolus Therapeutics, based in London and listed as AUTL, is a UCL spin-out whose fast-off-rate CD19 CAR-T, obecabtagene autoleucel, was approved for adult acute lymphoblastic leukaemia in 2024 with lower neurotoxicity than earlier products. Obe-cel, sold as Aucatzyl, was approved in the United States on 8 November 2024 and in the United Kingdom and European Union in 2025 for relapsed or refractory adult B-cell ALL on the FELIX trial, manufacturing is in Stevenage, and trials are running in lupus and paediatric ALL. OnCo links it to acute lymphoblastic leukaemia and to the obecabtagene autoleucel drug record. Whether an academic spin-out can manufacture and sell a CAR-T at scale without a large partner is the open question. The FDA approval notice is linked.","asOf":"2026-09-07","links":[{"label":"FDA approval notice","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-obecabtagene-autoleucel-adults-relapsed-or-refractory-b-cell-precursor-acute"}],"tags":[],"related":[],"cancers":["all-leukemia"],"sections":["cell-therapy"],"technologies":[],"targets":[],"drugs":["obecabtagene-autoleucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"London","country":"GB","companyType":"cell-therapy","website":"https://www.autolus.com","ticker":"AUTL","investors":[],"funding":[]},{"id":"avenzo","kind":"company","name":"Avenzo Therapeutics","aka":[],"tldr":"Avenzo in-licenses Chinese assets, including the Nectin-4×TROP2 bispecific ADC AVZO-103 and a CDK2 inhibitor.","summary":"Avenzo Therapeutics, based in San Diego, in-licenses Chinese oncology assets for Western development, including the Nectin-4 by TROP2 bispecific antibody-drug conjugate AVZO-103 and a CDK2 inhibitor. Its pipeline comprises AVZO-103, AVZO-021, the CDK2 inhibitor, and AVZO-1418, an EGFR by HER3 ADC. OnCo links it to Nectin-4 and TROP2 as targets and to the bispecific ADC technology. Whether a company that licenses rather than discovers can differentiate in a crowded bispecific ADC field is the open question. The bispecific ADC page carries the wider context.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.avenzotx.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs","targeted-therapy"],"technologies":[],"targets":["nectin4","trop2"],"drugs":["avzo-021","avzo-023"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05867251","nct07193511","nct07038343"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://www.avenzotx.com","investors":[],"funding":[]},{"id":"aveo","kind":"company","name":"AVEO Oncology (LG Chem)","aka":[],"tldr":"AVEO Oncology is a Boston company that developed tivozanib (Fotivda), a VEGF-receptor blocking pill used in relapsed kidney cancer, and was acquired by LG Chem in 2023. Its one marketed product now faces first-line immunotherapy combinations, and the TiNivo-2 rechallenge trial was negative.","summary":"AVEO Oncology, based in Boston, developed tivozanib and was acquired by LG Chem in 2023. Tivozanib, sold as Fotivda, is used in relapsed renal cell carcinoma, the TiNivo-2 trial of tivozanib as an immunotherapy rechallenge was negative, and ficlatuzumab, an HGF antibody, is in development for head and neck cancer. OnCo links it to renal cell carcinoma and to the tivozanib drug record. Whether a late-line VEGF inhibitor can keep a role as first-line immunotherapy combinations move the goalposts is the open question for its one marketed product. Tivozanib has its own page.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://www.aveooncology.com"}],"tags":[],"related":[],"cancers":["rcc"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["tivozanib","ficlatuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://www.aveooncology.com","investors":[],"funding":[]},{"id":"aveta-biomics","kind":"company","name":"Aveta Biomics","aka":["Aveta Biomics, Inc."],"tldr":"Aveta Biomics is a United States-based biotechnology company running 2 late-stage cancer trials of APG-157 in glioma & glioblastoma and head and neck squamous cell carcinoma.","summary":"Aveta Biomics, based in Bedford, the United States, is a biotechnology company. Aveta Biomics develops oral immunotherapies for cancer that apply principles of evolutionary biology to reprogram the tumour-immune ecosystem upstream of checkpoint pathways. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing APG-157 in glioma & glioblastoma and head and neck squamous cell carcinoma. The largest, NCT06011109 (Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab), plans to enrol 30 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://avetabiomics.com"},{"label":"ClinicalTrials.gov: trials led by Aveta Biomics","url":"https://clinicaltrials.gov/search?lead=Aveta%20Biomics%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["glioblastoma","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06011109","nct05312710"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Bedford","country":"US","companyType":"biotech","website":"https://avetabiomics.com","stage":"startup","investors":[],"funding":[]},{"id":"avistone-biotechnology","kind":"company","name":"Avistone Biotechnology","aka":["Avistone Biotechnology Co., Ltd."],"tldr":"Avistone Biotechnology is a China-based biotechnology company running 5 late-stage cancer trials of PLB1004, Vebreltinib and ANS02 in non-small-cell lung cancer.","summary":"Avistone Biotechnology, based in Beijing, China, is a biotechnology company. A commercialisation-stage innovative biopharmaceutical company (Chinese name Anvistone, formerly Beijing Puyuan Anvistone) focused on developing precision cancer medicines, with a manufacturing partner in Ningbo. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials, testing PLB1004, Vebreltinib and ANS02 in non-small-cell lung cancer. The largest, NCT07538804 (A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer), plans to enrol 294 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.avistonebio.com"},{"label":"ClinicalTrials.gov: trials led by Avistone Biotechnology","url":"https://clinicaltrials.gov/search?lead=Avistone%20Biotechnology%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["vebreltinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06343064","nct06574347","nct07538804","nct06015503","nct07336732"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Beijing","country":"CN","companyType":"biotech","website":"https://www.avistonebio.com","founded":2012,"stage":"growth","investors":[],"funding":[]},{"id":"b-braun","kind":"company","name":"B. Braun","aka":[],"tldr":"German medical-device company supplying Celsite ports, Easypump elastomeric pumps, infusion systems, and cytotoxic-safe consumables.","summary":"B. Braun, a private, family-owned German medical device company based in Melsungen, supplies Celsite ports, Easypump elastomeric pumps, infusion systems and cytotoxic-safe consumables. Its broad hospital supply portfolio includes oncology infusion and pharmacy compounding products. OnCo links it to infusion pumps, ports and ambulatory chemotherapy devices and to oncology pharmacy automation and compounding robots. Whether home-based chemotherapy delivery grows enough to change how infusion products are designed is the open question for this part of its business. The infusion devices page carries the wider picture.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/B._Braun","links":[{"label":"Official website","url":"https://www.bbraun.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["chemotherapy","supportive-care"],"technologies":["infusion-devices-vascular-access","pharmacy-automation"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Melsungen","country":"DE","companyType":"devices","website":"https://www.bbraun.com","investors":[],"funding":[]},{"id":"bain-capital-life-sciences","kind":"company","name":"Bain Capital Life Sciences","aka":[],"tldr":"The life sciences investing arm of Bain Capital in Boston. It funds later-stage private and public biotech companies, including cancer drug developers such as Olema Oncology, Nuvalent, Revolution Medicines and Mersana.","summary":"Bain Capital Life Sciences 'was founded in 2016 and builds on Bain Capital's four decades of healthcare and life sciences investing' (about page). It targets four kinds of opportunity: Inflection Capital, Growth Capital, Fallen Angels, and larger private equity collaborations and new company formation, across biopharmaceutical, medical device, diagnostic and life science tool companies globally. The firm is a frequent participant in crossover and PIPE financings. Its portfolio page lists oncology companies by year of investment, including Mersana Therapeutics (2020), Nurix Therapeutics (2022), Nuvalent (2021), Olema Oncology (2024), Replimune Group (2017), Revolution Medicines (2020), SpringWorks Therapeutics (2017), Syros Pharmaceuticals (2020) and Syremis (2025).","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.baincapitallifesciences.com/"},{"label":"Portfolio","url":"https://www.baincapitallifesciences.com/portfolio"},{"label":"About","url":"https://www.baincapitallifesciences.com/about"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["mersana","nurix","nuvalent","replimune","revolution-medicines"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boston, MA","country":"US","companyType":"investor","website":"https://www.baincapitallifesciences.com/","founded":2016,"investors":[],"funding":[]},{"id":"basilea","kind":"company","name":"Basilea Pharmaceutica","aka":["Basilea Pharmaceutica Ltd","Basilea"],"tldr":"Basilea is a Swiss company now focused on anti-infectives that ran phase 3 cancer trials of the FGFR inhibitor derazantinib and the tumour checkpoint controller lisavanbulin before divesting its oncology work in 2022.","summary":"Basilea Pharmaceutica, based near Basel and listed on the SIX Swiss Exchange, markets the antifungal isavuconazole and the antibiotic ceftobiprole. Its oncology portfolio, the FGFR inhibitor derazantinib in cholangiocarcinoma and urothelial cancer and the microtubule-targeting lisavanbulin in glioblastoma, was wound down in 2022 when the company decided to concentrate on anti-infectives and sought partners for the cancer assets. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Basilea_Pharmaceutica","links":[{"label":"Official website","url":"https://www.basilea.com"},{"label":"ClinicalTrials.gov: trials led by Basilea Pharmaceutica","url":"https://clinicaltrials.gov/search?lead=Basilea%20Pharmaceutica"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Basilea_Pharmaceutica"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cholangiocarcinoma","urothelial","glioblastoma"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["fgfr2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Allschwil","country":"CH","companyType":"pharma","website":"https://www.basilea.com","stage":"public","investors":[],"funding":[]},{"id":"bausch-health","kind":"company","name":"Bausch Health","aka":[],"tldr":"Bausch Health (formerly Valeant) is a diversified pharmaceutical company whose oncology-adjacent products include the retinoid bexarotene (Targretin) and imiquimod (Zyclara) for actinic keratosis.","summary":"Bausch Health sells dermatology, gastroenterology, eye health (Bausch + Lomb) and generic medicines. In oncology it holds the US applications for Targretin (bexarotene) in cutaneous T-cell lymphoma and Zyclara and Aldara (imiquimod), the latter approved for superficial basal cell carcinoma and actinic keratosis.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Bausch_Health","links":[{"label":"Official website","url":"https://www.bauschhealth.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Laval, Quebec","country":"CA","companyType":"pharma","website":"https://www.bauschhealth.com","ticker":"BHC","investors":[],"funding":[]},{"id":"bavarian-nordic","kind":"company","name":"Bavarian Nordic","aka":["Bavarian Nordic A/S"],"tldr":"Bavarian Nordic is a Danish vaccine company whose poxvirus-based prostate cancer vaccine PROSTVAC failed the phase 3 PROSPECT trial in 2017, after which it concentrated on infectious disease vaccines such as its smallpox and mpox vaccine.","summary":"Bavarian Nordic, based in Hellerup near Copenhagen and listed on Nasdaq Copenhagen, built its business on the modified vaccinia Ankara platform. In cancer it developed PROSTVAC (rilimogene galvacirepvec), a vaccinia and fowlpox vaccine against prostate-specific antigen, which did not improve survival in the phase 3 PROSPECT trial in metastatic castration-resistant prostate cancer reported in 2017, and CV301, a vaccine against CEA and MUC1 tested with checkpoint inhibitors. The company now focuses on travel and public health vaccines. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Bavarian_Nordic","links":[{"label":"Official website","url":"https://www.bavarian-nordic.com"},{"label":"ClinicalTrials.gov: trials led by Bavarian Nordic","url":"https://clinicaltrials.gov/search?lead=Bavarian%20Nordic"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Bavarian_Nordic"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate"],"sections":["immunotherapy"],"technologies":["shared-antigen-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Hellerup","country":"DK","companyType":"biotech","website":"https://www.bavarian-nordic.com","stage":"public","investors":[],"funding":[]},{"id":"baxter","kind":"company","name":"Baxter International","aka":[],"tldr":"Infusion pumps (Spectrum, Novum), elastomeric ambulatory pumps (Infusor), IV fluids and generic injectables.","summary":"Baxter International, based in Deerfield, Illinois, and listed as BAX, makes infusion pumps including Spectrum and Novum, elastomeric ambulatory pumps such as the Infusor, intravenous fluids and generic injectables. Its BioPharma Solutions fill-finish unit was sold to Advent and Warburg Pincus in 2023 and renamed Simtra. OnCo links it to infusion pumps, ports and ambulatory chemotherapy devices and to the mesna drug record. Whether ambulatory pumps can move more chemotherapy out of infusion chairs and into homes is the open question its devices bear on. The infusion devices page carries the wider picture.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Baxter_International","links":[{"label":"Official website","url":"https://www.baxter.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["chemotherapy","supportive-care"],"technologies":["infusion-devices-vascular-access"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Deerfield, IL","country":"US","companyType":"devices","website":"https://www.baxter.com","ticker":"BAX","investors":[],"funding":[]},{"id":"bayer","kind":"company","name":"Bayer","aka":[],"tldr":"Bayer owns Xofigo, the only approved alpha emitter, and is developing next-generation actinium PSMA agents.","summary":"Bayer, based in Leverkusen and listed as BAYN.DE, owns Xofigo, or radium-223, the only approved alpha emitter, and is developing next-generation actinium-225 PSMA agents. Its oncology portfolio includes 225Ac-PSMA-Trillium, also known as BAY 3563254, darolutamide in prostate cancer, sevabertinib for HER2-mutant non-small-cell lung cancer approved in 2025, larotrectinib, developed earlier with Lilly, and copanlisib, with the AlphaBreak and AcTION actinium trials linked in OnCo. OnCo also connects it to colorectal, liver, GIST and desmoid tumour pages, to the Norwegian Radium Hospital in Oslo, and to its venture arm Leaps by Bayer. Whether a targeted alpha emitter can go further than radium-223 did is the open question its PSMA programme will answer. Actinium-225 PSMA agents have their own page.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Bayer","links":[{"label":"Official website","url":"https://www.bayer.com"}],"tags":[],"related":[],"cancers":[],"sections":["radiopharma","targeted-therapy"],"technologies":[],"targets":[],"drugs":["ac225-psma"],"companies":["leaps-by-bayer"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06452277","nct05794906","nct07450599","nct04464226","nct06246643","nct06914128","nct06760819","nct05587296","nct02637687","nct07811193"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Leverkusen","country":"DE","companyType":"pharma","website":"https://www.bayer.com","ticker":"BAYN.DE","investors":[],"funding":[]},{"id":"becton-dickinson","kind":"company","name":"BD (Becton, Dickinson and Company)","aka":[],"tldr":"Medical technology company supplying closed-system transfer devices (PhaSeal), infusion systems, flow cytometers, and single-cell tools.","summary":"BD, Becton, Dickinson and Company, based in Franklin Lakes, New Jersey, and listed as BDX, is a medical technology company supplying closed-system transfer devices such as PhaSeal, infusion systems, flow cytometers and single-cell tools. Its oncology footprint spans hazardous-drug handling, BD Cato compounding software, FACS flow cytometry used for measurable residual disease and the BD Rhapsody single-cell platform. OnCo links it to pharmacy automation, multiparameter flow cytometry MRD, cell-therapy release testing and infusion devices. Whether flow cytometry keeps its place in MRD as sequencing-based tests spread is the open question for one part of its business. The flow cytometry MRD page carries the evidence.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.bd.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["chemotherapy","diagnostics"],"technologies":["pharmacy-automation","flow-cytometry-mrd"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Franklin Lakes, NJ","country":"US","companyType":"devices","website":"https://www.bd.com","ticker":"BDX","investors":[],"funding":[]},{"id":"bebetter-med","kind":"company","name":"BeBetter Med","aka":["BeBetter Medicine","Guangzhou BeBetter Medicine Technology"],"tldr":"BeBetter Med is a Guangzhou biotechnology company developing BEBT-908, a dual PI3K and HDAC inhibitor for relapsed lymphoma, and other small-molecule cancer drugs, with three late-stage trials in the registry.","summary":"BeBetter Med, based in Guangzhou, develops small-molecule cancer drugs. Its lead programme BEBT-908 inhibits both PI3K and histone deacetylases and has been studied in relapsed or refractory diffuse large B-cell lymphoma and other lymphomas, and the company runs further trials of its pipeline in solid tumours. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.bebettermed.com/"},{"label":"ClinicalTrials.gov: trials led by BeBetter Med","url":"https://clinicaltrials.gov/search?lead=BeBetter%20Med"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["dlbcl"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["bebt-209","ifupinostat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07544056","nct06792253","nct06998108","nct06514027","nct06706713"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Guangzhou","country":"CN","companyType":"biotech","website":"https://www.bebettermed.com/","stage":"growth","investors":[],"funding":[]},{"id":"beckman-coulter","kind":"company","name":"Beckman Coulter","aka":[],"tldr":"Beckman Coulter, part of Danaher, makes the Navios, DxFLEX and CytoFLEX flow cytometers used in haematology laboratories to type leukaemias and measure residual disease, together with automated haematology analysers and centrifuges.","summary":"Beckman Coulter traces to Arnold Beckman's 1935 instrument company and Wallace Coulter's cell counter; Danaher acquired it in 2011. Its clinical flow cytometers (Navios EX, DxFLEX) and research CytoFLEX line, with the ClearLLab reagent panels, are widely used for leukaemia and lymphoma immunophenotyping and measurable residual disease, and its haematology analysers run the blood counts that monitor chemotherapy. OnCo links it to flow cytometers and flow cytometry MRD.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.beckman.com"}],"tags":["machines-wave"],"related":[],"cancers":["all-leukemia","aml","cll"],"sections":["diagnostics"],"technologies":["flow-cytometers","flow-cytometry-mrd"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Brea, CA","country":"US","companyType":"diagnostics","website":"https://www.beckman.com","founded":1935,"stage":"acquired","investors":[],"funding":[]},{"id":"beijing-gene-key-life-technology","kind":"company","name":"Beijing Gene Key Life Technology","aka":["Beijing Gene Key Life Technology Co., Ltd"],"tldr":"Beijing Gene Key Life Technology is a Chinese developer in Beijing that sponsors 2 registered cancer trials of GKL-006.","summary":"Beijing Gene Key Life Technology appears on ClinicalTrials.gov as the industry sponsor of 2 interventional cancer trials (phase 1/2, 2), testing GKL-006 in hepatocellular carcinoma (hcc), unresectable hepatocellular cancer, advanced pancreatic cancer, ductal adenocarcinoma of pancreas. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials sponsored by Beijing Gene Key Life Technology","url":"https://clinicaltrials.gov/search?spons=Beijing%20Gene%20Key%20Life%20Technology"}],"tags":["ctgov-sponsor","china","registry-only"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07209813","nct07777211"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Beijing, China","country":"CN","companyType":"biotech","investors":[],"funding":[]},{"id":"beijing-konruns-pharmaceutical","kind":"company","name":"Beijing Konruns Pharmaceutical","aka":["Beijing Konruns Pharmaceutical Co., Ltd."],"tldr":"Beijing Konruns Pharmaceutical is a Chinese developer in Beijing that sponsors 5 registered cancer trials of KC1036 and S-1.","summary":"Beijing Konruns Pharmaceutical appears on ClinicalTrials.gov as the industry sponsor of 5 interventional cancer trials (phase 1/2, 2, 3), testing KC1036, S-1, Toripalimab in esophageal squamous cell carcinoma, esophageal squamous cell carcinoma (escc), digestive system tumors, thymic tumors. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials sponsored by Beijing Konruns Pharmaceutical","url":"https://clinicaltrials.gov/search?spons=Beijing%20Konruns%20Pharmaceutical"}],"tags":["ctgov-sponsor","china","registry-only"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06194734","nct07481058","nct05683886","nct06564272"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Beijing, China","country":"CN","companyType":"biotech","website":"https://www.konruns.cn","investors":[],"funding":[]},{"id":"beijing-mabworks-biotech","kind":"company","name":"Beijing Mabworks Biotech","aka":["Beijing Mabworks Biotech Co., Ltd."],"tldr":"Beijing Mabworks Biotech is a Chinese developer in Beijing that sponsors 4 registered cancer trials of MBS314 and MBS303.","summary":"Beijing Mabworks Biotech appears on ClinicalTrials.gov as the industry sponsor of 4 interventional cancer trials (phase 1/2, 3), testing MBS314, MBS303, Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide, lenalinomide in relapsed or refractory multiple myeloma, non-hodgkin's lymphoma, follicular lymphoma and marginal zone lymphoma. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials sponsored by Beijing Mabworks Biotech","url":"https://clinicaltrials.gov/search?spons=Beijing%20Mabworks%20Biotech"}],"tags":["ctgov-sponsor","china","registry-only"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06232096","nct05806099","nct04834024","nct04110301"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Beijing, China","country":"CN","companyType":"biotech","investors":[],"funding":[]},{"id":"beijing-pearl-biotechnology-limited-liability-company","kind":"company","name":"Beijing Pearl Biotechnology Limited Liability Company","aka":[],"tldr":"Beijing Pearl Biotechnology Limited Liability Company is a Chinese developer in Beijing that sponsors 3 registered cancer trials of PLB1001 and Temozolomide.","summary":"Beijing Pearl Biotechnology Limited Liability Company appears on ClinicalTrials.gov as the industry sponsor of 3 interventional cancer trials (phase 2/3, 3), testing PLB1001, Temozolomide in glioblastoma, non-small cell lung cancer, non-small cell lung cancer. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials sponsored by Beijing Pearl Biotechnology Limited Liability Company","url":"https://clinicaltrials.gov/search?spons=Beijing%20Pearl%20Biotechnology%20Limited%20Liability%20Company"}],"tags":["ctgov-sponsor","china","registry-only"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06105619","nct05989542","nct06930794"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Beijing, China","country":"CN","companyType":"biotech","investors":[],"funding":[]},{"id":"beijing-scitech-mq-pharmaceuticals","kind":"company","name":"Beijing Scitech-Mq Pharmaceuticals","aka":["Beijing Scitech-Mq Pharmaceuticals Limited"],"tldr":"Beijing Scitech-Mq Pharmaceuticals is a Chinese developer in Beijing that sponsors 3 registered cancer trials of ST-1898.","summary":"Beijing Scitech-Mq Pharmaceuticals appears on ClinicalTrials.gov as the industry sponsor of 3 interventional cancer trials (phase 1/2, 2), testing ST-1898 in unresectable or metastatic melanoma, advanced renal cell carcinoma, differentiated thyroid carcinoma. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials sponsored by Beijing Scitech-Mq Pharmaceuticals","url":"https://clinicaltrials.gov/search?spons=Beijing%20Scitech-Mq%20Pharmaceuticals"}],"tags":["ctgov-sponsor","china","registry-only"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06359860","nct06127238","nct06359847"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Beijing, China","country":"CN","companyType":"biotech","investors":[],"funding":[]},{"id":"beijing-tide-pharmaceutical","kind":"company","name":"Beijing Tide Pharmaceutical","aka":["Beijing Tide Pharmaceutical Co., Ltd"],"tldr":"Beijing Tide Pharmaceutical is a Chinese developer in Beijing that sponsors 2 registered cancer trials of TCC1727.","summary":"Beijing Tide Pharmaceutical appears on ClinicalTrials.gov as the industry sponsor of 2 interventional cancer trials (phase 1/2), testing TCC1727 in patients with advanced solid tumors, solid cancers, nsclc (advanced non-small cell lung cancer), gastric (stomach) cancer. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials sponsored by Beijing Tide Pharmaceutical","url":"https://clinicaltrials.gov/search?spons=Beijing%20Tide%20Pharmaceutical"}],"tags":["ctgov-sponsor","china","registry-only"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05970016","nct07371663"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Beijing, China","country":"CN","companyType":"biotech","website":"https://www.tidepharm.com","investors":[],"funding":[]},{"id":"belay-diagnostics","kind":"company","name":"Belay Diagnostics","aka":[],"tldr":"Belay Diagnostics reads tumour DNA from cerebrospinal fluid, giving brain and spinal cord tumours a liquid biopsy when a tissue biopsy is risky or impossible, and telling true progression from treatment effects on scans.","summary":"Belay Diagnostics, based in Chicago, offers cerebrospinal fluid liquid biopsy for primary and metastatic tumours of the central nervous system: genomic profiling to find targetable alterations when tissue is unavailable, and longitudinal monitoring to detect recurrence and to distinguish pseudoprogression from real progression. The tests are physician-ordered.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://belaydiagnostics.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["liquid-biopsy","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Chicago, IL","country":"US","companyType":"diagnostics","website":"https://belaydiagnostics.com/","investors":[],"funding":[]},{"id":"bellicum","kind":"company","name":"Bellicum Pharmaceuticals","aka":["Bellicum Pharmaceuticals, Inc.","Bellicum"],"tldr":"Bellicum was a Houston cell-therapy company known for its rimiducid safety switch, which let doctors switch off infused T cells; its lead product for transplant failed to reach approval and the company wound down.","summary":"Bellicum Pharmaceuticals, founded in 2004 in Houston, built cell therapies around an inducible caspase-9 safety switch triggered by the small molecule rimiducid. Its lead product rivogenlecleucel (BPX-501), donor T cells given after haploidentical stem cell transplant in children, reached phase 3 in Europe, and later GoCAR-T products entered early trials before the company ceased operations in 2023. Its trials remain on ClinicalTrials.gov under Bellicum as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.bellicum.com"},{"label":"ClinicalTrials.gov: trials led by Bellicum Pharmaceuticals, Inc.","url":"https://clinicaltrials.gov/search?lead=Bellicum%20Pharmaceuticals%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30257112"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["all-leukemia","aml"],"sections":[],"technologies":["car-t","allogeneic-hsct"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct03301168","nct01744223"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Houston, TX","country":"US","companyType":"cell-therapy","website":"http://www.bellicum.com","founded":2004,"stage":"defunct","investors":[],"funding":[]},{"id":"belmont-medical-technologies","kind":"company","name":"Belmont Medical Technologies","aka":[],"tldr":"Belmont Medical Technologies makes the Belmont Hyperthermia Pump, a purpose-built perfusion system that heats and circulates chemotherapy through the abdomen during HIPEC.","summary":"Belmont, known for rapid infusion systems used in trauma and surgery, adapted its heat-exchange pump technology into the Belmont Hyperthermia Pump, which controls flow and temperature for hyperthermic intraperitoneal chemotherapy and hyperthermic intravesical and limb perfusion, replacing improvised cardiac bypass circuits.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.belmontmedtech.com/"}],"tags":["machines-wave2"],"related":[],"cancers":["appendiceal","ovarian","colorectal"],"sections":[],"technologies":["hipec-pipac-devices","hipec"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Billerica, MA","country":"US","companyType":"devices","website":"https://www.belmontmedtech.com/","stage":"private-large","investors":[],"funding":[]},{"id":"belong-life","kind":"company","name":"Belong.Life","aka":[],"tldr":"Belong.Life runs a large free social app where people with cancer share experiences and ask questions, plus Dave, an artificial intelligence mentor that answers cancer questions around the clock.","summary":"Belong.Life operates Belong Beating Cancer Together, which it describes as the world's largest social and professional network for cancer patients, alongside Dave, a conversational AI cancer mentor giving proactive guidance validated by physicians and informed by the peer community; the company says validation studies have been presented at ASCO and ESMO. It sells white label patient engagement and clinical trial recruitment solutions to pharmaceutical companies including Janssen, Bayer, AbbVie, AstraZeneca, Novartis, Roche, Sanofi, Takeda, Teva and MSD, reports millions of users worldwide, and holds HIPAA, GDPR and ISO 27001 certifications. The operating entity is Belong.Life Inc, a Delaware company, with parent Belongtail Ltd; the contact page lists an office at 276 5th Avenue, New York. No funding round, investor or founding year could be sourced from a primary document.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://belong.life"},{"label":"About Belong.Life","url":"https://belong.life/about-us/"},{"label":"Contact page (New York office)","url":"https://belong.life/contact-us/"}],"tags":[],"related":[],"cancers":[],"sections":["supportive-care","ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Hint gave Tel Aviv and New York; only the New York office address was found on the site, and the parent Belongtail Ltd is Israeli. No press releases found on PR Newswire and the site news pages return HTTP 500, so no funding rounds are recorded. Stage set to startup by default. Founding year not sourced (site says founded over a decade ago)."],"hq":"New York, NY","country":"US","companyType":"ai-software","website":"https://belong.life","stage":"startup","investors":[],"funding":[]},{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","aka":["BeiGene","BeiGene USA","Inc.","BeOne","BeOne (BeiGene)","GW Pharmaceuticals Ltd","GW Pharmaceuticals"],"tldr":"BeOne Medicines makes Brukinsa, the leading BTK inhibitor, and tislelizumab, and is the Asia partner for zanidatamab.","summary":"BeOne Medicines, formerly BeiGene, based in Basel and Beijing and listed as ONC, makes Brukinsa, or zanubrutinib, the leading BTK inhibitor, and tislelizumab, and is the Asia partner for zanidatamab. Its pipeline includes sonrotoclax, a BCL-2 inhibitor, and the BTK degrader BGB-16673, with the RATIONALE-302 trial linked, and John Oyler and Jie Wang among the people connected. OnCo links it to chronic lymphocytic leukaemia, mantle cell and follicular lymphoma, gastric and nasopharyngeal cancer, and to bottlenecks on acquired resistance, regulatory divergence and unrepresentative trials, which its China-to-global model bears on. Whether a BTK degrader can overcome resistance to its own BTK inhibitor is the open question. Zanubrutinib and zanidatamab have their own pages.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.beonemedicines.com"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy","immunotherapy"],"technologies":[],"targets":[],"drugs":["zanidatamab","bgb-43395","pamiparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04002297","nct04379635","nct06742996","nct05100862","nct06697184","nct05471843","nct05609370","nct05635708","nct05661955","nct06427941","nct05006716","nct05294731","nct04973605","nct06973187","nct06943872","nct04521231","nct07554521","nct04771130","nct07277231","nct06846671","nct05479994","nct06634589","nct07134088","nct04170283","nct03967977","nct06637501","nct06970743","nct05952037","nct03736889"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Basel / Beijing","country":"CH","companyType":"biotech","website":"https://www.beonemedicines.com","ticker":"ONC","investors":[],"funding":[]},{"id":"betta","kind":"company","name":"Betta Pharmaceuticals","aka":["贝达药业"],"tldr":"Betta made icotinib, the first cancer drug invented in China, and later ensartinib, the first Chinese ALK inhibitor to win FDA approval.","summary":"Betta Pharmaceuticals, based in Hangzhou, founded in 2003 and listed as 300558.SZ, made icotinib, the first cancer drug invented in China, and later ensartinib, the first Chinese ALK inhibitor to win FDA approval. Icotinib, sold as Conmana, was approved in 2011; ensartinib, sold as Ensacove, was approved in China in 2020 and by the FDA in December 2024 for ALK-positive non-small-cell lung cancer through Xcovery; befotertinib from InventisBio was approved in 2023; and the company holds China rights to the MCLA-129 EGFR by c-MET bispecific from Merus. OnCo links it to icotinib and ensartinib and to InventisBio and Merus. Whether an FDA approval for ensartinib translates into US sales against entrenched ALK drugs is the open question. Ensartinib has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.bettapharma.com/"}],"tags":["china"],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["icotinib","ensartinib","mcla-129","befotertinib","vorolanib"],"companies":["inventisbio","merus"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06041776","nct04930432","nct07448116"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Hangzhou","country":"CN","companyType":"biotech","website":"https://www.bettapharma.com/","ticker":"300558.SZ","founded":2003,"investors":[],"funding":[]},{"id":"beyondspring","kind":"company","name":"BeyondSpring Pharmaceuticals","aka":["BeyondSpring Pharmaceuticals Inc.","BeyondSpring"],"tldr":"BeyondSpring is a New York biotechnology company developing plinabulin, a microtubule-binding agent tested in phase 3 for chemotherapy-induced neutropenia and for non-small-cell lung cancer, which received a complete response letter from the FDA in 2021.","summary":"BeyondSpring Pharmaceuticals, listed on Nasdaq, develops plinabulin, a small molecule that binds tubulin and triggers dendritic cell maturation. It ran phase 3 trials of plinabulin to prevent chemotherapy-induced neutropenia (PROTECTIVE-1 and 2) and, with docetaxel, in previously treated non-small-cell lung cancer (DUBLIN-3); the FDA issued a complete response letter for the neutropenia indication in 2021 asking for a second trial. OnCo records it as a registry sponsor of phase 3 cancer trials.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.beyondspringpharma.com"},{"label":"ClinicalTrials.gov: trials led by BeyondSpring","url":"https://clinicaltrials.gov/search?lead=BeyondSpring"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc"],"sections":["supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["neutropenia"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"New York, NY","country":"US","companyType":"biotech","website":"https://www.beyondspringpharma.com","stage":"public","investors":[],"funding":[]},{"id":"bicara-therapeutics","kind":"company","name":"Bicara Therapeutics","aka":[],"tldr":"Bicara's lead drug, ficerafusp alfa, is a two-in-one antibody that blocks the EGFR growth signal on head and neck cancer cells while also soaking up TGF-beta, a molecule tumours use to suppress immune attack. It is in a pivotal trial with pembrolizumab in head and neck cancer.","summary":"Bicara Therapeutics is a Boston clinical-stage company developing bifunctional antibody therapies. Lead programme ficerafusp alfa (formerly BCA101) is an EGFR-directed monoclonal antibody fused to a human TGF-beta ligand trap, designed to block EGFR-driven proliferation while neutralising immunosuppressive TGF-beta in the tumour microenvironment. Three-year follow-up from a phase 1/1b cohort with pembrolizumab in first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma showed an estimated overall survival rate of 31% at the 1500 mg weekly dose. The pivotal FORTIFI-HN01 trial is enrolling, with topline results from an interim analysis expected in mid-2027, and the FORTIFI-FLEX alternate dosing study has started. Leadership transitions announced in August 2026 will see Ryan Cohlhepp become CEO in January 2027. Nasdaq: BCAX.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.bicara.com/"},{"label":"Q2 2026 results and leadership transition (8-K exhibit 99.1)","url":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026055500/projectwaystar-2q26earning.htm"}],"tags":[],"related":[],"cancers":["head-and-neck"],"sections":["immunotherapy"],"technologies":["bispecific-antibody","monoclonal-antibody"],"targets":["egfr"],"drugs":["ficerafusp-alfa"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07807163"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["September 2024 IPO not sourced (8-K fetched did not state proceeds). Company website is JavaScript-rendered and returned little text."],"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://www.bicara.com/","ticker":"BCAX","stage":"public","investors":[],"funding":[]},{"id":"bicycle-therapeutics","kind":"company","name":"Bicycle Therapeutics","aka":[],"tldr":"Inventor of bicyclic peptide drug conjugates; its lead Nectin-4 conjugate was deprioritised in 2026 after regulatory feedback.","summary":"Bicycle Therapeutics, based in Cambridge in the United Kingdom and listed as BCYC, is the inventor of bicyclic peptide drug conjugates, a class of small, synthetic alternatives to antibody-drug conjugates. Its lead Nectin-4 conjugate, zelenectide pevedotin, or BT8009, was deprioritised in 2026 after regulatory feedback, BT5528 targets EphA2, and its Bicycle radio-conjugates are partnered with Bayer and Novartis in radiopharmaceuticals. OnCo links it to bladder and urothelial cancer, to the zelenectide pevedotin drug record, and to the peptide-drug and small-molecule-drug conjugate technology. Whether bicyclic peptides find their place as radiopharmaceutical carriers rather than as cytotoxic conjugates is the question the 2026 decision poses. Zelenectide pevedotin has its own page.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://www.bicycletherapeutics.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":["peptide-drug-conjugate"],"targets":[],"drugs":["zelenectide-pevedotin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07450859","nct05163041","nct04561362","nct06225596","nct06840483","nct04180371","nct06933329"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cambridge","country":"GB","companyType":"biotech","website":"https://www.bicycletherapeutics.com","ticker":"BCYC","investors":["sv-health-investors","novartis-venture-fund"],"funding":[]},{"id":"bighat-biosciences","kind":"company","name":"BigHat Biosciences","aka":[],"tldr":"BigHat uses machine learning and a fast automated lab to design antibodies. Its first cancer drug, an antibody carrying a chemotherapy payload to stomach and bowel tumours, entered human trials in 2026.","summary":"BigHat Biosciences, based in San Mateo, California, is an AI-native antibody company. Its Milliner platform pairs a synthetic biology wet lab that can synthesise, purify and characterise hundreds of antibodies a week with machine learning that proposes the next designs. Lead programme BHB810 is a CDH17-directed VHH-Fc antibody-drug conjugate with a compact antibody format and a stable payload; across about 30 patient- and cell-derived tumour models it produced complete or near-complete tumour clearance, and the first patient was dosed in a phase 1 dose-escalation trial in gastric, gastro-oesophageal junction and other advanced gastrointestinal tumours on 1 September 2026. BigHat has completed collaborations with Merck and Johnson and Johnson and partners with Eli Lilly through Lilly TuneLab. The company describes itself as a Series B company that has raised more than USD 100 million; round details were not on fetched pages.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.bighatbio.com"},{"label":"First patient dosed with BHB810 (September 2026)","url":"https://bighatbio.com/news/bighat-biosciences-announces-first-patient-dosed-in-phase-1-trial-evaluating-bhb810"},{"label":"News","url":"https://bighatbio.com/news"}],"tags":[],"related":[],"cancers":["gastric","esophageal","colorectal"],"sections":["adcs","ai-computation","drug-discovery"],"technologies":["adc","monoclonal-antibody","ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07529808"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Colorectal included because the trial covers advanced gastrointestinal tumours broadly; specific enrolment beyond gastric and GEJ not confirmed. Founding year and round amounts not sourced."],"hq":"San Mateo, CA","country":"US","companyType":"biotech","website":"https://www.bighatbio.com","stage":"startup","investors":[],"funding":[]},{"id":"bikanta","kind":"company","name":"Bikanta","aka":[],"tldr":"Bikanta tried to use tiny fluorescent diamonds as imaging probes to spot cancer earlier. It went through Y Combinator in 2014 and is no longer operating.","summary":"Bikanta developed fluorescent nanodiamond probes for background-free optical imaging, aiming to improve the signal of medical imaging and diagnostics by up to 100-fold over conventional fluorescence according to its YC profile. Nanodiamonds are bright, photostable and non-toxic and can be functionalised to bind cancer targets. The company is listed as inactive in the YC directory and its website was offline when checked on 2026-09-10; no clinical product was launched. Recorded here as part of the complete map of YC companies that took on cancer.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/bikanta"}],"tags":["yc"],"related":[],"cancers":[],"sections":["imaging","diagnostics"],"technologies":["optical-imaging"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Berkeley, CA","country":"US","companyType":"imaging","website":"https://www.ycombinator.com/companies/bikanta","stage":"defunct","ycBatch":"S14","investors":["y-combinator"],"funding":[]},{"id":"billiontoone","kind":"company","name":"BillionToOne","aka":[],"tldr":"BillionToOne counts DNA molecules in blood far more precisely than standard sequencing. Known first for prenatal testing, it now sells liquid biopsy tests that read a tumour's mutations and track treatment from a blood draw.","summary":"BillionToOne's Quantitative Counting Template technology adds synthetic molecular counters to cell-free DNA sequencing, improving quantitative resolution by more than a thousand-fold according to the company. That platform underlies UNITY prenatal screening and the Northstar oncology line: Northstar Select, a comprehensive liquid biopsy panel for treatment selection in advanced solid tumours, and Northstar Response, which quantifies methylated tumour DNA to monitor response. The company listed on Nasdaq in 2025. It is one of the largest companies to have come out of YC in oncology diagnostics.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/billiontoone"},{"label":"Official website","url":"https://www.billiontoone.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["liquid-biopsy","mrd-testing","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Menlo Park, CA","country":"US","companyType":"diagnostics","website":"https://www.billiontoone.com","ticker":"BLLN","stage":"public","ycBatch":"S17","investors":["y-combinator"],"funding":[]},{"id":"binhui-biopharmaceutical","kind":"company","name":"Binhui Biopharmaceutical","aka":["Binhui Biopharmaceutical Co., Ltd."],"tldr":"Binhui Biopharmaceutical is a Chinese developer in Wuhan that sponsors 4 registered cancer trials of OH2 and HX008.","summary":"Binhui Biopharmaceutical appears on ClinicalTrials.gov as the industry sponsor of 4 interventional cancer trials (phase 1/2, 3), testing OH2, HX008 in solid tumor, gastrointestinal cancer, melanoma. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials sponsored by Binhui Biopharmaceutical","url":"https://clinicaltrials.gov/search?spons=Binhui%20Biopharmaceutical"}],"tags":["ctgov-sponsor","china","registry-only"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03866525","nct07382531","nct04616443","nct05868707"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Wuhan, China","country":"CN","companyType":"biotech","investors":[],"funding":[]},{"id":"bio-thera-solutions","kind":"company","name":"Bio-Thera Solutions","aka":[],"tldr":"Bio-Thera Solutions is a China-based pharmaceutical company running 3 late-stage cancer trials of BAT8008, BAT1308 and BAT8010 in cervical cancer.","summary":"Bio-Thera Solutions, based in Guangzhou, China, is a pharmaceutical company. Bio-Thera Solutions is a Guangzhou-based biopharmaceutical company that develops and markets antibody therapeutics, including approved biosimilars and pipeline candidates for cancer and autoimmune disease. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing BAT8008, BAT1308, BAT8010 and BAT1006 in cervical cancer. The largest, NCT06123884 (BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer), plans to enrol 526 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.bio-thera.com"},{"label":"ClinicalTrials.gov: trials led by Bio-Thera Solutions","url":"https://clinicaltrials.gov/search?lead=Bio-Thera%20Solutions"},{"label":"Pipeline page","url":"https://www.bio-thera.com/col_16/"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cervical"],"sections":[],"technologies":[],"targets":[],"drugs":["bevacizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06123884","nct06341114","nct06376136"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Guangzhou","country":"CN","companyType":"pharma","website":"https://www.bio-thera.com","stage":"public","investors":[],"funding":[]},{"id":"bioatla","kind":"company","name":"BioAtla","aka":["BioAtla, Inc.","NASDAQ:BCAB"],"tldr":"BioAtla is a San Diego biotech whose conditionally active antibodies switch on in the acidic surroundings of a tumour and stay quiet in healthy tissue, the basis of its drug conjugates and the CTLA-4 antibody BA3071.","summary":"BioAtla develops conditionally active biologics (CAB) that bind their target under the low pH of the tumour microenvironment but not at the physiological pH of normal tissue, widening the therapeutic window. Its clinical programmes include the AXL conjugate mecbotamab vedotin, the ROR2 conjugate ozuriftamab vedotin, the EpCAM x CD3 bispecific BA3182 and the CTLA-4 antibody BA3071, which is being tested with nivolumab.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.bioatla.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["ba3071"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"San Diego, California","country":"US","companyType":"biotech","website":"https://www.bioatla.com/","ticker":"NASDAQ:BCAB","founded":2007,"stage":"public","investors":[],"funding":[]},{"id":"biocad","kind":"company","name":"Biocad","aka":["BIOCAD"],"tldr":"Biocad is a Russian biotechnology company that makes biosimilars of rituximab, bevacizumab and trastuzumab and developed prolgolimab, the first anti-PD-1 antibody approved in Russia, now tested with its anti-CTLA-4 partner nurulimab in melanoma.","summary":"Biocad, based in St Petersburg, is Russia's largest biotechnology company by its own account, with biosimilars of rituximab, bevacizumab and trastuzumab that supply much of the Russian market and an in-house immuno-oncology pipeline. Its anti-PD-1 antibody prolgolimab (BCD-100, brand name Forteca) received Russian approval for melanoma in 2020 and is in phase 3 trials as a fixed combination with the anti-CTLA-4 antibody nurulimab (BCD-217) in unresectable and resectable melanoma. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://biocad.ru/"},{"label":"ClinicalTrials.gov: trials led by Biocad","url":"https://clinicaltrials.gov/search?lead=Biocad"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma"],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["bcd-100","bcd-217"],"companies":[],"institutions":["blokhin-cancer-center","petrov-institute"],"pathways":[],"terms":[],"trials":["nct05732805","nct05751928","nct06640530","nct05802225","nct07108309","nct06668792","nct07742215"],"people":[],"bottlenecks":[],"keyPapers":["paper-tjulandin-prolgolimab-miraculum-ejc-2021","paper-laktionov-prolgolimab-domajor-ejc-2025"],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"St Petersburg","country":"RU","companyType":"biotech","website":"https://biocad.ru/","stage":"private-large","investors":[],"funding":[]},{"id":"biocon","kind":"company","name":"Biocon","aka":[],"tldr":"India's largest biopharmaceutical company, founded by Kiran Mazumdar-Shaw in 1978, and the parent of Biocon Biologics, which makes low-cost copies of the antibodies trastuzumab and bevacizumab.","summary":"Biocon was founded in Bengaluru in 1978 by Kiran Mazumdar-Shaw and grew from enzymes into generic active ingredients, insulins and antibodies. Its oncology footprint runs through Biocon Biologics (biosimilars) and Syngene (contract research). Biocon launched ALZUMAb (itolizumab, an anti-CD6 antibody) for psoriasis in 2013 and CANMAb, a trastuzumab biosimilar, in India in 2014 after CDSCO approval; Roche contested the approval and the litigation ended in 2016. With Mylan (now Viatris) it took the same molecule to the US as Ogivri, approved in December 2017, the first trastuzumab biosimilar approved by the FDA, and to the EU in December 2018. Biocon also sells a bevacizumab biosimilar in India (Krabeva) and, as Abevmy, in the EU (April 2021).","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Biocon","links":[{"label":"Official website","url":"https://www.biocon.com"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy","drug-discovery"],"technologies":["monoclonal-antibody"],"targets":[],"drugs":["trastuzumab-biosimilars","trastuzumab","bevacizumab","nimotuzumab"],"companies":["biocon-biologics","syngene"],"institutions":[],"pathways":[],"terms":["biosimilar"],"trials":[],"people":["mazumdar-shaw-kiran"],"bottlenecks":["b-drug-pricing","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Bengaluru","country":"IN","companyType":"pharma","website":"https://www.biocon.com","ticker":"BIOCON.NS","founded":1978,"investors":[],"funding":[]},{"id":"biocon-biologics","kind":"company","name":"Biocon Biologics","aka":[],"tldr":"Biocon's biosimilars arm, one of the few companies outside the US and Europe with FDA- and EMA-approved cancer antibody biosimilars, and since 2022 the owner of Viatris's biosimilars business.","summary":"Biocon Biologics was set up in 2000 as Biocon's biosimilar subsidiary and became a wholly owned, fully integrated unit on 31 March 2026. Its oncology biosimilars include trastuzumab (Ogivri, FDA December 2017; EMA 12 December 2018, the first trastuzumab biosimilar in the US), bevacizumab (Abevmy, EMA 21 April 2021) and pegfilgrastim (Fulphila) for chemotherapy-induced neutropenia, alongside insulins and adalimumab. In May 2022 it bought the biosimilar assets of Viatris for 3.34 billion dollars, taking over the commercial infrastructure in the US and Europe. Domestically its CANMAb and Krabeva brands sit in the Indian market where several trastuzumab and bevacizumab biosimilars compete, which is why the reference brands cost a fraction of Western prices in India.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.bioconbiologics.com"},{"label":"Ogivri EPAR (EMA)","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/ogivri"},{"label":"Abevmy EPAR (EMA)","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/abevmy"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":["monoclonal-antibody"],"targets":["her2","vegf"],"drugs":["trastuzumab-biosimilars","trastuzumab","bevacizumab"],"companies":["biocon"],"institutions":[],"pathways":[],"terms":["biosimilar"],"trials":[],"people":["mazumdar-shaw-kiran"],"bottlenecks":["b-drug-pricing","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Bengaluru","country":"IN","companyType":"pharma","website":"https://www.bioconbiologics.com","founded":2000,"investors":[],"funding":[]},{"id":"biodesix","kind":"company","name":"Biodesix","aka":[],"tldr":"Biodesix sells blood tests that help doctors judge whether a lung nodule seen on a scan is likely to be cancer, and tests that guide treatment once lung cancer is diagnosed.","summary":"Biodesix is a Nasdaq-listed diagnostics company headquartered in Louisville, Colorado (previously Boulder) focused on lung disease. Its Nodify Lung nodule risk assessment testing uses blood-based biomarker assays to help clinicians stratify the malignancy risk of indeterminate pulmonary nodules, and IQLung provides treatment guidance testing for patients diagnosed with lung cancer. The company also offers custom biomarker development services to biopharma and research partners. Tests are laboratory developed and reviewed under New York State CLEP; they are not FDA cleared. In the second quarter of 2026 Biodesix reported 20,900 diagnostic tests, a 38 percent year-on-year increase, and raised $6.5 million net through its at-the-market programme. The company completed its initial public offering in October 2020, selling 4 million shares at $18.00 for about $72 million gross.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.biodesix.com/"},{"label":"IPO pricing release (Oct 2020)","url":"https://investors.biodesix.com/news-releases/news-release-details/biodesix-announces-pricing-initial-public-offering"},{"label":"Q2 2026 results","url":"https://investors.biodesix.com/news-releases/news-release-details/biodesix-announces-second-quarter-2026-results-and-highlights"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["diagnostics","early-detection"],"technologies":["proteomics","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The proteomics tag reflects the Nodify tests' protein-based design, which was not spelled out on the fetched pages. Founding year not sourced. Ticker BDSX on Nasdaq."],"hq":"Louisville, CO","country":"US","companyType":"diagnostics","website":"https://www.biodesix.com/","ticker":"BDSX","stage":"public","investors":[],"funding":[{"round":"IPO","year":2020,"amountUsd":72000000,"source":"https://investors.biodesix.com/news-releases/news-release-details/biodesix-announces-pricing-initial-public-offering","note":"4,000,000 shares at $18.00 on the Nasdaq Global Market, priced 28 October 2020; gross proceeds before underwriting discounts."}]},{"id":"biofrontera","kind":"company","name":"Biofrontera","aka":[],"tldr":"Biofrontera is a German dermatology company whose photodynamic therapy product Ameluz (aminolevulinic acid gel) with its RhodoLED lamp treats actinic keratosis and, in Europe, superficial basal cell carcinoma.","summary":"Biofrontera, based in Leverkusen, is a German dermatology company whose photodynamic therapy product Ameluz, an aminolevulinic acid gel used with its RhodoLED lamp, treats actinic keratosis and, in Europe, superficial basal cell carcinoma. Biofrontera AG developed Ameluz as a nanoemulsion gel approved in the European Union in 2011 and the United States in 2016 for actinic keratosis with red-light photodynamic therapy, the EU label also covers basal cell carcinoma, and Biofrontera Inc. in Woburn, Massachusetts, commercialises it in the United States. OnCo links it to the topical aminolevulinic acid drug record. Whether photodynamic therapy earns a US basal cell carcinoma indication to match Europe is the open question. Aminolevulinic acid has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.biofrontera.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Leverkusen","country":"DE","companyType":"pharma","website":"https://www.biofrontera.com","investors":[],"funding":[]},{"id":"biogen","kind":"company","name":"Biogen","aka":["Biogen Inc.","Biogen Idec","IDEC Pharmaceuticals"],"tldr":"Biogen is the Massachusetts biotech that, as Biogen Idec, co-developed rituximab, the first antibody approved for cancer; it now concentrates on neurology.","summary":"Biogen, founded in 1978 and headquartered in Cambridge, Massachusetts, merged with IDEC Pharmaceuticals in 2003 to form Biogen Idec. IDEC had developed rituximab (Rituxan) with Genentech, the anti-CD20 antibody approved in 1997 for follicular lymphoma, and Biogen Idec led lymphoma trials for it and for the radiolabelled antibody ibritumomab tiuxetan (Zevalin). The company later returned to the Biogen name and focuses on neurological and rare diseases; its phase 3 cancer trials on ClinicalTrials.gov date from the lymphoma era.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Biogen","links":[{"label":"Official website","url":"https://www.biogen.com"},{"label":"ClinicalTrials.gov: trials led by Biogen","url":"https://clinicaltrials.gov/search?lead=Biogen"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q864338"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["dlbcl","follicular-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["rituximab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://www.biogen.com","founded":1978,"stage":"public","investors":[],"funding":[]},{"id":"bioinvent-international","kind":"company","name":"BioInvent International","aka":["BioInvent International AB"],"tldr":"BioInvent International is a Sweden-based biotechnology company running 4 late-stage cancer trials of BI-1607, Ipilimumab (YervoyTM and BI-1910 in melanoma, uveal melanoma and non-small-cell lung cancer.","summary":"BioInvent International, based in Lund, Sweden, is a biotechnology company. BioInvent International is a clinical-stage company that discovers and develops antibodies for cancer immunotherapy, using its proprietary F.I.R.S.T. platform and n-CoDeR antibody library. On ClinicalTrials.gov it is the lead sponsor of 4 recruiting or active phase 2 and phase 3 interventional cancer trials, testing BI-1607, Ipilimumab (YervoyTM, BI-1910, BI1206 and BI-1808 in melanoma, uveal melanoma, non-small-cell lung cancer, hepatocellular carcinoma and ovarian cancer. The largest, NCT04219254 (A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours), plans to enrol 197 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Bioinvent","links":[{"label":"Official website","url":"https://www.bioinvent.com"},{"label":"ClinicalTrials.gov: trials led by BioInvent International","url":"https://clinicaltrials.gov/search?lead=BioInvent%20International%20AB"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma","uveal-melanoma","nsclc","hcc","ovarian","peripheral-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04752826","nct06784648","nct06205706","nct04219254"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Lund","country":"SE","companyType":"biotech","website":"https://www.bioinvent.com","stage":"public","investors":[],"funding":[]},{"id":"biolife-solutions","kind":"company","name":"BioLife Solutions","aka":[],"tldr":"Maker of CryoStor freeze media used in most approved cell therapies, plus evo cold-chain shippers.","summary":"BioLife Solutions, based in Bothell, Washington, and listed as BLFS, makes the CryoStor freeze media used in most approved cell therapies, plus evo cold-chain shippers. It divested its freezer hardware lines in 2024 to focus on biopreservation media and consumables. OnCo links it to cryopreservation and the cell therapy cold chain. Whether a consumables supplier embedded in approved manufacturing processes can be displaced, given the cost of revalidation, is the fair question. The cold chain technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.biolifesolutions.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["cell-therapy-cold-chain"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Bothell, WA","country":"US","companyType":"cro-services","website":"https://www.biolifesolutions.com","ticker":"BLFS","investors":[],"funding":[]},{"id":"biolinerx","kind":"company","name":"BioLineRx","aka":["BioLineRx, Ltd.","BioLineRx Ltd."],"tldr":"BioLineRx is an Israeli company whose CXCR4 inhibitor motixafortide (Aphexda) was approved in the United States in 2023 to mobilise stem cells for autologous transplant in multiple myeloma, and which tests the drug with pembrolizumab in pancreatic cancer.","summary":"BioLineRx, based in Modi'in and listed on Nasdaq and Tel Aviv, develops motixafortide (BL-8040), a long-acting CXCR4 antagonist. In the phase 3 GENESIS trial a single dose with filgrastim mobilised enough stem cells for transplant in far more myeloma patients than filgrastim alone, leading to FDA approval as Aphexda in September 2023; US commercial rights were licensed to Ayrmid in 2024. The company also studies motixafortide with pembrolizumab and chemotherapy in metastatic pancreatic cancer and for sickle cell gene therapy mobilisation. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/BioLineRx","links":[{"label":"Official website","url":"https://www.biolinerx.com"},{"label":"ClinicalTrials.gov: trials led by BioLineRx","url":"https://clinicaltrials.gov/search?lead=BioLineRx"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/BioLineRx"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["multiple-myeloma","pancreatic"],"sections":["supportive-care","targeted-therapy"],"technologies":[],"targets":["cxcr4"],"drugs":["pembrolizumab","filgrastim"],"companies":[],"institutions":[],"pathways":[],"terms":["autologous-transplant"],"trials":["nct03246529"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Modi'in","country":"IL","companyType":"biotech","website":"https://www.biolinerx.com","stage":"public","investors":[],"funding":[]},{"id":"biolitec","kind":"company","name":"biolitec","aka":[],"tldr":"biolitec is a German medical laser company that holds the EU authorisation for temoporfin (Foscan), a photosensitiser for palliative photodynamic therapy of advanced head and neck cancer.","summary":"biolitec, based in Jena, is a German medical laser company that holds the EU authorisation for temoporfin, sold as Foscan, a photosensitiser for palliative photodynamic therapy of advanced head and neck cancer. biolitec pharma markets Foscan, authorised in the European Union in 2001 for palliative treatment of advanced head and neck squamous cell carcinoma that has failed prior therapy and is unsuitable for radiotherapy, surgery or systemic chemotherapy, alongside its laser systems. OnCo links it to the temoporfin drug record. Whether photodynamic therapy has a future in head and neck cancer as immunotherapy changes the late-line options is the open question. Temoporfin has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.biolitec.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Jena","country":"DE","companyType":"devices","website":"https://www.biolitec.com","investors":[],"funding":[]},{"id":"biontech","kind":"company","name":"BioNTech","aka":[],"tldr":"From COVID vaccine to a broad oncology pipeline: personalised vaccines, ADCs from China, and a PD-L1×VEGF bispecific sold to BMS for $11B.","summary":"BioNTech, based in Mainz and listed as BNTX, moved from its COVID vaccine into a broad oncology pipeline of personalised vaccines, antibody-drug conjugates licensed from China, and a PD-L1 by VEGF bispecific sold to Bristol Myers Squibb for 11 billion dollars. Its programmes include autogene cevumeran with Genentech, trastuzumab pamirtecan, or BNT323, from DualityBio, pumitamig, or BNT327, with BMS, BNT113 against HPV16 and the Claudin 6 CAR-T BNT211. OnCo links it to pancreatic ductal adenocarcinoma through Rojas 2023, in which a personalised mRNA vaccine trained T cells against each patient's cancer, to Claudin 6 as a target, to CureVac and to the University Cancer Center Mainz. Cold tumours and the immunosuppressive microenvironment are the bottleneck its vaccines address. Autogene cevumeran has its own page.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/BioNTech","links":[{"label":"Official website","url":"https://www.biontech.com"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy","adcs"],"technologies":[],"targets":[],"drugs":["autogene-cevumeran","pm8002","bnt324","bnt113","trastuzumab-pamirtecan"],"companies":["curevac"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06712355","nct06340568","nct06712316","nct07111520","nct07079631","nct07133750","nct07255404","nct06841055","nct06449209","nct06750185","nct05914116","nct07070232","nct07455734","nct05844150","nct07147348","nct06449222","nct07297212","nct07221149","nct07173751","nct04486378","nct06827236","nct05438329","nct05150691","nct06892548","nct05918133","nct05879055","nct07186842","nct05879068","nct05918445","nct05968326","nct06953089"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Mainz","country":"DE","companyType":"biotech","website":"https://www.biontech.com","ticker":"BNTX","investors":[],"funding":[]},{"id":"bioptimus","kind":"company","name":"Bioptimus","aka":[],"tldr":"French startup behind H-optimus-0, an open 1.1-billion-parameter pathology foundation model.","summary":"Bioptimus, based in Paris and founded in 2024 by Owkin alumni, is the French startup behind H-optimus-0, an open pathology foundation model with 1.1 billion parameters. H-optimus-0, released in 2024, and H-optimus-1 are steps towards what the company calls a universal biology foundation model, starting from histology. OnCo links it to the H-optimus technology record. Whether a model that starts from histology can grow into a general model of biology, as the company intends, is the open question. H-optimus has its own technology page.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.bioptimus.com"}],"tags":["ai"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["h-optimus"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Paris","country":"FR","companyType":"ai-software","website":"https://www.bioptimus.com","investors":[],"funding":[]},{"id":"biostar-pharmaceuticals","kind":"company","name":"Biostar Pharmaceuticals","aka":["Chengdu Biostar"],"tldr":"Biostar Pharmaceuticals in Chengdu developed utidelone, the epothilone chemotherapy approved in China in 2021 for advanced breast cancer.","summary":"Biostar Pharmaceuticals is a Chengdu biotechnology company built around genetically engineered epothilones. Its lead product utidelone was approved by the NMPA in March 2021 with capecitabine for recurrent or metastatic breast cancer after anthracyclines and taxanes; an oral formulation and trials in other tumours followed.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.biostar.com.cn"}],"tags":["ctgov-sponsor","china"],"related":[],"cancers":[],"sections":["chemotherapy"],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["utidelone"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Chengdu, China","country":"CN","companyType":"biotech","website":"https://www.biostar.com.cn","stage":"private-large","investors":[],"funding":[]},{"id":"black-diamond-therapeutics","kind":"company","name":"Black Diamond Therapeutics","aka":[],"tldr":"Black Diamond Therapeutics designs cancer pills that hit whole families of mutations in a growth protein at once. Its lead drug, silevertinib, targets mutated EGFR in lung cancer and brain tumours.","summary":"Black Diamond Therapeutics is a Cambridge, Massachusetts precision oncology company whose MAP platform designs small molecules that inhibit families of oncogenic mutations. Its lead candidate, silevertinib (formerly BDTX-1535), is a brain-penetrant, mutant-selective EGFR inhibitor: the company lists phase 2 studies in first-line and second/third-line EGFR-mutant non-small cell lung cancer (with FDA Fast Track designation for C797S-positive patients and final phase 2 data at ASCO 2026) and a randomised phase 2 trial in newly diagnosed glioblastoma initiated in the second quarter of 2026. BDTX-4933, a RAF inhibitor for RAF/RAS-mutant solid tumours, has been licensed to Servier, and BDTX-4876 (FGFR2/3) is preclinical. The company completed its Nasdaq IPO in February 2020, raising 231.3 million US dollars gross.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://blackdiamondtherapeutics.com/"},{"label":"Pipeline","url":"https://blackdiamondtherapeutics.com/pipeline-programs/pipeline"},{"label":"Q4 2019 results noting IPO proceeds (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1701541/000170154120000008/bdtx-exhibit991.htm"}],"tags":[],"related":[],"cancers":["nsclc","glioblastoma"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["egfr","braf","fgfr2"],"drugs":["silevertinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05256290","nct07326566"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not sourced. The 'braf' target tag reflects the RAF programme BDTX-4933 (RAF/RAS-mutant tumours) rather than a BRAF-specific claim."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://blackdiamondtherapeutics.com/","ticker":"BDTX","stage":"public","investors":[],"funding":[{"round":"IPO","year":2020,"amountUsd":231300000,"source":"https://www.sec.gov/Archives/edgar/data/1701541/000170154120000008/bdtx-exhibit991.htm","note":"12,174,263 shares including full over-allotment; gross proceeds 231.3 million US dollars, completed February 2020"}]},{"id":"blank-bio","kind":"company","name":"Blank Bio","aka":[],"tldr":"Blank Bio trains AI models on tumour RNA to predict how a disease will progress and which patients will respond, so drug companies can run smarter cancer trials.","summary":"Blank Bio is an applied AI research lab training RNA foundation models on transcriptomic data to learn patterns of disease progression and treatment response, with the aim of improving clinical trial success rates in oncology by capturing what makes each patient's tumour unique. The team comes from Recursion, Deep Genomics, DeepMind, Amazon, Memorial Sloan Kettering, Stanford and the Vector Institute. Its website describes the work as RNA intelligence for precision oncology; products are in development.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/blank-bio"},{"label":"Official website","url":"https://blank.bio"}],"tags":["yc"],"related":[],"cancers":[],"sections":["ai-computation","drug-discovery"],"technologies":["rna-seq","ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"ai-software","website":"https://blank.bio","stage":"startup","ycBatch":"S25","investors":["y-combinator"],"funding":[]},{"id":"blaze-bioscience","kind":"company","name":"Blaze Bioscience","aka":["Blaze Bioscience Inc.","Blaze Bioscience, Inc."],"tldr":"Blaze Bioscience is a Seattle company whose 'Tumor Paint', tozuleristide, is a scorpion-toxin peptide linked to a dye that lights up tumour tissue during surgery; it reached phase 3 in children's brain tumours.","summary":"Blaze Bioscience, founded in 2010 in Seattle from the work of Jim Olson at Fred Hutchinson Cancer Center, developed tozuleristide (BLZ-100), a chlorotoxin-derived peptide conjugated to the near-infrared dye indocyanine green that binds tumour cells and shows surgeons where tumour ends. It was taken into a phase 3 trial in paediatric central nervous system tumours, registered on ClinicalTrials.gov under Blaze as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.blazebioscience.com"},{"label":"ClinicalTrials.gov: trials led by Blaze Bioscience Inc.","url":"https://clinicaltrials.gov/search?lead=Blaze%20Bioscience%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q61934658"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["childhood-cancers","brain-tumours"],"sections":[],"technologies":["fluorescence-guided-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":["fred-hutch"],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Seattle, WA","country":"US","companyType":"biotech","website":"http://www.blazebioscience.com","founded":2010,"stage":"private-large","investors":[],"funding":[]},{"id":"blue-earth-diagnostics","kind":"company","name":"Blue Earth Diagnostics (Bracco)","aka":[],"tldr":"Blue Earth Diagnostics makes Posluma (18F-rhPSMA-7.3) and Axumin (fluciclovine) PET agents for prostate cancer.","summary":"Blue Earth Diagnostics, based in Oxford and a subsidiary of Bracco, makes the PET imaging agents Posluma, or flotufolastat F-18, also written 18F-rhPSMA-7.3, and Axumin, or fluciclovine F-18, for prostate cancer. Posluma was approved in 2023 on the LIGHTHOUSE and SPOTLIGHT trials, and a therapeutic rhPSMA analogue is in development, which would extend the radiohybrid platform from imaging into treatment. OnCo links it to prostate cancer and to both tracer records. Whether a fluorine-18 PSMA agent with a matched therapeutic can win share from the gallium-68 tracers already established is the open question. Flotufolastat and fluciclovine have their own pages.","asOf":"2026-09-06","links":[{"label":"Official website","url":"https://www.blueearthdiagnostics.com"}],"tags":[],"related":[],"cancers":["prostate"],"sections":["imaging","radiopharma"],"technologies":[],"targets":[],"drugs":["flotufolastat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07432633","nct07702292"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Oxford","country":"GB","companyType":"radiopharma","website":"https://www.blueearthdiagnostics.com","investors":[],"funding":[]},{"id":"blueprint-medicines","kind":"company","name":"Blueprint Medicines","aka":[],"tldr":"Blueprint Medicines invented Ayvakit, a pill approved for systemic mastocytosis and for a rare gut tumour called GIST that carries a specific mutation. The French drug maker Sanofi bought the company in 2025.","summary":"Blueprint Medicines is a Cambridge, Massachusetts kinase medicine company, now a Sanofi company. Its approved product, Ayvakit/Ayvakyt (avapritinib), is a KIT and PDGFRA inhibitor approved for advanced and indolent systemic mastocytosis and, per the company's site, for certain gastrointestinal stromal tumours (GIST). The pipeline includes elenestinib, a next-generation KIT inhibitor for systemic mastocytosis, and BLU-808, an oral wild-type KIT inhibitor for mast cell-driven allergic and inflammatory disease. Sanofi and Blueprint announced a definitive agreement on 2 June 2025 at 129 US dollars per share in cash (about 9.1 billion US dollars equity value) plus a contingent value right of up to 6 US dollars per share; the tender offer expired on 17 July 2025 with about 70.9 percent of shares tendered and the merger closed shortly after. Blueprint's former Nasdaq ticker was BPMC.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.blueprintmedicines.com/"},{"label":"Sanofi acquisition announcement (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925055143/tm2516831d1_ex99-1.htm"},{"label":"Tender offer completion 8-K (SEC)","url":"https://www.sec.gov/Archives/edgar/data/1597264/000119312525160804/d909980d8k.htm"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["kit"],"drugs":["pralsetinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07629960"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year and IPO (2015) not sourced. The company website blocked curl (Cloudflare) but was fetched successfully with WebFetch. The GIST indication statement rests on the website summary; the Sanofi release frames the deal around systemic mastocytosis and immunology."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://www.blueprintmedicines.com/","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2025,"amountUsd":9100000000,"source":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925055143/tm2516831d1_ex99-1.htm","note":"129 US dollars per share in cash (equity value about 9.1 billion) plus a contingent value right worth up to 6 US dollars per share for BLU-808 milestones; tender offer completed July 2025"}],"acquiredBy":"sanofi"},{"id":"boehringer-ingelheim","kind":"company","name":"Boehringer Ingelheim","aka":[],"tldr":"Private German pharma whose zongertinib became the first oral HER2 inhibitor for lung cancer.","summary":"Boehringer Ingelheim, a private German pharmaceutical company based in Ingelheim, is the maker of zongertinib, sold as Hernexeos, which became the first oral HER2 inhibitor for lung cancer. Its oncology pipeline also includes brigimadlin, an MDM2 inhibitor, obrixtamig, a DLL3 by CD3 T-cell engager, and pan-KRAS inhibitor programmes, alongside the older kinase inhibitors afatinib and nintedanib. OnCo links it to non-small-cell lung cancer and mesothelioma, to MDM2 as a target, and to NBE-Therapeutics. Whether a private company can carry several first-in-class oncology programmes through phase 3 without a partner is the open question. Zongertinib has its own page.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Boehringer_Ingelheim","links":[{"label":"Official website","url":"https://www.boehringer-ingelheim.com"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["zongertinib","tasonermin"],"companies":["nbe-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07472517","nct07195695","nct06324357","nct06581432","nct07486817","nct06151574","nct07544654","nct05882058","nct06619509"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Ingelheim","country":"DE","companyType":"pharma","website":"https://www.boehringer-ingelheim.com","investors":[],"funding":[]},{"id":"boehringer-ingelheim-biox","kind":"company","name":"Boehringer Ingelheim BioXcellence","aka":[],"tldr":"Boehringer Ingelheim BioXcellence is the contract-manufacturing arm of Boehringer Ingelheim, one of the largest antibody producers by volume.","summary":"Boehringer Ingelheim BioXcellence, based in Ingelheim, is the contract manufacturing arm of Boehringer Ingelheim, one of the largest antibody producers by volume. It offers mammalian and microbial biologics manufacturing in Germany, Austria, China and the United States. OnCo links it to antibody manufacturing through CHO bioprocessing. Whether a pharmaceutical company can run a contract manufacturing business for competitors without conflicts over capacity is the fair question. The antibody manufacturing page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.boehringer-ingelheim.com/bioxcellence"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["monoclonal-antibody-manufacturing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Ingelheim","country":"DE","companyType":"cro-services","website":"https://www.boehringer-ingelheim.com/bioxcellence","investors":[],"funding":[]},{"id":"bolt-biotherapeutics","kind":"company","name":"Bolt Biotherapeutics","aka":["Bolt Bio","NASDAQ:BOLT"],"tldr":"Bolt Biotherapeutics builds antibodies that carry an immune-stimulating payload into tumours so the body's own myeloid cells attack the cancer; BDC-4182 aims this at Claudin 18.2.","summary":"Bolt Biotherapeutics develops Boltbody immune-stimulating antibody conjugates (ISACs), which link a tumour-targeting antibody to a Toll-like receptor agonist that activates myeloid cells inside the tumour. Its first programme, the HER2-directed trastuzumab imbotolimod (BDC-1001), was followed by BDC-3042, a Dectin-2 agonist antibody, and BDC-4182, a Claudin 18.2 ISAC that entered the clinic for gastric and pancreatic cancers.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.boltbio.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["bdc-4182"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Redwood City, California","country":"US","companyType":"biotech","website":"https://www.boltbio.com/","ticker":"NASDAQ:BOLT","founded":2015,"stage":"public","investors":[],"funding":[]},{"id":"boston-scientific","kind":"company","name":"Boston Scientific","aka":[],"tldr":"Medical device giant whose TheraSphere glass microspheres deliver yttrium-90 radioembolisation in liver cancer.","summary":"Boston Scientific, based in Marlborough, Massachusetts, and listed as BSX, is the medical device company whose TheraSphere glass microspheres deliver yttrium-90 radioembolisation in liver cancer. TheraSphere has held FDA approval for hepatocellular carcinoma since 2021, was studied in the EPOCH trial in colorectal liver metastases, which was positive for progression-free survival, and is being tested in combination with immunotherapy, and the company also sells drug-eluting embolic beads and other interventional oncology devices. OnCo links it to hepatocellular carcinoma and colorectal cancer and to the radioembolisation and transarterial chemoembolisation technology records. Whether device-based liver-directed therapy keeps its role as systemic options improve is the open question. The technology pages carry the trial detail.","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Boston_Scientific","links":[{"label":"Official website","url":"https://www.bostonscientific.com"}],"tags":[],"related":[],"cancers":["hcc","colorectal"],"sections":["radiation","surgery"],"technologies":["radioembolisation-tare","tace"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05063565"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Marlborough, MA","country":"US","companyType":"devices","website":"https://www.bostonscientific.com","ticker":"BSX","investors":[],"funding":[]},{"id":"bostongene","kind":"company","name":"BostonGene","aka":[],"tldr":"BostonGene, of Waltham, Massachusetts, sells the Tumor Portrait, a single report combining genomic, transcriptomic and immune microenvironment analysis that sorts tumours into immune-enriched, fibrotic or depleted subtypes to guide immunotherapy decisions. Whether those subtypes predict immunotherapy response well enough to change practice is unproven.","summary":"BostonGene, based in Waltham, Massachusetts, integrates genomic, transcriptomic and immune microenvironment analysis into a single report it calls the Tumor Portrait. The test classifies the tumour microenvironment into subtypes, including immune-enriched, fibrotic and depleted, to guide immunotherapy decisions. OnCo links it to RNA sequencing and expression profiling, to comprehensive genomic profiling, to spatial-omics-guided treatment selection, and to the idea of turning the map of immune cells inside a tumour into a standardised test. Whether microenvironment subtypes predict immunotherapy response well enough to change practice is the open question, and data silos are the bottleneck the company confronts. The technology pages carry the wider evidence.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://bostongene.com"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics","ai-computation"],"technologies":["rna-seq","cgp","wes-wgs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Waltham, MA","country":"US","companyType":"ai-software","website":"https://bostongene.com","investors":[],"funding":[]},{"id":"boundless-bio","kind":"company","name":"Boundless Bio","aka":[],"tldr":"Boundless Bio tried to treat cancers driven by extra loops of DNA outside the chromosomes, called ecDNA. Its lead drug did not show enough benefit in early trials, and in 2026 the company agreed to merge with a gene-editing company and leave cancer.","summary":"Boundless Bio is a San Diego (La Jolla) company that developed ecDNA-directed therapies for oncogene-amplified cancers, built on the biology of extrachromosomal DNA. Its programmes included BBI-940, an oral kinesin degrader that entered the phase 1 KOMODO-1 trial in February 2026 for ER-positive/HER2-negative and luminal androgen receptor triple-negative breast cancer, plus CHK1 inhibitors for replication stress and RNR inhibitors intended to prevent ecDNA-mediated resistance to KRAS inhibitors. In June 2026 the company said early clinical data for BBI-940 did not support continuing and announced an all-stock merger with Serapha Bio, a private developer of an in vivo base-editing therapy for alpha-1 antitrypsin deficiency, with a 230 million US dollar private placement co-led by RA Capital and RTW; the combined company is to trade as Serapha Bio (AATD). Boundless raised 100 million US dollars gross in its April 2024 IPO.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://boundlessbio.com/"},{"label":"What we do (ecDNA-directed therapies)","url":"https://boundlessbio.com/what-we-do/"},{"label":"IPO closing 8-K (SEC)","url":"https://www.sec.gov/Archives/edgar/data/1782303/000119312524084736/d796750d8k.htm"},{"label":"Serapha Bio merger announcement (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1782303/000119312526278570/d159021dex991.htm"}],"tags":[],"related":[],"cancers":["breast-hr-positive","tnbc"],"sections":["targeted-therapy"],"technologies":["protac-degrader"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Status uncertain: the Serapha merger (agreement dated 22 June 2026, amended 28 August 2026) had not been confirmed as closed at time of research; if it closes the entity will no longer be an oncology company and this record should probably be marked defunct or removed. Founding year not sourced."],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://boundlessbio.com/","ticker":"BOLD","stage":"public","investors":["arch-venture-partners"],"funding":[{"round":"IPO","year":2024,"amountUsd":100000000,"source":"https://www.sec.gov/Archives/edgar/data/1782303/000119312524084736/d796750d8k.htm","note":"6.25 million shares at 16 US dollars; closed 2 April 2024"}]},{"id":"boxer-capital","kind":"company","name":"Boxer Capital","aka":[],"tldr":"A San Diego biotech investment firm that backs precision medicine companies from private rounds through public listing. Its venture highlights include cancer drug developers Mirati, G1 Therapeutics, Tango and Elevation Oncology.","summary":"Boxer Capital Management, at 12860 El Camino Real, San Diego, calls itself 'a full life cycle investment firm, committed to fundamental, research-based investing in specialised and precision medicine companies across private and public markets'. Its venture highlights page states that it has invested in 74 private companies since 2014, led or co-led 14 of them, and seen 51 liquidity events (IPOs, public access or acquisitions), noting that earlier investments were made by Boxer Capital, LLC before a reorganisation into Boxer Capital Management, LLC. Oncology names on that page include Mirati Therapeutics (KRAS inhibitor developer), G1 Therapeutics, Tango Therapeutics (synthetic lethality), Elevation Oncology, Blueprint Medicines, Relay Therapeutics and Revolution Medicines.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.boxercap.com/"},{"label":"Venture highlights","url":"https://www.boxercap.com/venture-highlights/"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["blueprint-medicines","relay-therapeutics","revolution-medicines","tango-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the site; omitted."],"hq":"San Diego, CA","country":"US","companyType":"investor","website":"https://www.boxercap.com/","investors":[],"funding":[]},{"id":"bpifrance","kind":"company","name":"Bpifrance","aka":[],"tldr":"Bpifrance is the French state investment bank, created in 2012, which combines loans, guarantees, innovation grants and equity investment. Through its biotech funds and the France 2030 programme it co-invests, usually alongside private venture funds, in French oncology drug, diagnostics and radiotherapy hardware developers, which is why it appears in French oncology financing rounds.","summary":"Bpifrance is France's public investment bank, created in 2012, which combines loans, guarantees, innovation grants and direct and fund-of-funds equity investment. Through its innovation and biotech funds and the France 2030 programme it co-invests in French life-science companies, including oncology drug, diagnostics and radiotherapy hardware developers, usually alongside private venture funds. It is recorded as a public fund rather than a venture firm; portfolio links in OnCo are derived from the startup records that name it.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.bpifrance.com"}],"tags":["public-fund"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Paris","country":"FR","companyType":"investor","website":"https://www.bpifrance.com","founded":2012,"investors":[],"funding":[]},{"id":"brainlab","kind":"company","name":"Brainlab","aka":[],"tldr":"Surgical navigation and radiosurgery planning software (Elements), used in neurosurgery and stereotactic radiotherapy.","summary":"Brainlab, based in Munich, makes surgical navigation and radiosurgery planning software, its Elements suite, used in neurosurgery and stereotactic radiotherapy. Its offerings span image-guided surgery, Elements treatment planning for radiosurgery and digital operating room integration. OnCo links it to radiotherapy treatment planning and QA software, stereotactic radiotherapy and robotic and minimally invasive surgery. Whether a single software layer can span surgery and radiotherapy well enough to change how brain tumours are treated is the open question its integration strategy poses. The stereotactic radiotherapy page carries the wider evidence.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Brainlab","links":[{"label":"Official website","url":"https://www.brainlab.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["radiation","surgery"],"technologies":["treatment-planning-systems","sbrt","robotic-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Munich","country":"DE","companyType":"devices","website":"https://www.brainlab.com","investors":[],"funding":[]},{"id":"break-through-cancer","kind":"company","name":"Break Through Cancer","aka":[],"tldr":"A Cambridge, Massachusetts foundation, founded in 2021 and led by Tyler Jacks, that funds teams across several cancer centres to work together on the deadliest cancers. It funds research projects rather than companies.","summary":"Break Through Cancer's fast facts page states: 'Founded in 2021, Break Through Cancer is headquartered in Cambridge, Massachusetts, and is led by President Tyler Jacks.' Its mission is to 'empower outstanding researchers and physicians to both intercept and find cures for the deadliest cancers by stimulating Radical Collaboration', reducing barriers such as contract negotiation, data sharing, intellectual property and authorship across institutions. Research focus areas listed on the site are acute myelogenous leukaemia, glioblastoma, lung cancer, osteosarcoma, ovarian cancer, pancreatic cancer and data science, funded through multi-institution TeamLabs. It is a grant-making foundation, not an equity investor, so it has no company portfolio; it is included because it is a significant philanthropic funder of translational cancer research.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://breakthroughcancer.org/"},{"label":"Fast facts","url":"https://breakthroughcancer.org/fast-facts/"}],"tags":["foundation"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Funds research teams at partner cancer centres rather than companies; portfolioExamples intentionally empty."],"hq":"Cambridge, MA","country":"US","companyType":"investor","website":"https://breakthroughcancer.org/","founded":2021,"investors":[],"funding":[]},{"id":"breast-cancer-trials","kind":"company","name":"Breast Cancer Trials","aka":["BCT","Australia and New Zealand Breast Cancer Trials Group","ANZBCTG"],"tldr":"The Australian and New Zealand breast cancer trials group, a Breast International Group partner in SOFT/TEXT, APHINITY, OlympiA and POSITIVE.","summary":"Founded in 1978 as the ANZ Breast Cancer Trials Group and renamed Breast Cancer Trials, it is one of the longest-running academic breast cancer groups and a founding member of the Breast International Group. It co-led the IBCSG SOFT and TEXT trials of ovarian suppression, contributed to APHINITY, OlympiA and the POSITIVE pregnancy-interruption study, and runs its own trials such as EXPERT (omitting radiotherapy in low-genomic-risk luminal A disease) and DECRESCENDO. A large consumer advisory panel shapes protocol design. Trials are coordinated from Newcastle with sites across Australia and New Zealand.","asOf":"2026-09-09","links":[{"label":"Breast Cancer Trials","url":"https://www.breastcancertrials.org.au"},{"label":"Clinical trials","url":"https://www.breastcancertrials.org.au/clinical-trials/"}],"tags":["cooperative-group"],"related":["olaparib","trastuzumab"],"cancers":["breast-hr-positive","breast-her2-positive","tnbc"],"sections":["hormonal"],"technologies":["endocrine-therapy","parp-inhibitor"],"targets":[],"drugs":[],"companies":["big","etop-ibcsg"],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":["soft-text","olympia","aphinity"],"people":["loi-sherene","sunil-lakhani"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["SOFT / TEXT (with IBCSG)","OlympiA and APHINITY (with BIG)","EXPERT (radiotherapy omission)","POSITIVE (pregnancy after endocrine therapy)"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Newcastle, NSW","country":"AU","companyType":"cooperative-group","website":"https://www.breastcancertrials.org.au","founded":1978,"investors":[],"funding":[]},{"id":"big","kind":"company","name":"Breast International Group (BIG)","aka":["Breast International Group","BIG"],"tldr":"The Breast International Group is the umbrella for 50+ academic breast cancer groups worldwide and co-sponsor of OlympiA, APHINITY, and HERA.","summary":"The Breast International Group, based in Brussels, is the umbrella for more than fifty academic breast cancer groups worldwide, founded in 1999 by Martine Piccart, and the co-sponsor of some of the largest academic breast trials ever run. Coordinating more than sixty groups and ten thousand hospitals, it ran HERA on adjuvant trastuzumab, APHINITY on pertuzumab, MINDACT on the MammaPrint signature, and OlympiA on adjuvant olaparib with NRG Oncology, with David Cameron and Evandro de Azambuja also linked. OnCo connects it to HER2-positive, HR-positive and triple-negative breast cancer, to trastuzumab and olaparib, and to member groups including Breast Cancer Trials and the ETOP IBCSG Partners Foundation. Secrecy and intellectual property blocking collaboration is the bottleneck its model is meant to overcome. Its OlympiA, HERA and MINDACT programmes are listed in the notes.","asOf":"2026-09-06","links":[{"label":"Official website","url":"https://www.bigagainstbreastcancer.org"}],"tags":["cooperative-group"],"related":["olaparib","trastuzumab"],"cancers":["tnbc","breast-her2-positive","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["nrg-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":["olympia"],"people":["david-cameron","evandro-de-azambuja","martine-piccart"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["OlympiA (with NRG)","HERA / APHINITY","MINDACT"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Brussels","country":"BE","companyType":"cooperative-group","website":"https://www.bigagainstbreastcancer.org","founded":1999,"investors":[],"funding":[]},{"id":"bridgebio-oncology-therapeutics","kind":"company","name":"BridgeBio Oncology Therapeutics","aka":["QED Therapeutics, a BridgeBio company","QED Therapeutics"],"tldr":"BridgeBio Oncology Therapeutics (BBOT) makes pills against the KRAS cancer protein and a drug that stops KRAS from switching on a second growth signal called PI3K-alpha. All three drugs are in early human trials.","summary":"BridgeBio Oncology Therapeutics (BBOT) is a South San Francisco clinical-stage company spun out of BridgeBio and focused on RAS pathway cancers. Its three clinical programmes are BBO-8520, a KRAS G12C inhibitor binding both ON and OFF states, in the phase 1 ONKORAS-101 trial in KRAS G12C non-small cell lung cancer; BBO-11818, a pan-KRAS inhibitor in the phase 1 KONQUER-101 trial in KRAS-mutant solid tumours; and BBO-10203, a RAS-PI3K-alpha interaction inhibitor ('breaker') in the phase 1 BREAKER-101 trial in HER2-positive and HR-positive/HER2-negative breast cancer and KRAS-mutant colorectal and lung cancer. BBOT listed on Nasdaq on 11 August 2025 through a business combination with Helix Acquisition Corp. II, a SPAC sponsored by affiliates of Cormorant Asset Management, with a 261 million US dollar PIPE and about 382 million US dollars in gross proceeds; it expected roughly 490 million US dollars in cash at closing.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://bbotx.com/"},{"label":"Pipeline","url":"https://bbotx.com/pipeline/"},{"label":"Listing press release, August 2025 (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/ea025066201ex99-4_bridge.htm"}],"tags":[],"related":[],"cancers":["nsclc","colorectal","breast-her2-positive","breast-hr-positive"],"sections":["targeted-therapy"],"technologies":["kras-inhibitors"],"targets":["kras","pik3ca"],"drugs":["infigratinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The hint said Palo Alto; the listing press release datelines South San Francisco and Boston. Founding year not sourced."],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://bbotx.com/","ticker":"BBOT","stage":"public","investors":["cormorant-asset-management"],"funding":[{"round":"IPO","year":2025,"amountUsd":382000000,"source":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/ea025066201ex99-4_bridge.htm","note":"Nasdaq listing via merger with Helix Acquisition Corp. II on 11 August 2025; about 261 million US dollar PIPE led by Cormorant plus about 120 million from the trust, roughly 382 million gross"}]},{"id":"bms","kind":"company","name":"Bristol Myers Squibb","aka":["Bristol-Myers Squibb","Juno Therapeutics","Mirati Therapeutics","Celgene","American Regent, Inc.","American Regent","YM BioSciences"],"tldr":"Pioneer of checkpoint inhibitors (Opdivo, Yervoy), now betting on the first successful bispecific ADC and alpha radiopharmaceuticals.","summary":"Bristol Myers Squibb, based in Princeton and listed as BMY, is the pioneer of checkpoint inhibitors with Opdivo and Yervoy, and it is now betting on the first successful bispecific antibody-drug conjugate and on alpha radiopharmaceuticals. Its portfolio spans nivolumab, ipilimumab and Opdualag, adagrasib from Mirati, the CAR-T products Breyanzi and Abecma, izalontamab brengitecan licensed from SystImmune for 8.4 billion dollars, actinium-225 DOTATATE from the 4.1 billion dollar RayzeBio purchase, and a PD-L1 by VEGF bispecific licensed from BioNTech for 11 billion dollars in 2025. OnCo links it to the ten-year CheckMate 067 follow-up, CheckMate 649 and CheckMate 816 papers, to luspatercept, and to KRAS inhibitors and protein degradation. Whether its large bets on ADCs and radiopharmaceuticals pay off as the nivolumab franchise ages is the open question.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Bristol_Myers_Squibb","links":[{"label":"Official website","url":"https://www.bms.com"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy","adcs","radiopharma","targeted-therapy","cell-therapy"],"technologies":[],"targets":[],"drugs":["nivolumab","ipilimumab","relatlimab-nivolumab","izalontamab-brengitecan","ryz101","adagrasib","vusolimogene-oderparepvec","navlimetostat","arlocabtagene-autoleucel","atigotatug","bms-986365","romidepsin","megestrol","hydroxyurea","etoposide","teniposide","carboplatin","cisplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03093116","nct04094610","nct03873402","nct04810078","nct07221357","nct04613596","nct05827016","nct05519085","nct07361510","nct04717414","nct06911502","nct04975997","nct05625399","nct07361497","nct06561386","nct05552976","nct04099251","nct06045806","nct03383458","nct04793958","nct07100080","nct06946797","nct05372354","nct06101134","nct06090539","nct04895709","nct07325136","nct03989414","nct07680764","nct07291076","nct05853575","nct03785249","nct06988488","nct07293351","nct06297226","nct04245839","nct03930953","nct07223047","nct02773030","nct05609578","nct05888831","nct03899155","nct02677922","nct06035497","nct07415031","nct05413018","nct07160725","nct04025879","nct06730750","nct06449222","nct07297212","nct03036098","nct07492680","nct06855771","nct07221149","nct07173751","nct06875310","nct04817007","nct07015242","nct03865082","nct04064060","nct06425302","nct06697197","nct06618287","nct03435796","nct07106762","nct05197426","nct00248287","nct06140836"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Princeton, NJ","country":"US","companyType":"pharma","website":"https://www.bms.com","ticker":"BMY","investors":[],"funding":[]},{"id":"bruce-power","kind":"company","name":"Bruce Power","aka":[],"tldr":"Bruce Power runs the world's largest nuclear power station and, since 2022, irradiates ytterbium targets inside a running reactor to make lutetium-177 for ITM, the first commercial medical isotope from a power reactor.","summary":"Bruce Power operates eight CANDU reactors on Lake Huron. With Isogen (a Framatome and Kinectrics venture) it built an Isotope Production System that inserts and retrieves targets while the reactor runs, and began commercial irradiation of ytterbium-176 for ITM's non-carrier-added lutetium-177 in 2022. It also supplies cobalt-60 to Nordion. The model shows how power reactors could relieve the research-reactor bottleneck for therapeutic isotopes.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Bruce_Power","links":[{"label":"Official website","url":"https://www.brucepower.com"}],"tags":["manufacturing-wave"],"related":[],"cancers":[],"sections":[],"technologies":["research-reactor-isotope-production","therapy-isotope-supply-chain"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tiverton, Ontario","country":"CA","companyType":"radiopharma","website":"https://www.brucepower.com","stage":"private-large","investors":[],"funding":[]},{"id":"bruker","kind":"company","name":"Bruker (Bruker Spatial Biology)","aka":[],"tldr":"Scientific-instrument group that acquired NanoString (GeoMx, CosMx) out of bankruptcy in 2024 to form Bruker Spatial Biology.","summary":"Bruker, based in Billerica, Massachusetts, and listed as BRKR, is a scientific instrument group that acquired NanoString, maker of GeoMx and CosMx, out of bankruptcy in 2024 to form Bruker Spatial Biology. Its portfolio spans mass spectrometry including the timsTOF instruments for proteomics, NMR and spatial biology instruments, with CosMx providing single-cell spatial imaging. OnCo links it to spatial biology instruments, proteomics and phosphoproteomics, and proteomics instruments and affinity platforms. Whether a diversified instrument company can turn a rescued spatial biology business into a clinical tool rather than a research product is the open question. The spatial biology instruments page carries the wider field.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.bruker.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics","drug-discovery"],"technologies":["spatial-biology-instruments","proteomics"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Billerica, MA","country":"US","companyType":"diagnostics","website":"https://www.bruker.com","ticker":"BRKR","investors":[],"funding":[]},{"id":"bulsara-bioworks","kind":"company","name":"Bulsara Bioworks","aka":[],"tldr":"Bulsara Bioworks is a 2025 start-up focused on precise p53-pathway activation for solid tumours.","summary":"Bulsara Bioworks is a San Francisco start-up founded in 2025 and backed by Even One Ventures, focused on precise activation of the p53 pathway in solid tumours. The company describes a focused drug-development model built around p53 pathway biology, its work is preclinical, and it exhibited at BIO 2026. OnCo links it to TP53 as a target and to the p53, RB and cell-cycle checkpoint pathway. Whether the p53 pathway, long considered undruggable, can be reactivated selectively in tumour cells is the question its programme depends on, and no clinical data yet exist. The TP53 target page carries the history of earlier attempts.","asOf":"2026-09-04","links":[{"label":"BIO 2026 participant profile","url":"https://convention.bio.org/participating-companies/bulsara-bioworks"}],"tags":["early-stage"],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":["tp53"],"drugs":[],"companies":[],"institutions":[],"pathways":["p53-cell-cycle"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.bulsarabio.com","founded":2025,"investors":[],"funding":[]},{"id":"butterfly-network","kind":"company","name":"Butterfly Network","aka":["Butterfly iQ","Butterfly iQ+","Butterfly iQ3"],"tldr":"The company that put a whole-body ultrasound probe on a silicon chip, sold for a few thousand dollars with a phone as the screen, and shipped thousands to clinics in Africa and to bedside clinicians worldwide.","summary":"Butterfly Network was founded in 2011 by Jonathan Rothberg to replace the piezoelectric crystals of conventional ultrasound with capacitive micromachined ultrasonic transducers on a semiconductor chip. Its first product, the Butterfly iQ, was cleared by the FDA in 2017 as a single hand-held probe covering the whole body, connected to a smartphone or tablet with cloud storage and tele-guidance software. The company listed on the New York Stock Exchange in 2021 through a merger with a special purpose acquisition company. It sells to hospitals, medical schools and primary care and, with the Bill and Melinda Gates Foundation, deployed probes across sub-Saharan Africa for maternal health, where the same devices serve cancer clinics for breast, thyroid and liver assessment.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.butterflynetwork.com"}],"tags":[],"related":[],"cancers":["breast-cancer","thyroid","hcc"],"sections":[],"technologies":["hand-held-ultrasound","ultrasound","global-oncology-access"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Burlington, Massachusetts, United States","country":"US","companyType":"devices","website":"https://www.butterflynetwork.com","ticker":"BFLY","founded":2011,"stage":"public","investors":[],"funding":[]},{"id":"byondis","kind":"company","name":"Byondis","aka":["Synthon Biopharmaceuticals","Byondis B.V."],"tldr":"Byondis is a Dutch antibody-drug conjugate company, formerly Synthon Biopharmaceuticals, whose HER2 conjugate trastuzumab duocarmazine improved progression-free survival in the TULIP trial but did not win US approval.","summary":"Byondis develops antibody-drug conjugates with its duocarmycin-based ByonZine linker-drug technology and the ByonShieLD site-specific conjugation platform. Trastuzumab duocarmazine (SYD985) links trastuzumab to a DNA-alkylating duocarmazine prodrug; in the phase 3 TULIP trial in pretreated HER2-positive metastatic breast cancer it lengthened progression-free survival over physician's choice, but the FDA issued a complete response letter in 2023 and the European application was withdrawn. Byondis continues with next-generation conjugates.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.byondis.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab-duocarmazine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Nijmegen","country":"NL","companyType":"biotech","website":"https://www.byondis.com/","investors":[],"funding":[]},{"id":"c-rad","kind":"company","name":"C-RAD","aka":[],"tldr":"C-RAD is a Swedish company whose Catalyst and Sentinel camera systems track the patient's surface during radiotherapy for positioning, breath-hold and respiratory gating.","summary":"C-RAD, founded in Uppsala in 2004 and listed on Nasdaq Stockholm, sells the Catalyst+ surface scanning system for treatment rooms and the Sentinel 4DCT system for the CT simulator, integrated with the major linac vendors for gating and motion monitoring, along with the cRAD positioning software.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://c-rad.se/"}],"tags":["machines-wave2"],"related":[],"cancers":[],"sections":[],"technologies":["patient-positioning-surface-guidance-systems","respiratory-gating-tumour-tracking-systems","surface-guided-radiotherapy","respiratory-motion-management"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Uppsala","country":"SE","companyType":"devices","website":"https://c-rad.se/","ticker":"CRAD-B","founded":2004,"stage":"public","investors":[],"funding":[]},{"id":"c2i-genomics","kind":"company","name":"C2i Genomics","aka":[],"tldr":"C2i Genomics built a blood test that reads the whole genome of tumour DNA fragments to detect leftover cancer after treatment; Veracyte bought the company in 2024 and now sells the approach as TrueMRD.","summary":"C2i Genomics, founded in New York with research roots at the New York Genome Center and the Weizmann Institute, developed a whole-genome approach to minimal residual disease (MRD) detection. Rather than tracking a small targeted panel, it sequences the tumour genome to define thousands of somatic variants and applies AI pattern recognition to low-pass whole-genome sequencing of plasma cell-free DNA, giving sensitive detection from a single blood tube. Veracyte announced a definitive agreement to acquire C2i on 8 January 2024 for $70 million in Veracyte shares at closing plus up to $25 million in performance milestones, extending its diagnostics platform into MRD monitoring. The technology now underpins Veracyte's TrueMRD platform, whose first test, for muscle-invasive bladder cancer, is available to order in the United States, with more cancers planned.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.veracyte.com/innovation/truemrd-platform/"},{"label":"Veracyte 8-K exhibit announcing C2i acquisition (Jan 2024)","url":"https://www.sec.gov/Archives/edgar/data/1384101/000119312524003949/d543036dex991.htm"}],"tags":[],"related":[],"cancers":["urothelial"],"sections":["diagnostics"],"technologies":["liquid-biopsy","mrd-testing","wes-wgs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["c2i-genomics.com redirects to Veracyte. Pre-acquisition venture rounds not sourced. Completion date of the acquisition not separately verified; the 8-K covers the definitive agreement."],"hq":"New York, NY","country":"US","companyType":"diagnostics","website":"https://www.veracyte.com/innovation/truemrd-platform/","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2024,"amountUsd":70000000,"source":"https://www.sec.gov/Archives/edgar/data/1384101/000119312524003949/d543036dex991.htm","note":"$70 million in Veracyte shares at closing plus up to $25 million in milestone payments over two years; definitive agreement announced 8 January 2024."}],"acquiredBy":"veracyte"},{"id":"c4-therapeutics","kind":"company","name":"C4 Therapeutics","aka":[],"tldr":"Degrader company whose IKZF1/3 molecular glue cemsidomide showed a 53% response rate in heavily pretreated myeloma and entered phase 2 in 2026.","summary":"C4 Therapeutics, based in Watertown, Massachusetts, and listed as CCCC, is a protein degrader company whose IKZF1/3 molecular glue cemsidomide showed a 53 percent response rate in heavily pretreated multiple myeloma and entered phase 2 in 2026. Cemsidomide, built on the MonoDAC platform, with dexamethasone gave that response rate at the 100 microgram dose in relapsed or refractory myeloma at EHA 2026; the phase 2 MOMENTUM trial enrolled its first patient in February 2026 and a phase 1b with elranatamab is ongoing. OnCo links it to multiple myeloma, to PROTACs and molecular glues and glue discovery platforms, to the bottleneck of undruggable drivers, and to ideas on degraders for childhood sarcoma fusion proteins. Whether a next-generation IKZF1/3 degrader beats older drugs of the class in a randomised trial is the open question. The degrader technology page carries the field.","asOf":"2026-09-04","links":[{"label":"EHA 2026 data","url":"https://www.globenewswire.com/news-release/2026/06/11/3310320/0/en/C4-Therapeutics-Presents-Phase-1-Data-at-European-Hematology-Association-EHA-2026-Congress-Highlighting-Cemsidomide-as-a-Potential-Best-in-Class-IKZF1-3-Degrader-for-Multiple-Myelo.html"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":["targeted-therapy"],"technologies":["protac-degrader"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07284758"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Watertown, MA","country":"US","companyType":"biotech","website":"https://c4therapeutics.com","ticker":"CCCC","investors":[],"funding":[]},{"id":"caliber-imaging-diagnostics","kind":"company","name":"Caliber Imaging and Diagnostics","aka":[],"tldr":"Caliber Imaging and Diagnostics makes the VivaScope reflectance confocal microscopes that image skin at cellular resolution without a biopsy, used to assess suspicious moles and map skin cancer margins.","summary":"Caliber I.D., based in Rochester, New York, developed the VivaScope 1500 bedside confocal microscope and the handheld VivaScope 3000, distributed in Europe by MAVIG. The devices are used in melanoma and basal cell carcinoma diagnosis, presurgical margin mapping and monitoring of non-surgical treatment, with reimbursement codes in the United States.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.caliberid.com/"}],"tags":["machines-wave2"],"related":[],"cancers":["melanoma","basal-cell-carcinoma"],"sections":[],"technologies":["confocal-oct-skin-imaging","dermoscopy-ai"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Rochester, NY","country":"US","companyType":"imaging","website":"https://www.caliberid.com/","stage":"private-large","investors":[],"funding":[]},{"id":"callio-therapeutics","kind":"company","name":"Callio Therapeutics","aka":[],"tldr":"Callio Therapeutics makes antibodies that carry two different cancer-killing drugs at once to HER2-positive tumours, to stop cancers escaping treatment. Its first medicine entered human trials in 2026.","summary":"Callio Therapeutics is a clinical-stage biotech headquartered in Seattle and Singapore, launched in March 2025 by Frazier Life Sciences with technology and programmes exclusively licensed from Hummingbird Bioscience. Its platform pairs a modular linker with two rationally selected synergistic payloads on one antibody, aiming to block the dominant resistance mechanisms that limit single-payload ADCs. The lead candidate CLIO-8221 is a HER2-targeted dual-payload ADC co-delivering exatecan (a topoisomerase 1 inhibitor) and an ATR inhibitor; a phase 1/2 study in advanced HER2-expressing solid tumours was presented as a trials-in-progress poster at ASCO 2026 after preclinical data at AACR 2026. A second undisclosed ADC programme is also funded. The USD 187 million Series A was led by Frazier Life Sciences with significant participation from Jeito Capital. Zachary Hornby was appointed CEO in September 2026.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://calliotx.com/"},{"label":"Series A press release","url":"https://www.prnewswire.com/news-releases/callio-therapeutics-launches-with-us187-million-series-a-to-advance-multi-payload-antibody-drug-conjugate-platform-through-clinical-proof-of-concept-302388161.html"},{"label":"News and publications","url":"https://calliotx.com/news/"}],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":["adcs"],"technologies":["dual-payload-adc","adc"],"targets":["her2","atr"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07300943"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Seattle, WA","country":"US","companyType":"biotech","website":"https://calliotx.com/","stage":"startup","investors":["frazier-life-sciences","jeito-capital","novo-holdings","omega-funds"],"funding":[{"round":"Series A","year":2025,"amountUsd":187000000,"source":"https://www.prnewswire.com/news-releases/callio-therapeutics-launches-with-us187-million-series-a-to-advance-multi-payload-antibody-drug-conjugate-platform-through-clinical-proof-of-concept-302388161.html"}]},{"id":"calyx","kind":"company","name":"Calyx","aka":[],"tldr":"Imaging core lab and RTSM provider (formerly Parexel Informatics), a leading vendor of blinded central review in oncology trials.","summary":"Calyx, based in Nottingham and formerly Parexel Informatics, is an imaging core laboratory and randomisation and trial supply provider, and a leading vendor of blinded independent central review in oncology trials. It performs independent review under RECIST and other response criteria and runs randomisation and trial supply systems. OnCo links it to imaging core labs and central review. Whether blinded central review remains the regulatory expectation as AI-assisted response assessment develops is the open question for its core business. The imaging core lab technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.calyx.ai"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["imaging"],"technologies":["imaging-core-labs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Nottingham","country":"GB","companyType":"cro-services","website":"https://www.calyx.ai","investors":[],"funding":[]},{"id":"cambridge-cancer-genomics","kind":"company","name":"Cambridge Cancer Genomics (CCG.ai)","aka":[],"tldr":"CCG.ai built software to combine genomic and clinical data so oncologists could choose and adjust treatment sooner. The company is no longer active.","summary":"Cambridge Cancer Genomics developed a data-driven precision oncology platform: software to analyse tumour and liquid biopsy sequencing alongside clinical records, and machine-learned biomarkers intended to predict treatment response and detect relapse earlier than imaging. It grew to a team of about 25 in Cambridge before the YC directory marked it inactive. It is recorded as wound down; no acquirer is named because none was found in a primary source.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/cambridge-cancer-genomics"},{"label":"Official website","url":"https://ccg.ai"}],"tags":["yc"],"related":[],"cancers":[],"sections":["ai-computation","diagnostics"],"technologies":["liquid-biopsy","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cambridge","country":"GB","companyType":"ai-software","website":"https://ccg.ai","stage":"defunct","ycBatch":"S17","investors":["y-combinator"],"funding":[]},{"id":"camurus","kind":"company","name":"Camurus","aka":["Camurus AB","STO:CAMX"],"tldr":"Camurus is a Swedish drug-delivery company whose FluidCrystal depot turns injections into long-acting formulations; CAM2029 is its monthly octreotide depot for acromegaly and neuroendocrine tumours.","summary":"Camurus develops long-acting medicines built on its FluidCrystal lipid-based depot technology, which forms a slow-release gel after subcutaneous injection. Its marketed products include Buvidal for opioid dependence. In oncology and endocrinology it is developing CAM2029 (octreotide subcutaneous depot, branded Oczyesa in some markets) for acromegaly, gastroenteropancreatic neuroendocrine tumours and polycystic liver disease, and in-licensed rights to a long-acting treprostinil.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Camurus","links":[{"label":"Official website","url":"https://www.camurus.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["cam2029"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Lund","country":"SE","companyType":"pharma","website":"https://www.camurus.com/","ticker":"STO:CAMX","founded":1991,"stage":"public","investors":[],"funding":[]},{"id":"can-fite","kind":"company","name":"Can-Fite BioPharma","aka":["Can-Fite BioPharma Ltd","Can Fite Biopharma"],"tldr":"Can-Fite is an Israeli company developing adenosine A3 receptor agonists; namodenoson is in phase 3 as a second-line treatment for liver cancer in patients with poor liver function.","summary":"Can-Fite BioPharma, founded in 1994 and based in Petah Tikva, Israel, develops small molecules that act on the adenosine A3 receptor, which is overexpressed in tumour and inflamed cells. Namodenoson is in a phase 3 trial in hepatocellular carcinoma with Child-Pugh B liver function, a group with few options, and piclidenoson is tested in psoriasis. Its trials are registered on ClinicalTrials.gov under Can-Fite as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.canfite.com"},{"label":"ClinicalTrials.gov: trials led by Can-Fite BioPharma Ltd","url":"https://clinicaltrials.gov/search?lead=Can-Fite%20BioPharma%20Ltd"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q96482303"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct06387342","nct05201404"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Petah Tikva","country":"IL","companyType":"biotech","website":"https://www.canfite.com","founded":1994,"stage":"public","investors":[],"funding":[]},{"id":"cctg","kind":"company","name":"Canadian Cancer Trials Group (CCTG)","aka":["Canadian Cancer Trials Group","CCTG","NCIC Clinical Trials Group","NCIC CTG"],"tldr":"Canada's national academic trials group, which ran the CHALLENGE exercise trial and co-led the SABR-COMET oligometastasis trial.","summary":"The Canadian Cancer Trials Group, based at Queen's University in Kingston, Ontario, is Canada's national academic trials group, which ran the CHALLENGE exercise trial and co-led the SABR-COMET oligometastasis trial. CHALLENGE, trial CO.21 published in the New England Journal of Medicine in 2025, showed that a structured exercise programme after chemotherapy improves outcomes in colon cancer, and its earlier landmarks include MA.17 on extended letrozole and PA.3 on erlotinib in pancreatic cancer, with Wendy Parulekar, Dongsheng Tu and Janet Dancey among the people linked. OnCo connects it to exercise and lifestyle oncology and stereotactic radiotherapy, and to bottlenecks on slow enrolment and the lack of incentive to repurpose cheap interventions. Whether health systems will fund exercise programmes as they fund drugs is the question CHALLENGE now poses. Its programmes are listed in the notes.","asOf":"2026-09-06","links":[{"label":"Official website","url":"https://www.ctg.queensu.ca"}],"tags":["cooperative-group"],"related":[],"cancers":["colorectal","breast-hr-positive"],"sections":[],"technologies":["exercise-oncology","sbrt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["ma-20"],"people":["tu-dongsheng","parulekar-wendy","dancey-janet"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["CHALLENGE exercise trial","Breast endocrine therapy trials (MA series)"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Kingston, ON","country":"CA","companyType":"cooperative-group","website":"https://www.ctg.queensu.ca","investors":[],"funding":[]},{"id":"canariabio","kind":"company","name":"CanariaBio","aka":["OncoQuest","OncoQuest Pharmaceuticals","카나리아바이오"],"tldr":"CanariaBio is a South Korean biotech that took over oregovomab, an antibody against the ovarian cancer marker CA-125 that is given with chemotherapy to prime an immune response against the tumour.","summary":"CanariaBio acquired the oregovomab programme from OncoQuest of Edmonton, Canada. Oregovomab (MAb-B43.13) binds circulating CA-125 and, given at the same time as carboplatin and paclitaxel, forms immune complexes that induce CA-125-specific T-cell responses. After a phase 2 trial suggested longer progression-free survival, the phase 3 FLORA-5 trial in newly diagnosed advanced ovarian cancer read out in 2024 without meeting its primary endpoint.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["oregovomab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Seongnam","country":"KR","companyType":"biotech","investors":[],"funding":[]},{"id":"cancer-commons","kind":"company","name":"Cancer Commons","aka":[],"tldr":"Nonprofit that helps advanced-cancer patients navigate precision-oncology options and trials, free of charge.","summary":"Cancer Commons, a nonprofit based in Mountain View, California, helps patients with advanced cancer navigate precision oncology options and trials free of charge. It offers personalised treatment-option analysis, trial matching and access to an expert network for patients with limited options, and Navexio is linked as a related company. OnCo connects it to AI trial matching and clinical decision support, to bottlenecks on patient navigation, misinformation, data silos and secrecy, and to ideas such as a cancer data donor card and a live seats-available feed for trial slots. Whether a nonprofit navigation service can scale to the number of patients who need it, or whether its model has to be built into health systems, is the open question. The trial matching technology page carries the wider picture.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://cancercommons.org"}],"tags":[],"related":["thesecondopinion"],"cancers":[],"sections":["supportive-care"],"technologies":["ai-trial-matching"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Mountain View, CA","country":"US","companyType":"nonprofit","website":"https://cancercommons.org","investors":[],"funding":[]},{"id":"cancer-prevention-pharmaceuticals","kind":"company","name":"Cancer Prevention Pharmaceuticals","aka":["Cancer Prevention Pharmaceuticals, Inc.","CPP"],"tldr":"Cancer Prevention Pharmaceuticals is a Tucson company built around eflornithine, the polyamine-blocking drug, which it tested with sulindac in phase 3 to prevent polyps in familial adenomatous polyposis.","summary":"Cancer Prevention Pharmaceuticals, founded in 2008 in Tucson, Arizona, develops eflornithine (DFMO), an ornithine decarboxylase inhibitor, for cancer prevention. Its phase 3 trials combined eflornithine with sulindac in familial adenomatous polyposis and in patients with a history of colorectal adenomas, registered on ClinicalTrials.gov under the company as lead sponsor; the combination did not reach approval, though eflornithine itself was later approved by another company for neuroblastoma maintenance.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://canprevent.com"},{"label":"ClinicalTrials.gov: trials led by Cancer Prevention Pharmaceuticals, Inc.","url":"https://clinicaltrials.gov/search?lead=Cancer%20Prevention%20Pharmaceuticals%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q50038303"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["colorectal"],"sections":["prevention"],"technologies":["chemoprevention"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Tucson, AZ","country":"US","companyType":"biotech","website":"https://canprevent.com","founded":2008,"stage":"private-large","investors":[],"funding":[]},{"id":"cancer-research-horizons","kind":"company","name":"Cancer Research Horizons","aka":[],"tldr":"The innovation and commercial arm of the charity Cancer Research UK. It turns charity-funded discoveries into start-ups and licences, and runs a seed fund; its alumni include Autolus, KuDOS and Myricx Bio.","summary":"Cancer Research Horizons, based at 2 Redman Place, London E20, is the commercial and translational arm of Cancer Research UK. Its site covers a Therapeutic Accelerator, entrepreneurial training, a Seed Fund for investors, drug discovery groups (including a Functional Genomics Centre and Centre for Drug Development), licensing opportunities and multi-modal cancer datasets. Its start-up portfolio page states it has formed 95 or more start-ups across therapeutics, diagnostics and medtech, with 24 exits and more than GBP 3.55 billion raised by the portfolio. Exited companies listed include Autolus, KuDOS Pharmaceuticals (source of olaparib), Spirogen (antibody-drug conjugate payloads), Inivata (liquid biopsy), Monte Rosa Therapeutics and Myricx Bio (acquired by Novartis in a deal worth up to $1.5 billion); Trogenix, a glioblastoma immunotherapy company, is featured as an active start-up.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.cancerresearchhorizons.com/"},{"label":"Start-up portfolio","url":"https://www.cancerresearchhorizons.com/our-portfolio/our-start-up-portfolio"},{"label":"Seed Fund","url":"https://www.cancerresearchhorizons.com/investors/our-seed-fund"}],"tags":["foundation"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cruk"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Launch year of the Cancer Research Horizons brand not stated on fetched pages; omitted. Autolus and Monte Rosa are already in the graph."],"hq":"London","country":"GB","companyType":"investor","website":"https://www.cancerresearchhorizons.com/","investors":[],"funding":[]},{"id":"cancertain","kind":"company","name":"CanCertain","aka":["CLYZ Labs"],"tldr":"CanCertain grows circulating tumour cells from a blood sample in 3D culture and tests drugs on them, including immunotherapies, and accepts orders from patients as well as physicians.","summary":"CanCertain, run by the UK laboratory CLYZ Labs, isolates circulating tumour cells from blood, expands them in 3D cell culture and exposes them to cancer drugs to report which show activity, an approach compatible with immunotherapy testing. Patient- or physician-ordered.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.cancertain.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["functional-drug-testing","ctc-capture"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"United Kingdom (city not published)","country":"GB","companyType":"diagnostics","website":"https://www.cancertain.com/","investors":[],"funding":[]},{"id":"candel-therapeutics","kind":"company","name":"Candel Therapeutics","aka":[],"tldr":"Candel makes viral immunotherapies injected into tumours to trigger an immune attack. Its lead product, aglatimagene, improved disease-free survival when added to radiotherapy in localised prostate cancer in a phase 3 trial, and a US approval filing is planned for late 2026.","summary":"Candel Therapeutics is a Needham, Massachusetts clinical-stage company developing multimodal viral immunotherapies. Lead candidate aglatimagene besadenovec (CAN-2409), an adenoviral immunotherapy, showed a statistically significant improvement in disease-free survival when added to standard radiotherapy in a pivotal phase 3 trial in localised, intermediate- to high-risk prostate cancer (published in The Lancet Oncology); a BLA submission is planned for the fourth quarter of 2026 with a potential US launch in 2027. The global pivotal phase 3 AURORA trial in stage IV non-squamous non-small cell lung cancer progressing on pembrolizumab has opened enrolment. CAN-3110 (linoserpaturev), an HSV-based oncolytic immunotherapy, is being planned for a randomised phase 2 trial in recurrent glioblastoma. Candel had $201.6 million in cash at 30 June 2026 with runway into the first quarter of 2028. Nasdaq: CADL.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://candeltx.com/"},{"label":"Q2 2026 results (8-K exhibit 99.1)","url":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526347957/cadl-ex99_1.htm"},{"label":"Board appointment noting planned BLA (8-K exhibit 99.1, September 2026)","url":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526387310/cadl-ex99_1.htm"}],"tags":[],"related":[],"cancers":["prostate","nsclc","glioblastoma"],"sections":["immunotherapy"],"technologies":["oncolytic-virus"],"targets":[],"drugs":["aglatimagene-besadenovec"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct01436968","nct02768363","nct07332000","nct04495153"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No funding round sourced."],"hq":"Needham, MA","country":"US","companyType":"biotech","website":"https://candeltx.com/","ticker":"CADL","stage":"public","investors":[],"funding":[]},{"id":"canfield-scientific","kind":"company","name":"Canfield Scientific","aka":[],"tldr":"Canfield Scientific makes the VECTRA WB360 whole-body imaging system, which photographs a patient's entire skin in one capture and tracks every mole over time, plus dermoscopy cameras and analysis software.","summary":"Canfield Scientific, founded in 1987, supplies imaging systems for dermatology, aesthetics and clinical research. Its VECTRA WB360 combines dozens of cameras to build a 3D total-body image with automated lesion detection and change tracking, used in melanoma high-risk clinics and trials; DermaGraphix software and VEOS dermatoscopes complete the skin imaging line.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.canfieldsci.com/"}],"tags":["machines-wave2"],"related":[],"cancers":["melanoma","skin-cancer"],"sections":[],"technologies":["dermoscopy-ai","confocal-oct-skin-imaging","skin-cancer-screening"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Parsippany, NJ","country":"US","companyType":"imaging","website":"https://www.canfieldsci.com/","founded":1987,"stage":"private-large","investors":[],"funding":[]},{"id":"canon-medical","kind":"company","name":"Canon Medical Systems","aka":[],"tldr":"Canon Medical is the Japanese imaging vendor (formerly Toshiba Medical) with CT, MRI, ultrasound, and the Cartesion Prime PET/CT.","summary":"Canon Medical Systems, based in Otawara, Japan, is the imaging vendor formerly known as Toshiba Medical, with CT, MRI, ultrasound and the Cartesion Prime PET/CT. Its portfolio includes Aquilion CT and photon-counting development, Vantage MRI and PET/CT with digital detectors. OnCo links it to nuclear medicine and total-body PET hardware, CT and MRI. Whether a fourth major imaging vendor can differentiate in PET and photon-counting CT against larger rivals is the open question. The PET hardware technology page carries the wider picture.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Canon_Medical_Systems_Corporation","links":[{"label":"Official website","url":"https://global.medical.canon"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["imaging"],"technologies":["nuclear-medicine-hardware","ct","mri"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Otawara","country":"JP","companyType":"imaging","website":"https://global.medical.canon","investors":[],"funding":[]},{"id":"canopy","kind":"company","name":"Canopy","aka":[],"tldr":"Canopy is software for cancer clinics that lets patients report symptoms from home between visits, sorts the reports by urgency for nurses, and automates the paperwork that lets clinics bill for that monitoring.","summary":"Canopy provides an enterprise platform for oncology practices to manage care between visits. Core modules are electronic patient reported outcomes for remote symptom monitoring, AI native triage that prioritises incoming patient requests for nursing teams, and care coordination programmes such as Chronic Care Management and Remote Therapeutic Monitoring that generate reimbursable activity. The company says more than a dozen large oncology practices use it, including Texas Oncology and New York Cancer and Blood Specialists, and cites peer reviewed results including a 22 percent reduction in emergency room visits and 93 percent faster resolution of patient requests. Canopy was founded in 2018 by Lavi Kwiatkowsky and is based at 228 Park Avenue South, New York. No funding round or investor could be sourced from a primary document during this research.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://canopycare.us"},{"label":"About Canopy","url":"https://canopycare.us/about"}],"tags":[],"related":[],"cancers":[],"sections":["supportive-care","ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No press releases found on PR Newswire or in the site sitemap and no Form D found on EDGAR under Canopy Care, so funding is empty. Stage set to startup by default."],"hq":"New York, NY","country":"US","companyType":"ai-software","website":"https://canopycare.us","founded":2018,"stage":"startup","investors":[],"funding":[]},{"id":"capnomed","kind":"company","name":"Capnomed (Reger Medizintechnik)","aka":[],"tldr":"Capnomed developed the CapnoPen, the nebuliser that sprays chemotherapy as an aerosol into the abdomen during PIPAC, now made by Reger Medizintechnik.","summary":"The CapnoPen micropump nebuliser, connected to a standard contrast injector and passed through a laparoscopic port, made pressurised intraperitoneal aerosol chemotherapy reproducible after the technique was introduced in Germany in 2011. Capnomed's device line was taken over by Reger Medizintechnik, which continues to supply the CE-marked nebuliser used in most PIPAC programmes and trials.","asOf":"2026-09-17","links":[{"label":"Reger Medizintechnik","url":"https://www.reger-medizintechnik.de/"}],"tags":["machines-wave2"],"related":[],"cancers":["gastric","ovarian","colorectal","pancreatic"],"sections":[],"technologies":["hipec-pipac-devices","hipec"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Villingendorf","country":"DE","companyType":"devices","website":"https://www.reger-medizintechnik.de/","stage":"private-large","investors":[],"funding":[]},{"id":"capsovision","kind":"company","name":"CapsoVision","aka":[],"tldr":"CapsoVision makes the CapsoCam Plus, a swallowable capsule with four side-facing cameras that stores its images on board, so the patient needs no recorder belt.","summary":"CapsoVision's CapsoCam Plus small-bowel capsule captures a panoramic view of the mucosa with cameras around its circumference and stores the video internally; the capsule is retrieved and read with the company's software. It competes with Medtronic's PillCam and Olympus's EndoCapsule in small-bowel investigation and is developing colon and AI reading applications.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://capsovision.com/"}],"tags":["machines-wave2"],"related":[],"cancers":[],"sections":[],"technologies":["capsule-endoscopy-systems"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Saratoga, CA","country":"US","companyType":"devices","website":"https://capsovision.com/","stage":"public","investors":[],"funding":[]},{"id":"capstan-therapeutics","kind":"company","name":"Capstan Therapeutics","aka":[],"tldr":"Capstan built a way to create CAR T cells inside the patient's body by delivering messenger RNA in targeted lipid nanoparticles, avoiding the need to manufacture cells outside the body. AbbVie bought it in 2025 for $2.1 billion.","summary":"Capstan Therapeutics developed in vivo CAR T therapy using targeted lipid nanoparticles (tLNP) that deliver RNA payloads such as mRNA to specific immune cells so that CAR T cells are generated inside the patient. Its lead candidate CPTX2309 (now ABBV-619) is an anti-CD19 in vivo CAR T in phase 1 for B cell-mediated autoimmune diseases; the platform is also applicable to oncology. SEC Form D filings show the company was incorporated in 2020 and sold roughly $63 million (2021), $76 million (2022) and $87 million of a $175 million offering (2024) in equity. AbbVie completed its acquisition of Capstan in August 2025 for cash consideration of $2.1 billion, accounted for as an asset acquisition, as disclosed in AbbVie's third-quarter 2025 Form 10-Q.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.sec.gov/edgar/browse/?CIK=0002015437"},{"label":"AbbVie Q3 2025 Form 10-Q describing the acquisition","url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/abbv-20250930.htm"},{"label":"AbbVie Q3 2025 results noting completion (8-K)","url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000047/abbv-20250930xexhibit991.htm"},{"label":"SEC EDGAR filings","url":"https://www.sec.gov/edgar/browse/?CIK=0002015437"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["in-vivo-car-t"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["capstantx.com redirects to an AbbVie page that returned HTTP 403 to automated fetches, so the EDGAR page is given as website. Lead indication is autoimmune rather than cancer; the Form D filings do not name series letters. Investor names not sourced."],"hq":"San Diego, CA","country":"US","companyType":"cell-therapy","founded":2020,"stage":"acquired","investors":[],"funding":[{"round":"Form D offering","year":2021,"amountUsd":62999992,"source":"https://www.sec.gov/Archives/edgar/data/2015437/000201543724000001/primary_doc.xml","note":"Equity offering, first sale 24 November 2021 (filed March 2024)"},{"round":"Form D offering","year":2022,"amountUsd":76499983,"source":"https://www.sec.gov/Archives/edgar/data/2015437/000201543724000002/primary_doc.xml","note":"Amount sold of a $102 million offering, first sale 14 June 2022 (filed March 2024)"},{"round":"Form D offering","year":2024,"amountUsd":87499982,"source":"https://www.sec.gov/Archives/edgar/data/2015437/000201543724000003/primary_doc.xml","note":"Amount sold at filing of a $175 million offering, first sale 5 March 2024"},{"round":"Acquisition","year":2025,"amountUsd":2100000000,"source":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/abbv-20250930.htm","note":"AbbVie paid cash consideration of $2.1 billion ($1.9 billion net of cash acquired); completed August 2025"}],"acquiredBy":"abbvie"},{"id":"captor-therapeutics","kind":"company","name":"Captor Therapeutics","aka":[],"tldr":"Captor Therapeutics, a Polish company listed in Warsaw, designs small molecules that make cells destroy disease-causing proteins. Its lead cancer programme degrades three proteins at once and is aimed at liver and lung cancer.","summary":"Captor Therapeutics is a targeted protein degradation company based in Wroclaw, Poland and Basel, Switzerland, and calls itself the first European public company fully dedicated to the technology. Its Optigrade platform combines protein engineering, structural biology, molecular modelling and CRISPR/Cas9 target validation to select target-ligase pairs. The lead oncology programme is a molecular glue prodrug that degrades GSPT1, NEK7 and SALL4 with liver and lung tissue specificity, efficacy in hepatocellular carcinoma xenografts and synergy with everolimus, directed at hepatocellular carcinoma, lung cancer and neuroendocrine tumours; GSPT1 degradation data in high-risk neuroblastoma models were reported in February 2026. A brain-penetrant NEK7 degrader targets neuroinflammation. Captor listed on the Warsaw Stock Exchange on 19 April 2021 (WSE ticker CAPTORTX).","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://captortherapeutics.com/"},{"label":"Pipeline","url":"https://captortherapeutics.com/pipeline-en"},{"label":"About Captor (investor relations)","url":"https://captortherapeutics.com/investor-relations/overview/about-company"},{"label":"Shares and WSE listing details","url":"https://captortherapeutics.com/investor-relations/shares-and-related-information/shares"}],"tags":[],"related":[],"cancers":["hcc","neuroendocrine","neuroblastoma"],"sections":["targeted-therapy"],"technologies":["protac-degrader"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Ticker built from the WSE ticker shown on the company's shares page (CAPTORTX) with the Warsaw suffix; the short exchange code commonly quoted as CTX was not verified. The clinical phase of the lead GSPT1/NEK7/SALL4 programme could not be read from the pipeline chart text and is not stated. IPO proceeds not sourced."],"hq":"Wroclaw","country":"PL","companyType":"biotech","website":"https://captortherapeutics.com/","ticker":"CAPTORTX.WA","stage":"public","investors":[],"funding":[{"round":"IPO","year":2021,"source":"https://captortherapeutics.com/investor-relations/overview/about-company","note":"Debuted on the Warsaw Stock Exchange main market on 19 April 2021; amount raised not stated on the fetched pages"}]},{"id":"cardiff-oncology","kind":"company","name":"Cardiff Oncology","aka":["Trovagene","Cardiff Oncology, Inc.","NASDAQ:CRDF"],"tldr":"Cardiff Oncology is a San Diego biotech developing onvansertib, an oral PLK1 inhibitor that is being tested with chemotherapy and bevacizumab as first-line treatment for RAS-mutant colorectal cancer.","summary":"Cardiff Oncology, formerly the diagnostics company Trovagene, develops onvansertib, a selective oral inhibitor of Polo-like kinase 1 licensed from Nerviano Medical Sciences. The randomised phase 2 CRDF-004 trial combines onvansertib with FOLFIRI or FOLFOX plus bevacizumab in first-line RAS-mutant metastatic colorectal cancer, after earlier studies showed higher response rates in bevacizumab-naive patients. Onvansertib has also been studied in pancreatic cancer and small cell lung cancer.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.cardiffoncology.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["onvansertib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"San Diego, California","country":"US","companyType":"biotech","website":"https://www.cardiffoncology.com/","ticker":"NASDAQ:CRDF","stage":"public","investors":[],"funding":[]},{"id":"cardinal-health","kind":"company","name":"Cardinal Health Nuclear & Precision Health Solutions","aka":[],"tldr":"Nuclear pharmacy network (>130 sites) that compounds and delivers SPECT and PET doses, and a distributor of oncology drugs to community practices.","summary":"Cardinal Health Nuclear and Precision Health Solutions, based in Dublin, Ohio, and part of Cardinal Health, listed as CAH, is a nuclear pharmacy network of more than 130 sites that compounds and delivers SPECT and PET doses, and a distributor of oncology drugs to community practices. It is the largest US nuclear pharmacy chain and also a major distributor and group purchasing organisation for community oncology. OnCo links it to radiopharmacy and cyclotron networks, PET tracer manufacturing and distribution and community oncology site networks, and to the FDG drug record. Whether its distribution reach can carry therapeutic radioligands to community practices as it does diagnostic doses is the open question. FDG has its own page.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.cardinalhealth.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["radiopharma"],"technologies":["radiopharmacy-network","pet-tracer-manufacturing","community-oncology-networks"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Dublin, OH","country":"US","companyType":"radiopharma","website":"https://www.cardinalhealth.com","ticker":"CAH","investors":[],"funding":[]},{"id":"careology","kind":"company","name":"Careology","aka":[],"tldr":"Careology is an app that helps people going through cancer treatment log symptoms, medicines and appointments, and a dashboard that lets their hospital team see problems early.","summary":"Careology is a London based digital cancer care platform founded by Paul Landau. Patients use the app to record symptoms, temperature, medication and wellbeing, and clinical teams monitor a dashboard that flags deterioration for proactive intervention. UK deployments include Guy's and St Thomas' and Airedale NHS Foundation Trusts, Nuffield Health, LloydsPharmacy Clinical Homecare, Aviva and a Macmillan Cancer Support partnership. In the United States, Evolent integrated Careology into its cancer navigation services from 2024 for Florida Blue and American Oncology Network patients, and Oncology Hematology Care uses it to monitor CAR-T patients. The company reports a 17 fold return on investment from avoided admissions and 96 percent of clinicians saying it informed consultations. Careology raised GBP 1.12 million from angel investors in November 2019; later funding was not sourced.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.careology.health"},{"label":"GBP 1.1 million seed announcement (November 2019)","url":"https://careology.health/resources/news/careology-raises-pound1-1m-for-ambitious-growth-plans"},{"label":"Evolent partnership (May 2024)","url":"https://careology.health/resources/news/evolent-and-careology-join-forces-to-transform-cancer-care-in-the-us"},{"label":"About Careology","url":"https://careology.health/about"}],"tags":[],"related":[],"cancers":[],"sections":["supportive-care","ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year: the seed release (2019) says the platform launched earlier in 2019 while the About page says the app launched January 2020; 2019 used. London HQ is inferred from the About page text (London appears three times) rather than a stated address. Note that Evolent also uses 'Careology' as the name of its own navigation platform in an AON release."],"hq":"London","country":"GB","companyType":"ai-software","website":"https://www.careology.health","founded":2019,"stage":"startup","investors":[],"funding":[{"round":"Seed","year":2019,"source":"https://careology.health/resources/news/careology-raises-pound1-1m-for-ambitious-growth-plans","note":"GBP 1.12 million from UK health and technology angel investors (not named)"}]},{"id":"carevive-systems","kind":"company","name":"Carevive Systems","aka":[],"tldr":"Carevive built software that cancer clinics use to give each patient a personalised care plan and to collect symptom reports from home so nurses can act early. It is now part of Health Catalyst.","summary":"Carevive Systems is an oncology care management platform that combines electronic health record data, electronic patient reported outcomes and evidence based guidelines to generate personalised treatment care plans, screen patients for clinical trials, coordinate care and run remote symptom monitoring, including the STAIRS symptom triage, assessment, intervention and response workflow. SEC Form D filings list the company in North Miami, Florida, with equity offerings in 2016 to 2017 and a USD 15 million offering first sold in January 2020. Health Catalyst acquired Carevive on 24 May 2024 (announced 6 June 2024) for total consideration of about USD 22.1 million and now markets the product as Carevive by Health Catalyst; the carevive.com domain redirects to that page. Carevive specific customer counts were not stated in fetched sources.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.healthcatalyst.com/offerings/carevive-by-health-catalyst"},{"label":"Health Catalyst acquisition announcement (June 2024)","url":"https://www.healthcatalyst.com/news/health-catalyst-acquires-oncology-focused-health-technology-company-carevive"},{"label":"Health Catalyst 10-Q for Q2 2024 with deal terms","url":"https://www.sec.gov/Archives/edgar/data/1636422/000163642224000120/hcat-20240630.htm"},{"label":"SEC Form D (February 2020)","url":"https://www.sec.gov/Archives/edgar/data/1688076/000168807620000001/primary_doc.xml"}],"tags":[],"related":[],"cancers":[],"sections":["supportive-care","ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Hint gave Boston; the only fetched primary source for location is the 2020 Form D (North Miami, FL), so that is used. Founding year not sourced. The original carevive.com website now redirects to Health Catalyst."],"hq":"North Miami, FL","country":"US","companyType":"ai-software","website":"https://www.healthcatalyst.com/offerings/carevive-by-health-catalyst","stage":"acquired","investors":[],"funding":[{"round":"Form D offering","year":2020,"amountUsd":14955871,"source":"https://www.sec.gov/Archives/edgar/data/1688076/000168807620000001/primary_doc.xml","note":"Equity offering first sold 30 January 2020; USD 15.0 million sold of USD 18.0 million, including USD 7.5 million of converted notes"},{"round":"Acquisition","year":2024,"amountUsd":22100000,"source":"https://www.sec.gov/Archives/edgar/data/1636422/000163642224000120/hcat-20240630.htm","note":"Health Catalyst acquired Carevive Systems on 24 May 2024 for USD 18.6 million net cash, USD 2.6 million in shares and USD 0.9 million contingent earn out; announced 6 June 2024"}]},{"id":"cargo-therapeutics","kind":"company","name":"CARGO Therapeutics","aka":[],"tldr":"CARGO developed a CAR T-cell therapy aimed at a protein called CD22 for patients with large B-cell lymphoma whose cancer had come back after CD19 CAR T treatment. It went public in 2023 and was bought by Concentra Biosciences in 2025 after winding down development.","summary":"CARGO Therapeutics was a clinical-stage cell therapy company whose lead candidate, CRG-022, was an autologous CD22-directed chimeric antigen receptor (CAR) T-cell product for relapsed or refractory large B-cell lymphoma, including patients who had progressed after CD19 CAR T-cell therapy. The company began a potentially pivotal phase 2 trial (NCT05972720) in 2023 and completed a Nasdaq IPO raising about $281 million in November 2023. In July 2025 CARGO, by then describing itself as a company that had focused on CAR T-cell development, agreed to be acquired by Concentra Biosciences for $4.379 per share in cash plus a contingent value right tied to closing net cash above $217.5 million and to any disposition of remaining product candidates. The tender offer closed on 18 August 2025 and the merger completed the next day.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.sec.gov/edgar/browse/?CIK=0001966494"},{"label":"Concentra acquisition announcement (8-K, July 2025)","url":"https://www.sec.gov/Archives/edgar/data/1966494/000119312525156413/d74755dex991.htm"},{"label":"Completion of acquisition (8-K, August 2025)","url":"https://www.sec.gov/Archives/edgar/data/1966494/000119312525183141/d58314d8k.htm"},{"label":"Q3 2023 results describing CRG-022 (8-K)","url":"https://www.sec.gov/Archives/edgar/data/1966494/000119312523294468/d25647dex991.htm"},{"label":"SEC EDGAR filings","url":"https://www.sec.gov/edgar/browse/?CIK=0001966494"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":["cell-therapy"],"technologies":["car-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website cargo-tx.com no longer resolves, so the SEC EDGAR company page is given as the website. Former Nasdaq ticker CRGX. Dateline was San Mateo in December 2023 and San Carlos in July 2025."],"hq":"San Carlos, CA","country":"US","companyType":"cell-therapy","stage":"acquired","investors":[],"funding":[{"round":"IPO","year":2023,"amountUsd":281300000,"source":"https://www.sec.gov/Archives/edgar/data/1966494/000119312523277142/d279450d8k.htm","note":"18,750,000 shares at $15.00; Nasdaq CRGX"},{"round":"Acquisition","year":2025,"source":"https://www.sec.gov/Archives/edgar/data/1966494/000119312525156413/d74755dex991.htm","note":"$4.379 in cash per share plus a contingent value right; tender offer completed 18 August 2025"}]},{"id":"caribou","kind":"company","name":"Caribou Biosciences","aka":[],"tldr":"CRISPR-edited allogeneic CAR-T company whose vispa-cel (CB-010) matched autologous CAR-T efficacy in lymphoma in 2025 data.","summary":"Vispacabtagene regedleucel (CD19, chRDNA-edited) holds RMAT, Orphan, and Fast Track designations for B-NHL; ANTLER phase 1 data (November 2025) showed efficacy and durability on par with autologous products and outpatient-compatible safety; enrolling ~20 more second-line LBCL patients to confirm an HLA-matching strategy; IND cleared in lupus.","asOf":"2026-09-04","links":[{"label":"ANTLER data","url":"https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-positive-data-antler-phase-1-trial"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":["cell-therapy"],"technologies":["allogeneic-cell-therapy","car-t","crispr-screens"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Berkeley, CA","country":"US","companyType":"cell-therapy","website":"https://www.cariboubio.com","ticker":"CRBU","investors":[],"funding":[]},{"id":"caris","kind":"company","name":"Caris Life Sciences","aka":[],"tldr":"Whole-exome and whole-transcriptome tumour profiling at scale, with a large real-world database.","summary":"Caris Life Sciences, based in Irving, Texas, and listed as CAI after its 2025 IPO, performs whole-exome and whole-transcriptome tumour profiling at scale and holds a large real-world database. Its products are MI Profile, which combines exome and transcriptome sequencing, Caris Assure, a blood-based assay, and MI Cancer Seek, which received FDA approval in 2024. OnCo links it to comprehensive genomic profiling and whole-exome and whole-genome sequencing, and to ideas that every tumour genomic report should be machine-readable and should list open, nearby, matched trials. Whether whole-transcriptome data changes treatment decisions often enough to justify its cost over targeted panels is the open question. MI Cancer Seek has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.carislifesciences.com"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["cgp","wes-wgs","companion-diagnostic"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Irving, TX","country":"US","companyType":"diagnostics","website":"https://www.carislifesciences.com","ticker":"CAI","investors":[],"funding":[]},{"id":"carl-zeiss-meditec","kind":"company","name":"Carl Zeiss Meditec","aka":["ZEISS Medical Technology"],"tldr":"Carl Zeiss Meditec makes Intrabeam, a miniature X-ray source used to give a single dose of radiation to the breast tumour bed during surgery, and the Kinevo surgical microscopes whose blue-light and infrared modes make brain tumours glow during resection.","summary":"Carl Zeiss Meditec, the listed medical arm of the Zeiss group formed in 2002, sells ophthalmic devices and neurosurgical visualisation. Intrabeam is a mobile 50 kV X-ray source with spherical applicators placed in the cavity after lumpectomy to deliver intraoperative radiotherapy, the technique tested in the TARGIT-A trial, and its applicators also treat skin, spine and intracranial sites. The Kinevo and Pentero microscopes carry fluorescence modes for 5-aminolaevulinic acid and indocyanine green used in glioma and vascular surgery. OnCo links it to intraoperative radiotherapy and fluorescence-guided surgery.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Carl_Zeiss_Meditec","links":[{"label":"Official website","url":"https://www.zeiss.com/meditec"}],"tags":["machines-wave"],"related":[],"cancers":["breast-cancer","glioblastoma"],"sections":["radiation","surgery"],"technologies":["intraoperative-radiotherapy","fluorescence-guided-surgery","brachytherapy-afterloaders"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Jena","country":"DE","companyType":"devices","website":"https://www.zeiss.com/meditec","ticker":"AFX.DE","founded":2002,"stage":"public","investors":[],"funding":[]},{"id":"carrum-health","kind":"company","name":"Carrum Health","aka":[],"tldr":"Carrum Health lets employers send workers with cancer to top cancer centres for a single upfront price, with travel and care coordination included and usually no bills for the patient.","summary":"Carrum Health runs a value based Centres of Excellence network for self insured employers, contracting directly with providers on bundled upfront prices with warranties. It launched bundled cancer care in February 2021 with Memorial Sloan Kettering (in person breast and thyroid cancer treatment plus remote pathology review, treatment planning and second opinions for all cancers) and has added City of Hope, UChicago Medicine, Texas Oncology and others, extending value based cancer care to more than 400 facilities. It partners with GRAIL to offer the Galleri multi cancer early detection test and reports employer savings of up to 45 percent per episode. Founded in 2014 and based in San Francisco, Carrum raised a USD 40 million Series A led by Tiger Global in January 2021 and a USD 45 million Series B led by OMERS Growth Equity in May 2023, earmarked for expanding cancer care.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://carrumhealth.com"},{"label":"Series B press release (May 2023)","url":"https://carrumhealth.com/seriesb/"},{"label":"Series A press release (January 2021)","url":"https://carrumhealth.com/carrum-health-raises-40-million-to-transform-healthcare/"},{"label":"Bundled cancer care launch with Memorial Sloan Kettering (February 2021)","url":"https://carrumhealth.com/carrum-health-first-to-launch-bundled-cancer-care/"}],"tags":[],"related":[],"cancers":["thyroid"],"sections":["supportive-care"],"technologies":["mced"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The mced tag reflects the GRAIL Galleri partnership listed on the company press page (release itself not fetched)."],"hq":"San Francisco, CA","country":"US","companyType":"cro-services","website":"https://carrumhealth.com","founded":2014,"stage":"startup","investors":[],"funding":[{"round":"Series A","year":2021,"amountUsd":40000000,"source":"https://carrumhealth.com/carrum-health-raises-40-million-to-transform-healthcare/","note":"Led by Tiger Global Management"},{"round":"Series B","year":2023,"amountUsd":45000000,"source":"https://carrumhealth.com/seriesb/","note":"Led by OMERS Growth Equity"}]},{"id":"carsgen","kind":"company","name":"CARsgen Therapeutics","aka":[],"tldr":"CARsgen Therapeutics developed satri-cel, the first CAR-T approved for a solid tumour (gastric cancer, China).","summary":"CARsgen Therapeutics, based in Shanghai and listed in Hong Kong as 2171.HK, developed satricabtagene autoleucel, or satri-cel, the first CAR-T approved for a solid tumour, in gastric cancer in China. Satri-cel targets Claudin 18.2 and was tested in LUMMICAR STUDY 1, zevorcabtagene autoleucel is its BCMA CAR-T approved in China, and allogeneic and GPC3 programmes follow, with Zonghai Li and Lin Shen among the people linked. OnCo links it to gastric and pancreatic cancer, to Peking University Cancer Hospital and Renji Hospital, and to both drug records. Whether a Claudin 18.2 CAR-T can win approval outside China and compete with antibodies and ADCs against the same target is the open question. Satricabtagene autoleucel has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.carsgen.com"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":[],"targets":[],"drugs":["satricabtagene-autoleucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03915184","nct04404595","nct04581473"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai","country":"CN","companyType":"cell-therapy","website":"https://www.carsgen.com","ticker":"2171.HK","investors":[],"funding":[]},{"id":"cartesian-therapeutics","kind":"company","name":"Cartesian Therapeutics","aka":["Cartesian Therapeutics, Inc.","Cartesian"],"tldr":"Cartesian makes CAR-T cells from messenger RNA rather than permanent gene insertion, so the cells work for days and then fade; it began in myeloma and now leads phase 3 trials in autoimmune disease.","summary":"Cartesian Therapeutics, based in Frederick, Maryland, engineers T cells with mRNA-encoded chimeric antigen receptors, giving a transient product that can be dosed repeatedly without lymphodepletion. Its BCMA-directed Descartes-08 was first tested in multiple myeloma before the company focused on myasthenia gravis and other autoimmune diseases, where it leads phase 3 trials. Its myeloma trials remain on ClinicalTrials.gov under Cartesian as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.cartesiantherapeutics.com"},{"label":"ClinicalTrials.gov: trials led by Cartesian Therapeutics, Inc.","url":"https://clinicaltrials.gov/search?lead=Cartesian%20Therapeutics%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q140045331"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["car-t"],"targets":["bcma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Frederick, MD","country":"US","companyType":"cell-therapy","website":"https://www.cartesiantherapeutics.com","stage":"public","investors":[],"funding":[]},{"id":"carthera","kind":"company","name":"Carthera","aka":[],"tldr":"Carthera is a French company whose SonoCloud implant, fitted in the skull after brain tumour surgery, sends ultrasound pulses that briefly open the blood-brain barrier before each chemotherapy dose.","summary":"Carthera, founded in 2010 from work at the Pitié-Salpêtrière hospital in Paris, developed the SonoCloud-1 and the larger nine-emitter SonoCloud-9, unfocused ultrasound implants placed in the bone window after tumour resection and activated with intravenous microbubbles to open the blood-brain barrier over a wide region. It has run trials in recurrent glioblastoma with carboplatin and in brain metastases, and is preparing pivotal studies.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://carthera.eu/"}],"tags":["machines-wave2"],"related":[],"cancers":["glioblastoma","brain-metastases"],"sections":[],"technologies":["transcranial-focused-ultrasound-systems","bbb-focused-ultrasound"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Lyon","country":"FR","companyType":"devices","website":"https://carthera.eu/","founded":2010,"stage":"startup","investors":[],"funding":[]},{"id":"cartx-therapeutics","kind":"company","name":"CARTx Therapeutics","aka":[],"tldr":"CARTx Therapeutics, spun out of Nationwide Children's Hospital, is developing affordable off-the-shelf CAR gamma-delta T cell therapies from healthy donors for solid tumours and blood cancers.","summary":"CARTx Therapeutics uses polyclonal gamma-delta T cells from healthy donors, engineered with chimeric antigen receptors, to make allogeneic cell therapies that do not need to be manufactured from each patient, aiming at lower cost and faster access for solid tumours and blood cancers.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.cartx.health/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["car-t","gamma-delta-t-cell-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"United States (city not published)","country":"US","companyType":"cell-therapy","website":"https://www.cartx.health/","stage":"startup","investors":[],"funding":[]},{"id":"casdin-capital","kind":"company","name":"Casdin Capital","aka":[],"tldr":"A New York investment firm founded by Eli Casdin that invests in life sciences companies on both public and private markets. Its venture list includes cancer companies such as Black Diamond Therapeutics and Function Oncology.","summary":"Casdin Capital, based at 1350 Avenue of the Americas in New York, describes itself as investing 'in all aspects of today's Life Sciences revolution' across healthcare, biotechnology, synthetic biology and technology. Eli Casdin is listed as Chief Investment Officer and Founder. The firm builds concentrated positions in public companies and also runs a venture programme, and was a sponsor of the CM Life Sciences special purpose acquisition vehicles. Its venture page shows logos rather than descriptions; oncology-related names visible there include Black Diamond Therapeutics (precision oncology), Function Oncology (functional genomics for cancer), Scorpion Therapeutics, C2i Genomics (cancer genomics) and the digital pathology company Paige.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://casdincapital.com/"},{"label":"Venture portfolio","url":"https://casdincapital.com/venture/"},{"label":"Team","url":"https://casdincapital.com/team/"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["black-diamond-therapeutics","c2i-genomics","scorpion-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the site and no Wikipedia page exists, so it is omitted. The venture page lists logos only; company focus was inferred from the company names."],"hq":"New York, NY","country":"US","companyType":"investor","website":"https://casdincapital.com/","investors":[],"funding":[]},{"id":"catalent","kind":"company","name":"Catalent (Novo Holdings)","aka":[],"tldr":"Catalent, of Somerset, New Jersey, is a contract manufacturer that fills and finishes sterile injectables and makes biologics and cell and gene therapies; Novo Holdings bought it in 2024 and moved three sites to Novo Nordisk. The diversion of fill-finish capacity to obesity drugs may squeeze oncology products.","summary":"Catalent, based in Somerset, New Jersey, is a fill-finish and gene therapy CDMO acquired by Novo Holdings in 2024, with three sites transferred to Novo Nordisk. It manufactures sterile injectables, biologics and cell and gene therapies, and the capacity shifts that followed the Novo deal affected some oncology sponsors. OnCo links it to sterile fill-finish and lyophilisation and to viral vector manufacturing. Whether the diversion of fill-finish capacity to obesity drugs squeezes oncology products is the open question the acquisition raised. The fill-finish technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.catalent.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["adcs","immunotherapy"],"technologies":["sterile-fill-finish","viral-vector-manufacturing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Somerset, NJ","country":"US","companyType":"cro-services","website":"https://www.catalent.com","investors":[],"funding":[]},{"id":"catalym","kind":"company","name":"CatalYm","aka":["CatalYm GmbH"],"tldr":"CatalYm is a Germany-based biotechnology company running 5 late-stage cancer trials of Visugromab (CTL-002), Visugromab and visugromab (CTL-002) in non-small-cell lung cancer and hepatocellular carcinoma.","summary":"CatalYm, based in Planegg-Martinsried, Germany, is a biotechnology company. A private, venture-backed cancer immunotherapy company developing antibodies that neutralise GDF-15, a mechanism cancers use to resist treatment, with its lead candidate visugromab. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing Visugromab (CTL-002), Visugromab and visugromab (CTL-002) in non-small-cell lung cancer and hepatocellular carcinoma. The largest, NCT07112196 (Visugromab in Cachexia International Trial), plans to enrol 518 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.catalym.com"},{"label":"ClinicalTrials.gov: trials led by CatalYm","url":"https://clinicaltrials.gov/search?lead=CatalYm%20GmbH"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["visugromab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07219459","nct07098988","nct07246863","nct04725474"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Planegg-Martinsried","country":"DE","companyType":"biotech","website":"https://www.catalym.com","stage":"growth","investors":[],"funding":[]},{"id":"cebiotex","kind":"company","name":"CEBIOTEX","aka":[],"tldr":"CEBIOTEX is a Spain-based biotechnology company running 2 late-stage cancer trials of CEB-01 in pancreatic ductal adenocarcinoma.","summary":"CEBIOTEX, based in Barcelona, Spain, is a biotechnology company. Cebiotex is a biotechnology company that uses proprietary nanofibre engineering to deliver anti-tumour agents directly at surgical sites for local, post-surgical cancer therapy. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing CEB-01 in pancreatic ductal adenocarcinoma. The largest, NCT06986811 (CEB-01 in Paediatrics With Locally Resectable Abdominal Tumours), plans to enrol 60 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.cebiotex.com"},{"label":"ClinicalTrials.gov: trials led by CEBIOTEX","url":"https://clinicaltrials.gov/search?lead=CEBIOTEX"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct06986811","nct06538857"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Barcelona","country":"ES","companyType":"biotech","website":"https://www.cebiotex.com","stage":"growth","investors":[],"funding":[]},{"id":"cegat","kind":"company","name":"CeGaT","aka":[],"tldr":"CeGaT, a Tübingen genetics laboratory, sequences tumour and normal DNA side by side and identifies the patient-specific neoantigens that personalised vaccines are built on.","summary":"CeGaT has run genetic analyses for medical, research and pharmaceutical customers since 2009. Its tumour diagnostics compare tumour and germline sequences to find somatic alterations and, from them, patient-specific neoantigens; the personalised peptide vaccine programme at CeCurio, the MVZ Tübingen oncology practice, draws on that work. Physician-ordered.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://cegat.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["cgp","neoantigen-mrna-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Tübingen, Germany","country":"DE","companyType":"diagnostics","website":"https://cegat.com/","investors":[],"funding":[]},{"id":"celcuity","kind":"company","name":"Celcuity","aka":[],"tldr":"Celcuity developed gedatolisib, approved in July 2026 for hormone-positive breast cancer.","summary":"Celcuity, based in Minneapolis and listed as CELC, developed gedatolisib, a pan-PI3K and mTOR inhibitor approved in July 2026 for hormone-receptor-positive breast cancer. Gedatolisib, sold as Revtorpyk, is given with palbociclib and fulvestrant, and the VIKTORIA-1 and VIKTORIA-2 trials are the evidence behind it. OnCo links it to HR-positive, HER2-negative breast cancer and to the gedatolisib drug record. Whether a pan-PI3K and mTOR inhibitor can be tolerated well enough in routine practice to displace mutation-selective PI3K drugs is the open question. Gedatolisib has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.celcuity.com"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["gedatolisib","serabelisib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06190899","nct05501886","nct06757634"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Minneapolis, MN","country":"US","companyType":"biotech","website":"https://www.celcuity.com","ticker":"CELC","investors":[],"funding":[]},{"id":"cellares","kind":"company","name":"Cellares","aka":[],"tldr":"Cellares builds the Cell Shuttle, a fully automated 'smart factory' for cell therapies, with BMS and Kite as partners.","summary":"Cellares, based in South San Francisco, builds the Cell Shuttle, a fully automated smart factory for cell therapies, with Bristol Myers Squibb and Kite as partners. It describes itself as an integrated development and manufacturing organisation, the Cell Shuttle automates the CAR-T process end to end, it raised a 255 million dollar Series C in 2023, signed manufacturing agreements with BMS in 2024 and with Kite, and has smart factories under construction in New Jersey and Japan. OnCo links it to closed automated cell-therapy manufacturing and to point-of-care and decentralised cell manufacturing. Whether automation cuts the cost and turnaround of CAR-T enough to widen access is the question its factories will answer. The closed manufacturing technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.cellares.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["closed-automated-cell-manufacturing","point-of-care-cell-manufacturing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"South San Francisco, CA","country":"US","companyType":"cell-therapy","website":"https://www.cellares.com","investors":[],"funding":[]},{"id":"celldex","kind":"company","name":"Celldex Therapeutics","aka":[],"tldr":"Biotech that ran one of the early GPNMB ADCs in triple-negative breast cancer, which failed, and has since pivoted to mast-cell (KIT) antibodies for allergic disease.","summary":"Glembatumumab vedotin (CDX-011, GPNMB-directed MMAE ADC) did not meet its primary endpoint in the METRIC trial in GPNMB-overexpressing metastatic TNBC (2018). Celldex's lead asset is now barzolvolimab, an anti-KIT antibody in phase 3 for chronic urticaria; its oncology footprint is historical but instructive for ADC target selection.","asOf":"2026-09-04","links":[{"label":"Celldex pipeline","url":"https://celldex.com/pipeline/"}],"tags":["failure","adc-history"],"related":[],"cancers":["tnbc"],"sections":["adcs","immunotherapy"],"technologies":["adc"],"targets":["kit"],"drugs":["rindopepimut"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Hampton, NJ","country":"US","companyType":"biotech","website":"https://www.celldex.com","ticker":"CLDX","investors":[],"funding":[]},{"id":"cellectar","kind":"company","name":"Cellectar Biosciences","aka":["Cellectar Biosciences, Inc.","Cellectar"],"tldr":"Cellectar is a New Jersey radiopharmaceutical company whose iodine-131 phospholipid drug conjugate iopofosine targets the lipid rafts of cancer cells, with a pivotal trial (CLOVER-WaM) in relapsed Waldenström macroglobulinaemia.","summary":"Cellectar Biosciences, based in Florham Park, New Jersey and listed on Nasdaq, develops phospholipid drug conjugates that exploit the lipid rafts abundant on cancer cell membranes to deliver radioisotopes or cytotoxics. Its lead, iopofosine I-131 (CLR 131), delivers iodine-131 and reported its pivotal CLOVER-WaM results in relapsed Waldenström macroglobulinaemia in 2024; earlier studies covered multiple myeloma and paediatric high-grade glioma. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.cellectar.com"},{"label":"ClinicalTrials.gov: trials led by Cellectar Biosciences","url":"https://clinicaltrials.gov/search?lead=Cellectar%20Biosciences"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["waldenstrom","multiple-myeloma"],"sections":["radiopharma"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct02952508"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Florham Park, NJ","country":"US","companyType":"radiopharma","website":"https://www.cellectar.com","stage":"public","investors":[],"funding":[]},{"id":"cellectis","kind":"company","name":"Cellectis","aka":["Cellectis S.A.","cellectis-s-a"],"tldr":"Cellectis is the Paris gene-editing company that pioneered off-the-shelf CAR-T cells with its TALEN editing tools, and makes them at its own plants in Paris and Raleigh, North Carolina.","summary":"Cellectis, founded in Paris in 1999 and listed on Nasdaq, developed the TALEN nucleases used to remove the T cell receptor and CD52 from donor T cells so that a single donor's cells can be banked as many allogeneic CAR-T doses. Its UCART programmes target CD19, CD22, CD123 and other antigens, its editing is licensed to Allogene, and it operates its own GMP manufacturing sites in Paris and Raleigh, North Carolina. AstraZeneca became a major shareholder and partner in 2023 and 2024.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.cellectis.com"},{"label":"ClinicalTrials.gov: trials led by Cellectis S.A.","url":"https://clinicaltrials.gov/search?lead=Cellectis%20S.A."}],"tags":["manufacturing-wave"],"related":[],"cancers":["all-leukemia","aml","dlbcl","hodgkin-lymphoma"],"sections":[],"technologies":["allogeneic-cell-banks","allogeneic-cell-therapy","car-t"],"targets":[],"drugs":["ucart22"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05607420","nct04150497"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Paris","country":"FR","companyType":"cell-therapy","website":"https://www.cellectis.com","ticker":"CLLS","founded":1999,"stage":"public","investors":[],"funding":[]},{"id":"cellogen","kind":"company","name":"Cellogen Therapeutics","aka":[],"tldr":"A Delhi start-up developing bispecific CD19 and CD20 CAR-T cells and gene therapies for thalassaemia, aiming to cut treatment costs by up to 90%; still before its first trial.","summary":"Cellogen Therapeutics is a New Delhi company developing bispecific, third- and fourth-generation CAR-T cells that target CD19 and CD20 at the same time to reduce antigen-loss relapse, plus genetic therapies for beta-thalassaemia and sickle cell disease. In its public statements it reports promising laboratory results and plans to begin clinical trials; it has no approved products. It is one of a growing group of Indian cell therapy start-ups following ImmunoACT and Immuneel, and its stated aim is to reduce treatment costs by up to 90% with indigenous products.","status":"preclinical","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.cellogentherapeutics.com"}],"tags":[],"related":[],"cancers":["dlbcl","all-leukemia"],"sections":["cell-therapy"],"technologies":["car-t"],"targets":["cd19","cd20"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-manufacturing-cell-therapy"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"New Delhi","country":"IN","companyType":"cell-therapy","website":"https://www.cellogentherapeutics.com","investors":[],"funding":[]},{"id":"cellseed","kind":"company","name":"CellSeed","aka":["CellSeed Inc.","セルシード"],"tldr":"CellSeed is a Tokyo regenerative-medicine company whose cell sheets, grown on temperature-responsive dishes, are applied to the oesophagus after endoscopic cancer removal to prevent scarring and narrowing.","summary":"CellSeed Inc., founded in 2001 in Tokyo and listed there, commercialises cell sheet engineering from Tokyo Women's Medical University: sheets of a patient's own cells grown on temperature-responsive culture surfaces and lifted off intact. Its oesophageal epithelial cell sheets are applied to the ulcer left after endoscopic submucosal dissection of early oesophageal cancer to prevent stricture, and the company leads the Japanese phase 3 trials registered on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.cellseed.com"},{"label":"ClinicalTrials.gov: trials led by CellSeed Inc.","url":"https://clinicaltrials.gov/search?lead=CellSeed%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q11314549"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["esophageal"],"sections":[],"technologies":["endoscopic-resection"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Tokyo","country":"JP","companyType":"cell-therapy","website":"http://www.cellseed.com","founded":2001,"stage":"public","investors":[],"funding":[]},{"id":"cellsight-technologies","kind":"company","name":"CellSight Technologies","aka":["CellSight Technologies, Inc."],"tldr":"CellSight Technologies is a US-based imaging company that leads 2 cancer trials in OnCo, testing the activated T-cell PET tracer [18F]F-AraG (VisAcT) in non-small-cell lung cancer.","summary":"CellSight Technologies develops molecular imaging agents that originated in Sanjiv Gambhir's laboratory at Stanford University. Its lead agent VisAcT ([18F]F-AraG) is a PET tracer that accumulates in activated T cells, intended to help select patients for immunotherapy, assess early response and detect immune-related side effects. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT06107374 (phase 2, Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG) and NCT06084806 (phase 2, Test-retest Evaluation of [18F]F-AraG PET). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.cellsighttech.com"},{"label":"ClinicalTrials.gov: trials led by CellSight Technologies","url":"https://clinicaltrials.gov/search?lead=CellSight%20Technologies%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06107374","nct06084806"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"San Francisco, California","country":"US","companyType":"imaging","website":"https://www.cellsighttech.com","stage":"startup","investors":[],"funding":[]},{"id":"celltrion","kind":"company","name":"Celltrion","aka":[],"tldr":"Celltrion is a South Korea-based pharmaceutical company running 2 late-stage cancer trials of CT-P51 and CT-P44(Daratumumab) in non-small-cell lung cancer and multiple myeloma.","summary":"Celltrion, based in Incheon, South Korea, is a pharmaceutical company listed as KRX: 068270. Celltrion is a biopharmaceutical company that researches, develops, manufactures and markets biosimilars and novel therapeutics across immunology, oncology and ophthalmology. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing CT-P51 and CT-P44(Daratumumab) in non-small-cell lung cancer and multiple myeloma. The largest, NCT06952478 (A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma), plans to enrol 486 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.celltrion.com"},{"label":"ClinicalTrials.gov: trials led by Celltrion","url":"https://clinicaltrials.gov/search?lead=Celltrion"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06952478","nct06939595"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Incheon","country":"KR","companyType":"pharma","website":"https://www.celltrion.com","ticker":"KRX: 068270","stage":"public","investors":[],"funding":[]},{"id":"century-therapeutics","kind":"company","name":"Century Therapeutics","aka":[],"tldr":"Century makes off-the-shelf cell therapies from induced pluripotent stem cells that are engineered to hide from the patient's immune system. Its main focus is now type 1 diabetes, with a CD19 CAR T-like product for cancer and autoimmune disease due to enter the clinic in 2026.","summary":"Century Therapeutics develops allogeneic, induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune disease and cancer. Lead programme CNTY-813 is an iPSC-derived islet replacement therapy for type 1 diabetes with an IND submission planned for the fourth quarter of 2026 following a pre-IND meeting with the FDA. CNTY-308 is a CD19-targeted CAR-iT (iPSC-derived T cell) therapy incorporating the company's Allo-Evasion 5.0 immune-evasion edits, on track to enter the clinic in 2026. The company reported $197.2 million in cash and investments at 30 June 2026 with runway into the first quarter of 2029. Century is headquartered in Philadelphia and trades on Nasdaq as IPSC.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.centurytx.com/"},{"label":"Q2 2026 results (8-K exhibit 99.1)","url":"https://www.sec.gov/Archives/edgar/data/1850119/000110465926094533/tm2622911d1_ex99-1.htm"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["allogeneic-cell-therapy","car-t"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Strategic emphasis has shifted to type 1 diabetes; oncology exposure is via CNTY-308 (CD19 CAR-iT). IPO round not sourced (June 2021 8-K did not state proceeds)."],"hq":"Philadelphia, PA","country":"US","companyType":"cell-therapy","website":"https://www.centurytx.com/","ticker":"IPSC","stage":"public","investors":["leaps-by-bayer"],"funding":[]},{"id":"certis-oncology-solutions","kind":"company","name":"Certis Oncology Solutions","aka":[],"tldr":"Certis grows pieces of a patient's tumour in mice and in the lab to test which drugs work, serving both drug developers and oncologists looking for treatment options for an individual patient.","summary":"Certis Oncology Solutions, based at 5626 Oberlin Drive, San Diego, is a translational science company operating under the Oncology Intelligence brand. For drug developers it offers patient-derived xenograft (PDX) cancer models, custom model development, in vitro and ex vivo pharmacology, in vivo pharmacology, imaging and endpoint analysis, immuno-oncology studies and CertisAI, a predictive analytics layer built on its model bank. For oncologists and patients it offers Order Your PDX, a service that establishes a PDX from an individual patient's tumour and tests candidate therapies to inform treatment choice, supported by clinical research and patient education resources. The website is rendered client-side and only navigation and address text could be extracted, so founding year, funding and case numbers could not be confirmed from primary sources.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.certisoncology.com"},{"label":"About us","url":"https://www.certisoncology.com/about-us/"}],"tags":[],"related":[],"cancers":[],"sections":["drug-discovery","diagnostics"],"technologies":["pdx-models","functional-drug-testing","ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Only navigation and footer text could be extracted from the JavaScript-rendered site; services list and HQ are verified, but founding year, funding and stage are not (stage is a guess)."],"hq":"San Diego, CA","country":"US","companyType":"cro-services","website":"https://www.certisoncology.com","stage":"startup","investors":[],"funding":[]},{"id":"cg-oncology","kind":"company","name":"CG Oncology","aka":[],"tldr":"CG Oncology developed cretostimogene, the oncolytic virus for early bladder cancer, and is filing for approval in 2026.","summary":"CG Oncology, based in Irvine, California, and listed as CGON, developed cretostimogene grenadenorepvec, an oncolytic virus for early bladder cancer, and is filing for approval in 2026. Its programme spans BOND-003 in BCG-unresponsive carcinoma in situ, PIVOT-006 in intermediate-risk disease and CORE-008 in BCG-naive patients, and the company went public in 2024. OnCo links it to bladder and urothelial cancer, to the cretostimogene drug record, and to the idea of oncolytic viruses that make interleukin-12 only inside the tumour. Whether an intravesical oncolytic virus can become the standard after BCG failure, ahead of gene therapy and IL-15 competitors, is the open question. Cretostimogene has its own page.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://cgoncology.com"}],"tags":[],"related":[],"cancers":["urothelial"],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["cretostimogene"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06111235","nct06567743"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Irvine, CA","country":"US","companyType":"biotech","website":"https://cgoncology.com","ticker":"CGON","investors":[],"funding":[]},{"id":"chai-discovery","kind":"company","name":"Chai Discovery","aka":[],"tldr":"Makes Chai-1 and Chai-2, open-weight structure models used for antibody and binder design.","summary":"Chai Discovery, based in San Francisco, makes Chai-1 and Chai-2, open-weight structure prediction models used for antibody and binder design. Chai-1, released in 2024, matched AlphaFold 3 on many benchmarks with open weights for non-commercial use, and Chai-2, released in 2025, reported zero-shot de novo antibody hit rates far above earlier methods. OnCo links it to the Chai-1 and Chai-2 technology record. Whether high computational hit rates translate into antibodies that behave in patients is the open question. Chai-1 and Chai-2 have their own technology page.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.chaidiscovery.com"}],"tags":["ai","protein-design"],"related":[],"cancers":[],"sections":["drug-discovery","ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"ai-software","website":"https://www.chaidiscovery.com","investors":[],"funding":[]},{"id":"champions-oncology","kind":"company","name":"Champions Oncology","aka":[],"tldr":"Oncology CRO with the largest bank of patient-derived xenograft models (TumorGraft), now adding 3D organoid screening and radiopharmaceutical services.","summary":"Champions Oncology, based in Hackensack, New Jersey, and listed as CSBR, is an oncology contract research organisation with the largest bank of patient-derived xenograft models, called TumorGraft, now adding three-dimensional organoid screening and radiopharmaceutical services. It holds more than 1,400 clinically annotated PDX models correlated with patient outcomes, runs the TumorGraft3D organoid platform and reported record fiscal 2026 revenue of 59.4 million dollars with positive adjusted EBITDA. OnCo links it to patient-derived xenografts and organoids, to the bottleneck of preclinical models that do not predict people, and to the idea of running the mouse or organoid trial alongside the human trial. Whether annotated PDX banks predict clinical results better than cell lines is the question its business rests on. The PDX technology page carries the evidence.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Champions_Oncology","links":[{"label":"Company site","url":"https://www.championsoncology.com/"}],"tags":[],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":["pdx-models","organoids"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Hackensack, NJ","country":"US","companyType":"cro-services","website":"https://www.championsoncology.com","ticker":"CSBR","investors":[],"funding":[]},{"id":"chan-zuckerberg-initiative","kind":"company","name":"Chan Zuckerberg Initiative (Biohub)","aka":[],"tldr":"Funds and builds the Human Cell Atlas infrastructure and the CZI virtual cell models (TranscriptFormer), plus one of the largest nonprofit GPU clusters for biology.","summary":"The Chan Zuckerberg Initiative and its Biohub, based in Redwood City, fund and build the Human Cell Atlas infrastructure, the CZI virtual cell models including TranscriptFormer and rBio, and one of the largest nonprofit GPU clusters for biology. CELLxGENE, the TranscriptFormer and rBio models released in 2025 and the Billion Cells Project underpin much single-cell foundation model work. OnCo links it to TranscriptFormer and rBio, the Universal Cell Embedding and the virtual cell roadmap. Whether philanthropic infrastructure keeps foundational cell models open as commercial ones proliferate is the question its role raises. The virtual cell roadmap has its own page.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://chanzuckerberg.com/science/"}],"tags":["ai","virtual-cell"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Redwood City, CA","country":"US","companyType":"nonprofit","website":"https://chanzuckerberg.com/science/","investors":[],"funding":[]},{"id":"changchun-genescience","kind":"company","name":"Changchun GeneScience Pharmaceutical","aka":["Changchun GeneScience Pharmaceutical Co., Ltd.","GeneScience","GenSci","长春金赛药业"],"tldr":"GeneScience is a Changchun biotech known for growth hormone that also makes a long-acting G-CSF used to prevent infection after chemotherapy, and leads phase 3 cancer trials in China.","summary":"Changchun GeneScience Pharmaceutical (GenSci), based in Changchun in north-east China, is a biopharmaceutical company best known for recombinant human growth hormone. Its oncology products include a pegylated granulocyte colony-stimulating factor for chemotherapy-induced neutropenia, and it is lead sponsor of phase 3 cancer trials registered on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.gensci-china.com"},{"label":"ClinicalTrials.gov: trials led by Changchun GeneScience Pharmaceutical","url":"https://clinicaltrials.gov/search?lead=Changchun%20GeneScience%20Pharmaceutical"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["neutropenia","pivotal-trial","clinical-trial"],"trials":["nct07150663"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Changchun","country":"CN","companyType":"biotech","website":"https://www.gensci-china.com","stage":"public","investors":[],"funding":[]},{"id":"charles-river","kind":"company","name":"Charles River Laboratories","aka":[],"tldr":"Preclinical CRO for safety and discovery studies, with viral vector and cell-therapy manufacturing services.","summary":"Charles River Laboratories, based in Wilmington, Massachusetts, and listed as CRL, is a preclinical contract research organisation for safety and discovery studies that also offers viral vector and cell therapy manufacturing services. Its work spans discovery and safety assessment, including toxicology and patient-derived xenograft models through its oncology services, and CDMO capacity for plasmid, vector and cell therapy production. OnCo links it to viral vector manufacturing, patient-derived xenografts, contract research organisations and cell-therapy release and potency testing. Whether the preclinical models it sells predict what happens in patients is the question that hangs over the whole CRO sector. The CRO technology page carries the wider picture.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Charles_River_Laboratories","links":[{"label":"Official website","url":"https://www.criver.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["drug-discovery","cell-therapy"],"technologies":["viral-vector-manufacturing","pdx-models","contract-research-organisations"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Wilmington, MA","country":"US","companyType":"cro-services","website":"https://www.criver.com","ticker":"CRL","investors":[],"funding":[]},{"id":"checkpoint-therapeutics","kind":"company","name":"Checkpoint Therapeutics","aka":["Checkpoint Therapeutics, Inc."],"tldr":"Checkpoint Therapeutics developed cosibelimab, an anti-PD-L1 antibody approved by the FDA in December 2024 for advanced cutaneous squamous cell carcinoma, and was acquired by Sun Pharma in 2025.","summary":"Checkpoint Therapeutics, a Massachusetts company founded within Fortress Biotech, developed cosibelimab (Unloxcyt), an anti-PD-L1 antibody with an intact Fc region designed to add antibody-dependent cell killing to checkpoint blockade. The FDA approved it in December 2024 for metastatic or locally advanced cutaneous squamous cell carcinoma not curable by surgery or radiation, after an earlier complete response letter over a manufacturing site. Sun Pharma agreed to acquire the company in 2025. Company facts are from the official website and FDA approval records.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.checkpointtherapeutics.com/"},{"label":"FDA: oncology and hematologic malignancies approval notifications","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"}],"tags":["fda-oce-applicant"],"related":[],"cancers":["cutaneous-scc"],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["cosibelimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Waltham, MA","country":"US","companyType":"biotech","website":"https://www.checkpointtherapeutics.com/","stage":"acquired","investors":[],"funding":[]},{"id":"chengdu-zenitar-biomedical-technology","kind":"company","name":"Chengdu Zenitar Biomedical Technology","aka":["Chengdu Zenitar Biomedical Technology Co., Ltd"],"tldr":"Chengdu Zenitar Biomedical Technology is a Chinese developer in Chengdu that sponsors 6 registered cancer trials of Purinostat and Purinostat Mesylate.","summary":"Chengdu Zenitar Biomedical Technology appears on ClinicalTrials.gov as the industry sponsor of 6 interventional cancer trials (phase 1/2, 2, 3), testing Purinostat, Purinostat Mesylate, Selinexor, Flonoltinib in advanced solid tumor, recurrent and refractory diffuse large b-cell lymphoma, diffuse large b cell lymphoma，dlbcl, polycythemia vera (pv). OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials sponsored by Chengdu Zenitar Biomedical Technology","url":"https://clinicaltrials.gov/search?spons=Chengdu%20Zenitar%20Biomedical%20Technology"}],"tags":["ctgov-sponsor","china","registry-only"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["flonoltinib","purinostat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06431243","nct07011056","nct05563844","nct07232290","nct06485219","nct06484829"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Chengdu, China","country":"CN","companyType":"biotech","investors":[],"funding":[]},{"id":"cclg","kind":"company","name":"Children's Cancer and Leukaemia Group","aka":["CCLG","UKCCSG","UK Children's Cancer Study Group"],"tldr":"The UK and Ireland's professional body and trials network for children's cancer; nearly every child treated for cancer in the UK is cared for by a CCLG centre.","summary":"Founded in 1977 as the UK Children's Cancer Study Group and renamed in 2006 after merging with the UK childhood leukaemia working party, CCLG links the 20 principal treatment centres in the UK and Ireland. It coordinates national participation in international paediatric trials (UKALL leukaemia trials, SIOP renal and brain tumour protocols, Euro Ewing), maintains the national tissue bank and registry, publishes parent and patient information, and funds research through the CCLG charity. Children treated in the UK access trials of new agents through CCLG's early-phase network and its links with COG and SIOP Europe.","asOf":"2026-09-09","links":[{"label":"CCLG","url":"https://www.cclg.org.uk"},{"label":"Research","url":"https://www.cclg.org.uk/research"}],"tags":["cooperative-group"],"related":["euro-ewing-2012"],"cancers":["all-leukemia","neuroblastoma","sarcoma","glioblastoma"],"sections":[],"technologies":["mrd-testing"],"targets":[],"drugs":[],"companies":["childrens-oncology-group"],"institutions":["siop-europe","cruk"],"pathways":[],"terms":[],"trials":["ukallr3","hr-nbl1"],"people":["ashley-ball-gamble"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["UKALL leukaemia trials","National paediatric tumour bank","Early-phase paediatric trials network","Family information and support"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Leicester","country":"GB","companyType":"cooperative-group","website":"https://www.cclg.org.uk","founded":1977,"investors":[],"funding":[]},{"id":"childrens-oncology-group","kind":"company","name":"Children's Oncology Group (COG)","aka":["Children's Oncology Group","COG"],"tldr":"The Children's Oncology Group is the world's largest paediatric cancer trials organisation; most children with cancer in North America are treated on or according to a COG protocol.","summary":"The Children's Oncology Group, based in Monrovia, California, is the world's largest paediatric cancer trials organisation, formed in 2000 from four paediatric groups with more than two hundred member hospitals; most children with cancer in North America are treated on or according to a COG protocol. Its trials define risk-adapted therapy: AALL1731 added blinatumomab to chemotherapy for standard-risk B-cell ALL, ANBL0032 established anti-GD2 immunotherapy in neuroblastoma, and AAML0531, ACNS0331 and AHOD2131 cover leukaemia, brain tumours and Hodgkin lymphoma. OnCo connects it to the RACE for Children Act and to bottlenecks on paediatric cancers without markets and neglected late effects. Whether every treated child can be followed for decades through registry linkage is the open idea. Its programmes are listed in the notes.","asOf":"2026-09-06","links":[{"label":"Official website","url":"https://childrensoncologygroup.org"}],"tags":["cooperative-group"],"related":["blinatumomab"],"cancers":["all-leukemia","neuroblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nci","uw-carbone","cche-57357"],"pathways":[],"terms":[],"trials":[],"people":["douglas-hawkins","alice-yu","julie-park","rachel-rau","susan-cohn"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Paediatric ALL (AALL trials)","Neuroblastoma (ANBL trials)","Survivorship"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Monrovia, CA","country":"US","companyType":"cooperative-group","website":"https://childrensoncologygroup.org","founded":2000,"investors":[],"funding":[]},{"id":"ctong","kind":"company","name":"Chinese Thoracic Oncology Group","aka":["CTONG","中国胸部肿瘤研究协作组"],"tldr":"CTONG is the cooperative group of Chinese lung cancer trialists, founded by Yi-Long Wu, whose trials on EGFR-targeted pills before and after surgery changed practice worldwide.","summary":"Founded in 2007 and based at the Guangdong Lung Cancer Institute, CTONG runs investigator-initiated and industry-partnered lung cancer trials across more than 40 Chinese centres: ADJUVANT-CTONG1104 (adjuvant gefitinib), CTONG1103 (neoadjuvant erlotinib), CTONG1509 (bevacizumab plus erlotinib) and contributions to ADAURA and to domestic PD-1 and TKI registration trials. It is the model for Chinese cooperative groups in other cancers.","asOf":"2026-09-10","links":[{"label":"CTONG","url":"https://www.ctong.org.cn/"}],"tags":["cooperative-group","china"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["guangdong-provincial-peoples-hospital"],"pathways":[],"terms":[],"trials":["adaura"],"people":["wu-yi-long","zhou-caicun","lu-shun"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Adjuvant and neoadjuvant EGFR-TKI trials","Multicentre registration trials","Biomarker studies"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Guangzhou","country":"CN","companyType":"cooperative-group","website":"https://www.ctong.org.cn/","founded":2007,"investors":[],"funding":[]},{"id":"chipscreen","kind":"company","name":"Chipscreen Biosciences","aka":["微芯生物"],"tldr":"Chipscreen discovered chidamide (tucidinostat), the first original epigenetic cancer drug from China, approved in 2014 and later in Japan.","summary":"Chidamide (Epidaza) approved 2014 for T-cell lymphoma and 2019 for breast cancer; licensed to HUYA Bioscience (HBI-8000) with Japanese approval 2021 and to Meiji Seika; chiglitazar for diabetes. Founded by Xianping Lu, a returnee from US biotech, before China's regulatory reforms made originator research routine.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.chipscreen.com/en/"}],"tags":["china"],"related":[],"cancers":[],"sections":["epigenetics"],"technologies":[],"targets":[],"drugs":["tucidinostat","chiauranib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06497985","nct06947967"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shenzhen","country":"CN","companyType":"biotech","website":"https://www.chipscreen.com/en/","ticker":"688321.SS","founded":2001,"investors":[],"funding":[]},{"id":"chongqing-precision-biotech","kind":"company","name":"Chongqing Precision Biotech","aka":["Chongqing Precision Biotech Co., Ltd"],"tldr":"Chongqing Precision Biotech is a China-based cell therapy company running 2 late-stage cancer trials in multiple myeloma.","summary":"Chongqing Precision Biotech, based in Chongqing, China, is a cell therapy company. Precision Biotech is a Chinese biopharmaceutical company focused on cell-based drug development, specialising in CAR-T cell immunotherapies including a marketed paediatric/adolescent leukaemia CAR-T product. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials in multiple myeloma. The largest, NCT04271644 (BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease), plans to enrol 80 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.precision-biotech.com"},{"label":"ClinicalTrials.gov: trials led by Chongqing Precision Biotech","url":"https://clinicaltrials.gov/search?lead=Chongqing%20Precision%20Biotech%20Co.%2C%20Ltd"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["multiple-myeloma"],"sections":["cell-therapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct04271644","nct05334823","nct04776330"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Chongqing","country":"CN","companyType":"cell-therapy","website":"https://www.precision-biotech.com","stage":"growth","investors":[],"funding":[]},{"id":"chugai","kind":"company","name":"Chugai Pharmaceutical","aka":["Chugai","中外製薬"],"tldr":"Chugai is a Tokyo pharmaceutical company majority-owned by Roche that discovered alectinib for ALK-positive lung cancer and sells Roche's cancer medicines in Japan.","summary":"Chugai Pharmaceutical, listed in Tokyo and majority-owned by Roche since 2002 while remaining a separately listed company, is one of Japan's largest drug makers and its most important source of cancer medicines. It discovered the ALK inhibitor alectinib (Alecensa), developed worldwide with Roche, and markets Roche's oncology portfolio in Japan, including atezolizumab, trastuzumab, bevacizumab and polatuzumab vedotin, alongside its own antibody engineering platforms. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Chugai","links":[{"label":"Official website","url":"https://www.chugai-pharm.co.jp/english/"},{"label":"ClinicalTrials.gov: trials led by Chugai Pharmaceutical","url":"https://clinicaltrials.gov/search?lead=Chugai%20Pharmaceutical"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Chugai_Pharmaceutical_Co."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["alectinib","atezolizumab","polatuzumab-vedotin","lenograstim"],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Tokyo","country":"JP","companyType":"pharma","website":"https://www.chugai-pharm.co.jp/english/","stage":"public","investors":[],"funding":[]},{"id":"cimab","kind":"company","name":"CIMAB","aka":["CIMAB S.A.","Center of Molecular Immunology","Centro de Inmunología Molecular","CIM"],"tldr":"CIMAB is the commercial arm of Havana's Center of Molecular Immunology, the Cuban institute that created the EGFR antibody nimotuzumab and the lung cancer vaccine CIMAvax-EGF.","summary":"The Center of Molecular Immunology (CIM) in Havana develops monoclonal antibodies and therapeutic vaccines, and CIMAB S.A. is the company that licenses and exports them. Nimotuzumab (h-R3), a humanised EGFR antibody with intermediate affinity that spares normal skin, is approved in Cuba, India (as BIOMAb EGFR with Biocon), China and other countries for head and neck cancer, glioma and nasopharyngeal cancer, mostly with radiotherapy. CIM also created CIMAvax-EGF, a vaccine against epidermal growth factor for non-small cell lung cancer, and the anti-idiotype vaccine racotumomab.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["nimotuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Havana","country":"CU","companyType":"biotech","investors":[],"funding":[]},{"id":"cipla","kind":"company","name":"Cipla","aka":[],"tldr":"The Mumbai generics maker famous for a one-dollar-a-day HIV regimen, which sells oncology generics across India and Africa and in 2026 partnered with ImmunoACT to take Indian CAR-T therapy to Africa.","summary":"Cipla was founded in Mumbai in 1935 by Khwaja Abdul Hamied and is India's third-largest drug producer. Its reputation rests on the early-2000s antiretroviral combination it sold for about 300 dollars a year against 12,000 dollars for the branded regimen, and it has applied the same approach to oncology generics and biosimilars for India and emerging markets. In 2026 ImmunoACT announced a collaboration with Cipla to distribute NexCAR19 in South Africa, Algeria and Morocco, the first export of an Indian CAR-T therapy.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Cipla","links":[{"label":"Official website","url":"https://www.cipla.com"}],"tags":[],"related":[],"cancers":[],"sections":["chemotherapy","cell-therapy"],"technologies":["car-t","cytotoxic-chemotherapy"],"targets":[],"drugs":["talicabtagene-autoleucel"],"companies":["immunoact"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-global-access","b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Mumbai","country":"IN","companyType":"pharma","website":"https://www.cipla.com","ticker":"CIPLA.NS","founded":1935,"investors":[],"funding":[]},{"id":"circle-pharma","kind":"company","name":"Circle Pharma","aka":[],"tldr":"Circle Pharma is developing CID-078, the first oral cyclin A/B RxL inhibitor, aimed at cancers with a broken G1/S checkpoint such as small-cell lung and triple-negative breast cancer.","summary":"CID-078 is an orally bioavailable macrocyclic peptide that blocks RxL-motif interactions of cyclins A and B, selectively killing E2F-high, RB1-altered tumour cells. Phase 1 (NCT06577987) began in October 2024 in advanced solid tumours including SCLC, TNBC, and ER+ breast cancer after CDK4/6 inhibitors; preclinical work published in Nature; clinical and preclinical updates at AACR 2026.","asOf":"2026-09-04","links":[{"label":"AACR 2026 presentations","url":"https://circlepharma.com/circle-pharma-to-present-new-clinical-and-preclinical-data-at-aacr-2026"}],"tags":[],"related":[],"cancers":["sclc","tnbc","breast-hr-positive"],"sections":["targeted-therapy"],"technologies":[],"targets":["cdk4-6"],"drugs":[],"companies":[],"institutions":[],"pathways":["p53-cell-cycle"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://circlepharma.com","investors":[],"funding":[]},{"id":"citius-pharmaceuticals","kind":"company","name":"Citius Pharmaceuticals","aka":[],"tldr":"Citius Pharmaceuticals brought denileukin diftitox back to market as Lymphir, approved in 2024 for relapsed cutaneous T-cell lymphoma, through its Citius Oncology subsidiary.","summary":"Citius Pharmaceuticals, based in Cranford, New Jersey, and listed as CTXR, brought denileukin diftitox back to market as Lymphir, approved in 2024 for relapsed cutaneous T-cell lymphoma, through its Citius Oncology subsidiary. It licensed the reformulated denileukin diftitox, known as E7777, from Eisai in 2021 and secured FDA approval in August 2024 for adults with relapsed or refractory stage I to III cutaneous T-cell lymphoma after at least one systemic therapy. OnCo links it to the denileukin diftitox drug record. Whether a revived fusion toxin finds a stable place among the newer options for a rare lymphoma is the open question. Denileukin diftitox has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.citiuspharma.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["denileukin-diftitox"],"companies":["eisai"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cranford, New Jersey","country":"US","companyType":"biotech","website":"https://www.citiuspharma.com","ticker":"CTXR","investors":[],"funding":[]},{"id":"civatech-oncology","kind":"company","name":"CivaTech Oncology","aka":[],"tldr":"CivaTech Oncology is a United States-based medical device company running 2 late-stage cancer trials in pancreatic ductal adenocarcinoma and non-small-cell lung cancer.","summary":"CivaTech Oncology, based in Research Triangle Park, Durham, NC, the United States, is a medical device company. CivaTech Oncology develops brachytherapy devices, including a flexible, bioabsorbable, polymer-encapsulated planar radiation source for treating solid tumours with minimal patient trauma. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials in pancreatic ductal adenocarcinoma and non-small-cell lung cancer. The largest, NCT02843945 (Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source), plans to enrol 80 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.civatechoncology.com"},{"label":"ClinicalTrials.gov: trials led by CivaTech Oncology","url":"https://clinicaltrials.gov/search?lead=CivaTech%20Oncology"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["pancreatic","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03290534","nct02843945"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Research Triangle Park, Durham, NC","country":"US","companyType":"devices","website":"https://www.civatechoncology.com","stage":"startup","investors":[],"funding":[]},{"id":"civica-rx","kind":"company","name":"Civica Rx","aka":[],"tldr":"Non-profit generic drug maker formed by hospital systems to secure supply of essential injectables, including oncology drugs.","summary":"Civica Rx, a nonprofit based in Lehi, Utah, is a generic drug maker formed by hospital systems to secure the supply of essential injectables, including oncology drugs. It contracts for and manufactures shortage-prone sterile injectables and operates a plant in Petersburg, Virginia. OnCo links it to generic oncology drug supply and shortage mitigation and to the idea of a non-profit manufacturer for shortage-prone generic chemotherapy. Whether a nonprofit can hold prices and supply steady through the recurring shortages of injectable chemotherapy is the question it was created to answer. The drug shortage technology page carries the wider picture.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Civica_Rx","links":[{"label":"Official website","url":"https://civicarx.org"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["chemotherapy"],"technologies":["generic-drug-shortage-response"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Lehi, UT","country":"US","companyType":"nonprofit","website":"https://civicarx.org","investors":[],"funding":[]},{"id":"clario","kind":"company","name":"Clario","aka":[],"tldr":"Clario is the endpoint technology company (Bioclinica and ERT merger) for imaging, eCOA, and cardiac data in trials.","summary":"Clario, based in Philadelphia, is the endpoint technology company formed from the merger of Bioclinica and ERT, covering imaging, electronic clinical outcome assessment and cardiac data in trials. Its services span central review of medical imaging, electronic clinical outcome assessments and respiratory and cardiac endpoints. OnCo links it to imaging core labs and central review and to clinical trial software. Whether one vendor collecting imaging, patient-reported and cardiac endpoints together improves trial data quality, or concentrates risk, is the open question. The imaging core lab technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://clario.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["imaging","ai-computation"],"technologies":["imaging-core-labs","clinical-trial-software"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05642780"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Philadelphia, PA","country":"US","companyType":"cro-services","website":"https://clario.com","investors":[],"funding":[]},{"id":"clarity-pharmaceuticals","kind":"company","name":"Clarity Pharmaceuticals","aka":[],"tldr":"Clarity Pharmaceuticals, a Sydney radiopharmaceutical company, pairs copper isotopes with SAR-bisPSMA, a molecule that binds PSMA on prostate cancer cells: copper-64 for PET imaging, in the phase 3 AMPLIFY and CLARIFY trials, and copper-67 for therapy in the SECuRE trial. The copper-67 therapy is still at the dose-finding stage.","summary":"Co-PSMA head-to-head data (EAU 2026) showed Cu-64 SAR-bisPSMA more than doubled lesion and patient detection versus Ga-68 PSMA-11; FDA Fast Track in biochemical recurrence; commercial manufacturing agreement with Nucleus RadioPharma (April 2026). SECuRE therapy trial: 7 of 19 patients at 8 GBq 67Cu reached complete response or undetectable disease (July 2026).","asOf":"2026-09-04","links":[{"label":"SECuRE update","url":"https://www.prnewswire.com/news-releases/clarity-pharmaceuticals-announces-secure-trial-update-on-8-gbq-67cu-sar-bispsma-dose-level-with-two-additional-complete-responses-302843184.html"}],"tags":[],"related":[],"cancers":["prostate"],"sections":["radiopharma","imaging"],"technologies":["psma-pet","radioligand-therapy"],"targets":["psma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["theranostics"],"trials":["nct06970847","nct04868604","nct06056830"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Sydney","country":"AU","companyType":"radiopharma","website":"https://www.claritypharmaceuticals.com","ticker":"CU6.AX","investors":[],"funding":[]},{"id":"clear-gene","kind":"company","name":"Clear Gene","aka":[],"tldr":"Clear Gene is developing tests that tell a surgeon, quickly, whether all of the cancer was removed during an operation.","summary":"Clear Gene develops molecular assays for surgical margin assessment, intended to show whether tumour tissue remains at the edge of a resection so that re-operation rates can fall, with breast surgery as the first application. The tests use epigenetic and genomic markers rather than conventional histology. The company remains active in the YC directory; it has not announced a marketed product or pivotal validation in a primary source found at the time of checking.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/clear-gene"},{"label":"Official website","url":"https://cleargene.com"}],"tags":["yc"],"related":[],"cancers":["tnbc","breast-hr-positive","breast-her2-positive"],"sections":["diagnostics","surgery"],"technologies":["methylation-profiling"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Carlos, CA","country":"US","companyType":"diagnostics","website":"https://cleargene.com","stage":"startup","ycBatch":"S18","investors":["y-combinator"],"funding":[]},{"id":"clearnote-health","kind":"company","name":"ClearNote Health","aka":[],"tldr":"ClearNote Health sells blood tests that look for chemical marks on DNA fragments in the blood to catch pancreatic and ovarian cancer early in people at high risk.","summary":"ClearNote Health (formerly Bluestar Genomics) is a San Diego epigenomics company whose Avantect tests analyse cell-free DNA in plasma with a proprietary platform that captures epigenomic changes, combined with machine learning, to detect cancer signal in high-risk groups. The Avantect Pancreatic Cancer Test targets people with new-onset diabetes and other risk factors; an Avantect Ovarian Cancer Test and a multi-cancer detection programme are in development. The pancreatic test runs from a CLIA-certified, CAP-accredited laboratory, received a first in vitro diagnostic approval in July 2025 and a UK approval in September 2025, and validation data were shown at AACR, DDW and ASCO in 2026. In May 2026 the company closed a $52 million Series D led by founding investor Mattias Westman, with Sandy Weill and Stephen Quake participating, for over $185 million raised in total.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.clearnotehealth.com/"},{"label":"Series D press release (May 2026)","url":"https://www.clearnotehealth.com/clearnote-health-secures-52-million-in-series-d-financing-and-strengthens-leadership-team-to-accelerate-growth-in-early-cancer-detection/"},{"label":"Press release archive","url":"https://www.clearnotehealth.com/category/press-release/"}],"tags":[],"related":[],"cancers":["pancreatic","ovarian"],"sections":["early-detection","diagnostics"],"technologies":["liquid-biopsy","methylation-profiling","mced"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The 5-hydroxymethylcytosine (5hmC) basis of the platform is not stated on the fetched pages, so it is described generically as epigenomic. Earlier rounds (Series B, C) not sourced. Founding year not sourced."],"hq":"San Diego, CA","country":"US","companyType":"diagnostics","website":"https://www.clearnotehealth.com/","stage":"growth","investors":[],"funding":[{"round":"Series D","year":2026,"amountUsd":52000000,"source":"https://www.clearnotehealth.com/clearnote-health-secures-52-million-in-series-d-financing-and-strengthens-leadership-team-to-accelerate-growth-in-early-cancer-detection/","note":"Led by founding investor Mattias Westman; cumulative funding stated as over $185 million."}]},{"id":"clovis-oncology","kind":"company","name":"Clovis Oncology","aka":["Clovis Oncology, Inc."],"tldr":"Clovis Oncology was the Colorado company that brought the PARP inhibitor rucaparib (Rubraca) to market for ovarian and prostate cancer before filing for bankruptcy in December 2022; its products passed to pharma& in 2023.","summary":"Clovis Oncology, based in Boulder, Colorado and listed on Nasdaq, developed rucaparib (Rubraca), a PARP inhibitor approved in the United States from 2016 for BRCA-mutated ovarian cancer, then as maintenance therapy (ARIEL3) and for BRCA-mutated metastatic castration-resistant prostate cancer (TRITON2). An earlier lead, the EGFR inhibitor rociletinib, was abandoned in 2016 after disputed response data. Competition from other PARP inhibitors and a restricted label left the company unable to service its debt; it filed for Chapter 11 in December 2022 and sold Rubraca to pharma& in 2023. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Clovis_Oncology","links":[{"label":"ClinicalTrials.gov: trials led by Clovis Oncology","url":"https://clinicaltrials.gov/search?lead=Clovis%20Oncology"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Clovis_Oncology"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["ovarian","prostate"],"sections":["targeted-therapy"],"technologies":[],"targets":["parp"],"drugs":["rucaparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03899155"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Boulder, CO","country":"US","companyType":"biotech","website":"https://www.clovisoncology.com","stage":"defunct","investors":[],"funding":[]},{"id":"cmr-surgical","kind":"company","name":"CMR Surgical","aka":[],"tldr":"CMR Surgical makes Versius, a compact modular surgical robot from Cambridge whose small independent arms fit existing operating theatres; it is used for colorectal, gynaecological and urological cancer operations in Europe, India and elsewhere and received US authorisation in 2024.","summary":"Founded in 2014, CMR Surgical designed Versius around small, cart-mounted arms modelled on the human arm so that hospitals could adopt robotics without a dedicated theatre, with an open console and a pay-per-use model to lower the barrier. It has been used in more than a hundred thousand procedures, mainly colorectal, gynaecological, upper gastrointestinal and urological surgery, and gained US marketing authorisation in 2024. OnCo links it to surgical robot platforms and robotic surgery.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/CMR_Surgical","links":[{"label":"Official website","url":"https://cmrsurgical.com"}],"tags":["machines-wave"],"related":[],"cancers":["colorectal","endometrial","prostate"],"sections":["surgery","devices"],"technologies":["surgical-robot-platforms","robotic-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cambridge","country":"GB","companyType":"devices","website":"https://cmrsurgical.com","founded":2014,"stage":"growth","investors":[],"funding":[]},{"id":"cnside-diagnostics","kind":"company","name":"CNSide Diagnostics","aka":[],"tldr":"CNSide captures tumour cells from cerebrospinal fluid to diagnose and track leptomeningeal disease, cancer spread to the linings of the brain and spine that conventional cytology often misses.","summary":"CNSide Diagnostics runs a cerebrospinal fluid assay that captures and counts circulating tumour cells and profiles their molecular markers, used to diagnose leptomeningeal metastases and to follow them over time during treatment. Future of Cancer Care Today notes it often detects cases that conventional cytology misses; it is physician-ordered.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://cnsidediagnostics.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["liquid-biopsy","ctc-capture"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"United States (city not published)","country":"US","companyType":"diagnostics","website":"https://cnsidediagnostics.com/","investors":[],"funding":[]},{"id":"cofactor-genomics","kind":"company","name":"Cofactor Genomics","aka":[],"tldr":"Cofactor Genomics reads the RNA of a tumour sample to model the immune cells inside it, and uses that to predict who will respond to immunotherapy.","summary":"Cofactor Genomics builds RNA-based diagnostics using what it calls Predictive Immune Modeling: multidimensional RNA expression models of the tumour immune microenvironment trained on large datasets. Its OncoPrism assay is intended to predict response to checkpoint inhibitors, with validation work presented in head and neck and other solid tumours and analytical validation published in molecular diagnostics journals. The company is CAP and CLIA accredited and, per its YC profile, is backed by Menlo Ventures, DCVC and Ascension Ventures. Evidence is at the clinical validation stage rather than randomised proof of benefit.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Cofactor_Genomics","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/cofactor-genomics"},{"label":"Official website","url":"https://cofactorgenomics.com"}],"tags":["yc"],"related":[],"cancers":["head-and-neck","nsclc"],"sections":["diagnostics","immunotherapy"],"technologies":["rna-seq","companion-diagnostic"],"targets":["pd1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"St. Louis, MO","country":"US","companyType":"diagnostics","website":"https://cofactorgenomics.com","stage":"growth","ycBatch":"S15","investors":["y-combinator"],"funding":[]},{"id":"cogent-biosciences","kind":"company","name":"Cogent Biosciences","aka":[],"tldr":"Cogent Biosciences makes bezuclastinib, a pill that blocks a mutated protein called KIT. It is being tested in a rare gut tumour called GIST and in systemic mastocytosis, a disease of overactive immune cells.","summary":"Cogent Biosciences is a Waltham, Massachusetts and Boulder, Colorado company developing precision therapies for genetically defined diseases. Its lead candidate, bezuclastinib, is a selective tyrosine kinase inhibitor of KIT D816V and other KIT mutations. In November 2025 it reported positive top-line SUMMIT results in non-advanced systemic mastocytosis (FDA Breakthrough Therapy designation; NDA planned for year-end 2025) and awaited the phase 3 PEAK trial of bezuclastinib plus sunitinib in second-line gastrointestinal stromal tumours (GIST) and the registration-directed APEX trial in advanced systemic mastocytosis. Preclinical programmes include a JAK2 V617F mutant-selective inhibitor, a pan-KRAS(ON/OFF) inhibitor, and selective ErbB2 (HER2), PI3K-alpha and FGFR2 inhibitors. Cogent (formerly Unum Therapeutics) trades on Nasdaq as COGT and reported about 430 million US dollars pro forma cash in November 2025.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.cogentbio.com/"},{"label":"Pipeline and publications","url":"https://www.cogentbio.com/pipeline-publications/"},{"label":"Q3 2025 results and business update (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1622229/000119312525261797/cogt-ex99_1.htm"},{"label":"December 2020 public offering 8-K (SEC)","url":"https://www.sec.gov/Archives/edgar/data/1622229/000119312520308501/d72504d8k.htm"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["kit","her2","kras","pik3ca","fgfr2"],"drugs":["bezuclastinib","cgt4859"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05186753","nct04996875","nct06777316"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["PEAK and APEX results (expected November and December 2025) were not verified."],"hq":"Waltham, MA","country":"US","companyType":"biotech","website":"https://www.cogentbio.com/","ticker":"COGT","stage":"public","investors":[],"funding":[]},{"id":"coherus","kind":"company","name":"Coherus BioSciences","aka":["Coherus BioSciences, Inc.","Coherus Oncology"],"tldr":"Coherus is a Californian company that grew up on biosimilars and now holds the US rights to toripalimab, the anti-PD-1 antibody approved in 2023 for nasopharyngeal carcinoma, the first FDA approval for that cancer.","summary":"Coherus BioSciences, based in Redwood City, California, built its business on biosimilars of pegfilgrastim and other biologics before refocusing on oncology. It licensed the anti-PD-1 antibody toripalimab from Junshi Biosciences for the United States and Canada and won FDA approval in October 2023 for recurrent or metastatic nasopharyngeal carcinoma with chemotherapy, the first drug approved in the United States for that disease. The company is developing toripalimab combinations and other immuno-oncology candidates. Company facts are from the official website and FDA approval records.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.coherus.com/"},{"label":"FDA: oncology and hematologic malignancies approval notifications","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"}],"tags":["fda-oce-applicant"],"related":[],"cancers":["head-and-neck","esophageal"],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["toripalimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06975293"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Redwood City, CA","country":"US","companyType":"biotech","website":"https://www.coherus.com/","stage":"public","investors":[],"funding":[]},{"id":"color-health","kind":"company","name":"Color Health","aka":[],"tldr":"Color Health runs a cancer programme for employers and health plans that gets people screened, follows up abnormal results, and gives those diagnosed access to an online clinic staffed by oncologists.","summary":"Color Health, founded in 2015, has moved from population genomics to an oncologist led Virtual Cancer Clinic sold to employers, unions, health plans and public bodies. The programme covers screening outreach (including at home HPV cervical screening with Waters Corporation and AI supported breast screening access with Google Cloud), full follow up of abnormal screens, diagnosis review, treatment management and survivorship, delivered by a 50 state medical group. It has partnered with the American Cancer Society since 2023 and in May 2026 became the first virtual cancer clinic to earn ASCO Certified status; more than 1 million people will have access in 2026. SEC Form D filings show USD 127.2 million of equity sold in a round first closed in December 2020 and a further USD 45.7 million by November 2021. Those filings list Burlingame, CA; 2026 releases are datelined South San Francisco.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.color.com"},{"label":"ASCO Certified Virtual Cancer Clinic press release (May 2026)","url":"https://www.prnewswire.com/news-releases/color-health-becomes-first-virtual-cancer-clinic-to-earn-asco-certified-status-for-compliance-with-quality-and-safety-standards-302764322.html"},{"label":"SEC Form D (January 2021)","url":"https://www.sec.gov/Archives/edgar/data/1683327/000168332721000001/primary_doc.xml"},{"label":"SEC Form D (November 2021)","url":"https://www.sec.gov/Archives/edgar/data/1683327/000168332721000002/primary_doc.xml"},{"label":"About Color Health","url":"https://www.color.com/about-us"}],"tags":[],"related":[],"cancers":["cervical"],"sections":["early-detection","supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Hint gave Burlingame; Form D filings (2021) list Burlingame but 2026 releases are datelined South San Francisco, which is used. Series names for the 2020 to 2021 rounds were not found in a fetched primary source, so rounds are recorded as Form D offerings. Investors not named in any fetched source."],"hq":"South San Francisco, CA","country":"US","companyType":"ai-software","website":"https://www.color.com","founded":2015,"stage":"growth","investors":[],"funding":[{"round":"Form D offering","year":2021,"amountUsd":127224203,"source":"https://www.sec.gov/Archives/edgar/data/1683327/000168332721000001/primary_doc.xml","note":"Form D filed 4 January 2021; first sale 17 December 2020; USD 127.2 million sold of a USD 167.2 million equity offering"},{"round":"Form D offering","year":2021,"amountUsd":45690932,"source":"https://www.sec.gov/Archives/edgar/data/1683327/000168332721000002/primary_doc.xml","note":"Form D filed 9 November 2021; first sale 26 October 2021; USD 45.7 million sold of a USD 100 million equity offering at filing"}]},{"id":"comecer","kind":"company","name":"Comecer (ATS)","aka":[],"tldr":"Comecer, of Castel Bolognese, Italy, and part of ATS Corporation, makes hot cells, isolators and dose calibrators, the shielded enclosures and automation that radiopharmacies need to handle radioactive drugs aseptically. Therapeutic radioligands need more shielding than diagnostic tracers, and whether hospitals build enough of it is the open question.","summary":"Comecer, based in Castel Bolognese, Italy, and part of ATS Corporation, makes hot cells, isolators and dose calibrators for radiopharmacies. Its shielded enclosures and automation serve aseptic processing for radiopharmaceuticals and for cell therapies. OnCo links it to medical cyclotrons, hot cells and synthesis modules. Whether hospitals build enough shielded capacity for therapeutic radioligands, which need more protection than diagnostic tracers, is the open question its products address. The cyclotron and synthesis technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.comecer.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["radiopharma"],"technologies":["medical-cyclotrons-synthesis-modules"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Castel Bolognese","country":"IT","companyType":"radiopharma","website":"https://www.comecer.com","investors":[],"funding":[]},{"id":"compass-therapeutics","kind":"company","name":"Compass Therapeutics","aka":[],"tldr":"Compass makes antibodies that hit two targets at once to reshape the blood supply and immune environment of tumours. Its lead drug, tovecimig, blocks two blood-vessel growth signals and is heading for a possible US approval filing in bile duct cancer.","summary":"Compass Therapeutics is a Boston clinical-stage, oncology-focused company developing antibody-based therapeutics. Lead candidate tovecimig is a DLL4 x VEGF-A bispecific antibody; data from the COMPANION-002 phase 2/3 study in biliary tract cancer were selected for an oral presentation at ESMO 2026, and the company expects FDA feedback in the third quarter of 2026 ahead of a potential BLA filing later in the year. CTX-8371, a PD-1 x PD-L1 bispecific, is in phase 1 cohort expansions in triple-negative breast cancer, Hodgkin lymphoma and non-small cell lung cancer, and CTX-10726, a PD-1 x VEGF-A bispecific, has dosed its first phase 1 patients with initial data expected in the fourth quarter of 2026. A phase 2 study of CTX-471, a CD137 agonist antibody, in NCAM (CD56)-expressing tumours is planned. Compass had $180 million in cash and marketable securities at 30 June 2026, expected to fund operations into 2028. Nasdaq: CMPX.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.compasstherapeutics.com/"},{"label":"Q2 2026 results (8-K exhibit 99.1)","url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm"}],"tags":[],"related":[],"cancers":["cholangiocarcinoma","tnbc","hodgkin-lymphoma","nsclc"],"sections":["immunotherapy"],"technologies":["bispecific-antibody","checkpoint-inhibitor","antiangiogenic"],"targets":["vegf","pd1","pdl1"],"drugs":["tovecimig"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No funding round sourced."],"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://www.compasstherapeutics.com/","ticker":"CMPX","stage":"public","investors":[],"funding":[]},{"id":"compugen","kind":"company","name":"Compugen","aka":["Compugen Ltd","Compugen Ltd."],"tldr":"An Israeli company that looks for new immune checkpoints in silico first and only then in the laboratory. It found PVRIG that way, and the antibody against it is in trials; its TIGIT antibody sits inside AstraZeneca's bispecific.","summary":"Compugen, listed on Nasdaq and the Tel Aviv Stock Exchange and based at 26 Harokmim Street in Holon, inverts the usual order of target discovery: it predicts candidate immune checkpoints computationally, on the platform it now calls Unigen, and validates the survivors experimentally. The approach produced PVRIG (CD112R), a receptor on T and natural killer cells that the company identified and then drugged with COM701, and its anti-TIGIT antibody COM902.\n\nThe pipeline is mostly partnered. COM701 is in trials alone and with COM902 and pembrolizumab, including a phase 1/2 study in relapsed platinum-sensitive ovarian cancer. The anti-TIGIT antibody licensed to AstraZeneca is the TIGIT arm of rilvegostomig, the PD-1 and TIGIT bispecific now in a large phase 3 programme. GS-0321, formerly COM503, is a high-affinity anti-IL-18 binding protein antibody licensed to Gilead, intended to free endogenous IL-18 inside the tumour.\n\nIt is the clearest Israeli example of the discovery-side business model: sell the target and the antibody rather than build the commercial infrastructure to sell a drug.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Compugen_(company)","links":[{"label":"Compugen","url":"https://www.cgen.com"},{"label":"SEC filer record (CIK 0001119774)","url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001119774&type=20-F"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":["immunotherapy","drug-discovery"],"technologies":["checkpoint-inhibitor","ai-drug-design","bispecific-antibody"],"targets":["pvrig","tigit","pd1"],"drugs":["rilvegostomig"],"companies":["astrazeneca","gilead"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06888921"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Holon","country":"IL","companyType":"biotech","website":"https://www.cgen.com","ticker":"CGEN","stage":"public","investors":[],"funding":[]},{"id":"concertai","kind":"company","name":"ConcertAI","aka":[],"tldr":"Oncology real-world data and AI company (ex-CancerLinQ data partner), supplying pharma and FDA-facing studies.","summary":"ConcertAI, based in Cambridge, Massachusetts, is an oncology real-world data and AI company, formerly the data partner for ASCO's CancerLinQ, supplying pharmaceutical companies and FDA-facing studies. Its offerings include curated electronic health record datasets, digital trial solutions and generative AI clinical tools, with partnerships with NVIDIA and ASCO. OnCo links it to oncology EHR and real-world data platforms. Whether curated real-world datasets reach the quality regulators need for approval decisions, rather than only for market analytics, is the open question for the sector. The real-world data platform page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.concertai.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["oncology-real-world-data"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cambridge, MA","country":"US","companyType":"ai-software","website":"https://www.concertai.com","investors":[],"funding":[]},{"id":"convergent-therapeutics","kind":"company","name":"Convergent Therapeutics","aka":[],"tldr":"Convergent Therapeutics attaches an alpha-emitting isotope to an antibody that homes in on prostate cancer cells, for men whose disease has progressed after standard radioligand treatment. Its lead medicine has reported mid-stage trial results.","summary":"Convergent Therapeutics develops alpha radioantibodies: antibodies that deliver alpha-emitting payloads directly into cancer cells while limiting exposure of healthy tissue. The lead candidate CONV01-α is a PSMA-directed actinium-225 radioantibody for metastatic castration-resistant prostate cancer in patients previously treated with 177Lu-PSMA. In June 2026 the company presented what it described as the largest prospective phase 2 dataset for an alpha radiopharmaceutical at ASCO 2026, reporting anti-tumour activity, durability and favourable tolerability in Lu-PSMA-exposed mCRPC.","asOf":"2026-09-10","links":[{"label":"Official website","url":"http://convergentrx.com/"}],"tags":[],"related":[],"cancers":["prostate"],"sections":["radiopharma"],"technologies":["radioimmunotherapy","targeted-alpha-therapy"],"targets":["psma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06549465"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The Business Wire releases (ASCO 2026 data, Series A) returned HTTP 403, so funding is omitted; trade press headlines report a USD 90 million Series A (2023) and a USD 40 million extension, unverified here. The domains convergenttx.com and convergenttherapeutics.com are parked; convergentrx.com blocks scripted requests but was fetched via WebFetch."],"hq":"Cambridge, MA","country":"US","companyType":"radiopharma","website":"http://convergentrx.com/","stage":"startup","investors":[],"funding":[]},{"id":"cook-medical","kind":"company","name":"Cook Medical","aka":[],"tldr":"Cook Medical is a family-owned maker of needles, stents and catheters, including the EchoTip needles used for endoscopic ultrasound biopsy of the pancreas and lymph nodes and the stents that relieve blocked bile ducts.","summary":"Cook Medical, founded in Bloomington, Indiana, in 1963, makes minimally invasive devices for endoscopy, interventional radiology and urology: EchoTip EUS aspiration and core biopsy needles, biliary and oesophageal stents, drainage catheters and embolisation products used across cancer care.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.cookmedical.com/"}],"tags":["machines-wave2"],"related":[],"cancers":[],"sections":[],"technologies":["endoscopic-ultrasound-systems","ultrasound"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Bloomington, IN","country":"US","companyType":"devices","website":"https://www.cookmedical.com/","founded":1963,"stage":"private-large","investors":[],"funding":[]},{"id":"corbus-pharmaceuticals","kind":"company","name":"Corbus Pharmaceuticals","aka":["Corbus Pharmaceuticals Inc."],"tldr":"Corbus Pharmaceuticals is a United States-based biotechnology company running 2 late-stage cancer trials of CRB-601 monoclonal antibody and CRB-701.","summary":"Corbus Pharmaceuticals, based in Norwood, MA, the United States, is a biotechnology company. Corbus Pharmaceuticals is a pharmaceutical company developing cancer treatments, including a Nectin-4-targeted therapy, alongside an obesity programme. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing CRB-601 monoclonal antibody and CRB-701. The largest, NCT06265727 (A Phase 1/2 Study to Investigate CRB-701 in Solid Tumours), plans to enrol 348 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.corbuspharma.com"},{"label":"ClinicalTrials.gov: trials led by Corbus Pharmaceuticals","url":"https://clinicaltrials.gov/search?lead=Corbus%20Pharmaceuticals%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["crb-701"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct06265727","nct06603844"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Norwood, MA","country":"US","companyType":"biotech","website":"https://www.corbuspharma.com","stage":"public","investors":[],"funding":[]},{"id":"corcept","kind":"company","name":"Corcept Therapeutics","aka":[],"tldr":"Corcept is a cortisol-modulation company whose relacorilant was approved in ovarian cancer in 2026.","summary":"Corcept Therapeutics, based in Redwood City, California, and listed as CORT, is a cortisol-modulation company whose relacorilant was approved in ovarian cancer in 2026. Relacorilant, sold as Lifyorli, is a cortisol modulator used in platinum-resistant ovarian cancer on the ROSELLA trial and in Cushing's syndrome. OnCo links it to ovarian cancer and adrenocortical carcinoma, to the ROSELLA trial record and to the relacorilant drug record. Whether blocking cortisol signalling helps chemotherapy in tumours beyond ovarian cancer is the open question its approval raises. Relacorilant has its own page.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Corcept_Therapeutics","links":[{"label":"Official website","url":"https://www.corcept.com"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["relacorilant"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07259317","nct06906341","nct07276373"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Redwood City, CA","country":"US","companyType":"biotech","website":"https://www.corcept.com","ticker":"CORT","investors":[],"funding":[]},{"id":"cormorant-asset-management","kind":"company","name":"Cormorant Asset Management","aka":[],"tldr":"A Boston biotech investment firm led by Bihua Chen that invests in private and public life sciences companies and is a frequent name in crossover rounds. Its website could not be reached at the time of research.","summary":"Cormorant Asset Management is a Boston-based life sciences investor that, according to the task hint, participates in private financings and public offerings of biotechnology companies, including oncology developers. At the time of research the domain cormorantcapital.com redirected to a GoDaddy 'for sale' parking page, an alternative (cormorantasset.com) did not resolve, and no Wikipedia article exists, so the firm's own description, founding year and portfolio could not be confirmed from a primary source.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://cormorantcapital.com/"},{"label":"Official website (parked at time of research)","url":"https://www.cormorantcapital.com/"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Website could not be fetched by the research pass on 2026-09-10 (bot protection, JavaScript-only or parked domain); location and description rest on the firm's public materials and on press releases that name it. cormorantcapital.com resolved on 2026-09-10 but its content could not be confirmed as the firm's site; treat the website link with caution."],"hq":"Boston, MA","country":"US","companyType":"investor","website":"https://cormorantcapital.com/","investors":[],"funding":[]},{"id":"cornerstone-pharmaceuticals","kind":"company","name":"Cornerstone Pharmaceuticals (formerly Rafael Pharmaceuticals)","aka":["Rafael Pharmaceuticals"],"tldr":"The company behind devimistat, a drug against cancer cell metabolism that failed its phase 3 trials in pancreatic cancer and leukaemia.","summary":"Rafael Pharmaceuticals, majority owned by Rafael Holdings, developed devimistat (CPI-613) for pancreatic cancer and acute myeloid leukaemia. After both phase 3 trials missed their endpoints in 2021 and 2022 the company was renamed Cornerstone Pharmaceuticals and refocused its pipeline.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.cornerstonepharma.com"}],"tags":[],"related":[],"cancers":["pancreatic","aml"],"sections":[],"technologies":[],"targets":[],"drugs":["devimistat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cranbury, New Jersey, United States","country":"US","companyType":"biotech","website":"https://www.cornerstonepharma.com","stage":"growth","investors":[],"funding":[]},{"id":"corvus-pharmaceuticals","kind":"company","name":"Corvus Pharmaceuticals","aka":["Corvus Pharmaceuticals, Inc.","NASDAQ:CRVS"],"tldr":"Corvus Pharmaceuticals is a Californian biotech whose oral ITK inhibitor soquelitinib rebalances T cells, with a registrational trial in relapsed T-cell lymphoma and studies in atopic dermatitis.","summary":"Corvus Pharmaceuticals develops soquelitinib (CPI-818), a selective covalent inhibitor of interleukin-2-inducible T-cell kinase (ITK) that blocks malignant T cells and steers helper T cells towards a Th1 profile. It is in a registrational phase 3 trial in relapsed peripheral T-cell lymphoma and in phase 1 trials in atopic dermatitis. The company also developed the adenosine A2A antagonist ciforadenant and the CD73 antibody mupadolimab.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.corvuspharma.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["soquelitinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Burlingame, California","country":"US","companyType":"biotech","website":"https://www.corvuspharma.com/","ticker":"NASDAQ:CRVS","founded":2014,"stage":"public","investors":[],"funding":[]},{"id":"cota-healthcare","kind":"company","name":"COTA","aka":[],"tldr":"Curated oncology real-world data with clinically abstracted endpoints, used in FDA-recognised RWE studies.","summary":"COTA, based in New York, provides curated oncology real-world data with clinically abstracted endpoints, used in FDA-recognised real-world evidence studies. Its data come from academic and community sites, it developed a nodal analysis method, and it emphasises regulatory-grade abstraction of outcomes from records. OnCo links it to oncology EHR and real-world data platforms. Whether manually abstracted endpoints can be produced at the scale and cost that make real-world evidence routine is the open question. The real-world data platform page carries the wider debate.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://cotahealthcare.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["oncology-real-world-data"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"New York, NY","country":"US","companyType":"ai-software","website":"https://cotahealthcare.com","investors":[],"funding":[]},{"id":"cradle-bio","kind":"company","name":"Cradle","aka":[],"tldr":"Cradle is a protein-engineering AI platform used by pharma to optimise antibodies and enzymes.","summary":"Cradle, based in Amsterdam and Zurich, is a protein engineering AI platform used by pharmaceutical companies to optimise antibodies and enzymes. It runs generative models over protein sequences with wet-lab feedback and raised a 73 million dollar Series B in 2024. OnCo links it to de novo designed protein binders. Whether AI-optimised antibodies show measurable advantages in the clinic over conventionally engineered ones is the open question. The de novo protein binder page carries the wider field.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.cradle.bio"}],"tags":["ai","protein-design"],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":["de-novo-protein-design","ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Amsterdam / Zurich","country":"NL","companyType":"ai-software","website":"https://www.cradle.bio","investors":[],"funding":[]},{"id":"crinetics-pharmaceuticals","kind":"company","name":"Crinetics Pharmaceuticals","aka":["Crinetics Pharmaceuticals Inc."],"tldr":"Crinetics Pharmaceuticals is a United States-based biotechnology company running 3 late-stage cancer trials of CRN09682 in neuroendocrine tumours and pancreatic ductal adenocarcinoma.","summary":"Crinetics Pharmaceuticals, based in San Diego, the United States, is a biotechnology company and part of Vertex Pharmaceuticals. Crinetics Pharmaceuticals is an endocrinology-focused pharmaceutical company that develops therapies for endocrine diseases and endocrine-related tumours. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing CRN09682 in neuroendocrine tumours and pancreatic ductal adenocarcinoma. The largest, NCT07129252 (A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumours), plans to enrol 150 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Crinetics_Pharmaceuticals","links":[{"label":"Official website","url":"https://www.crinetics.com"},{"label":"ClinicalTrials.gov: trials led by Crinetics Pharmaceuticals","url":"https://clinicaltrials.gov/search?lead=Crinetics%20Pharmaceuticals%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["neuroendocrine","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07129252","nct05804669","nct07087054"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Diego","country":"US","companyType":"biotech","website":"https://www.crinetics.com","stage":"acquired","investors":[],"funding":[]},{"id":"crispr-therapeutics","kind":"company","name":"CRISPR Therapeutics","aka":["CRISPR Therapeutics AG","NASDAQ:CRSP"],"tldr":"CRISPR Therapeutics is the gene-editing company co-founded by Emmanuelle Charpentier that shares Casgevy with Vertex and is building off-the-shelf CAR-T cells such as CTX112 for lymphoma and autoimmune disease.","summary":"CRISPR Therapeutics, headquartered in Zug with research in Boston, uses CRISPR/Cas9 to make gene-edited medicines. With Vertex it brought exagamglogene autotemcel (Casgevy) to approval for sickle cell disease and beta thalassaemia. In oncology it develops allogeneic CAR-T cells made from healthy donor T cells: CTX112 targets CD19 in B-cell malignancies and lupus, and CTX131 targets CD70 in solid tumours and haematological cancers. The company also has in vivo editing programmes for cardiovascular disease.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/CRISPR_Therapeutics","links":[{"label":"Official website","url":"https://www.crisprtx.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["ctx112"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Zug","country":"CH","companyType":"cell-therapy","website":"https://www.crisprtx.com/","ticker":"NASDAQ:CRSP","founded":2013,"stage":"public","investors":[],"funding":[]},{"id":"criterium","kind":"company","name":"Criterium","aka":["Criterium, Inc.","Criterium Inc"],"tldr":"Criterium is a US company in Saratoga Springs, New York, that is the lead sponsor of four cancer trials in OnCo, all testing other makers' drugs: fruquintinib with TAS-102 in colorectal cancer and tucatinib, alpelisib or palbociclib combinations in breast cancer.","summary":"Criterium, Inc. is a company based in Saratoga Springs, United States (Wikidata Q140045287, which also gives its website). ClinicalTrials.gov classes it as an industry sponsor. It leads four trials recorded in OnCo, none of a compound of its own: NCT06992258 (phase 2, fruquintinib with TAS-102 against fruquintinib alone in refractory metastatic colorectal cancer), NCT05230810 (phase 1/2, alpelisib with tucatinib in PIK3CA-mutant HER2-positive metastatic breast cancer), NCT04567420 (DARE, phase 2, circulating tumour DNA-guided second-line adjuvant palbociclib and fulvestrant in high-risk ER-positive HER2-negative breast cancer) and NCT05458674 (phase 2, tucatinib with trastuzumab and eribulin in pretreated HER2-positive metastatic breast cancer). The cro-services type reflects that pattern; Criterium's own description of its business was not consulted.","asOf":"2026-09-22","links":[{"label":"Official website","url":"https://www.criteriuminc.com"},{"label":"Wikidata Q140045287","url":"https://www.wikidata.org/wiki/Q140045287"},{"label":"ClinicalTrials.gov: trials led by Criterium, Inc.","url":"https://clinicaltrials.gov/search?lead=Criterium%2C%20Inc."}],"tags":["ctgov-sponsor","wave5-sponsor"],"related":[],"cancers":["colorectal","breast-her2-positive","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06992258","nct05230810","nct04567420","nct05458674"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo content wave 5 (Wikidata, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-22"},"hq":"Saratoga Springs, New York","country":"US","companyType":"cro-services","website":"https://www.criteriuminc.com","investors":[],"funding":[]},{"id":"cryoport","kind":"company","name":"Cryoport","aka":[],"tldr":"Cryoport is a specialist cryogenic logistics provider supporting most commercial CAR-T products and hundreds of cell-therapy trials.","summary":"Cryoport, based in Nashville and listed as CYRX, is a specialist cryogenic logistics provider supporting most commercial CAR-T products and hundreds of cell therapy trials. Its offerings include temperature-controlled shippers with telemetry, biostorage, the CRYOPDP courier network and MVE Biological Solutions cryogenic freezers. OnCo links it to cryopreservation and the cell therapy cold chain. Whether the cold chain can scale to in vivo and off-the-shelf cell therapies, or becomes less central as they arrive, is the open question for its business. The cold chain technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.cryoport.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["cell-therapy-cold-chain"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Nashville, TN","country":"US","companyType":"cro-services","website":"https://www.cryoport.com","ticker":"CYRX","investors":[],"funding":[]},{"id":"csl","kind":"company","name":"CSL Limited","aka":["CSL Behring","CSL Behring LLC","CSL Behring GmbH","Commonwealth Serum Laboratories","Vifor Pharma"],"tldr":"CSL is the Australian plasma-products and vaccines group whose CSL Behring arm makes immunoglobulins and clotting factors used in supportive cancer care, and which has sponsored phase 3 trials in cancer settings.","summary":"CSL Limited, listed in Melbourne since 1994 and descended from the Commonwealth Serum Laboratories, is one of the world's largest plasma-derived medicines makers through CSL Behring, based in King of Prussia, Pennsylvania, alongside its Seqirus vaccines business. In oncology its products are supportive: immunoglobulin replacement for patients with blood cancers or after CAR-T therapy, and haemostatic agents. ClinicalTrials.gov lists CSL Behring as lead sponsor of phase 3 trials in cancer-related settings.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/CSL_Limited","links":[{"label":"Official website","url":"https://www.csl.com"},{"label":"ClinicalTrials.gov: trials led by CSL Behring","url":"https://clinicaltrials.gov/search?lead=CSL%20Behring"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q908265"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":[],"targets":[],"drugs":["human-normal-immunoglobulin"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct07648264"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Melbourne","country":"AU","companyType":"pharma","website":"https://www.csl.com","founded":1994,"stage":"public","investors":[],"funding":[]},{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","aka":["CSPC","石药集团","CSPC Ouyi Pharmaceutical Co., Ltd.","CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd."],"tldr":"CSPC is a large Chinese pharma whose cancer business rests on albumin-bound paclitaxel and liposomal doxorubicin generics, an ADC pipeline and a growing list of licences to Western companies.","summary":"Domestic leader in nanoparticle albumin-bound paclitaxel (Keaili) and pegylated liposomal doxorubicin (Duomeisu); innovative pipeline includes the Nectin-4 ADC SYS6002, the Claudin 18.2 ADC SYSA1801, an EGFR ADC and a PD-1 x VEGF programme; licences include an AI-enabled discovery collaboration with AstraZeneca (June 2025) and ADC deals. Illustrates the shift of China's big generic houses into originator research.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/CSPC_Pharmaceutical_Group","links":[{"label":"Official website","url":"https://www.cspc.com.hk/"}],"tags":["china"],"related":[],"cancers":[],"sections":["chemotherapy","adcs","targeted-therapy"],"technologies":[],"targets":[],"drugs":["paclitaxel","pegylated-liposomal-doxorubicin","sys6010","hb1801","jskn003","kn026","jmt101","farletuzumab-exatecan","sys6023","jmt203"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06313086","nct07714668","nct07254585","nct05427383","nct07280832","nct07165886","nct07122063","nct07415863","nct06957379","nct06877650","nct06947291","nct07597629","nct06505395","nct07744763","nct04668690","nct06391944","nct06296706","nct07241936"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shijiazhuang","country":"CN","companyType":"pharma","website":"https://www.cspc.com.hk/","ticker":"1093.HK","founded":1997,"investors":[],"funding":[]},{"id":"cstone","kind":"company","name":"CStone Pharmaceuticals","aka":["基石药业","CStone","cstone-pharmaceuticals"],"tldr":"CStone developed sugemalimab, the first Chinese PD-L1 antibody approved in Europe, and brought pralsetinib, avapritinib and ivosidenib to China.","summary":"CStone Pharmaceuticals, based in Suzhou and Shanghai, founded in 2015 and listed in Hong Kong as 2616.HK, developed sugemalimab, the first Chinese PD-L1 antibody approved in Europe, and brought pralsetinib, avapritinib and ivosidenib to China. Sugemalimab, sold as Cejemly, was approved in China in 2021 and in the European Union in 2024 on the GEMSTONE-302 trial, the company holds Greater China rights to the three in-licensed drugs, and its pipeline includes ADCs and a PD-L1 by VEGF by CTLA-4 trispecific. OnCo links it to all four drugs and to GEMSTONE-302. The record describes it as a capital-constrained example of the 2015 biotech wave that relied on in-licensing plus one internal asset. Whether a European approval for a PD-L1 antibody can be turned into revenue in a crowded class is the open question.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.cstonepharma.com/en/"}],"tags":["china"],"related":[],"cancers":[],"sections":["immunotherapy","targeted-therapy"],"technologies":[],"targets":[],"drugs":["sugemalimab","pralsetinib","avapritinib","ivosidenib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["gemstone-302","nct04194775","nct05297890","nct06741644"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Suzhou / Shanghai","country":"CN","companyType":"biotech","website":"https://www.cstonepharma.com/en/","ticker":"2616.HK","founded":2015,"investors":[],"funding":[]},{"id":"cullgen","kind":"company","name":"Cullgen","aka":[],"tldr":"Cullgen designs drugs that tag disease-causing proteins for destruction by the cell's own recycling system, and links such drugs to antibodies. In May 2026 it became part of Gyre Therapeutics, a US and China company focused on fibrosis.","summary":"Cullgen is a San Diego clinical-stage biopharmaceutical company developing targeted protein degraders (TPDs) and degrader-antibody conjugates (DACs) for cancer, pain and inflammatory diseases, positioning DACs as the next generation of antibody-drug conjugates. Its discovery work uses novel E3 ligase ligands beyond cereblon and has operations in both the United States and China. On 2 March 2026 Nasdaq-listed Gyre Therapeutics (GYRE) agreed to acquire Cullgen in an all-stock transaction valued at about 300 million US dollars; the deal closed on 4 May 2026, Cullgen became a wholly owned subsidiary and its chief executive, Ying Luo, became president and chief executive of Gyre. Gyre describes the combined company as a US- and China-based, fully integrated biopharmaceutical company with a fibrosis-first commercial business and a degrader and DAC discovery engine.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.cullgen.com/"},{"label":"Gyre completes acquisition (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126018716/ef20072211_ex99-1.htm"},{"label":"Gyre agreement announcement (PDF on Cullgen site)","url":"https://www.cullgen.com/s/Cullgen-Gyreagreementpressrelease-4c4h.pdf"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy","adcs"],"technologies":["protac-degrader","degrader-antibody-conjugate"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Cullgen's pipeline page returned 404, so individual programme names (for example its TRK degrader) and clinical phases are not recorded. Pre-acquisition venture rounds were not found in SEC Form D searches. Headquarters recorded as San Diego per the company site; the group has substantial China operations but is not headquartered in mainland China."],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://www.cullgen.com/","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2026,"amountUsd":300000000,"source":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126018716/ef20072211_ex99-1.htm","note":"All-stock transaction valued at approximately 300 million US dollars; announced 2 March 2026, closed 4 May 2026"}]},{"id":"cullinan-therapeutics","kind":"company","name":"Cullinan Therapeutics","aka":[],"tldr":"Cullinan develops T-cell engager antibodies, which pull a patient's T cells onto target cells, for both cancer and autoimmune disease. Its cancer lead, CLN-049, targets FLT3 on acute myeloid leukaemia cells and is entering a potentially registrational trial.","summary":"Cullinan Therapeutics is a Cambridge, Massachusetts clinical-stage company advancing T-cell engagers (TCEs) in autoimmune disease and cancer. In oncology, CLN-049 is a FLT3xCD3 TCE for relapsed or refractory acute myeloid leukaemia; after a positive End-of-Phase 1 meeting with the FDA in July 2026 a potentially registrational phase 2 study is due to begin in the third quarter of 2026. Autoimmune programmes include CLN-978 (CD19xCD3 TCE) in lupus, rheumatoid arthritis and Sjogren's disease, and velinotamig (BCMAxCD3 TCE) in lupus, with phase 2 expansion studies planned for early 2027. The company reported $356 million in cash and investments at 30 June 2026 with runway into 2029. Nasdaq: CGEM.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://cullinantherapeutics.com/"},{"label":"Q2 2026 results (8-K exhibit 99.1)","url":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526336700/cgem-ex99_1.htm"}],"tags":[],"related":[],"cancers":["aml"],"sections":["immunotherapy"],"technologies":["t-cell-engager","bispecific-antibody"],"targets":["flt3","cd3","cd19","bcma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04036682"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No funding round sourced. Other oncology assets (for example zipalertinib) not covered by the fetched release and therefore omitted."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://cullinantherapeutics.com/","ticker":"CGEM","stage":"public","investors":[],"funding":[]},{"id":"cure-first","kind":"company","name":"Cure-First","aka":[],"tldr":"Cure-First is a nonprofit that grows organoids from a patient's tumour and screens them against dozens of anticancer drugs, and makes the results available to patients directly.","summary":"Cure-First offers organoid generation from patient tumour tissue and drug screening of more than 47 anticancer agents drawn from a library of over 200, as a nonprofit and patient-accessible service according to Future of Cancer Care Today.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://cure-first.org/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["organoids","functional-drug-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"United States (city not published)","country":"US","companyType":"nonprofit","website":"https://cure-first.org/","investors":[],"funding":[]},{"id":"curesponse","kind":"company","name":"Curesponse","aka":[],"tldr":"Israeli company whose cResponse test keeps a patient's tumour fragment alive, with its vessels and immune cells, to test which treatments it responds to.","summary":"Curesponse, based in Rehovot, Israel, and founded in 2018, is the company whose cResponse test keeps a fragment of a patient's tumour alive, with its blood vessels and immune cells intact, to test which treatments it responds to. The test combines ex vivo tumour-fragment culture with rapid genomics; a 2026 clinical utility study showed the assay can rule out ineffective regimens and reclassify predicted non-responders, and it is distributed in the United Kingdom through EDX Medical. OnCo links it to functional ex vivo drug testing and organoid-guided therapy at scale, to the bottleneck of preclinical models that do not predict people, and to ideas on testing drugs on freshly cut slices of the patient's own tumour. Whether functional testing improves outcomes in a randomised trial is the open question for the whole field. The functional testing page carries the evidence.","asOf":"2026-09-04","links":[{"label":"Clinical utility study (2026)","url":"https://doi.org/10.3390/jpm16060298"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["functional-drug-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-bar-j-pers-med"],"journals":[],"dependsOn":[],"notes":[],"hq":"Rehovot","country":"IL","companyType":"diagnostics","website":"https://www.curesponse.com","founded":2018,"investors":[],"funding":[]},{"id":"curevac","kind":"company","name":"CureVac","aka":[],"tldr":"CureVac was one of the pioneers of messenger RNA medicines and developed mRNA cancer vaccines for brain and head and neck cancer. It is now part of BioNTech, which bought the company.","summary":"CureVac N.V., based in Tübingen, Germany, was an early mRNA technology company. In oncology it advanced CVGBM, an off-the-shelf mRNA cancer vaccine encoding shared tumour-associated antigens for glioblastoma, and CVHNLC, a second oncology candidate, alongside partnered mRNA programmes and a broad mRNA manufacturing and intellectual property estate. The company's website now states that BioNTech has successfully closed its acquisition of CureVac and that CureVac is part of the BioNTech Group (Nasdaq: BNTX), redirecting visitors to biontech.com. Detailed programme status is now reported within BioNTech's pipeline. The acquisition consideration and closing date could not be confirmed from a fetched primary source (BioNTech's investor site blocked automated access), so the deal is recorded without an amount.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/CureVac","links":[{"label":"Official website","url":"https://www.curevac.com"}],"tags":[],"related":[],"cancers":["glioblastoma"],"sections":["immunotherapy"],"technologies":["shared-antigen-vaccine","neoantigen-mrna-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Acquisition completion confirmed on curevac.com; date and value not verified (BioNTech IR pages returned 403). CureVac's former Nasdaq ticker CVAC omitted because delisting status was not verified. Founding year not sourced. BioNTech itself is already in the graph."],"hq":"Tübingen","country":"DE","companyType":"biotech","website":"https://www.curevac.com","stage":"acquired","investors":[],"funding":[],"acquiredBy":"biontech"},{"id":"curis","kind":"company","name":"Curis","aka":["Curis, Inc."],"tldr":"Curis is a United States-based biotechnology company running 2 late-stage cancer trials of Emavusertib in chronic lymphocytic leukaemia and primary CNS lymphoma.","summary":"Curis, based in Lexington, MA, the United States, is a biotechnology company. Curis is a biotechnology company developing differentiated therapeutics for cancer patients, including an IRAK4 inhibitor in clinical development for haematologic malignancies. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing Emavusertib in chronic lymphocytic leukaemia and primary CNS lymphoma. The largest, NCT03328078 (CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)), plans to enrol 152 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.curis.com"},{"label":"ClinicalTrials.gov: trials led by Curis","url":"https://clinicaltrials.gov/search?lead=Curis%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cll","primary-cns-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["emavusertib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Lexington, MA","country":"US","companyType":"biotech","website":"https://www.curis.com","stage":"public","investors":[],"funding":[]},{"id":"curium","kind":"company","name":"Curium","aka":[],"tldr":"Curium is one of the largest nuclear-medicine companies, developing 177Lu-PSMA-I&T (ECLIPSE) as a competitor to Pluvicto.","summary":"Curium is a Paris-based private radiopharmaceutical group, one of the largest in nuclear medicine, supplying SPECT and PET isotopes and generators and developing 177Lu-PSMA-I&T as a competitor to Pluvicto in prostate cancer. Its ECLIPSE phase 3 trial of 177Lu-PSMA-I&T met its radiographic progression-free survival endpoint in taxane-naive metastatic castration-resistant prostate cancer, a Japanese registrational trial with PeptiDream and PDRadiopharma enrolled its first patient in February 2026, and the regulatory submission plan is under discussion with the FDA. OnCo links it to DOTATATE imaging agents, samarium-153 lexidronam, radionuclide generators and the therapeutic isotope supply chain. Whether a second lutetium PSMA agent can differentiate on supply and price rather than efficacy is the open question. The manufacturing cost of radioactive medicines is the bottleneck it bears on.","asOf":"2026-09-06","links":[{"label":"Official website","url":"https://www.curiumpharma.com"}],"tags":[],"related":[],"cancers":["prostate"],"sections":["radiopharma"],"technologies":[],"targets":[],"drugs":["lu177-psma-it","pylarify"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06235151"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Paris","country":"FR","companyType":"radiopharma","website":"https://www.curiumpharma.com","investors":[],"funding":[]},{"id":"cyclacel","kind":"company","name":"Cyclacel Pharmaceuticals","aka":["Cyclacel Pharmaceuticals, Inc.","Cyclacel"],"tldr":"Cyclacel is a cell-cycle drug company whose nucleoside analogue sapacitabine failed its phase 3 trial in older patients with acute myeloid leukaemia; it now develops CDK and PLK inhibitors.","summary":"Cyclacel Pharmaceuticals, founded in 1997 with roots in Dundee and headquartered in Berkeley Heights, New Jersey, ran the phase 3 SEAMLESS trial of oral sapacitabine alternating with decitabine in elderly acute myeloid leukaemia, which did not meet its survival endpoint. It continues with the CDK2/9 inhibitor fadraciclib and a PLK1 inhibitor in early trials, registered on ClinicalTrials.gov under Cyclacel as lead sponsor.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Cyclacel","links":[{"label":"Official website","url":"http://www.cyclacel.com"},{"label":"ClinicalTrials.gov: trials led by Cyclacel Pharmaceuticals, Inc.","url":"https://clinicaltrials.gov/search?lead=Cyclacel%20Pharmaceuticals%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q5198104"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Berkeley Heights, NJ","country":"US","companyType":"biotech","website":"http://www.cyclacel.com","founded":1997,"stage":"public","investors":[],"funding":[]},{"id":"cyted-health","kind":"company","name":"Cyted Health","aka":[],"tldr":"Cyted Health offers a swallowable capsule on a string that collects cells from the whole food pipe in a nurse-led appointment, so people with heartburn can be checked for Barrett's oesophagus and early oesophageal cancer without an endoscopy.","summary":"Cyted Health, spun out of the University of Cambridge and headquartered in Cambridge, UK with a US laboratory, provides early detection for oesophageal disease. Its EndoSign capsule sponge collects cells from the full length of the oesophagus in a minimally invasive, nurse-led procedure; samples are analysed with biomarker molecular testing to identify Barrett's oesophagus and oesophageal neoplasia in patients with reflux symptoms who would otherwise need endoscopy. EndoSign is FDA 510(k)-cleared, and the US laboratory is CLIA-certified (2024) and CAP-accredited (April 2026). More than 35,000 tests have been completed in the NHS, and the DETECT-ME US validation study began enrolling in March 2025 across 18 sites. In August 2026 the test launched in UK high street pharmacies. A $44 million Series B first close in August 2025 was led by EQT Life Sciences.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.cytedhealth.com/"},{"label":"Series B press release (Aug 2025)","url":"https://www.cytedhealth.com/post/cyted-health-secures-44-million-in-series-b-financing-to-accelerate-us-expansion"},{"label":"News and awards","url":"https://www.cytedhealth.com/news-awards"}],"tags":[],"related":[],"cancers":["esophageal"],"sections":["early-detection","diagnostics"],"technologies":["histopathology-ihc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on fetched pages (UK company number 11478299). US office address is Roswell, Georgia. The TFF3 immunohistochemistry basis of the assay is not stated on the fetched pages; histopathology-ihc is used as the closest technology tag."],"hq":"Cambridge","country":"GB","companyType":"diagnostics","website":"https://www.cytedhealth.com/","stage":"startup","investors":["eqt-life-sciences"],"funding":[{"round":"Series B","year":2025,"amountUsd":44000000,"source":"https://www.cytedhealth.com/post/cyted-health-secures-44-million-in-series-b-financing-to-accelerate-us-expansion","note":"First close, August 2025; led by EQT Life Sciences with co-leads Advent Life Sciences and British Business Bank."}]},{"id":"cytek-biosciences","kind":"company","name":"Cytek Biosciences","aka":[],"tldr":"Cytek Biosciences makes the Aurora and Northern Lights full-spectrum flow cytometers, which read the whole emission spectrum of every dye so forty or more markers can be measured on each cell, used in immunology, cell therapy development and clinical haematology.","summary":"Cytek Biosciences, listed on Nasdaq since 2021, pioneered full-spectrum cytometry: instead of one detector per dye, arrays of detectors capture each cell's complete emission spectrum and software unmixes the dyes, allowing very high-parameter panels on a compact instrument. Its Aurora, Northern Lights and Aurora CS sorter are used to characterise CAR-T and TIL products, profile immune responses to checkpoint inhibitors and, in clinical configurations, for leukaemia immunophenotyping. OnCo links it to flow cytometers.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://cytekbio.com"}],"tags":["machines-wave"],"related":[],"cancers":[],"sections":["diagnostics","cell-therapy"],"technologies":["flow-cytometers","closed-automated-cell-manufacturing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Fremont, CA","country":"US","companyType":"devices","website":"https://cytekbio.com","ticker":"CTKB","stage":"public","investors":[],"funding":[]},{"id":"cytiva","kind":"company","name":"Cytiva (Danaher)","aka":[],"tldr":"Danaher's bioprocessing arm (formerly GE Healthcare Life Sciences), supplying the Sefia cell-therapy platform, chromatography, and single-use systems.","summary":"Cytiva, based in Marlborough, Massachusetts, is Danaher's bioprocessing arm, formerly GE Healthcare Life Sciences, supplying the Sefia cell-therapy platform, chromatography and single-use systems. It provides bioprocess equipment and consumables for antibody and cell and gene therapy manufacturing, with the Sefia Select and Expansion systems for automated cell processing. OnCo links it to closed automated cell-therapy manufacturing and to viral vector manufacturing. Whether modular automation from a tools supplier or fully integrated factories win the cell therapy manufacturing market is the open question. The closed manufacturing technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.cytivalifesciences.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["closed-automated-cell-manufacturing","viral-vector-manufacturing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Marlborough, MA","country":"US","companyType":"cro-services","website":"https://www.cytivalifesciences.com","investors":[],"funding":[]},{"id":"cytomx-therapeutics","kind":"company","name":"CytomX Therapeutics","aka":[],"tldr":"CytomX Therapeutics makes 'masked' antibody medicines: a peptide covers the antibody's binding site until tumour enzymes cut it off, so the drug switches on mainly inside tumours and can hit targets that healthy tissue also carries. Its lead, an EpCAM-directed topoisomerase inhibitor conjugate for advanced bowel cancer, is in phase 1 with Fast Track status.","summary":"CytomX Therapeutics (Nasdaq: CTMX) is a clinical-stage biopharmaceutical company that pioneered conditionally activated biologics. Its Probody platform masks the antigen-binding site of an antibody with a peptide that is removed by tumour-associated proteases, so that ADCs, T-cell engagers and cytokines are activated preferentially in the tumour microenvironment, widening the therapeutic index against targets that are also expressed on healthy tissue. The lead candidate varsetatug masetecan (Varseta-M) is an EpCAM-directed, topoisomerase 1 inhibitor Probody ADC in phase 1 dose expansion for third-line or later metastatic colorectal cancer; the FDA granted Fast Track designation for relapsed or refractory metastatic colorectal cancer in August 2026. CX-801, a masked interferon alpha-2b, is in phase 1 in advanced melanoma, and CX-908 (P-cadherin x CD3) and Probody mRNA programmes are preclinical.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://cytomx.com/"},{"label":"Pipeline","url":"https://cytomx.com/pipeline/"}],"tags":[],"related":[],"cancers":["colorectal","melanoma"],"sections":["adcs","immunotherapy"],"technologies":["masked-adc","adc","t-cell-engager","cytokine-therapy"],"targets":["cd3"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Ticker, exchange and HQ confirmed via SEC EDGAR submissions data (CIK 0001501989). Investor relations pages (ir.cytomx.com) returned HTTP 403, so no funding rounds are listed; founding year not sourced."],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://cytomx.com/","ticker":"CTMX","stage":"public","investors":[],"funding":[]},{"id":"cytoreason","kind":"company","name":"CytoReason","aka":[],"tldr":"CytoReason builds computer models of human diseases from molecular and clinical data so drug companies can predict which targets and drugs are most likely to work, including in cancer immunotherapy.","summary":"CytoReason, founded in 2016 and headquartered in Tel Aviv with a US hub in Cambridge, Massachusetts, advances computational disease biology: it integrates human molecular and clinical data into computational disease models that give pharmaceutical and biotechnology companies predictive insights on assets, targets and indications. The platform spans immunology, inflammation, immuno-oncology and metabolism, and the company states that six of the world's top ten pharmaceutical companies use it, with Sanofi and Pfizer among disclosed partners. In July 2024 CytoReason announced an USD 80 million financing with investors including OurCrowd, NVIDIA, Pfizer and Thermo Fisher Scientific; the release does not name the round, so it is not recorded as a structured funding entry.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.cytoreason.com"},{"label":"Company page","url":"https://www.cytoreason.com/CytoReason%20Company.dc.html"},{"label":"USD 80 million financing (July 2024)","url":"https://www.cytoreason.com/CytoReason%20Press%20Release%2080M.dc.html"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation","drug-discovery"],"technologies":["ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["USD 80 million financing (July 2024) is sourced but the release gives no round label, so it is described in the summary rather than in funding. Website is a JavaScript application; content was read from static .dc.html pages found in the sitemap."],"hq":"Tel Aviv","country":"IL","companyType":"ai-software","website":"https://www.cytoreason.com","founded":2016,"stage":"growth","investors":["pfizer-ventures"],"funding":[]},{"id":"d3-bio-wuxi","kind":"company","name":"D3 Bio (Wuxi)","aka":["D3 Bio (Wuxi) Co., Ltd"],"tldr":"D3 Bio (Wuxi) is a China-based biotechnology company running 2 late-stage cancer trials.","summary":"D3 Bio (Wuxi), based in Wuxi, China, is a biotechnology company. D3 Bio is a private, clinical-stage biotechnology company developing precision oncology and immunology medicines targeting immune pathways and tumour-driving mutations. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials. The largest, NCT05410145 (A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumours With a KRAS p.G12C Mutation), plans to enrol 442 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website. Its website describes D3S-001 as a next-generation KRAS G12C-selective inhibitor for non-small-cell lung and colorectal cancers with that mutation, and D3S-003 as a KRAS G12D inhibitor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.d3bio.com"},{"label":"ClinicalTrials.gov: trials led by D3 Bio (Wuxi)","url":"https://clinicaltrials.gov/search?lead=D3%20Bio%20(Wuxi)%20Co.%2C%20Ltd"},{"label":"D3 Bio pipeline","url":"https://www.d3bio.com/"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","colorectal"],"sections":[],"technologies":["kras-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct05886920","nct05410145"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Wuxi","country":"CN","companyType":"biotech","website":"https://www.d3bio.com","founded":2020,"stage":"growth","investors":[],"funding":[]},{"id":"daehwa-pharmaceutical","kind":"company","name":"Daehwa Pharmaceutical","aka":["Daehwa Pharmaceutical Co., Ltd.","Dae Hwa Pharm","대화제약"],"tldr":"Daehwa is a Korean pharmaceutical company whose oral paclitaxel (Liporaxel) was approved in Korea for gastric cancer after a phase 3 trial it led, one of the few oral formulations of a taxane to reach the market.","summary":"Daehwa Pharmaceutical Co., Ltd., founded in 1984 and based in Seoul, developed Liporaxel, an oral liquid formulation of paclitaxel that uses a lipid-based system to achieve absorption, and won Korean approval for advanced gastric cancer on a phase 3 trial against intravenous paclitaxel. Further phase 3 trials in breast cancer are registered on ClinicalTrials.gov under Daehwa as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.dhpharm.co.kr"},{"label":"ClinicalTrials.gov: trials led by Daehwa Pharmaceutical Co., Ltd.","url":"https://clinicaltrials.gov/search?lead=Daehwa%20Pharmaceutical%20Co.%2C%20Ltd."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q56583329"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["gastric","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct03315364"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Seoul","country":"KR","companyType":"pharma","website":"http://www.dhpharm.co.kr","founded":1984,"stage":"public","investors":[],"funding":[]},{"id":"dahanca","kind":"company","name":"DAHANCA","aka":["Danish Head and Neck Cancer Group","Danish Head and Neck Cancer Study Group"],"tldr":"DAHANCA, the Danish Head and Neck Cancer Group established in September 1976, writes Denmark's head and neck cancer guidelines and ran the numbered DAHANCA radiotherapy trials, including DAHANCA 5 on the radiosensitiser nimorazole in OnCo.","summary":"DAHANCA, the Danish Head and Neck Cancer Study Group, was established in September 1976 and is part of the Danish Multidisciplinary Cancer Group (DMCG); it is responsible for national guidelines and for the national head and neck cancer database (dahanca.dk). Its website states no postal address, so no seat is given here. In OnCo it is the sponsor of DAHANCA 5 (phase 3, nimorazole with radiotherapy in head and neck squamous cell carcinoma, run from 1986 to 1994 before registry registration). It has no products of its own.","asOf":"2026-09-25","links":[{"label":"Official website","url":"https://www.dahanca.dk"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["dahanca-5"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"Denmark (seat not stated)","country":"DK","companyType":"cooperative-group","website":"https://www.dahanca.dk","founded":1976,"investors":[],"funding":[]},{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","aka":[],"tldr":"Daiichi Sankyo is the Japanese company whose DXd payload technology created the best ADC platform in the industry.","summary":"Daiichi Sankyo, based in Tokyo and listed as 4568.T, is the Japanese company whose DXd payload technology created the leading antibody-drug conjugate platform in the industry. Five DXd ADCs are in late development: trastuzumab deruxtecan and datopotamab deruxtecan with AstraZeneca, and patritumab deruxtecan against HER3, ifinatamab deruxtecan against B7-H3 and raludotatug deruxtecan against CDH6 with Merck, and Enhertu alone sells more than four billion dollars a year. OnCo links it to the DESTINY-Breast03, 04 and 06 papers that moved T-DXd into HER2-low and ultralow breast cancer, to TROPION-Breast01, to quizartinib and QuANTUM-First in FLT3-ITD leukaemia, and to the National Cancer Center Hospital investigators who ran its early trials. Whether the platform can keep winning as rival topoisomerase payloads arrive is the open question. Each ADC has its own page.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Daiichi_Sankyo","links":[{"label":"Official website","url":"https://www.daiichisankyo.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":[],"targets":[],"drugs":["trastuzumab-deruxtecan","datopotamab-deruxtecan","patritumab-deruxtecan","ifinatamab-deruxtecan","raludotatug-deruxtecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06899126","nct05215340","nct05555732","nct06819007","nct06174987","nct07022483","nct04619004","nct06172478","nct06644768","nct05280470","nct06362252","nct04145622","nct06864169","nct06731478","nct05875168","nct07720284","nct06330064","nct07405151","nct07630974","nct04488822","nct07129993","nct07286149","nct07060807","nct04538742","nct06797635","nct06863272","nct06596694","nct06686394","nct04938817","nct06941272","nct04703192","nct06112379","nct04379596","nct06780098","nct06644781","nct06780111","nct05950945","nct06271837","nct06445972","nct04458272","nct06824168","nct05460273","nct07220616","nct06780085","nct06660654","nct03793478","nct07205822"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tokyo","country":"JP","companyType":"pharma","website":"https://www.daiichisankyo.com","ticker":"4568.T","investors":[],"funding":[]},{"id":"damae-medical","kind":"company","name":"DAMAE Medical","aka":[],"tldr":"DAMAE Medical makes deepLive, a line-field confocal OCT device that shows skin in both vertical and horizontal sections at near-cellular resolution, for diagnosing skin cancers without a biopsy.","summary":"DAMAE Medical, a Paris spin-off from the Institut d'Optique founded in 2014, developed line-field confocal optical coherence tomography, combining the depth of OCT with the resolution of confocal microscopy in a handheld probe. Its deepLive device is CE-marked and studied for melanoma, basal cell and squamous cell carcinoma diagnosis and AI-assisted reading.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.damae-medical.com/"}],"tags":["machines-wave2"],"related":[],"cancers":["melanoma","basal-cell-carcinoma","skin-cancer"],"sections":[],"technologies":["confocal-oct-skin-imaging"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Paris","country":"FR","companyType":"imaging","website":"https://www.damae-medical.com/","founded":2014,"stage":"startup","investors":[],"funding":[]},{"id":"dbcg","kind":"company","name":"Danish Breast Cancer Group","aka":["Danish Breast Cancer Cooperative Group","DBCG"],"tldr":"The Danish Breast Cancer Group, established by the Danish Surgical Society in 1976, writes Denmark's national breast cancer guidelines, keeps the national database and ran the DBCG 82b and 82c postmastectomy radiotherapy trials in OnCo.","summary":"The Danish Breast Cancer Cooperative Group (DBCG) was established by the Danish Surgical Society in 1976 to ensure optimal diagnosis and treatment of breast cancer nationwide; from the start it has written evidence-based national guidelines for surgery, radiotherapy and systemic therapy and run a clinical database to which pathology, surgery and oncology departments report (dbcg.dk, About DBCG). Its secretariat is at Rigshospitalet, department 2501, Blegdamsvej 9, Copenhagen. In OnCo it is the sponsor of DBCG 82b and 82c (phase 3, postmastectomy radiotherapy in high-risk premenopausal and postmenopausal breast cancer, run before registry registration). It has no products of its own.","asOf":"2026-09-25","links":[{"label":"DBCG: About DBCG","url":"https://www.dbcg.dk/about-dbcg/"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["breast-hr-positive","breast-her2-positive","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["rigshospitalet"],"pathways":[],"terms":[],"trials":["dbcg-82bc"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"Copenhagen","country":"DK","companyType":"cooperative-group","website":"https://www.dbcg.dk","founded":1976,"investors":[],"funding":[]},{"id":"dantari","kind":"company","name":"Dantari","aka":[],"tldr":"Dantari built polymer-based drug carriers that let an antibody deliver far more chemotherapy to a tumour than standard antibody-drug conjugates, while sparing the bone marrow. Its first medicine was tested in breast cancer before the company sold off its assets in 2025.","summary":"Dantari, Inc. (Thousand Oaks, California) emerged from stealth in December 2022 with a USD 47 million Series A led by Westlake Village BioPartners. Its Targeted High-capacity Drug Conjugate (T-HDC) platform, derived from Caltech research, enables drug-to-antibody ratios of about 60 with tunable payload release, and its biodistribution was designed to reduce bone marrow exposure. The lead clinical asset DAN-222, a non-targeted high-capacity drug conjugate carrying a topoisomerase 1 inhibitor, was evaluated in a phase 1/2 trial in metastatic HER2-negative breast cancer, with early dose-escalation results presented at SABCS 2022; DAN-311, a HER2-targeted T-HDC for HER2-positive and HER2-low breast cancer, was planned to enter the clinic in 2023. In January 2025 Endpoints News reported that Dantari was selling off its assets, and the company domain is now parked.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://dantari.com/"},{"label":"Series A press release","url":"https://www.prnewswire.com/news-releases/dantari-debuts-with-47-million-series-a-to-advance-best-in-class-targeted-medicines-for-solid-tumors-301697300.html"},{"label":"Endpoints News: Dantari sells off assets","url":"https://endpoints.news/boehringer-merges-cancer-vaccine-and-oncolytic-virus-teams-dantari-sells-off-assets/"}],"tags":[],"related":["src-endpoints-news"],"cancers":["breast-hr-positive","tnbc"],"sections":["adcs"],"technologies":["adc","topoisomerase-inhibitors"],"targets":["her2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["dantari.com is reachable but redirects to a parked landing page. Defunct status is based on the Endpoints News headline of 24 January 2025 ('Dantari sells off assets'); the article body is paywalled, so details of the wind-down are unverified. Breast cancer ids reflect the HER2-negative trial population and are an interpretation."],"hq":"Thousand Oaks, CA","country":"US","companyType":"biotech","website":"https://dantari.com/","stage":"defunct","investors":["alexandria-venture-investments"],"funding":[{"round":"Series A","year":2022,"amountUsd":47000000,"source":"https://www.prnewswire.com/news-releases/dantari-debuts-with-47-million-series-a-to-advance-best-in-class-targeted-medicines-for-solid-tumors-301697300.html"}]},{"id":"data-driven-bioscience","kind":"company","name":"Data Driven Bioscience (Duoseq)","aka":[],"tldr":"Data Driven Bioscience is building a faster, cheaper sequencing-based way to diagnose and subtype cancers, starting with lymphoma.","summary":"Data Driven Bioscience, which trades as Duoseq, develops sequencing-based diagnostic assays that read DNA and RNA together to classify cancers more precisely and at lower cost than current pathology workups, with early work in lymphoma subtyping. Its YC pitch was cancer diagnosis ten times faster and ten times cheaper. The company is a Duke University area spin-out and remains active in the YC directory; published clinical validation is limited, so treat the evidence as early.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/data-driven-bioscience"},{"label":"Official website","url":"https://datadrivenbioscience.com"}],"tags":["yc"],"related":[],"cancers":["dlbcl"],"sections":["diagnostics"],"technologies":["rna-seq","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Durham, NC","country":"US","companyType":"diagnostics","website":"https://datadrivenbioscience.com","stage":"startup","ycBatch":"S18","investors":["y-combinator"],"funding":[]},{"id":"datavant","kind":"company","name":"Datavant","aka":[],"tldr":"Privacy-preserving record linkage (tokenisation) that lets real-world datasets be joined without exposing identities.","summary":"Datavant, based in San Francisco, provides privacy-preserving record linkage, known as tokenisation, that lets real-world datasets be joined without exposing patient identities. Its de-identification and linkage infrastructure is used by most US real-world data vendors and registries, which makes it the plumbing beneath much of the sector. OnCo links it to oncology EHR and real-world data platforms. Whether tokenised linkage stays private as datasets multiply and re-identification techniques improve is the open question that regulators and patients will keep asking. The real-world data platform page carries the wider debate.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.datavant.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["oncology-real-world-data"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"ai-software","website":"https://www.datavant.com","investors":[],"funding":[]},{"id":"day-one-biopharmaceuticals","kind":"company","name":"Day One Biopharmaceuticals","aka":[],"tldr":"Paediatric-first oncology company whose tovorafenib became the first targeted therapy approved for childhood low-grade glioma driven by BRAF fusions, following dabrafenib with trametinib (2023) for BRAF V600E tumours.","summary":"Day One Biopharmaceuticals, based in Brisbane, California, and listed as DAWN, is a paediatric-first oncology company whose tovorafenib became the first targeted therapy approved for childhood low-grade glioma driven by BRAF fusions, following dabrafenib with trametinib (2023) for BRAF V600E tumours. Ojemda, its brand of tovorafenib, was approved in the United States in 2024 on the FIREFLY-1 trial, Ipsen holds the rights outside the United States, the LOGGIPY-2 phase 3 tests it in the first-line setting, and pimasertib, a MEK inhibitor, is being developed in combinations. OnCo links it to glioma and paediatric low-grade glioma and to the bottleneck of rare and paediatric cancers without markets, which its model of developing drugs for children first is meant to answer. Whether a company can sustain itself on paediatric indications alone is the open question. Tovorafenib has its own page.","asOf":"2026-09-06","links":[{"label":"Official website","url":"https://www.dayonebio.com"}],"tags":[],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["tovorafenib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05377996","nct05566795"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Brisbane, CA","country":"US","companyType":"biotech","website":"https://www.dayonebio.com","ticker":"DAWN","investors":[],"funding":[]},{"id":"dcvc","kind":"company","name":"DCVC","aka":[],"tldr":"DCVC, once Data Collective, is a deep-tech venture firm whose DCVC Bio arm backs computational biology and cancer diagnostics companies.","summary":"DCVC is a venture capital firm founded in 2011 that invests in deep technology, with a dedicated DCVC Bio strategy for computational and engineering approaches to biology, agriculture and health. Its oncology investments have centred on data-heavy diagnostics and platform companies. Offices in Palo Alto and San Francisco; portfolio links in OnCo are derived from the startup records that name it.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.dcvc.com"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Palo Alto, CA","country":"US","companyType":"investor","website":"https://www.dcvc.com","founded":2011,"investors":[],"funding":[]},{"id":"debiopharm","kind":"company","name":"Debiopharm","aka":[],"tldr":"Debiopharm is the private Swiss developer of the WEE1 inhibitor zedoresertib (Debio 0123) and of dual-payload ADC research.","summary":"Zedoresertib is a brain-penetrant, selective WEE1 inhibitor in phase 1/2 as monotherapy and with carboplatin (platinum-resistant ovarian) or with the PKMYT1 inhibitor lunresertib in CCNE1/FBXW7/PPP2R1A-altered tumours (first data AACR 2026). Debiopharm also presented dual-payload ADC and AI-biomarker work at AACR 2026.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Debiopharm","links":[{"label":"Debiopharm AACR 2026","url":"https://www.debiopharm.com/drug-development/press-releases/debiopharm-to-unveil-new-pre-clinical-and-clinical-research-advances-in-ddr-inhibition-dual-payload-adcs-and-ai-driven-biomarkers-at-aacr-2026/"}],"tags":[],"related":[],"cancers":["ovarian","sclc"],"sections":["targeted-therapy","adcs"],"technologies":["synthetic-lethality-approaches","dual-payload-adc"],"targets":["wee1","tp53"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05765812","nct06969430"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Lausanne","country":"CH","companyType":"biotech","website":"https://www.debiopharm.com","investors":[],"funding":[]},{"id":"deciphera","kind":"company","name":"Deciphera Pharmaceuticals (Ono)","aka":[],"tldr":"Kinase-switch-control company behind ripretinib for GIST and vimseltinib for tenosynovial giant cell tumour; bought by Ono Pharmaceutical in 2024.","summary":"Deciphera Pharmaceuticals, based in Waltham, Massachusetts, is the kinase-switch-control company behind ripretinib for gastrointestinal stromal tumour and vimseltinib for tenosynovial giant cell tumour, and it was bought by Ono Pharmaceutical in 2024 for around 2.4 billion dollars. Ripretinib, sold as Qinlock, was approved in 2020 on the INVICTUS trial, with INTRIGUE and INSIGHT following, and vimseltinib, sold as Romvimza, was approved on 14 February 2025 on the MOTION trial. OnCo links it to GIST, soft tissue sarcomas and tenosynovial giant cell tumour, and to both drug records. Whether switch-control inhibition yields further drugs beyond these two rare indications is the open question now that it sits inside a Japanese pharma. Ripretinib and vimseltinib have their own pages.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://www.deciphera.com"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["ripretinib","vimseltinib","inlexisertib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03069469","nct06948448","nct07429266","nct03036098","nct04078295","nct03673501","nct05144854","nct06630234","nct07734116","nct06256328"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Waltham, MA","country":"US","companyType":"biotech","website":"https://www.deciphera.com","investors":[],"funding":[]},{"id":"deep-6-ai","kind":"company","name":"Deep 6 AI","aka":[],"tldr":"Deep 6 AI made software that reads hospital records, including free text notes, to find patients who match clinical trial criteria in minutes. It was bought by the genomics and data company Tempus in 2025.","summary":"Deep 6 AI Inc., based in Pasadena, developed natural language processing software that mines structured and unstructured electronic health record data to identify patients eligible for clinical trials, used by research sites and sponsors for feasibility and recruitment. SEC Form D filings made in November 2024 disclose three equity offerings: about USD 5.9 million first sold in 2017, USD 17.3 million first sold in 2019 and USD 26.9 million first sold in 2022. Tempus AI's 10-Q for the quarter ended 31 March 2025 records the acquisition of Deep 6 AI on 11 March 2025 as a business combination; the filing does not isolate the consideration paid for Deep 6, and a PR Newswire market report describes the price as undisclosed. The Deep 6 domain no longer resolves and Tempus's website rate limited every fetch, so product detail is limited to what filings support.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://web.archive.org/web/20260516224208/https://deep6.ai/"},{"label":"SEC Form D filings for Deep 6 AI Inc.","url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001930014&type=D&dateb=&owner=include&count=40"},{"label":"Tempus AI 10-Q for Q1 2025 recording the acquisition","url":"https://www.sec.gov/Archives/edgar/data/1717115/000095017025064447/tem-20250331.htm"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["ai-trial-matching"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Website deep6.ai does not resolve (DNS failure) and was NOT fetched; the URL is kept for identity only. Tempus press release about the acquisition could not be fetched (tempus.com returned HTTP 429 on every attempt), so the acquisition is sourced to the Tempus 10-Q. Product description (NLP trial matching) is from general knowledge consistent with the Form D industry group and Tempus's stated rationale, not from a fetched company page. Founding year not sourced."],"hq":"Pasadena, CA","country":"US","companyType":"ai-software","website":"https://web.archive.org/web/20260516224208/https://deep6.ai/","stage":"acquired","investors":[],"funding":[{"round":"Form D offering","year":2024,"amountUsd":5921393,"source":"https://www.sec.gov/Archives/edgar/data/1930014/000193001424000002/primary_doc.xml","note":"Late filing made 20 November 2024 for an equity offering first sold 29 November 2017; includes USD 3.4 million of converted notes"},{"round":"Form D offering","year":2024,"amountUsd":17295221,"source":"https://www.sec.gov/Archives/edgar/data/1930014/000193001424000003/primary_doc.xml","note":"Late filing made 20 November 2024 for an equity offering first sold 17 September 2019; includes USD 6.1 million of converted notes"},{"round":"Form D offering","year":2024,"amountUsd":26887862,"source":"https://www.sec.gov/Archives/edgar/data/1930014/000193001424000004/primary_doc.xml","note":"Late filing made 20 November 2024 for an equity offering first sold 26 April 2022; USD 26.9 million sold of USD 33.8 million"},{"round":"Acquisition","year":2025,"source":"https://www.sec.gov/Archives/edgar/data/1717115/000095017025064447/tem-20250331.htm","note":"Acquired by Tempus AI on 11 March 2025; Deep 6 specific consideration not broken out in the 10-Q"}],"acquiredBy":"tempus"},{"id":"deerfield-management","kind":"company","name":"Deerfield Management","aka":[],"tldr":"A New York healthcare investment firm that funds companies, runs its own drug discovery labs and a philanthropy arm. It founded and seeded Nuvalent, a lung cancer drug company that GSK agreed to buy for $10.6 billion.","summary":"Deerfield was founded in 1994 by Arnold Snider (Wikipedia) and describes its mission as 'Advancing Healthcare through Investment, Information & Philanthropy'. It invests in private and public companies across life science, medical devices, diagnostics, digital health and services at all stages, and builds companies through Deerfield Discovery and Development (3DC), its company-building R&D engine housed at the Cure building in New York City. Its flagship oncology outcome is Nuvalent: Deerfield's release states that Nuvalent 'is a clinical-stage precision oncology company founded in 2017 by Deerfield in collaboration with' Harvard chemical biologist Matthew Shair, that Deerfield was 'sole founding investor' and seeded the company in 2017, and that Nuvalent has 'two late-stage, potential best-in-class, next-generation, highly selective ROS1 and ALK inhibitors' for non-small cell lung cancer, with GSK agreeing to acquire it for $10.6 billion.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://deerfield.com/"},{"label":"Portfolio","url":"https://deerfield.com/what-we-do/investment/portfolio"},{"label":"Nuvalent acquisition release","url":"https://www.prnewswire.com/news-releases/deerfield-management-announces-portfolio-company-nuvalent-inc-to-be-acquired-by-gsk-302796995.html"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Deerfield_Management"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["nuvalent"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The portfolio page shown (Radiance, Boulevard Bio, Verana Health, Sequel Therapeutics and others) does not describe therapeutic areas, so only Nuvalent is cited as an oncology example."],"hq":"New York, NY","country":"US","companyType":"investor","website":"https://deerfield.com/","founded":1994,"investors":[],"funding":[]},{"id":"delcath","kind":"company","name":"Delcath Systems","aka":["Delcath","Delcath Systems, Inc.","melphalan for Injection/Hepatic Delivery System"],"tldr":"Delcath makes the Hepzato Kit, the melphalan percutaneous hepatic perfusion system approved by the FDA in 2023 for uveal melanoma that has spread to the liver, and sells the same device in Europe as Chemosat.","summary":"Delcath Systems, based in New York, developed percutaneous hepatic perfusion, a procedure that isolates the liver's blood supply to deliver high-dose melphalan directly to liver tumours while filtering the drug from blood returning to the body. Its Hepzato Kit was approved by the FDA in August 2023 for adults with uveal melanoma and unresectable liver metastases, the first approved liver-directed therapy for that disease, and the device is marketed in Europe as Chemosat. Company facts are from the official website and FDA approval records.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Delcath_Systems","links":[{"label":"Official website","url":"https://www.delcath.com/"},{"label":"FDA approval of melphalan as a liver-directed treatment for uveal melanoma","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-melphalan-liver-directed-treatment-uveal-melanoma"}],"tags":["fda-oce-applicant"],"related":[],"cancers":["uveal-melanoma"],"sections":["surgery","chemotherapy"],"technologies":[],"targets":[],"drugs":["hepzato"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05022901","nct06607458"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"New York, NY","country":"US","companyType":"devices","website":"https://www.delcath.com/","stage":"public","investors":[],"funding":[]},{"id":"delee","kind":"company","name":"Delee","aka":[],"tldr":"Delee, from Mexico, built a blood-testing device that catches circulating tumour cells to help diagnose cancer earlier and follow treatment.","summary":"Delee is a Monterrey-based medical device company whose CytoCatch system isolates and analyses circulating tumour cells from a blood sample for early diagnosis and treatment monitoring. It was one of the first Latin American oncology device companies through YC. The YC directory lists it as active, but the company domain no longer resolved to a company site when checked on 2026-09-10 and no peer-reviewed clinical validation of a marketed test was found, so its current status and evidence should be treated as unverified.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/delee"}],"tags":["yc"],"related":[],"cancers":[],"sections":["diagnostics","early-detection"],"technologies":["liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Monterrey","country":"MX","companyType":"diagnostics","website":"https://www.ycombinator.com/companies/delee","stage":"startup","ycBatch":"W17","investors":["y-combinator"],"funding":[]},{"id":"delfi-diagnostics","kind":"company","name":"DELFI Diagnostics","aka":[],"tldr":"Fragmentomics company whose FirstLook Lung blood test aims to raise lung-cancer screening uptake; first randomised clinical-utility data in 2026.","summary":"FirstLook Lung (launched 2023) analyses cfDNA fragmentation patterns to identify who should proceed to low-dose CT. The L301 FIRSTLUNG cluster-randomised trial (NCT06145750) was presented as a late-breaker at ATS 2026; AACR 2026 showed whole-genome cfDNA advances in detection and monitoring. Johns Hopkins spin-out.","asOf":"2026-09-04","links":[{"label":"ATS 2026","url":"https://www.biospace.com/press-releases/delfi-diagnostics-to-present-first-clinical-utility-data-for-blood-based-lung-cancer-screening-at-ats-2026-international-conference"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["early-detection"],"technologies":["fragmentomics","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":["johns-hopkins"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Baltimore, MD","country":"US","companyType":"diagnostics","website":"https://delfidiagnostics.com","investors":["illumina-ventures"],"funding":[]},{"id":"delta-fly-pharma","kind":"company","name":"Delta-Fly Pharma","aka":["Delta-Fly Pharma, Inc.","デルタフライファーマ"],"tldr":"Delta-Fly is a small Japanese company from Tokushima that improves existing chemotherapy drugs; its continuous-infusion cytarabine analogue DFP-10917 is in phase 3 for relapsed acute myeloid leukaemia.","summary":"Delta-Fly Pharma, based in Tokushima and listed in Tokyo, develops modified versions of established cytotoxic drugs. Its lead candidate DFP-10917, a deoxycytidine analogue given by continuous infusion, is in a phase 3 trial in relapsed or refractory acute myeloid leukaemia, and DFP-14323, an oral formulation of the protease inhibitor ubenimex, is tested in lung cancer. Its trials are registered on ClinicalTrials.gov under Delta-Fly as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.delta-flypharma.co.jp"},{"label":"ClinicalTrials.gov: trials led by Delta-Fly Pharma, Inc.","url":"https://clinicaltrials.gov/search?lead=Delta-Fly%20Pharma%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q60997589"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct06382168"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Tokushima","country":"JP","companyType":"biotech","website":"https://www.delta-flypharma.co.jp","stage":"public","investors":[],"funding":[]},{"id":"dendreon","kind":"company","name":"Dendreon","aka":["Dendreon Pharmaceuticals","Dendreon Corporation"],"tldr":"Dendreon makes sipuleucel-T (Provenge), the first autologous cellular immunotherapy approved for cancer, for metastatic prostate cancer; the company went bankrupt in 2014 and has been owned by China's Sanpower group since 2017.","summary":"Dendreon, now based in Seal Beach, California, developed sipuleucel-T (Provenge), an autologous cellular immunotherapy in which a patient's own antigen-presenting cells are activated against prostatic acid phosphatase and reinfused; it was approved by the FDA in 2010 for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer after the IMPACT trial. High cost and slow uptake led the company into bankruptcy in 2014; Valeant bought the assets in 2015 and sold the business to the Sanpower Group in 2017, which continues to market Provenge in the United States. OnCo records it as a registry sponsor of phase 3 cancer trials.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Dendreon","links":[{"label":"Official website","url":"https://www.dendreon.com"},{"label":"ClinicalTrials.gov: trials led by Dendreon","url":"https://clinicaltrials.gov/search?lead=Dendreon"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Dendreon"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate"],"sections":["cell-therapy","immunotherapy"],"technologies":[],"targets":[],"drugs":["sipuleucel-t"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06134232"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Seal Beach, CA","country":"US","companyType":"cell-therapy","website":"https://www.dendreon.com","stage":"private-large","investors":[],"funding":[]},{"id":"denovo-biopharma","kind":"company","name":"Denovo Biopharma","aka":["Denovo Biopharma LLC"],"tldr":"Denovo is a San Diego biotech that revives failed drugs by finding the genetic marker of patients who did respond; it took enzastaurin back into phase 3 in lymphoma and glioblastoma with its DGM1 biomarker.","summary":"Denovo Biopharma, based in San Diego, licenses drugs that failed in unselected populations and re-tests them in patients selected by germline biomarkers it discovers. Its lead programme, enzastaurin (DB102) with the DGM1 marker, was taken into the phase 3 ENGINE trial in diffuse large B-cell lymphoma and a phase 3 trial in glioblastoma, both registered on ClinicalTrials.gov under Denovo as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://denovobiopharma.com"},{"label":"ClinicalTrials.gov: trials led by Denovo Biopharma LLC","url":"https://clinicaltrials.gov/search?lead=Denovo%20Biopharma%20LLC"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q140046004"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["dlbcl","glioblastoma"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://denovobiopharma.com","stage":"private-large","investors":[],"funding":[]},{"id":"diakonos-oncology","kind":"company","name":"Diakonos Oncology","aka":[],"tldr":"Diakonos Oncology makes dendritic cell therapies from a patient's own cells, with trials under way in glioblastoma, pancreatic cancer and melanoma.","summary":"Diakonos Oncology develops patient-derived dendritic cell vaccines that present the patient's own tumour antigens to the immune system, and is running clinical trials in glioblastoma, pancreatic cancer and melanoma. Access is through trial enrolment.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.diakonosoncology.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":["glioblastoma","pancreatic","melanoma"],"sections":[],"technologies":["dendritic-cell-vaccines"],"targets":[],"drugs":["doc1021"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"United States (city not published)","country":"US","companyType":"cell-therapy","website":"https://www.diakonosoncology.com/","stage":"startup","investors":[],"funding":[]},{"id":"diffusion-pharmaceuticals","kind":"company","name":"Diffusion Pharmaceuticals","aka":["Diffusion Pharmaceuticals Inc","Diffusion Pharmaceuticals LLC"],"tldr":"Diffusion developed trans sodium crocetinate, a small molecule meant to carry more oxygen into tumours so radiotherapy works better; its phase 3 trial in glioblastoma was cut short and the company merged into another biotech in 2023.","summary":"Diffusion Pharmaceuticals, founded in 2001 in Charlottesville, Virginia, developed trans sodium crocetinate (TSC), a carotenoid derivative that increases oxygen diffusion into hypoxic tissue, as a radiosensitiser. Its phase 3 INTACT trial in newly diagnosed glioblastoma was terminated early, and the company merged with EIP Pharma in 2023. Its trials remain on ClinicalTrials.gov under Diffusion as lead sponsor.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Diffusion_Pharmaceuticals","links":[{"label":"Official website","url":"http://www.diffusionpharma.com"},{"label":"ClinicalTrials.gov: trials led by Diffusion Pharmaceuticals Inc","url":"https://clinicaltrials.gov/search?lead=Diffusion%20Pharmaceuticals%20Inc"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q5275432"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["glioblastoma"],"sections":["radiation"],"technologies":["radiosensitisers","tumour-hypoxia-modification"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Charlottesville, VA","country":"US","companyType":"biotech","website":"http://www.diffusionpharma.com","founded":2001,"stage":"acquired","investors":[],"funding":[]},{"id":"digistain","kind":"company","name":"Digistain","aka":[],"tldr":"Digistain shines infrared light through a breast tumour slide and reads its chemical fingerprint to score how likely the cancer is to return, giving a result in a day rather than weeks and at a fraction of the cost of genomic tests.","summary":"Digistain, an Imperial College London spin-out, measures the mid-infrared spectrum of a standard tumour section and applies an algorithm to produce a risk score for early breast cancer that is intended to guide chemotherapy decisions, an alternative to centralised genomic recurrence tests. The company cites a UK government-commissioned study showing clinical performance comparable to the market leader, and reports use with reimbursement at some cancer centres; it is supported by the NHS, YC and the European Investment Bank per its profile. Prospective outcome data are still limited.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/digistain"},{"label":"Official website","url":"https://digistain.co.uk"}],"tags":["yc"],"related":[],"cancers":["breast-hr-positive"],"sections":["diagnostics"],"technologies":["histopathology-ihc","digital-pathology-ai"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"London","country":"GB","companyType":"diagnostics","website":"https://digistain.co.uk","stage":"startup","ycBatch":"S21","investors":["y-combinator"],"funding":[]},{"id":"dignitana","kind":"company","name":"Dignitana","aka":[],"tldr":"Dignitana makes the DigniCap scalp cooling system, the first cooling cap the US FDA allowed on the market, in 2015, to reduce chemotherapy hair loss.","summary":"Dignitana, a Swedish company listed on Nasdaq First North, developed the DigniCap, a silicone cap with circulating coolant and temperature sensors; it received FDA marketing authorisation in December 2015 for breast cancer patients, extended to solid tumours in 2017, and is used in cancer centres in the United States, Europe and Asia under service agreements.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.dignicap.com/"},{"label":"FDA allows marketing of cooling cap to reduce hair loss during chemotherapy (2015)","url":"https://www.fda.gov/news-events/press-announcements/fda-allows-marketing-cooling-cap-reduce-hair-loss-during-chemotherapy"}],"tags":["machines-wave2"],"related":[],"cancers":["breast-cancer"],"sections":["rejuvenation"],"technologies":["scalp-cooling","cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Lund","country":"SE","companyType":"devices","website":"https://www.dignicap.com/","stage":"public","investors":[],"funding":[]},{"id":"disc-medicine","kind":"company","name":"Disc Medicine","aka":["Disc Medicine, Inc"],"tldr":"Disc Medicine is a US-based biotechnology company that leads 2 cancer trials in OnCo, testing DISC-0974 and DISC-3405 in myeloproliferative neoplasms and myelodysplastic syndromes / neoplasms.","summary":"Disc Medicine is a clinical-stage biopharmaceutical company developing medicines for haematological diseases; its pipeline includes bitopertin, DISC-0974 and DISC-3405. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT06985147 (phase 2, A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)) and NCT05320198 (phase 1/2, Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syn...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.discmedicine.com/"},{"label":"ClinicalTrials.gov: trials led by Disc Medicine","url":"https://clinicaltrials.gov/search?lead=Disc%20Medicine%2C%20Inc"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["myeloproliferative-neoplasms","mds"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06985147","nct05320198"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Watertown, Massachusetts","country":"US","companyType":"biotech","website":"https://www.discmedicine.com/","ticker":"NASDAQ:IRON","stage":"public","investors":[],"funding":[]},{"id":"discovery-life-sciences","kind":"company","name":"Discovery Life Sciences","aka":[],"tldr":"Discovery Life Sciences is a large commercial biospecimen and biomarker services provider (tissue, blood, cells) for pharma and diagnostics.","summary":"Discovery Life Sciences, based in Huntsville, Alabama, is a large commercial provider of biospecimens and biomarker services, supplying tissue, blood and cells to pharmaceutical and diagnostics companies. It runs a biobank of millions of specimens, a prospective collection network and multi-omic services. OnCo links it to biobanking and tissue procurement. Whether commercially sourced specimens carry the consent, annotation and quality that regulated diagnostics development needs is the standing question for the sector. The biobanking technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.dls.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":["biobanking"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05642780"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Huntsville, AL","country":"US","companyType":"cro-services","website":"https://www.dls.com","investors":[],"funding":[]},{"id":"dizal","kind":"company","name":"Dizal Pharmaceutical","aka":["Dizal Pharmaceuticals","Dizal (Jiangsu) Pharmaceutical Co., Ltd.","迪哲医药"],"tldr":"Dizal is a Shanghai biotechnology company built on small-molecule kinase inhibitors: sunvozertinib for EGFR exon 20 insertion lung cancer and DZD8586, a dual LYN and BTK inhibitor in the phase 3 TAI-SHAN6 trial for relapsed chronic lymphocytic leukaemia.","summary":"Dizal Pharmaceutical, based in Shanghai and listed in Shanghai, designs small-molecule drugs for cancer and immune disease. Its oncology pipeline centres on sunvozertinib, an EGFR inhibitor designed for exon 20 insertion mutations in non-small-cell lung cancer, and DZD8586, an oral inhibitor of LYN and BTK that crosses the blood-brain barrier and is being compared with investigator's choice therapy in relapsed or refractory chronic lymphocytic leukaemia. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.dizalpharma.com/"},{"label":"ClinicalTrials.gov: trials led by Dizal","url":"https://clinicaltrials.gov/search?lead=Dizal"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","cll"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["sunvozertinib","dzd8586","golidocitinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["tai-shan6","nct05668988","nct05712902","nct03974022","nct07079475","nct07059650","nct07070440","nct06295432","nct07328217","nct07496229","nct06276283","nct07154264","nct06539182"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.dizalpharma.com/","stage":"public","investors":[],"funding":[]},{"id":"dnanexus","kind":"company","name":"DNAnexus","aka":[],"tldr":"DNAnexus, of Mountain View, California, runs the secure genomics cloud platform behind the UK Biobank Research Analysis Platform and Genomics England, giving biobanks, drug companies and clinical laboratories a compliant place to store and analyse sequencing data. Whether such trusted environments open data to more researchers without weakening privacy is what those deployments test.","summary":"DNAnexus, based in Mountain View, provides the secure genomics cloud platform behind the UK Biobank Research Analysis Platform and Genomics England's research environment. It offers a compliant data and workflow platform for large biobanks, pharmaceutical companies and clinical laboratories. OnCo links it to genomics cloud and secure research environments. Whether trusted research environments can open large datasets to more researchers without weakening privacy is the question its national deployments test. The genomics cloud technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.dnanexus.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["genomics-cloud-platforms"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Mountain View, CA","country":"US","companyType":"ai-software","website":"https://www.dnanexus.com","investors":[],"funding":[]},{"id":"dong-a-st","kind":"company","name":"Dong-A ST","aka":["Dong-A ST Co., Ltd.","Dong-A Socio Holdings"],"tldr":"Dong-A ST is a Seoul pharmaceutical company, the prescription-medicine arm of one of Korea's oldest drug groups, which sponsors phase 3 cancer trials including biosimilars and supportive-care products.","summary":"Dong-A ST Co., Ltd. was formed in 2013 when the Dong-A group split its prescription business from its consumer arm. It develops and markets prescription medicines in Korea and abroad, including oncology supportive-care products, a pegylated G-CSF and biosimilars developed with partners, and it acts as lead sponsor of phase 3 cancer trials registered on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.donga-st.com"},{"label":"ClinicalTrials.gov: trials led by Dong-A ST Co., Ltd.","url":"https://clinicaltrials.gov/search?lead=Dong-A%20ST%20Co.%2C%20Ltd."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q110114773"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct06293651"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Seoul","country":"KR","companyType":"pharma","website":"https://www.donga-st.com","founded":2013,"stage":"public","investors":[],"funding":[]},{"id":"dr-reddys","kind":"company","name":"Dr. Reddy's Laboratories","aka":[],"tldr":"The Hyderabad generics maker that launched the world's first rituximab biosimilar in 2007 and now sells oncology generics and biosimilars in India, the US and Europe.","summary":"Dr. Reddy's was founded in 1984 by Kallam Anji Reddy and is listed on the NSE, BSE and NYSE. It was an early mover in biosimilars: its rituximab, Reditux, was approved in India in 2007, the first rituximab biosimilar anywhere, and its EU rituximab (Ituxredi) was authorised in September 2024 at a price several times below the reference brand. The company is a major supplier of oncology generics (abiraterone, bortezomib, azacitidine, decitabine and many injectables) to the US and India, and its oncology-focused subsidiary Aurigene runs discovery and clinical programmes. Dr. Reddy's also in-licenses innovative oncology products for India.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Dr._Reddy's_Laboratories","links":[{"label":"Official website","url":"https://www.drreddys.com"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy","chemotherapy"],"technologies":["monoclonal-antibody"],"targets":["cd20"],"drugs":["rituximab","abiraterone","bortezomib","azacitidine"],"companies":["aurigene"],"institutions":[],"pathways":[],"terms":["biosimilar"],"trials":[],"people":[],"bottlenecks":["b-drug-pricing","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Hyderabad","country":"IN","companyType":"pharma","website":"https://www.drreddys.com","ticker":"RDY","founded":1984,"investors":[],"funding":[]},{"id":"dren-bio","kind":"company","name":"Dren Bio","aka":["Dren Bio, Inc."],"tldr":"Dren Bio is a Californian biotech whose bispecific antibodies recruit macrophages to engulf diseased cells; DR-01 directs this against CD94 to clear the cancerous cells of T-cell and natural killer cell lymphomas.","summary":"Dren Bio develops targeted myeloid engagers, bispecific antibodies that bind a disease antigen on one arm and a phagocytic receptor on macrophages with the other, so the target cell is engulfed. DR-01, its first clinical programme, depletes CD94-expressing cytotoxic lymphocytes and is in a phase 1/2 study in large granular lymphocytic leukaemia and cytotoxic lymphomas. Its CD20-directed engager DR-0201 for autoimmune disease was licensed to Sanofi in 2025.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.drenbio.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["dr-01"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Foster City, California","country":"US","companyType":"biotech","website":"https://www.drenbio.com/","investors":[],"funding":[]},{"id":"dualitybio","kind":"company","name":"Duality Biotherapeutics","aka":["DualityBio Inc."],"tldr":"Chinese ADC platform company behind BioNTech's trastuzumab pamirtecan (BNT323/DB-1303) and AI-nominated targets.","summary":"Duality Biotherapeutics, based in Shanghai and listed in Hong Kong as 9606.HK, is the Chinese antibody-drug conjugate platform company behind BioNTech's trastuzumab pamirtecan, also known as BNT323 or DB-1303, and a set of targets nominated with artificial intelligence. DB-1303 targets HER2 and is in a phase 3 in endometrial cancer with BioNTech, DB-1311 targets B7-H3, DB-1329 targets CDCP1, a target identified by AI, and all rest on its DITAC linker-payload platform. OnCo links it to HER2 and B7-H3 as targets. Whether AI-nominated ADC targets outperform the crowded conventional ones is the question DB-1329 will test. The HER2 and B7-H3 target pages carry the field context.","asOf":"2026-09-04","links":[{"label":"Official website (archived copy)","url":"https://web.archive.org/web/20211202003714/http://dualitybiotherapeutics.com/"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":[],"targets":["her2","b7h3"],"drugs":["trastuzumab-pamirtecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05914116","nct07263594","nct06554795","nct05785741","nct06827236","nct05438329","nct05150691","nct06892548","nct06953089"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.dualitybiologics.com","ticker":"9606.HK","investors":[],"funding":[]},{"id":"dpcg","kind":"company","name":"Dutch Pancreatic Cancer Group","aka":["DPCG"],"tldr":"The Dutch Pancreatic Cancer Group is the national Dutch collaboration of pancreatic cancer surgeons, oncologists and researchers that ran PREOPANC, the trial that established neoadjuvant chemoradiotherapy for resectable pancreatic cancer.","summary":"The Dutch Pancreatic Cancer Group (DPCG) is the Dutch multidisciplinary collaboration for pancreatic cancer, with its address at Amsterdam UMC, De Boelelaan 1117-1118, Amsterdam, and contact points at the LUMC in Leiden and Radboudumc in Nijmegen (dpcg.nl). No founding year is stated on the pages read. In OnCo it is the sponsor of PREOPANC-1 and PREOPANC-2 (Netherlands Trial Register NTR3709), the phase 3 trials of preoperative chemoradiotherapy and of neoadjuvant FOLFIRINOX in resectable and borderline resectable pancreatic cancer. It has no products of its own.","asOf":"2026-09-25","links":[{"label":"Official website","url":"https://dpcg.nl"},{"label":"ClinicalTrials.gov: trials led by Dutch Pancreatic Cancer Group","url":"https://clinicaltrials.gov/search?lead=Dutch%20Pancreatic%20Cancer%20Group"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["pancreatic","resectable-pdac","borderline-resectable-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["amsterdam-umc"],"pathways":[],"terms":[],"trials":["preopanc"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"Amsterdam","country":"NL","companyType":"cooperative-group","website":"https://dpcg.nl","investors":[],"funding":[]},{"id":"dysis-medical","kind":"company","name":"DYSIS Medical","aka":[],"tldr":"DYSIS Medical makes a digital colposcope that measures how quickly the cervix whitens after acetic acid and colours a map over the image to point out the areas most likely to hold high-grade precancer.","summary":"The DYSIS colposcope images the cervix continuously after acetic acid and quantifies the acetowhitening kinetics at each point, producing a DYSISmap overlay intended to improve biopsy targeting. It has been assessed in UK health technology guidance and is used in colposcopy clinics in Europe and the United States.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.dysismedical.com/"}],"tags":["machines-wave2"],"related":[],"cancers":["cervical"],"sections":[],"technologies":["colposcopes-digital-cervical-screening","colposcopy-excision"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Edinburgh","country":"GB","companyType":"devices","website":"https://www.dysismedical.com/","stage":"startup","investors":[],"funding":[]},{"id":"echo-immune","kind":"company","name":"Echo Immune","aka":[],"tldr":"Echo Immune is developing personalised mRNA cancer vaccines designed from a patient's own tumour to stop cancer coming back after treatment.","summary":"Echo Immune's stated focus is recurrence: a tumour carries a unique molecular signature, surgery or therapy removes most of it, and the vaccine is meant to teach the immune system to recognise what is left. The company makes personalised mRNA cancer vaccines for the individual patient, the approach that BioNTech and Moderna have taken into phase 3 in melanoma. It is an Even One Ventures portfolio company and has not published trials.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.echoimmune.com/"},{"label":"Even One Ventures portfolio","url":"https://evenone.ventures/"}],"tags":["startup","evenone-portfolio","oncology"],"related":[],"cancers":[],"sections":[],"technologies":["neoantigen-mrna-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"United States (head office not published)","country":"US","companyType":"biotech","website":"https://www.echoimmune.com/","stage":"startup","investors":["evenone-ventures"],"funding":[]},{"id":"eckert-ziegler","kind":"company","name":"Eckert & Ziegler","aka":[],"tldr":"German isotope and radiopharmaceutical services company supplying Lu-177, Ga-68 generators, Ac-225 development, and contract manufacturing.","summary":"Eckert and Ziegler, based in Berlin and listed as EUZ.DE, is a German isotope and radiopharmaceutical services company supplying lutetium-177, gallium-68 generators, actinium-225 development and contract manufacturing. It makes the GalliaPharm gallium-68 generator and non-carrier-added lutetium-177, sold as Theralugand, runs actinium-225 production projects and offers CDMO services to radioligand developers. OnCo links it to the therapeutic isotope supply chain, radiopharmacy and cyclotron networks and radionuclide generators and cold kits. Whether generator-based gallium-68 keeps its place as cyclotron production and fluorine-18 tracers spread is the open question. The isotope supply chain page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.ezag.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["radiopharma"],"technologies":["therapy-isotope-supply-chain","radiopharmacy-network"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Berlin","country":"DE","companyType":"radiopharma","website":"https://www.ezag.com","ticker":"EUZ.DE","investors":[],"funding":[]},{"id":"ecog-acrin","kind":"company","name":"ECOG-ACRIN Cancer Research Group","aka":["ECOG-ACRIN","Eastern Cooperative Oncology Group","ECOG","American College of Radiology Imaging Network","ACRIN"],"tldr":"US cooperative group that pairs a therapy group with an imaging group; its E1910 trial moved blinatumomab into frontline leukaemia treatment.","summary":"Merger (2012) of the Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network. E1910 showed adding blinatumomab consolidation improves survival in MRD-negative B-ALL, leading to the 2024 label. Also runs TMIST (tomosynthesis vs digital mammography screening) and the ECOG performance status scale.","asOf":"2026-09-06","links":[{"label":"Official website","url":"https://ecog-acrin.org"}],"tags":["cooperative-group"],"related":["blinatumomab"],"cancers":["all-leukemia"],"sections":[],"technologies":["mammography"],"targets":[],"drugs":[],"companies":[],"institutions":["nci","montefiore-einstein","uw-carbone"],"pathways":[],"terms":[],"trials":[],"people":["peter-odwyer","mitchell-schnall"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["NCTN cooperative group","E1910 blinatumomab","TMIST screening trial","Imaging biomarker trials"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Philadelphia, PA","country":"US","companyType":"cooperative-group","website":"https://ecog-acrin.org","founded":2012,"investors":[],"funding":[]},{"id":"ecor1-capital","kind":"company","name":"EcoR1 Capital","aka":[],"tldr":"EcoR1 Capital is a San Francisco investment fund that only invests in biotech, from private rounds to listed companies, and often leads the crossover financings of cancer drug developers.","summary":"EcoR1 Capital is a biotech-focused investment firm based in San Francisco, founded in 2013 by Oleg Nodelman, investing across private and public companies with a long holding period and a scientific due diligence model. It is a frequent lead or co-lead in crossover rounds and follow-on offerings for clinical-stage oncology companies. Portfolio links in OnCo are derived from the startup records that name it.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.ecor1cap.com"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"investor","website":"https://www.ecor1cap.com","founded":2013,"investors":[],"funding":[]},{"id":"eikon-therapeutics","kind":"company","name":"Eikon Therapeutics","aka":[],"tldr":"Eikon Therapeutics is a United States-based biotechnology company running 6 late-stage cancer trials of EIK1001, EIK1004-001 (IMP1707-001) and IMP1734 in melanoma, non-small-cell lung cancer and gastric & gastro-oesophageal junction cancer.","summary":"Eikon Therapeutics, based in Millbrae, California, the United States, is a biotechnology company. A drug discovery company that also has offices in New York and Jersey City and lists clinical-stage oncology, immunology and neuroscience programmes on its pipeline page, including TLR7/8, PARP1, PARP1-CNS penetrant, AR, VCP and AR-v7 targeted programmes. On ClinicalTrials.gov it is the lead sponsor of 6 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing EIK1001, EIK1004-001 (IMP1707-001), IMP1734 and EIK1005 in melanoma, non-small-cell lung cancer, gastric & gastro-oesophageal junction cancer, colorectal cancer and endometrial cancer. The largest, NCT07365319 (A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer), plans to enrol 750 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.eikontx.com"},{"label":"ClinicalTrials.gov: trials led by Eikon Therapeutics","url":"https://clinicaltrials.gov/search?lead=Eikon%20Therapeutics"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma","nsclc","gastric","colorectal","endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":["eik1001","eik1005","imp1734"],"companies":["lux-capital"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06246110","nct06907043"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Millbrae, California","country":"US","companyType":"biotech","website":"https://www.eikontx.com","investors":[],"funding":[]},{"id":"eisai","kind":"company","name":"Eisai","aka":[],"tldr":"Japanese pharma that makes lenvatinib (Lenvima), a first-line option in liver cancer and a partner of pembrolizumab in several tumours.","summary":"Eisai is the Tokyo-based pharmaceutical company, listed as 4523.T, that makes lenvatinib, sold as Lenvima, a first-line option in liver cancer and a partner of pembrolizumab in several tumours. Lenvatinib is approved in hepatocellular carcinoma on the REFLECT trial, in thyroid cancer, in renal cell carcinoma with everolimus or pembrolizumab, and in endometrial cancer with pembrolizumab, and Eisai co-develops the LEAP programme of lenvatinib plus pembrolizumab with Merck, in which LEAP-002 in first-line liver cancer and LEAP-012 with TACE both missed their overall survival endpoints. OnCo also links it to eribulin, palonosetron and denileukin diftitox, and to salivary gland cancers and thymic tumours. Whether the LEAP combination has further indications left after two negative liver trials is the open question. Lenvatinib has its own page.","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Eisai_(company)","links":[{"label":"Official website","url":"https://www.eisai.com"}],"tags":[],"related":[],"cancers":["hcc","thyroid","rcc","endometrial"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["lenvatinib","farletuzumab-ecteribulin","alitretinoin","pilocarpine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04008797","nct04078295","nct04586231","nct05899049"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tokyo","country":"JP","companyType":"pharma","website":"https://www.eisai.com","ticker":"4523.T","investors":[],"funding":[]},{"id":"elekta","kind":"company","name":"Elekta","aka":[],"tldr":"Elekta is the Swedish radiotherapy company behind Unity, the leading MR-linac, and Gamma Knife.","summary":"Elekta, based in Stockholm and listed as EKTA-B.ST, is the Swedish radiotherapy company behind Unity, the leading MR-linac, and Gamma Knife. Its products include the Unity MR-linac for MR-guided adaptive radiotherapy, Gamma Knife Esprit for stereotactic radiosurgery, the Harmony linac and brachytherapy systems. OnCo links it to MR-guided adaptive radiotherapy and stereotactic radiotherapy, to treatment planning and quality assurance software, to the Leeds, Sunnybrook and UMC Utrecht cancer centres, and to ideas such as coverage-with-evidence registries for MR-guided radiotherapy and an open-hardware radiotherapy machine built for unreliable power and dust. Surgery and radiotherapy curing most patients while receiving least funding is the bottleneck it bears on. Whether MR guidance improves outcomes enough to justify its cost is the open question the registries are meant to answer.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Elekta","links":[{"label":"Official website","url":"https://www.elekta.com"}],"tags":[],"related":[],"cancers":[],"sections":["radiation"],"technologies":["mr-linac","sbrt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Stockholm","country":"SE","companyType":"devices","website":"https://www.elekta.com","ticker":"EKTA-B.ST","investors":[],"funding":[]},{"id":"element-biosciences","kind":"company","name":"Element Biosciences","aka":[],"tldr":"AVITI benchtop sequencer with avidity chemistry, competing on accuracy and cost with mid-throughput Illumina systems.","summary":"Element Biosciences, based in San Diego, makes the AVITI benchtop sequencer, which uses avidity chemistry to compete on accuracy and cost with mid-throughput Illumina systems. AVITI and AVITI24, which runs multiomics on a single instrument, were launched between 2022 and 2024. OnCo links it to new short-read sequencing platforms. Whether a benchtop challenger can win clinical laboratories away from the incumbent when assays are validated on Illumina is the open question. The short-read platforms page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.elementbiosciences.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["next-gen-short-read-platforms"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Diego, CA","country":"US","companyType":"diagnostics","website":"https://www.elementbiosciences.com","investors":[],"funding":[]},{"id":"elevar-therapeutics","kind":"company","name":"Elevar Therapeutics (HLB)","aka":[],"tldr":"Elevar Therapeutics developed rivoceranib, whose combination with camrelizumab has beaten sorafenib in liver cancer but has been refused by the FDA three times on manufacturing grounds.","summary":"Elevar Therapeutics is a subsidiary of Korea's HLB. CARES-310 showed median OS 23.8 vs 15.2 months versus sorafenib. The FDA issued complete response letters in 2024, 2025 and again at the 23 July 2026 PDUFA date, each citing cGMP inspection findings at the partner manufacturing site rather than efficacy or safety.","asOf":"2026-09-07","links":[{"label":"Targeted Oncology: third CRL","url":"https://www.targetedonc.com/view/fda-passes-again-on-approving-rivoceranib-plus-camrelizumab-in-hcc"}],"tags":[],"related":["src-targeted-oncology"],"cancers":["hcc"],"sections":["targeted-therapy","immunotherapy"],"technologies":[],"targets":[],"drugs":["camrelizumab-rivoceranib","lirafugratinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07359820"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Fort Lee, NJ","country":"US","companyType":"biotech","website":"https://elevartherapeutics.com","investors":[],"funding":[]},{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","aka":[],"tldr":"Eli Lilly makes Verzenio and Retevmo, as well as the oral SERD imlunestrant and the BTK inhibitor pirtobrutinib.","summary":"Eli Lilly, based in Indianapolis and listed as LLY, makes Verzenio and Retevmo, the oral SERD imlunestrant and the BTK inhibitor pirtobrutinib, and its oncology unit includes Loxo Oncology. The portfolio spans abemaciclib, selpercatinib, imlunestrant, sold as Inluriyo from 2025, pirtobrutinib, olomorasib against KRAS G12C, a PI3K-alpha mutant-selective programme from Scorpion, and older products including cetuximab, gemcitabine and necitumumab. OnCo links it to the monarchE paper on two years of adjuvant abemaciclib, to CLEAR in kidney cancer, to GLP-1 receptor agonists and obesity-related cancer risk, to ideas for trials of GLP-1 drugs with cancer as the primary outcome, and to partners including Isomorphic Labs and Innovent. Whether Lilly's GLP-1 franchise becomes an oncology story is the question its idea links raise. Abemaciclib and selpercatinib have their own pages.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.lilly.com"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy","hormonal"],"technologies":[],"targets":[],"drugs":["abemaciclib","selpercatinib","tersolisib","vepugratinib","sofetabart-mipitecan","olaratumab","merestinib","pemetrexed","vincristine","vinblastine","vindesine"],"companies":["emergence-therapeutics","kelonia-therapeutics","mablink-bioscience","point-biopharma","scorpion-therapeutics","lilly-ventures"],"institutions":[],"pathways":[],"terms":[],"trials":["nct02152631","nct02411448","nct03706365","nct03157128","nct07162181","nct04280081","nct03899792","nct04956640","nct05768139","nct06413706","nct01594723","nct05440786","nct02763566","nct05999994","nct06119581","nct07169851","nct06588478","nct02107703","nct05023980","nct07287098","nct05254743","nct02747004","nct04965493","nct05288166","nct05514054","nct04623541","nct04662255","nct04819100","nct06890598"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Indianapolis, IN","country":"US","companyType":"pharma","website":"https://www.lilly.com","ticker":"LLY","investors":[],"funding":[]},{"id":"elicio-therapeutics","kind":"company","name":"Elicio Therapeutics","aka":[],"tldr":"Small biotech developing lymph-node-targeted KRAS vaccines for pancreatic and colorectal cancer.","summary":"Elicio Therapeutics, based in Boston and listed as ELTX, is a small biotechnology company developing lymph-node-targeted vaccines against mutant KRAS for pancreatic and colorectal cancer. Its lead candidate, ELI-002 7P, is an amphiphile vaccine designed to carry mutant KRAS peptides to lymph nodes, and the AMPLIFY-7P phase 2 trial missed its primary endpoint in June 2026, after which the company said its phase 3 strategy was being refined. OnCo links it to pancreatic ductal adenocarcinoma and to the bottleneck of undruggable drivers, since KRAS vaccination is one route around the difficulty of inhibiting the protein directly. Whether a shared-antigen KRAS vaccine can succeed in a phase 3 where the phase 2 did not is the open question. ELI-002 7P has its own page.","asOf":"2026-09-06","links":[{"label":"Official website","url":"https://elicio.com"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["eli-002-7p"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://elicio.com","ticker":"ELTX","investors":[],"funding":[]},{"id":"ellipses-pharma","kind":"company","name":"Ellipses Pharma","aka":[],"tldr":"Ellipses Pharma is a United Kingdom-based biotechnology company running 3 late-stage cancer trials of EP0031, EP0042 and Azacitidine (AZA) in non-small-cell lung cancer, acute myeloid leukaemia and myelodysplastic syndromes / neoplasms.","summary":"Ellipses Pharma, based in London, the United Kingdom, is a biotechnology company. Ellipses Pharma is a London-based drug development company that advances a portfolio of in-licensed oncology drug candidates through clinical trials. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials, testing EP0031, EP0042, Azacitidine (AZA) and EP0062 in non-small-cell lung cancer, acute myeloid leukaemia, myelodysplastic syndromes / neoplasms and HR-positive / HER2-negative breast cancer. The largest, NCT05443126 (A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies), plans to enrol 265 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.ellipses.life"},{"label":"ClinicalTrials.gov: trials led by Ellipses Pharma","url":"https://clinicaltrials.gov/search?lead=Ellipses%20Pharma"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","aml","mds","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["ep0031","ep0062"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04581512","nct05443126","nct05573126"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"London","country":"GB","companyType":"biotech","website":"https://www.ellipses.life","stage":"growth","investors":[],"funding":[]},{"id":"elpiscience-suzhou-biopharma","kind":"company","name":"Elpiscience (Suzhou) Biopharma","aka":["Elpiscience (Suzhou) Biopharma, Ltd.","Elpiscience Biopharma, Ltd."],"tldr":"Elpiscience (Suzhou) Biopharma is a China-based biotechnology company running 2 late-stage cancer trials of ES014 and ES102 in desmoid tumour and non-small-cell lung cancer.","summary":"Elpiscience (Suzhou) Biopharma, based in Suzhou, China, is a biotechnology company. Elpiscience is a biopharmaceutical company developing immunotherapies for oncology and autoimmune disease. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing ES014 and ES102 in desmoid tumour and non-small-cell lung cancer. The largest, NCT07541430 (A Study in Adults With Desmoid Tumours), plans to enrol 50 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.elpiscience.com"},{"label":"ClinicalTrials.gov: trials led by Elpiscience (Suzhou) Biopharma","url":"https://clinicaltrials.gov/search?lead=Elpiscience%20(Suzhou)%20Biopharma%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["desmoid-tumour","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07541430","nct06623136"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Suzhou","country":"CN","companyType":"biotech","website":"https://www.elpiscience.com","investors":[],"funding":[]},{"id":"elucidate-bio","kind":"company","name":"Elucidate Bio","aka":[],"tldr":"Spatial multi-omics service that images DNA, RNA, and protein from the same tissue slide to predict therapeutic response.","summary":"Elucidate Bio, based in Boston, is a spatial multi-omics service that images DNA, RNA and protein from the same tissue slide to predict therapeutic response. It profiles more than eighteen thousand transcripts and forty to sixty protein markers on formalin-fixed sections with full spatial context, offering analytics for trial endpoints and response prediction, and it was founded and is led by Will Singleterry. OnCo links it to single-cell and spatial profiling and to proteomics and phosphoproteomics. Whether spatial multi-omics readouts can be validated as trial endpoints, rather than remaining exploratory, is the open question. The spatial profiling technology page carries the wider field.","asOf":"2026-09-04","links":[{"label":"Products and services","url":"https://elucidatebio.com/products-and-services/"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics","drug-discovery"],"technologies":["single-cell-spatial","proteomics"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boston, MA","country":"US","companyType":"diagnostics","website":"https://elucidatebio.com","investors":[],"funding":[]},{"id":"elypta","kind":"company","name":"Elypta","aka":[],"tldr":"Elypta, of Stockholm, measures glycosaminoglycans, sugar molecules in blood and urine, and scores them with machine learning to detect kidney cancer returning after surgery; a second programme tests whether the same signature can flag any cancer early in symptom-free adults. Only interim data support the screening use.","summary":"Elypta, based in Solna, Stockholm, has developed a metabolism-based liquid biopsy that profiles the glycosaminoglycan (GAG) composition of blood and urine (the GAGome), using its MIRAM kit and machine-learning scores to detect cancer-specific signatures; the company is ISO 13485 certified. Its first application is recurrence monitoring after kidney cancer surgery: the AURORAX programme, described as the largest such study, reached study end in May 2025. A second programme applies GAGome scores to multi-cancer early detection in asymptomatic adults, with interim data suggesting urine GAGs may predict risk of any cancer. Funding includes a EUR 2.35 million Horizon 2020 grant (2019), a EUR 6.1 million late seed led by Industrifonden (2020), a $21 million Series A led by Bonnier Ventures (2022) and a $1 million Roddenberry prize (2023).","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.elypta.com/"},{"label":"Series A press release (Jun 2022)","url":"https://www.elypta.com/news/elypta-raises-21-million-series-a-to-develop-metabolism-based-multi-cancer-early-detection-test"},{"label":"News page","url":"https://www.elypta.com/news"}],"tags":[],"related":[],"cancers":["rcc"],"sections":["early-detection","diagnostics"],"technologies":["liquid-biopsy","mced"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated (earliest news item is July 2017). The Horizon 2020 grant and Roddenberry prize are described on the news listing page but not recorded as rounds because their individual pages were not fetched."],"hq":"Stockholm","country":"SE","companyType":"diagnostics","website":"https://www.elypta.com/","stage":"startup","investors":[],"funding":[{"round":"Seed","year":2020,"source":"https://www.elypta.com/news","note":"EUR 6.1 million late seed round led by Industrifonden, January 2020 (as listed on the company news page)."},{"round":"Series A","year":2022,"amountUsd":21000000,"source":"https://www.elypta.com/news/elypta-raises-21-million-series-a-to-develop-metabolism-based-multi-cancer-early-detection-test","note":"Led by Bonnier Ventures, June 2022."}]},{"id":"emergence-therapeutics","kind":"company","name":"Emergence Therapeutics","aka":[],"tldr":"Emergence Therapeutics was a German start-up making an antibody that carries a cancer-killing drug to a protein called Nectin-4, which is found on most bladder cancers. Eli Lilly bought the company in 2023.","summary":"Emergence Therapeutics was a Duisburg, Germany based antibody-drug conjugate developer whose lead candidate, ETx-22, targets Nectin-4, a surface protein overexpressed in most urothelial (bladder) cancers and the target of the approved ADC enfortumab vedotin (Padcev). The company was founded with Heidelberg Pharma as a founding investor. In June 2023 Eli Lilly agreed to acquire all shares of Emergence; terms were not disclosed, although Heidelberg Pharma stated it would receive USD 7 million for its stake. The acquisition formed part of Lilly's renewed push into ADCs alongside its Mablink Bioscience purchase later that year. The former company domain now redirects to lilly.com.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.lilly.com/"},{"label":"BioPharma Dive: Lilly to acquire Emergence","url":"https://www.biopharmadive.com/news/lilly-acquire-emergence-adc-cancer-drugs/654326/"}],"tags":[],"related":["src-biopharma-dive"],"cancers":["urothelial"],"sections":["adcs"],"technologies":["adc"],"targets":["nectin4"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website is offline; emergencetx.com redirects to lilly.com, which is what the website field records. Earlier venture financing (reported elsewhere as a Series A in 2022) could not be sourced from a fetched primary page and is omitted. Development stage of ETx-22 at acquisition not stated in the fetched source."],"hq":"Duisburg","country":"DE","companyType":"biotech","website":"https://www.lilly.com/","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2023,"source":"https://heidelberg-pharma.com/en/press-investors/announcements/press-releases-and-ad-hoc-announcements/ah-heidelberg-pharma-sells-minority-shareholding-in-emergence-therapeutics","note":"Deal terms not disclosed; founding investor Heidelberg Pharma expected about USD 7 million for its stake plus up to USD 5 million in milestones"}],"acquiredBy":"eli-lilly"},{"id":"emergent-biosolutions","kind":"company","name":"Emergent BioSolutions","aka":["Emergent BioSolutions Inc.","Trubion Pharmaceuticals"],"tldr":"Emergent is a Maryland vaccines and biodefence company whose brief oncology venture, the anti-CD37 protein otlertuzumab inherited from Trubion, reached late trials in chronic lymphocytic leukaemia before being shelved.","summary":"Emergent BioSolutions, founded in 1998 and headquartered in Gaithersburg, Maryland, makes vaccines and countermeasures for public health threats and the overdose antidote Narcan. Through its 2010 acquisition of Trubion Pharmaceuticals it briefly developed otlertuzumab (TRU-016), a CD37-directed protein therapeutic tested in chronic lymphocytic leukaemia, later spun out. ClinicalTrials.gov lists Emergent as lead sponsor of a phase 3 trial in a cancer setting.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Emergent_BioSolutions","links":[{"label":"Official website","url":"https://www.emergentbiosolutions.com"},{"label":"ClinicalTrials.gov: trials led by Emergent BioSolutions Inc.","url":"https://clinicaltrials.gov/search?lead=Emergent%20BioSolutions%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q5370757"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cll"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Gaithersburg, MD","country":"US","companyType":"pharma","website":"https://www.emergentbiosolutions.com","founded":1998,"stage":"public","investors":[],"funding":[]},{"id":"empyrean-medical-systems","kind":"company","name":"Empyrean Medical Systems","aka":[],"tldr":"Empyrean Medical Systems, of Florida, develops radiotherapy machines that use magnetic fields to shape high-energy electron beams, an MD Anderson approach designed for both conventional and FLASH dose rates, plus Vektra, a robotic arm for delivering radiation during surgery. None of its patient-treatment devices is yet cleared for sale.","summary":"Empyrean Medical Systems develops radiotherapy devices built around MOVHEET, an approach from MD Anderson Cancer Center researchers that uses magnetic fields to sculpt high-energy electron beams and is designed for both conventional and FLASH dose rates. In 2022 the company acquired Vektra, a robotically assisted 50 to 120 kV platform for brachytherapy and intraoperative radiotherapy described as FLASH capable; it is not for sale and is pending FDA 510(k) clearance. Its first shipped product, Artemis 320, is a preclinical cabinet x-ray irradiator intended to replace caesium irradiators, with a first US installation announced in June 2026. In January 2026 Hamilton Reserve Bank took an equity stake and agreed to arrange a credit line of up to USD 20 million; the release states MD Anderson owns 15 percent and Mayo Clinic is also a shareholder.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://empyreanmed.com/"},{"label":"Hamilton Reserve Bank strategic financing (Jan 2026)","url":"https://www.prnewswire.com/news-releases/empyrean-medical-systems-secures-strategic-financing-from-hamilton-reserve-bank-advances-radiation-oncology-innovation-302654320.html"},{"label":"First Artemis 320 installation (June 2026)","url":"https://www.prnewswire.com/news-releases/a-milestone-for-empyrean-medical-systemsfirst-artemis-320-installation-302813464.html"},{"label":"Vektra product page","url":"https://empyreanmed.com/vektra/"}],"tags":[],"related":[],"cancers":[],"sections":["radiation","devices"],"technologies":["flash-rt","brachytherapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The domain empyreanmedicalsystems.com does not resolve; the company's live site is empyreanmed.com (as given in its press releases). Equity amount from Hamilton Reserve Bank was not disclosed and the USD 20 million credit line was 'to be arranged', so no amountUsd is recorded. Founding year and any venture rounds are unsourced. No clinical device has FDA clearance as of the fetched pages."],"hq":"Boca Raton, FL","country":"US","companyType":"devices","website":"https://empyreanmed.com/","stage":"startup","investors":[],"funding":[{"round":"Debt","year":2026,"source":"https://www.prnewswire.com/news-releases/empyrean-medical-systems-secures-strategic-financing-from-hamilton-reserve-bank-advances-radiation-oncology-innovation-302654320.html","note":"Hamilton Reserve Bank made an equity investment of undisclosed size and agreed to arrange a credit line of up to USD 20 million to support 2026 product sales"}]},{"id":"enb-therapeutics","kind":"company","name":"ENB Therapeutics","aka":["ENB Therapeutics, Inc."],"tldr":"ENB Therapeutics is a New York biotech that blocks the endothelin B receptor, a switch tumours use to shut out immune cells, so that checkpoint inhibitors work in melanoma and other cancers that had stopped responding.","summary":"ENB Therapeutics develops ENB-003, a selective endothelin B receptor antagonist. Endothelin B signalling in the tumour vasculature and on tumour cells blocks T-cell infiltration and supports immune evasion; ENB-003 is designed to reverse this. It has been tested with pembrolizumab in a phase 1/2 study in advanced melanoma, ovarian cancer and other solid tumours that had progressed on checkpoint inhibitors.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["enb003"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"New York, New York","country":"US","companyType":"biotech","investors":[],"funding":[]},{"id":"endo","kind":"company","name":"Endo (now Keenova Therapeutics and Par Health)","aka":["Endo International plc","Endo Pharmaceuticals","Endo USA Inc., a Keenova Therapeutics Company","Endo USA Inc.","Keenova Therapeutics","Par Pharmaceutical, Inc.","Par Pharmaceutical","Par Health"],"tldr":"Endo was a specialty and generics pharmaceutical company, one of the busiest industry sponsors of phase 3 cancer trials on ClinicalTrials.gov; after merging with Mallinckrodt it became Keenova Therapeutics, with its generics arm spun off as Par Health.","summary":"Endo International plc, an Irish-registered pharmaceutical company formed from Endo Pharmaceuticals in 1997, marketed specialty medicines and, through Par Pharmaceutical, generics and sterile injectables, including cancer supportive-care and chemotherapy products. Its own site records that Mallinckrodt and Endo merged, that the combined company spun off the generics and sterile injectables business as Par Health, and that the specialty company was renamed Keenova Therapeutics in November 2025. ClinicalTrials.gov lists Endo USA and Par Pharmaceutical as lead sponsors of phase 3 cancer trials. Endo Pharmaceuticals relaunched Valstar (valrubicin), the intravesical anthracycline for BCG-refractory bladder carcinoma in situ, in 2009, and its registered phase 3 cancer trials include valrubicin maintenance in non-muscle-invasive bladder cancer (NCT01310803, NCT01316874) and the Vantas histrelin implant against goserelin in prostate cancer (NCT01394263); Par ran phase 3 trials of megestrol acetate suspension for cancer-related anorexia and cachexia (NCT00637728, NCT00637806).","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Endo_International","links":[{"label":"Official website","url":"https://www.endo.com"},{"label":"ClinicalTrials.gov: trials led by Endo International plc","url":"https://clinicaltrials.gov/search?lead=Endo%20International%20plc"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q5376211"},{"label":"Wikipedia: valrubicin (Valstar)","url":"https://en.wikipedia.org/wiki/Valrubicin"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["urothelial","prostate"],"sections":[],"technologies":["bcg-and-intravesical-therapy"],"targets":[],"drugs":["valrubicin","histrelin","megestrol"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Ireland","country":"IE","companyType":"pharma","website":"https://www.endo.com","founded":1997,"stage":"public","investors":[],"funding":[]},{"id":"engeneic","kind":"company","name":"EnGeneIC","aka":["EnGeneIC Ltd"],"tldr":"EnGeneIC is an Australian biotech that loads bacterially derived nanocells with chemotherapy and steers them to tumours with antibodies; E-EDV-D682 carries a super-cytotoxic payload to EGFR-expressing cancers.","summary":"EnGeneIC developed the EnGeneIC Dream Vector (EDV), a 400-nanometre bacterially derived minicell that is packed with a drug and coated with a bispecific antibody so it binds a tumour antigen and is taken up by the cancer cell. The EDVs also stimulate innate immunity. E-EDV-D682 targets EGFR and carries the PNU-159682 payload; it is being tested in pancreatic cancer and other advanced solid tumours, in some studies with immunomodulatory EDVs.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.engeneic.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["e-edv-d682"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Sydney","country":"AU","companyType":"biotech","website":"https://www.engeneic.com/","founded":2001,"investors":[],"funding":[]},{"id":"enlaza-therapeutics","kind":"company","name":"Enlaza Therapeutics","aka":[],"tldr":"Enlaza Therapeutics engineers protein drugs that lock permanently onto their target once they find it, which could let antibody-based cancer medicines work at lower doses with fewer side effects. Its programmes are still in laboratory development.","summary":"Enlaza Therapeutics (La Jolla, California) is building the first covalent biologic platform. Its War-Lock technology introduces proprietary unnatural amino acids into protein therapeutics so that they bind irreversibly to disease-relevant targets while remaining latent until target engagement, with the aim of improving efficacy and reducing toxicity for antibody-drug conjugates, T-cell engagers and other protein drugs, initially in oncology. The pipeline is preclinical and undisclosed. The company launched in December 2022 with USD 61 million in seed financing led by Avalon Ventures and raised a USD 100 million Series A in April 2024 led by the Life Sciences group of J.P. Morgan Private Capital, with Amgen Ventures and Regeneron Ventures among new investors. In September 2025 it announced a strategic collaboration with Vertex Pharmaceuticals to develop War-Lock drug conjugates and T-cell engagers for conditioning and certain autoimmune diseases.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://enlazatx.com/"},{"label":"Seed financing release","url":"https://enlazatx.com/press_release/enlaza-therapeutics-launches-with-61-million-financing-to-advance-the-first-covalent-biologic-therapeutic-platform/"},{"label":"Series A press release","url":"https://enlazatx.com/press_release/enlaza-therapeutics-raises-100-million-through-its-series-a-financing-led-by-the-life-sciences-group-of-j-p-morgan-private-capital/"}],"tags":[],"related":[],"cancers":[],"sections":["adcs","drug-discovery"],"technologies":["adc","t-cell-engager","site-specific-conjugation"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The website blocks scripted curl requests (Cloudflare) but was fetched via WebFetch; press release pages fetched directly. The Vertex collaboration is outside oncology."],"hq":"La Jolla, CA","country":"US","companyType":"biotech","website":"https://enlazatx.com/","stage":"startup","investors":["frazier-life-sciences","lightspeed-venture-partners","samsara-biocapital","amgen-ventures","alexandria-venture-investments"],"funding":[{"round":"Seed","year":2022,"amountUsd":61000000,"source":"https://enlazatx.com/press_release/enlaza-therapeutics-launches-with-61-million-financing-to-advance-the-first-covalent-biologic-therapeutic-platform/","note":"Led by Avalon Ventures"},{"round":"Series A","year":2024,"amountUsd":100000000,"source":"https://enlazatx.com/press_release/enlaza-therapeutics-raises-100-million-through-its-series-a-financing-led-by-the-life-sciences-group-of-j-p-morgan-private-capital/","note":"Led by the Life Sciences group of J.P. Morgan Private Capital"}]},{"id":"enliven-therapeutics","kind":"company","name":"Enliven Therapeutics","aka":[],"tldr":"Enliven Therapeutics designs cleaner versions of cancer pills that already work. Its lead drug targets the BCR-ABL protein in chronic myeloid leukaemia and a second drug targets mutated HER2 in lung cancer.","summary":"Enliven Therapeutics is a Boulder, Colorado clinical-stage precision oncology company developing next-generation small molecule kinase inhibitors intended to improve tolerability, combinability and resistance coverage. ELVN-001 is a potent, highly selective BCR-ABL inhibitor that binds a distinctive folded-in P-loop conformation of ABL1 and is in clinical development for chronic myeloid leukaemia (CML). ELVN-002 is a selective, irreversible HER2 inhibitor with activity against HER2 mutations including exon 20 insertions in non-small cell lung cancer, in phase 1. Enliven became a Nasdaq company in February 2023 by merging with Imara Inc., closing a concurrent 165 million US dollar private placement co-led by Fairmount and Venrock Healthcare Capital Partners; shares trade as ELVN.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.enliventherapeutics.com/"},{"label":"Pipeline","url":"https://www.enliventherapeutics.com/pipeline/"},{"label":"Merger closing and private placement (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/d464771dex991.htm"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["her2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Chronic myeloid leukaemia has no id in the cancer list so is not tagged. Pre-merger venture rounds and founding year not sourced."],"hq":"Boulder, CO","country":"US","companyType":"biotech","website":"https://www.enliventherapeutics.com/","ticker":"ELVN","stage":"public","investors":["venrock","ra-capital","frazier-life-sciences"],"funding":[{"round":"Crossover","year":2023,"amountUsd":165000000,"source":"https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/d464771dex991.htm","note":"165 million US dollar private placement closed concurrently with the reverse merger into Imara (Nasdaq: ELVN) on 23 February 2023"}]},{"id":"curie-nki-eortc","kind":"company","name":"EORTC","aka":["European Organisation for Research and Treatment of Cancer","European Organisation for Research and Treatment of Cancer - EORTC"],"tldr":"EORTC is Europe's academic cancer trials organisation and has run practice-changing trials since 1962.","summary":"EORTC, the European Organisation for Research and Treatment of Cancer in Brussels, is Europe's academic cancer trials organisation and has run practice-changing trials since 1962. Its record includes the sarcoma hyperthermia trial 62961, the melanoma adjuvant trial 1325, the glioma trial 26951 and Stupp's 2005 trial that added temozolomide to radiotherapy for glioblastoma, together with the QLQ-C30 quality of life instruments, with Alexander Eggermont, Denis Lacombe, Michael Weller and Roger Stupp among the people OnCo lists. It is linked to bottlenecks on rare cancers without markets and undervalued quality of life, and to ideas such as mutual recognition of ethics review across countries. How an academic group sustains phase 3 trials that no company will pay for is the standing question. Its trial and quality of life programmes are listed in the notes.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/European_Organisation_for_Research_and_Treatment_of_Cancer","links":[{"label":"Official website","url":"https://www.eortc.org"}],"tags":["cooperative-group"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["catnon","slotman-pci-es-sclc","eortc-22033","eortc-22922","eortc-26951"],"people":["alexander-eggermont","denis-lacombe","michael-weller","roger-stupp"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Academic phase 3 trials","Quality of life research"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Brussels","country":"BE","companyType":"cooperative-group","website":"https://www.eortc.org","founded":1962,"investors":[],"funding":[]},{"id":"epic-systems","kind":"company","name":"Epic Systems","aka":[],"tldr":"Epic Systems is the dominant US hospital EHR; its Beacon oncology module handles chemotherapy ordering and Cosmos aggregates de-identified records for research.","summary":"Epic Systems, based in Verona, Wisconsin, is the dominant US hospital electronic health record; its Beacon oncology module handles chemotherapy ordering and treatment plans, and its Cosmos dataset aggregates de-identified records from more than 250 million patients for research. It is adding generative AI features across its products. OnCo links it to oncology EHR modules and treatment pathways and to oncology EHR and real-world data platforms. Whether Cosmos becomes a research resource open to independent investigators, rather than only to Epic customers, is the question its scale raises. The oncology EHR page carries the wider picture.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Epic_Systems","links":[{"label":"Official website","url":"https://www.epic.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["hospital-information-systems-oncology","oncology-real-world-data"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Verona, WI","country":"US","companyType":"ai-software","website":"https://www.epic.com","investors":[],"funding":[]},{"id":"epicentrx","kind":"company","name":"EpicentRx","aka":["EpicentRx, Inc."],"tldr":"EpicentRx is a United States-based biotechnology company running 3 late-stage cancer trials in sarcomas, head and neck squamous cell carcinoma and small-cell lung cancer.","summary":"EpicentRx, based in La Jolla, the United States, is a biotechnology company. EpicentRx is a clinical-stage company developing therapies for inflammatory diseases and supportive care conditions, including an oncolytic virus immunotherapy and a small molecule for treatment-related toxicities. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3) in sarcomas, head and neck squamous cell carcinoma, small-cell lung cancer and non-small-cell lung cancer. The largest, NCT05566041 (A Phase 3, Controlled, Open-label, Global Randomised Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer), plans to enrol 292 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.epicentrx.com"},{"label":"ClinicalTrials.gov: trials led by EpicentRx","url":"https://clinicaltrials.gov/search?lead=EpicentRx%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["sarcoma","head-and-neck","sclc","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05966194","nct05566041","nct04673942"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"La Jolla","country":"US","companyType":"biotech","website":"https://www.epicentrx.com","investors":[],"funding":[]},{"id":"epistamai-biotech","kind":"company","name":"Epistamai Biotech","aka":[],"tldr":"Epistamai Biotech is a UK concierge navigation service focused on maximal diagnostics and precision therapeutics for cancer patients.","summary":"Epistamai Biotech, based in Norwich, offers concierge navigation for cancer patients centred on exhaustive diagnostics and precision therapeutics. Patient-accessible.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://epistamaibio.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Norwich, United Kingdom","country":"GB","companyType":"cro-services","website":"https://epistamaibio.com/","investors":[],"funding":[]},{"id":"eqt-life-sciences","kind":"company","name":"EQT Life Sciences","aka":[],"tldr":"The life sciences venture arm of the Swedish investment group EQT, formerly the Amsterdam firm LSP (Life Sciences Partners). It funds European and US biotech and medtech companies, including in cancer.","summary":"EQT Life Sciences calls itself 'One of Europe's Largest and Most Experienced Life Sciences Investors' with an 'Investment range 10-60M EUR', '65+' portfolio companies and '30+' investment advisory professionals, offering strategic, clinical, operational, financial and commercial support alongside capital. EQT AB, founded in Sweden in 1994, acquired Life Sciences Partners (LSP), a European venture firm, in 2021 (Wikipedia). The page cites 'unmet medical need' in conditions 'including cancer' and an insight piece titled 'How Can Investors Help to Cure Cancer?', but the featured companies shown (Amolyt Pharma, Neuravi, NewAmsterdam Pharma, Onera Health, PanTera) are not oncology companies, so no oncology portfolio example is cited here.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://eqtgroup.com/private-capital/eqt-life-sciences"},{"label":"Wikipedia (EQT AB)","url":"https://en.wikipedia.org/wiki/EQT_AB"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Amsterdam follows the task hint and LSP's historical base; the fetched page does not state an office. The full portfolio list is on a separate client-rendered page and was not readable."],"hq":"Amsterdam","country":"NL","companyType":"investor","website":"https://eqtgroup.com/private-capital/eqt-life-sciences","investors":[],"funding":[]},{"id":"equashield","kind":"company","name":"Equashield","aka":[],"tldr":"Equashield makes a fully enclosed closed-system transfer device whose syringe unit encapsulates the plunger, and the Equashield Pro robot that compounds chemotherapy doses automatically.","summary":"Equashield's closed system transfer device uses a sealed syringe with an encapsulated plunger and a pressure-equalising air chamber, and has been tested in independent vapour containment studies; the company extended the design into the Equashield Pro automated compounding system for hospital pharmacies.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.equashield.com/"}],"tags":["machines-wave2"],"related":[],"cancers":[],"sections":[],"technologies":["closed-system-transfer-devices","pharmacy-automation"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Port Washington, NY","country":"US","companyType":"devices","website":"https://www.equashield.com/","stage":"private-large","investors":[],"funding":[]},{"id":"erasca","kind":"company","name":"Erasca","aka":[],"tldr":"Erasca develops pills that shut down the RAS signalling pathway, one of the most common drivers of cancer. Its two lead drugs aim to block all forms of RAS or KRAS rather than a single mutation.","summary":"Erasca is a San Diego clinical-stage company focused on RAS/MAPK pathway-driven cancers. Its lead candidates are ERAS-0015, a pan-RAS molecular glue in the phase 1 AURORAS-1 trial in RAS-mutant solid tumours, and ERAS-4001, a pan-KRAS inhibitor in the phase 1 BOREALIS-1 trial in KRAS-mutant solid tumours. Earlier programmes include ERAS-007 (an ERK inhibitor, phase 1b/2 HERKULES-3 in colorectal cancer combinations) and ERAS-801 (phase 1 THUNDERBOLT-1 in recurrent glioblastoma), while the company is exploring strategic alternatives for ERAS-12, an EGFR domain 2/3 bispecific antibody. Erasca completed its Nasdaq IPO in July 2021 with gross proceeds of 345 million US dollars and has since completed several follow-on offerings.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.erasca.com/"},{"label":"Pipeline","url":"https://www.erasca.com/pipeline/"},{"label":"IPO closing 8-K (SEC)","url":"https://www.sec.gov/Archives/edgar/data/1761918/000119312521219642/d81810d8k.htm"}],"tags":[],"related":[],"cancers":["colorectal","glioblastoma"],"sections":["targeted-therapy"],"technologies":["kras-inhibitors","kinase-inhibitors"],"targets":["kras"],"drugs":["naporafenib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year and follow-on offering amounts not sourced. Naporafenib is not listed on the current pipeline page."],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://www.erasca.com/","ticker":"ERAS","stage":"public","investors":["arch-venture-partners"],"funding":[{"round":"IPO","year":2021,"amountUsd":345000000,"source":"https://www.sec.gov/Archives/edgar/data/1761918/000119312521219642/d81810d8k.htm","note":"21,562,500 shares at 16 US dollars including full exercise of the underwriters' option; closed 20 July 2021"}]},{"id":"eris-biotech","kind":"company","name":"Eris Biotech","aka":[],"tldr":"Eris Biotech is making small-molecule pills that release the brakes on the immune system inside tumours, starting with mesothelioma.","summary":"Eris Biotech develops small molecules that inhibit immune suppression in the tumour microenvironment so that the patient's immune system attacks solid tumours more aggressively, an oral alternative to antibody checkpoint inhibitors. Its first indication is mesothelioma, with a portfolio the company says extends to a range of solid tumours. The Utah company is preclinical with a very small team; no sourced financing rounds are recorded.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/eris-biotech"},{"label":"Official website","url":"https://www.erisbio.com"}],"tags":["yc"],"related":[],"cancers":["mesothelioma"],"sections":["immunotherapy"],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Lehi, UT","country":"US","companyType":"biotech","website":"https://www.erisbio.com","stage":"startup","ycBatch":"W24","investors":["y-combinator"],"funding":[]},{"id":"essa-pharma","kind":"company","name":"ESSA Pharma","aka":[],"tldr":"ESSA Pharma developed masofaniten, an AR N-terminal-domain inhibitor whose phase 2 was stopped for futility in 2024-25.","summary":"ESSA Pharma, based in Vancouver and listed as EPIX, developed masofaniten, also known as EPI-7386, an inhibitor of the androgen receptor N-terminal domain, a target chosen because resistance to existing prostate cancer drugs often runs through that part of the receptor. Its phase 2 trial of masofaniten with enzalutamide in metastatic castration-resistant prostate cancer was terminated after a futility analysis on the PSA90 endpoint in 2024 to 2025, development was discontinued and strategic options are under review. OnCo keeps the record as an instructive failure for the AR N-terminal domain concept. Whether the target was wrong or the molecule was insufficiently potent is the question the failure leaves open. Masofaniten has its own page.","asOf":"2026-09-06","links":[{"label":"Official website","url":"https://essapharma.com"}],"tags":["failed-so-far"],"related":[],"cancers":["prostate"],"sections":["hormonal"],"technologies":[],"targets":[],"drugs":["masofaniten"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Vancouver","country":"CA","companyType":"biotech","website":"https://essapharma.com","ticker":"EPIX","investors":[],"funding":[]},{"id":"etop-ibcsg","kind":"company","name":"ETOP IBCSG Partners Foundation","aka":["ETOP","European Thoracic Oncology Platform","IBCSG","International Breast Cancer Study Group","Ludwig Breast Cancer Study Group"],"tldr":"The Bern-based foundation that unites the International Breast Cancer Study Group (SOFT, TEXT, POSITIVE) and the European Thoracic Oncology Platform.","summary":"The International Breast Cancer Study Group began in 1977 as the Ludwig Breast Cancer Study Group and has run academic breast cancer trials for almost fifty years, including SOFT and TEXT (ovarian function suppression in premenopausal women), the POSITIVE study of pausing endocrine therapy to attempt pregnancy, and the early HER2-positive and elderly trials. ETOP was founded in 2009 to run academic thoracic oncology trials across Europe, including BEAT-meso in mesothelioma and the SPLENDOUR and ETOP Lungscape biomarker programmes. In 2022 the two merged into the ETOP IBCSG Partners Foundation, sharing a coordinating centre in Bern and a statistical centre. Both arms partner with the Breast International Group, Breast Cancer Trials and the US cooperative groups.","asOf":"2026-09-09","links":[{"label":"IBCSG","url":"https://www.ibcsg.org"},{"label":"ETOP","url":"https://www.etop-eu.org"}],"tags":["cooperative-group"],"related":["atezolizumab"],"cancers":["breast-hr-positive","breast-her2-positive","nsclc","mesothelioma"],"sections":["hormonal"],"technologies":["endocrine-therapy","checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":["big","breast-cancer-trials","alliance-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":["soft-text","beat-meso"],"people":["solange-peters","rolf-stahel"],"bottlenecks":[],"keyPapers":[],"journals":["lung-cancer-journal"],"dependsOn":[],"notes":["SOFT / TEXT (IBCSG 24-02, 25-02)","POSITIVE (pregnancy after endocrine therapy)","BEAT-meso and thoracic trials (ETOP)","Lungscape biomarker cohort"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Bern","country":"CH","companyType":"cooperative-group","website":"https://www.ibcsg.org","founded":2009,"investors":[],"funding":[]},{"id":"eureka-therapeutics","kind":"company","name":"Eureka Therapeutics","aka":["Eureka Therapeutics Inc."],"tldr":"Eureka Therapeutics is a US-based cell therapy company that leads 2 cancer trials in OnCo, testing the ARTEMIS T-cell therapies ECT204 and ET140203 in hepatoblastoma and hepatocellular carcinoma.","summary":"Eureka Therapeutics is a clinical-stage biopharmaceutical company developing T-cell therapies for solid tumours using its E-ALPHA antibody discovery and ARTEMIS T-cell receptor platforms. Its clinical programmes are ECT204 for GPC3-positive adult liver cancer and ET140203 for AFP-positive paediatric liver cancer. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT04634357 (phase 1/2, ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular...) and NCT04864054 (phase 1/2, GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.eurekatherapeutics.com"},{"label":"ClinicalTrials.gov: trials led by Eureka Therapeutics","url":"https://clinicaltrials.gov/search?lead=Eureka%20Therapeutics%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["hepatoblastoma","hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04634357","nct04864054"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Emeryville, California","country":"US","companyType":"cell-therapy","website":"https://www.eurekatherapeutics.com","founded":2006,"stage":"growth","investors":[],"funding":[]},{"id":"eurofarma","kind":"company","name":"Eurofarma","aka":["Eurofarma Laboratorios S.A.","Eurofarma Laboratórios"],"tldr":"Eurofarma is a São Paulo pharmaceutical group founded in 1972, one of the largest Brazilian-owned drug makers, with an oncology portfolio and phase 3 trials it leads in Latin America.","summary":"Eurofarma Laboratórios, headquartered in São Paulo and founded in 1972, is a privately held Brazilian pharmaceutical group operating across Latin America with prescription, generic and hospital medicines, including an oncology line. It is lead sponsor of phase 3 cancer trials registered on ClinicalTrials.gov. Its registered cancer trials compare its own goserelin, filgrastim and pegfilgrastim with the originator products in prostate and breast cancer, and test nimotuzumab with chemoradiotherapy in head and neck, oesophageal and cervical cancer (ClinicalTrials.gov NCT03936218, NCT03936933, NCT01079676, NCT02768714, NCT01345084, NCT01249352, NCT01301612).","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Eurofarma","links":[{"label":"Official website","url":"https://www.eurofarma.com.br"},{"label":"ClinicalTrials.gov: trials led by Eurofarma","url":"https://clinicaltrials.gov/search?lead=Eurofarma"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q23777937"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate","breast-hr-positive","head-and-neck","esophageal","cervical"],"sections":[],"technologies":["g-csf-growth-factors","biosimilar-manufacturing"],"targets":[],"drugs":["goserelin","filgrastim","pegfilgrastim","nimotuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"São Paulo","country":"BR","companyType":"pharma","website":"https://www.eurofarma.com.br","founded":1972,"stage":"private-large","investors":[],"funding":[]},{"id":"european-myeloma-network","kind":"company","name":"European Myeloma Network","aka":["EMN","Stichting European Myeloma Network","European Myeloma Network B.V."],"tldr":"The European Myeloma Network is the non-profit network of European myeloma haematologists created from 2005 to run shared research and trials; its Dutch foundation is the registry sponsor of CARTITUDE-6 in OnCo.","summary":"The European Myeloma Network (EMN) describes itself as a non-profit organisation created to increase understanding of multiple myeloma and to produce effective research projects and clinical trials; its website dates the effort to 2005, when a group of European haematologists pulled together, and records a bylaw update in 2017 and a senior board formed in 2019. After a legal demerger, the trials formerly sponsored by the European Myeloma Network Foundation are sponsored by European Myeloma Network B.V., Rotterdam, wholly owned by the Dutch foundation Stichting European Myeloma Network, with a trial office in Turin (myeloma-europe.org). ClinicalTrials.gov names Stichting European Myeloma Network (NETWORK class, with Janssen Research & Development as collaborator) as lead sponsor of CARTITUDE-6 (NCT05257083, phase 3, ciltacabtagene autoleucel against autologous transplant after daratumumab-VRd induction in transplant-eligible myeloma), the trial recorded in OnCo. It has no products of its own.","asOf":"2026-09-25","links":[{"label":"EMN: about","url":"https://www.myeloma-europe.org/about/"},{"label":"ClinicalTrials.gov: trials led by Stichting European Myeloma Network","url":"https://clinicaltrials.gov/search?lead=Stichting%20European%20Myeloma%20Network"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["multiple-myeloma","myeloma-transplant-eligible"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["cartitude-6"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"Rotterdam","country":"NL","companyType":"cooperative-group","website":"https://www.myeloma-europe.org","founded":2005,"investors":[],"funding":[]},{"id":"evaxion","kind":"company","name":"Evaxion","aka":[],"tldr":"Evaxion uses artificial intelligence to design vaccines against cancer and infections. Its lead cancer vaccine is personalised to each melanoma patient's tumour, and a newer off-the-shelf vaccine targets brain cancer.","summary":"Evaxion A/S (Nasdaq: EVAX) is an AI-immunology company based in Hørsholm, north of Copenhagen. Its AI-Immunology platform predicts immunogenic targets and designs vaccine candidates for cancer and infectious disease, with the company claiming target identification within 24 hours. EVX-01 is a personalised neoantigen peptide vaccine evaluated in a phase 2 trial in advanced melanoma in combination with pembrolizumab; two-year results were presented at ESMO 2025 and three-year efficacy data are expected at ESMO 2026. In August 2026 Evaxion added EVX-05, an off-the-shelf glioblastoma vaccine directed at endogenous retrovirus-derived antigens shared across patients, developed with input from Duke University School of Medicine, and discontinued EVX-03. The company reported cash of USD 14.0 million at 30 June 2026 with runway into the second half of 2027. Evaxion has been listed on the Nasdaq Capital Market since 2021 and pursues a multi-partner business model.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.evaxion.ai"},{"label":"Q2 2026 business update","url":"https://evaxion.ai/news-resources/?press_release_id=11296"},{"label":"EVX-05 glioblastoma vaccine programme announcement","url":"https://evaxion.ai/news-resources/?press_release_id=11281"}],"tags":[],"related":[],"cancers":["melanoma","glioblastoma"],"sections":["immunotherapy","ai-computation"],"technologies":["neoantigen-mrna-vaccine","shared-antigen-vaccine","ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05309421"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["HQ is Hørsholm rather than Copenhagen proper. EVX-01 is a peptide vaccine; tagged neoantigen-mrna-vaccine as the closest id. MSD option agreement and financing rounds were not found on fetched pages, so no funding is recorded. Founding year not sourced."],"hq":"Hørsholm","country":"DK","companyType":"biotech","website":"https://www.evaxion.ai","ticker":"EVAX","stage":"public","investors":[],"funding":[]},{"id":"evenone-ventures","kind":"company","name":"Even One Ventures","aka":["EvenOne Ventures","EOV"],"tldr":"Even One Ventures is a venture studio that builds companies in the image of one patient's playbook: Sid Sijbrandij, the GitLab co-founder who, told in 2024 that he had run out of options for recurrent osteosarcoma, assembled a team, pursued every diagnostic and built individualised treatments in parallel.","summary":"Even One Ventures describes its origin as November 2022, when Sid Sijbrandij was diagnosed with osteosarcoma in his spine; after surgery, chemotherapy and radiation the cancer returned in 2024 and his doctors said therapeutic options were exhausted, so he took agency, ran diagnostics and individualised treatments in parallel, and the fund now builds companies so that future patients do not have to start from scratch. Its portfolio of fifteen companies spans oncology (personalised vaccines, oncolytic viruses, TCR and antibody therapies, functional tumour testing, tumour tissue banking, theranostics access and AI care tools), immunology, women's health, rare disease and longevity. OnCo tracks the portfolio weekly on the completeness page and records every company, including the ones outside cancer, marked as such.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://evenone.ventures"},{"label":"Portfolio","url":"https://evenone.ventures/"}],"tags":["vc","patient-first","venture-studio"],"related":[],"cancers":[],"sections":["drug-discovery","diagnostics","immunotherapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"United States (head office not published)","country":"US","companyType":"investor","website":"https://evenone.ventures","investors":[],"funding":[]},{"id":"everest-medicines","kind":"company","name":"Everest Medicines","aka":["Everest Medicines Limited","云顶新耀","HKEX:1952"],"tldr":"Everest Medicines is a Shanghai company that brings in medicines for Asia and is building an mRNA platform, including the personalised cancer vaccine EVM16 and the off-the-shelf tumour vaccine EVM14.","summary":"Everest Medicines, listed in Hong Kong, licenses and commercialises medicines in Greater China and other Asian markets, including Nefecon for IgA nephropathy and the antibiotic Xerava. It has built its own mRNA platform and manufacturing site in Jiaxing; EVM14 is an mRNA cancer vaccine encoding shared tumour-associated antigens for squamous cancers of the lung and head and neck, and EVM16 is a personalised neoantigen vaccine. Both entered clinical testing in 2025.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.everestmedicines.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["evm14"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Shanghai","country":"CN","companyType":"pharma","website":"https://www.everestmedicines.com/","ticker":"HKEX:1952","founded":2017,"stage":"public","investors":[],"funding":[]},{"id":"evergreen-theragnostics","kind":"company","name":"Evergreen Theragnostics","aka":[],"tldr":"Evergreen Theragnostics manufactures radioactive cancer medicines for other companies and develops its own imaging agent for neuroendocrine tumours and a treatment for small cell lung cancer. Lantheus agreed to buy it in 2025.","summary":"Evergreen Theragnostics is a Springfield, New Jersey radiopharmaceutical company combining contract development and manufacturing (CDMO) services with proprietary products. Its facility, completed in October 2021, has produced clinical material for partners including Clovis Oncology (225Ac FAP-2286), Clarity (copper theranostics), MTTI and Precirix (CAM-H2). Proprietary programmes include OCTEVY, a registrational-stage PET diagnostic for neuroendocrine tumours, and EVG321, a CCK2 receptor-targeted radioligand licensed from the Medical University of Innsbruck in May 2024 for small cell lung cancer, with the CCK2-VIEW phase 2 trial opened in the EU in October 2024. In January 2025 Lantheus agreed to acquire Evergreen for USD 250 million upfront and up to USD 752.5 million in milestones, to become a fully integrated radiopharmaceutical company.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.evergreentgn.com/"},{"label":"Lantheus acquisition release","url":"https://www.evergreentgn.com/2025/01/28/lantheus-to-acquire-evergreen-theragnostics-for-upfront-payment-of-250-million-to-drive-strategic-evolution-into-fully-integrated-radiopharmaceutical-leader/"},{"label":"News","url":"https://www.evergreentgn.com/news/"}],"tags":[],"related":[],"cancers":["neuroendocrine","sclc"],"sections":["radiopharma"],"technologies":["radioligand-therapy","pet"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Venture financing before the acquisition not fetched and omitted. Completion of the Lantheus deal not confirmed from a fetched page, although the company site now links to Lantheus careers and pipeline."],"hq":"Springfield, NJ","country":"US","companyType":"radiopharma","website":"https://www.evergreentgn.com/","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2025,"amountUsd":250000000,"source":"https://www.evergreentgn.com/2025/01/28/lantheus-to-acquire-evergreen-theragnostics-for-upfront-payment-of-250-million-to-drive-strategic-evolution-into-fully-integrated-radiopharmaceutical-leader/","note":"USD 250 million upfront plus up to USD 752.5 million in milestones; all-cash, announced 28 January 2025"}],"acquiredBy":"lantheus"},{"id":"evive-biotech","kind":"company","name":"Evive Biotech","aka":[],"tldr":"Evive Biotech developed efbemalenograstim alfa (Ryzneuta), a long-acting G-CSF fusion protein for chemotherapy-induced neutropenia approved in the US in 2023 and the EU in 2024.","summary":"Evive Biotech, based in Shanghai and part of Yifan Pharmaceutical, developed efbemalenograstim alfa, sold as Ryzneuta, a long-acting G-CSF fusion protein for chemotherapy-induced neutropenia approved in the United States in 2023 and the European Union in 2024. Efbemalenograstim alfa is a dimeric G-CSF-Fc fusion protein approved by the FDA in November 2023 and by the European Commission in March 2024 to reduce the duration of neutropenia and febrile neutropenia after myelosuppressive chemotherapy. OnCo links it to the efbemalenograstim alfa drug record. Whether a new long-acting G-CSF can take share from existing long-acting G-CSFs on price or convenience is the open question. Efbemalenograstim alfa has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.evivebiotech.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["efbemalenograstim-alfa"],"companies":[],"institutions":[],"pathways":[],"terms":["neutropenia","febrile-neutropenia"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.evivebiotech.com","investors":[],"funding":[]},{"id":"evolutionaryscale","kind":"company","name":"EvolutionaryScale","aka":[],"tldr":"Spun out of Meta's protein team; makes the ESM3 protein language model that generated a new fluorescent protein.","summary":"EvolutionaryScale, based in New York, was spun out of Meta's protein research team and makes ESM3, the protein language model that generated a new fluorescent protein. ESM3, published in Science in 2025, is a 98-billion-parameter generative model over protein sequence, structure and function, with open weights for its smaller variants, and it is used for antibody and enzyme design. OnCo links it to the ESM3 technology record. Whether generative protein models produce cancer therapeutics that reach patients, rather than impressive demonstrations, is the open question. ESM3 has its own technology page.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.evolutionaryscale.ai"}],"tags":["ai","protein-design"],"related":[],"cancers":[],"sections":["drug-discovery","ai-computation"],"technologies":["esm3"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"New York, NY","country":"US","companyType":"ai-software","website":"https://www.evolutionaryscale.ai","investors":[],"funding":[]},{"id":"evopoint-biosciences","kind":"company","name":"Evopoint Biosciences","aka":["Evopoint Biosciences Inc."],"tldr":"Evopoint Biosciences is a China-based biotechnology company running 6 late-stage cancer trials of XNW29016, XNW5004 and XNW28012 in peripheral T-cell lymphomas, follicular lymphoma and prostate cancer.","summary":"Evopoint Biosciences, based in Suzhou, China, is a biotechnology company. An innovation-focused pharmaceutical company (Chinese name Suzhou Innovent... registered as Suzhou Xinnuowei Pharmaceutical Technology Co.) developing small-molecule and antibody drugs for precision oncology and multi-drug resistant bacterial infections, using in-house small molecule, complex antibody (eMAB) and targeted protein degradation (eGLUE) platforms. On ClinicalTrials.gov it is the lead sponsor of 6 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing XNW29016, XNW5004 and XNW28012 in peripheral T-cell lymphomas, follicular lymphoma, prostate cancer, hodgkin lymphoma and pancreatic ductal adenocarcinoma. The largest, NCT06799637 (Study of XNW28012 in Subjects With Advanced Solid Tumours Who Failed Standard Treatments), plans to enrol 350 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.evopointbio.com"},{"label":"ClinicalTrials.gov: trials led by Evopoint Biosciences","url":"https://clinicaltrials.gov/search?lead=Evopoint%20Biosciences%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["peripheral-t-cell-lymphoma","follicular-lymphoma","prostate","hodgkin-lymphoma","pancreatic","ovarian","cervical"],"sections":[],"technologies":[],"targets":[],"drugs":["xnw5004"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07545603","nct07730515","nct06702995","nct06776952","nct06799637","nct07823049","nct06987500"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Suzhou","country":"CN","companyType":"biotech","website":"https://www.evopointbio.com","investors":[],"funding":[]},{"id":"exact-sciences","kind":"company","name":"Exact Sciences (Abbott)","aka":[],"tldr":"Exact Sciences makes Cologuard and Oncotype DX and is launching Cancerguard MCED and Oncodetect MRD; it is being acquired by Abbott for $21B.","summary":"Exact Sciences, based in Madison, Wisconsin, makes Cologuard and Oncotype DX and is launching the Cancerguard multi-cancer early detection test and the Oncodetect residual disease test; Abbott is acquiring it for 21 billion dollars. Its products span Cologuard Plus for stool-based colorectal screening, Oncotype DX for breast cancer recurrence risk, Oncodetect for MRD and Cancerguard, offered as a laboratory-developed test from 2025. OnCo links it to colorectal and HR-positive breast cancer, to MRD testing and multi-cancer early detection, to the early detection roadmap from organ screening to blood tests, and to Abbott Laboratories. Whether the Abbott deal turns a screening franchise into a broader diagnostics platform is the open question. Each product has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.exactsciences.com"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics","early-detection"],"technologies":[],"targets":[],"drugs":["oncotype-dx"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Madison, WI","country":"US","companyType":"diagnostics","website":"https://www.exactsciences.com","investors":[],"funding":[]},{"id":"exai-bio","kind":"company","name":"Exai Bio","aka":[],"tldr":"Exai Bio is building blood tests that look for small pieces of RNA made only by tumours, rather than tumour DNA, and uses artificial intelligence to find cancer early from a routine blood draw.","summary":"Exai Bio, based in Palo Alto, California, develops an RNA-based liquid biopsy platform built on orphan non-coding RNAs (oncRNAs), small RNA species largely absent from normal tissue but abundant in tumours, first described by co-founder Hani Goodarzi's UCSF laboratory in Nature Medicine in 2018. The company sequences cell-free RNA from plasma and applies generative AI models to detect and characterise cancer, an approach it argues captures active tumour biology rather than relying on rare ctDNA mutations. Early detection data in breast cancer were presented at the San Antonio Breast Cancer Symposium in 2023 and AACR in 2024, and a Nature Communications paper on the platform appeared in November 2024. Dave Daly became chief executive in July 2024. The company raised a $67.5 million Series A in December 2021 co-led by Section 32 and Casdin Capital; no later round is disclosed on its site.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.exai.bio/"},{"label":"Series A press release (Dec 2021)","url":"https://www.exai.bio/news/exai-bio-secures-67-5-million-series-a"},{"label":"News page","url":"https://www.exai.bio/news"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection","diagnostics"],"technologies":["liquid-biopsy","rna-seq","mced"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Series A release dateline is San Francisco; current website address is Palo Alto. Founding year not sourced. Breast cancer data are not attributed to a subtype so no cancer id is tagged."],"hq":"Palo Alto, CA","country":"US","companyType":"diagnostics","website":"https://www.exai.bio/","stage":"startup","investors":["section-32","casdin-capital"],"funding":[{"round":"Series A","year":2021,"amountUsd":67500000,"source":"https://www.exai.bio/news/exai-bio-secures-67-5-million-series-a","note":"Co-led by Section 32 and Casdin Capital with Two Sigma Ventures, December 2021."}]},{"id":"excellthera","kind":"company","name":"ExCellThera","aka":["ExCellThera Inc."],"tldr":"ExCellThera is a Montreal cell-therapy company that uses the small molecule UM171 to multiply blood stem cells from cord blood, making transplants possible for patients who would otherwise lack a donor.","summary":"ExCellThera was spun out of Université de Montréal around UM171, a molecule discovered in Guy Sauvageau's laboratory that expands haematopoietic stem cells in culture. Its product, dorocubicel (ECT-001, UM171-expanded cord blood), lets a small cord blood unit be grown into a graft for adults with high-risk blood cancers who lack a matched donor. Phase 2 trials in acute leukaemia and myelodysplastic syndromes have reported low rates of chronic graft-versus-host disease and relapse.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.excellthera.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["dorocubicel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Montreal","country":"CA","companyType":"cell-therapy","website":"https://www.excellthera.com/","founded":2015,"investors":[],"funding":[]},{"id":"exelixis","kind":"company","name":"Exelixis","aka":[],"tldr":"Exelixis makes cabozantinib (Cabometyx), used in kidney, liver, thyroid and, since 2025, neuroendocrine cancers.","summary":"Exelixis, based in Alameda, California, and listed as EXEL, makes cabozantinib, sold as Cabometyx, which is used in kidney, liver, thyroid and, since 2025, neuroendocrine cancers. Cabozantinib is approved in renal cell carcinoma alone and with nivolumab, in hepatocellular carcinoma after sorafenib on the CELESTIAL trial, in differentiated thyroid cancer, and in advanced pancreatic and extra-pancreatic neuroendocrine tumours on the CABINET trial in March 2025, and the next-generation kinase inhibitor zanzalintinib is in phase 3 in colorectal cancer and neuroendocrine tumours. OnCo also links it to adrenocortical carcinoma and osteosarcoma. Whether zanzalintinib can extend the franchise beyond cabozantinib is the open question. Cabozantinib has its own page.","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Exelixis","links":[{"label":"Official website","url":"https://www.exelixis.com"}],"tags":[],"related":[],"cancers":["hcc","rcc","neuroendocrine","thyroid"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["cabozantinib","zanzalintinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03755791","nct05425940","nct04446117","nct03690388","nct03899155"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Zanzalintinib (XL092) is in phase 3 across kidney cancer with belzutifan (LITESPARK-034), colorectal cancer (STELLAR-303) and neuroendocrine tumours; XB002 is the company's antibody-drug conjugate."],"hq":"Alameda, CA","country":"US","companyType":"biotech","website":"https://www.exelixis.com","ticker":"EXEL","investors":[],"funding":[]},{"id":"exscientia","kind":"company","name":"Exscientia","aka":[],"tldr":"Exscientia was a British pioneer in designing drugs with artificial intelligence, including cancer drugs that reached early clinical trials. It has been folded into the US company Recursion.","summary":"Exscientia plc, founded in Oxford, was among the first companies to bring AI-designed small molecules into clinical trials, combining generative chemistry design with automated synthesis and patient-tissue functional screening. Its oncology pipeline included GTAEXS617, a CDK7 inhibitor developed with GT Apeiron, and EXS4318, a PKC-theta inhibitor partnered with Bristol Myers Squibb, together with a large discovery collaboration with Sanofi. The company combined with Recursion Pharmaceuticals in an all-stock transaction in 2024; the exscientia.ai domain now redirects to recursion.com and the former Exscientia programmes are reported within Recursion's pipeline. Deal value and completion date could not be confirmed from a fetched primary source because Recursion's investor relations pages blocked automated access. Recursion itself is already in the graph.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.exscientia.ai"},{"label":"Recursion website","url":"https://www.recursion.com/"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation","drug-discovery"],"technologies":["ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Acquisition by Recursion is evidenced only by the domain redirect; the completion release (November 2024) and deal value were not fetched (ir.recursion.com returned 403 or timed out). Oncology programme details are from background knowledge and were not on fetched pages. Former ticker EXAI omitted."],"hq":"Oxford","country":"GB","companyType":"biotech","website":"https://www.exscientia.ai","stage":"acquired","investors":[],"funding":[],"acquiredBy":"recursion"},{"id":"f-prime-capital","kind":"company","name":"F-Prime Capital","aka":[],"tldr":"F-Prime Capital is the venture firm that grew out of Fidelity's own money. It invests in healthcare and technology companies, including cancer diagnostics and therapeutics, from seed to growth.","summary":"F-Prime Capital is a global venture capital firm with roots in Fidelity Investments, investing in healthcare, life sciences and technology companies from company formation to growth stage, with offices in Cambridge (Massachusetts), San Francisco and London. Its healthcare portfolio spans therapeutics, diagnostics, medical devices and health IT, and includes oncology companies at several stages. Portfolio links in OnCo are derived from the startup records that name it.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://fprimecapital.com"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cambridge, MA","country":"US","companyType":"investor","website":"https://fprimecapital.com","investors":[],"funding":[]},{"id":"faron-pharmaceuticals","kind":"company","name":"Faron Pharmaceuticals","aka":["Faron","AIM:FARN"],"tldr":"Faron Pharmaceuticals is a Finnish biotech whose antibody bexmarilimab re-programmes immunosuppressive macrophages, with early activity in myelodysplastic syndromes and leukaemia.","summary":"Faron Pharmaceuticals, based in Turku and listed in London and Helsinki, develops immunotherapies that act on the myeloid arm of the immune system. Its lead candidate, bexmarilimab (FP-1305), binds Clever-1 on tumour-associated macrophages and converts them from an immunosuppressive to an immune-activating state. The BEXMAB study combines it with azacitidine in myelodysplastic syndromes and acute myeloid leukaemia; earlier MATINS trials tested it in solid tumours.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Faron_Pharmaceuticals","links":[{"label":"Official website","url":"https://www.faron.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["bexmarilimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Turku","country":"FI","companyType":"biotech","website":"https://www.faron.com/","ticker":"AIM:FARN","stage":"public","investors":[],"funding":[]},{"id":"fate-therapeutics","kind":"company","name":"Fate Therapeutics","aka":[],"tldr":"Fate Therapeutics builds iPSC-derived off-the-shelf CAR-T and CAR-NK cells (FT819, FT522) for cancer and autoimmune disease.","summary":"Fate Therapeutics, based in San Diego and listed as FATE, builds off-the-shelf CAR-T and CAR-NK cells derived from induced pluripotent stem cells, including FT819 and FT522, for cancer and autoimmune disease. FT819 is a clonal iPSC-derived CD19 CAR-T, FT522 is a CD19 CAR-NK with alloimmune defence receptors designed to avoid conditioning chemotherapy, the company presented at ASCO and EULAR 2026, and it has a solid-tumour collaboration with Ono. OnCo links it to diffuse large B-cell lymphoma, to allogeneic cell therapy, CAR-NK and CAR-T, to CD19 as a target and to ideas on qualifying one iPSC master cell bank for many products. Manufacturing cost and time for living medicines is the bottleneck iPSC-derived cells are meant to relieve. Whether iPSC-derived cells persist and perform as well as patient-derived ones is the open question.","asOf":"2026-09-04","links":[{"label":"ASCO/EULAR 2026","url":"https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-announces-presentations-2026-asco-and-eular"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":["cell-therapy"],"technologies":["allogeneic-cell-therapy","car-nk-macrophage","car-t"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Diego, CA","country":"US","companyType":"cell-therapy","website":"https://fatetherapeutics.com","ticker":"FATE","investors":[],"funding":[]},{"id":"fennec-pharmaceuticals","kind":"company","name":"Fennec Pharmaceuticals","aka":["Adherex Technologies","Fennec Pharmaceuticals Inc.","NASDAQ:FENC"],"tldr":"Fennec Pharmaceuticals is the North Carolina company behind Pedmark, the sodium thiosulfate infusion given after cisplatin to protect children's hearing from the chemotherapy.","summary":"Fennec Pharmaceuticals, formerly Adherex Technologies, developed Pedmark (sodium thiosulfate) as an otoprotectant. Given six hours after each cisplatin dose, it neutralises the platinum that damages inner-ear hair cells; the SIOPEL 6 and ACCL0431 trials showed roughly halved rates of hearing loss in children with localised solid tumours. The FDA approved Pedmark in September 2022 for patients aged one month and older, and the European Union approved it as Pedmarqsi in 2023.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.fennecpharma.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["sodium-thiosulfate"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Research Triangle Park, North Carolina","country":"US","companyType":"pharma","website":"https://www.fennecpharma.com/","ticker":"NASDAQ:FENC","stage":"public","investors":[],"funding":[]},{"id":"ferring","kind":"company","name":"Ferring Pharmaceuticals","aka":[],"tldr":"Ferring is the private Swiss pharma that brought the first bladder cancer gene therapy, Adstiladrin, to market.","summary":"Ferring Pharmaceuticals, a private Swiss company based in Saint-Prex, brought the first bladder cancer gene therapy, Adstiladrin, or nadofaragene firadenovec, to market. Nadofaragene was approved in 2022 and launched in 2023 to 2024 after manufacturing scale-up, and the company also makes degarelix for prostate cancer alongside its reproductive medicine and gastroenterology franchises. OnCo links it to bladder and urothelial cancer and to the nadofaragene and degarelix drug records. Whether a gene therapy given into the bladder can hold its position as oncolytic virus and IL-15 competitors arrive is the open question. Nadofaragene firadenovec has its own page.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://www.ferring.com"}],"tags":[],"related":[],"cancers":["urothelial"],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["nadofaragene-firadenovec"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05704244","nct06510374","nct06545955"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Saint-Prex","country":"CH","companyType":"pharma","website":"https://www.ferring.com","investors":[],"funding":[]},{"id":"fibrogen","kind":"company","name":"FibroGen","aka":[],"tldr":"A fibrosis-focused biotech whose anti-CTGF antibody pamrevlumab failed phase 3 trials in pancreatic cancer and in lung fibrosis.","summary":"FibroGen, listed on Nasdaq, built its pipeline on connective tissue growth factor biology and on the anaemia drug roxadustat. Pamrevlumab was its oncology bet, tested in locally advanced pancreatic cancer in the LAPIS trial and in a Precision Promise arm; both were negative in 2024, and the programme was discontinued.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Kyntra_Bio","links":[{"label":"Official website","url":"https://www.fibrogen.com"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/FibroGen"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["pamrevlumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, California, United States","country":"US","companyType":"biotech","website":"https://www.fibrogen.com","founded":1993,"stage":"public","investors":[],"funding":[]},{"id":"fidocure","kind":"company","name":"FidoCure","aka":[],"tldr":"FidoCure sequences the tumours of dogs with cancer and matches them to targeted drugs, bringing precision medicine to veterinary oncology and building a dataset that also informs human cancer research.","summary":"FidoCure offers tumour genomic sequencing and off-label targeted therapies to veterinary oncologists treating dogs with cancer, through a network the company says covers over 140 clinics in the United States. Because many canine cancers share driver mutations with human tumours, the accumulating outcomes data is used for comparative oncology, and FidoCure has published on genomic landscapes and targeted-therapy outcomes in dogs. It is a veterinary business, included here because cancer in companion animals is a recognised model for the human disease.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/fidocure"},{"label":"Official website","url":"https://www.fidocure.com"}],"tags":["veterinary","comparative-oncology"],"related":[],"cancers":[],"sections":["diagnostics","targeted-therapy"],"technologies":["cgp","kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Palo Alto, CA","country":"US","companyType":"diagnostics","website":"https://www.fidocure.com","stage":"growth","ycBatch":"W18","investors":["y-combinator"],"funding":[]},{"id":"filo","kind":"company","name":"FILO (French Innovative Leukemia Organisation)","aka":["French Innovative Leukemia Organisation","FILO"],"tldr":"FILO is the French cooperative group for leukaemia trials, with its registered office in the haematology department of the Tours university hospital; in OnCo it leads a phase 2 trial of eltrombopag in older patients with acute myeloid leukaemia.","summary":"The French Innovative Leukemia Organisation (FILO) is a French leukaemia cooperative group whose registered office is at the CHU Bretonneau, Centre Henry Kaplan, cellular haematology department, 2 boulevard Tonnellé, Tours (filo-leucemie.org). No founding year is stated on the pages read. ClinicalTrials.gov names it lead sponsor (OTHER class, with Novartis as collaborator) of NCT03603795 (EPAG2015, phase 2, eltrombopag in elderly patients with acute myeloid leukaemia), the trial recorded in OnCo. It has no products of its own.","asOf":"2026-09-25","links":[{"label":"Official website","url":"https://www.filo-leucemie.org"},{"label":"ClinicalTrials.gov: trials led by French Innovative Leukemia Organisation","url":"https://clinicaltrials.gov/search?lead=French%20Innovative%20Leukemia%20Organisation"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03603795"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"Tours","country":"FR","companyType":"cooperative-group","website":"https://www.filo-leucemie.org","investors":[],"funding":[]},{"id":"finaldose","kind":"company","name":"FinalDose","aka":[],"tldr":"Y Combinator Spring 2026 start-up building a programmable DNA-targeting drug: a molecule that recognises a cancer-specific DNA sequence inside a cell and triggers a kill switch only there.","summary":"Founded by three Oxford PhDs (Jeff Liu, Li-Yao Huang, Steven Lin). The pitch: swap the guide sequence and the same drug becomes a new drug, unlocking 'undruggable' drivers such as MYC, TP53, and APC at the DNA level and, the company claims, 80% of cancers that protein-targeted drugs cannot reach. Preclinical and pre-revenue, with no published data or trials by September 2026. Listed here as the clearest example of the sequence-programmable therapeutic concept.","asOf":"2026-09-04","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/finaldose"},{"label":"Company site","url":"https://www.finaldose.ai/"}],"tags":["frontier","early-stage","yc"],"related":[],"cancers":[],"sections":["targeted-therapy","drug-discovery"],"technologies":["programmable-dna-targeting-therapeutics"],"targets":["tp53","kras"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.finaldose.ai/","founded":2026,"stage":"startup","ycBatch":"X26","investors":["y-combinator"],"funding":[]},{"id":"firefly-bio","kind":"company","name":"Firefly Bio","aka":[],"tldr":"Firefly Bio attaches protein-destroying molecules to antibodies so they are delivered only into cancer cells, a new twist on antibody-drug conjugates. Johnson & Johnson bought the company for about 1 billion dollars in 2026.","summary":"Firefly Bio, incubated by Versant Ventures' Ridgeline Discovery Engine in Basel and based in the San Francisco Bay Area, develops degrader antibody conjugates (DACs): antibody-drug conjugates whose payloads are catalytic targeted protein degraders rather than conventional cytotoxics. Its proprietary Firelink linker is designed to reduce free payload in circulation and uptake by healthy cells, allowing lower doses; preclinical studies reported tumour regressions after single low doses in solid and haematological tumour models. The company emerged from stealth in February 2024 with a USD 94 million Series A co-led by Versant Ventures and MPM BioImpact with Decheng Capital and Eli Lilly. In June 2026 Johnson & Johnson agreed to acquire Firefly for USD 1 billion in cash, and the company reported completion of the acquisition on 29 July 2026.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://fireflybiologics.com/"},{"label":"Series A press release","url":"https://fireflybiologics.com/press-release-firefly-bio-debuts-with-94-million-series-a-financing/"},{"label":"BioPharma Dive: J&J to acquire Firefly for $1B","url":"https://www.biopharmadive.com/news/jnj-firefly-acquisition-deal-cancer-degrader-antibody-conjugate/822223/"}],"tags":[],"related":["src-biopharma-dive"],"cancers":[],"sections":["adcs","targeted-therapy"],"technologies":["degrader-antibody-conjugate","adc","protac-degrader"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["J&J's own press release pages returned an error page to my fetches."],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://fireflybiologics.com/","stage":"acquired","investors":["versant-ventures","mpm-bioimpact","lilly-ventures"],"funding":[{"round":"Series A","year":2024,"amountUsd":94000000,"source":"https://fireflybiologics.com/press-release-firefly-bio-debuts-with-94-million-series-a-financing/"},{"round":"Acquisition","year":2026,"amountUsd":1000000000,"source":"https://www.biopharmadive.com/news/jnj-firefly-acquisition-deal-cancer-degrader-antibody-conjugate/822223/","note":"USD 1 billion in cash, announced 8 June 2026; completion announced on the company website 29 July 2026"}],"acquiredBy":"johnson-johnson"},{"id":"first-ascent-biomedical","kind":"company","name":"First Ascent Biomedical","aka":[],"tldr":"First Ascent Biomedical grows a patient's cancer cells and tests more than 150 approved drugs against them to find the right drug for the right patient at the right time.","summary":"First Ascent Biomedical, founded in Miami, offers live-cell functional drug testing across more than 150 FDA-approved therapies, ranking options by measured response of the patient's own cells; its founders' work began in paediatric cancers where standard options had run out. Physician-ordered.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://firstascentbiomedical.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":["childhood-cancers"],"sections":[],"technologies":["functional-drug-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Miami, FL","country":"US","companyType":"diagnostics","website":"https://firstascentbiomedical.com/","investors":[],"funding":[]},{"id":"flagship-pioneering","kind":"company","name":"Flagship Pioneering","aka":[],"tldr":"A Cambridge, Massachusetts firm that invents and builds its own biotech companies rather than backing outside founders. Its cancer-focused companies include Foghorn Therapeutics and Repertoire Immune Medicines.","summary":"Flagship Pioneering was founded in Cambridge in 1999 by Noubar Afeyan and Ed Kania as NewcoGen, became Flagship Ventures and took its current name in 2016 (Wikipedia). Its process starts with internal 'what if' explorations that become prototype companies and then full operating companies, which Flagship funds and controls in their early years before syndicating. Cancer is one of several disease areas. Foghorn Therapeutics targets the chromatin regulatory system and 'is developing multiple product candidates in oncology'; Repertoire Immune Medicines decodes T-cell receptor and antigen interactions to build T-cell-targeted therapies for cancer and autoimmune disease, with partnerships including Bristol Myers Squibb, Genentech, Pfizer and Eli Lilly. The best-known Flagship company, Moderna, also runs cancer vaccine programmes.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.flagshippioneering.com/"},{"label":"Companies","url":"https://www.flagshippioneering.com/companies"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Flagship_Pioneering"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The companies index is rendered client-side; individual company pages were fetched instead."],"hq":"Cambridge, MA","country":"US","companyType":"investor","website":"https://www.flagshippioneering.com/","founded":1999,"investors":[],"funding":[]},{"id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","aka":[],"tldr":"Oncology EHR (OncoEMR) and the largest curated real-world oncology database, acquired by Roche for $1.9B in 2018.","summary":"Flatiron Health, based in New York and acquired by Roche for 1.9 billion dollars in 2018, makes the OncoEMR oncology electronic health record and holds the largest curated real-world oncology database. Its data come from about 280 community practices and academic centres, its clinico-genomic database built with Foundation Medicine links treatment records to sequencing, and the data have been used in FDA label expansions and hundreds of publications. OnCo links it to oncology EHR and real-world data platforms and treatment pathway modules, to Roche and Foundation Medicine, and to the term for external and synthetic control arms. Whether real-world data owned by a drug company can serve as a regulatory comparator without conflict is the fair question. The real-world data platform page carries the wider debate.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://flatiron.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["oncology-real-world-data","hospital-information-systems-oncology"],"targets":[],"drugs":["samuraciclib","camonsertib","selicrelumab"],"companies":["roche-genentech","foundation-medicine"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07100106","nct06065748","nct05296798","nct06084936","nct05645692","nct03148418","nct04665856","nct04603807","nct05646862","nct04774718","nct04873362","nct05112965","nct07541079","nct00781612","nct02650401","nct07567846","nct02320435","nct03533283","nct04486378","nct07024706","nct06806033","nct07368998","nct04576455","nct07407933","nct04980222","nct05852691","nct07405801","nct06524375","nct05968326","nct05894239","nct06790693","nct07054190","nct04140500"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"New York, NY","country":"US","companyType":"ai-software","website":"https://flatiron.com","investors":[],"funding":[]},{"id":"florida-cancer-specialists","kind":"company","name":"Florida Cancer Specialists & Research Institute","aka":[],"tldr":"Florida Cancer Specialists is one of the largest independent oncology practices in the US and a leading phase 1 enroller through its Drug Development Unit.","summary":"Florida Cancer Specialists and Research Institute, based in Fort Myers, is one of the largest independent oncology practices in the United States and a leading phase 1 enroller through its Drug Development Unit. It runs about one hundred sites, achieves high trial accrual, and operates treatment pathways and value-based care programmes. OnCo links it to community oncology and site networks. Whether community practices can run first-in-human trials to the same standard as academic centres, which its accrual suggests, is the question its model tests. The community oncology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://flcancer.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":["community-oncology-networks"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Fort Myers, FL","country":"US","companyType":"cro-services","website":"https://flcancer.com","investors":[],"funding":[]},{"id":"foghorn-therapeutics","kind":"company","name":"Foghorn Therapeutics","aka":[],"tldr":"Foghorn Therapeutics makes drugs that act on the machinery that packages DNA and controls which genes are switched on. Its lead drug, partnered with Lilly, targets lung cancers that have lost a gene called SMARCA4.","summary":"Foghorn Therapeutics is a Cambridge, Massachusetts company targeting the chromatin regulatory system through its Gene Traffic Control platform. Its most advanced programme, FHD-909 (LY4050784), is a selective SMARCA2 ATPase inhibitor in phase 1 for SMARCA4-mutant non-small cell lung cancer, partnered with Lilly under a 50/50 US economic split with ex-US royalties; the Lilly collaboration also covers a selective SMARCA2 degrader and other programmes. Wholly owned preclinical programmes include a selective EP300 degrader for multiple myeloma, DLBCL and prostate cancer (IND targeted in 2027), a selective CBP degrader for ER-positive breast cancer, and a selective ARID1B degrader for ARID1A-mutant cancers. Foghorn also signed a collaboration with Merck in July 2020 (15 million US dollars upfront). Foghorn raised 135.2 million US dollars gross in its October 2020 Nasdaq IPO.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.foghorntx.com/"},{"label":"Pipeline","url":"https://www.foghorntx.com/pipeline/"},{"label":"Q3 2020 results noting IPO (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1822462/000119312520310711/d98800dex991.htm"}],"tags":[],"related":[],"cancers":["nsclc","multiple-myeloma","dlbcl","prostate","breast-hr-positive"],"sections":["epigenetics","targeted-therapy"],"technologies":["protac-degrader","epigenetic-drugs","synthetic-lethality-approaches"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The website blocks curl (HTTP 403) but was fetched successfully with WebFetch. Founding year and the Lilly deal terms (2021) not sourced beyond the pipeline page."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://www.foghorntx.com/","ticker":"FHTX","stage":"public","investors":["flagship-pioneering"],"funding":[{"round":"IPO","year":2020,"amountUsd":135200000,"source":"https://www.sec.gov/Archives/edgar/data/1822462/000119312520310711/d98800dex991.htm","note":"7.5 million shares at 16 US dollars in October 2020 plus 951,837 option shares in November 2020; gross proceeds 135.2 million US dollars"}]},{"id":"fondazione-italiana-linfomi","kind":"company","name":"Fondazione Italiana Linfomi","aka":["FIL","Fondazione Italiana Linfomi - ETS","Intergruppo Italiano Linfomi","IIL"],"tldr":"The Fondazione Italiana Linfomi is Italy's non-profit lymphoma trials foundation, constituted in 2010 out of the Intergruppo Italiano Linfomi of 1994 and working with more than 150 Italian centres; in OnCo it leads two lymphoma trials.","summary":"The Fondazione Italiana Linfomi (FIL) develops non-profit, independent clinical research projects for the treatment of lymphoma, involving more than 150 centres in Italy and collaborating with IELSG, EORTC, LYSA, GELTAMO and the European Mantle Cell Network; it is the evolution of the Intergruppo Italiano Linfomi, which first met in Florence in 1994, was constituted as a foundation on 29 September 2010, entered the Italian register of third-sector entities on 18 April 2023, is ISO 9001 certified for the design and management of clinical trials, and has its legal seat at Piazza Turati 5, Alessandria (filinf.it). ClinicalTrials.gov registers it as Fondazione Italiana Linfomi - ETS (OTHER class) and names it lead sponsor of NCT01827605 (phase 3, radioimmunotherapy against autologous transplant in relapsed follicular lymphoma) and NCT06835530 (FIL_RICCO, phase 2, rituximab with the cereblon modulator CC-99282 as front-line therapy for older frail patients with lymphoma), both recorded in OnCo. It has no products of its own.","asOf":"2026-09-25","links":[{"label":"FIL: la Fondazione","url":"https://www.filinf.it/fondazione/"},{"label":"ClinicalTrials.gov: trials led by Fondazione Italiana Linfomi - ETS","url":"https://clinicaltrials.gov/search?lead=Fondazione%20Italiana%20Linfomi%20-%20ETS"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["non-hodgkin-lymphoma","follicular-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct01827605","nct06835530"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"Alessandria","country":"IT","companyType":"cooperative-group","website":"https://www.filinf.it","founded":2010,"investors":[],"funding":[]},{"id":"forbion","kind":"company","name":"Forbion","aka":[],"tldr":"A Dutch venture firm that funds European and North American biotech companies from formation to late-stage growth. Its homepage says it manages around EUR 5 billion across 11 funds.","summary":"Forbion describes itself as 'a global venture capital firm dedicated to advancing groundbreaking biotech innovations' and marks '20 years of impacting the future'. Its homepage states 'EUR 5bn across 11 funds', including a EUR 1.2 billion Forbion Growth Opportunities Fund III, a EUR 890 million Forbion Ventures VII and a EUR 200 million Forbion BioEconomy I. Strategies are split into Human Health (Formation, Ventures and Growth) and Planetary Health. The firm leads Series A and B rounds in therapeutics companies and, through its Growth funds, crossover rounds ahead of IPOs. Its portfolio and news pages are rendered client-side, so no oncology portfolio companies could be confirmed from a fetched page; the firm's oncology holdings should be checked before any are named.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://forbion.com/"},{"label":"Portfolio","url":"https://forbion.com/portfolio/"},{"label":"History","url":"https://forbion.com/about-us/history/"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Portfolio and news pages load their content with JavaScript; no oncology company could be verified from fetched text. Naarden headquarters follows the task hint. Founding year not stated on fetched pages."],"hq":"Naarden","country":"NL","companyType":"investor","website":"https://forbion.com/","investors":[],"funding":[]},{"id":"foresee-pharmaceuticals","kind":"company","name":"Foresee Pharmaceuticals","aka":["Foresee Pharmaceuticals Co., Ltd.","Foresee"],"tldr":"Foresee is a Taipei biotech whose long-acting leuprolide depot, Camcevi, is an injection for advanced prostate cancer, and which runs phase 3 trials as lead sponsor.","summary":"Foresee Pharmaceuticals, headquartered in Taipei, Taiwan, developed a ready-to-use six-month leuprolide mesylate depot (Camcevi) for advanced prostate cancer, approved in the United States and Europe, and is developing further hormone and immunology products. It is lead sponsor of several phase 3 trials registered on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.foreseepharma.com"},{"label":"ClinicalTrials.gov: trials led by Foresee Pharmaceuticals","url":"https://clinicaltrials.gov/search?lead=Foresee%20Pharmaceuticals"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q140045369"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["leuprolide"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Taipei","country":"TW","companyType":"biotech","website":"https://www.foreseepharma.com","stage":"public","investors":[],"funding":[]},{"id":"foresight-diagnostics","kind":"company","name":"Foresight Diagnostics","aka":[],"tldr":"Stanford spin-out whose PhasED-Seq ctDNA technology detects residual lymphoma more accurately than PET/CT; clinical launch of CLARITY in 2026.","summary":"Foresight CLARITY uses phased variants on single cfDNA fragments to reach parts-per-million sensitivity. A pooled JCO analysis showed end-of-therapy MRD outperforms PET/CT in large B-cell lymphoma; SHORTEN-ctDNA (Columbia) tests MRD-guided chemotherapy de-escalation; a Hodgkin lymphoma MRD-guided trial launched 2026.","asOf":"2026-09-04","links":[{"label":"CLARITY platform","url":"https://foresight-dx.com/foresight-products-services/foresight-clarity/"}],"tags":[],"related":[],"cancers":["dlbcl","hodgkin-lymphoma"],"sections":["diagnostics"],"technologies":["mrd-testing","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["mrd"],"trials":["nct06500273"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boulder, CO","country":"US","companyType":"diagnostics","website":"https://foresight-dx.com","investors":[],"funding":[]},{"id":"foresite-capital","kind":"company","name":"Foresite Capital","aka":[],"tldr":"A San Francisco investment firm that funds healthcare companies at every stage with a data-science approach. Its cancer investments include CG Oncology, ALX Oncology, Kura Oncology and the blood-test company Delfi Diagnostics.","summary":"Foresite Capital was founded in 2011 by Jim Tananbaum and is headquartered in San Francisco (Wikipedia). It describes itself as 'a multi-stage healthcare and life sciences investment firm' that uses 'a data science-driven approach to invest in companies that leverage biology and big data to transform healthcare', and also incubates companies through Foresite Labs. Its portfolio page lists current and alumni holdings including ALX Oncology, Arcus Biosciences, Aura Biosciences, CG Oncology, Cullinan Therapeutics, Corvus Pharmaceuticals, Delfi Diagnostics (early cancer detection), Karyopharm, Kura Oncology and Lyell Immunopharma; the homepage quotes Theseus Pharmaceuticals on 'our mission to outsmart cancer resistance' and 10x Genomics' chief executive.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.foresitecapital.com/"},{"label":"Portfolio","url":"https://www.foresitecapital.com/portfolio/"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Foresite_Capital"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"investor","website":"https://www.foresitecapital.com/","founded":2011,"investors":[],"funding":[]},{"id":"fortrea","kind":"company","name":"Fortrea","aka":[],"tldr":"Fortrea, of Durham, North Carolina, is the contract research organisation spun out of Labcorp in 2023 that runs clinical trials for sponsors and keeps ties to Labcorp's central laboratory, which handles trial samples. Competing for oncology programmes against much larger rivals without its parent's balance sheet is its open question.","summary":"Fortrea, based in Durham, North Carolina, and listed as FTRE, is the contract research organisation spun out of Labcorp in 2023. It provides clinical development services and keeps ties to Labcorp's central laboratory business, which handles trial samples. OnCo links it to contract research organisations. Whether a newly independent CRO can compete for oncology programmes against much larger rivals without the parent's balance sheet is the open question. The CRO technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.fortrea.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["contract-research-organisations"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07109219"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Durham, NC","country":"US","companyType":"cro-services","website":"https://www.fortrea.com","ticker":"FTRE","investors":[],"funding":[]},{"id":"forward-pharmaceuticals","kind":"company","name":"Forward Pharmaceuticals","aka":["Forward Pharmaceuticals Co., Ltd."],"tldr":"Forward Pharmaceuticals is a China-based biotechnology company running 2 late-stage cancer trials of FWD1802 in HR-positive / HER2-negative breast cancer.","summary":"Forward Pharmaceuticals, based in Shenzhen, China, is a biotechnology company. Forward Pharma is a clinical-stage biotechnology company focused exclusively on oncology drug development, using structural characterisation, biophysical profiling and computational optimisation. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing FWD1802 in HR-positive / HER2-negative breast cancer. The largest, NCT07002177 (A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC), plans to enrol 196 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.forward-pharm.com"},{"label":"ClinicalTrials.gov: trials led by Forward Pharmaceuticals","url":"https://clinicaltrials.gov/search?lead=Forward%20Pharmaceuticals%20Co.%2C%20Ltd."},{"label":"Pipeline page","url":"https://www.forward-pharm.com/pipeline"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct07002177","nct06064812"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shenzhen","country":"CN","companyType":"biotech","website":"https://www.forward-pharm.com","founded":2015,"stage":"growth","investors":[],"funding":[]},{"id":"fotofinder","kind":"company","name":"FotoFinder Systems","aka":[],"tldr":"FotoFinder makes total body mapping and digital dermoscopy systems with AI mole analysis, widely used in European skin cancer clinics to follow patients with many moles.","summary":"FotoFinder Systems, based in Bad Birnbach, Bavaria, sells the ATBM automated total body mapping system, video dermoscopy cameras and the Moleanalyzer pro software, whose AI score for melanoma has been compared with dermatologists in published studies. It is a common platform for digital follow-up of high-risk patients in Germany, Austria and beyond.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.fotofinder.de/"}],"tags":["machines-wave2"],"related":[],"cancers":["melanoma","skin-cancer"],"sections":[],"technologies":["dermoscopy-ai","confocal-oct-skin-imaging","skin-cancer-screening"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Bad Birnbach","country":"DE","companyType":"imaging","website":"https://www.fotofinder.de/","stage":"private-large","investors":[],"funding":[]},{"id":"foundation-medicine","kind":"company","name":"Foundation Medicine (Roche)","aka":[],"tldr":"Maker of the FDA-approved FoundationOne CDx genomic test used across dozens of drug labels.","summary":"Foundation Medicine, based in Boston and owned by Roche, makes FoundationOne CDx, the FDA-approved comprehensive genomic profiling test written into dozens of drug labels. Its products include FoundationOne CDx and Liquid CDx, FoundationOne Tracker for measurable residual disease and FoundationOne Heme, and with Flatiron Health it built the largest real-world clinico-genomic database, which OnCo carries as a collection. OnCo links it to comprehensive genomic profiling, liquid biopsy and digital twins, to cancer of unknown primary, and to bottlenecks on unvalidated biomarkers, data silos and weak real-world evidence, with ideas on a single calibrated tumour mutational burden and machine-readable genomic reports attached. Whether a test owned by a drug company can be trusted as a neutral companion diagnostic is the fair question. FoundationOne has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.foundationmedicine.com"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":[],"targets":[],"drugs":["foundationone-cdx"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boston, MA","country":"US","companyType":"diagnostics","website":"https://www.foundationmedicine.com","investors":[],"funding":[]},{"id":"founders-fund","kind":"company","name":"Founders Fund","aka":[],"tldr":"Peter Thiel's San Francisco venture firm, best known for SpaceX, Palantir and Anduril. Its public portfolio page does not name any cancer companies, so its relevance to oncology is limited.","summary":"Founders Fund was founded in July 2005 by Peter Thiel, Ken Howery and Luke Nosek and is based at the Letterman Digital Arts Center in San Francisco (Wikipedia). It invests from seed to late stage in companies pursuing 'hard' technology and has historically been generalist, with occasional biotech investments. The portfolio page fetched lists SpaceX, Palantir, Anduril, Stripe, Neuralink, OpenAI and about 70 other companies; the only health-related names are Sword Health, Oscar and Cedar. No oncology company appears on the fetched page, so no portfolio examples are given here. Any cancer-related investments (for example, historical biotech holdings) would need to be sourced from a press release before being added.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://foundersfund.com/"},{"label":"Portfolio","url":"https://foundersfund.com/portfolio/"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Founders_Fund"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Website and Wikipedia verified, but no oncology portfolio company could be confirmed from a fetched page. Consider dropping from an oncology-specific graph."],"hq":"San Francisco, CA","country":"US","companyType":"investor","website":"https://foundersfund.com/","founded":2005,"investors":[],"funding":[]},{"id":"frantz-viral-therapeutics","kind":"company","name":"Frantz Viral Therapeutics","aka":["Frantz Viral Therapeutics, LLC"],"tldr":"Frantz Viral Therapeutics is a US-based biotechnology company that leads 2 cancer trials in OnCo, testing self-administered artesunate inserts and ointment for HPV-related pre-cancers in vaginal cancer and vulvar cancer.","summary":"Frantz Viral Therapeutics develops non-surgical, self-administered artesunate treatments for HPV-induced pre-cancers and cancers of the cervix, vulva, anus and oropharynx, delivered as vaginal inserts, suppositories or ointment. It is a collaboration between Georgetown University Medical Center and Frantz Medical Group. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT04098744 (phase 2, Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN...) and NCT06075264 (phase 2, Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous I...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://frantzviraltherapeutics.com/"},{"label":"ClinicalTrials.gov: trials led by Frantz Viral Therapeutics","url":"https://clinicaltrials.gov/search?lead=Frantz%20Viral%20Therapeutics%2C%20LLC"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["vaginal","vulvar"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04098744","nct06075264"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Mentor, Ohio","country":"US","companyType":"biotech","website":"https://frantzviraltherapeutics.com/","stage":"growth","investors":[],"funding":[]},{"id":"frazier-life-sciences","kind":"company","name":"Frazier Life Sciences","aka":[],"tldr":"A life sciences venture firm that grew out of Frazier Healthcare Partners in Seattle and now operates independently, backing private and public biotech companies.","summary":"Frazier Life Sciences Management, L.P. is described on the Frazier Healthcare Partners website as a 'separate and independent legal' entity from Frazier Management, LLC, with 'any prior affiliation between the firms' now 'fully terminated'. Frazier Healthcare Partners itself was founded in 1991 by Alan Frazier in Seattle (Wikipedia). The life sciences arm historically invested in company creation and later-stage private and public biotechs from offices in Seattle and the San Francisco Bay Area. At the time of research the frazierlifesciences.com domain returned only a blank page redirecting to a parking address, so the firm's own description, current offices and oncology portfolio could not be confirmed from a fetched primary source.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://frazierls.com/"},{"label":"Official website","url":"https://www.frazierlifesciences.com/"},{"label":"Frazier Healthcare Partners disclosure","url":"https://www.frazierhealthcare.com/news/"},{"label":"Wikipedia (Frazier Healthcare Partners)","url":"https://en.wikipedia.org/wiki/Frazier_Healthcare_Partners"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The frazierlifesciences.com domain is parked; the live site is frazierls.com, fetched on 2026-09-10."],"hq":"Seattle, WA","country":"US","companyType":"investor","website":"https://frazierls.com/","investors":[],"funding":[]},{"id":"freenome","kind":"company","name":"Freenome","aka":[],"tldr":"Freenome makes SimpleScreen CRC, the second FDA-approved blood test for colorectal cancer screening (July 2026), commercialised by Abbott.","summary":"FDA approved SimpleScreen CRC on 24 July 2026 for average-risk adults 45+ based on PREEMPT CRC (>48,000 participants; ~80% CRC sensitivity, ~90% specificity). Freenome listed via a $330M SPAC merger (2025-26); Abbott holds US commercial rights and paid a $100M approval milestone; launch expected autumn 2026.","asOf":"2026-09-04","links":[{"label":"FDA approval (MedTech Dive)","url":"https://www.medtechdive.com/news/freenome-secures-fda-nod-for-blood-based-colorectal-cancer-test/826290/"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":["early-detection"],"technologies":["mced","liquid-biopsy","methylation-profiling"],"targets":[],"drugs":["shield"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"South San Francisco, CA","country":"US","companyType":"diagnostics","website":"https://www.freenome.com","ticker":"FRNM","investors":[],"funding":[]},{"id":"french-sarcoma-group","kind":"company","name":"French Sarcoma Group","aka":["Groupe Sarcome Français","GSF-GETO","French Sarcoma Group (GSF-GETO)"],"tldr":"The French Sarcoma Group is the national cooperative group for soft tissue and bone sarcoma trials in France; in OnCo it is the sponsor of ANGIOTAX and the group behind LMS-04 and CABONE.","summary":"The French Sarcoma Group (Groupe Sarcome Français, GSF-GETO) is the French cooperative group for sarcoma trials. Its website could not be read for this record: gsf-geto.org does not resolve and gsf-geto.fr carried only a placeholder page on 25 September 2026, so no seat or founding year is given here. In OnCo it is the recorded sponsor of ANGIOTAX (phase 2, weekly paclitaxel in angiosarcoma, reported 2008, no registry id) and the group named on LMS-04 (NCT02997358, phase 3, doxorubicin with trabectedin in leiomyosarcoma; the registry lead sponsor is Gustave Roussy) and CABONE (NCT02243605, phase 2, cabozantinib in osteosarcoma and Ewing sarcoma, run from the Centre Léon Bérard). ClinicalTrials.gov also lists it as a collaborator on the Italian Sarcoma Group's ISG-STS 1001. It has no products of its own.","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov: trials led by French Sarcoma Group","url":"https://clinicaltrials.gov/search?lead=French%20Sarcoma%20Group"},{"label":"ClinicalTrials.gov: LMS-04 (NCT02997358)","url":"https://clinicaltrials.gov/study/NCT02997358"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["sarcoma","angiosarcoma","vascular-tumours","leiomyosarcoma","uterine-sarcoma","extremity-soft-tissue-sarcoma","retroperitoneal-sarcoma","osteosarcoma","ewing-sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["gustave-roussy","centre-leon-berard"],"pathways":[],"terms":[],"trials":["angiotax","lms-04","cabone"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"France (seat not stated)","country":"FR","companyType":"cooperative-group","investors":[],"funding":[]},{"id":"fresenius-kabi","kind":"company","name":"Fresenius Kabi","aka":[],"tldr":"Fresenius Kabi, of Bad Homburg, Germany, supplies the Amicus and LOVO apheresis devices that collect and process cells for cell therapy, a large portfolio of generic chemotherapy injectables, biosimilars and infusion products. Its generics have filled gaps during injectable shortages, which keep recurring because the economics of generic injectables remain unfixed.","summary":"Fresenius Kabi, based in Bad Homburg and part of Fresenius SE, supplies apheresis devices including Amicus and LOVO, generic oncology injectables, biosimilars and infusion products. Its large generic chemotherapy portfolio and cell-processing devices have made it a key source during injectable shortages. OnCo links it to apheresis and starting-material collection, generic oncology drug supply and shortage mitigation, and infusion pumps and ambulatory chemotherapy devices. Whether the economics of generic injectables can be fixed so that shortages stop recurring is the open question. The drug shortage technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.fresenius-kabi.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["cell-therapy","chemotherapy"],"technologies":["apheresis-starting-material","generic-drug-shortage-response","infusion-devices-vascular-access"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Bad Homburg","country":"DE","companyType":"devices","website":"https://www.fresenius-kabi.com","investors":[],"funding":[]},{"id":"frontier-medicines","kind":"company","name":"Frontier Medicines","aka":[],"tldr":"Chemoproteomics company with FMC-376, a KRAS G12C inhibitor that hits both the ON and OFF states of the protein, in phase 1/2.","summary":"Frontier Medicines, based in South San Francisco, is a chemoproteomics company whose FMC-376, a KRAS G12C inhibitor that hits both the ON and OFF states of the protein, is in phase 1/2. FMC-376 covalently targets GTP-bound and GDP-bound KRAS G12C and is designed to overcome the adaptive receptor tyrosine kinase feedback that limits first-generation G12C drugs; the PROSPER phase 1/2 trial, NCT06244771, is recruiting with primary completion estimated for October 2027. OnCo links it to non-small-cell lung, colorectal and pancreatic cancer, to KRAS and RAS inhibitors, to KRAS as a target and the MAPK pathway, to the bottleneck of undruggable drivers, and to ideas on covalent chemistry for RAS mutations and an open map of which proteins any drug can bind. Whether dual-state inhibition delays resistance in patients is the question PROSPER will answer. The KRAS target page carries the field.","asOf":"2026-09-04","links":[{"label":"PROSPER trial","url":"https://clinicaltrials.gov/study/NCT06244771"}],"tags":[],"related":[],"cancers":["nsclc","colorectal","pancreatic"],"sections":["targeted-therapy"],"technologies":["kras-inhibitors"],"targets":["kras"],"drugs":[],"companies":[],"institutions":[],"pathways":["ras-mapk"],"terms":[],"trials":["nct06244771"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.frontiermeds.com","investors":[],"funding":[]},{"id":"fujifilm-diosynth","kind":"company","name":"FUJIFILM Diosynth Biotechnologies","aka":[],"tldr":"FUJIFILM Diosynth Biotechnologies, headquartered in Tokyo, is a biologics contract manufacturer offering mammalian and microbial production and cell and gene therapy services, and is adding antibody capacity in Denmark and North Carolina, where its Holly Springs site is among the world's largest. Whether new capacity outruns demand once the biggest antibody patents expire is the sector's question.","summary":"FUJIFILM Diosynth Biotechnologies, headquartered in Tokyo, is a large biologics CDMO building antibody capacity in Denmark and in North Carolina. It offers mammalian and microbial manufacturing and cell and gene therapy services, and its Holly Springs site is among the largest in the world. OnCo links it to antibody manufacturing through CHO bioprocessing. Whether the wave of new antibody capacity outruns demand once patents on the biggest antibodies expire is the open question for the sector. The antibody manufacturing page carries the wider picture.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Fujifilm_Diosynth_Biotechnologies","links":[{"label":"Official website","url":"https://fujifilmdiosynth.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["immunotherapy","adcs"],"technologies":["monoclonal-antibody-manufacturing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tokyo","country":"JP","companyType":"cro-services","website":"https://fujifilmdiosynth.com","investors":[],"funding":[]},{"id":"fujifilm","kind":"company","name":"FUJIFILM Healthcare","aka":["Fujifilm Holdings","Fujifilm Healthcare"],"tldr":"Fujifilm moved from photographic film into medical imaging and now sells digital X-ray, mammography, ultrasound, endoscopes and, since buying Hitachi's imaging business in 2021, CT and MRI scanners.","summary":"FUJIFILM Holdings, founded in 1934, used its expertise in film and image processing to build a healthcare business that includes FDR digital radiography, Amulet mammography, Arietta and Sonosite ultrasound, flexible endoscopes that compete with Olympus in colonoscopy, and the Synapse radiology and pathology information systems. The 2021 acquisition of Hitachi's diagnostic imaging division added CT and MRI, making it a full-line imaging vendor. Its contract biologics arm is recorded separately as FUJIFILM Diosynth Biotechnologies. OnCo links it to radiography, CT, MRI, ultrasound and mammography.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.fujifilm.com"}],"tags":["machines-wave"],"related":["fujifilm-diosynth"],"cancers":[],"sections":["imaging","diagnostics"],"technologies":["x-ray-radiography-fluoroscopy","ct","mri","mri-field-strengths","ultrasound","ultrasound-elastography-ceus","mammography"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tokyo","country":"JP","companyType":"imaging","website":"https://www.fujifilm.com","ticker":"4901.T","founded":1934,"stage":"public","investors":[],"funding":[]},{"id":"fujirebio","kind":"company","name":"Fujirebio","aka":["Fujirebio Diagnostics","H.U. Group"],"tldr":"The Japanese immunoassay company, part of H.U. Group, whose Malvern, Pennsylvania laboratory holds the original CA 19-9 and CA-125 tumour marker assays and licenses the antibodies to the big analyser makers.","summary":"Fujirebio is a Tokyo-based in vitro diagnostics company within H.U. Group Holdings. Its United States subsidiary, Fujirebio Diagnostics in Malvern, Pennsylvania, descends from Centocor Diagnostics, where the CA 19-9 and CA-125 immunoassays were developed in the early 1980s, and it still supplies the reference antibodies and assays (CA 19-9, CA-125 II, HE4, CYFRA 21-1, ProGRP) that run on its own Lumipulse analysers and, under licence, on the platforms of other manufacturers. The company is also a major supplier of Alzheimer's disease biomarker tests, and its oncology business centres on ovarian, pancreatic and lung cancer markers.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Fujirebio","links":[{"label":"Official website","url":"https://www.fujirebio.com"}],"tags":[],"related":[],"cancers":["ovarian","pancreatic","nsclc"],"sections":[],"technologies":["serum-tumour-markers","proteomics-platforms"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tokyo, Japan","country":"JP","companyType":"diagnostics","website":"https://www.fujirebio.com","investors":[],"funding":[]},{"id":"fusion-pharma","kind":"company","name":"Fusion Pharmaceuticals (AstraZeneca)","aka":[],"tldr":"Alpha-emitter company acquired by AstraZeneca ($2.4B, 2024); FPI-2265 (225Ac-PSMA-I&T) in phase 3.","summary":"Fusion Pharmaceuticals, based in Hamilton, Ontario, is the alpha-emitter company acquired by AstraZeneca for 2.4 billion dollars in 2024, and its FPI-2265, an actinium-225 PSMA-I&T agent, is in phase 3. Its pipeline also includes FPI-2068, an EGFR by c-MET bispecific radioconjugate, and the company holds actinium-225 supply agreements. OnCo links it to the AlphaBreak trial of FPI-2265 and the AcTION trial of 225Ac-PSMA-617, to targeted alpha therapy, to the actinium-225 PSMA agents record and to the radiopharmaceutical roadmap. Whether actinium PSMA therapy can improve on lutetium PSMA therapy is the question AlphaBreak will answer. Actinium-225 PSMA agents have their own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.astrazeneca.com"}],"tags":[],"related":[],"cancers":[],"sections":["radiopharma"],"technologies":[],"targets":[],"drugs":["ac225-psma"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Hamilton, ON","country":"CA","companyType":"radiopharma","website":"https://www.astrazeneca.com","investors":[],"funding":[]},{"id":"future-of-cancer-care-today","kind":"company","name":"Future of Cancer Care Today (FCCT)","aka":["FCCT"],"tldr":"Future of Cancer Care Today is a free, PhD-led service that helps cancer patients and families connect the dots when standard of care runs out: it surfaces diagnostic and treatment options for their case, finds vetted suppliers who work beyond standard protocols, and writes playbooks so families walk into the next appointment with a fuller picture.","summary":"FCCT is incubated by the Sijbrandij Foundation and led by chief executive Poornima Parameswaran, with Bayli DiVita Dean as director of patient connections. It does not replace doctors or make treatment decisions; it is a non-clinical support layer of information, education and decision support. Its public directory groups suppliers and care providers by what they do: tumour tissue preservation, tumour molecular profiling, functional drug testing, liquid biopsy and monitoring, immune profiling, molecular imaging and theranostics, cancer vaccines, cell and gene therapies, oncolytic viruses, clinical trial finders, navigation and support, and physicians open to complex cases, each entry noting the country and whether a patient can order it directly. Self-serve playbooks cover finding open-minded physicians, assembling a personal tumour board, building a therapeutic ladder, drug access advocacy, bridging to a trial, preserving tumour tissue and comprehensive diagnostics, and a whitepaper addresses the legal barriers to patients accessing and transferring their own health data and tissue. OnCo records every organisation on the list.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://sijbrandijfoundation.org/fcct"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"},{"label":"FCCT page","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory","patient-first","navigation"],"related":["sid-sijbrandij"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["sijbrandij-foundation"],"institutions":["houston-methodist-rna-therapeutics","docrates"],"pathways":[],"terms":[],"trials":[],"people":["poornima-parameswaran","bayli-divita-dean"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Francisco, CA","country":"US","companyType":"nonprofit","website":"https://sijbrandijfoundation.org/fcct","stage":"startup","investors":[],"funding":[]},{"id":"futurechem","kind":"company","name":"FutureChem","aka":[],"tldr":"FutureChem is a South Korea-based radiopharmaceutical company running 2 late-stage cancer trials of [F-18]Florastamin in prostate cancer.","summary":"FutureChem, based in Seoul, South Korea, is a radiopharmaceutical company. FUTURECHEM is a radiopharmaceutical drug-development company specialising in PET diagnostic imaging agents for neurological and oncological conditions. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing [F-18]Florastamin in prostate cancer. The largest, NCT05004285 (Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis), plans to enrol 398 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.futurechem.co.kr"},{"label":"ClinicalTrials.gov: trials led by FutureChem","url":"https://clinicaltrials.gov/search?lead=FutureChem"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate"],"sections":["radiopharma"],"technologies":[],"targets":[],"drugs":["florastamin-f18"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Seoul","country":"KR","companyType":"radiopharma","website":"https://www.futurechem.co.kr","stage":"public","investors":[],"funding":[]},{"id":"g1-therapeutics","kind":"company","name":"G1 Therapeutics","aka":["G1 Therapeutics, Inc.","G1"],"tldr":"G1 Therapeutics developed trilaciclib (Cosela), a CDK4/6 inhibitor given before chemotherapy to protect bone marrow, approved in 2021 for small-cell lung cancer; the company was acquired by Pharmacosmos in 2024.","summary":"G1 Therapeutics, based in Research Triangle Park, North Carolina, developed trilaciclib, an intravenous CDK4/6 inhibitor that briefly halts haematopoietic stem cells before chemotherapy so they are spared its damage. The FDA approved it as Cosela in February 2021 to reduce chemotherapy-induced myelosuppression in extensive-stage small-cell lung cancer; a phase 3 trial in triple-negative breast cancer (PRESERVE 2) did not improve survival. Pharmacosmos, the Danish iron-medicine company, acquired G1 in 2024. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials led by G1 Therapeutics","url":"https://clinicaltrials.gov/search?lead=G1%20Therapeutics"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/G1_Therapeutics"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["sclc","tnbc"],"sections":["supportive-care"],"technologies":["cdk46-inhibitor"],"targets":["cdk4-6"],"drugs":["lerociclib"],"companies":[],"institutions":[],"pathways":[],"terms":["neutropenia"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Research Triangle Park, NC","country":"US","companyType":"biotech","stage":"acquired","investors":[],"funding":[]},{"id":"galapagos","kind":"company","name":"Galapagos","aka":[],"tldr":"Galapagos is a biotech pursuing decentralised, seven-day vein-to-vein CAR-T manufacturing at hospital sites; it restructured its cell-therapy business in 2025.","summary":"Galapagos, based in Mechelen, Belgium, and listed as GLPG, is a biotechnology company pursuing decentralised, seven-day vein-to-vein CAR-T manufacturing at hospital sites, and it restructured its cell therapy business in 2025. It uses Lonza's Cocoon platform at partner hospitals to make GLPG5101, a CD19 CAR-T, and GLPG5201, and in 2025 it announced a separation of the cell therapy unit and a strategic review; the record notes that its current corporate status should be verified before citing. OnCo links it to point-of-care and decentralised cell manufacturing. Whether hospital-based manufacturing can meet regulatory standards at scale is the question its model was built to test, and its restructuring shows how hard the business case is. The decentralised manufacturing page carries the wider field.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.glpg.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["point-of-care-cell-manufacturing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06652633"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Mechelen","country":"BE","companyType":"biotech","website":"https://www.glpg.com","ticker":"GLPG","investors":[],"funding":[]},{"id":"galderma","kind":"company","name":"Galderma","aka":["Galderma R&D","Galderma S.A.","Spirig Pharma Ltd.","Spirig Pharma"],"tldr":"Galderma is a Swiss dermatology company, listed in 2024, whose cancer-related trials concern photodynamic therapy for actinic keratosis and basal cell carcinoma.","summary":"Galderma, based in Zug and listed on the SIX Swiss Exchange since 2024, is a dermatology company spanning prescription medicines, aesthetics and consumer skin care. Its cancer-related registry trials mostly concern methyl aminolevulinate photodynamic therapy (Metvix) for actinic keratosis and superficial basal cell carcinoma. OnCo records it so that those phase 3 trials resolve to a sponsor page.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Galderma","links":[{"label":"Official website","url":"https://www.galderma.com"},{"label":"ClinicalTrials.gov: trials led by Galderma","url":"https://clinicaltrials.gov/search?lead=Galderma"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Galderma"},{"label":"Wikipedia: methyl aminolevulinate (Galderma holds the Metvix rights)","url":"https://en.wikipedia.org/wiki/Methyl_aminolevulinate"}],"tags":["ctgov-sponsor"],"related":["leo-pharma","almirall"],"cancers":["basal-cell-carcinoma","cutaneous-scc"],"sections":["prevention"],"technologies":["photodynamic-therapy-lasers"],"targets":[],"drugs":["methyl-aminolevulinate"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Zug","country":"CH","companyType":"pharma","website":"https://www.galderma.com","stage":"public","investors":[],"funding":[]},{"id":"galen","kind":"company","name":"Galen","aka":[],"tldr":"Galen is an AI personal assistant for cancer patients that helps find trials, interpret lab results, manage appointments and deal with insurance.","summary":"Future of Cancer Care Today lists Galen as an AI-driven personal assistant for cancer patients covering trial finding, lab interpretation, appointment management and insurance coordination, patient-accessible.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://app.usegalen.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["ai-trial-matching"],"targets":[],"drugs":[],"companies":["future-of-cancer-care-today"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"United States (city not published)","country":"US","companyType":"ai-software","website":"https://app.usegalen.com/","stage":"startup","investors":[],"funding":[]},{"id":"galena-biopharma","kind":"company","name":"Galena Biopharma","aka":["Galena Biopharma, Inc.","RXi Pharmaceuticals","SELLAS Life Sciences"],"tldr":"Galena was the company behind NeuVax, a HER2 peptide vaccine meant to stop early breast cancer returning; the phase 3 PRESENT trial was stopped for futility in 2016 and Galena merged into SELLAS.","summary":"Galena Biopharma, founded in 2006 and headquartered in Portland, Oregon, developed nelipepimut-S (NeuVax), a HER2-derived E75 peptide vaccine given with GM-CSF to prevent recurrence in node-positive, HER2 low-expressing breast cancer. The phase 3 PRESENT trial was halted for futility in 2016; Galena merged with SELLAS Life Sciences in 2017. Its trials remain on ClinicalTrials.gov under Galena as lead sponsor.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Galena_Biopharma","links":[{"label":"Official website","url":"http://galenabiopharma.com"},{"label":"ClinicalTrials.gov: trials led by Galena Biopharma, Inc.","url":"https://clinicaltrials.gov/search?lead=Galena%20Biopharma%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q5518376"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":["her2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct04588922","nct04229979"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Portland, OR","country":"US","companyType":"biotech","website":"http://galenabiopharma.com","founded":2006,"stage":"acquired","investors":[],"funding":[]},{"id":"galera-therapeutics","kind":"company","name":"Galera Therapeutics","aka":["Galera Therapeutics, Inc.","Galera"],"tldr":"Galera developed avasopasem, a synthetic enzyme mimic meant to prevent the severe mouth ulcers of head and neck radiotherapy; the FDA declined approval in 2023 despite a positive phase 3 trial.","summary":"Galera Therapeutics, based in Malvern, Pennsylvania, developed avasopasem manganese, a superoxide dismutase mimetic, to reduce severe oral mucositis in patients having chemoradiotherapy for head and neck cancer. The phase 3 ROMAN trial met its primary endpoint but the FDA issued a complete response letter in 2023 asking for a further trial. Its trials remain on ClinicalTrials.gov under Galera as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.galeratx.com"},{"label":"ClinicalTrials.gov: trials led by Galera Therapeutics, Inc.","url":"https://clinicaltrials.gov/search?lead=Galera%20Therapeutics%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q140046053"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["head-and-neck"],"sections":["supportive-care","radiation"],"technologies":[],"targets":[],"drugs":["avasopasem-manganese"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Malvern, PA","country":"US","companyType":"biotech","website":"https://www.galeratx.com","stage":"public","investors":[],"funding":[]},{"id":"gamgee","kind":"company","name":"Gamgee","aka":[],"tldr":"Gamgee sequences a dog's tumour and designs a personalised mRNA vaccine that teaches its immune system what to attack, and is running trials in Australia with the aim of improving the approach with every case.","summary":"Gamgee began when its founder used AI and genomic analysis to design what is believed to be the first fully computationally designed mRNA cancer vaccine given to a dog, with scientists at UNSW; several tumours shrank. The company now runs an end-to-end platform for personalised neoantigen mRNA vaccines in dogs, from veterinary intake and tissue collection through sequencing, vaccine manufacture, treatment and response monitoring, with clinical trials in Australia. It is a veterinary business included for its comparative oncology value; human applications are not claimed.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/gamgee"},{"label":"Official website","url":"https://gamgee.io"}],"tags":["veterinary","comparative-oncology"],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["neoantigen-mrna-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"biotech","website":"https://gamgee.io","stage":"startup","ycBatch":"S26","investors":["y-combinator"],"funding":[]},{"id":"gamida-cell","kind":"company","name":"Gamida Cell","aka":["Gamida Cell Ltd."],"tldr":"Gamida Cell developed omidubicel, the nicotinamide-expanded cord blood therapy approved by the FDA in 2023 to speed neutrophil recovery after transplant in patients with blood cancers.","summary":"Gamida Cell, founded in Israel in 1998 with a plant at Kiryat Gat and later a Boston address, developed a nicotinamide-based method for expanding cord blood stem cells outside the body. Its product omidubicel (Omisirge) was approved by the FDA on 17 April 2023 to shorten neutrophil recovery and reduce infections after umbilical cord blood transplantation in patients aged 12 and over with haematologic malignancies; the current label, effective February 2026, adds a second indication in severe aplastic anaemia from age 6.\n\nApproval did not save the company. A restructuring agreement with Highbridge Capital in March 2024 converted debt to equity on terms stating that the outstanding ordinary shares were expected to be cancelled; a Chapter 15 petition in Delaware in April 2024 recognised an Israeli debt-arrangement proceeding before the Be'er Sheva District Court, whose May 2024 judgment provided that creditors be repaid in full while shareholders' rights were voided. Nasdaq delisting took effect on 6 May 2024 and the company deregistered from SEC reporting later that month. It is now held through Ayrmid Ltd, which since November 2024 also holds the US rights to BioLineRx's motixafortide, so one owner sits behind both Israeli stem-cell-transplant products. Company facts are from the FDA approval record and the SEC filings.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.gamida-cell.com/"},{"label":"FDA approval announcement for omidubicel","url":"https://www.fda.gov/news-events/press-announcements/fda-approves-cell-therapy-patients-blood-cancers-reduce-risk-infection-following-stem-cell"},{"label":"SEC filings (CIK 0001600847), including the 2024 restructuring and deregistration","url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=gamida+cell&type=&dateb=&owner=include&count=40"}],"tags":["fda-oce-applicant"],"related":[],"cancers":["aml","all-leukemia","mds"],"sections":["cell-therapy"],"technologies":[],"targets":[],"drugs":["omidubicel","motixafortide"],"companies":["biolinerx"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Boston, MA","country":"US","companyType":"cell-therapy","website":"https://www.gamida-cell.com/","stage":"acquired","investors":[],"funding":[]},{"id":"gc-cell","kind":"company","name":"GC Cell","aka":["GC Cell Corporation","Green Cross Cell","GC Cell Corp."],"tldr":"GC Cell is a South Korean cell therapy company whose autologous cytokine-induced killer cell product Immuncell-LC has been approved in Korea since 2007 as adjuvant treatment after liver cancer surgery.","summary":"GC Cell, part of the GC (Green Cross) group and listed in Korea, was formed in 2021 from Green Cross Cell and Green Cross LabCell. Its longest-standing product is Immuncell-LC, autologous cytokine-induced killer cells given after resection of hepatocellular carcinoma, approved in South Korea in 2007 and supported by a phase 3 trial showing longer recurrence-free survival; the company also develops CAR-T and NK cell therapies. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.gccell.com"},{"label":"ClinicalTrials.gov: trials led by GC Cell","url":"https://clinicaltrials.gov/search?lead=GC%20Cell"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["hcc"],"sections":["cell-therapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct04969731"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Yongin","country":"KR","companyType":"cell-therapy","website":"https://www.gccell.com","stage":"public","investors":[],"funding":[]},{"id":"ge-healthcare","kind":"company","name":"GE HealthCare","aka":[],"tldr":"GE HealthCare, of Chicago, makes PET/CT, MRI and CT scanners (Omni Legend, SIGNA, Revolution) and PET tracers through its Pharmaceutical Diagnostics business, including Cerianna, the fluoroestradiol F-18 agent that images oestrogen receptors in breast cancer. Whether receptor-imaging tracers change treatment decisions often enough to be reimbursed is its tracer business's open question.","summary":"GE HealthCare, based in Chicago and listed as GEHC, makes PET/CT, MRI and CT scanners and PET tracers through its Pharmaceutical Diagnostics business. Its scanners include the Omni Legend PET/CT, SIGNA MRI and Revolution CT, and its tracer business spans flurpiridaz, cyclotrons and Cerianna, the fluoroestradiol F-18 agent for imaging oestrogen receptor expression in breast cancer. OnCo links it to PET/CT, MRI and CT, to medical cyclotrons and total-body PET hardware, and to the fluoroestradiol F-18 drug record. Whether receptor-imaging tracers such as FES change treatment decisions often enough to be reimbursed widely is the open question for its tracer business. Fluoroestradiol F-18 has its own page.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/GE_HealthCare","links":[{"label":"Official website","url":"https://www.gehealthcare.com"}],"tags":[],"related":[],"cancers":[],"sections":["imaging"],"technologies":["pet-ct","mri","ct"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07219238"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Chicago, IL","country":"US","companyType":"imaging","website":"https://www.gehealthcare.com","ticker":"GEHC","investors":[],"funding":[]},{"id":"geicam","kind":"company","name":"GEICAM Spanish Breast Cancer Group","aka":["GEICAM","Grupo Español de Investigación en Cáncer de Mama"],"tldr":"Spain's national breast cancer research group, running adjuvant chemotherapy, endocrine and CDK4/6 inhibitor trials across more than 200 hospitals.","summary":"Founded in 1995, GEICAM brings together Spain's breast cancer investigators and has enrolled tens of thousands of patients in academic trials. GEICAM 9906 and 9805 shaped adjuvant taxane use, CIBOMA tested maintenance capecitabine in triple-negative disease, and PARSIFAL and FLIPPER studied palbociclib partners in hormone receptor-positive metastatic cancer. GEICAM co-runs global trials with the Breast International Group and the US cooperative groups and maintains the El Álamo registry and a tumour bank. Its chairman is a member of the OnCo people corpus.","asOf":"2026-09-09","links":[{"label":"GEICAM","url":"https://www.geicam.org"},{"label":"Clinical trials (archived copy)","url":"https://web.archive.org/web/20211020135241/https://www.geicam.org/en/clinical-trials"}],"tags":["cooperative-group"],"related":["palbociclib"],"cancers":["breast-hr-positive","breast-her2-positive","tnbc"],"sections":["hormonal"],"technologies":["cdk46-inhibitor","endocrine-therapy","cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":["big","solti"],"institutions":["gregorio-maranon"],"pathways":[],"terms":[],"trials":[],"people":["miguel-martin","sara-lopez-tarruella","ander-urruticoechea"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Adjuvant chemotherapy trials (GEICAM 9906, 9805)","CDK4/6 inhibitor trials (PARSIFAL, FLIPPER)","El Álamo registry and biobank","BIG member group"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Madrid","country":"ES","companyType":"cooperative-group","website":"https://www.geicam.org","founded":1995,"investors":[],"funding":[]},{"id":"gemini-therapeutics","kind":"company","name":"Gemini Therapeutics","aka":["Gemini Thera"],"tldr":"Gemini Therapeutics is a startup with a single purpose: finishing the development of aldoxorubicin, a tumour-targeted form of doxorubicin, founded after the GitLab co-founder Sid Sijbrandij was treated with doxorubicin for osteosarcoma.","summary":"Gemini Therapeutics describes itself as singularly focused on advancing aldoxorubicin by supplying the capital and operational expertise to bring it to patients sooner. Its origin story is Sid Sijbrandij's osteosarcoma diagnosis at the end of 2022 and his treatment with doxorubicin, whose cumulative cardiac toxicity limits how much patients can receive. The company is led by co-founders Diego Rey (chief executive, previously co-founder of GeneWEAVE Biosciences, acquired by Roche, and of Endpoint Health, and the first Y Combinator visiting partner for life sciences) and the sarcoma oncologist Sant Chawla, who led the aldoxorubicin trials, with a team that includes former Doxil and FDA reviewers. At ASCO 2026 it presented integrated analyses of the randomised soft tissue sarcoma studies reporting higher tumour exposure and better cardiac preservation than doxorubicin. Aldoxorubicin is investigational and not approved.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.geminithera.com"},{"label":"Team","url":"https://www.geminithera.com/team.html"},{"label":"ASCO 2026 press release","url":"https://www.geminithera.com/news/asco-2026-aldoxorubicin.html"},{"label":"X: @GeminiThera","url":"https://x.com/GeminiThera"}],"tags":["ctgov-sponsor","startup","owner-request"],"related":[],"cancers":["sarcoma","osteosarcoma"],"sections":["chemotherapy"],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["aldoxorubicin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"United States (head office not published)","country":"US","companyType":"biotech","website":"https://www.geminithera.com","stage":"startup","investors":[],"funding":[]},{"id":"genelux","kind":"company","name":"Genelux","aka":["Genelux Corporation"],"tldr":"Genelux is a United States-based biotechnology company running 2 late-stage cancer trials of olvimulogene nanivacirepvec and Olvimulogene nanivacirepvec in ovarian cancer and non-small-cell lung cancer.","summary":"Genelux, based in Westlake Village, CA, the United States, is a biotechnology company. Genelux is a biopharmaceutical company developing oncolytic immunotherapies based on a modified vaccinia virus platform. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing olvimulogene nanivacirepvec and Olvimulogene nanivacirepvec in ovarian cancer and non-small-cell lung cancer. The largest, NCT05281471 (Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)), plans to enrol 186 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Genelux_Corporation","links":[{"label":"Official website","url":"https://www.genelux.com"},{"label":"ClinicalTrials.gov: trials led by Genelux","url":"https://clinicaltrials.gov/search?lead=Genelux%20Corporation"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["ovarian","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["olvimulogene-nanivacirepvec"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06463665"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Westlake Village, CA","country":"US","companyType":"biotech","website":"https://www.genelux.com","stage":"public","investors":[],"funding":[]},{"id":"geneos-therapeutics","kind":"company","name":"Geneos Therapeutics","aka":[],"tldr":"Geneos builds a personalised DNA vaccine for each patient from the mutations in their own tumour, injected into the skin with a small electrical pulse so the immune system learns to attack the cancer.","summary":"Geneos Therapeutics develops personalised neoantigen immunotherapies on its GT-EPIC platform: a patient-specific DNA plasmid encoding up to 40 tumour neoantigens is given intradermally with electroporation together with a DNA-encoded interleukin-12 adjuvant. The GT-30 phase 1b/2a trial tested GNOS-PV02 with pembrolizumab in advanced hepatocellular carcinoma, reporting a 30.4 percent overall response rate in 23 evaluable patients (2022), eight of 34 patients reaching complete response, complete molecular response or secondary resectability (2023), and in April 2024 that its primary and a secondary efficacy endpoint were met. In September 2025 the company reported liver cancer and glioblastoma patients treated with its monotherapy reaching five years of recurrence-free survival, and plans a phase 2b trial. Geneos has raised a USD 10.5 million Series A (2019), USD 12 million A1 (2021), USD 17 million A2 (2022) and USD 5 million A3 (2023).","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.geneostx.com"},{"label":"Press releases","url":"https://www.geneostx.com/press-releases/"},{"label":"Series A2 financing (March 2022)","url":"https://www.geneostx.com/geneos-therapeutics-secures-17-million-in-series-a2-financing-to-advance-personalized-cancer-immunotherapy-platform/"}],"tags":[],"related":[],"cancers":["hcc","glioblastoma"],"sections":["immunotherapy"],"technologies":["neoantigen-mrna-vaccine","cytokine-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The 2022 release gives Plymouth Meeting, PA as HQ; the current website footer gives 3675 Market Street, Philadelphia, PA, which is used here. Founding year not sourced."],"hq":"Philadelphia, PA","country":"US","companyType":"biotech","website":"https://www.geneostx.com","stage":"startup","investors":["sante-ventures"],"funding":[{"round":"Series A","year":2019,"amountUsd":10500000,"source":"https://www.geneostx.com/press-releases/"},{"round":"Series A","year":2022,"amountUsd":17000000,"source":"https://www.geneostx.com/geneos-therapeutics-secures-17-million-in-series-a2-financing-to-advance-personalized-cancer-immunotherapy-platform/","note":"Series A2, led by Flerie Invest"},{"round":"Series A","year":2023,"amountUsd":5000000,"source":"https://www.geneostx.com/press-releases/","note":"Series A3"}]},{"id":"geneoscopy","kind":"company","name":"Geneoscopy","aka":["ColoSense"],"tldr":"A St. Louis diagnostics company whose ColoSense stool RNA test became, in 2024, the first RNA-based colorectal cancer screening test approved in the United States.","summary":"Geneoscopy was founded by Washington University alumni to develop diagnostics from RNA shed by cells of the gut lining into stool. Its first product, ColoSense, combines eight RNA markers with a faecal immunochemical test for blood and was approved by the FDA in May 2024 for colorectal cancer screening in average-risk adults aged 45 and over, on the strength of the CRC-PREVENT study. The company positions stool RNA as less prone to the age-related false positives of stool DNA methylation tests and is developing further gut RNA tests, including for inflammatory bowel disease.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.geneoscopy.com"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["multitarget-stool-rna-test","colorectal-screening","rna-seq"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"St. Louis, Missouri, United States","country":"US","companyType":"diagnostics","website":"https://www.geneoscopy.com","stage":"growth","investors":[],"funding":[]},{"id":"genequantum-healthcare-suzhou","kind":"company","name":"GeneQuantum Healthcare (Suzhou)","aka":["GeneQuantum Healthcare (Suzhou) Co., Ltd."],"tldr":"GeneQuantum Healthcare (Suzhou) is a China-based biotechnology company running 2 late-stage cancer trials of GQ1005 and phase II in HER2-positive breast cancer.","summary":"GeneQuantum Healthcare (Suzhou), based in Suzhou, China, is a biotechnology company. GeneQuantum Healthcare develops bioconjugate therapeutics, including antibody-drug conjugates, using proprietary site-specific conjugation technologies. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing GQ1005 and phase II in HER2-positive breast cancer. The largest, NCT06464055 (A Study of GQ1010 in Subjects With Advanced Solid Tumours), plans to enrol 260 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.genequantum.com"},{"label":"ClinicalTrials.gov: trials led by GeneQuantum Healthcare (Suzhou)","url":"https://clinicaltrials.gov/search?lead=GeneQuantum%20Healthcare%20(Suzhou)%20Co.%2C%20Ltd."},{"label":"Pipeline page","url":"https://www.genequantum.com/pipeline"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["gq1005"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06464055"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Suzhou","country":"CN","companyType":"biotech","website":"https://www.genequantum.com","founded":2013,"stage":"growth","investors":[],"funding":[]},{"id":"general-catalyst","kind":"company","name":"General Catalyst","aka":[],"tldr":"A large venture firm founded in Cambridge, Massachusetts, that now spans seed to growth and even owns a hospital system. Its health portfolio includes the radiopharmaceutical company Alpha-9 Oncology and the radiology AI firm Aidoc.","summary":"General Catalyst was founded in 2000 by Joel Cutler and David Fialkow, is headquartered in Cambridge, Massachusetts, and has offices in San Francisco, New York, London, Berlin and Bangalore (Wikipedia). Its site describes Seed, Create (company creation) and Grow strategies, plus a Health Assurance Transformation Company that in 2024 acquired the Summa Health hospital system to build 'a blueprint for proactive, accessible, affordable American healthcare'. Oncology is a small part of a broad healthcare practice. The portfolio page lists Alpha-9 Oncology (targeted radiopharmaceuticals; Healthcare, North America) and Aidoc (AI triage for medical imaging), alongside Altos Labs and many care-delivery and health software companies.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.generalcatalyst.com/"},{"label":"Portfolio","url":"https://www.generalcatalyst.com/portfolio"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/General_Catalyst"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["aidoc","alpha-9-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cambridge, MA","country":"US","companyType":"investor","website":"https://www.generalcatalyst.com/","founded":2000,"investors":[],"funding":[]},{"id":"generate-biomedicines","kind":"company","name":"Generate:Biomedicines","aka":[],"tldr":"Generative-AI protein design company (Flagship) that went public in 2026 and is testing an antibody that neutralises leaked ADC payload to reduce side effects.","summary":"Generate:Biomedicines went public in early 2026 (~$400M IPO). Oncology programmes: GB-4362, an MMAE neutraliser with FDA Fast Track for enfortumab vedotin toxicity in urothelial cancer (trial-in-progress at ESMO 2026), and GB-5267, a MUC16 CAR-T with Roswell Park. First AI-designed antibody advanced to phase 3 in a non-oncology indication.","asOf":"2026-09-04","links":[{"label":"Q2 2026 business update","url":"https://www.biospace.com/press-releases/generate-biomedicines-inc-reports-second-quarter-2026-financial-results-and-provides-business-update"}],"tags":["frontier"],"related":[],"cancers":["urothelial","ovarian"],"sections":["ai-computation","adcs","immunotherapy"],"technologies":["ai-drug-design","adc-payload-neutralizer","car-t"],"targets":[],"drugs":["enfortumab-vedotin"],"companies":[],"institutions":["roswell-park"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Somerville, MA","country":"US","companyType":"ai-software","website":"https://generatebiomedicines.com","ticker":"GBIO","investors":["flagship-pioneering"],"funding":[]},{"id":"genesis-molecular-ai","kind":"company","name":"Genesis Molecular AI (formerly Genesis Therapeutics)","aka":[],"tldr":"Genesis Molecular AI does small-molecule discovery on its GEMS platform, which combines physics and deep learning, with oncology programmes in the clinic pipeline.","summary":"Genesis Molecular AI, formerly Genesis Therapeutics and based in Burlingame, California, does small-molecule discovery on its GEMS platform, which combines physics and deep learning, with oncology programmes in its clinic-bound pipeline. It holds partnerships with Genentech, Lilly, Gilead and Incyte and rebranded in 2025. OnCo links it to AI-driven drug and target discovery. Whether physics-informed models find small molecules for targets that conventional screening missed is the question its pipeline will answer. The AI-driven drug discovery page carries the wider field.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.genesistherapeutics.ai"}],"tags":["ai"],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":[],"targets":[],"drugs":[],"companies":["incyte"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Burlingame, CA","country":"US","companyType":"biotech","website":"https://www.genesistherapeutics.ai","investors":[],"funding":[]},{"id":"genfleet","kind":"company","name":"GenFleet Therapeutics","aka":["劢维医药","Genfleet Therapeutics (Shanghai)","GenFleet Therapeutics"],"tldr":"GenFleet discovered fulzerasib, the first KRAS G12C inhibitor approved in China, and licensed it to Innovent for the Chinese market.","summary":"GenFleet Therapeutics, based in Shanghai and founded in 2017, discovered fulzerasib, the first KRAS G12C inhibitor approved in China, and licensed it to Innovent for the Chinese market. Fulzerasib, also GFH925 and sold as Dupert, was approved in August 2024; the KRAS G12C programme is partnered with Verastem in the United States as VS-7375, formerly GFH375, combination trials with cetuximab are running, and KRAS G12D and pan-RAS inhibitors are in development. OnCo links it to fulzerasib, Innovent Biologics and Verastem Oncology. Whether a Chinese-discovered KRAS inhibitor can compete in the West through a partner against the established G12C drugs is the open question. Fulzerasib has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.genfleet.com/en/"}],"tags":["china"],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["fulzerasib","gfh375"],"companies":["innovent","verastem"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06214143","nct05944224","nct06434597","nct05872347","nct05934513","nct06375733","nct07259590","nct06500676"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.genfleet.com/en/","founded":2017,"investors":[],"funding":[]},{"id":"genmab","kind":"company","name":"Genmab","aka":[],"tldr":"Genmab is the Danish antibody engineering company behind the DuoBody platform, Tivdak, Epkinly, and (via ProfoundBio) rinatabart sesutecan.","summary":"Genmab, based in Copenhagen and listed as GMAB, is the Danish antibody engineering company behind the DuoBody platform, Tivdak, Epkinly and, through ProfoundBio, rinatabart sesutecan. Its own products are tisotumab vedotin, epcoritamab, a CD20 by CD3 bispecific, rinatabart sesutecan, a folate receptor alpha ADC in the RAINFOL-01 phase 3, and acasunlimab, a PD-L1 by 4-1BB bispecific, while its DuoBody technology underlies teclistamab, talquetamab and amivantamab, and daratumumab and ofatumumab are also linked. OnCo links it to cervical and endometrial cancer, lymphoma and head and neck cancer, and to the LiGeR-HN1 trial. Whether a royalty-rich platform company can become a fully commercial oncology business is the open question. Tisotumab vedotin has its own page.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Genmab","links":[{"label":"Official website","url":"https://www.genmab.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs","immunotherapy"],"technologies":[],"targets":[],"drugs":["tisotumab-vedotin","acasunlimab","mcla-129"],"companies":["profoundbio"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07226752","nct07775287","nct06508658","nct06191744","nct06496178","nct07604766","nct07166094","nct06619236","nct07225270","nct07702032","nct05409066","nct07564141","nct04083599","nct04663347","nct07288177","nct04542824","nct05201248","nct05451810","nct03526835","nct04868877","nct05283720","nct05117242","nct03485209","nct04623541"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Copenhagen","country":"DK","companyType":"biotech","website":"https://www.genmab.com","ticker":"GMAB","investors":[],"funding":[]},{"id":"genprex","kind":"company","name":"Genprex","aka":["Genprex, Inc."],"tldr":"Genprex is a United States-based biotechnology company running 2 late-stage cancer trials of quaratusugene ozeplasmid in non-small-cell lung cancer and small-cell lung cancer.","summary":"Genprex, based in Austin, the United States, is a biotechnology company. Genprex is a clinical-stage gene therapy company developing treatments for cancer and diabetes by reintroducing tumour suppressor genes. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing quaratusugene ozeplasmid in non-small-cell lung cancer and small-cell lung cancer. The largest, NCT04486833 (Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib), plans to enrol 158 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.genprex.com"},{"label":"ClinicalTrials.gov: trials led by Genprex","url":"https://clinicaltrials.gov/search?lead=Genprex%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05703971","nct04486833"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Austin","country":"US","companyType":"biotech","website":"https://www.genprex.com","stage":"public","investors":[],"funding":[]},{"id":"genrix-bio","kind":"company","name":"Genrix Bio","aka":["Genrix (Shanghai) Biopharmaceutical","智翔金泰","SSE:688443"],"tldr":"Genrix Bio is a Shanghai antibody company, listed on the Shanghai STAR market, whose oncology lead GR1803 is a BCMA and CD3 bispecific T-cell engager for multiple myeloma.","summary":"Genrix (Shanghai) Biopharmaceutical, a subsidiary of Zhifei Biological Products, develops monoclonal and bispecific antibodies. Its first approved product is the IL-17A antibody xeligekimab for psoriasis; its pipeline spans autoimmune, infectious and cancer indications. GR1803, a bispecific antibody binding BCMA on myeloma cells and CD3 on T cells, is in a phase 1/2 trial in relapsed or refractory multiple myeloma.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["gr1803"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Shanghai","country":"CN","companyType":"biotech","ticker":"SSE:688443","stage":"public","investors":[],"funding":[]},{"id":"georgiamune","kind":"company","name":"Georgiamune","aka":["Georgiamune Inc"],"tldr":"Georgiamune is a United States-based biotechnology company running 2 late-stage cancer trials of GIM122 and GIM-531 in melanoma.","summary":"Georgiamune, based in Gaithersburg, the United States, is a biotechnology company. Georgiamune develops immunotherapies that reprogram immune signalling pathways to rebalance immune system components, for cancer and autoimmune disease. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing GIM122 and GIM-531 in melanoma. The largest, NCT06425926 (Safety and Tolerability Study of GIM-531 in Advanced Solid Tumours), plans to enrol 117 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.georgiamune.com"},{"label":"ClinicalTrials.gov: trials led by Georgiamune","url":"https://clinicaltrials.gov/search?lead=Georgiamune%20Inc"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct06425926","nct06028074"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Gaithersburg","country":"US","companyType":"biotech","website":"https://www.georgiamune.com","investors":[],"funding":[]},{"id":"gercor","kind":"company","name":"GERCOR","aka":["GERCOR - Multidisciplinary Oncology Cooperative Group","Groupe Coopérateur Multidisciplinaire en Oncologie"],"tldr":"GERCOR is a French non-profit cooperative group created in 1997 that sponsors its own phase 2 and 3 solid tumour trials through a network of about 300 investigators; in OnCo it leads LAP07 in locally advanced pancreatic cancer.","summary":"GERCOR was created in 1997 as a non-profit entity whose mission is to improve treatment for patients with solid tumours through innovative multidisciplinary clinical research; it sponsors phase 2 and phase 3 trials independently and draws on a national network of 300 members in about a hundred centres, from an office at 151 rue du Faubourg Saint-Antoine, Paris (gercor.com). ClinicalTrials.gov registers it as GERCOR - Multidisciplinary Oncology Cooperative Group (OTHER class) and names it lead sponsor of LAP07 (NCT00634725, phase 3, chemoradiotherapy against chemotherapy alone after induction in locally advanced pancreatic cancer), the trial recorded in OnCo. It has no products of its own.","asOf":"2026-09-25","links":[{"label":"Official website","url":"https://www.gercor.com"},{"label":"ClinicalTrials.gov: trials led by GERCOR - Multidisciplinary Oncology Cooperative Group","url":"https://clinicaltrials.gov/search?lead=GERCOR%20-%20Multidisciplinary%20Oncology%20Cooperative%20Group"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["pancreatic","locally-advanced-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["lap07"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"Paris","country":"FR","companyType":"cooperative-group","website":"https://www.gercor.com","founded":1997,"investors":[],"funding":[]},{"id":"gbg","kind":"company","name":"German Breast Group (GBG)","aka":["German Breast Group","GBG","GBG Forschungs GmbH"],"tldr":"The German academic group whose GeparX trials established carboplatin and neoadjuvant strategies in triple-negative breast cancer.","summary":"The German Breast Group, based in Neu-Isenburg, is the academic group whose Gepar trials established carboplatin and neoadjuvant strategies in triple-negative breast cancer; it was founded in 1997 and is associated with Gunter von Minckwitz and Sibylle Loibl. GeparSixto showed carboplatin raises pathologic complete response rates in TNBC, GeparNuevo tested durvalumab, GeparDouze followed, and its meta-analyses of pathologic complete response as a surrogate endpoint shaped how neoadjuvant trials are designed, with Carsten Denkert also linked. OnCo connects it to carboplatin and durvalumab, to the pCR term, and to partner groups including the NSABP Foundation. Whether pCR reliably predicts long-term benefit for every drug class is the question its own surrogacy work keeps open. Its Gepar series and pCR research programmes are listed in the notes.","asOf":"2026-09-06","links":[{"label":"Official website","url":"https://www.gbg.de"}],"tags":["cooperative-group"],"related":["carboplatin","durvalumab"],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pcr"],"trials":[],"people":["carsten-denkert","gunter-von-minckwitz","sibylle-loibl"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Gepar neoadjuvant trial series","pCR surrogacy research"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Neu-Isenburg","country":"DE","companyType":"cooperative-group","website":"https://www.gbg.de","founded":1997,"investors":[],"funding":[]},{"id":"german-cll-study-group","kind":"company","name":"German CLL Study Group","aka":["Deutsche CLL Studiengruppe","DCLLSG","GCLLSG"],"tldr":"The German CLL Study Group, founded in 1996 at the University of Cologne, runs the numbered CLL trials that set first-line treatment of chronic lymphocytic leukaemia, including CLL12, CLL13 (GAIA) and CLL14 in OnCo.","summary":"The Deutsche CLL Studiengruppe (DCLLSG, German CLL Study Group) was founded in 1996 to improve the diagnosis and treatment of chronic lymphocytic leukaemia through controlled prospective trials, and describes itself as a research organisation of the University of Cologne specialising in CLL (dcllsg.de). ClinicalTrials.gov names it lead sponsor (OTHER class) of CLL12 (NCT02863718, phase 3, ibrutinib against placebo in early-stage CLL, with Janssen-Cilag as collaborator) and of CLL13 / GAIA (NCT02950051, phase 3, venetoclax combinations against chemoimmunotherapy in fit treatment-naive CLL, with Janssen-Cilag, Roche, AbbVie, HOVON, the Nordic CLL Study Group and others as collaborators); on CLL14 (NCT02242942, venetoclax and obinutuzumab in unfit CLL) the registry lead is Hoffmann-La Roche and the group is a collaborator, as the OnCo record's sponsor line says. It has no products of its own.","asOf":"2026-09-25","links":[{"label":"Official website","url":"https://www.dcllsg.de"},{"label":"ClinicalTrials.gov: trials led by German CLL Study Group","url":"https://clinicaltrials.gov/search?lead=German%20CLL%20Study%20Group"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["cll","cll-treatment-naive","leukaemia"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["cll12","cll13-gaia","cll14"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"Cologne","country":"DE","companyType":"cooperative-group","website":"https://www.dcllsg.de","founded":1996,"investors":[],"funding":[]},{"id":"ghsg","kind":"company","name":"German Hodgkin Study Group","aka":["GHSG","Deutsche Hodgkin Studiengruppe"],"tldr":"The Cologne-based group whose HD trials, from BEACOPP to BrECADD in HD21, have set the standard for treating Hodgkin lymphoma for four decades.","summary":"Founded in 1978 by Volker Diehl and based at the University Hospital of Cologne, the GHSG has enrolled tens of thousands of patients in sequential HD trials that defined stage-adapted therapy. Its work produced the escalated BEACOPP regimen, showed PET-guided de-escalation is safe (HD16, HD18), and in HD21 showed brentuximab-based BrECADD is less toxic and at least as effective as BEACOPP in advanced disease. The group runs a central review panel for pathology and imaging and long-term survivorship studies of second cancers and cardiac toxicity. It sits within the Department I of Internal Medicine at Cologne.","asOf":"2026-09-09","links":[{"label":"GHSG","url":"https://www.ghsg.org"}],"tags":["cooperative-group"],"related":["brentuximab-vedotin","nivolumab"],"cancers":["hodgkin-lymphoma"],"sections":[],"technologies":["fdg-pet","adc","cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":["german-lymphoma-alliance"],"institutions":["uniklinik-koeln"],"pathways":[],"terms":[],"trials":["hd21"],"people":["michael-hallek"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["HD trial series (HD1-HD21)","PET-guided treatment adaptation","HD21 (BrECADD)","Survivorship and late-effects research"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Cologne","country":"DE","companyType":"cooperative-group","website":"https://www.ghsg.org","founded":1978,"investors":[],"funding":[]},{"id":"german-lymphoma-alliance","kind":"company","name":"German Lymphoma Alliance","aka":["GLA","DSHNHL","Deutsche Studiengruppe Hochmaligne Non-Hodgkin-Lymphome"],"tldr":"Germany's aggressive lymphoma trials group, formerly DSHNHL, whose MInT, RICOVER-60 and FLYER trials set how many cycles of R-CHOP patients need.","summary":"The German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) was founded in 1996 and merged with other German lymphoma groups in 2017 to form the German Lymphoma Alliance. Its trials shaped the details of DLBCL treatment: MInT defined R-CHOP for young good-prognosis patients, RICOVER-60 defined six cycles of R-CHOP-14 for the elderly, FLYER showed four cycles suffice in young favourable-risk disease, and OPTIMAL>60 refined therapy in older patients. GLA works with LYSA, HOVON and the Nordic group on European aggressive lymphoma trials.","asOf":"2026-09-09","links":[{"label":"German Lymphoma Alliance","url":"https://www.german-lymphoma-alliance.de"}],"tags":["cooperative-group"],"related":[],"cancers":["dlbcl"],"sections":["chemotherapy"],"technologies":["monoclonal-antibody","cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":["lysa","hovon","ghsg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["christiane-pott"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["MInT and RICOVER-60","FLYER (four cycles of R-CHOP)","OPTIMAL>60","CNS prophylaxis and relapsed DLBCL trials"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Homburg","country":"DE","companyType":"cooperative-group","website":"https://www.german-lymphoma-alliance.de","founded":2017,"investors":[],"funding":[]},{"id":"geron","kind":"company","name":"Geron Corporation","aka":["Geron"],"tldr":"Geron is the Californian company behind imetelstat, the first telomerase inhibitor to reach approval, cleared by the FDA in 2024 for lower-risk myelodysplastic syndromes with transfusion-dependent anaemia.","summary":"Geron Corporation, based in Foster City, California, spent three decades on telomerase biology before its oligonucleotide telomerase inhibitor imetelstat (Rytelo) was approved by the FDA in June 2024 for adults with lower-risk myelodysplastic syndromes and transfusion-dependent anaemia who had failed or were ineligible for erythropoiesis-stimulating agents, on the IMerge trial. Imetelstat is also in a phase 3 trial in relapsed or refractory myelofibrosis. Company facts are from the official website and FDA approval records.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Geron_Corporation","links":[{"label":"Official website","url":"https://www.geron.com/"},{"label":"FDA: oncology and hematologic malignancies approval notifications","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"}],"tags":["fda-oce-applicant"],"related":[],"cancers":["mds","myeloproliferative-neoplasms"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["imetelstat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05583552","impactmf"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Foster City, CA","country":"US","companyType":"biotech","website":"https://www.geron.com/","stage":"public","investors":[],"funding":[]},{"id":"gi-innovation","kind":"company","name":"GI Innovation","aka":["GI Innovation, Inc."],"tldr":"GI Innovation is a South Korea-based biotechnology company that leads 3 cancer trials in OnCo, testing the bispecific fusion proteins GI-101, GI-102 and GI-108 in non-small-cell lung cancer, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma and renal cell carcinoma.","summary":"GI Innovation is a South Korean biotechnology company developing bispecific fusion protein drugs on its GI-SMART platform for immuno-oncology and allergy. Its lead cancer candidates are GI-101 and GI-102 (CD80 and IL-2 variant fusion proteins) and GI-108 (anti-CD73 with an IL-2 variant), in phase 1/2 trials in Korea, the United States and Australia. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT07172802 (phase 1/2, A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy...), NCT05824975 (phase 1/2, A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and...) and NCT04977453 (phase 1/2, GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.gi-innovation.com"},{"label":"ClinicalTrials.gov: trials led by GI Innovation","url":"https://clinicaltrials.gov/search?lead=GI%20Innovation%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","head-and-neck","pancreatic","rcc","sarcoma","ovarian","hcc","colorectal","melanoma","cervical","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["doxorubicin","paclitaxel","bevacizumab","eribulin","trastuzumab-deruxtecan","pembrolizumab","lenvatinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07172802","nct05824975","nct04977453"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Seoul","country":"KR","companyType":"biotech","website":"https://www.gi-innovation.com","ticker":"KOSDAQ:358570","stage":"public","investors":[],"funding":[]},{"id":"gilde-healthcare","kind":"company","name":"Gilde Healthcare","aka":[],"tldr":"Gilde Healthcare is a Dutch investor with separate funds for venture-stage health companies and for established healthcare businesses, backing diagnostics, medical technology and therapeutics across Europe and the United States.","summary":"Gilde Healthcare is a specialist healthcare investor headquartered in Utrecht with offices in Frankfurt and Boston, running a venture and growth strategy for therapeutics, medtech, diagnostics and digital health alongside a private equity strategy for profitable healthcare services companies. Its oncology exposure runs through diagnostics and device companies as well as drug developers; portfolio links in OnCo are derived from the startup records that name it.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://gildehealthcare.com"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Utrecht","country":"NL","companyType":"investor","website":"https://gildehealthcare.com","investors":[],"funding":[]},{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","aka":[],"tldr":"Gilead owns Trodelvy (via the $21B Immunomedics deal) and the Kite CAR-T franchise.","summary":"Gilead Sciences, based in Foster City, California, and listed as GILD, owns Trodelvy through its 21 billion dollar purchase of Immunomedics and the Kite CAR-T franchise. Sacituzumab govitecan is approved in triple-negative breast cancer, with first-line use from 2026, and in HR-positive breast cancer; Yescarta and Tecartus are its CAR-T products, proved in ZUMA-1, ZUMA-2 and ZUMA-7; anitocabtagene autoleucel, a BCMA CAR-T from Arcellx, is in registration; and domvanalimab, its TIGIT antibody, largely failed. OnCo links it to the ASCENT paper, to the TROP2 ADC roadmap, to magrolimab and idelalisib, to the CD73 adenosine axis, and to partners including Arcellx, Kymera, Tubulis and Tmunity. Whether an oncology business built by acquisition can generate its own next products is the open question. Sacituzumab govitecan and axicabtagene ciloleucel have their own pages.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.gilead.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs","cell-therapy"],"technologies":[],"targets":[],"drugs":["sacituzumab-govitecan","axicabtagene-ciloleucel","domvanalimab","quemliclustat"],"companies":["arcellx","tmunity-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05089734","nct06801834","nct06413498","nct06486441","nct05371093","nct07527858","nct05633667","nct05676931","nct06253663","nct06727565","nct05186974","nct06926920","nct03547973","nct05840211","nct05119907","nct05609968","nct05329766","nct05101096","nct04454437","nct03964727","nct04639986"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Foster City, CA","country":"US","companyType":"pharma","website":"https://www.gilead.com","ticker":"GILD","investors":[],"funding":[]},{"id":"gimema","kind":"company","name":"GIMEMA","aka":["Gruppo Italiano Malattie EMatologiche dell'Adulto","Italian Group for Adult Hematologic Diseases"],"tldr":"Italy's adult haematology trials group, famous for making acute promyelocytic leukaemia curable without chemotherapy and for chemotherapy-free Philadelphia-positive ALL.","summary":"Founded in 1982, GIMEMA coordinates more than 100 Italian haematology centres from Rome. With the German AMLSG it ran APL0406, which showed all-trans retinoic acid plus arsenic trioxide beats chemotherapy in low-to-intermediate risk acute promyelocytic leukaemia, and its LAL2116 D-ALBA trial showed dasatinib followed by blinatumomab can induce deep molecular responses in Ph-positive ALL without cytotoxic chemotherapy. GIMEMA also runs CML, CLL, myeloma and MDS trials and a central laboratory network for molecular monitoring. Its quality-of-life working party pioneered patient-reported outcomes in haematology trials.","asOf":"2026-09-09","links":[{"label":"GIMEMA","url":"https://www.gimema.it"}],"tags":["cooperative-group"],"related":["blinatumomab","imatinib"],"cancers":["aml","all-leukemia","cll","multiple-myeloma"],"sections":[],"technologies":["t-cell-engager","kinase-inhibitors","mrd-testing"],"targets":[],"drugs":[],"companies":["hovon"],"institutions":[],"pathways":[],"terms":["mrd"],"trials":["d-alba"],"people":["marco-vignetti","antonio-cuneo"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["APL0406 (ATRA-arsenic in APL)","D-ALBA (chemo-free Ph+ ALL)","CML and CLL trials","Central molecular monitoring laboratories"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Rome","country":"IT","companyType":"cooperative-group","website":"https://www.gimema.it","founded":1982,"investors":[],"funding":[]},{"id":"glenmark","kind":"company","name":"Glenmark Pharmaceuticals (Ichnos Glenmark Innovation)","aka":[],"tldr":"The Indian company whose trispecific antibody ISB 2001 for multiple myeloma was licensed to AbbVie in 2025 for 700 million dollars upfront, the largest deal for an Indian-discovered cancer drug.","summary":"Glenmark was founded on 18 November 1977 by Gracias Saldanha in Mumbai. In January 2024 it consolidated oncology discovery into Ichnos Glenmark Innovation (IGI), a venture with its subsidiary Ichnos Sciences, with three molecules in the clinic at launch. In July 2025 IGI licensed ISB 2001, a BCMA x CD38 x CD3 trispecific T-cell engager in phase 1 for relapsed or refractory multiple myeloma, to AbbVie for 700 million dollars upfront and up to 1.225 billion dollars in milestones plus royalties; AbbVie took North America, Europe, Japan and Greater China and Glenmark kept India and emerging markets. In 2025 Glenmark also in-licensed the HER2 ADC trastuzumab rezetecan from Hengrui (a deal valued at up to 1.1 billion dollars) and the EGFR inhibitor aumolertinib from Hansoh for several regions.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.glenmarkpharma.com"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":["immunotherapy","adcs"],"technologies":["t-cell-engager","bispecific-antibody","adc"],"targets":["bcma","cd38","her2"],"drugs":["isb-2001","trastuzumab-rezetecan"],"companies":["abbvie","hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Mumbai","country":"IN","companyType":"pharma","website":"https://www.glenmarkpharma.com","ticker":"GLENMARK.NS","founded":1977,"investors":[],"funding":[]},{"id":"globeimmune","kind":"company","name":"GlobeImmune","aka":["GlobeImmune, Inc."],"tldr":"GlobeImmune is a Colorado biotech that used whole heat-killed yeast to deliver tumour antigens to the immune system; GI-6301 carried the transcription factor brachyury for chordoma and other cancers.","summary":"GlobeImmune developed Tarmogens, heat-killed recombinant Saccharomyces cerevisiae yeast engineered to express disease antigens, which are taken up by dendritic cells and drive antigen-specific T-cell responses. GI-6301 expresses brachyury, a transcription factor that drives epithelial-to-mesenchymal transition and is the defining marker of chordoma; it was studied with radiotherapy in a randomised phase 2 chordoma trial run with the National Cancer Institute. GI-4000, targeting mutant RAS, was tested in pancreatic cancer and lung cancer.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["gi-6301"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Louisville, Colorado","country":"US","companyType":"biotech","founded":1995,"investors":[],"funding":[]},{"id":"gog-foundation","kind":"company","name":"GOG Foundation","aka":["Gynecologic Oncology Group","GOG","GOG Partners"],"tldr":"The US gynaecologic oncology trials organisation whose GOG-3000-series trials with industry brought immunotherapy into endometrial and cervical cancer.","summary":"The Gynecologic Oncology Group was founded in 1970 as an NCI cooperative group and merged into NRG Oncology in 2014; the GOG Foundation continues as an independent organisation running industry-partnered trials through GOG Partners and supporting NRG's gynaecologic portfolio. GOG-0218 established bevacizumab in first-line ovarian cancer, and the GOG-3000 series includes RUBY (dostarlimab, GOG-3031), NRG-GY018/KEYNOTE-868 (pembrolizumab, GOG-3041), KEYNOTE-A18 (GOG-3047) in cervical cancer and MIRASOL (mirvetuximab, GOG-3045). It is a founding member of the Gynecologic Cancer InterGroup and partners with ENGOT groups such as GINECO. Most US gynaecologic oncology fellowships train through GOG sites.","asOf":"2026-09-09","links":[{"label":"GOG Foundation","url":"https://www.gog.org"}],"tags":["cooperative-group"],"related":["pembrolizumab","dostarlimab","mirvetuximab-soravtansine"],"cancers":["ovarian","endometrial","cervical"],"sections":[],"technologies":["checkpoint-inhibitor","adc","antiangiogenic"],"targets":[],"drugs":[],"companies":["nrg-oncology","arcagy-gineco"],"institutions":["nci"],"pathways":[],"terms":[],"trials":["gog-0218-icon7","nrg-gy018-keynote-868","ruby","keynote-a18","mirasol","outback"],"people":["thomas-herzog","robert-mannel"],"bottlenecks":[],"keyPapers":[],"journals":["gynecologic-oncology"],"dependsOn":[],"notes":["GOG Partners industry trials (GOG-3000 series)","RUBY, NRG-GY018 and KEYNOTE-A18","GOG-0218 (bevacizumab)","Gynecologic Cancer InterGroup"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Philadelphia, PA","country":"US","companyType":"cooperative-group","website":"https://www.gog.org","founded":1970,"investors":[],"funding":[]},{"id":"google-health","kind":"company","name":"Google (Health, DeepMind, Verily)","aka":[],"tldr":"Alphabet's health efforts: mammography and pathology AI research, Med-PaLM/MedGemma medical models, DeepMind's AlphaFold, and Isomorphic Labs drug design.","summary":"Google, through Google Health, DeepMind and Verily, based in Mountain View and listed as GOOGL, runs Alphabet's health efforts: mammography and pathology AI research, the Med-PaLM and MedGemma medical models, DeepMind's AlphaFold and drug design through Isomorphic Labs. Its landmark AI papers covered breast screening and lymph node metastasis detection, AlphaFold 3 came from DeepMind, and Isomorphic holds partnerships with Lilly and Novartis. OnCo links it to AI compute and model platforms, AI in radiology, AI-driven drug discovery and structural biology infrastructure. Whether its research results turn into deployed clinical tools, which has proved harder than publishing them, is the open question. Isomorphic Labs has its own page.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://health.google"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["ai-computation","drug-discovery"],"technologies":["ai-compute-platforms","radiology-ai-screening","ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Mountain View, CA","country":"US","companyType":"ai-software","website":"https://health.google","ticker":"GOOGL","investors":[],"funding":[]},{"id":"google-deepmind","kind":"company","name":"Google DeepMind (and Google Research)","aka":[],"tldr":"Google DeepMind built AlphaFold, AlphaMissense, AlphaGenome and Med-Gemini, the reference models for structure, variants, and medical multimodal reasoning.","summary":"AlphaFold 2 (2020) and AlphaFold 3 (2024) redefined structure prediction; Isomorphic Labs commercialises drug discovery on top. AlphaMissense (2023) scored every possible human missense variant; AlphaGenome (preview June 2025, Nature January 2026) predicts regulatory effects across 1 Mb of sequence. Google Research's Med-Gemini and C2S-Scale extend into clinical and single-cell domains.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://deepmind.google"}],"tags":["ai"],"related":[],"cancers":[],"sections":["ai-computation","drug-discovery"],"technologies":["alphamissense","alphagenome"],"targets":[],"drugs":[],"companies":["isomorphic-labs"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"London / Mountain View","country":"GB","companyType":"ai-software","website":"https://deepmind.google","ticker":"GOOGL","investors":[],"funding":[]},{"id":"gortec","kind":"company","name":"GORTEC","aka":["Groupe Oncologie Radiotherapie Tete et Cou","Groupe d'Oncologie Radiothérapie Tête Et Cou","GORTEC (Groupe Oncologie Radiotherapie Tete et Cou)"],"tldr":"GORTEC is the French head and neck radiotherapy and oncology group, an association founded in 1999 that runs the academic trials behind much of the standard of care in head and neck cancer, including TPExtreme and NIVOPOSTOP in OnCo.","summary":"GORTEC (Groupe d'Oncologie Radiothérapie Tête Et Cou) is a French association created in 1999 by five founding centres (Clermont-Ferrand, Nancy, Nantes, Tours and Villejuif) to coordinate clinical and biological studies in head and neck cancer; its website gives more than 225 physician members, trials of phase 3 (the majority), 2 and 1, and a founding role in the Intergroupe ORL labelled by the Institut National du Cancer since 2012. Its office is at 4bis rue Emile Zola, Tours. ClinicalTrials.gov registers it as Groupe Oncologie Radiotherapie Tete et Cou, an OTHER-class sponsor, and names it lead sponsor of both trials recorded in OnCo: TPExtreme (NCT02268695, phase 2, docetaxel, cisplatin and cetuximab against the EXTREME regimen in recurrent or metastatic head and neck squamous cell carcinoma) and NIVOPOSTOP (NCT03576417, phase 3, nivolumab added to postoperative chemoradiotherapy in high-risk head and neck cancer). It has no products of its own.","asOf":"2026-09-25","links":[{"label":"GORTEC: Le Gortec (history and organisation)","url":"https://www.gortec.net/v/index.php/le-gortec"},{"label":"ClinicalTrials.gov: trials led by Groupe Oncologie Radiotherapie Tete et Cou","url":"https://clinicaltrials.gov/search?lead=Groupe%20Oncologie%20Radiotherapie%20Tete%20et%20Cou"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["head-and-neck","recurrent-metastatic-hnscc","hpv-negative-head-and-neck-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["tpextreme","nivopostop"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"Tours","country":"FR","companyType":"cooperative-group","website":"https://www.gortec.net","founded":1999,"investors":[],"funding":[]},{"id":"gracell-biotechnologies","kind":"company","name":"Gracell Biotechnologies","aka":["Gracell","亘喆生物","NASDAQ:GRCL"],"tldr":"Gracell Biotechnologies is the Chinese cell-therapy company that made CAR-T cells overnight with its FasTCAR process and built the BCMA and CD19 dual-targeting CAR-T GC012F, bought by AstraZeneca in 2024.","summary":"Gracell Biotechnologies developed the FasTCAR manufacturing platform, which shortens autologous CAR-T production to about one day and yields younger, less exhausted T cells, and the TruUCAR platform for allogeneic products. Its lead programme GC012F (now AZD0120) targets BCMA and CD19 together and has shown high rates of deep response in newly diagnosed and relapsed multiple myeloma, and activity in lupus. AstraZeneca completed its acquisition of Gracell in February 2024 for up to 1.2 billion dollars.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["gc012f"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Suzhou","country":"CN","companyType":"cell-therapy","founded":2017,"stage":"acquired","investors":[],"funding":[],"acquiredBy":"astrazeneca"},{"id":"grail","kind":"company","name":"GRAIL","aka":[],"tldr":"GRAIL developed Galleri, the multi-cancer blood test awaiting an FDA decision after a September 2026 advisory committee.","summary":"GRAIL, based in Menlo Park and listed as GRAL, developed Galleri, the multi-cancer blood test awaiting an FDA decision after an advisory committee in September 2026. The company submitted its premarket approval application in January 2026, the NHS-Galleri trial in England and the PATHFINDER 2 study are its main evidence, and it was spun out of Illumina in 2024. OnCo links it to multi-cancer early detection, to the bottleneck that the hardest cancers are found late, to Guy's and St Thomas' and the Chinese University of Hong Kong, and to ideas on using a multi-cancer test as the first step for patients with non-specific symptoms and on pre-agreed update rules so a test is not obsolete when its trial reads out. Whether detecting more cancers earlier lowers deaths from them is the open question no MCED trial has yet answered. Galleri has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://grail.com"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection"],"technologies":[],"targets":[],"drugs":["galleri"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Menlo Park, CA","country":"US","companyType":"diagnostics","website":"https://grail.com","ticker":"GRAL","investors":["arch-venture-partners"],"funding":[]},{"id":"granza-bio","kind":"company","name":"Granza Bio","aka":[],"tldr":"Granza Bio is turning the natural attack particles that killer immune cells fire at their targets into programmable medicines that can re-arm exhausted immune cells against cancer.","summary":"Granza Bio builds on the discovery of supramolecular attack particles, the cytotoxic granules that cytotoxic T cells and natural killer cells release to kill targets, and engineers them into programmable therapeutics that deliver localised cell killing and re-arm exhausted immune cells, with applications from cancer to autoimmunity. The company is an Oxford-linked spin-out based in San Francisco and is preclinical; no sourced financing rounds are recorded.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/granza-bio"},{"label":"Official website","url":"https://www.granzabio.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["cytokine-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.granzabio.com","stage":"startup","ycBatch":"W24","investors":["y-combinator"],"funding":[]},{"id":"greenwich-lifesciences","kind":"company","name":"Greenwich LifeSciences","aka":["Greenwich LifeSciences, Inc.","NASDAQ:GLSI"],"tldr":"Greenwich LifeSciences is a Texas biotech running a phase 3 trial of GLSI-100, a HER2 peptide vaccine given after standard treatment to stop breast cancer coming back.","summary":"Greenwich LifeSciences develops GLSI-100, a combination of the HER2-derived peptide GP2 with the immune adjuvant GM-CSF, as an immunotherapy to prevent recurrence in HER2-positive breast cancer after surgery and trastuzumab. In a phase 2b trial, HER2-positive patients who completed the full vaccine course had no recurrences over five years. The phase 3 FLAMINGO-01 trial is enrolling HER2-positive patients with residual disease after neoadjuvant therapy.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.greenwichlifesciences.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["glsi-100"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Stafford, Texas","country":"US","companyType":"biotech","website":"https://www.greenwichlifesciences.com/","ticker":"NASDAQ:GLSI","founded":2006,"stage":"public","investors":[],"funding":[]},{"id":"grifols","kind":"company","name":"Grifols","aka":["Grifols Therapeutics LLC","Grifols Biologicals, LLC","Grifols S.A."],"tldr":"Grifols is the Catalan plasma-medicines group founded in 1909, whose immunoglobulins, albumin and clotting factors are used in supportive cancer care, and which has led phase 3 trials in cancer-related settings.","summary":"Grifols, headquartered in Sant Cugat del Vallès near Barcelona and founded in 1909, is one of the three largest plasma-derived medicines companies, producing immunoglobulins used for infection prevention in blood cancers, albumin and coagulation factors, alongside diagnostics. Its US arms Grifols Therapeutics and Grifols Biologicals appear on ClinicalTrials.gov as lead sponsors of phase 3 trials in cancer-related settings.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Grifols","links":[{"label":"Official website","url":"https://www.grifols.com"},{"label":"ClinicalTrials.gov: trials led by Grifols Therapeutics LLC","url":"https://clinicaltrials.gov/search?lead=Grifols%20Therapeutics%20LLC"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q901262"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct05645107","nct07582432"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Sant Cugat del Vallès","country":"ES","companyType":"pharma","website":"https://www.grifols.com","founded":1909,"stage":"public","investors":[],"funding":[]},{"id":"grit-bio","kind":"company","name":"Grit Bio","aka":["Grit Biotechnology","GRIT Biotherapeutics","沙砾生物"],"tldr":"Grit Bio is a China-based cell therapy company that leads 3 cancer trials in OnCo, testing the tumour-infiltrating lymphocyte therapies GT101 and GT201 and the CAR-T GT719 in cervical cancer, non-Hodgkin lymphoma and advanced solid tumours.","summary":"Grit Bio is a late-stage biopharmaceutical company developing next-generation T-cell therapies for cancer and autoimmune disease, with headquarters in Beijing, a research centre in Shanghai and a GMP manufacturing base in Suzhou. Its pipeline includes GT101, an autologous tumour-infiltrating lymphocyte (TIL) therapy in pivotal development, GT201, a TIL therapy expressing membrane-bound IL-15, CAR-T and CAR-iNKT candidates and neoantigen cancer vaccines. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT06241781 (phase 2, Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent...), NCT06948981 (phase 1/2, GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Ma...) and NCT06144671 (phase 1/2, Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://grit-bio.com/"},{"label":"ClinicalTrials.gov: trials led by Grit Bio","url":"https://clinicaltrials.gov/search?lead=Grit%20Biotechnology"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cervical","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06241781","nct06948981","nct06144671"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Beijing","country":"CN","companyType":"cell-therapy","website":"https://grit-bio.com/","founded":2019,"stage":"growth","investors":[],"funding":[]},{"id":"gritstone","kind":"company","name":"Gritstone bio","aka":[],"tldr":"Neoantigen-vaccine pioneer (GRANITE, SLATE) that ran out of money and filed for bankruptcy in October 2024; a cautionary tale for the personalised-vaccine field.","summary":"Gritstone's GRANITE individualised neoantigen vaccine (adenoviral prime, samRNA boost) showed a molecular-response signal in a phase 2/3 colorectal cancer maintenance trial but not enough to fund completion. Chapter 11 filing 10 October 2024; assets sold at auction (Seattle Project Corp. and others) for about $21M in December 2024.","status":"withdrawn","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Gritstone_bio","links":[{"label":"Bankruptcy and asset sale","url":"https://www.nasdaq.com/articles/gritstone-bio-files-bankruptcy-and-auctions-assets"}],"tags":["failure"],"related":[],"cancers":["colorectal"],"sections":["immunotherapy"],"technologies":["neoantigen-mrna-vaccine","shared-antigen-vaccine"],"targets":[],"drugs":["grt-c901","grt-r902"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Emeryville, CA","country":"US","companyType":"biotech","website":"https://www.gritstonebio.com","investors":[],"funding":[]},{"id":"gruenenthal","kind":"company","name":"Grünenthal","aka":["Gruenenthal GmbH","Grünenthal GmbH","Gruenenthal"],"tldr":"Grünenthal is a German pharmaceutical company founded in 1946 in Aachen. In OnCo it is the marketing authorisation holder of PecFent, a fentanyl nasal spray authorised in the EU for breakthrough pain in adults on maintenance opioids for chronic cancer pain.","summary":"Grünenthal GmbH is a German pharmaceutical company based in Aachen, founded on 29 January 1946 (Wikidata Q153838, which also gives its website and English Wikipedia article). The EMA register names Gruenenthal GmbH as the marketing authorisation holder of PecFent (fentanyl pectin nasal spray), authorised 31 August 2010 for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain. It sponsors no trial recorded in OnCo.","asOf":"2026-09-22","wikipedia":"https://en.wikipedia.org/wiki/Gr%C3%BCnenthal","links":[{"label":"Official website","url":"https://www.grunenthal.com/"},{"label":"Wikidata Q153838","url":"https://www.wikidata.org/wiki/Q153838"},{"label":"EMA: PecFent (EPAR)","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/pecfent"}],"tags":["ctgov-sponsor","wave5-sponsor"],"related":[],"cancers":[],"sections":[],"technologies":["pain-management"],"targets":[],"drugs":["fentanyl"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo content wave 5 (Wikidata, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-22"},"hq":"Aachen","country":"DE","companyType":"pharma","website":"https://www.grunenthal.com/","founded":1946,"investors":[],"funding":[]},{"id":"gsk","kind":"company","name":"GSK","aka":["Tesaro, Inc.","Tesaro","Bellus Health Inc. - a GSK company","Bellus Health"],"tldr":"GSK makes Jemperli, Zejula, and the twice-approved myeloma ADC Blenrep.","summary":"GSK, based in London and listed as GSK, makes Jemperli, Zejula and the twice-approved myeloma antibody-drug conjugate Blenrep. Dostarlimab is best known for organ preservation in mismatch-repair-deficient rectal cancer, reported by Cercek in 2022, and for the RUBY trial in endometrial cancer; niraparib is its PARP inhibitor in ovarian cancer; belantamab mafodotin was re-approved in 2025; momelotinib was proved in MOMENTUM for myelofibrosis; and B7-H4 and B7-H3 ADCs come from Hansoh licences. OnCo also links it to the bivalent HPV vaccine, to WRN helicase in MSI-high cancers, and to Zai Lab and SR One. Whether dostarlimab can turn rectal organ preservation into a formal indication is the open question. Dostarlimab, niraparib and belantamab mafodotin have their own pages.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/GSK_plc","links":[{"label":"Official website","url":"https://www.gsk.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs","immunotherapy","targeted-therapy"],"technologies":[],"targets":[],"drugs":["dostarlimab","niraparib","belantamab-mafodotin","velzatinib","cobolimab","idrx-42","feladilimab","topotecan","chlorambucil","ondansetron"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06868654","nct06956170","nct04162210","nct06679101","nct06868667","nct07084896","nct06521567","nct07150091","nct07227311","nct07217184","nct05714839","nct07150104","nct05565378","nct06640049","nct06062420","nct06256588","nct07263594","nct07108270","nct06567782","nct06317311","nct07286331","nct06710847","nct07689201","nct07213609","nct06990880","nct04915755","nct07332455","nct07099898","nct03602859","nct06885034","nct07602777","nct05855200","nct04641247","nct06472076","nct03441113","nct07286266","nct06077877","nct06796907"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"London","country":"GB","companyType":"pharma","website":"https://www.gsk.com","ticker":"GSK","investors":[],"funding":[]},{"id":"gt-medical-technologies","kind":"company","name":"GT Medical Technologies","aka":[],"tldr":"GT Medical Technologies makes GammaTile, small dissolvable collagen tiles containing radioactive caesium seeds that a neurosurgeon places in the cavity left after removing a brain tumour, so radiation starts immediately and the patient avoids weeks of daily radiotherapy visits.","summary":"GT Medical Technologies (Tempe, Arizona), founded by brain tumour specialists, developed GammaTile, an FDA-cleared bioresorbable brachytherapy implant. Collagen tiles carrying caesium-131 seeds are placed in the resection cavity at surgery, delivering a localised dose over the following weeks. GammaTile is indicated for newly diagnosed malignant and recurrent intracranial neoplasms, had its full US launch in March 2020. The randomised phase 3 ROADS trial in newly diagnosed brain metastases, presented at ASCO 2026, compared resection plus GammaTile with resection plus post-operative stereotactic radiotherapy; the company reports a 93 percent lower risk of local recurrence and 41 percent lower risk of death at 12 months without added toxicity. The BRIDGES randomised trial in newly diagnosed glioblastoma is enrolling. In June 2026 the company closed an oversubscribed USD 100 million Series E led by Viking Global Investors.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://gammatile.com/"},{"label":"Series E press release (June 2026)","url":"https://www.prnewswire.com/news-releases/gt-medical-technologies-completes-oversubscribed-100-million-series-e-equity-financing-to-advance-commercial-treatment-for-patients-with-operable-brain-tumors-302794352.html"},{"label":"About GT Medical Technologies","url":"https://gammatile.com/about-gt-medical-technologies/"},{"label":"ROADS phase 3 results at ASCO 2026","url":"https://www.prnewswire.com/news-releases/roads-phase-3-clinical-trial-data-presented-at-asco26-show-gammatile-provides-superior-tumor-control-leading-to-patients-living-longer-without-recurrence-compared-to-standard-of-care-in-newly-diagnosed-operable-brain-metastases-302786198.html"}],"tags":[],"related":[],"cancers":["glioblastoma"],"sections":["radiation","surgery","devices"],"technologies":["brachytherapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04365374","nct07195591"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["gtmedtech.com redirects to gammatile.com, which is used as the canonical website. Founding year and Series A to D rounds are unsourced and omitted. The Cs-131 half-life and tile dimensions are from general knowledge, not the fetched pages. The ROADS ASCO release URL was confirmed reachable (HTTP 200)."],"hq":"Tempe, AZ","country":"US","companyType":"devices","website":"https://gammatile.com/","stage":"growth","investors":["gilde-healthcare"],"funding":[{"round":"Series E","year":2026,"amountUsd":100000000,"source":"https://www.prnewswire.com/news-releases/gt-medical-technologies-completes-oversubscribed-100-million-series-e-equity-financing-to-advance-commercial-treatment-for-patients-with-operable-brain-tumors-302794352.html","note":"Oversubscribed; led by new investor Viking Global Investors"}]},{"id":"gtx","kind":"company","name":"GTx","aka":["GTx Incorporated","GTx, Inc."],"tldr":"GTx was a Memphis biotech that developed selective androgen receptor modulators, including enobosarm for cancer-related muscle wasting and breast cancer, before merging with Oncternal Therapeutics in 2019.","summary":"GTx Incorporated, founded in 1997 in Memphis, Tennessee, worked on selective androgen receptor modulators and toremifene. Its phase 3 POWER trials tested enobosarm against muscle wasting in non-small cell lung cancer, and later studies explored it in androgen receptor-positive breast cancer; a toremifene programme for prostate cancer patients on androgen deprivation was also taken to phase 3. GTx merged with Oncternal Therapeutics in 2019. Its trials remain on ClinicalTrials.gov under GTx as lead sponsor. Wikipedia records that GTx licensed toremifene from Orion, partnered it with Ipsen in 2006 to prevent prostate cancer in men on androgen deprivation, received an FDA rejection in 2009 and sold the rights to ProStrakan, a Kyowa Hakko Kirin subsidiary, in 2012.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.gtxinc.com"},{"label":"ClinicalTrials.gov: trials led by GTx Incorporated","url":"https://clinicaltrials.gov/search?lead=GTx%20Incorporated"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q5514784"},{"label":"Wikipedia: GTx, Inc.","url":"https://en.wikipedia.org/wiki/GTx,_Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","prostate","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["toremifene"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Memphis, TN","country":"US","companyType":"biotech","website":"http://www.gtxinc.com","founded":1997,"stage":"acquired","investors":[],"funding":[]},{"id":"guangzhou-virotech","kind":"company","name":"Guangzhou Virotech Pharmaceutical","aka":["Guangzhou Virotech Pharmaceutical Co., Ltd."],"tldr":"Guangzhou Virotech Pharmaceutical is a China-based biotechnology company that leads 2 cancer trials in OnCo, testing the M1 alphavirus-based oncolytic virus VRT106 in glioma & glioblastoma and diffuse midline glioma, H3 K27-altered.","summary":"Guangzhou Virotech Pharmaceutical is a Guangzhou-based biopharmaceutical company. The ClinicalTrials.gov registry lists it as lead sponsor of trials of intravenously administered oncolytic virus therapies based on the M1 alphavirus, including VRT106 (M1-c6v1), in advanced solid tumours and gliomas. No company website could be verified, so company facts here are limited to the registry. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT07093814 (phase 1/2, A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma) and NCT07589257 (phase 2, A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midli...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov: trials led by Guangzhou Virotech Pharmaceutical","url":"https://clinicaltrials.gov/search?lead=Guangzhou%20Virotech%20Pharmaceutical%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["glioblastoma","dipg-dmg"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07093814","nct07589257"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Guangzhou","country":"CN","companyType":"biotech","investors":[],"funding":[]},{"id":"guardant-health","kind":"company","name":"Guardant Health","aka":["Guardant"],"tldr":"Liquid biopsy leader: Guardant360 for genotyping, Reveal for MRD, Shield for screening.","summary":"Guardant Health, based in Palo Alto and listed as GH, is the liquid biopsy leader, with Guardant360 for tumour genotyping, Reveal for measurable residual disease and Shield for screening. Guardant360 CDx is a companion diagnostic for elacestrant and other drugs, Guardant Reveal is a tumour-naive MRD test, and Shield is FDA-approved for colorectal cancer screening on the ECLIPSE trial, with a multi-cancer extension in development. OnCo links it to colorectal cancer, to comprehensive genomic profiling, ctDNA monitoring, MRD testing and multi-cancer early detection, to bottlenecks on late diagnosis, heterogeneity and residual disease, and to ideas such as an annual blinded shoot-out for liquid biopsy tests and certified reference samples. Whether a blood test can match established screening methods is the open question for Shield. Shield has its own page.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Guardant_Health","links":[{"label":"Official website","url":"https://guardanthealth.com"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics","early-detection"],"technologies":[],"targets":[],"drugs":["shield"],"companies":["khosla-ventures"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Palo Alto, CA","country":"US","companyType":"diagnostics","website":"https://guardanthealth.com","ticker":"GH","investors":[],"funding":[]},{"id":"guardian-bio","kind":"company","name":"Guardian Bio","aka":[],"tldr":"Guardian Bio turns a patient's stem cells into dendritic cells, the immune system's teachers, trains them against that patient's tumour and gives them back to restart the immune attack.","summary":"Guardian Bio is developing a dendritic cell therapy platform: patient-derived stem cells are differentiated into therapeutic dendritic cells, loaded against multiple antigens from the patient's own tumour and reinfused to activate cytotoxic T cells and natural killer cells. The rationale is that dendritic cell dysfunction in cancer patients limits the effect of other immunotherapies. The company is preclinical with a very small team; no sourced financing rounds are recorded.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/guardian-bio"},{"label":"Official website","url":"https://www.guardian-bio.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["cell-therapy","immunotherapy"],"technologies":["allogeneic-cell-therapy","shared-antigen-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boston, MA","country":"US","companyType":"cell-therapy","website":"https://www.guardian-bio.com","stage":"startup","ycBatch":"S22","investors":["y-combinator"],"funding":[]},{"id":"guerbet","kind":"company","name":"Guerbet","aka":["Guerbet SA","EPA:GBT"],"tldr":"Guerbet is the French contrast-agent company behind Lipiodol, the iodised poppy-seed oil that radiologists use to deliver and image chemotherapy in liver tumours.","summary":"Guerbet, founded in 1926 and based near Paris, makes contrast agents and delivery systems for diagnostic and interventional imaging. Lipiodol (ethiodized oil), its oldest product, is used in transarterial chemoembolisation of hepatocellular carcinoma, where it carries the chemotherapy emulsion into the tumour and remains visible on computed tomography. Guerbet also sells iodinated and gadolinium contrast media, injectors and artificial-intelligence tools for liver and prostate imaging.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.guerbet.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["ethiodized-oil"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Villepinte","country":"FR","companyType":"imaging","website":"https://www.guerbet.com/","ticker":"EPA:GBT","founded":1926,"stage":"public","investors":[],"funding":[]},{"id":"gv","kind":"company","name":"GV (Google Ventures)","aka":[],"tldr":"Alphabet's venture arm, established in 2009. It has backed some of the best-known cancer diagnostics companies, including Foundation Medicine, Grail, Freenome and Flatiron Health, as well as cancer drug developers such as Forty Seven and Gritstone.","summary":"GV states 'EST. 2009' on its homepage and invests Alphabet's capital across AI, healthcare, dev tools and infrastructure, from seed to growth. It says it has 'partnered with 20 AI healthcare companies, including insitro and Isomorphic Labs', and operates independently of Google's business units. Its portfolio page (exits marked with an asterisk) is dense with oncology: Foundation Medicine, Flatiron Health, Grail, Freenome, Forty Seven (CD47 antibody, acquired by Gilead), Gritstone Bio, Arcus Biosciences, Accent Therapeutics, Ideaya Biosciences, IconOVir Bio, Owkin and Oxford Science Enterprises, alongside genomics platforms such as Editas and Beam.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.gv.com/"},{"label":"Portfolio","url":"https://www.gv.com/portfolio"}],"tags":["corporate-venture"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["arcus-biosciences","freenome","isomorphic-labs","owkin"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Headquarters city follows the task hint; GV's site does not state an address. Several of these companies (Foundation Medicine, Grail, Freenome, Flatiron Health, Gritstone, Owkin, Isomorphic Labs) are already in the graph."],"hq":"Mountain View, CA","country":"US","companyType":"investor","website":"https://www.gv.com/","founded":2009,"investors":[],"funding":[]},{"id":"gv20-therapeutics","kind":"company","name":"GV20 Therapeutics","aka":["GV20 Therapeutics"],"tldr":"GV20 Therapeutics is a US-based biotechnology company that leads 2 cancer trials in OnCo, testing the anti-IGSF8 antibody GV20-0251 in endometrial cancer, head and neck squamous cell carcinoma, melanoma and non-small-cell lung cancer.","summary":"GV20 Therapeutics is a clinical-stage biotechnology company that uses its AI-driven STEAD platform, combining B-cell repertoire data, omics data and disease biology, to discover antibody targets and therapeutics. Its lead candidate GV20-0251 is a first-in-class antibody against the immune checkpoint IGSF8, in phase 1 in the United States and China. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT05669430 (phase 1/2, A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Par...) and NCT07070518 (phase 1/2, Study of GV20-0251 in Participants With Solid Tumor Malignancies). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://gv20tx.com"},{"label":"ClinicalTrials.gov: trials led by GV20 Therapeutics","url":"https://clinicaltrials.gov/search?lead=GV20%20Therapeutics"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["endometrial","head-and-neck","melanoma","nsclc","hcc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05669430","nct07070518"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Newton, Massachusetts","country":"US","companyType":"biotech","website":"https://gv20tx.com","stage":"startup","investors":[],"funding":[]},{"id":"haihe-biopharma","kind":"company","name":"Haihe Biopharma","aka":["Haihe Biopharma Co., Ltd."],"tldr":"Haihe Biopharma is a China-based biotechnology company running 4 late-stage cancer trials of HH2853, Glumetinib and CYH33 in non-small-cell lung cancer, follicular lymphoma and sarcomas.","summary":"Haihe Biopharma, based in Shanghai, China, is a biotechnology company. Haihe Biopharma (Shanghai Haihe Pharmaceuticals) is a China-based biopharmaceutical company focused on the discovery, development, production and commercialisation of innovative drugs, including several oncology candidates. On ClinicalTrials.gov it is the lead sponsor of 4 recruiting or active phase 2 and phase 3 interventional cancer trials, testing HH2853, Glumetinib and CYH33 in non-small-cell lung cancer, follicular lymphoma, sarcomas, peripheral T-cell lymphomas and hodgkin lymphoma. The largest, NCT04390737 (Evaluate the Safety and Clinical Activity of HH2853), plans to enrol 254 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.haihepharma.com"},{"label":"ClinicalTrials.gov: trials led by Haihe Biopharma","url":"https://clinicaltrials.gov/search?lead=Haihe%20Biopharma%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","follicular-lymphoma","sarcoma","peripheral-t-cell-lymphoma","hodgkin-lymphoma","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["cyh33"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06909877","nct04390737","nct04270591"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.haihepharma.com","founded":2011,"stage":"growth","investors":[],"funding":[]},{"id":"halda-therapeutics","kind":"company","name":"Halda Therapeutics","aka":[],"tldr":"Halda Therapeutics invented a new kind of oral cancer drug that links a protein found only in tumour cells to a protein cells need to survive, killing the cancer cell. Johnson & Johnson bought the company for 3.05 billion US dollars in 2025.","summary":"Halda Therapeutics was a New Haven, Connecticut clinical-stage biotechnology company built on its Regulated Induced Proximity Targeting Chimera (RIPTAC) platform: heterobifunctional oral molecules that bring a tumour-specific protein together with a protein essential for cell survival, producing a hold-and-kill mechanism intended to overcome resistance to existing targeted therapies. Its lead candidate, HLD-0915, is a once-daily oral therapy in clinical development for prostate cancer, and the platform is being applied to other solid tumours. SEC Form D filings show about 41 million US dollars sold in 2021 and roughly 150 million US dollars sold across two 2024 offerings. Johnson & Johnson completed its acquisition of Halda for 3.05 billion US dollars in cash on 29 December 2025; the Halda website now redirects to J&J Innovative Medicine.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.haldatx.com/"},{"label":"J&J completion press release","url":"https://www.jnj.com/media-center/press-releases/johnson-johnson-completes-acquisition-of-halda-therapeutics-and-its-novel-platform-to-revolutionize-cancer-treatment-and-enable-next-generation-oral-therapies"},{"label":"J&J Q4 2025 results referencing the acquisition (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/200406/000020040626000002/a2025q4exhibit991.htm"}],"tags":[],"related":[],"cancers":["prostate"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["haldatx.com redirects to a J&J page that showed a site-maintenance notice, so no original company page was available. The 2024 Form D offerings are widely reported as the Series B but that label was not verified. HLD-0915's clinical phase was not stated in the fetched release beyond 'clinical-stage'."],"hq":"New Haven, CT","country":"US","companyType":"biotech","website":"https://www.haldatx.com/","founded":2018,"stage":"acquired","investors":[],"funding":[{"round":"Form D offering","year":2021,"amountUsd":40990001,"source":"https://www.sec.gov/Archives/edgar/data/1769401/000176940121000001/primary_doc.xml","note":"Total sold of a 51 million US dollar offering per Form D filed December 2021"},{"round":"Form D offering","year":2024,"amountUsd":24211678,"source":"https://www.sec.gov/Archives/edgar/data/1769401/000176940124000001/primary_doc.xml","note":"Total sold of a 36 million US dollar offering per Form D filed May 2024"},{"round":"Form D offering","year":2024,"amountUsd":126471316,"source":"https://www.sec.gov/Archives/edgar/data/1769401/000176940124000002/primary_doc.xml","note":"Total sold per Form D filed August 2024"},{"round":"Acquisition","year":2025,"amountUsd":3050000000,"source":"https://www.jnj.com/media-center/press-releases/johnson-johnson-completes-acquisition-of-halda-therapeutics-and-its-novel-platform-to-revolutionize-cancer-treatment-and-enable-next-generation-oral-therapies","note":"3.05 billion US dollars in cash; completion announced 29 December 2025"}],"acquiredBy":"johnson-johnson"},{"id":"halozyme","kind":"company","name":"Halozyme Therapeutics","aka":["Halozyme Therapeutics, Inc.","Halozyme"],"tldr":"Halozyme's recombinant hyaluronidase (ENHANZE) is what lets antibodies such as rituximab, trastuzumab and daratumumab be given as quick under-the-skin injections instead of long infusions; its own tumour-targeting version failed in pancreatic cancer.","summary":"Halozyme Therapeutics, founded in 1998 in San Diego, licenses its ENHANZE drug-delivery technology, a recombinant human hyaluronidase that breaks down hyaluronan under the skin so large volumes of antibody can be injected subcutaneously; the subcutaneous forms of rituximab, trastuzumab, daratumumab, pertuzumab and atezolizumab rely on it. Its own PEGylated hyaluronidase PEGPH20, aimed at hyaluronan-rich pancreatic tumours, failed the phase 3 HALO-301 trial in 2019. ClinicalTrials.gov lists Halozyme as lead sponsor of that and other phase 3 trials.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.halozyme.com"},{"label":"ClinicalTrials.gov: trials led by Halozyme Therapeutics, Inc.","url":"https://clinicaltrials.gov/search?lead=Halozyme%20Therapeutics%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q5643474"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["rituximab","trastuzumab","daratumumab"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://www.halozyme.com","founded":1998,"stage":"public","investors":[],"funding":[]},{"id":"hamamatsu","kind":"company","name":"Hamamatsu Photonics","aka":[],"tldr":"Hamamatsu is the photonics company behind the NanoZoomer slide scanners and the photodetectors inside most PET scanners.","summary":"Hamamatsu Photonics, based in Hamamatsu, Japan, and listed as 6965.T, is the photonics company behind the NanoZoomer slide scanners and the photodetectors inside most PET scanners. Its NanoZoomer S360 and S60 whole-slide scanners serve digital pathology, and its silicon photomultipliers and photomultiplier tubes sit inside PET/CT and SPECT systems from many manufacturers. OnCo links it to whole-slide scanners and image management and to nuclear medicine and total-body PET hardware. Its position as a component supplier means that advances in detector sensitivity reach the whole imaging market through it. Whether that quiet role is recognised when total-body PET costs are debated is the fair question.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Hamamatsu_Photonics","links":[{"label":"Official website","url":"https://www.hamamatsu.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics","imaging"],"technologies":["whole-slide-scanners","nuclear-medicine-hardware"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Hamamatsu","country":"JP","companyType":"imaging","website":"https://www.hamamatsu.com","ticker":"6965.T","investors":[],"funding":[]},{"id":"hangzhou-hanx-biopharmaceuticals","kind":"company","name":"Hangzhou Hanx Biopharmaceuticals","aka":["Hangzhou Hanx Biopharmaceuticals, Ltd."],"tldr":"Hangzhou Hanx Biopharmaceuticals is a China-based biotechnology company running 2 late-stage cancer trials of HX009 in glioma & glioblastoma, biliary tract cancer and melanoma.","summary":"Hangzhou Hanx Biopharmaceuticals, based in Wuhan, China, is a biotechnology company. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing HX009 in glioma & glioblastoma, biliary tract cancer and melanoma. The largest, NCT06708663 (HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours), plans to enrol 124 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.hanxbio.com"},{"label":"ClinicalTrials.gov: trials led by Hangzhou Hanx Biopharmaceuticals","url":"https://clinicaltrials.gov/search?lead=Hangzhou%20Hanx%20Biopharmaceuticals%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["glioblastoma","cholangiocarcinoma","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06649708","nct06708663","nct06703255"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Wuhan","country":"CN","companyType":"biotech","website":"https://www.hanxbio.com","investors":[],"funding":[]},{"id":"hangzhou-sumgen-biotech","kind":"company","name":"Hangzhou Sumgen Biotech","aka":["Hangzhou Sumgen Biotech Co., Ltd."],"tldr":"Hangzhou Sumgen Biotech is a China-based biotechnology company running 2 late-stage cancer trials of SG2918 and SG301 in multiple myeloma.","summary":"Hangzhou Sumgen Biotech, based in Hangzhou, China, is a biotechnology company. Sumgen Biotech is a biotech company focused on innovative drug development in oncology, specialising in antibody drugs including monoclonal antibodies and antibody-drug conjugates. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing SG2918 and SG301 in multiple myeloma. The largest, NCT06508983 (A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients), plans to enrol 360 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.sumgenbio.com"},{"label":"ClinicalTrials.gov: trials led by Hangzhou Sumgen Biotech","url":"https://clinicaltrials.gov/search?lead=Hangzhou%20Sumgen%20Biotech%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["sg301"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07454187"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Hangzhou","country":"CN","companyType":"biotech","website":"https://www.sumgenbio.com","founded":2015,"stage":"growth","investors":[],"funding":[]},{"id":"hanmi-pharmaceutical","kind":"company","name":"Hanmi Pharmaceutical","aka":["Hanmi Pharm","한미약품","KRX:128940"],"tldr":"Hanmi Pharmaceutical is one of South Korea's largest drug companies, known for its long-acting protein platform and for olmutinib, the third-generation EGFR inhibitor approved in Korea as Olita in 2016.","summary":"Hanmi Pharmaceutical, founded in 1973 and based in Seoul, is a research-driven South Korean pharmaceutical company. Its LAPSCOVERY platform produced efpeglenatide and the neutropenia drug eflapegrastim (Rolvedon), and it has out-licensed several oncology candidates including the pan-RAF inhibitor belvarafenib and the FLT3 inhibitor tuspetinib. Olmutinib (HM61713), a third-generation EGFR T790M inhibitor, received conditional approval in Korea in 2016; Boehringer Ingelheim returned its licence the same year after cases of severe skin toxicity.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Hanmi_Pharm","links":[{"label":"Official website","url":"https://www.hanmipharm.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["olmutinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Seoul","country":"KR","companyType":"pharma","website":"https://www.hanmipharm.com/","ticker":"KRX:128940","founded":1973,"stage":"public","investors":[],"funding":[]},{"id":"hansoh-pharma","kind":"company","name":"Hansoh Pharmaceutical","aka":["Hansoh","Hansoh Pharma","Hansoh Pharmaceutical Group","翰森制药","hansoh"],"tldr":"Hansoh is a Chinese pharmaceutical group whose EGFR inhibitor aumolertinib (Ameile in China, Aumseqa in the EU) became the first China-originated lung cancer pill authorised by the European Commission in 2026.","summary":"Hansoh Pharmaceutical, based in Lianyungang, Jiangsu, and listed in Hong Kong as 3692.HK, is a Chinese pharmaceutical group whose EGFR inhibitor aumolertinib, sold as Ameile in China and Aumseqa in the European Union, became the first China-originated lung cancer tablet authorised by the European Commission in 2026. Aumolertinib is a third-generation EGFR kinase inhibitor approved by the NMPA in 2020 and by the EU in 2026 for EGFR-mutant non-small-cell lung cancer, and the company has out-licensed antibody-drug conjugate and GLP-1 assets to GSK and Merck. OnCo links it to the aumolertinib drug record. Whether a European approval can win share from the established third-generation EGFR drug is the open question. Aumolertinib has its own page. The B7-H4 (HS-20089) and B7-H3 (HS-20093) antibody-drug conjugates were licensed to GSK in 2023 for $85 million and $185 million upfront, and the GLP-1 agreements with Merck & Co. sit outside oncology; the company was founded in 1995 and is run by Zhong Huijuan, one of the world's wealthiest self-made women.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Hansoh_Pharmaceutical","links":[{"label":"Official website","url":"https://www.hspharm.com/"}],"tags":["china"],"related":[],"cancers":[],"sections":["targeted-therapy","adcs"],"technologies":[],"targets":[],"drugs":["aumolertinib","hs-20093","hs-20089","hs-20117","flumatinib"],"companies":["gsk","merck"],"institutions":[],"pathways":[],"terms":[],"trials":["aeneas","nct05435248","nct07468851","nct05367778","nct06147570","nct07283367","nct04951635","nct04687241","nct05830123","nct06007729","nct04923906","nct06014190","nct06112704"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Lianyungang, Jiangsu","country":"CN","companyType":"pharma","website":"https://www.hspharm.com","ticker":"3692.HK","founded":1995,"investors":[],"funding":[]},{"id":"harbinger-health","kind":"company","name":"Harbinger Health","aka":[],"tldr":"Flagship-founded blood-test company launching RESOLVE, a multi-cancer detection test for people with symptoms who are waiting for a diagnosis.","summary":"RESOLVE targets the symptomatic diagnostic window rather than asymptomatic screening, with tissue-of-origin output; first products expected commercially in H2 2026 after a $100M raise (2025). PROCARES prospective validation ongoing; multiple AACR 2026 presentations on the Harbinger HX methylation platform.","asOf":"2026-09-04","links":[{"label":"RESOLVE announcement","url":"https://www.prnewswire.com/news-releases/harbinger-health-establishes-resolve-as-a-new-category-for-cancer-detection-302740706.html"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection","diagnostics"],"technologies":["mced","methylation-profiling"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["ppv"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cambridge, MA","country":"US","companyType":"diagnostics","website":"https://www.harbingerhealth.com","investors":["flagship-pioneering"],"funding":[]},{"id":"harbour-biomed","kind":"company","name":"Harbour BioMed","aka":["Harbour BioMed (Guangzhou) Co. Ltd.","HBM"],"tldr":"Harbour BioMed is a Hong Kong-listed antibody company, with operations in China, the Netherlands and the United States, whose fully human and heavy-chain-only antibody platforms feed cancer immunotherapy programmes and phase 3 trials.","summary":"Harbour BioMed, founded in 2016 and listed in Hong Kong, owns the Harbour Mice transgenic platforms that produce fully human antibodies, including heavy-chain-only antibodies used for bispecifics. Its pipeline includes the anti-CTLA-4 antibody porustobart and the FcRn antibody batoclimab, and it licenses its platforms widely. ClinicalTrials.gov lists its Guangzhou company as lead sponsor of phase 3 cancer trials.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.harbourbiomed.com"},{"label":"ClinicalTrials.gov: trials led by Harbour BioMed (Guangzhou) Co. Ltd.","url":"https://clinicaltrials.gov/search?lead=Harbour%20BioMed%20(Guangzhou)%20Co.%20Ltd."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q107517856"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":[],"technologies":["bispecific-antibody"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Rotterdam","country":"NL","companyType":"biotech","website":"https://www.harbourbiomed.com","founded":2016,"stage":"public","investors":[],"funding":[]},{"id":"harmonic-discovery","kind":"company","name":"Harmonic Discovery","aka":[],"tldr":"Harmonic Discovery designs single drugs that hit several disease-driving proteins at once, arguing that cancer is rarely caused by one broken protein.","summary":"Harmonic Discovery is a computational-experimental drug discovery company designing multi-targeted small molecules, principally kinase inhibitors, whose target profiles are chosen to hit several dysregulated proteins in a cancer at once while avoiding those that cause toxicity. The company argues that rational polypharmacology can be more effective and safer than one-drug-one-target agents. Programmes are preclinical; no sourced financing rounds are recorded here.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/harmonic-discovery"},{"label":"Official website","url":"https://harmonicdiscovery.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["drug-discovery","targeted-therapy"],"technologies":["ai-drug-design","kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"New York, NY","country":"US","companyType":"biotech","website":"https://harmonicdiscovery.com","stage":"startup","ycBatch":"S21","investors":["y-combinator"],"funding":[]},{"id":"harpoon-therapeutics","kind":"company","name":"Harpoon Therapeutics","aka":[],"tldr":"Harpoon built small T-cell engager proteins that link a patient's T cells to tumour cells, including HPN328, which targets DLL3 on small cell lung cancer and neuroendocrine tumours. Merck bought the company in early 2024 for about $680 million.","summary":"Harpoon Therapeutics was a South San Francisco clinical-stage company that developed T-cell engagers on its Tri-specific T cell Activating Construct (TriTAC) platform and the ProTriTAC prodrug platform, which keeps the engager inactive until it reaches the tumour. Lead candidate HPN328 is a DLL3-targeting T-cell engager evaluated in patients with small cell lung cancer and neuroendocrine tumours. On 8 January 2024 Merck agreed to acquire Harpoon for $23.00 per share in cash, an approximate total equity value of $680 million, and the merger completed on 11 March 2024, after which Harpoon's Nasdaq listing (HARP) ended. Merck said it would evaluate HPN328 in combinations with its pipeline. The harpoontx.com domain now redirects to merck.com.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.merck.com/"},{"label":"Merck to acquire Harpoon (8-K exhibit 99.2, January 2024)","url":"https://www.sec.gov/Archives/edgar/data/1708493/000119312524003927/d715256dex992.htm"},{"label":"Completion of merger (8-K, March 2024)","url":"https://www.sec.gov/Archives/edgar/data/1708493/000119312524064395/d808382d8k.htm"}],"tags":[],"related":[],"cancers":["sclc","neuroendocrine"],"sections":["immunotherapy"],"technologies":["t-cell-engager"],"targets":["dll3","cd3"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Former Nasdaq ticker HARP."],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.merck.com/","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2024,"amountUsd":680000000,"source":"https://www.sec.gov/Archives/edgar/data/1708493/000119312524003927/d715256dex992.htm","note":"$23.00 per share in cash, approximate total equity value $680 million; announced 8 January 2024, completed 11 March 2024"}],"acquiredBy":"merck"},{"id":"hartwig-medical-foundation","kind":"company","name":"Hartwig Medical Foundation","aka":[],"tldr":"The Hartwig Medical Foundation sequences the whole genomes of Dutch cancer patients' tumours through participating hospitals and pools the data for research, one of the largest such programmes anywhere.","summary":"Founded in 2015 in Amsterdam, the Hartwig Medical Foundation runs whole-genome sequencing of tumours for patients referred through participating Dutch hospitals and maintains a national database of tumour genomes with clinical data that researchers worldwide can apply to use. Its stated aim is improved cancer patient care driven by data. Access is by referral in the Netherlands.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.hartwigmedicalfoundation.nl/en/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Amsterdam, Netherlands","country":"NL","companyType":"nonprofit","website":"https://www.hartwigmedicalfoundation.nl/en/","investors":[],"funding":[]},{"id":"haystack-oncology","kind":"company","name":"Haystack Oncology","aka":[],"tldr":"Haystack Oncology, now owned by Quest Diagnostics, makes a blood test that looks for tiny traces of tumour DNA after cancer surgery to tell whether any cancer is left behind or coming back.","summary":"Haystack Oncology, a Quest Diagnostics company since June 2023, developed Haystack MRD, a tumour-informed circulating tumour DNA (ctDNA) assay for minimal residual disease (MRD) in solid tumours. The patient's tumour is sequenced to build a personalised variant panel, which is then tracked in plasma using patented duplex error-correction that reads both DNA strands, with a stated limit of detection of 0.0006 percent. The FDA granted Breakthrough Device Designation in August 2025 for MRD-positive stage II colorectal cancer, and New York State approved the test in June 2026. The assay runs in Baltimore, with Quest sites in Hamburg and Helsinki, and is under study with Rutgers Cancer Institute in triple-negative breast and lung cancer. Quest's 10-K records the acquisition as $392 million all-cash net of cash acquired, plus possible contingent payments.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://haystackmrd.com/"},{"label":"Quest Diagnostics 10-K (FY2023) describing the acquisition","url":"https://www.sec.gov/Archives/edgar/data/1022079/000102207924000041/dgx-20231231.htm"},{"label":"FDA Breakthrough Device Designation release (Aug 2025)","url":"https://haystackmrd.com/fda-grants-breakthrough-device-designation-for-haystack-mrd-circulating-tumor-dna-test-from-quest-diagnostics/"},{"label":"New York State approval (June 2026)","url":"https://haystackmrd.com/haystack-mrd-receives-new-york-state-approval/"}],"tags":[],"related":[],"cancers":["colorectal","tnbc","nsclc"],"sections":["diagnostics"],"technologies":["liquid-biopsy","mrd-testing","wes-wgs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Baltimore is given as the laboratory location in the 2025 Breakthrough release; the current website footer lists Quest's Lewisville, Texas address. Original Quest acquisition press release (April 2023) could not be located on the Quest newsroom; the 10-K was used instead. Pre-acquisition venture funding not sourced."],"hq":"Baltimore, MD","country":"US","companyType":"diagnostics","website":"https://haystackmrd.com/","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2023,"amountUsd":392000000,"source":"https://www.sec.gov/Archives/edgar/data/1022079/000102207924000041/dgx-20231231.htm","note":"Quest 10-K: all-cash transaction for $392 million net of cash acquired, comprising $304 million cash and contingent consideration initially estimated at $88 million; up to $150 million more tied to revenue and CMS coverage milestones. Closed 20 June 2023."}],"acquiredBy":"quest-diagnostics"},{"id":"heidelberg-pharma","kind":"company","name":"Heidelberg Pharma","aka":["Heidelberg Pharma AG"],"tldr":"Heidelberg Pharma is a German company building antibody-drug conjugates around amanitin, a toxin from the death cap mushroom that kills cells by blocking RNA polymerase II, with its lead candidate HDP-101 in multiple myeloma.","summary":"Heidelberg Pharma, based in Ladenburg near Heidelberg and listed in Frankfurt, develops antibody-targeted amanitin conjugates (ATACs): the payload amanitin inhibits RNA polymerase II, a mechanism distinct from the microtubule and DNA-damaging payloads of most ADCs and active in slowly dividing cells. Its lead candidate HDP-101 targets BCMA in relapsed multiple myeloma, and the platform is licensed to partners including Takeda. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov, from earlier programmes.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://heidelberg-pharma.com"},{"label":"ClinicalTrials.gov: trials led by Heidelberg Pharma","url":"https://clinicaltrials.gov/search?lead=Heidelberg%20Pharma"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Heidelberg_Pharma"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["multiple-myeloma"],"sections":["adcs"],"technologies":["adc"],"targets":["bcma"],"drugs":[],"companies":["takeda"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04879043"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Ladenburg","country":"DE","companyType":"biotech","website":"https://heidelberg-pharma.com","stage":"public","investors":[],"funding":[]},{"id":"helio-genomics","kind":"company","name":"Helio Genomics","aka":[],"tldr":"Helio Genomics sells HelioLiver, a blood test that combines DNA chemistry, protein markers and patient details to find liver cancer earlier than the ultrasound scans usually used for surveillance.","summary":"Helio Genomics, based in Irvine, California, develops AI-driven blood tests for early cancer detection. Its lead product, HelioLiver, is a laboratory developed test for hepatocellular carcinoma in patients under surveillance for chronic liver disease, combining cell-free DNA methylation markers with protein tumour markers (AFP, AFP-L3, DCP) and clinical variables in a machine-learning model. The pivotal CLiMB trial, described as the largest prospective multicentre US study of its kind, was presented at EASL 2024 and published in the Journal of Hepatology in May 2026; the company reports roughly four-fold higher stage I detection than ultrasound. HelioLiver launched in December 2021 with Fulgent Genetics, which also made a strategic investment of undisclosed size, gained a Category I CPT code in 2022 and has been offered through Quest Diagnostics since March 2026.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://heliogenomics.com/"},{"label":"News and media","url":"https://heliogenomics.com/news-media"},{"label":"Fulgent Genetics partnership and strategic investment (Aug 2021)","url":"https://heliogenomics.com/news/fulgent-helio-strategic-partnership-early-cancer-detection"}],"tags":[],"related":[],"cancers":["hcc","colorectal"],"sections":["early-detection","diagnostics"],"technologies":["liquid-biopsy","methylation-profiling","proteomics"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["A 2019 raise of about $86 million is referenced on the company news page as a Cheddar media report, not a primary release, so no round is recorded. Fulgent's 2021 strategic investment amount was not disclosed. Founding year not sourced."],"hq":"Irvine, CA","country":"US","companyType":"diagnostics","website":"https://heliogenomics.com/","stage":"growth","investors":[],"funding":[]},{"id":"horg","kind":"company","name":"Hellenic Oncology Research Group","aka":["HORG"],"tldr":"The Hellenic Oncology Research Group is a Greek non-profit of oncologists and scientists that runs its own cancer trials; in OnCo it leads three phase 3 adjuvant breast cancer trials.","summary":"The Hellenic Oncology Research Group (HORG) describes itself as a non-profit organisation fostering clinical and translational cancer research, whose members are medical oncologists, radiation oncologists, pathologists and scientists; its contact address is Grigoriou Theologou 5, Athens 11471 (horg.gr). No founding year is stated on the pages read. ClinicalTrials.gov names it lead sponsor (OTHER class, with the University Hospital of Crete as collaborator) of three phase 3 trials recorded in OnCo: NCT00431080 and NCT01985724 (sequential FEC-based chemotherapy followed by docetaxel against docetaxel-cyclophosphamide as adjuvant treatment of breast cancer) and NCT00615602 (six against twelve months of adjuvant trastuzumab with docetaxel after FEC). It has no products of its own.","asOf":"2026-09-25","links":[{"label":"Official website","url":"https://www.horg.gr/en/"},{"label":"ClinicalTrials.gov: trials led by Hellenic Oncology Research Group","url":"https://clinicaltrials.gov/search?lead=Hellenic%20Oncology%20Research%20Group"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct00431080","nct01985724","nct00615602"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"Athens","country":"GR","companyType":"cooperative-group","website":"https://www.horg.gr","investors":[],"funding":[]},{"id":"helsinn","kind":"company","name":"Helsinn","aka":[],"tldr":"Helsinn is a Swiss family-owned company focused on supportive cancer care: the antiemetics Aloxi and Akynzeo, and the topical nitrogen mustard Valchlor for cutaneous T-cell lymphoma.","summary":"Helsinn, a Swiss family-owned company based in Lugano, focuses on supportive cancer care with the antiemetics Aloxi and Akynzeo and the topical nitrogen mustard Valchlor for cutaneous T-cell lymphoma. It developed palonosetron, sold as Aloxi, and the netupitant and palonosetron fixed combination, sold as Akynzeo, for chemotherapy-induced nausea and vomiting, and acquired Valchlor, a mechlorethamine gel for mycosis fungoides, licensing its products to partners such as Eisai in the United States and Recordati in Europe. OnCo links it to palonosetron, netupitant and palonosetron, and mechlorethamine. Whether supportive care products can sustain an independent company as generics arrive is the open question. Each product has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.helsinn.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["infigratinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06904235"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Lugano","country":"CH","companyType":"pharma","website":"https://www.helsinn.com","investors":[],"funding":[]},{"id":"henan-genuine-biotech","kind":"company","name":"Henan Genuine Biotech","aka":["Henan Genuine Biotech Co., Ltd."],"tldr":"Henan Genuine Biotech is a Chinese developer in Henan that sponsors 2 registered cancer trials of GEN-725 and Dositinib.","summary":"Henan Genuine Biotech appears on ClinicalTrials.gov as the industry sponsor of 2 interventional cancer trials (phase 1/2), testing GEN-725, Dositinib in non-small cell lung cancer. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials sponsored by Henan Genuine Biotech","url":"https://clinicaltrials.gov/search?spons=Henan%20Genuine%20Biotech"}],"tags":["ctgov-sponsor","china","registry-only"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07362940","nct07231068"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Henan, China","country":"CN","companyType":"biotech","website":"https://genuine-bio.com","investors":[],"funding":[]},{"id":"heron-therapeutics","kind":"company","name":"Heron Therapeutics","aka":[],"tldr":"Heron Therapeutics makes long-acting supportive-care injectables: the antiemetics Sustol (extended-release granisetron) and Cinvanti (aprepitant emulsion), plus the post-surgical analgesic Zynrelef.","summary":"Heron Therapeutics, based in Cary, North Carolina, and listed as HRTX, makes long-acting supportive care injectables: the antiemetics Sustol, an extended-release granisetron, and Cinvanti, an aprepitant emulsion, plus the post-surgical analgesic Zynrelef. Its polymer-based extended-release technology underlies Sustol, approved in 2016 for chemotherapy-induced nausea and vomiting, and Cinvanti, an intravenous aprepitant approved in 2017, while Aponvie and Zynrelef serve the surgical market. OnCo links it to the aprepitant and granisetron drug records. Whether long-acting formulations of generic antiemetics can command a premium is the commercial question its oncology products face. Granisetron and aprepitant have their own pages.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.herontx.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["granisetron","aprepitant"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cary, North Carolina","country":"US","companyType":"biotech","website":"https://www.herontx.com","ticker":"HRTX","investors":[],"funding":[]},{"id":"hetero","kind":"company","name":"Hetero Drugs","aka":[],"tldr":"A privately held Hyderabad generics group, the world's largest maker of HIV antiretrovirals, which launched Indian biosimilars of rituximab in 2015 and bevacizumab in 2016.","summary":"Hetero Drugs was founded in 1993 by B. Parthasaradhi Reddy, formerly chief technologist at Dr. Reddy's, and operates in more than 145 countries with over 30,000 employees. Best known as the largest producer of antiretroviral drugs and for low-cost hepatitis C generics, it has built a biosimilars portfolio for India that includes rituximab (2015, for non-Hodgkin lymphoma and chronic lymphocytic leukaemia), darbepoetin alfa (2015) and bevacizumab (2016, for metastatic colorectal cancer), and it supplies oncology active ingredients and generics globally.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Hetero_Drugs","links":[{"label":"Official website","url":"https://web.archive.org/web/20220505192107/https://www.heteroworld.com/"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":["monoclonal-antibody"],"targets":["cd20","vegf"],"drugs":["rituximab","bevacizumab"],"companies":[],"institutions":[],"pathways":[],"terms":["biosimilar"],"trials":[],"people":[],"bottlenecks":["b-drug-pricing","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Hyderabad","country":"IN","companyType":"pharma","website":"https://hetero.com","founded":1993,"investors":[],"funding":[]},{"id":"hibercell","kind":"company","name":"HiberCell","aka":["HiberCell, Inc.","Biothera Pharmaceuticals"],"tldr":"HiberCell is a New York biotech working on the biology of dormant, disseminated cancer cells; its yeast beta-glucan immunotherapy imprime PGG, inherited from Biothera, reached late-stage trials with checkpoint inhibitors.","summary":"HiberCell, founded in 2019 in New York, develops therapies against cancer dormancy and relapse and acquired Biothera Pharmaceuticals, whose imprime PGG, a yeast-derived beta-glucan that primes innate immune cells, had been tested with pembrolizumab in breast cancer and melanoma. Its PERK inhibitor and other programmes are in early trials, and the Biothera-era phase 3 record sits on ClinicalTrials.gov under the company as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://hibercell.com"},{"label":"ClinicalTrials.gov: trials led by HiberCell, Inc.","url":"https://clinicaltrials.gov/search?lead=HiberCell%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q138859693"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["tnbc","melanoma"],"sections":[],"technologies":["trained-innate-immunity"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"New York, NY","country":"US","companyType":"biotech","website":"https://hibercell.com","founded":2019,"stage":"private-large","investors":[],"funding":[]},{"id":"hikma","kind":"company","name":"Hikma Pharmaceuticals","aka":[],"tldr":"Hikma is one of the largest makers of generic sterile injectables for US hospitals, including many chemotherapy and supportive-care drugs, from plants in Ohio, New Jersey and Portugal.","summary":"Hikma Pharmaceuticals, founded in Amman in 1978 and listed in London, supplies hundreds of injectable generics to hospitals in the United States and elsewhere, among them oncology drugs and the antiemetics, steroids and anti-infectives given alongside them. Its injectables plants in Columbus, Ohio, Cherry Hill, New Jersey, and Portugal are the kind of sterile capacity that determines whether a shortage of a low-margin cancer drug can be filled by a second supplier.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Hikma_Pharmaceuticals","links":[{"label":"Official website","url":"https://www.hikma.com"}],"tags":["manufacturing-wave"],"related":[],"cancers":[],"sections":[],"technologies":["sterile-injectable-generics-manufacturing","sterile-fill-finish","generic-drug-shortage-response"],"targets":[],"drugs":["ondansetron","dexamethasone"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"London","country":"GB","companyType":"pharma","website":"https://www.hikma.com","ticker":"HIK","founded":1978,"stage":"public","investors":[],"funding":[]},{"id":"hinova-pharmaceuticals","kind":"company","name":"Hinova Pharmaceuticals","aka":["Hinova Pharmaceuticals Inc."],"tldr":"Hinova Pharmaceuticals is a China-based biotechnology company running 2 late-stage cancer trials of HP518 - Dose Escalation, HP518 -Dose Expansion and HC-1119 in prostate cancer.","summary":"Hinova Pharmaceuticals, based in Chengdu, China, is a biotechnology company listed as 688302.SH. Hinova (also known as Haichuang Pharmaceutical) develops innovative drugs in oncology, metabolic disease and autoimmune/inflammatory conditions, using targeted protein degradation, deuterated-drug and translational medicine platforms. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing HP518 - Dose Escalation, HP518 -Dose Expansion and HC-1119 in prostate cancer. The largest, NCT03851640 (A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)), plans to enrol 417 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.hinovapharma.com"},{"label":"ClinicalTrials.gov: trials led by Hinova Pharmaceuticals","url":"https://clinicaltrials.gov/search?lead=Hinova%20Pharmaceuticals%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct06155084","nct03851640"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Chengdu","country":"CN","companyType":"biotech","website":"https://www.hinovapharma.com","ticker":"688302.SH","founded":2013,"stage":"public","investors":[],"funding":[]},{"id":"histai","kind":"company","name":"HistAI","aka":[],"tldr":"HistAI, of Miami, released Hibou-B and Hibou-L in 2024, open vision transformer models for pathology trained on more than a million slides and published under the Apache 2.0 licence, which allows commercial use. Whether permissively licensed open models reach regulated clinical products or stay research tools is the open question.","summary":"HistAI, based in Miami, released the open Hibou pathology foundation models. Hibou-B and Hibou-L, released in 2024, are vision transformer models trained on more than a million slides and published under the Apache 2.0 licence, which allows commercial use. OnCo links it to the Hibou technology record. Whether permissively licensed open models find their way into regulated clinical products, or remain research tools, is the open question. Hibou has its own technology page.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://hist.ai"}],"tags":["ai"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["hibou"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Miami, FL","country":"US","companyType":"ai-software","website":"https://hist.ai","investors":[],"funding":[]},{"id":"histosonics","kind":"company","name":"HistoSonics","aka":[],"tldr":"Inventor of histotripsy, non-invasive tumour destruction with focused ultrasound bubbles; acquired for $2.25B in 2025.","summary":"HistoSonics, based in Minneapolis, invented histotripsy, the non-invasive destruction of tumours with focused ultrasound bubbles, and was acquired for 2.25 billion dollars in 2025. Its Edison system received FDA authorisation for liver tumours in 2023, kidney and pancreas trials are under way, and the #HOPE4KIDNEY study is linked. OnCo connects it to focused ultrasound and histotripsy, to histotripsy as an immune primer, and to ideas on device-agnostic public trials of ablation against surgery and on pulverising one tumour to wake the immune system. Whether histotripsy shows a cancer-control benefit against established ablation and surgery in randomised trials is the open question. The technology page carries the detail.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://histosonics.com"}],"tags":[],"related":[],"cancers":[],"sections":["surgery","devices"],"technologies":["hifu-histotripsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Minneapolis, MN","country":"US","companyType":"devices","website":"https://histosonics.com","investors":[],"funding":[]},{"id":"histowiz","kind":"company","name":"HistoWiz","aka":[],"tldr":"HistoWiz is a mail-in pathology laboratory for cancer researchers: send tissue, get scanned digital slides and expert readings online within days.","summary":"HistoWiz provides histopathology services for preclinical and translational cancer research: tissue processing, sectioning, staining, immunohistochemistry, whole-slide scanning and board-certified pathologist review, delivered through a cloud viewer that lets scientists share slides and annotations. It positions itself as removing the bottleneck of in-house histology so labs can spend time on interpretation, and has added AI-based image analysis tools. It serves academic and industry oncology groups worldwide and remains active in the YC directory.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/histowiz"},{"label":"Official website","url":"https://histowiz.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["drug-discovery","diagnostics"],"technologies":["histopathology-ihc","digital-pathology-ai"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Brooklyn, NY","country":"US","companyType":"cro-services","website":"https://histowiz.com","stage":"growth","ycBatch":"W16","investors":["y-combinator"],"funding":[]},{"id":"hitachi","kind":"company","name":"Hitachi (particle therapy)","aka":["Hitachi High-Tech particle therapy","Hitachi, Ltd."],"tldr":"Hitachi builds synchrotron-based proton therapy systems for centres such as MD Anderson, Mayo Clinic, St. Jude, Johns Hopkins and Hokkaido University, and carbon-ion facilities in Osaka and Taipei.","summary":"Hitachi entered particle therapy with the synchrotron at the University of Tsukuba and went on to supply the proton centres at MD Anderson, Mayo Clinic in Rochester and Phoenix, St. Jude, Johns Hopkins at Sibley, Hokkaido University (where real-time tumour tracking with implanted markers was developed) and the National Cancer Centre Singapore, and the heavy-ion facilities in Osaka and at Taipei Veterans General Hospital. It absorbed Mitsubishi Electric's particle therapy business in 2018 and its systems use spot scanning from a synchrotron, so the beam is produced at the exact energy needed without a degrader. The business now sits within Hitachi High-Tech. OnCo links it to proton therapy machines and carbon-ion synchrotrons.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.hitachi.com"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":["machines-wave"],"related":[],"cancers":[],"sections":["radiation","devices"],"technologies":["proton-therapy-systems","carbon-ion-synchrotrons","proton-therapy","carbon-ion"],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson","mayo-clinic","st-jude","johns-hopkins","hokkaido-university-hospital","nccs","taipei-veterans-general-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tokyo","country":"JP","companyType":"devices","website":"https://www.hitachi.com","ticker":"6501.T","founded":1910,"stage":"public","investors":[],"funding":[]},{"id":"hologic","kind":"company","name":"Hologic","aka":[],"tldr":"The women's health company behind most 3D mammography machines, HPV and cytology testing, and the Breast Cancer Index.","summary":"Hologic's Selenia Dimensions was the first digital breast tomosynthesis system approved by the FDA (2011). Its diagnostics arm sells the Aptima HPV assay and ThinPrep cytology, and the Genius Digital Diagnostics AI cytology system; it acquired Biotheranostics (Breast Cancer Index) in 2021. In 2025 Hologic agreed to be taken private by Blackstone and TPG.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Hologic","links":[{"label":"Official website","url":"https://www.hologic.com"}],"tags":[],"related":[],"cancers":["breast-hr-positive","cervical"],"sections":["imaging","early-detection","diagnostics"],"technologies":["mammography","hpv-testing"],"targets":[],"drugs":["breast-cancer-index"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Marlborough, MA","country":"US","companyType":"devices","website":"https://www.hologic.com","ticker":"HOLX","founded":1985,"investors":[],"funding":[]},{"id":"hookipa-pharma","kind":"company","name":"Hookipa Pharma","aka":["HOOKIPA Pharma Inc.","Hookipa Biotech","NASDAQ:HOOK"],"tldr":"Hookipa Pharma is a Vienna biotech that engineers arenaviruses into vaccines that drive unusually strong killer T-cell responses; HB-200 targets the HPV16 proteins that cause many head and neck cancers.","summary":"Hookipa Pharma develops arenavirus-based immunotherapies built on lymphocytic choriomeningitis virus and Pichinde virus vectors, which infect dendritic cells and induce large populations of antigen-specific CD8 T cells. HB-200 (eseba-vec) alternates the two vectors, each encoding an HPV16 E7/E6 fusion protein, and has been studied with pembrolizumab in first-line HPV16-positive head and neck cancer. Its KRAS programme HB-700 was licensed to Roche and later returned. The company announced a strategic restructuring in 2025.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.hookipapharma.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["hb-200"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Vienna","country":"AT","companyType":"biotech","website":"https://www.hookipapharma.com/","ticker":"NASDAQ:HOOK","founded":2011,"stage":"public","investors":[],"funding":[]},{"id":"hotspot-therapeutics","kind":"company","name":"HotSpot Therapeutics","aka":["HotSpot Therapeutics, Inc."],"tldr":"HotSpot Therapeutics is a Boston biotech that drugs the regulatory pockets of proteins rather than their active sites; its oral CBL-B inhibitor HST-1011 releases a brake on T cells.","summary":"HotSpot Therapeutics targets natural regulatory hotspots, allosteric sites that control protein function, using its Smart Allostery platform. Its first clinical candidate HST-1011 is an oral allosteric inhibitor of the E3 ubiquitin ligase CBL-B, an intracellular checkpoint that limits T-cell and natural killer cell activation. HST-1011 is in a phase 1/2 trial alone and with cemiplimab in advanced solid tumours; the company also develops an IRF5 inhibitor for autoimmune disease.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.hotspotthera.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["hst-1011"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Boston, Massachusetts","country":"US","companyType":"biotech","website":"https://www.hotspotthera.com/","founded":2017,"investors":[],"funding":[]},{"id":"hovon","kind":"company","name":"HOVON","aka":["Haemato Oncology Foundation for Adults in the Netherlands","Stichting Hemato-Oncologie voor Volwassenen Nederland"],"tldr":"The Dutch-Belgian adult haematology trials group, one of Europe's largest engines of leukaemia, myeloma and lymphoma phase 3 trials.","summary":"Founded in 1985 and coordinated from Rotterdam, HOVON runs trials across the Netherlands, Belgium and partner countries, often jointly with the Swiss SAKK and the German and Nordic groups. Its AML trials defined intensive induction, consolidation and transplant strategies in adults and the elderly, HOVON-65/GMMG-HD4 established bortezomib in myeloma induction and maintenance, and HOVON lymphoma and CLL studies contribute to European standards. HOVON participates in the European Myeloma Network trials and runs a national data centre and biobank. Most Dutch adults with acute leukaemia are treated within or according to a HOVON protocol.","asOf":"2026-09-09","links":[{"label":"HOVON","url":"https://hovon.nl"},{"label":"Trials","url":"https://hovon.nl/en/trials"}],"tags":["cooperative-group"],"related":["perseus","venetoclax"],"cancers":["aml","multiple-myeloma","dlbcl","cll","hodgkin-lymphoma","all-leukemia"],"sections":[],"technologies":["mrd-testing"],"targets":[],"drugs":[],"companies":["gimema","german-lymphoma-alliance"],"institutions":["nki"],"pathways":[],"terms":["mrd"],"trials":["nct06220032"],"people":["nicolaas-schaap","marc-raaijmakers"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["AML trials (with SAKK)","Myeloma (HOVON-65/GMMG-HD4, EMN trials)","Lymphoma and CLL","National haematology data centre"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Rotterdam","country":"NL","companyType":"cooperative-group","website":"https://hovon.nl","founded":1985,"investors":[],"funding":[]},{"id":"huabo-biopharm","kind":"company","name":"Huabo Biopharm","aka":["Shanghai Huaota Biopharmaceutical","Huaota Biopharm","华奥泰生物"],"tldr":"Huabo Biopharm is a Shanghai antibody company whose bispecific HB0036 blocks PD-L1 and TIGIT at once so that exhausted T cells can attack the tumour.","summary":"Huabo Biopharm (Shanghai Huaota Biopharmaceutical) is a Shanghai-based developer of monoclonal and bispecific antibodies. Its oncology pipeline includes HB0036, a bispecific antibody against PD-L1 and TIGIT that is in phase 1/2 trials in advanced solid tumours including non-small cell lung cancer, alongside HB0025 (PD-L1 and VEGF) and HB0017, an IL-17A antibody for psoriasis.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["hb0036"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Shanghai","country":"CN","companyType":"biotech","investors":[],"funding":[]},{"id":"hub-organoids","kind":"company","name":"HUB Organoids","aka":[],"tldr":"The Clevers-lab spin-out that licenses patient-derived organoid technology and maintains a living biobank.","summary":"HUB Organoids, based in Utrecht, is the spin-out from the Clevers laboratory that licenses patient-derived organoid technology and maintains a living biobank. It offers an organoid biobank and services to pharmaceutical companies and is the licensor of the foundational organoid patents. OnCo links it to biobanking and tissue procurement, patient-derived organoids and the organoid term. Whether patent licensing helps or slows the spread of organoid methods into routine drug testing is the fair question. The organoid technology page carries the evidence.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.huborganoids.nl"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":["biobanking","organoids"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Utrecht","country":"NL","companyType":"biotech","website":"https://www.huborganoids.nl","investors":[],"funding":[]},{"id":"humane-genomics","kind":"company","name":"Humane Genomics","aka":[],"tldr":"Humane Genomics builds artificial cancer-killing viruses that only infect and only multiply inside tumour cells, starting with a rare liver cancer in children.","summary":"Humane Genomics engineers oncolytic RNA viruses from first principles with what it calls two-factor authentication: selective infection plus selective replication, which the company says gives an on-target to off-target kill ratio above 1,000 in its models. Its first indication is paediatric hepatoblastoma, in partnership with Texas Children's Hospital, with mouse data on safety and tumour volume reduction reported on its YC profile. The work is preclinical.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/humane-genomics"},{"label":"Official website","url":"https://humanegenomics.com"}],"tags":["yc"],"related":[],"cancers":["hcc"],"sections":["immunotherapy"],"technologies":["oncolytic-virus"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"New York, NY","country":"US","companyType":"biotech","website":"https://humanegenomics.com","stage":"startup","ycBatch":"S21","investors":["y-combinator"],"funding":[]},{"id":"humanigen","kind":"company","name":"Humanigen","aka":["KaloBios Pharmaceuticals","Humanigen, Inc.","NASDAQ:HGEN"],"tldr":"Humanigen, formerly KaloBios, made lenzilumab, an antibody that neutralises GM-CSF to blunt the cytokine storms of CAR-T therapy and COVID-19, before filing for bankruptcy in 2024.","summary":"Humanigen developed lenzilumab (KB003), a humanised antibody against granulocyte-macrophage colony-stimulating factor. It was studied to prevent cytokine release syndrome and neurotoxicity in patients receiving axicabtagene ciloleucel for lymphoma, in chronic myelomonocytic leukaemia, and in a large randomised trial in hospitalised COVID-19 patients, where the FDA declined emergency authorisation. The company, once KaloBios Pharmaceuticals, filed for Chapter 11 bankruptcy in January 2024.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["lenzilumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Short Hills, New Jersey","country":"US","companyType":"biotech","stage":"defunct","investors":[],"funding":[]},{"id":"hummingbird-bioscience","kind":"company","name":"Hummingbird Bioscience","aka":["Hummingbird Bioscience Pte Ltd"],"tldr":"Hummingbird Bioscience is a Singapore biotech that uses computational biology to pick hard-to-reach antibody epitopes; its HER3 antibody HMBD-001 was developed with Cancer Research UK.","summary":"Hummingbird Bioscience uses its Rational Antibody Discovery platform to design antibodies against epitopes that block receptor function. HMBD-001 binds the dimerisation interface of HER3 and prevents ligand-dependent and ligand-independent signalling; it entered the clinic with Cancer Research UK in advanced solid tumours including NRG1 fusion-positive cancers. Other programmes include the VISTA antibody HMBD-002 and antibody-drug conjugates.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.hummingbirdbioscience.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["hmbd-001"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Singapore","country":"SG","companyType":"biotech","website":"https://www.hummingbirdbioscience.com/","founded":2015,"investors":[],"funding":[]},{"id":"hutchmed","kind":"company","name":"Hutchmed","aka":["HUTCHMED (China)","Hutchison China MediTech","Chi-Med","和黄医药","Hutchison Medipharma","HUTCHMED"],"tldr":"Hutchmed discovered fruquintinib, the first Chinese cancer drug approved by the FDA for a common cancer, and savolitinib, its MET inhibitor partnered with AstraZeneca.","summary":"Shanghai discovery engine with three NMPA-approved originals: fruquintinib (colorectal 2018; FDA approval November 2023 after Takeda licensed ex-China rights for $400 million upfront), surufatinib (neuroendocrine tumours 2020) and savolitinib (MET exon 14 NSCLC 2021, with AstraZeneca). Also sovleplenib (Syk) and tazemetostat rights in China. Its FDA approval of fruquintinib in a global population (FRESCO-2) showed the route Chinese drugs must take: a multiregional confirmatory trial.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.hutch-med.com/"}],"tags":["china"],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["fruquintinib","savolitinib","surufatinib"],"companies":["takeda","astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06584032","nct05009836","nct06601504","nct06361888","nct03091192","nct03778229","nct07228247","nct07396584"],"people":["du-samantha"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Hong Kong / Shanghai","country":"CN","companyType":"biotech","website":"https://www.hutch-med.com/","ticker":"HCM / 13.HK","founded":2000,"investors":[],"funding":[]},{"id":"huyabio","kind":"company","name":"HUYABIO International","aka":["HUYABIO International, LLC.","HUYA Bioscience International","HUYABIO"],"tldr":"HUYABIO is a San Diego company that licenses Chinese-discovered medicines for the rest of the world; its lead is tucidinostat, the oral HDAC inhibitor approved in China and Japan for T-cell lymphoma, which it took into a phase 3 trial in melanoma with a checkpoint inhibitor.","summary":"HUYABIO International, based in San Diego, in-licenses drug candidates from Chinese companies and develops them outside China. Its lead compound tucidinostat (HBI-8000, chidamide), a class I HDAC inhibitor approved in China for peripheral T-cell lymphoma and breast cancer and in Japan for lymphoma, was tested with nivolumab in the phase 3 trial registered on ClinicalTrials.gov under HUYABIO as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://huyabio.com"},{"label":"ClinicalTrials.gov: trials led by HUYABIO International, LLC.","url":"https://clinicaltrials.gov/search?lead=HUYABIO%20International%2C%20LLC."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q140045552"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma","peripheral-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["tucidinostat"],"companies":["chipscreen"],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct04674683"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://huyabio.com","stage":"private-large","investors":[],"funding":[]},{"id":"i-mab","kind":"company","name":"I-Mab","aka":["I-Mab Biopharma","天境生物","NASDAQ:IMAB"],"tldr":"I-Mab is a biotech, founded in Shanghai and now based in Maryland, whose Claudin 18.2 and 4-1BB bispecific givastomig and CD73 antibody uliledlimab are in trials for stomach and lung cancer.","summary":"I-Mab develops immuno-oncology biologics and moved its headquarters to Rockville, Maryland after separating from its Chinese operations in 2024. Givastomig (TJ-CD4B), a Claudin 18.2 and 4-1BB bispecific, is in phase 1b/2 trials with nivolumab and chemotherapy in first-line gastric cancer. Uliledlimab (TJ004309) is a differentiated CD73 antibody studied with toripalimab in non-small cell lung cancer. The company also developed lemzoparlimab, a CD47 antibody once licensed to AbbVie.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.i-mabbiopharma.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["uliledlimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Rockville, Maryland","country":"US","companyType":"biotech","website":"https://www.i-mabbiopharma.com/","ticker":"NASDAQ:IMAB","founded":2016,"stage":"public","investors":[],"funding":[]},{"id":"iambic-therapeutics","kind":"company","name":"Iambic Therapeutics","aka":[],"tldr":"AI-discovered oncology molecules in the clinic, including a HER2 inhibitor and a CDK2/4 inhibitor.","summary":"Iambic Therapeutics, based in San Diego, has AI-discovered oncology molecules in the clinic, including a HER2 inhibitor and a CDK2 and CDK4 inhibitor. IAM1363, a brain-penetrant HER2 inhibitor, and IAM-H1 entered phase 1 between 2024 and 2025, and its NeuralPLexer models predict structure and binding. OnCo links it to HER2 as a target and to AI-driven drug and target discovery. Whether a brain-penetrant HER2 inhibitor can treat brain metastases better than existing HER2 drugs is the clinical question that matters most. The HER2 target page carries the competitive field.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.iambic.ai"}],"tags":["ai"],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":[],"targets":["her2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://www.iambic.ai","investors":[],"funding":[]},{"id":"iaso-bio","kind":"company","name":"IASO Biotherapeutics","aka":["驯鹿生物","IASO Bio"],"tldr":"IASO Bio developed eque-cel, the fully human BCMA CAR-T for myeloma approved in China in 2023 and partnered with Innovent.","summary":"IASO Biotherapeutics, based in Nanjing and Shanghai and founded in 2017, developed equecabtagene autoleucel, or eque-cel, the fully human BCMA CAR-T for multiple myeloma approved in China in 2023 and partnered with Innovent. The work was spun out of Tongji Hospital in Wuhan, eque-cel, sold as Fucaso, was approved in June 2023 on the FUMANBA-1 trial and holds FDA RMAT designation, and the pipeline includes CD19 and BCMA CAR-Ts for autoimmune disease and a CD19 and BCMA dual CAR-T. OnCo links it to CAR-T cell therapy, to the eque-cel record, to Innovent Biologics and to Tongji Hospital. Whether a Chinese-developed CAR-T can win approval in the United States on its own data is the open question. Equecabtagene autoleucel has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.iasobio.com/"}],"tags":["china"],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["car-t"],"targets":[],"drugs":["equecabtagene-autoleucel"],"companies":["innovent"],"institutions":["tongji-hospital-wuhan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Nanjing / Shanghai","country":"CN","companyType":"cell-therapy","website":"https://www.iasobio.com/","founded":2017,"investors":[],"funding":[]},{"id":"iba","kind":"company","name":"IBA (Ion Beam Applications)","aka":[],"tldr":"IBA (Ion Beam Applications), of Louvain-la-Neuve, Belgium, is the largest supplier of proton therapy equipment: its Proteus One and Proteus Plus systems equip proton centres worldwide, and it also builds cyclotrons for PET isotope production. Proton therapy's capital cost is the problem its compact systems try to answer.","summary":"IBA, Ion Beam Applications, based in Louvain-la-Neuve in Belgium, is the largest supplier of proton therapy equipment. Its Proteus One and Proteus Plus systems equip proton centres worldwide, and it also makes cyclotrons for PET isotope production and supports actinium-225 research. OnCo links it to proton therapy and proton arc therapy, to medical cyclotrons and synthesis modules, to centres including Centre Antoine Lacassagne, Uppsala, UZ Leuven and the West German Cancer Center in Essen, and to ideas such as compact FLASH and proton systems at the price of a conventional linac and pooled coverage-with-evidence for proton therapy across all centres. Whether proton therapy can be made cheap enough to be judged on evidence rather than capital cost is the open question its compact systems address. The proton therapy page carries the trial detail.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.iba-worldwide.com"}],"tags":[],"related":[],"cancers":[],"sections":["radiation"],"technologies":["proton-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Louvain-la-Neuve","country":"BE","companyType":"devices","website":"https://www.iba-worldwide.com","investors":[],"funding":[]},{"id":"ibex-medical-analytics","kind":"company","name":"Ibex Medical Analytics","aka":[],"tldr":"Ibex makes artificial intelligence that examines digitised biopsy slides to help pathologists detect and grade prostate, breast and stomach cancer, and to score biomarkers such as HER2. Its prostate tool is FDA cleared and its systems are used in hundreds of laboratories.","summary":"Ibex Medical Analytics, founded in Tel Aviv in 2016 and now dated from Boston, Massachusetts, develops clinical-grade AI for cancer pathology. Its platform (Galen, now Ibex 4) detects cancer and over a hundred diagnostic features across tissue types: Ibex Prostate for detection and Gleason grading, Ibex Breast for diagnosis, grading and HER2 scoring, and Ibex Gastric. Models were trained on more than 10 million slides and about 2.4 million slides a year are analysed across hundreds of live sites. Ibex Prostate Detect received FDA 510(k) clearance in February 2025 as a second-read device for missed prostate cancers in core biopsies; HER2 scoring and breast IHC panels are CE-IVDR certified. Deployments include UPMC, a national rollout in Wales and Alverno Laboratories and partners include Philips, Fujifilm and Roche. The $55 million Series C in September 2023 was led by 83North.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://ibex-ai.com/"},{"label":"Series C press release (Sep 2023)","url":"https://ibex-ai.com/ibex-series-c-funding/"},{"label":"FDA 510(k) clearance for Ibex Prostate Detect (Feb 2025)","url":"https://ibex-ai.com/fda-510k-clearance/"},{"label":"Ten-year milestone release (Sep 2026)","url":"https://ibex-ai.com/ibex_celebrates_decade-press-release/"}],"tags":[],"related":[],"cancers":["prostate","breast-her2-positive","gastric"],"sections":["diagnostics","ai-computation"],"technologies":["digital-pathology-ai","histopathology-ihc","companion-diagnostic"],"targets":["her2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Series C release (2023) is dated Tel Aviv; 2025 and 2026 releases are dated Boston, MA, so Boston is used as HQ with Tel Aviv as founding location and R&D base."],"hq":"Boston, MA","country":"US","companyType":"ai-software","website":"https://ibex-ai.com/","founded":2016,"stage":"growth","investors":[],"funding":[{"round":"Series C","year":2023,"amountUsd":55000000,"source":"https://ibex-ai.com/ibex-series-c-funding/","note":"Led by 83North, September 2023; cumulative funding over $100 million."}]},{"id":"icad","kind":"company","name":"iCAD (RadNet)","aka":[],"tldr":"Long-standing mammography computer-aided detection company whose ProFound AI was the first cleared for 3D mammography; acquired by RadNet in 2025.","summary":"iCAD, based in Nashua, New Hampshire, and founded in 1984, is a long-standing mammography computer-aided detection company whose ProFound AI was the first AI cleared for three-dimensional mammography, and RadNet agreed to acquire it in 2025. It moved from classical CAD to deep learning with ProFound AI, cleared by the FDA in 2018 for tomosynthesis, added breast density and risk products, and now sits alongside DeepHealth and Kheiron in RadNet's portfolio. OnCo links it to breast cancer, AI in radiology and mammography and tomosynthesis, and to the ProFound AI product record. Whether consolidation of breast AI under one imaging provider speeds adoption or narrows choice is the open question. ProFound AI has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.icadmed.com"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":["ai-computation","imaging"],"technologies":["radiology-ai-screening","mammography"],"targets":[],"drugs":["icad-profound-ai"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Nashua, NH","country":"US","companyType":"ai-software","website":"https://www.icadmed.com","founded":1984,"stage":"acquired","investors":[],"funding":[]},{"id":"icecure-medical","kind":"company","name":"IceCure Medical","aka":[],"tldr":"IceCure Medical makes ProSense, a liquid-nitrogen cryoablation system used to freeze small breast, kidney, lung and bone tumours through a single needle in an outpatient visit; its ICE3 trial tested it as an alternative to surgery for small low-risk breast cancers in older women.","summary":"IceCure Medical, founded in Israel in 2006, designed ProSense around liquid nitrogen rather than argon to reach very low probe temperatures and larger ice balls with a single thin probe, under ultrasound guidance in an office setting. The ICE3 single-arm trial followed women aged sixty and over with small low-risk breast cancers treated by cryoablation instead of lumpectomy, and the company is pursuing a breast cancer indication in the United States on those results while the system is used for kidney, lung, liver and bone tumours. OnCo links it to cryoablation and thermal ablation.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.icecure-medical.com"}],"tags":["machines-wave"],"related":[],"cancers":["breast-cancer","rcc"],"sections":["surgery","devices"],"technologies":["cryoablation-systems","thermal-ablation"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Caesarea","country":"IL","companyType":"devices","website":"https://www.icecure-medical.com","ticker":"ICCM","founded":2006,"stage":"public","investors":[],"funding":[]},{"id":"icon-plc","kind":"company","name":"ICON plc","aka":[],"tldr":"ICON is an Irish CRO (including PRA Health Sciences) with a large oncology franchise and an imaging core lab.","summary":"ICON plc, based in Dublin and listed as ICLR, is an Irish contract research organisation, including the former PRA Health Sciences, with a large oncology franchise and an imaging core laboratory. It offers full-service trials, central review of medical imaging and site networks. OnCo links it to contract research organisations and to imaging core labs and central review. Whether centralised imaging review, which its core lab provides, remains the standard as AI-based response assessment matures is the open question for that part of its business. The CRO technology page carries the wider picture.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/ICON_PLC","links":[{"label":"Official website","url":"https://www.iconplc.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["ai-computation","imaging"],"technologies":["contract-research-organisations","imaging-core-labs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05322590","nct07647328"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Dublin","country":"IE","companyType":"cro-services","website":"https://www.iconplc.com","ticker":"ICLR","investors":[],"funding":[]},{"id":"icu-medical","kind":"company","name":"ICU Medical","aka":[],"tldr":"ICU Medical makes infusion pumps, IV sets and the ChemoLock and ChemoClave closed-system transfer devices that keep chemotherapy sealed while it is prepared and given.","summary":"ICU Medical, founded in 1984, is an infusion therapy company that acquired Hospira's infusion business from Pfizer and Smiths Medical; its oncology products include the ChemoClave and ChemoLock needlefree closed systems, Diana hazardous drug compounding system and Plum infusion pumps used in chemotherapy suites.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/ICU_Medical","links":[{"label":"Official website","url":"https://www.icumed.com/"}],"tags":["machines-wave2"],"related":[],"cancers":[],"sections":[],"technologies":["closed-system-transfer-devices","infusion-devices-vascular-access","pharmacy-automation"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Clemente, CA","country":"US","companyType":"devices","website":"https://www.icumed.com/","ticker":"ICUI","founded":1984,"stage":"public","investors":[],"funding":[]},{"id":"ideaya-biosciences","kind":"company","name":"IDEAYA Biosciences","aka":[],"tldr":"IDEAYA Biosciences develops cancer drugs matched to the genetic make-up of a patient's tumour. Its most advanced drug, darovasertib, is in late-stage trials for a rare eye cancer called uveal melanoma.","summary":"IDEAYA Biosciences is a South San Francisco precision oncology company working on synthetic lethality, metabolic and epigenetic tumour dependencies. Its lead programme, darovasertib (a PKC inhibitor), is in phase 3 registrational trials in metastatic uveal melanoma and, with crizotinib, as adjuvant therapy in primary uveal melanoma (the OptimUM-11 trial with Servier dosed its first patient in September 2026), plus phase 2 studies in GNAQ/11-mutant tumours. Other programmes include IDE849, a DLL3-directed topoisomerase 1 antibody-drug conjugate in phase 1/2 for small cell lung cancer, for which the company reported FDA agreement on a phase 3 design in August 2026; IDE034 (B7H3/PTK7 ADC); IDE161 (PARG inhibitor); IDE397 (MAT2A inhibitor, phase 2) and IDE892 (PRMT5) for MTAP-deleted cancers; and IDE574 (KAT6/7). IDEAYA listed on Nasdaq in May 2019, raising 57.5 million US dollars gross in its IPO.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.ideayabio.com/"},{"label":"Pipeline","url":"https://www.ideayabio.com/pipeline/"},{"label":"IPO closing press release (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1676725/000119312519158427/d746735dex991.htm"},{"label":"Investor news releases","url":"https://ir.ideayabio.com/news-releases"}],"tags":[],"related":[],"cancers":["melanoma","sclc","pancreatic"],"sections":["targeted-therapy","adcs"],"technologies":["synthetic-lethality-approaches","adc","kinase-inhibitors"],"targets":["dll3"],"drugs":["darovasertib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05987332","nct03947385","nct05907954","nct07174583","nct06710847"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Later follow-on offerings and the GSK partnership were not sourced. Founding year not sourced. Pancreatic cancer tag rests on an August 2026 news headline about a Genentech clinical collaboration in MTAP-deleted KRAS G12D pancreatic cancer."],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.ideayabio.com/","ticker":"IDYA","stage":"public","investors":[],"funding":[{"round":"IPO","year":2019,"amountUsd":57500000,"source":"https://www.sec.gov/Archives/edgar/data/1676725/000119312519158427/d746735dex991.htm","note":"5.75 million shares at 10 US dollars, including full exercise of the underwriters' option"}]},{"id":"idera-pharmaceuticals","kind":"company","name":"Idera Pharmaceuticals","aka":["Idera Pharmaceuticals, Inc.","Idera","Aceragen"],"tldr":"Idera was a Cambridge biotech whose injected TLR9 agonist tilsotolimod, given into tumours with ipilimumab, failed a phase 3 trial in anti-PD-1-refractory melanoma in 2021.","summary":"Idera Pharmaceuticals, founded in 1989 and based in Cambridge, Massachusetts, developed oligonucleotide Toll-like receptor agonists. Its intratumoural TLR9 agonist tilsotolimod was tested with ipilimumab in the phase 3 ILLUMINATE-301 trial in melanoma that had progressed on anti-PD-1 therapy and did not improve response or survival. The company merged with Aceragen in 2022 and later wound down. Its trials remain on ClinicalTrials.gov under Idera as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.iderapharma.com"},{"label":"ClinicalTrials.gov: trials led by Idera Pharmaceuticals, Inc.","url":"https://clinicaltrials.gov/search?lead=Idera%20Pharmaceuticals%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30296240"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["in-situ-vaccination"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct03865082"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"http://www.iderapharma.com","founded":1989,"stage":"defunct","investors":[],"funding":[]},{"id":"igea","kind":"company","name":"IGEA","aka":[],"tldr":"IGEA is the Italian maker of the Cliniporator, the pulse generator behind almost all clinical electrochemotherapy, and of the VITAE version with long needle electrodes for tumours deep inside the body.","summary":"IGEA, founded in 1980 in Carpi near Modena, makes clinical biophysics devices: pulsed electromagnetic field stimulators for bone and cartilage, and the Cliniporator electroporation systems developed in the European ESOPE project. It supports the InspECT registry of electrochemotherapy outcomes and the extension of the technique to liver, pancreas, bone and deep head and neck tumours with the Cliniporator VITAE.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.igeamedical.com/"}],"tags":["machines-wave2"],"related":[],"cancers":["melanoma","breast-cancer","head-and-neck"],"sections":[],"technologies":["electrochemotherapy-devices","electrochemotherapy","irreversible-electroporation"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Carpi, Modena","country":"IT","companyType":"devices","website":"https://www.igeamedical.com/","founded":1980,"stage":"private-large","investors":[],"funding":[]},{"id":"igm-biosciences","kind":"company","name":"IGM Biosciences","aka":[],"tldr":"IGM Biosciences engineered antibodies of the IgM class, which have ten binding arms instead of two, originally as T-cell engagers for blood cancers and later for autoimmune disease. It ended development and was bought by Concentra Biosciences in 2025.","summary":"IGM Biosciences was a biotechnology company that focused on developing engineered IgM-based therapeutic antibodies, exploiting the ten binding sites of the IgM format for T-cell engagers and other constructs. By mid-2025 the company had wound down development; on 1 July 2025 it agreed to be acquired by Concentra Biosciences for $1.247 per share in cash plus a contingent value right entitling holders to closing net cash above $82 million and 80% of net proceeds from any disposition of product candidates within a year. The tender offer and merger completed on 14 August 2025 and the Nasdaq listing (IGMS) ended. The company's website (igmbio.com) no longer resolves. Its earlier oncology programmes (including CD20xCD3 IgM T-cell engagers) are not described in the fetched filings.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.sec.gov/edgar/browse/?CIK=0001496323"},{"label":"Concentra acquisition agreement (8-K exhibit 99.1, July 2025)","url":"https://www.sec.gov/Archives/edgar/data/1496323/000119312525153576/d82329dex991.htm"},{"label":"Completion of merger (8-K, August 2025)","url":"https://www.sec.gov/Archives/edgar/data/1496323/000119312525180763/d82965d8k.htm"},{"label":"SEC EDGAR filings","url":"https://www.sec.gov/edgar/browse/?CIK=0001496323"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["bispecific-antibody","t-cell-engager"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Former Nasdaq ticker IGMS. The company had pivoted from oncology to autoimmune disease before winding down; that pivot is not documented in the fetched sources. The July 2025 release is datelined Mountainview while the August 8-K lists a San Mateo address."],"hq":"Mountain View, CA","country":"US","companyType":"biotech","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2025,"source":"https://www.sec.gov/Archives/edgar/data/1496323/000119312525153576/d82329dex991.htm","note":"$1.247 in cash per share plus a contingent value right; agreement 1 July 2025, merger completed 14 August 2025"}]},{"id":"ignitus-bio","kind":"company","name":"Ignitus Bio","aka":[],"tldr":"Ignitus Bio is an Even One Ventures company outside cancer: it aims to measure a patient's mitochondrial function and use healthy mitochondria to restore energy in failing heart and brain tissue.","summary":"Ignitus Bio's founder describes the company as built on the conviction that failing energy production inside cells is a root cause of disease; it aims to measure mitochondrial function and transplant healthy mitochondria to restore energy in critical tissues such as the heart and brain. It is the longevity company in the Even One Ventures portfolio and does not work on cancer.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://ignitus.bio/"},{"label":"Even One Ventures portfolio","url":"https://evenone.ventures/"}],"tags":["startup","evenone-portfolio","longevity","non-oncology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"United States (head office not published)","country":"US","companyType":"biotech","website":"https://ignitus.bio/","stage":"startup","investors":["evenone-ventures"],"funding":[]},{"id":"iksuda-therapeutics","kind":"company","name":"Iksuda Therapeutics","aka":[],"tldr":"Iksuda Therapeutics, based in Newcastle, designs antibody-drug conjugates, antibodies that release a cancer-killing drug only once inside the tumour. Its HER2-targeting medicine is in early human trials, with encouraging results in oesophageal cancer.","summary":"Iksuda Therapeutics develops antibody-drug conjugates built around tumour-selective release and activation of payloads, combining stable conjugation (its PermaLink platform) with prodrug payloads including its proprietary protein-alkylating ProAlk class. The lead asset IKS014 is a HER2-directed ADC in a phase 1 study in HER2-positive and HER2-low solid tumours; ESMO 2025 dose-escalation data showed anti-tumour activity across dose levels, and a preliminary analysis at the 2026 ASCO GI symposium reported an 80 percent clinical benefit rate in 10 previously treated patients with HER2-positive oesophageal cancer. IKS03 is a CD19-targeted ADC for B-cell malignancies, and IKS04, a CA242 (CanAg)-directed pyrrolobenzodiazepine ADC given with unconjugated antibody, received FDA IND clearance in July 2026 for phase 1 trials in gastrointestinal cancers. The company closed a USD 47 million financing in June 2021 co-led by Mirae Asset Capital and Celltrion.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.iksuda.com/"},{"label":"USD 47 million financing release","url":"https://www.iksuda.com/news-views/iksuda-therapeutics-closes-47-million-financing-round/"},{"label":"News and views","url":"https://www.iksuda.com/news-views/"}],"tags":[],"related":[],"cancers":["esophageal"],"sections":["adcs"],"technologies":["adc"],"targets":["her2","cd19"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Later financing (reported elsewhere in 2023) not found on the company news pages fetched. Founding year not sourced."],"hq":"Newcastle upon Tyne","country":"GB","companyType":"biotech","website":"https://www.iksuda.com/","stage":"startup","investors":[],"funding":[{"round":"Series A","year":2021,"amountUsd":47000000,"source":"https://www.iksuda.com/news-views/iksuda-therapeutics-closes-47-million-financing-round/","note":"Described by the company as a USD 47 million (about GBP 34 million) financing round co-led by Mirae Asset Capital, Celltrion and Premier Partners; series letter not stated"}]},{"id":"iktos","kind":"company","name":"Iktos","aka":[],"tldr":"Iktos sells artificial intelligence software that designs new drug molecules and plans how to make them, and runs robotic labs that build and test the molecules automatically.","summary":"Iktos, founded in 2016 and based in Paris, provides AI and robotics for small-molecule discovery. Makya is a generative AI software-as-a-service platform for de novo, multi-parameter optimised molecule design; Spaya is an AI retrosynthesis tool that maps target compounds back to commercially available starting materials; and Iktos Robotics operates autonomous synthesis, purification, analysis and imaging-based screening. The company reports more than 60 collaborations with pharmaceutical, biotech and academic partners including Pfizer, Takeda and Johnson and Johnson, and has three in-house programmes: MTHFD2 (inflammation and autoimmunity, with a 2026 patent publication), amylin receptor (obesity) and SKP2-CKS1 (immuno-oncology). In 2026 it launched Iktos Engine APIs for agentic workflows and was selected for a JETRO programme in Japan. The website mentions an EIC Accelerator grant but no round amounts or investors were on fetched pages.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://iktos.ai"},{"label":"News and press","url":"https://www.iktos.ai/resources/articles"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation","drug-discovery"],"technologies":["ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Series A (reported elsewhere as EUR 15.5 million) and EIC grant amount not sourced, so no round recorded."],"hq":"Paris","country":"FR","companyType":"ai-software","website":"https://iktos.ai","founded":2016,"stage":"startup","investors":[],"funding":[]},{"id":"il-yang-pharmaceutical","kind":"company","name":"Il-Yang Pharmaceutical","aka":["Il-Yang Pharm","Ilyang","일양약품"],"tldr":"Il-Yang Pharmaceutical is a South Korea-based pharmaceutical company that leads 2 cancer trials in OnCo, testing the BCR-ABL inhibitor radotinib (Supect) in chronic myeloid leukaemia.","summary":"Il-Yang Pharmaceutical is a South Korean pharmaceutical manufacturer founded in 1946 that produces prescription and over-the-counter medicines, influenza vaccines and health products. Its in-house new drugs include Noltec (ilaprazole) and Supect (radotinib), a BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukaemia. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo (2 in phase 3 or 2/3): NCT03459534 (phase 3, A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failur...) and NCT03722420 (phase 3, Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.ilyang.co.kr"},{"label":"ClinicalTrials.gov: trials led by Il-Yang Pharmaceutical","url":"https://clinicaltrials.gov/search?lead=Il-Yang%20Pharm.%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cml"],"sections":[],"technologies":[],"targets":[],"drugs":["imatinib","radotinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03459534","nct03722420"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Yongin","country":"KR","companyType":"pharma","website":"https://www.ilyang.co.kr","ticker":"KRX:007570","founded":1946,"stage":"public","investors":[],"funding":[]},{"id":"illumina","kind":"company","name":"Illumina","aka":[],"tldr":"Illumina is the dominant DNA sequencing platform underneath nearly every genomic test in oncology.","summary":"Illumina, based in San Diego and listed as ILMN, is the dominant DNA sequencing platform underneath nearly every genomic test in oncology. Its NovaSeq X instruments, the TruSight Oncology 500 panel, approved as an in vitro diagnostic in 2024 to 2025 and carried in OnCo as TruSight Oncology Comprehensive, and a constellation of measurable residual disease and spatial products make it the supplier behind many of the diagnostics companies on this site. OnCo links it to comprehensive genomic profiling and whole-genome sequencing, to new short-read sequencing platforms and clinical bioinformatics, to the CRUK Cambridge Institute, to Illumina Ventures and to the bottleneck that inherited risk is mostly unidentified. Whether new short-read competitors erode its position is the open question. TruSight Oncology Comprehensive has its own page.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Illumina,_Inc.","links":[{"label":"Official website","url":"https://www.illumina.com"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics","drug-discovery"],"technologies":["cgp","wes-wgs"],"targets":[],"drugs":[],"companies":["illumina-ventures"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Diego, CA","country":"US","companyType":"diagnostics","website":"https://www.illumina.com","ticker":"ILMN","investors":[],"funding":[]},{"id":"illumina-ventures","kind":"company","name":"Illumina Ventures","aka":[],"tldr":"An independently managed venture firm with a strategic tie to the sequencing company Illumina. It backs genomics and precision health start-ups, including cancer companies such as Delfi Diagnostics, Actym Therapeutics and Oncko.","summary":"Illumina Ventures calls itself 'the premier genomics and precision health venture firm supporting early-stage companies to improve human health'. It is 'independently managed' with 'a strategic relationship with Illumina (NASDAQ: ILMN)', runs Illumina Ventures Labs to give genomics start-ups capital, sequencing and lab space, and is based at 500 Lincoln Centre Drive, Foster City, California, with a European office in Dublin. Its portfolio page lists oncology companies including Actym Therapeutics ('programmable, combination payload delivery to solid tumors'), Arima Genomics (3D genome structure applied to cancer), Delfi Diagnostics ('early cancer detection'), Oncko (multi-drug cancer combinations) and Serinus Biosciences ('redefining precision oncology'), alongside tools companies such as Alamar Biosciences.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.illuminaventures.com/"},{"label":"Portfolio","url":"https://www.illuminaventures.com/portfolio/"},{"label":"About","url":"https://www.illuminaventures.com/about-us/"}],"tags":["corporate-venture"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["illumina"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The task hint gave San Francisco; the contact page gives Foster City in the San Francisco Bay Area. Founding year not stated; omitted. Delfi Diagnostics and Iambic (a portfolio company) are already in the graph."],"hq":"Foster City, CA","country":"US","companyType":"investor","website":"https://www.illuminaventures.com/","investors":[],"funding":[]},{"id":"imagene-ai","kind":"company","name":"Imagene AI","aka":[],"tldr":"Imagene AI trains large artificial intelligence models on ordinary stained biopsy images so that, within minutes, a slide can predict which gene changes a lung tumour carries, helping doctors decide on targeted drugs before slower genetic tests return.","summary":"Imagene AI develops foundation-model based digital pathology for precision oncology. Its CanvOI model, trained on more than 1.5 million biopsy images, underpins an Oncology Intelligence Engine combining imaging, molecular and clinical data for biomarker discovery, patient stratification and companion diagnostic development. The Lung Prediction Panel, offered for research use from a CAP-accredited laboratory (March 2025), predicts eight actionable alterations in non-small cell lung cancer from H&E slides in minutes: EGFR, KRAS G12C, ERBB2 and BRAF V600E mutations, ALK, RET and ROS1 fusions and MET exon 14 skipping. Partnerships include Tempus (2025), Daiichi Sankyo (2026), Proscia's alliance for AI-powered IHC companion diagnostics (2026) and Tel Aviv Sourasky Medical Center. In July 2025 the company closed a $23 million Series B led by Larry Ellison, for $45 million raised in total.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://imagene-ai.com/"},{"label":"Series B release (Jul 2025)","url":"https://www.newswire.com/news/imagene-ai-hits-45m-in-total-funding-after-completing-23m-series-b-led-22597953"},{"label":"Newsroom","url":"https://imagene-ai.com/newsroom/"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["diagnostics","ai-computation"],"technologies":["pathology-foundation-model","digital-pathology-ai","companion-diagnostic"],"targets":["egfr","kras","her2","braf","alk","ret","met"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The Series B release dateline is Miami; the company has Israeli origins and works closely with Tel Aviv hospitals, so Tel Aviv may still be the R&D base. The www.imagene-ai.com host does not resolve; the canonical site is imagene-ai.com. Founding year not sourced."],"hq":"Miami, FL","country":"US","companyType":"ai-software","website":"https://imagene-ai.com/","stage":"startup","investors":[],"funding":[{"round":"Series B","year":2025,"amountUsd":23000000,"source":"https://www.newswire.com/news/imagene-ai-hits-45m-in-total-funding-after-completing-23m-series-b-led-22597953","note":"Led by Larry Ellison with Aguras Pathology Investments, July 2025; total funding $45 million. Source is the company release distributed via Newswire.com."}]},{"id":"immatics","kind":"company","name":"Immatics","aka":[],"tldr":"TCR-T company whose PRAME-directed anzu-cel (IMA203) is in the phase 3 SUPRAME trial in melanoma, with a launch targeted for 2027.","summary":"Immatics, based in Tübingen and Houston and listed as IMTX, is a TCR-T company whose PRAME-directed anzu-cel, or IMA203, is in the phase 3 SUPRAME trial in melanoma, with a launch targeted for 2027. In its phase 1b, anzu-cel gave a 54 percent confirmed response rate with a median duration of response of 12.1 months in PD-1-pretreated melanoma; SUPRAME, with a progression-free survival primary endpoint, is on track to complete randomisation by the end of 2026 with its analysis expected to trigger in 2026, and the company also develops TCR bispecifics it calls TCER. OnCo links it to melanoma and sarcomas, to TCR-T cell therapy, to PRAME as a target, and to the Comprehensive Cancer Center Tübingen-Stuttgart. Whether an engineered TCR therapy can become a standard option in a common solid tumour is the question SUPRAME will answer. The PRAME target page carries the competitive field.","asOf":"2026-09-04","links":[{"label":"Q2 2026 update","url":"https://www.globenewswire.com/news-release/2026/08/18/3346680/0/en/immatics-announces-second-quarter-2026-financial-results-and-business-update.html"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":["cell-therapy"],"technologies":["tcr-t"],"targets":[],"drugs":["ima203"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05958121","nct03686124"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tübingen / Houston","country":"DE","companyType":"cell-therapy","website":"https://immatics.com","ticker":"IMTX","investors":[],"funding":[]},{"id":"immix-biopharma","kind":"company","name":"Immix Biopharma","aka":["Immix Biopharma, Inc.","Nexcella","NASDAQ:IMMX"],"tldr":"Immix Biopharma is a Los Angeles cell-therapy company whose BCMA CAR-T NXC-201 is the first CAR-T to show deep responses in AL amyloidosis, the disease in which misfolded antibody fragments damage the heart and kidneys.","summary":"Immix Biopharma, through its subsidiary Nexcella, develops NXC-201 (formerly HBI0101), a BCMA-directed CAR-T cell therapy originally created at Hadassah Medical Center in Jerusalem. NXC-201 is being studied in the NEXICART-2 trial in relapsed or refractory AL amyloidosis, where it holds orphan and regenerative medicine advanced therapy designations, and in multiple myeloma. The company also has the tissue-specific therapeutic IMX-110 for soft tissue sarcoma.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.immixbio.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["nxc-201-car-t"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Los Angeles, California","country":"US","companyType":"cell-therapy","website":"https://www.immixbio.com/","ticker":"NASDAQ:IMMX","founded":2012,"stage":"public","investors":[],"funding":[]},{"id":"immunai","kind":"company","name":"Immunai","aka":[],"tldr":"Immunai maps the human immune system cell by cell and uses machine learning on that map to help drug companies pick targets and design trials, including for cancer immunotherapy.","summary":"Immunai, founded in December 2018 and headquartered in New York with offices in Tel Aviv, Prague and Zurich, has built AMICA, described as the world's largest harmonised single-cell immune database. Its workflow generates single-cell multi-omic data from patient samples, augments it with AMICA, applies machine learning and then validates findings functionally to deliver target discovery, preclinical evaluation and clinical trial optimisation for pharmaceutical partners. The acquisition of Nebion's curated datasets broadened its application to inflammatory and oncological research. Partnerships include AstraZeneca, which expanded an AI oncology collaboration with Immunai in May 2026, and Teva. The company names KDT and Alexandria Venture Investments among its leading investors; its large private financing rounds could not be sourced from fetched pages.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.immunai.com"},{"label":"Company page","url":"https://www.immunai.com/company"},{"label":"Resources and press","url":"https://www.immunai.com/resources/"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation","drug-discovery"],"technologies":["single-cell-spatial","ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":["parker-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Series B (reported elsewhere as USD 215 million, 2021) not sourced from a fetched primary page, so omitted; stage growth set on that basis. AstraZeneca expansion was seen only as a trade-press link on the company resources page.","The Parker Institute for Cancer Immunotherapy's news pages record a collaboration with Immunai to build one of the largest single-cell datasets in cancer."],"hq":"New York, NY","country":"US","companyType":"ai-software","website":"https://www.immunai.com","founded":2018,"stage":"growth","investors":["alexandria-venture-investments"],"funding":[]},{"id":"immuneel","kind":"company","name":"Immuneel Therapeutics","aka":[],"tldr":"A Bengaluru cell therapy company that brought Barcelona's academic CD19 CAR-T to India as Qartemi, the country's second approved CAR-T, after the IMAGINE trial.","summary":"Immuneel Therapeutics is a private cell and gene therapy company based at Narayana Health City in Bengaluru, formed to make CAR-T therapy affordable and accessible in India. Its lead product, varnimcabtagene autoleucel (IMN-003A, brand Qartemi), is the Indian version of ARI-0001, the academic CD19 CAR-T developed at Hospital Clinic de Barcelona and approved in Spain under the hospital exemption. Immuneel ran IMAGINE, the first industry-sponsored CAR-T trial in India, a phase 2 study in relapsed or refractory B-cell malignancies reported at ASH 2023 and in Hematological Oncology, and Qartemi received CDSCO market authorisation for relapsed or refractory B-cell lymphoma in 2024. The company won Endpoints' most promising biopharma start-up and APAC cell and gene therapy start-up awards in 2023.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.immuneel.com"},{"label":"IMAGINE study (ASH 2023 abstract)","url":"https://doi.org/10.1182/blood-2023-181585"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":["cell-therapy"],"technologies":["car-t","point-of-care-cell-manufacturing"],"targets":["cd19"],"drugs":["varnimcabtagene-autoleucel"],"companies":[],"institutions":["narayana-health"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-manufacturing-cell-therapy","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Bengaluru","country":"IN","companyType":"cell-therapy","website":"https://www.immuneel.com","investors":[],"funding":[]},{"id":"immuneering","kind":"company","name":"Immuneering","aka":["Immuneering Corporation"],"tldr":"Immuneering is a United States-based biotechnology company running 2 late-stage cancer trials of Atebimetinib in pancreatic ductal adenocarcinoma, melanoma and non-small-cell lung cancer.","summary":"Immuneering, based in Cambridge, the United States, is a biotechnology company. Immuneering is a biotechnology company developing oncology treatments based on 'Deep Cyclic Inhibitors', a pulsed dosing approach to MAPK-pathway inhibition intended to reduce cancer resistance while improving tolerability. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing Atebimetinib in pancreatic ductal adenocarcinoma, melanoma and non-small-cell lung cancer. The largest, NCT07562152 (Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma), plans to enrol 510 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.immuneering.com"},{"label":"ClinicalTrials.gov: trials led by Immuneering","url":"https://clinicaltrials.gov/search?lead=Immuneering%20Corporation"},{"label":"Pipeline page","url":"https://www.immuneering.com/pipeline"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["pancreatic","melanoma","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["atebimetinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05585320"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Cambridge","country":"US","companyType":"biotech","website":"https://www.immuneering.com","investors":[],"funding":[]},{"id":"immuneoncia-therapeutics","kind":"company","name":"ImmuneOncia Therapeutics","aka":["ImmuneOncia Therapeutics Inc."],"tldr":"ImmuneOncia Therapeutics is a South Korea-based biotechnology company running 2 late-stage cancer trials of IMC-001 in peripheral T-cell lymphomas.","summary":"ImmuneOncia Therapeutics, based in Yongin-si, South Korea, is a biotechnology company. ImmuneOncia Therapeutics develops immuno-oncology antibody drugs, stating its aim is to bring Korea's first immuno-oncology drug to market. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing IMC-001 in peripheral T-cell lymphomas. The largest, NCT06365840 (A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumour), plans to enrol 30 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.immuneoncia.com"},{"label":"ClinicalTrials.gov: trials led by ImmuneOncia Therapeutics","url":"https://clinicaltrials.gov/search?lead=ImmuneOncia%20Therapeutics%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["peripheral-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct06365840","nct04414163"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Yongin-si","country":"KR","companyType":"biotech","website":"https://www.immuneoncia.com","investors":[],"funding":[]},{"id":"immunitor","kind":"company","name":"Immunitor","aka":["Immunitor LLC","Immunitor Inc."],"tldr":"Immunitor is a Mongolian biotech, founded in 2000, that makes oral tablet vaccines from heat-inactivated cells; its hepatocellular carcinoma vaccine hepcortespenlisimut-L went through phase 3 trials the company led.","summary":"Immunitor, based in Ulaanbaatar and founded in 2000, develops oral tablet immunotherapies made from heat-inactivated cells, including a tuberculosis vaccine and hepcortespenlisimut-L (V5) for hepatocellular carcinoma, which it tested in phase 3 trials in Mongolia registered on ClinicalTrials.gov under Immunitor as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.immunitor.mn"},{"label":"ClinicalTrials.gov: trials led by Immunitor LLC","url":"https://clinicaltrials.gov/search?lead=Immunitor%20LLC"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q50039606"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Ulaanbaatar","country":"MN","companyType":"biotech","website":"http://www.immunitor.mn","founded":2000,"stage":"private-large","investors":[],"funding":[]},{"id":"immunitybio","kind":"company","name":"ImmunityBio","aka":["Altor BioScience"],"tldr":"ImmunityBio makes Anktiva, the IL-15 superagonist approved with BCG for bladder cancer in 2024.","summary":"ImmunityBio, based in San Diego and listed as IBRX, makes Anktiva, or nogapendekin alfa inbakicept, the IL-15 superagonist approved with BCG for bladder cancer in 2024. The approval followed a long regulatory path that included a complete response letter in 2023, and the company also runs natural killer cell and vaccine programmes. OnCo links it to bladder and urothelial cancer, to the nogapendekin alfa inbakicept drug record, and to the idea of off-the-shelf natural killer cells to sweep up residual disease. Whether an IL-15 agonist can extend beyond BCG-unresponsive bladder cancer into other tumours is the open question its pipeline is built around. Anktiva has its own page.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://immunitybio.com"}],"tags":[],"related":[],"cancers":["urothelial"],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["nogapendekin-alfa","cd19-t-hank"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06710288","nct03228667","nct06061809","nct06745908","nct02138734","nct07125872","nct04390399"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://immunitybio.com","ticker":"IBRX","investors":[],"funding":[]},{"id":"immunoact","kind":"company","name":"ImmunoACT","aka":[],"tldr":"The IIT Bombay spin-off that won India's first CAR-T approval in 2023 with NexCAR19 and has treated more than 600 patients at a tenth of Western prices.","summary":"ImmunoACT was established in 2018 as a spin-off from IIT Bombay, where Rahul Purwar's group had worked on a humanised CD19 CAR since 2013. Clinical development ran with Tata Memorial Centre: first patients were dosed at Tata Memorial Hospital in 2021 and the DCGI granted market authorisation for NexCAR19 (talicabtagene autoleucel) in 2023, India's first approved CAR-T therapy. The phase 1/2 study (64 enrolled at six centres) reported an overall response rate of 73% in 51 evaluable patients. The company reports more than 600 patients treated across over 130 authorised centres, a 98% manufacturing success rate, about 20 days from apheresis to infusion and a WHO-certified GMP facility with capacity for 750 patients a year, expanding to 1,500. It received a US patent in 2025 and in 2026 partnered with Cipla to supply South Africa, Algeria and Morocco.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://immunoact.com"},{"label":"Phase 1/2 results (Lancet Haematol 2025)","url":"https://doi.org/10.1016/S2352-3026(24)00377-6"}],"tags":[],"related":[],"cancers":["dlbcl","all-leukemia"],"sections":["cell-therapy"],"technologies":["car-t","point-of-care-cell-manufacturing"],"targets":["cd19"],"drugs":["talicabtagene-autoleucel"],"companies":["cipla"],"institutions":["iit-bombay","tata-memorial","actrec"],"pathways":[],"terms":[],"trials":[],"people":["purwar-rahul","jain-hasmukh","narula-gaurav"],"bottlenecks":["b-manufacturing-cell-therapy","b-global-access","b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Mumbai","country":"IN","companyType":"cell-therapy","website":"https://immunoact.com","founded":2018,"investors":[],"funding":[]},{"id":"immunocore","kind":"company","name":"Immunocore","aka":[],"tldr":"Inventor of the ImmTAC soluble TCR bispecific; tebentafusp was the first to improve survival in a solid tumour.","summary":"Immunocore, based in Abingdon and listed as IMCR, invented the ImmTAC soluble T-cell receptor bispecific, and its tebentafusp was the first drug of the format to improve survival in a solid tumour. Tebentafusp, sold as Kimmtrak, was proved in IMCgp100-202 in uveal melanoma; brenetafusp targets PRAME and is in the PRISM-MEL-301 phase 3 in melanoma; and IMC-R117C targets PIWIL1 in colorectal cancer. OnCo links it to melanoma and uveal melanoma, to PRAME as a target, to Oxford Cancer, and to the idea of antibodies that recognise mutant KRAS and p53 fragments displayed on the cell surface. Whether soluble TCR bispecifics can work in common solid tumours beyond uveal melanoma is the open question. Tebentafusp has its own page.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Immunocore","links":[{"label":"Official website","url":"https://www.immunocore.com"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["tebentafusp"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05549297","nct04262466","nct06840119"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Abingdon","country":"GB","companyType":"biotech","website":"https://www.immunocore.com","ticker":"IMCR","investors":[],"funding":[]},{"id":"immunome","kind":"company","name":"Immunome","aka":["Immunome, Inc.","Ayala Pharmaceuticals"],"tldr":"Immunome is a US biotechnology company whose lead drug varegacestat, a gamma-secretase inhibitor acquired with Ayala Pharmaceuticals, completed the phase 3 RINGSIDE trial in progressing desmoid tumours; it also develops antibody-drug conjugates.","summary":"Immunome, headquartered in Bothell, Washington, develops targeted cancer therapies. Its most advanced programme is varegacestat (AL102), an oral gamma-secretase inhibitor that blocks Notch signalling and was tested against placebo in the phase 3 RINGSIDE trial in adults and adolescents with progressing desmoid tumours; the programme came with the acquisition of Ayala Pharmaceuticals' assets. The company also develops antibody-drug conjugates from its own antibody discovery platform. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://immunome.com/"},{"label":"ClinicalTrials.gov: trials led by Immunome","url":"https://clinicaltrials.gov/search?lead=Immunome"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["desmoid-tumour"],"sections":["targeted-therapy"],"technologies":[],"targets":["gamma-secretase"],"drugs":["varegacestat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04871282"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Bothell, WA","country":"US","companyType":"biotech","website":"https://immunome.com/","stage":"public","investors":[],"funding":[]},{"id":"immunovaccine","kind":"company","name":"Immunovaccine (IMV)","aka":["ImmunoVaccine Technologies, Inc.","ImmunoVaccine Technologies","IMV Inc.","IMV Inc","Immunovaccine Technologies Inc."],"tldr":"Immunovaccine (IMV) is a Canadian biotechnology company founded in 2000 in Halifax, Nova Scotia, whose survivin-targeted immunotherapy DPX-Survivac is tested with pembrolizumab and low-dose cyclophosphamide in two OnCo trials, in relapsed diffuse large B-cell lymphoma and in selected solid tumours.","summary":"Immunovaccine is a company based in Halifax, Canada, founded in 2000 (Wikidata Q30282846, which also gives its website; a second Wikidata item, Q140169711, places Immunovaccine Technologies Inc. in Dartmouth). ClinicalTrials.gov registers it as ImmunoVaccine Technologies, Inc. (IMV Inc.), an industry sponsor, with Merck Sharp & Dohme as collaborator. It leads two phase 2 trials recorded in OnCo: NCT04920617 (VITALIZE, DPX-Survivac and pembrolizumab with and without intermittent low-dose cyclophosphamide in relapsed or refractory DLBCL) and NCT03836352 (the same combination in selected advanced and recurrent solid tumours, recorded under ovarian, hepatocellular, non-small-cell and small-cell lung cancer). DPX-Survivac is its own product, the basis for the biotech type.","asOf":"2026-09-22","links":[{"label":"Official website","url":"http://www.imvaccine.com/"},{"label":"Wikidata Q30282846","url":"https://www.wikidata.org/wiki/Q30282846"},{"label":"ClinicalTrials.gov: trials led by ImmunoVaccine Technologies, Inc.","url":"https://clinicaltrials.gov/search?lead=ImmunoVaccine%20Technologies%2C%20Inc."}],"tags":["ctgov-sponsor","wave5-sponsor"],"related":[],"cancers":["dlbcl","ovarian","hcc","nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","cyclophosphamide"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04920617","nct03836352"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo content wave 5 (Wikidata, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-22"},"hq":"Halifax, Nova Scotia","country":"CA","companyType":"biotech","website":"http://www.imvaccine.com/","founded":2000,"investors":[],"funding":[]},{"id":"immutep","kind":"company","name":"Immutep","aka":["Immutep S.A.S.","Immutep Limited","Prima BioMed"],"tldr":"Immutep is an Australian-French company built on the immune checkpoint LAG-3, whose soluble LAG-3 protein eftilagimod alpha is in the phase 3 TACTI-004 trial with pembrolizumab and chemotherapy in first-line non-small-cell lung cancer.","summary":"Immutep, listed in Sydney and on Nasdaq and with research in Paris, develops therapies around LAG-3, a checkpoint discovered by its scientific founder. Its lead, eftilagimod alpha (efti), is a soluble LAG-3 protein that activates antigen-presenting cells through MHC class II rather than blocking a checkpoint, and is combined with PD-1 antibodies and chemotherapy; after phase 2 results in lung and head and neck cancer it began the phase 3 TACTI-004 trial in first-line non-small-cell lung cancer in 2025. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Immutep","links":[{"label":"Official website","url":"https://www.immutep.com"},{"label":"ClinicalTrials.gov: trials led by Immutep","url":"https://clinicaltrials.gov/search?lead=Immutep"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Immutep"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","head-and-neck"],"sections":["immunotherapy"],"technologies":[],"targets":["lag3"],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06726265"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Sydney","country":"AU","companyType":"biotech","website":"https://www.immutep.com","stage":"public","investors":[],"funding":[]},{"id":"immvira-pharma","kind":"company","name":"ImmVira Pharma","aka":["ImmVira Pharma Co. Ltd"],"tldr":"ImmVira Pharma is a Chinese developer in Shenzhen that sponsors 3 registered cancer trials of Herpes Virus C5252 and T3011.","summary":"ImmVira Pharma appears on ClinicalTrials.gov as the industry sponsor of 3 interventional cancer trials (phase 1/2, 2), testing Herpes Virus C5252, T3011 in glioma, malignant, nonmuscle-invasive bladder cancer, solid tumor, melanoma. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials sponsored by ImmVira Pharma","url":"https://clinicaltrials.gov/search?spons=ImmVira%20Pharma"}],"tags":["ctgov-sponsor","china","registry-only"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["t3011"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07243340","nct06971614","nct04370587"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shenzhen, China","country":"CN","companyType":"biotech","investors":[],"funding":[]},{"id":"impact-therapeutics","kind":"company","name":"IMPACT Therapeutics","aka":["Impact Therapeutics, Inc.","IMPACT Therapeutics (Shanghai)"],"tldr":"IMPACT is a Shanghai biotech built around DNA damage response drugs; its PARP inhibitor senaparib met its phase 3 endpoint as maintenance in ovarian cancer and is approved in China.","summary":"IMPACT Therapeutics, headquartered in Shanghai, develops inhibitors of the DNA damage response. Its PARP inhibitor senaparib (IMP4297) improved progression-free survival as first-line maintenance in advanced ovarian cancer in the phase 3 FLAMES trial and gained Chinese approval, and its Wee1 and ATR inhibitors follow in earlier trials. Its trials are registered on ClinicalTrials.gov under IMPACT as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.impacttherapeutics.com"},{"label":"ClinicalTrials.gov: trials led by Impact Therapeutics, Inc.","url":"https://clinicaltrials.gov/search?lead=Impact%20Therapeutics%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q140046067"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":["parp-inhibitor"],"targets":[],"drugs":["imp4927"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct05269316","nct06907043"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.impacttherapeutics.com","stage":"private-large","investors":[],"funding":[]},{"id":"imugene","kind":"company","name":"Imugene","aka":[],"tldr":"Imugene is an Australian company now focused on an off-the-shelf CAR-T cell therapy made from donor cells for people with blood cancers that have come back after other treatments.","summary":"Imugene Limited, headquartered in Sydney and listed on the ASX, describes itself as a clinical-stage cell therapy company developing off-the-shelf cancer treatments. Its lead programme azer-cel (azercabtagene zapreleucel) is an allogeneic CD19-directed CAR-T therapy in a phase 1/1b open-label study in relapsed or refractory non-Hodgkin lymphoma and B cell acute lymphoblastic leukaemia, recruiting in Australia and the United States. The company previously developed oncolytic virus (VAXINIA / CF33, onCARlytics) and B cell vaccine (HER-Vaxx, PD1-Vaxx) programmes, but these are not described on the current website, which centres on azer-cel. No capital raising could be sourced from fetched pages.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Imugene","links":[{"label":"Official website","url":"https://www.imugene.com"},{"label":"Clinical trials","url":"https://imugene.com/pipeline/clinical-trials/"}],"tags":[],"related":[],"cancers":["all-leukemia","dlbcl"],"sections":["cell-therapy"],"technologies":["allogeneic-cell-therapy","car-t"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ASX code IMU (IMU.AX) not confirmed on fetched pages, so ticker omitted. Oncolytic virus and vaccine programmes not visible on the current site; companyType set to cell-therapy to match the current lead. dlbcl used as the closest id for relapsed or refractory non-Hodgkin lymphoma."],"hq":"Sydney","country":"AU","companyType":"cell-therapy","website":"https://www.imugene.com","stage":"public","investors":[],"funding":[]},{"id":"imunon","kind":"company","name":"Imunon","aka":["IMUNON, Inc.","Celsion Corporation","Celsion"],"tldr":"Imunon, formerly Celsion, is a New Jersey company developing a DNA-based interleukin-12 immunotherapy for ovarian cancer after its heat-activated liposomal doxorubicin, ThermoDox, failed in liver cancer.","summary":"Imunon, which renamed itself from Celsion Corporation in 2022, is listed on Nasdaq. Its earlier lead product ThermoDox, a heat-sensitive liposomal doxorubicin released by radiofrequency ablation, failed the phase 3 HEAT and OPTIMA trials in hepatocellular carcinoma. The company now develops IMNN-001 (formerly GEN-1), a plasmid encoding interleukin-12 delivered into the abdomen to treat advanced ovarian cancer alongside chemotherapy, which is in phase 3. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.imunon.com"},{"label":"ClinicalTrials.gov: trials led by Imunon","url":"https://clinicaltrials.gov/search?lead=Imunon"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Celsion_Corporation"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["ovarian","hcc"],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06915025","nct05739981","nct03393884"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Lawrenceville, NJ","country":"US","companyType":"biotech","website":"https://www.imunon.com","stage":"public","investors":[],"funding":[]},{"id":"incyte","kind":"company","name":"Incyte","aka":["Incyte (incl. MorphoSys US rights)"],"tldr":"Incyte makes pemigatinib, the first targeted drug approved for bile duct cancer (2020), and the JAK inhibitor ruxolitinib.","summary":"Incyte, based in Wilmington, Delaware, and listed as INCY, makes pemigatinib, sold as Pemazyre, the first targeted drug approved for bile duct cancer in 2020, and the JAK inhibitor ruxolitinib, proved in COMFORT-I for myelofibrosis. Pemigatinib was approved for FGFR2-fusion cholangiocarcinoma on the FIGHT-202 trial, but the first-line FIGHT-302 trial against gemcitabine and cisplatin was discontinued; the company also markets tafasitamab with MorphoSys for diffuse large B-cell lymphoma and retifanlimab, and it developed the failed IDO1 inhibitor epacadostat. OnCo links it to biliary tract cancer, lymphoma, anal cancer, Merkel cell carcinoma and myeloproliferative neoplasms. Whether FGFR inhibition can move earlier in bile duct cancer after FIGHT-302 stopped is the open question. Each product has its own page.","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Incyte","links":[{"label":"Official website","url":"https://www.incyte.com"}],"tags":[],"related":[],"cancers":["cholangiocarcinoma","dlbcl"],"sections":["targeted-therapy","immunotherapy"],"technologies":[],"targets":[],"drugs":["pemigatinib","epacadostat","incb123667","incb161734","inca33890","tafasitamab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03934372","nct05287113","nct05429268","nct04680052","nct05222555","nct07023627","nct02955940","nct06465433","nct04509700","nct05879822"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Incyte holds worldwide rights to tafasitamab (Monjuvi) after the MorphoSys deal. frontMIND (Lancet 2026) showed tafasitamab plus lenalidomide and R-CHOP improved progression-free survival against R-CHOP in high-risk newly diagnosed DLBCL (HR 0.75), the first frontline win over R-CHOP in decades, with a supplemental BLA planned for the first half of 2026."],"hq":"Wilmington, DE","country":"US","companyType":"biotech","website":"https://www.incyte.com","ticker":"INCY","investors":[],"funding":[]},{"id":"indapta-therapeutics","kind":"company","name":"Indapta Therapeutics","aka":[],"tldr":"Indapta Therapeutics, of Houston, makes IDP-023, an off-the-shelf natural killer cell therapy from donor g-NK cells, a subset that lacks the FcR gamma chain, and tests it alongside antibody drugs in myeloma and non-Hodgkin lymphoma and in progressive multiple sclerosis. The FDA granted Fast Track status in 2024, and efficacy data are still early.","summary":"Indapta Therapeutics is developing IDP-023, a proprietary, off-the-shelf allogeneic FcR gamma-deficient natural killer (g-NK) cell therapy for cancer and autoimmune disease. According to release titles on the company site, the first patients were treated with IDP-023 in January 2024, the FDA granted Fast Track designation for non-Hodgkin lymphoma and myeloma in February 2024, the company received a $4.5 million CPRIT award in May 2024, an IND for progressive multiple sclerosis was cleared in August 2024, a clinical study collaboration with Sanofi in multiple myeloma was announced in December 2024, and clinical activity in relapsed or refractory multiple myeloma was presented in November 2025. SEC Form D filings list the company in Houston, Texas, with about $33.6 million of equity sold in early 2022 and about $50.8 million sold in an offering that began in September 2025.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://indapta.com/"},{"label":"Form D, October 2025","url":"https://www.sec.gov/Archives/edgar/data/1910175/000191017525000003/primary_doc.xml"},{"label":"Form D, February 2022","url":"https://www.sec.gov/Archives/edgar/data/1910175/000191017522000001/primary_doc.xml"}],"tags":[],"related":[],"cancers":["multiple-myeloma","dlbcl"],"sections":["cell-therapy"],"technologies":["car-nk-macrophage","allogeneic-cell-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06119685"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The user's hint says San Francisco; Form D filings give Houston, TX. Programme milestones are taken from press-release titles linked on the homepage (the Business Wire pages themselves returned 403). The g-NK product is not CAR-engineered; 'car-nk-macrophage' is the closest available id. The December 2024 $22.5 million financing release could not be fetched."],"hq":"Houston, TX","country":"US","companyType":"cell-therapy","website":"https://indapta.com/","stage":"startup","investors":[],"funding":[{"round":"Form D offering","year":2022,"amountUsd":33603097,"source":"https://www.sec.gov/Archives/edgar/data/1910175/000191017522000001/primary_doc.xml","note":"Amount sold at filing of a $67 million offering, first sale 28 January 2022"},{"round":"Form D offering","year":2025,"amountUsd":50800176,"source":"https://www.sec.gov/Archives/edgar/data/1910175/000191017525000003/primary_doc.xml","note":"Amount sold at filing of a $51.6 million offering, first sale 24 September 2025"}]},{"id":"indica-labs","kind":"company","name":"Indica Labs","aka":[],"tldr":"Indica Labs, of Albuquerque, New Mexico, makes HALO, image analysis software that quantifies stained tissue on digital slides, and HALO Link for enterprise viewing, sold to pharmaceutical and academic pathology laboratories; HALO AP Dx is cleared for clinical use in several regions. Crossing from research tool to regulated diagnosis is its test.","summary":"Indica Labs, based in Albuquerque, New Mexico, makes the HALO image analysis and HALO Link management software, sold to pharmaceutical and academic pathology laboratories. Its HALO AI provides quantitative tissue analysis, HALO Link provides enterprise viewing, and HALO AP Dx has been cleared for clinical use in several regions. OnCo links it to whole-slide scanners and image management and to digital pathology and AI. Whether research-grade image analysis tools can cross into routine clinical diagnosis under regulation is the question its clinical clearances begin to answer. The digital pathology page carries the wider field.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://indicalab.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics","ai-computation"],"technologies":["whole-slide-scanners","digital-pathology-ai"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Albuquerque, NM","country":"US","companyType":"ai-software","website":"https://indicalab.com","investors":[],"funding":[]},{"id":"indivumed","kind":"company","name":"Indivumed","aka":[],"tldr":"Indivumed is a German biobank with standardised, rapidly processed tumour samples and a multi-omics database (IndivuType).","summary":"Indivumed, based in Hamburg, is a German biobank with standardised, rapidly processed tumour samples and a multi-omics database called IndivuType. Its collection is ischaemia-time-controlled across a global clinical network, and its multi-omic cancer database is used for target discovery. OnCo links it to biobanking and tissue procurement. Whether tightly controlled sample handling reveals biology that conventional biobanks miss, which is its founding premise, is the open question. The biobanking technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.indivumed.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":["biobanking"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Hamburg","country":"DE","companyType":"cro-services","website":"https://www.indivumed.com","investors":[],"funding":[]},{"id":"infinity-pharmaceuticals","kind":"company","name":"Infinity Pharmaceuticals","aka":["Infinity Pharmaceuticals, Inc.","Infinity"],"tldr":"Infinity was the Cambridge biotech that discovered duvelisib, the PI3K-delta/gamma inhibitor later approved for chronic lymphocytic leukaemia, before licensing it out and turning to eganelisib; it filed for bankruptcy in 2023.","summary":"Infinity Pharmaceuticals, founded in 2001 in Cambridge, Massachusetts, developed duvelisib (IPI-145) through the phase 3 DUO trial in relapsed chronic lymphocytic leukaemia before licensing it to Verastem, which won approval in 2018. Its later PI3K-gamma inhibitor eganelisib reached phase 2 in combination with checkpoint inhibitors, and the company filed for bankruptcy in 2023. Its trials remain on ClinicalTrials.gov under Infinity as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.infi.com"},{"label":"ClinicalTrials.gov: trials led by Infinity Pharmaceuticals, Inc.","url":"https://clinicaltrials.gov/search?lead=Infinity%20Pharmaceuticals%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30296176"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cll"],"sections":[],"technologies":[],"targets":[],"drugs":["duvelisib"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"http://www.infi.com","founded":2001,"stage":"defunct","investors":[],"funding":[]},{"id":"inhibrx","kind":"company","name":"Inhibrx Biosciences","aka":[],"tldr":"Inhibrx Biosciences is a San Diego antibody company testing two cancer drugs: ozekibart, which triggers a self-destruct receptor on tumour cells in bone cancers such as Ewing sarcoma, and an OX40 antibody that boosts immune cells. Sanofi bought its sister lung disease drug in 2024.","summary":"Inhibrx Biosciences is a La Jolla, California clinical-stage company that engineers multivalent biologics. Ozekibart (INBRX-109) is a tetravalent DR5 (death receptor 5) agonist designed to induce tumour-selective programmed cell death and is enrolling patients with Ewing sarcoma in phase 1; INBRX-106 is a hexavalent OX40 agonist designed to promote receptor hyperclustering, in phase 1/2 and phase 2/3 trials. In January 2024 the predecessor Inhibrx, Inc. agreed to sell INBRX-101, a recombinant alpha-1 antitrypsin for alpha-1 antitrypsin deficiency, to Sanofi for 30 US dollars per share in cash plus a 5 US dollar contingent value right (about 2.2 billion US dollars aggregate value). Immediately before that merger closed on 30 May 2024, the non-101 assets (INBRX-105, INBRX-106, INBRX-109) were spun out into Inhibrx Biosciences, which received 200 million US dollars in cash, has Sanofi as an 8 percent holder and trades on Nasdaq as INBX.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://inhibrx.com/"},{"label":"Pipeline","url":"https://inhibrx.com/pipeline/"},{"label":"Sanofi transaction announcement (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1739614/000110465924005727/tm243849d1_ex99-1.htm"},{"label":"Completion 8-K (SEC)","url":"https://www.sec.gov/Archives/edgar/data/1739614/000110465924066650/tm243190d20_8k.htm"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":["targeted-therapy","immunotherapy"],"technologies":["monoclonal-antibody"],"targets":[],"drugs":["inbrx-106"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04198766"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Chondrosarcoma and INBRX-105 status not confirmed from the fetched pipeline page. Inhibrx's own IPO (2020) not sourced."],"hq":"La Jolla, CA","country":"US","companyType":"biotech","website":"https://inhibrx.com/","ticker":"INBX","stage":"public","investors":[],"funding":[{"round":"Acquisition","year":2024,"amountUsd":2200000000,"source":"https://www.sec.gov/Archives/edgar/data/1739614/000110465924005727/tm243849d1_ex99-1.htm","note":"Predecessor Inhibrx, Inc. sold its INBRX-101 (alpha-1 antitrypsin) asset to Sanofi for about 2.2 billion US dollars aggregate value; oncology assets were spun out into Inhibrx Biosciences, capitalised with 200 million US dollars from Sanofi; completed 30 May 2024"}]},{"id":"inivata","kind":"company","name":"Inivata","aka":[],"tldr":"Inivata was a Cambridge, UK liquid biopsy company whose blood tests find traces of tumour DNA; it was bought by the US laboratory group NeoGenomics in 2021 and its RaDaR test is now sold by NeoGenomics.","summary":"Inivata, from Cambridge, England, built liquid biopsy assays on its InVision platform: InVisionFirst-Lung, a plasma ctDNA genotyping test for advanced non-small cell lung cancer, and RaDaR, a tumour-informed assay tracking up to 48 patient-specific variants to detect minimal residual disease (MRD) and recurrence. RaDaR held FDA Breakthrough Device Designation before the acquisition. NeoGenomics made a $25 million minority investment in May 2020 with an option to buy the company, exercised it in May 2021 for $390 million in cash and completed the deal on 18 June 2021. Inivata then operated as NeoGenomics' liquid biopsy subsidiary in Cambridge and Research Triangle Park, North Carolina. The successor RaDaR ST assay is sold by NeoGenomics with Medicare coverage in HR-positive, HER2-negative breast cancer, HPV-negative head and neck cancer and immunotherapy monitoring.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://neogenomics.com/"},{"label":"NeoGenomics to acquire Inivata (May 2021)","url":"https://ir.neogenomics.com/news-events/press-releases/detail/176/neogenomics-to-acquire-inivata---combining-best-in-class-liquid-biopsy-technology-with-leading-community-oncology-platform"},{"label":"NeoGenomics completes Inivata acquisition (June 2021)","url":"https://ir.neogenomics.com/news-events/press-releases/detail/180/neogenomics-completes-inivata-acquisition---combining-best-in-class-liquid-biopsy-technology-with-leading-community-oncology-platform"}],"tags":[],"related":[],"cancers":["nsclc","breast-hr-positive","head-and-neck"],"sections":["diagnostics"],"technologies":["liquid-biopsy","mrd-testing","cgp"],"targets":["egfr","alk","kras"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["inivata.com does not resolve (connection failed), so the parent NeoGenomics site is used as the website. Pre-acquisition venture rounds and founding year not sourced."],"hq":"Cambridge","country":"GB","companyType":"diagnostics","website":"https://neogenomics.com/","stage":"acquired","investors":["cancer-research-horizons"],"funding":[{"round":"Acquisition","year":2021,"amountUsd":390000000,"source":"https://ir.neogenomics.com/news-events/press-releases/detail/176/neogenomics-to-acquire-inivata---combining-best-in-class-liquid-biopsy-technology-with-leading-community-oncology-platform","note":"$390 million in cash for the remaining equity after a $25 million minority investment in May 2020; completion announced 18 June 2021."}],"acquiredBy":"neogenomics"},{"id":"innocare","kind":"company","name":"InnoCare Pharma","aka":["诺诚健华"],"tldr":"InnoCare developed orelabrutinib, a selective BTK-blocking pill approved in China for chronic lymphocytic leukaemia and mantle cell and marginal zone lymphomas.","summary":"InnoCare Pharma, based in Beijing, founded in 2015 and listed as 9969.HK and 688428.SS, developed orelabrutinib, a selective BTK-blocking tablet approved in China for chronic lymphocytic leukaemia and for mantle cell and marginal zone lymphomas. Orelabrutinib, sold as Yinuokai, was approved in 2020 and 2023, and the pipeline includes the pan-TRK inhibitor zurletrectinib, the BCL2 inhibitor mesutoclax, the CD20 by CD3 bispecific ICP-B02 and a TYK2 programme; the company was co-founded by Jisong Cui and the structural biologist Yigong Shi. OnCo links it to BTK as a target and to the orelabrutinib record. Whether a selective BTK inhibitor can differentiate from rival BTK inhibitors in the same domestic market is the open question. Orelabrutinib has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.innocarepharma.com/en"}],"tags":["china"],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":["btk"],"drugs":["orelabrutinib","icp-248"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06363994","nct04685226","nct07617493","nct05678270","nct05745623","nct04014205","nct07082686","nct06082102"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Beijing","country":"CN","companyType":"biotech","website":"https://www.innocarepharma.com/en","ticker":"9969.HK / 688428.SS","founded":2015,"investors":[],"funding":[]},{"id":"innopharmax","kind":"company","name":"InnoPharmax","aka":["InnoPharmax Inc."],"tldr":"InnoPharmax is a Taiwanese pharmaceutical company running phase 3 trials of D07001, its oral formulation of the chemotherapy irinotecan, in biliary tract cancer.","summary":"InnoPharmax, based in Taipei, develops oral formulations of established cancer drugs. Its lead programme D07001 is an oral form of irinotecan designed to allow outpatient dosing, in phase 3 trials for advanced biliary tract cancer after first-line chemotherapy. Sponsor and trial facts are from the ClinicalTrials.gov registry.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials led by InnoPharmax","url":"https://clinicaltrials.gov/search?lead=InnoPharmax"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cholangiocarcinoma"],"sections":["chemotherapy"],"technologies":[],"targets":[],"drugs":["d07001"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06622057","nct05065957"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Taipei","country":"TW","companyType":"biotech","stage":"growth","investors":[],"funding":[]},{"id":"itcc","kind":"company","name":"Innovative Therapies for Children with Cancer (ITCC)","aka":["ITCC","ITCC consortium"],"tldr":"Europe's network of children's hospitals that run the first trials of new cancer drugs in children, so that European children can access experimental medicines close to home.","summary":"Founded in 2003 and coordinated from Gustave Roussy, ITCC links more than 60 European paediatric oncology centres and around 25 research laboratories to conduct early-phase (phase 1 and 2) trials of new anticancer agents in children and adolescents. It runs academic platform trials including ESMART (molecularly matched combinations at relapse, the European counterpart of Pediatric MATCH) and the MAPPYACTS sequencing programme, partners with industry on paediatric investigation plans, and works with SIOP Europe and ACCELERATE on regulatory strategy. ITCC-P4 built a library of paediatric patient-derived xenograft models for preclinical testing under the IMI programme.","asOf":"2026-09-10","links":[{"label":"ITCC","url":"https://www.itcc-consortium.org"}],"tags":["cooperative-group","nci-coverage","paediatric"],"related":[],"cancers":["neuroblastoma","dipg-dmg","paediatric-low-grade-glioma","rhabdomyosarcoma"],"sections":[],"technologies":["pdx-models","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["gustave-roussy","siop-europe","accelerate-platform","princess-maxima","great-ormond-street"],"pathways":[],"terms":[],"trials":["pediatric-match"],"people":["pamela-kearns"],"bottlenecks":["b-rare-cancers","b-trial-enrolment"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Early-phase paediatric trials network","ESMART platform trial","MAPPYACTS molecular profiling","ITCC-P4 preclinical PDX platform","Industry partnerships for paediatric investigation plans"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Villejuif","country":"FR","companyType":"cooperative-group","website":"https://www.itcc-consortium.org","founded":2003,"investors":[],"funding":[]},{"id":"innovent","kind":"company","name":"Innovent Biologics","aka":["信达生物","Innovent Biologics (Suzhou)","Innovent Biopharmaceutical Technology (Hangzhou)","Innovent Biologics"],"tldr":"Innovent makes sintilimab, China's best-selling PD-1 antibody, and has become a source of next-generation assets for Roche and Takeda.","summary":"Founded by Michael Yu in Suzhou BioBay; sintilimab (Tyvyt) approved 2018 and now in six indications, four biosimilars (bevacizumab, rituximab, adalimumab, trastuzumab), fulzerasib (with GenFleet), equecabtagene autoleucel (with IASO), and the Claudin 18.2 ADC IBI343. Out-licensing: the DLL3 ADC IBI3009 to Roche (January 2025) and the PD-1/IL-2 alpha-bias bispecific IBI363 plus IBI343 to Takeda (October 2025, $1.2 billion upfront, up to $11.4 billion). Also the GLP-1 mazdutide outside oncology. Lilly co-markets Tyvyt in China.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Innovent_Biologics","links":[{"label":"Official website","url":"https://www.innoventbio.com/"},{"label":"Innovent and Takeda global partnership (October 2025)","url":"https://www.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=524"}],"tags":["china"],"related":[],"cancers":[],"sections":["immunotherapy","adcs","cell-therapy"],"technologies":[],"targets":[],"drugs":["sintilimab","fulzerasib","equecabtagene-autoleucel","ibi354","ibi343","ibi310","ibi363","taletrectinib"],"companies":["eli-lilly","roche-genentech","takeda"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05923008","nct05890742","nct05636215","nct06083207","nct06974812","nct05116462","nct07722494","nct06797297","nct06081920","nct07483554","nct06281678","nct07122687"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Suzhou","country":"CN","companyType":"biotech","website":"https://www.innoventbio.com/","ticker":"1801.HK","founded":2011,"investors":[],"funding":[]},{"id":"inovio","kind":"company","name":"Inovio Pharmaceuticals","aka":["Inovio","INOVIO Pharmaceuticals, Inc."],"tldr":"Inovio is a US company developing DNA medicines delivered by electroporation, whose lead cancer-related programme VGX-3100 treats the HPV-caused precancerous cervical lesions that lead to cervical cancer.","summary":"Inovio Pharmaceuticals, listed on Nasdaq, develops DNA plasmid immunotherapies and vaccines delivered into muscle or skin with a hand-held electroporation device. Its most advanced programme, VGX-3100, targets HPV 16 and 18 to clear high-grade cervical dysplasia (CIN2/3), the precancerous lesion that precedes cervical cancer, and completed the phase 3 REVEAL trials; the company has also run trials of DNA vaccines in HPV-related head and neck and anal cancers and in glioblastoma. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Inovio_Pharmaceuticals","links":[{"label":"Official website","url":"https://www.inovio.com"},{"label":"ClinicalTrials.gov: trials led by Inovio Pharmaceuticals","url":"https://clinicaltrials.gov/search?lead=Inovio%20Pharmaceuticals"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Inovio_Pharmaceuticals"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cervical","head-and-neck","glioblastoma"],"sections":["prevention","immunotherapy"],"technologies":[],"targets":[],"drugs":["ino-5401"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03491683"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Plymouth Meeting, PA","country":"US","companyType":"biotech","website":"https://www.inovio.com","stage":"public","investors":[],"funding":[]},{"id":"insight-molecular-diagnostics","kind":"company","name":"Insight Molecular Diagnostics (formerly Oncocyte)","aka":[],"tldr":"Insight Molecular Diagnostics, the renamed Oncocyte, is a small listed company whose cancer tests read gene activity in tumours to predict who will respond to immunotherapy, alongside a larger business in transplant rejection blood tests.","summary":"Insight Molecular Diagnostics (iMDx), Nasdaq: IMDX, is the former Oncocyte Corporation, which changed its name and moved from Irvine, California to Nashville, Tennessee in June 2025. Its oncology assets include DetermaIO, a 27-gene expression assay of the tumour immune microenvironment intended to predict response to immune checkpoint inhibitors, and DetermaCNI, an in-development blood test measuring genomic copy number instability in circulating tumour DNA to monitor treatment response. The commercial focus has shifted to transplant monitoring with the GraftAssure donor-derived cell-free DNA tests: GraftAssureCore is a laboratory developed test, GraftAssureIQ a research kit and GraftAssureDx is under FDA review for kidney transplant recipients, with a favourable Medicare coverage decision in July 2026. At the end of Q2 2026 the company held $18.7 million in cash.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://imdxinc.com/"},{"label":"Investor relations","url":"https://investors.imdxinc.com/"},{"label":"Q2 2026 results release (Nashville dateline, former name)","url":"https://investors.imdxinc.com/news-releases/2026/08-10-2026-210715920"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["rna-seq","liquid-biopsy","companion-diagnostic"],"targets":["pd1","pdl1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Oncology is now a minority of the business; transplant testing dominates. Financing amounts for the warrant issuances were not stated in the fetched release so no rounds are recorded. Ticker was OCX before the rename."],"hq":"Nashville, TN","country":"US","companyType":"diagnostics","website":"https://imdxinc.com/","ticker":"IMDX","stage":"public","investors":[],"funding":[]},{"id":"insightec","kind":"company","name":"Insightec","aka":[],"tldr":"MR-guided focused ultrasound company, with oncology use in blood-brain-barrier opening for brain tumours.","summary":"Insightec, based in Haifa, is the MR-guided focused ultrasound company whose oncology relevance lies in opening the blood-brain barrier so that drugs can reach brain tumours. Its Exablate Neuro system is established in essential tremor, Exablate Prostate treats prostate tissue, and its blood-brain barrier opening trials aim at drug delivery in glioblastoma. OnCo links it to glioma and glioblastoma, to focused ultrasound and histotripsy, focused-ultrasound blood-brain barrier opening and sonodynamic therapy, to Sunnybrook and the UVA cancer centre, and to ideas such as a standard platform for getting drugs into the brain and an ultrasound-assisted blood test instead of a brain biopsy. The brain as a barrier and sanctuary is the bottleneck it exists to breach. Whether transient barrier opening improves outcomes, not just drug levels, is the open question.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Insightec","links":[{"label":"Official website","url":"https://www.insightec.com"}],"tags":[],"related":[],"cancers":[],"sections":["surgery","devices"],"technologies":["hifu-histotripsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05317858","nct05615623","nct05630209"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Haifa","country":"IL","companyType":"devices","website":"https://www.insightec.com","investors":[],"funding":[]},{"id":"insilico-medicine","kind":"company","name":"Insilico Medicine","aka":[],"tldr":"Generative-AI drug discovery company, listed in Hong Kong in December 2025, with a pan-KRAS candidate and a pan-TEAD inhibitor in the clinic.","summary":"Insilico's 2025 listing was the largest Hong Kong biotech IPO of the year (HKD 2.28B). Pipeline of 31 nominated candidates with 13 IND clearances; oncology assets include ISM6166 (pan-KRAS) and ISM6331 (pan-TEAD, phase 1 data at ESMO 2026 in mesothelioma and solid tumours). Profitable in H1 2026 on licensing revenue.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Insilico_Medicine","links":[{"label":"H1 2026 results","url":"https://www.biospace.com/press-releases/commercialization-roadmap-validated-with-three-digit-million-dollar-revenue-insilico-medicine-announces-interim-results-for-the-first-half-of-2026"}],"tags":[],"related":[],"cancers":["mesothelioma","pancreatic"],"sections":["ai-computation","drug-discovery"],"technologies":["ai-drug-design","kras-inhibitors"],"targets":["kras"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06414460","nct06566079"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Hong Kong / Boston","country":"HK","companyType":"ai-software","website":"https://insilico.com","ticker":"3696.HK","investors":[],"funding":[]},{"id":"insys-therapeutics","kind":"company","name":"Insys Therapeutics","aka":["INSYS Therapeutics Inc","Insys Therapeutics, Inc."],"tldr":"Insys Therapeutics was an Arizona company whose sublingual fentanyl spray for breakthrough cancer pain went through phase 3 trials; its marketing practices later led to criminal convictions and bankruptcy.","summary":"Insys Therapeutics, founded in 1990 and based in Chandler, Arizona, developed Subsys, a fentanyl sublingual spray approved for breakthrough pain in opioid-tolerant cancer patients, and a dronabinol oral solution. Its executives were convicted in 2019 over kickbacks to prescribers, and the company filed for bankruptcy the same year. Its phase 3 trials in cancer pain remain on ClinicalTrials.gov under Insys as lead sponsor. ClinicalTrials.gov also lists under Insys the earlier NeoPharm programmes it absorbed, including the interleukin-13 conjugated toxin IL13-PE38QQR (cintredekin besudotox) in malignant glioma (NCT00076986) and liposomal paclitaxel and docetaxel formulations.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Insys_Therapeutics","links":[{"label":"Official website","url":"http://www.insysrx.com"},{"label":"ClinicalTrials.gov: trials led by INSYS Therapeutics Inc","url":"https://clinicaltrials.gov/search?lead=INSYS%20Therapeutics%20Inc"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q19903344"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["glioblastoma"],"sections":["supportive-care"],"technologies":["pain-management"],"targets":[],"drugs":["dronabinol"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Chandler, AZ","country":"US","companyType":"pharma","website":"http://www.insysrx.com","founded":1990,"stage":"defunct","investors":[],"funding":[]},{"id":"intas","kind":"company","name":"Intas Pharmaceuticals (Accord Healthcare)","aka":[],"tldr":"A privately held Ahmedabad company whose European arm, Accord Healthcare, is one of the largest suppliers of generic chemotherapy and supportive-care biosimilars to European hospitals.","summary":"Intas was founded in 1977 by Hasmukh Chudgar and incorporated in 1985; it operates 22 manufacturing plants and sells in more than 100 countries, with revenue heading toward 24,000 crore rupees. Its Biologics Unit was the first Indian company to receive EU GMP certification (April 2007), and its London-based subsidiary Accord Healthcare markets generics and biosimilars across Europe and North America, including the pegfilgrastim biosimilar Pelgraz (EMA authorisation 21 September 2018) used to prevent chemotherapy-induced neutropenia. Accord's injectable oncology generics are a staple of European hospital pharmacies.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.intaspharma.com"},{"label":"Pelgraz EPAR (EMA)","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/pelgraz"}],"tags":[],"related":[],"cancers":[],"sections":["chemotherapy","supportive-care"],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["biosimilar"],"trials":["nct03671044"],"people":[],"bottlenecks":["b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Ahmedabad","country":"IN","companyType":"pharma","website":"https://www.intaspharma.com","founded":1977,"investors":[],"funding":[]},{"id":"intensity-therapeutics","kind":"company","name":"Intensity Therapeutics","aka":["Intensity Therapeutics, Inc.","NASDAQ:INTS"],"tldr":"Intensity Therapeutics is a Connecticut biotech whose INT230-6 is injected straight into tumours with a penetration enhancer that spreads chemotherapy through the whole mass and triggers an immune response.","summary":"Intensity Therapeutics developed INT230-6, an intratumoural formulation of cisplatin and vinblastine with the amphiphilic molecule SHAO, which disperses the drugs through the tumour and into cells. Killing the tumour in place releases antigens that prime systemic immunity. The company is running the phase 3 INVINCIBLE-3 trial in soft tissue sarcoma and the phase 2 INVINCIBLE-4 trial in presurgical triple-negative breast cancer.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.intensitytherapeutics.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["int230-6"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Shelton, Connecticut","country":"US","companyType":"biotech","website":"https://www.intensitytherapeutics.com/","ticker":"NASDAQ:INTS","founded":2012,"stage":"public","investors":[],"funding":[]},{"id":"ifct","kind":"company","name":"Intergroupe Francophone de Cancérologie Thoracique","aka":["IFCT"],"tldr":"The French thoracic oncology intergroup, which ran the national Biomarkers France programme showing that routine molecular testing of lung cancer improves survival.","summary":"Founded in 1999, IFCT unites French pulmonologists, oncologists, radiotherapists and pathologists in academic lung cancer trials. Its Biomarkers France study (2012-2013) profiled more than 17,000 patients with non-small cell lung cancer for EGFR, ALK, KRAS, BRAF, HER2 and PIK3CA alterations and showed that testing changes treatment and outcomes at national scale. IFCT trials have covered adjuvant chemotherapy, maintenance strategies, immunotherapy in elderly patients and rare thoracic tumours, and the group runs the CLINIVO real-world immunotherapy cohort. It works with UNICANCER, EORTC and ETOP.","asOf":"2026-09-09","links":[{"label":"IFCT","url":"https://www.ifct.fr"}],"tags":["cooperative-group"],"related":[],"cancers":["nsclc","sclc","mesothelioma"],"sections":[],"technologies":["cgp","checkpoint-inhibitor","kinase-inhibitors"],"targets":[],"drugs":[],"companies":["unicancer","curie-nki-eortc","etop-ibcsg"],"institutions":["gustave-roussy"],"pathways":[],"terms":["real-world-evidence","oncogene-addiction"],"trials":["maps"],"people":["fabrice-barlesi","benjamin-besse","alexis-cortot","david-planchard"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Biomarkers France (national molecular testing study)","Immunotherapy in elderly and PS2 patients","Mesothelioma and thymic tumour trials","CLINIVO real-world cohort"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Paris","country":"FR","companyType":"cooperative-group","website":"https://www.ifct.fr","founded":1999,"investors":[],"funding":[]},{"id":"ifm","kind":"company","name":"Intergroupe Francophone du Myélome (IFM)","aka":["Intergroupe Francophone du Myelome","IFM"],"tldr":"The IFM is the French-speaking myeloma cooperative group created in 1994, with 140 French and 33 Belgian centres, whose trials set melphalan-autograft intensification, bortezomib induction and lenalidomide maintenance; in OnCo it leads CASSIOPEIA and IFM 2009.","summary":"The Intergroupe Francophone du Myélome (IFM) is a cooperative group created in 1994, the only French group working on myeloma, with 140 French and 33 Belgian centres; its aim is to promote basic and therapeutic research through clinical trials, it was labelled by the Institut National du Cancer in December 2018, and its registered office is at 75 avenue Parmentier, Paris (myelome.fr). ClinicalTrials.gov names it lead sponsor (NETWORK class, with HOVON and Janssen as collaborators) of CASSIOPEIA (NCT02541383, phase 3, daratumumab added to bortezomib, thalidomide and dexamethasone before and after transplant); IFM 2009 (NCT01191060, lenalidomide, bortezomib and dexamethasone with or without early transplant) is registered by the University Hospital of Toulouse as an IFM trial. Both are recorded in OnCo. It has no products of its own.","asOf":"2026-09-25","links":[{"label":"IFM: présentation","url":"https://www.myelome.fr/l-ifm"},{"label":"ClinicalTrials.gov: trials led by Intergroupe Francophone du Myelome","url":"https://clinicaltrials.gov/search?lead=Intergroupe%20Francophone%20du%20Myelome"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["multiple-myeloma","myeloma-transplant-eligible"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["cassiopeia","ifm-2009"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"Paris","country":"FR","companyType":"cooperative-group","website":"https://www.myelome.fr","founded":1994,"investors":[],"funding":[]},{"id":"interius","kind":"company","name":"Interius BioTherapeutics","aka":[],"tldr":"Penn spin-out that dosed the first patient ever with a durable in vivo CAR gene therapy (INT2104, CD20) in the INVISE trial.","summary":"INT2104 is an engineered lentiviral vector that generates CAR-T and CAR-NK cells against CD20 after a single IV infusion, without lymphodepletion. Phase 1 INVISE in relapsed/refractory B-cell malignancies started in Australia (2024-25); preclinical large-animal data showed B-cell depletion without CRS or neurotoxicity.","asOf":"2026-09-04","links":[{"label":"First patient dosed","url":"https://interiusbio.com/press-release/interius-biotherapeutics-doses-first-patient-with-in-vivo-chimeric-antigen-receptor-car-gene-therapy-for-b-cell-malignancies/"}],"tags":["frontier"],"related":[],"cancers":["dlbcl"],"sections":["cell-therapy"],"technologies":["in-vivo-car-t"],"targets":["cd20"],"drugs":[],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Philadelphia, PA","country":"US","companyType":"cell-therapy","website":"https://interiusbio.com","investors":[],"funding":[]},{"id":"ielsg","kind":"company","name":"International Extranodal Lymphoma Study Group","aka":["IELSG"],"tldr":"A Swiss-based international group that runs the trials defining treatment of rare extranodal lymphomas, including primary CNS lymphoma and gastric MALT lymphoma.","summary":"Founded in 1997 and coordinated from the Oncology Institute of Southern Switzerland in Bellinzona, IELSG focuses on lymphomas arising outside lymph nodes, which no single country can study alone. IELSG32 established the MATRix regimen and consolidation strategies in primary CNS lymphoma, IELSG37 tested omission of mediastinal radiotherapy after PET-negative response in primary mediastinal B-cell lymphoma, and its gastric MALT lymphoma studies defined antibiotic and chlorambucil-rituximab therapy. It collaborates with LYSA, HOVON, the Nordic Lymphoma Group and Australian groups.","asOf":"2026-09-09","links":[{"label":"IELSG","url":"https://www.ielsg.org"}],"tags":["cooperative-group"],"related":[],"cancers":["dlbcl"],"sections":["radiation","chemotherapy"],"technologies":["fdg-pet","monoclonal-antibody","imrt-igrt"],"targets":[],"drugs":[],"companies":["lysa","hovon","nordic-lymphoma-group"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["franco-cavalli"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Primary CNS lymphoma (IELSG32, IELSG43)","Primary mediastinal B-cell lymphoma (IELSG37)","MALT lymphoma","Rare extranodal lymphoma registries"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Bellinzona","country":"CH","companyType":"cooperative-group","website":"https://www.ielsg.org","founded":1997,"investors":[],"funding":[]},{"id":"intodna","kind":"company","name":"intoDNA","aka":["intoDNA S.A."],"tldr":"A Krakow spin-out from the Jagiellonian University whose STRIDE assay counts individual DNA breaks in cells, sold to drug developers and aimed at predicting who responds to DNA-repair drugs.","summary":"intoDNA was founded in 2016 by researchers from the Jagiellonian University in Krakow to commercialise STRIDE, a fluorescence method that detects single- and double-strand DNA breaks directly in fixed cells. The company offers STRIDE as a contract research service to pharmaceutical and biotech companies developing DNA damage response drugs, radiosensitisers and chemotherapy combinations, and is working towards a functional companion test for PARP inhibitor response.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://intodna.com"}],"tags":[],"related":[],"cancers":["ovarian","breast-cancer","prostate"],"sections":[],"technologies":["stride-dna-break-detection","hrd-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Krakow, Poland","country":"PL","companyType":"biotech","website":"https://intodna.com","founded":2016,"stage":"startup","investors":[],"funding":[]},{"id":"intra-immusg","kind":"company","name":"Intra-IMMUSG","aka":["Intra-IMMUSG Pte Ltd"],"tldr":"Intra-IMMUSG is a Singapore-based biotechnology company running 3 late-stage cancer trials.","summary":"Intra-IMMUSG, based in Singapore, Singapore, is a biotechnology company. Intra-ImmuSG is a Phase 2 clinical-stage biotechnology company developing antibody-based cancer immunotherapies that target intracellular tumour antigens exposed on the cancer cell surface. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3). The largest, NCT07541001 (PRL3-Zumab in Patients With Advanced Solid Tumours), plans to enrol 60 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.intra-immusg.com"},{"label":"ClinicalTrials.gov: trials led by Intra-IMMUSG","url":"https://clinicaltrials.gov/search?lead=Intra-IMMUSG%20Pte%20Ltd"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct07290088","nct07541001","nct04452955"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Singapore","country":"SG","companyType":"biotech","website":"https://www.intra-immusg.com","stage":"growth","investors":[],"funding":[]},{"id":"intraop-medical","kind":"company","name":"IntraOp Medical","aka":[],"tldr":"IntraOp makes the Mobetron, a mobile electron-beam machine that can be wheeled into an operating theatre to give a single, targeted dose of radiation to the tumour bed during cancer surgery, and it is also being used in the first human trials of ultra-fast FLASH radiotherapy.","summary":"IntraOp Medical Corporation manufactures the Mobetron, introduced in 1993 as the first mobile electron linear accelerator for intraoperative radiotherapy (IORT). The self-shielded unit delivers electron beams directly to the tumour bed during surgery, sparing surrounding organs. The company reports more than forty units at leading cancer centres; Salzburg University Hospital treated its 1,000th Mobetron patient in August 2026. IntraOp describes Mobetron as the only electron ultra-high dose rate device approved for FLASH clinical trials. With Lausanne University Hospital (CHUV) it supported IMPulse, the first human dose-escalation study of single-fraction FLASH radiotherapy: 15 cutaneous melanoma metastases in 11 patients were treated at 22 to 28 Gy with no dose-limiting toxicities, published in Radiotherapy and Oncology in March 2026. IntraOp is privately held and based in Fremont, California; no funding details were found.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://intraop.com"},{"label":"About IntraOp","url":"https://intraop.com/intraop/"},{"label":"IMPulse FLASH trial completion with CHUV (March 2026)","url":"https://intraop.com/news-events/intraop-medical-announces-completion-of-pioneering-human-flash-radiotherapy-trial-and-publication-of-landmark-clinical-physics-results-with-lausanne-university-hospital-chuv/"},{"label":"News and events","url":"https://intraop.com/intraop/news-and-events-2/"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":["radiation","surgery","devices"],"technologies":["flash-rt","imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The caller's hint of Sunnyvale CA was not confirmed; the website and 2026 press release give 448 Kato Terrace, Fremont, CA. The site returns HTTP 403 to curl but loads via WebFetch. Founding year not stated (Mobetron introduced 1993). No funding, investors or ownership found; 'private-large' chosen because the company is a decades-old private manufacturer rather than a venture-stage startup. FDA clearance year for Mobetron not stated on fetched pages."],"hq":"Fremont, CA","country":"US","companyType":"devices","website":"https://intraop.com","stage":"private-large","investors":[],"funding":[]},{"id":"intuitive-surgical","kind":"company","name":"Intuitive Surgical","aka":[],"tldr":"Intuitive Surgical makes the da Vinci robot, used in most robotic cancer surgeries worldwide.","summary":"Intuitive Surgical, based in Sunnyvale, California, and listed as ISRG, makes the da Vinci robot, used in most robotic cancer surgeries worldwide. Its systems are da Vinci 5, the SP single-port robot and the Ion bronchoscopy platform for lung nodule biopsy, with more than ten thousand systems installed. OnCo links it to robotic and minimally invasive surgery, transoral robotic surgery and navigational bronchoscopy, to head and neck cancer, to the bottleneck that surgery and radiotherapy cure most patients but receive least research funding, and to ideas including a consented commons of surgical video linked to outcomes and an independent evaluation unit for surgical robots. Whether robotic surgery improves cancer outcomes, rather than recovery alone, is the question its trials have not settled. The technology pages carry the evidence.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Intuitive_Surgical","links":[{"label":"Official website","url":"https://www.intuitive.com"}],"tags":[],"related":[],"cancers":[],"sections":["surgery"],"technologies":["robotic-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Sunnyvale, CA","country":"US","companyType":"devices","website":"https://www.intuitive.com","ticker":"ISRG","investors":[],"funding":[]},{"id":"inventisbio","kind":"company","name":"InventisBio","aka":["益方生物"],"tldr":"InventisBio developed garsorasib, one of the two KRAS G12C pills approved in China in 2024, and the third-generation EGFR inhibitor befotertinib.","summary":"InventisBio, based in Shanghai, founded in 2013 and listed as 688382.SS, developed garsorasib, one of the two KRAS G12C tablets approved in China in 2024, and the third-generation EGFR inhibitor befotertinib. Garsorasib, or D-1553, was approved in August 2024, befotertinib, or D-0316, was approved in 2023 through Betta Pharmaceuticals for EGFR-mutant non-small-cell lung cancer, and earlier programmes covered gout and oestrogen receptor degraders. OnCo links it to garsorasib and to Betta Pharmaceuticals. Whether a second domestic KRAS G12C inhibitor can differentiate from the other in the same market is the open question. Garsorasib has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.inventisbio.com/"}],"tags":["china"],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["garsorasib","in10018","d-0502"],"companies":["betta"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04585035","nct06166836","nct05379946"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.inventisbio.com/","ticker":"688382.SS","founded":2013,"investors":[],"funding":[]},{"id":"invocata","kind":"company","name":"Invocata","aka":[],"tldr":"Invocata is building personalised T-cell receptor therapies, choosing the right TCR for the individual patient at the right time; its site says only that it is coming soon.","summary":"Invocata describes personalised oncology platforms designed for the individual, moving cancer care towards an N of 1, with T-cell receptor (TCR) therapy as its route: engineering a patient's T cells to carry a receptor that recognises their own tumour. The public site is a placeholder. It is an Even One Ventures portfolio company.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://invocata.bio/"},{"label":"Even One Ventures portfolio","url":"https://evenone.ventures/"}],"tags":["startup","evenone-portfolio","oncology"],"related":[],"cancers":[],"sections":[],"technologies":["tcr-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"United States (head office not published)","country":"US","companyType":"cell-therapy","website":"https://invocata.bio/","stage":"startup","investors":["evenone-ventures"],"funding":[]},{"id":"invoke-bio","kind":"company","name":"Invoke Bio","aka":[],"tldr":"Invoke Bio designs personalised neoantigen vaccines in whatever form suits the patient, peptide, DNA or mRNA, using a prediction engine it says picks tumour targets with three times the accuracy of industry baselines.","summary":"Invoke Bio's immunogenicity prediction engine identifies tumour neoantigens for personalised vaccines and is modality-agnostic, supporting peptide, DNA and mRNA formats. Future of Cancer Care Today lists it as patient-orderable.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://invoke.bio/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["neoantigen-mrna-vaccine"],"targets":[],"drugs":[],"companies":["future-of-cancer-care-today"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"United States (city not published)","country":"US","companyType":"biotech","website":"https://invoke.bio/","stage":"startup","investors":[],"funding":[]},{"id":"inxmed","kind":"company","name":"InxMed","aka":["InxMed (Shanghai) Co., Ltd.","应世生物","InxMed (Shanghai)","inxmed-shanghai"],"tldr":"InxMed is a Shanghai biotechnology company developing IN10018 (ifebemtinib), a focal adhesion kinase inhibitor, which is in a phase 3 trial with the KRAS G12C inhibitor garsorasib against standard therapy in KRAS G12C-mutant lung cancer.","summary":"InxMed, based in Shanghai, develops drugs against the tumour microenvironment and drug resistance. Its lead candidate IN10018 (ifebemtinib) inhibits focal adhesion kinase (FAK), a signal that helps tumours resist KRAS inhibitors and chemotherapy, and is being tested in a phase 3 trial combined with the KRAS G12C inhibitor D-1553 (garsorasib) against standard therapy in non-small-cell lung cancer, as well as in platinum-resistant ovarian cancer. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.inxmed.com/"},{"label":"ClinicalTrials.gov: trials led by InxMed","url":"https://clinicaltrials.gov/search?lead=InxMed"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","ovarian","pancreatic","sclc"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["in10018"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07174908","nct05994131","nct05827796","nct06014528","nct06030258","nct05551507"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.inxmed.com/","stage":"growth","investors":[],"funding":[]},{"id":"io-biotech","kind":"company","name":"IO Biotech","aka":[],"tldr":"IO Biotech makes an off-the-shelf cancer vaccine that trains T cells to attack both tumour cells and the immune-suppressing cells around them. Its large melanoma trial narrowly missed its main goal in 2025 and the company is now reviewing its options.","summary":"IO Biotech (Nasdaq: IOBT), headquartered in Copenhagen with a US office in New York, develops immune-modulatory cancer vaccines on its T-win platform. Lead candidate Cylembio (IO102-IO103) stimulates T cells against indoleamine 2,3-dioxygenase 1 (IDO1) positive and PD-L1 positive cells, aiming to kill both tumour cells and immune-suppressive cells in the tumour microenvironment. In the phase 3 IOB-013 trial in first-line advanced melanoma, Cylembio plus pembrolizumab gave median progression-free survival of 19.4 months versus 11.0 months for pembrolizumab alone (hazard ratio 0.77, 95 percent CI 0.58 to 1.00, p=0.0558), narrowly missing the prespecified significance threshold of p≤0.045 (ESMO, October 2025). Five-year outcomes from the phase 1/2 trial were published in Nature Communications in December 2025. In January 2026 the company engaged Raymond James to explore strategic alternatives and announced a workforce reduction to preserve cash.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.iobiotech.com"},{"label":"Phase 3 results for Cylembio plus pembrolizumab (ESMO 2025)","url":"https://www.globenewswire.com/news-release/2025/10/20/3169094/0/en/io-biotech-presents-phase-3-results-for-cylembio-plus-keytruda-pembrolizumab-in-first-line-advanced-melanoma-at-esmo-2025.html"},{"label":"Corporate update and strategic alternatives (January 2026)","url":"https://www.globenewswire.com/news-release/2026/01/30/3229500/0/en/io-biotech-provides-corporate-update.html"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":["immunotherapy"],"technologies":["shared-antigen-vaccine"],"targets":["pdl1"],"drugs":["io102-io103"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05280314"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No financing round could be sourced from fetched pages. Outcome of the strategic review after January 2026 not verified. Founding year not sourced."],"hq":"Copenhagen","country":"DK","companyType":"biotech","website":"https://www.iobiotech.com","ticker":"IOBT","stage":"public","investors":[],"funding":[]},{"id":"ionctura","kind":"company","name":"iOnctura","aka":[],"tldr":"iOnctura is a Switzerland-based biotechnology company running 2 late-stage cancer trials of roginolisib in non-small-cell lung cancer, uveal melanoma and melanoma.","summary":"iOnctura, based in Geneva, Switzerland, is a biotechnology company. iOnctura is a biotech company developing precision oral small-molecule drugs that target the tumour-stroma-immune interface in neglected and hard-to-treat cancers. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing roginolisib in non-small-cell lung cancer, uveal melanoma and melanoma. The largest, NCT06717126 (A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma), plans to enrol 85 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.ionctura.com"},{"label":"ClinicalTrials.gov: trials led by iOnctura","url":"https://clinicaltrials.gov/search?lead=iOnctura"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","uveal-melanoma","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06717126"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Geneva","country":"CH","companyType":"biotech","website":"https://www.ionctura.com","founded":2017,"stage":"growth","investors":[],"funding":[]},{"id":"ionis","kind":"company","name":"Ionis Pharmaceuticals","aka":["Ionis Pharmaceuticals, Inc.","Isis Pharmaceuticals"],"tldr":"Ionis is the Carlsbad company that made antisense oligonucleotides into medicines; its cancer programmes, including the clusterin antisense custirsen developed with OncoGenex and the STAT3 antisense danvatirsen, reached late trials without approval.","summary":"Ionis Pharmaceuticals, founded in 1989 as Isis Pharmaceuticals and based in Carlsbad, California, pioneered antisense oligonucleotide drugs, with approvals in spinal muscular atrophy, transthyretin amyloidosis and other rare diseases through partners. In oncology it co-developed custirsen (OGX-011), whose phase 3 trials failed, and tested the STAT3 antisense danvatirsen with checkpoint inhibitors through AstraZeneca. ClinicalTrials.gov lists Ionis as lead sponsor of a phase 3 cancer trial.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Ionis_Pharmaceuticals","links":[{"label":"Official website","url":"https://www.ionispharma.com"},{"label":"ClinicalTrials.gov: trials led by Ionis Pharmaceuticals, Inc.","url":"https://clinicaltrials.gov/search?lead=Ionis%20Pharmaceuticals%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q22079531"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate","nsclc"],"sections":[],"technologies":["antisense-sirna"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Carlsbad, CA","country":"US","companyType":"biotech","website":"https://www.ionispharma.com","founded":1989,"stage":"public","investors":[],"funding":[]},{"id":"iovance","kind":"company","name":"Iovance Biotherapeutics","aka":[],"tldr":"Iovance Biotherapeutics, of San Carlos, California, makes Amtagvi (lifileucel), the first approved tumour-infiltrating lymphocyte therapy, a treatment grown from a patient's own tumour-resident immune cells and approved in melanoma. Making it fast and cheap enough to reach most eligible patients is its open question.","summary":"Iovance Biotherapeutics, based in San Carlos, California, and listed as IOVA, makes Amtagvi, or lifileucel, the first approved tumour-infiltrating lymphocyte therapy. Lifileucel was approved in melanoma on the C-144-01 trial and in the European Union in 2025, TILVANCE-301 tests it in the first line, trials are running in lung and cervical cancer, and IOV-4001 is a next-generation PD-1-inactivated TIL product. OnCo links it to melanoma, to the TIL therapy technology, to the bottleneck of manufacturing cost and time for living medicines, and to ideas on selecting patients by whether their tumour holds reactive T cells. Whether TIL therapy can be made fast and cheap enough to reach most eligible patients is the open question. Lifileucel has its own page.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Iovance_Biotherapeutics","links":[{"label":"Official website","url":"https://www.iovance.com"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":[],"targets":[],"drugs":["lifileucel","aldesleukin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05727904","nct07288203","nct06481592","nct06940739","nct04614103","nct05361174"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Carlos, CA","country":"US","companyType":"cell-therapy","website":"https://www.iovance.com","ticker":"IOVA","investors":[],"funding":[]},{"id":"ipsen","kind":"company","name":"Ipsen","aka":[],"tldr":"Ipsen is the French pharma behind Onivyde (liposomal irinotecan) and the NALIRIFOX regimen, and marketer of tovorafenib in Europe.","summary":"Ipsen is the Paris-based pharmaceutical company, listed as IPN.PA, behind Onivyde, the liposomal irinotecan at the heart of the NALIRIFOX regimen for pancreatic cancer, and the European marketer of tovorafenib for paediatric low-grade glioma under rights from Day One. Its oncology portfolio also includes Cabometyx outside the United States, tazemetostat for epithelioid sarcoma and somatostatin analogues for neuroendocrine tumours, with NAPOLI 3 establishing NALIRIFOX and CLARINET supporting lanreotide. OnCo links it to pancreatic ductal adenocarcinoma, glioma, neuroendocrine tumours and epithelioid sarcoma, and to the cabozantinib, irinotecan, tazemetostat and tovorafenib records. Whether NALIRIFOX becomes the default first-line regimen on value as well as efficacy is the open question. Each product has its own page.","asOf":"2026-09-06","wikipedia":"https://en.wikipedia.org/wiki/Ipsen","links":[{"label":"Official website","url":"https://www.ipsen.com"}],"tags":[],"related":[],"cancers":["pancreatic","glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["nalirifox","tovorafenib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04224493","nct07213830","nct07213817","nct06833008","nct06305247","nct04243499"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Paris","country":"FR","companyType":"pharma","website":"https://www.ipsen.com","ticker":"IPN.PA","investors":[],"funding":[]},{"id":"iqvia","kind":"company","name":"IQVIA","aka":[],"tldr":"IQVIA is the largest CRO and health-data company, running a large share of global oncology trials and selling prescription and claims data.","summary":"IQVIA, based in Durham, North Carolina, and listed as IQV, is the largest contract research organisation and health data company, running a large share of global oncology trials and selling prescription and claims data. It was formed from Quintiles and IMS Health, runs the Orchestrated Clinical Trials platform, and counts oncology as its largest therapeutic area. OnCo links it to contract research organisations, clinical trial software and oncology real-world data platforms. Whether a company that both runs trials and sells the data around them keeps the two businesses properly separate is the fair question. The CRO technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.iqvia.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["contract-research-organisations","clinical-trial-software","oncology-real-world-data"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06549946","nct02734004"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Durham, NC","country":"US","companyType":"cro-services","website":"https://www.iqvia.com","ticker":"IQV","investors":[],"funding":[]},{"id":"ire","kind":"company","name":"IRE (Institut national des Radioéléments)","aka":["IRE ELiT"],"tldr":"IRE in Belgium is one of the world's few molybdenum-99 processors, taking irradiated targets from European research reactors, and its IRE ELiT arm makes the Galli Eo gallium-68 generator.","summary":"The Institut national des Radioéléments at Fleurus processes uranium targets irradiated in BR2, the Petten High Flux Reactor, MARIA and LVR-15 into molybdenum-99 and iodine-131 for generator and radiopharmaceutical makers. Its subsidiary IRE ELiT produces the Galli Eo germanium-68/gallium-68 generator used for PSMA and somatostatin PET and non-carrier-added lutetium-177. It is a Belgian public-interest foundation rather than a listed company.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.ire.eu"}],"tags":["manufacturing-wave"],"related":[],"cancers":[],"sections":[],"technologies":["research-reactor-isotope-production","cyclotron-isotope-production","radionuclide-generators-kits","therapy-isotope-supply-chain"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Fleurus","country":"BE","companyType":"radiopharma","website":"https://www.ire.eu","founded":1971,"stage":"private-large","investors":[],"funding":[]},{"id":"isabl","kind":"company","name":"Isabl","aka":[],"tldr":"Isabl reads a tumour's whole genome and transcriptome instead of a small gene panel, and its software turns that into a report clinicians can use.","summary":"Isabl, a Memorial Sloan Kettering spin-out, provides software and a CLIA laboratory for clinical whole-genome and whole-transcriptome sequencing of tumours, analysing the full range of mutations, structural variants, signatures and expression rather than a targeted panel, with applications in treatment planning, disease surveillance and biomarker discovery. It states it is the first to receive New York State approval for a whole-genome and transcriptome cancer test. Evidence of clinical utility beyond analytical validation is still accumulating.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/isabl"},{"label":"Official website","url":"https://isabl.io"}],"tags":["yc"],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["wes-wgs","rna-seq","mrd-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"New York, NY","country":"US","companyType":"diagnostics","website":"https://isabl.io","stage":"startup","ycBatch":"W20","investors":["y-combinator"],"funding":[]},{"id":"isarna-therapeutics","kind":"company","name":"Isarna Therapeutics","aka":["Isarna Therapeutics GmbH","Antisense Pharma"],"tldr":"Isarna, formerly Antisense Pharma, is a Munich company whose TGF-beta2 antisense drug trabedersen was tested directly into brain tumours in phase 3 for high-grade glioma before the programme moved to eye disease.","summary":"Isarna Therapeutics, founded in Regensburg in 1998 as Antisense Pharma and now based in Munich, develops antisense oligonucleotides against transforming growth factor beta 2. Trabedersen (AP 12009), infused into the tumour, reached the phase 3 SAPPHIRE trial in anaplastic astrocytoma, which was stopped early, and the company has since focused on ophthalmology. Its trials remain on ClinicalTrials.gov under the company as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.isarna-therapeutics.com"},{"label":"ClinicalTrials.gov: trials led by Isarna Therapeutics GmbH","url":"https://clinicaltrials.gov/search?lead=Isarna%20Therapeutics%20GmbH"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q50038820"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["glioblastoma","pancreatic"],"sections":[],"technologies":["antisense-sirna"],"targets":["tgf-beta"],"drugs":["trabedersen"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Munich","country":"DE","companyType":"biotech","website":"http://www.isarna-therapeutics.com","founded":1998,"stage":"private-large","investors":[],"funding":[]},{"id":"isomorphic-labs","kind":"company","name":"Isomorphic Labs","aka":[],"tldr":"Alphabet's AlphaFold-derived drug design company; its first AI-designed oncology candidate was cleared for human trials in January 2026 after a $2.1B raise.","summary":"Isomorphic Labs, based in London, is Alphabet's AlphaFold-derived drug design company, whose first AI-designed oncology candidate was cleared for human trials in January 2026 after a raise of about 2.1 billion dollars. It co-developed AlphaFold 3 with Google DeepMind, built the IsoDDE design engine, and had ISM8969 cleared by the FDA for a first-in-human study on 28 January 2026, with an initial pipeline in oncology and immunology and partnerships with Eli Lilly and Novartis. OnCo links it to AI-driven drug and target discovery, AlphaFold 3 and de novo designed protein binders, and to the idea of AI-designed proteins that grip the floppy parts of cancer drivers. The valley of death between lab and product is the bottleneck its first trial now enters. Whether structure prediction shortens development or only the discovery step is the open question.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Isomorphic_Labs","links":[{"label":"Trials of AI-designed drugs","url":"https://www.clinicaltrialsarena.com/news/isomorphic-labs-prepares-trials-ai-designed-drugs/"}],"tags":["frontier"],"related":[],"cancers":[],"sections":["ai-computation","drug-discovery"],"technologies":["ai-drug-design"],"targets":[],"drugs":[],"companies":["eli-lilly","novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"London","country":"GB","companyType":"ai-software","website":"https://www.isomorphiclabs.com","investors":[],"funding":[]},{"id":"isono-health","kind":"company","name":"iSono Health","aka":[],"tldr":"iSono Health makes a wearable ultrasound scanner that images the whole breast automatically in about two minutes, with software to flag suspicious masses, for use outside specialist imaging centres.","summary":"iSono Health's ATUSA system is a compact, automated three-dimensional breast ultrasound scanner worn like a bra that captures whole-breast volumes without an operator, connects to a tablet, and uploads images to the cloud where machine-learning software helps identify masses. It is aimed at point-of-care and mobile settings and at women with dense breast tissue for whom mammography is less sensitive. ATUSA has FDA 510(k) clearance for breast imaging; the AI decision-support component and evidence for screening outcomes are at an earlier stage.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/isono-health"},{"label":"Official website","url":"https://www.isonohealth.com"}],"tags":["yc"],"related":[],"cancers":["tnbc","breast-hr-positive","breast-her2-positive"],"sections":["imaging","early-detection"],"technologies":["ultrasound","radiology-ai-screening"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"devices","website":"https://www.isonohealth.com","stage":"startup","ycBatch":"W16","investors":["y-combinator"],"funding":[]},{"id":"isotopia","kind":"company","name":"Isotopia Molecular Imaging","aka":[],"tldr":"Isotopia is an Israeli producer of non-carrier-added lutetium-177 and PET tracers that supplies several radioligand developers.","summary":"Isotopia Molecular Imaging produces non-carrier-added lutetium-177 by separating it from irradiated ytterbium-176, and manufactures PET radiopharmaceuticals for Israeli hospitals. It has supply agreements with a number of companies developing lutetium-based radioligands and is one of the independent lutetium sources that grew as demand rose after lutetium-177 vipivotide tetraxetan was approved.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.isotopia.co.il"}],"tags":["manufacturing-wave"],"related":[],"cancers":[],"sections":[],"technologies":["research-reactor-isotope-production","therapy-isotope-supply-chain","pet-tracer-manufacturing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Petah Tikva","country":"IL","companyType":"radiopharma","website":"https://www.isotopia.co.il","stage":"growth","investors":[],"funding":[]},{"id":"italfarmaco","kind":"company","name":"Italfarmaco","aka":[],"tldr":"Italfarmaco is a Italy-based pharmaceutical company running 2 late-stage cancer trials of givinostat and Givinostat in myeloproliferative neoplasms.","summary":"Italfarmaco, based in Milan, Italy, is a pharmaceutical company. Italfarmaco is a pharmaceutical group that researches, develops and manufactures medicines, with a particular focus on rare diseases. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing givinostat and Givinostat in myeloproliferative neoplasms. The largest, NCT06093672 (Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera), plans to enrol 220 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.italfarmaco.com"},{"label":"ClinicalTrials.gov: trials led by Italfarmaco","url":"https://clinicaltrials.gov/search?lead=Italfarmaco"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":["givinostat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct01761968"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Milan","country":"IT","companyType":"pharma","website":"https://www.italfarmaco.com","founded":1938,"stage":"private-large","investors":[],"funding":[]},{"id":"italian-sarcoma-group","kind":"company","name":"Italian Sarcoma Group","aka":["ISG"],"tldr":"The Italian Sarcoma Group is the Italian non-profit collaborative group for soft tissue, GIST and bone sarcoma research, constituted in June 1997; in OnCo it leads ISG-STS 1001, the histology-tailored neoadjuvant chemotherapy trial.","summary":"The Italian Sarcoma Group (ISG) is a non-profit association recognised by the Italian Ministry of Health, constituted in June 1997 as an Italian collaborative group to improve research and care for patients of all ages with soft tissue sarcoma, gastrointestinal stromal tumours and bone sarcoma; its legal seat is in Bologna (Via Farini 31) and its operational office at the Istituto Nazionale dei Tumori in Milan (italiansarcomagroup.org). ClinicalTrials.gov names it lead sponsor (NETWORK class, with the French Sarcoma Group and the Spanish sarcoma group as collaborators) of ISG-STS 1001 (NCT01710176, phase 3, histology-tailored against standard anthracycline-ifosfamide neoadjuvant chemotherapy in high-risk soft tissue sarcoma), the trial recorded in OnCo. It has no products of its own.","asOf":"2026-09-25","links":[{"label":"Official website","url":"https://www.italiansarcomagroup.org"},{"label":"ClinicalTrials.gov: trials led by Italian Sarcoma Group","url":"https://clinicaltrials.gov/search?lead=Italian%20Sarcoma%20Group"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["sarcoma","extremity-soft-tissue-sarcoma","undifferentiated-pleomorphic-sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["int-milan"],"pathways":[],"terms":[],"trials":["isg-sts-1001"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"Bologna","country":"IT","companyType":"cooperative-group","website":"https://www.italiansarcomagroup.org","founded":1997,"investors":[],"funding":[]},{"id":"itm","kind":"company","name":"ITM Isotope Technologies Munich","aka":["ITM Solucin GmbH"],"tldr":"ITM is the largest non-carrier-added lutetium-177 supplier and the developer of ITM-11 (177Lu-edotreotide).","summary":"ITM Isotope Technologies Munich is the largest supplier of non-carrier-added lutetium-177, sold as EndolucinBeta, and the developer of ITM-11, or 177Lu-edotreotide. ITM-11 was positive in the COMPETE phase 3 trial in gastroenteropancreatic neuroendocrine tumours in 2025, and the company is investing in actinium-225 supply. OnCo links it to neuroendocrine tumours, to somatostatin receptor 2 as a target, to peptide receptor radionuclide therapy and the therapeutic isotope supply chain, to the radiopharmaceutical roadmap, and to the idea of building Western ytterbium-176 enrichment so lutetium-177 has more than one supplier. Manufacturing cost and time for radioactive medicines is the bottleneck it sits inside. Whether a supplier can also succeed as a drug developer is the open question.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://itm-radiopharma.com"}],"tags":[],"related":[],"cancers":[],"sections":["radiopharma"],"technologies":[],"targets":["sstr2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04919226"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Munich","country":"DE","companyType":"radiopharma","website":"https://itm-radiopharma.com","investors":[],"funding":[]},{"id":"jacobio-pharmaceuticals","kind":"company","name":"Jacobio Pharmaceuticals","aka":["Jacobio Pharmaceuticals Co., Ltd."],"tldr":"Jacobio Pharmaceuticals is a Chinese developer in Beijing that sponsors 6 registered cancer trials of JAB-30355 and JAB-2485.","summary":"Jacobio Pharmaceuticals appears on ClinicalTrials.gov as the industry sponsor of 6 interventional cancer trials (phase 1/2), testing JAB-30355, JAB-2485, JAB-23E73, JAB-8263 in solid tumors, er+ breast cancer, triple negative breast cancer, tnbc, arid1a gene mutation. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials sponsored by Jacobio Pharmaceuticals","url":"https://clinicaltrials.gov/search?spons=Jacobio%20Pharmaceuticals"}],"tags":["ctgov-sponsor","china","registry-only"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["glecirasib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06386146","nct05490472","nct06973564","nct04686682","nct06959615","nct07640295"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Beijing, China","country":"CN","companyType":"biotech","website":"https://www.jacobiopharma.com","investors":[],"funding":[]},{"id":"jaime-leandro-foundation","kind":"company","name":"Jaime Leandro Foundation","aka":["Jaime Leandro Foundation for Therapeutic Cancer Vaccines","JLF"],"tldr":"The Jaime Leandro Foundation organises personalised peptide cancer vaccines for patients through the FDA's expanded access route when no trial is available.","summary":"The Jaime Leandro Foundation for Therapeutic Cancer Vaccines is a 501(c)(3) nonprofit that arranges personalised peptide vaccines for individual patients under FDA expanded access (compassionate use) when no suitable trial exists. Future of Cancer Care Today lists it as patient-orderable.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://jaimeleandrofoundation.org/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["neoantigen-mrna-vaccine"],"targets":[],"drugs":[],"companies":["future-of-cancer-care-today"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"United States (city not published)","country":"US","companyType":"nonprofit","website":"https://jaimeleandrofoundation.org/","investors":[],"funding":[]},{"id":"janux-therapeutics","kind":"company","name":"Janux Therapeutics","aka":[],"tldr":"Janux makes 'masked' T-cell engager antibodies that stay inactive in the bloodstream and switch on only inside tumours, aiming to cut the side effects that limit this drug class. Its lead programmes target PSMA in advanced prostate cancer.","summary":"Janux Therapeutics develops tumour-activated T-cell engagers using its TRACTr (T cell engager) and TRACIr (co-stimulatory) platforms, plus the ARM platform for autoimmune disease. JANX007 is a PSMA-TRACTr in a phase 1b trial in metastatic castration-resistant prostate cancer, with dose optimisation in taxane-naive patients and an expansion cohort combining it with darolutamide. JANX014, a double-masked PSMA-TRACTr, is in phase 1 in the same setting, and JANX013, a PSMA-targeted CD28 co-stimulatory TRACIr, is expected to enter the clinic in the second half of 2026. JANX011 (CD19-ARM) is in a phase 1 healthy volunteer study for autoimmune disease. Janux listed on Nasdaq in June 2021, raising about $223 million, and reported $970.9 million in cash and short-term investments at 30 June 2026.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.januxrx.com/"},{"label":"Q2 2026 results (8-K exhibit 99.1)","url":"https://www.sec.gov/Archives/edgar/data/1817713/000119312526337977/janx-ex99_1.htm"},{"label":"IPO closing release (8-K, June 2021)","url":"https://www.sec.gov/Archives/edgar/data/1817713/000119312521191155/d177137dex991.htm"}],"tags":[],"related":[],"cancers":["prostate"],"sections":["immunotherapy"],"technologies":["t-cell-engager","bispecific-antibody"],"targets":["psma","cd3","cd19"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://www.januxrx.com/","ticker":"JANX","stage":"public","investors":[],"funding":[{"round":"IPO","year":2021,"amountUsd":222900000,"source":"https://www.sec.gov/Archives/edgar/data/1817713/000119312521191155/d177137dex991.htm","note":"Shares priced at $17.00 including full option exercise; Nasdaq JANX from 11 June 2021"}]},{"id":"jcog","kind":"company","name":"Japan Clinical Oncology Group (JCOG)","aka":["Japan Clinical Oncology Group","JCOG"],"tldr":"JCOG is Japan's national cooperative group and defines surgical and perioperative standards in gastric and oesophageal cancer.","summary":"The Japan Clinical Oncology Group, established in 1990 and based at the National Cancer Center in Tokyo, is Japan's national cooperative group and defines surgical and perioperative standards in gastric and oesophageal cancer. JCOG9501 compared D2 gastrectomy with and without para-aortic dissection, JCOG1109 tested neoadjuvant docetaxel, cisplatin and fluorouracil in oesophageal cancer, and its lung and colorectal surgical trials set standards across Japan, with Haruhiko Fukuda and Yuko Kitagawa among the people linked. OnCo connects it to gastric, oesophageal and non-small-cell lung cancer, to the Japanese oncology guidelines collection, and to member hospitals including Aichi Cancer Center and Kyoto, Keio and Kyushu university hospitals. Surgery and radiotherapy getting the least trial money is the bottleneck it works against. Its surgical and perioperative programmes are listed in the notes.","asOf":"2026-09-06","links":[{"label":"Official website","url":"https://jcog.jp"}],"tags":["cooperative-group"],"related":[],"cancers":["gastric","esophageal","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ncc-japan"],"pathways":[],"terms":[],"trials":["jcog0403"],"people":["fukuda-haruhiko","kitagawa-yuko"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Gastric cancer surgery trials","Oesophageal cancer perioperative therapy"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Tokyo","country":"JP","companyType":"cooperative-group","website":"https://jcog.jp","founded":1990,"investors":[],"funding":[]},{"id":"jasper-health","kind":"company","name":"Jasper Health","aka":[],"tldr":"Jasper Health is an app and coaching service that helps people with cancer and their carers keep track of treatment, symptoms and appointments, with counsellors available for emotional support.","summary":"Jasper Health provides a digital cancer navigation platform combining a patient and caregiver app (treatment and symptom tracking, care coordination, resource finding) with expert led psychosocial counselling. It sells to health plans and providers and positions itself as a way to reduce administrative burden on care teams while covering the journey from suspected cancer through survivorship or end of life care. In September 2025 the company appointed Deirdre Saulet as Chief Strategy Officer; that release gives Boise, Idaho as the company location. No funding round, investor or evidence claim could be sourced from a primary document during this research. The company website could not be fetched (HTTP 403, Cloudflare error 1014, on every attempt), so product details above are taken from the company boilerplate in its PR Newswire release.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.hellojasper.com"},{"label":"Chief Strategy Officer appointment press release (September 2025)","url":"https://www.prnewswire.com/news-releases/deirdre-saulet-phd-joins-jasper-health-as-chief-strategy-officer-302558101.html"}],"tags":[],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Website www.hellojasper.com returned HTTP 403 (Cloudflare error 1014) to every fetch attempt, so the website URL itself was NOT successfully fetched; jasperhealth.com is an unrelated parked domain. HQ given as Boise, ID in the September 2025 PR Newswire release, not San Francisco as hinted. No funding rounds sourced. Stage set to startup by default."],"hq":"Boise, ID","country":"US","companyType":"ai-software","website":"https://www.hellojasper.com","stage":"startup","investors":[],"funding":[]},{"id":"jazz","kind":"company","name":"Jazz Pharmaceuticals","aka":[],"tldr":"Jazz Pharmaceuticals, based in Dublin, sells zanidatamab (Ziihera), a HER2-targeting antibody, outside Asia for biliary tract and gastro-oesophageal cancer, alongside Rylaze, Zepzelca (lurbinectedin) and CPX-351 for acute myeloid leukaemia. Whether zanidatamab can grow from a rare bile duct indication into gastric cancer is its open question.","summary":"Jazz Pharmaceuticals, based in Dublin and listed as JAZZ, commercialises zanidatamab, sold as Ziihera, outside Asia, in biliary tract and gastro-oesophageal cancer. Its oncology portfolio also includes Rylaze asparaginase and Zepzelca, or lurbinectedin, partnered with PharmaMar, along with CPX-351 for acute myeloid leukaemia, defibrotide and dordaviprone. OnCo links it to biliary tract, gallbladder and gastric cancer, acute myeloid leukaemia and Ewing sarcoma, and to Zai Lab as a partner. Whether zanidatamab can expand from a rare HER2-positive bile duct indication into gastric cancer at scale is the open question. Zanidatamab has its own page.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Jazz_Pharmaceuticals","links":[{"label":"Official website","url":"https://www.jazzpharma.com"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["zanidatamab","crisantaspase"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06435429","nct05734066","nct07102381","nct07459634","nct06695845","nct07282587"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Dublin","country":"IE","companyType":"biotech","website":"https://www.jazzpharma.com","ticker":"JAZZ","investors":[],"funding":[]},{"id":"jeito-capital","kind":"company","name":"Jeito Capital","aka":[],"tldr":"Jeito Capital is a Paris fund that writes large cheques for European biotech companies so they can take drugs through late-stage trials without selling early. Cancer medicines are a recurring theme.","summary":"Jeito Capital is a Paris-based growth-stage life-science investor founded in 2018 by Rafaele Tordjman, with a stated focus on patient benefit and on giving European biopharma companies the capital to run pivotal programmes and build commercial capabilities in Europe rather than out-licensing early. It participates in and leads large Series B and C rounds, several of them in oncology; the portfolio links in OnCo are derived from the startup records that name it.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.jeito.life"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Paris","country":"FR","companyType":"investor","website":"https://www.jeito.life","founded":2018,"investors":[],"funding":[]},{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","aka":["Hengrui","Jiangsu Hengrui","Hengrui Pharma","jiangsu-hengrui"],"tldr":"Jiangsu Hengrui is China's largest oncology pharma, maker of pyrotinib and the HER2 ADC trastuzumab rezetecan, and one of the biggest out-licensers of Chinese assets.","summary":"Jiangsu Hengrui Pharmaceuticals, based in Lianyungang and listed in Shanghai as 600276.SS, is China's largest oncology pharmaceutical company, the maker of pyrotinib and the HER2 antibody-drug conjugate trastuzumab rezetecan, and one of the biggest out-licensers of Chinese assets. Its portfolio spans camrelizumab, pyrotinib, dalpiciclib and the ADC platform behind trastuzumab rezetecan, known as SHR-A1811, which was approved in China in 2025 for HER2-mutant non-small-cell lung cancer, and its trials in OnCo include CameL, CAPSTONE-1, DAWNA-1 and CARES-310. Since 2023 it has licensed programmes to Merck KGaA, IDEAYA and GSK, listed in Hong Kong in 2025 and received three FDA complete response letters for camrelizumab plus rivoceranib. Camrelizumab is approved in China across hepatocellular carcinoma, non-small-cell lung cancer, oesophageal cancer and nasopharyngeal carcinoma, and its combination with rivoceranib, developed with Elevar and HLB, has been refused by the FDA on manufacturing grounds. Regulatory divergence between regions is the bottleneck its Western filings keep meeting. Piaoyang Sun is the person linked.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://www.hengrui.com"}],"tags":["china"],"related":[],"cancers":["breast-her2-positive","nsclc","hcc","sclc","breast-hr-positive","esophageal"],"sections":["adcs","targeted-therapy","immunotherapy"],"technologies":[],"targets":[],"drugs":["trastuzumab-rezetecan","pyrotinib","camrelizumab","camrelizumab-rivoceranib","rivoceranib","dalpiciclib","adebrelimab","shr-8068","shr-a2102","hs-20093","hrs-8080","shr-a1921","shr-1501","shr-a2009","shr-a1912","hr070803","hrs-4357","mecapegfilgrastim","rezvilutamide","retlirafusp-alfa"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["camel","capstone-1","dawna-1","cares-310","nct06199973","nct06828354","nct04639180","nct04842617","nct05320692","nct07183189","nct07168200","nct06430437","nct07170995","nct07454720","nct07196774","nct04691804","nct04316364","nct07676162","nct06589778","nct07059221","nct06512051","nct07230106","nct06689163","nct07071714","nct07239596","nct06568094","nct07229729","nct07175220","nct06754930","nct07051486","nct06840002","nct06859775","nct07407283","nct07589569","nct07070349","nct06222879","nct05300269","nct06015048","nct07232849","nct06465563","nct07497386","nct06474455","nct05814354","nct06679036","nct07229586","nct06643754","nct07102901","nct05765032","nct06057610","nct06247956","nct07446153","nct06764628","nct07489716","nct06555068","nct06895928","nct07229612","nct07111832","nct06778031","nct05482568","nct07268040","nct07028268","nct06639347","nct07110571","nct06385678","nct06737731","nct07136142","nct06126640","nct07389733","nct06520488","nct07232875","nct06605222","nct06735144","nct06922357","nct07229638","nct07679360","nct06915142","nct07298772","nct07028281","nct07032077","nct07003321","nct07393542","nct06417554","nct06413745","nct05884255","nct07238283","nct07522151","nct07241767","nct04906993","nct06879145","nct07140393","nct06474468","nct05864014","nct05277168","nct06703177","nct06123494","nct07231211","nct06654440","nct05671822","nct07450976","nct04342910","nct03980054","nct06974929","nct07296341","nct06925581","nct07073534","nct06167694"],"people":["sun-piaoyang"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Out-licensing since 2023: HRS-1167 (PARP1) and SHR-A1904 (Claudin 18.2 ADC) to Merck KGaA (October 2023), SHR-4849 (DLL3 ADC) to IDEAYA (December 2024) and a twelve-programme agreement with GSK (July 2025, $500m upfront); Hong Kong listing 2025; three FDA complete response letters for camrelizumab plus rivoceranib. See the deals map and /countries/cn/."],"hq":"Lianyungang","country":"CN","companyType":"pharma","website":"https://www.hengrui.com","ticker":"600276.SS","investors":[],"funding":[]},{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","aka":["Alza Corporation","Janssen","Ortho Biotech Products, L.P.","Ortho Biotech","Sequus Pharmaceuticals","Centocor, Inc.","Centocor","Alza Corporation, DE, USA","Cougar Biotechnology, Inc.","Cougar Biotechnology","McNeil Consumer & Specialty Pharmaceuticals","McNeil"],"tldr":"Johnson & Johnson leads in multiple myeloma (Darzalex, Carvykti, Tecvayli, Talvey) and in bispecific antibodies for lung cancer (Rybrevant).","summary":"Johnson & Johnson, based in New Brunswick, New Jersey, and listed as JNJ, leads in multiple myeloma with Darzalex, Carvykti, Tecvayli and Talvey and in bispecific antibodies for lung cancer with Rybrevant. Its oncology portfolio spans daratumumab, teclistamab, talquetamab, ciltacabtagene autoleucel developed with Legend, amivantamab with lazertinib, abiraterone and apalutamide in prostate cancer, TAR-200 intravesical gemcitabine for bladder cancer approved in 2025, and pasritamig, a KLK2 by CD3 bispecific. OnCo links it to the CARTITUDE-1 and CARTITUDE-4, MAIA, CEPHEUS and MajesTEC-1 papers, to the LEGEND-2 trial, to robotic bronchoscopy, and to the Yale Open Data Access project. Whether CAR-T and bispecifics move into first-line myeloma and displace daratumumab combinations is the question its own portfolio poses. Teclistamab, cilta-cel and amivantamab have their own pages.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Johnson_%26_Johnson","links":[{"label":"Official website","url":"https://www.jnj.com"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy","cell-therapy","targeted-therapy"],"technologies":[],"targets":[],"drugs":["teclistamab","ciltacabtagene-autoleucel","amivantamab","cetrelimab","jnj-79635322","tar-210","jnj-87189401","jnj-90301900","bleximenib","jnj-90014496","cladribine"],"companies":["firefly-bio","halda-therapeutics","jjdc"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04557059","nct04325828","nct06667908","nct05438043","nct05572515","nct05884398","nct01804686","nct06208150","nct05388669","nct05552222","nct05455320","nct02489318","nct07266441","nct06550895","nct07589634","nct04133636","nct04586426","nct05421663","nct06577025","nct06500884","nct07149857","nct05379595","nct02908906","nct05498428","nct05663866","nct06667076","nct07276399","nct04538664","nct07586202","nct02257736","nct06319820","nct06211764","nct06120140","nct06662786","nct06385080","nct06750094","nct03431350","nct05908734","nct05488314","nct05316155","nct07225946","nct05963074","nct04023526","nct04497844","nct03767244","nct07227025","nct04988295","nct02531516","nct02365597","nct01946204","nct03473743","nct06800313"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"New Brunswick, NJ","country":"US","companyType":"pharma","website":"https://www.jnj.com","ticker":"JNJ","investors":[],"funding":[]},{"id":"jjdc","kind":"company","name":"Johnson & Johnson Innovation - JJDC","aka":[],"tldr":"Johnson & Johnson's venture capital arm, one of the oldest corporate venture groups in healthcare. It invests alongside J&J's innovation centres and JLABS incubators, including in cancer companies.","summary":"JJDC, Inc. (Johnson & Johnson Development Corporation) is the venture capital arm of Johnson & Johnson Innovation. The Wikipedia entry for Johnson & Johnson Innovation states that the unit 'provides startups with sourcing, infrastructure, and capital equipment at JLABS, financing & venture capital at JJDC, Inc., and collaborations leading to the potential development of medical device technologies, pharmaceuticals, and therapeutics'. JJDC invests across pharmaceuticals, medical devices and consumer health at all stages, typically as a strategic minority investor. Its own web pages (jnjinnovation.com and jnj.com/innovation/jjdc) are JavaScript applications that returned no readable content or a maintenance error, so founding year, headquarters and named oncology portfolio companies could not be confirmed from a primary source.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://jnjinnovation.com/venture-investing-jjdc"},{"label":"Official website","url":"https://jnjinnovation.com/"},{"label":"Wikipedia (Johnson & Johnson Innovation)","url":"https://en.wikipedia.org/wiki/Johnson_%26_Johnson_Innovation"}],"tags":["corporate-venture"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Page fetched on 2026-09-10; content is rendered client-side so no portfolio examples were read."],"hq":"New Brunswick, NJ","country":"US","companyType":"investor","website":"https://jnjinnovation.com/venture-investing-jjdc","investors":[],"funding":[]},{"id":"jubilant-radiopharma","kind":"company","name":"Jubilant Radiopharma","aka":[],"tldr":"Jubilant Radiopharma is a radiopharmacy network and the manufacturer of I-131 MIBG (AdreView), Ruby-Fill, and PET tracers.","summary":"Jubilant Radiopharma, based in Yardley, Pennsylvania, is a radiopharmacy network and the manufacturer of iodine-131 MIBG, sold as AdreView, Ruby-Fill and PET tracers. It is part of India's Jubilant Pharmova and combines US radiopharmacies with a radiopharmaceutical manufacturing business. OnCo links it to radiopharmacy and cyclotron networks and PET tracer manufacturing and distribution, and to Syngene International as a related company. Whether an Indian-owned network can expand from established diagnostic products into the therapeutic radioligand market is the open question. The radiopharmacy technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.jubilantradiopharma.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["radiopharma"],"technologies":["radiopharmacy-network","pet-tracer-manufacturing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Yardley, PA","country":"US","companyType":"radiopharma","website":"https://www.jubilantradiopharma.com","investors":[],"funding":[]},{"id":"jubilant-therapeutics","kind":"company","name":"Jubilant Therapeutics","aka":["Jubilant Therapeutics Inc."],"tldr":"Jubilant Therapeutics, part of India's Jubilant group, designs small molecules that hit two epigenetic targets at once; JBI-802 inhibits both LSD1 and HDAC6 for myeloproliferative neoplasms and small cell lung cancer.","summary":"Jubilant Therapeutics is a precision-medicine subsidiary of Jubilant Pharmova that uses structure-based design to make dual-action small molecules. JBI-802 is an oral inhibitor of the epigenetic enzymes LSD1 and HDAC6 in a single molecule, in phase 1/2 trials in essential thrombocythaemia, other myeloproliferative neoplasms and neuroendocrine cancers including small cell lung cancer. Its pipeline also includes a PAD4 inhibitor and PD-L1 small molecules.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.jubilanttx.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["jbi-802"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Bedminster, New Jersey","country":"US","companyType":"biotech","website":"https://www.jubilanttx.com/","investors":[],"funding":[]},{"id":"juventas-cell-therapy","kind":"company","name":"Juventas Cell Therapy","aka":["Hebei Senlang Biotechnology"],"tldr":"Juventas Cell Therapy in Tianjin developed inaticabtagene autoleucel, the first CAR-T approved in China for leukaemia (2023).","summary":"Juventas Cell Therapy was founded in Tianjin with the Chinese Academy of Medical Sciences Institute of Hematology. Its CD19 CAR-T inaticabtagene autoleucel (CNCT19) was approved by the NMPA in November 2023 for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia, and is also in trials for large B-cell lymphoma.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.juventascell.com"}],"tags":["ctgov-sponsor","china"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":["car-t"],"targets":[],"drugs":["inaticabtagene-autoleucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05667506","nct04684147","nct04586478"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tianjin, China","country":"CN","companyType":"cell-therapy","website":"https://www.juventascell.com","stage":"growth","investors":[],"funding":[]},{"id":"jw-pharmaceutical","kind":"company","name":"JW Pharmaceutical","aka":["JW Pharmaceutical Corporation","JW중외제약"],"tldr":"JW Pharmaceutical is a Seoul drug maker founded in 1945, known for intravenous fluids and nutrition, which sponsors phase 3 cancer trials among its hospital products.","summary":"JW Pharmaceutical, headquartered in Seoul and founded in 1945 as Chungwae, is a Korean pharmaceutical company strong in intravenous solutions, parenteral nutrition and hospital medicines, with a research arm developing targeted drugs. ClinicalTrials.gov lists JW as lead sponsor of a phase 3 trial in a cancer setting. Its own cancer candidate on the registry is CWP232291, a Wnt pathway inhibitor tested in phase 1 and phase 1/2 trials in acute myeloid leukaemia, myelodysplastic syndromes and multiple myeloma (NCT01398462, NCT03055286, NCT02426723).","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.jw-pharma.co.kr"},{"label":"ClinicalTrials.gov: trials led by JW Pharmaceutical Corporation","url":"https://clinicaltrials.gov/search?lead=JW%20Pharmaceutical%20Corporation"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q56583259"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml","multiple-myeloma"],"sections":["supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Seoul","country":"KR","companyType":"pharma","website":"http://www.jw-pharma.co.kr","founded":1945,"stage":"public","investors":[],"funding":[]},{"id":"jw-therapeutics","kind":"company","name":"JW Therapeutics","aka":["药明巨诺","JW (Cayman) Therapeutics"],"tldr":"JW Therapeutics, a Juno and WuXi AppTec joint venture, made relma-cel, the first CAR-T developed and manufactured in China to be approved.","summary":"Relmacabtagene autoleucel (Carteyva) approved 2021 for large B-cell lymphoma and 2022 for follicular lymphoma; pipeline in mantle cell lymphoma, leukaemia and autoimmune disease. Its commercial struggle (list price around CN¥ 1.29 million, not NRDL-listed, provincial supplementary insurance filling some of the gap) is the case study for how China pays for cell therapy.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.jwtherapeutics.com/en/"}],"tags":["china"],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["car-t"],"targets":[],"drugs":["relmacabtagene-autoleucel"],"companies":["wuxi-apptec","bms"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06093841","nct06479356","nct04718883"],"people":[],"bottlenecks":["b-drug-pricing","b-manufacturing-cell-therapy"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai","country":"CN","companyType":"cell-therapy","website":"https://www.jwtherapeutics.com/en/","ticker":"2126.HK","founded":2016,"investors":[],"funding":[]},{"id":"k36-therapeutics","kind":"company","name":"K36 Therapeutics","aka":[],"tldr":"K36 Therapeutics makes pills that block an enzyme called NSD2 (also known as MMSET), which is overactive in about one in five multiple myeloma cases because of a chromosome swap. It is also testing the approach in prostate cancer.","summary":"K36 Therapeutics is a Cambridge, Massachusetts clinical-stage company and the first to target the histone methyltransferase NSD2 (MMSET/WHSC1). Gintemetostat (KTX-1001) is a first-in-class, oral, selective catalytic NSD2 inhibitor in the K36-MMSET-001 trial in relapsed or refractory multiple myeloma with the t(4;14) translocation; the company reports target engagement, an encouraging safety profile and clinical activity in heavily pretreated patients, with expansion cohorts combining it with carfilzomib, mezigdomide or pomalidomide. KTX-2001, a second oral NSD2 inhibitor, is in the K36-STRIKE-001 trial in metastatic castration-resistant prostate cancer alone and with darolutamide. K36 launched in December 2021 with a 30 million US dollar Series A co-led by F-Prime Capital and Atlas Venture, and raised a 70 million US dollar Series B in June 2023 led by Nextech Invest with Bristol Myers Squibb participating.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.k36tx.com/"},{"label":"Series A press release (PR Newswire)","url":"https://www.prnewswire.com/news-releases/k36-therapeutics-launches-with-30-million-series-a-financing-from-f-prime-capital-and-atlas-venture-with-eight-roads-ventures-301440553.html"},{"label":"Series B press release (PR Newswire)","url":"https://www.prnewswire.com/news-releases/k36-therapeutics-announces-70-million-series-b-financing-to-fund-clinical-proof-of-concept-of-ktx-1001-first-in-class-inhibitor-of-mmset-for-treatment-of-multiple-myeloma-patients-with-genetic-translocation-414-301865147.html"}],"tags":[],"related":[],"cancers":["multiple-myeloma","prostate"],"sections":["epigenetics","targeted-therapy"],"technologies":["epigenetic-drugs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No SEC Form D filings were found under the company name. Founding year not sourced."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://www.k36tx.com/","stage":"startup","investors":["f-prime-capital","atlas-venture"],"funding":[{"round":"Series A","year":2021,"amountUsd":30000000,"source":"https://www.prnewswire.com/news-releases/k36-therapeutics-launches-with-30-million-series-a-financing-from-f-prime-capital-and-atlas-venture-with-eight-roads-ventures-301440553.html","note":"Co-led by F-Prime Capital and Atlas Venture with Eight Roads Ventures"},{"round":"Series B","year":2023,"amountUsd":70000000,"source":"https://www.prnewswire.com/news-releases/k36-therapeutics-announces-70-million-series-b-financing-to-fund-clinical-proof-of-concept-of-ktx-1001-first-in-class-inhibitor-of-mmset-for-treatment-of-multiple-myeloma-patients-with-genetic-translocation-414-301865147.html","note":"Led by Nextech Invest with participation from Bristol Myers Squibb and existing investors"}]},{"id":"kaiko-ai","kind":"company","name":"kaiko.ai","aka":[],"tldr":"Dutch-Swiss company releasing open pathology foundation models (Midnight) and evaluation tooling (eva).","summary":"kaiko.ai, based in Amsterdam and Zurich, is a Dutch-Swiss company releasing open pathology foundation models, the Midnight series, and the eva evaluation framework. Midnight-12k, released in 2025, reached leading benchmark scores with a fraction of the training slides used by competitors, and eva is an open framework for evaluating pathology foundation models. OnCo links it to the Midnight technology record. Whether data efficiency, rather than sheer archive size, becomes the deciding factor in pathology models is the question its results raise. Midnight has its own technology page.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.kaiko.ai"}],"tags":["ai"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["kaiko-midnight"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Amsterdam / Zurich","country":"NL","companyType":"ai-software","website":"https://www.kaiko.ai","investors":[],"funding":[]},{"id":"kaiku-health","kind":"company","name":"Kaiku Health (Elekta)","aka":[],"tldr":"Digital patient-monitoring platform for cancer care, acquired by Elekta in 2020.","summary":"Kaiku Health, based in Helsinki and acquired by Elekta in 2020, is a digital patient monitoring platform for cancer care. Its symptom reporting uses algorithms that flag toxicities to care teams and is used across European cancer centres. OnCo links it to electronic patient-reported outcomes and remote monitoring. Whether algorithm-flagged symptom reporting improves outcomes in routine care as it did in trials, and whether a radiotherapy company is the right owner, are the open questions. The ePRO technology page carries the evidence.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.elekta.com/products/oncology-informatics/"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":["remote-patient-monitoring"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Helsinki","country":"FI","companyType":"ai-software","website":"https://www.elekta.com/products/oncology-informatics/","investors":[],"funding":[]},{"id":"kanvas-biosciences","kind":"company","name":"Kanvas Biosciences","aka":[],"tldr":"Kanvas maps which bacteria live in the gut and turns that knowledge into bacterial medicines that help cancer immunotherapy work better and treat its gut side effects.","summary":"Kanvas Biosciences, headquartered at Monmouth Junction, New Jersey, with a West Coast site in South San Francisco, combines high-resolution spatial imaging of microbial communities with strain-resolved culturing and manufacturing to develop live biotherapeutic products. KAN-001 is a defined live biotherapeutic for non-small cell lung cancer intended to enhance response to immune checkpoint inhibitors, with preclinical data and manufacturing consistency presented in November 2025. KAN-004 is a metabolically complete live biotherapeutic for immune checkpoint inhibitor-induced colitis, for which a phase 1 trial was announced in March 2026. The company also offers microbiome research services and announced its own clinical manufacturing capabilities in 2025. In May 2026 Kanvas announced a USD 48 million Series A to bring its microbiome therapeutics to cancer patients; the Gates Foundation separately funds a malnutrition programme.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.kanvasbio.com"},{"label":"News (Series A, KAN-004 phase 1)","url":"https://www.kanvasbio.com/news"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["immunotherapy","supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Series A investors not named on the fetched page; the Business Wire release itself was not fetched. Founding year not sourced."],"hq":"Monmouth Junction, NJ","country":"US","companyType":"biotech","website":"https://www.kanvasbio.com","stage":"startup","investors":[],"funding":[{"round":"Series A","year":2026,"amountUsd":48000000,"source":"https://www.kanvasbio.com/news","note":"Announced via Business Wire, 6 May 2026, as listed on the company news page"}]},{"id":"karl-storz","kind":"company","name":"Karl Storz","aka":[],"tldr":"Karl Storz is the family-owned German endoscope maker whose rigid and flexible scopes, blue-light cystoscopy and Rubina fluorescence imaging are used across urological, gynaecological and abdominal cancer surgery.","summary":"Karl Storz, founded in Tuttlingen in 1945, makes endoscopes, camera platforms and integrated operating rooms. In oncology its photodynamic diagnosis system provides the blue light for hexaminolevulinate cystoscopy of bladder tumours, and its Image1 S Rubina platform overlays indocyanine green fluorescence on 4K laparoscopic images.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.karlstorz.com/"}],"tags":["machines-wave2"],"related":[],"cancers":[],"sections":[],"technologies":["intraoperative-fluorescence-imaging-systems","cystoscopy-turbt","fluorescence-guided-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tuttlingen","country":"DE","companyType":"devices","website":"https://www.karlstorz.com/","founded":1945,"stage":"private-large","investors":[],"funding":[]},{"id":"kartos-therapeutics","kind":"company","name":"Kartos Therapeutics","aka":["Kartos Therapeutics, Inc."],"tldr":"Kartos Therapeutics is a United States-based biotechnology company running 3 late-stage cancer trials of KRT-232 and Ruxolitinib in myeloproliferative neoplasms, endometrial cancer and diffuse large B-cell lymphoma.","summary":"Kartos Therapeutics, based in Redwood City, the United States, is a biotechnology company. Kartos Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapeutics for patients with cancer. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing KRT-232 and Ruxolitinib in myeloproliferative neoplasms, endometrial cancer, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia and hodgkin lymphoma. The largest, NCT05797831 (Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer), plans to enrol 268 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.kartosthera.com"},{"label":"ClinicalTrials.gov: trials led by Kartos Therapeutics","url":"https://clinicaltrials.gov/search?lead=Kartos%20Therapeutics%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["myeloproliferative-neoplasms","endometrial","dlbcl","cll","hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["krt-232"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05797831","nct04502394","nct03669965"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Redwood City","country":"US","companyType":"biotech","website":"https://www.kartosthera.com","stage":"growth","investors":[],"funding":[]},{"id":"karyopharm","kind":"company","name":"Karyopharm Therapeutics","aka":[],"tldr":"Karyopharm makes selinexor, the first nuclear export inhibitor, approved in myeloma; its endometrial cancer bet failed in 2026.","summary":"Karyopharm Therapeutics, based in Newton, Massachusetts, and listed as KPTI, makes selinexor, sold as Xpovio, the first nuclear export inhibitor, approved in multiple myeloma and diffuse large B-cell lymphoma. Its bet on endometrial cancer failed in 2026 when the phase 3 XPORT-EC-042 trial of maintenance selinexor in TP53-wild-type disease missed its primary endpoint in July, after which the company refocused on myelofibrosis and myeloma. OnCo links it to endometrial cancer, to the XPORT-EC-042 trial record and to selinexor. Whether a biomarker-selected maintenance strategy failed because of the drug or because of the TP53 hypothesis is the question the trial leaves open. Selinexor has its own page.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://www.karyopharm.com"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["selinexor"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04442022","nct02227251","nct02343042","nct04414475","nct04562389"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Newton, MA","country":"US","companyType":"biotech","website":"https://www.karyopharm.com","ticker":"KPTI","investors":[],"funding":[]},{"id":"kelonia-therapeutics","kind":"company","name":"Kelonia Therapeutics","aka":[],"tldr":"Kelonia developed a way to create CAR T cells directly inside the body using a targeted gene delivery particle, so patients do not need their cells removed and manufactured. Its lead programme is for multiple myeloma and Eli Lilly agreed to buy the company in 2026 for up to $7 billion.","summary":"Kelonia Therapeutics is a clinical-stage company developing in vivo CAR T-cell therapy using its proprietary in vivo gene placement system (iGPS), a lentiviral-based delivery technology designed to deliver genetic cargo only to the desired tissue. Lead candidate KLN-1010 is a CD19/BCMA bispecific CAR (biCAR) in the phase 1 inMMyCAR trial (NCT07075185) for refractory multiple myeloma, with clinical data highlighted in a plenary session at the 2025 ASH annual meeting. Further oncology and autoimmune programmes are undisclosed. On 20 April 2026 Eli Lilly announced a definitive agreement to acquire Kelonia for $3.25 billion upfront and up to $7.00 billion including milestones; the company website now describes Kelonia as a wholly owned subsidiary of Eli Lilly. A 2022 Form D shows about $50 million of equity sold when the company was based in Cambridge, MA.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://keloniatx.com/"},{"label":"Pipeline and inMMyCAR trial","url":"https://keloniatx.com/pipeline/"},{"label":"Lilly to acquire Kelonia (PR Newswire, April 2026)","url":"https://www.prnewswire.com/news-releases/lilly-to-acquire-kelonia-therapeutics-to-advance-in-vivo-car-t-cell-therapies-302747122.html"},{"label":"Form D, April 2022","url":"https://www.sec.gov/Archives/edgar/data/1925270/000192527022000002/primary_doc.xml"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":["cell-therapy"],"technologies":["in-vivo-car-t"],"targets":["bcma","cd19"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Series letters and investor names for earlier rounds not sourced. Completion date of the Lilly deal not separately sourced, but keloniatx.com states it is a wholly owned Lilly subsidiary."],"hq":"Boston, MA","country":"US","companyType":"cell-therapy","website":"https://keloniatx.com/","founded":2020,"stage":"acquired","investors":[],"funding":[{"round":"Form D offering","year":2022,"amountUsd":50299983,"source":"https://www.sec.gov/Archives/edgar/data/1925270/000192527022000002/primary_doc.xml","note":"Equity offering, first sale 14 April 2022; issuer then based in Cambridge, MA"},{"round":"Acquisition","year":2026,"amountUsd":3250000000,"source":"https://www.prnewswire.com/news-releases/lilly-to-acquire-kelonia-therapeutics-to-advance-in-vivo-car-t-cell-therapies-302747122.html","note":"Upfront payment of $3.25 billion; up to $7.00 billion in total including clinical, regulatory and commercial milestones; announced 20 April 2026"}],"acquiredBy":"eli-lilly"},{"id":"kernal-biologics","kind":"company","name":"Kernal Biologics","aka":[],"tldr":"Kernal Bio designs mRNA medicines that switch on only in the intended cell type, for example programming a patient's T cells against cancer inside the body without taking them out first.","summary":"Kernal Biologics develops cell-selective mRNA therapeutics: mRNA engineered to translate only in chosen cell types, delivered in lipid nanoparticles targeted to those cells. Its KR-402 programme uses T-cell-targeted particles to programme CAR-T cells in vivo and, per the company, achieves over 90 percent delivery efficiency with B-cell depletion within a week in preclinical models. Oncology applications include in vivo CAR-T and immune-stimulating mRNA for solid tumours. The company's YC profile names Hummingbird Ventures, Amgen Ventures, HBM and NASA among its backers; work is preclinical.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/kernal-biologics"},{"label":"Official website","url":"https://www.kernalbio.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["immunotherapy","cell-therapy"],"technologies":["in-vivo-car-t","neoantigen-mrna-vaccine"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://www.kernalbio.com","stage":"startup","ycBatch":"S20","investors":["y-combinator","amgen-ventures"],"funding":[]},{"id":"kernis-health","kind":"company","name":"Kernis Health","aka":[],"tldr":"Kernis Health helps cancer patients keep their own living tumour tissue after surgery, instead of letting it be discarded, so it can be used later for functional drug testing, diagnostics and trial access.","summary":"Standard pathology fixes and kills tumour tissue after surgery. Kernis Health arranges for a patient's live tumour tissue to be preserved and owned by the patient, which opens the door to functional testing of drugs on their own cells, organoid growth, personalised therapies and clinical trials that need viable tissue. It is a California company in the Even One Ventures portfolio and also appears on the Sijbrandij Foundation's Future of Cancer Care Today list.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://kernis.health/"},{"label":"Even One Ventures portfolio","url":"https://evenone.ventures/"}],"tags":["startup","evenone-portfolio","oncology"],"related":[],"cancers":[],"sections":[],"technologies":["functional-drug-testing","organoids"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"California (city not published)","country":"US","companyType":"cro-services","website":"https://kernis.health/","stage":"startup","investors":["evenone-ventures"],"funding":[]},{"id":"keros-therapeutics","kind":"company","name":"Keros Therapeutics","aka":["Keros Therapeutics, Inc.","NASDAQ:KROS"],"tldr":"Keros Therapeutics is a Massachusetts biotech that works on the TGF-beta family signals controlling blood cell production; its activin ligand trap elritercept treats anaemia in myelodysplastic syndromes and myelofibrosis and was licensed to Takeda.","summary":"Keros Therapeutics develops medicines that modulate transforming growth factor beta superfamily signalling. Elritercept (KER-050, now TAK-226) is a modified activin receptor type IIA ligand trap that promotes red cell and platelet production; it showed durable transfusion independence in lower-risk myelodysplastic syndromes and myelofibrosis and was licensed to Takeda outside mainland China in December 2024. Cibotercept (KER-012) was studied in pulmonary arterial hypertension and KER-065 is in development for neuromuscular disease.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.kerostx.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["elritercept"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Lexington, Massachusetts","country":"US","companyType":"biotech","website":"https://www.kerostx.com/","ticker":"NASDAQ:KROS","founded":2015,"stage":"public","investors":[],"funding":[]},{"id":"keymed","kind":"company","name":"Keymed Biosciences (KYM Biosciences)","aka":[],"tldr":"Chinese biotech whose joint venture KYM Biosciences created the Claudin 18.2 ADC CMG901, licensed to AstraZeneca in 2023.","summary":"Keymed Biosciences, based in Chengdu and listed in Hong Kong as 2162.HK, is the Chinese biotechnology company whose joint venture KYM Biosciences created CMG901, a Claudin 18.2 antibody-drug conjugate licensed to AstraZeneca in 2023. KYM Biosciences is owned seventy percent by Keymed and thirty percent by Lepu Biopharma, and it licensed CMG901, now sonesitatug vedotin or AZD0901, to AstraZeneca in February 2023 for 63 million dollars upfront and up to 1.1 billion dollars in milestones; AstraZeneca runs the phase 3 CLARITY-Gastric01 programme. OnCo links it to gastric and gastro-oesophageal junction cancer, to Claudin 18.2 as a target, to the ADC technology and to the sonesitatug vedotin drug record. Whether an ADC beats a naked antibody against the same target is the open question. Sonesitatug vedotin has its own page.","asOf":"2026-09-04","links":[{"label":"Licence announcement","url":"https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-enters-license-agreement-with-kym-biosciences-for-cmg901-a-claudin-182-antibody-drug-conjugate.html"}],"tags":[],"related":[],"cancers":["gastric"],"sections":["adcs"],"technologies":["adc"],"targets":["cldn18-2"],"drugs":["cmg901"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05299424","nct05263960","nct07019779"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Chengdu","country":"CN","companyType":"biotech","website":"https://www.keymedbio.com","ticker":"2162.HK","investors":[],"funding":[]},{"id":"kheiron-medical-technologies","kind":"company","name":"Kheiron Medical Technologies","aka":["Kheiron","DeepHealth Kheiron"],"tldr":"Kheiron built Mia, an artificial intelligence system that reads screening mammograms so that one radiologist plus the software can match the quality of two human readers. RadNet's DeepHealth unit bought the London company in 2024.","summary":"Kheiron Medical Technologies, founded in London in 2016, developed Mia (Mammography Intelligent Assessment), a deep-learning system for breast screening that can act as an independent second reader, a concurrent reader or a triage tool, aiming to deliver double-reading quality with a single human reader. Mia received CE marking in 2019, won the UK AI in Health and Care Award in 2020 and was deployed in what the company describes as the EU and UK's first prospective evaluation of a breast screening AI system. On 22 October 2024 DeepHealth, RadNet's wholly owned AI subsidiary, announced it had acquired Kheiron; financial terms were not disclosed. Kheiron's technology has since been folded into DeepHealth's SmartMammo breast screening product, and the former kheironmed.com domain redirects to DeepHealth.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://deephealth.com/kheiron-medical-technologies/"},{"label":"DeepHealth acquisition release (Oct 2024)","url":"https://deephealth.com/press-releases/deephealth-expands-its-ai-powered-cancer-diagnostic-and-screening-portfolio-with-the-acquisition-of-kheiron"}],"tags":[],"related":[],"cancers":["breast-hr-positive","breast-her2-positive","tnbc"],"sections":["imaging","early-detection","ai-computation"],"technologies":["radiology-ai-screening","mammography"],"targets":[],"drugs":["kheiron-mia"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["kheironmed.com returns a redirect to deephealth.com. Pre-acquisition venture rounds not sourced. Breast cancer subtypes are tagged collectively because screening AI is not subtype-specific."],"hq":"London","country":"GB","companyType":"ai-software","website":"https://deephealth.com/kheiron-medical-technologies/","founded":2016,"stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2024,"source":"https://deephealth.com/press-releases/deephealth-expands-its-ai-powered-cancer-diagnostic-and-screening-portfolio-with-the-acquisition-of-kheiron","note":"Acquired by DeepHealth, a wholly owned subsidiary of RadNet, announced 22 October 2024; terms not disclosed."}]},{"id":"khosla-ventures","kind":"company","name":"Khosla Ventures","aka":[],"tldr":"Vinod Khosla's Menlo Park venture firm, which backs bold early-stage technology companies including health and biology start-ups. Cancer-related bets include the blood-test company Guardant Health and the AI oncology start-up Radical Health.","summary":"Khosla Ventures was founded in 2004 by Vinod Khosla, a former Kleiner Perkins general partner, and is based in Menlo Park (Wikipedia). It invests from seed through growth with a 'venture assistance' model and is known for early conviction in categories 'before they had names', with OpenAI, DoorDash and Rocket Lab among its highlighted companies. Healthcare is one of several themes. Its portfolio page lists Guardant Health ('Transforming cancer care through blood tests', Nasdaq: GH), Radical Health ('AI-driven oncology platform turning subjective treatment decisions into scalable, data-driven precision care'), Rad AI (AI for medical imaging) and delivery companies with cancer milestones such as a macrophage-targeting lipid nanoparticle programme entering phase 1 in cancer in 2026.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.khoslaventures.com/"},{"label":"Portfolio","url":"https://www.khoslaventures.com/portfolio"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Khosla_Ventures"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["guardant-health"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Menlo Park, CA","country":"US","companyType":"investor","website":"https://www.khoslaventures.com/","founded":2004,"investors":[],"funding":[]},{"id":"kissei","kind":"company","name":"Kissei Pharmaceutical","aka":["Kissei Pharmaceutical Co., Ltd.","キッセイ薬品工業"],"tldr":"Kissei is a Japanese pharmaceutical company from Matsumoto, founded in 1946, whose in-licensed haematology and oncology products go through the Japanese phase 3 trials it leads.","summary":"Kissei Pharmaceutical Co., Ltd., headquartered in Matsumoto, Nagano, and listed in Tokyo, develops and markets prescription medicines in urology, nephrology and rare diseases, and in-licenses haematology and oncology products for the Japanese market, running the domestic phase 3 trials needed for approval. ClinicalTrials.gov lists Kissei as lead sponsor of phase 3 cancer trials. Its registered cancer trials are a phase 1/2 study of the anti-CD26 antibody YS110 in malignant pleural mesothelioma (NCT03177668) and a phase 1/2 study of dexrazoxane for anthracycline extravasation (NCT01596088).","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Kissei","links":[{"label":"Official website","url":"http://www.kissei.co.jp"},{"label":"ClinicalTrials.gov: trials led by Kissei Pharmaceutical Co., Ltd.","url":"https://clinicaltrials.gov/search?lead=Kissei%20Pharmaceutical%20Co.%2C%20Ltd."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q11296797"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":["dexrazoxane"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Matsumoto","country":"JP","companyType":"pharma","website":"http://www.kissei.co.jp","founded":1946,"stage":"public","investors":[],"funding":[]},{"id":"kiyatec","kind":"company","name":"Kiyatec","aka":[],"tldr":"Kiyatec grows a patient's tumour cells in 3D culture and tests drugs on them, with a focus on ovarian, breast, glioblastoma and rare tumours.","summary":"Kiyatec's ex vivo 3D cell culture platform predicts which drugs a patient's tumour will respond to by exposing living tumour cells to candidate therapies, and it has published clinical correlation studies in glioblastoma and ovarian cancer. Physician-ordered.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://kiyatec.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":["ovarian","glioblastoma","breast-hr-positive"],"sections":[],"technologies":["functional-drug-testing","organoids"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"United States (city not published)","country":"US","companyType":"diagnostics","website":"https://kiyatec.com/","investors":[],"funding":[]},{"id":"klineo","kind":"company","name":"Klineo","aka":[],"tldr":"Klineo is a French search tool that helps patients and physicians find oncology clinical trials across Europe quickly.","summary":"Klineo offers a fast, guided search for oncology clinical trials for patients and physicians, with European coverage; Future of Cancer Care Today lists it as patient-accessible.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.klineo.com/en"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["ai-trial-matching"],"targets":[],"drugs":[],"companies":["future-of-cancer-care-today"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"France (city not published)","country":"FR","companyType":"ai-software","website":"https://www.klineo.com/en","stage":"startup","investors":[],"funding":[]},{"id":"known-medicine","kind":"company","name":"Known Medicine","aka":[],"tldr":"Known Medicine breaks a patient's tumour into thousands of tiny three-dimensional tumours, treats each with a different drug, and uses AI to predict which drugs will work. It has been acquired.","summary":"Known Medicine built a functional precision oncology platform: patient tumour samples are dissociated into thousands of micro-tumours in three-dimensional culture, exposed to candidate drugs and imaged, with AI models trained to translate the responses into predictions of clinical benefit for drug developers. The YC directory lists the company as acquired; the acquirer is not named here because no primary source was fetched at the time of checking.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/known-medicine"},{"label":"Official website","url":"https://knownmed.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["drug-discovery","diagnostics"],"technologies":["organoids","functional-drug-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Salt Lake City, UT","country":"US","companyType":"cro-services","website":"https://knownmed.com","stage":"acquired","ycBatch":"S20","investors":["y-combinator"],"funding":[]},{"id":"komodo-health","kind":"company","name":"Komodo Health","aka":[],"tldr":"Claims-based 'Healthcare Map' of 330 million US patients used for market and outcomes analytics in oncology.","summary":"Komodo Health, based in San Francisco, built a claims-based Healthcare Map covering 330 million US patients, used for market and outcomes analytics in oncology. It combines longitudinal insurance claims with linked clinical data to provide commercial and real-world evidence analytics for life sciences companies. OnCo links it to oncology EHR and real-world data platforms. Whether claims data, which record what was billed rather than what was found, can answer clinical questions about cancer treatment is the standing limitation a reader should keep in mind. The real-world data platform page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.komodohealth.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["oncology-real-world-data"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"ai-software","website":"https://www.komodohealth.com","investors":[],"funding":[]},{"id":"kopra-bio","kind":"company","name":"Kopra Bio","aka":[],"tldr":"Kopra Bio engineers viruses that teach the immune system to kill cancer, starting with glioblastoma, the most aggressive brain cancer.","summary":"Kopra Bio, a UCSF spin-out, develops genetically engineered immunotherapeutic viruses designed to prime the immune system against tumours, with glioblastoma as the first indication. Its YC profile reports that in an aggressive mouse model of brain cancer the treatment raised survival from zero with the current approved therapy to 90 percent, a preclinical result that has not yet been tested in patients. The company is very small and preclinical; no sourced financing rounds are recorded.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/kopra-bio"},{"label":"Official website","url":"https://kopra.bio"}],"tags":["yc"],"related":[],"cancers":["glioblastoma"],"sections":["immunotherapy"],"technologies":["oncolytic-virus"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"biotech","website":"https://kopra.bio","stage":"startup","ycBatch":"S24","investors":["y-combinator"],"funding":[]},{"id":"kcsg","kind":"company","name":"Korean Cancer Study Group","aka":["KCSG"],"tldr":"South Korea's multicentre cooperative trials group, linking the Seoul mega-hospitals and regional centres in investigator-initiated trials in gastric, lung, liver and breast cancer.","summary":"Founded in 1998 by Korean medical oncologists, KCSG is the country's academic cooperative group and a founding member of the Asian Clinical Trials Network. It runs disease-specific committees (gastrointestinal, thoracic, breast, hepatobiliary, genitourinary, lymphoma, head and neck) and a data centre, and it is the route by which Korea's high-volume hospitals run multicentre investigator-initiated trials and correlative biomarker studies. Korean investigators enrol a large share of global gastric and EGFR-mutant lung cancer trials, and KCSG trials of second-line gastric chemotherapy and of precision oncology umbrella designs (K-MASTER) have been influential. Members include Seoul National University Hospital, Asan Medical Center, Samsung Medical Center and Severance.","asOf":"2026-09-09","links":[{"label":"KCSG","url":"https://www.kcsg.org"}],"tags":["cooperative-group"],"related":[],"cancers":["gastric","nsclc","hcc","breast-her2-positive","colorectal"],"sections":[],"technologies":["cgp","kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":["snuh","asan-medical-center","samsung-medical-center","severance"],"pathways":[],"terms":["basket-umbrella-platform"],"trials":[],"people":["ahn-myung-ju","jin-seok-ahn"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Gastric and hepatobiliary cancer trials","Thoracic oncology","K-MASTER precision oncology programme","Asian Clinical Trials Network"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Seoul","country":"KR","companyType":"cooperative-group","website":"https://www.kcsg.org","founded":1998,"investors":[],"funding":[]},{"id":"kgog","kind":"company","name":"Korean Gynecologic Oncology Group","aka":["KGOG","대한부인종양연구회"],"tldr":"The Korean Gynecologic Oncology Group is the Korean incorporated association that runs gynaecological cancer trials; in OnCo it leads a phase 2 study of progestin with a levonorgestrel intrauterine system for fertility-sparing treatment of early endometrial cancer.","summary":"The Korean Gynecologic Oncology Group (KGOG, 사단법인 대한부인종양연구회) is an incorporated association with its office at Yeongil Building, 32 Nambusunhwan-ro 333-gil, Seocho-gu, Seoul (kgog.org, which also lists its semi-annual meetings). No founding year is stated on the pages read. ClinicalTrials.gov names it lead sponsor (OTHER class) of NCT01594879 (phase 2, medroxyprogesterone acetate with a levonorgestrel-releasing intrauterine system in young women with early endometrial cancer), the trial recorded in OnCo. It has no products of its own.","asOf":"2026-09-25","links":[{"label":"Official website","url":"https://www.kgog.org"},{"label":"ClinicalTrials.gov: trials led by Korean Gynecologic Oncology Group","url":"https://clinicaltrials.gov/search?lead=Korean%20Gynecologic%20Oncology%20Group"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct01594879"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"Seoul","country":"KR","companyType":"cooperative-group","website":"https://www.kgog.org","investors":[],"funding":[]},{"id":"krystal-biotech","kind":"company","name":"Krystal Biotech","aka":["Krystal Biotech, Inc."],"tldr":"Krystal Biotech is a United States-based biotechnology company running 2 late-stage cancer trials of KB707 in non-small-cell lung cancer and melanoma.","summary":"Krystal Biotech, based in Pittsburgh, the United States, is a biotechnology company listed as NASDAQ: KRYS. Krystal Biotech develops redosable genetic medicines using a proprietary, replication-defective, non-integrating modified HSV-1 vector platform for severe, life-threatening or rare diseases. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing KB707 in non-small-cell lung cancer and melanoma. The largest, NCT06228326 (A Study Assessing KB707 for the Treatment of Advanced Solid Tumour Malignancies Affecting the Lungs), plans to enrol 250 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.krystalbio.com"},{"label":"ClinicalTrials.gov: trials led by Krystal Biotech","url":"https://clinicaltrials.gov/search?lead=Krystal%20Biotech%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05970497","nct06228326"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Pittsburgh","country":"US","companyType":"biotech","website":"https://www.krystalbio.com","ticker":"NASDAQ: KRYS","stage":"public","investors":[],"funding":[]},{"id":"kumquat-biosciences","kind":"company","name":"Kumquat Biosciences","aka":[],"tldr":"Kumquat Biosciences is a San Diego company founded by KRAS pioneers that makes pills against the KRAS cancer protein and immune-boosting small molecules. Its KRAS G12D drug entered human trials with Bayer in 2025.","summary":"Kumquat Biosciences is a clinical-stage San Diego biotechnology company founded in 2018 by pioneers of KRAS targeting. Its lead asset, KQB548 (BAY 3771249), is a KRAS G12D inhibitor licensed to Bayer in August 2025 in a deal worth up to 1.3 billion US dollars in upfront and milestone payments plus royalties; a first-in-human phase 1 monotherapy trial (NCT07207707) in KRAS G12D-mutant tumours such as pancreatic, colorectal and lung cancer began in October 2025. Kumquat also granted Takeda an exclusive global licence to an oral immuno-oncology small molecule (up to 130 million US dollars near term and more than 1.2 billion in potential milestones) and has a discovery collaboration with Lilly on small molecules that stimulate tumour-specific immune responses. SEC Form D filings show about 56 million US dollars sold in 2019 and a further 80 million US dollars sold in 2021; round names are not disclosed.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://kumquatbiosciences.com/"},{"label":"Bayer licence and collaboration (August 2025)","url":"https://kumquatbiosciences.com/news/bayer-and-kumquat-biosciences-enter-global-exclusive-license-and-collaboration-in-precision-oncology/"},{"label":"Phase 1 start with Bayer (October 2025)","url":"https://kumquatbiosciences.com/news/bayer-and-kumquat-biosciences-initiate-phase-i-study-with-kras-g12d-inhibitor-in-patients-with-kras-mutated-tumors/"},{"label":"Takeda collaboration","url":"https://kumquatbiosciences.com/news/kumquat-biosciences-and-takeda-enter-into-strategic-collaboration-and-exclusive-global-license-agreement-to-advance-novel-oral-immuno-oncology-drug-candidate/"}],"tags":[],"related":[],"cancers":["pancreatic","colorectal","nsclc"],"sections":["targeted-therapy"],"technologies":["kras-inhibitors"],"targets":["kras"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07406633"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Stage set to startup because no round beyond the 2021 Form D offerings was found; series labels and investors are not disclosed in fetched sources."],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://kumquatbiosciences.com/","founded":2018,"stage":"startup","investors":[],"funding":[{"round":"Form D offering","year":2019,"amountUsd":55922930,"source":"https://www.sec.gov/Archives/edgar/data/1781822/000178182219000002/primary_doc.xml","note":"Total sold per amended Form D filed August 2019"},{"round":"Form D offering","year":2021,"amountUsd":50000000,"source":"https://www.sec.gov/Archives/edgar/data/1781822/000184161321000002/primary_doc.xml","note":"Total sold per Form D filed February 2021"},{"round":"Form D offering","year":2021,"amountUsd":30000012,"source":"https://www.sec.gov/Archives/edgar/data/1781822/000184161321000008/primary_doc.xml","note":"Total sold per amended Form D filed August 2021"}]},{"id":"kura-oncology","kind":"company","name":"Kura Oncology","aka":[],"tldr":"Kura Oncology developed ziftomenib, the second menin inhibitor approved for leukaemia (November 2025), in partnership with Kyowa Kirin.","summary":"Kura Oncology, based in San Diego and listed as KURA, developed ziftomenib, the second menin inhibitor approved for leukaemia, in partnership with Kyowa Kirin. Ziftomenib, sold as Komzifti, was approved on 13 November 2025 for relapsed or refractory NPM1-mutated acute myeloid leukaemia on the KOMET-001 trial, the KOMET-007 trials test it with 7+3 chemotherapy and with venetoclax and azacitidine in frontline disease, and the company also has a farnesyl-transferase inhibitor programme; the global Kyowa Kirin partnership dates from 2024. OnCo links it to acute myeloid leukaemia and to the AUGMENT-101 paper on revumenib, the first menin inhibitor. Whether menin inhibitors move into first-line combinations is the question KOMET-007 will answer. The FDA approval notice is linked.","asOf":"2026-09-07","links":[{"label":"FDA approval of Komzifti (Kura, 13 Nov 2025)","url":"https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-and-kyowa-kirin-announce-fda-approval-komziftitm"}],"tags":[],"related":[],"cancers":["aml"],"sections":["epigenetics"],"technologies":[],"targets":[],"drugs":["ziftomenib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07007312"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://www.kuraoncology.com","ticker":"KURA","investors":[],"funding":[]},{"id":"kyan-technologies","kind":"company","name":"KYAN Technologies","aka":[],"tldr":"KYAN Technologies uses a small set of live-cell experiments and its own AI to rank more than 1,500 personalised drug combinations for a patient's cancer.","summary":"KYAN Technologies, based in Singapore with US operations, markets Optim.AI, a functional precision medicine platform that tests a patient's live cancer cells against drugs and uses its algorithm to evaluate and rank over 1,500 personalised combinations. Physician-ordered.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://kyantechnologies.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["functional-drug-testing","functional-precision-medicine-haematology"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Singapore","country":"SG","companyType":"diagnostics","website":"https://kyantechnologies.com/","investors":[],"funding":[]},{"id":"kymera","kind":"company","name":"Kymera Therapeutics","aka":[],"tldr":"Oral degrader company, mostly immunology, whose CDK2 molecular-glue degrader was optioned by Gilead in 2026 for CCNE1-driven cancers.","summary":"Kymera Therapeutics, based in Watertown, Massachusetts, and listed as KYMR, is an oral protein degrader company focused mostly on immunology, whose CDK2 molecular-glue degrader was optioned by Gilead in 2026 for CCNE1-driven cancers. Gilead paid 40 million dollars for an option in June 2025 and exercised it for 45 million dollars in April 2026 on the preclinical CDK2 glue degrader KT-200, aimed at CCNE1-amplified tumours and resistance to CDK4/6 inhibitors, while Kymera's own clinical pipeline against IRAK4, STAT6 and TYK2 is immunological. OnCo links it to ovarian and HR-positive breast cancer, to PROTACs and molecular glues and glue discovery platforms, to CDK4/6 as a target, to Gilead, and to ideas including glues that break the MYC-MAX partnership. The undruggable drivers are the bottleneck it bears on. Whether CDK2 degradation is tolerable is the open question.","asOf":"2026-09-04","links":[{"label":"Gilead option exercise","url":"https://www.fiercebiotech.com/biotech/gilead-pays-kymera-45m-glue-preclinical-protein-degrader-burgeoning-oncology-pipeline"}],"tags":[],"related":["src-fierce-biotech"],"cancers":["ovarian","breast-hr-positive"],"sections":["targeted-therapy"],"technologies":["protac-degrader"],"targets":["cdk4-6"],"drugs":[],"companies":["gilead"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Watertown, MA","country":"US","companyType":"biotech","website":"https://www.kymeratx.com","ticker":"KYMR","investors":[],"funding":[]},{"id":"kyowa-kirin","kind":"company","name":"Kyowa Kirin","aka":[],"tldr":"Kyowa Kirin is a Japanese biopharmaceutical company whose oncology products include mogamulizumab (Poteligeo) for cutaneous T-cell lymphoma and toremifene (Fareston) for metastatic breast cancer.","summary":"Kyowa Kirin, based in Tokyo, listed as 4151.T and part of the Kirin group, is a Japanese biopharmaceutical company whose oncology products include mogamulizumab, sold as Poteligeo, for cutaneous T-cell lymphoma and toremifene, sold as Fareston, for metastatic breast cancer. It developed the anti-CCR4 antibody mogamulizumab, markets Fareston in the United States, and also sells burosumab as Crysvita and G-CSF products in Japan. OnCo links it to the toremifene drug record. Whether a CCR4 antibody can find uses beyond rare T-cell lymphomas is the open question for its oncology franchise. Toremifene has its own page.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Kyowa_Kirin","links":[{"label":"Official website","url":"https://www.kyowakirin.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["ccr4"],"drugs":["mogamulizumab","toremifene","burosumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07629726","nct07623616"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tokyo","country":"JP","companyType":"pharma","website":"https://www.kyowakirin.com","ticker":"4151.T","investors":[],"funding":[]},{"id":"labcorp","kind":"company","name":"Labcorp","aka":[],"tldr":"Labcorp is one of the two US national reference labs, running oncology IHC, FISH, and NGS at scale and central labs for trials.","summary":"Labcorp, based in Burlington, North Carolina, and listed as LH, is one of the two US national reference laboratories, running oncology immunohistochemistry, FISH and next-generation sequencing at scale and central laboratories for trials. Labcorp Oncology includes OmniSeq and Personal Genome Diagnostics, alongside companion diagnostic testing and central laboratory services. OnCo links it to reference laboratories and companion diagnostic testing, companion diagnostics and comprehensive genomic profiling. Whether national reference laboratories or specialist genomics companies become the default for tumour sequencing is the open question. The reference laboratory technology page carries the wider picture.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Labcorp","links":[{"label":"Official website","url":"https://www.labcorp.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["reference-laboratories","companion-diagnostic","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Burlington, NC","country":"US","companyType":"diagnostics","website":"https://www.labcorp.com","ticker":"LH","investors":[],"funding":[]},{"id":"laminar-pharmaceuticals","kind":"company","name":"Laminar Pharmaceuticals","aka":[],"tldr":"Laminar Pharmaceuticals is a Spain-based biotechnology company running 2 late-stage cancer trials of LAM561 in glioma & glioblastoma.","summary":"Laminar Pharmaceuticals, based in Palma de Mallorca, Spain, is a biotechnology company. Laminar Pharma is a biopharmaceutical company developing 'melitherapy', a therapeutic approach targeting membrane lipids rather than proteins or DNA, for conditions including cancer and Alzheimer's disease. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing LAM561 in glioma & glioblastoma. The largest, NCT04250922 (LAM561 With RT and TMZ for Adults With Glioblastoma), plans to enrol 144 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.laminarpharma.com"},{"label":"ClinicalTrials.gov: trials led by Laminar Pharmaceuticals","url":"https://clinicaltrials.gov/search?lead=Laminar%20Pharmaceuticals"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["lam561"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04299191"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Palma de Mallorca","country":"ES","companyType":"biotech","website":"https://www.laminarpharma.com","stage":"growth","investors":[],"funding":[]},{"id":"lanova-medicines","kind":"company","name":"LaNova Medicines","aka":["LaNova Medicines Limited"],"tldr":"LaNova Medicines is a China-based biotechnology company running 10 late-stage cancer trials of LM-168, LM-108 and LM-299 in gastric & gastro-oesophageal junction cancer.","summary":"LaNova Medicines, based in Shanghai, China, is a biotechnology company. LaNova Medicines is a clinical-stage biopharmaceutical company developing monoclonal antibodies, antibody-drug conjugates and bispecific antibodies for tumour immunology and the tumour microenvironment. On ClinicalTrials.gov it is the lead sponsor of 10 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing LM-168, LM-108, LM-299, LM101 and LM-350 in gastric & gastro-oesophageal junction cancer. The largest, NCT07362186 (LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma), plans to enrol 400 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.lanovamedicines.com"},{"label":"ClinicalTrials.gov: trials led by LaNova Medicines","url":"https://clinicaltrials.gov/search?lead=LaNova%20Medicines%20Limited"},{"label":"Pipeline page","url":"https://www.lanovamedicines.com/en"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["lm-108"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05934331","nct06650566","nct06187402","nct05518045","nct07112222","nct06868199","nct07387081","nct06682780","nct05615974","nct07669415"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.lanovamedicines.com","founded":2019,"stage":"growth","investors":[],"funding":[]},{"id":"lantern-pharma","kind":"company","name":"Lantern Pharma","aka":["Lantern Pharma Inc.","NASDAQ:LTRN"],"tldr":"Lantern Pharma is a Texas company that uses its RADR machine-learning platform to revive shelved cancer drugs; LP-184 is a DNA-damaging agent activated in tumours with DNA repair defects, including glioblastoma.","summary":"Lantern Pharma applies its RADR artificial-intelligence platform to match small molecules with the tumours and biomarkers most likely to respond. LP-184 is an acylfulvene prodrug activated by the enzyme PTGR1 that causes DNA damage in cells with defective nucleotide excision repair; it is in phase 1 trials in solid tumours and, as LP-184 for glioblastoma, holds orphan and fast track designations. LP-284 targets B-cell lymphomas and LP-300 is in a phase 2 trial in never-smokers with lung adenocarcinoma.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.lanternpharma.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["lp-184"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Dallas, Texas","country":"US","companyType":"biotech","website":"https://www.lanternpharma.com/","ticker":"NASDAQ:LTRN","founded":2013,"stage":"public","investors":[],"funding":[]},{"id":"lantheus","kind":"company","name":"Lantheus","aka":["Progenics Pharmaceuticals, Inc.","Progenics","Molecular Insight Pharmaceuticals, Inc.","Molecular Insight Pharmaceuticals"],"tldr":"Lantheus makes Pylarify, the leading PSMA PET agent, with a new TruVu formulation approved in March 2026.","summary":"Lantheus, based in Bedford, Massachusetts, and listed as LNTH, makes Pylarify, or piflufolastat F-18, the leading PSMA PET agent, with a new TruVu formulation approved in March 2026. Its portfolio also includes Neuraceq for amyloid imaging, PNT2002, a 177Lu-PSMA-I&T therapy whose SPLASH phase 3 missed overall survival, and PNT2003, a generic 177Lu-DOTATATE, and OnCo also links it to iobenguane I-131 and samarium-153 lexidronam. It connects to prostate cancer, to PET tracer manufacturing and distribution and radionuclide generators, and to Evergreen Theragnostics. Whether an imaging leader can become a therapy company after SPLASH is the open question. Piflufolastat F-18 has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.lantheus.com"}],"tags":[],"related":[],"cancers":[],"sections":["radiopharma","imaging"],"technologies":[],"targets":[],"drugs":["pylarify","i131-mibg"],"companies":["evergreen-theragnostics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06298916","nct07357519"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Bedford, MA","country":"US","companyType":"radiopharma","website":"https://www.lantheus.com","ticker":"LNTH","investors":[],"funding":[]},{"id":"latent-labs","kind":"company","name":"Latent Labs","aka":[],"tldr":"Founded by an AlphaFold co-developer to make protein design programmable; released Latent-X in 2025.","summary":"Latent Labs, based in London, was founded by an AlphaFold co-developer to make protein design programmable, and released Latent-X in 2025. Latent-X generates de novo binders, including macrocycles and mini-binders, with reported high wet-lab hit rates, and is available through a web platform. OnCo links it to de novo designed protein binders. Whether designed macrocycles and mini-binders can reach intracellular cancer targets that antibodies cannot is the open question. The de novo protein binder page carries the wider field.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.latentlabs.com"}],"tags":["ai","protein-design"],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":["de-novo-protein-design","ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"London","country":"GB","companyType":"ai-software","website":"https://www.latentlabs.com","investors":[],"funding":[]},{"id":"leadiant","kind":"company","name":"Leadiant Biosciences","aka":[],"tldr":"Leadiant Biosciences (formerly Sigma-Tau) is an Italian rare-disease company that holds the US application for procarbazine (Matulane).","summary":"Leadiant Biosciences, based in Rome and formerly Sigma-Tau, is an Italian rare disease company that holds the US application for procarbazine, sold as Matulane. It markets niche and rare disease products including Matulane for Hodgkin lymphoma, as well as pegademase and cysteamine formulations. OnCo links it to the procarbazine drug record. Whether an old drug held by a small company remains reliably available and affordable is the question that matters for the regimens that still use it. Procarbazine has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.leadiant.com"}],"tags":[],"related":[],"cancers":["hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["procarbazine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Rome","country":"IT","companyType":"pharma","website":"https://www.leadiant.com","investors":[],"funding":[]},{"id":"leah-labs","kind":"company","name":"LEAH Labs","aka":[],"tldr":"LEAH Labs makes CAR-T cell therapy for dogs with lymphoma, using virus-free gene editing to bring the cost of a dose down to hundreds of dollars.","summary":"LEAH Labs (LifEngine Animal Health Laboratories) is developing CAR-T cell therapy for dogs with B-cell lymphoma, the naturally occurring counterpart of human non-Hodgkin lymphoma, using a non-viral gene-editing approach that the company says brings manufacturing cost to roughly $500 per dose. Its YC profile reports remissions in dogs with late-stage lymphoma. Veterinary cell therapies are regulated by the USDA rather than the FDA, which the company uses to iterate faster; the stated long-term aim is to carry the platform into human oncology.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/leah-labs"},{"label":"Official website","url":"https://www.leahlabs.com"}],"tags":["veterinary","comparative-oncology"],"related":[],"cancers":["dlbcl"],"sections":["cell-therapy"],"technologies":["car-t"],"targets":["cd20"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Minneapolis, MN","country":"US","companyType":"cell-therapy","website":"https://www.leahlabs.com","stage":"startup","ycBatch":"W19","investors":["y-combinator"],"funding":[]},{"id":"leaps-by-bayer","kind":"company","name":"Leaps by Bayer","aka":[],"tldr":"Bayer's impact investing unit, which funds companies tackling ten 'leaps' in health and agriculture, including curing cancer. Its website blocked automated access at the time of research.","summary":"Leaps by Bayer is the impact investment unit of Bayer AG that backs early-stage companies pursuing large 'leaps' in health and agriculture; one of its stated leaps concerns cancer, and it has invested in cell therapy and precision oncology start-ups. Its website (leaps.bayer.com) and the Leaps page on bayer.com both returned HTTP 403 with a 'Site Maintenance' bot-blocking message on every attempt, so the unit's own description, founding year, location and named oncology portfolio companies could not be confirmed from a primary source.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://leaps.bayer.com/"}],"tags":["corporate-venture"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["bayer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Website could not be fetched by the research pass on 2026-09-10 (bot protection, JavaScript-only or parked domain); location and description rest on the firm's public materials and on press releases that name it. leaps.bayer.com and bayer.com returned 403 bot-block pages via curl and WebFetch. Berlin follows the task hint (Bayer's pharmaceuticals division is based in Berlin; the group HQ is Leverkusen)."],"hq":"Berlin","country":"DE","companyType":"investor","website":"https://leaps.bayer.com/","investors":[],"funding":[]},{"id":"lees-pharmaceutical","kind":"company","name":"Lee's Pharmaceutical","aka":["Lee's Pharmaceutical Limited","Lee's Pharmaceutical Holdings","Lee's Pharm"],"tldr":"Lee's Pharmaceutical is a Hong Kong-listed company that licenses and develops medicines for Greater China, including cancer drugs it takes through phase 3 trials as lead sponsor.","summary":"Lee's Pharmaceutical Holdings, headquartered in Hong Kong and listed there, in-licenses and develops medicines for mainland China, Hong Kong and Taiwan across cardiovascular, women's health and oncology. It is lead sponsor of several phase 3 cancer trials registered on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.leespharm.com"},{"label":"ClinicalTrials.gov: trials led by Lee's Pharmaceutical","url":"https://clinicaltrials.gov/search?lead=Lee's%20Pharmaceutical"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["socazolimab"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Hong Kong","country":"HK","companyType":"pharma","website":"https://www.leespharm.com","stage":"private-large","investors":[],"funding":[]},{"id":"legend-biotech","kind":"company","name":"Legend Biotech","aka":[],"tldr":"Legend Biotech is the Chinese-origin developer of Carvykti, the most effective myeloma CAR-T, with J&J.","summary":"Legend Biotech, based in Somerset, New Jersey, and Nanjing and listed as LEGN, is the Chinese-origin developer of Carvykti, or ciltacabtagene autoleucel, the most effective myeloma CAR-T, in partnership with Johnson & Johnson. Cilta-cel was proved in LEGEND-2, CARTITUDE-1 and CARTITUDE-4, and the company is developing solid-tumour CAR-Ts including LB1908 against Claudin 18.2 and a DLL3 programme, with Fangliang Zhang among the people linked. OnCo links it to multiple myeloma, to the cilta-cel drug record and to the Comprehensive Cancer Center Mainfranken. Whether Legend can take a solid-tumour CAR-T as far as its myeloma product is the open question. Ciltacabtagene autoleucel has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.legendbiotech.com"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":[],"targets":[],"drugs":["ciltacabtagene-autoleucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Somerset, NJ / Nanjing","country":"US","companyType":"cell-therapy","website":"https://www.legendbiotech.com","ticker":"LEGN","investors":[],"funding":[]},{"id":"leica-biosystems","kind":"company","name":"Leica Biosystems (Danaher)","aka":[],"tldr":"Leica Biosystems, part of Danaher and based in Nussloch, Germany, makes the Aperio slide scanners (the GT 450 DX is FDA-cleared), the BOND immunohistochemistry stainers and companion diagnostic assays that pathology laboratories use to stain and digitise tissue. Whether routine pathology fully leaves the glass slide depends on suppliers like it.","summary":"Leica Biosystems, based in Nussloch, Germany, and part of Danaher, is a pathology workflow leader with the Aperio slide scanners, the BOND immunohistochemistry stainers and companion diagnostic assays. Its Aperio GT 450 DX scanner is FDA-cleared, the BOND-III and BOND-PRIME stainers automate staining, and its Novocastra antibodies supply the reagents. OnCo links it to whole-slide scanners and image management, histology automation and IHC autostainers, reference laboratories and companion diagnostic testing, and histopathology and immunohistochemistry. Whether the glass slide gives way fully to digital workflows in routine pathology depends on suppliers like this one. The whole-slide scanner page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.leicabiosystems.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["whole-slide-scanners","reference-laboratories","histopathology-ihc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Nussloch","country":"DE","companyType":"diagnostics","website":"https://www.leicabiosystems.com","investors":[],"funding":[]},{"id":"leo-cancer-care","kind":"company","name":"Leo Cancer Care","aka":[],"tldr":"Leo Cancer Care builds radiotherapy equipment that treats patients sitting upright instead of lying down, so the beam can stay fixed and the room, machine and building can be far smaller and cheaper.","summary":"Leo Cancer Care designs upright patient positioning and imaging for radiotherapy. Its Marie system rotates a seated patient in front of a fixed horizontal particle beam and includes an upright CT for planning and image guidance, removing the need for a multi-storey rotating gantry and cutting capital cost and shielding for proton and other particle centres. Grace, an upright photon system with fan-beam CT and a fast multileaf-collimator linac, was introduced at ASTRO 2025 and is not yet commercial. Marie received CE marking in May 2026 and has, the company says, already gained clinical momentum in the United States; European installation has begun at CNAO in Italy with treatments planned before the end of 2026. Partners include Mevion, Sumitomo Heavy Industries, IHH Healthcare, Centre Leon Berard and BNCT developers Aviko and Neutron Therapeutics. Offices are in Crawley, England and Middleton, Wisconsin. No funding round could be sourced.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://leocancercare.com/"},{"label":"CE mark for Marie press release (May 2026)","url":"https://www.prnewswire.com/news-releases/leo-cancer-care-secures-ce-mark-for-marie-advancing-upright-radiotherapy-in-europe-302777824.html"},{"label":"Contact page listing UK and US offices","url":"https://leocancercare.com/contact/"},{"label":"Grace upright photon therapy introduced at ASTRO 2025 (Middleton, WI dateline)","url":"https://www.prnewswire.com/news-releases/leo-cancer-care-introduces-grace-the-first-upright-photon-therapy-system-at-astro-2025-302568999.html"}],"tags":[],"related":[],"cancers":[],"sections":["radiation","devices"],"technologies":["proton-therapy","imrt-igrt","ct"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["HQ is ambiguous: the company lists a UK office in Crawley (dateline of the May 2026 CE mark release) and a US office in Middleton, WI (dateline of the Sept 2025 Grace launch release); Middleton is used per the US releases. Founding year and all funding rounds are unsourced and omitted; stage set to startup by default."],"hq":"Middleton, WI","country":"US","companyType":"devices","website":"https://leocancercare.com/","stage":"startup","investors":[],"funding":[]},{"id":"leo-pharma","kind":"company","name":"LEO Pharma","aka":["LEO Pharma A/S","Peplin"],"tldr":"LEO Pharma is a foundation-owned Danish dermatology company whose cancer-related trials concern actinic keratosis, the precancerous skin lesion that can progress to squamous cell carcinoma.","summary":"LEO Pharma, based in Ballerup near Copenhagen and majority-owned by the LEO Foundation, specialises in medical dermatology. Its registry footprint in cancer comes from actinic keratosis, the sun-damage lesion that can progress to cutaneous squamous cell carcinoma: it marketed ingenol mebutate gel (Picato) for the condition until the product's EU authorisation was withdrawn in 2020 over a possible skin cancer signal. OnCo records it so that those phase 3 trials resolve to a sponsor page.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Leo_Pharma","links":[{"label":"Official website","url":"https://www.leo-pharma.com"},{"label":"ClinicalTrials.gov: trials led by LEO Pharma","url":"https://clinicaltrials.gov/search?lead=LEO%20Pharma"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/LEO_Pharma"}],"tags":["ctgov-sponsor"],"related":["galderma","almirall"],"cancers":["cutaneous-scc"],"sections":["prevention"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Ballerup","country":"DK","companyType":"pharma","website":"https://www.leo-pharma.com","stage":"private-large","investors":[],"funding":[]},{"id":"lepu-biopharma","kind":"company","name":"Lepu Biopharma","aka":["Lepu Biopharma Co., Ltd."],"tldr":"Lepu Biopharma is a China-based biotechnology company running 8 late-stage cancer trials of MRG003, Pucotenlimab and MRG006A in head and neck squamous cell carcinoma, nasopharyngeal carcinoma and hepatocellular carcinoma.","summary":"Lepu Biopharma, based in Shanghai, China, is a biotechnology company. Lepu Biopharma is a China-based, globally focused biopharmaceutical company developing antibody-drug conjugates, oncolytic viruses and other immunotherapies for oncology. On ClinicalTrials.gov it is the lead sponsor of 8 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing MRG003, Pucotenlimab, MRG006A and Cretostimogene Grenadenorepvec in head and neck squamous cell carcinoma, nasopharyngeal carcinoma, hepatocellular carcinoma and bladder & urothelial cancer. The largest, NCT06976190 (A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma), plans to enrol 446 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.lepubiopharma.com"},{"label":"ClinicalTrials.gov: trials led by Lepu Biopharma","url":"https://clinicaltrials.gov/search?lead=Lepu%20Biopharma%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["head-and-neck","nasopharyngeal","hcc","urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["mrg003","pucotenlimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06976190","nct07479485","nct07586124","nct05126719","nct07283835","nct07093970","nct05688605"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.lepubiopharma.com","investors":[],"funding":[]},{"id":"lls-therapy-acceleration-program","kind":"company","name":"Leukemia & Lymphoma Society Therapy Acceleration Program","aka":[],"tldr":"The venture philanthropy arm of the blood cancer charity now called Blood Cancer United (formerly the Leukemia & Lymphoma Society). It invests charity money directly in companies developing blood cancer treatments.","summary":"The Therapy Acceleration Program (TAP) is the venture philanthropy programme of the charity founded in New York in 1949 as the Robert Roesler de Villiers Foundation, later the Leukemia Society of America, the Leukemia & Lymphoma Society (1999 to 2025) and now Blood Cancer United (Wikipedia). The charity funds research into leukaemia, lymphoma, myeloma and related blood cancers, and TAP makes equity investments and partnerships with biotech companies to accelerate blood cancer therapies. Both lls.org and bloodcancerunited.org returned HTTP 403 (Cloudflare) on every fetch attempt, so the programme's own description, launch year, current name and portfolio companies could not be confirmed from a primary source.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.lls.org/therapy-acceleration-program"},{"label":"Wikipedia (Blood Cancer United)","url":"https://en.wikipedia.org/wiki/Leukemia_and_Lymphoma_Society"}],"tags":["foundation"],"related":["leukemia-lymphoma-society"],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Website could not be fetched by the research pass on 2026-09-10 (bot protection, JavaScript-only or parked domain); location and description rest on the firm's public materials and on press releases that name it. Founded year is for the parent charity (Wikipedia). Rye Brook, NY follows the task hint. Website blocked automated access."],"hq":"Rye Brook, NY","country":"US","companyType":"investor","website":"https://www.lls.org/therapy-acceleration-program","founded":1949,"investors":[],"funding":[]},{"id":"ligachem-biosciences","kind":"company","name":"LigaChem Biosciences","aka":["LigaChem Biosciences, Inc."],"tldr":"LigaChem Biosciences is a South Korea-based biotechnology company running 2 late-stage cancer trials of LCB02A and LCB84.","summary":"LigaChem Biosciences, based in Daejeon, South Korea, is a biotechnology company. LigaChem Biosciences is a biotech company focused on drug research and development, specialising in antibody-drug conjugate (ADC) therapeutics, small molecule immunotherapies and synthetic drug development. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing LCB02A and LCB84. The largest, NCT05941507 (A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumours), plans to enrol 300 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.ligachembio.com"},{"label":"ClinicalTrials.gov: trials led by LigaChem Biosciences","url":"https://clinicaltrials.gov/search?lead=LigaChem%20Biosciences%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["lcb02a","lcb84"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05941507","nct07460375"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Daejeon","country":"KR","companyType":"biotech","website":"https://www.ligachembio.com","stage":"public","investors":[],"funding":[]},{"id":"lightpoint-medical","kind":"company","name":"Lightpoint Medical","aka":[],"tldr":"Lightpoint Medical is a British company that built LightPath, which images the faint Cerenkov light from PET tracers in a freshly removed tumour specimen, and SENSEI, a tiny gamma probe that a surgical robot can hold to find radioactive lymph nodes.","summary":"Lightpoint Medical, founded in 2012, developed Cerenkov luminescence imaging for intraoperative margin assessment, trialled in prostatectomy after gallium-68 PSMA injection, and the SENSEI drop-in gamma probe for robot-assisted sentinel node and PSMA-radioguided surgery, which is CE-marked and FDA-cleared. It works with radiopharmaceutical and robotics partners.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.lightpointmedical.com/"}],"tags":["machines-wave2"],"related":[],"cancers":["prostate","breast-cancer"],"sections":[],"technologies":["intraoperative-fluorescence-imaging-systems","gamma-probes-dose-calibrators","sentinel-node","psma-pet"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Chesham","country":"GB","companyType":"devices","website":"https://www.lightpointmedical.com/","founded":2012,"stage":"startup","investors":[],"funding":[]},{"id":"lightspeed-venture-partners","kind":"company","name":"Lightspeed Venture Partners","aka":[],"tldr":"Lightspeed is a large Silicon Valley venture firm best known for software, whose health practice backs cancer diagnostics, AI drug discovery and digital oncology companies.","summary":"Lightspeed Venture Partners is a multi-stage venture firm founded in 2000 and headquartered in Menlo Park, with a health and biotech practice investing in techbio, diagnostics, digital health and therapeutics platforms. In oncology it has backed companies that sit at the boundary of software and biology, such as AI-driven discovery and data companies, as well as care delivery. Portfolio links in OnCo are derived from the startup records that name it.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://lsvp.com"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Menlo Park, CA","country":"US","companyType":"investor","website":"https://lsvp.com","founded":2000,"investors":[],"funding":[]},{"id":"lila-sciences","kind":"company","name":"Lila Sciences","aka":[],"tldr":"Lila Sciences is Flagship Pioneering's 'scientific superintelligence' company, combining AI with autonomous labs, with life science as a first domain.","summary":"Lila Sciences, based in Cambridge, Massachusetts, is Flagship Pioneering's scientific superintelligence company, combining AI with autonomous laboratories, with life science as its first domain. It raised more than 500 million dollars in 2025 to build what it calls AI Science Factories that propose and run experiments in a closed loop, and its oncology applications are at an early stage. OnCo records it among the AI-driven discovery companies. Whether closed-loop automated science yields cancer biology that human-led laboratories miss is the open question, and there is little public evidence yet. The AI-driven drug discovery page carries the wider field.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.lila.ai"}],"tags":["ai"],"related":[],"cancers":[],"sections":["drug-discovery","ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cambridge, MA","country":"US","companyType":"ai-software","website":"https://www.lila.ai","investors":["flagship-pioneering"],"funding":[]},{"id":"lilly-ventures","kind":"company","name":"Lilly Ventures","aka":[],"tldr":"Eli Lilly's investment arm, part of its Lilly Catalyze360 programme for early biotech companies. It co-invests with venture syndicates across all disease areas, including cancer.","summary":"Lilly Ventures is described on Lilly's Catalyze360 page as 'our global investment arm', one of the pillars (with Lilly Gateway Labs, Lilly ExploR&D and Lilly TuneLab) 'built to engage biotechs at the earliest stages and agnostic of therapeutic area'. The page says Lilly Ventures 'makes investments to move the innovation needle in novel areas of science, extending to health tech, emerging platforms and other impact initiatives' and deploys 'customized engagement models to co-invest with world-class syndicate partners'. The lillyventures.com domain now redirects to Lilly's partnering site, and the fetched pages do not list portfolio companies, so no oncology portfolio examples are cited. Lilly's own oncology strategy (radiopharmaceuticals, KRAS, protein degraders) suggests the venture arm's cancer exposure, but this was not confirmed from a fetched page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.lilly.com/science/partners/catalyze-360"},{"label":"Lilly partnering","url":"https://www.lilly.com/science/partners"}],"tags":["corporate-venture"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["lillyventures.com redirects to lilly.com/science/partners. Founding year and portfolio not stated on fetched pages. Indianapolis follows Lilly's headquarters."],"hq":"Indianapolis, IN","country":"US","companyType":"investor","website":"https://www.lilly.com/science/partners/catalyze-360","investors":[],"funding":[]},{"id":"limbus-ai","kind":"company","name":"Limbus AI","aka":[],"tldr":"Limbus AI provides AI auto-contouring for radiotherapy, FDA-cleared and used across hundreds of centres.","summary":"Limbus AI, based in Regina, Canada, provides AI auto-contouring for radiotherapy that is FDA-cleared and used across hundreds of centres. Its Limbus Contour software segments organs at risk on CT and MR images in minutes and integrates with the major planning systems. OnCo links it to AI auto-contouring and adaptive planning. Whether automated contouring frees enough clinician time to expand radiotherapy capacity, which is the case made for it, is the open question that needs measuring. The auto-contouring technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://limbus.ai"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["radiation","ai-computation"],"technologies":["auto-contouring-ai"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Regina","country":"CA","companyType":"ai-software","website":"https://limbus.ai","investors":[],"funding":[]},{"id":"lindis-biotech","kind":"company","name":"Lindis Biotech","aka":["LINDIS Biotech GmbH"],"tldr":"Lindis Biotech is the German company that took over catumaxomab, the trifunctional antibody once sold as Removab for malignant ascites, and brought it back to regulators after its earlier withdrawal.","summary":"Lindis Biotech is a Munich-area biopharmaceutical company founded by the developers of the trifunctional antibody platform behind catumaxomab. Catumaxomab binds EpCAM on tumour cells and CD3 on T cells while its Fc region engages accessory immune cells; it was approved in the European Union in 2009 as Removab for malignant ascites and withdrawn for commercial reasons in 2017. Lindis resubmitted the drug to the European Medicines Agency and is developing it in gastric cancer and non-muscle-invasive bladder cancer.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["catumaxomab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Munich","country":"DE","companyType":"biotech","investors":[],"funding":[]},{"id":"linnaeus-therapeutics","kind":"company","name":"Linnaeus Therapeutics","aka":["Linnaeus Therapeutics, Inc."],"tldr":"Linnaeus Therapeutics is a New Jersey biotech whose oral drug LNS8801 activates the oestrogen receptor GPER, a pathway that pushes melanoma cells to stop dividing and become visible to the immune system.","summary":"Linnaeus Therapeutics develops LNS8801, an orally available agonist of the G protein-coupled oestrogen receptor (GPER), based on University of Pennsylvania research showing that GPER activation drives melanoma differentiation and lowers c-Myc. LNS8801 has been tested alone and with pembrolizumab in phase 1/2 trials in cutaneous melanoma and uveal melanoma, including patients who had progressed on checkpoint inhibitors.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["lns8801"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Haddonfield, New Jersey","country":"US","companyType":"biotech","investors":[],"funding":[]},{"id":"lisata","kind":"company","name":"Lisata Therapeutics","aka":["Lisata Therapeutics, Inc.","Caladrius Biosciences","Cend Therapeutics"],"tldr":"Lisata is a New Jersey biotech developing certepetide, a peptide that opens up the dense stroma of pancreatic tumours so chemotherapy can reach the cancer cells; it is tested with gemcitabine and nab-paclitaxel.","summary":"Lisata Therapeutics, formed when Caladrius Biosciences merged with Cend Therapeutics in 2022 and based in Basking Ridge, New Jersey, develops certepetide (LSTA1, formerly CEND-1), a cyclic peptide that binds alpha-v integrins and neuropilin-1 to increase drug penetration into solid tumours. It is tested in metastatic pancreatic cancer with standard chemotherapy and in other stroma-rich tumours, registered on ClinicalTrials.gov under Lisata as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.lisata.com"},{"label":"ClinicalTrials.gov: trials led by Lisata Therapeutics, Inc.","url":"https://clinicaltrials.gov/search?lead=Lisata%20Therapeutics%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Basking Ridge, NJ","country":"US","companyType":"biotech","website":"https://www.lisata.com","stage":"public","investors":[],"funding":[]},{"id":"liyfe","kind":"company","name":"Liyfe","aka":[],"tldr":"Liyfe built a digital nurse that checks in with cancer patients between visits, scores their symptoms and flags who needs a call, to cut emergency visits.","summary":"Liyfe developed a remote symptom management platform for oncology practices that automates nurse triage pathways with AI, standardising symptom assessment, detecting high-risk patients and aiming to reduce emergency department visits and hospital admissions. The YC directory lists it as active with a very small team and no website; no product deployments, evidence or financing were found in a primary source, so treat the record as a placeholder for a company whose status is unclear.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/liyfe"}],"tags":["yc"],"related":[],"cancers":[],"sections":["supportive-care","ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"New York, NY","country":"US","companyType":"ai-software","website":"https://www.ycombinator.com/companies/liyfe","stage":"startup","ycBatch":"S20","investors":["y-combinator"],"funding":[]},{"id":"loccioni","kind":"company","name":"Loccioni","aka":[],"tldr":"Loccioni is an Italian family engineering group whose APOTECAchemo robot prepares personalised chemotherapy doses inside a sealed cabinet, weighing every step, in hospital pharmacies on several continents.","summary":"Loccioni, founded in 1968 in the Marche region, applies measurement and automation engineering to industry and healthcare. Its APOTECA line, developed with Italian hospital pharmacists, includes the APOTECAchemo compounding robot, APOTECAunit for single doses and APOTECAps software, installed in oncology pharmacies in Europe, the United States and Asia to reduce dosing errors and staff exposure.","asOf":"2026-09-17","links":[{"label":"APOTECA","url":"https://www.apotecachemo.com/"}],"tags":["machines-wave2"],"related":[],"cancers":[],"sections":[],"technologies":["pharmacy-automation","closed-system-transfer-devices","cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Angeli di Rosora, Ancona","country":"IT","companyType":"devices","website":"https://www.apotecachemo.com/","founded":1968,"stage":"private-large","investors":[],"funding":[]},{"id":"logos-capital","kind":"company","name":"Logos Capital","aka":[],"tldr":"Logos Capital is a San Francisco healthcare investment firm that backs biotech companies from private rounds through their public life, and turns up repeatedly in cancer drug financings.","summary":"Logos Capital is a healthcare-focused investment firm based in San Francisco with offices in San Diego and Boston, investing in private and public biotechnology companies with a data-driven, clinically grounded approach. It appears as a participant in several of the sourced oncology rounds in OnCo, typically as part of a syndicate rather than as the company-creating lead. Portfolio links here are derived from the startup records that name it; the firm's own site describes its team and approach rather than listing a full portfolio.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.logoscapital.com"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"investor","website":"https://www.logoscapital.com","investors":[],"funding":[]},{"id":"longwood-fund","kind":"company","name":"Longwood Fund","aka":[],"tldr":"Longwood Fund is a Boston venture firm that founds and funds early biotech companies, several of them in cancer.","summary":"Longwood Fund is a Boston-based healthcare venture firm founded in 2010 that creates and invests in early-stage biotechnology companies, frequently as a founding investor working with academic scientists. Oncology has been a recurring area, including immuno-oncology and precision medicine companies. Portfolio links in OnCo are derived from the startup records that name it.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.longwoodfund.com"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boston, MA","country":"US","companyType":"investor","website":"https://www.longwoodfund.com","founded":2010,"investors":[],"funding":[]},{"id":"lonza","kind":"company","name":"Lonza","aka":[],"tldr":"Lonza is the largest contract manufacturer for biologics, ADCs, and cell therapies, and owns the Synaffix ADC linker technology and the Cocoon cell-manufacturing platform.","summary":"Lonza, based in Basel and listed as LONN.SW, is the largest contract manufacturer for biologics, antibody-drug conjugates and cell therapies, and it owns the Synaffix ADC linker technology and the Cocoon cell-manufacturing platform. It is a Swiss CDMO with bioconjugation capacity in Visp, mammalian manufacturing worldwide including the former Genentech Vacaville site acquired in 2024, cell and gene therapy sites in Houston and Geleen, and the Cocoon closed platform. OnCo links it to ADC bioconjugation, closed automated cell-therapy manufacturing, viral vector manufacturing, sterile fill-finish and payload-linker synthesis, to Synaffix, and to the CDMO term. Whether contract manufacturing capacity, rather than science, becomes the limiting factor for ADCs and cell therapies is the question its position raises. Synaffix has its own page.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Lonza_Group","links":[{"label":"Official website","url":"https://www.lonza.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["adcs","cell-therapy"],"technologies":["adc-cdmo-manufacturing","closed-automated-cell-manufacturing","viral-vector-manufacturing","sterile-fill-finish","high-potency-payload-synthesis"],"targets":[],"drugs":[],"companies":["synaffix"],"institutions":[],"pathways":[],"terms":["cdmo"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Basel","country":"CH","companyType":"cro-services","website":"https://www.lonza.com","ticker":"LONN.SW","investors":[],"funding":[]},{"id":"lucence","kind":"company","name":"Lucence","aka":[],"tldr":"Lucence offers blood tests that read both tumour DNA and tumour RNA from a single sample to help doctors choose targeted treatments, and is developing a multi-cancer screening test.","summary":"Lucence is a precision diagnostics company with laboratories in Singapore and Palo Alto, California, and an office in Hong Kong. Its AmpliMARK amplicon-based technology enables ultrasensitive detection of cell-free DNA and RNA. The flagship LiquidHALLMARK assay profiles circulating tumour DNA and RNA in one blood draw to identify actionable mutations and fusions in solid tumours, with a cerebrospinal fluid version for central nervous system cancers. LucenceINSIGHT is a multi-cancer early detection (MCED) test the company states screens at 99 percent specificity, and LucenceMONITOR addresses treatment monitoring. Laboratories are CAP-accredited and CLIA-certified. Data on combined ctDNA and ctRNA yield were presented at ASCO 2025, and in March 2026 Lucence, DxD Hub and the National Cancer Centre Singapore launched an S$6 million research collaboration.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.lucence.com/"},{"label":"News and updates","url":"https://www.lucence.com/news-updates"},{"label":"About Lucence","url":"https://www.lucence.com/about"}],"tags":[],"related":[],"cancers":["nsclc","colorectal","breast-hr-positive"],"sections":["diagnostics","early-detection"],"technologies":["liquid-biopsy","cgp","rna-seq","mced"],"targets":["egfr","alk","kras","ret","ntrk","met"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No funding round could be sourced from primary releases on the company site; stage set to startup provisionally. Founding year not sourced. Cancer and target tags reflect typical LiquidHALLMARK coverage described generically on the site rather than a fetched panel list."],"hq":"Singapore","country":"SG","companyType":"diagnostics","website":"https://www.lucence.com/","stage":"startup","investors":[],"funding":[]},{"id":"lumicell","kind":"company","name":"Lumicell","aka":[],"tldr":"MIT spin-out whose Lumisight dye and imaging system show leftover breast cancer in the lumpectomy cavity before the operation ends.","summary":"Lumicell, based in Newton, Massachusetts, and founded in 2008, is the MIT spin-out whose Lumisight dye and imaging system show leftover breast cancer in the lumpectomy cavity before the operation ends. Its pegulicianine, sold as Lumisight, and the Lumicell Direct Visualization System were approved by the FDA in April 2024 after the INSITE trial, making the combination the first optical imaging agent approved for breast cancer surgery. OnCo links it to HR-positive, triple-negative and HER2-positive breast cancer, fluorescence-guided surgery and optical imaging, and to the pegulicianine record. Whether intraoperative imaging reduces re-operations enough to justify its cost and time is the open question. Pegulicianine has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.lumicell.com"}],"tags":[],"related":[],"cancers":["breast-hr-positive","tnbc","breast-her2-positive"],"sections":["imaging","surgery"],"technologies":["fluorescence-guided-surgery","optical-imaging"],"targets":[],"drugs":["pegulicianine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct02584244"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Newton, MA","country":"US","companyType":"imaging","website":"https://www.lumicell.com","founded":2008,"stage":"growth","investors":[],"funding":[]},{"id":"luminate-medical","kind":"company","name":"Luminate Medical","aka":[],"tldr":"Luminate makes a wearable device that presses gently on the scalp during chemotherapy to stop the drug reaching the hair follicles, so patients keep their hair. It is in trials and no regulator has cleared it.","summary":"Luminate Medical, founded in Galway, developed Lily, a wearable cap that applies controlled compression to the scalp during chemotherapy infusion to restrict blood flow to hair follicles and prevent chemotherapy-induced hair loss, an alternative to cold-cap scalp cooling that needs no refrigeration. Its sister device Lilac applies low pressure to the hands and feet with the same intent for chemotherapy nerve damage.\n\nWhat can be verified independently is the registry, not the claim. The Lily trial, PREVAIL (NCT06786078), is a single-group open-label safety and efficacy study of 85 patients at four US sites, started December 2024, with hair preservation at four cycles graded by an independent clinician as its primary question; participants wear the device during the infusion and for two to four hours afterwards. Its registry record is still marked recruiting but was last updated in January 2025, past its own estimated completion, and no result has been published. The Lilac trial (NCT07142304) started in October 2025 with 142 participants and a sham arm.\n\nThe device is not cleared. Luminate appears nowhere among the devices the US Food and Drug Administration has authorised under the scalp cooling product code, and the company’s own website states that the information on it pertains to pre-clinical or clinical-stage medical devices in development that have not been approved by the Food and Drug Administration. That site is now largely about Lotus, a nurse-led home chemotherapy infusion service, rather than about the devices.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/luminate-medical"},{"label":"Official website","url":"https://www.luminatemed.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["rejuvenation","supportive-care","devices"],"technologies":["scalp-cooling"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Galway","country":"IE","companyType":"devices","website":"https://www.luminatemed.com","stage":"startup","ycBatch":"S21","investors":["y-combinator"],"funding":[]},{"id":"lunit","kind":"company","name":"Lunit","aka":[],"tldr":"Korean AI company spanning mammography reading (INSIGHT MMG), breast-density risk (Volpara), and AI pathology for immunotherapy biomarkers.","summary":"21 studies at ECR 2026 covering INSIGHT MMG, Scorecard (ex-Volpara density), and INSIGHT CXR; a large Dutch randomised trial using Scorecard showed supplemental MRI in dense breasts reduced advanced cancer incidence. Lunit SCOPE pathology AI partnered with Labcorp and CellCarta (2025-26) for companion diagnostics.","asOf":"2026-09-04","links":[{"label":"ECR 2026","url":"https://www.prnewswire.com/news-releases/lunit-to-be-featured-in-21-ai-imaging-studies-on-breast-cancer-and-lung-disease-at-ecr-2026-302703651.html"}],"tags":[],"related":[],"cancers":["breast-hr-positive","tnbc","nsclc"],"sections":["ai-computation","imaging","early-detection"],"technologies":["radiology-ai-screening","digital-pathology-ai","mammography"],"targets":[],"drugs":[],"companies":["volpara-health"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Seoul","country":"KR","companyType":"ai-software","website":"https://www.lunit.io","ticker":"328130.KQ","investors":[],"funding":[]},{"id":"lupeng-pharmaceuticals","kind":"company","name":"Lupeng Pharmaceuticals","aka":["Guangzhou Lupeng Pharmaceutical","鲁鹏医药"],"tldr":"Lupeng Pharmaceuticals is a China-based biotechnology company that leads 4 cancer trials in OnCo, testing the Bcl-2 inhibitor lacutoclax (LP-108) and the BTK inhibitor rocbrutinib (LP-168) in chronic lymphocytic leukaemia, mantle cell lymphoma, diffuse large B-cell lymphoma and follicular lymphoma.","summary":"Lupeng Pharmaceuticals develops next-generation small-molecule targeted drugs for malignant tumours and autoimmune diseases, focused on haematological cancers and the BTK, Bcl-2 and Bcl-xL pathways. Its site states that rocbrutinib (LP-168) is approved by China's NMPA and that lacutoclax (LP-108) has entered pivotal registration studies. On ClinicalTrials.gov it is the lead sponsor of 4 trials recorded in OnCo: NCT07609823 (phase 2, A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL), NCT07609862 (phase 1/2, A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies), NCT05716087 (phase 2, A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma) and NCT07189065 (phase 2, A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.lupengbio.com/"},{"label":"ClinicalTrials.gov: trials led by Lupeng Pharmaceuticals","url":"https://clinicaltrials.gov/search?lead=Guangzhou%20Lupeng%20Pharmaceutical%20Company%20LTD."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cll","mantle-cell-lymphoma","dlbcl","follicular-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["rocbrutinib","bendamustine","rituximab","lenalidomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07609823","nct07609862","nct05716087","nct07189065"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Guangzhou","country":"CN","companyType":"biotech","website":"https://www.lupengbio.com/","stage":"growth","investors":[],"funding":[]},{"id":"lupin","kind":"company","name":"Lupin","aka":[],"tldr":"A Mumbai generics and biosimilars company, founded in 1968, for which oncology is a growing segment of its Indian formulations business.","summary":"Lupin was founded in 1968 by Desh Bandhu Gupta, a chemistry professor, and grew into one of India's largest generics companies with a strong US presence in respiratory, cardiovascular and anti-infective medicines. Oncology is one of the therapy segments of its India formulations business, and its biologics unit (including the YL Biologics joint venture with Japan's Yoshindo, formed in 2014) develops biosimilars. Lupin is representative of the second tier of Indian companies that keep generic cancer drug prices low domestically and supply regulated markets.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.lupin.com"}],"tags":[],"related":[],"cancers":[],"sections":["chemotherapy"],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Mumbai","country":"IN","companyType":"pharma","website":"https://www.lupin.com","ticker":"LUPIN.NS","founded":1968,"investors":[],"funding":[]},{"id":"lux-capital","kind":"company","name":"Lux Capital","aka":[],"tldr":"A New York venture firm that backs deep technology companies, from defence and AI to biology. Its biotech holdings include the AI drug discovery company Recursion and the imaging-based drug hunter Eikon Therapeutics.","summary":"Lux Capital was founded in 2000 by Peter Hebert, Robert Paull and Josh Wolfe and is based in New York (Wikipedia). Its tagline is 'We turn sci-fi into sci-fact' and its companies page mixes defence (Anduril), AI (Hugging Face, Cognition) and space with life sciences. Biology-related holdings on the companies page are Recursion Pharma (high-throughput biology and machine learning for drug discovery, which runs oncology programmes), Eikon Therapeutics (single-molecule live-cell imaging for drug discovery), Kallyope (gut-brain axis), eGenesis (gene-edited organs) and Benchling (R&D software). Lux is a generalist rather than an oncology specialist, and its page does not describe disease areas, so its relevance to cancer is indirect.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.luxcapital.com/"},{"label":"Companies","url":"https://www.luxcapital.com/companies"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Lux_Capital"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["eikon-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No company on the fetched Lux pages is described as oncology-focused; Recursion and Eikon are cited as drug discovery platforms with cancer programmes known from elsewhere."],"hq":"New York, NY","country":"US","companyType":"investor","website":"https://www.luxcapital.com/","founded":2000,"investors":[],"funding":[]},{"id":"luye-pharma","kind":"company","name":"Luye Pharma Group","aka":["Luye Pharma Group Ltd.","Luye Pharma","绿叶制药","Shandong Boan Biotechnology Co., Ltd","Boan Biotech"],"tldr":"Luye Pharma is a Chinese pharmaceutical group, listed in Hong Kong, whose oncology business rests on paclitaxel liposome (Lipusu) and other reformulated cancer medicines.","summary":"Luye Pharma Group, based in Yantai in Shandong and listed on the Hong Kong stock exchange, develops and sells medicines in oncology, the central nervous system and cardiovascular disease, with a focus on new formulations and long-acting delivery. Its best-known cancer product is Lipusu, a liposomal formulation of paclitaxel widely used in China, and it runs phase 3 trials of reformulated chemotherapy and targeted agents. OnCo records it as a registry sponsor of phase 3 cancer trials.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.luye.cn"},{"label":"ClinicalTrials.gov: trials led by Luye Pharma","url":"https://clinicaltrials.gov/search?lead=Luye%20Pharma"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Luye_Pharma_Group"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":["chemotherapy"],"technologies":[],"targets":[],"drugs":["paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct06496048","nct06128837","nct06022861"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Yantai","country":"CN","companyType":"pharma","website":"https://www.luye.cn","stage":"public","investors":[],"funding":[]},{"id":"lyell-immunopharma","kind":"company","name":"Lyell Immunopharma","aka":[],"tldr":"Lyell makes next-generation CAR T-cell therapies designed to last longer in the body and resist exhaustion. Its lead product, ronde-cel, targets two proteins on lymphoma cells at once and is in pivotal trials for large B-cell lymphoma.","summary":"Lyell Immunopharma is a late-stage clinical company developing CAR T-cell therapies engineered to resist exhaustion and retain stem-like qualities. Lead candidate rondecabtagene autoleucel (ronde-cel) is an autologous dual-targeting CD19/CD20 CAR T-cell product with an OR logic gate, manufactured with a process that enriches CD62L-positive cells. It is in two pivotal trials in relapsed or refractory large B-cell lymphoma, PiNACLE (third line or later) and PiNACLE-H2H (second line); no grade 3 or higher cytokine release syndrome was seen in more than 100 patients. Pivotal data are expected mid-2027 with a BLA planned for late 2027. Ronde-cel holds RMAT and Fast Track designations. LYL273 is a CAR T candidate in a phase 1/2 trial in metastatic colorectal cancer. Lyell runs its own LyFE manufacturing centre, held about $228 million in cash at 30 June 2026 and trades on Nasdaq as LYEL.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Lyell_Immunopharma","links":[{"label":"Official website","url":"https://www.lyell.com"},{"label":"Q2 2026 results (8-K exhibit 99.1)","url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828026054330/lyel-20260806x8kexx991.htm"}],"tags":[],"related":[],"cancers":["dlbcl","colorectal"],"sections":["cell-therapy"],"technologies":["car-t"],"targets":["cd19","cd20"],"drugs":["rondecabtagene-autoleucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05826535","nct05319314"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No funding round sourced; the June 2021 IPO release was not located in EDGAR full-text search."],"hq":"South San Francisco, CA","country":"US","companyType":"cell-therapy","website":"https://www.lyell.com","ticker":"LYEL","stage":"public","investors":[],"funding":[]},{"id":"lysa","kind":"company","name":"LYSA (The Lymphoma Study Association)","aka":["LYSA","GELA","Groupe d'Etude des Lymphomes de l'Adulte","GOELAMS","LYSARC"],"tldr":"The French-Belgian lymphoma group, successor to GELA, whose LNH-98.5 trial made R-CHOP the standard for diffuse large B-cell lymphoma.","summary":"LYSA was formed in 2012 by merging GELA (founded 1984) and GOELAMS; LYSARC is its academic research organisation. GELA's LNH-98.5 was the trial that added rituximab to CHOP and changed the outcome of DLBCL worldwide, and PRIMA established rituximab maintenance in follicular lymphoma. LYSA co-ran POLARIX (polatuzumab-R-CHP) and leads trials of bispecific antibodies, CAR-T sequencing and PET-guided therapy across France, Belgium and Portugal. It maintains a national lymphoma pathology review network (Lymphopath) and the REALYSA real-world cohort.","asOf":"2026-09-09","links":[{"label":"LYSA","url":"https://www.lysa-lymphoma.org"}],"tags":["cooperative-group"],"related":["glofitamab","axicabtagene-ciloleucel"],"cancers":["dlbcl","hodgkin-lymphoma"],"sections":[],"technologies":["monoclonal-antibody","bispecific-antibody","car-t","fdg-pet"],"targets":[],"drugs":[],"companies":["ielsg","german-lymphoma-alliance"],"institutions":["institut-curie","centre-henri-becquerel"],"pathways":[],"terms":[],"trials":["prima","polarix"],"people":["steven-le-gouill","franck-morschhauser","herve-tilly"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["LNH-98.5 (R-CHOP)","PRIMA (rituximab maintenance)","POLARIX (with Roche)","REALYSA cohort and Lymphopath"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Pierre-Bénite (Lyon)","country":"FR","companyType":"cooperative-group","website":"https://www.lysa-lymphoma.org","founded":2012,"investors":[],"funding":[]},{"id":"lyvgen-biopharma","kind":"company","name":"Lyvgen Biopharma","aka":["Lyvgen Biopharma Holdings","礼进生物"],"tldr":"Lyvgen Biopharma is a Shanghai antibody company that builds agonists of immune-activating receptors such as CD137 and CD40; its CD137 antibody LVGN6051 is being tested with PD-1 blockade.","summary":"Lyvgen Biopharma develops next-generation immuno-oncology antibodies with engineered Fc regions that tune their crosslinking and activity. LVGN6051 is a CD137 (4-1BB) agonist designed to activate T cells within tumours while limiting the liver toxicity seen with earlier agents; it is in phase 1 trials alone and with pembrolizumab or anlotinib. LVGN7409 is a CD40 agonist and LVGN3616 is a PD-1 antibody.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.lyvgen.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["lvgn6051"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.lyvgen.com/","investors":[],"funding":[]},{"id":"maat-pharma","kind":"company","name":"MaaT Pharma","aka":[],"tldr":"MaaT Pharma makes gut microbiome treatments for people with blood cancer. Its lead product restores gut bacteria to treat a severe complication of stem cell transplants when standard drugs fail.","summary":"MaaT Pharma (Euronext Paris: MAAT), founded in 2014 in Lyon, develops Microbiome Ecosystem Therapies supported by its gutPrint AI discovery engine and in-house cGMP manufacturing. Lead product Xervyteg (MaaT013), a pooled full-ecosystem microbiome therapy, is intended for steroid-refractory gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation; more than 230 patients have been treated under early access across 13 countries. In June 2026 the EMA's CHMP issued a negative opinion and MaaT Pharma said it would request re-examination. MaaT033, an oral capsule, is in the PHOEBUS trial in allogeneic transplant recipients, described as potentially pivotal in Europe, with one-year overall survival data expected in late 2028. Cash was EUR 18.1 million at 31 March 2026; a EUR 6 million European Investment Bank loan tranche drawn in April 2026 extended runway to November 2026.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.maatpharma.com"},{"label":"Q1 2026 business update","url":"https://www.maatpharma.com/may-26-2026-maat-pharma-provides-business-update-and-reports-financial-results-for-the-first-quarter-2026/"},{"label":"Plan to request re-examination after negative CHMP opinion (June 2026)","url":"https://www.maatpharma.com/june-26-2026-maat-pharma-announces-plan-to-request-re-examination-following-negative-chmp-opinion-for-maat013-for-the-treatment-of-acute-graft-versus-host-disease/"}],"tags":[],"related":[],"cancers":[],"sections":["supportive-care","immunotherapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Lyon","country":"FR","companyType":"biotech","website":"https://www.maatpharma.com","ticker":"MAAT.PA","founded":2014,"stage":"public","investors":[],"funding":[{"round":"Debt","year":2026,"source":"https://www.maatpharma.com/may-26-2026-maat-pharma-provides-business-update-and-reports-financial-results-for-the-first-quarter-2026/","note":"Tranche B of EUR 6 million drawn from a European Investment Bank loan facility in April 2026"}]},{"id":"mabion","kind":"company","name":"Mabion","aka":["Mabion SA","Mabion S.A."],"tldr":"Mabion is a Polish biotech near Łódź that developed a rituximab biosimilar, MabionCD20, through phase 3 trials in lymphoma and rheumatoid arthritis, and now also manufactures biologics for partners.","summary":"Mabion S.A., based in Konstantynów Łódzki and listed in Warsaw, built a biologics plant to develop and make biosimilar antibodies. Its rituximab biosimilar MabionCD20 was taken through phase 3 comparative trials in diffuse large B-cell lymphoma and rheumatoid arthritis, registered on ClinicalTrials.gov under Mabion as lead sponsor, and the company now also offers contract manufacturing.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.mabion.eu"},{"label":"ClinicalTrials.gov: trials led by Mabion SA","url":"https://clinicaltrials.gov/search?lead=Mabion%20SA"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q19653276"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":["rituximab"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial","biosimilar"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Konstantynów Łódzki","country":"PL","companyType":"biotech","website":"https://www.mabion.eu","stage":"public","investors":[],"funding":[]},{"id":"mablink-bioscience","kind":"company","name":"Mablink Bioscience","aka":[],"tldr":"Mablink Bioscience, from Lyon, invented PSARlink, a water-soluble polysarcosine linker that hides the greasy cell-killing payload so an antibody can carry a higher load of drug molecules and still stay stable in the blood. Eli Lilly bought the company in 2023, before any of its medicines had reached patients.","summary":"Mablink Bioscience was a preclinical Lyon-based biotech whose PSARlink platform uses a hydrophilic polysarcosine linker arm to mask hydrophobic cytotoxic payloads, enabling homogeneous, plasma-stable antibody-drug conjugates with high drug-to-antibody ratios while preserving pharmacokinetics and tolerability; PSARlink ADCs showed an improved therapeutic index in animal models. The company was funded by a 2021 seed round led by Elaia Partners with UI Investissement and Relyens Innovation Santé, and a July 2022 Series A led by Sofinnova Partners and Mérieux Equity Partners. On 18 October 2023 Mablink announced an agreement to be acquired by Eli Lilly, subject to French Ministry of the Economy approval; terms were not disclosed. The company domain now redirects to lilly.com.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.lilly.com/"},{"label":"Acquisition announcement (BioSpace copy)","url":"https://www.biospace.com/mablink-bioscience-enters-an-agreement-to-be-acquired-by-lilly"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["mablink.com redirects to lilly.com, recorded as the website. Series A amount (reported elsewhere as EUR 31 million) not stated in the fetched source and omitted. GlobeNewswire original could not be fetched."],"hq":"Lyon","country":"FR","companyType":"biotech","website":"https://www.lilly.com/","stage":"acquired","investors":["sofinnova-partners"],"funding":[{"round":"Seed","year":2021,"source":"https://www.biospace.com/mablink-bioscience-enters-an-agreement-to-be-acquired-by-lilly","note":"Led by Elaia Partners; amount not stated in the fetched release copy"},{"round":"Series A","year":2022,"source":"https://www.biospace.com/mablink-bioscience-enters-an-agreement-to-be-acquired-by-lilly","note":"July 2022, led by Sofinnova Partners and Mérieux Equity Partners; amount not stated in the fetched release copy"},{"round":"Acquisition","year":2023,"source":"https://www.biospace.com/mablink-bioscience-enters-an-agreement-to-be-acquired-by-lilly","note":"Agreement announced 18 October 2023; terms not disclosed"}],"acquiredBy":"eli-lilly"},{"id":"mabwell-shanghai-bioscience","kind":"company","name":"Mabwell (Shanghai) Bioscience","aka":["Mabwell (Shanghai) Bioscience Co., Ltd."],"tldr":"Mabwell (Shanghai) Bioscience is a China-based biotechnology company running 11 late-stage cancer trials of Toripalimab (JS001 ) and JS207 in bladder & urothelial cancer, cervical cancer and colorectal cancer.","summary":"Mabwell (Shanghai) Bioscience, based in Shanghai, China, is a biotechnology company listed as 688062.SH, 02493.HK. Mabwell is an innovation-driven biopharmaceutical company covering the full chain of antibody drug research, manufacturing and commercialisation, with several marketed monoclonal antibody and biosimilar products. On ClinicalTrials.gov it is the lead sponsor of 11 recruiting or active phase 2 and phase 3 interventional cancer trials (3 in phase 3), testing Toripalimab (JS001 ) and JS207 in bladder & urothelial cancer, cervical cancer, colorectal cancer and triple-negative breast cancer. The largest, NCT06592326 (9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer), plans to enrol 460 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.mabwell.com/en/"},{"label":"ClinicalTrials.gov: trials led by Mabwell (Shanghai) Bioscience","url":"https://clinicaltrials.gov/search?lead=Mabwell%20(Shanghai)%20Bioscience%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["urothelial","cervical","colorectal","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06823427","nct07314723","nct06079112","nct06592326","nct06492005","nct07466160","nct06196736","nct06692166","nct07216560","nct07265622","nct05990452"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.mabwell.com/en/","ticker":"688062.SH, 02493.HK","founded":2017,"stage":"public","investors":[],"funding":[]},{"id":"mabxience-research-s-l","kind":"company","name":"mAbxience Research S.L.","aka":[],"tldr":"mAbxience Research S.L. is a Spain-based biotechnology company running 2 late-stage cancer trials in melanoma and non-small-cell lung cancer.","summary":"mAbxience Research S.L., based in Madrid, Spain, is a biotechnology company. mAbxience is a vertically integrated biopharmaceutical company that develops biosimilars and operates an independent contract development and manufacturing organisation (CDMO) platform. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3) in melanoma and non-small-cell lung cancer. The largest, NCT06687369 (A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)), plans to enrol 726 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.mabxience.com"},{"label":"ClinicalTrials.gov: trials led by mAbxience Research S.L.","url":"https://clinicaltrials.gov/search?lead=mAbxience%20Research%20S.L."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06687369","nct07221734"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Madrid","country":"ES","companyType":"biotech","website":"https://www.mabxience.com","investors":[],"funding":[]},{"id":"macrogenics","kind":"company","name":"MacroGenics","aka":[],"tldr":"MacroGenics is the antibody engineering company behind margetuximab and several bispecific and ADC programmes.","summary":"MacroGenics, based in Rockville, Maryland, and listed as MGNX, is an antibody engineering company behind margetuximab and a series of bispecific and antibody-drug conjugate programmes. Its Fc-optimisation and DART bispecific platforms produced margetuximab, sold as Margenza and approved in 2020 for HER2-positive breast cancer, vobramitamab duocarmazine, a B7-H3 ADC paused after toxicity, and lorigerlimab, a PD-1 by CTLA-4 bispecific. OnCo links it to HER2-positive breast cancer and to the margetuximab drug record. Whether platform companies can turn engineering advantages into products that beat entrenched antibodies is the question its record poses. Margetuximab has its own page.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://www.macrogenics.com"}],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":["targeted-therapy","adcs"],"technologies":[],"targets":[],"drugs":["margetuximab","lorigerlimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06730347"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Rockville, MD","country":"US","companyType":"biotech","website":"https://www.macrogenics.com","ticker":"MGNX","investors":[],"funding":[]},{"id":"maia-biotechnology","kind":"company","name":"Maia Biotechnology","aka":[],"tldr":"Maia Biotechnology is a United States-based biotechnology company running 2 late-stage cancer trials in non-small-cell lung cancer.","summary":"Maia Biotechnology, based in Chicago, the United States, is a biotechnology company. Maia Biotechnology is a clinical-stage biopharmaceutical company that develops telomere-targeting immunotherapies for cancer. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3) in non-small-cell lung cancer. The largest, NCT06908304 (A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC), plans to enrol 300 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.maiabiotech.com"},{"label":"ClinicalTrials.gov: trials led by Maia Biotechnology","url":"https://clinicaltrials.gov/search?lead=Maia%20Biotechnology"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["cemiplimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06908304","nct05208944"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Chicago","country":"US","companyType":"biotech","website":"https://www.maiabiotech.com","stage":"growth","investors":[],"funding":[]},{"id":"mammotome","kind":"company","name":"Mammotome (Danaher)","aka":[],"tldr":"Mammotome makes vacuum-assisted breast biopsy devices and, through Devicor, the Neoprobe gamma detection system used to find sentinel lymph nodes; it also acquired Endomag's magnetic tracer system.","summary":"Mammotome, part of Danaher, sells breast biopsy systems, specimen radiography, the Neoprobe gamma probe for sentinel node localisation and, after acquiring Endomag, the Sentimag probe with Magseed markers and Magtrace magnetic tracer, which localise lesions and nodes without radioactivity.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.mammotome.com/"}],"tags":["machines-wave2"],"related":[],"cancers":["breast-cancer","melanoma"],"sections":[],"technologies":["gamma-probes-dose-calibrators","sentinel-node"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cincinnati, OH","country":"US","companyType":"devices","website":"https://www.mammotome.com/","stage":"acquired","investors":[],"funding":[]},{"id":"marengo-therapeutics","kind":"company","name":"Marengo Therapeutics","aka":[],"tldr":"Marengo Therapeutics, of Cambridge, Massachusetts, makes antibodies that bind part of the T-cell receptor to activate selected subsets of a patient's T cells. Its lead, invikafusp alfa, is in trials in tumours with a high mutational burden that have stopped responding to checkpoint drugs, and with an antibody-drug conjugate in breast cancer.","summary":"Marengo Therapeutics is a clinical-stage Cambridge, Massachusetts company developing TCR-targeting antibodies that selectively modulate T-cell subsets. Its STAR platform (precision T-cell agonist) bispecifics include invikafusp alfa, in clinical development as monotherapy in immune checkpoint blockade-resistant, tumour mutational burden-high tumours (START-001) and in an antibody-drug conjugate combination in breast cancer (START-002), plus partnered STAR programmes. The TriSTAR platform (precision T-cell engager) includes TriSTAR0701 targeting Nectin-4 for bladder and other cancers and several partnered candidates, and the MSTAR platform (precision T-cell depleter) is aimed at autoimmune disease. Marengo's news page lists Apple Tree Partners as lead investor. Financing amounts and series were not stated on fetched pages.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://marengotx.com/"},{"label":"Pipeline","url":"https://marengotx.com/pipeline/"},{"label":"News and investors","url":"https://marengotx.com/news-investors/"}],"tags":[],"related":[],"cancers":["urothelial"],"sections":["immunotherapy"],"technologies":["bispecific-antibody","t-cell-engager"],"targets":["nectin4"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05592626","nct06827613"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No funding round sourced; press releases on the site are loaded client-side and could not be read."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://marengotx.com/","stage":"startup","investors":[],"funding":[]},{"id":"mariana-oncology","kind":"company","name":"Mariana Oncology","aka":[],"tldr":"Mariana Oncology designs small protein fragments that carry a radioactive isotope to tumours, starting with small cell lung cancer. Novartis bought the company in 2024 for 1 billion dollars up front.","summary":"Mariana Oncology, founded in 2021 in Watertown, Massachusetts by Atlas Venture, Access Biotechnology and RA Capital Management, built a fully integrated radiopharmaceutical platform combining peptide discovery, radiochemistry, in-house GMP manufacturing, isotope supply and formulations to extend product shelf life. Its portfolio of peptide-based radioligand therapies addresses a range of solid tumours; the lead candidate MC-339 is a radioligand therapy for small cell lung cancer that was expected to enter the clinic in 2024. The company closed a USD 175 million Series B in September 2023 co-led by Deep Track Capital and Forbion, and in May 2024 agreed to be acquired by Novartis for USD 1 billion upfront and up to USD 750 million in milestones. As a Novartis company it announced a USD 50 million expansion of radioligand R&D facilities in June 2025.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://marianaoncology.com/"},{"label":"Series B press release","url":"https://marianaoncology.com/news/mariana-oncology-announces-usd175-million-series-b-financing/"},{"label":"Novartis acquisition announcement","url":"https://marianaoncology.com/news/mariana-oncology-to-be-acquired-by-novartis-to-advance-precision-radiopharmaceuticals-to-treat-cancer/"}],"tags":[],"related":[],"cancers":["sclc"],"sections":["radiopharma"],"technologies":["radioligand-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["MC-339 target not stated on fetched pages. Series A not fetched and omitted."],"hq":"Watertown, MA","country":"US","companyType":"radiopharma","website":"https://marianaoncology.com/","founded":2021,"stage":"acquired","investors":["atlas-venture","ra-capital","forbion"],"funding":[{"round":"Series B","year":2023,"amountUsd":175000000,"source":"https://marianaoncology.com/news/mariana-oncology-announces-usd175-million-series-b-financing/"},{"round":"Acquisition","year":2024,"amountUsd":1000000000,"source":"https://marianaoncology.com/news/mariana-oncology-to-be-acquired-by-novartis-to-advance-precision-radiopharmaceuticals-to-treat-cancer/","note":"USD 1 billion upfront plus up to USD 750 million in milestones"}],"acquiredBy":"novartis"},{"id":"marker-therapeutics","kind":"company","name":"Marker Therapeutics","aka":[],"tldr":"Marker grows a patient's own T cells that naturally recognise several tumour proteins at once, without genetic engineering, and gives them back as a treatment. Its lead product has shown responses in relapsed lymphoma and is moving into pancreatic cancer.","summary":"Marker Therapeutics is a Houston clinical-stage immuno-oncology company developing Multi-Antigen Recognizing (MAR)-T cell therapies, non-engineered T-cell products enriched for reactivity against several tumour-associated antigens. Lead candidate MT-601 is in the phase 1 APOLLO study in relapsed non-Hodgkin lymphoma, where an update reported a 66% objective response rate including 50% complete responses; lymphodepletion was shown to enhance MT-601 expansion and persistence, and the study moved into dose expansion in relapsed diffuse large B-cell lymphoma with a further update expected in the second quarter of 2026. Baylor College of Medicine research published in Nature Medicine in early 2026 reported promising results with MAR-T cells in pancreatic cancer, and Marker plans a company-sponsored pancreatic cancer trial. Manufacturing is supported by a collaboration with Cellipont Bioservices. Nasdaq: MRKR.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://markertherapeutics.com/"},{"label":"Year-end 2025 results (8-K exhibit 99.1, March 2026)","url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465926031309/tm268941d1_ex99-1.htm"}],"tags":[],"related":[],"cancers":["dlbcl","pancreatic"],"sections":["cell-therapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No funding round sourced."],"hq":"Houston, TX","country":"US","companyType":"cell-therapy","website":"https://markertherapeutics.com/","ticker":"MRKR","stage":"public","investors":[],"funding":[]},{"id":"massive-bio","kind":"company","name":"Massive Bio","aka":[],"tldr":"Massive Bio uses artificial intelligence to read a cancer patient's medical records and match them to clinical trials they may be eligible for, anywhere in the world, with doctors checking the results.","summary":"Massive Bio, based in New York and co-founded by Selin Kurnaz, oncologist Arturo Loaiza-Bonilla and Cagatay Culcuoglu, runs the SYNERGY-AI platform, which analyses more than 500 clinical and molecular data elements from uploaded records to match patients to more than 19,000 active oncology and haematology trials, with physician review and a report within 24 hours. It reports more than 200,000 onboarded patients, 17 pharmaceutical customers and operations in 18 countries, and in November 2025 became the AI trial matching provider for the American Cancer Society's ACS ACTS clinical trial equity programme. In May 2020 Massive Bio raised USD 9 million led by Revo Capital and Kenan Turnacıoğlu with DEG participating; the release did not name the series, so it is not entered as a round. A later USD 2.6 million raise from strategic investors is undated on the company site.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://massivebio.com"},{"label":"USD 9 million financing announcement (May 2020)","url":"https://massivebio.com/mb-raises-9-million-to-scale-growth/"},{"label":"American Cancer Society ACS ACTS programme release (November 2025)","url":"https://www.prnewswire.com/news-releases/american-cancer-society-launches-nationwide-program-to-increase-equity-in-clinical-trials-302617253.html"},{"label":"About Massive Bio","url":"https://massivebio.com/about-us/"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["ai-trial-matching"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The 2020 USD 9 million round and the USD 2.6 million follow-on have no series names in company releases, so they are described in the summary only. Founding year not sourced. Stage set to startup by default."],"hq":"New York, NY","country":"US","companyType":"ai-software","website":"https://massivebio.com","stage":"startup","investors":[],"funding":[]},{"id":"mast-therapeutics","kind":"company","name":"Mast Therapeutics","aka":["Mast Therapeutics, Inc.","ADVENTRX Pharmaceuticals","Savara"],"tldr":"Mast, earlier called ADVENTRX, was a San Diego biotech whose fluorouracil modulator CoFactor reached phase 3 in colorectal cancer and failed; it later pursued sickle cell disease and merged into Savara in 2017.","summary":"Mast Therapeutics, formerly ADVENTRX Pharmaceuticals, developed ANX-510 (CoFactor), a folate analogue intended to enhance fluorouracil, through a phase 3 trial in metastatic colorectal cancer that did not show benefit, and later vepoloxamer for sickle cell crisis and heart failure, which also failed in phase 3. The company merged with Savara in 2017. Its trials remain on ClinicalTrials.gov under Mast and ADVENTRX as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://savarapharma.com"},{"label":"ClinicalTrials.gov: trials led by Mast Therapeutics, Inc.","url":"https://clinicaltrials.gov/search?lead=Mast%20Therapeutics%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30286592"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["fluorouracil"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://savarapharma.com","stage":"acquired","investors":[],"funding":[]},{"id":"mbrace-therapeutics","kind":"company","name":"MBrace Therapeutics","aka":[],"tldr":"MBrace Therapeutics is a United States-based biotechnology company running 2 late-stage cancer trials in prostate cancer, HR-positive / HER2-negative breast cancer and colorectal cancer.","summary":"MBrace Therapeutics, based in San Diego, CA, the United States, is a biotechnology company. MBrace Therapeutics is a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer, using a proprietary in vivo target-discovery platform called SPARTA. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials in prostate cancer, HR-positive / HER2-negative breast cancer, colorectal cancer, non-small-cell lung cancer and pancreatic ductal adenocarcinoma. The largest, NCT07145255 (Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumours), plans to enrol 150 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.mbracetrx.com"},{"label":"ClinicalTrials.gov: trials led by MBrace Therapeutics","url":"https://clinicaltrials.gov/search?lead=MBrace%20Therapeutics"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate","breast-hr-positive","colorectal","nsclc","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07145255","nct06014658"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://www.mbracetrx.com","stage":"startup","investors":[],"funding":[]},{"id":"mckesson-us-oncology","kind":"company","name":"McKesson / The US Oncology Network","aka":["US Oncology Research"],"tldr":"McKesson runs the largest US community oncology network (about 3,000 providers) and distributes drugs, and co-owns the Sarah Cannon Research Institute.","summary":"McKesson, based in Irving, Texas, and listed as MCK, runs The US Oncology Network, the largest US community oncology network with about three thousand providers, distributes cancer drugs, and co-owns the Sarah Cannon Research Institute. Its offerings span practice management, the Value Pathways treatment pathways, the Ontada data business and research through SCRI, with McKesson Ventures also linked. OnCo connects it to community oncology and site networks and to oncology EHR and real-world data platforms. Whether a drug distributor that also owns treatment pathways and practices can keep those pathways independent is the fair question. Sarah Cannon has its own page.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.usoncology.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":["community-oncology-networks","oncology-real-world-data"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04782687","nct03379428","nct00248287"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Irving, TX","country":"US","companyType":"cro-services","website":"https://www.usoncology.com","ticker":"MCK","investors":[],"funding":[]},{"id":"mckesson-ventures","kind":"company","name":"McKesson Ventures","aka":[],"tldr":"McKesson Ventures is the venture arm of the drug distributor McKesson, which also owns the largest US community oncology network, so it backs companies that change how cancer care is delivered and paid for.","summary":"McKesson Ventures is the corporate venture capital arm of McKesson Corporation, based in San Francisco, investing in healthcare technology and services companies that can work with McKesson's businesses, including The US Oncology Network and Ontada. Its oncology investments are typically in digital health, value-based care and practice-facing software rather than drug discovery. Portfolio links in OnCo are derived from the startup records that name it.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://ventures.mckesson.com"}],"tags":["corporate-venture"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["mckesson-us-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"investor","website":"https://ventures.mckesson.com","investors":[],"funding":[]},{"id":"mdxhealth","kind":"company","name":"MDxHealth","aka":[],"tldr":"Prostate diagnostics company that bought Oncotype DX GPS from Exact Sciences and sells the Select mdx and Confirm mdx tests.","summary":"MDxHealth, based in Irvine, California, and Herstal, Belgium, founded in 2003 and listed as MDXH, is a prostate diagnostics company that bought the Oncotype DX Genomic Prostate Score from Exact Sciences and sells the Select mdx and Confirm mdx tests. Its portfolio spans the pre-biopsy urine test Select mdx, the post-negative-biopsy methylation test Confirm mdx, the Genomic Prostate Score acquired in 2022 and Resolve mdx for urinary tract infections, and it moved its headquarters from Belgium to California in 2023. OnCo links it to prostate cancer, active surveillance and the Genomic Prostate Score record. Whether a suite of tests can reduce unnecessary biopsies and support active surveillance without missing aggressive disease is the question its products address. The Genomic Prostate Score has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://mdxhealth.com"}],"tags":[],"related":[],"cancers":["prostate"],"sections":["diagnostics"],"technologies":["active-surveillance"],"targets":[],"drugs":["oncotype-dx-gps"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Irvine, CA / Herstal","country":"US","companyType":"diagnostics","website":"https://mdxhealth.com","ticker":"MDXH","founded":2003,"investors":[],"funding":[]},{"id":"medable","kind":"company","name":"Medable","aka":[],"tldr":"Medable is a decentralised clinical trial platform (eConsent, eCOA, telehealth).","summary":"Medable, based in Palo Alto, is a decentralised clinical trial platform providing electronic consent, electronic clinical outcome assessment and telehealth. Its software has been used in hundreds of trials, including hybrid designs in oncology that mix site visits with remote follow-up. OnCo links it to decentralised and hybrid clinical trials. Whether decentralised tools widen who can join oncology trials, or mainly reduce sponsor cost, is the open question that enrolment data will answer. The decentralised trials page carries the wider evidence.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.medable.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["decentralised-clinical-trials"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Palo Alto, CA","country":"US","companyType":"ai-software","website":"https://www.medable.com","investors":[],"funding":[]},{"id":"medac","kind":"company","name":"medac","aka":["medac GmbH","medac Pharma"],"tldr":"medac is a German family-owned pharmaceutical company whose alkylating agent treosulfan, long used in Europe, was approved by the FDA in 2025 as conditioning treatment before stem cell transplantation in acute myeloid leukaemia and myelodysplastic syndromes.","summary":"medac GmbH, based in Wedel near Hamburg, is a privately held German company specialising in haematology, oncology, urology and autoimmune disease. Its alkylating agent treosulfan, approved in Europe for decades and marketed there as Trecondi for transplant conditioning, received FDA approval in January 2025 (Grafapex) with fludarabine as a preparative regimen before allogeneic haematopoietic stem cell transplantation in adults and children with acute myeloid leukaemia or myelodysplastic syndromes. Company facts are from the official website and FDA approval records.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Medac","links":[{"label":"Official website","url":"https://www.medac.de/"},{"label":"FDA: oncology and hematologic malignancies approval notifications","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"}],"tags":["fda-oce-applicant"],"related":[],"cancers":["aml","mds"],"sections":["chemotherapy","cell-therapy"],"technologies":[],"targets":[],"drugs":["treosulfan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Wedel","country":"DE","companyType":"pharma","website":"https://www.medac.de/","stage":"private-large","investors":[],"funding":[]},{"id":"medicxi","kind":"company","name":"Medicxi","aka":[],"tldr":"A London and Geneva venture firm that funds single-asset drug companies run by experienced drug hunters. Its cancer companies have included ProfoundBio (bought by Genmab), Kurome Therapeutics and Gadeta.","summary":"Medicxi has offices in London (25 Great Pulteney Street), Geneva and Jersey (contact page). Its approach is asset-centric: backing focused companies built around one or a few drug candidates, often with partners such as Verily, Novartis and GSK as limited partners. Its news room records a EUR 400 million Medicxi III fund closed in 2019 and a $40 million investment in D3 Bio in 2024. Oncology deals in the news room include Genmab's acquisition of ProfoundBio (antibody-drug conjugates), Kurome Therapeutics' $15 million Series A for kinase inhibitors in haematological cancers, Divide & Conquer (disrupting cell-to-cell communication in cancer), Yukin Therapeutics and Gilead's purchase of the gamma-delta T-cell company Gadeta. Non-oncology exits such as Centessa (Lilly) and Vicebio (Sanofi) dominate recent headlines.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.medicxi.com/"},{"label":"News room","url":"https://www.medicxi.com/news-room"},{"label":"Contact","url":"https://www.medicxi.com/contact"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["profoundbio","genmab"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on fetched pages and there is no Wikipedia article; omitted. The companies page is rendered client-side."],"hq":"London","country":"GB","companyType":"investor","website":"https://www.medicxi.com/","investors":[],"funding":[]},{"id":"medidata","kind":"company","name":"Medidata (Dassault Systèmes)","aka":[],"tldr":"Medidata, owned by Dassault Systèmes, makes Rave, the most used electronic data capture system in clinical trials, plus randomisation and outcome-assessment tools and synthetic control arms built from past trial data. Whether regulators accept synthetic controls for oncology approvals is the open question.","summary":"Medidata, based in New York and acquired by Dassault Systèmes in 2019, makes Rave, the most used electronic data capture system in clinical trials, and offers synthetic control arm services. Its products span Rave EDC, electronic clinical outcome assessment, randomisation and trial supply management, and Acorn AI for synthetic controls built from past trial data. OnCo links it to clinical trial software covering EDC, eCOA, CTMS and RTSM. Whether synthetic control arms drawn from historical trial data will be accepted by regulators for oncology approvals is the open question. The clinical trial software page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.medidata.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["clinical-trial-software"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"New York, NY","country":"US","companyType":"ai-software","website":"https://www.medidata.com","investors":[],"funding":[]},{"id":"medigene","kind":"company","name":"Medigene","aka":["MediGene AG","Medigene AG"],"tldr":"Medigene is a Munich-area biotech that develops T-cell receptor therapies and once sold a dendritic-cell vaccine programme; its earlier oncology products included the drug Veregen and phase 3 trials that carry its name.","summary":"Medigene AG, founded in 1994 and based in Planegg near Munich, discovers T-cell receptors for engineered T-cell therapies against solid tumours and licenses them to partners. Earlier it developed and sold Veregen (sinecatechins) and EndoTAG-1, a cationic liposomal paclitaxel taken to phase 3 in pancreatic cancer by its licensee, and ran a dendritic-cell vaccine programme in acute myeloid leukaemia. Its trials are registered on ClinicalTrials.gov under Medigene as lead sponsor.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/MediGene","links":[{"label":"Official website","url":"http://www.medigene.com"},{"label":"ClinicalTrials.gov: trials led by MediGene AG","url":"https://clinicaltrials.gov/search?lead=MediGene%20AG"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q1403929"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["pancreatic","aml"],"sections":[],"technologies":["tcr-t","dendritic-cell-vaccines"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Planegg","country":"DE","companyType":"cell-therapy","website":"http://www.medigene.com","founded":1994,"stage":"public","investors":[],"funding":[]},{"id":"medilink","kind":"company","name":"MediLink Therapeutics","aka":["MediLink Therapeutics (Suzhou)","MediLink Therapeutics"],"tldr":"MediLink developed the TMALIN ADC linker platform, licensed to Zai Lab, BioNTech, and Roche.","summary":"MediLink Therapeutics, based in Suzhou, developed the TMALIN antibody-drug conjugate linker platform, which it has licensed to Zai Lab, BioNTech and Roche. Its pipeline includes YL201, a B7-H3 ADC in phase 3 in small-cell lung cancer, ZL-6201 against LRRC15 with Zai Lab, and a c-MET ADC deal with Roche. OnCo links it to B7-H3 as a target and to Zai Lab as a partner. Whether a linker platform company can hold on to its own lead programme rather than out-license everything is the open question. The B7-H3 target page carries the competitive picture.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.medilinkthera.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":[],"targets":["b7h3"],"drugs":["yl201","yl202"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06459973","nct05434234","nct07197827","nct07258979","nct07208773","nct07169994","nct06241846","nct07202364","nct06107686","nct06439771","nct06057922"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Suzhou","country":"CN","companyType":"biotech","website":"https://www.medilinkthera.com","investors":[],"funding":[]},{"id":"mediso","kind":"company","name":"Mediso","aka":[],"tldr":"Mediso is a Hungarian nuclear medicine company making AnyScan SPECT/CT and PET/CT cameras for hospitals and nanoScan PET/MRI and SPECT/CT scanners for preclinical research.","summary":"Founded in Budapest in 1990, Mediso is one of the few independent makers of clinical gamma cameras and SPECT/CT systems (the AnyScan family, including combined SPECT/CT/PET) and is a leader in small-animal imaging with the nanoScan PET/MRI, PET/CT and SPECT/CT systems used in radiopharmaceutical development. OnCo links it to SPECT/CT and SPECT.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Mediso","links":[{"label":"Official website","url":"https://mediso.com"}],"tags":["machines-wave"],"related":[],"cancers":[],"sections":["imaging","radiopharma"],"technologies":["spect-ct","spect","pet-ct"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Budapest","country":"HU","companyType":"imaging","website":"https://mediso.com","founded":1990,"stage":"growth","investors":[],"funding":[]},{"id":"mednet","kind":"company","name":"Mednet (theMednet)","aka":[],"tldr":"theMednet is an online question-and-answer network where oncologists ask hard clinical questions and get answers from named experts, with AI now helping to search the archive.","summary":"theMednet started as a physician-only oncology network where treating doctors post questions about real cases and academic experts answer, building a searchable archive of curated clinical judgement that sits between guidelines and the literature. It has since expanded beyond oncology and layers AI search over the archive and the published evidence. The company states that over 40,000 US physicians use the platform. It was co-founded by siblings Samir and Nadine Housri, a radiation oncologist, after their father's cancer treatment.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/mednet"},{"label":"Official website","url":"https://www.themednet.org"}],"tags":["yc"],"related":[],"cancers":[],"sections":["ai-computation","supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"New York, NY","country":"US","companyType":"ai-software","website":"https://www.themednet.org","stage":"growth","ycBatch":"W17","investors":["y-combinator"],"funding":[]},{"id":"medpace","kind":"company","name":"Medpace","aka":[],"tldr":"Medpace, of Cincinnati, is a mid-sized full-service contract research organisation whose physician-led model keeps medical oversight, the imaging core laboratory and central laboratories in-house, a package that biotechnology companies buy for oncology programmes. Whether in-house imaging and laboratories give cleaner oncology endpoints than outsourcing is unproven.","summary":"Medpace, based in Cincinnati and listed as MEDP, is a mid-sized full-service contract research organisation whose clients are mostly biotechnology companies, including for oncology programmes. Its physician-led model keeps medical oversight in-house, as are its imaging core laboratory and central laboratories. OnCo links it to contract research organisations and to imaging core labs and central review. Whether keeping imaging and laboratory work in-house gives cleaner oncology endpoints than outsourcing them is the argument behind its model and the open question. The CRO technology page carries the wider picture.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Medpace","links":[{"label":"Official website","url":"https://www.medpace.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["contract-research-organisations","imaging-core-labs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07432633","nct07702292","nct05986851","nct07189871","nct07197580","nct04329728","nct06777433"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cincinnati, OH","country":"US","companyType":"cro-services","website":"https://www.medpace.com","ticker":"MEDP","investors":[],"funding":[]},{"id":"medpacto","kind":"company","name":"MedPacto","aka":["MedPacto Inc.","메드팩토","KOSDAQ:235980"],"tldr":"MedPacto is a South Korean biotech whose oral TGF-beta receptor inhibitor vactosertib is being tested with chemotherapy and checkpoint inhibitors in colorectal, stomach and bone-marrow cancers.","summary":"MedPacto, listed on KOSDAQ, develops vactosertib (TEW-7197), an oral inhibitor of the TGF-beta type 1 receptor kinase ALK5 that aims to relieve the immunosuppressive and fibrotic effects of TGF-beta in the tumour microenvironment. Vactosertib is in a phase 2/3 trial with FOLFIRI and bevacizumab in second-line metastatic colorectal cancer and has been studied with pembrolizumab in colorectal and gastric cancer, with pomalidomide in multiple myeloma and in osteosarcoma.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.medpacto.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["vactosertib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Seoul","country":"KR","companyType":"biotech","website":"https://www.medpacto.com/","ticker":"KOSDAQ:235980","stage":"public","investors":[],"funding":[]},{"id":"medtronic","kind":"company","name":"Medtronic","aka":[],"tldr":"Medtronic is the largest medical device company; in cancer care it sells the Hugo surgical robot, Emprint microwave and Cool-tip radiofrequency ablation systems, the O-arm intraoperative imaging and StealthStation navigation, and the GI Genius artificial-intelligence polyp detector.","summary":"Medtronic, founded in Minneapolis in 1949 and domiciled in Dublin since its 2015 merger with Covidien, sells across surgery, cardiology, neuroscience and diabetes. Its oncology-relevant hardware is the Hugo robotic-assisted surgery system, which is CE marked and entering the US market as the first broad rival to da Vinci, the Emprint microwave and Cool-tip radiofrequency ablation systems used for liver, kidney and lung tumours, surgical staplers and energy devices used in most cancer operations, the O-arm cone-beam imaging and StealthStation navigation used in spinal tumour surgery, and GI Genius, the first artificial-intelligence colonoscopy aid cleared in the United States. OnCo links it to surgical robots, thermal ablation, intraoperative imaging and AI polyp detection.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Medtronic","links":[{"label":"Official website","url":"https://www.medtronic.com"}],"tags":["machines-wave"],"related":[],"cancers":[],"sections":["surgery","devices"],"technologies":["surgical-robot-platforms","microwave-rf-ablation","thermal-ablation","intraoperative-mri-ct","ai-endoscopy-detection","robotic-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Dublin","country":"IE","companyType":"devices","website":"https://www.medtronic.com","ticker":"MDT","founded":1949,"stage":"public","investors":[],"funding":[]},{"id":"mei-pharma","kind":"company","name":"MEI Pharma","aka":["MEI Pharma, Inc."],"tldr":"MEI Pharma is a San Diego company whose PI3K-delta inhibitor zandelisib for follicular lymphoma was dropped in 2022 after the FDA signalled it would need a randomised trial, following the class-wide safety review of PI3K inhibitors.","summary":"MEI Pharma, listed on Nasdaq, developed zandelisib, an intermittently dosed PI3K-delta inhibitor partnered with Kyowa Kirin, for relapsed follicular and marginal zone lymphoma; it reached the phase 3 COASTAL trial before the FDA's 2022 reassessment of PI3K inhibitors in blood cancers led the partners to stop US development. The company also studied voruciclib, a CDK9 inhibitor, in acute myeloid leukaemia, and later wound down its pipeline. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.meipharma.com"},{"label":"ClinicalTrials.gov: trials led by MEI Pharma","url":"https://clinicaltrials.gov/search?lead=MEI%20Pharma"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["follicular-lymphoma","aml"],"sections":["targeted-therapy"],"technologies":["pi3k-akt-mtor-inhibitors"],"targets":["pik3cd"],"drugs":[],"companies":["kyowa-kirin"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://www.meipharma.com","stage":"public","investors":[],"funding":[]},{"id":"menarini","kind":"company","name":"Menarini / Stemline","aka":[],"tldr":"Menarini is the private Italian pharma that commercialises the first oral SERD, elacestrant.","summary":"Menarini, the private Italian pharmaceutical company based in Florence, commercialises the first oral SERD, elacestrant, through its Stemline oncology unit. Elacestrant, sold as Orserdu, is used in oestrogen-receptor-positive, HER2-negative breast cancer, and tagraxofusp, sold as Elzonris, treats blastic plasmacytoid dendritic cell neoplasm. OnCo links it to HR-positive, HER2-negative breast cancer and to BPDCN, and to both drug records. Whether the first oral SERD keeps its position as newer oral SERDs and degraders reach the market is the open question for Menarini's oncology business. Elacestrant has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.menarini.com"}],"tags":[],"related":[],"cancers":[],"sections":["hormonal"],"technologies":[],"targets":[],"drugs":["elacestrant"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07766018","nct05596409","nct05563220","nct06492616","nct06456463","nct05386108"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Florence","country":"IT","companyType":"pharma","website":"https://www.menarini.com","investors":[],"funding":[]},{"id":"menarini-silicon-biosystems","kind":"company","name":"Menarini Silicon Biosystems","aka":["Silicon Biosystems","CellSearch","DEPArray"],"tldr":"The Menarini group's diagnostics arm that owns CellSearch, the only regulator-cleared circulating tumour cell test, and DEPArray, an instrument that picks out single cells from a sample for sequencing.","summary":"Silicon Biosystems was founded in Bologna as a spin-out from the University of Bologna to commercialise DEPArray, a dielectrophoresis-based instrument that isolates individual cells from a mixed sample so they can be sequenced or analysed one at a time. The Menarini group acquired it in 2013 and in 2017 bought the CellSearch circulating tumour cell system from Janssen Diagnostics, uniting enumeration of circulating tumour cells with single-cell recovery. The company sells the instruments and reagents to hospital and research laboratories and runs a service laboratory in the United States; its main customers are pharmaceutical trials that use circulating tumour cell counts and single-cell analysis as biomarkers.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.siliconbiosystems.com"},{"label":"CellSearch","url":"https://www.cellsearchctc.com"}],"tags":[],"related":[],"cancers":["breast-cancer","prostate","colorectal"],"sections":[],"technologies":["cellsearch-ctc-count","ctc-capture","liquid-biopsy","single-cell-spatial"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Castel Maggiore (Bologna), Italy","country":"IT","companyType":"diagnostics","website":"https://www.siliconbiosystems.com","stage":"acquired","investors":[],"funding":[],"acquiredBy":"menarini"},{"id":"mendus","kind":"company","name":"Mendus","aka":[],"tldr":"Mendus makes an off-the-shelf cell-based cancer vaccine, given as a skin injection after standard treatment, to stop leukaemia and ovarian cancer from coming back.","summary":"Mendus AB (Nasdaq Stockholm: IMMU) is headquartered in Stockholm with research and development in Leiden. Lead programme vididencel (DCP-001) is an allogeneic active immunotherapy derived from a proprietary leukaemia cell line; given intradermally it triggers local immune activation and tumour-directed immune responses against residual disease. It is being developed as maintenance therapy in acute myeloid leukaemia (ADVANCE II and CADENCE), in high-risk ovarian cancer (ALISON), where in June 2026 the company reported long-term progression-free survival with broad immune activation and five participants progression-free at long-term follow-up, and in chronic myeloid leukaemia for treatment-free remission (VITAL-CML, first stage fully enrolled in 2026). A second asset, ilixadencel, is an intratumoural allogeneic dendritic cell product. No equity round could be sourced from fetched pages; in June 2026 the company repurchased outstanding warrants from Fenja for about SEK 3.7 million.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.mendus.com"},{"label":"Press releases","url":"https://www.mendus.com/investors/press-releases/"},{"label":"Pipeline and technology","url":"https://www.mendus.com/what-we-do/"}],"tags":[],"related":[],"cancers":["aml","ovarian"],"sections":["immunotherapy"],"technologies":["shared-antigen-vaccine","allogeneic-cell-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year and rights issues not sourced from fetched pages."],"hq":"Stockholm","country":"SE","companyType":"biotech","website":"https://www.mendus.com","ticker":"IMMU.ST","stage":"public","investors":[],"funding":[]},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","aka":[],"tldr":"Merck & Co. (MSD) makes Keytruda, the world's best-selling cancer drug, and is now building the next act around TROP2 ADCs and personalised vaccines.","summary":"Pembrolizumab anchors >40 indications. Post-2028 patent-cliff strategy: sacituzumab tirumotecan (Kelun licence, >10 phase 3 trials), ifinatamab/patritumab/raludotatug deruxtecan (Daiichi Sankyo alliance, up to $22B), intismeran autogene (Moderna), zilovertamab vedotin, belzutifan, and a PD-1×VEGF bispecific (LaNova).","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.merck.com"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy","adcs"],"technologies":[],"targets":[],"drugs":["pembrolizumab","sacituzumab-tirumotecan","belzutifan","intismeran-autogene","olaparib","patritumab-deruxtecan","ifinatamab-deruxtecan","raludotatug-deruxtecan","zilovertamab-vedotin","calderasib","zanzalintinib","opevesostat","mk-1045","bomedemstat","vibostolimab","boserolimab","favezelimab","temozolomide","interferon-alfa","peginterferon-alfa-2b","flutamide"],"companies":["harpoon-therapeutics","msd-global-health-innovation-fund"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06212752","nct06717347","nct06305754","nct06698042","nct07216703","nct07318558","nct06824467","nct06356311","nct06170788","nct06459180","nct06422143","nct06312137","nct06952504","nct06077760","nct06132958","nct02362594","nct04624204","nct06925737","nct05722015","nct06074588","nct04956692","nct07513376","nct02332668","nct06780137","nct03162536","nct07519772","nct07049926","nct03407144","nct06099782","keynote-158","nct04895722","nct06731907","nct05458297","nct07221474","nct04924075","nct04728893","nct05468697","nct02861573","nct06307431","nct06961006","nct06843447","nct07227597","nct06428409","nct06395103","nct04130516","nct06483334","nct04956640","nct06393374","nct07158918","nct06818643","nct06623422","nct04145622","nct06864169","nct03725059","nct06795412","nct06731478","nct06979596","nct05947851","nct06469944","nct06330064","nct07405151","nct07232602","nct05624554","nct05224141","nct04626479","nct07252739","nct06312176","nct07419295","nct05405595","nct07630974","nct07302347","nct04585035","nct07469774","nct06966700","nct07286149","nct06305767","nct07060807","nct06116136","nct05562830","nct06797635","nct03485209","nct01874353","nct06863272","nct05609968","nct05319730","nct06596694","nct06637423","nct06041802","nct04225117","nct06686394","nct04219254","nct04586231","nct05669430","nct04241185","nct05899049","nct04938817","nct06941272","nct05101070","nct04976634","nct04895358","nct04626518","nct05761223","nct05406401","nct07209111","nct06780098","nct03742895","nct06644781","nct06428396","nct06353386","nct05173987","nct04041310","nct06016920","nct06890884","nct06780111","nct05911295","nct06445972","nct06788912","nct03711032","nct07405164","nct06780085","nct06660654","nct07222488","nct04489771","nct05579132","nct06833073","nct05239741","nct04879329","nct06556563","nct05845814","nct04380636","nct06841354","nct04634877","nct06163430"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Rahway, NJ","country":"US","companyType":"pharma","website":"https://www.merck.com","ticker":"MRK","investors":[],"funding":[]},{"id":"merck-kgaa","kind":"company","name":"Merck KGaA (EMD Serono)","aka":["EMD Serono","EMD Serono, Inc.","EMD Serono Research & Development Institute, Inc.","Merck Healthcare KGaA","Merck KGaA, Darmstadt, Germany","Merck Serono"],"tldr":"Merck KGaA of Darmstadt, which trades as EMD Serono in North America, sells the anti-PD-L1 antibody avelumab, cetuximab outside the United States and the MET inhibitor tepotinib, and bought SpringWorks Therapeutics in 2025 to add nirogacestat and mirdametinib for rare tumours.","summary":"Merck KGaA, the Darmstadt science and technology company that is distinct from the US Merck & Co., runs its healthcare business as EMD Serono in the United States and Canada. Its oncology medicines include avelumab (Bavencio), an anti-PD-L1 antibody used as maintenance in urothelial cancer and in Merkel cell carcinoma; cetuximab (Erbitux), which it markets outside North America; and tepotinib (Tepmetko) for MET exon 14-skipping non-small-cell lung cancer. In 2025 it acquired SpringWorks Therapeutics, bringing the gamma-secretase inhibitor nirogacestat for desmoid tumours and the MEK inhibitor mirdametinib for neurofibromatosis-related plexiform neurofibromas. Company facts are from FDA approval records and the SpringWorks acquisition announcement.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Merck_Group","links":[{"label":"FDA: oncology and hematologic malignancies approval notifications","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"}],"tags":["fda-oce-applicant"],"related":[],"cancers":["urothelial","merkel-cell-carcinoma","nsclc","colorectal","head-and-neck","desmoid-tumour"],"sections":["immunotherapy","targeted-therapy"],"technologies":[],"targets":[],"drugs":["avelumab","cetuximab","capmatinib-tepotinib","nirogacestat","mirdametinib","precemtabart-tocentecan"],"companies":["springworks"],"institutions":[],"pathways":[],"terms":[],"trials":["nct02864992","nct06710132","nct03815643","nct05327530"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Darmstadt","country":"DE","companyType":"pharma","website":"https://www.merckgroup.com","stage":"public","investors":[],"funding":[]},{"id":"merrimack-pharmaceuticals","kind":"company","name":"Merrimack Pharmaceuticals","aka":["Merrimack Pharmaceuticals, Inc.","Merrimack"],"tldr":"Merrimack was the Cambridge biotech behind liposomal irinotecan (Onivyde), approved for pancreatic cancer in 2015 and later sold to Ipsen; its antibody programmes failed and the company wound down.","summary":"Merrimack Pharmaceuticals, founded in 2000 in Cambridge, Massachusetts, developed MM-398, a liposomal formulation of irinotecan approved in 2015 as Onivyde for metastatic pancreatic cancer after gemcitabine (the NAPOLI-1 trial), which it sold to Ipsen in 2017. Its systems-biology antibody programmes, including the HER3 antibody seribantumab, did not reach approval, and the company later returned remaining assets to shareholders. Its phase 3 trials remain on ClinicalTrials.gov under Merrimack as lead sponsor.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Merrimack_Pharmaceuticals","links":[{"label":"Official website","url":"http://www.merrimackpharma.com"},{"label":"ClinicalTrials.gov: trials led by Merrimack Pharmaceuticals, Inc.","url":"https://clinicaltrials.gov/search?lead=Merrimack%20Pharmaceuticals%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30287940"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["irinotecan"],"companies":["ipsen"],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"http://www.merrimackpharma.com","founded":2000,"stage":"defunct","investors":[],"funding":[]},{"id":"mersana","kind":"company","name":"Mersana Therapeutics","aka":[],"tldr":"ADC platform company betting on B7-H4: emiltatug ledadotin (Emi-Le) has Breakthrough designation in adenoid cystic carcinoma and activity in TNBC after TOP1 ADCs.","summary":"Mersana Therapeutics, based in Cambridge, Massachusetts, and listed as MRSN, is an antibody-drug conjugate platform company betting on B7-H4, whose emiltatug ledadotin, or Emi-Le, holds Breakthrough designation in adenoid cystic carcinoma and shows activity in triple-negative breast cancer after topoisomerase 1 ADCs. Emi-Le, also XMT-1660, produced a 23 percent objective response rate in TNBC previously treated with topoisomerase 1 ADCs and confirmed responses in adenoid cystic carcinoma, earning Breakthrough designation in May 2026, and the company also pioneered STING-agonist ADCs such as XMT-2056. OnCo links it to TNBC, head and neck, ovarian and endometrial cancer, to ADC sequencing as a term, and to the bottleneck of acquired resistance. Whether a non-topoisomerase payload can rescue patients after TOP1 ADCs fail is the open question.","asOf":"2026-09-04","links":[{"label":"Breakthrough designation (OncLive)","url":"https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-emi-le-for-adenoid-cystic-carcinoma"}],"tags":[],"related":[],"cancers":["tnbc","head-and-neck","ovarian","endometrial"],"sections":["adcs"],"technologies":["adc","immune-stimulating-adc"],"targets":[],"drugs":["upifitamab-rilsodotin"],"companies":[],"institutions":[],"pathways":[],"terms":["adc-sequencing"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://www.mersana.com","ticker":"MRSN","investors":[],"funding":[]},{"id":"merus","kind":"company","name":"Merus","aka":[],"tldr":"Dutch bispecific antibody company behind zenocutuzumab and petosemtamab; acquired by Genmab in 2025.","summary":"Merus, based in Utrecht and listed as MRUS, is the Dutch bispecific antibody company behind zenocutuzumab and petosemtamab, and Genmab announced its acquisition for around 8 billion dollars in 2025. Its Biclonics platform produced zenocutuzumab, approved in 2024 for NRG1 fusion cancers and expanded in 2026, and petosemtamab, an EGFR by LGR5 bispecific in phase 3 in head and neck cancer, through LiGeR-HN1, and colorectal cancer. OnCo links it to head and neck squamous cell carcinoma and biliary tract cancer, to both drug records and to Betta Pharmaceuticals. Whether petosemtamab can improve on current standards in head and neck cancer is the question the phase 3 will answer. Zenocutuzumab has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://merus.nl"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy","immunotherapy"],"technologies":[],"targets":[],"drugs":["zenocutuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Utrecht","country":"NL","companyType":"biotech","website":"https://merus.nl","ticker":"MRUS","investors":[],"funding":[]},{"id":"mesoblast","kind":"company","name":"Mesoblast","aka":["Mesoblast, Inc.","Mesoblast Limited"],"tldr":"Mesoblast is an Australian cell therapy company whose remestemcel-L became in December 2024 the first mesenchymal stromal cell therapy approved by the FDA, for children with steroid-refractory acute graft-versus-host disease.","summary":"Mesoblast, headquartered in Melbourne with a US base in New York, develops allogeneic mesenchymal stromal cell therapies from healthy donor bone marrow. After a long regulatory path including an earlier complete response letter, its product remestemcel-L (Ryoncil) was approved by the FDA in December 2024 for steroid-refractory acute graft-versus-host disease in children aged two months and older, a complication of stem cell transplantation for blood cancers. The company is also developing the platform for heart failure and back pain. Company facts are from FDA approval records.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Mesoblast","links":[{"label":"FDA approval announcement for remestemcel-L","url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-mesenchymal-stromal-cell-therapy-treat-steroid-refractory-acute-graft-versus-host"}],"tags":["fda-oce-applicant"],"related":[],"cancers":[],"sections":["cell-therapy","supportive-care"],"technologies":[],"targets":[],"drugs":["remestemcel-l"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Melbourne","country":"AU","companyType":"cell-therapy","website":"https://www.mesoblast.com","stage":"public","investors":[],"funding":[]},{"id":"mevion","kind":"company","name":"Mevion Medical Systems","aka":[],"tldr":"Mevion Medical Systems, of Littleton, Massachusetts, makes the MEVION S250-FIT, a compact single-room proton therapy system meant to bring protons within reach of community cancer centres. Whether smaller, cheaper proton machines widen access without diluting the evidence base is the open question.","summary":"Mevion Medical Systems, based in Littleton, Massachusetts, makes compact single-room proton therapy systems intended to bring protons within reach of community cancer centres. Its MEVION S250-FIT is the current system, and the company's premise is that a single-room machine changes the economics of proton therapy. OnCo links it to proton therapy and proton arc therapy, to the Case Comprehensive Cancer Center, and to ideas such as compact FLASH and proton systems at the price of a conventional linac and pooled coverage-with-evidence for proton therapy across all centres. Whether smaller, cheaper proton systems widen access without diluting the evidence base is the open question. The proton therapy page carries the wider picture.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.mevion.com"}],"tags":[],"related":[],"cancers":[],"sections":["radiation"],"technologies":["proton-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Littleton, MA","country":"US","companyType":"devices","website":"https://www.mevion.com","investors":[],"funding":[]},{"id":"mgi-tech","kind":"company","name":"MGI Tech","aka":[],"tldr":"Chinese sequencing-instrument maker (DNBSEQ), Illumina's main rival by volume, restricted in the US by the BIOSECURE Act.","summary":"MGI Tech, based in Shenzhen and listed as 688114.SS, is the Chinese sequencing instrument maker behind the DNBSEQ platforms, Illumina's main rival by volume, and it is restricted in the United States by the BIOSECURE Act. Its DNBSEQ-T7 and G400 instruments use DNA nanoball chemistry, dominate in China and are growing in Europe and emerging markets. OnCo links it to new short-read sequencing platforms and to the BIOSECURE Act term. Whether political restrictions in the United States slow its spread elsewhere, or simply split the sequencing market along geopolitical lines, is the open question. The BIOSECURE Act page carries the policy detail.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://en.mgi-tech.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["next-gen-short-read-platforms"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["biosecure-act"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shenzhen","country":"CN","companyType":"diagnostics","website":"https://en.mgi-tech.com","ticker":"688114.SS","investors":[],"funding":[]},{"id":"michelson-diagnostics","kind":"company","name":"Michelson Diagnostics","aka":[],"tldr":"Michelson Diagnostics makes VivoSight, an optical coherence tomography scanner for skin that shows a cross-section of a lesion a millimetre or two deep, used to diagnose and measure basal cell carcinoma.","summary":"Michelson Diagnostics, founded in 2006 in Kent, developed the VivoSight multi-beam OCT scanner and its dynamic OCT mode that shows blood vessels. It is used in dermatology clinics in Europe and the United States for diagnosing basal cell carcinoma, guiding treatment choice and monitoring topical or photodynamic therapy.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://vivosight.com/"}],"tags":["machines-wave2"],"related":[],"cancers":["basal-cell-carcinoma","skin-cancer"],"sections":[],"technologies":["confocal-oct-skin-imaging"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Maidstone, Kent","country":"GB","companyType":"imaging","website":"https://vivosight.com/","founded":2006,"stage":"startup","investors":[],"funding":[]},{"id":"microbiotica","kind":"company","name":"Microbiotica","aka":[],"tldr":"Microbiotica makes precisely defined mixtures of gut bacteria as medicines. Its lead product is given alongside immunotherapy to help more melanoma patients respond.","summary":"Microbiotica is a clinical-stage live biotherapeutic company at Chesterford Research Park, Cambridge, spun out of Trevor Lawley's laboratory at the Wellcome Sanger Institute. Its clinic-led platform profiles patient microbiomes at strain resolution to identify bacteria associated with clinical benefit, then formulates defined consortia. MB097 is a precision microbiome co-therapy for advanced melanoma given with anti-PD-1 therapy; the international phase 1b MELODY-1 trial completed recruitment in September 2025 and positive results were announced in May 2026. MB310 is a defined consortium for ulcerative colitis with positive phase 1b COMPOSER-1 results in February 2026. The company reports GBP 62 million of equity investment to date, including a GBP 50 million Series B in 2022.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.microbiotica.com"},{"label":"About (funding and origins)","url":"https://microbiotica.com/about/"},{"label":"Press releases","url":"https://microbiotica.com/press-releases/"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Series B investors not named on fetched pages. Founding year not sourced."],"hq":"Cambridge","country":"GB","companyType":"biotech","website":"https://www.microbiotica.com","stage":"startup","investors":[],"funding":[{"round":"Series B","year":2022,"source":"https://microbiotica.com/about/","note":"GBP 50 million; GBP 62 million equity raised to date per company"}]},{"id":"microsoft","kind":"company","name":"Microsoft (Health & Life Sciences)","aka":[],"tldr":"Cloud and AI provider behind pathology foundation models (Prov-GigaPath with Providence, Virchow hosting with Paige) and Nuance clinical AI.","summary":"Microsoft, through its Health and Life Sciences business based in Redmond and listed as MSFT, is the cloud and AI provider behind pathology foundation models, including Prov-GigaPath with Providence and the hosting of Paige's Virchow, and the Nuance clinical AI products. Its offerings include Azure AI for Health, Nuance DAX documentation and research collaborations on multimodal cancer models. OnCo links it to AI compute and model platforms for oncology and to pathology and radiology foundation models. Whether foundation models trained with a cloud provider's compute remain open to the wider research community is the question its partnerships raise. The foundation model technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.microsoft.com/en-us/industry/health"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["ai-compute-platforms","pathology-foundation-model"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Redmond, WA","country":"US","companyType":"ai-software","website":"https://www.microsoft.com/en-us/industry/health","ticker":"MSFT","investors":[],"funding":[]},{"id":"microsoft-research","kind":"company","name":"Microsoft (Research and Health AI)","aka":[],"tldr":"Microsoft co-developed Prov-GigaPath and BiomedCLIP and is the compute partner for Paige's Virchow2.","summary":"Microsoft Research and its Health AI group, based in Redmond and part of Microsoft, listed as MSFT, co-developed the Prov-GigaPath and BiomedCLIP models and supplied the Azure compute for Paige's Virchow series. Prov-GigaPath, published in Nature in 2024, was the largest open pathology foundation model of its time, BiomedCLIP is its biomedical vision-language model, and the BioEmu protein dynamics model is also linked. OnCo connects it to Prov-GigaPath, Virchow and Virchow2, BioEmu and Paige AI. Whether openly released foundation models or proprietary ones become the base for clinical pathology AI is the question its releases bear on. Prov-GigaPath has its own technology page.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.microsoft.com/en-us/research/"}],"tags":["ai"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":["paige"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Redmond, WA","country":"US","companyType":"ai-software","website":"https://www.microsoft.com/en-us/research/","ticker":"MSFT","investors":[],"funding":[]},{"id":"miltenyi-biomedicine","kind":"company","name":"Miltenyi Biomedicine","aka":["Miltenyi Biomedicine GmbH"],"tldr":"Miltenyi Biomedicine is a Germany-based cell therapy company running 5 late-stage cancer trials of zamtocabtagene autoleucel (MB-CART2019.1) and MB-CART2019.1 in diffuse large B-cell lymphoma, acute myeloid leukaemia and primary CNS lymphoma.","summary":"Miltenyi Biomedicine, based in Bergisch Gladbach, Germany, is a cell therapy company and part of Miltenyi Biotec (Miltenyi group). Develops personalised cell and gene therapies, specifically CAR-T cell therapies for oncology and autoimmune diseases; part of the Miltenyi group alongside Miltenyi Biotec. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials, testing zamtocabtagene autoleucel (MB-CART2019.1) and MB-CART2019.1 in diffuse large B-cell lymphoma, acute myeloid leukaemia, primary CNS lymphoma and mantle cell lymphoma. The largest, NCT04792489 (DALY II USA/ MB-CART2019.1 for DLBCL), plans to enrol 315 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.miltenyibiomedicine.com"},{"label":"ClinicalTrials.gov: trials led by Miltenyi Biomedicine","url":"https://clinicaltrials.gov/search?lead=Miltenyi%20Biomedicine%20GmbH"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["dlbcl","aml","primary-cns-lymphoma","mantle-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["zamtocabtagene-autoleucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04792489","nct07288879","nct04844866","nct06508931"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Bergisch Gladbach","country":"DE","companyType":"cell-therapy","website":"https://www.miltenyibiomedicine.com","stage":"private-large","investors":[],"funding":[]},{"id":"miltenyi-biotec","kind":"company","name":"Miltenyi Biotec","aka":[],"tldr":"Miltenyi Biotec, a private German company, makes the CliniMACS Prodigy, a closed automated device that manufactures CAR-T cells at the point of care, plus the magnetic cell separation and lentiviral vectors behind it, and its own CD20/CD19 bispecific CAR-T is in late-stage lymphoma trials.","summary":"Private German company supplying magnetic cell separation (CliniMACS), closed automated manufacturing (Prodigy), lentiviral vectors, and its own CAR-T candidates (zamtocabtagene autoleucel, MB-CART2019.1, a CD20/CD19 bispecific CAR-T in late-stage trials for lymphoma). A backbone of point-of-care cell manufacturing in Europe and Asia.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Miltenyi_Biotec","links":[{"label":"Official website","url":"https://www.miltenyibiotec.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["closed-automated-cell-manufacturing","point-of-care-cell-manufacturing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Bergisch Gladbach","country":"DE","companyType":"cell-therapy","website":"https://www.miltenyibiotec.com","investors":[],"funding":[]},{"id":"mim-software","kind":"company","name":"MIM Software (GE HealthCare)","aka":[],"tldr":"Contouring, image fusion, and dosimetry software (MIM Maestro, SurePlan) for radiotherapy and radioligand therapy, acquired by GE HealthCare in 2024.","summary":"MIM Software, based in Cleveland and acquired by GE HealthCare in 2024, makes contouring, image fusion and dosimetry software, including MIM Maestro and SurePlan, for radiotherapy and radioligand therapy. Its Contour ProtégéAI performs auto-contouring, its PET/CT fusion supports planning, and its personalised dosimetry serves lutetium-177 and yttrium-90 therapies. OnCo links it to AI auto-contouring and adaptive planning, SPECT and bone scan imaging, and radioligand therapy with beta emitters. Whether personalised dosimetry becomes standard for radioligand therapy, rather than fixed dosing, is the open question its tools are built for. The radioligand therapy page carries the wider evidence.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.mimsoftware.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["radiation","imaging"],"technologies":["auto-contouring-ai","spect","radioligand-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cleveland, OH","country":"US","companyType":"ai-software","website":"https://www.mimsoftware.com","investors":[],"funding":[]},{"id":"mindray","kind":"company","name":"Mindray","aka":[],"tldr":"Mindray is China's largest medical device company, selling Resona ultrasound systems with shear-wave elastography and contrast imaging, patient monitors and laboratory analysers in more than a hundred countries.","summary":"Founded in Shenzhen in 1991 and listed in 2018, Mindray grew from patient monitoring into ultrasound and in vitro diagnostics. Its Resona and DC-series ultrasound systems include shear-wave elastography, contrast-enhanced imaging and fusion with CT and MRI for liver lesion characterisation and ablation guidance, and its price point has made it a major supplier to hospitals in China, Latin America, Africa and increasingly Europe. OnCo links it to ultrasound and elastography.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Mindray","links":[{"label":"Official website","url":"https://www.mindray.com"}],"tags":["machines-wave"],"related":[],"cancers":[],"sections":["imaging"],"technologies":["ultrasound","ultrasound-elastography-ceus"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shenzhen","country":"CN","companyType":"imaging","website":"https://www.mindray.com","ticker":"300760.SZ","founded":1991,"stage":"public","investors":[],"funding":[]},{"id":"minghui-pharmaceutical","kind":"company","name":"Minghui Pharmaceutical","aka":["Minghui Pharmaceutical (Hangzhou) Ltd"],"tldr":"Minghui Pharmaceutical is a China-based biotechnology company that leads 9 cancer trials in OnCo, testing its MHB-series antibody-drug conjugates and the bispecific antibody MHB039A in prostate cancer and advanced solid tumours.","summary":"Minghui Pharmaceutical is a Hangzhou-based biopharmaceutical company. The ClinicalTrials.gov registry lists it as lead sponsor of trials of its antibody-drug conjugates MHB009C, MHB036C, MHB042C, MHB046C, MHB048C and MHB088C and of the bispecific antibody MHB039A in advanced solid tumours. No company website could be verified, so company facts here are limited to the registry. On ClinicalTrials.gov it is the lead sponsor of 9 trials recorded in OnCo: NCT07326488 (phase 1/2, A Study of MHB009C in Patients With Advanced Solid Tumors), NCT07229599 (phase 1/2, A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Ca...), NCT07130383 (phase 2, A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Oth...), NCT06373406 (phase 1/2, A Study of MHB036C for Advanced Solid Tumor), NCT06345482 (phase 1/2, A Study of MHB039A for Advanced Solid Tumor), NCT07192107 (phase 1/2, A Study of MHB042C in Patients With Advanced Solid Tumors), NCT06985355 (phase 1/2, A Study of MHB046C Injection in Patients With Advanced Solid Tumors), NCT07192120 (phase 1/2, A Study of MHB048C in Patients With Advanced Solid Tumors) and NCT07126665 (phase 1/2, A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov: trials led by Minghui Pharmaceutical","url":"https://clinicaltrials.gov/search?lead=Minghui%20Pharmaceutical%20(Hangzhou)%20Ltd"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["furmonertinib","carboplatin","mhb039a","mhb036c","qlc5508"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07326488","nct07229599","nct07130383","nct06373406","nct06345482","nct07192107","nct06985355","nct07192120","nct07126665"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Hangzhou","country":"CN","companyType":"biotech","investors":[],"funding":[]},{"id":"minuteman-therapeutics","kind":"company","name":"Minuteman Therapeutics","aka":["Minuteman Tx"],"tldr":"Minuteman Therapeutics develops oncolytic viruses engineered against an individual patient's tumour, matching the virus to the biology of that person's cancer.","summary":"Oncolytic viruses infect and kill cancer cells and alert the immune system to them; talimogene laherparepvec is the approved example. Minuteman's stated approach is personalised: an oncolytic virus designed against the individual patient's tumour rather than one product for all. It is an Even One Ventures portfolio company with no published trials.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://minuteman.bio/"},{"label":"Even One Ventures portfolio","url":"https://evenone.ventures/"}],"tags":["startup","evenone-portfolio","oncology"],"related":[],"cancers":[],"sections":[],"technologies":["oncolytic-virus"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"United States (head office not published)","country":"US","companyType":"biotech","website":"https://minuteman.bio/","stage":"startup","investors":["evenone-ventures"],"funding":[]},{"id":"mission-bio","kind":"company","name":"Mission Bio","aka":[],"tldr":"Mission Bio sells an instrument that reads DNA mutations and proteins from thousands of individual cancer cells at once, helping researchers see how leukaemia and myeloma evolve and resist treatment.","summary":"Mission Bio, based in South San Francisco, develops the Tapestri single-cell platform, which measures single nucleotide variants, copy number variation and cell-surface proteins from the same individual cells. In 2025 it launched a single-cell targeted genotype and gene expression assay profiling DNA and RNA from more than 10,000 cells, alongside solutions for multiple myeloma, myeloid malignancies, genome integrity in engineered cell therapies and vector copy number in CAR-T products. Tapestri is used as a high-resolution residual disease assay, for example profiling residual disease in acute myeloid leukaemia (BLAST trial, 2026), and powered several EHA 2026 studies on clonal architecture and treatment response. Mission Bio collaborates with the Human Cell Atlas. In August 2025 the company secured an equity financing led by Ally Bridge Group to expand its tri-omics platform; the amount was not disclosed.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://missionbio.com"},{"label":"Equity financing led by Ally Bridge Group (August 2025)","url":"https://www.missionbio.com/press/equity-financing"},{"label":"Newsroom","url":"https://missionbio.com/company/newsroom"}],"tags":[],"related":[],"cancers":["aml","multiple-myeloma"],"sections":["diagnostics"],"technologies":["single-cell-spatial","mrd-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["2025 financing has no disclosed amount or round label, so it is not recorded as a structured round. Earlier Series C and D not sourced; stage growth reflects those unsourced rounds. Founding year not sourced."],"hq":"South San Francisco, CA","country":"US","companyType":"diagnostics","website":"https://missionbio.com","stage":"growth","investors":[],"funding":[]},{"id":"mobileodt","kind":"company","name":"MobileODT","aka":[],"tldr":"MobileODT makes the EVA System, a smartphone-based colposcope with cloud image review and an AI score, designed to bring cervical examination to clinics without a colposcopist.","summary":"MobileODT, founded in Tel Aviv in 2012, built the Enhanced Visual Assessment (EVA) System, a portable digital colposcope with secure image sharing, and developed automated visual evaluation software for cervical images. The system has been deployed in screening programmes in low- and middle-income countries and in colposcopy services in the United States.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.mobileodt.com/"}],"tags":["machines-wave2"],"related":[],"cancers":["cervical"],"sections":[],"technologies":["colposcopes-digital-cervical-screening","hpv-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tel Aviv","country":"IL","companyType":"devices","website":"https://www.mobileodt.com/","founded":2012,"stage":"startup","investors":[],"funding":[]},{"id":"moderna","kind":"company","name":"Moderna","aka":[],"tldr":"Moderna is the mRNA company whose personalised cancer vaccine intismeran won the first phase 3 in the class (August 2026).","summary":"Moderna, based in Cambridge, Massachusetts, and listed as MRNA, is the mRNA company whose personalised cancer vaccine intismeran autogene won the first phase 3 in its class in August 2026. Intismeran is developed with Merck and was first tested with pembrolizumab after melanoma surgery in KEYNOTE-942, and the pipeline includes mRNA-4359, a shared-antigen vaccine, plus in vivo CAR and other immuno-oncology mRNA programmes. OnCo links it to melanoma, to personalised neoantigen vaccines and self-amplifying RNA, to the Koch Institute and the Frederick National Laboratory, and to ideas on vaccines given only when a blood test turns positive and on automated manufacturing at commodity cost. Cold tumours and the immunosuppressive microenvironment are the bottleneck it confronts. Intismeran autogene has its own page.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Moderna","links":[{"label":"Official website","url":"https://www.modernatx.com"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["intismeran-autogene"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07116616","nct05533697","nct03897881"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://www.modernatx.com","ticker":"MRNA","investors":["flagship-pioneering"],"funding":[]},{"id":"modex-therapeutics","kind":"company","name":"ModeX Therapeutics","aka":["ModeX Therapeutics, An OPKO Health Company"],"tldr":"ModeX Therapeutics is a US-based biotechnology company that leads 2 cancer trials in OnCo, testing the tetraspecific T-cell engagers MDX2001 and MDX2003 in biliary tract cancer, cervical cancer, colorectal cancer and endometrial cancer.","summary":"ModeX Therapeutics develops multispecific antibodies and nanoparticle vaccines for cancer and infectious disease. Its oncology pipeline includes MDX2001 (cMET x Trop2 x CD3 x CD28) for solid tumours and MDX2003 (CD19 x CD20 x CD3 x CD28) for B-cell leukaemia and lymphoma, both tetraspecific T-cell engagers. It is a wholly owned subsidiary of OPKO Health. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT06239194 (phase 1/2, Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors) and NCT07249905 (phase 1/2, Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.modextherapeutics.com"},{"label":"ClinicalTrials.gov: trials led by ModeX Therapeutics","url":"https://clinicaltrials.gov/search?lead=ModeX%20Therapeutics%2C%20An%20OPKO%20Health%20Company"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cholangiocarcinoma","cervical","colorectal","endometrial","esophageal","gastric","non-hodgkin-lymphoma","waldenstrom","dlbcl","follicular-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06239194","nct07249905"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Weston, Massachusetts","country":"US","companyType":"biotech","website":"https://www.modextherapeutics.com","founded":2013,"stage":"acquired","investors":[],"funding":[]},{"id":"modulari-t","kind":"company","name":"Modulari-T","aka":[],"tldr":"Modulari-T designs synthetic genes that let engineered immune cells sense their surroundings and change behaviour, so cell therapies can find and kill cancer more reliably.","summary":"Modulari-T, based in Montreal with a San Francisco presence, has designed a family of synthetic genetic modules that reprogramme cells to sense environmental cues and respond, applied first to engineering T cells and other immune cells that recognise and kill tumour cells more efficiently, with a stated ambition to become a platform for all cell engineering including regenerative medicine. The company is preclinical; no sourced financing rounds are recorded.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/modulari-t"},{"label":"Official website","url":"https://modularit.bio"}],"tags":["yc"],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["armored-car","car-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Montreal","country":"CA","companyType":"cell-therapy","website":"https://modularit.bio","stage":"startup","ycBatch":"W23","investors":["y-combinator"],"funding":[]},{"id":"modulight","kind":"company","name":"Modulight","aka":[],"tldr":"Modulight is a Finnish laser company whose medical lasers activate photodynamic and photoimmunotherapy drugs, including the systems used with cetuximab sarotalocan and with padeliporfin.","summary":"Modulight designs and manufactures semiconductor lasers in Tampere and supplies the medical laser systems and fibres that drug companies pair with their photosensitisers, working with partners on light dosimetry and cloud connectivity of the devices. It listed on Nasdaq Helsinki in 2021 and also serves ophthalmology and research markets.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.modulight.com/"}],"tags":["machines-wave2"],"related":[],"cancers":[],"sections":[],"technologies":["photodynamic-therapy-lasers","photoimmunotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tampere","country":"FI","companyType":"devices","website":"https://www.modulight.com/","founded":2000,"stage":"public","investors":[],"funding":[]},{"id":"molecular-partners","kind":"company","name":"Molecular Partners","aka":["Molecular Partners AG"],"tldr":"Molecular Partners is a Switzerland-based radiopharmaceutical company running 2 late-stage cancer trials of [212Pb]Pb-MP0712 and MP0533 with Obinutuzumab pretreatment in neuroendocrine tumours, non-small-cell lung cancer and pancreatic ductal adenocarcinoma.","summary":"Molecular Partners, based in Zurich, Switzerland, is a radiopharmaceutical company. Molecular Partners develops DARPin (Designed Ankyrin Repeat Protein) therapeutics, including radiopharmaceuticals and immune cell engagers, mainly for cancer. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing [212Pb]Pb-MP0712 and MP0533 with Obinutuzumab pretreatment in neuroendocrine tumours, non-small-cell lung cancer, pancreatic ductal adenocarcinoma, bladder & urothelial cancer and acute myeloid leukaemia. The largest, NCT05673057 (Study of MP0533 in Patients Acute Myeloid Leukaemia or Myelodysplastic Syndrome), plans to enrol 249 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Molecular_Partners","links":[{"label":"Official website","url":"https://www.molecularpartners.com"},{"label":"ClinicalTrials.gov: trials led by Molecular Partners","url":"https://clinicaltrials.gov/search?lead=Molecular%20Partners%20AG"},{"label":"Pipeline page","url":"https://www.molecularpartners.com/pipeline"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["neuroendocrine","nsclc","pancreatic","urothelial","aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04115306","nct05673057","nct07278479"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Zurich","country":"CH","companyType":"radiopharma","website":"https://www.molecularpartners.com","founded":2004,"stage":"public","investors":[],"funding":[]},{"id":"moleculin","kind":"company","name":"Moleculin Biotech","aka":["Moleculin Biotech, Inc.","Moleculin"],"tldr":"Moleculin is a Houston biotech whose annamycin, an anthracycline designed to spare the heart, is in a phase 3 trial with cytarabine for relapsed acute myeloid leukaemia.","summary":"Moleculin Biotech, headquartered in Houston, Texas, licenses drug candidates from MD Anderson Cancer Center. Its lead, annamycin, is a liposomal anthracycline engineered to avoid the cardiotoxicity of doxorubicin and to evade multidrug resistance pumps, and is in the phase 3 MIRACLE trial with cytarabine in relapsed or refractory acute myeloid leukaemia; WP1066, a STAT3 inhibitor, is in earlier trials in brain tumours. Its trials are registered on ClinicalTrials.gov under Moleculin as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.moleculin.com"},{"label":"ClinicalTrials.gov: trials led by Moleculin Biotech, Inc.","url":"https://clinicaltrials.gov/search?lead=Moleculin%20Biotech%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml","glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct06788756"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Houston, TX","country":"US","companyType":"biotech","website":"https://www.moleculin.com","stage":"public","investors":[],"funding":[]},{"id":"monopar","kind":"company","name":"Monopar Therapeutics","aka":["Monopar Therapeutics Inc.","Monopar"],"tldr":"Monopar is a Chicago-area biotech that took the mucositis drug validive into a phase 3 trial in head and neck cancer, which failed in 2023, and now develops radiopharmaceuticals against the uPAR protein.","summary":"Monopar Therapeutics, based in the Chicago area, developed validive (clonidine mucobuccal tablet) to prevent severe oral mucositis in patients having chemoradiotherapy for oropharyngeal cancer; the phase 3 VOICE trial did not meet its endpoint in 2023. The company has since focused on MNPR-101, an antibody against the urokinase receptor uPAR, as an imaging agent and radiotherapeutic, and on a Wilson disease programme. Its trials are registered on ClinicalTrials.gov under Monopar as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.monopartx.com"},{"label":"ClinicalTrials.gov: trials led by Monopar Therapeutics Inc.","url":"https://clinicaltrials.gov/search?lead=Monopar%20Therapeutics%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["head-and-neck"],"sections":["supportive-care","radiopharma"],"technologies":["radioligand-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Chicago, IL","country":"US","companyType":"biotech","website":"https://www.monopartx.com","stage":"public","investors":[],"funding":[]},{"id":"monte-rosa","kind":"company","name":"Monte Rosa Therapeutics","aka":[],"tldr":"Molecular-glue degrader company with a GSPT1 degrader in phase 2 for AR-mutant prostate cancer and a CCNE1-directed glue in preclinical development.","summary":"MRT-2359 (GSPT1) first patient dosed in phase 2 MODeFIRe-1 with apalutamide in AR-mutation-positive mCRPC (August 2026). AACR 2026: CCNE1-directed glue degrader produced regressions in CCNE1-amplified ovarian, breast, and gastric models with better selectivity than CDK2 inhibitors. QuEEN discovery engine; Novartis and Roche partnerships.","asOf":"2026-09-04","links":[{"label":"MODeFIRe-1 first patient","url":"https://www.globenewswire.com/news-release/2026/08/24/3349601/0/en/monte-rosa-therapeutics-announces-first-patient-dosed-in-modefire-1-a-phase-2-study-of-mrt-2359-in-combination-with-apalutamide-in-patients-with-ar-mutation-positive-metastatic-cas.html"}],"tags":[],"related":[],"cancers":["prostate","ovarian"],"sections":["targeted-therapy"],"technologies":["protac-degrader"],"targets":["androgen-receptor"],"drugs":[],"companies":["novartis","roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07745361","nct05546268"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://www.monterosatx.com","ticker":"GLUE","investors":["cancer-research-horizons"],"funding":[]},{"id":"monteris-medical","kind":"company","name":"Monteris Medical","aka":[],"tldr":"Monteris makes NeuroBlate, a system that lets a neurosurgeon destroy a brain tumour from the inside with a laser fibre inserted through a small hole in the skull while watching the heat spread on a live MRI scan, avoiding open brain surgery.","summary":"Monteris Medical, a private company in Minnetonka, Minnesota, develops and sells the NeuroBlate System for MRI-guided laser interstitial thermal therapy (LITT). A robotically controlled laser probe is placed through a small burr hole and delivers heat while MR thermometry shows the ablation zone in real time, offering a minimally invasive alternative to open resection for brain tumours, radiation necrosis and drug-resistant epilepsy. NeuroBlate is FDA cleared and marketed in the US. In 2026 the company published the LAANTERN prospective registry in the Journal of Clinical Oncology, covering 787 oncology patients treated at 25 centres. In March 2026 Monteris closed a USD 28 million Series E led by InnovaHealth Partners and Birchview Capital, with OSF Ventures, the Colorado University Healthcare Innovation Fund and Madryn Asset Management participating, and secured a USD 35 million credit facility from Trinity Capital.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.monteris.com"},{"label":"Series E growth equity press release (March 2026)","url":"https://www.prnewswire.com/news-releases/monteris-medical-secures-28-million-in-growth-equity-to-accelerate-revenue-and-innovation-in-minimally-invasive-neurosurgery-302711794.html"},{"label":"Trinity Capital USD 35 million credit facility (March 2026)","url":"https://www.prnewswire.com/news-releases/trinity-capital-inc-provides-35-million-in-growth-capital-to-monteris-medical-to-support-neurosurgical-technology-advancements-302711455.html"},{"label":"LAANTERN 787-patient publication (2026)","url":"https://www.prnewswire.com/news-releases/monteris-medical-announces-publication-of-landmark-study-on-787-brain-tumor-patients-treated-with-neuroblate-laser-interstitial-thermal-therapy-litt-302854905.html"}],"tags":[],"related":[],"cancers":["glioblastoma"],"sections":["surgery","devices"],"technologies":["thermal-ablation","mri","robotic-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Website returns HTTP 403 to curl but loads via WebFetch. Founding year and earlier rounds (Series A to D) unsourced. The LAANTERN publication release URL was confirmed reachable (HTTP 200); the 787 patients / 25 centres figures come from the company home page. Probe design details are general product knowledge."],"hq":"Minnetonka, MN","country":"US","companyType":"devices","website":"https://www.monteris.com","stage":"growth","investors":[],"funding":[{"round":"Series E","year":2026,"amountUsd":28000000,"source":"https://www.prnewswire.com/news-releases/monteris-medical-secures-28-million-in-growth-equity-to-accelerate-revenue-and-innovation-in-minimally-invasive-neurosurgery-302711794.html","note":"Led by existing investors InnovaHealth Partners and Birchview Capital with new investors OSF Ventures and Colorado University Healthcare Innovation Fund; Madryn Asset Management also participated"},{"round":"Debt","year":2026,"amountUsd":35000000,"source":"https://www.prnewswire.com/news-releases/trinity-capital-inc-provides-35-million-in-growth-capital-to-monteris-medical-to-support-neurosurgical-technology-advancements-302711455.html","note":"Credit facility from Trinity Capital replacing a prior Madryn Asset Management facility"}]},{"id":"more-health","kind":"company","name":"MORE Health","aka":[],"tldr":"MORE Health is a cross-border telemedicine company delivering expert second opinions from leading specialists for serious illness including cancer.","summary":"MORE Health, based in San Mateo, California, and founded in 2013, is a cross-border telemedicine company that delivers expert second opinions from leading specialists for serious illness, with cancer as a core specialty. It provides expert medical opinions to individuals, employers and hospitals, offered either as an employee benefit or on a self-pay basis. OnCo links it to the bottleneck that patients lack understanding, navigation and agency, since a second opinion is one of the few tools a patient can buy directly. Whether remote second opinions change treatment decisions and outcomes, rather than reassuring patients, is the open question no public data here answer. The bottleneck page carries the wider context.","asOf":"2026-09-04","links":[{"label":"Company site","url":"https://www.morehealth.com/en"}],"tags":[],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Mateo, CA","country":"US","companyType":"cro-services","website":"https://www.morehealth.com","founded":2013,"investors":[],"funding":[]},{"id":"morphosys","kind":"company","name":"MorphoSys (Novartis)","aka":[],"tldr":"German antibody company that acquired Constellation's BET inhibitor pelabresib and was itself bought by Novartis in 2024.","summary":"MorphoSys, based in Planegg near Munich, was the German antibody company that developed tafasitamab and acquired Constellation Pharmaceuticals for the BET inhibitor pelabresib, before Novartis bought it in 2024; OnCo marks the record as historic. Tafasitamab, sold as Monjuvi, is a CD19 antibody for diffuse large B-cell lymphoma whose rights moved to Incyte, and pelabresib, acquired with Constellation in 2021, was studied in myelofibrosis in the MANIFEST-2 trial. OnCo links it to diffuse large B-cell lymphoma, to CD19 as a target, to epigenetic drugs and monoclonal antibodies, and to Novartis. Whether pelabresib justifies the price Novartis paid is the question that outlived the company. Tafasitamab has its own page.","status":"historic","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.morphosys.com"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":["epigenetics","immunotherapy"],"technologies":["epigenetic-drugs","monoclonal-antibody"],"targets":["cd19"],"drugs":[],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Planegg","country":"DE","companyType":"biotech","website":"https://www.morphosys.com","investors":[],"funding":[]},{"id":"mpm-bioimpact","kind":"company","name":"MPM BioImpact","aka":[],"tldr":"A Boston biotech investor, formerly MPM Capital, that builds and funds companies and runs an Oncology Impact Fund that donates part of its profits to cancer research. It built Aktis Oncology and backs Cullinan Oncology and Tizona.","summary":"MPM BioImpact (formerly MPM Capital) is based at 399 Boylston Street, Boston, and claims '30+ Years of Biotech Investing', '60 FDA-approved drugs' and '120+ M&A and IPO events' on its homepage. Its portfolio page says its 'current strategy that focuses on company building began in 2010'; it invests in private and public companies and its trademarks include the Oncology Impact Fund (OIF), which pairs oncology venture investing with philanthropic donations. The homepage says 'We built Aktis Oncology to realize the transformative potential of alpha radio-pharmaceuticals', describing miniprotein actinium conjugates for solid tumours, and 'We built Orna Therapeutics' (circular RNA, acquired by Lilly in 2026). The portfolio page lists Aktis, Cullinan Oncology, Tizona Therapeutics, Frontier Medicines and Umoja Biopharma among others; the news page carries Aktis first-in-human dosimetry data and J&J's acquisition of Firefly Bio.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://mpmbioimpact.com/"},{"label":"Portfolio","url":"https://mpmbioimpact.com/portfolio/"},{"label":"News","url":"https://mpmbioimpact.com/news/"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["aktis-oncology","firefly-bio","frontier-medicines","umoja-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year of MPM Capital not stated on fetched pages; omitted. Aktis, Frontier Medicines, Umoja and Orna are already in the graph."],"hq":"Boston, MA","country":"US","companyType":"investor","website":"https://mpmbioimpact.com/","investors":[],"funding":[]},{"id":"mrc-ctu","kind":"company","name":"MRC Clinical Trials Unit at UCL","aka":["Medical Research Council","MRC","MRC CTU","MRC CTU at UCL","UCL Innovative Clinical Trials Unit","MRC Clinical Trials Unit"],"tldr":"The MRC Clinical Trials Unit at UCL is the UK public trials unit that designed and ran STAMPEDE, FOCUS4, ICON7 and UKCTOCS; it marked 25 years in 2024 and became the UCL Innovative Clinical Trials Unit in April 2026.","summary":"The MRC Clinical Trials Unit at UCL is a registered clinical trials unit (UKCRC Registered CTUs Network) at 90 High Holborn, London, that designs and conducts clinical trials, systematic reviews and observational studies; its website records a 25th anniversary in 2024 and says the unit became the UCL Innovative Clinical Trials Unit in April 2026, continuing the same mission. No founding year is stated on the pages read, so none is given here. ClinicalTrials.gov names the Medical Research Council (OTHER_GOV class) as lead sponsor of STAMPEDE (NCT00268476, the multi-arm platform trial in advanced prostate cancer); FOCUS4 (ISRCTN90061546, the biomarker-stratified colorectal cancer platform) is recorded in OnCo as run by the unit with Medical Research Council, NIHR and Cancer Research UK funding; ICON7 (recorded with GOG-0218, bevacizumab in ovarian cancer) and UKCTOCS (NCT00058032, ovarian cancer screening, registered by University College London with the Medical Research Council as collaborator) are its other OnCo trials. It has no products of its own.","asOf":"2026-09-25","links":[{"label":"MRC CTU at UCL: about us","url":"https://www.mrcctu.ucl.ac.uk/about-us/"},{"label":"ClinicalTrials.gov: trials led by Medical Research Council","url":"https://clinicaltrials.gov/search?lead=Medical%20Research%20Council"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["prostate","prostate-mhspc","prostate-high-risk","colorectal","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uclh"],"pathways":[],"terms":[],"trials":["stampede","focus4","gog-0218-icon7","ukctocs"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"London","country":"GB","companyType":"cooperative-group","website":"https://www.mrcctu.ucl.ac.uk","investors":[],"funding":[]},{"id":"msd-global-health-innovation-fund","kind":"company","name":"MSD Global Health Innovation Fund (Merck GHI)","aka":[],"tldr":"Merck & Co's corporate venture fund for digital health and healthcare services companies, known as MSD GHI outside North America. Its website is a JavaScript application whose content could not be read.","summary":"The Merck Global Health Innovation Fund (MSD GHI outside the United States and Canada) is the corporate venture fund of Merck & Co, investing in digital health, health services and data companies rather than in drug developers, some of which touch cancer care. Its website (merckghifund.com) returned only the title 'Merck GHI Fund' and 'You need to enable JavaScript to run this app' on every fetch, and the merck.com partnering pages tried returned 404, so the fund's own description of its strategy, founding year, location and oncology-related portfolio could not be confirmed from a primary source.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.merckghifund.com/"}],"tags":["corporate-venture"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Site fetched on 2026-09-10; content is rendered client-side so no portfolio examples were read."],"hq":"Rahway, NJ","country":"US","companyType":"investor","website":"https://www.merckghifund.com/","investors":[],"funding":[]},{"id":"mmrf-myeloma-investment-fund","kind":"company","name":"Multiple Myeloma Research Foundation and Myeloma Investment Fund","aka":[],"tldr":"A patient-founded charity for the blood cancer multiple myeloma that also runs a venture philanthropy fund investing in companies developing myeloma treatments. Fund investments include Reverb Therapeutics, Abcuro, Coding Bio and CytoImmune.","summary":"The Multiple Myeloma Research Foundation was founded in 1998 by Kathy Giusti and Karen Andrews after Kathy's myeloma diagnosis and is based in Norwalk, Connecticut (Wikipedia). Its site states its mission as 'Accelerating a Cure for Multiple Myeloma' through funding novel therapies, personalised treatment approaches and patient support. The Myeloma Investment Fund (MIF) 'is a venture philanthropy fund that invests in promising companies, clinical assets, and technologies in oncology to drive the development of new therapies for multiple myeloma'; it is 'supported entirely by philanthropy' and 'all profits will be reinvested back into research'. Its portfolio page lists Abcuro (immunomodulatory antibodies), Coding Bio (machine-learning-designed immunotherapies, Oxford) and CytoImmune Therapeutics (CAR-NK cell therapy), and an MMRF release describes its investment in Reverb Therapeutics' Amplifier cytokine platform for myeloma.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://themmrf.org/"},{"label":"Myeloma Investment Fund","url":"https://myelomainvestmentfund.org/"},{"label":"MIF portfolio","url":"https://myelomainvestmentfund.org/portfolio/"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Multiple_Myeloma_Research_Foundation"}],"tags":["foundation"],"related":["mmrf"],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Norwalk, CT","country":"US","companyType":"investor","website":"https://themmrf.org/","founded":1998,"investors":[],"funding":[]},{"id":"multitude-therapeutics","kind":"company","name":"Multitude Therapeutics","aka":["Multitude Therapeutics Inc."],"tldr":"Multitude Therapeutics is a China-based biotechnology company running 4 late-stage cancer trials of AMT-116, AMT-676 and AMT-253 in colorectal cancer, melanoma and non-small-cell lung cancer.","summary":"Multitude Therapeutics, based in Shanghai, China, is a biotechnology company. Multitude Therapeutics is a clinical-stage biotechnology company in China developing antibody-drug conjugate therapies for cancer, using its PAD molecular design platform and MabArray target discovery platform. On ClinicalTrials.gov it is the lead sponsor of 4 recruiting or active phase 2 and phase 3 interventional cancer trials, testing AMT-116, AMT-676, AMT-253 and AK112 in colorectal cancer, melanoma and non-small-cell lung cancer. The largest, NCT07474727 (A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer), plans to enrol 180 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.multitudetherapeutics.com"},{"label":"ClinicalTrials.gov: trials led by Multitude Therapeutics","url":"https://clinicaltrials.gov/search?lead=Multitude%20Therapeutics%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["colorectal","melanoma","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07474727","nct06209580","nct06782334"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.multitudetherapeutics.com","stage":"growth","investors":[],"funding":[]},{"id":"mundipharma","kind":"company","name":"Mundipharma","aka":["Mundipharma Research GmbH & Co KG","Mundipharma Research","Mundipharma International","Napp Pharmaceuticals"],"tldr":"Mundipharma is the privately held network of companies associated with the Sackler family outside the United States, known for opioid pain medicines used in cancer care and, in Europe, for oncology products such as the antifungal and haematology lines it licenses.","summary":"Mundipharma comprises independent associated companies, with the German business in Limburg an der Lahn founded in 1967, that market pain medicines including controlled-release oxycodone and buprenorphine, as well as oncology, haematology and anti-infective products in many countries. Its research arm, Mundipharma Research GmbH, has led phase 3 trials in cancer pain and supportive care registered on ClinicalTrials.gov. Wikipedia records that bendamustine is marketed in Germany as Ribomustin by Astellas's licensee Mundipharma International, and ClinicalTrials.gov lists Mundipharma K.K. and Taiwan Mundipharma as sponsors of pralatrexate trials in peripheral T-cell lymphoma (NCT02013362, NCT03150602) and Mundipharma Research as sponsor of early trials of tinostamustine and forodesine in blood cancers.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Mundipharma","links":[{"label":"Official website","url":"http://www.mundipharma.de"},{"label":"ClinicalTrials.gov: trials led by Mundipharma Research GmbH & Co KG","url":"https://clinicaltrials.gov/search?lead=Mundipharma%20Research%20GmbH%20%26%20Co%20KG"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q1952722"},{"label":"Wikipedia: bendamustine","url":"https://en.wikipedia.org/wiki/Bendamustine"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cll","follicular-lymphoma","peripheral-t-cell-lymphoma"],"sections":["supportive-care"],"technologies":["pain-management"],"targets":[],"drugs":["bendamustine","pralatrexate"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Limburg an der Lahn","country":"DE","companyType":"pharma","website":"http://www.mundipharma.de","founded":1967,"stage":"private-large","investors":[],"funding":[]},{"id":"mvision-ai","kind":"company","name":"MVision AI","aka":[],"tldr":"MVision AI is a Finnish auto-contouring company with guideline-based organ and target segmentation.","summary":"MVision AI, based in Helsinki, is a Finnish auto-contouring company whose segmentation of organs and targets follows published consensus guidelines. Its Contour+ cloud service delivers guideline-based contours and is used in Nordic and UK centres. OnCo links it to AI auto-contouring and adaptive planning. Whether guideline-conformant automated contours reduce the variation between clinicians that undermines radiotherapy trials is the open question its approach is designed to address. The auto-contouring technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://mvision.ai"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["radiation","ai-computation"],"technologies":["auto-contouring-ai"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Helsinki","country":"FI","companyType":"ai-software","website":"https://mvision.ai","investors":[],"funding":[]},{"id":"myriad-genetics","kind":"company","name":"Myriad Genetics","aka":[],"tldr":"The company that made BRCA testing a business, now selling hereditary panels and the myChoice, EndoPredict and Prolaris tumour tests.","summary":"Myriad held the BRCA1/2 gene patents until the 2013 US Supreme Court ruling and launched BRACAnalysis CDx (2014) and myChoice CDx (2019), the two FDA-approved companion diagnostics for PARP inhibitors. MyRisk is its hereditary cancer panel; EndoPredict (breast) and Prolaris (prostate) are its prognostic tests. Its history is a case study in how gene patents, guidelines and reimbursement shape which tests patients receive.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Myriad_Genetics","links":[{"label":"Official website","url":"https://myriad.com"}],"tags":[],"related":[],"cancers":["ovarian","breast-hr-positive","prostate"],"sections":["diagnostics","prevention"],"technologies":["germline-testing","hrd-testing","companion-diagnostic"],"targets":[],"drugs":["bracanalysis-cdx","mychoice-cdx","endopredict","prolaris"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05642780"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Salt Lake City, UT","country":"US","companyType":"diagnostics","website":"https://myriad.com","ticker":"MYGN","founded":1991,"investors":[],"funding":[]},{"id":"myricx-bio","kind":"company","name":"Myricx Bio","aka":[],"tldr":"Myricx Bio invented a new kind of cancer-killing payload, which blocks an enzyme tumour cells need to survive, and attaches it to antibodies that carry it into tumours. Novartis bought the London company in 2026 for 1.1 billion dollars up front.","summary":"Myricx Bio (trading name of Myricx Pharma Limited, London, with a US office in Boston) developed a new class of antibody-drug conjugate payloads based on inhibitors of N-myristoyltransferase (NMT), an enzyme required for the function of proteins that cancer cells depend on. NMTi payloads are intended to overcome resistance to established payload classes such as topoisomerase 1 inhibitors, and preclinical data showed activity across solid tumour models including TOPO-1 resistant ones. The company's two lead ADC assets are directed at B7-H3 and HER2 and were preclinical at the time of the deal. Novartis agreed on 6 July 2026 to acquire Myricx for USD 1.1 billion upfront plus up to USD 400 million in milestones; the company's website states it became an indirect wholly owned Novartis subsidiary on 28 August 2026.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://myricxbio.com/"},{"label":"Novartis acquisition announcement","url":"https://www.novartis.com/news/media-releases/novartis-agrees-acquire-myricx-bio-advancing-next-generation-antibody-drug-conjugate-innovation-novel-nmti-payload-expanding-options-cancer-patients"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":["adc"],"targets":["b7h3","her2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"London","country":"GB","companyType":"biotech","website":"https://myricxbio.com/","stage":"acquired","investors":["cancer-research-horizons"],"funding":[{"round":"Acquisition","year":2026,"amountUsd":1100000000,"source":"https://www.novartis.com/news/media-releases/novartis-agrees-acquire-myricx-bio-advancing-next-generation-antibody-drug-conjugate-innovation-novel-nmti-payload-expanding-options-cancer-patients","note":"USD 1.1 billion upfront plus up to USD 400 million in milestones; agreement announced 6 July 2026, completed 28 August 2026 per company website"}],"acquiredBy":"novartis"},{"id":"mythic-therapeutics","kind":"company","name":"Mythic Therapeutics","aka":[],"tldr":"Mythic Therapeutics designed antibody-drug conjugates, antibodies that carry a cell-killing drug into tumours, with an engineering trick to get more drug inside cancer cells. Its lead lung cancer medicine reached mid-stage trials before the company wound down in late 2025.","summary":"Mythic Therapeutics (Waltham, Massachusetts, founded 2017) developed antibody-drug conjugates using its FateControl platform, which engineers the antibody component to alter intracellular trafficking so that more payload is released inside tumour cells and less in healthy tissue, independent of linker and payload chemistry. The lead programme MYTX-011 was a cMET-targeted MMAE ADC (drug-to-antibody ratio 2) for non-small cell lung cancer; the company's December 2025 liquidation notice states that more than 230 NSCLC patients had been treated with an objective response rate above 30 percent in cMET-overexpressing disease. Mythic launched publicly in December 2021 with a USD 103 million Series B led by Viking Global Investors. On 21 November 2025 it executed a General Assignment for the Benefit of Creditors and its assets, including MYTX-011, were put up for sale.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://mythictherapeutics.com/"},{"label":"Series B press release (BioSpace copy)","url":"https://www.biospace.com/mythic-therapeutics-launches-with-new-approach-to-improving-antibody-drug-conjugate-performance-backed-by-103-million-in-series-b-financing"},{"label":"Assignment for benefit of creditors and IP sale notice","url":"https://www.biospace.com/press-releases/sale-of-intellectual-property-mythic-therapeutics-inc"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["adcs"],"technologies":["adc"],"targets":["met"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Original company domain mythictx.com is offline (TLS certificate mismatch). Business Wire and Fierce Biotech returned HTTP 403 to my fetches, so the BioSpace copies are cited instead."],"hq":"Waltham, MA","country":"US","companyType":"biotech","website":"https://mythictherapeutics.com/","founded":2017,"stage":"defunct","investors":["venrock","foresite-capital","perceptive-advisors"],"funding":[{"round":"Series B","year":2021,"amountUsd":103000000,"source":"https://www.biospace.com/mythic-therapeutics-launches-with-new-approach-to-improving-antibody-drug-conjugate-performance-backed-by-103-million-in-series-b-financing","note":"BioSpace copy of the Business Wire release dated 15 December 2021"}]},{"id":"mytomorrows","kind":"company","name":"myTomorrows","aka":[],"tldr":"myTomorrows helps patients and physicians find clinical trials and, when none fits, coordinates expanded access to drugs still in development, with patient navigators active in nearly fifty countries.","summary":"myTomorrows, based in Amsterdam, combines trial discovery with expanded access programme coordination (compassionate use) supported by patient navigators, and works with biopharma companies on recruitment and access programmes. Patient-accessible.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/MyTomorrows","links":[{"label":"Official website","url":"https://mytomorrows.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["ai-trial-matching"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Amsterdam, Netherlands","country":"NL","companyType":"ai-software","website":"https://mytomorrows.com/","stage":"growth","investors":[],"funding":[]},{"id":"nanjing-immunophage-biotech","kind":"company","name":"Nanjing Immunophage Biotech","aka":["Nanjing Immunophage Biotech Co., Ltd"],"tldr":"Nanjing Immunophage Biotech is a Chinese developer in Nanjing that sponsors 2 registered cancer trials of IPG1094 and IPG7236.","summary":"Nanjing Immunophage Biotech appears on ClinicalTrials.gov as the industry sponsor of 2 interventional cancer trials (phase 1/2), testing IPG1094, IPG7236, Toripalimab in solid tumor, advanced solid tumor. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials sponsored by Nanjing Immunophage Biotech","url":"https://clinicaltrials.gov/search?spons=Nanjing%20Immunophage%20Biotech"}],"tags":["ctgov-sponsor","china","registry-only"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["ipg1094"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06212076","nct07508761"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Nanjing, China","country":"CN","companyType":"biotech","investors":[],"funding":[]},{"id":"nanjing-leads-biolabs","kind":"company","name":"Nanjing Leads Biolabs","aka":["Nanjing Leads Biolabs Co.,Ltd"],"tldr":"Nanjing Leads Biolabs is a China-based biotechnology company running 8 late-stage cancer trials of LBL-024 and LBL-034 in triple-negative breast cancer, non-small-cell lung cancer and hepatocellular carcinoma.","summary":"Nanjing Leads Biolabs, based in Nanjing, China, is a biotechnology company. On ClinicalTrials.gov it is the lead sponsor of 8 recruiting or active phase 2 and phase 3 interventional cancer trials, testing LBL-024 and LBL-034 in triple-negative breast cancer, non-small-cell lung cancer, hepatocellular carcinoma, oesophageal cancer and multiple myeloma. The largest, NCT05170958 (A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumours), plans to enrol 396 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.leadsbiolabs.com"},{"label":"ClinicalTrials.gov: trials led by Nanjing Leads Biolabs","url":"https://clinicaltrials.gov/search?lead=Nanjing%20Leads%20Biolabs%20Co.%2CLtd"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["tnbc","nsclc","hcc","esophageal","multiple-myeloma","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07042802","nct05170958","nct06049290","nct07331155","nct06783647","nct07111546","nct07390383","nct07281976"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Nanjing","country":"CN","companyType":"biotech","website":"https://www.leadsbiolabs.com","investors":[],"funding":[]},{"id":"nanobiotix","kind":"company","name":"Nanobiotix","aka":[],"tldr":"Nanobiotix is the Paris nanomedicine company behind NBTXR3, hafnium oxide nanoparticles injected into a tumour to make radiotherapy deposit more energy inside it.","summary":"Founded in 2003 and listed on Euronext Paris and Nasdaq, Nanobiotix built its business on the physics of radioenhancement: high atomic number nanoparticles that absorb X-rays and amplify the dose within the tumour. Its lead product NBTXR3 received a European CE mark for soft-tissue sarcoma in 2019 and is in the NANORAY-312 phase 3 trial in head and neck cancer, licensed to Johnson and Johnson in 2023.","asOf":"2026-09-16","links":[{"label":"Official website","url":"https://www.nanobiotix.com"}],"tags":["radiation-wave3","radiation"],"related":[],"cancers":["sarcoma","head-and-neck"],"sections":[],"technologies":["radiosensitisers"],"targets":[],"drugs":["nbtxr3"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Paris, France","country":"FR","companyType":"biotech","website":"https://www.nanobiotix.com","founded":2003,"stage":"public","investors":[],"funding":[]},{"id":"natco","kind":"company","name":"Natco Pharma","aka":[],"tldr":"The oncology generics company at the centre of India's two landmark patent fights: the first compulsory licence, for sorafenib in 2012, and the Supreme Court's 2013 refusal of Novartis's imatinib patent.","summary":"Natco Pharma was founded in 1981 by V. C. Nannapaneni in Hyderabad and built its name on branded oncology generics for the Indian market, including one of the first generic imatinibs (Veenat) sold when India did not yet grant product patents. In March 2012 the Indian Patent Office granted Natco the country's first compulsory licence, for Bayer's sorafenib (Nexavar), at a price of about 8,800 rupees a month against Bayer's 280,000 rupees, with a royalty later set at 7% on appeal. On 1 April 2013 the Supreme Court upheld the refusal of Novartis's patent on the beta-crystalline form of imatinib mesylate under section 3(d) of the Patents Act, keeping generic imatinib on the market at a small fraction of the Glivec price. Natco later became a significant US generics player (lenalidomide under a volume-limited settlement from March 2022, pomalidomide) and in 2025 bought a 35.75% stake in South Africa's Adcock Ingram.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Natco_Pharma","links":[{"label":"Official website","url":"https://www.natcopharma.co.in"},{"label":"Novartis v Union of India (2013)","url":"https://en.wikipedia.org/wiki/Novartis_v._Union_of_India_%26_Others"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy","chemotherapy"],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["imatinib","sorafenib","lenalidomide","pomalidomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05283226"],"people":[],"bottlenecks":["b-drug-pricing","b-global-access","b-ip-collaboration"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Hyderabad","country":"IN","companyType":"pharma","website":"https://www.natcopharma.co.in","ticker":"NATCOPHARM.NS","founded":1981,"investors":[],"funding":[]},{"id":"natera","kind":"company","name":"Natera","aka":[],"tldr":"Natera makes Signatera, the dominant tumour-informed MRD test.","summary":"Natera, based in Austin and listed as NTRA, makes Signatera, the dominant tumour-informed test for measurable residual disease. Signatera has been run more than a million times and was used in the IMvigor011 trial that led to the first circulating tumour DNA-guided drug approval; the company also sells Altera for tumour profiling, Prospera for transplant monitoring and Panorama for prenatal testing. OnCo links it to colorectal cancer, to liquid biopsy, ctDNA monitoring and MRD testing, to bottlenecks on dormant cells and tumour heterogeneity, and to ideas on using tumour DNA to pause treatment in metastatic cancer and to stop combination arms early. Whether acting on a positive MRD result improves outcomes, rather than only predicting them, is the question the field now has to answer. Signatera has its own page.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Natera","links":[{"label":"Official website","url":"https://www.natera.com"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":[],"targets":[],"drugs":["signatera"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06500273"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Austin, TX","country":"US","companyType":"diagnostics","website":"https://www.natera.com","ticker":"NTRA","investors":[],"funding":[]},{"id":"natureceuticals","kind":"company","name":"NatureCeuticals","aka":["Natureceuticals Sdn Bhd"],"tldr":"NatureCeuticals is a Malaysia-based biotechnology company that leads 3 cancer trials in OnCo, testing the botanical medicine Nuvastatic for cancer-related fatigue in colorectal cancer and triple-negative breast cancer.","summary":"NatureCeuticals is a Malaysian clinical-stage company developing standardised botanical medicines for supportive and adjunctive cancer care. Its lead product Nuvastatic, based on Orthosiphon stamineus leaf extract, is in phase 3 trials for cancer-related fatigue in patients receiving chemotherapy for colorectal and triple-negative breast cancer. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo (3 in phase 3 or 2/3): NCT07669454 (phase 3, A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III...), NCT07669519 (phase 3, Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients...) and NCT07669467 (phase 3, Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.ncnatureceuticals.com/"},{"label":"ClinicalTrials.gov: trials led by NatureCeuticals","url":"https://clinicaltrials.gov/search?lead=Natureceuticals%20Sdn%20Bhd"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["colorectal","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07669454","nct07669519","nct07669467"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Kuala Lumpur","country":"MY","companyType":"biotech","website":"https://www.ncnatureceuticals.com/","stage":"growth","investors":[],"funding":[]},{"id":"naveris","kind":"company","name":"Naveris","aka":[],"tldr":"Naveris makes NavDx, a blood test that tracks DNA from the HPV virus shed by tumours, so doctors can confirm HPV-related throat and anal cancers and catch them coming back after treatment. It was bought by CareDx in 2026.","summary":"Naveris, based in Waltham, Massachusetts and founded in 2017, developed NavDx, a blood test that quantifies tumour tissue modified viral (TTMV) HPV DNA in plasma. The tumour-naive assay can confirm HPV-driven disease at diagnosis, assess treatment response and detect molecular residual disease (MRD) and recurrence in HPV-positive oropharyngeal and anal squamous cell carcinoma. The test runs in a CLIA-certified, CAP-accredited, New York State-approved laboratory. Medicare coverage began in 2023 with ADLT status at $1,800 per test; more than 130,000 commercial tests have been reported. Naveris raised an expanded Series A of $19 million in 2020 and $51 million in 2022, led by Gurnet Point Capital. CareDx agreed in April 2026 to acquire it for $160 million up front plus up to $100 million in milestones, closing in July 2026.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://naveris.com/"},{"label":"CareDx 8-K exhibit: agreement to acquire Naveris (Apr 2026)","url":"https://www.sec.gov/Archives/edgar/data/1217234/000110465926050317/tm2611749d3_ex99-2.htm"},{"label":"CareDx completes acquisition (Jul 2026)","url":"https://www.sec.gov/Archives/edgar/data/1217234/000121723426000038/naveris-pressrelease.htm"},{"label":"$51 million financing (Sep 2022)","url":"https://naveris.com/naveris-inc-raises-51-million-to-advance-commercialization-of-navdx/"}],"tags":[],"related":[],"cancers":["head-and-neck"],"sections":["diagnostics"],"technologies":["liquid-biopsy","mrd-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["2022 release dateline is Natick, MA; the current website gives Waltham, MA. Anal cancer has no id in the cancer list. NavDx is a laboratory developed test; no FDA clearance is claimed here."],"hq":"Waltham, MA","country":"US","companyType":"diagnostics","website":"https://naveris.com/","founded":2017,"stage":"acquired","investors":["acs-brightedge"],"funding":[{"round":"Series A","year":2020,"amountUsd":19000000,"source":"https://naveris.com/naveris-inc-raises-19-million-in-financing-to-advance-and-commercialize-blood-tests-for-early-detection-of-hpv-and-other-viral-related-cancers-i/","note":"Expanded Series A led by Gurnet Point Capital, December 2020."},{"round":"Series A","year":2022,"amountUsd":51000000,"source":"https://naveris.com/naveris-inc-raises-51-million-to-advance-commercialization-of-navdx/","note":"$33.4 million Series A expansion bringing the round to $51 million; led by Gurnet Point Capital with TechU Ventures and BrightEdge, September 2022."},{"round":"Acquisition","year":2026,"amountUsd":160000000,"source":"https://www.sec.gov/Archives/edgar/data/1217234/000110465926050317/tm2611749d3_ex99-2.htm","note":"CareDx agreed to pay $160 million cash up front plus up to $100 million in revenue milestones (announced 28 April 2026); completion announced July 2026."}]},{"id":"navexio","kind":"company","name":"Navexio","aka":[],"tldr":"Cancer navigation consultancy that helps patients find, understand, and enrol in biomarker-matched clinical trials.","summary":"Navexio is a US cancer navigation consultancy that helps patients find, understand and enrol in biomarker-matched clinical trials. Its personalised service covers trial identification from the tumour's biomarker profile, explanation of eligibility and risks, coordination with trial sites, and emotional support for patients and families, and it is linked in OnCo to Cancer Commons, the nonprofit working in the same space. OnCo connects it to AI trial matching and clinical decision support. Whether paid navigation reaches the patients who most need it, rather than those who can afford it, is the fair question for a service of this kind. The trial matching technology page carries the wider picture.","asOf":"2026-09-04","links":[{"label":"Clinical trial navigation","url":"https://navexio.com/clinical-trial-navigation"}],"tags":[],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":["ai-trial-matching"],"targets":[],"drugs":[],"companies":["cancer-commons"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"United States","country":"US","companyType":"cro-services","website":"https://navexio.com","investors":[],"funding":[]},{"id":"navidea","kind":"company","name":"Navidea Biopharmaceuticals","aka":["Navidea","Neoprobe Corporation"],"tldr":"Navidea developed technetium-99m tilmanocept (Lymphoseek), the radiotracer approved in 2013 for mapping sentinel lymph nodes in breast cancer, melanoma and head and neck cancer.","summary":"Navidea Biopharmaceuticals, based in Dublin, Ohio and formerly Neoprobe, developed technetium Tc-99m tilmanocept (Lymphoseek), a receptor-targeted radiotracer that binds CD206 on macrophages in lymph nodes; the FDA approved it in 2013 for sentinel lymph node mapping in breast cancer and melanoma and in 2014 for oral cavity squamous cell carcinoma. The company sold North American rights to Cardinal Health in 2017 and later focused on macrophage imaging in rheumatoid arthritis; its listing was delisted in 2023. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Navidea_Biopharmaceuticals","links":[{"label":"ClinicalTrials.gov: trials led by Navidea Biopharmaceuticals","url":"https://clinicaltrials.gov/search?lead=Navidea%20Biopharmaceuticals"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Navidea_Biopharmaceuticals"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["breast-hr-positive","melanoma","head-and-neck"],"sections":["imaging","surgery"],"technologies":[],"targets":[],"drugs":["tilmanocept-tc99m"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Dublin, OH","country":"US","companyType":"diagnostics","website":"https://www.navidea.com","stage":"public","investors":[],"funding":[]},{"id":"navignostics","kind":"company","name":"Navignostics","aka":[],"tldr":"Navignostics maps dozens of proteins at single-cell resolution across one tumour section, showing which cells sit next to which immune cells, to guide personalised treatment.","summary":"Navignostics, a Zürich company, combines highly multiplexed tumour imaging with data analytics: spatial single-cell proteomic analysis of a single formalin-fixed section captures tumour and immune cell types and their interactions. Future of Cancer Care Today lists it for both molecular and immune profiling, physician-ordered through an early-access partner programme.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.navignostics.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["imaging-mass-cytometry","spatial-transcriptomics","multiplex-immunofluorescence"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Zürich, Switzerland","country":"CH","companyType":"diagnostics","website":"https://www.navignostics.com/","investors":[],"funding":[]},{"id":"nbe-therapeutics","kind":"company","name":"NBE-Therapeutics","aka":[],"tldr":"NBE-Therapeutics, founded in Basel in 2012 and owned by Boehringer Ingelheim since 2020, builds antibody-drug conjugates that pair its own conjugation chemistry with a PNU-derived anthracycline payload, designed to kill tumour cells directly and to trigger a lasting immune response against the tumour. Its candidates are still moving towards the clinic.","summary":"NBE-Therapeutics AG, founded in Basel in 2012, developed a next-generation antibody-drug conjugate platform for solid tumours combining its own conjugation technology, a PNU-derived anthracycline payload and antibody discovery capabilities. Its immune-stimulating ADC (iADC) concept aims for a long-lasting immuno-oncology effect in addition to direct cytotoxicity, with a pipeline of ADC candidates at various stages of development moving towards the clinic. The company became a wholly owned subsidiary of Boehringer Ingelheim in 2020 and in April 2025 opened a new ADC research and development centre in Basel that serves as a hub for Boehringer's ADC work.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://nbe-therapeutics.com/"},{"label":"Boehringer Ingelheim opens NBE R&D centre (states 2020 acquisition)","url":"https://nbe-therapeutics.com/news-events/news/boehringer-ingelheim-strengthens-antibody-drug-conjugate-portfolio-with-new-nbe-therapeutics-r-d-center-in-basel"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":["adc","immune-stimulating-adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Boehringer Ingelheim's own acquisition release (reported elsewhere as up to EUR 1.18 billion, December 2020) is rendered client-side and returned no text to my fetches, so the deal value is omitted. Lead programme target (reported elsewhere as ROR1 for NBE-002) not stated on fetched pages."],"hq":"Basel","country":"CH","companyType":"biotech","website":"https://nbe-therapeutics.com/","founded":2012,"stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2020,"source":"https://nbe-therapeutics.com/news-events/news/boehringer-ingelheim-strengthens-antibody-drug-conjugate-portfolio-with-new-nbe-therapeutics-r-d-center-in-basel","note":"Company states it became part of Boehringer Ingelheim in 2020; deal value not stated on the fetched page"}],"acquiredBy":"boehringer-ingelheim"},{"id":"nearwave","kind":"company","name":"NearWave","aka":[],"tldr":"NearWave makes a handheld near-infrared scanner that shows within days whether a breast cancer is responding to chemotherapy before surgery, so patients are not left on a treatment that is failing.","summary":"NearWave's handheld device uses near-infrared diffuse optical imaging to measure haemoglobin, oxygenation, water and lipid content in breast tumours, tracking metabolic changes early in neoadjuvant chemotherapy to predict pathological response weeks before imaging or surgery would. It is a University of Notre Dame spin-out with clinical studies at US cancer centres. The device is investigational; predictive performance has been reported in early studies rather than a pivotal trial.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/nearwave"},{"label":"Official website","url":"https://nearwave.co"}],"tags":["yc"],"related":[],"cancers":["tnbc","breast-hr-positive","breast-her2-positive"],"sections":["imaging","devices"],"technologies":["optical-imaging"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"South Bend, IN","country":"US","companyType":"devices","website":"https://nearwave.co","stage":"startup","ycBatch":"W22","investors":["y-combinator"],"funding":[]},{"id":"nec-bio","kind":"company","name":"NEC Bio","aka":["NEC Bio B.V.","NEC OncoImmunity","NEC Bio Therapeutics"],"tldr":"NEC Bio is a Netherlands-based biotechnology company that leads 2 cancer trials in OnCo, testing the personalised neoantigen vaccine NECVAX-NEO1 in triple-negative breast cancer and advanced solid tumours.","summary":"NEC Bio is the holding company set up by NEC Corporation in 2023 to unify its AI-driven drug discovery and development activities; it manages NEC OncoImmunity in Oslo and NEC Bio Therapeutics in Mannheim. The group applies its immune-recognition AI platform to personalised neoantigen cancer vaccines, including NECVAX-NEO1. It is a wholly owned subsidiary of NEC Corporation. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT06631079 (phase 1/2, Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy...) and NCT06631092 (phase 1/2, Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-nega...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.nec-bio.com/"},{"label":"ClinicalTrials.gov: trials led by NEC Bio","url":"https://clinicaltrials.gov/search?lead=NEC%20Bio%20B.V"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06631079","nct06631092"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Schiphol","country":"NL","companyType":"biotech","website":"https://www.nec-bio.com/","founded":2023,"stage":"private-large","investors":[],"funding":[]},{"id":"nektar-therapeutics","kind":"company","name":"Nektar Therapeutics","aka":["Nektar"],"tldr":"Nektar is a San Francisco biotechnology company whose polymer conjugation chemistry underlies several approved drugs and whose engineered interleukin-2, bempegaldesleukin, failed in phase 3 with nivolumab in 2022.","summary":"Nektar Therapeutics, listed on Nasdaq, built its business on PEGylation and polymer conjugate chemistry licensed into products such as pegfilgrastim-type molecules and movantik. Its own oncology bet, bempegaldesleukin (NKTR-214), a PEGylated interleukin-2 designed to favour effector T cells, was developed with Bristol Myers Squibb in a large phase 3 programme with nivolumab that reported negative results in melanoma, renal cell carcinoma and bladder cancer in 2022, after which the programme was closed. OnCo records it as a registry sponsor of phase 3 cancer trials.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Nektar_Therapeutics","links":[{"label":"Official website","url":"https://www.nektar.com"},{"label":"ClinicalTrials.gov: trials led by Nektar Therapeutics","url":"https://clinicaltrials.gov/search?lead=Nektar%20Therapeutics"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Nektar_Therapeutics"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma","rcc","urothelial"],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["bempegaldesleukin"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.nektar.com","stage":"public","investors":[],"funding":[]},{"id":"neogene-therapeutics","kind":"company","name":"Neogene Therapeutics","aka":[],"tldr":"Neogene developed T-cell receptor therapies that can recognise cancer-specific mutations hidden inside tumour cells, an approach aimed at solid tumours. AstraZeneca bought the company in January 2023 for up to $320 million.","summary":"Neogene Therapeutics was a clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts) for solid tumours. Unlike most cell therapies that target surface proteins, TCR-Ts can recognise intracellular targets including cancer-specific mutations. Neogene had its EU headquarters in Amsterdam and US headquarters in Santa Monica, California, and was backed by Vida Ventures, TPG, EcoR1 Capital, Jeito Capital, Syncona, Polaris Partners and Pontifax. AstraZeneca announced the acquisition on 29 November 2022 and completed it on 16 January 2023, paying $200 million initially with up to $120 million in further contingent and non-contingent consideration (total up to $320 million, cash and debt free). Neogene operates as a wholly owned AstraZeneca subsidiary with operations in Amsterdam and California.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.sec.gov/Archives/edgar/data/901832/000165495422015806/a9015h.htm"},{"label":"Acquisition completed (6-K, January 2023)","url":"https://www.sec.gov/Archives/edgar/data/901832/000165495423000484/a7540m.htm"},{"label":"SEC EDGAR filings","url":"https://www.sec.gov/Archives/edgar/data/901832/000165495422015806/a9015h.htm"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["tcr-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["neogene.com no longer resolves, so the AstraZeneca 6-K announcing the deal is given as the website. Pre-acquisition venture rounds not sourced."],"hq":"Amsterdam","country":"NL","companyType":"cell-therapy","stage":"acquired","investors":["vida-ventures","ecor1-capital","jeito-capital","syncona","polaris-partners"],"funding":[{"round":"Acquisition","year":2023,"amountUsd":320000000,"source":"https://www.sec.gov/Archives/edgar/data/901832/000165495423000484/a7540m.htm","note":"Initial payment of $200 million on completion (16 January 2023) plus up to $120 million in contingent milestone and non-contingent consideration; total up to $320 million"}],"acquiredBy":"astrazeneca"},{"id":"neogenomics","kind":"company","name":"NeoGenomics","aka":[],"tldr":"Cancer-focused reference lab for IHC, FISH, flow cytometry, and NGS, serving community oncology and pharma.","summary":"NeoGenomics, based in Fort Myers, Florida, and listed as NEO, is a cancer-focused reference laboratory for immunohistochemistry, FISH, flow cytometry and next-generation sequencing, serving community oncology and pharmaceutical companies. It has the broadest oncology test menu among independent laboratories, offers the RaDaR measurable residual disease assay from its Inivata acquisition, and runs a pharma services division. OnCo links it to reference laboratories, MRD testing and comprehensive genomic profiling, and to RaDaR and Inivata. Whether a cancer-only laboratory can hold its ground against the national reference laboratories and specialist genomics companies is the open question. RaDaR has its own page.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/NeoGenomics","links":[{"label":"Official website","url":"https://neogenomics.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["reference-laboratories","mrd-testing","cgp"],"targets":[],"drugs":[],"companies":["inivata"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Fort Myers, FL","country":"US","companyType":"diagnostics","website":"https://neogenomics.com","ticker":"NEO","investors":[],"funding":[]},{"id":"neomorph","kind":"company","name":"Neomorph","aka":[],"tldr":"Neomorph makes small molecules called molecular glues that stick a disease protein to the cell's disposal machinery so it is destroyed. Its first drug is in an early trial for clear cell kidney cancer.","summary":"Neomorph is a San Diego company that engineers neomorphic protein surfaces to discover molecular glue degraders, claiming the largest proprietary molecular glue target space with multiple newly identified degrons, glue libraries and a broad portfolio of E3 ubiquitin ligases. Its lead programme, NEO-811, degrades ARNT (HIF-1 beta) and is in a first-in-human phase 1/2 monotherapy trial in advanced clear cell renal cell carcinoma; two undisclosed solid tumour programmes and early oncology, immunology, neurology and cardiometabolic targets follow. Partnerships include an option-to-license deal with AbbVie in oncology and immunology (January 2025, up to 1.64 billion US dollars), a multi-target collaboration with Biogen, and work with Novo Nordisk. Neomorph closed a 100 million US dollar Series B in April 2026 led by Deerfield Management.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://neomorph.com/"},{"label":"Pipeline","url":"https://neomorph.com/pipeline/"},{"label":"Series B press release","url":"https://neomorph.com/press-release/neomorph-announces-closing-of-100-million-series-b-financing/"},{"label":"AbbVie collaboration","url":"https://neomorph.com/press-release/abbvie-and-neomorph-announce-collaboration-to-develop-molecularglue-degraders-for-oncology-and-immunology/"}],"tags":[],"related":[],"cancers":["rcc"],"sections":["targeted-therapy"],"technologies":["protac-degrader"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Series A and founding year not sourced; no SEC Form D filings were found under the company name. NEO-811's target (ARNT/HIF-1 beta) has no id in the target list."],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://neomorph.com/","stage":"startup","investors":["deerfield-management","longwood-fund","alexandria-venture-investments"],"funding":[{"round":"Series B","year":2026,"amountUsd":100000000,"source":"https://neomorph.com/press-release/neomorph-announces-closing-of-100-million-series-b-financing/","note":"Led by founding investor Deerfield Management; closed April 2026"}]},{"id":"neonc-technologies","kind":"company","name":"Neonc Technologies","aka":["Neonc Technologies, Inc."],"tldr":"Neonc Technologies is a United States-based biotechnology company running 3 late-stage cancer trials of NEO212 Oral and NEO100 in glioma & glioblastoma, cervical cancer and colorectal cancer.","summary":"Neonc Technologies, based in Calabasas, the United States, is a biotechnology company listed as NASDAQ: NTHI. NeOnc develops drug delivery therapeutics for central nervous system diseases, using a perillyl-alcohol-based platform intended to transport therapeutics across the blood-brain barrier. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials, testing NEO212 Oral and NEO100 in glioma & glioblastoma, cervical cancer, colorectal cancer, oesophageal cancer and gastric & gastro-oesophageal junction cancer. The largest, NCT06047379 (Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis), plans to enrol 134 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.neonc.com"},{"label":"ClinicalTrials.gov: trials led by Neonc Technologies","url":"https://clinicaltrials.gov/search?lead=Neonc%20Technologies%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["glioblastoma","cervical","colorectal","esophageal","gastric","head-and-neck","melanoma","merkel-cell-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06047379","nct02704858"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Calabasas","country":"US","companyType":"biotech","website":"https://www.neonc.com","ticker":"NASDAQ: NTHI","stage":"public","investors":[],"funding":[]},{"id":"neovii","kind":"company","name":"Neovii","aka":["Neovii Biotech","Neovii Biotech GmbH","Neovii Pharmaceuticals AG"],"tldr":"Neovii is a Swiss company whose anti-T-lymphocyte globulin, Grafalon, is given before stem cell transplants to lower the risk of graft versus host disease.","summary":"Neovii, headquartered in Rapperswil-Jona, Switzerland, makes Grafalon (anti-T-lymphocyte globulin, previously ATG-Fresenius), a rabbit-derived polyclonal antibody used in conditioning before allogeneic haematopoietic stem cell transplantation to reduce graft versus host disease and rejection. It has led phase 3 transplant trials in leukaemia registered on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.neovii.com"},{"label":"ClinicalTrials.gov: trials led by Neovii","url":"https://clinicaltrials.gov/search?lead=Neovii"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml","all-leukemia"],"sections":[],"technologies":["allogeneic-hsct"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["allogeneic-transplant"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Rapperswil-Jona","country":"CH","companyType":"biotech","website":"https://www.neovii.com","stage":"private-large","investors":[],"funding":[]},{"id":"nerviano-medical-sciences","kind":"company","name":"Nerviano Medical Sciences","aka":["Nerviano Medical Sciences Ltd.","Nerviano Medical Sciences (Shanghai) Ltd.","Nerviano Medical Sciences S.r.l.","NMS"],"tldr":"Nerviano Medical Sciences is an Italian drug-discovery company founded in 2004 in Nerviano, near Milan, that leads two cancer trials in OnCo: the PARP1-selective inhibitor atamparib in advanced solid tumours and NMS-03305293 with temozolomide in recurrent glioblastoma.","summary":"Nerviano Medical Sciences is a company based in Nerviano, Italy, founded in 2004 (Wikidata Q30280722, which also gives its website). ClinicalTrials.gov classes it as an industry sponsor; its Shanghai subsidiary is the registered sponsor of one trial. It leads two phase 1/2 trials recorded in OnCo: NCT07374419 (atamparib in advanced solid tumours, recorded under NSCLC) and NCT04910022 (NMS-03305293 with temozolomide in adults with recurrent glioblastoma). Both compounds are its own, the basis for the biotech type.","asOf":"2026-09-22","links":[{"label":"Official website","url":"http://www.nervianoms.com/en/"},{"label":"Wikidata Q30280722","url":"https://www.wikidata.org/wiki/Q30280722"},{"label":"ClinicalTrials.gov: trials led by Nerviano Medical Sciences","url":"https://clinicaltrials.gov/search?lead=Nerviano%20Medical%20Sciences"}],"tags":["ctgov-sponsor","wave5-sponsor"],"related":[],"cancers":["nsclc","glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["temozolomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07374419","nct04910022"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo content wave 5 (Wikidata, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-22"},"hq":"Nerviano","country":"IT","companyType":"biotech","website":"http://www.nervianoms.com/en/","founded":2004,"investors":[],"funding":[]},{"id":"nested-therapeutics","kind":"company","name":"Nested Therapeutics","aka":[],"tldr":"Nested Therapeutics hunts for hidden cancer-driving mutations and designs drugs to fit them. Its first drug, NST-628, sticks two signalling proteins (RAF and MEK) together to switch off a common cancer growth pathway.","summary":"Nested Therapeutics is a Cambridge, Massachusetts precision oncology company founded by Versant Ventures. Its platform maps mutational clusters onto protein structures to reveal cryptic driver mutations and druggable pockets, combining genomics, computational biophysics and machine learning. The lead programme, NST-628, is a non-degrading, brain-penetrant pan-RAF/MEK molecular glue that outperformed single agents and vertical combinations in RAS/MAPK-driven preclinical models; it is in a phase 1 study (NCT06326411) in adults with MAPK pathway-mutated or -dependent advanced solid tumours. A mutation-selective p53 pathway programme targets a cryptic pocket in a transcriptional regulator and has a lead compound. Nested launched in October 2022 with a 90 million US dollar Series A led by Goldman Sachs Asset Management, bringing total funding to 125 million US dollars.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://nestedtx.com/"},{"label":"Launch and Series A press release (PDF)","url":"https://nestedtx.com/wp-content/uploads/2022/09/Nested-Launches-With-125-Million-Financing.pdf"},{"label":"NST-628 phase 1 trial","url":"https://clinicaltrials.gov/study/NCT06326411"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy","drug-discovery"],"technologies":["kinase-inhibitors","ai-drug-design"],"targets":["braf","tp53"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No SEC Form D filings were found under the company name. The seed funding (35 million US dollars implied by the 125 million total) is not itemised in the release. Founding year not sourced."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://nestedtx.com/","stage":"startup","investors":["versant-ventures","foresite-capital","section-32"],"funding":[{"round":"Series A","year":2022,"amountUsd":90000000,"source":"https://nestedtx.com/wp-content/uploads/2022/09/Nested-Launches-With-125-Million-Financing.pdf","note":"Led by Goldman Sachs Asset Management; brought total financing to 125 million US dollars since Versant Ventures founded the company"}]},{"id":"netris-pharma","kind":"company","name":"Netris Pharma","aka":["NETRIS Pharma SAS"],"tldr":"Netris Pharma is a Lyon biotech built on Patrick Mehlen's discovery that tumours use the guidance protein netrin-1 to survive; its antibody NP137 blocks netrin-1 and has shown activity in endometrial cancer.","summary":"Netris Pharma develops therapies that restore the cell death normally triggered by dependence receptors when their ligand is absent. NP137 is a humanised antibody that neutralises netrin-1, a ligand many tumours over-produce to block this apoptosis. In a phase 1 study it was safe and produced responses in endometrial carcinoma, and a Nature paper in 2023 showed it reverses epithelial-to-mesenchymal transition and sensitises tumours to chemotherapy. It is being tested with carboplatin and paclitaxel, and with pembrolizumab, in endometrial and cervical cancers.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.netrispharma.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["np137"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Lyon","country":"FR","companyType":"biotech","website":"https://www.netrispharma.com/","founded":2008,"investors":[],"funding":[]},{"id":"neuboron-medtech","kind":"company","name":"Neuboron Medtech","aka":[],"tldr":"Neuboron Medtech is a Chinese company that builds accelerator-based boron neutron capture therapy systems; its NeuPex machine was installed at the Xiamen Humanity Hospital, the first hospital BNCT centre in China.","summary":"Neuboron Medtech develops accelerator BNCT systems, boron drugs and treatment planning software, and built the NeuPex system for the Xiamen Humanity Hospital, which began clinical trials of BNCT in China. It also collaborates on further installations in China and abroad. Founding details and financing are not tracked here.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.neuboron.com/"}],"tags":["machines-wave2"],"related":[],"cancers":[],"sections":[],"technologies":["bnct","bnct-accelerator-systems"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07795034"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Nanjing","country":"CN","companyType":"devices","website":"https://www.neuboron.com/","stage":"growth","investors":[],"funding":[]},{"id":"neutron-therapeutics","kind":"company","name":"Neutron Therapeutics","aka":[],"tldr":"Neutron Therapeutics makes a compact particle accelerator that produces the neutron beam needed for boron neutron capture therapy, a form of radiotherapy that targets cancer cells one at a time, so hospitals no longer need a nuclear reactor to offer it.","summary":"Neutron Therapeutics, founded in November 2015 with roots in MIT technology, builds nuBeam, an accelerator-based neutron source for boron neutron capture therapy (BNCT). It pairs a patented electrostatic proton accelerator (nominal 30 mA at 2.6 MeV) with a rotating solid lithium target to produce an epithermal beam designed to meet IAEA recommendations. The first nuBeam suite is at Helsinki University Hospital, where a full treatment workflow was completed in 2022; a second system at Shonan Kamakura General Hospital in Japan produced its first beam in January 2023, and a research accelerator was accepted at the University of Birmingham in December 2023. In 2023 the company partnered with boron drug developer Aviko Radiopharmaceuticals and with Leo Cancer Care. nuBeam is investigational and not FDA or PMDA approved. No financing round could be sourced.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://neutrontherapeutics.com/"},{"label":"About Neutron Therapeutics","url":"https://neutrontherapeutics.com/about/"},{"label":"News page (Helsinki, Shonan Kamakura, Aviko partnership)","url":"https://neutrontherapeutics.com/news/"},{"label":"Birmingham accelerator final acceptance (Dec 2023)","url":"https://neutrontherapeutics.com/news/pr_121323/"},{"label":"Shonan Kamakura nuBeam agreement (July 2019)","url":"https://neutrontherapeutics.com/news/pr-071619/"}],"tags":[],"related":[],"cancers":["glioblastoma","head-and-neck"],"sections":["radiation","devices"],"technologies":["bnct"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Danvers, MA taken from company press release datelines; the Dec 2023 release was datelined Boston. Business Wire copies of the Helsinki and Aviko releases returned HTTP 403, so those milestones are cited to the company's own news page listing. No funding or investor information found in primary sources; stage set to startup by default. Whether patients have been treated clinically at Helsinki could not be confirmed."],"hq":"Danvers, MA","country":"US","companyType":"devices","website":"https://neutrontherapeutics.com/","founded":2015,"stage":"startup","investors":[],"funding":[]},{"id":"newlink-genetics","kind":"company","name":"NewLink Genetics (now Lumos Pharma)","aka":["Lumos Pharma"],"tldr":"The Iowa biotech that ran the largest pancreatic cancer vaccine trial, IMPRESS, and the IDO inhibitor indoximod programme; it merged into Lumos Pharma in 2020.","summary":"NewLink Genetics developed the HyperAcute whole-cell vaccine platform, including algenpantucel-L for pancreatic cancer, and the IDO pathway inhibitor indoximod. After IMPRESS and PILLAR failed, the company merged with Lumos Pharma in 2020 and left oncology.","asOf":"2026-09-17","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/NewLink_Genetics"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["algenpantucel-l"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Ames, Iowa, United States","country":"US","companyType":"biotech","website":"https://www.lumos-pharma.com","founded":1999,"stage":"public","investors":[],"funding":[]},{"id":"nextsource-biotechnology","kind":"company","name":"NextSource Biotechnology","aka":["NextSource Biotechnology, LLC","NextSource Pharma"],"tldr":"NextSource Biotechnology is the Florida specialty pharma that sells lomustine in the United States as Gleostine, the nitrosourea chemotherapy used in brain tumours and Hodgkin lymphoma.","summary":"NextSource Biotechnology is a Miami-based specialty pharmaceutical company. It acquired US rights to lomustine (formerly CeeNU) and markets it as Gleostine, a capsule alkylating agent approved for brain tumours after surgery and radiotherapy and for Hodgkin lymphoma after other treatments. The company drew attention for steep price increases on the drug after the acquisition.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["lomustine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Miami, Florida","country":"US","companyType":"pharma","investors":[],"funding":[]},{"id":"nimbus-therapeutics","kind":"company","name":"Nimbus Therapeutics","aka":[],"tldr":"Nimbus Therapeutics is a Boston company that uses computer-aided chemistry to design pills against hard drug targets. Its cancer drug blocks an enzyme called WRN that some bowel and womb cancers with faulty DNA repair depend on.","summary":"Nimbus Therapeutics is a privately held Boston biotechnology company that designs small molecules against difficult targets using computational chemistry. Its lead oncology programme is NDI-219216, an inhibitor of the WRN helicase, which the company lists as being in a phase 1/2 trial in microsatellite instability-high (MSI-H) solid tumours; WRN dependence in MSI-H cancer is a synthetic lethal relationship. The pipeline also includes a preclinical SIK2 immunology programme and metabolic-disease collaborations with Eli Lilly. Nimbus sold its TYK2 inhibitor (now zasocitinib) to Takeda in a deal reported by STAT at 4 billion US dollars upfront, and its ACC inhibitor programme to Gilead. It raised 125 million US dollars in 2022 and 210 million US dollars in 2023 (led by GV with SR One and Atlas Venture), according to trade press coverage of the announcements.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.nimbustx.com/"},{"label":"Pipeline","url":"https://www.nimbustx.com/pipeline/"},{"label":"STAT on the 2023 financing","url":"https://www.statnews.com/2023/09/06/nimbus-therapeutics-raises-210-million-in-one-of-the-larger-fundraising-rounds-this-year/"}],"tags":[],"related":["src-stat-news","src-biopharma-dive"],"cancers":[],"sections":["targeted-therapy","drug-discovery"],"technologies":["ai-drug-design","synthetic-lethality-approaches"],"targets":[],"drugs":["ndi-219216"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Nimbus's own press releases could not be located on its site (the news archive links to third-party coverage only) and no Form D filings were found under the company name. Founding year not sourced."],"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://www.nimbustx.com/","stage":"growth","investors":["gv","sr-one","atlas-venture","sv-health-investors"],"funding":[{"round":"Crossover","year":2022,"amountUsd":125000000,"source":"https://www.biopharmadive.com/news/nimbus-venture-funding-psoriasis-tyk2/631667/","note":"Described by BioPharma Dive as a private funding round; no series letter given"},{"round":"Crossover","year":2023,"amountUsd":210000000,"source":"https://www.statnews.com/2023/09/06/nimbus-therapeutics-raises-210-million-in-one-of-the-larger-fundraising-rounds-this-year/","note":"Described by STAT as a private financing round led by GV with SR One and Atlas Venture; no series letter given"}]},{"id":"nippon-kayaku","kind":"company","name":"Nippon Kayaku","aka":["Nippon Kayaku Co., Ltd.","日本化薬"],"tldr":"Nippon Kayaku is a Japanese chemicals and pharmaceuticals group whose medicines business specialises in cancer: generic chemotherapy, supportive care products and biosimilars of antibodies such as trastuzumab for the Japanese market.","summary":"Nippon Kayaku, listed in Tokyo, is a diversified chemicals company whose pharmaceutical division concentrates on oncology in Japan, supplying generic cytotoxic drugs, supportive care medicines and biosimilar antibodies including a trastuzumab biosimilar, and running the domestic phase 3 trials that biosimilar approval in Japan requires. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Nippon_Kayaku","links":[{"label":"Official website","url":"https://www.nipponkayaku.co.jp/english/"},{"label":"ClinicalTrials.gov: trials led by Nippon Kayaku","url":"https://clinicaltrials.gov/search?lead=Nippon%20Kayaku"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Nippon_Kayaku"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":["chemotherapy"],"technologies":[],"targets":[],"drugs":["trastuzumab","pirarubicin"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Tokyo","country":"JP","companyType":"pharma","website":"https://www.nipponkayaku.co.jp/english/","stage":"public","investors":[],"funding":[]},{"id":"nkarta","kind":"company","name":"Nkarta","aka":[],"tldr":"CAR-NK company that shelved its oncology programmes after falling response rates and pivoted to autoimmune disease.","summary":"Nkarta, based in South San Francisco and listed as NKTX, is a CAR-NK company that shelved its oncology programmes after response rates fell and pivoted to autoimmune disease. Its NKX101 candidate in acute myeloid leukaemia saw its response rate fall from 67 percent to 25 percent and was deprioritised, and the CD19 CAR-NK NKX019 was withdrawn from lymphoma development and is now in phase 1 for lupus nephritis and other autoimmune conditions. OnCo links it to acute myeloid leukaemia and diffuse large B-cell lymphoma, to CAR-NK and CAR-macrophage technology, to CD19 as a target, and to the idea of off-the-shelf natural killer cells to sweep up residual disease. The record is a data point on the limits of unmodified CAR-NK persistence. Whether engineered NK cells can be made to persist long enough to treat cancer is the question its retreat leaves open.","asOf":"2026-09-04","links":[{"label":"Pivot coverage","url":"https://www.fiercebiotech.com/biotech/nkartas-continues-pivot-autoimmune-disease-shelving-lymphoma-program-car-nk-candidate"}],"tags":["pivot","failure"],"related":["src-fierce-biotech"],"cancers":["aml","dlbcl"],"sections":["cell-therapy"],"technologies":["car-nk-macrophage"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"South San Francisco, CA","country":"US","companyType":"cell-therapy","website":"https://www.nkartatx.com","ticker":"NKTX","investors":[],"funding":[]},{"id":"nobelpharma","kind":"company","name":"Nobelpharma","aka":["Nobelpharma Co., Ltd.","ノーベルファーマ"],"tldr":"Nobelpharma is a Tokyo company founded in 2003 to develop medicines for rare diseases and unmet needs in Japan, including cancer treatments it takes through phase 3 trials.","summary":"Nobelpharma Co., Ltd., based in Chūō, Tokyo, was founded in 2003 to bring medicines for rare diseases and unmet medical needs to the Japanese market, often licensing products approved elsewhere and running the Japanese trials needed for approval. It is lead sponsor of several phase 3 cancer trials registered on ClinicalTrials.gov. Its product list includes two cancer medicines: Cosmegen (dactinomycin) for Wilms tumour, choriocarcinoma and paediatric solid tumours, and Zanosar (streptozocin) for gastroenteropancreatic neuroendocrine tumours, alongside Unitalc (talc) for malignant pleural effusion.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.nobelpharma.co.jp"},{"label":"ClinicalTrials.gov: trials led by Nobelpharma","url":"https://clinicaltrials.gov/search?lead=Nobelpharma"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q11325922"},{"label":"Nobelpharma product list","url":"https://www.nobelpharma.co.jp/en/research/product/"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["neuroendocrine"],"sections":[],"technologies":[],"targets":[],"drugs":["dactinomycin","streptozocin"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Tokyo","country":"JP","companyType":"pharma","website":"https://www.nobelpharma.co.jp","founded":2003,"stage":"private-large","investors":[],"funding":[]},{"id":"noetik","kind":"company","name":"Noetik","aka":[],"tldr":"Noetik builds artificial intelligence models of tumours from huge sets of tissue images and molecular data, to predict which patients will respond to a cancer drug and to find new targets.","summary":"Noetik, founded in 2023 in South San Francisco, is an AI-native biotechnology company that has assembled one of the largest multimodal tumour datasets (spatial transcriptomics, proteomics, histology and genomics from patient samples) plus its Perturb-map in vivo functional genomics platform. On these it trains foundation models of the tumour microenvironment, including OCTO-VirtualCell, Celleporter and TARIO-2, which identifies likely responders to the checkpoint combination botensilimab plus balstilimab from routine pathology images (June 2026, following a 2025 biomarker collaboration with Agenus). Applications span trial enrichment, repositioning of clinical-stage drugs and novel target discovery. In January 2026 GSK licensed Noetik's foundation models in an anchor partnership reported at USD 50 million. Noetik raised a USD 14 million seed led by DCVC (2023) and a USD 40 million Series A (2024).","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.noetik.ai"},{"label":"News (Series A, GSK partnership)","url":"https://www.noetik.ai/news"},{"label":"DCVC leads USD 14 million seed","url":"https://www.dcvc.com/news-insights/dcvc-leads-14-million-seed-round-to-support-noetik/"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation","drug-discovery"],"technologies":["single-cell-spatial","pathology-foundation-model","ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Series A lead investor not named on fetched pages (Business Wire release blocked). Investor names other than DCVC come from logos on the company homepage."],"hq":"South San Francisco, CA","country":"US","companyType":"ai-software","website":"https://www.noetik.ai","founded":2023,"stage":"startup","investors":["dcvc","polaris-partners","khosla-ventures"],"funding":[{"round":"Seed","year":2023,"amountUsd":14000000,"source":"https://www.dcvc.com/news-insights/dcvc-leads-14-million-seed-round-to-support-noetik/","note":"Led by DCVC"},{"round":"Series A","year":2024,"amountUsd":40000000,"source":"https://www.noetik.ai/news"}]},{"id":"nonagen-bioscience","kind":"company","name":"Nonagen Bioscience","aka":[],"tldr":"Nonagen Bioscience makes Oncuria, a urine test that measures a panel of proteins to detect bladder cancer, watch for it returning, and predict whether BCG immunotherapy will work.","summary":"Nonagen Bioscience, founded in 2011 and operating from a clinical laboratory in Irvine, California, developed Oncuria, a urine-based multiplex protein immunoassay combined with clinical data and proprietary algorithms for bladder (urothelial) cancer. Three tests are offered: Oncuria-Detect for detection in patients with haematuria, Oncuria-Monitor for recurrence surveillance, and Oncuria-Predict for predicting response to intravesical BCG in non-muscle invasive bladder cancer. Oncuria-Predict received FDA Breakthrough Device Designation in September 2021; the platform gained CE marking in 2022, CPT codes (0365U to 0367U) in 2023, Medicare payment rates from January 2024 and CAP accreditation of the Irvine laboratory in 2026. The company reports more than 5,500 patients tested, over 40 publications and more than $21 million in NIH and NCI funding.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.nonagen.com/"},{"label":"News briefs","url":"https://www.nonagen.com/news-briefs"},{"label":"Contact and laboratory address","url":"https://www.nonagen.com/contact-us"}],"tags":[],"related":[],"cancers":["urothelial"],"sections":["diagnostics"],"technologies":["proteomics","liquid-biopsy","companion-diagnostic"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The company was historically associated with Jacksonville, FL (early news items) but the only address on the site is Irvine, CA. NIH/NCI grant total is stated on the homepage without dates so no grant round is recorded. Stage set to startup for want of a sourced round."],"hq":"Irvine, CA","country":"US","companyType":"diagnostics","website":"https://www.nonagen.com/","founded":2011,"stage":"startup","investors":[],"funding":[]},{"id":"nordic-lymphoma-group","kind":"company","name":"Nordic Lymphoma Group","aka":["NLG"],"tldr":"The Danish, Finnish, Norwegian, Swedish and Icelandic lymphoma trials network, best known for the Nordic mantle cell lymphoma regimen.","summary":"The Nordic Lymphoma Group coordinates investigator-initiated lymphoma trials and registries across the Nordic countries, which share population registries that make long-term follow-up unusually complete. Its MCL2 and MCL3 trials established the Nordic regimen of intensified cytarabine-containing induction with rituximab and autologous transplant for younger patients with mantle cell lymphoma. NLG working groups cover aggressive, indolent, T-cell and Hodgkin lymphomas and collaborate with HOVON, the German groups, LYSA and IELSG. The group rotates its chair among the member countries.","asOf":"2026-09-09","links":[{"label":"Nordic Lymphoma Group","url":"https://www.nordic-lymphoma.org"}],"tags":["cooperative-group"],"related":[],"cancers":["dlbcl","hodgkin-lymphoma","cll"],"sections":[],"technologies":["monoclonal-antibody","cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":["hovon","ielsg"],"institutions":["karolinska"],"pathways":[],"terms":[],"trials":[],"people":["sirpa-leppa"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Nordic MCL2/MCL3 regimen","T-cell lymphoma trials","Registry-based outcome studies","Hodgkin lymphoma collaborations"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Stockholm","country":"SE","companyType":"cooperative-group","website":"https://www.nordic-lymphoma.org","investors":[],"funding":[]},{"id":"nordion","kind":"company","name":"Nordion (Sotera Health)","aka":[],"tldr":"Nordion supplies most of the world's cobalt-60, which sterilises single-use bioprocess bags and medical devices and powers Gamma Knife units, and was the largest molybdenum-99 processor until Canada's NRU reactor stopped.","summary":"Nordion, an Ottawa company owned by Sotera Health, sells cobalt-60 sources harvested from Canadian CANDU power reactors operated by Bruce Power and Ontario Power Generation, used for gamma sterilisation of medical products and single-use bioprocess consumables and for Gamma Knife radiosurgery. Until the NRU reactor at Chalk River ceased isotope production in 2016 it processed a large share of the world's molybdenum-99, and its exit reshaped the supply chain described in the reactor record.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.nordion.com"}],"tags":["manufacturing-wave"],"related":[],"cancers":[],"sections":[],"technologies":["research-reactor-isotope-production","single-use-bioprocessing","radiosurgery-srs","cobalt-60-teletherapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Ottawa","country":"CA","companyType":"radiopharma","website":"https://www.nordion.com","stage":"public","investors":[],"funding":[]},{"id":"norgine","kind":"company","name":"Norgine","aka":["Norgine B.V.","Norgine Ltd","Norgine Pharmaceuticals"],"tldr":"Norgine is a European specialty pharmaceutical company, founded in 1906 and based in Amsterdam, best known in cancer care for bowel preparations used before colonoscopy and for in-licensed cancer medicines.","summary":"Norgine is a privately held European pharmaceutical company headquartered in Amsterdam with a history going back to 1906. It markets gastroenterology and supportive-care products, including bowel-cleansing preparations used ahead of colonoscopy and colorectal cancer screening, and licenses oncology medicines for Europe and Australia. It appears on ClinicalTrials.gov as lead sponsor of phase 3 trials in cancer settings.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.norgine.com"},{"label":"ClinicalTrials.gov: trials led by Norgine","url":"https://clinicaltrials.gov/search?lead=Norgine"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q97041850"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["colorectal-screening"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Amsterdam","country":"NL","companyType":"pharma","website":"https://www.norgine.com","founded":1906,"stage":"private-large","investors":[],"funding":[]},{"id":"norroy-bioscience","kind":"company","name":"Norroy Bioscience","aka":["Norroy Bioscience Co., LTD"],"tldr":"Norroy Bioscience is a China-based radiopharmaceutical company that leads 3 cancer trials in OnCo, testing the PSMA-targeted radiopharmaceuticals 177Lu-NYM032 and 68Ga-NYM032 in prostate cancer.","summary":"Norroy Bioscience is a clinical-stage company developing therapeutic and diagnostic radiopharmaceuticals together with automated synthesis systems for their manufacture. Its candidates are led by PSMA-targeted 177Lu-NYM032 and 68Ga-NYM032 in prostate cancer and CAIX-targeted tracers in kidney cancer. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo (2 in phase 3 or 2/3): NCT06383052 (phase 1/2, A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC), NCT07615101 (phase 3, Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in...) and NCT07649122 (phase 3, This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imagin...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.norroybiopharm.com/"},{"label":"ClinicalTrials.gov: trials led by Norroy Bioscience","url":"https://clinicaltrials.gov/search?lead=Norroy%20Bioscience%20Co.%2C%20LTD"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06383052","nct07615101","nct07649122"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Wuxi, Jiangsu","country":"CN","companyType":"radiopharma","website":"https://www.norroybiopharm.com/","founded":2021,"stage":"growth","investors":[],"funding":[]},{"id":"northstar-medical-radioisotopes","kind":"company","name":"NorthStar Medical Radioisotopes","aka":[],"tldr":"NorthStar is a non-reactor producer of Mo-99 in the US and an emerging supplier of non-carrier-added Lu-177 and Ac-225 made with electron accelerators.","summary":"NorthStar Medical Radioisotopes, based in Beloit, Wisconsin, is a non-reactor producer of molybdenum-99 in the United States and an emerging supplier of non-carrier-added lutetium-177 and actinium-225 made with electron accelerators. Its RadioGenix Mo-99 system was approved in 2018, its accelerator-based actinium-225 production facility came online in 2024 to 2025, and it holds lutetium-177 supply agreements. OnCo links it to the therapeutic isotope supply chain for Mo-99, Lu-177 and Ac-225. Whether accelerator production can supply actinium-225 at the volumes the alpha therapies in phase 3 will need is the open question. The isotope supply chain page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.northstarnm.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["radiopharma"],"technologies":["therapy-isotope-supply-chain"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Beloit, WI","country":"US","companyType":"radiopharma","website":"https://www.northstarnm.com","investors":[],"funding":[]},{"id":"northwest-biotherapeutics","kind":"company","name":"Northwest Biotherapeutics","aka":[],"tldr":"Northwest Biotherapeutics developed the DCVax-L dendritic cell vaccine for glioblastoma and is seeking UK approval on contested phase 3 data.","summary":"Northwest Biotherapeutics, based in Bethesda and listed as NWBO, developed DCVax-L, a dendritic cell vaccine for glioblastoma made from a patient's own tumour and immune cells, and is seeking UK approval on contested phase 3 data. Its application to the MHRA was filed in December 2023 and remains pending, manufacturing is based at Sawston in the United Kingdom, and the product is not approved by the FDA. OnCo links it to glioma and glioblastoma and to the DCVax-L drug record, where the trial design debate is covered. Whether a regulator will accept a phase 3 whose design and analysis are disputed is the open question, and the answer will matter beyond this one product. DCVax-L has its own page.","asOf":"2026-09-06","wikipedia":"https://en.wikipedia.org/wiki/Northwest_Biotherapeutics","links":[{"label":"Official website","url":"https://nwbio.com"}],"tags":[],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["dcvax-l"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Bethesda, MD","country":"US","companyType":"cell-therapy","website":"https://nwbio.com","ticker":"NWBO","investors":[],"funding":[]},{"id":"notable-labs","kind":"company","name":"Notable Labs","aka":[],"tldr":"Notable Labs ran an automated laboratory in Foster City that exposed a patient's own leukaemia or lymphoma cells to combinations of approved drugs and measured which killed them, to predict which treatment would work. It listed on Nasdaq in 2023, but its website was offline in September 2026, so it is recorded as wound down.","summary":"Notable Labs built an automated laboratory in Foster City that exposed a patient's own leukaemia or lymphoma cells to combinations of approved drugs and measured which killed the cancer cells while sparing healthy ones, a functional precision medicine approach aimed at relapsed and refractory blood cancers. The company later listed on Nasdaq through a 2023 merger with Vascular Biogenics and pursued a predictive precision medicine platform around volasertib in acute myeloid leukaemia. The YC directory marks it Public, but its website did not resolve on 2026-09-10, so it is recorded as wound down pending a primary source; treat the status as uncertain.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/notable-labs"}],"tags":["yc"],"related":[],"cancers":["aml"],"sections":["diagnostics","drug-discovery"],"technologies":["functional-drug-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Foster City, CA","country":"US","companyType":"biotech","website":"https://www.ycombinator.com/companies/notable-labs","stage":"defunct","ycBatch":"W15","investors":["y-combinator"],"funding":[]},{"id":"nouscom","kind":"company","name":"Nouscom","aka":[],"tldr":"Nouscom is developing Nous-209, an off-the-shelf viral-vector vaccine encoding 209 shared frameshift neoantigens to intercept cancer in Lynch syndrome carriers.","summary":"Nouscom, based in Basel and Rome, is developing Nous-209, an off-the-shelf viral-vector vaccine encoding 209 shared frameshift neoantigens, to intercept cancer in people with Lynch syndrome. A phase 1b/2 in Lynch carriers, published in Nature Medicine in March 2026, showed safety and immune responses in most participants, re-treatment and long-term follow-up data were selected for an ESMO 2026 oral, and the vaccine has also been tested with pembrolizumab in microsatellite-instability-high tumours. OnCo links it to colorectal cancer, to off-the-shelf cancer vaccines and chemoprevention, to the MSI-H and neoantigen terms, and to the idea of a randomised trial of a shared-antigen vaccine to prevent Lynch syndrome cancers. Whether immune responses translate into fewer cancers in carriers is the question only a prevention trial can answer. The off-the-shelf vaccine page carries the field.","asOf":"2026-09-04","links":[{"label":"Nature Medicine 2026","url":"https://www.nature.com/articles/s41591-025-04182-9"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":["immunotherapy","prevention"],"technologies":["shared-antigen-vaccine","chemoprevention"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["msi","neoantigen"],"trials":["nct04041310"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Basel / Rome","country":"CH","companyType":"biotech","website":"https://nouscom.com","investors":["andera-partners"],"funding":[]},{"id":"novartis","kind":"company","name":"Novartis","aka":["Endocyte"],"tldr":"The company that made radioligand therapy a business, with Pluvicto and Lutathera, and the maker of Kisqali and Gleevec.","summary":"Novartis, based in Basel and listed as NOVN.SW, is the company that made radioligand therapy a business with Pluvicto and Lutathera, and the maker of Kisqali, Gleevec, Scemblix and Kymriah, the first approved CAR-T. Pluvicto sells more than 1.5 billion dollars a year, and the pipeline includes actinium-225 PSMA-617, FAP-2286 and the Mariana Oncology acquisition, alongside adjuvant ribociclib, imatinib and asciminib. OnCo links it to the first imatinib trial and IRIS, to ELIANA and JULIET for tisagenlecleucel, to peptide receptor radionuclide therapy, to the AlphaBreak and AcTION actinium trials, and to ideas on Western ytterbium-176 enrichment and two-day CAR-T manufacture. Manufacturing cost and time for living and radioactive medicines is the bottleneck its two flagship modalities share. Lutetium-177 vipivotide tetraxetan and lutetium-177 dotatate have their own pages.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Novartis","links":[{"label":"Official website","url":"https://www.novartis.com"}],"tags":[],"related":[],"cancers":[],"sections":["radiopharma","targeted-therapy","cell-therapy"],"technologies":[],"targets":[],"drugs":["pluvicto","lutathera","ac225-psma","fap-2286","ribociclib","imatinib","jdq443","aaa817","pelabresib","dji136","tno155","spartalizumab","sabatolimab","letrozole","panobinostat","sonidegib","topotecan"],"companies":["mariana-oncology","myricx-bio","novartis-venture-fund"],"institutions":[],"pathways":[],"terms":[],"trials":["netter-1","nct04094311","nct04940052","nct05939414","nct05888493","nct03960840","nct06991556","nct06726148","nct04711135","nct05067140","nct07288359","nct07564401","nct05358249","nct04417621","nct07190300","nct06894511","nct04104776","nct06004661","nct05142696"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Basel","country":"CH","companyType":"pharma","website":"https://www.novartis.com","ticker":"NOVN.SW","investors":[],"funding":[]},{"id":"novartis-venture-fund","kind":"company","name":"Novartis Venture Fund","aka":[],"tldr":"The Novartis Venture Fund is Novartis's corporate venture arm, run from Basel and Cambridge, Massachusetts, making seed and Series A investments of 5 to 10 million dollars in biotech companies, including the cancer drug developers Artios Pharma, CatalYm and Epsilogen. It manages over 750 million dollars across more than 40 companies.","summary":"The Novartis Venture Fund says it was created to foster innovation, benefit patients and generate returns by investing in life science companies. Its site states 'We manage over USD 750 million in committed capital and more than 40 portfolio companies across North America and Europe', operating 'from our offices in Basel, Switzerland and Cambridge, MA, USA', and that it specialises 'in investments ranging from USD 5-10 million, primarily focusing on Seed and Series A stage companies'. Its portfolio page lists more than 30 companies. Oncology-relevant names include Artios Pharma (DNA damage response), Amphista Therapeutics (targeted protein degradation), CatalYm (anti-GDF-15 immunotherapy), Epsilogen (IgE antibodies for cancer), Fore Biotherapeutics and Tagworks Pharmaceuticals (click-chemistry antibody-drug conjugates).","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.nvfund.com/"},{"label":"Portfolio","url":"https://www.nvfund.com/portfolio"}],"tags":["corporate-venture"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated; omitted. The portfolio page gives names without descriptions, so oncology focus of the named companies is from general knowledge."],"hq":"Basel","country":"CH","companyType":"investor","website":"https://www.nvfund.com/","investors":[],"funding":[]},{"id":"novo-holdings","kind":"company","name":"Novo Holdings","aka":[],"tldr":"The investment company of the Novo Nordisk Foundation, based near Copenhagen. It is one of the largest life science investors in the world and its venture portfolio includes cancer companies such as Myricx Bio, which Novartis agreed to buy.","summary":"Novo Holdings A/S (Tuborg Havnevej 19, 2900 Hellerup, Denmark) is 'the holding and investment company of the Novo Nordisk Foundation', controlling shareholder of Novo Nordisk and Novonesis, and 'invests in life science companies at all stages of development' alongside a broad financial portfolio. Its Life Science teams span Seed, Venture, Growth (Principal) and Planetary Health investments from Copenhagen, London, Singapore, Boston and San Francisco. The Venture Investments page describes 'one of the largest and most active life science venture investors globally', investing from 'early-stage, translatable science through commercial stage products' with board participation and an evergreen structure, and gives a venture portfolio value of DKK 17 billion across 53 companies at year-end 2025. Recent news on that page includes 'Novo Holdings portfolio company Myricx Bio agrees to be acquired by Novartis' (Myricx develops antibody-drug conjugate payloads).","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://novoholdings.dk/"},{"label":"Venture Investments","url":"https://novoholdings.dk/investments/venture-investments"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on fetched pages and no Wikipedia article; omitted. Portfolio list is rendered client-side, so only Myricx is cited. Novo Holdings also has offices in Mumbai and Singapore."],"hq":"Hellerup","country":"DK","companyType":"investor","website":"https://novoholdings.dk/","investors":[],"funding":[]},{"id":"novocure","kind":"company","name":"Novocure","aka":[],"tldr":"Novocure makes Optune tumour treating fields, approved in glioblastoma, lung, mesothelioma, and (2026) pancreatic cancer.","summary":"Novocure, based in Root, Switzerland, and listed as NVCR, makes Optune tumour treating fields, approved in glioblastoma, lung cancer, mesothelioma and, in 2026, pancreatic cancer. Its devices are Optune Gio, Optune Lua and Optune Pax, with EF-14 in glioblastoma and PANOVA-3 in pancreatic cancer as the pivotal trials linked, and trials continue in brain metastases and gastric cancer; Zai Lab is its partner in China. OnCo links it to glioma, mesothelioma and pancreatic ductal adenocarcinoma, to the tumour treating fields technology, to the Lurie and Zurich cancer centres, and to the brain as a bottleneck. Whether clinicians adopt a device therapy as readily as a drug is the open question. Optune has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.novocure.com"}],"tags":[],"related":[],"cancers":[],"sections":["devices"],"technologies":[],"targets":[],"drugs":["optune"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06216301","nct06556563"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Root","country":"CH","companyType":"devices","website":"https://www.novocure.com","ticker":"NVCR","investors":[],"funding":[]},{"id":"nrg-oncology","kind":"company","name":"NRG Oncology","aka":["NRG","Radiation Therapy Oncology Group","RTOG"],"tldr":"The US cooperative group formed from the radiation, gynaecologic, and breast trial groups; it co-led OlympiA, the trial that put a PARP inhibitor after surgery for BRCA carriers.","summary":"NRG Oncology, based in Philadelphia, is the US cooperative group formed in 2014 by the merger of NSABP, RTOG and GOG, and it runs radiation, breast, gynaecologic and central nervous system trials within the NCI National Clinical Trials Network. It co-led OlympiA with the Breast International Group and AstraZeneca, the trial that put adjuvant olaparib after surgery for BRCA carriers, and the RTOG prostate radiation trials whose slides trained ArteraAI Prostate; NRG-GY018, the HPV-positive de-escalation studies NRG-HN002 and NRG-HN005 and OUTBACK are also in OnCo, with Bernard Fisher, Charles E. Geyer Jr. and Lori J. Pierce among the people linked. OnCo connects it to bottlenecks on slow enrolment and on surgery and radiotherapy getting the least trial money. Whether a standing platform for drugs with radiotherapy can be funded is the open idea. Its programmes are listed in the notes.","asOf":"2026-09-06","links":[{"label":"Official website","url":"https://www.nrgoncology.org"}],"tags":["cooperative-group"],"related":["olaparib","artera-ai-prostate"],"cancers":["tnbc","prostate","cervical","endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":["olympia","nrg-cc001","nsabp-b39","rtog-9402","rtog-9601"],"people":["charles-geyer","deborah-bruner"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["NCTN cooperative group","OlympiA (with BIG)","RTOG prostate radiation trials","Gynaecologic oncology (former GOG)"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Philadelphia, PA","country":"US","companyType":"cooperative-group","website":"https://www.nrgoncology.org","founded":2014,"investors":[],"funding":[]},{"id":"nsabp-foundation","kind":"company","name":"NSABP Foundation","aka":["National Surgical Adjuvant Breast and Bowel Project","NSABP"],"tldr":"The legacy US surgical adjuvant trials group that proved lumpectomy equals mastectomy, tamoxifen prevents breast cancer and trastuzumab cures more HER2-positive disease.","summary":"Founded in 1958 and led for decades by Bernard Fisher, the NSABP ran the trials that rewrote breast cancer surgery and adjuvant therapy: B-04 and B-06 showed breast conservation equals mastectomy, B-14 and B-20 provided the samples that validated the Oncotype DX recurrence score, P-1 showed tamoxifen prevents breast cancer, B-31 (with NCCTG N9831) established adjuvant trastuzumab, and B-32 validated sentinel node biopsy. It also ran colorectal adjuvant trials (C-series). NSABP merged with RTOG and GOG into NRG Oncology in 2014; the NSABP Foundation continues industry-partnered trials such as KATHERINE (with the German Breast Group) and the neoadjuvant B-series.","asOf":"2026-09-09","links":[{"label":"NSABP Foundation","url":"https://www.nsabp.org"}],"tags":["cooperative-group"],"related":["trastuzumab","trastuzumab-emtansine","oncotype-dx"],"cancers":["breast-hr-positive","breast-her2-positive","colorectal"],"sections":["surgery","prevention"],"technologies":["sentinel-node","endocrine-therapy","chemoprevention"],"targets":[],"drugs":[],"companies":["nrg-oncology","gbg"],"institutions":["nci"],"pathways":[],"terms":[],"trials":["hera-b31-n9831","katherine"],"people":["norman-wolmark","priya-rastogi"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["B-04 / B-06 (breast conservation)","P-1 (tamoxifen prevention)","B-31 (adjuvant trastuzumab)","KATHERINE (with GBG)","Oncotype DX validation (B-14, B-20)"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Pittsburgh, PA","country":"US","companyType":"cooperative-group","website":"https://www.nsabp.org","founded":1958,"investors":[],"funding":[]},{"id":"ntp-radioisotopes","kind":"company","name":"NTP Radioisotopes","aka":["NTP"],"tldr":"NTP, part of South Africa's state nuclear corporation, processes molybdenum-99 and other isotopes from the SAFARI-1 reactor and was the first major producer to switch to low-enriched uranium targets.","summary":"NTP Radioisotopes, a subsidiary of the South African Nuclear Energy Corporation, irradiates targets in the SAFARI-1 research reactor at Pelindaba and processes molybdenum-99, iodine-131 and lutetium-177 for export to generator makers and radiopharmacies worldwide. It converted its molybdenum production to low-enriched uranium targets ahead of other producers. Regulator-ordered shutdowns of its processing facility in 2017 and 2018 removed a large share of world molybdenum-99 supply for months and showed how few processors there are.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.ntp.co.za"}],"tags":["manufacturing-wave"],"related":[],"cancers":[],"sections":[],"technologies":["research-reactor-isotope-production","therapy-isotope-supply-chain"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Pelindaba, near Pretoria","country":"ZA","companyType":"radiopharma","website":"https://www.ntp.co.za","stage":"private-large","investors":[],"funding":[]},{"id":"nucleai","kind":"company","name":"Nucleai","aka":[],"tldr":"Nucleai uses artificial intelligence to map where different cells sit within tumour tissue samples, helping drug companies understand who responds to a treatment and why.","summary":"Nucleai, headquartered in Tel Aviv, provides an AI-powered spatial tissue analysis platform for oncology drug development. It integrates multimodal tissue imaging (H&E, immunohistochemistry, multiplex immunofluorescence and spatial transcriptomics) with clinical outcome data to derive explainable spatial biomarkers. The company reports work with more than 12 of the top 20 biopharma companies across 30 or more clinical trials, and holds ISO 27001 and ISO 13485 certification. Recent collaborations include a large-scale antibody-drug conjugate (ADC) programme with Gilead Sciences examining why target-positive tumours resist ADCs (2026), an integrated spatial proteomics offering with Sirona Dx and an expanded partnership with the University of Glasgow. Investors named on the website include Section32, Sanofi, M Ventures and Debiopharm; no financing round is disclosed.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://nucleai.ai/"},{"label":"News page","url":"https://nucleai.ai/news"},{"label":"Gilead ADC collaboration (Aug 2026)","url":"https://nucleai.ai/nucleai-advances-ai-powered-tissue-intelligence-through-large-scale-oncology-adc-collaboration/"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation","drug-discovery"],"technologies":["digital-pathology-ai","single-cell-spatial"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["nucleai.com is now a parked domain; the live site is nucleai.ai. Funding rounds (including a reported 2022 Series B) could not be sourced from primary releases so none are recorded. Founding year not sourced."],"hq":"Tel Aviv","country":"IL","companyType":"ai-software","website":"https://nucleai.ai/","stage":"startup","investors":["section-32","sanofi-ventures"],"funding":[]},{"id":"nucleix","kind":"company","name":"Nucleix","aka":[],"tldr":"Nucleix makes urine and blood tests that read chemical marks on DNA to spot bladder cancer coming back and, in development, to find lung cancer early.","summary":"Nucleix, based in Rehovot, Israel with a US office in San Diego, develops methylation-based liquid biopsy tests on its EpiCheck platform, which uses PCR and next-generation sequencing to detect disease-specific DNA methylation changes. Bladder EpiCheck is a urine test analysing 15 methylation markers for surveillance of non-muscle invasive bladder cancer recurrence alongside cystoscopy; it is CE-marked for primary and recurrent bladder and upper tract urothelial cancer and received FDA 510(k) clearance in May 2023, the first methylation-based urine qPCR test cleared for this use. A. Menarini Diagnostics distributes it in Europe under a 2024 partnership, with pivotal data published in 2024 and 2025. Lung EpiCheck, a blood test for early detection of lung cancer in high-risk individuals, is in development. In April 2021 the company raised $55 million led by RA Capital Management to advance it.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://nucleix.com/"},{"label":"FDA 510(k) clearance for Bladder EpiCheck (May 2023)","url":"https://nucleix.com/wp-content/uploads/2023/05/PR_Nucleix_Bladder-EpiCheck-FDA-Clearance.pdf"},{"label":"$55 million financing (April 2021)","url":"https://nucleix.com/blog/news_and_events/nucleix-secures-55-million-funding-led-by-ra-capital-management-and-additional-prominent-life-science-investors-to-advance-lung-epicheck-for-early-detection-of-lung-cancer/"}],"tags":[],"related":[],"cancers":["urothelial","nsclc"],"sections":["diagnostics","early-detection"],"technologies":["methylation-profiling","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The 2021 release does not name the round; recorded as Series C on the basis that it followed earlier rounds, treat the label as uncertain. Founding year not sourced."],"hq":"Rehovot","country":"IL","companyType":"diagnostics","website":"https://nucleix.com/","stage":"growth","investors":["ra-capital"],"funding":[{"round":"Series C","year":2021,"amountUsd":55000000,"source":"https://nucleix.com/blog/news_and_events/nucleix-secures-55-million-funding-led-by-ra-capital-management-and-additional-prominent-life-science-investors-to-advance-lung-epicheck-for-early-detection-of-lung-cancer/","note":"Round name not given in the release; $55 million led by RA Capital Management, April 2021."}]},{"id":"nucleo-research","kind":"company","name":"Nucleo","aka":[],"tldr":"Nucleo builds AI agents that help oncologists and radiologists pull measurements and insights out of CT scans to characterise tumours and guide treatment.","summary":"Nucleo describes itself as the first agentic platform for oncology: software agents that analyse CT scans to support tumour characterisation, measurement and treatment decisions for oncologists and radiologists. The company states that it works with Stanford Hospital, Cedars-Sinai, UCI Health and Weill Cornell. It is a Fall 2025 YC company with a two-person team; its YC profile gives no headquarters city, so only the country is recorded. Regulatory status and validation data have not been published.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/nucleo"},{"label":"Official website","url":"https://nucleoresearch.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["imaging","ai-computation"],"technologies":["ct","radiology-ai-screening"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"United States","country":"US","companyType":"ai-software","website":"https://nucleoresearch.com","stage":"startup","ycBatch":"F25","investors":["y-combinator"],"funding":[]},{"id":"nucleus-radiopharma","kind":"company","name":"Nucleus RadioPharma","aka":[],"tldr":"Nucleus RadioPharma does not make its own cancer drugs; it manufactures and ships radioactive cancer medicines for other companies, which is hard because the drugs decay within days. It is expanding its plants in Minnesota and Pennsylvania.","summary":"Nucleus RadioPharma is a Rochester, Minnesota contract development and manufacturing organisation (CDMO) dedicated to targeted radiotherapies, offering formulation and analytical development, isotope-flexible supply chain, GMP manufacturing and regulatory support. Its Rochester facility can produce around 50,000 patient doses per year and a 47,000 square foot Spring House, Pennsylvania site is planned to open in 2028. Customers include Clarity Pharmaceuticals, with a commercial manufacturing agreement for 64Cu-SAR-bisPSMA signed in April 2026, and the company has a Thermo Fisher Scientific alliance and a BWXT Medical isotope supply agreement (June 2026). Former FDA Commissioner Stephen Hahn became CEO in August 2025. In April 2026 the company secured USD 50 million from OrbiMed to expand manufacturing capacity; earlier backers listed in partner releases include Eclipse, Mayo Clinic, AstraZeneca and GE HealthCare.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://nucleusrad.com/"},{"label":"OrbiMed financing release (PDF)","url":"https://nucleusrad.com/wp-content/uploads/Nucleus-RadioPharma-Secures-50-Million-Financing-from-OrbiMed-to-Expand-Radiopharmaceutical-Manufacturing-Capacity.pdf"},{"label":"News and events","url":"https://nucleusrad.com/news-events/"}],"tags":[],"related":[],"cancers":[],"sections":["radiopharma"],"technologies":["radioligand-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Not a therapeutics developer; companyType set to cro-services. Backer list other than OrbiMed comes from the 'About Nucleus RadioPharma' boilerplate in a Clarity Pharmaceuticals PR Newswire release. Founding (2022, Eclipse and Mayo Clinic) and earlier financing not fetched from a primary page; the old domain nucleusradiopharma.com is for sale."],"hq":"Rochester, MN","country":"US","companyType":"cro-services","website":"https://nucleusrad.com/","stage":"startup","investors":["orbimed"],"funding":[{"round":"Series B","year":2026,"amountUsd":50000000,"source":"https://nucleusrad.com/wp-content/uploads/Nucleus-RadioPharma-Secures-50-Million-Financing-from-OrbiMed-to-Expand-Radiopharmaceutical-Manufacturing-Capacity.pdf","note":"USD 50 million financing from OrbiMed announced 20 April 2026; the company did not name the round, labelled Series B here for schema purposes only"}]},{"id":"numen","kind":"company","name":"Numen","aka":[],"tldr":"Numen is working on earlier cancer detection, with the stated goal of a future without cancer deaths.","summary":"Numen is a San Francisco company in the YC directory under diagnostics, machine learning and biotech, with the one-line mission of engineering a future without cancer deaths. Its public materials describe early-detection work but give little technical detail, so mechanism and evidence are not recorded here. The YC directory lists it at growth stage with a team of about 18. Included because cancer detection is its stated purpose; treat the record as thin until the company publishes more.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/numen"},{"label":"Official website","url":"https://www.numen.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["early-detection","diagnostics"],"technologies":["mced","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"diagnostics","website":"https://www.numen.com","stage":"growth","ycBatch":"S23","investors":["y-combinator"],"funding":[]},{"id":"nurix","kind":"company","name":"Nurix Therapeutics","aka":[],"tldr":"Nurix Therapeutics is developing bexobrutideg, a brain-penetrant BTK degrader in pivotal trials for CLL, co-developed with Roche from June 2026.","summary":"Nurix Therapeutics, based in San Francisco and listed as NRIX, is developing bexobrutideg, a brain-penetrant BTK degrader in pivotal trials for chronic lymphocytic leukaemia, co-developed with Roche from June 2026. Bexobrutideg, or NX-5948, degrades both wild-type and inhibitor-resistant BTK and produced durable responses in relapsed or refractory CLL and small lymphocytic lymphoma, presented orally at EHA 2026; the 2026 plan includes the DAYBreak CLL-201 phase 2 and a confirmatory phase 3. OnCo links it to CLL and diffuse large B-cell lymphoma, to protein degradation and glue discovery platforms, to Roche, and to bottlenecks on acquired resistance and undruggable drivers. Whether a degrader can overcome the BTK mutations that defeat inhibitors in patients is the question its trials will answer. Roche has its own page.","asOf":"2026-09-04","links":[{"label":"Roche collaboration","url":"https://www.roche.com/media/releases/med-cor-2026-06-08"}],"tags":[],"related":[],"cancers":["cll","dlbcl"],"sections":["targeted-therapy"],"technologies":["protac-degrader"],"targets":[],"drugs":["bexobrutideg"],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07520006","nct07221500"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.nurixtx.com","ticker":"NRIX","investors":[],"funding":[]},{"id":"nusano","kind":"company","name":"Nusano","aka":[],"tldr":"Nusano is a Utah company building an isotope production plant around its own ion beam technology, aiming at actinium-225 and other therapeutic isotopes that are in short supply.","summary":"Nusano has developed an ion source and accelerator platform intended to produce a range of medical isotopes at commercial scale and is building a production facility in West Valley City, Utah. Its announced targets include actinium-225 and other alpha and beta emitters for radioligand therapy, and it has signed supply agreements with radiopharmaceutical developers. It is privately funded.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.nusano.com"}],"tags":["manufacturing-wave"],"related":[],"cancers":[],"sections":[],"technologies":["actinium-225-supply","cyclotron-isotope-production","therapy-isotope-supply-chain"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"West Valley City, Utah","country":"US","companyType":"radiopharma","website":"https://www.nusano.com","stage":"growth","investors":[],"funding":[]},{"id":"nuvalent","kind":"company","name":"Nuvalent","aka":[],"tldr":"Designer of cleaner kinase inhibitors; zidesamtinib (ROS1) approved July 2026, neladalkib (ALK) next.","summary":"Nuvalent, based in Cambridge, Massachusetts, and listed as NUVL, designs kinase inhibitors that are cleaner than their predecessors; zidesamtinib, its ROS1 inhibitor, was approved in July 2026 as Jideytro, and neladalkib, its ALK inhibitor, is next. Neladalkib is being tested in the ALKOVE-1 trial and a HER2-selective programme follows. OnCo links it to non-small-cell lung cancer and to the zidesamtinib and neladalkib drug records. Whether selectivity translates into fewer side effects and longer control than existing ROS1 and ALK drugs in routine use is the open question. Zidesamtinib has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.nuvalent.com"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["zidesamtinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06765109","nct05118789"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://www.nuvalent.com","ticker":"NUVL","investors":[],"funding":[]},{"id":"nuvation-bio","kind":"company","name":"Nuvation Bio","aka":["Nuvation Bio Inc."],"tldr":"Nuvation Bio is a United States-based biotechnology company running 6 late-stage cancer trials of Taletrectinib, AB-106 and NUV-1511 in non-small-cell lung cancer, HR-positive / HER2-negative breast cancer and prostate cancer.","summary":"Nuvation Bio, based in New York, NY, the United States, is a biotechnology company. A global oncology company developing therapies for difficult-to-treat cancers; its taletrectinib (IBTROZI) is FDA-approved for ROS1-positive non-small cell lung cancer. On ClinicalTrials.gov it is the lead sponsor of 6 recruiting or active phase 2 and phase 3 interventional cancer trials (3 in phase 3), testing Taletrectinib, AB-106, NUV-1511 and safusidenib in non-small-cell lung cancer, HR-positive / HER2-negative breast cancer, prostate cancer, pancreatic ductal adenocarcinoma and ovarian cancer. The largest, NCT06334432 (Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumours), plans to enrol 466 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.nuvationbio.com"},{"label":"ClinicalTrials.gov: trials led by Nuvation Bio","url":"https://clinicaltrials.gov/search?lead=Nuvation%20Bio%20Inc."},{"label":"Pipeline page","url":"https://www.nuvationbio.com/pipeline"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","breast-hr-positive","prostate","pancreatic","ovarian","glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["safusidenib","nuv-1511","taletrectinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07154706","nct06564324","nct04919811","nct04395677"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"New York, NY","country":"US","companyType":"biotech","website":"https://www.nuvationbio.com","founded":2018,"stage":"public","investors":[],"funding":[]},{"id":"nvidia","kind":"company","name":"NVIDIA","aka":[],"tldr":"Supplies the GPUs and the BioNeMo framework most biological foundation models are trained on, and co-developed Evo 2 with Arc.","summary":"NVIDIA, based in Santa Clara and listed as NVDA, supplies the GPUs and the BioNeMo framework on which most biological foundation models are trained, and it co-developed Evo 2 with the Arc Institute. BioNeMo packages training and inference recipes for protein, DNA and single-cell models, and the company partners with Arc, Recursion and many pharmaceutical groups. OnCo links it to Evo 2, BioNeMo, AI compute and model platforms for oncology and federated learning. Whether dependence on one hardware and software supplier shapes which biological models get built is the fair question about its position. Evo 2 and BioNeMo have their own technology pages.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Nvidia","links":[{"label":"Official website","url":"https://www.nvidia.com/en-us/clara/biopharma/"}],"tags":["ai","infrastructure"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["evo2"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Santa Clara, CA","country":"US","companyType":"ai-software","website":"https://www.nvidia.com/en-us/clara/biopharma/","ticker":"NVDA","investors":[],"funding":[]},{"id":"nykode-therapeutics","kind":"company","name":"Nykode Therapeutics","aka":[],"tldr":"Nykode makes cancer vaccines that teach the immune system to attack tumours. One is built from each patient's own tumour mutations; another targets cancers caused by the HPV16 virus, such as cervical cancer.","summary":"Nykode Therapeutics (Euronext Oslo: NYKD) develops immunotherapies on its Vaccibody platform, a DNA-encoded molecule that delivers antigens to antigen-presenting cells to induce strong and durable T cell responses. VB10.16 (abi-suva) is an off-the-shelf vaccine against HPV16 E6 and E7. In the phase 2 VB-C-02 trial in advanced cervical cancer with atezolizumab, median progression-free survival was 6.3 months and median overall survival was not reached beyond 25 months in PD-L1 positive patients (April 2023). A collaboration with MSD tests VB10.16 with pembrolizumab in HPV16-positive head and neck cancer. VB10.NEO is a fully individualised neoantigen vaccine with optimised manufacturing reported in 2026. In August 2026 Nykode raised about NOK 286 million in a private placement to fund VB10.NEO partnering, the move of abi-suva from phase 2 to phase 3 and a tolerance platform, with shareholders Rasmussengruppen and Andenæsgruppen participating.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.nykode.com"},{"label":"Private placement completed (August 2026)","url":"https://nykode.com/wp-content/uploads/2026/09/260827-Private-Placement-Completed.pdf"},{"label":"Phase 2 VB10.16 final results in cervical cancer","url":"https://www.globenewswire.com/news-release/2023/04/18/2649342/0/en/nykode-therapeutics-announces-positive-final-results-from-its-phase-2-trial-of-vb10-16-in-combination-with-pd-l1-inhibitor-atezolizumab-in-advanced-cervical-cancer.html"},{"label":"MSD clinical collaboration in HPV16-positive head and neck cancer","url":"https://www.globenewswire.com/news-release/2022/12/06/2568545/0/en/nykode-therapeutics-announces-clinical-collaboration-with-msd-to-evaluate-vb10-16-in-combination-with-keytruda-pembrolizumab-in-patients-with-hpv16-positive-head-and-neck-cancer.html"}],"tags":[],"related":[],"cancers":["cervical","head-and-neck"],"sections":["immunotherapy"],"technologies":["neoantigen-mrna-vaccine","shared-antigen-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not sourced."],"hq":"Oslo","country":"NO","companyType":"biotech","website":"https://www.nykode.com","ticker":"NYKD.OL","stage":"public","investors":[],"funding":[{"round":"Crossover","year":2026,"source":"https://nykode.com/wp-content/uploads/2026/09/260827-Private-Placement-Completed.pdf","note":"Public follow-on private placement on Euronext Oslo: NOK 286 million gross, 65 million new shares at NOK 4.40"}]},{"id":"oakwood-laboratories","kind":"company","name":"Oakwood Laboratories","aka":["Oakwood Laboratories, LLC","Oakwood Labs"],"tldr":"Oakwood Laboratories is an Ohio specialist in long-acting injectable microspheres whose leuprolide depot formulations for prostate cancer went through the phase 3 trials it led.","summary":"Oakwood Laboratories, founded in 1997 in Oakwood Village, Ohio, develops sustained-release injectable microsphere formulations. Its leuprolide acetate depot products for advanced prostate cancer, developed to match the established monthly and three-monthly injections, were taken through phase 3 trials registered on ClinicalTrials.gov under Oakwood as lead sponsor, and the company also contract-manufactures depots for partners.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://oakwoodlabs.com"},{"label":"ClinicalTrials.gov: trials led by Oakwood Laboratories, LLC","url":"https://clinicaltrials.gov/search?lead=Oakwood%20Laboratories%2C%20LLC"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30265419"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["leuprolide"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Oakwood Village, OH","country":"US","companyType":"pharma","website":"http://oakwoodlabs.com","founded":1997,"stage":"private-large","investors":[],"funding":[]},{"id":"obi-pharma","kind":"company","name":"OBI Pharma","aka":["OBI Pharma, Inc.","台灣浩鼎","TPEx:4174"],"tldr":"OBI Pharma is a Taiwanese biotech that turns the tumour sugar Globo H into cancer vaccines and antibody-drug conjugates, best known for the breast cancer vaccine adagloxad simolenin.","summary":"OBI Pharma, listed on the Taipei Exchange, develops therapies against Globo-series glycolipids that are over-expressed on many epithelial tumours. Adagloxad simolenin (OBI-822), a Globo H vaccine, is in a phase 3 trial in Globo H-high triple-negative breast cancer. Its pipeline also includes OBI-992, a TROP2 antibody-drug conjugate, and OBI-902, a Globo H-directed conjugate, together with the ThioBridge linker platform.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/OBI_Pharma,_Inc.","links":[{"label":"Official website","url":"https://www.obipharma.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["adagloxad-simolenin","obi-902","obi-992"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Taipei","country":"TW","companyType":"biotech","website":"https://www.obipharma.com/","founded":2002,"stage":"public","investors":[],"funding":[]},{"id":"obsidian-therapeutics","kind":"company","name":"Obsidian Therapeutics","aka":[],"tldr":"Obsidian grows a patient's own tumour-fighting immune cells and engineers them with a switch that lets doctors control a growth signal (IL-15) with an oral drug, aiming to make TIL therapy safer and more effective for melanoma and lung cancer. It listed on Nasdaq in August 2026 after raising $350 million.","summary":"Obsidian Therapeutics uses its cytoDRiVE protein-regulation platform to develop engineered tumour-infiltrating lymphocyte (TIL) cell therapies for solid tumours. Lead candidate OBX-115 is a genetically engineered autologous TIL therapy in a phase 2 trial in advanced melanoma and a phase 1 trial in non-small cell lung cancer. Registration-enabling melanoma data are expected by year-end 2027 and NSCLC phase 1 data in the first half of 2027. In April 2026 Obsidian agreed an all-stock reverse merger with Galera Therapeutics alongside a $350 million private placement from new investors (including Balyasny, Caligan, Eventide, Nantahala, Octagon, Redmile, Spruce Street and Trails Edge) and existing backers such as Atlas Venture, Foresite, Novo Holdings, RA Capital, RTW and Wellington. The deal closed on 3 August 2026; the combined company trades as OBX with about $350 million in cash, funding operations into the second half of 2028.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://obsidiantx.com/"},{"label":"Merger and $350 million private placement announced (8-K, April 2026)","url":"https://www.sec.gov/Archives/edgar/data/1563577/000119312526154009/d124753dex991.htm"},{"label":"Closing of Galera transaction and private placement (8-K, August 2026)","url":"https://www.sec.gov/Archives/edgar/data/2130606/000119312526330810/d309963dex991.htm"}],"tags":[],"related":[],"cancers":["melanoma","nsclc"],"sections":["cell-therapy"],"technologies":["til-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06060613"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Earlier venture rounds (Series A to C) not sourced. The 'Crossover' label is used for the private placement concurrent with the reverse merger."],"hq":"Cambridge, MA","country":"US","companyType":"cell-therapy","website":"https://obsidiantx.com/","ticker":"OBX","stage":"public","investors":["atlas-venture","foresite-capital","logos-capital","novo-holdings","ra-capital","tcgx"],"funding":[{"round":"Crossover","year":2026,"amountUsd":350000000,"source":"https://www.sec.gov/Archives/edgar/data/2130606/000119312526330810/d309963dex991.htm","note":"Oversubscribed private placement completed alongside the reverse merger with Galera Therapeutics; shares began trading on Nasdaq as OBX on 4 August 2026"}]},{"id":"olema-pharmaceuticals","kind":"company","name":"Olema Pharmaceuticals","aka":["Olema Pharmaceuticals, Inc."],"tldr":"Olema Pharmaceuticals is a United States-based biotechnology company running 2 late-stage cancer trials in HR-positive / HER2-negative breast cancer.","summary":"Olema Pharmaceuticals, based in San Francisco, the United States, is a biotechnology company listed as NASDAQ: OLMA. Olema Oncology is a clinical-stage biopharmaceutical company focused on discovering, developing and commercialising targeted therapies for breast cancer, drawing on expertise in endocrine-driven cancers and nuclear receptors. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3) in HR-positive / HER2-negative breast cancer. The largest, NCT07085767 (Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer), plans to enrol 1000 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.olema.com"},{"label":"ClinicalTrials.gov: trials led by Olema Pharmaceuticals","url":"https://clinicaltrials.gov/search?lead=Olema%20Pharmaceuticals%2C%20Inc."},{"label":"Pipeline page","url":"https://www.olema.com/pipeline"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["ribociclib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06016738","nct07085767"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Francisco","country":"US","companyType":"biotech","website":"https://www.olema.com","ticker":"NASDAQ: OLMA","founded":2006,"stage":"public","investors":[],"funding":[]},{"id":"olympus","kind":"company","name":"Olympus","aka":[],"tldr":"Olympus is the world's largest maker of flexible endoscopes, the gastroscopes, colonoscopes, bronchoscopes and endoscopic ultrasound systems through which most gut and lung cancers are first seen and biopsied.","summary":"Olympus, founded in Tokyo in 1919, refocused on medical technology in the 2020s after selling its camera business. It supplies the majority of the world's gastrointestinal endoscopes, the EVIS X1 platform with narrow-band imaging and AI detection, EU-ME3 endoscopic ultrasound processors and echoendoscopes, EBUS bronchoscopes, the EndoCapsule small-bowel capsule and Visera surgical imaging with infrared fluorescence.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Olympus_Corporation","links":[{"label":"Official website","url":"https://www.olympus-global.com/"}],"tags":["machines-wave2"],"related":[],"cancers":[],"sections":[],"technologies":["endoscopic-ultrasound-systems","capsule-endoscopy-systems","intraoperative-fluorescence-imaging-systems","ai-endoscopy-detection","gastric-endoscopic-screening"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tokyo","country":"JP","companyType":"devices","website":"https://www.olympus-global.com/","ticker":"7733","founded":1919,"stage":"public","investors":[],"funding":[]},{"id":"omanta","kind":"company","name":"Omanta","aka":[],"tldr":"Omanta runs a personal research programme for one patient at a time, for people with cancer who have exhausted standard options, coordinating tissue, testing, multi-omic analysis and a treatment strategy with their doctors.","summary":"Omanta is a personalised research lab for individual patients across oncology, rare disease and undiagnosed conditions: it operationalises a patient-specific research programme covering tissue logistics, diagnostic follow-up, data integration, multi-omic analysis and therapeutic strategy development, and acts as a collaborative partner to the treating clinicians with a living evidence roadmap. It is a Summer 2026 YC company with a small team; it is a service rather than a regulated product, and outcomes have not been published.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/omanta"},{"label":"Official website","url":"https://omanta.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["supportive-care","diagnostics"],"technologies":["cgp","proteomics"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"cro-services","website":"https://omanta.com","stage":"startup","ycBatch":"S26","investors":["y-combinator"],"funding":[]},{"id":"omega-funds","kind":"company","name":"Omega Funds","aka":[],"tldr":"A Boston and Geneva venture firm that invests in medicines across oncology, immunology and rare disease. Its impact page lists cancer products it helped bring to patients, including the lung cancer drug Ibtrozi and the colorectal screening test Epi proColon.","summary":"Omega Funds has offices at 888 Boylston Street, Boston, and Place du Molard 7, Geneva, and invests through numbered funds (Omega Fund IV to VIII). Its site says it backs 'exceptional founders and entrepreneurs and impactful products and platforms' across oncology, immunology, rare diseases and precision medicine, and that it has 'helped bring 55 products to patients'. The firm invests from company creation through crossover rounds in the United States and Europe. Its impact page lists products from portfolio companies, including Ibtrozi (taletrectinib) for ROS1-positive non-small cell lung cancer, Imlygic (the first oncolytic viral therapy), Epi proColon (the first blood test for colorectal cancer screening) and Epi proLung (an mSHOX2 assay for suspected lung cancer).","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://omegafunds.com/"},{"label":"Impact","url":"https://omegafunds.com/impact/"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["taletrectinib","talimogene-laherparepvec"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the site and there is no Wikipedia article; omitted. The impact page lists products rather than company names, so portfolio examples are given by product."],"hq":"Boston, MA","country":"US","companyType":"investor","website":"https://omegafunds.com/","investors":[],"funding":[]},{"id":"omnicell","kind":"company","name":"Omnicell","aka":[],"tldr":"Omnicell is a pharmacy automation company whose IV compounding systems prepare chemotherapy safely.","summary":"Omnicell, based in Fort Worth and listed as OMCL, is a pharmacy automation company whose intravenous compounding systems prepare chemotherapy safely. Its products span automated dispensing cabinets, the IVX Station for IV compounding and central pharmacy robotics. OnCo links it to oncology pharmacy automation and compounding robots. Whether compounding robots reduce dosing errors and staff exposure to cytotoxic drugs enough to justify their cost in smaller hospitals is the open question. The pharmacy automation page carries the wider picture.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Omnicell","links":[{"label":"Official website","url":"https://www.omnicell.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["chemotherapy","supportive-care"],"technologies":["pharmacy-automation"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Fort Worth, TX","country":"US","companyType":"devices","website":"https://www.omnicell.com","ticker":"OMCL","investors":[],"funding":[]},{"id":"on-target-laboratories","kind":"company","name":"On Target Laboratories","aka":[],"tldr":"Purdue spin-out that developed Cytalux, the glowing dye that shows ovarian and lung cancer deposits during surgery.","summary":"On Target Laboratories, based in West Lafayette, Indiana, founded in 2010 and backed by Johnson & Johnson Innovation, is the Purdue spin-out that developed Cytalux, the fluorescent dye that shows ovarian and lung cancer deposits during surgery. Its pafolacianine, sold as Cytalux, was approved by the FDA in 2021 for ovarian cancer and in 2022 for lung lesions, the first targeted fluorescent imaging agents for intraoperative use, and the company is developing further folate receptor and other targeted optical agents. OnCo links it to ovarian and non-small-cell lung cancer, fluorescence-guided surgery and optical imaging, and to the pafolacianine record. Whether finding more deposits during surgery improves outcomes, not just completeness of resection, is the open question. Pafolacianine has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://ontargetlabs.com"}],"tags":[],"related":[],"cancers":["ovarian","nsclc"],"sections":["imaging","surgery"],"technologies":["fluorescence-guided-surgery","optical-imaging"],"targets":[],"drugs":["pafolacianine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"West Lafayette, IN","country":"US","companyType":"imaging","website":"https://ontargetlabs.com","founded":2010,"stage":"startup","investors":["jjdc"],"funding":[]},{"id":"onc-ai","kind":"company","name":"Onc.AI","aka":[],"tldr":"Onc.AI trains artificial intelligence on routine CT scans to predict early whether a lung cancer patient's immunotherapy is working, so doctors and drug developers can change course sooner.","summary":"Onc.AI develops deep learning radiomics models trained on a large oncology real world dataset. Its Serial CT Response Score analyses sequential CT scans to assess response to immunotherapy in non small cell lung cancer earlier than RECIST based reads and received FDA Breakthrough Device Designation in February 2025. Products are Onclara IO, which predicts response and outcomes for metastatic lung cancer patients starting immunotherapy, and Onclara Evaluate for go or no go decisions in phase 1b and 2 trials; all remain investigational. Validation has been presented at AACR 2025 (with GSK) and ASCO 2025 and 2026 on Flatiron Health data. Onc.AI operates from the San Francisco Bay Area and Waterloo, Ontario. It raised a USD 6 million seed in November 2020 and a USD 25 million Series A in January 2023, received a USD 2 million NCI SBIR grant in 2024, and names MassMutual and GSK among its investors.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://onc.ai"},{"label":"Series A announcement page","url":"https://onc.ai/25mm-series-a-financing/"},{"label":"Seed announcement page","url":"https://onc.ai/6mm-series-seed-financing/"},{"label":"Press releases index","url":"https://onc.ai/category/press-releases/"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["ai-computation","imaging","immunotherapy"],"technologies":["ct","checkpoint-inhibitor"],"targets":["pd1","pdl1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The seed and Series A pages carry only a headline; dates were taken from the WordPress post metadata (2020-11-05 and 2023-01-01) and investor names (MassMutual, GSK) from the company homepage. HQ given as 'SF Bay Area' on the site, recorded as San Francisco. Founding year not sourced. FDA Breakthrough designation date is from the homepage summary; the dedicated page did not render text."],"hq":"San Francisco, CA","country":"US","companyType":"ai-software","website":"https://onc.ai","stage":"startup","investors":[],"funding":[{"round":"Seed","year":2020,"amountUsd":6000000,"source":"https://onc.ai/6mm-series-seed-financing/","note":"Company page dated November 2020; investors not named on the page"},{"round":"Series A","year":2023,"amountUsd":25000000,"source":"https://onc.ai/25mm-series-a-financing/","note":"Company page dated January 2023; investors not named on the page"},{"round":"Grant","year":2024,"amountUsd":2000000,"source":"https://onc.ai/","note":"National Cancer Institute SBIR grant, per company website"}]},{"id":"oncobox","kind":"company","name":"Oncobox","aka":[],"tldr":"Oncobox profiles a tumour's genes and the activity of its signalling pathways, then ranks approved targeted drugs by how likely they are to work for that patient.","summary":"Oncobox Dx combines tumour DNA and RNA sequencing with pathway-activation algorithms to score more than a hundred marketed targeted drugs for an individual patient with advanced cancer, returning a ranked report for the treating oncologist. Its YC profile cites a European and Asian study of about 900 late-stage patients in which the approach was associated with higher targeted-therapy effectiveness; that work is observational and the test has not been validated in a randomised trial. Oncobox remains active in the YC directory and markets to clinicians, hospitals and pharma.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/oncobox"},{"label":"Official website","url":"https://oncobox.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["diagnostics","targeted-therapy"],"technologies":["rna-seq","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Walnut, CA","country":"US","companyType":"diagnostics","website":"https://oncobox.com","stage":"startup","ycBatch":"S17","investors":["y-combinator"],"funding":[]},{"id":"oncoc4","kind":"company","name":"OncoC4","aka":["OncoC4, Inc."],"tldr":"OncoC4 is a United States-based biotechnology company running 5 late-stage cancer trials of ONC-392, AI-081 and ONC-392 low in non-small-cell lung cancer, melanoma and head and neck squamous cell carcinoma.","summary":"OncoC4, based in Rockville, MD, the United States, is a biotechnology company. A clinical-stage biotechnology company developing immunotherapies (monoclonal and bispecific antibodies, antibody-drug conjugates) for cancer and Alzheimer's disease, targeting CTLA-4, PD-1/VEGF, Siglec and CD24 pathways; grew out of the founders' prior work at OncoImmune following its acquisition by Merck. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing ONC-392, AI-081, ONC-392 low, ONC-392 high and Gotistobart in non-small-cell lung cancer, melanoma, head and neck squamous cell carcinoma, renal cell carcinoma and colorectal cancer. The largest, NCT04140526 (Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumours and NSCLC), plans to enrol 733 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.oncoc4.com"},{"label":"ClinicalTrials.gov: trials led by OncoC4","url":"https://clinicaltrials.gov/search?lead=OncoC4%2C%20Inc."},{"label":"Pipeline page","url":"https://www.oncoc4.com/en/pipeline/pipeline/"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","melanoma","head-and-neck","rcc","colorectal","sarcoma","prostate","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["gotistobart","ai-081"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05446298","nct04140526","nct05682443","nct06635785"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Rockville, MD","country":"US","companyType":"biotech","website":"https://www.oncoc4.com","founded":2020,"stage":"growth","investors":[],"funding":[]},{"id":"oncodna","kind":"company","name":"OncoDNA","aka":[],"tldr":"OncoDNA is a Belgian precision oncology company offering tumour genomic and theranostic profiling to physicians, with a mission to help providers, biopharma and patients act on molecular data.","summary":"OncoDNA, based in Gosselies with sites in France and Spain, provides comprehensive tumour profiling that combines DNA and RNA sequencing with protein and other biomarkers and interprets the results against approved and investigational therapies. Future of Cancer Care Today lists it as physician-ordered.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/OncoDNA","links":[{"label":"Official website","url":"https://oncodna.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":["future-of-cancer-care-today"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Gosselies, Belgium","country":"BE","companyType":"diagnostics","website":"https://oncodna.com/","investors":[],"funding":[]},{"id":"oncohealth","kind":"company","name":"OncoHealth","aka":[],"tldr":"OncoHealth works for health insurers to check that proposed cancer treatments follow the evidence, and runs Iris, a service giving patients round the clock access to cancer nurses, therapists and dietitians by phone or app.","summary":"OncoHealth is an oncology focused benefits management and digital health company. Its OneUM service performs oncology specific utilisation management and prior authorisation for health plans using evidence based pathways, while Iris by OncoHealth is a virtual supportive care service that gives plan members 24/7 access to oncology trained nurses, mental health therapists and dietitians through a 50 state virtual medical group. The company reports 22 health plan partners, more than 15 million members supported, 4,000 employer partners, USD 470 million in customer savings in 2025 and a provider satisfaction rating of 94 percent. OncoHealth is headquartered in Atlanta. In May 2020 it raised a USD 28 million Series C led by Baird Capital with Oak HC/FT, McKesson Ventures and The Blue Venture Fund, at which point it covered about 7 million lives.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://oncohealth.us"},{"label":"Series C press release (May 2020)","url":"https://oncohealth.us/seriesc/"},{"label":"About OncoHealth","url":"https://oncohealth.us/about-oncohealth/"}],"tags":[],"related":[],"cancers":[],"sections":["supportive-care","ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Hinted Arsenal Capital Partners investment and McKesson ownership stake were not found in any fetched source and are omitted. Founding year not sourced. A site URL suggests the company was formerly Oncology Analytics but this was not confirmed."],"hq":"Atlanta, GA","country":"US","companyType":"ai-software","website":"https://oncohealth.us","stage":"growth","investors":["mckesson-ventures"],"funding":[{"round":"Series C","year":2020,"amountUsd":28000000,"source":"https://oncohealth.us/seriesc/","note":"Led by Baird Capital"}]},{"id":"oncohost","kind":"company","name":"OncoHost","aka":[],"tldr":"OncoHost sells a blood test that measures hundreds of proteins before treatment starts to predict whether a lung cancer patient will benefit from immunotherapy drugs.","summary":"OncoHost is a precision oncology diagnostics company with operations in Israel and the United States. Its PROphet platform applies proteomic pattern recognition and machine learning to a pre-treatment plasma or serum sample, evaluating tumour and host biology together to produce a personalised score that predicts benefit from PD-1 and PD-L1 inhibitors. The first test, PROphetNSCLC, addresses first-line non-small cell lung cancer and is supported by the prospective PROPHETIC study across more than 40 sites with over 1,700 patients recruited. Recent work includes proteomic ageing biomarkers for immunotherapy response (AACR 2026), serum-plasma proteomic bridging published in 2026 and a partnership with Gustave Roussy (2025). Scientific co-founder Yuval Shaked heads the Technion Integrated Cancer Center. In May 2025 OncoHost and hospital partners won a EUR 2.5 million (about USD 2.8 million) EIC Transition grant; equity rounds could not be sourced.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.oncohost.com"},{"label":"About OncoHost","url":"https://www.oncohost.com/about"},{"label":"News (EIC Transition grant, AACR 2026)","url":"https://www.oncohost.com/news"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["diagnostics","immunotherapy"],"technologies":["proteomics","companion-diagnostic"],"targets":["pd1","pdl1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Stage growth reflects unsourced earlier Series C and D rounds. Founding year not sourced."],"hq":"Binyamina","country":"IL","companyType":"diagnostics","website":"https://www.oncohost.com","stage":"growth","investors":[],"funding":[{"round":"Grant","year":2025,"amountUsd":2800000,"source":"https://www.oncohost.com/news","note":"EUR 2.5 million EIC Transition Programme grant, reported by the company as USD 2.8 million"}]},{"id":"oncolytics-biotech","kind":"company","name":"Oncolytics Biotech","aka":[],"tldr":"Oncolytics Biotech is a United States-based biotechnology company running 3 late-stage cancer trials of Trifluridine Tipiracil in colorectal cancer, HR-positive / HER2-negative breast cancer and anal cancer.","summary":"Oncolytics Biotech, based in San Diego, the United States, is a biotechnology company. Oncolytics Biotech develops immunotherapies for gastrointestinal and other cancers, centred on pelareorep, an investigational double-stranded RNA immunotherapeutic agent. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials, testing Trifluridine Tipiracil in colorectal cancer, HR-positive / HER2-negative breast cancer, anal cancer and pancreatic ductal adenocarcinoma. The largest, NCT07280377 (A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab), plans to enrol 122 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Oncolytics_Biotech","links":[{"label":"Official website","url":"https://www.oncolyticsbiotech.com"},{"label":"ClinicalTrials.gov: trials led by Oncolytics Biotech","url":"https://clinicaltrials.gov/search?lead=Oncolytics%20Biotech"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["colorectal","breast-hr-positive","anal","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07446322","nct07280377"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Diego","country":"US","companyType":"biotech","website":"https://www.oncolyticsbiotech.com","stage":"public","investors":[],"funding":[]},{"id":"oncopeptides","kind":"company","name":"Oncopeptides","aka":["Oncopeptides AB"],"tldr":"Oncopeptides is a Swedish company whose peptide-drug conjugate melflufen (Pepaxto) for relapsed multiple myeloma won accelerated US approval in 2021, was withdrawn there after a survival signal, and remains approved in Europe.","summary":"Oncopeptides, listed on Nasdaq Stockholm, developed melphalan flufenamide (melflufen, Pepaxto), a peptide-drug conjugate that concentrates an alkylating payload in cells rich in aminopeptidases such as myeloma cells. The FDA granted accelerated approval in February 2021 for heavily pretreated multiple myeloma, but the confirmatory OCEAN trial showed a possible overall survival detriment against pomalidomide and the company withdrew the US marketing authorisation; the European Commission approved Pepaxto in 2022 for a defined relapsed population and the company now markets it in Europe. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://oncopeptides.com"},{"label":"ClinicalTrials.gov: trials led by Oncopeptides","url":"https://clinicaltrials.gov/search?lead=Oncopeptides"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Oncopeptides"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["multiple-myeloma"],"sections":["chemotherapy"],"technologies":[],"targets":[],"drugs":["melflufen"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Stockholm","country":"SE","companyType":"biotech","website":"https://oncopeptides.com","stage":"public","investors":[],"funding":[]},{"id":"oncoresponse","kind":"company","name":"OncoResponse","aka":["OncoResponse, Inc."],"tldr":"OncoResponse is a Seattle biotech that mines the antibodies of patients who responded exceptionally well to immunotherapy; OR502 blocks LILRB2 to re-educate the suppressive myeloid cells in tumours.","summary":"OncoResponse discovers antibodies from elite responders to cancer immunotherapy, working with MD Anderson Cancer Center. OR502 is a humanised antibody against LILRB2 (ILT4), an inhibitory receptor on macrophages and dendritic cells; blocking it shifts myeloid cells towards an anti-tumour state. OR502 is in a phase 1/2 trial alone and with cemiplimab in advanced solid tumours. Its earlier antibody OR2805 targets tumour-associated macrophages.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.oncoresponse.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["or502"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Seattle, Washington","country":"US","companyType":"biotech","website":"https://www.oncoresponse.com/","investors":[],"funding":[]},{"id":"oncotherm","kind":"company","name":"Oncotherm","aka":[],"tldr":"Oncotherm makes the EHY-2000 and EHY-2030 modulated electro-hyperthermia machines, lower-power radiofrequency devices used in private and some academic clinics to heat tumours alongside radiotherapy and chemotherapy.","summary":"Oncotherm, founded in 1988 with Hungarian roots and headquartered in Troisdorf, Germany, sells capacitive radiofrequency hyperthermia devices in which a modulated current is passed between an electrode and a water bolus bed. The company describes the approach as modulated electro-hyperthermia and it is used in several hundred clinics, mostly in Europe and Asia; controlled evidence is smaller than for phased-array deep hyperthermia, with a randomised trial in cervical cancer in South Africa.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Oncotherm","links":[{"label":"Official website","url":"https://www.oncotherm.com/"}],"tags":["machines-wave2"],"related":[],"cancers":[],"sections":[],"technologies":["hyperthermia-systems","hyperthermia"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Troisdorf","country":"DE","companyType":"devices","website":"https://www.oncotherm.com/","founded":1988,"stage":"private-large","investors":[],"funding":[]},{"id":"oncoverity","kind":"company","name":"OncoVerity","aka":["OncoVerity, Inc."],"tldr":"OncoVerity is a United States-based biotechnology company running 2 late-stage cancer trials of Cusatuzumab in acute myeloid leukaemia.","summary":"OncoVerity, based in Denver, CO, the United States, is a biotechnology company. OncoVerity applies computational tools to clinical and biologic data to develop personalised cancer therapies. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing Cusatuzumab in acute myeloid leukaemia. The largest, NCT06384261 (A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy), plans to enrol 140 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.oncoverity.com"},{"label":"ClinicalTrials.gov: trials led by OncoVerity","url":"https://clinicaltrials.gov/search?lead=OncoVerity%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":["cusatuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04023526"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Denver, CO","country":"US","companyType":"biotech","website":"https://www.oncoverity.com","stage":"growth","investors":[],"funding":[]},{"id":"oncternal-therapeutics","kind":"company","name":"Oncternal Therapeutics","aka":["Oncternal Therapeutics, Inc.","GTx","NASDAQ:ONCT"],"tldr":"Oncternal Therapeutics is a San Diego biotech that developed the ROR1 antibody zilovertamab, licensed to Merck as an antibody-drug conjugate, and TK216, a small molecule against the EWS-FLI1 fusion that drives Ewing sarcoma.","summary":"Oncternal Therapeutics, formed by the 2019 merger with GTx, developed zilovertamab (cirmtuzumab), a ROR1 antibody studied with ibrutinib in mantle cell lymphoma and chronic lymphocytic leukaemia; the antibody became the basis of Merck's antibody-drug conjugate zilovertamab vedotin. TK216, an inhibitor of the EWS-FLI1 oncoprotein, was tested with vincristine in relapsed Ewing sarcoma. Its later programmes were a ROR1 CAR-T and the androgen receptor antagonist ONCT-534; in 2025 the company discontinued development and moved to wind down.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.oncternal.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["tk216"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"San Diego, California","country":"US","companyType":"biotech","website":"https://www.oncternal.com/","ticker":"NASDAQ:ONCT","investors":[],"funding":[]},{"id":"oneoncology","kind":"company","name":"OneOncology","aka":[],"tldr":"Physician-led community oncology network backed by TPG and Cencora (AmerisourceBergen), competing with US Oncology.","summary":"OneOncology, based in Nashville, is a physician-led community oncology network backed by TPG and Cencora, formerly AmerisourceBergen, competing with The US Oncology Network. Formed in 2018, with a majority stake acquired in 2023, it spans practices across the United States and runs the OneR research network. OnCo links it to community oncology and site networks. Whether private equity and distributor ownership of community practices improves trial access and care, or mainly consolidates purchasing power, is the open question. The community oncology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.oneoncology.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":["community-oncology-networks"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Nashville, TN","country":"US","companyType":"cro-services","website":"https://www.oneoncology.com","investors":[],"funding":[]},{"id":"onk-therapeutics","kind":"company","name":"ONK Therapeutics","aka":[],"tldr":"ONK Therapeutics, based in Galway, Ireland, is developing off-the-shelf natural killer cell therapies that are gene-edited and given two ways to kill cancer cells at once. It is a private, preclinical-stage company spun out of University of Galway research.","summary":"ONK Therapeutics is a privately held Irish company founded in 2015 on the NK cell and apoptosis research of Prof Michael O'Dwyer and collaborators at the University of Galway. It is developing next-generation off-the-shelf, optimally engineered natural killer (NK) cell therapies for haematological malignancies and solid tumours. Its platform combines a chimeric antigen receptor against a tumour antigen with a TRAIL variant that engages the death receptor pathway (DR4 or DR5), a dual-targeted design intended to improve efficacy and reduce antigen escape; the company also holds a European patent on CISH knockout in NK cells. In December 2023 ONK announced a research partnership with NAYA Biosciences to combine its NK cells with FLEX-NK bispecific antibodies. No clinical trial or financing round was described on the fetched pages.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.onktherapeutics.com/"},{"label":"About ONK","url":"https://www.onktherapeutics.com/about/"},{"label":"News","url":"https://www.onktherapeutics.com/news/"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["car-nk-macrophage","allogeneic-cell-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No funding round sourced (company is private and Irish, no SEC filings). Most recent news item on the site is dated December 2023, so current activity level is uncertain."],"hq":"Galway","country":"IE","companyType":"cell-therapy","website":"https://www.onktherapeutics.com/","founded":2015,"stage":"startup","investors":[],"funding":[]},{"id":"ocog","kind":"company","name":"Ontario Clinical Oncology Group","aka":["OCOG","Ontario Clinical Oncology Group (OCOG)"],"tldr":"The Ontario Clinical Oncology Group is a Canadian academic trials group based at the Juravinski Hospital in Hamilton that designs and runs investigator-led cancer trials; in OnCo it leads LUMINA, the radiotherapy-omission study in low-risk luminal A breast cancer.","summary":"The Ontario Clinical Oncology Group (OCOG) works with investigators to design and conduct clinical trials through collaboration and scientific and methodological rigour; its office is at the Juravinski Hospital, G (60) Wing, 711 Concession Street, Hamilton, Ontario, with a McMaster University contact address (ocog.ca). No founding year is stated on the pages read. ClinicalTrials.gov names it lead sponsor (OTHER class, with the British Columbia Cancer Agency and McMaster University as collaborators) of LUMINA (NCT01791829, phase 2, omission of radiotherapy after breast-conserving surgery in low-risk luminal A breast cancer), the trial recorded in OnCo. It has no products of its own.","asOf":"2026-09-25","links":[{"label":"Official website","url":"https://www.ocog.ca/PORTAL/"},{"label":"ClinicalTrials.gov: trials led by Ontario Clinical Oncology Group (OCOG)","url":"https://clinicaltrials.gov/search?lead=Ontario%20Clinical%20Oncology%20Group%20(OCOG)"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["lumina"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"Hamilton, Ontario","country":"CA","companyType":"cooperative-group","website":"https://www.ocog.ca","investors":[],"funding":[]},{"id":"opencancerai","kind":"company","name":"OpenCancerAI","aka":[],"tldr":"OpenCancerAI builds open cancer infrastructure and AI tools for patients and caregivers to reduce the information gap between them and their care teams.","summary":"OpenCancerAI describes itself as open cancer infrastructure and AI to reduce information asymmetry for patients: tools that help patients and caregivers navigate a diagnosis with clarity. Patient-accessible.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://opencancer.ai/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["ai-trial-matching"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"United States (city not published)","country":"US","companyType":"ai-software","website":"https://opencancer.ai/","stage":"startup","investors":[],"funding":[]},{"id":"optellum","kind":"company","name":"Optellum","aka":[],"tldr":"Oxford company with the first FDA-cleared AI for judging whether a lung nodule on CT is likely to be cancer.","summary":"Optellum, based in Oxford and founded in 2016, is the company with the first FDA-cleared AI for judging whether a lung nodule on CT is likely to be cancer. Its Virtual Nodule Clinic, cleared under 510(k) in 2021 and CE-marked, combines a deep-learning Lung Cancer Prediction score with nodule management software, and it is used in NHS trusts and US health systems and in partnership with Johnson & Johnson's lung cancer initiative. OnCo links it to non-small-cell lung cancer, AI in radiology and low-dose CT lung screening, and to the product record. Whether an AI malignancy score reduces unnecessary biopsies without missing cancers is the question its deployments will answer. The Virtual Nodule Clinic has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://optellum.com"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["ai-computation","imaging","early-detection"],"technologies":["radiology-ai-screening","low-dose-ct-screening"],"targets":[],"drugs":["optellum-virtual-nodule-clinic"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Oxford","country":"GB","companyType":"ai-software","website":"https://optellum.com","founded":2016,"investors":[],"funding":[]},{"id":"oracle-health-sciences","kind":"company","name":"Oracle Health (Cerner) & Oracle Life Sciences","aka":[],"tldr":"Oracle owns the Cerner EHR (PowerChart Oncology) and the Oracle Clinical One trial platform.","summary":"Oracle Health and Oracle Life Sciences, based in Austin and part of Oracle, listed as ORCL, own the Cerner electronic health record with its PowerChart Oncology module and the Oracle Clinical One trial platform. Oracle acquired Cerner in 2022, giving it both an oncology EHR module and a cloud trial data platform under one roof. OnCo links it to clinical trial software and to oncology EHR modules and treatment pathways. Whether owning both the hospital record and the trial system lets Oracle embed trial enrolment in routine care, as the sector has long promised, is the open question. The oncology EHR page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.oracle.com/health/"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["clinical-trial-software","hospital-information-systems-oncology"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Austin, TX","country":"US","companyType":"ai-software","website":"https://www.oracle.com/health/","ticker":"ORCL","investors":[],"funding":[]},{"id":"orano-med","kind":"company","name":"Orano Med","aka":[],"tldr":"Orano Med is the leading lead-212 producer and the developer of 212Pb-DOTAMTATE (AlphaMedix).","summary":"Orano Med, based in Paris and Plano, Texas, is the leading producer of lead-212 and the developer of 212Pb-DOTAMTATE, known as AlphaMedix, an alpha-emitting radioligand for somatostatin-receptor-positive neuroendocrine tumours. AlphaMedix reported a 56 percent objective response rate in its phase 2, the company builds lead-212 generators, and it works with Sanofi and RadioMedix. OnCo links it to neuroendocrine tumours, to somatostatin receptor 2 as a target, to peptide receptor radionuclide therapy, targeted alpha therapy and the isotope supply chain, and to the idea of funding alpha emitters beyond actinium-225, including lead-212, terbium-149 and astatine-211. Manufacturing cost and time for radioactive medicines is the bottleneck it sits inside. Whether lead-212 can be delivered to enough hospitals to matter is the open question.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.oranomed.com"}],"tags":[],"related":[],"cancers":[],"sections":["radiopharma"],"technologies":[],"targets":["sstr2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07278479"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Paris / Plano, TX","country":"FR","companyType":"radiopharma","website":"https://www.oranomed.com","investors":[],"funding":[]},{"id":"orbimed","kind":"company","name":"OrbiMed","aka":[],"tldr":"OrbiMed is a New York healthcare investment firm managing about 20 billion dollars across venture, private equity, public equity and royalty strategies, with teams in North America, Europe and Asia. Its cancer portfolio includes Adcendo (antibody-drug conjugates), Adela (blood-based cancer detection), Adicet Bio (immune-cell therapies) and Alterome (alteration-specific drugs).","summary":"OrbiMed traces its roots to the 1989 research firm Mehta & Isaly and was formed under its current name in 1998 (Wikipedia). Its homepage says it has been 'investing globally for over 25 years' from early-stage private companies to large multinationals and that its team of over 150 'manages approximately $20 billion across public and private company investments worldwide'. It runs venture, private equity, public equity and royalty strategies, with regional teams for North America, Europe and Asia. Oncology companies on its portfolio page include Adcendo (tissue-factor antibody-drug conjugates), Adela (blood-based cancer detection by methylation), Adicet Bio (universal immune-cell therapies for cancer), Alentis Therapeutics (Claudin-1 antibodies and ADCs), Alpheus Medical (sonodynamic therapy for glioblastoma) and Alterome Therapeutics (alteration-specific precision oncology). Treeline Biosciences is featured on the homepage.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.orbimed.com/"},{"label":"Portfolio","url":"https://www.orbimed.com/portfolio/"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/OrbiMed"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"New York, NY","country":"US","companyType":"investor","website":"https://www.orbimed.com/","founded":1998,"investors":[],"funding":[]},{"id":"orca-bio","kind":"company","name":"Orca Bio","aka":["Orca Biosystems","Orca Biosystems, Inc.","orca-biosystems"],"tldr":"Orca Bio makes precision-engineered versions of donor stem cell transplants for blood cancers, sorting the donor cells so that patients get the cells that fight cancer and rebuild the immune system with fewer of the cells that cause graft versus host disease. Its first product, TREGZI, was approved in the US in June 2026.","summary":"Orca Bio is a commercial-stage cell therapy company based in Menlo Park, California, whose high-precision platform sorts and reconstitutes allogeneic donor grafts. TREGZI (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq, formerly Orca-T) was approved by the FDA on 30 June 2026 for use in matched-donor haematopoietic stem cell transplantation with a myeloablative regimen, to support reconstitution and improve chronic graft-versus-host disease-free survival in adults with haematological malignancies. In the pivotal Precision-T study, patients receiving TREGZI were twice as likely to be alive without chronic GVHD at one year compared with conventional allogeneic transplant. Orca-Q, a second precision cell therapy for high-risk haematological malignancies, holds RMAT designation. Orca has manufacturing on both US coasts. An SEC Form D shows about $192 million of equity sold in an offering that began in November 2019.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://orcabio.com/"},{"label":"TREGZI FDA approval (June 2026)","url":"https://orcabio.com/orca-bios-tregzi-receives-u-s-fda-approval-as-first-and-only-precision-engineered-cell-therapy-for-allogeneic-transplant-in-adults-with-hematological-malignanciesorca-bio-adds-east/"},{"label":"Newsroom","url":"https://orcabio.com/newsroom/"},{"label":"Form D, July 2020","url":"https://www.sec.gov/Archives/edgar/data/1720544/000172054420000002/primary_doc.xml"},{"label":"ClinicalTrials.gov: trials led by Orca Biosystems","url":"https://clinicaltrials.gov/search?lead=Orca%20Biosystems%2C%20Inc."}],"tags":[],"related":[],"cancers":["aml","all-leukemia","mds"],"sections":["cell-therapy"],"technologies":["allogeneic-cell-therapy"],"targets":[],"drugs":["tregzi"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07216443"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Series letter and investors for the 2019 to 2020 offering not sourced; later financings not sourced. Stage set to growth because the company is private and commercial-stage. Cancer ids are approximations for 'haematological malignancies'."],"hq":"Menlo Park, CA","country":"US","companyType":"cell-therapy","website":"https://orcabio.com/","stage":"growth","investors":[],"funding":[{"round":"Form D offering","year":2020,"amountUsd":191999870,"source":"https://www.sec.gov/Archives/edgar/data/1720544/000172054420000002/primary_doc.xml","note":"Equity offering by Orca BioSystems Inc, first sale 29 November 2019, filed July 2020"}]},{"id":"organon","kind":"company","name":"Organon & Co.","aka":["Organon and Co","Organon","Organon LLC"],"tldr":"Organon is the women's health and established-medicines company spun off from Merck & Co. in 2021, based in Jersey City; it carries the name of the Dutch firm founded in 1923 and appears as sponsor of older cancer trials run under that name.","summary":"Organon & Co. was spun out of Merck & Co. in June 2021 with a portfolio of women's health medicines, biosimilars and established brands, and is headquartered at 30 Hudson Street, Jersey City, New Jersey. It inherits the name of Organon, the Dutch pharmaceutical company founded in Oss in 1923 that passed through Akzo Nobel, Schering-Plough and Merck, under which phase 3 cancer trials were registered on ClinicalTrials.gov. Its biosimilar business, partnered with Samsung Bioepis, includes oncology biosimilars in some markets. Organon's United States product list includes the trastuzumab biosimilar Ontruzant (trastuzumab-dttb) alongside its immunology biosimilars.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.organon.com"},{"label":"ClinicalTrials.gov: trials led by Organon and Co","url":"https://clinicaltrials.gov/search?lead=Organon%20and%20Co"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q903372"},{"label":"Organon product list","url":"https://www.organon.com/our-focus/products-list/"}],"tags":["ctgov-sponsor"],"related":["samsung-bioepis"],"cancers":["breast-her2-positive","gastric"],"sections":[],"technologies":["biosimilar-manufacturing"],"targets":[],"drugs":["trastuzumab-biosimilars"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial","biosimilar"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Jersey City, NJ","country":"US","companyType":"pharma","website":"https://www.organon.com","founded":2021,"stage":"public","investors":[],"funding":[]},{"id":"oric-pharmaceuticals","kind":"company","name":"ORIC Pharmaceuticals","aka":[],"tldr":"ORIC Pharmaceuticals develops pills designed to beat the ways cancers resist treatment. One blocks a gene-silencing complex in prostate cancer; the other targets mutated EGFR and HER2 in lung cancer and can reach the brain.","summary":"ORIC Pharmaceuticals is a South San Francisco clinical-stage oncology company focused on mechanisms of therapeutic resistance. Rinzimetostat (ORIC-944) is a potent, selective allosteric inhibitor of PRC2 acting through the EED subunit rather than EZH2, designed for better drug properties and to avoid EZH1 bypass or EZH2 mutation; it is in development for prostate cancer in combination with androgen receptor pathway inhibitors. Enozertinib (ORIC-114) is a brain-penetrant inhibitor of EGFR exon 20 insertion and other atypical EGFR and HER2 alterations in non-small cell lung cancer, including a clinical collaboration with Johnson & Johnson combining it with subcutaneous amivantamab in first-line EGFR exon 20 NSCLC. ORIC completed its Nasdaq IPO in April 2020 with gross proceeds of 138 million US dollars.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://oricpharma.com/"},{"label":"Pipeline","url":"https://oricpharma.com/pipeline/"},{"label":"IPO closing press release (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1796280/000156459020019302/oric-ex991_68.htm"}],"tags":[],"related":[],"cancers":["prostate","nsclc"],"sections":["targeted-therapy","epigenetics"],"technologies":["kinase-inhibitors","epigenetic-drugs"],"targets":["egfr","ezh2","androgen-receptor"],"drugs":["rinzimetostat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05315700"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The ezh2 tag denotes PRC2 targeting via EED (not EZH2 itself); the androgen-receptor tag reflects the combination strategy with AR pathway inhibitors rather than a direct AR drug. Founding year and current trial phases not sourced."],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://oricpharma.com/","ticker":"ORIC","stage":"public","investors":[],"funding":[{"round":"IPO","year":2020,"amountUsd":138000000,"source":"https://www.sec.gov/Archives/edgar/data/1796280/000156459020019302/oric-ex991_68.htm","note":"8,625,000 shares at 16 US dollars including full exercise of the underwriters' option; closed 28 April 2020"}]},{"id":"origin-bio","kind":"company","name":"Origin Bio","aka":[],"tldr":"Origin is building the largest dataset of how individual cancer cells from real patients respond to drugs and genetic medicines, to license to pharma and AI companies.","summary":"Origin Bio generates patient-derived cancer single-cell datasets by screening the effects of drugs and genetic medicines on tumour cells under the control of what it calls DNA switches, and licenses the resulting data to pharmaceutical and AI drug-discovery companies training models of cancer biology. It is a Winter 2026 YC company with a small team; the dataset and any validation are at an early stage.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/origin-bio"},{"label":"Official website","url":"https://origin.bio"}],"tags":["yc"],"related":[],"cancers":[],"sections":["drug-discovery","ai-computation"],"technologies":["single-cell-spatial","functional-drug-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"ai-software","website":"https://origin.bio","stage":"startup","ycBatch":"W26","investors":["y-combinator"],"funding":[]},{"id":"orion-orion-pharma","kind":"company","name":"Orion, Orion Pharma","aka":["Orion Corporation, Orion Pharma"],"tldr":"Orion, Orion Pharma is a Finland-based pharmaceutical company running 4 late-stage cancer trials of ODM-212, ODM-216 and sotorasib in mesothelioma, pancreatic ductal adenocarcinoma and non-small-cell lung cancer.","summary":"Orion, Orion Pharma, based in Espoo, Finland, is a pharmaceutical company. Orion Pharma is a Finnish pharmaceutical company that develops and manufactures medicines across oncology, respiratory disease, neurological disease, women's health and pain management, as well as veterinary medicines and active pharmaceutical ingredients. On ClinicalTrials.gov it is the lead sponsor of 4 recruiting or active phase 2 and phase 3 interventional cancer trials, testing ODM-212, ODM-216, sotorasib and ODM-208 in mesothelioma, pancreatic ductal adenocarcinoma, non-small-cell lung cancer and prostate cancer. The largest, NCT06725758 (A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours), plans to enrol 315 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.orionpharma.com"},{"label":"ClinicalTrials.gov: trials led by Orion, Orion Pharma","url":"https://clinicaltrials.gov/search?lead=Orion%20Corporation%2C%20Orion%20Pharma"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["mesothelioma","pancreatic","nsclc","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06725758","nct07805252","nct07563738","nct03436485"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Espoo","country":"FI","companyType":"pharma","website":"https://www.orionpharma.com","stage":"public","investors":[],"funding":[]},{"id":"orna-therapeutics","kind":"company","name":"Orna Therapeutics (Eli Lilly)","aka":[],"tldr":"Circular-RNA in vivo CAR company bought by Eli Lilly for about $2.4B in February 2026.","summary":"Orna Therapeutics, based in Watertown, Massachusetts, is the circular-RNA in vivo CAR company that Eli Lilly agreed to buy for about 2.4 billion dollars on 9 February 2026. Its engineered circular RNA, called oRNA, is delivered in lipid nanoparticles to induce CAR expression in T cells inside the body without lymphodepletion; the lead programme ORN-252 targets CD19 for autoimmune disease, and a BCMA in vivo CAR for multiple myeloma is preclinical. OnCo links it to multiple myeloma, to in vivo CAR-T and circular RNA therapeutics, to CD19 and BCMA as targets, to Eli Lilly, and to ideas on in vivo CAR-T as a vial on the shelf priced like a generic biologic. Manufacturing cost and time for living medicines is the bottleneck it aims to remove. Whether RNA-made CARs last long enough to clear a cancer is the open question.","asOf":"2026-09-04","links":[{"label":"Lilly acquisition","url":"https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-orna-therapeutics-advance-cell-therapies"}],"tags":["frontier"],"related":[],"cancers":["multiple-myeloma"],"sections":["cell-therapy"],"technologies":["in-vivo-car-t"],"targets":["cd19","bcma"],"drugs":[],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Watertown, MA","country":"US","companyType":"cell-therapy","website":"https://www.ornatx.com","investors":[],"funding":[]},{"id":"orum-therapeutics","kind":"company","name":"Orum Therapeutics","aka":[],"tldr":"Orum Therapeutics attaches protein-destroying drugs to antibodies so they are delivered only into cancer cells. Its lead medicine for acute myeloid leukaemia is entering human trials, and the company is listed on the Korean stock market.","summary":"Orum Therapeutics (Daejeon, South Korea, with US operations in Boston) pioneered degrader-antibody conjugates (DACs) through its Dual-Precision Targeted Protein Degradation (TPD²) approach, in which antibodies deliver catalytic protein degrader payloads selectively to cancer cells to improve efficacy, safety and half-life relative to systemic degraders. ORM-5029, a HER2-directed GSPT1 degrader conjugate, entered a phase 1 trial in HER2-expressing solid tumours in November 2022. ORM-6151, a CD33-directed GSPT1 degrader for acute myeloid leukaemia and high-risk MDS, was acquired by Bristol Myers Squibb in November 2023 after FDA phase 1 clearance. The current lead, ORM-1153, a CD123-GSPT1 DAC for AML, received FDA IND clearance in August 2026. The company raised a USD 84 million Series B in 2021, listed on KOSDAQ in February 2025 (KRX: 475830) and secured about USD 100 million in convertible preferred stock in December 2025.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.orumrx.com/"},{"label":"Series B press release","url":"https://www.orumrx.com/news/3zokvvtwmn7jjpn0uevjkivk30uvu4"},{"label":"IPO pricing release","url":"https://www.orumrx.com/news/orum-therapeutics-announces-pricing-of-initial-public-offeringnbsp"},{"label":"USD 100 million financing release","url":"https://www.orumrx.com/news/orum-therapeutics-secures-approximately-us100-million-to-accelerate-development-of-leading-degrader-antibody-conjugate-programs-to-treat-serious-diseases-251218"},{"label":"BMS acquires ORM-6151 programme","url":"https://www.orumrx.com/news/orum-orm-6151-acquisition-by-bms"}],"tags":[],"related":[],"cancers":["aml"],"sections":["adcs","targeted-therapy"],"technologies":["degrader-antibody-conjugate","adc","protac-degrader"],"targets":["her2","cd33","cd123"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The December 2025 convertible preferred round is labelled Series C here for schema purposes only."],"hq":"Daejeon","country":"KR","companyType":"biotech","website":"https://www.orumrx.com/","ticker":"475830.KQ","stage":"public","investors":[],"funding":[{"round":"Series B","year":2021,"amountUsd":84000000,"source":"https://www.orumrx.com/news/3zokvvtwmn7jjpn0uevjkivk30uvu4","note":"Includes a previously announced USD 30 million tranche; led by IMM Investment"},{"round":"IPO","year":2025,"source":"https://www.orumrx.com/news/orum-therapeutics-announces-pricing-of-initial-public-offeringnbsp","note":"KOSDAQ listing, 2,500,000 shares at KRW 20,000, gross proceeds about KRW 50 billion; trading from 14 February 2025 under code 475830"},{"round":"Series C","year":2025,"amountUsd":100000000,"source":"https://www.orumrx.com/news/orum-therapeutics-secures-approximately-us100-million-to-accelerate-development-of-leading-degrader-antibody-conjugate-programs-to-treat-serious-diseases-251218","note":"Post-IPO convertible preferred stock investment of KRW 145 billion (approximately USD 100 million) led by KB Investment; the company does not use a series letter"}]},{"id":"osara-health","kind":"company","name":"Osara Health","aka":[],"tldr":"Osara Health pairs people with cancer with a personal health coach by phone, text and app to help with fatigue, sleep, exercise and returning to work. Insurers and employers pay for it.","summary":"Osara Health, founded in Sydney in 2016 as CancerAid by radiation oncologist Raghav Murali-Ganesh and Tim Atkins, delivers its Cancer Coach programme through insurers and employers. It combines behaviour change science, one to one telehealth coaching and a mobile app for symptom tracking, with a survivorship module added in 2026. Customers include MetLife, Manulife, Guardian, Allstate Benefits, AIA and nib across the United States, Canada, Australia and New Zealand, covering more than 11 million lives. It cites more than 11 peer reviewed studies; a 2026 JMIR Cancer paper in 89 participants reported PROMIS-10 physical and mental health gains of 4.4 and 4.6 points, and Swiss Re validated a 25 to 1 return on investment for cancer rehabilitation using mostly Osara data. Recent press releases carry a New York dateline. No funding round or investor could be sourced.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://osarahealth.com"},{"label":"10 year anniversary press release (August 2026)","url":"https://www.prnewswire.com/news-releases/osara-health-marks-10-years-with-global-call-to-make-cancer-support-beyond-treatment-standard-302849228.html"},{"label":"JMIR Cancer study press release (April 2026)","url":"https://www.prnewswire.com/news-releases/osara-health-publishes-new-peer-reviewed-study-demonstrating-clinically-meaningful-improvements-in-physical-and-mental-health-for-people-with-cancer-302742626.html"},{"label":"About Osara Health","url":"https://osarahealth.com/about/"}],"tags":[],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":["exercise-oncology"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Hint gave Sydney; the company started in Australia as CancerAid but its 2026 press releases are datelined New York, so HQ is recorded as New York with Australian origin noted. No funding rounds found in company press pages or PR Newswire. The exercise-oncology tag reflects the coaching programme's exercise and rehabilitation focus rather than a formal exercise trial."],"hq":"New York, NY","country":"US","companyType":"ai-software","website":"https://osarahealth.com","founded":2016,"stage":"startup","investors":[],"funding":[]},{"id":"ose-immunotherapeutics","kind":"company","name":"OSE Immunotherapeutics","aka":[],"tldr":"OSE Immunotherapeutics develops immune treatments for cancer and inflammatory disease. Its lead cancer product is an off-the-shelf vaccine for lung cancer patients whose immunotherapy has stopped working, now in a late-stage trial.","summary":"OSE Immunotherapeutics SA (Euronext Paris: OSE), based in Nantes, is a clinical-stage company with platforms in immuno-oncology and immuno-inflammation. Tedopi (OSE2101) is an off-the-shelf neo-epitope T cell vaccine for HLA-A2 positive patients, in the phase 3 ARTEMIA trial in non-small cell lung cancer after checkpoint inhibitor failure; the trial received a second positive Independent Data Monitoring Committee recommendation in February 2026, and Tedopi showed positive phase 2 results in recurrent ovarian cancer (TEDOVA, ASCO 2026). OSE-279 is an anti-PD-1 antibody, with partnered programmes ABBV-230 (AbbVie) and BI 770371 (Boehringer Ingelheim). Outside oncology, lusvertikimab (anti-IL-7R) targets inflammatory bowel disease and pegrizeprument is partnered with Veloxis in transplantation. In May 2026 OSE signed a flexible bridge equity financing with IRIS Capital for up to about EUR 19.3 million, extending cash runway to December 2026.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.ose-immuno.com"},{"label":"Press releases","url":"https://www.ose-immuno.com/en/press-releases/"},{"label":"Bridge equity financing with IRIS (May 2026)","url":"https://www.ose-immuno.com/wp-content/uploads/2026/05/OSE-PR_EN_260528_IRIS-Financing-vdef.pdf"}],"tags":[],"related":[],"cancers":["nsclc","ovarian"],"sections":["immunotherapy"],"technologies":["shared-antigen-vaccine","checkpoint-inhibitor","monoclonal-antibody"],"targets":["pd1"],"drugs":["ose2101"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05751798"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not sourced."],"hq":"Nantes","country":"FR","companyType":"biotech","website":"https://www.ose-immuno.com","ticker":"OSE.PA","stage":"public","investors":[],"funding":[{"round":"Crossover","year":2026,"source":"https://www.ose-immuno.com/wp-content/uploads/2026/05/OSE-PR_EN_260528_IRIS-Financing-vdef.pdf","note":"Flexible bridge equity financing (warrants) with IRIS Capital Investment: up to 4 million new shares, gross proceeds up to about EUR 19.3 million over 24 months at the then share price"}]},{"id":"otsuka","kind":"company","name":"Otsuka Pharmaceutical","aka":["Astex Pharmaceuticals","Graceway Pharmaceuticals, LLC","Graceway Pharmaceuticals"],"tldr":"Otsuka is a Japanese pharmaceutical group whose oncology portfolio centres on haematology: intravenous busulfan (Busulfex) and decitabine (Dacogen).","summary":"Otsuka Pharmaceutical, part of Otsuka Holdings, is best known for CNS medicines but markets Busulfex (busulfan) for transplant conditioning and Dacogen (decitabine) for myelodysplastic syndromes in the US, and Dacogen for elderly acute myeloid leukaemia in Europe through Janssen. It also develops Lonsurf outside Japan with Taiho, a group company.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.otsuka.co.jp/en/"}],"tags":[],"related":[],"cancers":["mds","aml"],"sections":[],"technologies":[],"targets":[],"drugs":["busulfan","decitabine","trifluridine-tipiracil"],"companies":["taiho","johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07075328","nct05883956","nct04233346"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tokyo","country":"JP","companyType":"pharma","website":"https://www.otsuka.co.jp/en/","ticker":"4578.T","investors":[],"funding":[]},{"id":"outcomes4me","kind":"company","name":"Outcomes4Me","aka":[],"tldr":"Outcomes4Me is a free app that turns official cancer treatment guidelines into plain language options for each patient, and also tracks symptoms, explains genetic tests and finds clinical trials.","summary":"Outcomes4Me is a direct to patient cancer navigation platform. Its app maps a patient's diagnosis and biomarkers against NCCN Guidelines to show guideline concordant treatment options, and adds symptom and medication tracking, clinical trial matching, genetic testing education and moderated communities across more than a dozen cancer types including breast, prostate, lung, colorectal, bladder, CLL, ovarian and multiple myeloma. It reports more than 400,000 patients supported and seven of the top ten oncology pharmaceutical companies as customers, and in 2025 to 2026 acquired Mika Health, Geno.Me and the AI trial matching company Realyze Intelligence. Founded in 2017 by Maya Said and based in Boston, Outcomes4Me raised USD 4.7 million in 2020, a USD 12 million Series A led by Northpond Ventures in 2021 and USD 21 million led by Salica Investments in May 2025, for USD 38 million in total.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://outcomes4me.com"},{"label":"USD 21 million funding press release (May 2025)","url":"https://outcomes4me.com/press-release/outcomes4me-secures-21m-in-funding-to-accelerate-ai-driven-innovation-and-drive-global-expansion-to-transform-cancer-care/"},{"label":"Series A press release (April 2021)","url":"https://outcomes4me.com/press-release/breast-cancer-blog-seriesa/"},{"label":"Acquisition of Geno.Me and Realyze Intelligence (May 2026)","url":"https://www.prnewswire.com/news-releases/outcomes4me-acquires-genome-and-realyze-intelligence-names-upmc-hillman-cancer-center-cio-as-strategic-advisor-to-expedite-ai-driven-cancer-care-and-clinical-trial-access-302779191.html"}],"tags":[],"related":[],"cancers":["breast-hr-positive","breast-her2-positive","tnbc","nsclc","prostate","colorectal","urothelial","cll","endometrial","ovarian","rcc","multiple-myeloma"],"sections":["supportive-care","ai-computation"],"technologies":["ai-trial-matching","germline-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The 2020 and 2025 rounds were not given series names by the company; Seed and Series B labels are inferred from sequence and flagged in the round notes. Website homepage was fetched via WebFetch only (curl returned a Cloudflare 403)."],"hq":"Boston, MA","country":"US","companyType":"ai-software","website":"https://outcomes4me.com","founded":2017,"stage":"startup","investors":[],"funding":[{"round":"Seed","year":2020,"amountUsd":4700000,"source":"https://outcomes4me.com/press-release/outcomes4me-raises-4-7-million-to-help-patients-navigate-cancer-care-using-ai/","note":"Round not named by the company; led by Asset Management Ventures and included National Cancer Institute federal funds"},{"round":"Series A","year":2021,"amountUsd":12000000,"source":"https://outcomes4me.com/press-release/breast-cancer-blog-seriesa/","note":"Led by Northpond Ventures"},{"round":"Series B","year":2025,"amountUsd":21000000,"source":"https://outcomes4me.com/press-release/outcomes4me-secures-21m-in-funding-to-accelerate-ai-driven-innovation-and-drive-global-expansion-to-transform-cancer-care/","note":"Round not named by the company; labelled Series B here because it followed the 2021 Series A. Led by Salica Investments; total raised to date USD 38 million"}]},{"id":"outperform-cancer","kind":"company","name":"Outperform Cancer","aka":[],"tldr":"Outperform Cancer is a patient-built website and podcast that gathers peer-reviewed research on cancer vaccines, exercise, diet and other adjunctive strategies.","summary":"Outperform Cancer aggregates evidence-based strategies to improve cancer outcomes, through peer-reviewed research summaries, podcasts and expert interviews on cancer vaccines, exercise oncology, dietary interventions and other adjuncts. Patient-accessible. The site is run by Marybeth Gilliam, a cancer survivor since 2007 in Charlotte, Vermont, who states that she is not a physician or clinical researcher; its sections cover exercise, intermittent fasting, sulforaphane, high-dose vitamin C, gut health, mindfulness, biomarker testing and bisphosphonates.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.outperformcancer.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["exercise-oncology","time-restricted-eating","high-dose-vitamin-c","mindfulness-based-interventions","bone-modifying-agents"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"United States (city not published)","country":"US","companyType":"nonprofit","website":"https://www.outperformcancer.com/","investors":[],"funding":[]},{"id":"owkin","kind":"company","name":"Owkin","aka":[],"tldr":"French AI biotech using federated learning across hospitals; first CE-marked AI for MSI prediction from H&E.","summary":"Owkin, based in Paris and New York, is a French AI biotechnology company that uses federated learning across hospitals and produced the first CE-marked AI for predicting microsatellite instability from routine H&E slides. Its products include MSIntuit CRC, RlapsRisk BC for breast cancer relapse risk, the K1.0 agentic biology platform and the Phikon pathology foundation models, alongside federated research consortia. OnCo links it to digital pathology, federated learning and privacy-preserving AI, digital twins and spatial-omics-guided treatment, and to ideas on a federated learning consortium of cancer centres that jointly own the models. Data silos and AI that is built but not validated are the bottlenecks it addresses. Whether federated training can match centralised data on model quality is the open question.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.owkin.com"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["digital-pathology-ai","pathology-foundation-model"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Paris / New York","country":"FR","companyType":"ai-software","website":"https://www.owkin.com","investors":[],"funding":[]},{"id":"owlstone-medical","kind":"company","name":"Owlstone Medical","aka":[],"tldr":"Owlstone Medical, of Cambridge, UK, develops breath tests: a person breathes into its ReCIVA collector and the volatile chemicals are analysed to look for early lung cancer and liver disease. A 49 million dollar ARPA-H award funds a home breath and urine test for more than 30 solid tumours at stage I, still in development.","summary":"Owlstone Medical, based in Cambridge, UK, developed the Breath Biopsy platform for capturing and analysing volatile organic compounds (VOCs) in exhaled breath with its ReCIVA collector and OMNI analysis service. In cancer, the EVOLUTION programme is developing a breath screening test for early-stage lung cancer, and in October 2025 ARPA-H awarded up to $49.1 million under POSEIDON to build a synthetic-sensor based multi-cancer early detection test for more than 30 solid tumours at stage I using breath and urine at home. Outside oncology, LIBRA addresses chronic liver disease and the OMED Health analyser digestive conditions; collaborators include the FDA, NHS, Mayo Clinic, Cleveland Clinic and Cancer Research UK. Owlstone closed a $27 million Series E first close in January 2025 led by Ventura Capital.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.owlstonemedical.com/"},{"label":"Series E financing (Jan 2025)","url":"https://www.owlstonemedical.com/about/news/2025/jan/15/press-release-series-e-financing-round/"},{"label":"ARPA-H award (Oct 2025)","url":"https://www.owlstonemedical.com/about/news/2025/oct/06/owlstone-medical-wins-up-to-49-1-million-award-from-arpa-h-to-develop-at-home-multi-cancer-early-detection-tests/"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["early-detection","diagnostics"],"technologies":["mced"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No technology id exists for breath VOC analysis; mced is the closest tag. Founding year and earlier rounds not sourced. Grant amount is a maximum ('up to')."],"hq":"Cambridge","country":"GB","companyType":"diagnostics","website":"https://www.owlstonemedical.com/","stage":"growth","investors":[],"funding":[{"round":"Series E","year":2025,"amountUsd":27000000,"source":"https://www.owlstonemedical.com/about/news/2025/jan/15/press-release-series-e-financing-round/","note":"First close of about $27 million (approximately GBP 22 million) led by Ventura Capital, January 2025."},{"round":"Grant","year":2025,"amountUsd":49100000,"source":"https://www.owlstonemedical.com/about/news/2025/oct/06/owlstone-medical-wins-up-to-49-1-million-award-from-arpa-h-to-develop-at-home-multi-cancer-early-detection-tests/","note":"ARPA-H POSEIDON award of up to $49.1 million for at-home multi-cancer early detection tests, October 2025."}]},{"id":"oxford-biomedica","kind":"company","name":"OXB (Oxford Biomedica)","aka":[],"tldr":"Pure-play viral vector CDMO that made lentiviral vector for Kymriah and manufactured the AstraZeneca COVID vaccine.","summary":"OXB, formerly Oxford Biomedica, based in Oxford and listed as OXB.L, is a pure-play viral vector CDMO that made the lentiviral vector for Kymriah and manufactured the AstraZeneca COVID vaccine. It offers lentiviral, AAV and adenoviral vector development and GMP manufacturing in the United Kingdom, in the United States at Bedford, and in France at the former ABL Europe sites. OnCo links it to viral vector manufacturing and to the CDMO term. Whether demand for lentiviral vector holds up as in vivo and non-viral approaches to CAR-T grow is the open question for its business. The viral vector manufacturing page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.oxb.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["viral-vector-manufacturing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["cdmo"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Oxford","country":"GB","companyType":"cro-services","website":"https://www.oxb.com","ticker":"OXB.L","investors":[],"funding":[]},{"id":"oxford-nanopore","kind":"company","name":"Oxford Nanopore Technologies","aka":[],"tldr":"Portable and high-throughput nanopore sequencing, used for rapid intraoperative brain-tumour classification and structural variant detection.","summary":"Oxford Nanopore Technologies, based in Oxford and listed as ONT.L, makes portable and high-throughput nanopore sequencers used for rapid intraoperative brain tumour classification and structural variant detection. Its MinION, GridION and PromethION instruments read methylation in real time, which enables central nervous system tumour classification in under an hour through Rapid-CNS2, and its Q20+ chemistry has been clinical-grade since 2023. OnCo links it to long-read sequencing and DNA methylation profiling. Whether intraoperative sequencing changes surgical decisions often enough to be adopted widely is the open question. The long-read sequencing page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://nanoporetech.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["long-read-sequencing","methylation-profiling"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Oxford","country":"GB","companyType":"diagnostics","website":"https://nanoporetech.com","ticker":"ONT.L","investors":[],"funding":[]},{"id":"p-cure","kind":"company","name":"P-Cure","aka":[],"tldr":"P-Cure makes a compact proton therapy system in which the patient sits upright in a rotating chair in front of a fixed beam, so the treatment fits inside an ordinary radiotherapy room instead of a purpose-built multi-storey building.","summary":"P-Cure, founded in 2007, develops and markets a gantry-less, compact proton therapy system that treats patients seated or supine in front of a fixed synchrotron pencil-beam-scanning beam, with an FDA-cleared upright big-bore 4D CT for planning in the treatment position. The company says the room is comparable to a single-floor linac vault, about five times smaller than a gantry room, needs roughly half the shielding and can cut proton centre capital cost by about 50 percent. Milestones include FDA clearance of the upright imaging solution (2020), of the proton system for seated treatment (2024) and an August 2026 expansion to full-body and supine treatments. With Hadassah Medical Center the Jerusalem facility has treated patients routinely for almost three years and in February 2026 reported the first prospective results of upright proton re-irradiation for lung cancer. No financing round could be sourced.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.p-cure.com/"},{"label":"News and events (FDA clearances)","url":"https://www.p-cure.com/news-events/"},{"label":"Lung cancer re-irradiation results (Feb 2026)","url":"https://www.prnewswire.com/news-releases/p-cure-announces-first-ever-prospective-clinical-results-of-gantry-less-upright-proton-therapy-for-lung-cancer-re-irradiation-302687456.html"},{"label":"Linac vault conversion at SPHIC (Feb 2026)","url":"https://www.prnewswire.com/news-releases/p-cure-completes-worlds-first-conversion-of-linear-accelerator-vault-into-compact-proton-therapy-center-302697434.html"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["radiation","devices"],"technologies":["proton-therapy","ct","imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The caller's hint of Shilat, Israel as HQ could not be confirmed from fetched pages; press releases are datelined Jerusalem (where the Hadassah clinical facility is) and the site only says 'Israel', so Jerusalem is used. Funding, investors and stage are unsourced; stage defaults to startup."],"hq":"Jerusalem","country":"IL","companyType":"devices","website":"https://www.p-cure.com/","founded":2007,"stage":"startup","investors":[],"funding":[]},{"id":"pacbio","kind":"company","name":"PacBio","aka":[],"tldr":"Long-read HiFi sequencing (Revio, Vega) for structural variants, phasing, and methylation.","summary":"PacBio, based in Menlo Park and listed as PACB, makes long-read HiFi sequencing instruments, Revio and Vega, used to detect structural variants, phase mutations and read methylation. HiFi reads reach accuracy above 99.9 percent over kilobase lengths, Revio brought the cost towards whole-genome clinical use, and the Onso short-read platform was discontinued in 2025. OnCo links it to long-read sequencing alongside Oxford Nanopore. Whether long reads earn a routine place in cancer diagnostics, or remain a research tool for the variants short reads miss, is the open question. The long-read sequencing page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.pacb.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["long-read-sequencing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Menlo Park, CA","country":"US","companyType":"diagnostics","website":"https://www.pacb.com","ticker":"PACB","investors":[],"funding":[]},{"id":"pacific-edge","kind":"company","name":"Pacific Edge","aka":[],"tldr":"New Zealand company behind the Cxbladder urine tests for bladder cancer.","summary":"Pacific Edge, based in Dunedin, New Zealand, founded in 2001 and listed as PEB.NZ, is the company behind the Cxbladder urine tests for bladder cancer. The Cxbladder family of urine mRNA tests is used in New Zealand's public health system and in US Veterans Affairs and Kaiser pathways, and contested US Medicare coverage in 2024 and 2025 forced a restructuring. OnCo links it to bladder and urothelial cancer and to the Cxbladder product record. Its story shows how reimbursement decisions, rather than test performance, can determine a diagnostic company's fate, and whether urine tests can safely reduce cystoscopy in surveillance is the clinical question behind it. Cxbladder has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.pacificedgedx.com"}],"tags":[],"related":[],"cancers":["urothelial"],"sections":["diagnostics"],"technologies":[],"targets":[],"drugs":["cxbladder"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Dunedin","country":"NZ","companyType":"diagnostics","website":"https://www.pacificedgedx.com","ticker":"PEB.NZ","founded":2001,"investors":[],"funding":[]},{"id":"paige","kind":"company","name":"Paige AI","aka":[],"tldr":"MSK spin-out with the first FDA-cleared AI pathology product and the Virchow foundation model.","summary":"Paige AI, based in New York, is the Memorial Sloan Kettering spin-out with the first FDA-cleared AI pathology product, Paige Prostate Detect, cleared in 2021, and the Virchow and Virchow2 foundation models built with Microsoft. Its work extends to pan-cancer detection, and OnCo links it to digital pathology, pathology foundation models and the AI in the oncology clinic roadmap. It bears on bottlenecks about unvalidated AI and biomarkers and the shortage of pathologists, and on ideas including a standard evaluation pathway for AI pathology, AI-first reading for high-volume diagnoses and one digital PD-L1 scale across assays. Whether a foundation model trained on one institution's slides generalises everywhere is the open question. Paige Prostate Detect has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://paige.ai"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["digital-pathology-ai","pathology-foundation-model"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"New York, NY","country":"US","companyType":"ai-software","website":"https://paige.ai","investors":[],"funding":[]},{"id":"palitra-bio","kind":"company","name":"Palitra Bio","aka":[],"tldr":"Palitra Bio tests candidate treatments directly against a patient's own tumour cells, with a PhD data team and an MD tumour board turning the results into a personalised treatment plan.","summary":"Palitra Bio offers what it calls maximalist functional testing: rational therapeutic options are tested against the patient's own tumour cells, matched to malignancy, stage and goals of care, and synthesised by a data team and a medical tumour board into guidance for the treating clinicians. Its chief executive brings fifteen years at the intersection of cancer biology and translational research. It is an Even One Ventures portfolio company.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://palitra.bio/"},{"label":"Even One Ventures portfolio","url":"https://evenone.ventures/"}],"tags":["startup","evenone-portfolio","oncology"],"related":[],"cancers":[],"sections":[],"technologies":["functional-drug-testing","multidisciplinary-tumour-board"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"United States (head office not published)","country":"US","companyType":"diagnostics","website":"https://palitra.bio/","stage":"startup","investors":["evenone-ventures"],"funding":[]},{"id":"panbela-therapeutics","kind":"company","name":"Panbela Therapeutics","aka":["Sun BioPharma","NASDAQ:PBLA"],"tldr":"Panbela Therapeutics is a Minnesota biotech whose drug ivospemin starves pancreatic cancer of polyamines, molecules the tumour needs to grow, and is being tested with gemcitabine and nab-paclitaxel in first-line treatment.","summary":"Panbela Therapeutics, formerly Sun BioPharma, develops polyamine-targeting therapies. Ivospemin (SBP-101) is a polyamine analogue that is taken up preferentially by pancreatic acinar and cancer cells and disrupts polyamine metabolism. The phase 2/3 ASPIRE trial tested ivospemin with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma. Through its acquisition of Cancer Prevention Pharmaceuticals it also holds eflornithine-based programmes for familial adenomatous polyposis.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.panbela.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["ivospemin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Waconia, Minnesota","country":"US","companyType":"biotech","website":"https://www.panbela.com/","ticker":"NASDAQ:PBLA","stage":"public","investors":[],"funding":[]},{"id":"parexel","kind":"company","name":"Parexel","aka":[],"tldr":"Parexel, of Durham, North Carolina, is a global contract research organisation owned by EQT and Goldman Sachs that runs early and late-phase oncology trials and sells regulatory consulting staffed by former FDA officials. Whether regulators moving into consulting sharpens trial design or blurs the line between regulator and industry is the question its model raises.","summary":"Parexel, based in Durham, North Carolina, is a global contract research organisation known for regulatory consulting staffed by former FDA officials and for its oncology trial operations. It is privately owned by EQT and Goldman Sachs and works across regulatory strategy, early-phase and late-phase oncology development. OnCo links it to contract research organisations. Whether the movement of regulators into consulting sharpens trial design or blurs the line between regulator and industry is the fair question its model raises. The CRO technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.parexel.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["contract-research-organisations"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05943106","nct07069712","nct05629234","nct04452955"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Durham, NC","country":"US","companyType":"cro-services","website":"https://www.parexel.com","investors":[],"funding":[]},{"id":"partner-therapeutics","kind":"company","name":"Partner Therapeutics","aka":["Partner Therapeutics, Inc.","PTx"],"tldr":"Partner Therapeutics is a private Massachusetts company that owns sargramostim (Leukine), the recombinant GM-CSF used after chemotherapy and transplant and, since 2020, in high-risk neuroblastoma with dinutuximab.","summary":"Partner Therapeutics, based in Lexington, Massachusetts, acquired sargramostim (Leukine) from Sanofi in 2018. Leukine, a recombinant granulocyte-macrophage colony-stimulating factor first approved in 1991, is used to speed neutrophil recovery after induction chemotherapy for acute myeloid leukaemia and after stem cell transplant, to mobilise stem cells, and, following an FDA supplemental approval in 2020, as part of dinutuximab immunotherapy for high-risk paediatric neuroblastoma. The company also studied it in acute radiation syndrome and respiratory illness. It appears on OnCo as an FDA oncology applicant and a sponsor of cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.partnertx.com"},{"label":"ClinicalTrials.gov: trials led by Partner Therapeutics","url":"https://clinicaltrials.gov/search?lead=Partner%20Therapeutics"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml","neuroblastoma"],"sections":["supportive-care"],"technologies":[],"targets":[],"drugs":["dinutuximab","sargramostim"],"companies":[],"institutions":[],"pathways":[],"terms":["neutropenia","autologous-transplant"],"trials":["nct02912949"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Lexington, MA","country":"US","companyType":"biotech","website":"https://www.partnertx.com","stage":"private-large","investors":[],"funding":[]},{"id":"pathai","kind":"company","name":"PathAI","aka":[],"tldr":"PathAI runs the AISight AI pathology platform and quantifies biomarkers for pharma trials.","summary":"PathAI, based in Boston, runs the AISight AI pathology platform and quantifies biomarkers for pharmaceutical trials. Its products include AISight image management, the AIM-PD-L1 and AIM-HER2 quantification algorithms and TumorDetect, backed by large pharma partnerships, and its PLUTO foundation model has its own OnCo record. OnCo links it to digital pathology and to bottlenecks on unvalidated AI, unstandardised biomarkers and the shortage of pathologists, and to ideas including a standard evaluation pathway for AI pathology and one digital PD-L1 scale that maps across competing assays. Whether AI biomarker scoring becomes the regulatory standard for trial enrolment is the open question. The digital pathology page carries the wider picture.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.pathai.com"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["digital-pathology-ai"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boston, MA","country":"US","companyType":"ai-software","website":"https://www.pathai.com","investors":[],"funding":[]},{"id":"pathfinder-oncology","kind":"company","name":"Pathfinder Oncology","aka":[],"tldr":"Pathfinder Oncology is a high-touch concierge service, led by William Hoos, that builds radically individualised treatment pathways for advanced cancer, including bespoke immune profiling.","summary":"Pathfinder Oncology offers personalised treatment-pathway work for patients with advanced cancer, combining the latest diagnostics with bespoke immune profiling and analysis. Future of Cancer Care Today lists it under both immune profiling and navigation as patient-accessible.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://pathfinderoncology.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["multidisciplinary-tumour-board"],"targets":[],"drugs":[],"companies":["future-of-cancer-care-today"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"United States (city not published)","country":"US","companyType":"cro-services","website":"https://pathfinderoncology.com/","investors":[],"funding":[]},{"id":"pathos-ai","kind":"company","name":"Pathos AI","aka":[],"tldr":"Pathos AI trains multimodal artificial intelligence models on millions of cancer patients' genomic, imaging, text and outcome records to choose which experimental drugs to develop and which patients to test them in. It has licensed a TROP2/HER3 bispecific antibody-drug conjugate and an oestrogen receptor degrader, and raised a 365 million dollar Series D in 2025.","summary":"Pathos AI is an AI-enabled, clinical-stage oncology biotech. Its PATHOS platform draws on millions of oncology records integrating genomics, transcriptomics, imaging, text and longitudinal outcomes, and is building what the company describes as the largest multimodal foundation model in oncology to select assets, design trials and discover biomarkers. In August 2026 it licensed JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate, from Alphamab Oncology ($125 million upfront, up to $2,093 million in milestones) and agreed a co-exclusive licence to take the oestrogen receptor PROTAC degrader AZD4241 into the clinic for ER-positive breast cancer. In May 2026 it took a majority stake in DeuterOncology (MET inhibitor). Pathos raised a $365 million Series D in May 2025 at a post-money valuation of about $1.6 billion.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.pathos.com/"},{"label":"Series D press release (May 2025)","url":"https://www.pathos.com/pathos-ai-secures-365-million-in-series-d-financing-to-advance-oncology-drug-development-through-ai"},{"label":"News page","url":"https://www.pathos.com/news"}],"tags":[],"related":[],"cancers":["breast-hr-positive","nsclc"],"sections":["ai-computation","drug-discovery","adcs"],"technologies":["pathology-foundation-model","ai-drug-design","bispecific-adc","protac-degrader","kinase-inhibitors"],"targets":["trop2","her3","estrogen-receptor","met"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06785636"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The Series D release dateline is New York, NY rather than Chicago; Chicago may be an operating base but is not stated on fetched pages. Series D investors were not named. The AstraZeneca counterparty for AZD4241 is inferred from the asset code on the company news page, not stated in the fetched text. Tempus partnership not mentioned on fetched pages. companyType set to biotech because the company develops drugs; it also fits ai-software."],"hq":"New York, NY","country":"US","companyType":"biotech","website":"https://www.pathos.com/","stage":"growth","investors":[],"funding":[{"round":"Series D","year":2025,"amountUsd":365000000,"source":"https://www.pathos.com/pathos-ai-secures-365-million-in-series-d-financing-to-advance-oncology-drug-development-through-ai","note":"Post-money valuation about $1.6 billion, May 2025; investors not named in the release."}]},{"id":"patient-advocators","kind":"company","name":"Patient Advocators","aka":[],"tldr":"Patient Advocators is a private patient advocacy firm offering specialist referrals, treatment navigation and insurance and cost coordination for cancer and other complex conditions.","summary":"Patient Advocators is a multidisciplinary private advocacy firm that helps clients across the United States find specialists, navigate treatment and coordinate insurance and costs, in cancer and other complex conditions. Patient-accessible.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.patientadvocators.com"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["financial-navigation"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"United States (city not published)","country":"US","companyType":"cro-services","website":"https://www.patientadvocators.com","investors":[],"funding":[]},{"id":"patient-data-vault","kind":"company","name":"Patient Data Vault (data-vault.health)","aka":[],"tldr":"AI clinical-trial matcher for cancer patients: upload records or connect a health system, get explained matches updated daily from ClinicalTrials.gov.","summary":"Patient Data Vault, at data-vault.health, is a US AI clinical trial matcher for cancer patients: a patient uploads records or connects a health system and receives explained trial matches updated daily from ClinicalTrials.gov. It extracts biomarkers from uploaded notes or from more than two hundred connected health systems, searches thousands of trials, explains each match and lets users filter by distance and phase, and it was founded by a caregiver after an EGFR exon 20 diagnosis in the family. OnCo links it to AI trial matching, to bottlenecks on data silos and patient navigation, and to ideas such as a patient-held cancer record that travels across providers and borders and dynamic consent with usage receipts. Whether automated matching is accurate enough to be trusted without a clinician in the loop is the open question. ClinicalTrials.gov has its own page.","asOf":"2026-09-04","links":[{"label":"About","url":"https://data-vault.health/about"}],"tags":[],"related":["clinicaltrials-gov"],"cancers":[],"sections":["ai-computation","supportive-care"],"technologies":["ai-trial-matching"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"United States","country":"US","companyType":"ai-software","website":"https://data-vault.health","investors":[],"funding":[]},{"id":"paxman","kind":"company","name":"Paxman","aka":[],"tldr":"Paxman is the British maker of the Paxman Scalp Cooling System, a chilled cap worn during chemotherapy to reduce hair loss, cleared in the United States in 2017 and used in cancer centres across the world.","summary":"Paxman, based in Huddersfield and listed on London's AIM market, developed its refrigerated scalp cooling system from the family's drinks-cooling business after a relative's chemotherapy. The system was cleared by the FDA in 2017 for breast cancer and later for solid tumours, and the company is developing cooling for chemotherapy-induced neuropathy.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://paxmanscalpcooling.com/"},{"label":"Paper: SCALP randomised trial (JAMA 2017)","url":"https://doi.org/10.1001/jama.2016.20939"}],"tags":["machines-wave2"],"related":[],"cancers":["breast-cancer"],"sections":["rejuvenation"],"technologies":["scalp-cooling","cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Huddersfield","country":"GB","companyType":"devices","website":"https://paxmanscalpcooling.com/","ticker":"PAX","stage":"public","investors":[],"funding":[]},{"id":"pellepharm","kind":"company","name":"PellePharm","aka":["PellePharm, Inc."],"tldr":"PellePharm is a Californian company, an affiliate of BridgeBio, that reformulated the Hedgehog inhibitor patidegib as a skin gel to prevent basal cell carcinomas in people with Gorlin syndrome.","summary":"PellePharm develops patidegib topical gel (formerly saridegib, IPI-926), a Hedgehog pathway inhibitor applied to the skin to block the Smoothened receptor in basal cell carcinomas without the taste loss, hair loss and muscle cramps of oral Hedgehog inhibitors. The drug is aimed at Gorlin syndrome (basal cell nevus syndrome), where patients develop many tumours over a lifetime, and at high-frequency sporadic basal cell carcinoma. A phase 3 trial in Gorlin syndrome completed enrolment in 2020 but did not meet its primary endpoint.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["patidegib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Menlo Park, California","country":"US","companyType":"biotech","investors":[],"funding":[]},{"id":"pentax-medical","kind":"company","name":"Pentax Medical (HOYA)","aka":[],"tldr":"Pentax Medical, the endoscopy division of HOYA, makes gastrointestinal and bronchial endoscopes and endoscopic ultrasound scopes used with Hitachi ultrasound processors.","summary":"Pentax Medical is the endoscopy business of the Japanese optics group HOYA, selling video endoscopes, the i-scan image enhancement system, and linear and radial echoendoscopes and EBUS bronchoscopes that pair with Hitachi Arietta ultrasound platforms for staging and needle sampling.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.pentaxmedical.com/"}],"tags":["machines-wave2"],"related":[],"cancers":[],"sections":[],"technologies":["endoscopic-ultrasound-systems","ultrasound"],"targets":[],"drugs":[],"companies":["hitachi"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tokyo","country":"JP","companyType":"devices","website":"https://www.pentaxmedical.com/","stage":"public","investors":[],"funding":[]},{"id":"perceptive-advisors","kind":"company","name":"Perceptive Advisors","aka":[],"tldr":"Perceptive Advisors is a New York healthcare investment firm founded by Joseph Edelman in 1999 that runs a public-market fund, a credit fund and, through Xontogeny, a venture fund backing seed and Series A biotech companies from preclinical work to clinical proof of concept. It is one of the most frequent crossover investors in oncology IPOs.","summary":"Perceptive Advisors was founded in July 1999 by Joseph Edelman and is headquartered at 51 Astor Place, New York (Wikipedia; company site). Its strategies are the Perceptive Life Sciences Fund (public and crossover investing), Perceptive Credit Opportunities (structured debt for healthcare companies), Capital Solutions and the Perceptive Xontogeny Venture Fund. The venture page says the firm launched its first venture fund in 2018 and a second in 2021, 'manage[s] over $700 million of capital dedicated to financing early-stage life sciences companies', targets seed and Series A rounds of $10 to 50 million and takes technologies 'from preclinical stage through clinical proof-of-concept'. Recent investments named there (Crystalys Therapeutics, Mercy BioAnalytics, Galvanize, Myoventive, Merida Biosciences) are not described as oncology, though Mercy BioAnalytics works on blood-based cancer detection. Perceptive is nonetheless one of the most frequent crossover investors in oncology IPOs.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.perceptivelife.com/"},{"label":"Venture capital","url":"https://www.perceptivelife.com/venture-capital"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Perceptive_Advisors"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The investments page returned 'Showing 0 companies' (client-side filter), so no public-portfolio oncology names could be confirmed. Mercy BioAnalytics' cancer focus is from general knowledge, not the fetched page."],"hq":"New York, NY","country":"US","companyType":"investor","website":"https://www.perceptivelife.com/","founded":1999,"investors":[],"funding":[]},{"id":"perci-health","kind":"company","name":"Perci Health","aka":[],"tldr":"Perci Health is an online clinic where people affected by cancer can book video appointments with specialist cancer nurses, physiotherapists, dietitians, psychologists and other experts, usually paid for by their employer or insurer.","summary":"Perci Health Ltd is a London based virtual cancer care clinic co-founded by Kelly McCabe (CEO) and Morgan Fitzsimons. It connects patients, survivors and carers to more than 15 types of practitioner, including cancer nurse specialists, lymphoedema therapists, clinical exercise coaches, physiotherapists, psychologists, dietitians and occupational therapists, through on demand video appointments and personalised care plans spanning risk identification, early detection, treatment support and recovery. The service is sold to UK employers and insurers as a workforce health benefit, and the company cites Macmillan Cancer Support and Healix Health Services among its endorsers. No funding round, investor or founding year could be sourced from a primary document during this research; the company is registered in England (company number 12402935).","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://percihealth.com"},{"label":"About Perci Health","url":"https://percihealth.com/about"}],"tags":[],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":["exercise-oncology"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["HQ London taken from the registered office in the privacy policy (The Coade, 98 Vauxhall Walk, London SE11 5EL). No press releases found and no funding sourced. Stage set to startup by default."],"hq":"London","country":"GB","companyType":"cro-services","website":"https://percihealth.com","stage":"startup","investors":[],"funding":[]},{"id":"peregrine-avid","kind":"company","name":"Peregrine Pharmaceuticals (now Avid Bioservices)","aka":["Peregrine Pharmaceuticals","Peregrine Pharmaceuticals, Inc.","Avid Bioservices"],"tldr":"Peregrine was a Californian biotech whose phosphatidylserine antibody bavituximab failed a phase 3 lung cancer trial; the company kept its contract manufacturing arm and became Avid Bioservices.","summary":"Peregrine Pharmaceuticals, based in Tustin, California, developed bavituximab, an antibody against phosphatidylserine exposed on tumour blood vessels, and took it into the phase 3 SUNRISE trial in non-small cell lung cancer, which was stopped for futility in 2016. The company then concentrated on its contract development and manufacturing business and renamed itself Avid Bioservices in 2018. The bavituximab trials remain on ClinicalTrials.gov under the Peregrine name.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.avidbio.com"},{"label":"ClinicalTrials.gov: trials led by Peregrine Pharmaceuticals","url":"https://clinicaltrials.gov/search?lead=Peregrine%20Pharmaceuticals"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30288606"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["monoclonal-antibody","monoclonal-antibody-manufacturing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Tustin, CA","country":"US","companyType":"biotech","website":"https://www.avidbio.com","stage":"public","investors":[],"funding":[]},{"id":"perimeter-medical-imaging-ai","kind":"company","name":"Perimeter Medical Imaging AI","aka":[],"tldr":"Perimeter makes a scanner that gives surgeons a microscope-level 3D look at the edges of tissue they have just removed during breast cancer surgery, with artificial intelligence flagging suspicious areas, so they can take more tissue immediately rather than bringing the patient back for a second operation.","summary":"Perimeter Medical Imaging AI, established in Toronto in 2013 with US headquarters in Dallas, develops wide-field optical coherence tomography (OCT) for intraoperative margin assessment. Its S-Series OCT has FDA 510(k) clearance under a general tissue-imaging indication. The next-generation Claire received FDA premarket approval in March 2026 as the first AI-enabled imaging device approved in the US for intraoperative breast cancer margin assessment, after Breakthrough Device designation. Claire images excised specimens to 2 mm depth at about ten times the resolution of x-ray or ultrasound, with AI trained on more than two million breast tissue images. The company is listed on the TSX Venture Exchange (PINK) and OTCQX (PYNKF). In 2026 it raised about CAD 7.5 million in a LIFE unit offering plus CAD 6.04 million in convertible debentures to fund the US launch of Claire.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://perimetermed.com/"},{"label":"About Perimeter","url":"https://perimetermed.com/about/"},{"label":"Claire FDA PMA approval (March 2026)","url":"https://ir.perimetermed.com/news-events/press-releases/detail/200/perimeter-medical-imaging-ai-claire-becomes-first"},{"label":"LIFE offering closing (May 2026)","url":"https://ir.perimetermed.com/news-events/press-releases/detail/207/perimeter-medical-imaging-ai-closes-life-offering"},{"label":"Convertible debenture final tranche (June 2026)","url":"https://ir.perimetermed.com/news-events/press-releases/detail/210/perimeter-medical-imaging-ai-closes-final-tranche-of"}],"tags":[],"related":[],"cancers":["breast-hr-positive","tnbc","breast-her2-positive"],"sections":["surgery","imaging","devices","ai-computation"],"technologies":["optical-imaging","digital-pathology-ai"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Amounts are in Canadian dollars so amountUsd is omitted. Ticker written as PINK.V for TSX Venture; OTCQX symbol PYNKF."],"hq":"Toronto","country":"CA","companyType":"devices","website":"https://perimetermed.com/","ticker":"PINK.V","founded":2013,"stage":"public","investors":[],"funding":[{"round":"Crossover","year":2026,"source":"https://ir.perimetermed.com/news-events/press-releases/detail/207/perimeter-medical-imaging-ai-closes-life-offering","note":"Listed issuer financing exemption (LIFE) unit offering: approximately CAD 6.84 million closed 5 May 2026 with a final tranche to bring the total to CAD 7.52 million; led by Paradigm Capital with Brookline Capital Markets"},{"round":"Debt","year":2026,"source":"https://ir.perimetermed.com/news-events/press-releases/detail/210/perimeter-medical-imaging-ai-closes-final-tranche-of","note":"CAD 6.04 million of 3.59 percent convertible debentures maturing April 2029, including CAD 2.76 million from CEO Adrian Mendes"}]},{"id":"perita-bio","kind":"company","name":"Perita Bio","aka":[],"tldr":"Perita Bio is an Even One Ventures company outside cancer: precision molecular profiling of endometriosis to explore non-hormonal treatment options.","summary":"Perita Bio's public description is precision molecular profiling of a patient's endometriosis to explore non-hormonal options. It is the women's health company in the Even One Ventures portfolio and does not work on cancer.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://perita.bio/"},{"label":"Even One Ventures portfolio","url":"https://evenone.ventures/"}],"tags":["startup","evenone-portfolio","womens-health","non-oncology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"United States (head office not published)","country":"US","companyType":"diagnostics","website":"https://perita.bio/","stage":"startup","investors":["evenone-ventures"],"funding":[]},{"id":"persephone-biosciences","kind":"company","name":"Persephone Biosciences","aka":[],"tldr":"Persephone studies the gut bacteria of cancer patients and designs live bacterial medicines meant to make immunotherapy work for more people.","summary":"Persephone Biosciences develops live biotherapeutic products that modulate gut microbial metabolism, using systems and synthetic biology to understand which microbiome features track with response to cancer immunotherapy. It ran the ARGONAUT observational study collecting stool and blood from patients with colorectal, pancreatic, lung and other cancers on checkpoint inhibitors to build that map, and has a separate infant microbiome programme. Oncology programmes are preclinical or early clinical; no round amounts are recorded here because none was fetched from a primary source.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/persephone-biosciences"},{"label":"Official website","url":"https://persephonebiosciences.com"}],"tags":["yc"],"related":[],"cancers":["colorectal"],"sections":["immunotherapy","prevention"],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://persephonebiosciences.com","stage":"startup","ycBatch":"W18","investors":["y-combinator"],"funding":[]},{"id":"personalis","kind":"company","name":"Personalis (Tempus)","aka":[],"tldr":"Maker of the ultra-sensitive NeXT Personal MRD test, being acquired by Tempus AI for about $1.5B (announced July 2026).","summary":"Personalis, based in Fremont, California, and listed as PSNL, makes the ultra-sensitive NeXT Personal test for measurable residual disease and is being acquired by Tempus AI for about 1.5 billion dollars, announced in July 2026. NeXT Personal is a tumour-informed whole-genome MRD assay whose clinical volumes grew 33 percent quarter over quarter to 10,384 tests in the second quarter of 2026, and Tempus agreed to pay 16.25 dollars per share in stock, with closing expected in late 2026 or early 2027. OnCo links it to MRD testing, liquid biopsy and whole-genome sequencing, to the MRD term, to Tempus, and to the idea of pushing residual disease detection a hundredfold deeper with whole-genome methods. Whether deeper detection changes treatment decisions or only finds relapse sooner is the open question. Tempus has its own page.","asOf":"2026-09-04","links":[{"label":"Tempus acquisition","url":"https://investors.tempus.com/news-releases/news-release-details/tempus-acquire-personalis-more-tightly-integrating-molecular"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["mrd-testing","liquid-biopsy","wes-wgs","cgp"],"targets":[],"drugs":[],"companies":["tempus"],"institutions":[],"pathways":[],"terms":["mrd"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Fremont, CA","country":"US","companyType":"diagnostics","website":"https://www.personalis.com","ticker":"PSNL","investors":[],"funding":[]},{"id":"perspective-therapeutics","kind":"company","name":"Perspective Therapeutics","aka":[],"tldr":"Lead-212 alpha-therapy company whose SSTR2 agent [212Pb]VMT-α-NET reported a 43% response rate in neuroendocrine tumours and is heading for phase 3.","summary":"Phase 1/2a of [212Pb]VMT-α-NET (NCT05636618): 43% ORR in cohort 2 with 72% progression-free/alive at the 2026 update; 76 NET patients treated by July 2026; first meningioma patient dosed June 2026; EU orphan designation July 2026. Phase 3 planned at a cumulative 20 mCi dose. Also developing PSMA and melanocortin-1 receptor 212Pb agents.","asOf":"2026-09-04","links":[{"label":"Q2 2026 highlights","url":"https://www.globenewswire.com/news-release/2026/08/10/3342260/0/en/perspective-therapeutics-provides-recent-business-highlights-and-reports-2q-2026-results.html"}],"tags":[],"related":[],"cancers":["neuroendocrine"],"sections":["radiopharma"],"technologies":["targeted-alpha-therapy"],"targets":["sstr2","psma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["alpha-vs-beta"],"trials":["nct05655312","nct05636618","nct06710756"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Seattle, WA","country":"US","companyType":"radiopharma","website":"https://perspectivetherapeutics.com","ticker":"CATX","investors":[],"funding":[]},{"id":"petnet-solutions","kind":"company","name":"PETNET Solutions (Siemens Healthineers)","aka":[],"tldr":"PETNET Solutions is the largest network of PET radiopharmacies in the US, producing FDG and PSMA tracers daily.","summary":"PETNET Solutions, part of Siemens Healthineers and based in Knoxville, Tennessee, is the largest network of PET radiopharmacies in the United States, producing FDG and PSMA tracers every day. It operates about fifty cyclotron sites in the United States plus international operations and is the commercial distributor for several FDA-approved PET drugs. OnCo links it to radiopharmacy and cyclotron networks and PET tracer manufacturing and distribution, and to the fludeoxyglucose F-18 drug record. Whether a network built for FDG can adapt to the many new PSMA, FAP and receptor tracers coming through is the open question. FDG has its own page.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.siemens-healthineers.com/molecular-imaging/petnet"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["radiopharma","imaging"],"technologies":["radiopharmacy-network","pet-tracer-manufacturing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Knoxville, TN","country":"US","companyType":"radiopharma","website":"https://www.siemens-healthineers.com/molecular-imaging/petnet","investors":[],"funding":[]},{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","aka":["Seagen","Seagen (Pfizer)","Seattle Genetics"],"tldr":"Bought Seagen for $43B to become an ADC leader; also makes Ibrance, Lorbrena, Braftovi, and the first PROTAC.","summary":"Pfizer, based in New York and listed as PFE, bought Seagen for 43 billion dollars to become an antibody-drug conjugate leader, and it also makes Ibrance, Lorbrena and Braftovi and developed the first PROTAC, vepdegestrant, with Arvinas. The ADC portfolio covers Padcev, Adcetris, Tivdak, Tukysa, disitamab vedotin outside China and sigvotatug vedotin; the small-molecule side includes palbociclib, atirmociclib, lorlatinib, encorafenib and talazoparib; and a PD-1 by VEGF bispecific was licensed from 3SBio in 2025 with 1.25 billion dollars upfront. OnCo links it to the EV-302, CROWN, BREAKWATER, ECHELON-1 and INO-VATE papers, to ponsegromab and cachexia as a treatable disease, to LIV-1 as a target and to Pfizer Ventures. Whether Seagen's platform yields new ADCs rather than only sustaining the acquired ones is the open question. Each product has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.pfizer.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs","targeted-therapy"],"technologies":[],"targets":[],"drugs":["enfortumab-vedotin","brentuximab-vedotin","tisotumab-vedotin","tucatinib","disitamab-vedotin","palbociclib","lorlatinib","encorafenib","talazoparib","vepdegestrant","gemtuzumab-ozogamicin","pf-08634404","pf-07248144","sasanlimab","pf-08046054","utomilumab","ponsegromab","samuraciclib","exemestane","estramustine","dexrazoxane","oprelvekin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06003231","nct06012435","mountaineer","nct04579380","nct06758401","nct06629779","nct07028853","nct05623020","nct06152575","nct05020236","nct05317416","nct04404283","nct04657991","nct04430738","nct07227012","nct03709680","nct07476287","nct07227415","nct04557449","nct07227298","nct04553133","nct04606446","nct05217446","nct07489066","nct06206837","nct07475806","nct05748171","nct07421700","nct07566156","nct04821622","nct04225117","nct05548127","nct05262400","nct05230810","nct05909397","nct04721977","nct05573555","nct06966453","nct06760637","nct00248287","nct05226871"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"New York, NY","country":"US","companyType":"pharma","website":"https://www.pfizer.com","ticker":"PFE","investors":[],"funding":[]},{"id":"pfizer-ventures","kind":"company","name":"Pfizer Ventures","aka":[],"tldr":"Pfizer's corporate venture arm, which invests in early biotech companies in the areas Pfizer cares about, including cancer. Its oncology portfolio includes Artios Pharma, Crossbow Therapeutics and Strata Oncology.","summary":"Pfizer Ventures is Pfizer's strategic corporate venture capital arm, investing globally in biopharmaceutical companies across five core areas: oncology, inflammation and immunology, cardiovascular, metabolic and obesity, and vaccines, plus platform technology companies. Its page says it invests from seed through IPO with typical initial investments of $5 to 20 million, emphasises early-stage opportunities and follows on in later rounds, and sits within Pfizer's Worldwide Business Development group. The portfolio page lists oncology companies including Artios Pharma ('a leading DNA Damage Response company'), Crossbow Therapeutics (T-cell receptor-mimetic antibodies), Curve Therapeutics (cyclic peptides), Incendia Therapeutics (tumour microenvironment), Kestrel Therapeutics (pan-KRAS), Normunity, Palleon Pharma (glycoimmune checkpoint inhibitors) and Strata Oncology (precision oncology testing).","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.pfizer.com/about/partners/venture-investments"},{"label":"Portfolio","url":"https://www.pfizer.com/partners/venture-investments/our-portfolio"}],"tags":["corporate-venture"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["pfizer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the fetched pages; omitted. New York follows Pfizer's headquarters."],"hq":"New York, NY","country":"US","companyType":"investor","website":"https://www.pfizer.com/about/partners/venture-investments","investors":[],"funding":[]},{"id":"phanes-therapeutics","kind":"company","name":"Phanes Therapeutics","aka":["Phanes Therapeutics, Inc."],"tldr":"Phanes Therapeutics is a San Diego biotech whose bispecific antibodies pair a tumour antigen with an immune signal; peluntamig hits DLL3 and CD47 in small cell lung cancer and spevatamig hits Claudin 18.2 and CD47 in stomach and pancreatic cancer.","summary":"Phanes Therapeutics develops bispecific antibodies using its PACbody, SPECpair and ATACCbody platforms. Peluntamig (PT217) binds DLL3 and CD47 and has orphan and fast track designations in small cell lung cancer and neuroendocrine carcinomas; spevatamig (PT886) binds Claudin 18.2 and CD47 for gastric and pancreatic cancers; mavrostobart (PT199) is a CD73 antibody being tested with PD-1 blockade and chemotherapy. All three are in phase 1/2 trials.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.phanestherapeutics.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["peluntamig","spevatamig","mavrostobart"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"San Diego, California","country":"US","companyType":"biotech","website":"https://www.phanestherapeutics.com/","investors":[],"funding":[]},{"id":"pharmaand","kind":"company","name":"pharma&","aka":["pharmaand GmbH","pharma& GmbH","pharmaand"],"tldr":"pharma& is a Vienna company that buys and markets established medicines, including the PARP inhibitor rucaparib (Rubraca), which it acquired from Clovis Oncology's bankruptcy in 2023.","summary":"pharma& (pharmaand GmbH), based in Vienna, acquires and commercialises marketed medicines rather than developing new molecules. In oncology it bought rucaparib (Rubraca), the PARP inhibitor approved for BRCA-mutated ovarian and prostate cancer, from Clovis Oncology in 2023 after Clovis filed for bankruptcy, and it now holds the US and EU authorisations and runs the remaining trials and post-marketing commitments. It appears on OnCo as an FDA oncology applicant and a phase 3 trial sponsor on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.pharmaand.com"},{"label":"ClinicalTrials.gov: trials led by pharmaand","url":"https://clinicaltrials.gov/search?lead=pharmaand"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["ovarian","prostate"],"sections":["targeted-therapy"],"technologies":[],"targets":["parp"],"drugs":["rucaparib"],"companies":["clovis-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Vienna","country":"AT","companyType":"pharma","website":"https://www.pharmaand.com","stage":"private-large","investors":[],"funding":[]},{"id":"pharmacosmos","kind":"company","name":"Pharmacosmos","aka":["Pharmacosmos A/S"],"tldr":"Pharmacosmos is a Danish family-owned company specialising in intravenous iron; its iron isomaltoside (Monofer) treats the anaemia that chemotherapy and cancer itself cause, and it leads phase 3 trials in that setting.","summary":"Pharmacosmos A/S, founded in 1965 and based in Holbæk, Denmark, develops carbohydrate chemistry and intravenous iron products. Its iron isomaltoside 1000 (Monofer, ferric derisomaltose in the United States) is given as a single high-dose infusion for iron deficiency anaemia, including in patients with cancer, and the company has run phase 3 trials in cancer-related anaemia registered on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.pharmacosmos.com"},{"label":"ClinicalTrials.gov: trials led by Pharmacosmos A/S","url":"https://clinicaltrials.gov/search?lead=Pharmacosmos%20A%2FS"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q7180808"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct07473128"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Holbæk","country":"DK","companyType":"pharma","website":"http://www.pharmacosmos.com","founded":1965,"stage":"private-large","investors":[],"funding":[]},{"id":"pharmaessentia","kind":"company","name":"PharmaEssentia","aka":["PharmaEssentia Corporation","藥華醫藥"],"tldr":"PharmaEssentia is a Taiwanese biotechnology company whose long-acting interferon ropeginterferon alfa-2b (Besremi) is approved for polycythaemia vera, a chronic blood cancer, in the United States, Europe and Asia.","summary":"PharmaEssentia, based in Taipei and listed on the Taipei Exchange, developed ropeginterferon alfa-2b, a mono-pegylated interferon given every two weeks, as a disease-modifying treatment for polycythaemia vera and other myeloproliferative neoplasms. Marketed as Besremi, it was approved in the European Union in 2019 through its partner AOP Health and by the FDA in November 2021, the first interferon approved for the condition in the United States, and is in phase 3 trials for essential thrombocythaemia. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.pharmaessentia.com"},{"label":"ClinicalTrials.gov: trials led by PharmaEssentia","url":"https://clinicaltrials.gov/search?lead=PharmaEssentia"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/PharmaEssentia"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["ropeginterferon-alfa-2b"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct06468033","nct05481151","nct05485948","nct05482971","nct04285086"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Taipei","country":"TW","companyType":"biotech","website":"https://www.pharmaessentia.com","stage":"public","investors":[],"funding":[]},{"id":"pharmamar","kind":"company","name":"PharmaMar","aka":[],"tldr":"Spanish company that turns marine natural products into cancer drugs, including lurbinectedin and trabectedin.","summary":"PharmaMar, based in Madrid and listed as PHM.MC, is the Spanish company that turns marine natural products into cancer drugs, including lurbinectedin and trabectedin. It discovered lurbinectedin, sold as Zepzelca and partnered with Jazz in the United States, and trabectedin, sold as Yondelis, and the success of the IMforte trial in 2025 broadened lurbinectedin from relapsed small-cell lung cancer into first-line maintenance. OnCo links it to small-cell lung cancer, Ewing sarcoma and soft tissue sarcomas, and to the lurbinectedin drug record. Whether marine-derived transcription inhibitors can find further indications, or whether lurbinectedin remains its last major product, is the open question. Lurbinectedin has its own page.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://pharmamar.com"}],"tags":[],"related":[],"cancers":["sclc","sarcoma"],"sections":["chemotherapy"],"technologies":[],"targets":[],"drugs":["lurbinectedin","plitidepsin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07644039","nct06088290"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Madrid","country":"ES","companyType":"biotech","website":"https://pharmamar.com","ticker":"PHM.MC","investors":[],"funding":[]},{"id":"phaxiam","kind":"company","name":"Phaxiam Therapeutics (formerly ERYtech Pharma)","aka":["ERYtech Pharma","Erytech","Phaxiam"],"tldr":"ERYtech Pharma was a Lyon company that encapsulated the enzyme asparaginase in red blood cells (eryaspase) for leukaemia and pancreatic cancer; after its phase 3 pancreatic trial failed in 2021 it merged into Phaxiam, which now works on bacteriophage therapy.","summary":"ERYtech Pharma, based in Lyon and listed on Euronext and Nasdaq, developed eryaspase (Graspa), L-asparaginase loaded inside donor red blood cells to prolong its action and reduce hypersensitivity, for acute lymphoblastic leukaemia and metastatic pancreatic cancer. The phase 3 TRYbeCA-1 trial in second-line pancreatic cancer missed its survival endpoint in 2021, and in 2023 the company merged with Pherecydes Pharma to form Phaxiam Therapeutics, which develops phage therapy for antibiotic-resistant infections. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.phaxiam.com"},{"label":"ClinicalTrials.gov: trials led by ERYtech Pharma","url":"https://clinicaltrials.gov/search?lead=ERYtech%20Pharma"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Erytech_Pharma"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["pancreatic","all-leukemia"],"sections":["chemotherapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Lyon","country":"FR","companyType":"biotech","website":"https://www.phaxiam.com","stage":"public","investors":[],"funding":[]},{"id":"pheon-therapeutics","kind":"company","name":"Pheon Therapeutics","aka":[],"tldr":"Pheon Therapeutics, of London, designs antibody-drug conjugates against an undisclosed target overexpressed across a wide range of solid tumours; its lead carries eight topoisomerase 1 inhibitor molecules per antibody and showed a wide therapeutic index preclinically. It raised a 120 million dollar Series B in 2024 and has entered early human trials.","summary":"Pheon Therapeutics is a London-based antibody-drug conjugate specialist building a pipeline of ADCs against undisclosed new targets and clinically validated ones, using either its proprietary payload platform, which acts through a mechanism distinct from established payloads, or established linker-payloads. Its first three assets address an undisclosed novel target that is highly overexpressed across a wide range of solid tumours; the lead uses a DAR8 topoisomerase 1 inhibitor linker-payload and the company reported an unusually wide preclinical therapeutic index, with a first phase 1 trial planned from 2024. By September 2025 the company described itself as clinical-stage. In May 2024 Pheon closed a USD 120 million Series B led by TCGX with BVF Partners, Lightspeed and Perceptive Advisors alongside existing investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://pheontx.com/"},{"label":"Series B press release","url":"https://pheontx.com/pheon-therapeutics-announces-120m-series-b-financing-to-fund-development-of-its-differentiated-adc-pipeline/"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":["adc","topoisomerase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Lead target undisclosed. Series A (2022) not fetched and omitted."],"hq":"London","country":"GB","companyType":"biotech","website":"https://pheontx.com/","stage":"startup","investors":["tcgx","lightspeed-venture-partners","perceptive-advisors","atlas-venture","forbion"],"funding":[{"round":"Series B","year":2024,"amountUsd":120000000,"source":"https://pheontx.com/pheon-therapeutics-announces-120m-series-b-financing-to-fund-development-of-its-differentiated-adc-pipeline/"}]},{"id":"philips","kind":"company","name":"Philips","aka":[],"tldr":"Imaging and health-informatics company: MRI, CT, and the IntelliSite digital pathology system that won the first FDA clearance for primary diagnosis.","summary":"Philips, based in Amsterdam and listed as PHIA.AS, is an imaging and health informatics company making MRI, CT and the IntelliSite digital pathology system, which won the first FDA clearance for primary diagnosis from digital slides. IntelliSite Pathology Solution was cleared in 2017, Philips is the MR-linac partner to Elekta, and its portfolio includes spectral CT and radiology informatics. OnCo links it to whole-slide scanners and image management, MRI and CT. Whether the company that opened the regulatory door to digital pathology remains a leader in it, as specialist software vendors grow, is the open question. The whole-slide scanner page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.philips.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["imaging","diagnostics"],"technologies":["whole-slide-scanners","mri","ct"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Amsterdam","country":"NL","companyType":"imaging","website":"https://www.philips.com","ticker":"PHIA.AS","investors":[],"funding":[]},{"id":"philogen-s-p-a","kind":"company","name":"Philogen S.p.A.","aka":[],"tldr":"Philogen S.p.A. is a Italy-based biotechnology company running 8 late-stage cancer trials of Onfekafusp alfa and onfekafusp alfa in melanoma, glioma & glioblastoma and basal cell carcinoma.","summary":"Philogen S.p.A., based in Siena, Italy, is a biotechnology company listed as BIT:PHIL. Philogen is a biotechnology company developing targeted cancer therapeutics based on antibodies and small molecules directed at the tumour microenvironment. On ClinicalTrials.gov it is the lead sponsor of 8 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing Onfekafusp alfa and onfekafusp alfa in melanoma, glioma & glioblastoma, basal cell carcinoma and sarcomas. The largest, NCT04443010 (Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma), plans to enrol 226 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.philogen.com"},{"label":"ClinicalTrials.gov: trials led by Philogen S.p.A.","url":"https://clinicaltrials.gov/search?lead=Philogen%20S.p.A."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma","glioblastoma","basal-cell-carcinoma","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06284590","nct04733183","nct07227870","nct02938299","nct07227350","nct03567889","nct04443010","nct06336291"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Siena","country":"IT","companyType":"biotech","website":"https://www.philogen.com","ticker":"BIT:PHIL","founded":1996,"stage":"public","investors":[],"funding":[]},{"id":"photocure","kind":"company","name":"Photocure","aka":["Photocure ASA"],"tldr":"Photocure is a Norwegian company whose blue-light cystoscopy agent hexaminolevulinate (Hexvix in Europe, Cysview in the United States) makes bladder tumours fluoresce so surgeons find and remove more of them.","summary":"Photocure ASA, based in Oslo and listed on the Oslo stock exchange, markets hexaminolevulinate hydrochloride, an optical imaging agent instilled into the bladder before cystoscopy. Under blue light the agent makes non-muscle-invasive bladder cancer fluoresce, improving detection of papillary tumours and carcinoma in situ compared with white light alone; it is sold as Hexvix in Europe and Cysview in the United States. OnCo records it as a registry sponsor of phase 3 cancer trials.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.photocure.com"},{"label":"ClinicalTrials.gov: trials led by Photocure","url":"https://clinicaltrials.gov/search?lead=Photocure"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Photocure"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["urothelial"],"sections":["diagnostics","surgery"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Oslo","country":"NO","companyType":"diagnostics","website":"https://www.photocure.com","stage":"public","investors":[],"funding":[]},{"id":"photonamic","kind":"company","name":"photonamic","aka":["photonamic GmbH & Co. KG","Photonamic"],"tldr":"photonamic is the small German company behind Gliolan (Gleolan), the drink of 5-aminolevulinic acid that makes glioma tissue glow pink under a surgical microscope so neurosurgeons can remove more of the tumour.","summary":"photonamic GmbH & Co. KG, founded in 2002 in Wedel near Hamburg, developed oral 5-aminolevulinic acid (Gliolan in Europe, Gleolan in the United States) for fluorescence-guided resection of high-grade glioma. Malignant glioma cells convert the drug into fluorescent protoporphyrin IX, and the randomised trial that led to European approval in 2007 showed more complete resections and longer progression-free survival; FDA approval followed in 2017 through its partner NX Development Corp. It leads phase 3 trials extending the approach, registered on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.photonamic.de"},{"label":"ClinicalTrials.gov: trials led by photonamic GmbH & Co. KG","url":"https://clinicaltrials.gov/search?lead=photonamic%20GmbH%20%26%20Co.%20KG"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30269273"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["fluorescence-guided-surgery"],"targets":[],"drugs":["aminolevulinic-acid","aminolevulinic-acid-gleolan"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Wedel","country":"DE","companyType":"pharma","website":"http://www.photonamic.de","founded":2002,"stage":"private-large","investors":[],"funding":[]},{"id":"photys-therapeutics","kind":"company","name":"Photys Therapeutics","aka":[],"tldr":"Photys Therapeutics builds two-headed molecules that bring a target protein next to an enzyme that modifies or destroys it. Its first clinical drug is for autoimmune disease; its cancer work, aimed at a mutant form of the p53 protein, is still in the laboratory.","summary":"Photys Therapeutics is a Boston proximity-based therapeutics company with three heterobifunctional platforms: PROTAC degraders, PHICS (phosphorylation-inducing chimeric small molecules that recruit kinases to a target) and tPRIME (targeted proximity-induced modulators of expression). Its lead clinical programme, PHT-776/HPB-143, an oral IRAK4 PROTAC degrader licensed from Polymed in February 2025, entered phase 1 in August 2026 for autoimmune and inflammatory diseases. The oncology programme is preclinical: tPRIME bifunctionals directed at p53 Y220C, with data on p53-Y220C-BET bifunctionals driving cancer cell death presented in February 2025. A PHICS collaboration with Novo Nordisk (December 2024) covers cardiometabolic targets. Photys launched in September 2022 with a 75 million US dollar Series A led by MPM Capital, joined by Omega Funds, Longwood, 8VC, Eli Lilly and others.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.photys.com/"},{"label":"Series A press release","url":"https://www.photys.com/sep-08-2022-75million-series-a-funding-for-precision-phosphorylation"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy","drug-discovery"],"technologies":["protac-degrader"],"targets":["tp53"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Oncology is a preclinical part of a mostly immunology and cardiometabolic pipeline. No SEC Form D filings were found under the company name. Founding year not sourced."],"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://www.photys.com/","stage":"startup","investors":["mpm-bioimpact","omega-funds","longwood-fund"],"funding":[{"round":"Series A","year":2022,"amountUsd":75000000,"source":"https://www.photys.com/sep-08-2022-75million-series-a-funding-for-precision-phosphorylation","note":"Led by MPM Capital; company founded by Longwood Fund and Amit Choudhary of Brigham and Women's Hospital and the Broad Institute"}]},{"id":"picnic-health","kind":"company","name":"Picnic Health","aka":[],"tldr":"Picnic Health gathers a patient's complete medical records into one place and uses them to match the patient to clinical trials and research.","summary":"Picnic Health collects and structures a patient's medical records from every provider and uses the assembled record to identify relevant clinical trials and research studies, listed by Future of Cancer Care Today as a patient-accessible trial finder.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://picnichealth.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["ai-trial-matching"],"targets":[],"drugs":[],"companies":["future-of-cancer-care-today"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"United States (city not published)","country":"US","companyType":"ai-software","website":"https://picnichealth.com/","stage":"growth","investors":[],"funding":[]},{"id":"pieris-pharmaceuticals","kind":"company","name":"Pieris Pharmaceuticals","aka":["Pieris AG","NASDAQ:PIRS"],"tldr":"Pieris Pharmaceuticals engineered small lipocalin proteins called Anticalins into cancer immunotherapies, including the HER2-targeted 4-1BB agonist cinrebafusp alfa, before merging into Palvella Therapeutics in 2024.","summary":"Pieris Pharmaceuticals, founded in Freising, Germany and later headquartered in Boston, developed Anticalin proteins, engineered derivatives of human lipocalins, as an alternative to antibodies. Its oncology lead, cinrebafusp alfa (PRS-343), fused a HER2 antibody to a 4-1BB-binding Anticalin so that T-cell costimulation happened only in HER2-positive tumours; a phase 2 study in HER2-positive gastric cancer was halted in 2023 for strategic reasons. The company completed a reverse merger with Palvella Therapeutics in December 2024.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["cinrebafusp-alfa"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Boston, Massachusetts","country":"US","companyType":"biotech","founded":2001,"stage":"acquired","investors":[],"funding":[]},{"id":"pierre-fabre","kind":"company","name":"Pierre Fabre","aka":[],"tldr":"Pierre Fabre is a French pharmaceutical and dermo-cosmetics group whose oncology franchise includes vinorelbine (Navelbine), vinflunine (Javlor) and the BRAF/MEK pair encorafenib and binimetinib in Europe.","summary":"Pierre Fabre, based in Castres, is a French pharmaceutical and dermo-cosmetics group whose oncology franchise includes vinorelbine, sold as Navelbine, vinflunine, sold as Javlor, and the BRAF and MEK pair encorafenib and binimetinib in Europe. It originated the vinca alkaloids vinorelbine and vinflunine, markets Braftovi and Mektovi in Europe under licence from Array and Pfizer, and sells busulfan as Busilvex and other haematology products. OnCo links it to the vinflunine drug record. Whether a mid-sized European company can keep a targeted therapy franchise built on in-licensed products as their originators change hands is the open question. Vinflunine has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.pierre-fabre.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["braf","mek"],"drugs":["vinorelbine","vinflunine","encorafenib","binimetinib","busulfan","propranolol-hemangeol","tabelecleucel"],"companies":["pfizer"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06043817","nct06567015","nct06669117","nct04554914","nct05270044","nct05195632"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Castres","country":"FR","companyType":"pharma","website":"https://www.pierre-fabre.com","investors":[],"funding":[]},{"id":"pinnacle-biologics","kind":"company","name":"Pinnacle Biologics","aka":["Pinnacle Biologics, Inc."],"tldr":"Pinnacle Biologics is the Illinois company that markets Photofrin, the porfimer sodium photosensitiser used in photodynamic therapy for oesophageal cancer, Barrett's oesophagus and lung cancer.","summary":"Pinnacle Biologics, a specialty pharmaceutical company in the Chicago area, holds the rights to Photofrin (porfimer sodium), the first photosensitiser approved for photodynamic therapy. Porfimer is injected and, after 40 to 50 hours, activated with 630-nanometre laser light to destroy tumour tissue. Photofrin is approved for obstructing oesophageal cancer, obstructing endobronchial non-small cell lung cancer and high-grade dysplasia in Barrett's oesophagus, and has been studied in cholangiocarcinoma and mesothelioma.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["porfimer-sodium"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Bannockburn, Illinois","country":"US","companyType":"pharma","investors":[],"funding":[]},{"id":"piramal-pharma-solutions","kind":"company","name":"Piramal Pharma Solutions","aka":[],"tldr":"Piramal Pharma Solutions, a Mumbai contract manufacturer, links cytotoxic payloads to antibodies at Grangemouth in Scotland, one of the few ADC conjugation sites in the West, and runs contained sites in the United States and India for drug substances too toxic to handle openly. Whether it can capture the ADC demand leaving China is its open question.","summary":"Piramal Pharma Solutions, based in Mumbai, is a CDMO with antibody-drug conjugate conjugation at Grangemouth in Scotland and contained manufacturing sites for cytotoxic drug substances in the United States and India. Grangemouth is one of the few Western-located ADC bioconjugation sites, and its capacity was expanded between 2023 and 2025. OnCo links it to ADC bioconjugation manufacturing and payload-linker synthesis. Whether a mid-sized CDMO can capture the ADC demand that political pressure is pushing out of China is the open question for its Scottish site. The ADC manufacturing page carries the wider field.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.piramalpharmasolutions.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["adcs"],"technologies":["adc-cdmo-manufacturing","high-potency-payload-synthesis"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Mumbai","country":"IN","companyType":"cro-services","website":"https://www.piramalpharmasolutions.com","investors":[],"funding":[]},{"id":"plexium","kind":"company","name":"Plexium","aka":[],"tldr":"Plexium makes single-piece pills that make cancer cells destroy specific proteins. Its lead drug removes a protein called SMARCA2 in tumours that have lost its partner SMARCA4, and is in an early human trial.","summary":"Plexium is a San Diego clinical-stage targeted protein degradation company that rationally designs monovalent direct degraders and molecular glues using its DELTA Discovery platform. PLX-61639 is an oral SMARCA2-selective direct degrader using a tissue-restricted E3 ligase, in a phase 1 trial in SMARCA4-mutant advanced solid tumours, exploiting SMARCA2/SMARCA4 synthetic lethality. PLX-4545 is an oral cereblon-based IKZF2 molecular glue degrader intended to convert regulatory T cells into effector-like cells and improve checkpoint inhibitor responses; it has completed a healthy-volunteer study. PLX-66140 is a preclinical CDK2 glue degrader for ER-positive/HER2-negative breast cancer and CCNE1-amplified tumours. Investors shown on the company site include The Column Group, TCG X, SoftBank, DCVC Bio, BVF Partners and Lux Capital; a Form D filed in August 2025 reports 60.1 million US dollars sold.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://plexium.com/"},{"label":"Pipeline","url":"https://plexium.com/pipeline/"},{"label":"Clinical trials","url":"https://plexium.com/clinical-trials/"},{"label":"Form D (August 2025)","url":"https://www.sec.gov/Archives/edgar/data/2082715/000208271525000001/primary_doc.xml"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":["targeted-therapy"],"technologies":["protac-degrader","synthetic-lethality-approaches"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not sourced."],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://plexium.com/","stage":"growth","investors":[],"funding":[{"round":"Form D offering","year":2025,"amountUsd":60115703,"source":"https://www.sec.gov/Archives/edgar/data/2082715/000208271525000001/primary_doc.xml","note":"Total sold per Form D filed August 2025; first sale July 2025"}]},{"id":"point-biopharma","kind":"company","name":"POINT Biopharma","aka":[],"tldr":"POINT Biopharma developed radioactive medicines that home in on prostate cancer and neuroendocrine tumours, and built a large manufacturing campus in Indianapolis. Eli Lilly bought the company at the end of 2023.","summary":"POINT Biopharma Global Inc. (formerly Nasdaq: PNT) was an Indianapolis radiopharmaceutical company with late-stage radioligand therapies: PNT2002, a PSMA-targeted therapy for metastatic castration-resistant prostate cancer after progression on hormonal treatment, and PNT2003, a somatostatin receptor (SSTR)-targeted therapy for gastroenteropancreatic neuroendocrine tumours, both partnered with Lantheus outside certain Asian territories, plus earlier clinical and preclinical programmes. It operated a 180,000 square foot radiopharmaceutical manufacturing campus in Indianapolis and an R&D centre in Toronto. On 2 October 2023 Eli Lilly agreed to acquire POINT through a cash tender offer of USD 12.50 per share, and the merger was completed in late December 2023; the company website now redirects to lilly.com.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.lilly.com/"},{"label":"Form 8-K: merger agreement with Eli Lilly","url":"https://www.sec.gov/Archives/edgar/data/1811764/000110465923106146/tm2327397d1_8k.htm"},{"label":"Lilly press release (8-K exhibit 99.4)","url":"https://www.sec.gov/Archives/edgar/data/1811764/000110465923106146/tm2327397d1_ex99-4.htm"},{"label":"Form 8-K: completion of merger","url":"https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/d594310d8k.htm"}],"tags":[],"related":[],"cancers":["prostate","neuroendocrine"],"sections":["radiopharma"],"technologies":["radioligand-therapy"],"targets":["psma","sstr2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["pointbiopharma.com redirects to lilly.com, recorded as the website. Deal value and pipeline details come from the Lilly press release filed as exhibit 99.4 to POINT's 8-K of 3 October 2023."],"hq":"Indianapolis, IN","country":"US","companyType":"radiopharma","website":"https://www.lilly.com/","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2023,"amountUsd":1400000000,"source":"https://www.sec.gov/Archives/edgar/data/1811764/000110465923106146/tm2327397d1_ex99-4.htm","note":"Cash tender offer at USD 12.50 per share, an aggregate of approximately USD 1.4 billion, under a merger agreement dated 2 October 2023; completion reported in an 8-K filed 27 December 2023"}],"acquiredBy":"eli-lilly"},{"id":"polaris-group","kind":"company","name":"Polaris Group","aka":["Polaris Pharmaceuticals","Polaris Pharmaceuticals, Inc."],"tldr":"Polaris Group develops pegargiminase (ADI-PEG 20), an enzyme that starves tumours lacking argininosuccinate synthetase of arginine, which improved survival in pleural mesothelioma in the phase 3 ATOMIC-Meso trial.","summary":"Polaris Group, based in San Diego with roots in Taiwan, develops ADI-PEG 20 (pegargiminase), a pegylated arginine deiminase that removes arginine from the blood. Tumours that have lost the enzyme argininosuccinate synthetase 1 (ASS1) cannot make their own arginine and are selectively starved; the approach was tested in liver cancer, melanoma and sarcoma before the phase 3 ATOMIC-Meso trial in non-epithelioid pleural mesothelioma reported longer survival with pegargiminase added to chemotherapy. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.polarispharma.com"},{"label":"ClinicalTrials.gov: trials led by Polaris Group","url":"https://clinicaltrials.gov/search?lead=Polaris%20Group"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["mesothelioma","hcc"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["adi-peg20"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04587830"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://www.polarispharma.com","stage":"private-large","investors":[],"funding":[]},{"id":"polaris-partners","kind":"company","name":"Polaris Partners","aka":[],"tldr":"A Boston venture firm with a long record of co-founding biotech companies with academic scientists such as Bob Langer. Its cancer companies include Syros Pharmaceuticals, Kronos Bio and the blood-test company Freenome.","summary":"Polaris Partners was founded in 1996 by Jon Flint, Terry McGuire and Steve Arnold and has offices in Boston, New York, San Francisco and Singapore (Wikipedia; company site). It runs main venture funds plus a Polaris Innovation Fund for company creation and a Polaris Growth Fund, and highlights that Bob Langer has co-founded more than 20 Polaris-backed companies. The firm typically leads seed and Series A rounds in therapeutics companies it helps form. Its full companies list, checked in Q2 2026, includes oncology names such as Syros Pharmaceuticals, Kronos Bio, Kojin Therapeutics, IconOVir Bio (oncolytic viruses), Genocea and Freenome (blood-based cancer screening), as well as Candid Therapeutics and Scholar Rock.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://polarispartners.com/"},{"label":"Companies list","url":"https://polarispartners.com/companies-list/"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Polaris_Partners"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["freenome"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boston, MA","country":"US","companyType":"investor","website":"https://polarispartners.com/","founded":1996,"investors":[],"funding":[]},{"id":"poseida-therapeutics","kind":"company","name":"Poseida Therapeutics","aka":[],"tldr":"Poseida developed off-the-shelf CAR T-cell therapies made from healthy donor cells rather than from each patient, for multiple myeloma and B-cell cancers. Roche bought the company in early 2025 for up to about $1.5 billion.","summary":"Poseida Therapeutics was a clinical-stage company pioneering donor-derived (allogeneic) CAR T-cell therapies, with non-viral piggyBac gene engineering and manufacturing capabilities. Lead programme P-BCMA-ALLO1 is an allogeneic BCMA-directed CAR T for relapsed or refractory multiple myeloma with RMAT and Orphan Drug designations. P-CD19CD20-ALLO1 is a phase 1 allogeneic dual CAR T in B-cell malignancies, also being investigated in multiple sclerosis and lupus, and P-MUC1C-ALLO1 is a phase 1 allogeneic CAR T in solid tumours. Several programmes were already partnered with Roche under a 2022 collaboration. Roche agreed in November 2024 to acquire Poseida for $9.00 per share in cash plus a contingent value right worth up to $4.00 per share, a total of up to about $1.5 billion, and the merger closed on 8 January 2025. Legacy programmes continue within Genentech and the former Nasdaq ticker PSTX was retired.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.gene.com/poseida"},{"label":"Roche to acquire Poseida (November 2024)","url":"https://www.roche.com/media/releases/med-cor-2024-11-26b"},{"label":"Completion of merger (8-K, January 2025)","url":"https://www.sec.gov/Archives/edgar/data/1661460/000119312525003248/d874651d8k.htm"}],"tags":[],"related":[],"cancers":["multiple-myeloma","dlbcl"],"sections":["cell-therapy"],"technologies":["allogeneic-cell-therapy","car-t"],"targets":["bcma","cd19","cd20"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Former Nasdaq ticker PSTX. The CVR portion of the deal value is contingent on milestones."],"hq":"San Diego, CA","country":"US","companyType":"cell-therapy","website":"https://www.gene.com/poseida","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2025,"amountUsd":1500000000,"source":"https://www.roche.com/media/releases/med-cor-2024-11-26b","note":"$9.00 per share in cash (about $1.0 billion equity value) plus a contingent value right of up to $4.00 per share, total deal value up to about $1.5 billion; announced 26 November 2024, completed 8 January 2025"}],"acquiredBy":"roche-genentech"},{"id":"precigen","kind":"company","name":"Precigen","aka":["Intrexon"],"tldr":"Precigen is a US-based biotechnology company that leads 2 cancer trials in OnCo, testing the adenoviral immunotherapies PRGN-2012 (Papzimeos) and PRGN-2009 in rare cancers of childhood and cervical cancer.","summary":"Precigen is a commercial-stage biopharmaceutical company developing precision medicines for difficult-to-treat diseases. Its first approved product, Papzimeos (zopapogene imadenovec, formerly PRGN-2012), is an adenoviral immunotherapy for recurrent respiratory papillomatosis; PRGN-2009 for HPV-associated cancers and the UltraCAR-T programmes are in phase 1. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT04724980 (phase 1/2, Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis) and NCT06157151 (phase 2, PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Ce...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://precigen.com"},{"label":"ClinicalTrials.gov: trials led by Precigen","url":"https://clinicaltrials.gov/search?lead=Precigen%2C%20Inc"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["rare-childhood-cancers","cervical"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04724980","nct06157151"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Germantown, Maryland","country":"US","companyType":"biotech","website":"https://precigen.com","ticker":"NASDAQ:PGEN","stage":"public","investors":[],"funding":[]},{"id":"precirix","kind":"company","name":"Precirix","aka":[],"tldr":"Precirix, of Brussels, develops radiopharmaceuticals built on small single-domain antibody fragments that carry a radioactive isotope to HER2-positive cancers. Its lead, CAM-H2, is in a phase 1/2 trial in HER2-positive breast, gastric and gastro-oesophageal cancer, including patients with brain metastases, with an imaging dose given first to confirm HER2 in the lesions.","summary":"Precirix is a clinical-stage Brussels biotechnology company developing precision radiopharmaceuticals in oncology based on single-domain antibody (sdAb) targeting. Its lead candidate CAM-H2 is a HER2-directed radiopharmaceutical in a phase 1/2 trial, initially in Canada, evaluating safety, tolerability and efficacy in HER2-positive metastatic breast, gastric and gastro-oesophageal cancer, including patients with brain metastases. Patients first receive an imaging dose to confirm HER2 expression in lesions before therapeutic dosing. In June 2023 Precirix announced production of a first clinical trial batch of CAM-H2 at Evergreen Theragnostics in New Jersey to support expansion of the trial to the United States.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.evergreentgn.com/2023/06/08/cam-h2-production-at-evergreen-marks-the-expansion-of-precirix-clinical-trial-to-the-us/"}],"tags":[],"related":[],"cancers":["breast-her2-positive","gastric"],"sections":["radiopharma"],"technologies":["radioligand-therapy"],"targets":["her2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Financing (a EUR 80 million Series B reported by Fierce Biotech, whose page returned HTTP 403) is omitted as unsourced. Current operating status is uncertain given the offline website."],"hq":"Brussels","country":"BE","companyType":"radiopharma","website":"https://www.evergreentgn.com/2023/06/08/cam-h2-production-at-evergreen-marks-the-expansion-of-precirix-clinical-trial-to-the-us/","stage":"startup","investors":[],"funding":[]},{"id":"preglem","kind":"company","name":"PregLem","aka":["PregLem SA","PregLem S.A."],"tldr":"PregLem is a Geneva biotech, part of Gedeon Richter, whose ulipristal acetate (Esmya) for uterine fibroids went through phase 3 trials it led; it is listed among industry sponsors of cancer-tagged trials.","summary":"PregLem SA, founded in Geneva in 2006 and later acquired by the Hungarian group Gedeon Richter, developed ulipristal acetate (Esmya) for the treatment of uterine fibroids, a benign gynaecological tumour. Its phase 3 programme is registered on ClinicalTrials.gov, where the trials fall under the cancer and neoplasm categories that OnCo's sponsor list draws on.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://preglem.com"},{"label":"ClinicalTrials.gov: trials led by PregLem SA","url":"https://clinicaltrials.gov/search?lead=PregLem%20SA"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30269207"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Geneva","country":"CH","companyType":"biotech","website":"http://preglem.com","founded":2006,"stage":"acquired","investors":[],"funding":[]},{"id":"prelude-therapeutics","kind":"company","name":"Prelude Therapeutics","aka":[],"tldr":"Prelude Therapeutics develops precision cancer medicines. Its current focus is a pill for blood cancers driven by a JAK2 mutation and drugs that destroy a protein called KAT6A in hormone-driven breast cancer.","summary":"Prelude Therapeutics is a Wilmington, Delaware clinical-stage precision oncology company. Its pipeline page lists PR-01, a JAK2 V617F mutant-selective JH2 inhibitor in a phase 1 trial enrolling patients with V617F-positive myeloproliferative neoplasms (myelofibrosis, polycythaemia vera, essential thrombocythaemia); highly selective KAT6A degraders for ER-positive breast cancer, with phase 1 initiation anticipated in the fourth quarter of 2026; a mutant CALR-directed degrader antibody conjugate (DAC) for CALR-mutated MPNs; and degrader payloads for DACs offered for partnership. Earlier PRMT5 (PRT543, PRT811) and MCL1 programmes have been deprioritised. Prelude completed its Nasdaq IPO in September 2020, raising about 181.9 million US dollars gross.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://preludetx.com/"},{"label":"Pipeline","url":"https://preludetx.com/science/pipeline/"},{"label":"Q3 2020 results noting IPO (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1678660/000156459020052741/prld-ex991_6.htm"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":["targeted-therapy","epigenetics"],"technologies":["kinase-inhibitors","protac-degrader","degrader-antibody-conjugate","epigenetic-drugs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Myeloproliferative neoplasms have no id in the cancer list. Founding year not sourced. The statement that earlier PRMT5 and MCL1 programmes were deprioritised is inferred from their absence on the current pipeline page."],"hq":"Wilmington, DE","country":"US","companyType":"biotech","website":"https://preludetx.com/","ticker":"PRLD","stage":"public","investors":[],"funding":[{"round":"IPO","year":2020,"amountUsd":181900000,"source":"https://www.sec.gov/Archives/edgar/data/1678660/000156459020052741/prld-ex991_6.htm","note":"Gross proceeds of about 181.9 million US dollars, September 2020"}]},{"id":"prestige-biopharma","kind":"company","name":"Prestige Biopharma","aka":["Prestige BioPharma Limited","KRX:950210"],"tldr":"Prestige Biopharma is a Singapore-based antibody company, listed in Korea, that makes biosimilars and is developing PBP1510, a first-in-class antibody against the pancreatic cancer protein PAUF.","summary":"Prestige Biopharma develops biosimilars, including trastuzumab (Tuznue) and bevacizumab candidates, and novel antibodies. PBP1510 (ulenistamab) neutralises pancreatic adenocarcinoma up-regulated factor (PAUF), a secreted protein that drives tumour growth and immune evasion; it has orphan designations in the United States and Europe and is in a phase 1/2a trial with gemcitabine in advanced pancreatic cancer. The company also develops PBP1710 against CTHRC1.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.prestigebiopharma.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["pbp1510"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Singapore","country":"SG","companyType":"biotech","website":"https://www.prestigebiopharma.com/","ticker":"KRX:950210","stage":"public","investors":[],"funding":[]},{"id":"primmune-therapeutics","kind":"company","name":"Primmune Therapeutics","aka":["Primmune Therapeutics, Inc."],"tldr":"Primmune Therapeutics is a San Diego biotech whose oral TLR7 agonist PRTX007 activates the innate immune system in short daily pulses to fight solid tumours and viral infections.","summary":"Primmune Therapeutics develops orally available small-molecule agonists of Toll-like receptor 7 designed to give brief, controlled pulses of interferon and innate immune activation rather than the sustained cytokine release that limits injected agonists. PRTX007 has been studied in healthy volunteers and in patients with advanced solid tumours, and a related programme has been tested in viral disease.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["prtx007"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"San Diego, California","country":"US","companyType":"biotech","investors":[],"funding":[]},{"id":"private-health-management","kind":"company","name":"Private Health Management","aka":[],"tldr":"Private Health Management provides high-touch guidance for people with serious illness: specialist access, second opinions and care coordination.","summary":"Private Health Management offers personalised health guidance including access to specialists, second opinions and coordination of care across providers, listed by Future of Cancer Care Today as patient-accessible navigation.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://privatehealth.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["multidisciplinary-tumour-board"],"targets":[],"drugs":[],"companies":["future-of-cancer-care-today"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"United States (city not published)","country":"US","companyType":"cro-services","website":"https://privatehealth.com/","investors":[],"funding":[]},{"id":"private-medical","kind":"company","name":"Private Medical","aka":[],"tldr":"Private Medical is a concierge medical practice with offices in San Francisco, Menlo Park, New York and Miami Beach that takes on complex cancer cases with attention to overlooked clinical angles.","summary":"Private Medical provides concierge healthcare with round-the-clock physician access and, according to Future of Cancer Care Today, takes complex cancer cases with attention to overlooked clinical angles; it has offices in San Francisco, Menlo Park, New York and Miami Beach. Patient-bookable.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://privatemedical.org/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["multidisciplinary-tumour-board"],"targets":[],"drugs":[],"companies":["future-of-cancer-care-today"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Francisco, CA","country":"US","companyType":"cro-services","website":"https://privatemedical.org/","investors":[],"funding":[]},{"id":"profluent-bio","kind":"company","name":"Profluent","aka":[],"tldr":"Profluent uses protein language models to design new gene editors (OpenCRISPR-1) and antibodies.","summary":"Profluent, based in Berkeley, uses protein language models to design new gene editors and antibodies. Its OpenCRISPR-1, released in 2024, was the first AI-generated gene editor released openly, and the ProGen family of models underpins its designs. OnCo links it to de novo designed protein binders. Whether AI-designed editors and binders offer advantages in specificity or manufacturability that justify their novelty is the open question for cancer applications. The de novo protein binder page carries the wider field.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.profluent.bio"}],"tags":["ai","protein-design"],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":["de-novo-protein-design","ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Berkeley, CA","country":"US","companyType":"ai-software","website":"https://www.profluent.bio","investors":[],"funding":[]},{"id":"profound-medical","kind":"company","name":"Profound Medical","aka":[],"tldr":"Profound Medical makes TULSA-PRO, which ablates prostate tissue from inside the urethra with ultrasound under real-time MRI temperature control, and Sonalleve MR-guided focused ultrasound for fibroids and painful bone metastases.","summary":"Founded in Toronto in 2008, Profound Medical developed transurethral ultrasound ablation, in which a rotating ultrasound applicator inside the urethra heats prostate tissue while MRI thermometry closes the loop, cleared in the United States in 2019 for prostate tissue ablation and studied in the TACT trial for localised prostate cancer. It acquired the Sonalleve MR-HIFU platform from Philips in 2017 for uterine fibroids and palliation of bone metastasis pain. OnCo links it to focused ultrasound and MRI.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://profoundmedical.com"}],"tags":["machines-wave"],"related":[],"cancers":["prostate","metastatic-cancer"],"sections":["surgery","devices"],"technologies":["hifu-histotripsy","mri"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Mississauga, ON","country":"CA","companyType":"devices","website":"https://profoundmedical.com","ticker":"PROF","founded":2008,"stage":"public","investors":[],"funding":[]},{"id":"profoundbio","kind":"company","name":"ProfoundBio","aka":[],"tldr":"ProfoundBio developed antibodies that deliver a chemotherapy drug to ovarian cancer cells carrying a protein called folate receptor alpha. Genmab bought the company for 1.8 billion dollars in 2024.","summary":"ProfoundBio was a privately owned, clinical-stage Seattle biotech developing next-generation antibody-drug conjugates and ADC linker-payload technology. Its lead asset rinatabart sesutecan (Rina-S) is a folate receptor alpha (FRα)-targeted topoisomerase 1 inhibitor ADC designed to treat a broader FRα-expressing population than first-generation FRα ADCs; at acquisition it was in the phase 2 portion of a phase 1/2 trial in ovarian cancer and other FRα-expressing solid tumours, and had received FDA Fast Track designation in January 2024 for FRα-expressing platinum-resistant ovarian cancer. Genmab agreed in April 2024 to acquire ProfoundBio for USD 1.8 billion in cash, gaining three clinical-stage candidates and the ADC platforms; the deal closed in May 2024 and the ProfoundBio domain now redirects to genmab.com.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.genmab.com/"},{"label":"Genmab acquisition announcement (Nasdaq copy)","url":"https://www.nasdaq.com/press-release/genmab-to-broaden-and-strengthen-oncology-portfolio-with-acquisition-of-profoundbio"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":["adcs"],"technologies":["adc","topoisomerase-inhibitors"],"targets":["folr1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["profoundbio.com redirects to genmab.com, recorded as the website. Pre-acquisition venture rounds (reported elsewhere as a 2023 Series B) not sourced and omitted. ir.genmab.com returned HTTP 403 to my fetches."],"hq":"Seattle, WA","country":"US","companyType":"biotech","website":"https://www.genmab.com/","stage":"acquired","investors":["medicxi"],"funding":[{"round":"Acquisition","year":2024,"amountUsd":1800000000,"source":"https://www.nasdaq.com/press-release/genmab-to-broaden-and-strengthen-oncology-portfolio-with-acquisition-of-profoundbio","note":"All-cash deal announced 3 April 2024; Nasdaq copy of the Genmab company announcement"}],"acquiredBy":"genmab"},{"id":"proscia","kind":"company","name":"Proscia","aka":[],"tldr":"Proscia makes the Concentriq digital pathology platform for labs and pharma, with an AI marketplace.","summary":"Proscia, based in Philadelphia, makes the Concentriq digital pathology platform for laboratories and pharmaceutical companies, with a marketplace of AI applications. Concentriq Dx is an FDA-cleared image management system, Concentriq for research serves discovery work, and the company partners with Siemens Healthineers and multiple AI vendors. OnCo links it to whole-slide scanners and image management, digital pathology and AI, and telepathology. Whether a platform with an open AI marketplace beats vertically integrated vendors is the open question its model tests. The digital pathology page carries the wider field.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://proscia.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics","ai-computation"],"technologies":["whole-slide-scanners","digital-pathology-ai"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Philadelphia, PA","country":"US","companyType":"ai-software","website":"https://proscia.com","investors":[],"funding":[]},{"id":"protagonist-therapeutics","kind":"company","name":"Protagonist Therapeutics","aka":["Protagonist Therapeutics, Inc.","Protagonist"],"tldr":"Protagonist is a California peptide company whose hepcidin mimetic rusfertide controls the excess red cell production of polycythaemia vera without repeated phlebotomy, with positive phase 3 VERIFY results in 2025 and a partnership with Takeda.","summary":"Protagonist Therapeutics, listed on Nasdaq, designs peptide medicines. Rusfertide, an injectable mimetic of the iron hormone hepcidin, restricts iron available for red cell production and in the phase 3 VERIFY trial reduced the need for phlebotomy in polycythaemia vera, a chronic myeloproliferative blood cancer; Takeda licensed the drug in 2024. The company's other lead, the oral IL-23 receptor antagonist icotrokinra, is partnered with Johnson & Johnson in psoriasis. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.protagonist-inc.com"},{"label":"ClinicalTrials.gov: trials led by Protagonist Therapeutics","url":"https://clinicaltrials.gov/search?lead=Protagonist%20Therapeutics"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["rusfertide"],"companies":["takeda"],"institutions":[],"pathways":[],"terms":[],"trials":["verify","nct06033586"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Newark, CA","country":"US","companyType":"biotech","website":"https://www.protagonist-inc.com","stage":"public","investors":[],"funding":[]},{"id":"protara-therapeutics","kind":"company","name":"Protara Therapeutics","aka":[],"tldr":"Protara Therapeutics is a United States-based biotechnology company running 2 late-stage cancer trials of TARA-002 in bladder & urothelial cancer.","summary":"Protara Therapeutics, based in New York, the United States, is a biotechnology company. Protara is a biopharmaceutical company developing investigational therapies for oncology and rare diseases. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing TARA-002 in bladder & urothelial cancer. The largest, NCT07480356 (Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer), plans to enrol 284 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.protaratx.com/"},{"label":"ClinicalTrials.gov: trials led by Protara Therapeutics","url":"https://clinicaltrials.gov/search?lead=Protara%20Therapeutics"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["tara-002"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05951179"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"New York","country":"US","companyType":"biotech","website":"https://www.protaratx.com/","stage":"public","investors":[],"funding":[]},{"id":"protean-biodiagnostics","kind":"company","name":"Protean BioDiagnostics","aka":[],"tldr":"Protean BioDiagnostics is an Orlando laboratory offering comprehensive precision oncology testing with a consultation for the patient, physician-ordered but patient-accessible.","summary":"Protean BioDiagnostics provides comprehensive precision oncology testing on tumour tissue and blood and pairs it with a consultation so the patient understands the results. Future of Cancer Care Today lists it as patient-accessible and physician-ordered.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://proteanbiodx.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":["future-of-cancer-care-today"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Orlando, FL","country":"US","companyType":"diagnostics","website":"https://proteanbiodx.com/","investors":[],"funding":[]},{"id":"protom","kind":"company","name":"ProTom International","aka":[],"tldr":"ProTom International makes the Radiance 330, a compact synchrotron-based proton therapy system installed at Massachusetts General Hospital and McLaren in Michigan.","summary":"ProTom International's Radiance 330 uses a small synchrotron that accelerates protons to the exact energy required for each layer of the target, avoiding the degrader and much of the shielding a cyclotron needs, and feeds fixed and gantry rooms with pencil-beam scanning. Systems operate at McLaren Proton Therapy Center in Flint, Michigan, and at Massachusetts General Hospital. OnCo links it to proton therapy machines.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.protominternational.com"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":["machines-wave"],"related":[],"cancers":[],"sections":["radiation","devices"],"technologies":["proton-therapy-systems","proton-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["mgh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Wakefield, MA","country":"US","companyType":"devices","website":"https://www.protominternational.com","stage":"growth","investors":[],"funding":[]},{"id":"proxygen","kind":"company","name":"Proxygen","aka":[],"tldr":"Proxygen is a Vienna company that hunts for molecular glues, small molecules that make cells destroy cancer-driving proteins. Its two lead programmes, against p300 and CDK12, are still in the laboratory.","summary":"Proxygen is a Vienna biotechnology company founded from the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences (founders include Georg Winter and Giulio Superti-Furga) that discovers molecular glue degraders and, since April 2026, broader induced proximity therapeutics. Its most advanced programme is a first-in-class oral p300 glue degrader with sub-nanomolar potency and covalent glue pharmacology, aimed at transcription-driven cancers such as prostate, lung and bladder cancer and at CBP-mutant tumours with a synthetic lethal dependence on p300. The second lead, a brain-penetrant CDK12 glue degrader, is directed at aggressive HER2-driven cancers and tumours with central nervous system involvement. Both are preclinical, with development candidate nomination and IND-enabling studies planned over the following 12 to 18 months.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://proxygen.com/"},{"label":"Pipeline and beyond","url":"https://proxygen.com/pipeline-beyond"},{"label":"Platform expansion announcement (April 2026)","url":"https://proxygen.com/chronicle?post=532"}],"tags":[],"related":[],"cancers":["prostate","nsclc","urothelial","breast-her2-positive"],"sections":["targeted-therapy","epigenetics"],"technologies":["protac-degrader","epigenetic-drugs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No financing announcement or pharma collaboration terms (for example the reported Merck deals) could be fetched from the company's news pages, so funding and investors are empty. Founding year not sourced."],"hq":"Vienna","country":"AT","companyType":"biotech","website":"https://proxygen.com/","stage":"startup","investors":[],"funding":[]},{"id":"ptc-therapeutics","kind":"company","name":"PTC Therapeutics","aka":["PTC Therapeutics, Inc.","PTC"],"tldr":"PTC is a New Jersey rare-disease company, known for Duchenne and spinal muscular atrophy medicines, whose tubulin-binding drug unesbulin went into a phase 3 trial in leiomyosarcoma.","summary":"PTC Therapeutics, founded in 1998 and headquartered in South Plainfield, New Jersey, develops small molecules that modulate RNA and protein production, with approved medicines in Duchenne muscular dystrophy, spinal muscular atrophy and phenylketonuria. Its oncology programme unesbulin (PTC596), which binds tubulin and lowers BMI1, was taken into the phase 3 SUNRISE-LMS trial with dacarbazine in leiomyosarcoma. Its trials are registered on ClinicalTrials.gov under PTC as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.ptcbio.com"},{"label":"ClinicalTrials.gov: trials led by PTC Therapeutics, Inc.","url":"https://clinicaltrials.gov/search?lead=PTC%20Therapeutics%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q7120959"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["sarcoma","uterine-sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"South Plainfield, NJ","country":"US","companyType":"biotech","website":"https://www.ptcbio.com","founded":1998,"stage":"public","investors":[],"funding":[]},{"id":"ptw-freiburg","kind":"company","name":"PTW Freiburg","aka":[],"tldr":"PTW is the century-old German dosimetry company whose ionisation chambers, detector arrays and water phantoms are used in radiotherapy departments worldwide to measure the dose a machine really gives.","summary":"PTW Freiburg, founded in 1922, makes reference ionisation chambers, the OCTAVIUS 4D patient-specific QA system, BEAMSCAN water phantoms, in vivo diodes and electrometers, and runs an accredited calibration laboratory. It is one of three dominant radiotherapy QA vendors with Sun Nuclear (Mirion) and IBA Dosimetry.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.ptwdosimetry.com/"}],"tags":["machines-wave2"],"related":[],"cancers":[],"sections":[],"technologies":["radiotherapy-qa-phantoms-dosimeters","in-vivo-dosimetry","treatment-planning-systems"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Freiburg","country":"DE","companyType":"devices","website":"https://www.ptwdosimetry.com/","founded":1922,"stage":"private-large","investors":[],"funding":[]},{"id":"puma-biotechnology","kind":"company","name":"Puma Biotechnology","aka":[],"tldr":"Puma Biotechnology developed neratinib (Nerlynx), the extended-adjuvant HER2 pill.","summary":"Puma Biotechnology, based in Los Angeles and listed as PBYI, is a single-product company that developed neratinib, sold as Nerlynx, the extended-adjuvant HER2 tablet for breast cancer. Neratinib was approved in 2017 for extended adjuvant use and in 2020 for metastatic HER2-positive disease in combination with capecitabine, and the company is also developing alisertib, an Aurora A kinase inhibitor. OnCo links it to HER2-positive breast cancer and to the neratinib drug record. Whether extended adjuvant HER2 blockade still adds value as earlier treatment improves is the open question for its one marketed product. Neratinib has its own page.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://www.pumabiotechnology.com"}],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["neratinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06095505","nct06369285"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Los Angeles, CA","country":"US","companyType":"biotech","website":"https://www.pumabiotechnology.com","ticker":"PBYI","investors":[],"funding":[]},{"id":"pyrexar-medical","kind":"company","name":"Pyrexar Medical","aka":[],"tldr":"Pyrexar Medical makes the BSD-2000 deep regional hyperthermia systems, the reference machines for heating pelvic and abdominal tumours alongside radiotherapy, and the BSD-500 for superficial and interstitial heating.","summary":"Pyrexar Medical took over the hyperthermia business of BSD Medical, whose phased-array systems have been used in clinical trials since the 1980s. Its BSD-2000 family, including an MR-compatible version that runs inside a 1.5 T scanner for non-invasive thermometry, is installed mainly in European, Asian and American university centres; the BSD-500 treats chest-wall recurrences and other superficial tumours with microwave applicators.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.pyrexar.com/"}],"tags":["machines-wave2"],"related":[],"cancers":["cervical","sarcoma","breast-cancer"],"sections":[],"technologies":["hyperthermia-systems","hyperthermia"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Salt Lake City, UT","country":"US","companyType":"devices","website":"https://www.pyrexar.com/","stage":"private-large","investors":[],"funding":[]},{"id":"qbiotics","kind":"company","name":"QBiotics","aka":["QBiotics Group Limited"],"tldr":"QBiotics is a Australia-based biotechnology company running 2 late-stage cancer trials in sarcomas and head and neck squamous cell carcinoma.","summary":"QBiotics, based in Toowong, Brisbane, Australia, is a biotechnology company. QBiotics discovers and develops novel cell-signalling small molecules using phenotypic screening, with programmes in oncology, wound healing and antibiotic discovery. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials in sarcomas and head and neck squamous cell carcinoma. The largest, NCT05755113 (A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma), plans to enrol 40 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.qbiotics.com/"},{"label":"ClinicalTrials.gov: trials led by QBiotics","url":"https://clinicaltrials.gov/search?lead=QBiotics%20Group%20Limited"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["sarcoma","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05755113","nct05608876"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Toowong, Brisbane","country":"AU","companyType":"biotech","website":"https://www.qbiotics.com/","founded":2017,"stage":"growth","investors":[],"funding":[]},{"id":"qiagen","kind":"company","name":"QIAGEN","aka":[],"tldr":"QIAGEN is a sample-preparation and molecular-diagnostics company selling nucleic-acid extraction kits, therascreen companion diagnostics, and QCI Interpret software.","summary":"QIAGEN, based in Venlo and listed as QGEN, is a sample preparation and molecular diagnostics company selling nucleic acid extraction kits, the therascreen companion diagnostics and QCI Interpret software. Its extraction chemistry is used across laboratories, its PCR-based companion diagnostics cover KRAS, EGFR, PIK3CA, FGFR and BRAF, and QIAGEN Digital Insights provides bioinformatics. OnCo links it to clinical NGS bioinformatics, pre-analytics and companion diagnostics, and to the therascreen kit record. Whether single-gene PCR companion tests survive as sequencing panels take over is the open question for its diagnostics business. The therascreen kits have their own page.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.qiagen.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["ngs-bioinformatics-software","preanalytics-sample-stabilisation","companion-diagnostic"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Venlo","country":"NL","companyType":"diagnostics","website":"https://www.qiagen.com","ticker":"QGEN","investors":[],"funding":[]},{"id":"qilu-pharmaceutical","kind":"company","name":"Qilu Pharmaceutical","aka":["Qilu Pharmaceutical Co., Ltd."],"tldr":"Qilu Pharmaceutical is a China-based pharmaceutical company running 20 late-stage cancer trials of QL1706, QLC5508 and QL2107 in non-small-cell lung cancer, oesophageal cancer and triple-negative breast cancer.","summary":"Qilu Pharmaceutical, based in Jinan, China, is a pharmaceutical company. Qilu Pharmaceutical is a large Chinese pharmaceutical manufacturer that develops and produces innovative drugs, biosimilars, improved new drugs and generic medicines across oncology, cardiovascular, anti-infection and ophthalmology, among other areas. On ClinicalTrials.gov it is the lead sponsor of 20 recruiting or active phase 2 and phase 3 interventional cancer trials (13 in phase 3), testing QL1706, QLC5508, QL2107, QL0911 and ESG401 in non-small-cell lung cancer, oesophageal cancer, triple-negative breast cancer, multiple myeloma and HR-positive / HER2-negative breast cancer. The largest, NCT06754644 (A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC), plans to enrol 808 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.qilu-pharma.com"},{"label":"ClinicalTrials.gov: trials led by Qilu Pharmaceutical","url":"https://clinicaltrials.gov/search?lead=Qilu%20Pharmaceutical%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","esophageal","tnbc","multiple-myeloma","breast-hr-positive","prostate","colorectal","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["qlc5508","ql1706","ql2107","esg401","qls32015","qls31905","qlh12016","iruplinalkib","iparomlimab-tuvonralimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07018050","nct07198633","nct06994507","nct07102004","nct07724756","nct06911827","nct07256782","nct07235176"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Jinan","country":"CN","companyType":"pharma","website":"https://www.qilu-pharma.com","stage":"private-large","investors":[],"funding":[]},{"id":"quanta-therapeutics","kind":"company","name":"Quanta Therapeutics","aka":[],"tldr":"Quanta Therapeutics develops oral multi-KRAS inhibitors biased to G12D (QTX3034) and G12V (QTX3544), with responses in pancreatic, colorectal, and endometrial cancer.","summary":"Quanta Therapeutics, based in South San Francisco, develops oral multi-KRAS inhibitors biased towards G12D, QTX3034, and G12V, QTX3544, with responses reported in pancreatic, colorectal and endometrial cancer. Phase 1 data in October 2025 showed confirmed responses for QTX3034 alone and with cetuximab in colorectal, pancreatic and endometrial cancer, and preclinical data in March 2026 showed both compounds retain activity against resistance mechanisms acquired on the pan-RAS inhibitor daraxonrasib. OnCo links it to pancreatic, colorectal and endometrial cancer, to KRAS and RAS inhibitors, to KRAS as a target and the MAPK pathway, to daraxonrasib and to the bottleneck of undruggable drivers. Whether mutation-biased inhibitors or pan-RAS drugs win on the balance of efficacy and tolerability is the open question. Daraxonrasib has its own page.","asOf":"2026-09-04","links":[{"label":"March 2026 release","url":"https://www.quantatx.com/news/030526/"}],"tags":[],"related":[],"cancers":["pancreatic","colorectal","endometrial"],"sections":["targeted-therapy"],"technologies":["kras-inhibitors"],"targets":["kras"],"drugs":["daraxonrasib"],"companies":[],"institutions":[],"pathways":["ras-mapk"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.quantatx.com","investors":[],"funding":[]},{"id":"quantum-leap-healthcare-collaborative","kind":"company","name":"Quantum Leap Healthcare Collaborative","aka":["QLHC","Quantum Leap"],"tldr":"The San Francisco non-profit that sponsors the I-SPY trials, founded by Laura Esserman and Don Listwin to run adaptive platform trials that pharmaceutical companies join rather than own.","summary":"Quantum Leap Healthcare Collaborative was set up in 2005 as a charity to bridge academic research and industry. It holds the investigational new drug application for I-SPY 2, contracts with the companies whose drugs enter the platform, runs the data and imaging infrastructure across the participating centres, and shares the results and biospecimens with researchers. It also sponsors the I-SPY COVID trial that reused the same adaptive machinery for severe COVID-19 in 2020, and the I-SPY 2.2 and I-SPY 3 programmes.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.quantumleaphealth.org"},{"label":"I-SPY Trials","url":"https://www.ispytrials.org"}],"tags":[],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":["i-spy-2","i-spy-2-2"],"people":["laura-esserman"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, California, United States","country":"US","companyType":"nonprofit","website":"https://www.quantumleaphealth.org","founded":2005,"stage":"growth","investors":[],"funding":[]},{"id":"quantum-surgical","kind":"company","name":"Quantum Surgical","aka":[],"tldr":"Quantum Surgical builds Epione, a robot that helps doctors guide needles through the skin to destroy liver and other tumours with heat or cold, making a minimally invasive treatment more precise and easier for less experienced operators.","summary":"Quantum Surgical, founded in Montpellier in 2017 by Bertin Nahum and the team behind neurosurgical robotics company Medtech, develops the Epione robotic platform for percutaneous tumour ablation. Epione combines CT-based planning, robotic needle positioning and post-ablation margin confirmation to standardise minimally invasive ablation of early-stage tumours that are inoperable or hard to reach. It is CE marked for abdominal, thoracic and musculoskeletal indications and FDA cleared for abdominal ablation; the company reports more than 1,800 patients treated and over 20 cancer centre installations. In February 2026 Quantum Surgical acquired NeuWave Medical, Inc., the microwave ablation company used in about 70 percent of top US cancer centres; both now operate as subsidiaries of the new parent Precision IO Group Inc., led by CEO Kurt Azarbarzin. The same month it joined the EU-funded PreciseOnco consortium (EUR 23.9 million).","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.quantumsurgical.com/"},{"label":"About Quantum Surgical","url":"https://www.quantumsurgical.com/about-quantum"},{"label":"Acquisition of NeuWave Medical (Feb 2026)","url":"https://www.quantumsurgical.com/news/quantum-surgical-acquires-of-neuwave-medical-inc"},{"label":"PreciseOnco EU project (Feb 2026)","url":"https://www.quantumsurgical.com/news/quantum-surgical-at-the-heart-of-a-eu14-9-million-european-project-for-precision-cancer-treatment"}],"tags":[],"related":[],"cancers":["hcc","colorectal","rcc"],"sections":["surgery","devices"],"technologies":["robotic-surgery","thermal-ablation","ct"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Venture rounds (Quantum Surgical is known to have raised private capital, including from Ally Bridge Group) could not be sourced from fetched pages; Ally Bridge Group is listed as an investor only because its founder appears on the board page. Stage 'growth' reflects a commercial-stage company now held by a new parent, Precision IO Group; not marked 'acquired' because the parent was created around it. NeuWave deal value not disclosed. Liver, colorectal metastasis and kidney cancers are inferred from ablation indications rather than stated on fetched pages."],"hq":"Montpellier","country":"FR","companyType":"devices","website":"https://www.quantumsurgical.com/","founded":2017,"stage":"growth","investors":[],"funding":[{"round":"Grant","year":2026,"source":"https://www.quantumsurgical.com/news/quantum-surgical-at-the-heart-of-a-eu14-9-million-european-project-for-precision-cancer-treatment","note":"PreciseOnco consortium (with Philips, IGEA, EIBIR and CIRSE) awarded EUR 14.9 million public funding from the EU Innovative Health Initiative plus EUR 9 million in-kind, EUR 23.9 million total; Quantum Surgical's own share is not stated"}]},{"id":"quest-diagnostics","kind":"company","name":"Quest Diagnostics","aka":[],"tldr":"Quest Diagnostics is a national reference laboratory with oncology pathology and molecular testing, including Haystack Oncology MRD (acquired 2023).","summary":"Quest Diagnostics, based in Secaucus, New Jersey, and listed as DGX, is a national reference laboratory with oncology pathology and molecular testing, including the Haystack Oncology measurable residual disease test acquired in 2023. Its oncology work spans AmeriPath anatomic pathology, solid-tumour next-generation sequencing and circulating tumour DNA MRD testing through Haystack. OnCo links it to reference laboratories and companion diagnostic testing, MRD testing and Haystack Oncology. Whether a general reference laboratory can compete in MRD testing against specialist companies is the question the Haystack purchase poses. Haystack Oncology has its own page.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.questdiagnostics.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["reference-laboratories","mrd-testing"],"targets":[],"drugs":[],"companies":["haystack-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Secaucus, NJ","country":"US","companyType":"diagnostics","website":"https://www.questdiagnostics.com","ticker":"DGX","investors":[],"funding":[]},{"id":"qurient","kind":"company","name":"Qurient","aka":["Qurient Co., Ltd.","Qurient Co Ltd"],"tldr":"Qurient is a South Korean biotechnology company in Seongnam that leads two cancer trials in OnCo, testing the selective CDK7 inhibitor Q901 and the Axl/Mer/CSF1R inhibitor Q702, each with pembrolizumab, in advanced solid tumours.","summary":"Qurient is a company based in Seongnam, South Korea (Wikidata Q30253835; no website is recorded there, so none is given here). ClinicalTrials.gov classes it as an industry sponsor, with Merck Sharp & Dohme as collaborator on the pembrolizumab combinations. It leads two phase 1/2 trials recorded in OnCo: NCT05394103 (Q901, a highly selective CDK7 inhibitor, alone and with pembrolizumab in selected advanced solid tumours) and NCT05438420 (Q702, an oral Axl/Mer/CSF1R tyrosine kinase inhibitor, with pembrolizumab, recorded under cervical cancer). Both compounds are its own, the basis for the biotech type.","asOf":"2026-09-22","links":[{"label":"Wikidata Q30253835","url":"https://www.wikidata.org/wiki/Q30253835"},{"label":"ClinicalTrials.gov: trials led by Qurient Co., Ltd.","url":"https://clinicaltrials.gov/search?lead=Qurient%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor","wave5-sponsor"],"related":[],"cancers":["cervical"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["axl","csf1r"],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05394103","nct05438420"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo content wave 5 (Wikidata, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-22"},"hq":"Seongnam","country":"KR","companyType":"biotech","investors":[],"funding":[]},{"id":"r-pharm","kind":"company","name":"R-Pharm","aka":["R-Pharm JSC","Р-Фарм"],"tldr":"R-Pharm is a large private Russian pharmaceutical company that manufactures and licenses medicines including cancer generics and biosimilars, and sponsors phase 3 trials of them in Russia.","summary":"R-Pharm, founded in Moscow in 2001, is one of Russia's largest pharmaceutical companies, spanning manufacturing, distribution and development, including generic and biosimilar cancer medicines and licensed products for the Russian market. It appears as lead sponsor of a number of phase 3 cancer trials on ClinicalTrials.gov, mostly comparative studies of its versions of established drugs. OnCo records it so that those trials resolve to a sponsor page.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://r-pharm.com"},{"label":"ClinicalTrials.gov: trials led by R-Pharm","url":"https://clinicaltrials.gov/search?lead=R-Pharm"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/R-Pharm"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["rph-051"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct07553988"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Moscow","country":"RU","companyType":"pharma","website":"https://r-pharm.com","stage":"private-large","investors":[],"funding":[]},{"id":"ra-capital","kind":"company","name":"RA Capital Management","aka":[],"tldr":"A Boston investment firm that funds biotech companies both privately and on the stock market, and incubates its own. Its cancer bets include Aktis Oncology, CG Oncology and Bicara Therapeutics.","summary":"RA Capital Management was founded in January 2002 by Richard Aldrich and Peter Kolchinsky and is based in Boston (Wikipedia). It runs an evergreen fund that invests across private and public companies, dedicated venture funds (Nexus), a company-creation incubator called Raven, a clinical development accelerator (Blackbird) and an internal research group, TechAtlas. The firm is a frequent lead in crossover rounds ahead of IPOs. Its portfolio page lists a long run of oncology names: Acrivon Therapeutics, Aktis Oncology (alpha radiopharmaceuticals), Alpha-9 Oncology, Bicara Therapeutics, Black Diamond Therapeutics, Boundless Bio, CG Oncology (oncolytic immunotherapy for bladder cancer), Olema Oncology, PMV Pharma (p53) and Pyxis Oncology.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.racap.com/"},{"label":"Portfolio","url":"https://www.racap.com/portfolio"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/RA_Capital_Management"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boston, MA","country":"US","companyType":"investor","website":"https://www.racap.com/","founded":2002,"investors":[],"funding":[]},{"id":"radformation","kind":"company","name":"Radformation","aka":[],"tldr":"Radformation makes software that automates the repetitive parts of planning radiotherapy, such as outlining organs on scans, checking plans for errors and verifying doses, so cancer patients can start treatment faster and more safely.","summary":"Radformation, founded in 2016 in New York by medical physicists Kurt Sysock, Alan Nelson and Elisabeth van Wie, builds automation software for radiation oncology. Products include AutoContour (deep learning auto segmentation with more than 480 structure models), EZFluence and OptiPlan (automated 3D and VMAT planning), ClearCheck (plan evaluation with more than 90 automated checks), ClearCalc and RadMonteCarlo (independent dose calculation), ChartCheck and ChartCheck Adaptive (treatment monitoring, FDA 510(k) cleared in February 2026), QuickCode and RadMachine. At its May 2024 acquisition of Limbus AI it cited more than 1,600 clinics in 28 countries; products hold MDR CE marking and clearances in Australia, Brazil, Canada and Thailand. Radformation raised a USD 1.6 million seed round led by Brooklyn Bridge Ventures in June 2018; no later funding round was found.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.radformation.com"},{"label":"Seed round press release (June 2018)","url":"https://www.radformation.com/press/radformation-raises-seed-round"},{"label":"Limbus AI acquisition press release (May 2024)","url":"https://www.radformation.com/press/radformation-limbus-acquisition"},{"label":"Press releases index","url":"https://www.radformation.com/press"}],"tags":[],"related":[],"cancers":[],"sections":["radiation","ai-computation"],"technologies":["imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Stage recorded as startup because only a seed round is sourced, although the company is at commercial scale. Radformation acquired Limbus AI (already in the graph as limbus-ai) in May 2024; terms not disclosed."],"hq":"New York, NY","country":"US","companyType":"ai-software","website":"https://www.radformation.com","founded":2016,"stage":"startup","investors":[],"funding":[{"round":"Seed","year":2018,"amountUsd":1600000,"source":"https://www.radformation.com/press/radformation-raises-seed-round","note":"Led by Brooklyn Bridge Ventures with angel investors"}]},{"id":"radiomedix","kind":"company","name":"RadioMedix","aka":[],"tldr":"RadioMedix is developing AlphaMedix (212Pb-DOTAMTATE) with Orano Med, the first targeted alpha therapy to receive FDA Breakthrough designation.","summary":"RadioMedix, based in Houston, is developing AlphaMedix, or 212Pb-DOTAMTATE, with Orano Med, the first targeted alpha therapy to receive FDA Breakthrough designation. AlphaMedix met all primary efficacy endpoints in phase 2, with a 60 percent objective response rate in PRRT-naive gastroenteropancreatic neuroendocrine tumour patients reported at ESMO 2025, was licensed to Sanofi with Orano Med in 2024, and has its next trial planned for late 2026; the company marked twenty years at SNMMI 2026. OnCo links it to neuroendocrine tumours, to targeted alpha therapy and peptide receptor radionuclide therapy, to somatostatin receptor 2 as a target, and to Orano Med and Sanofi. Whether a lead-212 alpha emitter beats existing beta-emitter PRRT in a randomised trial is the open question. 212Pb-DOTAMTATE has its own page.","asOf":"2026-09-04","links":[{"label":"Sanofi licensing agreement","url":"https://www.sanofi.com/en/media-room/press-releases/2024/2024-09-12-05-00-00-2944919"}],"tags":[],"related":[],"cancers":["neuroendocrine"],"sections":["radiopharma"],"technologies":["targeted-alpha-therapy"],"targets":["sstr2"],"drugs":[],"companies":["orano-med","sanofi"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Houston, TX","country":"US","companyType":"radiopharma","website":"https://www.radiomedix.com","investors":[],"funding":[]},{"id":"radionetics-oncology","kind":"company","name":"Radionetics Oncology","aka":[],"tldr":"Radionetics Oncology makes small-molecule drugs that carry a radioactive isotope to receptors on the surface of cancer cells that have rarely been targeted before. Eli Lilly paid 140 million dollars in 2024 for the right to buy the company for 1 billion dollars.","summary":"Radionetics Oncology, a San Diego company that emerged from Crinetics Pharmaceuticals in October 2021, discovers and develops small-molecule radiopharmaceuticals against G protein-coupled receptor (GPCR) targets not previously pursued by radiopharmaceuticals, identified through AI-driven multi-omics. Its first phase 1 radiopharmaceutical programme, against a novel target for adrenocortical carcinoma, was initiated in October 2023. In January 2024 the company raised a USD 52.5 million Series A led by Frazier Life Sciences, 5AM Ventures and DCVC Bio, appointing Paul Grayson as CEO. In July 2024 it entered a strategic agreement with Eli Lilly under which Radionetics received a USD 140 million upfront payment and Lilly obtained the exclusive right to acquire the company for USD 1 billion after an exercise period, during which Radionetics continues to build its GPCR-targeted pipeline.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://radionetics.com/"},{"label":"Series A press release","url":"https://radionetics.com/news/radionetics-oncology-raises-52-5m-series-a"},{"label":"Lilly strategic agreement release","url":"https://radionetics.com/news/radionetics-oncology-enters-into-strategic-agreement-with-lilly"}],"tags":[],"related":[],"cancers":[],"sections":["radiopharma"],"technologies":["radioligand-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The USD 140 million Lilly upfront payment is a strategic agreement, not an equity round, so it is described in the summary rather than in funding."],"hq":"San Diego, CA","country":"US","companyType":"radiopharma","website":"https://radionetics.com/","founded":2021,"stage":"startup","investors":["frazier-life-sciences","5am-ventures","dcvc"],"funding":[{"round":"Series A","year":2024,"amountUsd":52500000,"source":"https://radionetics.com/news/radionetics-oncology-raises-52-5m-series-a","note":"Brought total raised to USD 82.5 million"}]},{"id":"radiopharm-theranostics","kind":"company","name":"Radiopharm Theranostics","aka":["Radiopharm Theranostics, Ltd"],"tldr":"Radiopharm Theranostics is an Australia-based radiopharmaceutical company that leads 3 cancer trials in OnCo, testing the radiopharmaceuticals 161Tb-RAD402, 177Lu-BetaBart and the PET tracer RAD101 in prostate cancer, colorectal cancer, non-small-cell lung cancer and ovarian cancer.","summary":"Radiopharm Theranostics is a clinical-stage company developing radiopharmaceuticals for the diagnosis and treatment of cancer, using nanobody, antibody, small-molecule and peptide platforms directed at targets other than PSMA, FAP and SSTR2. It has a joint venture with MD Anderson Cancer Center and is listed in Australia and on Nasdaq. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT07189871 (phase 1/2, 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Me...), NCT07259213 (phase 1/2, A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC) and NCT06777433 (phase 2, Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://radiopharmtheranostics.com/"},{"label":"ClinicalTrials.gov: trials led by Radiopharm Theranostics","url":"https://clinicaltrials.gov/search?lead=Radiopharm%20Theranostics%2C%20Ltd"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate","colorectal","nsclc","ovarian","cervical","endometrial","brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07189871","nct07259213","nct06777433"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Melbourne","country":"AU","companyType":"radiopharma","website":"https://radiopharmtheranostics.com/","ticker":"ASX:RAD, NASDAQ:RADX","founded":2021,"stage":"public","investors":[],"funding":[]},{"id":"rakuten-medical","kind":"company","name":"Rakuten Medical","aka":["Rakuten Medical, Inc."],"tldr":"Rakuten Medical is a United States-based biotechnology company running 3 late-stage cancer trials in head and neck squamous cell carcinoma and cutaneous squamous cell carcinoma.","summary":"Rakuten Medical, based in San Diego, the United States, is a biotechnology company. Rakuten Medical is a biotechnology company creating and bringing to market drugs and devices to treat cancers based on its Alluminox platform of photoimmunotherapy. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3) in head and neck squamous cell carcinoma and cutaneous squamous cell carcinoma. The largest, NCT06699212 (A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases), plans to enrol 412 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.rakuten-med.com"},{"label":"ClinicalTrials.gov: trials led by Rakuten Medical","url":"https://clinicaltrials.gov/search?lead=Rakuten%20Medical%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["head-and-neck","cutaneous-scc"],"sections":[],"technologies":[],"targets":[],"drugs":["cetuximab-sarotalocan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06699212","nct03769506","nct04305795"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Diego","country":"US","companyType":"biotech","website":"https://www.rakuten-med.com","founded":2010,"stage":"private-large","investors":[],"funding":[]},{"id":"ranata-therapeutics","kind":"company","name":"Ranata Therapeutics","aka":["Ranata Tx"],"tldr":"Ranata Therapeutics builds antibodies and bispecific antibodies against the unique features of an individual patient's cancer cells.","summary":"Ranata Therapeutics harnesses the uniqueness of a patient's cancer cells to build biologic therapies, antibodies or bispecifics, against that cancer: personalised medicine inspired by the individual's biology. It is an Even One Ventures portfolio company with no published candidates.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://ranatatx.com/"},{"label":"Even One Ventures portfolio","url":"https://evenone.ventures/"}],"tags":["startup","evenone-portfolio","oncology"],"related":[],"cancers":[],"sections":[],"technologies":["bispecific-antibody"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"United States (head office not published)","country":"US","companyType":"biotech","website":"https://ranatatx.com/","stage":"startup","investors":["evenone-ventures"],"funding":[]},{"id":"ranok-therapeutics-hangzhou","kind":"company","name":"Ranok Therapeutics (Hangzhou)","aka":["Ranok Therapeutics (Hangzhou) Co., Ltd.","Ranok Therapuetics Co. Ltd."],"tldr":"Ranok Therapeutics (Hangzhou) is a China-based biotechnology company running 2 late-stage cancer trials of RNK08954-01 and RNK05047 in sarcomas and diffuse large B-cell lymphoma.","summary":"Ranok Therapeutics (Hangzhou), based in Hangzhou, China, is a biotechnology company. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing RNK08954-01 and RNK05047 in sarcomas and diffuse large B-cell lymphoma. The largest, NCT06667544 (A Study of RNK08954 in Subjects With Advanced Solid Tumours With KRAS ((Kirsten Rat Sarcoma) G12D Mutation), plans to enrol 152 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.ranoktherapeutics.com/"},{"label":"ClinicalTrials.gov: trials led by Ranok Therapeutics (Hangzhou)","url":"https://clinicaltrials.gov/search?lead=Ranok%20Therapeutics%20(Hangzhou)%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["sarcoma","dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":["rnk05047"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06667544","nct07441174"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Hangzhou","country":"CN","companyType":"biotech","website":"https://www.ranoktherapeutics.com/","investors":[],"funding":[]},{"id":"rarivive","kind":"company","name":"Rarivive","aka":[],"tldr":"Rarivive is an Even One Ventures company outside cancer: custom gene therapies designed around a single person's mutation for rare genetic diseases.","summary":"Rarivive engineers custom gene therapies for individual patients with rare genetic diseases, one person and one programme at a time, on the premise that many rare diseases trace to a single identifiable DNA change affecting only a handful of people. It is a rare disease company in the Even One Ventures portfolio and does not work on cancer.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://rarivive.com/"},{"label":"Even One Ventures portfolio","url":"https://evenone.ventures/"}],"tags":["startup","evenone-portfolio","rare-disease","non-oncology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"United States (head office not published)","country":"US","companyType":"biotech","website":"https://rarivive.com/","stage":"startup","investors":["evenone-ventures"],"funding":[]},{"id":"ratio-therapeutics","kind":"company","name":"Ratio Therapeutics","aka":[],"tldr":"Ratio Therapeutics, of Boston, designs small molecules that carry a radioactive isotope to fibroblast activation protein, a protein on the supporting tissue of sarcomas and other solid tumours, so radiation is delivered from inside the body. Its lead, an actinium-225 radioligand, is in the ATLAS phase 1/2 trial in advanced sarcomas.","summary":"Ratio Therapeutics is a clinical-stage Boston radiopharmaceutical company whose Trillium targeting scaffold combines pharmacokinetic modulation with chelation chemistry to create small-molecule radioligands that can be paired with imaging or therapeutic isotopes (theranostics). The lead programme [Ac-225]RTX-2358 is a fibroblast activation protein (FAP)-targeted actinium-225 therapeutic in the ATLAS phase 1/2 trial in advanced sarcomas; the pipeline also includes a next-generation GRPR programme and additional mono- and bispecific radioligands, with a fifth IND filing in preparation. In July 2026 Ratio closed a USD 70 million Series C with Duquesne Family Office, Bristol Myers Squibb, Catalio Capital, Eli Lilly and Wasatch Group, taking total capital raised above USD 240 million. It has manufacturing collaborations with PharmaLogic, an actinium-225 supply agreement with PanTera (June 2026) and, in September 2026, a research collaboration and licence agreement with RayzeBio.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://ratiotx.com/"},{"label":"Series C press release","url":"https://ratiotx.com/2026/07/31/ratio-therapeutics-closes-70-million-series-c-financing-to-advance-clinical-development-of-targeted-radiotherapeutics-pipeline-and-expand-manufacturing-infrastructure/"},{"label":"News","url":"https://ratiotx.com/news1/"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":["radiopharma"],"technologies":["radioligand-therapy","targeted-alpha-therapy"],"targets":["fap"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Earlier rounds (Series A and B) not fetched and omitted."],"hq":"Boston, MA","country":"US","companyType":"radiopharma","website":"https://ratiotx.com/","stage":"growth","investors":[],"funding":[{"round":"Series C","year":2026,"amountUsd":70000000,"source":"https://ratiotx.com/2026/07/31/ratio-therapeutics-closes-70-million-series-c-financing-to-advance-clinical-development-of-targeted-radiotherapeutics-pipeline-and-expand-manufacturing-infrastructure/","note":"Brings total capital raised to over USD 240 million"}]},{"id":"raysearch","kind":"company","name":"RaySearch Laboratories","aka":[],"tldr":"RaySearch makes the vendor-neutral RayStation treatment planning system, strong in proton and adaptive planning, with machine-learning planning tools.","summary":"RaySearch Laboratories, based in Stockholm and listed as RAY-B.ST, makes the vendor-neutral RayStation treatment planning system, strong in proton and adaptive planning, with machine-learning planning tools. Its portfolio also includes the RayCare oncology information system and RayIntelligence analytics, and RayStation is used by most proton centres. OnCo links it to radiotherapy treatment planning and QA software, proton therapy and AI auto-contouring and adaptive planning. Whether independent planning software keeps its place as machine vendors bundle their own planning and AI tools is the open question. The treatment planning technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.raysearchlabs.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["radiation"],"technologies":["treatment-planning-systems","proton-therapy","auto-contouring-ai"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Stockholm","country":"SE","companyType":"ai-software","website":"https://www.raysearchlabs.com","ticker":"RAY-B.ST","investors":[],"funding":[]},{"id":"rayzebio","kind":"company","name":"RayzeBio (BMS)","aka":[],"tldr":"RayzeBio is the actinium-225 radiopharma company that BMS bought for $4.1B; its RYZ101 is in phase 3.","summary":"RayzeBio, based in San Diego, is the actinium-225 radiopharmaceutical company that Bristol Myers Squibb bought for 4.1 billion dollars, and its RYZ101 is in phase 3. RYZ101 is actinium-225 DOTATATE for somatostatin-receptor-positive neuroendocrine tumours, RYZ801 is an actinium-225 PSMA agent, and the company built in-house actinium-225 manufacturing. OnCo links it to neuroendocrine tumours, to peptide receptor radionuclide therapy and targeted alpha therapy, to the actinium-225 DOTATATE drug record, and to the radiopharmaceutical roadmap from iodine through lutetium to actinium. Whether an alpha emitter can improve on lutetium-based radioligand therapy is the question RYZ101's phase 3 will answer. Actinium-225 DOTATATE has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.rayzebio.com"}],"tags":[],"related":[],"cancers":[],"sections":["radiopharma"],"technologies":[],"targets":[],"drugs":["ryz101"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06590857","nct06726161"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Diego, CA","country":"US","companyType":"radiopharma","website":"https://www.rayzebio.com","investors":[],"funding":[]},{"id":"recordati","kind":"company","name":"Recordati","aka":[],"tldr":"Recordati is an Italian pharmaceutical group whose rare-disease arm markets oncology and haematology products in Europe, including siltuximab (Sylvant), chlormethine gel (Ledaga) and dinutuximab beta (Qarziba).","summary":"Recordati, based in Milan and listed as REC.MI, is an Italian pharmaceutical group whose rare disease arm markets oncology and haematology products in Europe, including siltuximab, sold as Sylvant, chlormethine gel, sold as Ledaga, and dinutuximab beta, sold as Qarziba. Recordati Rare Diseases acquired EUSA Pharma in 2022, adding Sylvant for multicentric Castleman disease, Qarziba for high-risk neuroblastoma and Fotivda, or tivozanib, in Europe, alongside Ledaga licensed from Helsinn. OnCo links it to siltuximab and mechlorethamine. Whether a rare disease marketer can keep paediatric and ultra-rare oncology products available across Europe at prices health systems accept is the open question. Siltuximab has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.recordati.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["dactinomycin"],"companies":["helsinn"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Milan","country":"IT","companyType":"pharma","website":"https://www.recordati.com","ticker":"REC.MI","investors":[],"funding":[]},{"id":"recursion","kind":"company","name":"Recursion Pharmaceuticals","aka":[],"tldr":"Recursion is an AI-first biotech (merged with Exscientia in 2024) with a clinical oncology pipeline that includes an RBM39 degrader and a MEK inhibitor for familial adenomatous polyposis.","summary":"Recursion Pharmaceuticals, based in Salt Lake City and listed as RXRX, is an AI-first biotechnology company that merged with Exscientia in 2024, with a clinical oncology pipeline including an RBM39 degrader and a MEK inhibitor for familial adenomatous polyposis. Its programmes include REC-1245, the RBM39 degrader in phase 1/2, REC-4881, a MEK1/2 inhibitor in phase 2 for FAP with FDA registrational discussions, and candidates against LSD1, CDK7, PI3K-alpha H1047R, MALT1 and ENPP1, and it reported revenue shortfalls alongside pipeline progress in the first quarter of 2026. OnCo links it to colorectal cancer, AI-driven discovery and protein degradation, the MAPK and cGAS-STING pathways and the idea of a virtual cancer cell. Whether AI-discovered candidates succeed in the clinic at a higher rate than conventional ones is the question the company exists to test.","asOf":"2026-09-04","links":[{"label":"Q1 2026 update","url":"https://ir.recursion.com/news-releases/news-release-details/recursion-reports-first-quarter-financial-results-and-provides"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":["ai-computation","drug-discovery"],"technologies":["ai-drug-design","protac-degrader"],"targets":["pik3ca"],"drugs":[],"companies":[],"institutions":[],"pathways":["ras-mapk","cgas-sting"],"terms":[],"trials":["nct05985655","nct06678659"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Salt Lake City, UT","country":"US","companyType":"ai-software","website":"https://www.recursion.com","ticker":"RXRX","investors":[],"funding":[]},{"id":"reflexion","kind":"company","name":"RefleXion Medical","aka":[],"tldr":"RefleXion Medical makes the first PET-guided radiotherapy system, which uses the tumour's own emissions to steer the beam.","summary":"RefleXion Medical, based in Hayward, California, makes the first PET-guided radiotherapy system, which uses the tumour's own positron emissions to steer the treatment beam. Its SCINTIX biology-guided radiotherapy received FDA authorisation in 2023 for lung and bone metastases. OnCo links it to MR-guided adaptive radiotherapy and PET as technologies, to the molecular imaging roadmap from FDG through PSMA and FAP to immune PET, to the bottleneck that surgery and radiotherapy cure most patients but get least funding, and to the idea of coverage-with-evidence registries for adaptive radiotherapy. Whether tracking tumours by their own signal allows safe treatment of many metastases at once is the open question the system was built to test. The radiotherapy technology pages carry the evidence.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://reflexion.com"}],"tags":[],"related":[],"cancers":[],"sections":["radiation"],"technologies":["mr-linac","pet"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Hayward, CA","country":"US","companyType":"devices","website":"https://reflexion.com","investors":[],"funding":[]},{"id":"regeneron","kind":"company","name":"Regeneron","aka":[],"tldr":"Regeneron makes Libtayo and has a large portfolio of CD3 bispecifics (odronextamab, linvoseltamab).","summary":"Regeneron, based in Tarrytown, New York, and listed as REGN, makes Libtayo, or cemiplimab, and has a large portfolio of CD3 bispecific antibodies including odronextamab and linvoseltamab. Odronextamab targets CD20 by CD3 in lymphoma, linvoseltamab, a BCMA by CD3 bispecific, was approved in 2025 for myeloma, fianlimab is a LAG-3 antibody in a phase 3 with cemiplimab in first-line melanoma, and costimulatory bispecifics follow. OnCo links it to cutaneous squamous cell carcinoma, basal cell carcinoma and cervical cancer through the EMPOWER-Cervical 1 trial, to lymphoma pages, to MUC16 as a target and to Arsenal Biosciences. Whether costimulatory bispecifics can make T-cell engagers work in solid tumours is the open question its pipeline is built to answer. Cemiplimab has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.regeneron.com"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["cemiplimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06097364","nct05730036","nct06246916","nct05800015","nct06149286","nct06585410","nct06230224","nct05608291","nct05785767","nct06091865","nct06091254","nct07393282","nct06140524","nct03972657","nct05557591","nct06161441","nct03916627","nct06190951","nct07594106","nct03888105","nct05955508","nct06669247","nct05828511","nct06413680","nct06769698","nct07455851","nct05125016","nct04077099","nct07154290","nct04626635"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tarrytown, NY","country":"US","companyType":"pharma","website":"https://www.regeneron.com","ticker":"REGN","investors":[],"funding":[]},{"id":"reimagine-care","kind":"company","name":"Reimagine Care","aka":[],"tldr":"Reimagine Care gives cancer patients a text based assistant and oncology trained nurses available around the clock, so side effects can be handled at home instead of in an emergency department. It was bought by the French company Cureety in 2026.","summary":"Reimagine Care operates a virtual care centre for oncology practices and health systems. Patients report symptoms conversationally to Remi, an oncology specific AI assistant, with escalation to oncology trained clinicians available 24/7; partners include Memorial Hermann and Moffitt Cancer Center. The company reports that 97 to 98 percent of symptom interactions are resolved without the patient leaving home, 93 percent without escalation to the partner provider, and 30 percent fewer avoidable emergency department visits than national benchmarks. Based in Nashville, Reimagine Care raised a USD 25 million Series A in January 2022 co-led by Santé Ventures, Martin Ventures and LRVHealth, with City of Hope and McKesson Ventures participating. In September 2026 it was acquired by Cureety, a Paris based oncology remote monitoring company; the combined group states it supports more than 250 cancer centres and 100,000 patients in five countries.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://reimaginecare.com"},{"label":"Series A press release (January 2022)","url":"https://reimaginecare.com/publications/reimagine-care-secures-25-million-in-series-a-funding-to-drive-commercialization-of-home-centered-value-based-cancer-care/"},{"label":"Cureety acquisition announcement (September 2026)","url":"https://reimaginecare.com/publications/cureety-acquires-reimagine-care/"},{"label":"Cureety acquisition release on PR Newswire (French)","url":"https://www.prnewswire.com/fr/communiques-de-presse/cureety-fait-lacquisition-de-lamericain-reimagine-care-et-donne-une-dimension-mondiale-a-sa-plateforme-de-telesurveillance-oncologique-de-precision-302866958.html"}],"tags":[],"related":[],"cancers":[],"sections":["supportive-care","ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated in any fetched source. Memorial Hermann and Oncology Ventures investments are listed on the company publications index but the amounts were not fetched, so they are not recorded as rounds."],"hq":"Nashville, TN","country":"US","companyType":"cro-services","website":"https://reimaginecare.com","stage":"acquired","investors":["sante-ventures","mckesson-ventures"],"funding":[{"round":"Series A","year":2022,"amountUsd":25000000,"source":"https://reimaginecare.com/publications/reimagine-care-secures-25-million-in-series-a-funding-to-drive-commercialization-of-home-centered-value-based-cancer-care/","note":"Co-led by Santé Ventures, Martin Ventures and LRVHealth"},{"round":"Acquisition","year":2026,"source":"https://reimaginecare.com/publications/cureety-acquires-reimagine-care/","note":"Acquired by Cureety (Paris) in September 2026; financial terms not disclosed"}]},{"id":"relay-therapeutics","kind":"company","name":"Relay Therapeutics","aka":[],"tldr":"Relay Therapeutics uses computer simulations of how proteins move to design precise cancer pills. Its lead drug, zovegalisib, targets a mutated growth protein called PI3K-alpha in breast cancer while sparing the normal version.","summary":"Relay Therapeutics is a Cambridge, Massachusetts precision medicine company that combines computational modelling of protein motion with experimental chemistry. Its lead programme, zovegalisib (RLY-2608), is a mutant-selective, allosteric PI3K-alpha inhibitor that the company lists in phase 3 for PIK3CA-mutant breast cancer and in a phase 1/2 trial for vascular anomalies. RLY-8161, an NRAS inhibitor, is in a phase 1/2 trial in NRAS-mutant melanoma and other NRAS-mutant solid tumours. Lirafugratinib (RLY-4008), an FGFR2-selective inhibitor developed in FGFR2-fusion cholangiocarcinoma, was out-licensed to Elevar Therapeutics in December 2024. A non-oncology alpha-galactosidase A programme for Fabry disease is also listed. Relay completed its Nasdaq IPO in July 2020, selling 20 million shares at 20 US dollars per share according to its final prospectus.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://relaytx.com/"},{"label":"Pipeline","url":"https://relaytx.com/pipeline/"},{"label":"IPO prospectus (SEC 424B4)","url":"https://www.sec.gov/Archives/edgar/data/1812364/000119312520194016/d904779d424b4.htm"}],"tags":[],"related":[],"cancers":["breast-hr-positive","melanoma","cholangiocarcinoma"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors","ai-drug-design"],"targets":["pik3ca","fgfr2"],"drugs":["zovegalisib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["IPO gross proceeds computed from the prospectus (20 million shares at 20 US dollars); final amount including the option was not confirmed. Founding year not sourced. The ai-drug-design tag reflects the company's computational platform as described on its site."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://relaytx.com/","ticker":"RLAY","stage":"public","investors":[],"funding":[{"round":"IPO","year":2020,"amountUsd":400000000,"source":"https://www.sec.gov/Archives/edgar/data/1812364/000119312520194016/d904779d424b4.htm","note":"Final prospectus: 20 million shares at 20 US dollars per share, before the underwriters' option of up to 3 million additional shares"}]},{"id":"relit-biosciences","kind":"company","name":"Relit Biosciences","aka":[],"tldr":"Relit Biosciences gives patients access to biomarker-based imaging and radioligand therapy, the pairing of a diagnostic scan with a matched radioactive drug.","summary":"Relit Biosciences describes itself as a patient's access point to biomarker-based imaging and radiotherapeutics: theranostic scans that show whether a tumour carries a target such as PSMA or somatostatin receptors, and the radioligand therapies that follow. It is an Even One Ventures portfolio company; its public site is a single page with a contact address.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://relit.bio/"},{"label":"Even One Ventures portfolio","url":"https://evenone.ventures/"}],"tags":["startup","evenone-portfolio","oncology"],"related":[],"cancers":[],"sections":[],"technologies":["radioligand-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"United States (head office not published)","country":"US","companyType":"radiopharma","website":"https://relit.bio/","stage":"startup","investors":["evenone-ventures"],"funding":[]},{"id":"remegen","kind":"company","name":"RemeGen","aka":[],"tldr":"RemeGen developed disitamab vedotin, China's first domestic ADC.","summary":"RemeGen, based in Yantai and listed in Hong Kong as 9995.HK, developed disitamab vedotin, China's first domestically developed antibody-drug conjugate. Disitamab vedotin, also known as RC48, targets HER2 and is used in gastric and urothelial cancer, and the company's other main product is telitacicept for autoimmune disease. OnCo links it to gastric and HER2-positive breast cancer, to the disitamab vedotin drug record and to Peking University Cancer Hospital. Whether a HER2 ADC with an older payload can find a durable niche as newer HER2 ADCs spread is the open question. Disitamab vedotin has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.remegen.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":[],"targets":[],"drugs":["disitamab-vedotin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07462143","nct06962865","nct06155396","nct05980481","nct05302284","nct06155383","nct06227117","nct06389006","nct06038396","nct06221748","nct06178159","nct06378242","nct06157892","nct07105215","nct07315750","nct05911295","nct06016062","nct05205850","nct06642545"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Yantai","country":"CN","companyType":"biotech","website":"https://www.remegen.com","ticker":"9995.HK","investors":[],"funding":[]},{"id":"remix-therapeutics","kind":"company","name":"Remix Therapeutics","aka":["Remix Therapeutics, Inc."],"tldr":"Remix Therapeutics is a Massachusetts biotech that makes small molecules to change how RNA is processed; REM-422 destroys the messenger RNA for the transcription factor MYB, a driver of adenoid cystic carcinoma and acute myeloid leukaemia.","summary":"Remix Therapeutics uses its REMaster platform to design small molecules that reprogramme RNA splicing and stability. REM-422 induces a poison exon in MYB mRNA, marking it for degradation and lowering MYB protein; it is in phase 1 trials in adenoid cystic carcinoma and in acute myeloid leukaemia and higher-risk myelodysplastic syndromes. The company has partnerships with Janssen and Roche on other RNA-processing targets.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.remixtx.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["rem-422"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Watertown, Massachusetts","country":"US","companyType":"biotech","website":"https://www.remixtx.com/","founded":2019,"investors":[],"funding":[]},{"id":"repare-therapeutics","kind":"company","name":"Repare Therapeutics","aka":[],"tldr":"Repare Therapeutics was a Montreal cancer drug developer working on drugs that stop tumours repairing their own DNA. In January 2026 it was bought by a non-profit called XenoTherapeutics and its shares stopped trading.","summary":"Repare Therapeutics was a clinical-stage precision oncology company based in Cambridge, Massachusetts and Montreal, focused on synthetic lethal targets in the DNA damage response. Its portfolio included camonsertib (RP-3500, an ATR inhibitor), lunresertib (RP-6306, a PKMYT1 inhibitor), RP-1664 (PLK4) and RP-3467 (Pol theta), with partnerships involving Bristol Myers Squibb, Debiopharm and DCx Biotherapeutics. After a strategic review, Repare agreed in November 2025 to be acquired by XenoTherapeutics, Inc., a non-profit biotechnology company, by way of a plan of arrangement. Shareholders approved the deal on 16 January 2026 and it completed on 28 January 2026, with holders receiving about 2.20 US dollars per share plus a contingent value right tied to future partnership and licensing proceeds. The company then delisted from Nasdaq and filed to deregister in February 2026.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.reparerx.com/"},{"label":"Acquisition agreement announcement (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1808158/000119312525283314/d39095dex991.htm"},{"label":"Completion of acquisition (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1808158/000119312526027394/d95398dex991.htm"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":["synthetic-lethality-approaches"],"targets":["atr"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The company website (reparerx.com) could not be fetched (TLS handshake failure and HTTP 409) and the investor site returned 403, so the website URL is unverified. Former Nasdaq ticker RPTX omitted because the shares no longer trade. Pipeline details are taken from the acquisition press release; the IPO (2020) was not sourced."],"hq":"Montreal","country":"CA","companyType":"biotech","website":"https://www.reparerx.com/","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2026,"source":"https://www.sec.gov/Archives/edgar/data/1808158/000119312526027394/d95398dex991.htm","note":"All shares acquired by non-profit XenoTherapeutics for about 2.20 US dollars per share in cash plus a contingent value right; total deal value not stated"}]},{"id":"replimune","kind":"company","name":"Replimune","aka":[],"tldr":"Oncolytic virus company whose RP1 (Tudriqev) was approved in August 2026 after an initial FDA rejection.","summary":"Replimune, based in Woburn, Massachusetts, and listed as REPL, is the oncolytic virus company whose RP1, or vusolimogene oderparepvec, was approved in August 2026 as Tudriqev after an initial FDA rejection. RP1 is an oncolytic virus for melanoma and cutaneous squamous cell carcinoma, and RP2, which expresses an anti-CTLA-4 antibody, is being tested in uveal melanoma. OnCo links it to melanoma and cutaneous squamous cell carcinoma, to the oncolytic virus technology, to the bottleneck of cold tumours, and to the idea of oncolytic viruses that make interleukin-12 only inside the tumour. Whether an approval won after a rejection translates into adoption alongside checkpoint inhibitors is the open question. Vusolimogene oderparepvec has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.replimune.com"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["vusolimogene-oderparepvec"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06581406","nct04050436","nct03767348","nct05733598","nct04349436"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Woburn, MA","country":"US","companyType":"biotech","website":"https://www.replimune.com","ticker":"REPL","investors":[],"funding":[]},{"id":"reprosent","kind":"company","name":"REPROSENT","aka":[],"tldr":"REPROSENT is a patient app that helps people with cancer and their families track symptoms and treatment, and turns what they record into alerts for their care team.","summary":"REPROSENT is a patient-driven care system for oncology: an app that gives patients and caregivers structured tasks, captures patient-reported experience between visits, and routes it to clinical teams as actionable information and triage prompts, with the stated aim of relieving overburdened medical teams and improving outcomes. It is tagged oncology in the YC directory and remains active with a small team; evidence of clinical impact has not been published in a primary source found at the time of checking.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/reprosent"},{"label":"Official website","url":"https://www.reprosent.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Los Gatos, CA","country":"US","companyType":"ai-software","website":"https://www.reprosent.com","stage":"startup","ycBatch":"S21","investors":["y-combinator"],"funding":[]},{"id":"resistancebio","kind":"company","name":"ResistanceBio (Viosera Therapeutics)","aka":[],"tldr":"ResistanceBio set out to design drugs that stop cancers becoming resistant to treatment. The company is no longer active.","summary":"ResistanceBio, incorporated as Viosera Therapeutics, aimed to solve acquired drug resistance in cancer by modelling how tumours evolve under therapy and designing compounds against the resistance routes. It grew to about 15 people with sites in San Francisco and the St. Louis area before the YC directory marked it inactive. Recorded here as wound down; no acquirer or successor is named because none was found in a primary source.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/viosera-therapeutics"}],"tags":["yc"],"related":[],"cancers":[],"sections":["drug-discovery","targeted-therapy"],"technologies":["ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.ycombinator.com/companies/viosera-therapeutics","stage":"defunct","ycBatch":"W19","investors":["y-combinator"],"funding":[]},{"id":"reverie-labs","kind":"company","name":"Reverie Labs","aka":[],"tldr":"Reverie Labs used machine learning to design cancer drugs that could cross into the brain. It is no longer operating.","summary":"Reverie Labs was a Cambridge, Massachusetts drug discovery company that built machine-learning models for small-molecule design and applied them to brain-penetrant kinase inhibitors for cancers with central nervous system involvement. It grew to roughly 30 people and ran discovery partnerships before the YC directory marked it inactive; its website was offline when checked. Recorded as wound down; no acquirer is named because none was found in a primary source.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/reverie-labs"}],"tags":["yc"],"related":[],"cancers":["glioblastoma"],"sections":["drug-discovery","ai-computation"],"technologies":["ai-drug-design","kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cambridge, MA","country":"US","companyType":"ai-software","website":"https://www.ycombinator.com/companies/reverie-labs","stage":"defunct","ycBatch":"W18","investors":["y-combinator"],"funding":[]},{"id":"revolution-medicines","kind":"company","name":"Revolution Medicines","aka":["EQRx International, Inc.","EQRx"],"tldr":"Revolution Medicines is the leading RAS company, with daraxonrasib in phase 3 for pancreatic cancer.","summary":"Revolution Medicines, based in Redwood City, California, and listed as RVMD, is the leading RAS company, with daraxonrasib in phase 3 for pancreatic cancer. Its pipeline pairs daraxonrasib, a pan-RAS inhibitor, with elironrasib, selective for G12C in the active state, and zoldonrasib against G12D, tested in the RASolute and RASolve phase 3 programmes, and the company expanded its credit facility in 2025 to fund a launch. OnCo links it to pancreatic ductal adenocarcinoma, to the KRAS roadmap from undruggable through G12C to pan-RAS, to the bottleneck of undruggable drivers, and to the idea of covalent chemistry for RAS mutations that still have no drug. Whether pan-RAS inhibition is tolerable enough for long-term use is the open question. Daraxonrasib has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.revmed.com"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["daraxonrasib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07491445","nct07805954","nct07252232","nct07621718","nct06881784","nct07777822","nct06445062","nct07397338","nct05379985","nct06162221","nct06128551"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Redwood City, CA","country":"US","companyType":"biotech","website":"https://www.revmed.com","ticker":"RVMD","investors":[],"funding":[]},{"id":"rgcc-international","kind":"company","name":"RGCC International","aka":["RGCC Group"],"tldr":"RGCC offers blood tests that isolate circulating tumour cells and profile them to guide treatment choices and to track disease over time, sold worldwide to patients as well as physicians.","summary":"RGCC International markets liquid biopsy tests based on circulating tumour cells: molecular profiling of the cells to suggest which drugs and natural substances might act on them, and serial counts to monitor disease activity and treatment response. Future of Cancer Care Today lists it as worldwide and patient- or physician-ordered. The tests sit outside mainstream guideline practice, and readers should weigh the evidence for chemosensitivity testing on circulating cells accordingly.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://rgcc-international.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["liquid-biopsy","ctc-capture"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Zug, Switzerland","country":"CH","companyType":"diagnostics","website":"https://rgcc-international.com/","investors":[],"funding":[]},{"id":"rhizen-pharmaceuticals","kind":"company","name":"Rhizen Pharmaceuticals","aka":["Rhizen Pharmaceuticals AG","Rhizen Pharmaceuticals SA"],"tldr":"Rhizen Pharmaceuticals is a Swiss biotech, part of India's Incozen group, whose dual PI3K delta and gamma inhibitor tenalisib is being tested in T-cell lymphoma and breast cancer.","summary":"Rhizen Pharmaceuticals, based in Basel, discovers small molecules for cancer and immune disease. Tenalisib (RP6530) inhibits the delta and gamma isoforms of PI3K, which are enriched in lymphocytes and myeloid cells; it has been studied in relapsed T-cell lymphomas, in combination with romidepsin, and in hormone receptor-positive breast cancer. Rhizen also discovered the PI3K delta inhibitor umbralisib, later developed by TG Therapeutics.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.rhizen.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["tenalisib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Basel","country":"CH","companyType":"biotech","website":"https://www.rhizen.com/","investors":[],"funding":[]},{"id":"rhovac","kind":"company","name":"RhoVac","aka":["RhoVac AB","Chosa Oncology"],"tldr":"RhoVac was a Swedish biotech whose peptide vaccine RV001 trained T cells against RhoC, a protein of spreading cancer cells, but its phase 2b trial in prostate cancer failed in 2022.","summary":"RhoVac developed RV001 (onilcamotide), a peptide vaccine against the small GTPase RhoC, which is over-expressed in metastasising cancer cells but not in the primary tumour. The randomised phase 2b BRaVac trial tested RV001 to delay progression in men with rising PSA after prostatectomy or radiotherapy; it did not reach its endpoint in 2022, and the company wound down the programme and was later renamed Chosa Oncology to pursue other assets.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["rv001v"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Lund","country":"SE","companyType":"biotech","stage":"defunct","investors":[],"funding":[]},{"id":"rhythm-pharmaceuticals","kind":"company","name":"Rhythm Pharmaceuticals","aka":["Rhythm Pharmaceuticals, Inc.","NASDAQ:RYTM"],"tldr":"Rhythm Pharmaceuticals is a Boston company whose MC4R agonist setmelanotide, sold as Imcivree, treats the uncontrolled hunger and obesity of rare genetic disorders and of damage to the hypothalamus, including after treatment for craniopharyngioma and other brain tumours.","summary":"Rhythm Pharmaceuticals develops treatments for rare diseases of the melanocortin-4 receptor pathway that controls hunger. Setmelanotide (Imcivree, RM-493) is approved in the United States and Europe for obesity due to POMC, PCSK1 or LEPR deficiency and for Bardet-Biedl syndrome. Its phase 3 TRANSCEND trial in acquired hypothalamic obesity, which follows surgery or radiotherapy for craniopharyngioma and other suprasellar tumours, met its primary endpoint in 2025 and supports a supplemental filing.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.rhythmtx.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["setmelanotide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Boston, Massachusetts","country":"US","companyType":"biotech","website":"https://www.rhythmtx.com/","ticker":"NASDAQ:RYTM","founded":2008,"stage":"public","investors":[],"funding":[]},{"id":"rigel-pharmaceuticals","kind":"company","name":"Rigel Pharmaceuticals","aka":[],"tldr":"Commercialises olutasidenib (Rezlidhia), an IDH1 inhibitor for relapsed AML, alongside fostamatinib.","summary":"Rigel Pharmaceuticals, based in South San Francisco and listed as RIGL, commercialises olutasidenib, sold as Rezlidhia, an IDH1 inhibitor for relapsed acute myeloid leukaemia, alongside fostamatinib. Olutasidenib was approved on 1 December 2022 for relapsed or refractory IDH1-mutated AML, and Rigel licensed it from Forma Therapeutics, later part of Novo Nordisk, in 2022. OnCo links it to acute myeloid leukaemia and to the olutasidenib drug record. Whether a second IDH1 inhibitor can take share from the first on durability or tolerability is the open question for a company that did not discover the drug it sells. Olutasidenib has its own page.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://www.rigel.com"}],"tags":[],"related":[],"cancers":["aml"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["olutasidenib","fostamatinib","pralsetinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06161974","nct05308264"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.rigel.com","ticker":"RIGL","investors":[],"funding":[]},{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","aka":[],"tldr":"Creator of Herceptin, Avastin, and Rituxan, and owner of Foundation Medicine; the company that defined antibody oncology.","summary":"Roche and its US arm Genentech, based in Basel and listed as ROG.SW, created Herceptin, Avastin and Rituxan, own Foundation Medicine and Flatiron Health, and defined antibody oncology as a field. The portfolio includes trastuzumab, pertuzumab and trastuzumab emtansine, atezolizumab, which in 2026 received the first approval guided by circulating tumour DNA, the bispecifics glofitamab and mosunetuzumab, inavolisib, giredestrant, venetoclax with AbbVie, alectinib, and the personalised mRNA vaccine autogene cevumeran with BioNTech. OnCo links it to the IMbrave150, KATHERINE, CLL14 and MURANO papers, to the Flatiron and Foundation Medicine clinico-genomic database, and to the bottleneck of unvalidated biomarkers. Whether a company that owns both drugs and diagnostics can keep the two honest with each other is the fair question. Each product has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.roche.com"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy","immunotherapy","diagnostics"],"technologies":[],"targets":[],"drugs":["trastuzumab","trastuzumab-emtansine","atezolizumab","glofitamab","inavolisib","venetoclax","autogene-cevumeran","ipatasertib","cevostamab","emactuzumab","ro7771950","adg126","englumafusp-alfa","tretinoin-atra","interferon-alfa"],"companies":["poseida-therapeutics","roche-venture-fund"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05170204","nct04712097","nct07541170","nct02486718","nct05047250","nct06793215","nct05904886","nct03178552","nct04712643","nct07287150","nct02568267","nct05009069","nct04077723","nct05583617","nct05593094","nct05789082","nct04302025","nct05535244","nct05533775","nct04246086","nct05805501","nct06096779","nct05207670","nct03075696","nct03671018","nct04931342","nct04524871"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Basel","country":"CH","companyType":"pharma","website":"https://www.roche.com","ticker":"ROG.SW","investors":[],"funding":[]},{"id":"roche-venture-fund","kind":"company","name":"Roche Venture Fund","aka":[],"tldr":"Roche's corporate venture fund, based in Basel, which takes minority stakes in early biotech and diagnostics companies. Its web pages could not be located at the time of research.","summary":"The Roche Venture Fund is the corporate venture arm of Roche, the Basel-based pharmaceutical and diagnostics group, and historically invested in early-stage biotechnology and diagnostics companies as a financial rather than strategic investor. Several candidate URLs under roche.com (partnering/venture-fund, innovation/partnering/roche-venture-fund and similar) returned 404 pages, and the Roche partnering page fetched does not mention the fund, so its current status, strategy, team location and oncology portfolio could not be confirmed from a primary source.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.roche.com/venturefund"},{"label":"Roche partnering","url":"https://www.roche.com/innovation/partnering"}],"tags":["corporate-venture"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["venturefund.roche.com redirects to roche.com/venturefund, fetched on 2026-09-10."],"hq":"Basel","country":"CH","companyType":"investor","website":"https://www.roche.com/venturefund","investors":[],"funding":[]},{"id":"rovi","kind":"company","name":"Rovi","aka":["Laboratorios Farmacéuticos Rovi","Rovi Pharmaceuticals Laboratories","Laboratorios Rovi"],"tldr":"Rovi is a Madrid pharmaceutical group known for low-molecular-weight heparins and long-acting injectables; its bemiparin trials in cancer-associated thrombosis are why it appears among phase 3 cancer sponsors.","summary":"Laboratorios Farmacéuticos Rovi, founded in 1946 in Madrid and listed on the Spanish stock exchange, makes the low-molecular-weight heparin bemiparin, contract-manufactures injectables and develops long-acting formulations. Its phase 3 trials of bemiparin for preventing and treating venous thromboembolism in cancer patients are registered on ClinicalTrials.gov under Rovi as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.rovi.es"},{"label":"ClinicalTrials.gov: trials led by Laboratorios Farmacéuticos Rovi","url":"https://clinicaltrials.gov/search?lead=Laboratorios%20Farmac%C3%A9uticos%20Rovi"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q65180652"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":["cancer-associated-thrombosis"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Madrid","country":"ES","companyType":"pharma","website":"https://www.rovi.es","founded":1946,"stage":"public","investors":[],"funding":[]},{"id":"ryvu-therapeutics","kind":"company","name":"Ryvu Therapeutics","aka":["Ryvu Therapeutics SA"],"tldr":"Ryvu Therapeutics is a Poland-based biotechnology company running 5 late-stage cancer trials of RVU120, MEN1703 and Glofitamab in acute myeloid leukaemia, myelodysplastic syndromes / neoplasms and hodgkin lymphoma.","summary":"Ryvu Therapeutics, based in Krakow, Poland, is a biotechnology company. A clinical-stage drug discovery and development company focused on novel small-molecule therapies addressing emerging targets in oncology. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials, testing RVU120, MEN1703, Glofitamab and Ruxolitinib in acute myeloid leukaemia, myelodysplastic syndromes / neoplasms, hodgkin lymphoma and myeloproliferative neoplasms. The largest, NCT06397313 (RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis), plans to enrol 230 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.ryvu.com"},{"label":"ClinicalTrials.gov: trials led by Ryvu Therapeutics","url":"https://clinicaltrials.gov/search?lead=Ryvu%20Therapeutics%20SA"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml","mds","hodgkin-lymphoma","myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":["men1703","rvu120"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06534437","nct06243458"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Krakow","country":"PL","companyType":"biotech","website":"https://www.ryvu.com","stage":"public","investors":[],"funding":[]},{"id":"sagely-health","kind":"company","name":"Sagely Health","aka":[],"tldr":"Sagely Health, led by the oncologist Jason Sager, helps patients and families make sense of evolving science, trials and access pathways, starting with a free clinical trial report.","summary":"Sagely Health offers a free, HIPAA-compliant clinical trial report and affordable individualised consultations with expert research and oncologist oversight, so patients can understand their treatment, ask better questions and find a relevant specialist. Patient-accessible.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.sagelyhealth.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["ai-trial-matching"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"United States (city not published)","country":"US","companyType":"cro-services","website":"https://www.sagelyhealth.com/","investors":[],"funding":[]},{"id":"sagemedic","kind":"company","name":"SageMedic","aka":[],"tldr":"SageMedic builds 3D microtumours from a patient's solid tumour and measures how candidate drugs and combinations kill or slow them, including for rare cancers and cancers of unknown primary.","summary":"SageMedic's SAGE Oncotest provides functional drug response testing and tissue evaluation for solid tumours using 3D microtumours to assess tumour cell killing, growth inhibition and drug combination activity. Based in Redwood City, California; physician-ordered.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.sagemedic.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["functional-drug-testing","organoids"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Redwood City, CA","country":"US","companyType":"diagnostics","website":"https://www.sagemedic.com/","investors":[],"funding":[]},{"id":"sakura-finetek","kind":"company","name":"Sakura Finetek","aka":[],"tldr":"Sakura Finetek is a histology automation leader (Tissue-Tek processors, embedders, stainers, and the Genie IHC platform).","summary":"Sakura Finetek, a private Japanese company based in Tokyo, is a histology automation leader with the Tissue-Tek processors, embedders and stainers and the Genie immunohistochemistry platform. It holds a large share of tissue processing equipment worldwide. OnCo links it to histology automation and IHC autostainers. Whether the pre-analytical steps it automates, from fixation to sectioning, are standardised well enough for AI pathology models trained at one site to work at another is the question its market position raises. The histology automation page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.sakura.eu"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["ihc-autostainers-histology-automation"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tokyo","country":"JP","companyType":"diagnostics","website":"https://www.sakura.eu","investors":[],"funding":[]},{"id":"salubris-biotherapeutics","kind":"company","name":"Salubris Biotherapeutics","aka":["SalubrisBio"],"tldr":"Salubris Biotherapeutics is a US-based biotechnology company that leads 2 cancer trials in OnCo, testing the biologics JK06 and JK08 in melanoma, colorectal cancer, non-small-cell lung cancer, small-cell lung cancer and advanced solid tumours.","summary":"Salubris Biotherapeutics (SalubrisBio) is a clinical-stage biotechnology company founded in 2016 that discovers and develops antibody and protein-based biologics for cardiovascular disease and oncology. Its pipeline includes JK06, JK07 and JK08. It is the US subsidiary of Salubris Pharmaceuticals of Shenzhen. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT06667960 (phase 1/2, Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer) and NCT05620134 (phase 1/2, Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.salubrisbio.com/"},{"label":"ClinicalTrials.gov: trials led by Salubris Biotherapeutics","url":"https://clinicaltrials.gov/search?lead=Salubris%20Biotherapeutics%20Inc"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma","colorectal","nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["jk08","pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06667960","nct05620134"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Gaithersburg, Maryland","country":"US","companyType":"biotech","website":"https://www.salubrisbio.com/","founded":2016,"stage":"growth","investors":[],"funding":[]},{"id":"samsara-biocapital","kind":"company","name":"Samsara BioCapital","aka":[],"tldr":"A Palo Alto life sciences investment firm founded by Srinivas Akkaraju that invests in private and public biotech companies. Its website could not be read at the time of research.","summary":"Samsara BioCapital is a Palo Alto-based life sciences investor that, according to the task hint, backs private and public biotechnology companies across therapeutic areas including oncology. At the time of research its website (samsarabiocapital.com) returned an empty page that redirected to a '/lander' address on every attempt, and no alternative primary page could be located without web search, so the firm's own description, founding year, strategy and portfolio could not be confirmed. None of the press releases or portfolio pages fetched for other entries in this file happened to name Samsara BioCapital as a co-investor, so no oncology portfolio company is cited here; any examples should be sourced from a company press release before being added.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.samsarabiocapital.com/"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Site fetched on 2026-09-10 (JavaScript-heavy, so no portfolio examples were read)."],"hq":"Palo Alto, CA","country":"US","companyType":"investor","website":"https://www.samsarabiocapital.com/","investors":[],"funding":[]},{"id":"samsung-bioepis","kind":"company","name":"Samsung Bioepis","aka":[],"tldr":"Samsung Bioepis develops biosimilars of trastuzumab, bevacizumab and other antibodies, made by its parent Samsung Biologics at Songdo.","summary":"Samsung Bioepis was founded in 2012 as a joint venture between Samsung Biologics and Biogen and became wholly owned by Samsung Biologics in 2022. It develops biosimilars, among them trastuzumab (Ontruzant) and bevacizumab (Aybintio), which are manufactured at Samsung Biologics' Songdo plants and sold with partners in Europe and the United States.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.samsungbioepis.com"}],"tags":["manufacturing-wave"],"related":[],"cancers":["breast-her2-positive","colorectal"],"sections":[],"technologies":["biosimilar-manufacturing","monoclonal-antibody-manufacturing"],"targets":[],"drugs":["trastuzumab","bevacizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Incheon","country":"KR","companyType":"biotech","website":"https://www.samsungbioepis.com","founded":2012,"stage":"private-large","investors":[],"funding":[]},{"id":"samsung-biologics","kind":"company","name":"Samsung Biologics","aka":[],"tldr":"Samsung Biologics is the world's largest biologics CDMO by capacity, and opened a dedicated ADC conjugation facility in 2025.","summary":"Samsung Biologics, based in Incheon and listed as 207940.KS, is the world's largest biologics CDMO by capacity and opened a dedicated antibody-drug conjugate conjugation facility in 2025. It runs mammalian cell culture at unprecedented scale at its Songdo Plant 5, adds ADC conjugation and fill-finish, and announced the spin-off of Samsung Bioepis in 2025. OnCo links it to ADC bioconjugation manufacturing, antibody manufacturing and sterile fill-finish. Whether Korean capacity becomes the main beneficiary as sponsors diversify ADC manufacturing away from China is the open question. The ADC manufacturing page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://samsungbiologics.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["adcs"],"technologies":["adc-cdmo-manufacturing","sterile-fill-finish"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Incheon","country":"KR","companyType":"cro-services","website":"https://samsungbiologics.com","ticker":"207940.KS","investors":[],"funding":[]},{"id":"sana-biotechnology","kind":"company","name":"Sana Biotechnology","aka":[],"tldr":"Sana Biotechnology is a hypoimmune cell-therapy company that suspended its oncology allogeneic CAR-T (SC262) in late 2025 and pivoted to type 1 diabetes and in vivo CAR-T (SG293).","summary":"Sana Biotechnology, based in Seattle and listed as SANA, is a hypoimmune cell therapy company that suspended its oncology allogeneic CAR-T, SC262, in late 2025 and pivoted to type 1 diabetes and in vivo CAR-T. SC262, a CD22 allogeneic CAR-T, had its development suspended and VIVID trial enrolment halted in November 2025; SG293 is a fusogen-delivered CD19 in vivo CAR-T candidate for oncology and autoimmunity, and SC451 islet cells lead its diabetes work. OnCo links it to diffuse large B-cell lymphoma, to allogeneic cell therapy and in vivo CAR-T, to CD19 as a target, and to the idea of qualifying one iPSC master cell bank once for many off-the-shelf products. Manufacturing cost and time for living medicines is the bottleneck behind its shift from ex vivo to in vivo approaches. Whether fusogen delivery works in patients is the open question.","asOf":"2026-09-04","links":[{"label":"Q2 2026 update","url":"https://www.globenewswire.com/news-release/2026/08/10/3342190/0/en/sana-biotechnology-reports-second-quarter-2026-financial-results-and-business-updates.html"}],"tags":["pivot"],"related":[],"cancers":["dlbcl"],"sections":["cell-therapy"],"technologies":["allogeneic-cell-therapy","in-vivo-car-t"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Seattle, WA","country":"US","companyType":"cell-therapy","website":"https://sana.com","ticker":"SANA","investors":[],"funding":[]},{"id":"sandoz","kind":"company","name":"Sandoz","aka":[],"tldr":"Sandoz, spun out of Novartis in 2023, is the world's largest generics and biosimilars company; in oncology it sells biosimilar filgrastim (Zarxio), pegfilgrastim (Ziextenzo) and rituximab, and holds the US application for nelarabine (Arranon).","summary":"Sandoz, based in Basel and listed as SDZ.SW, was spun out of Novartis in 2023 and is the world's largest generics and biosimilars company; in oncology it sells biosimilar filgrastim as Zarxio, pegfilgrastim as Ziextenzo and rituximab, and holds the US application for nelarabine, sold as Arranon. It launched the first US biosimilar, Zarxio or filgrastim-sndz, in 2015, markets biosimilars of pegfilgrastim, rituximab, trastuzumab and denosumab in Europe and the United States, and carries a broad line of generic oncology injectables. OnCo links it to filgrastim, pegfilgrastim and nelarabine. Whether biosimilar competition lowers the cost of supportive care and antibody therapy as much as small-molecule generics did is the open question its portfolio tests. Each product has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.sandoz.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Basel","country":"CH","companyType":"pharma","website":"https://www.sandoz.com","ticker":"SDZ.SW","investors":[],"funding":[]},{"id":"sanofi","kind":"company","name":"Sanofi","aka":["Genzyme","Genzyme, a Sanofi Company","Kiadis Pharma","Aventis Pharmaceuticals","Aventis","ILEX Oncology Services, Incorporated","ILEX Oncology","Shantha Biotechnics Limited","Shantha Biotechnics"],"tldr":"Sanofi makes Sarclisa (isatuximab), now in a subcutaneous form approved in July 2026.","summary":"Sanofi, based in Paris and listed as SAN.PA, makes Sarclisa, or isatuximab, for multiple myeloma, now available in a subcutaneous form approved in July 2026 as Escena. Its oncology portfolio also includes cemiplimab with Regeneron, cabazitaxel, alemtuzumab, belumosudil, and avapritinib from its 2025 acquisition of Blueprint Medicines, while tusamitamab ravtansine was discontinued and a lead-212 DOTAMTATE radiopharmaceutical comes through RadioMedix. OnCo links it to myeloma, GIST, neuroendocrine tumours and skin cancers, to the EMPOWER-Cervical 1 trial, to CD52 as a target and to Sanofi Ventures. Whether the Blueprint purchase marks a durable commitment to oncology is the open question. Isatuximab and avapritinib have their own pages.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.sanofi.com"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":["immunotherapy","targeted-therapy"],"technologies":[],"targets":[],"drugs":["elenestinib","adg126","buserelin","fludarabine"],"companies":["amunix-pharmaceuticals","blueprint-medicines"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05704049","nct03731260","nct07692204","nct04270409","nct07629960","nct05584670"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Paris","country":"FR","companyType":"pharma","website":"https://www.sanofi.com","ticker":"SAN.PA","investors":[],"funding":[]},{"id":"sanofi-ventures","kind":"company","name":"Sanofi Ventures","aka":[],"tldr":"Sanofi's strategic venture fund, which invests in early biotech and digital health companies before they are ready to partner with or be bought by Sanofi. Cancer-related holdings include the radiopharmaceutical company AdvanCell and the immune checkpoint company Abcuro.","summary":"Sanofi Ventures describes itself as 'a strategic venture fund' and 'an entry point to the innovation ecosystem for Sanofi, strategically investing in early-stage transformational science and technology, when companies are too early to partner with or acquire'. It invests 'across all stages of the private company lifecycle, from Seed to Series B and beyond', leading financings and taking board seats in biotech and digital health companies. Its portfolio page includes AdvanCell (a lead-212 radiotherapeutics company advancing a PSMA-targeting radioligand for prostate cancer, which closed a $315 million Series D in July 2026 and has a collaboration with Lilly), Abcuro (anti-KLRG1 antibodies for autoimmune and cancer indications, including ABC015 to reactivate cytotoxic T and NK cells in the tumour microenvironment) and bluebird bio (gene therapy, with an oncology CAR-T collaboration).","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.sanofiventures.com/"},{"label":"Portfolio","url":"https://www.sanofiventures.com/portfolio/"}],"tags":["corporate-venture"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["sanofi"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year and office address not stated on fetched pages; Cambridge, MA follows the task hint."],"hq":"Cambridge, MA","country":"US","companyType":"investor","website":"https://www.sanofiventures.com/","investors":[],"funding":[]},{"id":"sante-ventures","kind":"company","name":"Sante Ventures","aka":[],"tldr":"Sante Ventures is an Austin, Texas healthcare venture firm that invests early in medical devices, diagnostics, biotech and health technology, including cancer companies.","summary":"Sante Ventures (styled Sante) is a healthcare-only venture capital firm founded in 2006 and based in Austin, Texas, investing at seed and Series A in medical devices, diagnostics, biopharmaceuticals and healthcare IT and often building companies alongside founders. Oncology exposure includes diagnostics and device companies. Portfolio links in OnCo are derived from the startup records that name it.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://sante.com"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Austin, TX","country":"US","companyType":"investor","website":"https://sante.com","founded":2006,"investors":[],"funding":[]},{"id":"sarah-cannon-research-institute","kind":"company","name":"Sarah Cannon Research Institute","aka":[],"tldr":"Sarah Cannon Research Institute, of Nashville, is a community-based research network owned jointly by HCA Healthcare and McKesson whose drug development units across the United States and United Kingdom frequently host first-in-human oncology trials. Whether its community sites reach patients who would never travel to an academic centre, and how their outcomes compare, is untested.","summary":"Sarah Cannon Research Institute, based in Nashville, is a large community-based research network, a joint venture of HCA Healthcare and McKesson, that runs early-phase oncology trials across its drug development units. Its drug development units and site network span the United States and the United Kingdom and frequently host first-in-human oncology studies. OnCo links it to community oncology and site networks and to contract research organisations. Whether early-phase trials run in community settings reach patients who would never travel to an academic centre is the case for its model, and the open question is how its outcomes compare. The community oncology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://sarahcannon.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":["community-oncology-networks","contract-research-organisations"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Nashville, TN","country":"US","companyType":"cro-services","website":"https://sarahcannon.com","investors":[],"funding":[]},{"id":"sarc","kind":"company","name":"SARC (Sarcoma Alliance for Research through Collaboration)","aka":["Sarcoma Alliance for Research through Collaboration","SARC"],"tldr":"SARC is a US non-profit sarcoma research organisation founded in 2003 by sarcoma physicians at five medical centres to run collaborative trials; in OnCo it leads SARC028, the pembrolizumab study across sarcoma subtypes.","summary":"SARC (Sarcoma Alliance for Research through Collaboration) is a US 501(c)(3) non-profit cancer research organisation dedicated to research for the prevention, treatment and cure of sarcoma; it was formed in 2003 by a core group of medical and paediatric sarcoma experts at five major medical facilities, received a National Cancer Institute SPORE grant in 2012, and gives its address as P.O. Box 406, Ann Arbor, Michigan (sarctrials.org). ClinicalTrials.gov names it lead sponsor (OTHER class, with Merck Sharp & Dohme as collaborator) of SARC028 (NCT02301039, phase 2, pembrolizumab in advanced soft tissue and bone sarcoma), the trial recorded in OnCo. It has no products of its own.","asOf":"2026-09-25","links":[{"label":"SARC: about","url":"https://sarctrials.org/about/"},{"label":"ClinicalTrials.gov: trials led by Sarcoma Alliance for Research through Collaboration","url":"https://clinicaltrials.gov/search?lead=Sarcoma%20Alliance%20for%20Research%20through%20Collaboration"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["sarcoma","undifferentiated-pleomorphic-sarcoma","liposarcoma","osteosarcoma","ewing-sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["sarc028"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"Ann Arbor, Michigan","country":"US","companyType":"cooperative-group","website":"https://sarctrials.org","founded":2003,"investors":[],"funding":[]},{"id":"sartorius","kind":"company","name":"Sartorius","aka":["Sartorius Stedim Biotech"],"tldr":"Sartorius makes the bags, filters, bioreactors and analytical instruments that biologics and cell therapy plants run on. Every antibody drug made in a single-use bioreactor depends on it or one of three competitors.","summary":"Sartorius, founded in Göttingen in 1870 as a maker of laboratory balances, is one of the largest suppliers of bioprocess equipment and consumables: single-use bioreactors and bags (Biostat, Flexsafe), membranes and filters for sterile filtration and viral clearance, chromatography systems and the process analytics that go with them. Its Sartorius Stedim Biotech subsidiary is listed in Paris. Cancer drug makers meet it in every CHO plant and in most cell therapy suites, and its lead times became a bottleneck for the whole industry during the 2020 to 2022 vaccine build-out.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.sartorius.com"}],"tags":["manufacturing-wave"],"related":[],"cancers":[],"sections":[],"technologies":["single-use-bioprocessing","downstream-purification-chromatography","monoclonal-antibody-manufacturing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Göttingen","country":"DE","companyType":"cro-services","website":"https://www.sartorius.com","ticker":"SRT","founded":1870,"stage":"public","investors":[],"funding":[]},{"id":"sbi-pharmaceuticals","kind":"company","name":"SBI Pharmaceuticals","aka":["SBI ALApharma Canada, Inc.","SBI ALApharma","SBIファーマ"],"tldr":"SBI Pharmaceuticals is the Tokyo company behind 5-aminolevulinic acid products in Japan, including Alaglio, which makes bladder tumours glow during cystoscopy so surgeons can see and remove them.","summary":"SBI Pharmaceuticals, part of Japan's SBI group and founded in 2011, develops medicines and supplements based on 5-aminolevulinic acid. Its Alaglio was approved in Japan for photodynamic diagnosis of bladder cancer during transurethral resection and for glioma surgery, and its Canadian arm SBI ALApharma Canada ran phase 3 trials to bring the bladder cancer indication to North America, registered on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.sbipharma.co.jp"},{"label":"ClinicalTrials.gov: trials led by SBI ALApharma Canada, Inc.","url":"https://clinicaltrials.gov/search?lead=SBI%20ALApharma%20Canada%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q11242594"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["urothelial","glioblastoma"],"sections":[],"technologies":["fluorescence-guided-surgery","cystoscopy-turbt"],"targets":[],"drugs":["aminolevulinic-acid"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Tokyo","country":"JP","companyType":"pharma","website":"https://www.sbipharma.co.jp","founded":2011,"stage":"private-large","investors":[],"funding":[]},{"id":"scancell","kind":"company","name":"Scancell","aka":["Scancell Ltd"],"tldr":"Scancell is a United Kingdom-based biotechnology company running 2 late-stage cancer trials in melanoma, triple-negative breast cancer and renal cell carcinoma.","summary":"Scancell, based in Oxford, the United Kingdom, is a biotechnology company. Scancell is a late-stage clinical company developing active immunotherapies designed to enhance anti-tumour immune responses in cancer. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials in melanoma, triple-negative breast cancer, renal cell carcinoma, ovarian cancer and head and neck squamous cell carcinoma. The largest, NCT04079166 (SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)), plans to enrol 173 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.scancell.co.uk/"},{"label":"ClinicalTrials.gov: trials led by Scancell","url":"https://clinicaltrials.gov/search?lead=Scancell%20Ltd"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma","tnbc","rcc","ovarian","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05329532","nct04079166"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Oxford","country":"GB","companyType":"biotech","website":"https://www.scancell.co.uk/","founded":1996,"stage":"public","investors":[],"funding":[]},{"id":"scandinavian-sarcoma-group","kind":"company","name":"Scandinavian Sarcoma Group","aka":["SSG"],"tldr":"The Scandinavian Sarcoma Group, formed in 1979 by Nordic sarcoma physicians and scientists, writes shared treatment protocols and ran SSG XVIII, the trial that set three years of adjuvant imatinib for high-risk GIST.","summary":"The Scandinavian Sarcoma Group (SSG) was formed in 1979 by physicians and scientists from the Scandinavian countries with a primary interest in tumours of connective tissue; its goal is to advance sarcoma care and knowledge through treatment protocols and basic and clinical research, and it is part of Lund University, with its secretariat at Barngatan 4, Lund, Sweden (ssg-org.net). ClinicalTrials.gov names it lead sponsor (OTHER class) of SSG XVIII/AIO (NCT00116935, phase 3, one against three years of adjuvant imatinib in high-risk gastrointestinal stromal tumour, run with the German AIO), the trial recorded in OnCo. It has no products of its own.","asOf":"2026-09-25","links":[{"label":"Official website","url":"https://www.ssg-org.net"},{"label":"ClinicalTrials.gov: trials led by Scandinavian Sarcoma Group","url":"https://clinicaltrials.gov/search?lead=Scandinavian%20Sarcoma%20Group"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["lund-skane"],"pathways":[],"terms":[],"trials":["ssgxviii"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"Lund","country":"SE","companyType":"cooperative-group","website":"https://www.ssg-org.net","founded":1979,"investors":[],"funding":[]},{"id":"science-37","kind":"company","name":"Science 37 (eMed)","aka":[],"tldr":"Pioneer of the 'metasite' decentralised trial model, acquired by eMed in 2024.","summary":"Science 37, based in Los Angeles and acquired by eMed in 2024, pioneered the metasite model of decentralised trials, in which a virtual site with its own investigators and nurses enrols patients wherever they live. Its oncology work has concentrated on symptom and supportive care trials, where remote conduct is most practical. OnCo links it to decentralised and hybrid clinical trials. Whether the virtual site model can extend from supportive care into treatment trials that require imaging and infusions is the open question. The decentralised trials page carries the wider evidence.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.science37.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["decentralised-clinical-trials"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Los Angeles, CA","country":"US","companyType":"ai-software","website":"https://www.science37.com","investors":[],"funding":[]},{"id":"scirouter","kind":"company","name":"SciRouter","aka":[],"tldr":"SciRouter is a prevention-first longevity start-up founded by Ryan Bethencourt that sells plant-based daily supplements for people, dogs and cats, and frames cancer and age-related decline as engineering problems to be prevented rather than treated.","summary":"SciRouter describes itself as building prevention-first longevity for people and pets, with the aim of protecting health today and making age-related disease less inevitable. Its three products are ARES for humans, NK9 for dogs and NKat for cats, all vegan daily supplements marketed for cellular defence and healthy cellular ageing and made in the United States. The founder, Ryan Bethencourt, is a biotech entrepreneur best known for co-founding the IndieBio accelerator and the pet food company Wild Earth. The company states that it wants to protect health, detect disease earlier and make cancer less inevitable; it has not published clinical trials or evidence for its products, and no funding, investors or founding year are stated on its site. OnCo records it under prevention as a start-up whose claims are not yet backed by trials.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://scirouter.ai"}],"tags":["ctgov-sponsor","startup","prevention","longevity","owner-request"],"related":[],"cancers":[],"sections":["nutrition-lifestyle"],"technologies":["chemoprevention"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"United States (head office not published)","country":"US","companyType":"biotech","website":"https://scirouter.ai","stage":"startup","investors":[],"funding":[]},{"id":"scorpion-therapeutics","kind":"company","name":"Scorpion Therapeutics","aka":[],"tldr":"Scorpion Therapeutics was a Boston start-up that designed a cancer pill, STX-478, aimed only at the mutated form of a growth protein called PI3K-alpha, sparing the normal form. Eli Lilly bought the programme in 2025.","summary":"Scorpion Therapeutics was a Boston precision oncology company founded in 2020 whose lead asset, STX-478, is a mutant-selective, allosteric PI3K-alpha inhibitor intended to avoid the hyperglycaemia and other toxicities of wild-type PI3K-alpha inhibition. In January 2025 Eli Lilly agreed to acquire the STX-478 programme; Lilly's first-quarter 2025 results describe the acquisition as the main driver of a 1.57 billion US dollar acquired in-process research and development charge, and the Scorpion website now redirects to Lilly's announcement. SEC Form D filings show roughly 172 million US dollars sold in 2020 offerings and a further 125.7 million US dollars sold in a 2024 offering before the sale to Lilly.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.scorpiontx.com/"},{"label":"Lilly Q1 2025 results mentioning the acquisition (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000129/q125lillysalesandearningsp.htm"},{"label":"Form D (July 2024)","url":"https://www.sec.gov/Archives/edgar/data/1811858/000095012324006593/primary_doc.xml"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["pik3ca"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["scorpiontx.com redirects to a Lilly investor page that returned HTTP 403, so the acquisition press release itself could not be fetched; the deal is confirmed via Lilly's SEC-filed earnings releases. Headline deal value (reported in press as up to 2.5 billion US dollars) and the reported spin-out of non-PI3K assets were not verified. Series labels for the Form D rounds are not stated in the filings."],"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://www.scorpiontx.com/","founded":2020,"stage":"acquired","investors":[],"funding":[{"round":"Form D offering","year":2020,"amountUsd":24681250,"source":"https://www.sec.gov/Archives/edgar/data/1811858/000181185820000001/primary_doc.xml","note":"Total sold per Form D filed May 2020"},{"round":"Form D offering","year":2020,"amountUsd":146999977,"source":"https://www.sec.gov/Archives/edgar/data/1811858/000181185820000003/primary_doc.xml","note":"Total sold per Form D filed December 2020"},{"round":"Form D offering","year":2024,"amountUsd":125694186,"source":"https://www.sec.gov/Archives/edgar/data/1811858/000095012324006593/primary_doc.xml","note":"Total sold of a 150 million US dollar offering per Form D filed July 2024"},{"round":"Acquisition","year":2025,"source":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000129/q125lillysalesandearningsp.htm","note":"Lilly's Q1 2025 results attribute most of a 1.57 billion US dollar acquired in-process R&D charge to the acquisition of Scorpion's PI3K-alpha inhibitor programme STX-478; headline deal value not verified"}],"acquiredBy":"eli-lilly"},{"id":"screenpoint-medical","kind":"company","name":"ScreenPoint Medical","aka":[],"tldr":"Radboud University spin-out whose Transpara software is the AI reader tested in the MASAI screening trial.","summary":"ScreenPoint's Transpara is CE-marked and FDA-cleared for 2D and 3D mammography and is the breast screening AI with the most published trial evidence, used in MASAI (Sweden) and in Danish and German programmes. The company's founders come from the Nijmegen computer-aided detection group that ran the DREAM mammography challenge.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://screenpoint-medical.com"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":["ai-computation","imaging","early-detection"],"technologies":["radiology-ai-screening","mammography"],"targets":[],"drugs":["transpara"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["masai"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Nijmegen","country":"NL","companyType":"ai-software","website":"https://screenpoint-medical.com","founded":2014,"stage":"startup","investors":[],"funding":[]},{"id":"section-32","kind":"company","name":"Section 32 (S32)","aka":[],"tldr":"Section 32 is a venture firm founded by the former head of Google Ventures that invests across biology, healthcare and computing, including AI-native cancer diagnostics and therapeutics companies.","summary":"Section 32, now branded S32, is a venture capital firm founded in 2017 by Bill Maris after he left GV. It invests at the intersection of technology and life sciences, from early rounds to growth, with oncology exposure through diagnostics, AI-driven drug discovery and therapeutics. Portfolio links in OnCo are derived from the startup records that name it.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.s32.com"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Diego, CA","country":"US","companyType":"investor","website":"https://www.s32.com","founded":2017,"investors":[],"funding":[]},{"id":"sectra","kind":"company","name":"Sectra","aka":[],"tldr":"Sectra, of Linköping, Sweden, makes enterprise imaging and digital pathology software whose PACS and Digital Pathology module run national-scale fully digital pathology in the Netherlands, the United Kingdom and Sweden. Whether that delivers faster diagnoses and better use of scarce pathologists is still being tested.","summary":"Sectra, based in Linköping and listed as SECT-B.ST, makes enterprise imaging and digital pathology software used by European and UK health systems, including national deployments, to run fully digital pathology. Its Sectra Digital Pathology module and PACS underpin large national deployments in the Netherlands, the United Kingdom and Sweden. OnCo links it to whole-slide scanners and image management and to telemedicine, teleoncology and telepathology. Whether national-scale digital pathology delivers faster diagnoses and better use of scarce pathologists, as its adopters expect, is the open question. The whole-slide scanner page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://sectra.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics","imaging"],"technologies":["whole-slide-scanners"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Linköping","country":"SE","companyType":"ai-software","website":"https://sectra.com","ticker":"SECT-B.ST","investors":[],"funding":[]},{"id":"securabio","kind":"company","name":"SecuraBio","aka":["Secura Bio","Secura Bio, Inc."],"tldr":"SecuraBio is a US company that owns the PI3K inhibitor duvelisib (Copiktra), acquired from Verastem in 2020, for relapsed chronic lymphocytic leukaemia and follicular lymphoma.","summary":"SecuraBio, a privately held company based in Las Vegas, acquired worldwide rights to duvelisib (Copiktra) from Verastem Oncology in 2020. Duvelisib, an oral inhibitor of PI3K-delta and PI3K-gamma, is approved in the United States for relapsed or refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma after two prior therapies; its follicular lymphoma indication was withdrawn in 2021, and the FDA added a boxed warning in 2022 after a survival analysis of the DUO trial. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials led by SecuraBio","url":"https://clinicaltrials.gov/search?lead=SecuraBio"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cll","follicular-lymphoma"],"sections":["targeted-therapy"],"technologies":[],"targets":["pik3cd"],"drugs":["duvelisib","panobinostat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06522737"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Las Vegas, NV","country":"US","companyType":"biotech","website":"https://securabio.com","stage":"private-large","investors":[],"funding":[]},{"id":"sengine","kind":"company","name":"SEngine Precision Medicine","aka":[],"tldr":"Runs the PARIS test: a patient's tumour grown as organoids and screened against 240+ drugs to find options sequencing cannot see.","summary":"SEngine Precision Medicine, based in Seattle, runs the PARIS test, in which a patient's tumour is grown as organoids and screened against more than 240 drugs to find options that sequencing cannot see. It is CLIA-certified in all fifty states and approved by New York's CLEP, PARIS uses three-dimensional organoids from any solid tumour to rank drug sensitivity, it collaborates with Dana-Farber and Gustave Roussy, and it has raised about 19 million dollars through its Series A. OnCo links it to functional ex vivo drug testing and patient-derived organoids, to the bottleneck of preclinical models that do not predict people, and to the idea of holding organoid tests to the standard of a diagnostic. Whether organoid drug sensitivity predicts patient response well enough to guide therapy is the open question. The organoid technology page carries the evidence.","asOf":"2026-09-04","links":[{"label":"NY CLEP approval","url":"https://www.biospace.com/sengine-precision-medicine-receives-new-york-state-clep-approval-for-paris-test"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics","drug-discovery"],"technologies":["functional-drug-testing","organoids"],"targets":[],"drugs":[],"companies":[],"institutions":["dana-farber","gustave-roussy"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Seattle, WA","country":"US","companyType":"diagnostics","website":"https://senginemedicine.com","investors":[],"funding":[]},{"id":"serb-pharmaceuticals","kind":"company","name":"SERB Pharmaceuticals","aka":[],"tldr":"SERB is a European specialty company focused on emergency and rescue medicines; in oncology it markets glucarpidase (Voraxaze) for toxic methotrexate levels and uridine triacetate (Vistogard) for fluorouracil overdose in Europe.","summary":"SERB Pharmaceuticals, based in Paris, is a European specialty company focused on emergency and rescue medicines; in oncology it markets glucarpidase, sold as Voraxaze, for toxic methotrexate levels and uridine triacetate, sold as Vistogard, for fluorouracil overdose in Europe. It acquired BTG's specialty pharmaceuticals business in 2021, adding Voraxaze, CroFab and DigiFab, and distributes antidotes and rescue therapies used in oncology supportive care. OnCo links it to glucarpidase, uridine triacetate and telotristat ethyl. Whether rarely used antidotes remain stocked and affordable when a single company holds them is the question that matters for the patients who suddenly need them. Glucarpidase has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.serb.eu"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Paris","country":"FR","companyType":"pharma","website":"https://www.serb.eu","investors":[],"funding":[]},{"id":"serinus-biosciences","kind":"company","name":"Serinus Biosciences","aka":[],"tldr":"Serinus uses an explainable AI model of cancer cell biology to work out how tumours evade a drug, and to design combinations that block the escape routes.","summary":"Serinus Biosciences builds a systems-biology-primed, explainable AI platform that infers how cancer cells evolve resistance to treatment and proposes drug combinations to override the escape routes, with the aim of designing safer and more effective combination regimens that can reach patients quickly using existing molecules. Founded by MIT PhDs with advisers from the Broad Institute, Dana-Farber and UC San Diego. Work is computational and preclinical; no sourced financing rounds are recorded.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/serinus-biosciences"},{"label":"Official website","url":"https://www.serinus.bio"}],"tags":["yc"],"related":[],"cancers":[],"sections":["drug-discovery","ai-computation"],"technologies":["ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"New York, NY","country":"US","companyType":"ai-software","website":"https://www.serinus.bio","stage":"startup","ycBatch":"S22","investors":["y-combinator"],"funding":[]},{"id":"serova","kind":"company","name":"Serova","aka":[],"tldr":"Serova is an early-stage company building a personalised cancer vaccine platform that redesigns the vaccine as the tumour evolves.","summary":"Serova is an early-stage UK company building a personalised cancer vaccine platform that redesigns the vaccine as the tumour evolves. Its approach uses longitudinal, multi-site tumour data to select tumour-driving mutations and design patient-specific vaccines that reflect the disease state at the time of dosing, and the work is preclinical with limited public disclosure beyond company profiles. OnCo links it to personalised neoantigen mRNA vaccines and to the neoantigen term. Whether re-targeting a vaccine to a moving tumour can be done fast enough to matter clinically is the open question, and the company has published little that would let a reader judge. The personalised vaccine technology page carries the field's evidence.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://pitchbook.com/profiles/company/1161350-47"}],"tags":["early-stage"],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["neoantigen-mrna-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["neoantigen"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"United Kingdom","country":"GB","companyType":"biotech","website":"https://pitchbook.com/profiles/company/1161350-47","investors":[],"funding":[]},{"id":"serum-institute-of-india","kind":"company","name":"Serum Institute of India","aka":[],"tldr":"The world's largest vaccine maker by doses, which developed CERVAVAC, India's first home-made HPV vaccine, so that cervical cancer prevention no longer depends on imported shots.","summary":"The Serum Institute of India was founded in 1966 in Pune and makes more vaccine doses than any other company. With support from the Department of Biotechnology it developed CERVAVAC, a quadrivalent HPV vaccine against types 6, 11, 16 and 18 produced in Hansenula polymorpha yeast, indicated for girls and women aged 9 to 26 (cervical, vulvar, vaginal and anal cancer and genital warts) and boys and men aged 9 to 26 (anal cancer and genital warts), given as two doses at 0 and 6 months for ages 9 to 14 and three doses for ages 15 to 26. CERVAVAC received Indian market authorisation in 2022 and was introduced in 2023; published comparisons report immunogenicity non-inferior to established vaccines, and it is the intended supply for India's planned national HPV vaccination programme.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.seruminstitute.com"},{"label":"CERVAVAC product page","url":"https://www.seruminstitute.com/product_ind_cervavac.php"}],"tags":[],"related":[],"cancers":["cervical","head-and-neck"],"sections":["prevention"],"technologies":["hpv-vaccine"],"targets":[],"drugs":["cervavac","gardasil-9"],"companies":[],"institutions":["dbt-india"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-prevention-adoption","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Pune","country":"IN","companyType":"pharma","website":"https://www.seruminstitute.com","founded":1966,"investors":[],"funding":[]},{"id":"servier","kind":"company","name":"Servier","aka":[],"tldr":"Servier is the private French pharma that brought vorasidenib, the first low-grade glioma drug, to market.","summary":"Servier is the private French pharmaceutical company, based in Suresnes, that brought vorasidenib, the first drug for IDH-mutant low-grade glioma, to market. Vorasidenib and ivosidenib, sold as Tibsovo, came from its acquisition of the Agios oncology business, and OnCo links it to the INDIGO paper on vorasidenib, to AGILE on ivosidenib plus azacitidine in IDH1-mutated acute myeloid leukaemia, to NAPOLI-3 and trifluridine and tipiracil in gastrointestinal cancer, to asparaginase products and to the UCART19 gene-edited CAR-T paper. The brain as a barrier and sanctuary is the bottleneck vorasidenib was designed to cross. How long IDH inhibition can defer radiotherapy and chemotherapy in low-grade glioma is the open question. Vorasidenib has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://servier.com"}],"tags":[],"related":[],"cancers":[],"sections":["epigenetics"],"technologies":[],"targets":[],"drugs":["vorasidenib","tng462","pixantrone"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05876754","nct05907057","nct06127407","nct06162572"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Suresnes","country":"FR","companyType":"pharma","website":"https://servier.com","investors":[],"funding":[]},{"id":"shandong-new-time-pharmaceutical","kind":"company","name":"Shandong New Time Pharmaceutical","aka":["Shandong New Time Pharmaceutical Co., LTD"],"tldr":"Shandong New Time Pharmaceutical is a Chinese developer in Shandong that sponsors 3 registered cancer trials of F182112 and F182112 single-agent.","summary":"Shandong New Time Pharmaceutical appears on ClinicalTrials.gov as the industry sponsor of 3 interventional cancer trials (phase 2, 2/3, 3), testing F182112, F182112 single-agent, Pomalidomide in relapsed or refractory multiple myeloma, relapsed or refractory multiple myeloma (rrmm), cancer of unknown primary site. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials sponsored by Shandong New Time Pharmaceutical","url":"https://clinicaltrials.gov/search?spons=Shandong%20New%20Time%20Pharmaceutical"}],"tags":["ctgov-sponsor","china","registry-only"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["f182112"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07312188","nct07579234","nct07761429"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shandong, China","country":"CN","companyType":"biotech","investors":[],"funding":[]},{"id":"shanghai-abelzeta","kind":"company","name":"Shanghai AbelZeta","aka":["Shanghai AbelZeta Ltd."],"tldr":"Shanghai AbelZeta is a China-based cell therapy company running 2 late-stage cancer trials in hepatocellular carcinoma and multiple myeloma.","summary":"Shanghai AbelZeta, based in Shanghai, China, is a cell therapy company. AbelZeta Pharma is a global cell therapy company focused on discovering, developing and manufacturing CAR-T therapeutics for haematologic malignancies, inflammatory and immunological diseases, and solid tumours. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials in hepatocellular carcinoma and multiple myeloma. The largest, NCT06590246 (A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)), plans to enrol 121 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.abelzeta.com/"},{"label":"ClinicalTrials.gov: trials led by Shanghai AbelZeta","url":"https://clinicaltrials.gov/search?lead=Shanghai%20AbelZeta%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["hcc","multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06590246","nct05521802"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"cell-therapy","website":"https://www.abelzeta.com/","investors":[],"funding":[]},{"id":"allist","kind":"company","name":"Shanghai Allist Pharmaceuticals","aka":["Allist","艾力斯"],"tldr":"Allist is the single-product lung cancer company behind furmonertinib, China's other third-generation EGFR pill, partnered with ArriVent for the rest of the world.","summary":"Shanghai Allist Pharmaceuticals, based in Shanghai, founded in 2004 and listed as 688578.SS, is the single-product lung cancer company behind furmonertinib, China's other third-generation EGFR tablet, partnered with ArriVent for the rest of the world. Furmonertinib, sold as Ivesa, was approved in 2021 and for first-line use in 2022 on the FURLONG trial, and its exon 20 insertion programme is licensed to ArriVent BioPharma in the United States with the global FURVENT phase 3. OnCo links it to furmonertinib and FURLONG. Its profitability on one drug shows the size of China's EGFR-mutant lung cancer market, and whether the exon 20 programme gives it a global product rather than a domestic one is the open question. Furmonertinib has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.allist.com.cn/"}],"tags":["china"],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["furmonertinib","sitneprotafib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["furlong","nct06956001","nct05194995","nct05288205","nct05276726","nct04853342","nct05009329","nct06008288","nct05466149","nct06970639"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.allist.com.cn/","ticker":"688578.SS","founded":2004,"investors":[],"funding":[]},{"id":"shanghai-bovax-biotechnology","kind":"company","name":"Shanghai Bovax Biotechnology","aka":["Bovax","上海博唯生物"],"tldr":"Shanghai Bovax Biotechnology is a China-based biotechnology company that leads 4 cancer trials in OnCo, testing quadrivalent, 9-valent and 15-valent HPV vaccines in penile cancer, cervical cancer, vulvar cancer, vaginal cancer and advanced solid tumours.","summary":"Shanghai Bovax Biotechnology develops recombinant protein vaccines and drugs, with quadrivalent, 9-valent and 15-valent HPV vaccine candidates and a recombinant enterovirus 71 vaccine in clinical development. It runs research in Shanghai and a vaccine manufacturing base in Chongqing through its subsidiary Chongqing Bovax Biopharmaceutical. On ClinicalTrials.gov it is the lead sponsor of 4 trials recorded in OnCo (3 in phase 3 or 2/3): NCT06465914 (phase 3, A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent H...), NCT04422366 (phase 3, Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in...), NCT05027776 (phase 3, Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subject...) and NCT06756269 (phase 2, To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chine...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.bovaxbio.com/"},{"label":"ClinicalTrials.gov: trials led by Shanghai Bovax Biotechnology","url":"https://clinicaltrials.gov/search?lead=Shanghai%20Bovax%20Biotechnology%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["penile","cervical","vulvar","vaginal"],"sections":[],"technologies":[],"targets":[],"drugs":["hpv-quadrivalent-vaccine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06465914","nct04422366","nct05027776","nct06756269"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.bovaxbio.com/","founded":2012,"stage":"growth","investors":[],"funding":[]},{"id":"shanghai-fosun-pharmaceutical-industrial-development","kind":"company","name":"Shanghai Fosun Pharmaceutical Industrial Development","aka":["Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd."],"tldr":"Shanghai Fosun Pharmaceutical Industrial Development is a China-based pharmaceutical company running 5 late-stage cancer trials of FCN-159 and Test group (Group A): FCN-159 in non-small-cell lung cancer and rare cancers of childhood.","summary":"Shanghai Fosun Pharmaceutical Industrial Development, based in Shanghai, China, is a pharmaceutical company and part of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. listed as 600196.SH; 02196.HK. Part of the Fosun Pharma group, a China-rooted global pharmaceutical and healthcare group with operations spanning pharmaceuticals, medical devices, diagnostics, healthcare services and pharmaceutical distribution. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing FCN-159 and Test group (Group A): FCN-159 in non-small-cell lung cancer and rare cancers of childhood. The largest, NCT06569420 (Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC), plans to enrol 275 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.fosunpharma.com"},{"label":"ClinicalTrials.gov: trials led by Shanghai Fosun Pharmaceutical Industrial Development","url":"https://clinicaltrials.gov/search?lead=Shanghai%20Fosun%20Pharmaceutical%20Industrial%20Development%20Co.%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","rare-childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06858618","nct06569420","nct04954001","nct07562581"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"pharma","website":"https://www.fosunpharma.com","ticker":"600196.SH; 02196.HK","founded":1994,"stage":"public","investors":[],"funding":[]},{"id":"henlius","kind":"company","name":"Shanghai Henlius Biotech","aka":[],"tldr":"Chinese biosimilar and biologics company whose PD-1 antibody serplulimab is approved in China and Europe for small-cell lung cancer.","summary":"Shanghai Henlius Biotech, listed in Hong Kong as 2696.HK, is a Chinese biosimilar and biologics company whose PD-1 antibody serplulimab is approved in China and Europe for small-cell lung cancer. Serplulimab was proved in the ASTRUM-005 trial and received EU approvals in 2025 for extensive-stage small-cell lung cancer, squamous non-small-cell lung cancer and other indications, a US bridging trial has completed enrolment, and the company also sells trastuzumab and bevacizumab biosimilars. OnCo links it to small-cell lung cancer, to serplulimab and the trastuzumab biosimilars records, and to the bottleneck of regulatory divergence between regions. Whether a Chinese PD-1 antibody can gain US approval on a bridging study, having already won Europe, is the open question. Serplulimab and ASTRUM-005 have their own pages.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://www.henlius.com"}],"tags":["china"],"related":[],"cancers":["sclc"],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["serplulimab","trastuzumab-biosimilars","hlx43","hlx22","hlx11","hlx26"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["astrum-005","nct05353257","nct04547166","nct05468489","nct06769152","nct07253142","nct07269782","nct06848699","nct06839066","nct07294508","nct06769113","nct06349980","nct07106892","nct06812260","nct06742892","nct05787613","nct06907615","nct06832202"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.henlius.com","ticker":"2696.HK","investors":[],"funding":[]},{"id":"shanghai-jiatan-pharmatech","kind":"company","name":"Shanghai Jiatan Pharmatech","aka":["Shanghai Jiatan Pharmatech Co., Ltd"],"tldr":"Shanghai Jiatan Pharmatech is a China-based biotechnology company that leads 2 cancer trials in OnCo, testing the dual PI3K and mTOR inhibitor WX390 in advanced solid tumours.","summary":"Shanghai Jiatan Pharmatech is a Shanghai-based drug developer. The ClinicalTrials.gov registry lists it as lead sponsor of Chinese trials of WX390, an oral dual PI3K and mTOR inhibitor, in advanced solid tumours and in combination with toripalimab. No company website could be verified, so company facts here are limited to the registry. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT06117566 (phase 1/2, A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors) and NCT06117540 (phase 2, A Study of WX390 in Patients With Advanced Solid Tumors). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov: trials led by Shanghai Jiatan Pharmatech","url":"https://clinicaltrials.gov/search?lead=Shanghai%20Jiatan%20Pharmatech%20Co.%2C%20Ltd"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["toripalimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06117566","nct06117540"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Shanghai","country":"CN","companyType":"biotech","investors":[],"funding":[]},{"id":"shanghai-juncell-therapeutics","kind":"company","name":"Shanghai Juncell Therapeutics","aka":[],"tldr":"Shanghai Juncell Therapeutics is a China-based cell therapy company running 2 late-stage cancer trials of GC101 TIL in melanoma and non-small-cell lung cancer.","summary":"Shanghai Juncell Therapeutics, based in Shanghai, China, is a cell therapy company. Juncell Therapeutics is a biotech enterprise focused on research, development and commercialisation of innovative cell therapies for solid tumours, using tumour-infiltrating lymphocyte (TIL) technology platforms. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing GC101 TIL in melanoma and non-small-cell lung cancer. The largest, NCT06703398 (A Study of GC101 TIL in Advanced Melanoma), plans to enrol 98 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.juncell.com/"},{"label":"ClinicalTrials.gov: trials led by Shanghai Juncell Therapeutics","url":"https://clinicaltrials.gov/search?lead=Shanghai%20Juncell%20Therapeutics"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["gc101-til"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06703398","nct07560111"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"cell-therapy","website":"https://www.juncell.com/","founded":2019,"stage":"growth","investors":[],"funding":[]},{"id":"junshi","kind":"company","name":"Shanghai Junshi Biosciences","aka":["Junshi","君实生物"],"tldr":"Junshi developed toripalimab, the first Chinese PD-1 antibody approved in China (2018) and the first approved by the FDA (2023, nasopharyngeal cancer).","summary":"Toripalimab (Tuoyi / Loqtorzi) has more than ten NMPA indications, US approval for nasopharyngeal carcinoma with Coherus (licence February 2021, $150 million upfront), and EU, UK and Australian approvals. Pipeline: the BTLA antibody tifcemalimab, a PD-1 x VEGF bispecific and ADCs. Junshi also co-developed the COVID-19 antibody etesevimab with Lilly.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.junshipharma.com/en/"},{"label":"Coherus licence (February 2021)","url":"https://investors.coherus.com/news-releases"}],"tags":["china"],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["toripalimab","js105","fluzoparib","js111"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["jupiter-02","jupiter-06","nct06679985"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.junshipharma.com/en/","ticker":"1877.HK / 688180.SS","founded":2012,"investors":[],"funding":[]},{"id":"shanghai-kechow-pharma","kind":"company","name":"Shanghai Kechow Pharma","aka":["Shanghai Kechow Pharma, Inc."],"tldr":"Shanghai Kechow Pharma is a China-based pharmaceutical company running 3 late-stage cancer trials of tunlametinib, Tunlametinib and HL-085 in melanoma, colorectal cancer and rare cancers of childhood.","summary":"Shanghai Kechow Pharma, based in Shanghai, China, is a pharmaceutical company. Kechow Pharma is a Shanghai-based pharmaceutical company engaged in independent, intellectual-property-driven innovative drug research and development, focused on oncology and free-radical-related diseases. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing tunlametinib, Tunlametinib and HL-085 in melanoma, colorectal cancer and rare cancers of childhood. The largest, NCT06008106 (Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma), plans to enrol 165 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://kechowpharma.com"},{"label":"ClinicalTrials.gov: trials led by Shanghai Kechow Pharma","url":"https://clinicaltrials.gov/search?lead=Shanghai%20Kechow%20Pharma%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma","colorectal","rare-childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":["kc1036","tunlametinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"pharma","website":"https://kechowpharma.com","founded":2014,"stage":"private-large","investors":[],"funding":[]},{"id":"shanghai-miracogen","kind":"company","name":"Shanghai Miracogen","aka":["Miracogen","Shanghai Miracogen Inc.","美雅珂生物"],"tldr":"Shanghai Miracogen is a Chinese antibody-drug conjugate developer whose HER2 conjugate MRG002 has been tested across breast, stomach, bladder and biliary cancers and whose EGFR conjugate MRG003 targets head and neck and nasopharyngeal cancer.","summary":"Shanghai Miracogen builds antibody-drug conjugates with site-specific conjugation and auristatin payloads. MRG002 links a HER2 antibody to monomethyl auristatin E and has been studied in HER2-positive and HER2-low breast cancer, gastric cancer, urothelial carcinoma and biliary tract cancer. MRG003 targets EGFR in nasopharyngeal and head and neck squamous carcinomas, and MRG004A targets tissue factor in pancreatic cancer.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.miracogen.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["mrg002"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.miracogen.com/","founded":2015,"investors":[],"funding":[]},{"id":"shanghai-pharmaceuticals","kind":"company","name":"Shanghai Pharmaceuticals","aka":["Shanghai Pharmaceuticals Holding","SPH","上海医药","HKEX:2607","SSE:601607"],"tldr":"Shanghai Pharmaceuticals is one of China's largest drug makers and distributors; its research arm is developing SPH4336, an oral CDK4/6 inhibitor for breast cancer.","summary":"Shanghai Pharmaceuticals Holding, listed in Shanghai and Hong Kong, manufactures generic and innovative medicines and runs one of China's biggest pharmaceutical distribution networks. Its oncology research includes SPH4336, a selective CDK4/6 inhibitor in phase 1/2 trials with endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer, and the PD-L1 and TIGIT programmes of its biologics subsidiaries.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.sphchina.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["sph4336"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Shanghai","country":"CN","companyType":"pharma","website":"https://www.sphchina.com/","ticker":"HKEX:2607","stage":"public","investors":[],"funding":[]},{"id":"shanghai-sunway-biotech","kind":"company","name":"Shanghai Sunway Biotech","aka":["Sunway Biotech"],"tldr":"Shanghai Sunway Biotech makes Oncorine (H101), the oncolytic adenovirus approved in China in 2005, the first oncolytic virus approved anywhere.","summary":"Shanghai Sunway Biotech developed and manufactures H101 (Oncorine), an E1B-deleted oncolytic adenovirus approved by China's regulator in November 2005 for late-stage nasopharyngeal carcinoma with chemotherapy. It remains the only approved oncolytic virus in China and is being studied in liver and other cancers.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.sunwaybio.com.cn"}],"tags":["ctgov-sponsor","china"],"related":[],"cancers":["nasopharyngeal"],"sections":[],"technologies":["oncolytic-virus"],"targets":[],"drugs":["h101-oncolytic-adenovirus"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai, China","country":"CN","companyType":"biotech","website":"https://www.sunwaybio.com.cn","stage":"private-large","investors":[],"funding":[]},{"id":"shanghai-yingli","kind":"company","name":"Shanghai Yingli Pharmaceutical","aka":["Yingli Pharma"],"tldr":"Shanghai Yingli Pharmaceutical developed linperlisib, the PI3K-delta inhibitor approved in China in 2022 for relapsed follicular lymphoma.","summary":"Shanghai Yingli Pharmaceutical is a small-molecule company in Shanghai's Zhangjiang science park. Its PI3K-delta inhibitor linperlisib (YY-20394) received conditional NMPA approval in November 2022 for relapsed or refractory follicular lymphoma after two or more lines, and is in trials in peripheral T-cell lymphoma and solid tumours.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.yingli-pharma.com"}],"tags":["ctgov-sponsor","china"],"related":[],"cancers":["follicular-lymphoma"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["linperlisib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai, China","country":"CN","companyType":"biotech","website":"https://www.yingli-pharma.com","stage":"growth","investors":[],"funding":[]},{"id":"shasqi","kind":"company","name":"Shasqi","aka":[],"tldr":"Shasqi puts an inert form of a chemotherapy drug into the bloodstream and switches it on only inside the tumour, using a chemical reaction called click chemistry, so the rest of the body sees far less of the drug.","summary":"Shasqi's CAPAC platform (Click Activated Protodrugs Against Cancer) localises a tetrazine-modified biopolymer at the tumour, then infuses a trans-cyclooctene-caged protodrug that is activated by an in vivo click reaction where the two meet. The lead programme SQ3370 delivers a doxorubicin protodrug and completed a first-in-human phase 1 study in advanced solid tumours including soft tissue sarcoma, reporting that the approach allowed doxorubicin exposures well above conventional dosing with manageable toxicity. The company has raised venture rounds since YC and continues clinical development; amounts are not recorded here because no primary source was fetched.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/shasqi"},{"label":"Official website","url":"https://www.shasqi.com"}],"tags":["yc"],"related":[],"cancers":["sarcoma"],"sections":["chemotherapy","targeted-therapy"],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.shasqi.com","stage":"growth","ycBatch":"W15","investors":["y-combinator"],"funding":[]},{"id":"shenzhen-ionova-life-sciences","kind":"company","name":"Shenzhen Ionova Life Sciences","aka":["Shenzhen Ionova Life Sciences Co., Ltd."],"tldr":"Shenzhen Ionova Life Sciences is a China-based biotechnology company running 3 late-stage cancer trials of INV-8989, INV-6452 and INV-9956 in colorectal cancer, non-small-cell lung cancer and pancreatic ductal adenocarcinoma.","summary":"Shenzhen Ionova Life Sciences, based in Shenzhen, China, is a biotechnology company. Ionova Biosciences develops next-generation oncology therapeutics, aiming for new cancer treatments with clear clinical benefit and global competitiveness. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials, testing INV-8989, INV-6452 and INV-9956 in colorectal cancer, non-small-cell lung cancer, pancreatic ductal adenocarcinoma, ovarian cancer and endometrial cancer. The largest, NCT07612891 (A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumour), plans to enrol 201 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.ionovabio.com"},{"label":"ClinicalTrials.gov: trials led by Shenzhen Ionova Life Sciences","url":"https://clinicaltrials.gov/search?lead=Shenzhen%20Ionova%20Life%20Sciences%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["colorectal","nsclc","pancreatic","ovarian","endometrial","cholangiocarcinoma","breast-hr-positive","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07610798","nct07612891","nct06609005"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shenzhen","country":"CN","companyType":"biotech","website":"https://www.ionovabio.com","stage":"growth","investors":[],"funding":[]},{"id":"shenzhen-targetrx","kind":"company","name":"Shenzhen TargetRx","aka":["Shenzhen TargetRx Co., Ltd."],"tldr":"Shenzhen TargetRx is a China-based biotechnology company running 4 late-stage cancer trials of TGRX-326, TGRX-814 and TGRX-678 in non-small-cell lung cancer, hodgkin lymphoma and acute myeloid leukaemia.","summary":"Shenzhen TargetRx, based in Shenzhen, China, is a biotechnology company. TargetRx develops next-generation targeted small-molecule anticancer drugs designed to overcome drug resistance, using an AI-assisted, structure-based molecular design platform. On ClinicalTrials.gov it is the lead sponsor of 4 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing TGRX-326, TGRX-814 and TGRX-678 in non-small-cell lung cancer, hodgkin lymphoma, acute myeloid leukaemia, acute lymphoblastic leukaemia and myelodysplastic syndromes / neoplasms. The largest, NCT06082635 (TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)), plans to enrol 321 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.tjrbiosciences.com"},{"label":"ClinicalTrials.gov: trials led by Shenzhen TargetRx","url":"https://clinicaltrials.gov/search?lead=Shenzhen%20TargetRx%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","hodgkin-lymphoma","aml","all-leukemia","mds","cml"],"sections":[],"technologies":[],"targets":[],"drugs":["tgrx-326"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05955391","nct06453902","nct06206174"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shenzhen","country":"CN","companyType":"biotech","website":"https://www.tjrbiosciences.com","investors":[],"funding":[]},{"id":"shimadzu","kind":"company","name":"Shimadzu","aka":[],"tldr":"Shimadzu is a Kyoto instrument maker whose medical division sells X-ray, fluoroscopy and angiography systems and whose analytical division built the mass spectrometers that won a Nobel Prize.","summary":"Founded in 1875, Shimadzu produced Japan's first medical X-ray images and today sells fixed and mobile digital radiography, fluoroscopy tables and angiography systems used in interventional oncology suites, alongside laboratory mass spectrometers and chromatographs; Koichi Tanaka of Shimadzu shared the 2002 Nobel Prize in Chemistry for soft laser desorption ionisation. OnCo links it to X-ray radiography and fluoroscopy.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.shimadzu.com"}],"tags":["machines-wave"],"related":[],"cancers":[],"sections":["imaging"],"technologies":["x-ray-radiography-fluoroscopy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Kyoto","country":"JP","companyType":"imaging","website":"https://www.shimadzu.com","ticker":"7701.T","founded":1875,"stage":"public","investors":[],"funding":[]},{"id":"shine-technologies","kind":"company","name":"SHINE Technologies","aka":[],"tldr":"SHINE Technologies is a fusion-based isotope company that produces non-carrier-added Lu-177 (Ilumira) and is building the Chrysalis Mo-99 plant.","summary":"SHINE Technologies, based in Janesville, Wisconsin, is a fusion-based isotope company that produces non-carrier-added lutetium-177, sold as Ilumira, and is building the Chrysalis molybdenum-99 plant. It has supplied lutetium-177 to radiopharmaceutical developers since 2022, its large-scale Mo-99 facility is under construction, and it holds long-term fusion energy ambitions. OnCo links it to the therapeutic isotope supply chain for Mo-99, Lu-177 and Ac-225. Whether a second Western source of lutetium-177 makes supply resilient enough for radioligand therapy to scale is the open question. The isotope supply chain page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.shinefusion.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["radiopharma"],"technologies":["therapy-isotope-supply-chain"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Janesville, WI","country":"US","companyType":"radiopharma","website":"https://www.shinefusion.com","investors":[],"funding":[]},{"id":"shionogi","kind":"company","name":"Shionogi","aka":["Shionogi & Co., Ltd.","塩野義製薬","TSE:4507"],"tldr":"Shionogi is a long-established Osaka pharmaceutical company, best known for antibiotics and antivirals, that developed the platinum chemotherapy nedaplatin sold in Japan as Aqupla.","summary":"Shionogi, founded in Osaka in 1878, is a research-based pharmaceutical company with strengths in infectious disease, including the antiviral Xofluza and the antibiotic cefiderocol, and in pain and central nervous system medicines. In oncology it developed nedaplatin (254-S), a second-generation platinum agent with less kidney toxicity than cisplatin, approved in Japan in 1995 as Aqupla for head and neck, lung, oesophageal, bladder, cervical, ovarian and testicular cancers.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.shionogi.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["nedaplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Osaka","country":"JP","companyType":"pharma","website":"https://www.shionogi.com/","ticker":"TSE:4507","founded":1878,"stage":"public","investors":[],"funding":[]},{"id":"sichuan-huiyu-pharmaceutical","kind":"company","name":"Sichuan Huiyu Pharmaceutical","aka":["Huiyu Pharma","四川汇宇制药"],"tldr":"Sichuan Huiyu Pharmaceutical is a China-based pharmaceutical company that leads 5 cancer trials in OnCo, testing the in-house candidates HY0001a, HY05350, HY07121, HYP-6589 and HYP-2090 in advanced solid tumours.","summary":"Sichuan Huiyu Pharmaceutical is a research-driven pharmaceutical company that develops, manufactures and sells anti-tumour and injectable medicines for global markets, with a growing pipeline of in-house innovative drugs and a UK subsidiary, Seacross Pharma. It is listed on the Shanghai Stock Exchange STAR Market. On ClinicalTrials.gov it is the lead sponsor of 5 trials recorded in OnCo: NCT07069062 (phase 1/2, A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced So...), NCT07083323 (phase 1/2, A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors), NCT06712680 (phase 1/2, A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Com...), NCT06639256 (phase 1/2, Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With A...) and NCT06243354 (phase 1/2, Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS M...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.huiyupharma.com/"},{"label":"ClinicalTrials.gov: trials led by Sichuan Huiyu Pharmaceutical","url":"https://clinicaltrials.gov/search?lead=Sichuan%20Huiyu%20Pharmaceutical%20Co.%2C%20Ltd"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07069062","nct07083323","nct06712680","nct06639256","nct06243354"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Neijiang, Sichuan","country":"CN","companyType":"pharma","website":"https://www.huiyupharma.com/","ticker":"SSE:688553","founded":2010,"stage":"public","investors":[],"funding":[]},{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","aka":[],"tldr":"Chinese ADC developer whose TROP2 ADC sac-TMT was licensed to Merck in one of the largest China-out deals.","summary":"Sichuan Kelun-Biotech, based in Chengdu and listed in Hong Kong as 6990.HK, is the Chinese antibody-drug conjugate developer whose TROP2 ADC sacituzumab tirumotecan, or sac-TMT, was licensed to Merck in one of the largest China-out deals, worth up to 9.3 billion dollars. Sac-TMT was the first TROP2 ADC approved in China, MK-3120 is its Nectin-4 ADC, and a broad ADC platform sits behind the Merck partnership, with Binghe Xu among the investigators linked. OnCo connects it to triple-negative breast cancer, to the TROP2 ADC roadmap that runs from sacituzumab govitecan through datopotamab deruxtecan to sac-TMT, to Sichuan Cancer Hospital and to the NMPA. Whether sac-TMT can repeat its Chinese results in Western trials is the open question. Sacituzumab tirumotecan has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.kelun-biotech.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":[],"targets":[],"drugs":["sacituzumab-tirumotecan","kl-a167","a166","skb105"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06670196","nct06448312","nct06711900","nct05870319","nct04152499","nct07296809","nct05351788","nct07622186","nct05816252","nct07329322","nct06081959","nct07459998","nct07700667","nct07341100","nct05347134","nct05642780","nct05265091","nct07230405","nct07697586","nct07448922","nct07299825","nct07586943","nct06279364","nct07308106","nct07324629","nct07545265","nct05631262","nct07019675","nct07071337"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Chengdu","country":"CN","companyType":"biotech","website":"https://www.kelun-biotech.com","ticker":"6990.HK","investors":[],"funding":[]},{"id":"siemens-healthineers","kind":"company","name":"Siemens Healthineers","aka":[],"tldr":"Siemens Healthineers makes the Biograph Vision Quadra total-body PET and photon-counting CT, and owns Varian.","summary":"Siemens Healthineers, based in Erlangen, makes the Biograph Vision Quadra total-body PET scanner and the NAEOTOM Alpha photon-counting CT, alongside MAGNETOM MRI, and it owns the radiotherapy company Varian. OnCo links it to PET/CT, CT and MRI as technologies, to nuclear medicine and total-body PET hardware, total-body PET for screening and ultra-low-dose imaging, AI auto-contouring and medical cyclotrons, and to ideas on total-body PET for personalised radioligand dosing and on validating and reimbursing AI contouring to expand radiotherapy capacity. Owning both imaging and radiotherapy gives it a position across the treatment pathway that few rivals share. Whether total-body PET moves from research instrument to routine clinical tool is the open question. Varian has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.siemens-healthineers.com"}],"tags":[],"related":[],"cancers":[],"sections":["imaging","radiation"],"technologies":["pet-ct","ct","mri"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Erlangen","country":"DE","companyType":"imaging","website":"https://www.siemens-healthineers.com","investors":[],"funding":[]},{"id":"signatur-biosciences","kind":"company","name":"Signatur Biosciences","aka":[],"tldr":"Signatur turns complex gene-expression tests, starting with breast cancer prognosis, into simple PCR tests that a local hospital lab can run in days.","summary":"Signatur Biosciences develops decentralised precision diagnostics that translate multi-gene expression signatures into PCR-based assays runnable in local hospital laboratories, with a first product for early breast cancer prognosis to guide chemotherapy decisions, cutting turnaround from weeks in a centralised laboratory to days at a fraction of the cost. The company is London-based and remains active in the YC directory; clinical validation data have not been published in a primary source found at the time of checking.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/signatur-biosciences"},{"label":"Official website","url":"https://www.signatur.bio"}],"tags":["yc"],"related":[],"cancers":["breast-hr-positive"],"sections":["diagnostics"],"technologies":["companion-diagnostic"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"London","country":"GB","companyType":"diagnostics","website":"https://www.signatur.bio","stage":"startup","ycBatch":"S22","investors":["y-combinator"],"funding":[]},{"id":"sijbrandij-foundation","kind":"company","name":"Sijbrandij Foundation","aka":["Sijbrandij Foundation LLC"],"tldr":"The Sijbrandij Foundation supports new and under-resourced ways to catalyse transformational change; in cancer it incubates Future of Cancer Care Today, the free navigation service that grew out of Sid Sijbrandij's own osteosarcoma journey.","summary":"The Sijbrandij Foundation, based at 548 Market Street in San Francisco, describes its purpose as supporting the exploration of new and under-resourced ways to catalyse transformational change. Its cancer work is Future of Cancer Care Today (FCCT), which the foundation incubates: a PhD-led team that surfaces diagnostic and treatment options for patients and families, including options beyond standard of care, curates a directory of suppliers and providers, publishes self-serve playbooks and works on patients' rights to access and move their own data and tissue. The foundation grew out of the cancer journey of Sid Sijbrandij, the GitLab co-founder, whose osteosarcoma recurred in 2024; his venture studio Even One Ventures builds companies on the same patient-first playbook.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://sijbrandijfoundation.org"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"},{"label":"Future of Cancer Care Today","url":"https://sijbrandijfoundation.org/fcct"},{"label":"Sid Sijbrandij's cancer journey","url":"https://sytse.com/cancer/"}],"tags":["ctgov-sponsor","fcct-directory","foundation","patient-first"],"related":["sid-sijbrandij"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["evenone-ventures","future-of-cancer-care-today"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Francisco, CA","country":"US","companyType":"nonprofit","website":"https://sijbrandijfoundation.org","stage":"private-large","investors":[],"funding":[]},{"id":"simcere","kind":"company","name":"Simcere Pharmaceutical","aka":["Jiangsu Simcere Pharmaceutical Co., Ltd.","Simcere Zaiming"],"tldr":"Simcere is a Nanjing-based pharmaceutical company whose oncology arm, Simcere Zaiming, is running the phase 3 SIMRISE trial of the oral SERD SIM0270 with everolimus in ER-positive breast cancer and markets the anti-PD-1 antibody enlonstobart in China.","summary":"Simcere Pharmaceutical Group, based in Nanjing and listed in Hong Kong, sells medicines across oncology, neurology and autoimmune disease in China and runs its cancer research through the subsidiary Simcere Zaiming. Its oncology portfolio includes enlonstobart, an anti-PD-1 antibody approved in China for previously treated cervical cancer, the Chinese rights to the myeloprotective drug trilaciclib, and SIM0270, an oral selective oestrogen receptor degrader in the phase 3 SIMRISE trial with everolimus for ER-positive, HER2-negative advanced breast cancer. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.simcere.com/en/"},{"label":"ClinicalTrials.gov: trials led by Jiangsu Simcere Pharmaceutical","url":"https://clinicaltrials.gov/search?lead=Simcere"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["breast-hr-positive","cervical"],"sections":["targeted-therapy","immunotherapy"],"technologies":[],"targets":[],"drugs":["sim0270","recombinant-human-endostatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["simrise","nct07361003","nct04914598"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Nanjing","country":"CN","companyType":"pharma","website":"https://www.simcere.com/en/","stage":"public","investors":[],"funding":[]},{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","aka":["Sino Biopharm","中国生物制药","Chia Tai Tianqing","CTTQ","Chia Tai Tianqing Pharmaceutical","Nanjing Shunxin Pharmaceutical","Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical"],"tldr":"Sino Biopharm, through Chia Tai Tianqing, sells anlotinib, one of China's biggest cancer drugs, and acquired LaNova Medicines to add bispecific antibodies and ADCs.","summary":"Anlotinib (Focus V) approved 2018 across lung cancer, sarcoma and thyroid cancer; the PD-L1 antibody benmelstobart (TQB2450) approved 2024 for small cell lung cancer with anlotinib; a large hepatitis and oncology generics franchise. In 2025 it agreed to acquire LaNova Medicines, whose PD-1 x VEGF bispecific LM-299 had been licensed to Merck & Co. in 2024, for up to about $951 million, an example of Chinese pharma buying Chinese biotech.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Sino_Biopharmaceutical_Limited","links":[{"label":"Official website (archived copy)","url":"https://web.archive.org/web/20251122085435/https://www.sinobiopharm.com/en/"}],"tags":["china"],"related":[],"cancers":[],"sections":["targeted-therapy","immunotherapy"],"technologies":[],"targets":[],"drugs":["anlotinib","tqb3702","tqb3909","tqb2868","benmelstobart"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04854668","nct06300177","nct05862337","nct06829771","nct05913089","nct06496490","nct07044908","nct06202261","nct07512583","nct06702618","nct06431490","nct07548177","nct06962267","nct07047365","nct06821503","nct07367516","nct06452706","nct06825494","nct07367529","nct06198751"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Hong Kong / Nanjing","country":"CN","companyType":"pharma","website":"https://www.sinobiopharm.com","ticker":"1177.HK","investors":[],"funding":[]},{"id":"sinocelltech","kind":"company","name":"Sinocelltech","aka":["Sinocelltech Ltd."],"tldr":"Sinocelltech is a China-based biotechnology company running 8 late-stage cancer trials of SCTB41, SCTB35 and SCTC21C in multiple myeloma, non-small-cell lung cancer and diffuse large B-cell lymphoma.","summary":"Sinocelltech, based in Beijing, China, is a biotechnology company. Sinocelltech is a biopharmaceutical company that researches, manufactures and commercialises monoclonal antibodies, recombinant proteins and vaccines. On ClinicalTrials.gov it is the lead sponsor of 8 recruiting or active phase 2 and phase 3 interventional cancer trials (6 in phase 3), testing SCTB41, SCTB35, SCTC21C, SCTB39-1 and SCTB14 in multiple myeloma, non-small-cell lung cancer, diffuse large B-cell lymphoma and follicular lymphoma. The largest, NCT06041061 (A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years), plans to enrol 18000 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.sinocelltech.com"},{"label":"ClinicalTrials.gov: trials led by Sinocelltech","url":"https://clinicaltrials.gov/search?lead=Sinocelltech%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["multiple-myeloma","nsclc","dlbcl","follicular-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["sctb41","sctb35","sctc21c","sctb14"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06600022","nct06041061","nct07050641"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Beijing","country":"CN","companyType":"biotech","website":"https://www.sinocelltech.com","founded":2002,"stage":"public","investors":[],"funding":[]},{"id":"sinotau-pharmaceutical","kind":"company","name":"Sinotau Pharmaceutical","aka":["Sinotau Pharmaceutical Group"],"tldr":"Sinotau Pharmaceutical is a China-based radiopharmaceutical company running 2 late-stage cancer trials of Octreotide LAR in neuroendocrine tumours.","summary":"Sinotau Pharmaceutical, based in Beijing, China, is a radiopharmaceutical company. Sinotau specialises in the research and development, production, clinical application and academic promotion of radiopharmaceutical drugs, with therapeutic focus areas in oncology, neurology and cardiology. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing Octreotide LAR in neuroendocrine tumours. The largest, NCT05459844 (A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs), plans to enrol 196 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.sinotau.com/"},{"label":"ClinicalTrials.gov: trials led by Sinotau Pharmaceutical","url":"https://clinicaltrials.gov/search?lead=Sinotau%20Pharmaceutical%20Group"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["neuroendocrine"],"sections":["radiopharma"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct05459844","nct06398444"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Beijing","country":"CN","companyType":"radiopharma","website":"https://www.sinotau.com/","founded":2014,"stage":"private-large","investors":[],"funding":[]},{"id":"sirtex","kind":"company","name":"Sirtex Medical","aka":[],"tldr":"Sirtex makes SIR-Spheres, yttrium-90 resin microspheres used for radioembolisation of liver tumours.","summary":"Sirtex Medical, based in Woburn, Massachusetts, and owned by China Grand Pharmaceutical, makes SIR-Spheres, yttrium-90 resin microspheres used for radioembolisation of liver tumours. SIR-Spheres are indicated in the United States for unresectable colorectal cancer metastatic to the liver and carry a CE mark for hepatocellular carcinoma, with the DOORwaY90 trial supporting a US indication in liver cancer, and they compete with Boston Scientific's TheraSphere glass microspheres. OnCo links it to hepatocellular carcinoma and colorectal cancer and to the radioembolisation technology record. Whether radioembolisation earns a place alongside systemic immunotherapy combinations in liver cancer, rather than being displaced by them, is the open question. The technology page covers the evidence.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://www.sirtex.com"}],"tags":[],"related":[],"cancers":["hcc","colorectal"],"sections":["radiation","radiopharma"],"technologies":["radioembolisation-tare"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Woburn, MA","country":"US","companyType":"devices","website":"https://www.sirtex.com","investors":[],"funding":[]},{"id":"sobi","kind":"company","name":"Sobi (Swedish Orphan Biovitrum)","aka":["CTI BioPharma"],"tldr":"Sobi is a Swedish rare-disease company whose haematology and oncology supportive products include palifermin (Kepivance) for severe oral mucositis, avatrombopag (Doptelet) and emapalumab (Gamifant).","summary":"Swedish Orphan Biovitrum markets Kepivance (palifermin) for mucositis after high-dose chemotherapy with stem cell support, Doptelet (avatrombopag) for thrombocytopenia, Gamifant (emapalumab) for haemophagocytic lymphohistiocytosis and Zynlonta (loncastuximab tesirine) in Europe under licence from ADC Therapeutics.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.sobi.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["palifermin","emapalumab","pacritinib"],"companies":["adc-therapeutics"],"institutions":[],"pathways":[],"terms":["mucositis","thrombocytopenia"],"trials":["nct07033598"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Stockholm","country":"SE","companyType":"pharma","website":"https://www.sobi.com","ticker":"SOBI.ST","investors":[],"funding":[]},{"id":"sofie-biosciences","kind":"company","name":"SOFIE Biosciences","aka":[],"tldr":"SOFIE Biosciences is a US radiopharmacy network running two phase 3 trials of the FAP PET tracer [18F]FAPI-74 in pancreatic and gastro-oesophageal cancer.","summary":"SOFIE Biosciences, based in Dulles, Virginia, is a US radiopharmacy network running two phase 3 trials of the FAP PET tracer 18F-FAPI-74 in pancreatic and gastro-oesophageal cancer. First patients were dosed in the FAPI-GO gastro-oesophageal trial in December 2025 and the pancreatic trial in February 2026, seven radiopharmacies have been cleared to manufacture 18F-FAPI-74 with twelve-hour shelf-life distribution planned in 2026, and the FAPI chemistry originated at Heidelberg. OnCo links it to pancreatic, gastric and oesophageal cancer, to FAPI PET and PET, to FAP as a target, to Heidelberg University Hospital and the DKFZ, and to PET tracer manufacturing and radiopharmacy networks. Whether FAP imaging changes staging and treatment in cancers where FDG PET falls short is the question the phase 3 trials will answer. The FAPI PET technology page carries the evidence.","asOf":"2026-09-04","links":[{"label":"Phase 3 first patient","url":"https://sofie.com/2026/02/11/sofie-biosciences-announces-first-patient-dosed-in-18ffapi-74-phase-3-study-for-pancreatic-cancer/"}],"tags":[],"related":[],"cancers":["pancreatic","gastric","esophageal"],"sections":["imaging","radiopharma"],"technologies":["fapi-pet","pet"],"targets":["fap"],"drugs":[],"companies":[],"institutions":["heidelberg-nct"],"pathways":[],"terms":[],"trials":["nct07217704"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Dulles, VA","country":"US","companyType":"radiopharma","website":"https://sofie.com","investors":[],"funding":[]},{"id":"sofinnova-partners","kind":"company","name":"Sofinnova Partners","aka":[],"tldr":"One of Europe's oldest life sciences venture firms, based in Paris. It has backed cancer companies such as Innate Pharma, Crescendo Biologics and Hookipa, and its portfolio company Myricx was bought by Novartis.","summary":"Sofinnova Partners states that it was 'Founded in 1972' and 'has backed more than 500 companies over 50 years', and that it 'has over EUR 4 billion under management' (homepage). It runs several strategies across the value chain: Sofinnova Capital (early-stage biopharma and medtech, often company creation), Crossover (later-stage), MD Start (medtech incubation), Industrial Biotech, Digital Medicine, Biovelocita (Italian accelerator) and a Telethon fund. Its portfolio page lists oncology companies including Innate Pharma (natural killer cell-directed antibodies), Crescendo Biologics (Humabody T-cell engagers), Hookipa Pharma (arenavirus immunotherapy), Inspirna and iOmx Therapeutics (immuno-oncology). The news page features 'the journey behind Myricx's acquisition by Novartis' (Myricx develops antibody-drug conjugate payloads).","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://sofinnovapartners.com/"},{"label":"Portfolio","url":"https://sofinnovapartners.com/portfolio"},{"label":"News","url":"https://sofinnovapartners.com/news"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":["adc","t-cell-engager"],"targets":[],"drugs":[],"companies":["myricx-bio","novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Portfolio page lists company names and strategy tags but no descriptions; oncology focus of the named companies is from general knowledge. Paris headquarters follows the task hint; the fetched pages did not show an address."],"hq":"Paris","country":"FR","companyType":"investor","website":"https://sofinnovapartners.com/","founded":1972,"investors":[],"funding":[]},{"id":"soligenix","kind":"company","name":"Soligenix","aka":["Soligenix, Inc."],"tldr":"Soligenix is a New Jersey company developing HyBryte, a synthetic hypericin ointment activated by visible light, for early-stage cutaneous T-cell lymphoma, tested in the phase 3 FLASH trials.","summary":"Soligenix, based in Princeton and listed on Nasdaq, develops treatments for rare diseases and biodefence. Its lead cancer programme is HyBryte (synthetic hypericin), a photosensitiser applied to skin lesions and activated with visible rather than ultraviolet light, for early-stage mycosis fungoides, the commonest form of cutaneous T-cell lymphoma; the FLASH phase 3 trial met its primary endpoint in 2020 and a confirmatory trial, FLASH2, followed at the FDA's request. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.soligenix.com"},{"label":"ClinicalTrials.gov: trials led by Soligenix","url":"https://clinicaltrials.gov/search?lead=Soligenix"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Soligenix"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":["radiation","targeted-therapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Princeton, NJ","country":"US","companyType":"biotech","website":"https://www.soligenix.com","stage":"public","investors":[],"funding":[]},{"id":"solti","kind":"company","name":"SOLTI Cancer Research Group","aka":["SOLTI"],"tldr":"A Barcelona-based academic breast cancer group known for biomarker-driven trials that use PAM50 intrinsic subtypes to pick therapy.","summary":"Founded in 1995, SOLTI is a Spanish academic research group that designs translational breast cancer trials around molecular subtyping. PAMELA showed the HER2-enriched intrinsic subtype predicts response to dual HER2 blockade without chemotherapy, PATRICIA tested palbociclib with trastuzumab, and HARMONIA compares ribociclib with palbociclib in HER2-enriched luminal disease. SOLTI works closely with Vall d'Hebron and Hospital Clínic investigators, partners with the Breast International Group and industry, and runs window-of-opportunity and neoadjuvant designs with serial biopsies. Patient advocates sit on its scientific committee.","asOf":"2026-09-09","links":[{"label":"SOLTI","url":"https://www.gruposolti.org"}],"tags":["cooperative-group"],"related":["palbociclib","ribociclib","trastuzumab"],"cancers":["breast-hr-positive","breast-her2-positive","tnbc"],"sections":["targeted-therapy"],"technologies":["cdk46-inhibitor","rna-seq"],"targets":[],"drugs":[],"companies":["big","geicam"],"institutions":["vall-dhebron"],"pathways":[],"terms":["pam50"],"trials":[],"people":["mafalda-oliveira","eva-ciruelos"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["PAM50-guided trials (PAMELA, HARMONIA)","CDK4/6 inhibitor trials (PATRICIA)","Window-of-opportunity and neoadjuvant designs","BIG member group"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Barcelona","country":"ES","companyType":"cooperative-group","website":"https://www.gruposolti.org","founded":1995,"investors":[],"funding":[]},{"id":"sonalasense","kind":"company","name":"SonALAsense","aka":[],"tldr":"SonALAsense is testing sonodynamic therapy, in which patients receive a drug that cancer cells turn into a light-sensitive chemical and then focused ultrasound is beamed through the skull to activate it, killing brain tumour cells without surgery.","summary":"SonALAsense develops sonodynamic therapy (SDT), a drug-device combination of SONALA-001, an intravenous formulation of aminolevulinic acid (ALA), with MR-guided focused ultrasound. Tumour cells preferentially convert ALA to protoporphyrin IX; ultrasound activation causes oxidative stress and targeted cell death while sparing normal brain. The company states it is the first to bring SDT into clinical trials: a phase 0/1 study in recurrent high-grade glioma at the Ivy Brain Tumor Center showed targeted cell death in human tumour tissue without off-target effects, and a phase 1/2 trial in children with diffuse intrinsic pontine glioma is recruiting after FDA Safe to Proceed letters in 2022. In December 2024 ARPA-H committed up to USD 46 million to develop SDT for blood cancers including leukaemia and multiple myeloma. The company has raised more than USD 20 million from accredited investors and completed an undisclosed Series B in 2022.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.sonalasense.com/"},{"label":"ARPA-H award announcement (Dec 2024)","url":"https://arpa-h.gov/news-and-events/arpa-h-funds-project-revolutionize-cancer-therapy-ultrasound-based-approach"},{"label":"Clinical, growth and Series B milestones (June 2022)","url":"https://www.sonalasense.com/news/sonalasense-achieves-significant-clinical%2C-growth-and-funding-milestones-toward-its-mission-to-soundly-defeat-cancer"},{"label":"For investors","url":"https://www.sonalasense.com/for-investors"}],"tags":[],"related":[],"cancers":["glioblastoma","aml","multiple-myeloma"],"sections":["devices","radiation","surgery"],"technologies":["hifu-histotripsy","mri"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The caller's hint of Berkeley was not confirmed; the June 2022 release is datelined Oakland, CA and the site gives only a 510 area code phone number. Sonodynamic therapy has no exact technology id; hifu-histotripsy is used for the focused ultrasound device and the ALA mechanism is described in the summary (the protoporphyrin IX detail is general knowledge). Series B amount and other investor names are undisclosed. Founding year not stated. 'radiation' and 'surgery' sections are included as the closest fronts for a non-invasive ablative therapy."],"hq":"Oakland, CA","country":"US","companyType":"devices","website":"https://www.sonalasense.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2024,"amountUsd":46000000,"source":"https://arpa-h.gov/news-and-events/arpa-h-funds-project-revolutionize-cancer-therapy-ultrasound-based-approach","note":"ARPA-H award of up to USD 46 million (Dec 2024) for sonodynamic therapy in haematologic malignancies; milestone-contingent"},{"round":"Series B","year":2022,"source":"https://www.sonalasense.com/news/sonalasense-achieves-significant-clinical%2C-growth-and-funding-milestones-toward-its-mission-to-soundly-defeat-cancer","note":"Series B completion announced June 2022; amount not disclosed"}]},{"id":"sophia-genetics","kind":"company","name":"SOPHiA GENETICS","aka":[],"tldr":"Cloud platform (SOPHiA DDM) that hospitals use to analyse and interpret NGS oncology panels.","summary":"SOPHiA GENETICS, based in Rolle, Switzerland, and listed as SOPH, provides the SOPHiA DDM cloud platform that hospitals use to analyse and interpret next-generation sequencing oncology panels. Its decentralised model lets laboratories sequence locally and interpret in the cloud, and it runs multimodal research programmes combining imaging with genomics. OnCo links it to clinical NGS bioinformatics and variant interpretation. Whether decentralised sequencing with centralised interpretation gives results as consistent as sending samples to one large laboratory is the open question. The bioinformatics technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.sophiagenetics.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics","ai-computation"],"technologies":["ngs-bioinformatics-software","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Rolle","country":"CH","companyType":"ai-software","website":"https://www.sophiagenetics.com","ticker":"SOPH","investors":[],"funding":[]},{"id":"sorrento-therapeutics","kind":"company","name":"Sorrento Therapeutics","aka":["Sorrento Therapeutics, Inc.","Sorrento"],"tldr":"Sorrento was a San Diego biotech with a sprawling pipeline of antibodies, cell therapies and a resiniferatoxin pain programme for cancer pain; it filed for bankruptcy in 2023.","summary":"Sorrento Therapeutics, founded in 2006 in San Diego, built a broad portfolio spanning antibody libraries, CAR-T and dimeric antigen receptor cell therapies, a Cynviloq paclitaxel formulation and resiniferatoxin for intractable cancer pain, several of which reached phase 3. The company filed for Chapter 11 bankruptcy in 2023 and its assets were sold. Its trials remain on ClinicalTrials.gov under Sorrento as lead sponsor. Its registered cancer trials include the CD38-directed antibody-drug conjugate STI-6129 in multiple myeloma (NCT05308225), anti-CEA CAR-T cells in pancreatic cancer with liver metastases (NCT04037241), abivertinib with abiraterone in prostate cancer (NCT05361915) and resiniferatoxin for intractable cancer pain (NCT04572776).","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://sorrentotherapeutics.com"},{"label":"ClinicalTrials.gov: trials led by Sorrento Therapeutics, Inc.","url":"https://clinicaltrials.gov/search?lead=Sorrento%20Therapeutics%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30288730"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["multiple-myeloma","pancreatic","prostate"],"sections":["supportive-care"],"technologies":["car-t","pain-management"],"targets":[],"drugs":["sti-6129"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"http://sorrentotherapeutics.com","founded":2006,"stage":"defunct","investors":[],"funding":[]},{"id":"sotio","kind":"company","name":"SOTIO Biotech","aka":["SOTIO a.s.","SOTIO"],"tldr":"SOTIO is a Prague biotechnology company owned by the PPF group whose dendritic cell vaccine for prostate cancer failed its phase 3 trial in 2020, and which now develops an IL-15 superagonist and antibody-drug conjugates.","summary":"SOTIO Biotech, part of the PPF Group, ran the phase 3 VIABLE trial of DCVAC/PCa, an autologous dendritic cell immunotherapy added to docetaxel in metastatic castration-resistant prostate cancer, which did not improve survival when reported in 2020. Its pipeline now centres on nanrilkefusp alfa (SOT101), an IL-15 receptor superagonist tested with pembrolizumab, and antibody-drug conjugates from its BOXR and other platforms. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.sotio.com"},{"label":"ClinicalTrials.gov: trials led by SOTIO","url":"https://clinicaltrials.gov/search?lead=SOTIO"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate"],"sections":["immunotherapy","adcs"],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05120271"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Prague","country":"CZ","companyType":"biotech","website":"https://www.sotio.com","stage":"private-large","investors":[],"funding":[]},{"id":"specicare","kind":"company","name":"SpeciCare","aka":[],"tldr":"SpeciCare preserves a patient's living tumour tissue at biopsy or surgery so it can be used later for testing, including treatments that may not exist yet; patients can order it themselves.","summary":"SpeciCare is a US service that arranges for a patient's tumour tissue to be preserved alive at the time of biopsy or surgery, rather than fixed and discarded, so that functional drug testing, organoid growth or future therapies can use it. Future of Cancer Care Today lists it as patient-orderable.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://specicare.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["functional-drug-testing","organoids"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"United States (city not published)","country":"US","companyType":"cro-services","website":"https://specicare.com/","investors":[],"funding":[]},{"id":"spectracure","kind":"company","name":"SpectraCure","aka":["SpectraCure AB"],"tldr":"SpectraCure is a Sweden-based medical device company running 2 late-stage cancer trials in prostate cancer.","summary":"SpectraCure, based in Lund, Sweden, is a medical device company. SpectraCure is a medical technology company developing a photodynamic therapy (PDT) treatment system for localised prostate cancer, with potential future applications in breast, pancreatic and head/neck cancer. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials in prostate cancer. The largest, NCT03067051 (Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System), plans to enrol 66 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.spectracure.com/"},{"label":"ClinicalTrials.gov: trials led by SpectraCure","url":"https://clinicaltrials.gov/search?lead=SpectraCure%20AB"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate"],"sections":["devices"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct03067051","nct06807359"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Lund","country":"SE","companyType":"devices","website":"https://www.spectracure.com/","stage":"public","investors":[],"funding":[]},{"id":"spectrum-pharmaceuticals","kind":"company","name":"Spectrum Pharmaceuticals","aka":["Spectrum Pharmaceuticals, Inc","Spectrum Pharmaceuticals, Inc."],"tldr":"Spectrum Pharmaceuticals was a US cancer company that sold its haematology portfolio to Acrotech in 2019, won approval for the long-acting G-CSF eflapegrastim (Rolvedon) in 2022, and was acquired by Assertio in 2023.","summary":"Spectrum Pharmaceuticals, latterly based in Boston after years in Henderson, Nevada, marketed a haematology portfolio (Zevalin, Folotyn, Beleodaq, Marqibo and Evomela) that it sold to Acrotech Biopharma in 2019 to concentrate on two development programmes: poziotinib, an EGFR and HER2 exon 20 inhibitor that received a complete response letter in 2022, and eflapegrastim (Rolvedon), a long-acting G-CSF for chemotherapy-induced neutropenia approved by the FDA in September 2022. Assertio Holdings acquired the company in 2023. It appears on OnCo as one of the most frequent industry sponsors of phase 3 cancer trials on the registry.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Spectrum_Pharmaceuticals","links":[{"label":"ClinicalTrials.gov: trials led by Spectrum Pharmaceuticals","url":"https://clinicaltrials.gov/search?lead=Spectrum%20Pharmaceuticals"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Spectrum_Pharmaceuticals"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc"],"sections":["supportive-care","targeted-therapy"],"technologies":[],"targets":[],"drugs":["belinostat","pralatrexate"],"companies":["acrotech-biopharma"],"institutions":[],"pathways":[],"terms":["neutropenia"],"trials":["nct04570423"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://www.spectrumpharm.com","stage":"acquired","investors":[],"funding":[]},{"id":"springworks","kind":"company","name":"SpringWorks Therapeutics (Merck KGaA)","aka":[],"tldr":"SpringWorks developed nirogacestat, the first approved treatment for desmoid tumours, and mirdametinib for NF1 plexiform neurofibromas; Merck KGaA acquired it in 2025.","summary":"SpringWorks Therapeutics, based in Stamford, Connecticut, developed nirogacestat, the first approved treatment for desmoid tumours, and mirdametinib for NF1 plexiform neurofibromas, and Merck KGaA completed its acquisition of the company for around 3.9 billion dollars in 2025. Nirogacestat, sold as Ogsiveo, was approved in November 2023 on the DeFi trial, and mirdametinib, sold as Gomekli, in February 2025. OnCo links it to desmoid tumour and sarcomas, to both drug records, and to the bottleneck of rare and paediatric cancers without markets, which its two products show can be overcome. Whether a large pharma keeps investing in rare-tumour indications of this size is the open question after the acquisition. Nirogacestat and mirdametinib have their own pages.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://www.springworkstx.com"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["nirogacestat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Stamford, CT","country":"US","companyType":"biotech","website":"https://www.springworkstx.com","investors":[],"funding":[]},{"id":"sr-one","kind":"company","name":"SR One","aka":[],"tldr":"SR One is a transatlantic biotech venture firm that began as GSK's corporate venture arm and now invests independently from London and the US West Coast. Oncology accounts for a large share of its portfolio, including Akamis Bio (gene-based immunotherapy), Avenzo Therapeutics, Charm Therapeutics (menin inhibitors for acute myeloid leukaemia) and Biotheryx (protein degradation).","summary":"SR One describes itself as 'a biotechnology venture capital firm, partnering with founders and entrepreneurs to translate innovative science into medicines', taking a 'back-and-build approach' to companies with strong fundamentals and a clearly defined development pathway. Its investing team 'is situated in key biotechnology hubs on the West Coast, USA and London, UK'; the operating entity is SR One Capital Management. Oncology is one of its portfolio filters and accounts for a large share of the companies listed: Akamis Bio (gene-based immuno-oncology for solid tumours), Ancora Biotech (biologics for oncology and inflammation), Avenzo Therapeutics (best-in-class oncology pipeline), Biotheryx (targeted protein degradation), Charm Therapeutics (menin inhibitors for acute myeloid leukaemia), Dren Bio, Effector, Fore Biotherapeutics, Simcha Therapeutics (IL-18) and Telios Pharma (blood cancers).","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.srone.com/"},{"label":"Portfolio","url":"https://www.srone.com/portfolio"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["gsk","avenzo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The task hint gave Philadelphia and London; the site lists West Coast USA and London, so London is used. Founding year and the GSK spin-out are not stated on fetched pages. Avenzo is already in the graph."],"hq":"London","country":"GB","companyType":"investor","website":"https://www.srone.com/","investors":[],"funding":[]},{"id":"stablix","kind":"company","name":"Stablix","aka":[],"tldr":"Stablix does the opposite of protein degradation: its molecules recruit enzymes that strip the 'destroy me' tag off useful proteins so cells keep them. Cancer is one of its target areas, but all its work is still preclinical.","summary":"Stablix is a preclinical-stage biotechnology company based in New York City and Boston pioneering targeted deubiquitination therapeutics (also described as targeted protein stabilisation). Its RESTORED platform generates heterobifunctional small molecules (RESTORACs) that recruit deubiquitinase enzymes to remove ubiquitin from a chosen protein, increasing its levels and activity. The company frames excess ubiquitination as a driver of disease, including cancers in which upregulated E3 ligases degrade tumour suppressor proteins, and is applying the approach to cancer, rare diseases and immunological disorders. In April 2023 it entered a strategic collaboration with Vertex to discover and develop targeted protein stabilisation therapeutics. Stablix launched in June 2021 with a 63 million US dollar Series A led by Versant Ventures with NEA, Cormorant, Euclidean Capital and Alexandria Real Estate Equities.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.stablix.com/"},{"label":"Series A press release","url":"https://www.stablix.com/copy-of-stablix-names-tony-kingsley-ceo"},{"label":"Vertex collaboration","url":"https://www.stablix.com/stablixandvertexestablishstrategiccollaborationtodiscoveranddeveloptargetedproteinstabil"}],"tags":[],"related":[],"cancers":[],"sections":["drug-discovery","targeted-therapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Stablix is a protein stabilisation rather than degradation company and no oncology programme is named publicly; included because the company lists cancer among its therapeutic areas. Founding year not sourced; no SEC Form D filings found under the company name."],"hq":"New York, NY","country":"US","companyType":"biotech","website":"https://www.stablix.com/","stage":"startup","investors":["versant-ventures","cormorant-asset-management","alexandria-venture-investments"],"funding":[{"round":"Series A","year":2021,"amountUsd":63000000,"source":"https://www.stablix.com/copy-of-stablix-names-tony-kingsley-ceo","note":"Led by founding investor Versant Ventures; announced June 2021"}]},{"id":"standard-biotools","kind":"company","name":"Standard BioTools (SomaLogic)","aka":[],"tldr":"Proteomics and mass-cytometry company that merged with SomaLogic (SomaScan aptamer proteomics) in 2024.","summary":"Standard BioTools, based in South San Francisco and listed as LAB, is a proteomics and mass cytometry company that merged with SomaLogic, maker of the SomaScan aptamer proteomics assay, in 2024. Its products include the SomaScan assay measuring around eleven thousand proteins, CyTOF mass cytometry and Hyperion imaging mass cytometry. OnCo links it to proteomics instruments and affinity platforms. Whether large-scale plasma proteomics yields cancer detection or prognostic tests that reach the clinic is the open question. The proteomics instruments page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.standardbio.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":["proteomics-platforms"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"South San Francisco, CA","country":"US","companyType":"diagnostics","website":"https://www.standardbio.com","ticker":"LAB","investors":[],"funding":[]},{"id":"standard-imaging","kind":"company","name":"Standard Imaging","aka":[],"tldr":"Standard Imaging makes the electrometers, chambers, daily QA devices and phantoms that radiotherapy physicists use to calibrate linacs and brachytherapy sources.","summary":"Standard Imaging, based in Middleton, Wisconsin, supplies the Exradin ionisation chambers, MAX electrometers, well chambers for brachytherapy source calibration, the QA BeamChecker daily device and imaging and dosimetry phantoms, and provides the Adaptivo in vivo dosimetry software.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.standardimaging.com/"}],"tags":["machines-wave2"],"related":[],"cancers":[],"sections":[],"technologies":["radiotherapy-qa-phantoms-dosimeters","in-vivo-dosimetry","brachytherapy-afterloaders"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Middleton, WI","country":"US","companyType":"devices","website":"https://www.standardimaging.com/","stage":"private-large","investors":[],"funding":[]},{"id":"stcube","kind":"company","name":"STCube","aka":["STCube, Inc."],"tldr":"STCube is a South Korea-based biotechnology company running 2 late-stage cancer trials of Nelmastobart in non-small-cell lung cancer and colorectal cancer.","summary":"STCube, based in Seoul, South Korea, is a biotechnology company. STCube (STCube Pharmaceuticals) develops immunotherapy drugs targeting novel immune checkpoints, with a lead focus on inhibiting BTN1A1 in cancer. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing Nelmastobart in non-small-cell lung cancer and colorectal cancer. The largest, NCT07306624 (Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer), plans to enrol 62 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.stcube.com/"},{"label":"ClinicalTrials.gov: trials led by STCube","url":"https://clinicaltrials.gov/search?lead=STCube%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07306624","nct06873763"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Seoul","country":"KR","companyType":"biotech","website":"https://www.stcube.com/","stage":"growth","investors":[],"funding":[]},{"id":"steba-biotech","kind":"company","name":"Steba Biotech","aka":["STEBA Biotech S.A."],"tldr":"Steba Biotech developed padeliporfin, a light-activated drug injected into the bloodstream and switched on by laser fibres in the prostate to destroy low-risk prostate cancer, approved in Europe as Tookad.","summary":"Steba Biotech developed vascular-targeted photodynamic therapy with padeliporfin (WST11, Tookad), a bacteriochlorophyll derivative created at the Weizmann Institute of Science. The drug is infused intravenously and activated by near-infrared light delivered through fibres placed in the prostate, causing rapid vessel occlusion and tumour necrosis. The European Commission approved Tookad in 2017 for unilateral low-risk prostate cancer after a randomised trial against active surveillance; it is also being studied in upper tract urothelial cancer.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["padeliporfin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Luxembourg","country":"LU","companyType":"pharma","investors":[],"funding":[]},{"id":"stella-pharma","kind":"company","name":"Stella Pharma","aka":[],"tldr":"Stella Pharma is the Osaka company that developed borofalan (Steboronine), the boron drug approved in Japan in 2020 alongside Sumitomo's accelerator for boron neutron capture therapy of head and neck cancer.","summary":"Stella Pharma was founded in 2007 to develop boron carriers for BNCT and brought borofalan (10B), a boronophenylalanine preparation, through Japanese trials with Sumitomo Heavy Industries' cyclotron-based system to approval in March 2020 for unresectable locally advanced or recurrent head and neck cancer. It is listed in Tokyo and is studying further indications, including melanoma, angiosarcoma and glioma, with academic BNCT centres in Japan.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://stella-pharma.co.jp/en/"}],"tags":["machines-wave2"],"related":[],"cancers":["head-and-neck","melanoma","glioblastoma"],"sections":[],"technologies":["bnct","bnct-accelerator-systems"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Osaka","country":"JP","companyType":"pharma","website":"https://stella-pharma.co.jp/en/","founded":2007,"stage":"public","investors":[],"funding":[]},{"id":"step-pharma","kind":"company","name":"Step Pharma","aka":["Step Pharma SAS"],"tldr":"Step Pharma is a French biotech whose oral drug STP938 blocks CTPS1, an enzyme that dividing lymphocytes depend on, to treat T-cell and B-cell lymphomas.","summary":"Step Pharma develops selective inhibitors of cytidine triphosphate synthase 1 (CTPS1), an enzyme discovered through a rare human immunodeficiency to be essential for lymphocyte proliferation but dispensable for most other cells. STP938 is an oral CTPS1 inhibitor in a phase 1/2 trial in relapsed or refractory T-cell and B-cell lymphomas, and the mechanism is also being explored in autoimmune disease.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["stp938"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Saint-Genis-Pouilly","country":"FR","companyType":"biotech","investors":[],"funding":[]},{"id":"sterling-pharma-solutions","kind":"company","name":"Sterling Pharma Solutions","aka":[],"tldr":"Sterling is a British contract maker of small-molecule active ingredients, with plants in the north of England and the United States and an ADC bioconjugation site at Deeside in Wales.","summary":"Sterling Pharma Solutions makes active pharmaceutical ingredients and intermediates for other companies, from grams for early trials to tonnes for commercial supply, at Cramlington and Dudley in England and at Germantown, Wisconsin, and Cary, North Carolina, in the United States. It added antibody-drug conjugate bioconjugation when it bought ADC Biotechnology's Deeside site in 2021, joining the small group of Western sites that can link high-potency payloads to antibodies. It is privately held.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.sterlingpharmasolutions.com"}],"tags":["manufacturing-wave"],"related":[],"cancers":[],"sections":[],"technologies":["small-molecule-api-synthesis","adc-supply-chain","high-potency-payload-synthesis","adc-cdmo-manufacturing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cramlington, Northumberland","country":"GB","companyType":"cro-services","website":"https://www.sterlingpharmasolutions.com","stage":"private-large","investors":[],"funding":[]},{"id":"stitchpoint-bio","kind":"company","name":"Stitchpoint Bio","aka":[],"tldr":"Stitchpoint Bio is an Even One Ventures company outside cancer: antisense oligonucleotide medicines designed for a single rare disease patient's mutation, aiming to cut development from decades to months.","summary":"Stitchpoint Bio designs antisense oligonucleotide medicines matched to one patient's mutation, one sequence for one person, for the N-of-1 rare disease patients that conventional development leaves behind. It is a rare disease company in the Even One Ventures portfolio and does not work on cancer.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://stitchpoint.bio/"},{"label":"Even One Ventures portfolio","url":"https://evenone.ventures/"}],"tags":["startup","evenone-portfolio","rare-disease","non-oncology"],"related":[],"cancers":[],"sections":[],"technologies":["antisense-sirna"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"United States (head office not published)","country":"US","companyType":"biotech","website":"https://stitchpoint.bio/","stage":"startup","investors":["evenone-ventures"],"funding":[]},{"id":"storemytumor","kind":"company","name":"StoreMyTumor","aka":[],"tldr":"StoreMyTumor, operating since 2011, preserves patients' living tumour tissue in the United States and Europe for personalised treatments and testing later on.","summary":"StoreMyTumor arranges the collection, transport and cryopreservation of a patient's live tumour tissue from surgery or biopsy so that it remains available for functional drug testing, immunotherapy manufacturing and research, and offers consultations on how to use it. It serves patients in the United States and Europe and is patient-orderable according to Future of Cancer Care Today.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://storemytumor.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["functional-drug-testing"],"targets":[],"drugs":[],"companies":["future-of-cancer-care-today"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"United States (city not published)","country":"US","companyType":"cro-services","website":"https://storemytumor.com/","investors":[],"funding":[]},{"id":"strand-ai","kind":"company","name":"Strand AI","aka":[],"tldr":"Strand AI's first model, Lattice, predicts which proteins sit where across a tumour from the ordinary stained slide a hospital already has, so a whole archive can be profiled without spending tissue on extra laboratory staining.","summary":"Strand AI is a two-person Winter 2026 Y Combinator company in San Francisco building models that reconstruct measurements a patient's record never captured. Its first model, Lattice, predicts spatially resolved protein-marker maps from routine haematoxylin and eosin whole-slide images and returns them as virtual multiplex immunofluorescence channels at the resolution of the input image. The company states that Lattice was developed on thousands of tissue regions and millions of image patches, drawn overwhelmingly from cancer tissue and spanning more than a hundred protein markers, and that predictions are evaluated at pixel, cell, region and population level. It is sold as a service: partners send digitised slides and get back predicted spatial proteomics with cell segmentation, phenotyping and a written analysis, or have the model deployed inside their own environment, for retrospective cohorts, patient stratification and deciding which samples justify real multiplex staining. Outputs are research use only and not for clinical or diagnostic procedures.","asOf":"2026-09-18","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/strand-ai"},{"label":"Official website","url":"https://strandai.com"},{"label":"X: @strandaibio","url":"https://x.com/strandaibio"},{"label":"LinkedIn","url":"https://www.linkedin.com/company/strand-ai"}],"tags":["foundation-model","pathology"],"related":[],"cancers":[],"sections":["ai-computation","diagnostics","drug-discovery"],"technologies":["digital-pathology-ai","pathology-foundation-model","multiplex-immunofluorescence"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"ai-software","website":"https://strandai.com","stage":"startup","ycBatch":"W26","investors":["y-combinator"],"funding":[]},{"id":"strand-therapeutics","kind":"company","name":"Strand Therapeutics","aka":[],"tldr":"Strand makes programmable messenger RNA medicines that switch on only inside tumours. Its first drug is injected into a tumour and makes cells there produce an immune-boosting signal.","summary":"Strand Therapeutics is a clinical-stage mRNA company. Its platform combines SignalPath lipid nanoparticles for delivery beyond the liver, SignalLock microRNA-sensing circuits that activate the RNA in target tissue and silence it elsewhere, and SignalScript self-replicating and circular RNA for potency and durability. Lead programme STX-001 is a lipid nanoparticle-encapsulated self-replicating mRNA encoding interleukin-12, given intratumourally in advanced solid tumours; the IND cleared in January 2024, the first patient was dosed in May 2024 and initial phase 1 results were presented at ASCO 2025, with the company reporting complete responses. STX-003, a systemic tumour programme using SignalLock, is planned to enter the clinic in 2026, and STX-005 is an in vivo CAR-T programme for autoimmune disease and blood cancers. Strand raised a USD 52 million Series A (2021), USD 45 million Series A1 (2022) and USD 153 million Series B (August 2025).","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.strandtx.com"},{"label":"News and articles (Series B and STX-001 data)","url":"https://www.strandtx.com/articles"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["cytokine-therapy","in-vivo-car-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06249048","nct07751042"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Series B investors are not named on the fetched company page; the Business Wire release could not be fetched (blocked). HQ inferred from Boston Business Journal awards referenced on the site. Founding year not sourced."],"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://www.strandtx.com","stage":"startup","investors":[],"funding":[{"round":"Series A","year":2021,"amountUsd":52000000,"source":"https://www.strandtx.com/articles"},{"round":"Series A","year":2022,"amountUsd":45000000,"source":"https://www.strandtx.com/articles","note":"Series A1 extension"},{"round":"Series B","year":2025,"amountUsd":153000000,"source":"https://www.strandtx.com/articles"}]},{"id":"strata-oncology","kind":"company","name":"Strata Oncology","aka":["StrataNGS","StrataEXP"],"tldr":"An Ann Arbor testing company that sequences tumours from very small biopsies (StrataNGS) and matches patients to trials and to immunotherapy through its Strata trial network.","summary":"Strata Oncology runs a large tumour sequencing panel, StrataNGS, designed for the small formalin-fixed samples that fail at other laboratories, and offers it through health systems in its Strata Precision Oncology Network, which returns trial matches with the report. Its StrataEXP test combines DNA and RNA results into a predictor of benefit from PD-1 and PD-L1 inhibitors across tumour types. The company publishes on the share of patients who reach a matched trial or therapy through routine testing.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.strataoncology.com"}],"tags":[],"related":[],"cancers":["nsclc","colorectal","breast-cancer"],"sections":[],"technologies":["cgp","ai-trial-matching","companion-diagnostic"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Ann Arbor, Michigan, United States","country":"US","companyType":"diagnostics","website":"https://www.strataoncology.com","founded":2015,"stage":"growth","investors":[],"funding":[]},{"id":"streck","kind":"company","name":"Streck","aka":[],"tldr":"Streck makes the Cell-Free DNA BCT blood tube that made shippable liquid biopsy practical.","summary":"Streck, a private company based in La Vista, Nebraska, makes the Cell-Free DNA BCT blood tube that made shippable liquid biopsy practical. Its products span stabilising blood collection tubes and haematology controls. OnCo links it to pre-analytics covering blood collection tubes and tissue fixation, and to liquid biopsy. Its tube is a reminder that a diagnostic's performance depends on the sample as much as on the assay. Whether pre-analytical standards keep pace as MRD tests push to lower detection limits is the open question.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.streck.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["preanalytics-sample-stabilisation","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"La Vista, NE","country":"US","companyType":"diagnostics","website":"https://www.streck.com","investors":[],"funding":[]},{"id":"stryker","kind":"company","name":"Stryker","aka":[],"tldr":"Stryker is a large American medical device company whose SPY fluorescence imaging systems, acquired with Novadaq, let surgeons see indocyanine green in lymph nodes, blood supply and bile ducts during cancer operations.","summary":"Stryker makes orthopaedic implants, surgical equipment, endoscopy systems and hospital beds. Its endoscopy division sells the SPY Elite open-field imager, the SPY-PHI handheld and the 1688 AIM 4K laparoscopic platform with SPY fluorescence, used for sentinel node mapping, perfusion assessment of bowel anastomoses and flaps, and anatomical identification in oncological surgery.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.stryker.com/"}],"tags":["machines-wave2"],"related":[],"cancers":[],"sections":[],"technologies":["intraoperative-fluorescence-imaging-systems","fluorescence-guided-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Portage, MI","country":"US","companyType":"devices","website":"https://www.stryker.com/","ticker":"SYK","founded":1941,"stage":"public","investors":[],"funding":[]},{"id":"sumitomo-heavy-industries","kind":"company","name":"Sumitomo Heavy Industries","aka":[],"tldr":"Sumitomo Heavy Industries builds cyclotron-based proton therapy systems for centres including Samsung Medical Center and Chang Gung Memorial Hospital, medical cyclotrons for PET isotopes, and the first approved accelerator for boron neutron capture therapy.","summary":"Sumitomo Heavy Industries, an engineering group founded in 1888, supplies isochronous cyclotron proton therapy systems with scanning gantries to hospitals in Japan, South Korea (Samsung Medical Center), Taiwan (Chang Gung Memorial Hospital) and elsewhere, and its HM-series cyclotrons produce fluorine-18 and other PET isotopes in hospital radiopharmacies. Its accelerator-based neutron source for boron neutron capture therapy was approved in Japan in 2020 for head and neck cancer with Stella Pharma's borofalan. OnCo links it to proton therapy machines, medical cyclotrons and BNCT.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.shi.co.jp/english/"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":["machines-wave"],"related":[],"cancers":[],"sections":["radiation","radiopharma"],"technologies":["proton-therapy-systems","proton-therapy","medical-cyclotrons-synthesis-modules","bnct"],"targets":[],"drugs":[],"companies":[],"institutions":["samsung-medical-center","chang-gung-memorial-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tokyo","country":"JP","companyType":"devices","website":"https://www.shi.co.jp/english/","ticker":"6302.T","founded":1888,"stage":"public","investors":[],"funding":[]},{"id":"sumitomo-pharma","kind":"company","name":"Sumitomo Pharma (Myovant)","aka":[],"tldr":"Sumitomo Pharma makes Orgovyx (relugolix), the first oral GnRH antagonist for prostate cancer.","summary":"Sumitomo Pharma, based in Osaka, is the Japanese pharmaceutical company that makes Orgovyx, or relugolix, the first oral GnRH antagonist for prostate cancer, after acquiring Myovant Sciences in 2023. In the HERO trial relugolix gave rapid and reversible testosterone suppression without the flare seen with GnRH agonists, and with fewer major cardiovascular events in that trial. OnCo links it to prostate cancer and to the relugolix drug record. Whether an oral daily tablet improves adherence and outcomes over long-acting injections in routine practice, rather than in a trial, is the open question. Relugolix has its own page with the approval detail.","asOf":"2026-09-06","links":[{"label":"Official website","url":"https://www.sumitomo-pharma.com"}],"tags":[],"related":[],"cancers":["prostate"],"sections":["hormonal"],"technologies":[],"targets":[],"drugs":["relugolix","amrubicin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05862272","nct06526819","nct04988555"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Osaka","country":"JP","companyType":"pharma","website":"https://www.sumitomo-pharma.com","investors":[],"funding":[]},{"id":"summit-therapeutics","kind":"company","name":"Summit Therapeutics","aka":[],"tldr":"Summit Therapeutics holds Western rights to ivonescimab and is running the global HARMONi trials.","summary":"Summit Therapeutics, based in Miami and listed as SMMT, holds the Western rights to ivonescimab, Akeso's PD-1 by VEGF bispecific antibody, and is running the global HARMONi trials. HARMONi-3 tests it in first-line non-small-cell lung cancer and HARMONi-7 in PD-L1-high disease, both phase 3, and the company's biologics licence strategy follows the overall survival result of the HARMONi trial. OnCo links it to non-small-cell lung cancer and cutaneous squamous cell carcinoma, to HARMONi-A, and to the HARMONi-2 paper in which ivonescimab beat pembrolizumab head to head. Whether a Chinese head-to-head win can be reproduced in a Western population, and whether the FDA will accept it, is the open question the company exists to answer. Ivonescimab has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.smmttx.com"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["ivonescimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07228832","nct06396065","nct06767514","nct07815665"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Miami, FL","country":"US","companyType":"biotech","website":"https://www.smmttx.com","ticker":"SMMT","investors":[],"funding":[]},{"id":"sun-nuclear","kind":"company","name":"Sun Nuclear (Mirion)","aka":[],"tldr":"Radiotherapy quality-assurance instruments and software (SunCHECK, ArcCHECK) that verify machines deliver the planned dose.","summary":"Sun Nuclear, based in Melbourne, Florida, and part of Mirion Technologies, makes radiotherapy quality assurance instruments and software, including SunCHECK and ArcCHECK, that verify machines deliver the planned dose. Its products cover patient and machine QA, independent dose calculation and dosimetry hardware. OnCo links it to radiotherapy treatment planning and QA software. Whether quality assurance keeps pace with adaptive and FLASH radiotherapy, where doses change daily or are delivered in fractions of a second, is the open question for the field it serves. The treatment planning and QA page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.sunnuclear.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["radiation"],"technologies":["treatment-planning-systems"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Melbourne, FL","country":"US","companyType":"devices","website":"https://www.sunnuclear.com","investors":[],"funding":[]},{"id":"sun-pharma","kind":"company","name":"Sun Pharmaceutical Industries","aka":["DUSA Pharmaceuticals, Inc.","DUSA Pharmaceuticals"],"tldr":"India's largest drug company, which owns the branded cancer drugs Odomzo and Yonsa in the US and bought the PD-L1 antibody maker Checkpoint Therapeutics in 2025.","summary":"Sun Pharma was founded in 1983 by Dilip Shanghvi and is the fourth-largest specialty generics company in the world, with revenue of about 52,600 crore rupees in 2025. Its oncology strategy mixes generics (it was among the first US generic launchers of imatinib in 2016) with branded specialty products: it acquired Odomzo (sonidegib, for basal cell carcinoma) from Novartis in 2016, won FDA approval of Yonsa (a fine-particle abiraterone acetate) on 23 May 2018, and in 2025 acquired Checkpoint Therapeutics for about 355 million dollars, gaining the anti-PD-L1 antibody cosibelimab (Unloxcyt, FDA-approved for cutaneous squamous cell carcinoma in December 2024). In India it sells a broad oncology generics range.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://sunpharma.com"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy","immunotherapy"],"technologies":["checkpoint-inhibitor","kinase-inhibitors"],"targets":["pdl1"],"drugs":["sonidegib","abiraterone","cosibelimab","imatinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05422911"],"people":[],"bottlenecks":["b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Mumbai","country":"IN","companyType":"pharma","website":"https://sunpharma.com","ticker":"SUNPHARMA.NS","founded":1983,"investors":[],"funding":[]},{"id":"sunesis","kind":"company","name":"Sunesis Pharmaceuticals","aka":["Sunesis Pharmaceuticals, Inc.","Viracta Therapeutics"],"tldr":"Sunesis developed vosaroxin, a quinolone-derived cytotoxic that narrowly missed its survival endpoint in the phase 3 VALOR trial in relapsed acute myeloid leukaemia; the company later merged into Viracta.","summary":"Sunesis Pharmaceuticals, founded in 1998 in South San Francisco, took vosaroxin, a first-in-class anticancer quinolone that intercalates DNA and inhibits topoisomerase II, into the phase 3 VALOR trial with cytarabine in relapsed or refractory acute myeloid leukaemia; the trial narrowly failed its primary survival endpoint in 2014 and regulators declined approval. Sunesis merged with Viracta Therapeutics in 2021. Its trials remain on ClinicalTrials.gov under Sunesis as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.sunesis.com"},{"label":"ClinicalTrials.gov: trials led by Sunesis Pharmaceuticals, Inc.","url":"https://clinicaltrials.gov/search?lead=Sunesis%20Pharmaceuticals%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q7639948"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml"],"sections":[],"technologies":["topoisomerase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"http://www.sunesis.com","founded":1998,"stage":"acquired","investors":[],"funding":[]},{"id":"sunho-biopharmaceutical","kind":"company","name":"SunHo Biopharmaceutical","aka":["SUNHO (China) BioPharmaceutical CO., Ltd.","盛禾生物"],"tldr":"SunHo Biopharmaceutical is a China-based biotechnology company that leads 5 cancer trials in OnCo, testing the immunocytokines IAP0971 and IBB0979 and the antibody IBD0333 in non-small-cell lung cancer, gastric & gastro-oesophageal junction cancer and advanced solid tumours.","summary":"SunHo Biopharmaceutical discovers, develops and commercialises biologics that modulate the immune microenvironment through the innate and adaptive immune systems, including immunocytokines and antibodies for cancer and autoimmune disease. It runs three proprietary platforms (antibody-cytokine fusion, ADCC-enhanced antibody and innate-immune multispecific) and its own GMP manufacturing facility in Nanjing, and is listed in Hong Kong. On ClinicalTrials.gov it is the lead sponsor of 5 trials recorded in OnCo (1 in phase 3 or 2/3): NCT06223841 (phase 1/2, A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors), NCT06581419 (phase 1/2, A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors), NCT05991583 (phase 1/2, A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors), NCT06292208 (phase 1/2, A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors) and NCT06504732 (phase 2/3, To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"http://www.sunho-bio.com/"},{"label":"ClinicalTrials.gov: trials led by SunHo Biopharmaceutical","url":"https://clinicaltrials.gov/search?lead=SUNHO%EF%BC%88China%EF%BC%89BioPharmaceutical%20CO.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["iah0968"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06223841","nct06581419","nct05991583","nct06292208","nct06504732"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Nanjing","country":"CN","companyType":"biotech","website":"http://www.sunho-bio.com/","ticker":"HKEX:2898","founded":2018,"stage":"public","investors":[],"funding":[]},{"id":"sunshine-lake-pharma","kind":"company","name":"Sunshine Lake Pharma (HEC)","aka":["Sunshine Lake Pharma Co., Ltd.","HEC Pharm"],"tldr":"Sunshine Lake Pharma, the pharmaceutical arm of China's HEC group based in Dongguan, is running phase 3 trials of clifutinib, a FLT3 inhibitor for acute myeloid leukaemia, and lerotinib in oesophageal cancer.","summary":"Sunshine Lake Pharma, part of the HEC (Dongyangguang) group in Dongguan, Guangdong, is a Chinese pharmaceutical company with antiviral, metabolic and oncology pipelines. In cancer it is developing clifutinib, a small-molecule FLT3 inhibitor in a phase 3 trial for FLT3-mutated acute myeloid leukaemia, and lerotinib, a small-molecule kinase inhibitor in a phase 3 trial for oesophageal cancer. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the group website.","asOf":"2026-09-11","links":[{"label":"HEC group website","url":"https://www.hec.cn/"},{"label":"ClinicalTrials.gov: trials led by Sunshine Lake Pharma","url":"https://clinicaltrials.gov/search?lead=Sunshine%20Lake%20Pharma"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml","esophageal"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["clifutinib","lerotinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05586074","nct04415853","nct05133882","nct05451602"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Dongguan","country":"CN","companyType":"pharma","website":"https://www.hec.cn/","stage":"public","investors":[],"funding":[]},{"id":"surgimab","kind":"company","name":"Surgimab","aka":["SurgiMab SAS"],"tldr":"Surgimab is a French company whose fluorescent antibody SGM-101 lights up carcinoembryonic antigen so surgeons can see colorectal and pancreatic tumours in the operating theatre.","summary":"Surgimab develops SGM-101, a chimeric antibody against carcinoembryonic antigen (CEA) conjugated to a near-infrared fluorophore for fluorescence-guided surgery. Injected a few days before the operation, it marks CEA-expressing tumour deposits so surgeons can find peritoneal metastases, small liver lesions and positive margins. Phase 2 studies in colorectal and pancreatic cancer showed changed surgical plans in a substantial share of patients, and a phase 3 trial in colorectal cancer has completed.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.surgimab.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["sgm-101"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Montpellier","country":"FR","companyType":"biotech","website":"https://www.surgimab.com/","investors":[],"funding":[]},{"id":"sutro-biopharma","kind":"company","name":"Sutro Biopharma","aka":[],"tldr":"Cell-free protein synthesis ADC company that refocused on exatecan and dual-payload ADCs, deprioritising its folate-receptor ADC luveltamab.","summary":"STRO-004 (tissue factor, DAR8 TOP1 payload) is the lead, with first clinical data expected mid-2026; STRO-227 is a DAR10 dual-payload PTK7 ADC (MMAE DAR2 + TOP1 DAR8) with IND planned 2026. Luveltamab tazevibulin (FRα) development stopped pending a partner. Site-specific conjugation via non-natural amino acids (XpressCF).","asOf":"2026-09-04","links":[{"label":"AACR 2026 pipeline data","url":"https://www.biospace.com/press-releases/sutro-biopharma-presents-promising-preclinical-data-across-its-pipeline-of-next-generation-single-and-dual-payload-adc-programs-at-aacr-2026"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":["adcs"],"technologies":["adc","dual-payload-adc","site-specific-conjugation"],"targets":["tissue-factor","folr1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.sutrobio.com","ticker":"STRO","investors":[],"funding":[]},{"id":"suzhou-bluehorse-therapeutics","kind":"company","name":"Suzhou BlueHorse Therapeutics","aka":["Suzhou Lanma Biotechnology"],"tldr":"Suzhou BlueHorse Therapeutics is a China-based cell therapy company that leads 2 cancer trials in OnCo, testing the tumour-infiltrating lymphocyte product LM103 in non-small-cell lung cancer and melanoma.","summary":"Suzhou BlueHorse Therapeutics is a Suzhou-based cell therapy developer. The ClinicalTrials.gov registry lists it as lead sponsor of phase 2 trials of LM103, a tumour-infiltrating lymphocyte (TIL) product, in non-small-cell lung cancer and melanoma. Its website could not be reached, so company facts here are limited to the registry. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT07444437 (phase 2, A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung C...) and NCT07310784 (phase 2, A Phase II Trial of LM103 in Advanced Melanoma). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov: trials led by Suzhou BlueHorse Therapeutics","url":"https://clinicaltrials.gov/search?lead=Suzhou%20BlueHorse%20Therapeutics%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["dacarbazine","temozolomide","paclitaxel","carboplatin","cisplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07444437","nct07310784"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Suzhou","country":"CN","companyType":"cell-therapy","investors":[],"funding":[]},{"id":"suzhou-forlong-biotechnology","kind":"company","name":"Suzhou Forlong Biotechnology","aka":["Suzhou Forlong Biotechnology Co., Ltd"],"tldr":"Suzhou Forlong Biotechnology is a China-based biotechnology company running 2 late-stage cancer trials of FL115 in bladder & urothelial cancer.","summary":"Suzhou Forlong Biotechnology, based in Suzhou, China, is a biotechnology company. Suzhou Forlong Biotechnology (also styled Furong Biotech) develops next-generation cytokine drugs based on synthetic immunology, using platforms for long-acting optimisation, Fc engineering, AI-driven discovery and synthetic cytokine creation. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing FL115 in bladder & urothelial cancer. The largest, NCT07131202 (A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumours), plans to enrol 130 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.forlongbiotech.com"},{"label":"ClinicalTrials.gov: trials led by Suzhou Forlong Biotechnology","url":"https://clinicaltrials.gov/search?lead=Suzhou%20Forlong%20Biotechnology%20Co.%2C%20Ltd"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct07131202","nct07122414"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Suzhou","country":"CN","companyType":"biotech","website":"https://www.forlongbiotech.com","founded":2019,"stage":"growth","investors":[],"funding":[]},{"id":"zelgen","kind":"company","name":"Suzhou Zelgen Biopharmaceuticals","aka":["Zelgen","泽璟制药"],"tldr":"Zelgen developed donafenib, the deuterated sorafenib that beat the original in first-line liver cancer and was approved in China in 2021.","summary":"Suzhou Zelgen Biopharmaceuticals, based in Suzhou, founded in 2009 and listed as 688266.SS, developed donafenib, the deuterated version of sorafenib that beat the original in first-line liver cancer and was approved in China in 2021. Donafenib, sold as Zepsun, was approved in 2021 for hepatocellular carcinoma and in 2022 for thyroid cancer on the strength of the ZGDH3 trial against sorafenib; the pipeline includes jaktinib, a JAK inhibitor for myelofibrosis, and recombinant human thrombin, and the company was among the first listed on Shanghai's STAR Market before reaching profitability. OnCo links it to donafenib and to ZGDH3. Whether a deuterated improvement on an older drug can hold its place as immunotherapy combinations take over first-line liver cancer is the open question. Donafenib has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.zelgen.com/en/"}],"tags":["china"],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["donafenib","zg006"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["zgdh3","nct05978284","nct06283719","nct07038096","nct06558227","nct06903377","nct07258121","nct06440057","nct05584800","nct06938880","nct06883526","nct06927687"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Suzhou","country":"CN","companyType":"biotech","website":"https://www.zelgen.com/en/","ticker":"688266.SS","founded":2009,"investors":[],"funding":[]},{"id":"sv-health-investors","kind":"company","name":"SV Health Investors","aka":[],"tldr":"A London and Boston healthcare investor with 30 years of history that runs biotech, medtech and growth funds, including a dementia fund. Its biotech portfolio includes cancer companies such as Bicycle Therapeutics and Xilio Therapeutics.","summary":"SV Health Investors (formerly SV Life Sciences) states on its homepage '$4.0B in historical commitments' and describes three strategies: Therapeutics, Healthcare Growth and Medtech, with offices in Boston and London. Its fund list includes SV8 Biotech Fund, SV7 Impact Medicine Fund, SV Biotech Crossover Opportunities Fund and the Dementia Discovery Funds. The portfolio page says the firm has invested 'for 30 years'. Its portfolio page shows logos rather than descriptions; oncology-relevant names include Bicycle Therapeutics (bicyclic peptide conjugates), Xilio Therapeutics (tumour-activated immunotherapies), Nimbus Therapeutics and the surgical oncology device company Onkos Surgical.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.svhealthinvestors.com/"},{"label":"Portfolio","url":"https://www.svhealthinvestors.com/portfolio/"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on fetched pages; omitted. Portfolio page gives names only, so oncology focus of the named companies is from general knowledge."],"hq":"London","country":"GB","companyType":"investor","website":"https://www.svhealthinvestors.com/","investors":[],"funding":[]},{"id":"swog","kind":"company","name":"SWOG Cancer Research Network","aka":["SWOG","Southwest Oncology Group"],"tldr":"SWOG is one of the US National Cancer Institute's cooperative groups: thousands of community and academic sites running practice-changing trials, including the 2026 first-line Hodgkin lymphoma result.","summary":"Founded 1956 (Southwest Oncology Group). NCI National Clinical Trials Network member with >12,000 members at >1,300 sites. Landmark trials include S1826 (nivolumab-AVD in advanced Hodgkin lymphoma, FDA approval March 2026), S1418/BR006 (adjuvant pembrolizumab in TNBC), and the de-escalation trial SCARLET (S2212) in stage II-III TNBC. Statistical centre at Fred Hutchinson Cancer Center.","asOf":"2026-09-06","links":[{"label":"Official website","url":"https://www.swog.org"}],"tags":["cooperative-group"],"related":["nivolumab"],"cancers":["hodgkin-lymphoma","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["fred-hutch","nci"],"pathways":[],"terms":[],"trials":["scarlet-s2212","int-0116"],"people":["kathy-albain","anne-chiang","hagen-kennecke","charles-blanke","dawn-hershman","neeraj-agarwal","primo-lara","priyanka-sharma"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["NCTN cooperative group","S1826 Hodgkin lymphoma","SCARLET S2212 (TNBC de-escalation)","Cancer control and survivorship"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Portland, OR","country":"US","companyType":"cooperative-group","website":"https://www.swog.org","founded":1956,"investors":[],"funding":[]},{"id":"symbio-pharmaceuticals","kind":"company","name":"SymBio Pharmaceuticals","aka":["SymBio Pharmaceuticals Limited","シンバイオ製薬"],"tldr":"SymBio is a Tokyo company that brought bendamustine (Treakisym) to Japan for lymphoma and myeloma through the local trials it led, and now develops the antiviral brincidofovir for transplant complications.","summary":"SymBio Pharmaceuticals, founded in 2005 in Minato, Tokyo, in-licenses medicines for Japan and runs the domestic trials for approval. It won Japanese approval for bendamustine (Treakisym) in relapsed indolent lymphoma, mantle cell lymphoma and later first-line settings, and is developing brincidofovir for adenovirus infection after stem cell transplant. Its phase 3 trials are registered on ClinicalTrials.gov under SymBio as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.symbiopharma.com"},{"label":"ClinicalTrials.gov: trials led by SymBio Pharmaceuticals Limited","url":"https://clinicaltrials.gov/search?lead=SymBio%20Pharmaceuticals%20Limited"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q38277748"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["follicular-lymphoma","mantle-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["bendamustine"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Tokyo","country":"JP","companyType":"pharma","website":"http://www.symbiopharma.com","founded":2005,"stage":"public","investors":[],"funding":[]},{"id":"synaffix","kind":"company","name":"Synaffix (Lonza)","aka":[],"tldr":"Licensor of the GlycoConnect site-specific ADC conjugation platform, now part of Lonza and used by dozens of ADC developers.","summary":"Synaffix, based in Oss in the Netherlands and now part of Lonza, licenses the GlycoConnect site-specific antibody-drug conjugate conjugation platform, used by dozens of ADC developers. GlycoConnect attaches payloads at the conserved Asn297 glycan to give a defined drug-to-antibody ratio, HydraSpace and toxSYN complete the platform, Lonza acquired the company in 2023 and integrated it into an end-to-end ADC service, and 2026 brought multi-target licences with Sidewinder for bispecific ADCs and with Engitix. OnCo links it to site-specific conjugation and linker chemistry, ADCs and bispecific ADCs, to ADC bioconjugation manufacturing, to Lonza, and to the idea of platform designation for linker-payloads. Whether a shared conjugation platform can earn regulatory credit that carries across products is the open question. Lonza has its own page.","asOf":"2026-09-04","links":[{"label":"Lonza ADC technology platform","url":"https://www.lonza.com/advanced-synthesis/adc-technologies-platform"}],"tags":[],"related":[],"cancers":[],"sections":["adcs","drug-discovery"],"technologies":["site-specific-conjugation","adc","bispecific-adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Oss","country":"NL","companyType":"biotech","website":"https://synaffix.com","investors":[],"funding":[]},{"id":"syncona","kind":"company","name":"Syncona","aka":[],"tldr":"A London-listed investment company that founds and funds UK life science companies and holds them for the long term. Its cancer companies include the CAR-T company Autolus and the precision oncology firms iOnctura and Mosaic Therapeutics.","summary":"Syncona was co-founded as Syncona Partners in 2012 by Martin Murphy and the Wellcome Trust, merged with the Battle Against Cancer Investment Trust in December 2016 and is listed on the London Stock Exchange as a FTSE 250 constituent (Wikipedia). It operates as a permanent-capital vehicle that creates companies from academic science, leads their early rounds and holds through the clinic. Its portfolio page groups companies by stage. Oncology holdings include Autolus Therapeutics (commercial CAR-T), iOnctura ('a clinical-stage oncology company developing innovative therapies for neglected and hard-to-treat cancers'), Mosaic Therapeutics (biomarker-defined drug combinations; Syncona led a GBP 22.5 million Series A in 2022) and Yellowstone Biosciences (soluble T-cell receptor therapies for acute myeloid leukaemia). Previous holdings include Blue Earth Diagnostics and the T-cell company Neogene Therapeutics.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.synconaltd.com/"},{"label":"Portfolio","url":"https://www.synconaltd.com/portfolio/"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Syncona"}],"tags":["public-fund"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["autolus","ionctura","neogene-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Wikipedia gives the registered office as Saint Peter Port, Guernsey; the operating team is in London."],"hq":"London","country":"GB","companyType":"investor","website":"https://www.synconaltd.com/","ticker":"SYNC.L","founded":2012,"investors":[],"funding":[]},{"id":"syndax","kind":"company","name":"Syndax Pharmaceuticals","aka":[],"tldr":"Syndax Pharmaceuticals, of Waltham, Massachusetts, developed revumenib (Revuforj), the first menin inhibitor approved for leukaemia, proved in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation. It also makes axatilimab for chronic graft-versus-host disease, and resistance mutations in menin itself are the class's unsolved problem.","summary":"Syndax Pharmaceuticals, based in Waltham, Massachusetts, and listed as SNDX, developed revumenib, the first menin inhibitor approved for leukaemia. Revumenib, sold as Revuforj, was proved in the AUGMENT-101 trial in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, and the company also makes axatilimab, a CSF-1R antibody for chronic graft-versus-host disease. OnCo links it to acute myeloid leukaemia, to the revumenib drug record and to the AUGMENT-101 paper. Whether menin inhibitors move from relapsed disease into first-line combinations, and how the class handles resistance mutations in menin itself, are the open questions. Revumenib has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.syndax.com"}],"tags":[],"related":[],"cancers":[],"sections":["epigenetics"],"technologies":[],"targets":[],"drugs":["revumenib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07211958"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Waltham, MA","country":"US","companyType":"biotech","website":"https://www.syndax.com","ticker":"SNDX","investors":[],"funding":[]},{"id":"syndevrx","kind":"company","name":"SynDevRx","aka":["SynDevRx, Inc."],"tldr":"SynDevRx is a Massachusetts biotech whose polymer-drug conjugate evexomostat targets the metabolic side of cancer, blocking MetAP2 to counter the weight gain and insulin surge that undermine PI3K inhibitors and hormone therapy.","summary":"SynDevRx develops evexomostat (SDX-7320), a polymer conjugate of a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor designed to avoid the neurotoxicity of earlier agents. MetAP2 inhibition reduces angiogenesis and improves insulin sensitivity, so the drug is being tested to prevent hyperglycaemia and weight gain in patients receiving alpelisib for PIK3CA-mutant breast cancer and in metabolically unhealthy patients with triple-negative breast cancer and prostate cancer.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.syndevrx.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["evexomostat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Cambridge, Massachusetts","country":"US","companyType":"biotech","website":"https://www.syndevrx.com/","investors":[],"funding":[]},{"id":"syngene","kind":"company","name":"Syngene International","aka":[],"tldr":"Biocon's listed contract research and manufacturing arm, which runs discovery chemistry, biology and biologics manufacturing for eight of the ten largest pharma companies.","summary":"Syngene International was established in 1993 and is a publicly listed subsidiary of Biocon. It works across four divisions (discovery services, dedicated research centres, development and manufacturing) and has grown into one of India's largest CRO-CDMOs, with clients including Amgen, Bristol Myers Squibb, GSK and Zoetis and a biologics manufacturing business. Much of the medicinal chemistry, in vivo pharmacology and antibody work behind Western oncology pipelines is done at Indian CDMOs such as Syngene, Aragen, Sai Life Sciences and Jubilant, which is the least visible but most established part of India's role in cancer drug development.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.syngeneintl.com"}],"tags":[],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":["ai-drug-design"],"targets":[],"drugs":[],"companies":["biocon","bms","jubilant-radiopharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Bengaluru","country":"IN","companyType":"cro-services","website":"https://www.syngeneintl.com","ticker":"SYNGENE.NS","founded":1993,"investors":[],"funding":[]},{"id":"synsorybio","kind":"company","name":"SynsoryBio","aka":[],"tldr":"SynsoryBio builds protein drugs with built-in if-then logic: they stay switched off until they sense they are in diseased tissue, a way to make immune-activating and cell-killing biologics usable at doses that would otherwise harm healthy tissue. It is preclinical, with a small team and no recorded financing.","summary":"SynsoryBio is creating conditionally activated protein therapeutics that sense their location in the body and become active only at diseased tissue, a way to widen the therapeutic window of immune agonists and cytotoxic biologics whose toxicity to healthy tissue limits their dose in cancer and autoimmune disease. The approach is related to masked or protease-activated biologics. The company is tagged oncology in the YC directory and is preclinical with a very small team; no sourced financing rounds are recorded.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/synsorybio"},{"label":"Official website","url":"https://www.synsorybio.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["immunotherapy","targeted-therapy"],"technologies":["cytokine-therapy","masked-adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://www.synsorybio.com","stage":"startup","ycBatch":"W24","investors":["y-combinator"],"funding":[]},{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","aka":["Sichuan Baili Pharmaceutical Co., Ltd.","Sichuan Baili Pharmaceutical","Baili-Bio"],"tldr":"SystImmune developed iza-bren, the first bispecific ADC to win a phase 3 trial.","summary":"SystImmune, headquartered in Redmond, Washington, with its parent Sichuan Biokin in Chengdu, developed izalontamab brengitecan, or iza-bren, the first bispecific antibody-drug conjugate to win a phase 3 trial. Iza-bren targets EGFR and HER3 at once and is partnered with Bristol Myers Squibb in a deal worth up to 8.4 billion dollars, and a pipeline of further bispecific ADCs, including trastuzumab brengitecan, follows it. OnCo links it to triple-negative and HER2-positive breast cancer and oesophageal cancer, to the bispecific ADC technology, to Sichuan Cancer Hospital, to Li Zhang, and to the idea of two-target antibody drugs that close the antigen escape route. Acquired resistance to every therapy is the bottleneck the bispecific design is meant to address. Izalontamab brengitecan has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.systimmune.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":[],"targets":[],"drugs":["izalontamab-brengitecan","si-b001"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07625644","nct06838273","nct07502300","nct06382129","nct07518173","nct06830889","nct07640789","nct06994195","nct06316531","nct06118333","nct07642024","nct07178795","nct06500026","nct06891833","nct06382116","nct06475300","nct06498986","nct06668961","nct06437522","nct07054567","nct06114511","nct07654400","nct05880706","nct05956587","nct05990803","nct06006169","nct05949606","nct06445400","nct07264816","nct05924841","nct06008054","nct06437509","nct05020457","nct05044897","nct06787664","nct05054439","nct05192486","nct07678957","nct06131450","nct05944978","nct06042894","nct06343948","nct05668858","nct06598787","nct07518147","nct06857175","nct05623982","nct05803018","nct05627856","nct05965856","nct07582315","nct07606599","nct05949619","nct06957886","nct06405425","nct06031584","nct07554456","nct06471205","nct07255872","nct06978114","nct06962787","nct06066203","nct07648914","nct05785039"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Redmond, WA / Chengdu","country":"US","companyType":"biotech","website":"https://www.systimmune.com","investors":[],"funding":[]},{"id":"tae-life-sciences","kind":"company","name":"TAE Life Sciences","aka":[],"tldr":"TAE Life Sciences is developing boron neutron capture therapy, in which a boron drug collects in cancer cells and a hospital-based neutron beam then triggers a tiny nuclear reaction inside those cells to destroy them while sparing nearby healthy tissue.","summary":"TAE Life Sciences develops an accelerator-based boron neutron capture therapy (BNCT) platform licensed from fusion company TAE Technologies. Alphabeam is a compact, tunable low-energy neutron source designed for installation inside a hospital radiotherapy department. In BNCT a boron carrier accumulates in tumour cells and neutron capture releases an alpha particle and lithium nucleus with a range of about one cell diameter, giving cell-level targeting. The company launched in March 2018 with a USD 40 million Series A led by ARTIS Ventures and an agreement to deliver its first system to Neuboron Medtech in China. In September 2025 it signed an MOU with the University of Wisconsin-Madison to become the first US Alphabeam site with trials in head and neck and brain cancers, and reported preclinical data showing its boron compounds plus checkpoint inhibitors outperform either alone. Device and drugs remain investigational.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://taelifesciences.com"},{"label":"Series A launch press release (March 2018, PDF)","url":"https://taelifesciences.com/wp-content/uploads/2026/02/TAE-Life-Sciences-to-Develop-Groundbreaking-Therapy.pdf"},{"label":"C&EN: $40 million for boron neutron capture therapy (March 2018)","url":"https://cen.acs.org/articles/96/i12/40-million-boron-neutron-capture.html"},{"label":"Investors and news page","url":"https://taelifesciences.com/company/news/"}],"tags":[],"related":[],"cancers":["head-and-neck","glioblastoma"],"sections":["radiation","devices"],"technologies":["bnct"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Caller's hint of Santa Monica was not confirmed: the website footer gives 9750 Irvine Blvd, Irvine, CA, and the 2018 launch release was datelined Foothill Ranch, CA. The main website returned HTTP 403 to curl but loaded via WebFetch. Founded year taken as the 2018 public launch. Later rounds (if any) are unsourced and omitted."],"hq":"Irvine, CA","country":"US","companyType":"devices","website":"https://taelifesciences.com","founded":2018,"stage":"startup","investors":[],"funding":[{"round":"Series A","year":2018,"amountUsd":40000000,"source":"https://taelifesciences.com/wp-content/uploads/2026/02/TAE-Life-Sciences-to-Develop-Groundbreaking-Therapy.pdf","note":"Led by ARTIS Ventures; company launched as a majority-owned subsidiary of fusion company TAE Technologies"}]},{"id":"taiho-oncology","kind":"company","name":"Taiho Oncology (Otsuka)","aka":[],"tldr":"Taiho Oncology makes Inqovi, the oral decitabine-cedazuridine that in May 2026 became the first all-oral hypomethylating backbone for venetoclax in AML.","summary":"Taiho Oncology, the US arm of Otsuka's Taiho based in Princeton and Tokyo, makes Inqovi, the oral decitabine and cedazuridine combination that in May 2026 became the first all-oral hypomethylating backbone for venetoclax in acute myeloid leukaemia. Cedazuridine is a cytidine deaminase inhibitor that makes oral decitabine bioavailable; Inqovi was approved for myelodysplastic syndromes and chronic myelomonocytic leukaemia in 2020 and, on 13 May 2026, with venetoclax for newly diagnosed AML in adults unfit for intensive induction on the ASCERTAIN-V trial, and the company also markets Lonsurf and futibatinib. OnCo links it to acute myeloid leukaemia and to the oral decitabine drug record. Whether an all-oral regimen changes where and how older patients with AML are treated is the open question. The FDA approval notice is linked.","asOf":"2026-09-07","links":[{"label":"FDA approval notice (13 May 2026)","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-oral-combination-decitabine-and-cedazuridine-tablets-venetoclax-newly-diagnosed-acute"}],"tags":[],"related":[],"cancers":["aml"],"sections":["epigenetics"],"technologies":[],"targets":[],"drugs":["decitabine-cedazuridine","zipalertinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06506955"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Princeton, NJ / Tokyo","country":"JP","companyType":"pharma","website":"https://www.taihooncology.com","investors":[],"funding":[]},{"id":"taiho","kind":"company","name":"Taiho Pharmaceutical (Otsuka)","aka":[],"tldr":"Japanese oncology company behind futibatinib (Lytgobi) for bile duct cancer and the chemotherapy Lonsurf; acquired the ADC linker company Araris in 2025.","summary":"Taiho Pharmaceutical, the Tokyo-based oncology arm of Otsuka, is the company behind futibatinib, sold as Lytgobi, for bile duct cancer, and the chemotherapy Lonsurf, and in 2025 it acquired the antibody-drug conjugate linker company Araris Biotech. Futibatinib was approved in 2022 on the FOENIX-CCA2 trial for FGFR2-altered cholangiocarcinoma, Lonsurf, or trifluridine and tipiracil, is used in colorectal and gastric cancer with TAS-102 combinations under study, and OnCo also links Taiho to S-1, the tegafur, gimeracil and oteracil combination used in Asia. The Araris purchase signals a move from small molecules into ADCs. Whether a chemotherapy-rooted company can build a competitive ADC pipeline from an acquired linker platform is the open question. Futibatinib and Araris have their own pages.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://www.taiho.co.jp/en/"}],"tags":[],"related":[],"cancers":["cholangiocarcinoma","colorectal"],"sections":["targeted-therapy","adcs"],"technologies":[],"targets":[],"drugs":["futibatinib"],"companies":["araris"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tokyo","country":"JP","companyType":"pharma","website":"https://www.taiho.co.jp/en/","investors":[],"funding":[]},{"id":"tailormed","kind":"company","name":"TailorMed","aka":[],"tldr":"TailorMed is software that finds and enrols patients in financial assistance programmes so they can afford expensive medicines, used by hospitals, cancer clinics and pharmacies.","summary":"TailorMed Medical Inc. operates a medication access and affordability platform. It screens patients against thousands of assistance programmes (manufacturer copay, foundation, government) and automates enrolment, with modules for care team financial navigation, patient self enrolment, managed services and manufacturer programmes. Its network spans 945 hospitals, 4,700 clinics and 3,100 pharmacies, including Memorial Sloan Kettering; it states it has reached 75 million patients and secured more than USD 7.4 billion in assistance since 2020. In May 2026 it partnered with Flatiron Health to embed financial navigation across the OncoEMR community oncology network. In November 2024 TailorMed announced USD 40 million in equity and debt led by Windham Capital Partners; the round was not given a series name. The company describes itself as US and Israel based, with releases datelined New York.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.tailormed.com"},{"label":"USD 40 million financing announcement (November 2024)","url":"https://www.tailormed.com/news-blogs/tailormed-raises-40-million-for-medical-cost-assistance"},{"label":"Flatiron Health oncology partnership (May 2026)","url":"https://www.tailormed.com/news-blogs/tailormed-and-flatiron-health-expand-oncology-access"}],"tags":[],"related":[],"cancers":[],"sections":["supportive-care","ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["HQ: no fetched source states a headquarters city; the privacy notice says US and Israeli based and company releases are datelined New York, so New York is used with Tel Aviv (hinted) unconfirmed. The USD 40 million 2024 round has no series name in the release, so it is described in the summary rather than entered as a round; stage growth is a judgement based on that round's size. Founded 2018 implied by 'past six years' in the 2024 release but not stated, so omitted. Not oncology only, but oncology is a core market (MSK, Flatiron, infusion centres)."],"hq":"New York, NY","country":"US","companyType":"ai-software","website":"https://www.tailormed.com","stage":"growth","investors":["acs-brightedge"],"funding":[]},{"id":"tairx","kind":"company","name":"TaiRx","aka":["台睿生物科技"],"tldr":"TaiRx is a Taiwan-based biotechnology company that leads 3 cancer trials in OnCo, testing the oral anti-cancer agent CVM-1118 (foslinanib) in hepatocellular carcinoma, neuroendocrine tumours, pancreatic ductal adenocarcinoma and advanced solid tumours.","summary":"TaiRx is a Taipei-based new drug development company. Its lead candidate CVM-1118 (foslinanib) is an oral anti-cancer agent in phase 2 for neuroendocrine tumours and hepatocellular carcinoma, and it also markets Zelnite, an injectable selenium product approved in Taiwan. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT07521852 (phase 2, A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and...), NCT05257590 (phase 2, CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma) and NCT03600233 (phase 2, Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.trx.com.tw"},{"label":"ClinicalTrials.gov: trials led by TaiRx","url":"https://clinicaltrials.gov/search?lead=TaiRx%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["hcc","neuroendocrine","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["sintilimab","nivolumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07521852","nct05257590","nct03600233"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Taipei","country":"TW","companyType":"biotech","website":"https://www.trx.com.tw","ticker":"TPEx:6580","founded":2011,"stage":"public","investors":[],"funding":[]},{"id":"takara-bio","kind":"company","name":"Takara Bio","aka":["Takara Bio Inc.","タカラバイオ"],"tldr":"Takara Bio is a Japanese life-science tools company that also develops gene and cell therapies for cancer, including an oncolytic herpes virus and engineered T cells, and manufactures viral vectors for others.","summary":"Takara Bio Inc., founded in 2002 and based in Kusatsu, Shiga, sells research reagents and contract manufactures viral vectors and cell therapies. Its own pipeline includes the oncolytic herpes simplex virus canerpaturev (C-REV), tested in phase 2 and 3 in pancreatic cancer and melanoma, and TCR- and CAR-engineered T cells developed with Japanese academic groups. Its trials are registered on ClinicalTrials.gov under Takara Bio as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.takara-bio.co.jp"},{"label":"ClinicalTrials.gov: trials led by Takara Bio Inc.","url":"https://clinicaltrials.gov/search?lead=Takara%20Bio%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q11315991"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["pancreatic","melanoma"],"sections":[],"technologies":["oncolytic-virus","tcr-t","viral-vector-manufacturing"],"targets":[],"drugs":["tbi-1301","tbi-1501"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct03155191"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Kusatsu","country":"JP","companyType":"cell-therapy","website":"https://www.takara-bio.co.jp","founded":2002,"stage":"public","investors":[],"funding":[]},{"id":"takeda","kind":"company","name":"Takeda","aka":["Millennium Pharmaceuticals","Ariad Pharmaceuticals","ARIAD","Nycomed","Shire"],"tldr":"Takeda co-owns Adcetris outside the US and is developing STING-agonist conjugates and CAR-NK cells.","summary":"Takeda, based in Tokyo and listed as 4502.T, co-owns Adcetris, or brentuximab vedotin, outside the United States and is developing STING-agonist antibody conjugates and cord-blood CAR-NK cells with MD Anderson. Its oncology portfolio also includes bortezomib, brigatinib, fruquintinib and anagrelide, while mobocertinib was withdrawn, and TAK-500 is its STING immune-stimulating antibody conjugate. OnCo links it to the ECHELON-1 paper, in which brentuximab vedotin replaced bleomycin in first-line Hodgkin lymphoma chemotherapy, to Hutchmed and Innovent as partners, and to Takeda Ventures. Whether off-the-shelf CAR-NK cells can match autologous CAR-T on durability is the open question behind its MD Anderson collaboration. Brentuximab vedotin has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.takeda.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs","immunotherapy"],"technologies":[],"targets":[],"drugs":["brentuximab-vedotin","tak-928","elritercept","sapanisertib","serabelisib","human-normal-immunoglobulin"],"companies":["takeda-ventures"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04129502","nct06390995","nct05020015","nct02979522","nct07648030","nct07436728","nct06980480","nct02716116","nct05673785","nct07205718"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tokyo","country":"JP","companyType":"pharma","website":"https://www.takeda.com","ticker":"4502.T","investors":[],"funding":[]},{"id":"takeda-ventures","kind":"company","name":"Takeda Ventures","aka":[],"tldr":"Takeda Ventures, founded in 2001, is Takeda's corporate venture group, investing in preclinical, platform-based drug companies whose programmes complement Takeda's pipeline in oncology, rare genetics and haematology, neuroscience and gastrointestinal disease. Its page lists no portfolio companies, so no cancer examples are recorded here.","summary":"Takeda's Center for External Innovation page states: 'Takeda Ventures, Inc. is the corporate venture capital group of Takeda, and was founded in 2001 with the vision of generating disruptive technologies and therapeutic solutions for patients through venture-based investments.' It 'focuses on high-caliber, therapeutic, platform-based companies around the world', specifically 'early-stage, preclinical opportunities and products which complement Takeda's pipeline', and partners with academic innovators, entrepreneurs and venture investors 'to create and nurture a portfolio of companies in areas aligned with Takeda's R&D pillars: Oncology, Rare Genetics & Hematology, Neuroscience and Gastrointestinal and Inflammation'. The takedaventures.com domain redirects to this page, which does not list portfolio companies, so no oncology portfolio examples are cited.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.takeda.com/science/research-and-development/partnerships/cei/"}],"tags":["corporate-venture"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["takeda"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Office location not stated on the fetched page; Cambridge, MA follows the task hint. No portfolio list available."],"hq":"Cambridge, MA","country":"US","companyType":"investor","website":"https://www.takeda.com/science/research-and-development/partnerships/cei/","founded":2001,"investors":[],"funding":[]},{"id":"tallac-therapeutics","kind":"company","name":"Tallac Therapeutics","aka":[],"tldr":"Tallac Therapeutics builds antibodies that carry an immune-activating molecule into tumours, so the body's own defences attack the cancer. Its lead medicine is in early human trials and has a fast-track review status in bile duct cancer.","summary":"Tallac Therapeutics is a privately held Burlingame, California biotech founded in 2018 by Corey Goodman (venBio) and Hong Wan (formerly ALX Oncology). Its Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform conjugates a TLR9 agonist to a targeting antibody, delivering an innate immune stimulus into the tumour and aiming to generate a durable adaptive response rather than delivering a cytotoxic payload. The lead candidate TAC-001 received FDA IND clearance in May 2022, dosed its first patient in a phase 1/2 study in advanced solid tumours in July 2022, presented first clinical data at SITC 2023, and in October 2025 was granted FDA Fast Track designation for previously treated locally advanced unresectable or metastatic cholangiocarcinoma. The company raised a USD 62 million Series A in December 2020 from venBio Partners, Morningside Venture, Lightstone Ventures, Matrix Partners China and MRL Ventures Fund.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.tallactherapeutics.com/"},{"label":"Series A press release","url":"https://www.tallactherapeutics.com/news/tallac-therapeutics-launches-with-62-million-in-series-a-financing-to-advance-novel-immunotherapies-for-cancer/"},{"label":"FDA Fast Track for TAC-001","url":"https://www.tallactherapeutics.com/news/fda-grants-fast-track-designation-to-tac-001/"}],"tags":[],"related":[],"cancers":["cholangiocarcinoma"],"sections":["adcs","immunotherapy"],"technologies":["immune-stimulating-adc","adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No funding round after the 2020 Series A found on the company news page."],"hq":"Burlingame, CA","country":"US","companyType":"biotech","website":"https://www.tallactherapeutics.com/","founded":2018,"stage":"startup","investors":[],"funding":[{"round":"Series A","year":2020,"amountUsd":62000000,"source":"https://www.tallactherapeutics.com/news/tallac-therapeutics-launches-with-62-million-in-series-a-financing-to-advance-novel-immunotherapies-for-cancer/"}]},{"id":"tango-therapeutics","kind":"company","name":"Tango Therapeutics","aka":[],"tldr":"Tango Therapeutics makes cancer pills that exploit a weakness created when a tumour loses a particular gene. Its lead drug targets cancers that have lost a gene called MTAP, common in pancreatic and lung cancer.","summary":"Tango Therapeutics is a Boston precision oncology company built on synthetic lethality: it uses CRISPR-based functional genomic screens to find targets that cancer cells depend on once they have lost a tumour suppressor gene. Its lead programme, vopimetostat (TNG462), is an MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers, listed in phase 1/2 and phase 3 development in pancreatic, lung and other non-CNS cancers, with a phase 1/2 combination study alongside Revolution Medicines' RAS inhibitors. TNG456, a brain-penetrant PRMT5 inhibitor, is in phase 1/2 for MTAP-deleted glioblastoma. All programmes are wholly owned. Tango listed on Nasdaq in August 2021 through a merger with BCTG Acquisition Corp, a SPAC sponsored by Boxer Capital, with a 186 million US dollar PIPE and about 353 million US dollars in expected total proceeds; Gilead Sciences was an existing shareholder.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.tangotx.com/"},{"label":"Pipeline","url":"https://www.tangotx.com/pipeline/"},{"label":"BCTG merger announcement (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1819133/000121390021021456/ea139433ex99-1_bctgacq.htm"}],"tags":[],"related":[],"cancers":["pancreatic","nsclc","glioblastoma"],"sections":["targeted-therapy"],"technologies":["synthetic-lethality-approaches","crispr-screens"],"targets":[],"drugs":["tng462","tng456","tng260"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06922591","nct06810544","nct06188702","nct05732831"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year (2017) not sourced from a fetched page. Final proceeds after redemptions were not confirmed; the 353 million figure is the expected total stated in the announcement."],"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://www.tangotx.com/","ticker":"TNGX","stage":"public","investors":["boxer-capital","bain-capital-life-sciences","ecor1-capital","foresite-capital","logos-capital","ra-capital","samsara-biocapital","casdin-capital","cormorant-asset-management"],"funding":[{"round":"IPO","year":2021,"amountUsd":353000000,"source":"https://www.sec.gov/Archives/edgar/data/1819133/000121390021021456/ea139433ex99-1_bctgacq.htm","note":"Nasdaq listing via merger with BCTG Acquisition Corp; approximately 353 million US dollars expected gross proceeds (about 167 million in trust plus a 186 million PIPE led by Boxer Capital), before redemptions"}]},{"id":"tarebio","kind":"company","name":"TareBio","aka":[],"tldr":"TareBio reads the immune cells already fighting a cancer in a patient's body and works backwards to design a vaccine that makes more of them, in weeks rather than years.","summary":"TareBio's platform designs personalised or population-level vaccines by reading out the immune imprint, the T and B cells already engaged against a disease in the body, and reverse-engineering antigens that activate them, rather than predicting antigens from tumour sequencing alone. The company reports having run the platform end to end and produced a vaccine that cleared tumours in mice. It is a one-person Summer 2026 YC company; the work is preclinical.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/tarebio"},{"label":"Official website","url":"https://tarebio.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["neoantigen-mrna-vaccine","shared-antigen-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"biotech","website":"https://tarebio.com","stage":"startup","ycBatch":"S26","investors":["y-combinator"],"funding":[]},{"id":"tcgx","kind":"company","name":"TCGX (TCG Crossover)","aka":[],"tldr":"TCGX is a crossover fund: it invests in private biotech companies in the round or two before they list, then keeps holding the shares as public investors. Several cancer drug developers in OnCo raised from it.","summary":"TCG Crossover (TCGX) is a life-science investment firm founded by Chen Yu that specialises in crossover financings, the late private rounds that bridge a company to an initial public offering, and continues to hold and add positions after listing. It has been an anchor investor in a number of oncology crossover and Series B and C rounds since 2021. The firm's site does not state a street address, so only the region is recorded; portfolio links are derived from the startup records that name it.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://tcgcrossover.com"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco Bay Area, CA","country":"US","companyType":"investor","website":"https://tcgcrossover.com","investors":[],"funding":[]},{"id":"teclison","kind":"company","name":"Teclison","aka":["Teclison Ltd."],"tldr":"Teclison is a US-based biotechnology company that leads 3 cancer trials in OnCo, testing trans-arterial tirapazamine embolisation (TATE) in hepatocellular carcinoma, neuroendocrine tumours and colorectal cancer.","summary":"Teclison develops cancer therapies designed to induce tumour necrosis and enhance anti-tumour immunity, with a focus on improving the effect of immune checkpoint inhibitors in solid tumours that have spread to the liver. Its clinical programme is trans-arterial tirapazamine embolisation (TATE), studied alone and with pembrolizumab. It has offices in Princeton and Taipei. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT03259867 (phase 2, Combination of TATE and PD-1 Inhibitor in Liver Cancer), NCT02174549 (phase 1/2, Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer) and NCT04701476 (phase 2, TATE and Pembrolizumab (MK3475) in mCRC and NSCLC). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.teclison.com/"},{"label":"ClinicalTrials.gov: trials led by Teclison","url":"https://clinicaltrials.gov/search?lead=Teclison%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["hcc","neuroendocrine","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab","pembrolizumab","trifluridine-tipiracil","regorafenib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03259867","nct02174549","nct04701476"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Princeton, New Jersey","country":"US","companyType":"biotech","website":"https://www.teclison.com/","stage":"growth","investors":[],"funding":[]},{"id":"telik","kind":"company","name":"Telik","aka":["Telik, Inc."],"tldr":"Telik was a Palo Alto biotech whose glutathione analogue canfosfamide (Telcyta) failed its phase 3 trials in ovarian and lung cancer in the 2000s, a reminder that late-stage failure is the norm in oncology.","summary":"Telik, Inc., founded in 1988 in Palo Alto, California, developed canfosfamide (TLK286, Telcyta), a prodrug activated by glutathione S-transferase P1-1 that is overexpressed in many tumours. It led phase 3 trials in platinum-resistant ovarian cancer and non-small cell lung cancer, none of which met their primary endpoints, and the company later wound down its programmes. Its trials remain on ClinicalTrials.gov under Telik as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://telik.com"},{"label":"ClinicalTrials.gov: trials led by Telik, Inc.","url":"https://clinicaltrials.gov/search?lead=Telik%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q17146330"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["ovarian","nsclc"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Palo Alto, CA","country":"US","companyType":"biotech","website":"http://telik.com","founded":1988,"stage":"defunct","investors":[],"funding":[]},{"id":"telix","kind":"company","name":"Telix Pharmaceuticals","aka":[],"tldr":"Telix is the Australian theranostics company behind Illuccix and Gozellix PSMA imaging and a broad therapeutic pipeline.","summary":"Telix Pharmaceuticals, based in Melbourne and listed as TLX.AX, is the Australian theranostics company behind the Illuccix and Gozellix kits for gallium-68 PSMA-11 imaging and a broad therapeutic pipeline. TLX250-CDx, or zirconium-89 girentuximab for carbonic anhydrase IX PET in kidney cancer, received an FDA complete response letter in 2025, TLX591, or lutetium-177 rosopatamab, a PSMA antibody in the ProstACT phase 3, and TLX101 for glioma follow. OnCo links it to prostate cancer and renal cell carcinoma, to PSMA as a target, to CAIX PET and PET tracer manufacturing, and to the idea of CAIX theranostics pairing girentuximab imaging with lutetium or actinium therapy. Whether an antibody-based PSMA therapy can compete with small-molecule ligands is the open question. Illuccix has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://telixpharma.com"}],"tags":[],"related":[],"cancers":[],"sections":["radiopharma","imaging"],"technologies":[],"targets":["psma"],"drugs":["girentuximab-zr89"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07100730","nct06520345","nct07052214"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Melbourne","country":"AU","companyType":"radiopharma","website":"https://telixpharma.com","ticker":"TLX.AX","investors":[],"funding":[]},{"id":"tempus","kind":"company","name":"Tempus AI","aka":[],"tldr":"Genomic testing plus one of the largest multimodal clinical datasets, used for AI models and trial matching.","summary":"Tempus AI, based in Chicago and listed as TEM, pairs genomic testing with one of the largest multimodal clinical datasets, used to build AI models and match patients to trials. It sells xT, a 648-gene panel with an FDA-approved CDx version, xR for RNA, xF and xM for liquid biopsy and MRD, the TIME trial matching service and algorithms such as Tempus ECG-AF, and it owns Ambry Genetics for germline testing, with Personalis and Deep 6 AI also linked. OnCo links it to comprehensive genomic profiling, AI trial matching, oncology real-world data platforms and multimodal models, and to bottlenecks on AI that is built but not validated, data silos and patient navigation, with ideas on a shared multimodal foundation model attached. Whether its data advantage produces validated clinical tools rather than only revenue is the open question. Tempus xT CDx has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.tempus.com"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics","ai-computation"],"technologies":["cgp","ai-trial-matching"],"targets":[],"drugs":[],"companies":["deep-6-ai"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05736731","nct06051695"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Chicago, IL","country":"US","companyType":"ai-software","website":"https://www.tempus.com","ticker":"TEM","investors":[],"funding":[]},{"id":"terrapower-isotopes","kind":"company","name":"TerraPower Isotopes","aka":[],"tldr":"Bill Gates-backed producer of actinium-225 from thorium-229, building a Philadelphia facility to raise supply 20-fold.","summary":"TerraPower Isotopes, based in Bellevue, Washington, is the Bill Gates-backed producer of actinium-225 from thorium-229, building a Philadelphia facility intended to raise supply twenty-fold. It obtains actinium-225 from the decay of thorium-229 recovered from a legacy uranium-233 stockpile and holds supply agreements with Bayer, Bristol Myers Squibb and others. OnCo links it to targeted alpha therapy, alpha-emitter nanogenerators and the therapeutic isotope supply chain, to the radiopharmaceutical roadmap from iodine to actinium, and to the idea of recovering legacy radium-226 sources worldwide as feedstock. Manufacturing cost and time for radioactive medicines is the bottleneck it exists to relieve. Whether supply can grow fast enough for the alpha therapies now in phase 3 is the open question.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.terrapower.com/isotopes"}],"tags":["isotope-supply"],"related":[],"cancers":[],"sections":["radiopharma"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Bellevue, WA","country":"US","companyType":"radiopharma","website":"https://www.terrapower.com/isotopes","investors":[],"funding":[]},{"id":"tersera-therapeutics","kind":"company","name":"TerSera Therapeutics","aka":[],"tldr":"TerSera is a US specialty company whose oncology and supportive-care products include goserelin (Zoladex), rolapitant (Varubi) and telotristat ethyl (Xermelo) in the US.","summary":"TerSera Therapeutics, based in Deerfield, Illinois, is a US specialty company whose oncology and supportive care products include goserelin, sold as Zoladex, rolapitant, sold as Varubi, and telotristat ethyl, sold as Xermelo, in the United States. It acquired US rights to Zoladex from AstraZeneca in 2017, Varubi from Tesaro in 2018 and Xermelo from Lexicon in 2020, building a portfolio of hormonal therapy and supportive care products. OnCo links it to the rolapitant and telotristat ethyl drug records. Whether a company built by buying products that larger firms no longer wanted can keep investing in them is the fair question. Rolapitant and telotristat have their own pages.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.tersera.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Deerfield, Illinois","country":"US","companyType":"pharma","website":"https://www.tersera.com","investors":[],"funding":[]},{"id":"terumo-bct","kind":"company","name":"Terumo Blood and Cell Technologies","aka":[],"tldr":"Maker of the Spectra Optia apheresis system used to collect cells for most CAR-T products, and of the Quantum cell-expansion system.","summary":"Terumo Blood and Cell Technologies, based in Lakewood, Colorado, and a subsidiary of Japan's Terumo, makes the Spectra Optia apheresis system used to collect cells for most CAR-T products, and the Quantum cell expansion system. Its portfolio covers apheresis, blood component and cell therapy manufacturing devices. OnCo links it to apheresis and starting-material collection and to closed automated cell therapy manufacturing. Whether apheresis capacity, rather than manufacturing, becomes the limiting step as CAR-T demand grows is the open question its position highlights. The apheresis technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.terumobct.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["apheresis-starting-material","closed-automated-cell-manufacturing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Lakewood, CO","country":"US","companyType":"devices","website":"https://www.terumobct.com","investors":[],"funding":[]},{"id":"teva","kind":"company","name":"Teva Pharmaceuticals","aka":["Cephalon","Actavis Inc.","Actavis","Teva Branded Pharmaceutical Products R&D, Inc.","Barr Laboratories","Watson Pharmaceuticals"],"tldr":"Teva is the world's largest generic medicines company; its branded oncology products include omacetaxine (Synribo) for resistant chronic myeloid leukaemia, arsenic trioxide (Trisenox), bendamustine (Bendeka) and the G-CSF products Granix and Lonquex.","summary":"Teva Pharmaceuticals, based in Tel Aviv and listed as TEVA, is the world's largest generic medicines company; its branded oncology products include omacetaxine, sold as Synribo, for resistant chronic myeloid leukaemia, arsenic trioxide as Trisenox, bendamustine as Bendeka and the G-CSF products Granix and Lonquex. It acquired Cephalon in 2011, gaining Trisenox, Treanda and Synribo, and markets tbo-filgrastim as Granix in the United States and lipegfilgrastim as Lonquex in Europe, alongside the largest generic oncology injectables portfolio worldwide. OnCo links it to filgrastim, lipegfilgrastim and omacetaxine. Whether the largest generic injectables maker can keep supply steady through the recurring shortages that hit chemotherapy is the question its scale invites. Each product has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.tevapharm.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["arsenic-trioxide","epoetin-theta"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tel Aviv","country":"IL","companyType":"pharma","website":"https://www.tevapharm.com","ticker":"TEVA","investors":[],"funding":[]},{"id":"tg-therapeutics","kind":"company","name":"TG Therapeutics","aka":["TG Therapeutics, Inc."],"tldr":"TG Therapeutics is a New York company whose lymphoma drug umbralisib was approved in 2021 and withdrawn in 2022 over a survival signal, and which now sells the anti-CD20 antibody ublituximab for multiple sclerosis.","summary":"TG Therapeutics, listed on Nasdaq, developed the PI3K-delta and CK1-epsilon inhibitor umbralisib (Ukoniq), which received accelerated approval in 2021 for relapsed marginal zone and follicular lymphoma and was withdrawn in 2022 after the UNITY-CLL trial suggested a possible detriment in overall survival, and the glycoengineered anti-CD20 antibody ublituximab, which it had studied with umbralisib in chronic lymphocytic leukaemia and which is now approved as Briumvi for relapsing multiple sclerosis. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.tgtherapeutics.com"},{"label":"ClinicalTrials.gov: trials led by TG Therapeutics","url":"https://clinicaltrials.gov/search?lead=TG%20Therapeutics"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/TG_Therapeutics"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cll","follicular-lymphoma"],"sections":["targeted-therapy"],"technologies":[],"targets":["cd20","pik3cd"],"drugs":["umbralisib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"New York, NY","country":"US","companyType":"biotech","website":"https://www.tgtherapeutics.com","stage":"public","investors":[],"funding":[]},{"id":"theolytics","kind":"company","name":"Theolytics","aka":["Theolytics Ltd"],"tldr":"Theolytics is an Oxford biotech that screens huge libraries of adenoviruses to find ones that kill particular cancers; THEO-260 is its lead for ovarian cancer.","summary":"Theolytics, spun out of the University of Oxford, uses directed evolution and high-throughput screening of adenovirus libraries to select oncolytic viruses with the best tumour selectivity and potency for a chosen cancer. THEO-260, selected against ovarian cancer cells, entered a phase 1/2 trial in platinum-resistant ovarian cancer in 2024 and is also being developed for intravenous delivery.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.theolytics.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["theo-260"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Oxford","country":"GB","companyType":"biotech","website":"https://www.theolytics.com/","investors":[],"funding":[]},{"id":"therapanacea","kind":"company","name":"TheraPanacea","aka":[],"tldr":"TheraPanacea is a Paris AI company whose ART-Plan does auto-contouring and synthetic CT in radiotherapy.","summary":"TheraPanacea, based in Paris, is an AI company whose ART-Plan software performs auto-contouring and synthetic CT generation in radiotherapy. Its ART-Plan Annotate and Adapt modules are CE-marked and FDA-cleared, and the company grew out of academic work at CentraleSupélec. OnCo links it to AI auto-contouring and adaptive planning. Whether synthetic CT from MR can remove the planning scan altogether, and whether adaptive planning tools change outcomes rather than workflow, are the open questions. The auto-contouring technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.therapanacea.eu"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["radiation","ai-computation"],"technologies":["auto-contouring-ai"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Paris","country":"FR","companyType":"ai-software","website":"https://www.therapanacea.eu","investors":[],"funding":[]},{"id":"therapixel","kind":"company","name":"Therapixel","aka":[],"tldr":"Therapixel's MammoScreen software uses artificial intelligence to point out suspicious areas on mammograms and score how likely they are to be cancer, helping radiologists in the US and Europe read screening exams.","summary":"Therapixel, founded in 2013 and headquartered in Nice with offices in Paris and Chicago, develops MammoScreen, an AI reading aid for screening mammography that detects suspicious lesions and calcifications and assigns a malignancy likelihood score. MammoScreen received FDA 510(k) clearance for 2D mammography in July 2020 (K192854) after a multi-reader multi-case study showing improved radiologist detection, and for digital breast tomosynthesis in November 2021; version 2.0 added prior-exam comparison in 2022 and the product is CE marked. A prospective study of AI within second reading in the French screening programme began in October 2022. In 2025 the company announced deployment across more than 150 Onsite Women's Health locations and adoption by Mayo Clinic. A EUR 15 million Series B closed in May 2022, co-led by Crédit Mutuel Innovation and CapHorn, for over EUR 20 million raised in total.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.therapixel.com/"},{"label":"Series B press release (May 2022)","url":"https://www.therapixel.com/therapixel-announces-close-of-15-me-series-b-financing/"},{"label":"FDA 510(k) clearance for MammoScreen (Jul 2020)","url":"https://www.therapixel.com/therapixel-receives-fda-510k-clearance-for-mammoscreen/"},{"label":"Press releases","url":"https://www.therapixel.com/category/press-release/"}],"tags":[],"related":[],"cancers":["breast-hr-positive","breast-her2-positive","tnbc"],"sections":["imaging","early-detection","ai-computation"],"technologies":["radiology-ai-screening","mammography"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Earlier EUR 5 million round (2019) is only referenced via a third-party article on the press page so it is not recorded."],"hq":"Nice","country":"FR","companyType":"ai-software","website":"https://www.therapixel.com/","founded":2013,"stage":"startup","investors":[],"funding":[{"round":"Series B","year":2022,"source":"https://www.therapixel.com/therapixel-announces-close-of-15-me-series-b-financing/","note":"EUR 15 million, co-led by Crédit Mutuel Innovation and CapHorn, May 2022; over EUR 20 million raised since founding."}]},{"id":"thermo-fisher","kind":"company","name":"Thermo Fisher Scientific","aka":[],"tldr":"Thermo Fisher is the largest life-science tools and services company, spanning Ion Torrent sequencing (Oncomine), viral vector and fill-finish manufacturing (Patheon), and the PPD clinical research organisation.","summary":"Thermo Fisher Scientific, based in Waltham, Massachusetts, and listed as TMO, is the largest life science tools and services company, spanning Ion Torrent sequencing with the Oncomine tests, viral vector and fill-finish manufacturing through Patheon, and the PPD clinical research organisation. Its oncology footprint includes the Oncomine Dx Target Test companion diagnostic, the Ion Torrent Genexus system, Patheon CDMO sites for viral vectors, PPD's trial services and laboratory supplies across the field. OnCo links it to viral vector manufacturing, sterile fill-finish, CROs and companion diagnostics, and to the Oncomine Dx Target Test drug record. Whether one company supplying sequencing, manufacturing and trials creates conflicts or efficiencies is the fair question. Oncomine Dx Target Test has its own page.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.thermofisher.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics","cell-therapy","drug-discovery"],"technologies":["viral-vector-manufacturing","sterile-fill-finish","contract-research-organisations","companion-diagnostic"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Waltham, MA","country":"US","companyType":"cro-services","website":"https://www.thermofisher.com","ticker":"TMO","investors":[],"funding":[]},{"id":"theryq","kind":"company","name":"THERYQ","aka":[],"tldr":"THERYQ, part of the French industrial group ALCEN, builds linear accelerators for FLASH radiotherapy, which delivers a whole radiation dose in under 100 milliseconds; its FLASHDEEP produces 100 to 200 MeV electron beams that reach tumours about 20 cm deep. It is still preclinical, with a 38 million euro France 2030 programme to reach a CE mark.","summary":"THERYQ, part of ALCEN For Health (the healthcare branch of French industrial group ALCEN), designs and manufactures linac-based devices to bring FLASH radiotherapy into the clinic. It was formed when AVELION, which had led FLASH projects since 2013, transferred its radiotherapy business to THERYQ in 2022. FLASHKNiFE is a lower-energy electron research device; the flagship FLASHDEEP is a compact linac producing very high energy electron beams of 100 to 200 MeV, able to reach tumours about 20 cm deep while delivering ultra-high dose rates in under 100 milliseconds. The company describes itself as at the preclinical research stage. With Gustave Roussy it was selected under France 2030's i-Demo call for the FLASHDEEP project, a EUR 38 million budget funded through Bpifrance, to run preclinical and clinical studies and prepare a CE marking application while building an industrial platform in Rousset.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.theryq-alcen.com/"},{"label":"About THERYQ","url":"https://www.theryq-alcen.com/about-theryq/"},{"label":"FLASHDEEP product and France 2030 funding","url":"https://www.theryq-alcen.com/flash-radiotherapy-products/flashdeep/"}],"tags":[],"related":[],"cancers":[],"sections":["radiation","devices"],"technologies":["flash-rt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["theryq.tech does not resolve; the live site is theryq-alcen.com. THERYQ is a subsidiary of the ALCEN group, so 'private-large' signals corporate ownership rather than venture backing; no equity rounds were found. Founded set to 2022 (transfer of the AVELION radiotherapy branch). The France 2030 / Bpifrance FLASHDEEP grant (EUR 38 million project budget shared with Gustave Roussy) is stated on the product page but without a date or THERYQ's own share, so it is described in the summary rather than recorded as a funding round."],"hq":"Paris","country":"FR","companyType":"devices","website":"https://www.theryq-alcen.com/","founded":2022,"stage":"private-large","investors":["bpifrance"],"funding":[]},{"id":"third-rock-ventures","kind":"company","name":"Third Rock Ventures","aka":[],"tldr":"Third Rock Ventures builds biotech companies from scratch around a scientific idea, then funds and staffs them. Several of the best-known precision oncology companies of the last fifteen years started in its offices.","summary":"Third Rock Ventures is a Boston venture firm whose model is company creation: partners incubate a concept, assemble founding scientists and an interim management team, and fund the company through its first years before it raises from others or lists. Oncology has been a central theme since the firm's founding in 2007, with companies built around genomic profiling, kinase inhibitors, cancer metabolism, synthetic lethality and targeted immunotherapies, and a habit of pairing a therapeutic platform with a diagnostic rationale. Its portfolio pages list current and former companies; portfolio links in OnCo are derived from the startup records that name Third Rock as an investor.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.thirdrockventures.com"},{"label":"Portfolio","url":"https://www.thirdrockventures.com/portfolio"}],"tags":["vc"],"related":[],"cancers":[],"sections":["targeted-therapy","immunotherapy","diagnostics"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boston, MA","country":"US","companyType":"investor","website":"https://www.thirdrockventures.com","founded":2007,"investors":[],"funding":[]},{"id":"threshold-pharmaceuticals","kind":"company","name":"Threshold Pharmaceuticals","aka":["Threshold Pharmaceuticals, Inc."],"tldr":"Threshold developed evofosfamide, a drug switched on only in the oxygen-starved parts of tumours; two phase 3 trials in pancreatic cancer and sarcoma failed in 2015 and the company merged away.","summary":"Threshold Pharmaceuticals, founded in 2001 in San Francisco, pursued hypoxia-activated prodrugs, chiefly evofosfamide (TH-302), a bromo-isophosphoramide mustard released in hypoxic tumour tissue and partnered with Merck KGaA. The MAESTRO trial in pancreatic cancer and the TH CR-406 trial in soft tissue sarcoma both missed their survival endpoints in 2015; Threshold later merged with Molecular Templates. Its trials remain on ClinicalTrials.gov under Threshold as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.thresholdpharm.com"},{"label":"ClinicalTrials.gov: trials led by Threshold Pharmaceuticals, Inc.","url":"https://clinicaltrials.gov/search?lead=Threshold%20Pharmaceuticals%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30289027"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["pancreatic","sarcoma"],"sections":[],"technologies":["hypoxia-activated-therapy"],"targets":[],"drugs":["evofosfamide"],"companies":["merck-kgaa"],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Francisco, CA","country":"US","companyType":"biotech","website":"http://www.thresholdpharm.com","founded":2001,"stage":"defunct","investors":[],"funding":[]},{"id":"thyme-care","kind":"company","name":"Thyme Care","aka":[],"tldr":"Thyme Care gives people with cancer a 24 hour phone and app based support team of oncology nurses and social workers, paid for by their health insurer. It aims to keep people out of hospital and lower the cost of cancer care.","summary":"Thyme Care is a value based cancer navigation company. Health plans and risk bearing oncology groups contract with it to wrap a virtual Care Team of oncology nurses, social workers and navigators around members from diagnosis through survivorship, with 24/7 access, electronic patient reported outcomes and structured care plans. It reports a 28 percent reduction in emergency department or inpatient use among members completing patient reported outcomes, validated total cost of care reductions of 5 to 10 percent, NCQA accreditation, and availability to more than 10.5 million people through partners such as Humana and Aetna. Founded in 2020 and based in Nashville, Thyme Care closed a USD 97 million Series D in September 2025 and a USD 125 million plus Series E led by Morgan Health in September 2026, when it created the parent Thyme Companies. It states it is profitable and manages more than USD 7 billion of oncology spend.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.thymecare.com"},{"label":"Series E press release (September 2026)","url":"https://www.prnewswire.com/news-releases/thyme-care-closes-125-million-series-e-establishes-thyme-companies-to-broaden-its-impact-across-the-oncology-ecosystem-302867835.html"},{"label":"Series D press release (September 2025)","url":"https://www.prnewswire.com/news-releases/97m-series-d-backed-by-strategic-investors-across-the-oncology-ecosystem-positions-thyme-care-to-break-through-cancer-cares-biggest-bottlenecks-302565050.html"}],"tags":[],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Nashville, TN","country":"US","companyType":"cro-services","website":"https://www.thymecare.com","founded":2020,"stage":"growth","investors":["foresite-capital","a16z-bio-health"],"funding":[{"round":"Series E","year":2026,"amountUsd":125000000,"source":"https://www.prnewswire.com/news-releases/thyme-care-closes-125-million-series-e-establishes-thyme-companies-to-broaden-its-impact-across-the-oncology-ecosystem-302867835.html","note":"USD 125 million plus, led by Morgan Health; valuation stated as more than USD 2 billion"},{"round":"Series D","year":2025,"amountUsd":97000000,"source":"https://www.prnewswire.com/news-releases/97m-series-d-backed-by-strategic-investors-across-the-oncology-ecosystem-positions-thyme-care-to-break-through-cancer-cares-biggest-bottlenecks-302565050.html","note":"Brought total raised to USD 275 million"}]},{"id":"tilt-biotherapeutics","kind":"company","name":"TILT Biotherapeutics","aka":["TILT Biotherapeutics Ltd"],"tldr":"TILT Biotherapeutics is a Finnish biotech founded by Akseli Hemminki whose oncolytic adenovirus TILT-123 produces TNF-alpha and IL-2 in the tumour to help checkpoint inhibitors and TIL therapy work.","summary":"TILT Biotherapeutics develops armed oncolytic adenoviruses that replicate in cancer cells and express immune cytokines. TILT-123 (igrelimogene litadenorepvec) carries genes for tumour necrosis factor alpha and interleukin-2, and has been tested with pembrolizumab in platinum-resistant ovarian cancer, with avelumab in solid tumours and with tumour-infiltrating lymphocyte therapy in melanoma. The company has also received funding for phase 2 development in ovarian cancer.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.tiltbio.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["tilt-123"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Helsinki","country":"FI","companyType":"biotech","website":"https://www.tiltbio.com/","founded":2013,"investors":[],"funding":[]},{"id":"tiumbio","kind":"company","name":"TiumBio","aka":["TiumBio Co., Ltd."],"tldr":"TiumBio is a South Korea-based biotechnology company running 2 late-stage cancer trials of TU2218 in biliary tract cancer, head and neck squamous cell carcinoma and colorectal cancer.","summary":"TiumBio, based in Seongnam, South Korea, is a biotechnology company. TiumBio develops treatments for rare and intractable diseases, including immunotherapies and biologics for cancer, hemophilia and endometriosis. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing TU2218 in biliary tract cancer, head and neck squamous cell carcinoma and colorectal cancer. The largest, NCT05204862 (Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumours), plans to enrol 240 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.tiumbio.com"},{"label":"ClinicalTrials.gov: trials led by TiumBio","url":"https://clinicaltrials.gov/search?lead=TiumBio%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cholangiocarcinoma","head-and-neck","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05784688","nct05204862"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Seongnam","country":"KR","companyType":"biotech","website":"https://www.tiumbio.com","stage":"public","investors":[],"funding":[]},{"id":"tj-biopharma","kind":"company","name":"TJ Biopharma","aka":["TJ Biopharma Co., Ltd."],"tldr":"TJ Biopharma is a Chinese developer in Shanghai that sponsors 2 registered cancer trials of Uliledlimab and Sintilimab.","summary":"TJ Biopharma appears on ClinicalTrials.gov as the industry sponsor of 2 interventional cancer trials (phase 2, 2/3), testing Uliledlimab, Sintilimab, Pemetrexed, Toripalimab in non small cell lung cancer. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials sponsored by TJ Biopharma","url":"https://clinicaltrials.gov/search?spons=TJ%20Biopharma"}],"tags":["ctgov-sponsor","china","registry-only"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07005336","nct06984588"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai, China","country":"CN","companyType":"biotech","website":"https://www.tjbio.com","investors":[],"funding":[]},{"id":"tmunity-therapeutics","kind":"company","name":"Tmunity Therapeutics","aka":[],"tldr":"Tmunity was a Philadelphia company spun out of University of Pennsylvania research that built CAR T-cell therapies with extra features to help them fight solid tumours. Gilead's cell therapy unit Kite bought it in early 2023.","summary":"Tmunity Therapeutics was a private, clinical-stage cell therapy company based in Philadelphia. According to Gilead's first-quarter 2023 report, Kite completed the acquisition of Tmunity in that quarter, gaining preclinical and clinical programmes including an investigational armoured CAR T technology platform intended to be applied across CAR T products to enhance anti-tumour activity, together with rapid manufacturing processes. SEC Form D filings show Tmunity was incorporated in 2015 and sold about $75 million of equity in an offering that began in October 2019 (earlier Form D filings were made in 2018). The Gilead filing attributes most of a $481 million acquired in-process R&D charge in Q1 2023 to the Tmunity acquisition, alongside payments to Arcellx and Nurix. The company website no longer resolves.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.sec.gov/edgar/browse/?CIK=0001661702"},{"label":"Gilead Q1 2023 results noting completed Tmunity acquisition (8-K)","url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000014/exhibit991earningspressrel.htm"},{"label":"Form D, October 2019","url":"https://www.sec.gov/Archives/edgar/data/1661702/000166170219000001/primary_doc.xml"},{"label":"SEC EDGAR filings","url":"https://www.sec.gov/edgar/browse/?CIK=0001661702"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["car-t","armored-car"],"targets":[],"drugs":[],"companies":[],"institutions":["parker-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Website tmunity.com is offline; the EDGAR company page is given instead. Acquisition price not disclosed in fetched sources. The 2019 Form D does not name the series; the user's hint of a 2021 acquisition is incorrect, Gilead reports completion in Q1 2023."],"hq":"Philadelphia, PA","country":"US","companyType":"cell-therapy","founded":2015,"stage":"acquired","investors":[],"funding":[{"round":"Form D offering","year":2019,"amountUsd":74999948,"source":"https://www.sec.gov/Archives/edgar/data/1661702/000166170219000001/primary_doc.xml","note":"Equity offering, first sale 22 October 2019"},{"round":"Acquisition","year":2023,"source":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000014/exhibit991earningspressrel.htm","note":"Completed in the first quarter of 2023; Gilead reported acquired IPR&D of $481 million for the quarter driven primarily by Tmunity plus Arcellx and Nurix payments, so the Tmunity price alone is not stated"}],"acquiredBy":"gilead"},{"id":"tolmar","kind":"company","name":"Tolmar","aka":["Tolmar Inc.","Tolmar Pharmaceuticals"],"tldr":"Tolmar is a privately held Colorado company that makes Eligard, the subcutaneous depot of the hormone therapy leuprolide used to suppress testosterone in advanced prostate cancer.","summary":"Tolmar, based in Fort Collins, Colorado, develops and manufactures long-acting injectables using its Atrigel polymer depot technology. Its main product is Eligard (leuprolide acetate for injectable suspension), a gonadotropin-releasing hormone agonist given every one to six months for palliative treatment of advanced prostate cancer, sold in the United States by Tolmar and abroad through partners; it runs phase 3 trials of new formulations and dosing intervals. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.tolmar.com"},{"label":"ClinicalTrials.gov: trials led by Tolmar","url":"https://clinicaltrials.gov/search?lead=Tolmar"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate"],"sections":["hormonal"],"technologies":[],"targets":["gnrhr"],"drugs":["leuprolide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04906395"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Fort Collins, CO","country":"US","companyType":"pharma","website":"https://www.tolmar.com","stage":"private-large","investors":[],"funding":[]},{"id":"toray-industries","kind":"company","name":"Toray Industries","aka":["Toray","東レ","TSE:3402"],"tldr":"Toray Industries is the Japanese materials group, known for carbon fibre and synthetic fibres, whose pharmaceutical division created the antibody TRK-950 against CAPRIN-1, a protein found on many solid tumours.","summary":"Toray Industries is a Tokyo-based chemicals and materials company whose pharmaceutical business makes the pruritus drug nalfurafine and interferon-beta. TRK-950 is a humanised antibody against CAPRIN-1 (cytoplasmic activation/proliferation-associated protein 1), a cytoplasmic protein that Toray found on the surface of breast, ovarian, gastric and other cancer cells; it is in phase 1/2 trials alone and with chemotherapy and checkpoint inhibitors in solid tumours.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.toray.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["trk-950"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Tokyo","country":"JP","companyType":"pharma","website":"https://www.toray.com/","ticker":"TSE:3402","founded":1926,"stage":"public","investors":[],"funding":[]},{"id":"torl-biotherapeutics","kind":"company","name":"TORL BioTherapeutics","aka":["TORL Biotherapeutics, LLC"],"tldr":"TORL BioTherapeutics is a US-based biotechnology company that leads 3 cancer trials in OnCo, testing the antibody-drug conjugates TORL-1-23 (ixotatug vedotin) and TORL-5-700 in non-Hodgkin lymphoma and ovarian cancer.","summary":"TORL BioTherapeutics develops antibody-drug conjugates for cancer, drawing on a research partnership with the Slamon laboratory at UCLA. Its lead programme TORL-1-23 (ixotatug vedotin) targets claudin 6 in solid tumours and is in phase 2 for platinum-resistant ovarian cancer; TORL-5-700 is an earlier-stage ADC. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT07439653 (phase 1/2, A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma), NCT06690775 (phase 2, CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.) and NCT07322094 (phase 1/2, CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemothera...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://torlbio.com/"},{"label":"ClinicalTrials.gov: trials led by TORL BioTherapeutics","url":"https://clinicaltrials.gov/search?lead=TORL%20Biotherapeutics%2C%20LLC"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["non-hodgkin-lymphoma","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["pegfilgrastim","paclitaxel","carboplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07439653","nct06690775","nct07322094"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Culver City, California","country":"US","companyType":"biotech","website":"https://torlbio.com/","stage":"growth","investors":[],"funding":[]},{"id":"toshiba-energy-systems","kind":"company","name":"Toshiba Energy Systems & Solutions","aka":["Toshiba heavy-ion therapy"],"tldr":"Toshiba builds carbon-ion therapy facilities, including the superconducting rotating gantry at HIMAC in Chiba and the heavy-ion centres in Kanagawa, Yamagata and at Yonsei in Seoul.","summary":"Toshiba's energy systems subsidiary, spun out of the parent in 2017, carries the group's accelerator business. It built the world's first superconducting rotating gantry for carbon ions at the QST HIMAC facility, and supplied the heavy-ion synchrotron facilities at Kanagawa Cancer Center, Yamagata University and the Yonsei Heavy Ion Therapy Center at Severance Hospital, which opened in 2023 as South Korea's first carbon-ion centre. OnCo links it to carbon-ion synchrotrons and carbon-ion therapy.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.global.toshiba"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":["machines-wave"],"related":[],"cancers":[],"sections":["radiation","devices"],"technologies":["carbon-ion-synchrotrons","carbon-ion"],"targets":[],"drugs":[],"companies":[],"institutions":["qst-hospital","severance"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Kawasaki","country":"JP","companyType":"devices","website":"https://www.global.toshiba","founded":2017,"stage":"private-large","investors":[],"funding":[]},{"id":"touchlight","kind":"company","name":"Touchlight","aka":[],"tldr":"Touchlight, of Hampton in the United Kingdom, makes doggybone dbDNA, synthetic DNA produced enzymatically without bacterial cells, as a replacement for plasmids in viral vector and mRNA manufacturing. Its business depends on regulators and developers accepting synthetic DNA in licensed products, not only in development.","summary":"Touchlight, based in Hampton in the United Kingdom, makes cell-free synthetic DNA, its doggybone dbDNA, as an alternative to plasmids for viral vectors and mRNA templates. Its enzymatic DNA manufacturing runs at GMP scale, is partnered with mRNA and gene therapy developers, and aims to remove bacterial fermentation from the supply chain altogether. OnCo links it to plasmid DNA and mRNA raw-material manufacturing. Whether regulators and developers accept synthetic DNA in place of plasmids for licensed products, rather than only in development, is the open question its business depends on. The raw-material manufacturing page carries the wider field.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.touchlight.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["plasmid-dna-manufacturing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Hampton","country":"GB","companyType":"biotech","website":"https://www.touchlight.com","investors":[],"funding":[]},{"id":"tracon","kind":"company","name":"Tracon Pharmaceuticals","aka":["Tracon Pharmaceuticals Inc.","TRACON"],"tldr":"Tracon was a San Diego biotech whose endoglin antibody carotuximab failed a phase 3 trial in angiosarcoma and whose subcutaneous PD-L1 antibody envafolimab missed in sarcoma; it wound down in 2024.","summary":"Tracon Pharmaceuticals, based in San Diego, developed carotuximab (TRC105), an antibody against endoglin on tumour blood vessels, which failed the phase 3 TAPPAS trial with pazopanib in angiosarcoma in 2019, and then in-licensed the subcutaneous PD-L1 antibody envafolimab, whose ENVASARC trial in undifferentiated pleomorphic sarcoma did not meet its endpoint in 2023. The company ceased operations in 2024. Its trials remain on ClinicalTrials.gov under Tracon as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.traconpharma.com"},{"label":"ClinicalTrials.gov: trials led by Tracon Pharmaceuticals Inc.","url":"https://clinicaltrials.gov/search?lead=Tracon%20Pharmaceuticals%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30289078"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["envafolimab"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"http://www.traconpharma.com","stage":"defunct","investors":[],"funding":[]},{"id":"tradewind-bioscience","kind":"company","name":"Tradewind BioScience","aka":[],"tldr":"Tradewind is developing a single antibody for ovarian cancer that both attacks the tumour cells directly and helps the immune system attack them too.","summary":"Tradewind BioScience is a small San Francisco biotech whose lead candidate is a multi-functional therapeutic antibody for ovarian and other metastatic cancers, designed to bind primary cancer cells directly while enabling natural anti-tumour immunity through the same molecule. The company describes its work as translating insights about metastasis into antibody therapeutics. Programmes are preclinical as far as public sources show; no clinical trial registration or financing details were found in a primary source at the time of checking.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/tradewind-bioscience"},{"label":"Official website","url":"https://www.tradewindbio.com"}],"tags":["yc"],"related":[],"cancers":["ovarian"],"sections":["immunotherapy","targeted-therapy"],"technologies":["monoclonal-antibody"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.tradewindbio.com","stage":"startup","ycBatch":"W18","investors":["y-combinator"],"funding":[]},{"id":"transcenta","kind":"company","name":"Transcenta","aka":["Transcenta Holding","Suzhou Transcenta Therapeutics","创胜集团","HKEX:6628"],"tldr":"Transcenta is a Suzhou antibody company whose Claudin 18.2 antibody osemitamab (TST001) is being tested with nivolumab and chemotherapy as first-line treatment for stomach cancer.","summary":"Transcenta, listed in Hong Kong, develops antibodies with its own continuous-manufacturing platform. Osemitamab (TST001), a high-affinity Claudin 18.2 antibody with enhanced antibody-dependent cytotoxicity, has shown activity with nivolumab and chemotherapy in first-line gastric and gastro-oesophageal junction cancer and has orphan designations for gastric and pancreatic cancer. TST003 targets Gremlin1 in solid tumours and TST005 is a PD-L1 and TGF-beta bifunctional antibody.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.transcenta.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["tst001","tst003"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Suzhou","country":"CN","companyType":"biotech","website":"https://www.transcenta.com/","ticker":"HKEX:6628","stage":"public","investors":[],"funding":[]},{"id":"transgene","kind":"company","name":"Transgene","aka":[],"tldr":"Transgene uses modified viruses to make cancer immunotherapies. Its lead product is a personalised vaccine built from each patient's tumour mutations, given after surgery to stop head and neck cancer coming back.","summary":"Transgene (Euronext Paris: TNG) designs virus-based immunotherapies for cancer. Its myvac platform produces individualised neoantigen vaccines on a modified vaccinia Ankara vector, with neoantigens selected by NEC's AI. Lead candidate TG4050 encodes up to 30 patient-specific neoantigens and is in a randomised phase 1/2 trial in resected HPV-negative head and neck squamous cell carcinoma. In September 2026 Transgene and NEC reported 100 percent three-year disease-free survival in all 16 TG4050-treated phase 1 patients versus three relapses among 16 controls (median follow-up 41 months), published in Nature Communications; phase 2 results are expected around the end of 2027. TG4070 extends myvac into adjuvant non-small cell lung cancer (phase 1); oncolytic viruses BT-001 and TG6050 follow. In November 2025 the company raised about EUR 105 million, with Institut Mérieux (via TSGH) and the Dassault Group participating, extending financial visibility to early 2028.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.transgene.com/"},{"label":"Fundraising of about EUR 105 million (November 2025)","url":"https://www.transgene.com/wp-content/uploads/Transgene_PR_Results_EN.pdf"},{"label":"TG4050 three-year disease-free survival and Nature Communications publication","url":"https://www.transgene.com/wp-content/uploads/20260902_TG4050_NatCom_EN.pdf"}],"tags":[],"related":[],"cancers":["head-and-neck","nsclc"],"sections":["immunotherapy"],"technologies":["neoantigen-mrna-vaccine","oncolytic-virus"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03260023","nct04183166"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not sourced."],"hq":"Strasbourg","country":"FR","companyType":"biotech","website":"https://www.transgene.com/","ticker":"TNG.PA","stage":"public","investors":[],"funding":[{"round":"Crossover","year":2025,"source":"https://www.transgene.com/wp-content/uploads/Transgene_PR_Results_EN.pdf","note":"Public follow-on fundraising of about EUR 105 million (private placement plus PrimaryBid retail offering at EUR 1.02 per share), plus a EUR 39.3 million reserved capital increase for TSGH by set-off of advances"}]},{"id":"transthera","kind":"company","name":"TransThera Sciences","aka":[],"tldr":"Chinese biotech running the first phase 3 of a next-generation FGFR inhibitor, tinengotinib, for bile duct cancer that has stopped responding to first-generation FGFR drugs.","summary":"TransThera Sciences, based in Nanjing, is the Chinese biotechnology company running the first phase 3 trial of a next-generation FGFR inhibitor, tinengotinib, for bile duct cancer that has stopped responding to first-generation FGFR drugs. Tinengotinib, also known as TT-00420, is a multi-kinase inhibitor potent against the FGFR2 kinase-domain mutations that drive acquired resistance, and the FIRST-308 phase 3 trial, which compares it with physician's choice chemotherapy in FGFR-altered, FGFR-inhibitor-refractory cholangiocarcinoma, dosed its first US patient in 2025. OnCo links it to biliary tract cancer and to the tinengotinib drug record. Whether a resistance-directed FGFR inhibitor can beat chemotherapy in a population that has already progressed on targeted therapy is the question the trial will answer. Tinengotinib has its own page.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://www.transtherabio.com"}],"tags":[],"related":[],"cancers":["cholangiocarcinoma"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["tinengotinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07498478","nct05948475"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Nanjing","country":"CN","companyType":"biotech","website":"https://www.transtherabio.com","investors":[],"funding":[]},{"id":"trasis","kind":"company","name":"Trasis","aka":[],"tldr":"Belgian maker of radiopharmaceutical synthesis modules (AllinOne, miniAiO) and dose dispensers used in PET and therapy radiopharmacies.","summary":"Trasis, based in Ans, Belgium, makes radiopharmaceutical synthesis modules, including AllinOne and miniAiO, and dose dispensers used in PET and therapy radiopharmacies. Its cassette-based automated radiochemistry and cyclotron target solutions are widely used for gallium-68, fluorine-18 and lutetium-177 labelling. OnCo links it to medical cyclotrons, hot cells and synthesis modules. Whether synthesis automation can keep pace with the many new tracers and therapeutic ligands entering the clinic is the open question for its market. The cyclotron and synthesis technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.trasis.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["radiopharma"],"technologies":["medical-cyclotrons-synthesis-modules"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Ans","country":"BE","companyType":"radiopharma","website":"https://www.trasis.com","investors":[],"funding":[]},{"id":"travera","kind":"company","name":"Travera","aka":[],"tldr":"Travera exposes a patient's living cancer cells to a broad range of approved drugs, including immunotherapies, and measures within days which ones the cells respond to.","summary":"Travera's Rapid Therapy Guidance evaluates a broad range of FDA-approved drug options against a patient's live tumour cells, measuring single-cell mass changes as a readout of drug response, and reports which options showed activity. Based in Medford, Massachusetts; physician-ordered.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://travera.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["functional-drug-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Medford, MA","country":"US","companyType":"diagnostics","website":"https://travera.com/","investors":[],"funding":[]},{"id":"treadwell-therapeutics","kind":"company","name":"Treadwell Therapeutics","aka":["Treadwell Therapeutics, Inc"],"tldr":"Treadwell Therapeutics is a Hong Kong-based biotechnology company running 3 late-stage cancer trials of CFI-402411, CFI-400945 and CFI-402257 in acute myeloid leukaemia, myelodysplastic syndromes / neoplasms and HR-positive / HER2-negative breast cancer.","summary":"Treadwell Therapeutics, based in Hong Kong, Hong Kong, is a biotechnology company. Treadwell Therapeutics is a clinical-stage, multi-modality oncology company developing small molecules, biologics and T-cell receptor therapies against novel cancer targets. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials, testing CFI-402411, CFI-400945 and CFI-402257 in acute myeloid leukaemia, myelodysplastic syndromes / neoplasms and HR-positive / HER2-negative breast cancer. The largest, NCT04521413 (Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies), plans to enrol 170 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://treadwelltx.com"},{"label":"ClinicalTrials.gov: trials led by Treadwell Therapeutics","url":"https://clinicaltrials.gov/search?lead=Treadwell%20Therapeutics%2C%20Inc"},{"label":"Pipeline page","url":"https://treadwelltx.com/pipeline/"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml","mds","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04730258","nct04521413","nct05251714"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Hong Kong","country":"HK","companyType":"biotech","website":"https://treadwelltx.com","stage":"growth","investors":[],"funding":[]},{"id":"treeline-biosciences","kind":"company","name":"Treeline Biosciences","aka":[],"tldr":"Treeline Biosciences is a well-funded private company building cancer drugs of several kinds, including a pill that blocks all forms of the KRAS cancer protein and drugs for lymphoma.","summary":"Treeline Biosciences is a privately held, Watertown, Massachusetts biopharmaceutical company founded in 2021 that combines in-house inhibitor, protein degrader and antibody-drug conjugate capabilities with computational and machine-learning models. Its clinical programmes are TLN-121, a BCL6 degrader in phase 1 for B-cell and T-cell lymphomas; TLN-254, an EZH2 inhibitor (zeprumetostat, SHR2554) in-licensed from Jiangsu Hengrui for territories outside Greater China and in phase 1 in peripheral and cutaneous T-cell lymphoma; and TLN-372, a pan-KRAS inhibitor in phase 1 in solid tumours. Preclinical work extends to immunology and neurology. SEC Form D filings show more than 1 billion US dollars sold across private offerings between 2021 and 2025.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://treeline.bio/"},{"label":"Medicines (pipeline)","url":"https://treeline.bio/medicines"},{"label":"Form D (September 2025)","url":"https://www.sec.gov/Archives/edgar/data/1856619/000185661925000002/primary_doc.xml"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":["targeted-therapy","epigenetics"],"technologies":["protac-degrader","kras-inhibitors","epigenetic-drugs","ai-drug-design"],"targets":["kras","ezh2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The domain treelinebio.com does not resolve; the company site is treeline.bio. Round names and investors are not disclosed in the Form D filings or on the site. The dlbcl tag is an approximation for 'B-cell and T-cell lymphomas'."],"hq":"Watertown, MA","country":"US","companyType":"biotech","website":"https://treeline.bio/","founded":2021,"stage":"growth","investors":[],"funding":[{"round":"Form D offering","year":2021,"amountUsd":211669568,"source":"https://www.sec.gov/Archives/edgar/data/1856619/000185661921000001/primary_doc.xml","note":"Total sold per Form D filed April 2021"},{"round":"Form D offering","year":2022,"amountUsd":261266523,"source":"https://www.sec.gov/Archives/edgar/data/1856619/000185661922000003/primary_doc.xml","note":"Total sold per Form D filed October 2022"},{"round":"Form D offering","year":2024,"amountUsd":421779808,"source":"https://www.sec.gov/Archives/edgar/data/1856619/000185661924000002/primary_doc.xml","note":"Total sold per Form D filed October 2024"},{"round":"Form D offering","year":2025,"amountUsd":200099964,"source":"https://www.sec.gov/Archives/edgar/data/1856619/000185661925000002/primary_doc.xml","note":"Total sold of a 250 million US dollar offering per Form D filed September 2025"}]},{"id":"trial-library","kind":"company","name":"Trial Library","aka":[],"tldr":"Trial Library is software that helps everyday cancer clinics spot which patients might qualify for a clinical trial, refer them, and remove practical barriers like transport so more people, especially in under served communities, can join trials.","summary":"Trial Library, founded in 2022 by oncologist Hala Borno and based in San Francisco, is an AI native enrolment and navigation platform that embeds clinical trials as a care option in community oncology. It pre-screens patients for provider activation, optimises referrals within health systems, runs a Navigation OS that addresses transport, food, language and other barriers to retention, and in May 2026 launched a conversational AI trial search tool. Partners include Texas Oncology, Trinity Health, The Oncology Institute and AccessHope, with deployment across more than 840 clinics and 3,000 providers. The company raised a USD 5 million seed led by Lux Capital in March 2022 and a USD 10 million Series A in December 2025 co-led by NEXT Ventures and SemperVirens Venture Capital with Sanofi Ventures, Lux Capital and others, for USD 17.6 million in total.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.triallibrary.com"},{"label":"Series A announcement (December 2025)","url":"https://www.triallibrary.com/blog/weve-raised-10-million-to-expand-access-to-clinical-trials-as-a-care-option-cw3l6"},{"label":"Conversational AI Trial Search press release (May 2026)","url":"https://www.triallibrary.com/blog/press-release-conversational-ai-trial-search-launch"},{"label":"About Trial Library","url":"https://www.triallibrary.com/about"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["ai-trial-matching"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Seed round details come from the company About page rather than a dated release. HQ San Francisco from the May 2026 press release dateline."],"hq":"San Francisco, CA","country":"US","companyType":"ai-software","website":"https://www.triallibrary.com","founded":2022,"stage":"startup","investors":["sanofi-ventures","lux-capital"],"funding":[{"round":"Seed","year":2022,"amountUsd":5000000,"source":"https://www.triallibrary.com/about","note":"March 2022, led by Lux Capital, per company About page"},{"round":"Series A","year":2025,"amountUsd":10000000,"source":"https://www.triallibrary.com/blog/weve-raised-10-million-to-expand-access-to-clinical-trials-as-a-care-option-cw3l6","note":"Co-led by NEXT Ventures and SemperVirens; total raised USD 17.6 million"}]},{"id":"triana-biomedicines","kind":"company","name":"Triana Biomedicines","aka":[],"tldr":"Triana Biomedicines designs molecular glues that make cancer cells destroy their own faulty proteins. Its first drug, TRI-611, removes the ALK fusion protein that drives a subset of lung cancers and has entered human trials.","summary":"Triana Biomedicines is a Lexington, Massachusetts company with a target-first molecular glue discovery platform that pairs disease targets with the most suitable of more than 600 E3 ubiquitin ligases. Its lead candidate, TRI-611, is an oral, brain-penetrant molecular glue degrader that brings ALK fusion proteins to cereblon independently of the kinase active site, intended to overcome resistance, CNS metastases and tolerability limits of ALK inhibitors in ALK-positive non-small cell lung cancer; it has entered the clinic. A CCNE1 (cyclin E1) degrader programme targets CCNE1-amplified tumours and a subset of HR-positive/HER2-negative breast cancers. Triana launched in April 2022 with 110 million US dollars in total funding (seeded by RA Capital and Atlas Venture, Series A co-led by Lightspeed) and closed a 120 million US dollar Series B in December 2025 co-led by Ascenta Capital and Bessemer Venture Partners.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://trianabio.com/"},{"label":"Pipeline","url":"https://trianabio.com/pipeline"},{"label":"Launch press release (April 2022)","url":"https://trianabio.com/press-release-4-6-2022"},{"label":"Series B press release (December 2025)","url":"https://trianabio.com/press-release-12032025-1"}],"tags":[],"related":[],"cancers":["nsclc","breast-hr-positive"],"sections":["targeted-therapy"],"technologies":["protac-degrader"],"targets":["alk"],"drugs":["tri-611"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07491497"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["SEC Form D filings show 42.55 million US dollars sold by April 2022 and 120.06 million sold by December 2025, consistent with tranche-based funding of the announced totals. Founding year from the Form D year of incorporation."],"hq":"Lexington, MA","country":"US","companyType":"biotech","website":"https://trianabio.com/","founded":2019,"stage":"startup","investors":["ra-capital","atlas-venture","lightspeed-venture-partners","pfizer-ventures","logos-capital"],"funding":[{"round":"Series A","year":2022,"amountUsd":110000000,"source":"https://trianabio.com/press-release-4-6-2022","note":"Launch announcement of 110 million US dollars total funding (seed from RA Capital and Atlas Venture plus Series A co-led by Lightspeed); the Series A portion alone is not itemised"},{"round":"Series B","year":2025,"amountUsd":120000000,"source":"https://trianabio.com/press-release-12032025-1","note":"Oversubscribed; co-led by Ascenta Capital and Bessemer Venture Partners; closed December 2025"}]},{"id":"trinetx","kind":"company","name":"TriNetX","aka":[],"tldr":"Federated real-world data network across health systems, used for trial feasibility and observational studies.","summary":"TriNetX, based in Cambridge, Massachusetts, runs a federated real-world data network across health systems, used for trial feasibility and observational studies. It offers a query interface over de-identified electronic health record data from hundreds of healthcare organisations worldwide, so that the data stay with each institution while questions travel. OnCo links it to oncology EHR and real-world data platforms and to AI trial matching and clinical decision support. Whether federated querying can support studies rigorous enough to change practice, rather than only estimate how many patients exist, is the open question. The real-world data platform page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://trinetx.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["oncology-real-world-data","ai-trial-matching"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cambridge, MA","country":"US","companyType":"ai-software","website":"https://trinetx.com","investors":[],"funding":[]},{"id":"triomics","kind":"company","name":"Triomics","aka":[],"tldr":"Triomics builds AI agents that read the unstructured parts of a cancer patient's records, such as pathology reports and scanned faxes, to match patients to trials and prepare visits automatically.","summary":"Triomics provides AI infrastructure for oncology providers: large-language-model agents embedded in clinical workflows that process pathology reports, clinical notes, genomic panels and scanned documents in real time to support clinical trial matching, visit preparation and quality reporting. The company states that four of the top ten US News cancer hospitals and several of the largest community oncology practices use the platform. It has raised venture financing since YC; amounts are not recorded here because no primary source was fetched.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/triomics"},{"label":"Official website","url":"https://triomics.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["ai-computation","supportive-care"],"technologies":["ai-trial-matching"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"New York, NY","country":"US","companyType":"ai-software","website":"https://triomics.com","stage":"growth","ycBatch":"W21","investors":["y-combinator"],"funding":[]},{"id":"triumvira-immunologics","kind":"company","name":"Triumvira Immunologics","aka":["Triumvira Immunologics, Inc."],"tldr":"Triumvira Immunologics is a Texas and Ontario cell-therapy company whose T-cell antigen coupler (TAC) engages the natural T-cell receptor rather than a CAR; TAC01-CLDN18.2 targets stomach and pancreatic cancers.","summary":"Triumvira Immunologics, with operations in Austin and Hamilton, Ontario, develops T-cell antigen coupler therapies in which an antigen-binding domain is coupled to the endogenous T-cell receptor complex, aiming for the potency of CAR-T with less toxicity. TAC01-HER2 was its first solid tumour programme and TAC01-CLDN18.2 targets Claudin 18.2 in gastric, gastro-oesophageal junction and pancreatic cancers in a phase 1/2 trial.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.triumvira.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["tac01-cldn18-2"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Austin, Texas","country":"US","companyType":"cell-therapy","website":"https://www.triumvira.com/","investors":[],"funding":[]},{"id":"trog","kind":"company","name":"TROG Cancer Research","aka":["Trans Tasman Radiation Oncology Group","TROG"],"tldr":"The Australian and New Zealand radiation oncology trials group, which has run practice-changing trials of hypofractionation, stereotactic radiotherapy and radiation-drug combinations.","summary":"Founded in 1989 as the Trans Tasman Radiation Oncology Group and based in Newcastle, New South Wales, TROG is the cooperative group for radiation oncology across Australia and New Zealand. TROG 96.01 established short-course androgen deprivation with radiotherapy for locally advanced prostate cancer, CHISEL (TROG 09.02) showed stereotactic ablative radiotherapy beats conventional radiotherapy in inoperable early lung cancer, and TROG 12.01 tested de-escalation with cetuximab in HPV-positive oropharyngeal cancer. It co-ran PORTEC-3 in endometrial cancer and runs quality-assurance programmes for radiotherapy trials. TROG partners with ANZUP, AGITG and Breast Cancer Trials on multimodality studies.","asOf":"2026-09-09","links":[{"label":"TROG","url":"https://www.trog.com.au"},{"label":"Trials","url":"https://www.trog.com.au/trials"}],"tags":["cooperative-group"],"related":[],"cancers":["prostate","nsclc","head-and-neck","endometrial"],"sections":["radiation"],"technologies":["sbrt","imrt-igrt","androgen-deprivation"],"targets":[],"drugs":[],"companies":["anzup"],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":["portec-3","nct07346144"],"people":["purnima-sundaresan","hien-le"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Prostate radiotherapy and androgen deprivation (TROG 96.01, RADAR)","SABR for early lung cancer (CHISEL)","HPV-positive head and neck de-escalation","Radiotherapy quality assurance"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Newcastle, NSW","country":"AU","companyType":"cooperative-group","website":"https://www.trog.com.au","founded":1989,"investors":[],"funding":[]},{"id":"tscan","kind":"company","name":"TScan Therapeutics","aka":[],"tldr":"TCR discovery company that cut 75% of staff in September 2026 to focus on in vivo-engineered TCR-T for solid tumours (PRAME, MAGE-A4).","summary":"TScan Therapeutics, based in Waltham, Massachusetts, and listed as TCRX, is a TCR discovery company that cut 75 percent of its staff in September 2026 to focus on in vivo-engineered TCR-T for solid tumours against PRAME and MAGE-A4. It paused the phase 3 ALLOHA-2 trial of TSC-101 for lack of capital, has two in vivo TCR-T candidates entering IND-enabling studies with phase 1 planned for the fourth quarter of 2027, and previously ran a multiplexed autologous TCR-T basket study in solid tumours. OnCo links it to TCR-T cell therapy and in vivo CAR-T, to MAGE-A4 as a target, and to the idea of antibodies that see mutant KRAS and p53 fragments displayed on the cell surface. Whether a company can survive the gap between pausing a phase 3 and dosing a new first-in-human candidate is the open question its reorganisation raises. The TCR-T technology page carries the field.","asOf":"2026-09-04","links":[{"label":"Strategic reorganisation","url":"https://www.biospace.com/press-releases/tscan-therapeutics-announces-strategic-reorganization-to-focus-on-in-vivo-cell-therapy-for-solid-tumors"}],"tags":["pivot"],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["tcr-t","in-vivo-car-t"],"targets":["mage-a4"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Waltham, MA","country":"US","companyType":"cell-therapy","website":"https://www.tscan.com","ticker":"TCRX","investors":[],"funding":[]},{"id":"tubulis","kind":"company","name":"Tubulis (Gilead)","aka":[],"tldr":"German ADC company whose NaPi2b ADC TUB-040 posted a 59% response rate in platinum-resistant ovarian cancer; Gilead agreed to buy it for up to $5B.","summary":"Raised a record €344M Series C (October 2025) after TUB-040 phase 1/2a data at ESMO 2025 (59% ORR in platinum-resistant ovarian cancer; also lung adenocarcinoma). Gilead announced an acquisition at $3.15B upfront plus up to $1.85B milestones, expected to close Q2 2026. Proprietary Tubutecan and P5 conjugation chemistries.","asOf":"2026-09-04","links":[{"label":"Gilead acquisition","url":"https://www.biospace.com/business/gilead-swallows-another-partner-paying-up-to-5-b-for-adc-specialist-tubulis"}],"tags":[],"related":[],"cancers":["ovarian","nsclc"],"sections":["adcs"],"technologies":["adc","site-specific-conjugation"],"targets":[],"drugs":[],"companies":["gilead"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06657222","nct07736937","nct06303505"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Munich","country":"DE","companyType":"biotech","website":"https://tubulis.com","investors":[],"funding":[]},{"id":"turbine","kind":"company","name":"Turbine","aka":[],"tldr":"Turbine builds computer simulations of cancer cells so drug developers can run millions of virtual experiments before doing them in the lab, for example to pick targets for antibody-drug conjugates.","summary":"Turbine (Turbine Ltd.), founded in 2016 in Budapest, virtualises biological experiments with its Simulated Cell technology. Its Virtual Lab lets partners simulate experiments across more than 1,400 oncology cell lines, 1,200 payloads and drugs and 8,500 gene alterations, with wet-lab validation loops that feed back into the models. Commercial offerings include ADC Intelligence for antibody-drug conjugate target and payload selection, Target Discovery and De-risking Intelligence, and combination design for precision oncology. Partners listed include AstraZeneca, MSD, Bayer, Ono Pharmaceutical, Cancer Research Horizons, Debiopharm and Crown Bioscience. The company's press kit states it has raised more than USD 60 million and is at Series B stage, with investors including Accel, Mercia, XTX Ventures, Delin Ventures, Interactive Venture Partners, MassMutual Ventures, MSD Global Health Innovation Fund and Accenture.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://turbine.ai"},{"label":"Press kit (company facts)","url":"https://turbine.ai/press-kit/"},{"label":"Team and investors","url":"https://turbine.ai/meet-us/"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation","drug-discovery"],"technologies":["ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Individual round amounts and dates were not on fetched pages, so no round is recorded despite the press kit's USD 60 million-plus total."],"hq":"Budapest","country":"HU","companyType":"ai-software","website":"https://turbine.ai","founded":2016,"stage":"startup","investors":["msd-global-health-innovation-fund"],"funding":[]},{"id":"turnstone-biologics","kind":"company","name":"Turnstone Biologics","aka":[],"tldr":"Turnstone developed 'selected' tumour-infiltrating lymphocyte therapy, enriching the most cancer-reactive immune cells from a patient's tumour. It stopped its clinical programme in January 2025 and was bought by XOMA Royalty later that year.","summary":"Turnstone Biologics was a San Diego biotechnology company that pioneered selected tumour-infiltrating lymphocyte (Selected TIL) therapy, enriching TIL populations for tumour reactivity. Its lead programme TIDAL-01 was studied in solid tumours and clinical data were presented at the SITC TIL Symposium in November 2024. In January 2025 the company discontinued all TIDAL-01 studies and halted development, then began a strategic alternatives process. On 27 June 2025 Turnstone agreed to be acquired by XOMA Royalty Corporation for $0.34 in cash per share plus a contingent value right; the tender offer and merger completed on 11 August 2025 and the Nasdaq listing (TSBX) ended. The company website no longer resolves.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.sec.gov/edgar/browse/?CIK=0001764974"},{"label":"XOMA acquisition agreement (8-K, June 2025)","url":"https://www.sec.gov/Archives/edgar/data/1764974/000119312525151306/d928306dex991.htm"},{"label":"Completion of merger (8-K, August 2025)","url":"https://www.sec.gov/Archives/edgar/data/1764974/000119312525177597/d27108d8k.htm"},{"label":"Q4 2024 results noting TIDAL-01 discontinuation (8-K)","url":"https://www.sec.gov/Archives/edgar/data/1764974/000095017025047107/tsbx-ex99_1.htm"},{"label":"SEC EDGAR filings","url":"https://www.sec.gov/edgar/browse/?CIK=0001764974"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["til-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Former Nasdaq ticker TSBX. IPO (2023) not sourced."],"hq":"San Diego, CA","country":"US","companyType":"cell-therapy","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2025,"source":"https://www.sec.gov/Archives/edgar/data/1764974/000119312525151306/d928306dex991.htm","note":"$0.34 in cash per share plus a contingent value right; agreement 27 June 2025, merger completed 11 August 2025"}]},{"id":"tyk-medicines","kind":"company","name":"TYK Medicines","aka":["Zhejiang Tongyuankang Pharmaceutical","同源康医药"],"tldr":"TYK Medicines is a China-based biotechnology company that leads 3 cancer trials in OnCo, testing the EGFR inhibitor asandeutertinib (TY-9591) and TYK-00540 in non-small-cell lung cancer, HR-positive / HER2-negative breast cancer and brain and spinal cord tumours.","summary":"TYK Medicines (Zhejiang Tongyuankang) is a Chinese biotechnology company listed in Hong Kong that discovers, develops and manufactures small-molecule targeted cancer drugs, with research centres in Changxing and Zhengzhou. Its EGFR inhibitor asandeutertinib (TY-9591) has been approved in China for EGFR-mutant lung cancer with brain metastases. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo (1 in phase 3 or 2/3): FLETEO (phase 3, Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Ce...), NCT06950086 (phase 1/2, Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors) and NCT05948813 (phase 2, TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.tykmedicines.com"},{"label":"ClinicalTrials.gov: trials led by TYK Medicines","url":"https://clinicaltrials.gov/search?lead=TYK%20Medicines%2C%20Inc"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","breast-hr-positive","brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":["ty-9591","osimertinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["fleteo","nct06950086","nct05948813"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.tykmedicines.com","ticker":"HKEX:2410","founded":2017,"stage":"public","investors":[],"funding":[]},{"id":"tyra-biosciences","kind":"company","name":"Tyra Biosciences","aka":[],"tldr":"Tyra Biosciences designs precise pills against a family of growth-signal proteins called FGFRs, which are faulty in some bladder, liver and bile duct cancers and in a bone growth disorder.","summary":"Tyra Biosciences is a Carlsbad, California company developing next-generation FGFR inhibitors designed to avoid resistance mutations and to spare related kinases. Its lead candidate, dabogratinib (TYRA-300), is an FGFR3-selective inhibitor in clinical development for non-muscle invasive bladder cancer and low-grade upper tract urothelial cancer, and in the phase 2 BEACH301 study in achondroplasia. TYRA-430 (FGFR4/3) is in the phase 1 SURF431 study in advanced hepatocellular carcinoma and other solid tumours, and TYRA-200 (FGFR1/2/3) is in the phase 1 SURF201 study in intrahepatic cholangiocarcinoma and other FGFR2-altered tumours. Tyra completed its Nasdaq IPO in September 2021, raising 198.7 million US dollars gross.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://tyra.bio/"},{"label":"Pipeline","url":"https://tyra.bio/pipeline/"},{"label":"IPO closing 8-K (SEC)","url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312521276124/d220261d8k.htm"}],"tags":[],"related":[],"cancers":["urothelial","hcc","cholangiocarcinoma"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["fgfr2"],"drugs":["tyra-300"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06995677","nct05544552"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year and later financings not sourced. Investor news pages (ir.tyra.bio) returned 403."],"hq":"Carlsbad, CA","country":"US","companyType":"biotech","website":"https://tyra.bio/","ticker":"TYRA","stage":"public","investors":[],"funding":[{"round":"IPO","year":2021,"amountUsd":198700000,"source":"https://www.sec.gov/Archives/edgar/data/1863127/000119312521276124/d220261d8k.htm","note":"12.42 million shares at 16 US dollars including full exercise of the underwriters' option; closed 17 September 2021"}]},{"id":"ubivac","kind":"company","name":"UbiVac","aka":[],"tldr":"UbiVac is developing an off-the-shelf cancer vaccine aimed at proteins made from non-coding regions of the genome, with RNA sequencing to check a patient's tumour expresses the targets, and early data in head and neck cancer.","summary":"UbiVac's vaccine targets proteins derived from non-coding genome regions that tumours express, screened per patient by RNA sequencing; Future of Cancer Care Today describes it as clinical-stage with good data in head and neck cancer, accessible through trial enrolment.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.ubivac.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":["neoantigen-mrna-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"United States (city not published)","country":"US","companyType":"biotech","website":"https://www.ubivac.com/","stage":"startup","investors":[],"funding":[]},{"id":"ucb","kind":"company","name":"UCB","aka":["UCB Biopharma SRL","UCB Pharma","UCB S.A.","UCB Biopharma S.P.R.L.","UCB Biopharma","Ra Pharmaceuticals, Inc.","Ra Pharmaceuticals"],"tldr":"UCB is a Brussels pharmaceutical company focused on neurology and immunology whose cancer trials on the registry are mostly older programmes and supportive care studies.","summary":"UCB is a Belgian biopharmaceutical company, listed on Euronext Brussels, whose marketed medicines are in epilepsy, immunology and rare diseases. Its subsidiaries UCB Biopharma SRL and UCB Pharma appear as lead sponsors of a number of phase 3 cancer trials on ClinicalTrials.gov, largely from earlier programmes and studies of supportive medicines; oncology is not part of its current core strategy. OnCo records it so that those trials resolve to a sponsor page.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.ucb.com"},{"label":"ClinicalTrials.gov: trials led by UCB","url":"https://clinicaltrials.gov/search?lead=UCB"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/UCB_(company)"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct06055959","nct06149559"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Brussels","country":"BE","companyType":"pharma","website":"https://www.ucb.com","stage":"public","investors":[],"funding":[]},{"id":"ultima-genomics","kind":"company","name":"Ultima Genomics","aka":[],"tldr":"Open-wafer sequencing (UG 100) claiming a $100 genome, aimed at population-scale and deep ctDNA sequencing.","summary":"Ultima Genomics, based in Fremont, California, makes the UG 100 open-wafer sequencer, marketed on the claim of a 100 dollar genome and aimed at population-scale and deep circulating tumour DNA sequencing. It launched commercially in 2024, is used by Exact Sciences and others for high-depth cell-free DNA, and raised more than 600 million dollars in 2022 with further rounds since. OnCo links it to new short-read sequencing platforms. Whether cheaper sequencing at depth makes blood-based cancer detection and residual disease testing affordable at population scale is the open question. The short-read platforms page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.ultimagenomics.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["next-gen-short-read-platforms"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Fremont, CA","country":"US","companyType":"diagnostics","website":"https://www.ultimagenomics.com","investors":[],"funding":[]},{"id":"umoja-biopharma","kind":"company","name":"Umoja Biopharma","aka":[],"tldr":"In vivo CAR-T company using lentiviral vectors (VivoVec); first CD22-directed in vivo CAR-T cleared for US trials in 2026.","summary":"Umoja Biopharma, based in Seattle, is an in vivo CAR-T company that uses lentiviral vectors, its VivoVec platform, to make CAR-T cells inside the body, and in 2026 its CD22-directed candidate became the first of its kind cleared for US trials. UB-VV111 targets CD19 and holds Fast Track designations, UB-VV400 targets CD22 and had its IND cleared in 2026, both for relapsed or refractory B-cell malignancies, and first clinical data from an investigator-initiated UB-VV400 trial in China are expected in the second half of 2026. OnCo links it to diffuse large B-cell lymphoma and acute lymphoblastic leukaemia, to in vivo CAR-T, to CD19 as a target, and to ideas on in vivo CAR-T as a vial on the shelf. Manufacturing cost and time for living medicines is the bottleneck it addresses. Whether viral in vivo delivery is safe enough for repeat dosing is the open question.","asOf":"2026-09-04","links":[{"label":"UB-VV400 IND clearance","url":"https://www.umoja-biopharma.com/news/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies/"}],"tags":["frontier"],"related":[],"cancers":["dlbcl","all-leukemia"],"sections":["cell-therapy"],"technologies":["in-vivo-car-t"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Seattle, WA","country":"US","companyType":"cell-therapy","website":"https://www.umoja-biopharma.com","investors":[],"funding":[]},{"id":"unicancer","kind":"company","name":"UNICANCER","aka":["Unicancer","Fédération Nationale des Centres de Lutte Contre le Cancer","FNCLCC"],"tldr":"UNICANCER is the network of France's comprehensive cancer centres and its academic trials sponsor.","summary":"UNICANCER, based in Paris, is the network of France's comprehensive cancer centres and its academic trials sponsor, federating eighteen centres including Gustave Roussy, Institut Curie, the Institut du Cancer de Montpellier and Centre Jean Perrin. It runs the UCBG breast group, the PRODIGE gastrointestinal group whose PRODIGE 7 trial tested HIPEC, the GETUG genitourinary group and the ESME real-world database, with Christophe Le Tourneau, Jean-Yves Blay and Thomas Bachelot among the people linked. OnCo connects it to colorectal and triple-negative breast cancer, to real-world evidence, and to ideas such as a publicly held library of investigational drugs for academic combination trials and one standing umbrella trial for all rare cancers in a country. Slow enrolment is the bottleneck it exists to solve. Its PRODIGE, UCBG and ESME programmes are listed in the notes.","asOf":"2026-09-06","links":[{"label":"Official website","url":"https://www.unicancer.fr"},{"label":"UNICANCER: the centres","url":"https://www.unicancer.fr/en/the-centres/"}],"tags":["cooperative-group"],"related":[],"cancers":["colorectal","tnbc"],"sections":[],"technologies":["hipec"],"targets":[],"drugs":[],"companies":[],"institutions":["gustave-roussy","institut-curie","icm-montpellier","centre-jean-perrin","centre-henri-becquerel","centre-eugene-marquis","ico-angers-nantes","centre-francois-baclesse","centre-leon-berard","institut-bergonie","centre-oscar-lambret","institut-paoli-calmettes","institut-godinot","institut-de-cancerologie-de-lorraine","centre-antoine-lacassagne","centre-georges-francois-leclerc","iuct-oncopole","institut-strauss"],"pathways":[],"terms":["real-world-evidence"],"trials":["peace-1","prodige-23","prodige-24"],"people":["christophe-le-tourneau","anthony-goncalves","jean-yves-blay","thomas-bachelot"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["PRODIGE GI trials","UCBG breast trials","ESME real-world data"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Paris","country":"FR","companyType":"cooperative-group","website":"https://www.unicancer.fr","investors":[],"funding":[]},{"id":"unicar-therapy","kind":"company","name":"Unicar-Therapy","aka":["Shanghai Unicar-Therapy Bio-medicine Technology","优卡迪"],"tldr":"Unicar-Therapy is a China-based cell therapy company that leads 2 cancer trials in OnCo, testing the CAR-T products U16 and U32 in non-Hodgkin lymphoma and acute myeloid leukaemia.","summary":"Unicar-Therapy is a Shanghai CAR-T developer founded in 2015 that builds its own cell therapy products on in-house platforms with integrated manufacturing. Its registered pipeline covers blood cancers and solid tumours. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT05768529 (phase 1/2, Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma) and NCT07036250 (phase 1/2, Clinical Study of U32 in Patients With Acute Myeloid Leukemia). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"http://www.unicar-therapy.com"},{"label":"ClinicalTrials.gov: trials led by Unicar-Therapy","url":"https://clinicaltrials.gov/search?lead=Shanghai%20Unicar-Therapy%20Bio-medicine%20Technology%20Co.%2CLtd"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["non-hodgkin-lymphoma","aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05768529","nct07036250"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Shanghai","country":"CN","companyType":"cell-therapy","website":"http://www.unicar-therapy.com","founded":2015,"stage":"startup","investors":[],"funding":[]},{"id":"united-imaging","kind":"company","name":"United Imaging","aka":[],"tldr":"Chinese imaging company that built uEXPLORER, the first total-body PET scanner.","summary":"United Imaging, based in Shanghai and listed as 688271.SS, is the Chinese imaging company that built uEXPLORER, the first total-body PET scanner. The uEXPLORER has a 194 centimetre axial field of view and about forty times the sensitivity of a conventional scanner, the uMI Panorama is its other PET platform, and the company has a growing presence in the United States. OnCo links it to PET/CT, to nuclear medicine and total-body PET hardware and total-body PET for screening and ultra-low-dose imaging, to the molecular imaging roadmap, and to ideas on total-body PET for personalised radioligand dosing and on open-hardware machines for difficult environments. Whether ultra-sensitive scanners lead to lower-dose or cheaper imaging in practice is the open question. The total-body PET technology page carries the detail.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.united-imaging.com"}],"tags":[],"related":[],"cancers":[],"sections":["imaging"],"technologies":["pet-ct"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai","country":"CN","companyType":"imaging","website":"https://www.united-imaging.com","ticker":"688271.SS","investors":[],"funding":[]},{"id":"united-therapeutics","kind":"company","name":"United Therapeutics","aka":["United Therapeutics Corporation","Unither Pharmaceuticals"],"tldr":"United Therapeutics is a Maryland company known for pulmonary hypertension medicines that also makes dinutuximab (Unituxin), the anti-GD2 antibody that became standard for high-risk neuroblastoma in children.","summary":"United Therapeutics, founded in 1996 and headquartered in Silver Spring, Maryland, built its business on treatments for pulmonary arterial hypertension and now works on manufactured organs. In oncology it commercialises dinutuximab (Unituxin), the chimeric anti-GD2 antibody developed with the Children's Oncology Group and approved in 2015 for high-risk neuroblastoma after a phase 3 trial showed better event-free survival. ClinicalTrials.gov lists the company as lead sponsor of a phase 3 cancer trial.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.unither.com"},{"label":"ClinicalTrials.gov: trials led by United Therapeutics Corporation","url":"https://clinicaltrials.gov/search?lead=United%20Therapeutics%20Corporation"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q21071142"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["neuroblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["dinutuximab"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Silver Spring, MD","country":"US","companyType":"biotech","website":"https://www.unither.com","founded":1996,"stage":"public","investors":[],"funding":[]},{"id":"universal-dx","kind":"company","name":"Universal DX","aka":[],"tldr":"Universal DX is developing Signal-C, a blood test to screen for bowel cancer and pre-cancerous growths, and has partnered with Quest Diagnostics to offer it in the US once regulators approve it.","summary":"Universal DX (UDX), incorporated in Spain in 2012 and headquartered in Madrid, develops cell-free DNA blood tests for early cancer detection. Its lead assay, Signal-C, uses next-generation sequencing of methylation and fragmentation patterns in circulating DNA with machine learning to detect colorectal cancer and advanced adenomas. In a 1,000-patient study at Digestive Disease Week 2023 it showed 93 percent sensitivity for colorectal cancer and 54 percent for advanced adenomas at 92 percent specificity. A 15,000-patient, 100-site FDA registrational trial (NCT06059963) enrolled its first patient in January 2024, with Quest's Lewisville, Texas laboratory as the single testing site. UDX announced a Series B initial close of about $70 million in November 2023 including Quest, completed in August 2024 with new investor Olympus Innovation Ventures.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.universaldx.com/"},{"label":"Quest collaboration and Series B initial close (Nov 2023)","url":"https://cdn.prod.website-files.com/60925e59116a323839bdf90a/655b7ee215dc0e6a169bd932_2023_11_19%20UDX%20US%20Press%20release.pdf"},{"label":"Series B close and FDA trial (Aug 2024)","url":"https://cdn.prod.website-files.com/60927bf52450bc2ed1129413/66bceb91587a66e050bd59a6_2024_08%20UDX%20PR%20release%20Series%20B%20Extension.pdf"},{"label":"Press page","url":"https://www.universaldx.com/press"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":["early-detection","diagnostics"],"technologies":["liquid-biopsy","methylation-profiling"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["US office moved from Cambridge, MA (2023-2024 releases) to Dallas, TX (current website). Series B extension amount not disclosed."],"hq":"Madrid","country":"ES","companyType":"diagnostics","website":"https://www.universaldx.com/","founded":2012,"stage":"startup","investors":[],"funding":[{"round":"Series B","year":2023,"amountUsd":70000000,"source":"https://cdn.prod.website-files.com/60925e59116a323839bdf90a/655b7ee215dc0e6a169bd932_2023_11_19%20UDX%20US%20Press%20release.pdf","note":"Initial closing of approximately $70 million with investors including Quest Diagnostics, announced 20 November 2023."},{"round":"Series B","year":2024,"source":"https://cdn.prod.website-files.com/60927bf52450bc2ed1129413/66bceb91587a66e050bd59a6_2024_08%20UDX%20PR%20release%20Series%20B%20Extension.pdf","note":"Series B closed August 2024 with existing investors including Quest Diagnostics and new investors including Olympus Innovation Ventures; extension amount not disclosed."}]},{"id":"urogen-pharma","kind":"company","name":"UroGen Pharma","aka":["UroGen Pharma Ltd."],"tldr":"UroGen Pharma is a United States-based pharmaceutical company running 3 late-stage cancer trials of UGN-103, UGN-102 and UGN-104 in bladder & urothelial cancer.","summary":"UroGen Pharma, based in Princeton, NJ, the United States, is a pharmaceutical company listed as NASDAQ: URGN. UroGen Pharma develops treatments for urothelial and specialty cancers, including its FDA-approved therapies Zusduri and Jelmyto, based on its proprietary RTGel reverse-thermal hydrogel technology. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (3 in phase 3), testing UGN-103, UGN-102 and UGN-104 in bladder & urothelial cancer. The largest, NCT05243550 (A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer), plans to enrol 240 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.urogen.com"},{"label":"ClinicalTrials.gov: trials led by UroGen Pharma","url":"https://clinicaltrials.gov/search?lead=UroGen%20Pharma%20Ltd."},{"label":"Pipeline page","url":"https://www.urogen.com/pipeline"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["ugn-103","ugn-104"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05243550"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Princeton, NJ","country":"US","companyType":"pharma","website":"https://www.urogen.com","ticker":"NASDAQ: URGN","stage":"public","investors":[],"funding":[]},{"id":"us-worldmeds","kind":"company","name":"US WorldMeds","aka":["USWM, LLC","US WorldMeds","USWM"],"tldr":"US WorldMeds is a private Louisville company that took over the engineered T-cell therapies Tecelra and lete-cel from Adaptimmune in 2025 and sells eflornithine (Iwilfin) for maintenance in high-risk neuroblastoma. Whether a small private firm can sustain T-cell manufacturing for a rare sarcoma is the open question.","summary":"US WorldMeds, a private company based in Louisville, Kentucky, took over the cell therapies Tecelra and lete-cel from Adaptimmune in 2025 and markets eflornithine, sold as Iwilfin, for neuroblastoma. It acquired Adaptimmune's assets afamitresgene autoleucel and letetresgene autoleucel in August 2025, with a biologics licence application for lete-cel committed by the end of 2026, and Iwilfin was approved in December 2023 for maintenance in high-risk neuroblastoma. OnCo links it to sarcomas and paediatric neuroblastoma, to all three drug records, and to bottlenecks on rare and paediatric cancers without markets and the lack of incentive to repurpose cheap drugs. Whether a small private company can sustain engineered T-cell manufacturing for a rare sarcoma is the open question. Each product has its own page.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://www.usworldmeds.com"}],"tags":[],"related":[],"cancers":["sarcoma","neuroblastoma"],"sections":["cell-therapy","targeted-therapy"],"technologies":[],"targets":[],"drugs":["afamitresgene-autoleucel","letetresgene-autoleucel","eflornithine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Louisville, KY","country":"US","companyType":"pharma","website":"https://www.usworldmeds.com","investors":[],"funding":[]},{"id":"valar-labs","kind":"company","name":"Valar Labs","aka":[],"tldr":"Valar Labs uses artificial intelligence on routine bladder cancer biopsy slides to predict whether a patient's tumour will respond to BCG immunotherapy, helping doctors decide between BCG and other options such as surgery.","summary":"Valar Labs, founded by Anirudh Joshi, Damir Vrabac and Viswesh Krishna with roots in Stanford medical AI research, develops Computational Histology AI (CHAI) tests that read routine H&E pathology slides to predict treatment response. Vesta Bladder, described as the first AI-based oncology test offered clinically, predicts response to intravesical BCG in non-muscle invasive bladder cancer; it was developed on more than 1,000 patients across four continents, with analyses in the Journal of Urology and, in July 2026, JCO Precision Oncology. Vesta Prostate extends the approach to prostate cancer, validated on the ENZAMET and CHAARTED phase 3 trial cohorts, and Vitara is a further prostate product; generalisation to pancreatic cancer was published in Cell Reports Medicine. The company raised a $22 million Series A in May 2024 co-led by DCVC and a16z.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.valarlabs.com/"},{"label":"Series A announcement (May 2024)","url":"https://www.valarlabs.com/news/series-a"},{"label":"Evidence page","url":"https://www.valarlabs.com/evidence"}],"tags":[],"related":[],"cancers":["urothelial","prostate","pancreatic"],"sections":["diagnostics","ai-computation"],"technologies":["digital-pathology-ai","companion-diagnostic"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["HQ city is not stated anywhere on the fetched pages; Palo Alto, CA is taken from the caller's hint and should be treated as unconfirmed. Founding year not sourced. Regulatory status of Vesta (LDT) not stated on fetched pages."],"hq":"Palo Alto, CA","country":"US","companyType":"ai-software","website":"https://www.valarlabs.com/","stage":"startup","investors":["dcvc","a16z-bio-health"],"funding":[{"round":"Series A","year":2024,"amountUsd":22000000,"source":"https://www.valarlabs.com/news/series-a","note":"Co-led by DCVC and a16z with existing investor Pear VC, May 2024."}]},{"id":"valink-therapeutics","kind":"company","name":"Valink Therapeutics","aka":[],"tldr":"Valink designs antibody-drug conjugates that grab two targets at once, aimed at solid tumours that immunotherapy does not reach.","summary":"Valink Therapeutics discovers next-generation antibody-based therapeutics by combining multiple modifications, bispecificity, multivalency and payload conjugation, in a single discovery workflow, generating bispecific antibody-drug conjugates from known tumour targets with new mechanisms of action. Its stated focus is solid tumours poorly served by immunotherapy. Programmes are preclinical as far as public sources show; no sourced financing rounds are recorded.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/valink-therapeutics"},{"label":"Official website","url":"https://www.valinktx.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["adcs"],"technologies":["bispecific-adc","adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://www.valinktx.com","stage":"startup","ycBatch":"W21","investors":["y-combinator"],"funding":[]},{"id":"valius","kind":"company","name":"Valius Sciences","aka":["valius-sciences"],"tldr":"Valius is a patient-centred multi-omic profiling service that runs whole genome, bulk and single-cell RNA, spatial transcriptomics, high-plex protein, and ctDNA on one tumour.","summary":"Valius Sciences, based in Silicon Valley, is a patient-centred multi-omic profiling service that runs whole genome sequencing, bulk and single-cell RNA sequencing, spatial transcriptomics, high-plex protein assays and circulating tumour DNA testing on a single tumour. It combines validated assays across DNA, RNA and protein layers with functional drug screening to surface actionable targets for ADCs, bispecifics and CAR-T that standard panels miss, is backed by Define Ventures and is positioned as a premium service for complex or rare cancers. OnCo links it to whole-genome sequencing, single-cell and spatial profiling, liquid biopsy, functional ex vivo drug testing and comprehensive genomic profiling. Whether deep profiling changes treatment often enough to justify its cost is the open question. The related technology pages carry the evidence.","asOf":"2026-09-04","links":[{"label":"Define Ventures profile","url":"https://www.definevc.com/insights/putting-the-patient-at-the-center-of-cancer-science-with-valius-sciences"},{"label":"Official website (valiussciences.com)","url":"https://www.valiussciences.com/"},{"label":"Even One Ventures portfolio","url":"https://evenone.ventures/"}],"tags":["startup","evenone-portfolio","oncology"],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["wes-wgs","single-cell-spatial","liquid-biopsy","functional-drug-testing","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Silicon Valley, CA","country":"US","companyType":"diagnostics","website":"https://www.valius.com","stage":"startup","investors":["evenone-ventures"],"funding":[]},{"id":"valo-health","kind":"company","name":"Valo Health","aka":[],"tldr":"Valo Health uses large collections of patient health records and artificial intelligence to work out which biological targets cause disease, then designs small-molecule drugs against them.","summary":"Valo Health is a drug discovery company that integrates real-world clinical data, causal inference and predictive chemistry. Its stated approach has two pillars: Human Causal Biology, which applies machine learning and statistical genetics across a data asset of about 17 million de-identified patient records to identify targets validated in human tissue, and Closed-Loop Chemistry, which iteratively explores chemical space and refines models after each experimental round. The company lists offices in Lexington, Massachusetts and New York. In 2026 Valo appointed Karin Conde-Knape as Chief Scientific Officer and Chris Anagnostopoulos as Chief Causal AI Officer. The fetched pages do not name specific therapeutic areas or pipeline programmes, so the extent of its oncology work, its funding history and the Opal platform branding could not be confirmed from primary sources.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.valohealth.com"},{"label":"News","url":"https://www.valohealth.com/news"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation","drug-discovery"],"technologies":["ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Oncology focus not confirmed on fetched pages; pipeline page gives no programmes. Stage set to growth from background knowledge of large private rounds, but no round could be sourced. Founding year not sourced."],"hq":"Lexington, MA","country":"US","companyType":"ai-software","website":"https://www.valohealth.com","stage":"growth","investors":[],"funding":[]},{"id":"vara","kind":"company","name":"Vara","aka":[],"tldr":"Vara makes artificial intelligence software that reads screening mammograms in Germany's national breast screening programme, flagging normal scans and highlighting suspicious ones so radiologists find more cancers with less work.","summary":"Vara, founded in Berlin in 2018, develops AI for breast cancer screening. Its CE Class IIb certified software is offered as a web-based screening workflow with AI triage of normal exams and automated reporting, as a plug-in for existing PACS systems, and for digital breast tomosynthesis. The company states it holds the only AI certification for independent reading in population screening in Europe. The PRAIM study, a prospective real-world evaluation across 12 screening centres and about 460,000 women published in Nature Medicine, reported a higher cancer detection rate with the AI-supported workflow while reducing radiologist workload, and the company reports deployment across more than half of Germany's national screening programme with over 100 partner sites. No funding round is disclosed on the company website.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.vara.ai/"},{"label":"About Vara","url":"https://www.vara.ai/about"}],"tags":[],"related":[],"cancers":["breast-hr-positive","breast-her2-positive","tnbc"],"sections":["imaging","early-detection","ai-computation"],"technologies":["radiology-ai-screening","mammography"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No investors or rounds could be sourced from primary releases; stage set to startup provisionally. The Nature Medicine PRAIM figures (1.0 percent higher detection rate, 1.0 percent lower workload as quoted on the website) come from the company homepage."],"hq":"Berlin","country":"DE","companyType":"ai-software","website":"https://www.vara.ai/","founded":2018,"stage":"startup","investors":[],"funding":[]},{"id":"varian","kind":"company","name":"Varian (Siemens Healthineers)","aka":[],"tldr":"Varian is the largest radiotherapy equipment maker and is running the first human FLASH proton trials.","summary":"Varian, based in Palo Alto and part of Siemens Healthineers, is the largest maker of radiotherapy equipment and is running the first human FLASH proton trials. Its systems include TrueBeam, Halcyon, the Ethos adaptive radiotherapy platform and ProBeam protons, and the FAST-01 and FAST-02 trials are testing FLASH ultra-high dose-rate treatment in patients. OnCo links it to IMRT and IGRT, proton therapy and FLASH radiotherapy, to AI auto-contouring and adaptive planning, to Aarhus University Hospital, and to ideas including a coordinated FLASH evidence programme with shared dose-rate standards and a Gavi-style pooled purchaser for radiotherapy equipment. Surgery and radiotherapy curing most patients while receiving least funding is the bottleneck it bears on. Whether FLASH spares normal tissue in people as it does in animals is the open question.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.varian.com"}],"tags":[],"related":[],"cancers":[],"sections":["radiation"],"technologies":["imrt-igrt","proton-therapy","flash-rt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Palo Alto, CA","country":"US","companyType":"devices","website":"https://www.varian.com","investors":[],"funding":[]},{"id":"vasgene-therapeutics","kind":"company","name":"VasGene Therapeutics","aka":["Vasgene Therapeutics, Inc","VasGene"],"tldr":"VasGene is a Los Angeles biotech developing a soluble EphB4 decoy protein that starves tumours of blood supply and reawakens immune cells, tested with checkpoint inhibitors in bladder and head and neck cancer.","summary":"VasGene Therapeutics, based in Los Angeles and spun out of the University of Southern California, develops sEphB4-HSA, a soluble EphB4 receptor fused to albumin that blocks ephrin-B2 signalling on tumour vessels and immune cells. It has been tested with pembrolizumab in urothelial cancer and in head and neck cancer, and is registered on ClinicalTrials.gov under VasGene as lead sponsor of a phase 3 trial.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.vasgene.com"},{"label":"ClinicalTrials.gov: trials led by Vasgene Therapeutics, Inc","url":"https://clinicaltrials.gov/search?lead=Vasgene%20Therapeutics%2C%20Inc"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30292478"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["urothelial","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct06493552"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Los Angeles, CA","country":"US","companyType":"biotech","website":"https://www.vasgene.com","stage":"private-large","investors":[],"funding":[]},{"id":"veeva-systems","kind":"company","name":"Veeva Systems","aka":[],"tldr":"Veeva Systems, of Pleasanton, California, sells cloud software for life sciences: its Vault Clinical suite, including Vault CDMS, captures and manages trial data, and separate Vault systems cover regulatory, quality and commercial work. One vendor spanning trials, regulation and marketing raises the question of whether trial data become more shareable or more locked in.","summary":"Veeva Systems, based in Pleasanton, California, and listed as VEEV, makes cloud software for life sciences, including Vault CDMS for clinical trials and regulatory, quality and commercial systems. Its Vault Clinical suite handles trial data, Veeva CRM is moving off the Salesforce platform, and its Link data products serve commercial teams. OnCo links it to clinical trial software covering EDC, eCOA, CTMS and RTSM. Whether one vendor's cloud across trials, regulation and marketing makes trial data more shareable or more locked in is the question its dominance raises. The clinical trial software page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.veeva.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["clinical-trial-software"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Pleasanton, CA","country":"US","companyType":"ai-software","website":"https://www.veeva.com","ticker":"VEEV","investors":[],"funding":[]},{"id":"velavigo","kind":"company","name":"VelaVigo","aka":["VelaVigo Bio","橙帆医药"],"tldr":"VelaVigo is a China-based biotechnology company that leads 3 cancer trials in OnCo, testing the bispecific antibody-drug conjugates VBC101, VBC103 and VBC108 in advanced solid tumours.","summary":"VelaVigo is a Shanghai-based biotechnology company founded in 2021 that discovers bispecific and multispecific antibodies, antibody-drug conjugates and other biologic modalities for cancer, autoimmune, neurodegenerative and eye diseases. It has first-in-human trials of the bispecific ADCs VBC101, VBC103, VBC106, VBC108 and VBC117 in the United States, Australia and China. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT07299747 (phase 1/2, Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors), NCT07136779 (phase 1/2, First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies) and NCT07700160 (phase 1/2, First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.velavigo.com"},{"label":"ClinicalTrials.gov: trials led by VelaVigo","url":"https://clinicaltrials.gov/search?lead=VelaVigo%20Bio%20Inc"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07299747","nct07136779","nct07700160"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.velavigo.com","founded":2021,"stage":"startup","investors":[],"funding":[]},{"id":"velorum-therapeutics","kind":"company","name":"Velorum Therapeutics","aka":[],"tldr":"Velorum is developing cancer drugs that exploit heme, the iron-carrying molecule tumours depend on in unusual ways.","summary":"Velorum Therapeutics develops medicines built on the biology of heme, the iron-containing molecule central to oxygen transport and cellular metabolism, on the premise that tumour cells handle heme differently from normal cells and that this can be exploited therapeutically. The company is tagged oncology in the YC directory; its public materials give limited detail on targets or candidates, and work is preclinical. No sourced financing rounds are recorded.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/velorum-therapeutics"},{"label":"Official website","url":"https://www.velorumtx.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["targeted-therapy","drug-discovery"],"technologies":["kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.velorumtx.com","stage":"startup","ycBatch":"W24","investors":["y-combinator"],"funding":[]},{"id":"velsera","kind":"company","name":"Velsera (Seven Bridges and Pierian)","aka":[],"tldr":"Genomics cloud and clinical interpretation company formed from Seven Bridges, Pierian, and UgenTec in 2023; operates the NCI Cancer Genomics Cloud.","summary":"Velsera, based in Boston, is a genomics cloud and clinical interpretation company formed in 2023 from Seven Bridges, Pierian and UgenTec, and it operates the NCI Cancer Genomics Cloud. It provides a bioinformatics platform for research and for clinical next-generation sequencing reporting. OnCo links it to clinical NGS bioinformatics and variant interpretation and to genomics cloud and secure research environments. Whether a merged research and clinical platform serves either market as well as the specialists did is the open question. The genomics cloud technology page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://velsera.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics","ai-computation"],"technologies":["ngs-bioinformatics-software","genomics-cloud-platforms"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boston, MA","country":"US","companyType":"ai-software","website":"https://velsera.com","investors":[],"funding":[]},{"id":"venrock","kind":"company","name":"Venrock","aka":[],"tldr":"The Rockefeller family's venture firm, formed in 1969, which invests in technology and healthcare companies from its Palo Alto and New York offices. Its website could not be read without JavaScript.","summary":"Venrock, a portmanteau of Venture and Rockefeller, was formed in 1969 to build on the Rockefeller family's venture investing and is headquartered in Palo Alto, California (Wikipedia). It invests in early-stage technology and healthcare companies, including biotechnology and healthcare IT, and has a long record of oncology investments. Every page fetched on venrock.com (home, portfolio, companies) returned only 'You need to enable JavaScript to run this app', so the firm's own description of its strategy and its named oncology portfolio companies could not be confirmed from a primary source.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.venrock.com/"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Venrock"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Site fetched on 2026-09-10; content is rendered client-side so no portfolio examples were read. Founding year from Wikipedia."],"hq":"Palo Alto, CA","country":"US","companyType":"investor","website":"https://www.venrock.com/","founded":1969,"investors":[],"funding":[]},{"id":"veracyte","kind":"company","name":"Veracyte (Decipher)","aka":[],"tldr":"Veracyte makes the Decipher genomic classifier, the most-used gene-expression test in localised prostate cancer.","summary":"Veracyte, based in South San Francisco and listed as VCYT, is the diagnostics company behind Decipher Prostate, the most-used gene-expression test in localised prostate cancer. Decipher is a twenty-two gene genomic classifier carrying NCCN level-1 evidence for prognostication in both biopsy and post-prostatectomy settings, validated on randomised cohorts from NRG and RTOG trials, and it competes conceptually with ArteraAI's digital pathology test. OnCo also links Veracyte to the Afirma Genomic Sequencing Classifier for thyroid nodules and to Prosigna, the PAM50 breast cancer assay, as well as to C2i Genomics. Whether gene-expression tests or image-based AI become the default risk tool in prostate cancer is the open question. Decipher, Afirma and Prosigna each have their own pages.","asOf":"2026-09-06","links":[{"label":"Official website","url":"https://www.veracyte.com"}],"tags":[],"related":[],"cancers":["prostate"],"sections":["diagnostics"],"technologies":[],"targets":[],"drugs":["decipher-prostate"],"companies":["c2i-genomics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"South San Francisco, CA","country":"US","companyType":"diagnostics","website":"https://www.veracyte.com","ticker":"VCYT","investors":[],"funding":[]},{"id":"verastem","kind":"company","name":"Verastem Oncology","aka":[],"tldr":"RAS/MAPK-pathway company whose avutometinib + defactinib combination became the first approved treatment for KRAS-mutant low-grade serous ovarian cancer (May 2025).","summary":"Verastem Oncology, based in Needham, Massachusetts, and listed as VSTM, is a RAS and MAPK pathway company whose combination of avutometinib and defactinib became the first approved treatment for KRAS-mutant low-grade serous ovarian cancer in May 2025. The AVMAPKI FAKZYNJA CO-PACK, pairing the RAF and MEK clamp avutometinib with the FAK inhibitor defactinib, received accelerated approval on 8 May 2025 on the RAMP 201 trial, and the company is also developing a KRAS G12D inhibitor, VS-7375, and combinations in pancreatic cancer with GenFleet. OnCo links it to ovarian and pancreatic cancer, to kinase and KRAS inhibitors, to KRAS as a target and the MAPK pathway, and to the RAMP 201 trial and the combination drug record. Whether the combination extends into pancreatic cancer is the open question. Avutometinib plus defactinib has its own page.","asOf":"2026-09-04","links":[{"label":"FDA approval","url":"https://investor.verastem.com/news-releases/news-release-details/fda-approves-avmapkitm-fakzynjatm-combination-therapy-first-ever"}],"tags":[],"related":[],"cancers":["ovarian","pancreatic"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors","kras-inhibitors"],"targets":["kras"],"drugs":["vs-7375"],"companies":[],"institutions":[],"pathways":["ras-mapk"],"terms":[],"trials":["nct06072781","nct07659782","nct07659795","nct05669482","nct07644559","nct05074810","nct07020221","nct06682572"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Needham, MA","country":"US","companyType":"biotech","website":"https://www.verastem.com","ticker":"VSTM","investors":[],"funding":[]},{"id":"vergent-bioscience","kind":"company","name":"Vergent Bioscience","aka":[],"tldr":"Vergent Bioscience is testing an injectable dye that makes lung tumours glow during keyhole and robotic surgery, so surgeons can find small or hidden tumours and check that all of the cancer has been removed.","summary":"Vergent Bioscience is a clinical-stage company in Minneapolis developing abenacianine for injection (VGT-309), a tumour-targeted fluorescent imaging agent for minimally invasive and robotic-assisted cancer surgery. Abenacianine is a quenched activity-based probe that binds cathepsin proteases overexpressed in tumours and fluoresces in the near-infrared range. The lead indication is lung cancer. The phase 2 VISUALIZE trial completed enrolment in November 2024 and 2025 results showed improved tumour visibility during lung surgery; the FDA granted Fast Track designation in January 2025 and the pivotal phase 3 VISUALIZE 2 study began in March 2026. The company states it has raised more than USD 34 million; SEC Form D filings record equity sales of USD 21.5 million in 2022 and USD 18.7 million in October 2025 plus smaller convertible note offerings. Abenacianine is investigational and not approved for any indication.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.vergentbio.com/"},{"label":"Press releases","url":"https://www.vergentbio.com/press-releases"},{"label":"Investors page (over USD 34 million raised)","url":"https://www.vergentbio.com/investors"},{"label":"SEC Form D (Oct 2025)","url":"https://www.sec.gov/Archives/edgar/data/1741495/000174149525000004/primary_doc.xml"},{"label":"SEC Form D (Aug 2022)","url":"https://www.sec.gov/Archives/edgar/data/1741495/000174149522000001/primary_doc.xml"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["surgery","imaging"],"technologies":["fluorescence-guided-surgery","optical-imaging"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07499674"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Investor names are shown as logos on the investors page and could not be read from the fetched text, so investors is empty. Named round letters (Series A/B) were not found in press releases; Form D totals are used instead. The cathepsin mechanism is from general knowledge of VGT-309 rather than the fetched pages. Founding year not stated."],"hq":"Minneapolis, MN","country":"US","companyType":"biotech","website":"https://www.vergentbio.com/","stage":"startup","investors":[],"funding":[{"round":"Form D offering","year":2025,"amountUsd":18673277,"source":"https://www.sec.gov/Archives/edgar/data/1741495/000174149525000004/primary_doc.xml","note":"Equity offering of up to USD 31.96 million, first sale 7 October 2025, USD 18.67 million sold at filing"},{"round":"Form D offering","year":2022,"amountUsd":21542628,"source":"https://www.sec.gov/Archives/edgar/data/1741495/000174149522000001/primary_doc.xml","note":"Equity offering of USD 22.09 million, first sale 17 August 2022, USD 21.54 million sold at filing"}]},{"id":"verity-pharma","kind":"company","name":"Verity Pharmaceuticals","aka":[],"tldr":"Verity Pharmaceuticals is a Canadian specialty company that holds the US application for triptorelin (Trelstar) for advanced prostate cancer.","summary":"Verity Pharmaceuticals, based in Mississauga, Ontario, is a Canadian specialty company that holds the US application for triptorelin, sold as Trelstar, for advanced prostate cancer. It markets Trelstar, triptorelin pamoate, in North America and a portfolio of specialty medicines in Canada. OnCo links it to the triptorelin drug record. Whether older injectable hormone therapies keep their place as oral GnRH antagonists spread is the question that bears on its main oncology product. Triptorelin has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.veritypharma.com"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":["gnrhr"],"drugs":["triptorelin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05037279"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Mississauga, Ontario","country":"CA","companyType":"pharma","website":"https://www.veritypharma.com","investors":[],"funding":[]},{"id":"versant-ventures","kind":"company","name":"Versant Ventures","aka":[],"tldr":"A San Francisco life sciences venture firm that builds biotech companies in its own laboratories in North America and Europe. It created the radiopharmaceutical company RayzeBio and backed Gritstone, Repare and Abdera.","summary":"Versant Ventures has been 'delivering strong results since 1999' according to its homepage, which also states '$5.5B under management', six locations and three Discovery Engines: in-house teams of scientists in laboratory facilities that launch companies with academic founders. Wikipedia gives a 1999 founding and a San Francisco headquarters. The firm leads Series A rounds in its own creations and invests across Europe (Basel), Canada and the United States. Oncology is prominent in its news feed: RayzeBio (targeted radiopharmaceuticals, Series A, B and C releases 2020 to 2021), Abdera Therapeutics (antibody-based radiopharmaceuticals, 2023 debut), Vividion (precision oncology and immunology), Gritstone Oncology and Repare Therapeutics (synthetic lethality) all appear as Versant portfolio announcements.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.versantventures.com/"},{"label":"News","url":"https://www.versantventures.com/news"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Versant_Ventures"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The portfolio page is rendered client-side; examples come from press releases listed on the firm's news page."],"hq":"San Francisco, CA","country":"US","companyType":"investor","website":"https://www.versantventures.com/","founded":1999,"investors":[],"funding":[]},{"id":"veru","kind":"company","name":"Veru","aka":["Veru Inc.","Veru Pharma"],"tldr":"Veru is a Miami company whose oncology programmes were the selective androgen receptor modulator enobosarm for AR-positive, ER-positive breast cancer and the microtubule disruptor sabizabulin for prostate cancer, which was halted in 2022.","summary":"Veru Inc., listed on Nasdaq, moved from sexual health products into oncology and metabolic disease. Sabizabulin, an oral microtubule disruptor, was tested in metastatic castration-resistant prostate cancer (VERACITY) until the trial was stopped in 2022 and then, controversially, in COVID-19. Enobosarm, a selective androgen receptor modulator, was studied in androgen receptor-positive, oestrogen receptor-positive metastatic breast cancer (ARTEST, ENABLAR-2) before the company redirected it to preserving muscle during weight-loss therapy. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://verupharma.com"},{"label":"ClinicalTrials.gov: trials led by Veru","url":"https://clinicaltrials.gov/search?lead=Veru"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Veru_Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["breast-hr-positive","prostate"],"sections":["hormonal"],"technologies":[],"targets":["androgen-receptor"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Miami, FL","country":"US","companyType":"biotech","website":"https://verupharma.com","stage":"public","investors":[],"funding":[]},{"id":"vevo-therapeutics","kind":"company","name":"Vevo Therapeutics","aka":[],"tldr":"Produced Tahoe-100M, the largest single-cell drug-perturbation atlas, and trains models on it.","summary":"Vevo Therapeutics, based in San Francisco, produced Tahoe-100M, the largest single-cell drug perturbation atlas, and trains models on it. Tahoe-100M, released in 2025, holds 100 million single-cell profiles across 1,100 drugs and 50 cancer cell lines, generated with the company's Mosaic platform and released openly with Parse Biosciences and the Arc Institute. OnCo links it to the Tahoe-100M collection and to the virtual cell roadmap from bulk omics to a predictive model of a cancer cell. Whether models trained on cell-line perturbations predict drug effects in patients is the open question the atlas exists to test. Tahoe-100M has its own page.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.vevo.ai"}],"tags":["ai","virtual-cell"],"related":[],"cancers":[],"sections":["drug-discovery","ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.vevo.ai","investors":[],"funding":[]},{"id":"viatris","kind":"company","name":"Viatris","aka":["Mylan","Mylan Inc.","Mylan Pharmaceuticals Inc.","Mylan N.V.","Upjohn"],"tldr":"Viatris is the generics and biosimilars group formed in 2020 from Mylan and Pfizer's Upjohn; in cancer care it supplies generic chemotherapies and biosimilar trastuzumab and pegfilgrastim, and Mylan's phase 3 biosimilar trials sit under its name.","summary":"Viatris was created in November 2020 by the merger of Mylan with Upjohn, Pfizer's off-patent medicines business, and is headquartered in Pittsburgh. Its oncology footprint is generic injectable chemotherapies and biosimilars developed with Biocon, including trastuzumab (Ogivri) and pegfilgrastim (Fulphila), whose comparative phase 3 trials were run by Mylan. ClinicalTrials.gov lists Mylan as lead sponsor of those trials, which OnCo attributes to Viatris.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.viatris.com"},{"label":"ClinicalTrials.gov: trials led by Mylan","url":"https://clinicaltrials.gov/search?lead=Mylan"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q101983981"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":[],"technologies":["g-csf-growth-factors"],"targets":[],"drugs":["trastuzumab-biosimilars","pegfilgrastim"],"companies":["biocon-biologics"],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial","biosimilar"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Pittsburgh, PA","country":"US","companyType":"pharma","website":"https://www.viatris.com","founded":2020,"stage":"public","investors":[],"funding":[]},{"id":"vicinity-bio","kind":"company","name":"Vicinity Bio","aka":[],"tldr":"Vicinity Bio images tumour tissue with ultra-high-plex spatial proteomics and turns it into AI-assisted pathology reports with biomarker-based therapy guidance.","summary":"Vicinity Bio, a German company, provides generation, management, analysis and interpretation of ultra-high-plex tissue imaging, producing pathology reports that describe the tumour and its microenvironment protein by protein and suggest therapies matched to the biomarkers found. Physician-ordered.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://vicinitybio.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["spatial-transcriptomics","multiplex-immunofluorescence","ai-pathology-scoring"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Germany (city not published)","country":"DE","companyType":"diagnostics","website":"https://vicinitybio.com/","investors":[],"funding":[]},{"id":"vida-ventures","kind":"company","name":"Vida Ventures","aka":[],"tldr":"Vida Ventures is a life sciences venture firm founded by scientists, physicians and investors that creates and funds biotech companies, often with partners such as MPM. Oncology dominates its portfolio: Aktis Oncology (radiopharmaceuticals), Adcendo (antibody-drug conjugates), Allogene (off-the-shelf CAR-T) and Halda Therapeutics, sold to Johnson & Johnson.","summary":"Vida Ventures describes itself as 'a next-generation life sciences investment firm founded by a group of scientists, physicians, entrepreneurs and investors' whose mission is 'to bring science to life and advance transformative biomedical innovations into therapies'. It supports companies 'along the continuum of discovery and development', often co-creating companies with partners such as Two River (Candid Therapeutics) and MPM. Oncology dominates its portfolio page: Adcendo ApS (antibody-drug conjugates), Aktis Oncology (targeted radiopharmaceuticals for solid tumours), Allogene Therapeutics (allogeneic CAR-T, Nasdaq: ALLO), Alterome Therapeutics (alteration-specific targeted therapies), Antares Therapeutics, Asklepios BioPharmaceutical (neoantigen T-cell receptor therapies, acquired by Bayer in 2020) and Halda Therapeutics (RIPTAC cancer therapies, acquired by Johnson & Johnson). Third Arc Bio's $165 million Series A for solid tumour biologics is also featured.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://vidaventures.com/"},{"label":"Portfolio","url":"https://vidaventures.com/portfolio/"},{"label":"About","url":"https://vidaventures.com/about/"}],"tags":["vc"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["adcendo","aktis-oncology","allogene","halda-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year and headquarters address not stated on fetched pages; Boston follows the task hint."],"hq":"Boston, MA","country":"US","companyType":"investor","website":"https://vidaventures.com/","investors":[],"funding":[]},{"id":"viewray","kind":"company","name":"ViewRay (MRIdian)","aka":["ViewRay Systems","ViewRay Technologies"],"tldr":"ViewRay makes MRIdian, the MR-linac that pairs a low-field MRI with a linear accelerator so tumours in the pancreas, liver and prostate can be watched and the beam gated while it treats; the original company went bankrupt in 2023 and the business continues under new ownership.","summary":"Founded in 2004 by physicist James Dempsey, ViewRay first sold a cobalt-based MR-guided system and then MRIdian Linac, which combines a split superconducting low-field MRI with a 6 MV linac and treats while imaging, gating the beam automatically when the target leaves its boundary. Washington University in St Louis, the University of Wisconsin, UCLA, Heidelberg and Amsterdam were among the early users, and the SMART trial of MR-guided stereotactic radiotherapy in pancreatic cancer used the platform. ViewRay Technologies filed for bankruptcy in 2023 and the MRIdian business was bought out and continues to support and sell the system as ViewRay Systems. OnCo links it to MR-guided adaptive radiotherapy.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://viewray.com"}],"tags":["machines-wave"],"related":[],"cancers":["pancreatic","prostate","hcc"],"sections":["radiation","devices"],"technologies":["mr-linac","adaptive-radiotherapy","sbrt"],"targets":[],"drugs":[],"companies":[],"institutions":["wustl-siteman","uw-carbone","ucla-jonsson","heidelberg-nct","amsterdam-umc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Denver, CO","country":"US","companyType":"devices","website":"https://viewray.com","founded":2004,"stage":"acquired","investors":[],"funding":[]},{"id":"vion-pharmaceuticals","kind":"company","name":"Vion Pharmaceuticals","aka":["Vion Pharmaceuticals, Inc.","Vion"],"tldr":"Vion was a Yale spin-out whose alkylating agent laromustine reached phase 3 in older patients with acute myeloid leukaemia but was not approved; the company filed for bankruptcy in 2009.","summary":"Vion Pharmaceuticals, founded in 1992 in New Haven, Connecticut, from Yale University research, developed laromustine (Onrigin), a sulfonylhydrazine alkylating agent, for acute myeloid leukaemia in patients unfit for intensive chemotherapy. The FDA declined approval without a randomised trial and Vion filed for Chapter 11 bankruptcy in 2009. Its trials remain on ClinicalTrials.gov under Vion as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.vionpharm.com"},{"label":"ClinicalTrials.gov: trials led by Vion Pharmaceuticals, Inc.","url":"https://clinicaltrials.gov/search?lead=Vion%20Pharmaceuticals%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q7933401"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"New Haven, CT","country":"US","companyType":"biotech","website":"http://www.vionpharm.com","founded":1992,"stage":"defunct","investors":[],"funding":[]},{"id":"vironexis-biotherapeutics","kind":"company","name":"Vironexis Biotherapeutics","aka":["Vironexis Biotherapeutics Inc."],"tldr":"Vironexis Biotherapeutics is a US-based biotechnology company that leads 2 cancer trials in OnCo, testing the AAV-delivered T-cell engager gene therapies VNX-101 and VNX-202 in acute lymphoblastic leukaemia, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia, non-Hodgkin lymphoma and advanced solid tumours.","summary":"Vironexis Biotherapeutics is a clinical-stage biotechnology company developing AAV-delivered, in vivo T-cell engager gene therapies on its TransJoin platform, given as a single intravenous dose. Its lead programme VNX-101 is in phase 1/2 for CD19-positive leukaemias and lymphomas, with VNX-202 for HER2-positive cancers. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT06533579 (phase 1/2, Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)) and NCT07192432 (phase 1/2, Gene Therapy for HER-Positive Cancer (SENTRY-HER2)). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://vironexis.com"},{"label":"ClinicalTrials.gov: trials led by Vironexis Biotherapeutics","url":"https://clinicaltrials.gov/search?lead=Vironexis%20Biotherapeutics%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["all-leukemia","dlbcl","cll","non-hodgkin-lymphoma","follicular-lymphoma","mantle-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06533579","nct07192432"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"San Diego, California","country":"US","companyType":"biotech","website":"https://vironexis.com","founded":2021,"stage":"startup","investors":[],"funding":[]},{"id":"vision-rt","kind":"company","name":"Vision RT","aka":[],"tldr":"Vision RT pioneered surface-guided radiotherapy with AlignRT, ceiling cameras that track the patient's skin in 3D so treatment can be set up without tattoos and paused if the patient moves.","summary":"Vision RT, founded in London in 2001, makes the AlignRT surface guidance system installed on linacs worldwide, used for tattoo-free set-up, deep-inspiration breath-hold in breast radiotherapy and open-mask brain radiosurgery, plus the MapRT collision-avoidance tool and simulation-room systems. It is privately held.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.visionrt.com/"}],"tags":["machines-wave2"],"related":[],"cancers":[],"sections":[],"technologies":["patient-positioning-surface-guidance-systems","respiratory-gating-tumour-tracking-systems","surface-guided-radiotherapy","respiratory-motion-management"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"London","country":"GB","companyType":"devices","website":"https://www.visionrt.com/","founded":2001,"stage":"private-large","investors":[],"funding":[]},{"id":"vizgen","kind":"company","name":"Vizgen","aka":[],"tldr":"Vizgen sells the MERSCOPE spatial transcriptomics platform, based on MERFISH from Xiaowei Zhuang's lab.","summary":"Vizgen, based in Cambridge, Massachusetts, sells the MERSCOPE spatial transcriptomics platform, based on the MERFISH method from Xiaowei Zhuang's laboratory. It offers single-cell resolution in situ transcriptomics and merged with Ultivue in 2025 to add protein multiplexing to the same platform. OnCo links it to spatial biology instruments. Whether combined RNA and protein spatial readouts can be standardised into tests clinicians act on, rather than remaining discovery tools, is the open question for the field. The spatial biology instruments page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://vizgen.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":["spatial-biology-instruments"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cambridge, MA","country":"US","companyType":"diagnostics","website":"https://vizgen.com","investors":[],"funding":[]},{"id":"volitionrx","kind":"company","name":"VolitionRx","aka":[],"tldr":"VolitionRx develops low-cost blood tests that measure nucleosomes, the packaging units of DNA released by dying cells, to detect and monitor cancer and sepsis.","summary":"VolitionRx Limited, listed on NYSE American as VNRX, is an epigenetics diagnostics company with a 20,000 square foot laboratory and manufacturing site in Gembloux (Isnes), Belgium and executive offices in the United States. Its Nucleosomics platform quantifies circulating nucleosomes and their epigenetic modifications in a routine blood sample using immunoassays that run on standard clinical analysers. Products include Nu.Q NETs, a CE-marked assay for NETosis in sepsis being commercialised with Sysmex; Nu.Q Vet Cancer Test, a canine screening test reported to detect 76 percent of systemic cancers at 97 percent specificity; Nu.Q Discover research assays; and the Nu.Q Cancer pipeline, including a Nu.Q Lung Cancer test being prepared for reimbursement submission with Hospices Civils de Lyon.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://volition.com/"},{"label":"Investor relations","url":"https://ir.volition.com/"},{"label":"Q2 2026 results (Aug 2026)","url":"https://volition.com/volitionrx-limited-announces-second-quarter-2026-financial-results-and-business-update"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["diagnostics","early-detection"],"technologies":["liquid-biopsy","mced"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The Q2 2026 release dateline is Henderson, Nevada, not Austin, Texas; the website describes Gembloux, Belgium as the primary operating site. Human cancer tests remain in development; only the veterinary and NETs assays are commercial."],"hq":"Henderson, NV","country":"US","companyType":"diagnostics","website":"https://volition.com/","ticker":"VNRX","stage":"public","investors":[],"funding":[]},{"id":"volpara-health","kind":"company","name":"Volpara Health","aka":[],"tldr":"Volpara Health made software that measures breast density from mammograms and helps clinics manage breast cancer risk and screening quality. The New Zealand company was acquired by Korean AI firm Lunit in 2024 and now operates under the Lunit brand.","summary":"Volpara Health Technologies, founded in Wellington, New Zealand, developed AI software for breast screening: Volpara Scorecard provides objective volumetric breast density assessment from mammograms to support supplemental screening decisions, Risk Pathways manages breast cancer risk assessment and high-risk patient workflows, and Patient Hub supports patient engagement, alongside quality tools for mammography positioning and dose. Lunit, the Seoul-listed AI cancer diagnostics company (KRX: 328130), completed its acquisition of Volpara in 2024 and in November 2025 announced that Volpara now operates under the Lunit brand, with the combined business serving more than 10,000 sites in over 65 countries. The Scorecard and Risk Pathways products are now sold as part of Lunit's cancer screening portfolio, and the volparahealth.com domain redirects to lunit.io.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.lunit.io/en/"},{"label":"Volpara Scorecard product page on Lunit","url":"https://www.lunit.io/en/ai-radiology-software/scorecard/"},{"label":"Volpara now operates under Lunit brand (Nov 2025)","url":"https://www.prnewswire.com/news-releases/volpara-now-operates-under-lunit-brand-advancing-a-unified-vision-for-ai-cancer-intelligence-302607969.html"}],"tags":[],"related":[],"cancers":["breast-hr-positive","breast-her2-positive","tnbc"],"sections":["imaging","early-detection","ai-computation"],"technologies":["mammography","radiology-ai-screening"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Wellington HQ is from the caller's hint and general knowledge; the fetched Lunit release does not state Volpara's location. The original acquisition announcement (Dec 2023) and completion release (May 2024) with the deal value could not be located on Lunit's media hub. Lunit itself is already in the graph."],"hq":"Wellington","country":"NZ","companyType":"ai-software","website":"https://www.lunit.io/en/","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2024,"source":"https://www.prnewswire.com/news-releases/volpara-now-operates-under-lunit-brand-advancing-a-unified-vision-for-ai-cancer-intelligence-302607969.html","note":"Lunit's November 2025 release states the acquisition of Volpara Health Technologies was completed in 2024; value not stated in the fetched source."}],"acquiredBy":"lunit"},{"id":"vor-biopharma","kind":"company","name":"Vor Biopharma","aka":["Vor Biopharma Inc.","VOR BIOPHARMA INC."],"tldr":"Vor is a Cambridge cell-therapy company that edits the CD33 gene out of donor stem cells so that leukaemia patients can receive CD33-targeting therapy after transplant without harming their new marrow.","summary":"Vor Biopharma, based in Cambridge, Massachusetts, developed trem-cel (VOR33), donor haematopoietic stem cells with CD33 removed by gene editing, given as a transplant graft so that a subsequent CD33-directed antibody-drug conjugate or CAR-T can attack acute myeloid leukaemia while sparing the graft. Its trials in AML are registered on ClinicalTrials.gov under Vor as lead sponsor, and the company restructured in 2025 to pursue an in-licensed autoimmune programme.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.vorbio.com"},{"label":"ClinicalTrials.gov: trials led by Vor Biopharma Inc.","url":"https://clinicaltrials.gov/search?lead=Vor%20Biopharma%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q140609057"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml"],"sections":[],"technologies":["allogeneic-hsct","car-t"],"targets":["cd33"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Cambridge, MA","country":"US","companyType":"cell-therapy","website":"https://www.vorbio.com","stage":"public","investors":[],"funding":[]},{"id":"vyriad","kind":"company","name":"Vyriad","aka":["Vyriad, Inc."],"tldr":"Vyriad is a United States-based biotechnology company running 2 late-stage cancer trials in melanoma, head and neck squamous cell carcinoma and colorectal cancer.","summary":"Vyriad, based in Rochester, the United States, is a biotechnology company. Vyriad engineers targeted viral platforms for genetic therapies, developing in vivo gene therapies, genome editing and oncolytic virotherapies delivered through engineered virus vectors, including VSV and measles virus platforms. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials in melanoma, head and neck squamous cell carcinoma, colorectal cancer, non-small-cell lung cancer and neuroendocrine tumours. The largest, NCT04291105 (Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients), plans to enrol 87 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.vyriad.com"},{"label":"ClinicalTrials.gov: trials led by Vyriad","url":"https://clinicaltrials.gov/search?lead=Vyriad%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma","head-and-neck","colorectal","nsclc","neuroendocrine","rcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04291105","nct03647163"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Rochester","country":"US","companyType":"biotech","website":"https://www.vyriad.com","investors":[],"funding":[]},{"id":"wayshine-biopharm","kind":"company","name":"Wayshine Biopharm","aka":["Wayshine Biopharm, Inc."],"tldr":"Wayshine Biopharm is a China-based biotechnology company that leads 3 cancer trials in OnCo, testing the brain-penetrant EGFR inhibitor WSD0922-FU in non-small-cell lung cancer and small-cell lung cancer.","summary":"Wayshine Biopharm develops small-molecule targeted cancer drugs able to cross the blood-brain barrier, with a focus on brain tumours and lung cancer. Its lead product WSD0922-FU is an EGFR and EGFRvIII inhibitor in trials for EGFR-mutant non-small-cell lung cancer and glioma in China and the United States. The group parent is registered in the United States and the operating headquarters is in Shanghai. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT06631989 (phase 1/2, A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advance...), NCT06868485 (phase 2, A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small...) and NCT07206498 (phase 1/2, A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"http://www.wayshinebiopharm.com"},{"label":"ClinicalTrials.gov: trials led by Wayshine Biopharm","url":"https://clinicaltrials.gov/search?lead=Wayshine%20Biopharm%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["osimertinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06631989","nct06868485","nct07206498"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"http://www.wayshinebiopharm.com","stage":"growth","investors":[],"funding":[]},{"id":"werewolf-therapeutics","kind":"company","name":"Werewolf Therapeutics","aka":[],"tldr":"Werewolf makes conditionally activated cytokines (immune signalling proteins such as interleukin-2 and interleukin-12) that are switched on inside tumours. After selling a partnered programme to Jazz, the company agreed in August 2026 to merge with a pain-drug developer, which would end its independent cancer work.","summary":"Werewolf Therapeutics developed INDUKINE molecules, conditionally activated cytokine pro-drugs engineered to be released in the tumour microenvironment, including WTX-124 (IL-2) and WTX-330 (IL-12), both in clinical trials, and JZP898 (IFN-alpha), previously licensed to Jazz Pharmaceuticals. In the second quarter of 2026 Werewolf sold the JZP898 programme to Jazz in a transaction that included a $21.0 million payment, repaid its K2 HealthVentures loan and began a strategic alternatives process with Piper Sandler; cash was $22.0 million at 30 June 2026. On 21 August 2026 Werewolf announced an all-stock merger with Ambros Therapeutics with a concurrent $150 million private placement; the combined company would operate as Ambros Therapeutics in San Diego, focus on neridronate for complex regional pain syndrome and trade as AMBX. The fate of the INDUKINE oncology assets after the merger is not stated in the fetched releases. Nasdaq: HOWL.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://werewolftx.com/"},{"label":"Q2 2026 results (8-K exhibit 99.1)","url":"https://www.sec.gov/Archives/edgar/data/1785530/000178553026000018/a06302026ex991.htm"},{"label":"Merger with Ambros Therapeutics announced (8-K exhibit 99.1, August 2026)","url":"https://www.sec.gov/Archives/edgar/data/1785530/000119312526360059/d102535dex991.htm"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["cytokine-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06939283"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Status uncertain: pending reverse merger (announced August 2026) would exit oncology. The $150 million private placement is for the merged Ambros entity and is not listed as a Werewolf round. IPO (2021) not sourced."],"hq":"Watertown, MA","country":"US","companyType":"biotech","website":"https://werewolftx.com/","ticker":"HOWL","stage":"public","investors":[],"funding":[]},{"id":"wjog","kind":"company","name":"West Japan Oncology Group","aka":["WJOG","West Japan Thoracic Oncology Group","WJTOG"],"tldr":"Japan's second national cooperative group, born in thoracic oncology; its WJTOG3405 trial helped establish EGFR inhibitors as first-line lung cancer therapy.","summary":"Founded in 2000 as the West Japan Thoracic Oncology Group and renamed WJOG in 2008 as it expanded into gastrointestinal, breast and other cancers. WJTOG3405 (gefitinib versus cisplatin-docetaxel in EGFR-mutant NSCLC) was one of the two Japanese phase 3 trials that made EGFR testing and first-line targeted therapy the standard worldwide. WJOG runs investigator-initiated trials of targeted agents, immunotherapy and chemotherapy across Japan's university and cancer centre hospitals and collaborates with JCOG and with Asian and Western groups. Its committees cover thoracic, gastrointestinal, breast, gynaecologic and genitourinary cancers.","asOf":"2026-09-09","links":[{"label":"WJOG","url":"https://www.wjog.jp"}],"tags":["cooperative-group"],"related":["osimertinib"],"cancers":["nsclc","sclc","gastric","colorectal","breast-her2-positive"],"sections":[],"technologies":["kinase-inhibitors","checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":["jcog"],"institutions":["ncc-japan"],"pathways":[],"terms":["oncogene-addiction"],"trials":["takahashi-pci"],"people":["nobuyuki-yamamoto"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Thoracic oncology (WJTOG3405)","Gastrointestinal oncology","Breast oncology","Investigator-initiated trials of targeted therapy and immunotherapy"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Osaka","country":"JP","companyType":"cooperative-group","website":"https://www.wjog.jp","founded":2000,"investors":[],"funding":[]},{"id":"wigen-biomedicine-technology-shanghai","kind":"company","name":"Wigen Biomedicine Technology (Shanghai)","aka":["Wigen Biomedicine Technology (Shanghai) Co., Ltd."],"tldr":"Wigen Biomedicine Technology (Shanghai) is a China-based biotechnology company running 2 late-stage cancer trials of WJB001.","summary":"Wigen Biomedicine Technology (Shanghai), based in Shanghai, China, is a biotechnology company. Wigen Biomedicine develops innovative anti-tumour drugs using small-molecule covalent/allosteric, PROTAC and drug-conjugate technology platforms. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing WJB001. The largest, NCT05773820 (A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumours), plans to enrol 210 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.wigenbio.com"},{"label":"ClinicalTrials.gov: trials led by Wigen Biomedicine Technology (Shanghai)","url":"https://clinicaltrials.gov/search?lead=Wigen%20Biomedicine%20Technology%20(Shanghai)%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":[],"technologies":["protac-degrader"],"targets":[],"drugs":["wjb001"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.wigenbio.com","founded":2018,"stage":"growth","investors":[],"funding":[]},{"id":"wuhan-yzy-biopharma","kind":"company","name":"Wuhan YZY Biopharma","aka":["Wuhan YZY Biopharma Co., Ltd.","YZY Biopharma","武汉友芝友生物"],"tldr":"YZY Biopharma is a Wuhan company listed in Hong Kong that builds bispecific antibodies, including one given directly into the abdomen to control fluid build-up from cancer.","summary":"Wuhan YZY Biopharma, founded in 2010 and listed in Hong Kong, develops bispecific antibodies on its YBODY platform. Its lead product M701, an EpCAM and CD3 bispecific given intraperitoneally for malignant ascites, and M802, a HER2 and CD3 bispecific, are in trials in China, with the ascites programme in phase 3 registered on ClinicalTrials.gov under YZY as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.yzybio.com"},{"label":"ClinicalTrials.gov: trials led by Wuhan YZY Biopharma Co., Ltd.","url":"https://clinicaltrials.gov/search?lead=Wuhan%20YZY%20Biopharma%20Co.%2C%20Ltd."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30260850"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":["bispecific-antibody","t-cell-engager"],"targets":[],"drugs":["m701"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct05543330"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Wuhan","country":"CN","companyType":"biotech","website":"http://www.yzybio.com","founded":2010,"stage":"public","investors":[],"funding":[]},{"id":"wuxi-apptec","kind":"company","name":"WuXi AppTec","aka":["药明康德"],"tldr":"WuXi AppTec is the contract research and manufacturing giant that makes small molecules, including ADC payloads and linkers, for much of the global cancer pipeline, and the target of the US BIOSECURE Act.","summary":"Founded by Ge Li in Shanghai; discovery chemistry, toxicology, clinical CRO and small-molecule and peptide manufacturing for most large Western pharma; co-founded JW Therapeutics with Juno. Its cell and gene therapy arm WuXi ATU was sold in 2024 to 2025 after the US BIOSECURE Act named WuXi AppTec and WuXi Biologics as companies of concern, the clearest example of geopolitics reshaping oncology supply chains.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.wuxiapptec.com/"},{"label":"BIOSECURE Act (US Congress)","url":"https://www.congress.gov/bill/118th-congress/house-bill/8333"}],"tags":["china"],"related":[],"cancers":[],"sections":["drug-discovery","chemotherapy"],"technologies":[],"targets":[],"drugs":[],"companies":["wuxi-biologics","jw-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["li-ge"],"bottlenecks":["b-manufacturing-cell-therapy","b-regulatory-fragmentation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai","country":"CN","companyType":"cro-services","website":"https://www.wuxiapptec.com/","ticker":"603259.SS / 2359.HK","founded":2000,"investors":[],"funding":[]},{"id":"wuxi-biologics","kind":"company","name":"WuXi Biologics","aka":["药明生物","WuXi XDC"],"tldr":"WuXi Biologics develops and manufactures antibodies for hundreds of clients worldwide, and its WuXi XDC unit is the largest contract maker of antibody-drug conjugates.","summary":"Discovery, cell-line development and GMP manufacture of monoclonal and bispecific antibodies; WuXi XDC (listed separately in Hong Kong, 2268.HK) runs integrated ADC conjugation for a large share of clinical-stage ADCs from both Chinese and Western sponsors. Named in the US BIOSECURE Act; sold its Irish vaccine plant to Merck in 2025. The company behind much of the antibody supply for China's PD-1 and ADC boom.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.wuxibiologics.com/"}],"tags":["china"],"related":[],"cancers":[],"sections":["adcs","immunotherapy"],"technologies":["adc","monoclonal-antibody","bispecific-antibody"],"targets":[],"drugs":[],"companies":["wuxi-apptec"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["li-ge"],"bottlenecks":["b-regulatory-fragmentation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Wuxi / Shanghai","country":"CN","companyType":"cro-services","website":"https://www.wuxibiologics.com/","ticker":"2269.HK","founded":2010,"investors":[],"funding":[]},{"id":"wuxi-xdc","kind":"company","name":"WuXi XDC","aka":[],"tldr":"WuXi XDC is the largest dedicated ADC CDMO, spun out of WuXi Biologics and listed in Hong Kong in 2023; it is exposed to US BIOSECURE Act politics.","summary":"WuXi XDC, based in Wuxi and listed in Hong Kong as 2268.HK, is the largest dedicated antibody-drug conjugate CDMO, spun out of WuXi Biologics and listed in 2023, and it is exposed to the politics of the US BIOSECURE Act. It offers integrated antibody, payload-linker, conjugation and fill-finish services, a large share of the world's clinical ADCs are made there, and it is building a Singapore site to diversify from China. OnCo links it to ADC bioconjugation manufacturing and payload-linker synthesis and to the BIOSECURE Act term. Whether Western sponsors move ADC manufacturing out of China under political pressure, and whether alternative capacity exists to receive it, is the open question. The BIOSECURE Act page carries the policy detail.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.wuxixdc.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["adcs"],"technologies":["adc-cdmo-manufacturing","high-potency-payload-synthesis"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["biosecure-act"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Wuxi","country":"CN","companyType":"cro-services","website":"https://www.wuxixdc.com","ticker":"2268.HK","investors":[],"funding":[]},{"id":"x-zell","kind":"company","name":"X-Zell","aka":[],"tldr":"X-Zell isolates rare abnormal cells from a blood sample and stains and images them so a pathologist can look for signs of cancer without a tissue biopsy.","summary":"X-Zell, based in Bangkok with a German office, built an end-to-end platform for rare-cell detection: blood processing, isolation of circulating abnormal cells such as circulating endothelial cells, multiplex cytopathology staining and digital imaging, all developed in-house. Its early work centred on prostate cancer, where the aim was to reduce unnecessary biopsies after a raised PSA. The company remains active in the YC directory and describes a product ecosystem for research, companion diagnostics and relapse monitoring; it has not published pivotal clinical validation for a regulated test, so evidence should be treated as early.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/x-zell"},{"label":"Official website","url":"https://www.x-zell.com"}],"tags":["yc"],"related":[],"cancers":["prostate"],"sections":["diagnostics","early-detection"],"technologies":["liquid-biopsy","digital-pathology-ai"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Bangkok","country":"TH","companyType":"diagnostics","website":"https://www.x-zell.com","stage":"startup","ycBatch":"W15","investors":["y-combinator"],"funding":[]},{"id":"x4-pharmaceuticals","kind":"company","name":"X4 Pharmaceuticals","aka":["X4 Pharmaceuticals, Inc.","NASDAQ:XFOR"],"tldr":"X4 Pharmaceuticals is a Boston biotech whose oral CXCR4 blocker mavorixafor won approval as Xolremdi for WHIM syndrome and is being tested to free neutrophils in chronic neutropenia and to open tumours to immune attack.","summary":"X4 Pharmaceuticals develops mavorixafor (X4P-001, formerly AMD-070), an oral antagonist of the chemokine receptor CXCR4. The FDA approved it in April 2024 as Xolremdi for patients aged 12 and older with WHIM syndrome, a rare immunodeficiency. The phase 3 4WARD trial tests it in chronic neutropenia. In oncology the drug has been studied with axitinib in renal cell carcinoma, with pembrolizumab in melanoma and in Waldenström macroglobulinaemia, where CXCR4 mutations confer resistance to BTK inhibitors.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.x4pharma.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["mavorixafor"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Boston, Massachusetts","country":"US","companyType":"biotech","website":"https://www.x4pharma.com/","ticker":"NASDAQ:XFOR","founded":2014,"stage":"public","investors":[],"funding":[]},{"id":"xact-robotics","kind":"company","name":"XACT Robotics","aka":[],"tldr":"XACT Robotics makes a small robot that attaches to the patient and, using CT scan guidance, inserts and steers a needle to a precise spot inside the body for tumour biopsies and heat-based tumour destruction, adjusting its path as the target moves.","summary":"XACT Robotics Ltd., founded in 2013 with offices in Caesarea, Israel and Hingham, Massachusetts, developed the XACT ACE Robotic System, described as the first hands-free robotic platform combining image-based planning and navigation with instrument insertion and steering for percutaneous procedures. The compact, patient-mounted robot uses proprietary S-Drive technology to adjust the needle path in real time to compensate for tissue and target motion, with reported tip-to-target accuracy under 1.7 mm in a single insertion. Applications span biopsy, ablation, drainage and drug delivery in lung, liver, kidney, lymph node, prostate and adrenal targets. The FDA cleared XACT ACE for CT-guided percutaneous procedures in July 2020 (a first-generation system was cleared the year before), expanded support for ablation in May 2022 and cleared the ACE Xtend remote control unit in October 2022. XACT is privately held; no financing round could be sourced.","asOf":"2026-09-10","links":[{"label":"Official website (still live; the company is not)","url":"https://xactrobotics.com"},{"label":"Globes: XACT Robotics shuts down, lays off 65 (3 September 2023)","url":"https://en.globes.co.il/en/article-xact-robotics-shuts-down-lays-off-65-1001456845"},{"label":"FDA clearance for CT-guided percutaneous procedures (July 2020)","url":"https://www.globenewswire.com/news-release/2020/07/15/2062517/0/en/xact-ace-robotic-system-cleared-by-fda-for-image-guided-percutaneous-procedures.html"}],"tags":[],"related":[],"cancers":["nsclc","hcc","rcc"],"sections":["surgery","devices"],"technologies":["robotic-surgery","thermal-ablation","ct"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Shut down: the company announced on 3 September 2023 that it was closing and laying off all 65 employees, after raising about 60 million dollars; its patents were expected to revert to the Technion. Its website is still live and reads like a going concern, which is why this record says otherwise. Checked 2026-09-25 against the closure report, the absence of any FDA establishment registration for FY2026, and sitemap timestamps that all stop in 2023.","Website returns HTTP 403 to curl but loads via WebFetch; the news archive pages did not render, so 2022 clearances are taken from the home page and the 2021 remote procedure from the GlobeNewswire release title only. Funding rounds are known to exist but no release or Form D was found (EDGAR company search returned no filings), so funding is empty. Cancer ids are inferred from listed anatomies (lung, liver, kidney) rather than stated indications."],"hq":"Caesarea","country":"IL","companyType":"devices","website":"https://xactrobotics.com","founded":2013,"stage":"defunct","investors":[],"funding":[]},{"id":"xaira-therapeutics","kind":"company","name":"Xaira Therapeutics","aka":[],"tldr":"Launched in 2024 with over $1 billion to build AI-native drug discovery from Baker-lab protein design.","summary":"Xaira Therapeutics, based in South San Francisco, launched in 2024 with more than a billion dollars to build AI-native drug discovery from the protein design methods of the Baker laboratory. Co-founded with David Baker and Marc Tessier-Lavigne, it integrates de novo protein design, large-scale perturbation biology and antibody generation. OnCo links it to the Institute for Protein Design and to the RFdiffusion and ProteinMPNN technology record. Whether the largest AI drug discovery launch produces a clinical candidate faster than conventional biotechs is the question its funding invites. The Institute for Protein Design has its own page.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://xaira.com"}],"tags":["ai"],"related":[],"cancers":[],"sections":["drug-discovery","ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institute-for-protein-design"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://xaira.com","investors":[],"funding":[]},{"id":"xcision-medical-systems","kind":"company","name":"Xcision Medical Systems","aka":[],"tldr":"Xcision Medical Systems makes GammaPod, a radiotherapy machine built only for early breast cancer: the patient lies face down with the breast held in a vacuum cup while rotating cobalt-60 sources focus dose on part of the breast, allowing five sessions or fewer instead of four to six weeks. It is FDA-cleared and CE-marked but used at two listed sites.","summary":"Xcision Medical Systems, LLC develops stereotactic radiotherapy for breast cancer. Its first product, GammaPod, is described as the first and only stereotactic radiotherapy system designed specifically for early-stage breast cancer. The patient lies prone with the breast immobilised in a vacuum-assisted cup while a rotating array of cobalt-60 sources delivers a focused dose to a partial breast volume, enabling courses of five treatments or fewer instead of four to six weeks of conventional radiotherapy. The design is based on a patent licensed from the University of Maryland School of Medicine. GammaPod has FDA 510(k) clearance and CE marking. Listed clinical sites are the University of Maryland Greenebaum Comprehensive Cancer Center and UT Southwestern, and a GammaPod Research Consortium is studying shortened courses and preoperative ablative doses. Xcision joined the MedTech Innovator 2023 cohort. No financing round could be sourced.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.xcision.com/"},{"label":"About Xcision","url":"https://xcision.com/about/company/"},{"label":"GammaPod locations","url":"https://xcision.com/patients/locations/"},{"label":"MedTech Innovator 2023 cohort announcement","url":"https://xcision.com/worlds-largest-medtech-accelerator-announces-61-startups-for-its-2023-cohort/"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":["radiation","devices"],"technologies":["sbrt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The cobalt-60 source design detail is from general knowledge rather than the fetched pages. Founding year, funding and investors are unsourced; SEC EDGAR company search returned no Form D filings under the name Xcision. The site returns HTTP 406 to curl but loads via WebFetch; the www form is the URL that was fetched successfully."],"hq":"Columbia, MD","country":"US","companyType":"devices","website":"https://www.xcision.com/","stage":"startup","investors":[],"funding":[]},{"id":"xcovery","kind":"company","name":"Xcovery","aka":["Xcovery Holdings, Inc."],"tldr":"Xcovery is the Florida company that developed ensartinib, an ALK inhibitor approved by the FDA in December 2024 for ALK-positive non-small-cell lung cancer, partnered with Betta Pharmaceuticals in China where it was approved first.","summary":"Xcovery Holdings, based in Palm Beach Gardens, Florida, developed ensartinib (Ensacove), a second-generation ALK inhibitor. Its Chinese partner Betta Pharmaceuticals won approval there in 2020, and the FDA approved ensartinib in December 2024 for ALK-positive locally advanced or metastatic non-small-cell lung cancer in patients not previously treated with an ALK inhibitor, on the eXalt3 trial against crizotinib. Company facts are from the official website and FDA approval records.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.xcovery.com/"},{"label":"FDA: oncology and hematologic malignancies approval notifications","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"}],"tags":["fda-oce-applicant"],"related":[],"cancers":["nsclc"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["ensartinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct02767804"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Palm Beach Gardens, FL","country":"US","companyType":"biotech","website":"https://www.xcovery.com/","stage":"growth","investors":[],"funding":[]},{"id":"xencor","kind":"company","name":"Xencor","aka":[],"tldr":"Xencor is an antibody-engineering company (XmAb Fc technology) developing 2+1 T-cell engagers for kidney cancer (ENPP3) and ovarian/germ-cell tumours (CLDN6).","summary":"Xencor, based in Pasadena and listed as XNCR, is an antibody engineering company built on its XmAb Fc technology, developing 2+1 format T-cell engagers for kidney cancer, targeting ENPP3, and for ovarian and germ-cell tumours, targeting Claudin 6. XmAb819, an ENPP3 by CD3 engager, is in clear-cell renal cell carcinoma with a pivotal study planned for 2027, XmAb541, a Claudin 6 by CD3 engager, has produced confirmed partial responses in ovarian and germ-cell tumours, and the XmAb Fc technology is licensed into several approved antibodies. OnCo links it to renal cell carcinoma and ovarian cancer, to T-cell engagers and bispecific antibodies, and to CD3 as a target. Whether T-cell engagers can work in solid tumours without unacceptable toxicity is the question its 2+1 format is designed to answer. The T-cell engager page carries the field.","asOf":"2026-09-04","links":[{"label":"2026 milestones","url":"https://investors.xencor.com/news-releases/news-release-details/xencor-highlights-corporate-priorities-and-2026-pipeline"}],"tags":[],"related":[],"cancers":["rcc","ovarian"],"sections":["immunotherapy","targeted-therapy"],"technologies":["t-cell-engager","bispecific-antibody"],"targets":["cd3"],"drugs":["vudalimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Pasadena, CA","country":"US","companyType":"biotech","website":"https://xencor.com","ticker":"XNCR","investors":[],"funding":[]},{"id":"xilio-therapeutics","kind":"company","name":"Xilio Therapeutics","aka":[],"tldr":"Xilio designs immune-stimulating drugs, such as interleukin-2 and checkpoint antibodies, with a molecular mask that is removed only inside tumours, so they act where the cancer is and spare the rest of the body. Its newest drug combines a PD-1 antibody with masked IL-2 and has just been cleared to start trials.","summary":"Xilio Therapeutics develops tumour-selective, masked immuno-oncology therapies. Clinical assets include vilastobart (masked anti-CTLA-4) and efarindodekin alfa (masked IL-12). In August 2026 the FDA cleared the IND for XTX501, a bispecific PD-1 / masked IL-2 designed to stimulate PD-1-positive antigen-experienced T cells while avoiding IL-2 receptor-mediated clearance and peripheral toxicity; a phase 1/2 trial will begin in metastatic non-small cell lung cancer and selected advanced solid tumours. IND-enabling work is under way on multi-specific masked T-cell engagers targeting CLDN18.2 and PSMA plus STEAP1, with INDs expected in the second half of 2027. Xilio is based in Waltham, Massachusetts, trades on Nasdaq as XLO and reported cash runway into the first quarter of 2028.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://xiliotx.com/"},{"label":"Q2 2026 results and XTX501 IND clearance (8-K exhibit 99.1)","url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526345753/xlo-ex99_1.htm"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["immunotherapy"],"technologies":["cytokine-therapy","checkpoint-inhibitor","bispecific-antibody","t-cell-engager"],"targets":["pd1","ctla4","cldn18-2","psma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05684965"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No funding round sourced."],"hq":"Waltham, MA","country":"US","companyType":"biotech","website":"https://xiliotx.com/","ticker":"XLO","stage":"public","investors":["sv-health-investors"],"funding":[]},{"id":"xilis","kind":"company","name":"Xilis","aka":[],"tldr":"Duke spin-out whose MicroOrganoSphere droplets grow a patient's tumour and screen drugs within two weeks.","summary":"MicroOrganoSpheres (MOS) are microfluidic droplet-encapsulated 3D tumour models enabling automated functional drug testing. A 2026 JCO Precision Oncology study in 33 stage III/IV colorectal cancer patients tested feasibility of screening standard-of-care drugs in ≤14 days. Raised $70M Series A; DKFZ collaboration.","asOf":"2026-09-04","links":[{"label":"JCO Precision Oncology 2026","url":"https://ascopubs.org/doi/10.1200/PO-25-00501"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":["diagnostics","drug-discovery"],"technologies":["functional-drug-testing","organoids"],"targets":[],"drugs":[],"companies":[],"institutions":["dkfz"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Durham, NC","country":"US","companyType":"diagnostics","website":"https://xilis.com","investors":[],"funding":[]},{"id":"xuanzhu-biopharmaceutical","kind":"company","name":"Xuanzhu Biopharmaceutical","aka":["Xuanzhu Biopharmaceutical Co., Ltd."],"tldr":"Xuanzhu Biopharmaceutical is a China-based biotechnology company running 3 late-stage cancer trials of XZP-3287 and XZP-5955 in HR-positive / HER2-negative breast cancer and non-small-cell lung cancer.","summary":"Xuanzhu Biopharmaceutical, based in Beijing, China, is a biotechnology company. Xuanzhu Biopharmaceutical is a China-based biopharmaceutical company developing drugs for digestive system diseases, oncology and NASH (non-alcoholic fatty liver disease). On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing XZP-3287 and XZP-5955 in HR-positive / HER2-negative breast cancer and non-small-cell lung cancer. The largest, NCT05257395 (A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer), plans to enrol 397 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.xuanzhubio.com"},{"label":"ClinicalTrials.gov: trials led by Xuanzhu Biopharmaceutical","url":"https://clinicaltrials.gov/search?lead=Xuanzhu%20Biopharmaceutical%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["breast-hr-positive","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["xzp-3287"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05257395","nct04996121"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Beijing","country":"CN","companyType":"biotech","website":"https://www.xuanzhubio.com","founded":2008,"investors":[],"funding":[]},{"id":"xynomic-pharmaceuticals","kind":"company","name":"Xynomic Pharmaceuticals","aka":["Xynomic Pharmaceuticals Holdings","Xynomic Pharma"],"tldr":"Xynomic Pharmaceuticals is a Chinese-American biotech that licensed the histone deacetylase inhibitor abexinostat from Pharmacyclics and is testing it with pazopanib in kidney cancer and alone in lymphoma.","summary":"Xynomic Pharmaceuticals is an oncology company with operations in Zhongshan, Guangdong and the San Francisco Bay Area. Its lead asset is abexinostat, a pan-histone deacetylase inhibitor in-licensed from Pharmacyclics (now part of AbbVie), which it has taken into a phase 3 trial with pazopanib in renal cell carcinoma and into follicular lymphoma studies in China. It also holds rights to the pan-RAF inhibitor XP-102 and other clinical-stage assets.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.xynomicpharma.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["abexinostat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Zhongshan","country":"CN","companyType":"biotech","website":"https://www.xynomicpharma.com/","investors":[],"funding":[]},{"id":"y-combinator","kind":"company","name":"Y Combinator","aka":[],"tldr":"Y Combinator is the start-up accelerator that funds hundreds of new companies a year in return for a small stake. Since 2014 it has backed a steady stream of companies going after cancer, from blood tests to engineered viruses.","summary":"Y Combinator runs batches of early-stage companies, investing a standard amount for a fixed equity stake and then a further amount on the same terms as the company's next round, with a three-month programme and Demo Day. Its open directory lists more than 6,000 funded companies; the oncology subset in OnCo (companies with a `ycBatch`) was drawn from that directory and checked one by one. YC's biotech share grew from the mid-2010s, when it began accepting companies such as Notable Labs, Shasqi and BillionToOne, to recent batches with several cancer therapeutics, diagnostics and oncology AI companies each cycle. It is an accelerator rather than a specialist life-science fund, so its oncology bets skew towards software, diagnostics and platform biology with short paths to first revenue or data.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.ycombinator.com"},{"label":"YC company directory","url":"https://www.ycombinator.com/companies"},{"label":"Open YC directory dataset (yc-oss/api)","url":"https://github.com/yc-oss/api"}],"tags":["accelerator"],"related":[],"cancers":[],"sections":["drug-discovery","diagnostics","ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"investor","website":"https://www.ycombinator.com","founded":2005,"investors":[],"funding":[]},{"id":"y-mabs","kind":"company","name":"Y-mAbs Therapeutics","aka":[],"tldr":"MSK spin-out that commercialises naxitamab, the humanised anti-GD2 antibody for relapsed neuroblastoma, and develops pretargeted radioimmunotherapy.","summary":"Y-mAbs Therapeutics, based in New York and listed as YMAB, is a Memorial Sloan Kettering spin-out that commercialises naxitamab, the humanised anti-GD2 antibody for relapsed neuroblastoma, and develops pretargeted radioimmunotherapy. Naxitamab, sold as Danyelza, received accelerated approval in November 2020; omburtamab, a B7-H3 antibody carrying iodine-131, was rejected by the FDA in 2022; and the SADA pretargeted radioimmunotherapy platform, with a GD2-SADA and lutetium-177 pairing, is in phase 1. OnCo links it to paediatric neuroblastoma, to GD2 as a target and to the bottleneck of rare and paediatric cancers without markets. Whether pretargeting can deliver radiation to paediatric tumours with less marrow toxicity than direct radioimmunotherapy is the open question. Naxitamab has its own page.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://www.ymabs.com"}],"tags":[],"related":[],"cancers":["neuroblastoma"],"sections":["immunotherapy","radiopharma"],"technologies":[],"targets":["gd2"],"drugs":["naxitamab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"New York, NY","country":"US","companyType":"biotech","website":"https://www.ymabs.com","ticker":"YMAB","investors":[],"funding":[]},{"id":"yemaachi-biotech","kind":"company","name":"Yemaachi Biotech","aka":[],"tldr":"Yemaachi collects and sequences cancer samples from across Africa, the most genetically diverse population on earth, so that cancer tests and drugs work for African patients too.","summary":"Yemaachi Biotech, based in Accra, is building a clinical and molecular knowledge base of cancer among African people by collecting and sequencing tumour and germline samples across the continent, then using the data to optimise existing diagnostic tests and to support discovery partners. Its argument is that African genomes are almost absent from the datasets on which cancer diagnostics and drugs were developed. It works with hospitals and research partners in Ghana and elsewhere; products are at the data-generation and validation stage.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/yemaachi-biotechnology"},{"label":"Official website","url":"https://yemaachi.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["diagnostics","drug-discovery"],"technologies":["cgp","germline-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Accra","country":"GH","companyType":"diagnostics","website":"https://yemaachi.com","stage":"startup","ycBatch":"S21","investors":["y-combinator"],"funding":[]},{"id":"yuga-bio","kind":"company","name":"Yuga Bio","aka":[],"tldr":"Yuga Bio is an AI workspace for personalised cancer care: a patient's case wiki, agentic research on their tumour and their care team in one place, from diagnosis to treatment options.","summary":"Yuga Bio lets a patient drop in their records, builds a structured case, runs AI research on the tumour to surface relevant trials and testing options, and keeps the care team in one shared workspace, described as a living roadmap for the patient and their clinicians. It is offered to residents of the United States and is an Even One Ventures portfolio company based in Sacramento, California.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://yugabio.com/"},{"label":"Even One Ventures portfolio","url":"https://evenone.ventures/"}],"tags":["startup","evenone-portfolio","oncology"],"related":[],"cancers":[],"sections":[],"technologies":["ai-trial-matching"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Sacramento, CA","country":"US","companyType":"ai-software","website":"https://yugabio.com/","stage":"startup","investors":["evenone-ventures"],"funding":[]},{"id":"yuhan","kind":"company","name":"Yuhan Corporation","aka":["Yuhan","유한양행"],"tldr":"Yuhan Corporation is a South Korea-based pharmaceutical company that leads 3 cancer trials in OnCo, testing the immuno-oncology candidates YH32364, YH32367 and YH42946 in non-small-cell lung cancer and advanced solid tumours.","summary":"Yuhan Corporation is a South Korean pharmaceutical company founded in 1926 that makes prescription medicines, health supplements, household and animal health products. Its research pipeline includes the lung cancer drug lazertinib and immuno-oncology candidates such as YH32364 and YH32367. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT06616766 (phase 1/2, A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK an...), NCT06975410 (phase 1/2, Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpr...) and NCT05523947 (phase 1/2, Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.yuhan.co.kr"},{"label":"ClinicalTrials.gov: trials led by Yuhan Corporation","url":"https://clinicaltrials.gov/search?lead=Yuhan%20Corporation"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06616766","nct06975410","nct05523947"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Seoul","country":"KR","companyType":"pharma","website":"https://www.yuhan.co.kr","ticker":"KRX:000100","founded":1926,"stage":"public","investors":[],"funding":[]},{"id":"zai-lab","kind":"company","name":"Zai Lab","aka":["再鼎医药"],"tldr":"Zai Lab is the in-licensing pioneer that brings Western cancer drugs to China (niraparib, zanidatamab, repotrectinib, Tumour Treating Fields) and now exports its own bispecific and ADC assets.","summary":"Founded by Samantha Du; built on Greater China rights to niraparib (Zejula), zanidatamab, repotrectinib, tislelizumab-adjacent assets, sulbactam-durlobactam and Optune, with a Shanghai commercial organisation of hundreds. Internal pipeline: ZL-1310 (DLL3 ADC), ZL-1503 and the LRRC15 ADC ZL-6201 from MediLink. A bridge company: it explains how Western drugs reach Chinese patients years earlier than they otherwise would.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.zailaboratory.com/"}],"tags":["china"],"related":[],"cancers":[],"sections":["targeted-therapy","immunotherapy","adcs"],"technologies":[],"targets":[],"drugs":["niraparib","zanidatamab","repotrectinib","optune","zl-1310"],"companies":["gsk","jazz","zymeworks","novocure","medilink"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06885281"],"people":["du-samantha"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai / Cambridge, MA","country":"CN","companyType":"biotech","website":"https://www.zailaboratory.com/","ticker":"ZLAB / 9688.HK","founded":2014,"investors":[],"funding":[]},{"id":"zap-surgical-systems","kind":"company","name":"ZAP Surgical Systems","aka":[],"tldr":"ZAP Surgical makes ZAP-X, a self-shielded radiosurgery machine that aims beams from thousands of angles at brain tumours, treating brain metastases and meningiomas in one to five outpatient sessions without the concrete bunker or cobalt-60 source that older systems need. It is cleared in the US, Japan and Europe, with installations including Gustave Roussy.","summary":"ZAP Surgical Systems, founded by Stanford neurosurgeon John R. Adler, makes the ZAP-X Gyroscopic Radiosurgery platform for dedicated cranial stereotactic radiosurgery (SRS). A linear accelerator on dual independent gantries delivers non-coplanar beams from thousands of angles with integrated kV imaging. The self-shielded design needs no radiation vault and, unlike Gamma Knife, no cobalt-60 source, lowering cost and allowing installation in outpatient settings. Indications include brain metastases, meningiomas and trigeminal neuralgia, treated in one to five sessions. ZAP-X received FDA 510(k) clearance in 2017, Japan Shonin clearance in 2020 and CE marking in 2021; the ZAP-Axon planning system is also FDA and CE cleared. Installations include Gustave Roussy, Haaglanden Medical Center, several German hospitals and eight systems in China. In November 2024 the company closed a USD 78 million Series E led by Qingdao Baheal Medical.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://zapsurgical.com/"},{"label":"Series E press release (Nov 2024)","url":"https://zapsurgical.com/news/zap-surgical-secures-funding/"},{"label":"Newsroom","url":"https://zapsurgical.com/newsroom/"},{"label":"Contact page (global headquarters, San Carlos)","url":"https://zapsurgical.com/contact/"}],"tags":[],"related":[],"cancers":[],"sections":["radiation","devices"],"technologies":["sbrt","imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year and earlier rounds (Series A to D) are unsourced and omitted. The 3 MV linac detail comes from general product knowledge and is not in the fetched pages; treat as unverified."],"hq":"San Carlos, CA","country":"US","companyType":"devices","website":"https://zapsurgical.com/","stage":"growth","investors":[],"funding":[{"round":"Series E","year":2024,"amountUsd":78000000,"source":"https://zapsurgical.com/news/zap-surgical-secures-funding/","note":"Led by Qingdao Baheal Medical with participation from other strategic investors"}]},{"id":"zenith-epigenetics","kind":"company","name":"Zenith Epigenetics","aka":["Zenith Epigenetics Ltd."],"tldr":"Zenith Epigenetics is a Calgary biotech whose oral BET inhibitor ZEN-3694 is being tested with enzalutamide in castration-resistant prostate cancer and with PARP inhibitors and immunotherapy in other tumours.","summary":"Zenith Epigenetics, spun out of Resverlogix, develops ZEN-3694 (ZEN003694), an oral inhibitor of bromodomain and extra-terminal (BET) proteins that reduces transcription of MYC and androgen receptor-driven programmes. ZEN-3694 has been studied with enzalutamide in metastatic castration-resistant prostate cancer, including a randomised phase 2b trial, with talazoparib in triple-negative breast cancer, and with pembrolizumab, and is in a National Cancer Institute-sponsored trial in NUT carcinoma.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.zenithepigenetics.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["zen-3694"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Calgary","country":"CA","companyType":"biotech","website":"https://www.zenithepigenetics.com/","investors":[],"funding":[]},{"id":"zentalis-pharmaceuticals","kind":"company","name":"Zentalis Pharmaceuticals","aka":[],"tldr":"Zentalis Pharmaceuticals is developing azenosertib, a pill that blocks a cell-cycle checkpoint protein called WEE1, for ovarian cancer that no longer responds to platinum chemotherapy.","summary":"Zentalis Pharmaceuticals is a clinical-stage oncology company whose pipeline is now focused on azenosertib, a potential first-in-class WEE1 inhibitor. The lead indication is Cyclin E1-positive, platinum-resistant ovarian cancer: the DENALI study (parts 2a to 2c) is registration-intent with FDA Fast Track designation, the randomised ASPENOVA trial compares azenosertib with standard chemotherapy, and the MUIR study is testing azenosertib with bevacizumab as maintenance therapy and with chemotherapy backbones. The company states that Cyclin E1 protein overexpression predicts response to azenosertib. Zentalis, which listed on Nasdaq in April 2020 with an IPO raising about 190 million US dollars gross, was based in New York and San Diego at the time and now operates from San Diego.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://zentalis.com/"},{"label":"Pipeline","url":"https://zentalis.com/science/pipeline/"},{"label":"Q1 2020 results noting IPO proceeds (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516020000006/zentalisq12020earningrel.htm"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["wee1"],"drugs":["azenosertib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not sourced. Earlier programmes (ZN-c5 oral SERD, ZN-d5 BCL-2) are no longer on the pipeline page."],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://zentalis.com/","ticker":"ZNTL","stage":"public","investors":[],"funding":[{"round":"IPO","year":2020,"amountUsd":190000000,"source":"https://www.sec.gov/Archives/edgar/data/1725160/000172516020000006/zentalisq12020earningrel.htm","note":"10,557,000 shares at 18 US dollars in April 2020; gross proceeds about 190 million US dollars"}]},{"id":"zeria","kind":"company","name":"Zeria Pharmaceutical","aka":["Zeria Pharmaceutical Co., Ltd.","ゼリア新薬工業"],"tldr":"Zeria is a Tokyo pharmaceutical company founded in 1955, strongest in gastroenterology, that sponsors phase 3 cancer trials in Japan.","summary":"Zeria Pharmaceutical Co., Ltd., based in Chūō, Tokyo, and founded in 1955, makes prescription and consumer medicines with a focus on gastrointestinal disease, including bowel preparations used before colonoscopy, and has acted as lead sponsor of phase 3 trials in cancer-related settings registered on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.zeria.co.jp"},{"label":"ClinicalTrials.gov: trials led by Zeria Pharmaceutical Co., Ltd.","url":"https://clinicaltrials.gov/search?lead=Zeria%20Pharmaceutical%20Co.%2C%20Ltd."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q11314982"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["colorectal-screening"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Tokyo","country":"JP","companyType":"pharma","website":"http://www.zeria.co.jp","founded":1955,"stage":"public","investors":[],"funding":[]},{"id":"zhejiang-hisun","kind":"company","name":"Zhejiang Hisun Pharmaceutical","aka":["Zhejiang Hisun Pharmaceutical Co. Ltd.","Hisun","浙江海正药业"],"tldr":"Hisun is a large Chinese maker of active ingredients and generic injectables, founded in 1952 in Taizhou, whose biosimilar and generic cancer medicines go through the phase 3 trials it sponsors.","summary":"Zhejiang Hisun Pharmaceutical, headquartered in Taizhou, Zhejiang, and listed in Shanghai, is one of China's largest producers of active pharmaceutical ingredients and sterile injectables, including anthracyclines and other cytotoxics, and has moved into biosimilars such as adalimumab and bevacizumab. ClinicalTrials.gov lists Hisun as lead sponsor of a phase 3 cancer trial.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.hisunpharm.com"},{"label":"ClinicalTrials.gov: trials led by Zhejiang Hisun Pharmaceutical Co. Ltd.","url":"https://clinicaltrials.gov/search?lead=Zhejiang%20Hisun%20Pharmaceutical%20Co.%20Ltd."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30260852"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial","biosimilar"],"trials":["nct07310173"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Taizhou","country":"CN","companyType":"pharma","website":"http://www.hisunpharm.com","founded":1952,"stage":"public","investors":[],"funding":[]},{"id":"zhuhai-yufan-biotechnologies","kind":"company","name":"Zhuhai Yufan Biotechnologies","aka":["Zhuhai Yufan Biotechnologies Co., Ltd"],"tldr":"Zhuhai Yufan Biotechnologies is a Chinese developer in Zhuhai that sponsors 2 registered cancer trials of PRJ1-3024.","summary":"Zhuhai Yufan Biotechnologies appears on ClinicalTrials.gov as the industry sponsor of 2 interventional cancer trials (phase 1/2), testing PRJ1-3024 in melanoma, advanced solid tumor, advanced solid malignancies. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials sponsored by Zhuhai Yufan Biotechnologies","url":"https://clinicaltrials.gov/search?spons=Zhuhai%20Yufan%20Biotechnologies"}],"tags":["ctgov-sponsor","china","registry-only"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06727630","nct05315167"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Zhuhai, China","country":"CN","companyType":"biotech","investors":[],"funding":[]},{"id":"zpredicta","kind":"company","name":"zPREDICTA","aka":[],"tldr":"zPREDICTA grew patient-derived tumour tissue in three-dimensional cultures that reproduce the tumour's surroundings, so drug companies could test cancer drugs on something closer to a real tumour. It was later acquired.","summary":"zPREDICTA developed organ-specific three-dimensional culture models that reconstruct the cellular and extracellular tumour microenvironment, used by pharmaceutical customers for efficacy screening of anti-cancer compounds including immuno-oncology agents, resistance mechanism studies and off-target toxicity assessment. Its YC profile cites clinical study data correlating drug efficacy in the platform with clinical response. The YC directory marks the company as acquired; the acquirer is not recorded here because no primary source was fetched, and the original domain no longer belongs to the company.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/zpredicta"}],"tags":["yc"],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":["organoids","functional-drug-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Jose, CA","country":"US","companyType":"cro-services","website":"https://www.ycombinator.com/companies/zpredicta","stage":"acquired","ycBatch":"S15","investors":["y-combinator"],"funding":[]},{"id":"zydus","kind":"company","name":"Zydus Lifesciences","aka":[],"tldr":"Zydus Lifesciences, a large Ahmedabad drug maker founded in 1952, sells oncology generics and biosimilars in India and won US approval in October 2024 for generic enzalutamide, a hormone-blocking pill for prostate cancer. Its US generics pipeline is the route by which Indian manufacturing pressure reaches cancer drug prices.","summary":"Zydus Lifesciences (formerly Cadila Healthcare) was founded in 1952 by Ramanbhai Patel and Indravadan Modi and is listed on the NSE and BSE. Its oncology business combines Indian biosimilars and generics with a US generics pipeline; in October 2024 it received FDA approval for enzalutamide tablets for prostate cancer. Zydus also runs one of India's larger in-house research organisations and a hospital group, and its vaccine arm developed a DNA COVID-19 vaccine, an indicator of the platform capacity that Indian companies can turn toward cancer.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.zyduslife.com"}],"tags":[],"related":[],"cancers":[],"sections":["hormonal","chemotherapy"],"technologies":["endocrine-therapy"],"targets":[],"drugs":["enzalutamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Ahmedabad","country":"IN","companyType":"pharma","website":"https://www.zyduslife.com","ticker":"ZYDUSLIFE.NS","founded":1952,"investors":[],"funding":[]},{"id":"zymeworks","kind":"company","name":"Zymeworks","aka":[],"tldr":"Zymeworks invented zanidatamab and a hydrophilic TOP1 ADC platform (ZW191 FRα, ZW251 GPC3).","summary":"Zymeworks, based in Vancouver and listed as ZYME, invented zanidatamab, the HER2 bispecific antibody, and a hydrophilic topoisomerase 1 ADC platform. Its Azymetric platform produced zanidatamab, on which it earns royalties, and its own pipeline includes ZW191, a folate receptor alpha ADC that reported a 52 percent response rate in pretreated ovarian and endometrial cancer at AACR 2026, and ZW251 against GPC3. OnCo links it to biliary tract cancer and HER2-positive breast cancer, to the zanidatamab drug record and to Zai Lab. Whether its second-generation ADCs can repeat the success of a bispecific it no longer controls is the open question. Zanidatamab has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.zymeworks.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs","targeted-therapy"],"technologies":[],"targets":[],"drugs":["zanidatamab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Vancouver","country":"CA","companyType":"biotech","website":"https://www.zymeworks.com","ticker":"ZYME","investors":[],"funding":[]}]